[["0",{"pageContent":"FUNDAMENTOS\n\nDE\n \nHEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":2,"lines":{"from":1,"to":5}}}}],["1",{"pageContent":"FUNDAMENTOS\nDE\n \nHEMATOLOGÍA\nGuillermo José Ruiz Argüelles\n\nDirector General del Centro de Hematología y Medicina Interna de Puebla\nConsultor de Hematología de Clínica Ruiz, Laboratorios\nCatedrático de Hematología. Universidad de las Américas, Puebla\nPresidente de la Agrupación Mexicana para el Estudio de la Hematología (1993-1995)\nMiembro de la Academia Nacional de Medicina, Miembro del Sistema Nacional de Investigadores, Nivel III\nMiembro de la Academia Mexicana de Ciencias\nPresidente del Consejo (Chair of Council) de la Sociedad Internacional de Hematología (2005-2009)\nPresidente de la Sociedad Internacional de Hematología (2010-2012)\n\nGuillermo José Ruiz Delgado","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":4,"lines":{"from":1,"to":16}}}}],["2",{"pageContent":"Guillermo José Ruiz Delgado\n\nSubdirector del Centro de Hematología y Medicina Interna de Puebla\nConsultor de Hematología de Clínica Ruiz, Laboratorios\nCatedrático de Hematología. Universidad Popular Autónoma del Estado de Puebla\nMiembro de la Agrupación Mexicana para el Estudio de la Hematología\nMiembro del Sistema Nacional de Investigadores, Nivel I\nMiembro de la Sociedad Internacional de Hematología\nMiembro de la Sociedad Americana de Hematología\nMiembro de la Academia Nacional de Medicina\nwww.medicapanamericana.com\nBUENOS AIRES • BOGOTÁ • CARACAS • MADRID • MÉXICO • PORTO ALEGRE\n\n5ª Edición","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":4,"lines":{"from":16,"to":29}}}}],["3",{"pageContent":"Titulo: Fundamentos de Hematología. 5a Ed.\n© 2014 Guillermo José Ruiz Argüelles / Guillermo José Ruiz Delgado\n© 2014 Editorial Médica Panamericana, S.A de C.V.\nLos editores han hecho todos los esfuerzos para localizar a los poseedores del copyright del material fuente utilizado. Si\ninadvertidamente hubieran omitido alguno, con gusto harán los arreglos necesarios en la primera oportunidad que se les presente\npara tal fin.\n\nGracias por comprar el original. Este libro es producto del esfuerzo de profesionales como usted, o de sus profesores, si usted\nes estudiante. Tenga en cuenta que fotocopiarlo es una falta de respeto hacia ellos y un robo de sus derechos intelectuales.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":5,"lines":{"from":1,"to":9}}}}],["4",{"pageContent":"Las ciencias de la salud están en permanente cambio. A medida que las nuevas investigaciones y la experiencia clínica amplían\nnuestro conocimiento, se requieren modificaciones en las modalidades terapéuticas y en los tratamientos farmacológicos. Los\nautores de esta obra han verificado toda la información con fuentes confiables para asegurarse de que ésta sea completa y acorde\ncon los estándares aceptados en el momento de la publicación. Sin embargo, en vista de la posibilidad de un error humano\no de cambios en las ciencias de la salud, ni los autores, ni la editorial o cualquier otra persona implicada en la preparación\no la publicación de este trabajo, garantizan que la totalidad de la información aquí contenida sea exacta o completa y no se\nresponsabilizan por errores u omisiones o por los resultados obtenidos del uso de esta información. Se aconseja a los lectores","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":5,"lines":{"from":11,"to":17}}}}],["5",{"pageContent":"responsabilizan por errores u omisiones o por los resultados obtenidos del uso de esta información. Se aconseja a los lectores\nconfirmarla con otras fuentes. Por ejemplo, y en particular, se recomienda a los lectores revisar el prospecto de cada fármaco que\nplanean administrar para cerciorarse de que la información contenida en este libro sea correcta y que no se hayan producido\ncambios en las dosis sugeridas o en las contraindicaciones para su administración. Esta recomendación cobra especial importancia\ncon relación a fármacos nuevos o de uso infrecuente.\nEste libro representa la experiencia profesional de sus autores, basada en la evidencia científica a la fecha de su publicación, y no\nrefleja necesariamente la opinión de la Editorial o de los laboratorios que tienen la patente de los medicamentos que se mencionan,\npor lo que no se responsabilizan por eventuales errores, omisiones u otros problemas que pudieran presentarse con su uso.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":5,"lines":{"from":17,"to":24}}}}],["6",{"pageContent":"por lo que no se responsabilizan por eventuales errores, omisiones u otros problemas que pudieran presentarse con su uso.\nTodos los derechos reservados. Este libro o cualquiera de sus\npartes no podrán ser reproducidos ni archivados en sistemas\nrecuperables, ni transmitidos en ninguna forma o por ningún\nmedio,\n \nya\n \nsean\n \nmecánicos\n \no\n \nelectrónicos,\n \nfotocopiadoras,\ngrabaciones o cualquier otro, sin el permiso previo de Editorial\nMédica Panamericana, S.A de C.V.\n© 2014 Editorial Médica Panamericana, S.A. de C.V.\nHegel 141, 2\no\n \npiso, Col. Chapultepec Morales, C.P. 11570,\nMéxico, D.F.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":5,"lines":{"from":24,"to":48}}}}],["7",{"pageContent":"Argentina\nEditorial Médica Panamericana S.A.\n\nMarcelo T. de Alvear 2145 (1122), Buenos Aires, Argentina.\nTels.: (54-11) 4821-2066 / 5520/ Fax: (54-11) 4821-1214\ninfo@medicapanamericana.com\n\nEspaña\nEditorial Médica Panamericana S.A.\n\nEdificio Arcis c/ Quintanapalla no 8, 4\n0\n \nB, (28050)\nMadrid, España\nTel.: (34) 91 1317821 / Fax: (34) 91 4570919\ninfo@medicapanamericana.es\n\nColombia\nEditorial Médica Internacional, LTDA\n\nCarrera 7a A No. 69-19, Bogotá, Colombia.\nTel.: (57-1) 345-4508 / 314-5014\nFax: (57-1) 314-5015/ 345-0019\ninfomp@medicapanamericana.com.co\n\nMéxico\nEditorial Médica Panamericana S.A. de C.V.\n\nHegel No. 141, 2\n \no\n. piso, Col. Chapultepec Morales,\nDelegación Miguel Hidalgo, C.P. 11570, México, D.F.\nTels.: (52-55) 5250-0664 / 5203-0176 /\nFax: (52-55) 2624-2827\ninfomp@medicapanamericana.com.mx\n\nVenezuela\nEditorial Médica Panamericana C.A.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":5,"lines":{"from":50,"to":89}}}}],["8",{"pageContent":"Venezuela\nEditorial Médica Panamericana C.A.\n\nEdificio Polar, Torre Oeste, Piso 6, Of. 6-C Plaza Venezuela.\nUrbanización Los Caobos Parroquia El Recreo,\nMunicipio Libertador Caracas D.C., Venezuela.\nTels.: (58-212) 793-2857 / 6906 / 5985 / 1666\nFax: (58-212) 793-5885\ninfo@medicapanamericana.com.ve\nVisite nuestra página Web:\n\nwww.medicapanamericana.com\n\nISBN: 978-607-9356-13-2 versión electrónica","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":5,"lines":{"from":89,"to":102}}}}],["9",{"pageContent":"V\n\nCOLABORADORES\n\nÁlvaro Aguayo\n\nMiembro de la AMEH\nInstituto Nacional de Ciencias Médicas\ny de la Nutrición Dr. Salvador Zubirán\nAcademia Nacional de Medicina\nSistema Nacional de Investigadores\n\nEliakym Arámbula Meraz\n\nLaboratorio de Genética y Biología\nMolecular Facultad de Ciencias\nQuímico-Biológicas,\nUAS\nSistema Nacional de Investigadores\n\nJorge Cuervo Sierra\n\nMiembro de la AMEH\nHospital Universitario, UANL\n\nJosé Luis Delgado Lamas\n\nVocal de Actividades Científicas de la AMEH\n(1993-1995)\nHematólogo Titular de Servicios\nMédicos Especializados, S.C.\nInstructor de Morfología Hemática\nHospital de Especialidades del Centro\nMédico Nacional de Occidente, IMSS\n\nOscar Miguel Garcés Ruiz\n\nMiembro de la AMEH\nPresidente del Colegio Jalisciense\nde Hematología (2012-2013)\nJefe del Servicio de Hematología Clínica\ndel Hospital de Especialidades del Centro\nMédico Nacional de Occidente, IMSS\n\nDavid Gómez Almaguer","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":6,"lines":{"from":1,"to":45}}}}],["10",{"pageContent":"David Gómez Almaguer\n\nPresidente de la AMEH (2009-2011)\nHospital Universitario, UANL\nAcademia Nacional de Medicina\nSistema Nacional de Investigadores\n\nAndrés Gómez de León\n\nHospital Universitario,\nUANL\n\nRenán A. Góngora Biachi\n\nPresidente de la AMEH (2005-2006)\nCentro de Investigaciones Regionales\nHideyo Noguchi, UADY\nSistema Nacional de Invesigadores\n\nPedro González Martínez\n\nMiembro de la AMEH\nCentro de Investigaciones Regionales\nHideyo Noguchi, UADY\n\nGuillermo Gutiérrez Espíndola\n\nMiembro de la AMEH\nHospital de Especialidades del Centro\nMédico Nacional Siglo XXI. IMSS\n\nBertha Ibarra Cortés\n\nMiembro de la AMEH\nInstituto de Genética Humana\nDivisión de Biología Molecular y Genómica\nCentro Universitario en Ciencias de la Salud\nU. de G.\nSistema Nacional de Investigadores\n\nJosé Carlos Jaime Pérez\n\nMiembro de la AMEH\nHospital Universitario, UANL\nSistema Nacional de Investigadores\n\nEucario León Rodríguez","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":6,"lines":{"from":45,"to":91}}}}],["11",{"pageContent":"José Carlos Jaime Pérez\n\nMiembro de la AMEH\nHospital Universitario, UANL\nSistema Nacional de Investigadores\n\nEucario León Rodríguez\n\nMiembro de la AMEH\nInstituto Nacional de Ciencias\nMédicas y de la Nutrición\nDr. Salvador Zubirán\nAcademia Nacional de Medicina\nSistema Nacional de Investigadores\n\nRubén Lisker Y.\n\nPresidente de la AMEH (1965-1967)\nInstituto Nacional de Ciencias Médicas\ny de la Nutrición Dr. Salvador Zubirán\nAcademia Nacional de Medicina\nSistema Nacional de Investigadores\n\nAbel Lomelí Guerrero\n\nVocal de Actividades Sociales de la AMEH\n(1991-1993)\nCentro Estatal de la Transfusión\nSanguínea de Jalisco\n\nXavier López Karpovitch\n\nPresidente de la AMEH (2013-2015)\nInstituto Nacional de Ciencias\nMédicas y de la Nutrición\nDr. Salvador Zubirán\nAcademia Nacional de Medicina","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":6,"lines":{"from":91,"to":127}}}}],["12",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\nVI\n\nCarlos Martínez Murillo\n\nPresidente de la AMEH\n(2011-2013)\nHospital de Especialidades del Centro\nMédico Nacional Siglo XXI. IMSS\nSistema Nacional de Investigadores\n\nAbraham Majluf Cruz\n\nMiembro de la AMEH\nHospital Regional No. 1 Gabriel Mancera.\nIMSS\nAcademia Nacional de Medicina\nSistema Nacional de Investigadores\n\nYvette Neme Yunes\n\nMiembro de la AMEH\nHospital ABC. Hematología/Medicina Interna\n\nRuy Perez Tamayo\n\nUNAM\nHospital General de México\nAcademia Nacional de Medicina\nSistema Nacional de Investigadores\n\nJavier Pizzuto Chávez\n\nSecretario de la AMEH (1969-1970)\nHospital de Especialidades del Centro\nMédico Nacional Siglo XXI. IMSS\nAcademia Nacional de Medicina\n\nSandra Quintana\n\nSecretaria del Comité de Hemostasia\ny Trombosis de la AMEH\nHospital de Especialidades del Centro\nMédico Nacional Siglo XXI. IMSS\n\nJosé Rodríguez Carrillo\n\nMiembro de la AMEH\nHospital de Especialidades.\nCentro Médico de Occidente. IMSS\n\nFernando Romero García","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":7,"lines":{"from":1,"to":53}}}}],["13",{"pageContent":"José Rodríguez Carrillo\n\nMiembro de la AMEH\nHospital de Especialidades.\nCentro Médico de Occidente. IMSS\n\nFernando Romero García\n\nPresidente de la AMEH (1984-1986)\nFacultad de Medicina, UAG\n\nAlejandro Ruiz Argüelles\n\nMiembro de la AMEH\nClínica Ruiz, Laboratorios\nAcademia Nacional de Medicina\nSistema Nacional de Investigadores\n\nGuillermo José Ruiz Argüelles\n\nPresidente de la AMEH (1993-1995)\nPresidente de la Sociedad Internacional\nde Hematología (2010-2012)\nCentro de Hematología\ny Medicina Interna de Puebla\nClínica Ruiz, Laboratorios\nPresidente del Consejo de la Sociedad\nInternacional de Hematología (2005-2009)\nAcademia Nacional de Medicina\nSistema Nacional de Investigadores\n\nGuillermo José Ruiz Delgado\n\nMiembro de la AMEH\nClínica Ruiz, Laboratorios Centro de\nHematología y Medicina Interna de Puebla\nSistema Nacional de Investigadores\nMiembro de la Academia Nacional\nde Medicina\n\nGuillermo Ruiz Reyes","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":7,"lines":{"from":53,"to":93}}}}],["14",{"pageContent":"Miembro de la AMEH\nClínica Ruiz, Laboratorios Centro de\nHematología y Medicina Interna de Puebla\nSistema Nacional de Investigadores\nMiembro de la Academia Nacional\nde Medicina\n\nGuillermo Ruiz Reyes\n\nPresidente de la AMEH (1969-1971)\nClínica Ruiz, Laboratorios\nPresidente de la Sociedad Internacional\nde Hematología (1992-1994)\nAcademia Nacional de Medicina\n\nJosé Salazar Pachicano\n\nMiembro de la AMEH\nFacultad de Medicina, UASLP\n\nEnrique Torre López\n\nMiembro de la AMEH\nFacultad de Medicina, UASLP\n\nMiguel A. Velázquez Ferrari\n\nMiembro de la AMEH\nHospital del Carmen de Guadalajara","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":7,"lines":{"from":93,"to":121}}}}],["15",{"pageContent":"VII","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":8,"lines":{"from":1,"to":1}}}}],["16",{"pageContent":"Una receta que parecería infalible para escribir un buen libro de texto es primero hacer una encuesta\nentre usuarios, o sea entre los estudiantes, basada en la pregunta: “¿Qué espera usted de un libro de\ntexto?”. Pero tal ejercicio sería un fracaso, porque en estos tiempos la mayoría de los estudiantes no\nesperan nada de sus libros de texto, a los que les prestan la menor atención compatible con pasar la\nmateria y de los que se desprenden con gran soltura y elegancia en cuanto lo hacen. Parece que se ha\ncorrido la voz de que la palabra “estudiante” significa “el que estudiaba antes”. Pero este desinterés\nen el estudio y este desamor por los libros de texto no se debe a que los estudiantes de hoy sean es-\npecialmente malévolos y perversos, sino a que los libros de texto actuales son pesados y aburridos.\nNaturalmente que hay excepciones que solo confirman la regla; la gran mayoría de los libros de texto","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":8,"lines":{"from":3,"to":11}}}}],["17",{"pageContent":"pecialmente malévolos y perversos, sino a que los libros de texto actuales son pesados y aburridos.\nNaturalmente que hay excepciones que solo confirman la regla; la gran mayoría de los libros de texto\ncontemporáneos para estudiantes de Medicina (y creo que este juicio es válido para varias otras pro-\nfesiones) son grandes tomos, atiborrados de información, con tipografía antigua y cansada, y casi\nsiempre escritos en un castellano tedioso, cuando no lamentable. “Un buen libro – dice el refrán – es\nel mejor amigo”, pero la verdad es que los estudiantes de hoy están muy lejos de considerar a casi todos\nsus libros de texto como sus mejores amigos; más bien los miran como obstáculos molestos, o hasta\ncomo enemigos mortales. No sorprende que se quieran deshacer de ellos en cuanto han dejado de\nservirles como muletas para pasar la materia. El mejor amigo es el que nos comprende y nos aprecia, el\nque nos apoya y nos ayuda, el que nos enseña y nos divierte, el que se anticipa a nuestras necesidades","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":8,"lines":{"from":11,"to":20}}}}],["18",{"pageContent":"que nos apoya y nos ayuda, el que nos enseña y nos divierte, el que se anticipa a nuestras necesidades\ny favorece nuestros intereses, el que responde cuando preguntamos y calla si no hay interrogantes, el\nque habla solo cuando puede ser mejor que el silencio, el que ignora nuestros defectos y acepta nuestras\ninconsistencias con una sonrisa, el que nos acompaña en la ruta y camina cuando caminamos, corre\ncuando corremos, se detiene cuando descansamos, y se duerme cuando dormimos.\nEste nuevo libro de texto sobre Hematología aspira a ser un buen amigo del estudiante de pre-\ngrado de Medicina. Desea introducirlo en la materia sin apabullarlo con minucias de especialista,\neducarlo en esa rama de la medicina interna contemporánea sin secuestrarlo de todas las otras ramas\nque la conforman, instruirlo en las reglas del juego hematológico tal como se juega hoy, y hacer todo\nlo anterior de manera amigable y sin lágrimas. Los autores de este nuevo libro de texto de Hemato-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":8,"lines":{"from":20,"to":29}}}}],["19",{"pageContent":"que la conforman, instruirlo en las reglas del juego hematológico tal como se juega hoy, y hacer todo\nlo anterior de manera amigable y sin lágrimas. Los autores de este nuevo libro de texto de Hemato-\nlogía están admirablemente capacitados para lograrlo: todos ellos son especialistas en la materia y la\nejercen en forma cotidiana, y también son profesores e investigadores en varias escuelas de Medicina\nde México. Y (nota importante), como buenos médicos, todos ellos siguen siendo estudiantes. A eso\nse debe su estilo informal, su entusiasmo en la materia, su ausencia de dogmatismo y su apertura al\nfuturo. Por eso es que no es un libro de texto tradicional más para estudiantes de Medicina de pre-\ngrado sino la invitación fácil y amable a una aventura maravillosa: el descubrimiento y la comprensión\nde lo que hoy se sabe y se está haciendo en el mundo de la sangre normal y patológica. Los invitados\nson los estudiantes de hoy, que serán los médicos de mañana. Recordando mis tiempos de estudiante","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":8,"lines":{"from":29,"to":38}}}}],["20",{"pageContent":"de lo que hoy se sabe y se está haciendo en el mundo de la sangre normal y patológica. Los invitados\nson los estudiantes de hoy, que serán los médicos de mañana. Recordando mis tiempos de estudiante\n(hace 50 años) y muchos de los libros de texto que me tocó estudiar entonces (desde luego, ninguno\nde Hematología), no puedo hacer otra cosa que envidiar y felicitar a los estudiantes de hoy, por haber\nadquirido este generoso y buen amigo, este nuevo texto de Hematología, que seguramente los acom-\npañará durante toda su vida.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":8,"lines":{"from":38,"to":43}}}}],["21",{"pageContent":"Dr. Ruy Pérez Tamayo\nCiudad de México, 1994\n\nPRESENTACIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":8,"lines":{"from":45,"to":48}}}}],["22",{"pageContent":"IX","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":10,"lines":{"from":1,"to":1}}}}],["23",{"pageContent":"Resulta muy placentero tener la oportunidad de escribir el prólogo a la quinta edición de FUNDA-\nMENTOS DE HEMATOLOGÍA, libro publicado por primera vez hace 20 años, en 1994, durante el\nCongreso Mundial de Hematología celebrado en Cancún, México. Es particularmente grato advertir\nque nuevos autores jóvenes, algunos de ellos hijos y nietos de ilustres hematólogos, ahora aparecen como\nautores de la nueva edición de este libro. La incoporación de “sangre joven” a un libro que trata sobre\n“la sangre” le dará seguramente más trascendencia a la obra y constituye el preámbulo del relevo de las\ngeneraciones de hematólogos quienes vieron nacer esta obra hace 20 años.\nMi agradecimiento a la Agrupación Mexicana para el Estudio de la Hematología y a todos los au-\ntores, pasados y presentes, del libro. Sin la intervención generosa y desinteresada de todos ellos no ha-\nbríamos podido distribuir más de 30 mil ejemplares en todo el mundo, ni habríamos podido llegar a la","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":10,"lines":{"from":3,"to":12}}}}],["24",{"pageContent":"bríamos podido distribuir más de 30 mil ejemplares en todo el mundo, ni habríamos podido llegar a la\nquinta edición enfocada principalmente en los jóvenes estudiantes hispanoparlantes de todas las disci-\nplinas biológicas. Enhorabuena a los autores y a los lectores de este libro.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":10,"lines":{"from":12,"to":14}}}}],["25",{"pageContent":"Dr. Guillermo J. Ruiz Argüelles\nPuebla de los Ángeles, 2014\n\nPRÓLOGO A LA\nQUINTA EDICIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":10,"lines":{"from":16,"to":20}}}}],["26",{"pageContent":"XI\n\nEn la Presentación de la primera edición de\n \nFundamentos de Hematología,\n \nque apareció en 1994,escribí\nque ese nuevo libro aspiraba “\na ser un buen amigo del estudiante de pregrado de Medicina”\n, y en el breve\n\nAddendum\n \nincluido en su cuarta edición, publicada en 2009, celebré que el libro había “\ncumplido con su\naspiración inicial”,\n \no sea que se había convertido en “\nun compañero amable y útil para los estudiosos del arte\nde curar”.\n \nPara esta quinta edición, que aparece en 2014, o sea 20 años después de la primera y apenas\ncuatro años después de la cuarta, me complace constatar que\n \nFundamentos de Hematología\n \nes ya un","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":12,"lines":{"from":1,"to":27}}}}],["27",{"pageContent":"viejo\n \ny buen amigo de los estudiantes de Medicina.\nComo muchos de ellos lo conservan y lo siguen usando en el ejercicio de la profesión, la utilidad\nde este texto rebasa las aulas y se extiende a los consultorios; yo lo he visto en los libreros y en los\nescritorios de varios de mis amigos médicos, y siempre lo tengo a la mano para refrescar mi memoria\ny resolver dudas hematológicas.\nEsta no es una reimpresión del texto de 2009. Los autores han incorporado un caudal de nueva\ninformación en casi cada capítulo, haciendo justicia a los avances registrados en la disciplina, que han\nsido muchos y muy benéficos para los pacientes hematológicos. Esto se refleja en las listas de citas\nbibliográficas, cuidadosamente actualizadas. Felicito a los autores por su excelente actualización de\n\nFundamentos de Hematología,\n \ny a todos los usuarios que se seguirán beneficiando con su estudio.\n\nDr. Ruy Pérez Tamayo\n\nADDENDUM\n \nA LA\nPRESENTACIÓN DE\n\nFUNDAMENTOS DE\nHEMATOLOGÍA\n \nPARA\nLA QUINTA EDICIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":12,"lines":{"from":29,"to":56}}}}],["28",{"pageContent":"XIII\n\nÍNDICE\n\nCOLABORADORES\nPRESENTACIÓN\n\nRuy Pérez Tamayo\n\nPRÓLOGO\nA LA QUINTA EDICIÓN\n\nGuillermo J. Ruiz Argüelles\n\nADDENDUM\nA LA PRESENTACIÓN\nDE FUNDAMENTOS\nDE HEMATOLOGÍA\nPARA LA QUINTA\nEDICIÓN\n\nRuy Pérez Tamayo\n\nABREVIATURAS\n\nPARTE 1\nASPECTOS\nGENERALES\n\n01\n\nHEMATOPOYESIS\n\nXavier López Karpovitch\nIntroducción\nCélula troncal\nhematopoyética\nMicroambiente y nicho\nhematopoyéticos\nCompartimento\npluripotencial\nCompartimento bipotencial\nCompartimento unipotencial\nCompartimento terminal\nRegulación\nCorolario\nConclusiones\nReconocimiento\nPreguntas de autoevaluación\nBibliografía\n\n02\n\nCITOMETRÍA HEMÁTICA\nY SU INTERPRETACIÓN\n\nGuillermo J. Ruiz Argüelles\nGuillermo Ruiz Reyes\nGuillermo J. Ruiz Delgado\nIntroducción\nSerie roja\nSerie blanca\nOtras células en sangre periférica\nSerie trombocítica\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\nPARTE 2\nANEMIAS\n\n03\n\nANEMIA POR DEFICIENCIA\nDE HIERRO","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":14,"lines":{"from":1,"to":75}}}}],["29",{"pageContent":"PARTE 2\nANEMIAS\n\n03\n\nANEMIA POR DEFICIENCIA\nDE HIERRO\n\nJosé Carlos Jaime Pérez\nJorge Cuervo Sierra\nIntroducción\nMetabolismo y regulación\nde la homeostasis del hierro\nEpidemiología\nEtiología de la deficiencia de hierro\nManifestaciones clínicas\nPruebas de laboratorio\nTratamiento\nDeficiencia genética de hierro\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\n04\n\nANEMIAS\nMEGALOBLÁSTICAS\n\nFernando Romero García\nJosé Rodríguez Carrillo\nIntroducción\nIncidencia y etiopatogenia\n\nVII\nIX\nXI\nXIX\n1\n29\n31\n45\n3\n15\n3\n4\n5\n6\n7\n7\n8\n9\n12\n12\n12\n13\n13\n15\n15\n21\n24\n25\n26\n26\n27\n31\n31\n34\n35\n37\n38\n39\n41\n41\n42\n42\n45\n46\nV","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":14,"lines":{"from":75,"to":152}}}}],["30",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\nXIV\n\nCáncer, enfermedad\ntrombótica y enfermedad\nneurodegenerativa\nBioquímica y etiopatogenia\nConsideraciones clínicas\nCuadro hematológico\nOtras causas de anemias\nmegaloblásticas\nAnemia megaloblástica aguda\nDiagnóstico\nMedición de ácido\nmetilmalónico sérico\ny homocisteína total\nExámenes para\ndeterminar la causa\ndel déficit de vitamina B12\nTratamiento\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\n05\n\nANEMIAS HEMOLÍTICAS.\nASPECTOS GENERALES\n\nYvette Neme\nÁlvaro Aguayo\nIntroducción\nClasificación etiopatogénica\nCuadro clínico\nDiagnóstico\nAbordaje diagnóstico\nde las anemias hemolíticas\nTratamiento\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\n06\n\nANEMIAS\nHEMOLÍTICAS\nCAUSADAS\nPOR TRASTORNOS\nDE LA MEMBRANA\nERITROCÍTICA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":15,"lines":{"from":1,"to":51}}}}],["31",{"pageContent":"06\n\nANEMIAS\nHEMOLÍTICAS\nCAUSADAS\nPOR TRASTORNOS\nDE LA MEMBRANA\nERITROCÍTICA\n\nRenán A. Góngora Biachi\nPedro González Martínez\nIntroducción\nCaracterísticas y componentes\nde la membrana eritrocítica\nEstructura del citoesqueleto\nAnemias hemolíticas asociadas\ncon defectos de membrana\neritrocítica\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\n07\n\nHEMOGLOBINOPATÍAS\nY TALASEMIAS\n\nGuillermo Ruiz Reyes\nIntroducción\nComposición y variantes\nnormales de la hemoglobina\nTrastornos hereditarios\nque afectan la estructura\ny la síntesis de la hemoglobina\nHemoglobinopatías\nEl laboratorio en la identificación\nde las anormalidades de\nla hemoglobina\nDrepanocitosis\nHemoglobina S o forma\nheterocigota (portadores o rasgo\ndrepanocítico)\nHemoglobina S homocigota (SS)\no anemia drepanocítica\nCombinaciones de la hemoglobina\nS con otras anormalidades\nde la hemoglobina\nOtras hemoglobinopatías\nmenos frecuentes\nTalasemias\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\n08","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":15,"lines":{"from":51,"to":105}}}}],["32",{"pageContent":"08\n\nANEMIAS HEMOLITÍCAS\nPOR ALTERACIONES\nDE ENZIMAS\nERITROCITARIAS\n\nRubén Lisker Y.\nEliakim Arámbula Meraz\nBertha Ibarra\nIntroducción\nHemólisis asociada a deficiencia\nde enzimas glucolíticas\nHemólisis asociada a deficiencia\nde enzimas de la vía de las pentosas\nHemólisis asociada\na anormalidades eritrocíticas\ndel metabolismo de nucleótidos\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\n67\n99\n115\n77\n48\n48\n51\n55\n56\n56\n56\n59\n60\n62\n63\n63\n64\n67\n67\n69\n71\n72\n72\n72\n73\n74\n99\n99\n100\n100\n104\n104\n105\n106\n107\n108\n108\n112\n112\n112\n115\n116\n119\n123\n124\n124\n125\n77\n77\n79\n80\n95\n95\n95","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":15,"lines":{"from":105,"to":180}}}}],["33",{"pageContent":"ÍNDICE\n\nXV\n\n09\n\nANEMIAS HEMOLÍTICAS\nINMUNITARIAS\n\nAlejandro Ruiz Argüelles\nIntroducción\nAnemia hemolítica\nautoinmunitaria\nAnemia hemolítica\naloinmunitaria\nAnemia hemolítica\ndel recién nacido\nAnemia hemolítica inducida\npor fármacos\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\n10\n\nHIPOPLASIAS Y DISPLASIAS\nMEDULARES\n\nGuillermo J. Ruiz Argüelles\nGuillermo J. Ruiz Delgado\nIntroducción\nAlgunos conceptos\nde la hematopoyesis\nHipoplasias medulares\nDisplasias medulares o síndromes\nmielodisplásicos\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\n11\n\nANEMIAS SECUNDARIAS\nA PADECIMIENTOS\nNO HEMÁTICOS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":16,"lines":{"from":1,"to":45}}}}],["34",{"pageContent":"11\n\nANEMIAS SECUNDARIAS\nA PADECIMIENTOS\nNO HEMÁTICOS\n\nEnrique Torre López\nJosé Salazar Pachicano\nIntroducción\nAnemia de los trastornos\ncrónicos\nAnemias secundarias\na infecciones\nAnemia de la insuficiencia\nrenal crónica\nAnemias en pacientes\ncon trastornos endocrinos\ny metabólicos\nAnemias secundarias a neoplasias\nmalignas no hemáticas\nAnemias secundarias\na alcoholismo crónico y cirrosis\nAnemias secundarias\na inflamaciones crónicas\nAnemia por desnutrición\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\nPARTE 3\nONCOLOGÍA HEMÁTICA\n\n12\n\nLEUCEMIAS AGUDAS\n\nGuillermo J. Ruiz Argüelles\nGuillermo J. Ruiz Delgado\nIntroducción\nEtiología\nClasificación\nCuadro clínico\nDiagnóstico\nTratamiento\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\n13\n\nLEUCEMIAS CRÓNICAS\n\nDavid Gómez Almaguer\nIntroducción\nLeucemia granulocítica crónica\nLeucemia linfocítica crónica\nLeucemia de células peludas\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\n14\n\nNEOPLASIAS\nMIELOPROLIFERATIVAS\nCRÓNICAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":16,"lines":{"from":45,"to":110}}}}],["35",{"pageContent":"14\n\nNEOPLASIAS\nMIELOPROLIFERATIVAS\nCRÓNICAS\n\nLuz Tarín Arzaga\nAndrés Gómez de León\nIntroducción\nMutación JAK2\n \nv617F\nPolicitemia vera\nTrombocitosis esencial\nMielofibrosis primaria\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\n137\n165\n167\n183\n195\n151\n127\n127\n132\n133\n133\n134\n134\n135\n167\n167\n168\n170\n171\n172\n179\n179\n180\n183\n183\n187\n190\n191\n191\n192\n195\n196\n197\n198\n200\n201\n202\n202\n137\n137\n138\n143\n147\n148\n148\n151\n152\n153\n156\n158\n159\n160\n127\n \n161\n162\n162\n162\n163","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":16,"lines":{"from":110,"to":187}}}}],["36",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\nXVI\n\n15\n\nLINFOMAS\n\nEucario León Rodríguez\nKarla Adriana Espinosa Bautista\nIntroducción\nEpidemiología\nEtiología\nDiagnóstico y evaluación\ninicial\nClasificación\nModo de presentación\ny diagnóstico diferencial\nDeterminación de la extensión\nTratamiento\nLinfomas cutáneos\nTrasplante autólogo de células\nprogenitoras hematopoyéticas\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\n16\n\nLINFOMA DE HODGKIN\n\nJosé Luis Delgado Lamas\nÓscar Miguel Garcés Ruiz\nIntroducción\nAnatomía patológica\nCuadro clínico\nDiagnóstico diferencial\nEstudios de laboratorio\nEstudios de gabinete\nEstadios de extensión\ndel linfoma de Hodgkin\nEvaluación clínica\nTratamiento\nTerapia para recaída\no enfermedad refractaria\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\n17\n\nTRASTORNOS\nINMUNOPROLIFERATIVOS\nMALIGNOS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":17,"lines":{"from":1,"to":54}}}}],["37",{"pageContent":"17\n\nTRASTORNOS\nINMUNOPROLIFERATIVOS\nMALIGNOS\n\nGuillermo Ruiz Reyes\nAlejandro Ruiz Argüelles\nIntroducción\nEstructura de\nlas inmunoglobulinas\nConceptos de policlonalidad\ny monoclonalidad\nMieloma múltiple\nMacroglobulinemia\nde Waldenström\nEnfermedades de cadenas\npesadas\nAmiloidosis\nCrioglobulinemia\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\nPARTE 4\nSISTEMA\nDE LA COAGULACIÓN\nY HEMOSTASIA\n\n18\n\nFISIOLOGÍA\nDE LA HEMOSTASIA\n\nAbraham Majluf Cruz\nIntroducción\nDefiniciones\nEl sistema de coagulación\nen condiciones normales\nHemostasia\nFibrinólisis\nMecanismos de regulación\ndel sistema de coagulación\nPruebas de escrutinio\nhemostático\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\n19\n\nTROMBOCITOPENIAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":17,"lines":{"from":54,"to":105}}}}],["38",{"pageContent":"19\n\nTROMBOCITOPENIAS\n\nGuillermo R. Gutiérrez Espíndola\nJavier Pizzuto Chávez\nIntroducción\nTrombocitopenias\npor producción insuficiente\nde plaquetas\nTrombocitopenias por\naumento en la destrucción\nde plaquetas\nTrombocitopenia por distribución\ny almacenamiento inadecuados\nde plaquetas\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\n223\n255\n257\n277\n239\n205\n205\n205\n207\n207\n209\n211\n212\n216\n218\n220\n220\n221\n257\n257\n258\n258\n267\n268\n270\n273\n274\n274\n277\n277\n282\n295\n297\n298\n299\n223\n224\n224\n227\n227\n227\n228\n228\n230\n233\n234\n234\n235\n239\n239\n241\n205\n \n242\n248\n248\n251\n251\n252\n252\n252","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":17,"lines":{"from":105,"to":185}}}}],["39",{"pageContent":"ÍNDICE\n\nXVII\n\n20\n\nCOAGULOPATÍAS\nHEREDITARIAS\n\nCarlos Martínez Murillo\nSandra Quintana González\nIntroducción\nClasificación\nHemofilia A y B\nDiagnóstico\nTratamiento\nComplicaciones\nOtros defectos hereditarios raros\nde la coagulación\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\n21\n\nTROMBOFILIA\n\nGuillermo J. Ruiz Argüelles,\nGuillermo J. Ruiz Delgado\nIntroducción\nTrombosis arterial\nTrombosis venosa\nCaracterísticas generales\nde la trombofilia\nEstados de trombofilia primaria\no hereditaria\nEstados de trombofilia secundaria\nEvaluación de pacientes con riesgo\ntrombótico alto\nProfilaxis y tratamiento\nde los trastornos trombóticos\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\nPARTE 5\nASPECTOS\nTERAPÉUTICOS\n\n22\n\nTERAPÉUTICA\nTRANSFUSIONAL\n\nAbel Lomelí Guerrero\nMiguel Velázquez Ferrari\nIntroducción\nSangre total\nConcentrado eritrocitario\nPlasma","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":18,"lines":{"from":1,"to":60}}}}],["40",{"pageContent":"PARTE 5\nASPECTOS\nTERAPÉUTICOS\n\n22\n\nTERAPÉUTICA\nTRANSFUSIONAL\n\nAbel Lomelí Guerrero\nMiguel Velázquez Ferrari\nIntroducción\nSangre total\nConcentrado eritrocitario\nPlasma\n\n303\n327\n \n361\n369\n379\n339\n341\n303\n303\n304\n311\n315\n320\n322\n323\n324\n324\n327\n327\n327\n328\n331\n329\n332\n332\n334\n334\n335\n341\n341\n342\n342\n361\n361\n362\n363\n363\n364\n364\n364\n365\n365\n366\n366\n\nPlasma fresco congelado\nConcentrado de factor IX\nCrioprecipitado y concentrado\nde factor VIII\nTransfusión de plaquetas\nTransfusión de granulocitos\nTransfusión de albúmina\nGeneralidades de la aféresis\nEfectos adversos\nde las transfusiones\nLeucorreducción\nAlternativas de la transfusión\nde sangre homóloga\nHemovigilancia\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\n23\n\nTRASPLANTE\nDE CÉLULAS\nHEMATOPOYÉTICAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":18,"lines":{"from":60,"to":144}}}}],["41",{"pageContent":"23\n\nTRASPLANTE\nDE CÉLULAS\nHEMATOPOYÉTICAS\n\nGuillermo J. Ruiz Argüelles\nGuillermo J. Ruiz Delgado\nDavid Gómez Almaguer\nIntroducción\nFuentes de células\nhematopoyéticas totipotenciales\nAUTO-TCH\nALO-TCH\nIndicaciones de los trasplantes\nde células hematopoyéticas\nEtapas del trasplante\nEsquemas de acondicionamiento\nResultados\nComplicaciones\nConclusiones\nPreguntas de autoevaluación\nBibliografía\n\nGLOSARIO\nÍNDICE ANALÍTICO\n\n343\n343\n343\n344\n345\n346\n346\n347\n355\n356\n356\n357\n358\n358","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":18,"lines":{"from":144,"to":184}}}}],["42",{"pageContent":"XIX\n\nABREVIATURAS\n\nα\n\nβ\nγ\nε\nζ\nδ\n\n2-3-DPG\nA\nABVD\nACD\nAcMo\nADA\nADP\nAg\nAgsHB\nAHAL\nAHAU\nAHCNE\nAlfa-2-AP\nAML1/ETO\nAMP\nAPSAC\nAPUC\nATC\nAT-III\naTP\nATP\nATRA\nAZT\nBACOP\nBCNU\nCCNU\nBCR/ABL\nBHK\nBL\nC\nC5b-9\nCAPD\n\nA\nB\nC","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":20,"lines":{"from":1,"to":48}}}}],["43",{"pageContent":"A\nB\nC\n\nalfa\nbeta\ngamma\népsilon\nzeta\ndelta\n2,3-difosfoglicerato\nAldolasa\nAdriamicina, bleomicina, vinblastina y dacarbacina\nSolución anticoagulante compuesta por adenina, citrato y dextrosa\nAnticuerpos monoclonales\nAdenosina desaminasa\nDifosfato de adenosina\nAntígenos\nAntígeno de superficie del virus de la hepatitis B\nAnemia hemolítica aloinmunitaria\nAnemia hemolítica autoinmunitaria\nAnemia hemolítica crónica no esferocítica\nAlfa-2-antiplasmina\nGen quimérico\nMonofosfato de adenosina\nComplejo activador de plasminógeno/estreptocinasa\nActivador del plasminógeno tipo UC\nAnemia de trastornos crónicos\nAntitrombina III\nActivador tisular del plasminógeno\nTrifosfato de adenosina\nÁcido holotransrretinoico\nZidovudina\nBleomicina, adriamicina, ciclofosfamida, vincristina y prednisona\nBis-cloroetil nitrosurea\nCis-cloroetil nitrosurea\nGen quimérico (\nBreakpoint cluster region\n/Abelson)\n\nGen baby hamster kidney\n\nBlastos\nComplemento\nFracción citolítica del complemento","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":20,"lines":{"from":48,"to":92}}}}],["44",{"pageContent":"Gen baby hamster kidney\n\nBlastos\nComplemento\nFracción citolítica del complemento\n\nChronic ambulatory peritoneal dialysis\n/diálisis peritoneal\nambulatoria crónica","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":20,"lines":{"from":92,"to":100}}}}],["45",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\nXX\n\nCAPM\nCB\nCBPM\nCCP\nCCR\nCD\nCD14\nCD41\nCD42\nCD42a\nCD42b\nCD61\nCID\nCLFB\n12\nCM\nCmHb\nC-MOPP\nCMV\nCOX\nCoII-Hep\nCOMLA\nCOP-BLAM III\nCP\nCPD S\nCPDA-1\nCTH\nCVP, COP\nCV-VGM\nCyA\nCH\nCHO\nCHOP\nDAF / CD55\nDDAVP\nDDT\nDHL\nDL\nDNA\nDPA\ndTT / TdT\nEC\nECOG\nEH\nEL-H\nELISA\nEN\n\nCininógeno de alto peso molecular\nCuenta blanca\nCininógeno de bajo peso molecular\nConcentrados de complejo protrombínico\nCuenta corregida de reticulocitos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":21,"lines":{"from":1,"to":57}}}}],["46",{"pageContent":"Cluster designation\n \n(designación de grupo)\nProteína fijadora de endotoxinas\nGlucoproteína IIb/IIIa\nGlucoproteína Ib/IX\nGlucoproteína IX\nGlucoproteína Ib\nGlucoproteína IIIa\nCoagulación intravascular diseminada\nCapacidad libre de fijación de vitamina B12\nCelularidad mixta\nConcentración media de hemoglobina\nCiclofosfamida, vincristina, procarbacina y prednisona\nCitomegalovirus\nCiclooxigenasa\nCofactor II de la heparina\nCiclofosfamida, vincristina, metotrexato, leucovorina y ara-C\nCiclofosfamida, oncovin (vincristina), prednisona,\nbleomicina, adriamicina y procarbazina\nCuenta de plaquetas\nSolución anticoagulante compuesta por citrato,\nfosfato y dextrosa\nSolución anticoagulante compuesta por citrato, fosfato,\ndextrosay adenina\nCélula totipotencial hematopoyética (\nstem cell\n)\nCiclofosfamida, vincristina y prednisona\nCoeficiente de variación del VGM\nCiclosporina A\nCitometría hemática\n\nGen Chinese hamster ovary\n\nCiclofosfamida, adriamicina, vincristina y prednisona","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":21,"lines":{"from":59,"to":94}}}}],["47",{"pageContent":"Gen Chinese hamster ovary\n\nCiclofosfamida, adriamicina, vincristina y prednisona\n\nDecay-accelerating factor\n \n/ Factor acelerador de degradación\nDesmopresina (1-desamino-8-d-arginina-vasopresina)\nDicloro-difenil-tricloroetano\nDeshidrogenasa láctica\nÁcido desoxirribonucleico\nDisminución linfocítica\nDexametasona, ara-C, cisplatino\nTransferasa de desoxinucleótidos terminales\nEstudio clínico\nEastern Cooperative Oncology Group\nEsferocitosis hereditaria\nEliptocitosis hereditaria\nInmunoanálisis enzimático de fase sólida\nEsclerosis nodular\n\nD\nE","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":21,"lines":{"from":94,"to":116}}}}],["48",{"pageContent":"ABREVIATURAS\n\nXXI\n\nEo\nEORTC\nEP\nEPI\nEPO\nEPOrHu\nEvW\nF-a\nFAB\nFAL\nFAP\nFc\nFEC/CSF\nFH4\nFI\nFIGLU\nFIX\nFIX:C\nFLC\nFNT/TNF\nFP4\nFPA\nFPB\nFT\nFVIII:C\nFvW\nFvW:Ag\nFvW:RiCof\nFX:C\nG\nGAT\nGB\nGELA\nGEMM\nG-CSF/FEC-G\nGM-CSF/FEC-GM\nGG\nGla\nGlu\nGM\nGP\nGPI\nGPIb/IX\nGPIIb / IIIa\nGR\nGSH","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":22,"lines":{"from":1,"to":50}}}}],["49",{"pageContent":"Eosinófilos\nEuropean Organization for Research and Treatment\nof Cancer\nEstudio patológico\nInhibidor de la vía extrínseca\nEritropoyetina\nEritropoyetina recombinante humana\nEnfermedad de von Willebrand\nFactor hemostático activado\n»e French-American-British Cooperative Group\nFosfatasa alcalina de linfocitos\nFactor activador de plaquetas\nFracción cristalizable\nFactor estimulante de colonias\nÁcido tetrahidrofólico\nFactor intrínseco\nÁcido formiminoglutámico\nFactor IX\nFactor IX de la coagulación\nFosfolipasa C\nFactor de necrosis tumoral\nFactor plaquetario 4\nFibrinopéptido A\nFibrinopéptido B\nTromboplastina tisular\nFactor VIII de la coagulación\nFactor de von Willebrand\nAntígeno del factor VIII de von Willebrand\nCofactor de ristocetina del factor\nde von Willebrand\nFactor X de la coagulación\nGranulocitos\nGlobulina antitimocito\nGlóbulos blancos\nGrupo de Investigación en Linfomas del Adulto\nGranulocitos-eritrocitos-monocitos-megacariocitos\nFactor estimulante de colonias de granulocitos\nFactor estimulante de colonias de granulocitos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":22,"lines":{"from":52,"to":89}}}}],["50",{"pageContent":"Grupo de Investigación en Linfomas del Adulto\nGranulocitos-eritrocitos-monocitos-megacariocitos\nFactor estimulante de colonias de granulocitos\nFactor estimulante de colonias de granulocitos\ny monocitos\nGranular grande\nResiduos de ácido\n \nγ\n-carboxiglutámico\nÁcido glutámico\nGranulocitos-monocitos\nGlucoproteínas\nGlucosilfosfatidilinositol\nReceptor plaquetario para colágeno\nReceptor de membrana para fibrinógeno\nGlóbulos rojos\nGlutamilcistenilglicina","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":22,"lines":{"from":89,"to":106}}}}],["51",{"pageContent":"F\nG","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":22,"lines":{"from":108,"to":109}}}}],["52",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\nXXII\n\nH\nH\n \n2\n \nO\n2\nHb\nHB\nHBPM\nHC\nHCII\nHCM\nHCO\n3\nHtc\nHELLP\nHEMPAS\nHLA\nHLA-DR\nHPA\nHPN\nHPT\nHRF\nHRGP\nHTLV-I\nHTLV-II\nIaTP-1\nICE\nIFN\nIgGIV\nIL\nILSG\nINC / NCI\nINR\nIPCa/TP3\nIPI\nIRC\nISI\nIVFT\nK\nKi\nKM\nL\nL1\nL2\nL3\nLA\n\nHeavy\n \n(cadena pesada)\nPeróxido de hidrógeno\nHemoglobina\nHepatitis B\nHeparinas de bajo peso molecular\nHexocinasas\nCofactor II de la heparina\nHemoglobina corpuscular media\nBicarbonato\nHematocrito\nHemólisis, enzimas hepáticas elevadas, cuenta baja de plaquetas\nAnemia eritroblástica congénita tipo II\nAntígeno leucocitario humano\nAntígeno leucocitario relacionado a D\nAntígenos plaquetarios humanos\nHemoglobinuria paroxística nocturna\nHepatitis postransfusión","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":23,"lines":{"from":1,"to":72}}}}],["53",{"pageContent":"Homologous restriction factor\n \n(factor de restricción homólogo)\nGlucoproteína rica en histidina\nVirus T-linfotrópico humano de tipo I\nVirus T-linfotrópico humano de tipo II\nInhibidor del aTP tipo 1\nEnzima convertidora de interleucina 1 beta\nInterferón\nInmunoglobulina G intravenosa\nInterleucina\nGrupo Internacional de Estudio de Linfomas\nInstituto Nacional del Cáncer\n\nInternational normalized ratio\n \n(cociente estandarizado\ninternacional)\nInhibidor de la proteína C activada\nÍndice pronóstico internacional\nInsuficiencia renal crónica\nÍndice de sensibilidad internacional\nInhibidor de la vía del factor tisular\n\nKoagullerung\n \n(coagulación)\n\nKinase insert\n \n(inserto de cinasa)\nConstante de Michaelis\n\nLight\n \n(cadena ligera)\nLinfoblástica “típica”\nLinfoblástica “atípica”\nParecida al linfoma de Burkitt\nLeucemia aguda\n\nH\nI\nK\nL","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":23,"lines":{"from":74,"to":118}}}}],["54",{"pageContent":"ABREVIATURAS\n\nXXIII\n\nLAL / ALL\nLAL-B\nLAL-T\nLAM / AML\nLB\nLCPNH\nLCR\nLDCG\nLDCPH\nLDLP\nLDM\nLEG\nLFCG\nLFM\nLGC\nLGG\nLI\nLis\nLK\nLM\nLNH / NHL\nLT\nLL\nM\nM0\nM1\nM2\nM3\nM4\nM4Eo\nM5\nM6\nM7\nMACOP-B\nMALT\nm-BACOD\nMeg\nMF\nMIC\nMIH\nMIRL/CD59\nMLL\nMMA\nMO\nMOPP\nMPOc\nMRC\nMTHFR\nMTX\nMYC","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":24,"lines":{"from":1,"to":54}}}}],["55",{"pageContent":"Leucemia aguda linfoblástica\nLeucemia aguda linfoblástica B\nLeucemia aguda linfoblástica T\nLeucemia aguda mieloblástica\nLinfocitos B\nLinfoma de células pequeñas no hendidas\nLíquido cefalorraquídeo\nLinfoma difuso de células grandes\nLinfoma folicular mixto\nLinfoma de linfocitos pequeños\nLinfoma difuso mixto\nLupus eritematoso generalizado\nLinfoma folicular de células grandes\nLinfoma difuso de células pequeñas hendidas\nLeucemia granulocítica crónica\nLinfocito granular grande\nLinfoma inmunoblástico\nLisina\nFactor hemolinfopoyético-1/de mastocitos/de células estaminales\n(ligando c-kit)\nLinfoide-mieloide\nLinfoma no Hodgkin\nLinfocitos T\nLinfoma linfoblástico\nMonocitos\nMieloblástica diferenciada mínimamente\nMieloblástica inmadura\nMieloblástica madura\nPromielocítica hipergranular\nMielomonoblástica\nMielomonoblástica con eosinofilia\nMonoblástica pura\nEritroleucemia\nMegacarioblástica\nMetotrexato, adriamicina, ciclofosfamida, vincristina,\nprednisona, bleomicina\nTejido linfoide asociado a mucosa","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":24,"lines":{"from":56,"to":92}}}}],["56",{"pageContent":"Mielomonoblástica con eosinofilia\nMonoblástica pura\nEritroleucemia\nMegacarioblástica\nMetotrexato, adriamicina, ciclofosfamida, vincristina,\nprednisona, bleomicina\nTejido linfoide asociado a mucosa\nMetotrexato, bleomicina, adriamicina, ciclofosfamida,\nvincristina y dexametasona\nMegacariocitos\nMielofibrosis primaria\nMorfológica, inmunológica y citogenética\nMicroambiente inductivo hematopoyético","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":24,"lines":{"from":92,"to":104}}}}],["57",{"pageContent":"Membrane inhibitor of reactive lysis\n \n(inhibidor de membrana de lisis reactivo)\n\nMixed lineage leukemia\n \n(leucemia de linaje mezclado)\nMetaplasia mieloide agnogénica\nMédula ósea\nMostaza nitrogenada, vincristina, prednisona y procarbazina\nMieloperoxidasa citoplásmática\nMaterial de reacción cruzada\nReductasa del metilentetrahidrofolato\nMetotrexato\n\nMyelocytomatosis virus\n \n(virus de la mielocitomatosis)\n\nM","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":24,"lines":{"from":106,"to":125}}}}],["58",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\nXXIV\n\nN\n2\n \nO\nNADPH\nNK\nO\n2\nOMS/WHO\np\nPAI\nPAN\nPC\nPC/PS\nPCa\nPCC\nPCD\nPCR\nPDf\nPDF\nPDGF\nPET\nPFC\npg\nPGC\nPGI\n2\nPh1/CrPh1\nPIG-A\nPir 5 ́-N\nPK\nPL\nPLT\nPML/RAR-\nα\n\nPO\n2\nPPH\nPPZ\nPro-MACE-CytaBOM\nProMACE-MOPP\nPT\nPTI\nPTT\nPUC\nPV\nq\nQt\n\nÓxido nitroso\nNicotinamida-adenina-dinucleótido-fosfato\nCélulas asesinas naturales\nPeróxido de oxígeno\nOrganización Mundial de la Salud (World Health Organization)\nBrazo corto cromosómico\nInhibidor del activador del plasminógeno\nPéptido activador de neutrófilos\nPiruvatocinasa\nSistema proteína C/proteína S\nProteína C activada\nProteincinasa\nPentoxifilina, ciprofloxacina, dexametasona","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":25,"lines":{"from":1,"to":67}}}}],["59",{"pageContent":"Polymerase chain reaction\n \n(reacción en cadena de la polimerasa)\nProductos de la degradación de la fibrina\nProductos de la degradación del fibrinógeno\nFactor de crecimiento derivado de las plaquetas\nTomografía por emisión de positrones\nFosfofructocinasa\nPicogramos\nFosfogliceratocinasa\nProstaciclina\nCromosoma Filadelfia\nFosfatidil-inositol-glucano-A\nPirimidina-5 ’-nucleotidasa\nPrecalicreína\nPredominio linfocítico\nPlaquetas\n\nPromyelocytic leukemia/retinoid acid receptor alpha\n \n(Gen quimérico)\nPresión parcial de oxígeno\nPiropoiquilocitosis hereditaria\nProtoporfirina/cinc\nProcarbazina, metotrexato, adriamicina, ciclofosfamida,\netopósido, citarabina, bleomicina y vincristina\nEtopósido, ciclofosfamida, adriamicina, metotrexato, predinsona\ny leucovorina\nPúrpura trombocitopénica\nPúrpura trombocitopénica inmunitaria\nPúrpura trombocitopénica trombótica\nProurocinasa\nPolicitemia vera\nBrazo largo cromosómico\nQuimioterapia\n\nN\nO\nP\nQ","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":25,"lines":{"from":69,"to":108}}}}],["60",{"pageContent":"ABREVIATURAS\n\nXXV\n\nQtDA\nRAS\nRCT\nRDW\nREAL\nRFLP\nRh\nRHNM\nRM\nRNA\nRPCa\nRt\nSAF\nSALT\nscu-PA\nSG\nSIDA\nSIRPA\nSK\nSLE\nSMM\nSMP\nSNC\nSP\nSS\nSPP\nST\nSTI-571\nSUH\nSVE\nt\nTAC/TC\nTACHT\nTANM\nTC\nTCH\nTE\nTGF\nβ\n\nTGF-\nα\n\nTH\nTm\nTMO\nTNF-\nα\n\nTP\nt-PA\n\nQuimioterapia en dosis altas\nOncogén del virus del sarcoma murino\nRadioterapia corporal total\n\nRed cell distribution width\n \n(ancho de distribución eritrocitaria)\nRevised European-American Lymphoma Classification\nAnálisis de polimorfismo de fragmentos de restricción\nFactor Rh (Rhesus)\nRegistro Histopatológico de Neoplasias en México\nResonancia magnética\nÁcido ribonucleico\nResistencia a la proteína C activada\nRadioterapia\nSíndrome de anticuerpos antifosfolípido","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":26,"lines":{"from":1,"to":72}}}}],["61",{"pageContent":"Skin-associated lymphoid tissue\n \n(tejido linfoide asociado a piel)\nActivador del plasminógeno tipo UC de cadena única\nSupervivencia global\nSíndrome de inmunodeficiencia adquirida\nSíndrome de insuficiencia respiratoria del paciente adulto\nEstreptocinasa\nSupervivencia libre de enfermedad\nSíndrome mieloproliferativo maligno\nSíndromes mieloproliferativos\nSistema nervioso central\nSangre periférica\nSíndrome de Sézary\nSíndrome de plaquetas “pegajosas”\nSintetasa de tromboxanos\nMesilato de imatinib\nSíndrome urémico hemolítico\nSupervivencia eritrocítica\nTranslocación\nTomografía axial computarizada\nTrasplante autólogo de células hematopoyéticas totipotenciales\nTrasplante alogénico no mieloablativo\nTranscobalamina\nTrasplante de células hematopoyéticas\nTrombocitemia esencial/trombocitosis primaria\nFactor de transformación de crecimiento beta\nFactor de transformación de crecimiento alfa\nTiempo de hemorragia o de sangrado\nTrombomodulina\nTrasplante de médula ósea\nFactor de necrosis tumoral alfa\nTiempo de protrombina","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":26,"lines":{"from":74,"to":106}}}}],["62",{"pageContent":"Factor de transformación de crecimiento alfa\nTiempo de hemorragia o de sangrado\nTrombomodulina\nTrasplante de médula ósea\nFactor de necrosis tumoral alfa\nTiempo de protrombina\nActivador del plasminógeno tipo tisular","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":26,"lines":{"from":106,"to":112}}}}],["63",{"pageContent":"R\nS\nT","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":26,"lines":{"from":114,"to":116}}}}],["64",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\nXXVI\n\nTPI\nTPO\nTTPa\nTS\nTT\nTxA\n \n2\nUC\nUFB/BFU\nUFC/CFU\nUK\nu-PA\nVAD\nVE\nVEB\nVGM\nVHB/HBV\nVHC/HCV\nVIH\nVP\nVPM\nWF\n\nIsomerasa del fosfato de triosa\nTrombopoyetina\nTiempo de tromboplastina parcial activada\nTiempo de sangrado\nTiempo de trombina\nTromboxano A\n \n2\nUrocinasa\nUnidad formadora de brotes eritroides\nUnidad formadora de colonias\nUrocinasa\nActivador del plasminógeno tipo urocinasa\nVincristina, doxorrubicina, dexametasona\nVolumen eritrocítico\nVirus de Epstein-Barr\nVolumen globular medio\nVirus de la hepatitis B\nVirus de la hepatitis C\nVirus de la inmunodeficiencia humana\nVolumen plasmático\nVolumen plaquetario medio\n\nWorking formulation\n\nU\nV\nW","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":27,"lines":{"from":1,"to":56}}}}],["65",{"pageContent":"01\n\nHematopoyesis\n\n02\n\nCitometría\n \nH\nemáti\nC\na y su interpreta\nC\nión\n\n3\n15\n\nPARTE 1\nAspectos generales","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":28,"lines":{"from":1,"to":20}}}}],["66",{"pageContent":"3\n\nObjetivos de aprendizaje\n\n•\n \n\u0003)'*,\u001f(\u001e\u001f, \u001f& .ï,'#()\n \nhematopoyesis\n.\n\n•\n \n\u0004#-.#(!/#, &)- \u001d)'*\u001b,.#'\u001f(.)- *&/,#*).\u001f(\u001d#\u001b&6 \u001c#*).\u001f(\u001d#\u001b&6 /(#*).\u001f(\u001d#\u001b& 3 .\u001f,'#(\u001b& \u001e\u001f& -#-.\u001f'\u001b\n\"\u001f'\u001b.)*)3ï.#\u001d)8\n•\n \n\u0003)'*,\u001f(\u001e\u001f, &\u001b- \u001e#0\u001f,-\u001b- \u001b\u001d\u001d#)(\u001f- *,)\u001e/\u001d#\u001e\u001b- *), &)- \u001b\u001d.),\u001f- \u001e\u001f \u001d,\u001f\u001d#'#\u001f(.) 3 &\u001b- #(.\u001f,&\u001f/\u001d#(\u001b-8\n\nINTRODUCCIÓN\n\n\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e#\u001b,#\u001b \u001e\u001f \u001f,#.,)\u001d#.)-6 *&\u001b+/\u001f.\u001b- 3 !,\u001b(/&)\u001d#.)- \u001f( \u001f& \u001b\u001e/&.) (),'\u001b& \u001f- \u001e\u001f \u001b*,)2#\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":30,"lines":{"from":1,"to":23}}}}],["67",{"pageContent":"'\u001b\u001e\u001b'\u001f(.\u001f i  gf\n9\n6 h6k  gf\n9\n \n3 g  gf\n9\n \n*), %#&)!,\u001b') \u001e\u001f *\u001f-) \u001d),*),\u001b&6 ,\u001f-*\u001f\u001d.#0\u001b'\u001f(.\u001f8 \u0005-.\u001f\n(#0\u001f& \u001e\u001f *,)\u001e/\u001d\u001d#ĉ( -\u001f \u001b$/-.\u001b \u001b &\u001b- (\u001f\u001d\u001f-#\u001e\u001b\u001e\u001f- \u001e\u001f& #(\u001e#0#\u001e/) 3 */\u001f\u001e\u001f 0\u001b,#\u001b, \u001e\u001f-\u001e\u001f \u001d\u001b-# \u001d\u001f,) \"\u001b-.\u001b\n'/\u001d\"\u001b- 0\u001f\u001d\u001f- &) (),'\u001b&8\n \n\u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b B\n \n\u000fC -\u001f \u001f(\u001d\u001b,!\u001b .\u001b'\u001c#ï( \u001e\u001f &\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f ')()\u001d#.)-\n3 '\u001b\u001d,ĉ \u001b!)-6 \u001b-ù \u001d)') \u001e\u001f &#( )\u001d#.)- 3 \u001dï&/&\u001b- *&\u001b-'á.#\u001d\u001b-8 \u0005& *\u001f-) \u001b*,)2#'\u001b\u001e) \u001e\u001f &\u001b\n \n\u000f \u001f( \u001f&\n\u001b\u001e/&.)6 \u001d\u001b&\u001d/&\u001b\u001e) \u001f( \u001f-./\u001e#)- \u001e\u001f (\u001f\u001d,)*-#\u001b6 \u001f- \u001e\u001f i6j \u001b k6oz \u001e\u001f& *\u001f-) \u001d),*),\u001b& .).\u001b&8 \u0003)( \u001f& \u001f'*&\u001f)\n\u001e\u001f \u001d)&)#\u001e\u001f- ,\u001b\u001e#)\u001b\u001d.#0)- -\u001f \"\u001b \u001f-.#'\u001b\u001e) +/\u001f \u001f& *\u001f-) \u001b*,)2#'\u001b\u001e) \u001e\u001f &\u001b\n \n\u000f \"\u001f'\u001b.)*)3ï.#\u001d\u001b'\u001f(.\u001f\n\u001b\u001d.#0\u001b \u001f( \u001f& \u001b\u001e/&.) \u001f- \u001e\u001f g fff ! 3 +/\u001f \u001f-.\u001f -\u001f \u001e#-.,#\u001c/3\u001f \u001f( *\u001f&0#- BijzC6 0ï,.\u001f\u001c,\u001b- BhnzC6 \u001d,á(\u001f)\n3 '\u001b(\u001eù\u001c/&\u001b BgizC6 \u001f-.\u001f,(ĉ( 3 \u001d)-.#&&\u001b- BgfzC6 \"Ě'\u001f,)-6 \u001f-\u001dá*/&\u001b- 3 \u001d&\u001b0ù\u001d/&\u001b- BnzC 3 \u001f(\n \nï'/,\u001f-\nBjzC8\n \n\u001b\n \nhematopoyesis\n \n)\n \nhemopoyesis\n \n-\u001f */\u001f\u001e\u001f \u001e\u001fl·(#, \u001d)') &\u001b -\u001f,#\u001f \u001e\u001f \u001f(ĉ'\u001f()- \u001d)(\u001d\u001b.\u001f(\u001b\u001e)- +/\u001f\n\u001d)'#\u001f(4\u001b( \u001b (#0\u001f& \u001e\u001f &\u001b \u001dï&/&\u001b .,)(\u001d\u001b& \"\u001f'\u001b.)*)3ï.#\u001d\u001b B\u0003\u0014\bC \u001d)( &\u001b \u001b/.),,\u001f()0\u001b\u001d#ĉ(6 -\u001f!/#\u001e)- \u001e\u001f","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":30,"lines":{"from":25,"to":62}}}}],["68",{"pageContent":"ï'/,\u001f-\nBjzC8\n \n\u001b\n \nhematopoyesis\n \n)\n \nhemopoyesis\n \n-\u001f */\u001f\u001e\u001f \u001e\u001fl·(#, \u001d)') &\u001b -\u001f,#\u001f \u001e\u001f \u001f(ĉ'\u001f()- \u001d)(\u001d\u001b.\u001f(\u001b\u001e)- +/\u001f\n\u001d)'#\u001f(4\u001b( \u001b (#0\u001f& \u001e\u001f &\u001b \u001dï&/&\u001b .,)(\u001d\u001b& \"\u001f'\u001b.)*)3ï.#\u001d\u001b B\u0003\u0014\bC \u001d)( &\u001b \u001b/.),,\u001f()0\u001b\u001d#ĉ(6 -\u001f!/#\u001e)- \u001e\u001f\n&\u001b \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( 3 '\u001b\u001e/,\u001b\u001d#ĉ(6 \u001d/&'#(\u001b(\u001e) \u001d)( &\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f \u001f&\u001f'\u001f(.)-\n \n),'\u001f- -\u001b(!/ù(\u001f)-\n/(\u001d#)(\u001b&\u001f-8 \u0013\u001f \u001d)(-#\u001e\u001f,\u001b\n \ndiferenciación\n \n\u001d)') &\u001b -\u001f\u001d/\u001f(\u001d#\u001b \u001e\u001f \"\u001f\u001d\")- !\u001f(ï.#\u001d)- +/\u001f *\u001f,'#.\u001f( \u001b\n/(\u001b \u001dï&/&\u001b -#(.\u001f.#4\u001b, *,)\u001e/\u001d.)- \u001f-*\u001f\u001dùl·\u001d)-6 &)- \u001d/\u001b&\u001f- &\u001f \u001d)(l·\u001f,\u001f( *).\u001f(\u001d#\u001b&#\u001e\u001b\u001e *\u001b,\u001b \u001e\u001f.\u001f,'#(\u001b\u001e\u001b\n/(\u001d#ĉ(8\n \n\u001b\n \nmaduración\n \n\u001f- &\u001b -\u001f\u001d/\u001f(\u001d#\u001b \u001e\u001f\n \n\u001f(ĉ'\u001f()- \u001c#)+/ù'#\u001d)- 3 '), )&ĉ!#\u001d)- #(#\u001d#\u001b\u001e)- *), &\u001b\n\u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( 3 +/\u001f \u001d)(l·\u001f,\u001f( \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e\n \n/(\u001d#)(\u001b& \u001b &\u001b \u001dï&/&\u001b8 \u0015.#&#4\u001b(\u001e) &\u001b -\u001f,#\u001f \u001f,#.,)#\u001e\u001f \u001d)')\n\u001f$\u001f'*&)6 &\u001b \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( *)\u001e,ù\u001b \u001d)(\u001d\u001f\u001c#,-\u001f \u001d)') &\u001b \u001b\u001d.#0\u001b\u001d#ĉ( \u001e\u001f &)- !\u001f(\u001f- \u001f-*\u001f\u001dùl·\u001d)- \u001e\u001f &\u001b- !&)\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":30,"lines":{"from":62,"to":97}}}}],["69",{"pageContent":"\u001c#(\u001b- \u001f( \u001f& á\u001d#\u001e) \u001e\u001f-)2#,,#\u001c)(/\u001d&\u001f#\u001d) B\u0004\u000e\u0001C (/\u001d&\u001f\u001b,6 '#\u001f(.,\u001b- +/\u001f &\u001b '\u001b\u001e/,\u001b\u001d#ĉ( \u001d)'\u001f(4\u001b,ù\u001b \u001d)(\n&\u001b .,\u001b(-\u001d,#*\u001d#ĉ( \u001e\u001f& \u001dĉ\u001e#!) \u001b& á\u001d#\u001e) ,#\u001c)(/\u001d&\u001f#\u001d) '\u001f(-\u001b$\u001f,) B'\u0012\u000e\u0001C6 \u001d)(\u001d&/3\u001f(\u001e) \u001d)( &\u001b -ù(.\u001f-#-\n\u001e\u001f \u001d\u001b\u001e\u001f(\u001b- !&)\u001cù(#\u001d\u001b- \u001f #(\u001d),*),\u001b\u001d#ĉ( \u001e\u001f& !,/*) \"\u001f') \u001b (#0\u001f& \u001d#.)*&\u001b-'á.#\u001d)8 \u0019\u001b +/\u001f &\u001b '\u001b3),ù\u001b \u001e\u001f\n&)- \u001f&\u001f'\u001f(.)-\n \n),'\u001f- -\u001b(!/ù(\u001f)- .#\u001f(\u001f( -/*\u001f,0#0\u001f(\u001d#\u001b- ,\u001f&\u001b.#0\u001b'\u001f(.\u001f \u001d),.\u001b-6 &\u001b- \u0003\u0014\b -)( ,\u001f\n-\n\n+/\u001f,#\u001e\u001b- \u001b &) &\u001b,!) \u001e\u001f &\u001b 0#\u001e\u001b *\u001b,\u001b -/-.#./#, \u001b \u001b+/\u001f&&\u001b- +/\u001f -\u001f \u001e# \u001f,\u001f(\u001d#\u001b,)( 3 '\u001b\u001e/,\u001b,)( \u001b &#(\u001b$\u001f-\n\u001d\u001f&/&\u001b,\u001f- \u001f-*\u001f\u001dùl·\u001d)-8\n\u0005( \u001f-.\u001f \u001d\u001b*ù./&) -\u001f *,\u001f-\u001f(.\u001b #( ),'\u001b\u001d#ĉ( \u001f( ,\u001f&\u001b\u001d#ĉ( \u001d)( &\u001b- \u0003\u0014\b6 \u001f& '#\u001d,)\u001b'\u001c#\u001f(.\u001f #(\u001e/\u001d.#\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":30,"lines":{"from":99,"to":110}}}}],["70",{"pageContent":"0) \"\u001f'\u001b.)*)3ï.#\u001d) B\n \n\bC 3 \u001f& (#\u001d\") \"\u001f'\u001b.)*)3ï.#\u001d)6 \u001b-ù \u001d)') \u001e\u001f &)- '\u001f\u001d\u001b(#-')- #(0)&/\u001d,\u001b\u001e)- \u001f(\n&\u001b ,\u001f!/&\u001b\u001d#ĉ( \u001e\u001f &\u001b \"\u001f'\u001b.)*)3\u001f-#-8 \u0005- *\u001f,.#(\u001f(.\u001f '\u001f(\u001d#)(\u001b, +/\u001f \u001f& \u001b0\u001b(\u001d\u001f \u001d)!()-\u001d#.#0) \u001f( \u001f-.\u001b á,\u001f\u001b\n\u001e\u001f &\u001b \u001c#)&)!ù\u001b -\u001f \u001e\u001f,#0\u001b \u001f( !,\u001b( *\u001b,.\u001f \u001e\u001f \u001f-./\u001e#)- \u001f( \u001b(#'\u001b&\u001f-6 \u001f( *\u001b,.#\u001d/&\u001b, \u001f( ,)\u001f\u001e),\u001f-6 3 \u001b&!/()- \u001e\u001f\n\u001f-.)- \"\u001b&&\u001b4!)- -\u001f \"\u001b( \u001d)(l·,'\u001b\u001e) \u001f( \u001f& \"/'\u001b() \u001b .,\u001b0ï- \u001e\u001f& /-) .\u001f,\u001b*ï/.#\u001d) \u001e\u001f& .,\u001b-*&\u001b(.\u001f \u001e\u001f \u001dï&/&\u001b-\n\"\u001f'\u001b.)*)3ï.#\u001d\u001b- 3 '\u001f\u001e#\u001b(.\u001f \u001f(-\u001b3)- #( 0#.,) \u001d)()\u001d#\u001e)- \u001d)')\n \nunidades formadoras de colonias\n \nB\u0015\u0006\u0003C8\n\nCAPÍTULO 1\n\nXavier López Karpovitch\nLa\n \n\"\u001f'\u001b.)*)3\u001f-#-\n \no\n \nhemo-\n\n*)3\u001f-#-\n \nse puede definir como\nla serie de fenómenos concate -\nnados que comienzan a nivel\nunicelular con la autodupli-\ncación y maduración, culmi-\nnando con la producción de\nelementos formes sanguíneos\nfuncionales.\n\nHEMATOPOYESIS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":30,"lines":{"from":112,"to":146}}}}],["71",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n4\n\nCÉLULA TRONCAL HEMATOPOYÉTICA\n\n\u001b \u001f'\u001c,#)&)!ù\u001b ()- \"\u001b \u001f(-\u001fĄ\u001b\u001e) +/\u001f &\u001b -\u001b(!,\u001f -\u001f ),#!#(\u001b \u001f( \u001f& .\u001f$#\u001e) '\u001f-)\u001eï,'#\u001d) 3 &)- \u001f-./\u001e#)- '), )&ĉ!#\u001d)-\n\"\u001b( -/!\u001f,#\u001e)6 \u001e\u001f .#\u001f'*) \u001b.,á-6 +/\u001f \u001f& \"\u001f'\u001b(!#)\u001c&\u001b-.) \u001f- *,\u001f\u001d/,-), \u001d)'Ě( \u001e\u001f &)- &#(\u001b$\u001f- \u001f(\u001e).\u001f&#\u001b& 3 \"\u001f'\u001b.)*)\n-\n\n3ï.#\u001d)8 \u0005( \u001f'\u001c,#)(\u001f- \u001e\u001f '\u001b'ù \u001f,)- -\u001f *\u001f(-ĉ6 ),#!#(\u001b&'\u001f(.\u001f6 +/\u001f &\u001b- \u0003\u0014\b \u001b\u001e+/#,ù\u001b( -/ *).\u001f(\u001d#\u001b&#\u001e\u001b\u001e \u001c#)&ĉ!#\u001d\u001b\n\u001f( &\u001b- #-&\u001b- -\u001b(!/ù(\u001f\u001b- \u001e\u001f& -\u001b\u001d) 0#.\u001f&#() *\u001b,\u001b \u001e\u001f-*/ï- '#!,\u001b, 3 \u001d)&)(#4\u001b, \u001f& \"ù!\u001b\u001e) \u001f.\u001b& 3 \u001b-\u001f(.\u001b,-\u001f \u001b& l·(\u001b& \u001e\u001f\n&\u001b !\u001f-.\u001b\u001d#ĉ( \u001f( -/ -#.#) \u001e\u001fl·(#.#0)6 &\u001b\n \n\u000f8 \u0013#( \u001f'\u001c\u001b,!)6 \u001d/\u001b(\u001e) -\u001f \u001f-./\u001e#\u001b( \u001f'\u001c,#)(\u001f- \"/'\u001b()- -\u001f )\u001c-\u001f,0\u001b\n+/\u001f \u001f(.,\u001f &\u001b \u001d/\u001b,.\u001b 3 -\u001f2.\u001b -\u001f'\u001b(\u001b \u001e\u001f-*/ï- \u001e\u001f &\u001b \u001d)(\u001d\u001f*\u001d#ĉ( -\u001f #\u001e\u001f(.#l·\u001d\u001b( \u001d)&)(#\u001b- \u001e\u001f \u001c&\u001b-.)- B\u001dï&/&\u001b- +/\u001f \u001f(\n\u001d/&.#0) */\u001f\u001e\u001f( \u001e# \u001f,\u001f(\u001d#\u001b,-\u001f \u001f( \u001dï&/&\u001b- \"\u001f'\u001b.)*)3ï.#\u001d\u001b-6 \u001f(\u001e).\u001f&#\u001b&\u001f- 3 \u001e\u001f 'Ě-\u001d/&) &#-)C6 *,#'\u001f,) \u001f( &\u001b ,\u001f!#ĉ(\n\u001b),.\u001b7!ĉ(\u001b\u001e\u001b7'\u001f-)(\u001f ,)- B\u0001\u0007\n \nC 3 *)\u001d) \u001e\u001f-*/ï- \u001f( \u001f& -\u001b\u001d) 0#.\u001f&#()\n \n(fig. 1-1)\n8\n \n\u001b ,\u001f!#ĉ( \u0001\u0007\n \n\u001f- .\u001f$#\u001e) \u001f'\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":31,"lines":{"from":1,"to":28}}}}],["72",{"pageContent":"\u001c,#)(\u001b,#) ),'\u001b\u001e) \u001b *\u001b,.#, \u001e\u001f &\u001b \u001f-*&\u001b\u001d()*&\u001f/,\u001b *\u001b,\u001bĉ,.#\u001d\u001b \u001d)(-.#./ù\u001e\u001b *), &\u001b \u001b),.\u001b \u001e),-\u001b& 3 \u001f& *&#\u001f!/\u001f /,)!\u001f(#.\u001b&8\n\u001b- *,)*#\u001f\u001e\u001b\u001e\u001f- +/\u001f \u001e\u001fl·(\u001f( \u001b &\u001b \u0003\u0014\b -)( -/ \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e \u001e\u001f \u001b/.),,\u001f()0\u001b\u001d#ĉ(6 &\u001b \u001d/\u001b& ,\u001f-/&.\u001b \u001f( *,)!\u001f(#\u001f-\n\u001d)( &\u001b- '#-'\u001b- \u001d\u001b,\u001b\u001d.\u001f,ù-.#\u001d\u001b-6 3 &\u001b \u001e\u001f \u001e\u001b, ),#!\u001f( \u001b .)\u001e)- &)- \u001f&\u001f'\u001f(.)- ),'\u001f- -\u001b(!/ù(\u001f)-6 +/\u001f #(\u001d&/3\u001f( &)-\n\u001e\u001f &\u001b -\u001f,#\u001f '#\u001f&)#\u001e\u001f6 \u001d)') &)- \u001f,#.,)\u001d#.)-6 !,\u001b(/&)\u001d#.)- B(\u001f/.,ĉl·&)-6 \u001f)-#(ĉl·&)- 3 \u001c\u001b-ĉl·&)-C6 '\u001b-.)\u001d#.)-6 ')\n-\n\n()\u001d#.)-I'\u001b\u001d,ĉ \u001b!)- 3 *&\u001b+/\u001f.\u001b-6 \u001b-ù \u001d)') &)- &#( )\u001d#.)- \u0014 3 \u0002 3 &\u001b- \u001dï&/&\u001b- *&\u001b-'á.#\u001d\u001b-8 \u0005( \u001d/&.#0)6 \u001f'*&\u001f\u001b(\n-\n\n\u001e) \u001dï&/&\u001b- \"/'\u001b(\u001b- \u001e\u001f \u001d),\u001eĉ( /'\u001c#&#\u001d\u001b&6 -\u001f \"\u001b \u001f-.\u001b\u001c&\u001f\u001d#\u001e) +/\u001f \u001f& .#\u001f'*) \u001e\u001f \u001b/.),,\u001f()0\u001b\u001d#ĉ( \u001e\u001f &\u001b \u0003\u0014\b \u001f- \u001e\u001f\n\u001b*,)2#'\u001b\u001e\u001b'\u001f(.\u001f lk \"),\u001b-6 +/\u001f *)-\u001f\u001f /( -)&) (Ě\u001d&\u001f)6 -/ \u001b*\u001b,#\u001f(\u001d#\u001b \u001f- ,\u001f ,\u001b\u001d.#0\u001b \u001d)( \u001d#.)*&\u001b-'\u001b .,\u001b(-&Ě\u001d#\u001e)\n3 +/\u001f .#\u001f(\u001f \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e '#!,\u001b.),#\u001b8 \u0005( &\u001b \u001b\u001d./\u001b&#\u001e\u001b\u001e -\u001f ,\u001f\u001d)()\u001d\u001f( \u001e)- .#*)- \u001e\u001f \u0003\u0014\b9 &\u001b 'á- *,#'#.#0\u001b6 +/\u001f\n\u001d\u001b,\u001f\u001d\u001f \u001e\u001f &)- \u001b(.ù!\u001f()- \u0003\u0004ij 3 \u0003\u0004in6 \u001b-ù \u001d)') \u001e\u001f &)- \u001b(.ù!\u001f()- \u001e\u001f \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( \u001b-)\u001d#\u001b\u001e)- \u001b &#(\u001b$\u001f !,\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":31,"lines":{"from":30,"to":43}}}}],["73",{"pageContent":"(/&)\u001dù.#\u001d)6 ')()\u001dù.#\u001d)6 '\u001f!\u001b\u001d\u001b,#)\u001dù.#\u001d) 3 &#( )#\u001e\u001f \u0014 3 \u0002 B\n \n#(\n–\nC 3 \u001f2*,\u001f-\u001b \u001f& ,\u001f\u001d\u001f*.), \u001d7%#. ) \u001b(.ù!\u001f() \u0003\u0004ggm\nB\u0003\u0004ij\n–\n6 \u0003\u0004in\n–\n6\n \n#(\n–\n6 \u0003\u0004ggm\n+\nC6 3 ).,\u001b \u001d)( \u001f& #('/() \u001f().#*) B\u0003\u0004ij\n+\n6 \u0003\u0004in\nI@\n \n6\n \n#(\n–\n6 \u0003\u0004ggm\n+\nC8\n\u001b\n \nautorrenovación\n \n\u001f- /(\u001b \u001e#0#-#ĉ( \u001d\u001f&/&\u001b, \u001f-*\u001f\u001d#\u001b&#4\u001b\u001e\u001b \u001f( &\u001b +/\u001f /(\u001b ) \u001b'\u001c\u001b- \u001dï&/&\u001b- \"#$\u001b- ,\u001f.#\u001f(\u001f( \u001f&\n'#-') *).\u001f(\u001d#\u001b& \u001c#)&ĉ!#\u001d) \u001e\u001f &\u001b \u001dï&/&\u001b ),#!#(\u001b&8\n \n\u001b '\u001b3),ù\u001b \u001e\u001f &\u001b- \u0003\u0014\b \u001f( &\u001b\n \n\u000f *\u001f,'\u001b(\u001f\u001d\u001f( \u001f( \u001f-.\u001b\u001e)\n+/#\u001f-\u001d\u001f(.\u001f B \u001b-\u001f \u0007f \u001e\u001f& \u001d#\u001d&) \u001d\u001f&/&\u001b,C6 \u001d)(-\u001f,0\u001b(\u001e) \u001b-ù -/ \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e \u001e\u001f \u001b/.),,\u001f()0\u001b\u001d#ĉ(8\n \n\u001b- \u0003\u0014\b \u001f(.,\u001b(\n\u001b \u001d#\u001d&) \u001d\u001f&/&\u001b, /(\u001b 0\u001f4 \u001b& '\u001f- \u001f( *,)'\u001f\u001e#)8 \u0005& .\u001b'\u001bĄ) \u001e\u001f &\u001b *)4\u001b \u001e\u001f \u0003\u0014\b \u001f- ,\u001f!/&\u001b\u001e) *), \u001f& \u001f+/#&#\u001c,#)\n\u001f(.,\u001f \u001b/.),,\u001f()0\u001b\u001d#ĉ( 3 \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( 3 *), &\u001b- \u001e#0#-#)(\u001f- \u001d\u001f&/&\u001b,\u001f- -#'ï.,#\u001d\u001b- B\u001f2*\u001b(-#ĉ( \u001e\u001f &\u001b \u0003\u0014\bC 3\n\u001b-#'ï.,#\u001d\u001b- B'\u001b(.\u001f(#'#\u001f(.) \u001e\u001f &\u001b \u0003\u0014\bC6 \u001b-ù \u001d)') *), &\u001b \u001b*)*.)-#- B'/\u001f,.\u001f \u001d\u001f&/&\u001b, *,)!,\u001b'\u001b\u001e\u001bC8 \u0001\u001e\u001f'á-6\n-\u001f \"\u001b *,)*/\u001f-.) +/\u001f \u001f& \u001f-.,ï- l·-#)&ĉ!#\u001d) \u001f- ,\u001f&\u001f0\u001b(.\u001f \u001f( &\u001b 0#\u001e\u001b 3 '/\u001f,.\u001f \u001e\u001f &\u001b- \u0003\u0014\b8 \u0010), \u001f$\u001f'*&)6 &\u001b- \u0003\u0014\b\n.#*) \u0003\u0004ij\n+\n6 \u0003\u0004in\n \nI@\n \n6\n \n#(\n–\n6 \u0003\u0004ggm\n+","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":31,"lines":{"from":45,"to":100}}}}],["74",{"pageContent":"-\u001f \"\u001b *,)*/\u001f-.) +/\u001f \u001f& \u001f-.,ï- l·-#)&ĉ!#\u001d) \u001f- ,\u001f&\u001f0\u001b(.\u001f \u001f( &\u001b 0#\u001e\u001b 3 '/\u001f,.\u001f \u001e\u001f &\u001b- \u0003\u0014\b8 \u0010), \u001f$\u001f'*&)6 &\u001b- \u0003\u0014\b\n.#*) \u0003\u0004ij\n+\n6 \u0003\u0004in\n \nI@\n \n6\n \n#(\n–\n6 \u0003\u0004ggm\n+\n6 \u001b& -\u001f, #(\u001d/\u001c\u001b\u001e\u001b- \u001d)( \u001d)(\u001d\u001f(.,\u001b\u001d#)(\u001f- \u001c\u001b$\u001b- \u001e\u001f \u001d#.)\u001d#(\u001b- B-\u001fĄ\u001b&#4\u001b\u001d#ĉ(","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":31,"lines":{"from":100,"to":113}}}}],["75",{"pageContent":"Figura 1-1.\n \n\u0013#.#)- !\u001f(\u001f,\u001b\u001e),\u001f- \u001e\u001f \u0003\u0014\b \u001f( \u001f& \u001f'\u001c,#ĉ(8\n \n\u001b- *,#'\u001f,\u001b- \u0003\u0014\b -\u001f !\u001f(\u001f,\u001b( \u001f( &\u001b \u001b),.\u001b \u001e\u001f(.,) \u001e\u001f &\u001b\n,\u001f!#ĉ( \u001d)()\u001d#\u001e\u001b \u001d)') \u0001\u0007\n \nB\u001b),.\u001b7!ĉ(\u001b\u001e\u001b7'\u001f-)(\u001f ,)-C6 *\u001b,\u001b \u001e\u001f-*/ï- '#!,\u001b, \u001b& -\u001b\u001d) 0#.\u001f&#()6 \u001d),\u001eĉ( /'\u001c#&#\u001d\u001b&6\n\"ù!\u001b\u001e) 3 *&\u001b\u001d\u001f(.\u001b8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":31,"lines":{"from":115,"to":123}}}}],["76",{"pageContent":"CAPÍTULO 1. HEMATOPOYESIS\n\n5\n\n\u001b.\u001f(/\u001b\u001e\u001bC6 -/ ,\u001f( \u001b*)*.)-#- #('\u001f\u001e#\u001b.\u001b6 '#\u001f(.,\u001b- +/\u001f &\u001b- \u0003\u0014\b 'á- *,#'#.#0\u001b- B\u0003\u0004ij\n–\n6 \u0003\u0004in\n–\n6\n \n#(\n–\n6\n\u0003\u0004ggm\n+\nC -)\u001c,\u001f0#0\u001f( \u001f( \u001f-.\u001b\u001e) +/#\u001f-\u001d\u001f(.\u001f8\n\nMICROAMBIENTE Y NICHO HEMATOPOYÉTICOS\n\n\u0005&\n \nmicroambiente hematopoyético\n \nB\n \n\bC6 .ï,'#() \u001b\u001d/Ą\u001b\u001e) *), \u0003/,,3 3 \u0014,\u001f(.#( \u001f( golm6 -\u001f \u001e\u001fl·(\u001f \u001cá-#\u001d\u001b'\u001f(.\u001f\n*), -/ /(\u001d#ĉ( \u001d)') /( \u001d)'*&\u001f$) \"\u001f.\u001f,)!ï(\u001f) \u001e\u001f \u001dï&/&\u001b- 3 \u001e\u001f -/- ,\u001f-*\u001f\u001d.#0)- *,)\u001e/\u001d.)-6 (\u001f\u001d\u001f-\u001b,#)- *\u001b,\u001b '\u001b(\n-\n\n.\u001f(\u001f, 3 ,\u001f!/&\u001b, \u001f& \u001d,\u001f\u001d#'#\u001f(.) \u001e\u001f &\u001b \u0003\u0014\b8 \u0005-.\u001f \u001d)'*&\u001f$) /(\u001d#)(\u001b& \u001f-.á \u001d)(-.#./#\u001e) *), /(\u001b '\u001b.,#4 \u001d\u001f&/&\u001b, 3\n/(\u001b \u001f2.,\u001b\u001d\u001f&/&\u001b,\n \n(cuadro 1-1)\n8\n \n\u001b- *,/\u001f\u001c\u001b- \u001f2*\u001f,#'\u001f(.\u001b&\u001f- -/!#\u001f,\u001f( +/\u001f \u001f&\n \n\b #(-.,/3\u001f \u001b &\u001b \u0003\u0014\b *\u001b,\u001b +/\u001f\n\u001f-.\u001b -\u001f \u001e# \u001f,\u001f(\u001d#\u001f \"\u001b\u001d#\u001b /(\u001b &ù(\u001f\u001b \u001d\u001f&/&\u001b, \u001e\u001f.\u001f,'#(\u001b\u001e\u001b8 \u0013\u001f \"\u001b( *,)*/\u001f-.) \u001e)- \"#*ĉ.\u001f-#- \u001b\u001d\u001f,\u001d\u001b \u001e\u001f &\u001b /(\u001d#ĉ( \u001e\u001f&\n\b \u001f( &\u001b ,\u001f!/&\u001b\u001d#ĉ( \"\u001f'\u001b.)*)3ï.#\u001d\u001b8\n \n\u001b *,#'\u001f,\u001b \u001b-/'\u001f +/\u001f \u001f&\n \n\b &#\u001c\u001f,\u001b -/-.\u001b(\u001d#\u001b- \u001d\u001b*\u001b\u001d\u001f- \u001e\u001f #(\u001e/\u001d#, \u001f2\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":32,"lines":{"from":1,"to":45}}}}],["77",{"pageContent":"*,\u001f-#ĉ( \u001e\u001f !\u001f(\u001f- \u001e\u001f \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( \u001f( &\u001b \u0003\u0014\b8\n \n\u001b -\u001f!/(\u001e\u001b \"#*ĉ.\u001f-#- -)-.#\u001f(\u001f +/\u001f &\u001b \u0003\u0014\b */\u001f\u001e\u001f \u001e# \u001f,\u001f(\u001d#\u001b,-\u001f\n\u001e\u001f '\u001b(\u001f,\u001b \u001f-.)\u001dá-.#\u001d\u001b ) \u001b& \u001b4\u001b, 3 +/\u001f \u001f&\n \n\b Ě(#\u001d\u001b'\u001f(.\u001f \u001f- ,\u001f-*)(-\u001b\u001c&\u001f \u001e\u001f &\u001b -\u001f&\u001f\u001d\u001d#ĉ( \u001e\u001f& &#(\u001b$\u001f \u001d\u001f&/&\u001b,8\n\u001b- \u001dï&/&\u001b- \u001f(\u001e).\u001f&#\u001b&\u001f- -\u001f /\u001c#\u001d\u001b( \u001f( &\u001b -/*\u001f,l·\u001d#\u001f #(.\u001f,(\u001b \u001e\u001f& -#(/-)#\u001e\u001f \u001e\u001f &\u001b\n \n\u000f: \u001d)(.,)&\u001b( &\u001b \u001f(\n-\n\n.,\u001b\u001e\u001b \u001e\u001f -/-.\u001b(\u001d#\u001b- +/ù'#\u001d\u001b- 3 *\u001b,.ù\u001d/&\u001b- 3 \u001f2*,\u001f-\u001b( ,\u001f\u001d\u001f*.),\u001f- *\u001b,\u001b \u001b\u001d.), \u001e\u001f 0)( \u0017#&&\u001f\u001c,\u001b(\u001e6 \u001d)&á!\u001f(\u001b\n.#*)\n \n\u0016 3 &\u001b'#(#(\u001b8 \u0010), *)-\u001f\u001f, ')&ï\u001d/&\u001b- \u001e\u001f \u001b\u001e\"\u001f-#ĉ(6 \u001f( *\u001b,.#\u001d/&\u001b,\n \n\u0003\u0001\n \n7i6 ,\u001f),!\u001b(#4\u001b( -/ \u001d#.)\u001f-\n-\n\n+/\u001f&\u001f.) ,\u001f!/&\u001b(\u001e) \u001b-ù \u001f& .,ál·\u001d) \u001d\u001f&/&\u001b,8\n\u0005& \u001d#.)*&\u001b-'\u001b \u001e\u001f &\u001b- \u001dï&/&\u001b- ,\u001f.#\u001d/&\u001b,\u001f- \u001b\u001e0\u001f(.#\u001d#\u001b- \u001f(0/\u001f&0\u001f &\u001b *\u001b,\u001f\u001e \u001f2.\u001f,(\u001b \u001e\u001f& -#(/-)#\u001e\u001f ),'\u001b(\u001e) /(\u001b\n0\u001b#(\u001b8 \u0005-.\u001b- -#(.\u001f.#4\u001b( l·\u001c,\u001b- ,\u001f.#\u001d/&\u001b,\u001f- B\u001b,!\u001f(.) ù&#\u001d\u001b-C \u001f( \u001e)(\u001e\u001f \u001e\u001f-\u001d\u001b(-\u001b( &\u001b- \u001dï&/&\u001b- \"\u001f'\u001b.)*)3ï.#\u001d\u001b-8\n)- \u001b\u001e#*)\u001d#.)- .#\u001f(\u001f( -/ ),#!\u001f(6 '\u001f\u001e#\u001b(.\u001f &#*)!ï(\u001f-#-6 \u001b *\u001b,.#, \u001e\u001f &)- l·\u001c,)\u001c&\u001b-.)-8 \u0013)(\n \n/\u001f(.\u001f \u001e\u001f \u001b\u001e#\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":32,"lines":{"from":47,"to":74}}}}],["78",{"pageContent":"*)(\u001f\u001d.#(\u001b6 -/-.\u001b(\u001d#\u001b +/\u001f #(\"#\u001c\u001f &\u001b \u001b*)*.)-#- \u001e\u001f &\u001b \u001dï&/&\u001b \u001f(\u001e).\u001f&#\u001b&6 \u001b-ù \u001d)') \u001e\u001f &\u001f*.#(\u001b 3 )-.\u001f)\u001d\u001b&\u001d#(\u001b6 +/\u001f\n*,)'/\u001f0\u001f( &\u001b !,\u001b(/&)*)3\u001f-#- 3 )-.\u001f)!ï(\u001f-#- \u001f #(\"#\u001c\u001f( &\u001b &#( )*)3\u001f-#-8\n\u001b- \u001dï&/&\u001b- \u001f-.,)'\u001b&\u001f- -)( &\u001b- ()\u001e,#4\u001b- \u001e\u001f &\u001b- \u001dï&/&\u001b- \"\u001f'\u001b.)*)3ï.#\u001d\u001b-8 \u00052*,\u001f-\u001b( \u001f& ,\u001f\u001d\u001f*.), *\u001b,\u001b \u001f&\n\u001b\u001d.), \u001e\u001f \u001d,\u001f\u001d#'#\u001f(.) (\u001f/,\u001b&6 *)-\u001f\u001f( \u0016\u0003\u0001\n \n7g B\u001e\u001f\n \nvascular cell adhesion protein 1\nC6 .\u001f(\u001b-\u001d#(\u001b6 \u001f(\u001e)!&#(\u001b 3\n\u001d)&á!\u001f(\u001b .#*)-\n \n\u0016 3 \u0016 8 \u0005$\u001f\u001d/.\u001b( #(.\u001f,\u001b\u001d\u001d#)(\u001f- \u001d\u001f&/&\u001b,\u001f- #(\"#\u001c#\u001f(\u001e) &\u001b \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( '#\u001f&)#\u001e\u001f 3 \u001f-.#'/\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":32,"lines":{"from":76,"to":88}}}}],["79",{"pageContent":"&\u001b(\u001e) &\u001b -\u001f\u001d,\u001f\u001d#ĉ( \u001e\u001f )-.\u001f)*)(.#(\u001b6 +/\u001f \u001b\u001d.#0\u001b \u001b &\u001b- \u001dï&/&\u001b- \u00148\n)- )-.\u001f)\u001c&\u001b-.)- -\u001f\u001d,\u001f.\u001b( \u001b\u001d.),\u001f- \u001f-.#'/&\u001b(.\u001f- \u001e\u001f \u001d)&)(#\u001b- \u001e\u001f !,\u001b(/&)\u001d#.)-6 '\u001b\u001d,ĉ \u001b!)-6 !,\u001b(/&)\u001d#.)-\n3 ')()\u001d#.)- \u001f #(.\u001f,&\u001f/\u001d#(\u001b- B\n \nC g 3 l6 \u001b-ù \u001d)') \u001b\u001d.),\u001f- #(\"#\u001c#\u001e),\u001f- \u001e\u001f &\u001b \"\u001f'\u001b.)*)3\u001f-#-8\n\u0005( gomn6 \u0013\u001d\")l·\u001f&\u001e *,)*/-) \u001f& \u001d)(\u001d\u001f*.) \u001e\u001f\n \nnicho hematopoyético\n \n*\u001b,\u001b \u001e\u001f-\u001d,#\u001c#, \u001f& '#\u001d,)\u001b'\u001c#\u001f(.\u001f \u001f( \u001f&\n+/\u001f ,\u001f-#\u001e\u001f &\u001b \u0003\u0014\b8 \u0013\u001f *)\u001e,ù\u001b \u001e\u001f\u001d#, +/\u001f \u001f& \u001d)(\u001d\u001f*.) \u001e\u001f\n \n\b \u001f- *,#(\u001d#*\u001b&'\u001f(.\u001f l·-#)&ĉ!#\u001d)6 \u001f( .\u001b(.) +/\u001f\n\u001f& \u001e\u001f (#\u001d\") \"\u001f'\u001b.)*)3ï.#\u001d) #(\u001d&/3\u001f6 \u001b\u001e\u001f'á-6 \u001d)(\u001d\u001f*.)- \u001b(\u001b.ĉ'#\u001d)-8\n \n\u001b *,\u001f-\u001f(\u001d#\u001b \u001e\u001f\n \n\u000f \u001e\u001f(.,) \u001e\u001f &\u001b-\n\u001d\u001b0#\u001e\u001b\u001e\u001f- ĉ-\u001f\u001b- -/!#\u001f,\u001f /(\u001b #(.\u001f,\u001e\u001f*\u001f(\u001e\u001f(\u001d#\u001b \u001f(.,\u001f \u001b'\u001c)- .\u001f$#\u001e)-8\n\u001b\n \n\u000f \u001d)(-#-.\u001f \u001e\u001f /(\u001b *),\u001d#ĉ( \"\u001f'\u001b.)*)3ï.#\u001d\u001b ,)\u001e\u001f\u001b\u001e\u001b \u001e\u001f \u001dï&/&\u001b- '\u001f-\u001f(+/#'\u001b.)-\u001b-8\n \n\u001b- \u001dï&/&\u001b- .,)(\n-\n\n\u001d\u001b&\u001f- '\u001f-\u001f(+/#'\u001b.)-\u001b- \u001e\u001b( ),#!\u001f( \u001b &)- '#)\u001d#.)- B'Ě-\u001d/&)C6 \u001b\u001e#*)\u001d#.)- B!,\u001b-\u001bC6 l·\u001c,)\u001c&\u001b-.)- B.\u001f$#\u001e) \u001d)(\u001f\u001d\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":32,"lines":{"from":90,"to":117}}}}],["80",{"pageContent":"\u001d\u001b&\u001f- '\u001f-\u001f(+/#'\u001b.)-\u001b- \u001e\u001b( ),#!\u001f( \u001b &)- '#)\u001d#.)- B'Ě-\u001d/&)C6 \u001b\u001e#*)\u001d#.)- B!,\u001b-\u001bC6 l·\u001c,)\u001c&\u001b-.)- B.\u001f$#\u001e) \u001d)(\u001f\u001d\n-\n\n.#0)C6 \u001dï&/&\u001b- \u001f(\u001e).\u001f&#\u001b&\u001f- B0\u001b-)- -\u001b(!/ù(\u001f)-C 3 )-.\u001f)\u001c&\u001b-.)- B\"/\u001f-)C8 \u0005& \u001f(\u001e)-.#) 3\u001b\u001d\u001f \u001f(.,\u001f \u001f& \"/\u001f-) 3 \u001f&\n-#-.\u001f'\u001b \"\u001f'\u001b.)*)3ï.#\u001d)6 -#.#) #\u001eĉ(\u001f) \u001f( \u001e)(\u001e\u001f &\u001b- \u0003\u0014\b ,\u001f\u001b&#4\u001b( -/- \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e\u001f- l·-#)&ĉ!#\u001d\u001b-9 \u001b(#\u001e\u001b'#\u001f(.)6\n'\u001b(.\u001f(#'#\u001f(.) \u001b &\u001b,!) *&\u001b4) B+/#\u001f-\u001d\u001f(\u001d#\u001b 3 \u001b/.),,\u001f()0\u001b\u001d#ĉ(C6 \u001d)'*,)'#-) \u001e\u001f &#(\u001b$\u001f 3 ')0#&#4\u001b\u001d#ĉ(\n \n(fig.1-2)\n.\n\nCuadro 1-1.\n \nMicroambiente inductivo hematopoyético (MIH)\n\nMatriz celular\n \nMatriz extracelular\n\n\u0001\u001e#*)\u001d#.)-\n \n\u0001\u001e#*)(\u001f\u001d.#(\u001b\n\u0003ï&/&\u001b- \u001f(\u001e).\u001f&#\u001b&\u001f-\n \n\u0003)&á!\u001f(\u001b\n\u0003ï&/&\u001b- \u001f-.,)'\u001b&\u001f-\n \n\u0006#\u001c,)(\u001f\u001d.#(\u001b\n\u0003ï&/&\u001b- ,\u001f.#\u001d/&\u001b,\u001f- \u001b\u001e0\u001f(.#\u001d#\u001b-\n \n\b\u001f')(\u001f\u001d.#(\u001b\n\u0006#\u001c,)\u001c&\u001b-.)-\n \n\u001b'#(#(\u001b\n#( )\u001d#.)-\n \n\u0010,).\u001f)!&#\u001d\u001b()-\n)()\u001d#.)-I'\u001b\u001d,ĉ \u001b!)-\n \n\u0014\u001f(\u001b-\u001d#(\u001b\n\u000f-.\u001f)\u001c&\u001b-.)-\n \n\u0014,)'\u001c)-*)(\u001e#(\u001b\n\u000f-.\u001f)\u001d&\u001b-.)-\n \n\u0016#.,)(\u001f\u001d.#(\u001b","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":32,"lines":{"from":117,"to":161}}}}],["81",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n6\n\n\u0010\u001b,\u001b '\u001b3), \u001d&\u001b,#\u001e\u001b\u001e \u001f( &\u001b *,\u001f-\u001f(.\u001b\u001d#ĉ(6 &\u001b \"\u001f'\u001b.)*)3\u001f-#- -\u001f \u001e#0#\u001e#ĉ \u001f( &)- \u001d)'*\u001b,.#'\u001f(.)- *&/,#*).\u001f(\u001d#\u001b&6\n\u001c#*).\u001f(\u001d#\u001b&6 /(#*).\u001f(\u001d#\u001b& 3 .\u001f,'#(\u001b&\n \n(cuadro 1-2)\n.\n\nCOMPARTIMENTO PLURIPOTENCIAL\n\n\u0005( &\u001b l·!/,\u001b g7h -\u001f '/\u001f-.,\u001b /( ')\u001e\u001f&) \u001e\u001f \"\u001f'\u001b.)*)3\u001f-#-8 \u0003)( \u001f& \u001f(-\u001b3) #( 0#.,) \u001e\u001f #(')0#&#4\u001b\u001d#ĉ( \u001d&)(\u001b&6\n.\u001b'\u001c#ï( \u001d)()\u001d#\u001e) \u001d)')\n \nunidad formadora de colonias\n \nB\u0015\u0006\u0003C6 *), &\u001b *,)*#\u001f\u001e\u001b\u001e\n \nù-#\u001d\u001b \u001e\u001f &)- '\u001f\u001e#)- \u001e\u001f\n\u001d/&.#0) B\u001b!\u001b, ) '\u001f.#&\u001d\u001f&/&)-\u001bC *\u001b,\u001b '\u001b(.\u001f(\u001f, /(#\u001e\u001b &\u001b *,)!\u001f(#\u001f \u001d\u001f&/&\u001b,6 -\u001f *)-./&\u001b +/\u001f6 \u001f( \u001f& -\u001f, \"/'\u001b()6\n\u001e\u001f(.,) \u001e\u001f \u001f-.\u001f \u001d)'*\u001b,.#'\u001f(.) -\u001f \u001f(\u001d/\u001f(.,\u001b( \u001b+/\u001f&&\u001b- \u001dï&/&\u001b- +/\u001f \u001bĚ( () \u001f&#!\u001f( /( &#(\u001b$\u001f B\u001f-.#,*\u001fC \u001e\u001f.\u001f,'#\n-\n\n(\u001b\u001e) B#,,\u001f-.,#\u001d.\u001b-C9 &\u001b \u0003\u0014\b6 #\u001e\u001f(.#l·\u001d\u001b\u001e\u001b \u001f( \u001d/&.#0) *), &\u001b \u0015\u0006\u0003 \u001e\u001f \u001c&\u001b-.)- B\u0002\n \nC6 3 &\u001b- \u001dï&/&\u001b- +/\u001f -\u001f \u001d)'\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":33,"lines":{"from":1,"to":28}}}}],["82",{"pageContent":"(\u001b\u001e) B#,,\u001f-.,#\u001d.\u001b-C9 &\u001b \u0003\u0014\b6 #\u001e\u001f(.#l·\u001d\u001b\u001e\u001b \u001f( \u001d/&.#0) *), &\u001b \u0015\u0006\u0003 \u001e\u001f \u001c&\u001b-.)- B\u0002\n \nC6 3 &\u001b- \u001dï&/&\u001b- +/\u001f -\u001f \u001d)'\n-\n\n*,)'\u001f.\u001f(6 \u001b\u001e+/#,#\u001f(\u001e) \u001b-ù \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e *\u001b,\u001b \u001e# \u001f,\u001f(\u001d#\u001b,-\u001f \"\u001b\u001d#\u001b /(\u001b &ù(\u001f\u001b \u001d\u001f&/&\u001b, \"\u001f'\u001b.)*)3ï.#\u001d\u001b \u001e\u001fl·(#\u001e\u001b\nB,\u001f-.,#(!#\u001e\u001bC6 3\u001b -\u001f\u001b '#\u001f&)#\u001e\u001f ) &#( )#\u001e\u001f8\n\u0001*,)2#'\u001b\u001e\u001b'\u001f(.\u001f hg \u001eù\u001b- \u001e\u001f-*/ï- \u001e\u001f -\u001f'\u001c,\u001b\u001e\u001b- &\u001b- \u001dï&/&\u001b- \u001e\u001f\n \n\u000f \"/'\u001b(\u001b6 \u001d/&.#0\u001b\u001e\u001b- \u001f( \u001b!\u001b, )\n'\u001f.#&\u001d\u001f&/&)-\u001b \u001f( *,\u001f-\u001f(\u001d#\u001b \u001e\u001f\n \n\u001b\u001d.),\u001f- \u001e\u001f \u001d,\u001f\u001d#'#\u001f(.) 3 \u001f( \u001d)(\u001e#\u001d#)(\u001f- ĉ*.#'\u001b-6 \u001b*\u001b,\u001f\u001d\u001f( \u001f( \u001f& \u001d/&.#0)\n\u001b!,\u001f!\u001b\u001e)- \u001d\u001f&/&\u001b,\u001f- &&\u001b'\u001b\u001e)-\n \ncolonias\n8\n \n\u001b \u001e#-\u001f\u001d\u001d#ĉ( 3 \u001d\u001b,\u001b\u001d.\u001f,#4\u001b\u001d#ĉ( \u001e\u001f \u001f-.\u001b- ,\u001f0\u001f&\u001b +/\u001f \u001b&!/(\u001b-6 &\u001b-\n'\u001f()-6 \u001d)(.#\u001f(\u001f( .)\u001e) .#*) \u001e\u001f *,\u001f\u001d/,-),\u001f- \"\u001f'\u001b.)*)3ï.#\u001d)-6 #(\u001d&/3\u001f(\u001e) &#( )\u001d#.)-8 \u000f.,\u001b- \u001d)&)(#\u001b-6 \u001f(\n'\u001b3), \u001d/\u001b(.ù\u001b6 \u001f-.á( ),'\u001b\u001e\u001b- *), *,\u001f\u001d/,-),\u001f- !,\u001b(/&)\u001dù.#\u001d)-6 \u001f,#.,)#\u001e\u001f-6 ')()\u001dù.#\u001d)- 3 '\u001f!\u001b\u001d\u001b,#)\u001dù.#\n-\n\n\u001d)-8 \u0005& *,#'\u001f, .#*) \u001e\u001f \u001d)&)(#\u001b ,\u001f*,\u001f-\u001f(.\u001b \u001b &\u001b \u0015\u0006\u0003 &#( )#\u001e\u001f 3 '#\u001f&)#\u001e\u001f B\n \nC6 3 \u001f& -\u001f!/(\u001e) \u001b &\u001b \u001e\u001f-\u001d\u001f(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":33,"lines":{"from":28,"to":54}}}}],["83",{"pageContent":"\u001d)-8 \u0005& *,#'\u001f, .#*) \u001e\u001f \u001d)&)(#\u001b ,\u001f*,\u001f-\u001f(.\u001b \u001b &\u001b \u0015\u0006\u0003 &#( )#\u001e\u001f 3 '#\u001f&)#\u001e\u001f B\n \nC6 3 \u001f& -\u001f!/(\u001e) \u001b &\u001b \u001e\u001f-\u001d\u001f(\n-\n\n\u001e\u001f(\u001d#\u001b \u001e\u001f \u001f-.\u001b6 \u001f- \u001e\u001f\u001d#,6 \u001b &\u001b \u001dï&/&\u001b *&/,#*).\u001f(\u001d#\u001b& '#\u001f&)#\u001e\u001f6 \u001d/3) .ï,'#() )*\u001f,\u001b.#0) \u001f- \u0015\u0006\u00037\u0007\u0005\n \n8\n\u001b\n \n,\u001f\u001d/\u001f(\u001d#\u001b \u001e\u001f \u001b*\u001b,#\u001d#ĉ( \u001e\u001f &\u001b \u0015\u0006\u0003 &#( )#\u001e\u001f B\n \nC \u001f( \u001d/&.#0) \u001f- \u001c\u001b$\u001b6 3 \u001d)( \u001f& \u001f'*&\u001f) \u001e\u001f #-)\u001f(4#'\u001b- \u0001\n3 \u0002 \u001e\u001f &\u001b !&/\u001d)-\u001b7l7 )- \u001b.) \u001e\u001f-\"#\u001e,)!\u001f(\u001b-\u001b -\u001f \"\u001b \u001d)(\u001d&/#\u001e) +/\u001f &\u001b \u0015\u0006\u00037\n \n\u001e\u001f-\u001d#\u001f(\u001e\u001f \u001e\u001f &\u001b \u0015\u0006\u00037\n \n6 3\n\u001f-.\u001b \u001b -/ 0\u001f4 \u001e\u001b ),#!\u001f( \u001b &\u001b \u0015\u0006\u00037\n \n\u0002 3 \u0015\u0006\u00037\n \n\u00148 \u0013\u001f #!(),\u001b -# &\u001b \u0015\u0006\u0003 \u001e\u001f &#( )\u001d#.)- !,\u001b(\u001e\u001f- !,\u001b(/&\u001b,\u001f-\nB\n \n\u0007\u0007C .#\u001f(\u001f \u001d)') \u001b(\u001d\u001f-.,) \u001d)'Ě( &\u001b \u0015\u0006\u00037\n \n8\n\u001b \u0015\u0006\u00037\n \n3 &\u001b \u0015\u0006\u00037\u0007\u0005\n \n6 \u001b& #!/\u001b& +/\u001f -/ \u001b(.\u001f\u001d\u001f-),6 -\u001f \u001e#0#\u001e\u001f( 3 .#\u001f(\u001f( \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e '#!,\u001b.),#\u001b6\n\u001d)(.#(Ě\u001b( \u001f2*,\u001f-\u001b(\u001e) \u001f& \u001b(.ù!\u001f() \u0003\u0004ij 3 .\u001b'\u001c#ï( \u001f2*,\u001f-\u001b( \u001f& \u001b(.ù!\u001f() \b\n \n\u00017\u0004\u00128\n \n\u001b \u0015\u0006\u00037\u0007\u0005\n\u001f2*,\u001f-\u001b \u001b\u001e\u001f'á- &)- \u001b(.ù!\u001f()- \u0003\u0004ii 3 \u0003\u0004gi8\n \n\u001b \u001d\u001b,\u001b\u001d.\u001f,#4\u001b\u001d#ĉ( #('/() \u001f().ĉ*#\u001d\u001b \u001e\u001f &\u001b \u001dï&/&\u001b +/\u001f \u001e\u001b\n),#!\u001f( \u001b &\u001b \u0015\u0006\u00037\n \n\u001f- *,\u001f\u001d\u001b,#\u001b6 3 \"\u001b-.\u001b \u001b\"),\u001b -\u001f \u001b\u001d\u001f*.\u001b +/\u001f \u001f-.\u001b \u001d)(.#\u001f(\u001f \u001b &\u001b \u001f(4#'\u001b \u001e\u001f-)2#(/\u001d&\u001f).#\u001e#&","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":33,"lines":{"from":54,"to":97}}}}],["84",{"pageContent":"Figura 1-2.\n \n\u000e#\u001d\") \"\u001f'\u001b.)*)3ï.#\u001d) \u001f( \u001f& \u001b\u001e/&.)8\n \n\u001b- \u0003\u0014\b -\u001f \u001f(\u001d/\u001f(.,\u001b( \u001b\u001e3\u001b\u001d\u001f(.\u001f- \u001b &)- )-.\u001f)\u001c&\u001b-.)-6 +/\u001f\n\u001f-.á( ,\u001f!/&\u001b\u001e)- *), &\u001b *,).\u001fù(\u001b ĉ-\u001f\u001b '), )!\u001f(ï.#\u001d\u001b B\u0010\u000f\n \nC B(#\u001d\") )-.\u001f)\u001c&á-.#\u001d)C8\n \n\u001b- \u0003\u0014\b .\u001b'\u001c#ï( -\u001f &)\n-\n\n\u001d\u001b&#4\u001b( \u001b\u001e3\u001b\u001d\u001f(.\u001f- \u001b &)- 0\u001b-)- -\u001b(!/ù(\u001f)- B(#\u001d\") 0\u001b-\u001d/&\u001b,C8\n \n\u001b +/#'#)\u001d#(\u001b \u0003\u0018\u0003\n \ngh ,\u001f!/&\u001b &\u001b '#!,\u001b\u001d#ĉ( \u001e\u001f\n&\u001b- \u0003\u0014\b \u001e\u001f &\u001b \u001d#,\u001d/&\u001b\u001d#ĉ( \u001b &\u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b8 \u0005& \u001f-*\u001b\u001d#) '\u001f\u001e/&\u001b, \u001d)(.#\u001f(\u001f \u001dï&/&\u001b- \u001f-.,)'\u001b&\u001f- Bl·\u001c,)\u001c&\u001b-.)-C\n+/\u001f -)*),.\u001b( &\u001b \"\u001f'\u001b.)*)3\u001f-#- 3 \u001b\u001e\u001f'á- *,)\u001e/\u001d\u001f( \u001d#.)\u001d#(\u001b- B&#!\u001b(\u001e) \u001d7%#.6 \u001f(.,\u001f ).,\u001b-C +/\u001f \u001f-.#'/&\u001b( \u001b &\u001b-\n\u0003\u0014\b 3 \u001b &)- *,)!\u001f(#.),\u001f- \"\u001f'\u001b.)*)3ï.#\u001d)-8\n\nEn el ser humano, dentro del\ncompartimento\n \npluripoten-\ncial, se encuentran aquellas\ncélulas que aún no eligen un\nlinaje\n \n(estirpe)\n \ndetermina-\ndo\n \n(irrestrictas):\n \nla\n \nCTH,\nidentificada en cultivo por la\nUFC de blastos (BL), y las\ncélulas que se comprometen,\nadquiriendo\n \nasí\n \ncapacidad\npara diferenciarse hacia una\nlínea celular hematopoyética\ndefinida.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":33,"lines":{"from":99,"to":148}}}}],["85",{"pageContent":"CAPÍTULO 1. HEMATOPOYESIS\n\n7\n\n.,\u001b(- \u001f,\u001b-\u001b .\u001f,'#(\u001b& B\u001e\u0014\u0014C 3 +/\u001f \u001f2*,\u001f-\u001b \u001f& \u001b(.ù!\u001f() \b\n \n\u00017\u0004\u00126 *\u001f,) () \u001f2*,\u001f-\u001b (#(!/() \u001e\u001f &)- \u001b(.ù!\u001f()-\n\u001e\u001f \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( \u0014 B\u0003\u0004g6 \u0003\u0004h6 \u0003\u0004i6 \u0003\u0004k6 \u0003\u0004mC ) \u0002 B\u0003\u0004gf6 \u0003\u0004go6 \u0003\u0004hf6 \u0003\u0004hg6 \u0003\u0004hh6 \u0003\u0004moC8\n\u0005( \u001b&!Ě( ')'\u001f(.) \u001f( &\u001b 0#\u001e\u001b \u001e\u001f &\u001b- \u001dï&/&\u001b- *&/,#*).\u001f(\u001d#\u001b&\u001f- #,,\u001f-.,#\u001d.\u001b- 3 ,\u001f-.,#(!#\u001e\u001b-6 \u001f& (Ě'\u001f,) \u001e\u001f\n^*,)!,\u001b'\u001b- \u001e\u001f \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ(_ \u001e#-*)(#\u001c&\u001f- \u001f( \u001f&&\u001b- -\u001f 0/\u001f&0\u001f &#'#.\u001b\u001e)6 \"\u001b-.\u001b /( */(.) \u001f( +/\u001f &\u001b \u001e# \u001f,\u001f(\u001d#\u001b\n-\n\n\u001d#ĉ( -#!/\u001f /(\u001b -)&\u001b &ù(\u001f\u001b 3 &\u001b *,)!\u001f(#\u001f \u001d\u001f&/&\u001b, \u001e\u001f-\u001f'*\u001fĄ\u001b /(\u001d#)(\u001f- #(\"\u001f,\u001f(.\u001f- \u001b -/ \u001d)\"),.\u001f8 \u0005-.\u001b -\u001f,#\u001f \u001e\u001f\n\u001f-.\u001b\u001e#)- -\u001f\u001d/\u001f(\u001d#\u001b&\u001f- \u001e\u001f &\u001b \"\u001f'\u001b.)*)3\u001f-#-6 \u001e\u001f *&/,#*).\u001f(\u001d#\u001b& \u001b \u001c#*).\u001f(\u001d#\u001b& ) /(#*).\u001f(\u001d#\u001b&6 \u001f- #,,\u001f0\u001f,-#\u001c&\u001f8\n\nCOMPARTIMENTO BIPOTENCIAL\n\n\u0010&/4(#% 3 \u0013\u001b\u001d\"-6 \u001f( golk6 /\u001f,)( &)- *,#'\u001f,)- \u001f( \u001d/&.#0\u001b, \u001d)( ï2#.) \u001dï&/&\u001b- \u001e\u001f 'ï\u001e/&\u001b ĉ-\u001f\u001b8 \u0005'*&\u001f\u001b(\u001e) \u001f&\n-#-.\u001f'\u001b \u001e\u001f \u001d/&.#0) \u001f( \u001b!\u001b, \u001e\u001f \u0010#%\u001f 3 \u0012)\u001c#(-)(6 &\u001b- \u001d)&)(#\u001b- +/\u001f \u001f'\u001f,!\u001f( \u001b&,\u001f\u001e\u001f\u001e), \u001e\u001f& \u001eù\u001b m \u001f-.á( \u001d)(-\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":34,"lines":{"from":1,"to":20}}}}],["86",{"pageContent":".#./#\u001e\u001b- *,#(\u001d#*\u001b&'\u001f(.\u001f *), /(\u001b '\u001f4\u001d&\u001b \u001e\u001f !,\u001b(/&)\u001d#.)- 3 ')()\u001d#.)-8\n \n) \u001b(.\u001f,#), #(\u001e#\u001d\u001b +/\u001f \u001f-.\u001f \u001f(-\u001b3)\n#\u001e\u001f(.#l·\u001d\u001b \u001b /( *,)!\u001f(#.), \"\u001f'\u001b.)*)3ï.#\u001d) \u001c#*).\u001f(\u001d#\u001b&6 &\u001b \u0015\u0006\u00037\u0007\n \n8\n \n\u001b \u001dï&/&\u001b +/\u001f \u001e\u001b ),#!\u001f( \u001b &\u001b \u0015\u0006\u00037\n\u0007\n \n\u001f2*,\u001f-\u001b &)- \u001b(.ù!\u001f()- '#\u001f&)#\u001e\u001f- \u0003\u0004ii6 \u0003\u0004gk 3 \u0003\u0004gi6 *,)\u001c\u001b\u001c&\u001f'\u001f(.\u001f \u001f2*,\u001f-\u001b &)- \u001b(.ù!\u001f()- \u0003\u0004gj\nB')()\u001dù.#\u001d)C 3 \b\n \n\u00017\u0004\u00126 3 &\u001b \u001f2*,\u001f-#ĉ( \u001e\u001f& \u001b(.ù!\u001f() \u0003\u0004ij \u001f- \u001eï\u001c#&8\n \n\u001b \u0015\u0006\u00037\u0007\n \n\u001d)(-\u001f,0\u001b &\u001b \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e\n\u001e\u001f \u001d#,\u001d/&\u001b, \u001f( \u001f& .),,\u001f(.\u001f -\u001b(!/ù(\u001f) 3 *#\u001f,\u001e\u001f &\u001b *,)*#\u001f\u001e\u001b\u001e \u001e\u001f \u001e#0#\u001e#,-\u001f8\n \n\u001b )\u001c-\u001f,0\u001b\u001d#ĉ( #( 0#.,) \u001e\u001f /(\u001b\n\u001b&.\u001b\n \n,\u001f\u001d/\u001f(\u001d#\u001b \u001e\u001f \u001d)&)(#\u001b- '#2.\u001b-6 \u001d)(-.#./#\u001e\u001b- *), \u001dï&/&\u001b- \u001f,#.,)#\u001e\u001f-7'\u001f!\u001b\u001d\u001b,#)\u001dù.#\u001d\u001b- 3 \u001f,#.,)#\u001e\u001f-7!,\u001b\n-\n\n(/&)\u001dù.#\u001d\u001b-6 -/!#\u001f,\u001f &\u001b \u001f2#-.\u001f(\u001d#\u001b \u001e\u001f ).,)- *,\u001f\u001d/,-),\u001f- \u001c#*).\u001f(\u001d#\u001b&\u001f- \u001d)') &\u001b \u0015\u0006\u00037\u0005\n \n\u001f! 3 &\u001b \u0015\u0006\u00037\u0005\u00076\n'#-')- +/\u001f6 \u001f( &\u001b )(.)!\u001f(#\u001b \"\u001f'\u001b.)*)3ï.#\u001d\u001b6 \u001f-.\u001b,ù\u001b( /\u001c#\u001d\u001b\u001e)- \u001f(.,\u001f &\u001b \u0015\u0006\u00037\u0007\u0005\n \n3 &)- *,\u001f\u001d/,-),\u001f-\n/(#*).\u001f(\u001d#\u001b&\u001f-8\n \n\u001b \u001f2#-.\u001f(\u001d#\u001b \u001e\u001f *,)!\u001f(#.),\u001f- \u001c#*).\u001f(\u001d#\u001b&\u001f- *)\u001e,ù\u001b \u001f2*&#\u001d\u001b, \u001f( *\u001b,.\u001f \u001f& \u001f \u001f\u001d.) *&\u001f).,ĉ*#\u001d)\n+/\u001f .#\u001f(\u001f( \u001b&!/()- \u001b\u001d.),\u001f- \u001e\u001f \u001d,\u001f\u001d#'#\u001f(.)8\n\nCOMPARTIMENTO UNIPOTENCIAL","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":34,"lines":{"from":22,"to":59}}}}],["87",{"pageContent":"COMPARTIMENTO UNIPOTENCIAL\n\n\u0005-.\u001f \u001d)'*\u001b,.#'\u001f(.) \u001f-.á ),'\u001b\u001e) *), \u001dï&/&\u001b- #,,\u001f\u001d)()\u001d#\u001c&\u001f- '), )&ĉ!#\u001d\u001b'\u001f(.\u001f 3 -)&) #\u001e\u001f(.#l·\u001d\u001b\u001e\u001b- *), -/\n\u001d\u001b*\u001b\u001d#\u001e\u001b\u001e *\u001b,\u001b ),'\u001b, \u001d)&)(#\u001b- \u001f( \u001d/&.#0) B\u001dï&/&\u001b- *,)!\u001f(#.),\u001b-C 3 *), \u001b+/\u001f&&\u001b- \u001d)( \u001d\u001b,\u001b\u001d.\u001f,ù-.#\u001d\u001b- '), )\n-\n\n&ĉ!#\u001d\u001b- \u001e\u001fl·(#\u001e\u001b- B\u001dï&/&\u001b- *,\u001f\u001d/,-),\u001b-C8\n\u0015\u0006\u0003  /(#\u001e\u001b\u001e ),'\u001b\u001e),\u001b \u001e\u001f \u001d)&)(#\u001b-: \u0015\u0006\u0002  /(#\u001e\u001b\u001e ),'\u001b\u001e),\u001b \u001e\u001f \u001c,).\u001f-: \u0002\n \n \u001c&\u001b-.)-:\n \n &#( )#\u001e\u001f7'#\u001f&)#\u001e\u001f: \u0007\u0005\n !,\u001b(/&)\u001d#.)-6 \u001f,#.,)\u001d#.)-6 ')()\u001d#.)-6 '\u001f!\u001b\u001d\u001b,#)\u001d#.)-:\n \n &#( )#\u001e\u001f: \u0007\n \n !,\u001b(/&)\u001d#.)-6 ')()\u001d#.)-: \u0005  \u001f,#.,)#\u001e\u001f:\n \n ')\n-\n\n()\u001d#.)-: \u0007  !,\u001b(/&)\u001d#.)-:\n \n\u001f!  '\u001f!\u001b\u001d\u001b,#)\u001d#.)-: \u0002\u001b-  \u001c\u001b-ĉl·&)-: \u0005)  \u001f)-#(ĉl·&)-:\n \n\u0002  &#( )\u001d#.)- \u0002:\n \n\u0014  &#( )\u001d#.)- \u0014: \u0007\u0007\n !,\u001b(\u001e\u001f !,\u001b(/&\u001b,8\n\nCuadro 1-2.\n \nCompartimentos hematopoyéticos\n\nCompartimento\npluripotencial\n\n,,\u001f-.,#\u001d.)\n \n\u0015\u0006\u00037\u0002\n \n6 \u0015\u0006\u00037\n\u0012\u001f-.,#(!#\u001e)\n \n\u0015\u0006\u00037\u0007\u0005\n \n6 \u0015\u0006\u00037\n\nCompartimento\nbipotencial\n \n\u0015\u0006\u00037\u0005\u00076 \u0015\u0006\u00037\u0007\n \n6 \u0015\u0006\u00037\u0005\n \n\u001f!\n\nCompartimento\nunipotencial\nCélulas progenitoras\n\n\u0015\u0006\u00027\u00056 \u0015\u0006\u00037\u00056 \u0015\u0006\u00037\n \n6 \u0015\u0006\u00037\u00076 \u0015\u0006\u00027\n \n\u001f!6 \u0015\u0006\u00037\n \n\u001f!6\n\u0015\u0006\u00037\u0002\u001b-6 \u0015\u0006\u00037\u0005)6 \u0015\u0006\u00037\n \n\u00026 \u0015\u0006\u00037\n \n\u00146 \u0015\u0006\u00037\n \n\u0007\u0007","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":34,"lines":{"from":59,"to":133}}}}],["88",{"pageContent":"Compartimento\nunipotencial\nCélulas progenitoras\n\n\u0015\u0006\u00027\u00056 \u0015\u0006\u00037\u00056 \u0015\u0006\u00037\n \n6 \u0015\u0006\u00037\u00076 \u0015\u0006\u00027\n \n\u001f!6 \u0015\u0006\u00037\n \n\u001f!6\n\u0015\u0006\u00037\u0002\u001b-6 \u0015\u0006\u00037\u0005)6 \u0015\u0006\u00037\n \n\u00026 \u0015\u0006\u00037\n \n\u00146 \u0015\u0006\u00037\n \n\u0007\u0007\n\nCélulas precursoras\n\n\u0010,)\u001f,#.,)\u001c&\u001b-.)6 ')()\u001c&\u001b-.)6 '#\u001f&)\u001c&\u001b-.)6 '\u001f!\u001b\u001d\u001b,#)\u001c&\u001b-.)6\n&#( )\u001c&\u001b-.)\n\nCompartimento\nterminal\n\n\u0005,#.,)\u001d#.)6 ')()\u001d#.)I'\u001b\u001d,ĉ \u001b!)6 (\u001f/.,ĉl·&)6 *&\u001b+/\u001f.\u001b6\n\u001c\u001b-ĉl·&)I'\u001b-.)\u001d#.)6 \u001f)-#(ĉl·&)6 &#( )\u001d#.)- \u00146 \u0002 3 \u0007\u0007\n\nEn algún momento en la vida\nde las células pluripotenciales\nirrestrictas\n \ny\n \nrestringidas\n \nel\nnúmero de “programas de dife-\nrenciación” disponibles en ellas\nse vuelve limitado, hasta un\npunto en que la diferenciación\nsigue una sola línea y la proge-\nnie celular desempeña funcio-\nnes inherentes a su cohorte.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":34,"lines":{"from":133,"to":178}}}}],["89",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n8\n\nCélulas progenitoras\n\n\u0005( &\u001b )(.)!\u001f(#\u001b \u001f,#.,)*)3ï.#\u001d\u001b6 &\u001b /(#\u001e\u001b\u001e\n \n),'\u001b\u001e),\u001b \u001e\u001f \u001c,).\u001f- \u001f,#.,)#\u001e\u001f- B\u0015\u0006\u00027\u0005C \u001b(.\u001f\u001d\u001f\u001e\u001f \u001b &\u001b \u0015\u0006\u0003\n\u001f,#.,)#\u001e\u001f B\u0005C 3 *,)\u001c\u001b\u001c&\u001f'\u001f(.\u001f \u001b'\u001c\u001b- .#\u001f(\u001f( \u001d)') *,)!\u001f(#.),\u001f- \u001d)'/(\u001f- #('\u001f\u001e#\u001b.)- \u001b &\u001b \u0015\u0006\u00037\u0005\n \n\u001f! 3 &\u001b\n\u0015\u0006\u00037\u0005\u00078 \u0005( \u001d/&.#0)6 &\u001b \u0015\u0006\u00027\u0005 \u001f'\u001f,!\u001f \u001f(.,\u001f \u001f& \u001eù\u001b n 3 \u001f& gj6 3 \u001f( \u001f& \u001eù\u001b j -\u001f 0#-/\u001b&#4\u001b &\u001b \u0015\u0006\u00037\u00058 \u0005-.)-\n\u001f-.\u001b\u001e#)- \u001e\u001f \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( -)( #\u001e\u001f(.#l·\u001d\u001b\u001e)- *), \u001f& .\u001b'\u001bĄ) \u001e\u001f &\u001b- \u001d)&)(#\u001b-6 *), -/ 0\u001f&)\u001d#\u001e\u001b\u001e \u001e\u001f -\u001f\u001e#'\u001f(.\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":35,"lines":{"from":1,"to":15}}}}],["90",{"pageContent":"\u001d#ĉ( \u001f( !,\u001b\u001e#\u001f(.\u001f- \u001e\u001f \u0010\u001f,\u001d)&& 3 *), -/ ,\u001f-*/\u001f-.\u001b \u001b \u001e#0\u001f,-)- \u001b\u001d.),\u001f- \u001e\u001f \u001d,\u001f\u001d#'#\u001f(.)8 \u0001& #!/\u001b& +/\u001f &\u001b \u0003\u0014\b\n3 &\u001b \u0015\u0006\u00037\u0007\u0005\n \n6 &\u001b \u0015\u0006\u00027\u0005 3 &\u001b \u0015\u0006\u00037\u0005 \u001d#,\u001d/&\u001b( \u001f( &\u001b -\u001b(!,\u001f8\n \n\u001b \u0015\u0006\u00027\u0005 \u001d)(-\u001f,0\u001b &\u001b \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e \u001e\u001f\n\u001e#0#\u001e#,-\u001f6 '#\u001f(.,\u001b- +/\u001f &\u001b \u0015\u0006\u00037\u0005 *#\u001f,\u001e\u001f \u001f-.\u001b \u001d\u001b,\u001b\u001d.\u001f,ù-.#\u001d\u001b8\n\u0005( &\u001b 0#\u001e\u001b \u001b\u001e/&.\u001b6 &)- *,)!\u001f(#.),\u001f- \u001f,#.,)#\u001e\u001f- \u001b\u001e+/#\u001f,\u001f( ) *#\u001f,\u001e\u001f( \u001b(.ù!\u001f()- )\n \n/(\u001d#)(\u001f- \u001b &) &\u001b,!)\n\u001e\u001f -/ \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ(8 \u0001-ù6 &\u001b \u001f2*,\u001f-#ĉ( \u001e\u001f &)- \u001b(.ù!\u001f()- *&/,#*).\u001f(\u001d#\u001b&\u001f- B\u0003\u0004ijC 3 '#\u001f&)#\u001e\u001f- .\u001f'*,\u001b()-\nB\u0003\u0004iiC \u001e\u001f\u001d,\u001f\u001d\u001f \u001b '\u001f\u001e#\u001e\u001b +/\u001f \u001b0\u001b(4\u001b &\u001b \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ(8\n \n) '#-') \u001b\u001d)(.\u001f\u001d\u001f \u001d)( \u001f& \u001b(.ù!\u001f() \b\n \n\u00017\u0004\u0012: -#(\n\u001f'\u001c\u001b,!)6 &\u001b \u001f2*,\u001f-#ĉ( \u001e\u001f \u001f-.\u001f \u001e\u001f*\u001f(\u001e\u001f 'á- \u001e\u001f& \u001d#\u001d&) \u001d\u001f&/&\u001b, +/\u001f \u001e\u001f& \u001f-.\u001b\u001e#) \u001e\u001f '\u001b\u001e/,\u001b\u001d#ĉ(6 \u001f2*,\u001f-á(\u001e)-\u001f\n'\u001b3),'\u001f(.\u001f \u001e/,\u001b(.\u001f &\u001b- \u001b-\u001f- \u0007h 3\n \n8\n\u0005(.,\u001f gi 3 gk \u001f- \u001f& (Ě'\u001f,) \u001e\u001f \u001e#0#-#)(\u001f- \u001d\u001f&/&\u001b,\u001f- +/\u001f ,\u001f\u001b&#4\u001b( &)- *,)!\u001f(#.),\u001f- \u001f,#.,)#\u001e\u001f- \u001b(.\u001f- \u001e\u001f\n\u001b&\u001d\u001b(4\u001b, \u001f& *,#'\u001f, \u001f-.\u001b\u001e#) \u001e\u001f '\u001b\u001e/,\u001b\u001d#ĉ( '), )&ĉ!#\u001d\u001b'\u001f(.\u001f ,\u001f\u001d)()\u001d#\u001c&\u001f6 \u001f& *,)\u001f,#.,)\u001c&\u001b-.)8\n\u001b- \u001dï&/&\u001b- *,)!\u001f(#.),\u001b- +/\u001f \u001e\u001b( ),#!\u001f( \u001b &\u001b \u0015\u0006\u0003 \u001e\u001f !,\u001b(/&)\u001d#.)- B\u0007C 3 \u001b &\u001b \u001e\u001f ')()\u001d#.)- B\n \nC \u001e\u001f-\u001d#\u001f(\u001e\u001f(","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":35,"lines":{"from":17,"to":41}}}}],["91",{"pageContent":"\u001b&\u001d\u001b(4\u001b, \u001f& *,#'\u001f, \u001f-.\u001b\u001e#) \u001e\u001f '\u001b\u001e/,\u001b\u001d#ĉ( '), )&ĉ!#\u001d\u001b'\u001f(.\u001f ,\u001f\u001d)()\u001d#\u001c&\u001f6 \u001f& *,)\u001f,#.,)\u001c&\u001b-.)8\n\u001b- \u001dï&/&\u001b- *,)!\u001f(#.),\u001b- +/\u001f \u001e\u001b( ),#!\u001f( \u001b &\u001b \u0015\u0006\u0003 \u001e\u001f !,\u001b(/&)\u001d#.)- B\u0007C 3 \u001b &\u001b \u001e\u001f ')()\u001d#.)- B\n \nC \u001e\u001f-\u001d#\u001f(\u001e\u001f(\n\u001e\u001f /( *,\u001f\u001d/,-), \u001c#*).\u001f(\u001d#\u001b& \u001d)'Ě( #('\u001f\u001e#\u001b.)6 &\u001b \u0015\u0006\u00037\u0007\n \n8 \u0005- *)-#\u001c&\u001f +/\u001f \u001b&!/(\u001b- \u0015\u0006\u00037\u0007 -\u001f ),#!#(\u001f( \u001e\u001f\n).,) *,\u001f\u001d/,-), \u001c#*).\u001f(\u001d#\u001b&6 &\u001b \u0015\u0006\u00037\u0005\u00078\n \n\u001b \u0015\u0006\u00037\u0007 3 \u0015\u0006\u00037\n \n\u001f-.á( *,\u001f-\u001f(.\u001f- \u001f( &\u001b \u001d#,\u001d/&\u001b\u001d#ĉ( 36 \u001b& #!/\u001b&\n+/\u001f &\u001b \u0015\u0006\u00037\u0007\n \n6 \u001e\u001f$\u001b( \u001e\u001f \u001e#0#\u001e#,-\u001f8\n \n)- \u001b(.ù!\u001f()- \u0003\u0004gk 3 \u0003\u0004gj -\u001f \u001f(\u001d/\u001f(.,\u001b( \u001f( &\u001b \u0015\u0006\u00037\u0007 3 \u0015\u0006\u00037\n \n6\n,\u001f-*\u001f\u001d.#0\u001b'\u001f(.\u001f8 \u0005& \u001d,\u001f\u001d#'#\u001f(.) \u001e\u001f &\u001b \u0015\u0006\u00037\u0007 3 \u0015\u0006\u00037\n \n\u001f- \u001b\u001c-)&/.\u001b'\u001f(.\u001f \u001e\u001f*\u001f(\u001e#\u001f(.\u001f \u001e\u001f &\u001b *,\u001f-\u001f(\u001d#\u001b\n\u001d)(.#(/\u001b \u001e\u001f \u001b\u001d.),\u001f- \u001e\u001f \u001d,\u001f\u001d#'#\u001f(.)8\n\u0015(\u001b \u001f0#\u001e\u001f(\u001d#\u001b \u001d&ù(#\u001d\u001b6 &\u001b \u001f)-#()l·&#\u001b 3 \u001f& #(\u001d,\u001f'\u001f(.) \u001e\u001f& (Ě'\u001f,) \u001e\u001f \u001c\u001b-ĉl·&)- -\u001b(!/ù(\u001f)- \u001f( \u001b/-\u001f(\u001d#\u001b \u001e\u001f /(\n\u001b/'\u001f(.) \u001e\u001f (\u001f/.,ĉl·&)- 3 ')()\u001d#.)-6 3 ).,) \u001e\u001b.) \u001f2*\u001f,#'\u001f(.\u001b&6 &\u001b *,\u001f-\u001f(\u001d#\u001b \u001f( \u001d/&.#0) \u001e\u001f \u001d)&)(#\u001b- */,\u001b'\u001f(.\u001f\n\u001f)-#() ù&#\u001d\u001b- 3 \u001e\u001f ).,\u001b- \u001d)(-.#./#\u001e\u001b- Ě(#\u001d\u001b'\u001f(.\u001f *), \u001c\u001b-ĉl·&)-6 \u001b*)3\u001b( \u001f& ),#!\u001f( /(#*).\u001f(\u001d#\u001b& \u001e\u001f &)- \u001f)-#(ĉl·&)-8\n\u0005( \u001d/&.#0)6 &\u001b \u0015\u0006\u0002 '\u001f!\u001b\u001d\u001b,#)\u001dù.#\u001d\u001b B\n \n\u001f!C \u001b(.\u001f\u001d\u001f\u001e\u001f \u001b &\u001b \u0015\u0006\u00037","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":35,"lines":{"from":41,"to":69}}}}],["92",{"pageContent":"\u001f)-#() ù&#\u001d\u001b- 3 \u001e\u001f ).,\u001b- \u001d)(-.#./#\u001e\u001b- Ě(#\u001d\u001b'\u001f(.\u001f *), \u001c\u001b-ĉl·&)-6 \u001b*)3\u001b( \u001f& ),#!\u001f( /(#*).\u001f(\u001d#\u001b& \u001e\u001f &)- \u001f)-#(ĉl·&)-8\n\u0005( \u001d/&.#0)6 &\u001b \u0015\u0006\u0002 '\u001f!\u001b\u001d\u001b,#)\u001dù.#\u001d\u001b B\n \n\u001f!C \u001b(.\u001f\u001d\u001f\u001e\u001f \u001b &\u001b \u0015\u0006\u00037\n \n\u001f! 3 \u001b'\u001c\u001b- .#\u001f(\u001f( \u001d)') *,\u001f\u001d/,-), \u001d)\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":35,"lines":{"from":69,"to":75}}}}],["93",{"pageContent":"'Ě( \u001b &\u001b \u0015\u0006\u00037\u0007\u0005\n \n8 \u0011/#4á- \u001b&!/(\u001b- \u0015\u0006\u00027\n \n\u001f! 3 \u0015\u0006\u00037\n \n\u001f! -\u001f\u001b( \u001e\u001f-\u001d\u001f(\u001e#\u001f(.\u001f- \u001e\u001f &\u001b \u0015\u0006\u00037\u0005\n \n\u001f!8\n \n\u001b\n\u0015\u0006\u00027\n \n\u001f!6 \u001b \u001e# \u001f,\u001f(\u001d#\u001b \u001e\u001f &\u001b \u0015\u0006\u00037\n \n\u001f!6 \u001d)(-\u001f,0\u001b &\u001b \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e \u001e\u001f \u001b/.)\u001e/*&#\u001d\u001b\u001d#ĉ(: \u001b'\u001c\u001b- \u001f-.á( *,\u001f-\u001f(.\u001f-\n\u001f( &\u001b \u001d#,\u001d/&\u001b\u001d#ĉ( -\u001b(!/ù(\u001f\u001b 3 \u001f2*,\u001f-\u001b( &)- \u001b(.ù!\u001f()- !*\n \n\u001cI\n \n\u001b 3 !*\n \n\u0018 #\u001e\u001f(.#l·\u001d\u001b\u001e)- *), &)- \u001b(.#\u001d/\u001f,*)-\n')()\u001d&)(\u001b&\u001f- \u001b(.#7\u0003\u0004jg 3 \u001b(.#7\u0003\u0004jh\u001b6 ,\u001f-*\u001f\u001d.#0\u001b'\u001f(.\u001f8\n \n\u001b .,)'\u001c)*)3\u001f.#(\u001b B\u0014\u0010\u000fC \u001f-.#'/&\u001b &\u001b *,)&# \u001f,\u001b\n-\n\n\u001d#ĉ( 3 \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( \u001e\u001f &)- '\u001f!\u001b\u001d\u001b,#)\u001d#.)- 3 &\u001b &#\u001c\u001f,\u001b\u001d#ĉ( \u001e\u001f *&\u001b+/\u001f.\u001b- \u001b *\u001b,.#, \u001e\u001f \u001f&&)-8\n\u001b \u001dï&/&\u001b +/\u001f \u001e\u001b ),#!\u001f( \u001b &\u001b \u0015\u0006\u0003 \u001e\u001f &#( )\u001d#.)- \u0014 B\n \n\u0014C \u001d)(.#\u001f(\u001f &\u001b \u001f(4#'\u001b \u001e\u0014\u0014 3 () \u001f 2*,\u001f-\u001b \u001f& \u001b(\n-\n\n.ù!\u001f() \b\n \n\u00017\u0004\u0012 (# &)- \u001b(.ù!\u001f()- \u001e\u001f &#(\u001b$\u001f \u00028 \u0001'\u001c\u001b- \u001d#,\u001d/&\u001b( \u001f( &\u001b -\u001b(!,\u001f 3 *,)\u001c\u001b\u001c&\u001f'\u001f(.\u001f \u001d)(.#(Ě\u001b(\n\u001e#0#\u001e#ï(\u001e)-\u001f8\n \n\u001b \u0015\u0006\u00037\n \n\u0002 3 &\u001b \u0015\u0006\u00037\n \n\u0014 .#\u001f(\u001f( \u001d)') *,\u001f\u001d/,-), *&/,#*).\u001f(\u001d#\u001b& \u001d)'Ě( \u001b &\u001b \u0015\u0006\u00037\n \n8 \u0013)(\n'Ě&.#*&\u001f- &\u001b- \u001d#.)\u001d#(\u001b- #(0)&/\u001d,\u001b\u001e\u001b- \u001f( \u001f& \u001d)(.,)& \u001e\u001f &\u001b &#( )*)3\u001f-#- 3 \u001d\u001b-# .)\u001e\u001b- .\u001b'\u001c#ï( \u001f$\u001f,\u001d\u001f( \u001b\u001d\u001d#)(\u001f-\n'#\u001f&)*)3ï.#\u001d\u001b-\n \n(cuadro 1-3)\n.\n\nCélulas precursoras","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":35,"lines":{"from":77,"to":129}}}}],["94",{"pageContent":"Células precursoras\n\n\u0005-.\u001f \u001d)'*\u001b,.#'\u001f(.) \u001f-.á \u001d)(-.#./#\u001e) *), *,)\u001f,#.,)\u001c&\u001b-.)-6 '#\u001f&)\u001c&\u001b-.)-6 ')()\u001c&\u001b-.)-6 '\u001f!\u001b\u001d\u001b,#)\u001c&\u001b-.)- 3\n&#( )\u001c&\u001b-.)-6 .)\u001e)- \u001d)( \u001d\u001b,\u001b\u001d.\u001f,ù-.#\u001d\u001b- '), )&ĉ!#\u001d\u001b- \u001e#-.#(.#0\u001b- 3 \u001d)( \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e \u001e\u001f \u001e/*&#\u001d\u001b\u001d#ĉ(8\n \n\u001b \u001b\u001d.#0#\n-\n\n\u001e\u001b\u001e '#.ĉ.#\u001d\u001b \u001e\u001f& *,)\u001f,#.,)\u001c&\u001b-.) \u001d)(.#(Ě\u001b \"\u001b-.\u001b &\u001b \u001f.\u001b*\u001b \u001e\u001f \u001f,#.,)\u001c&\u001b-.) *)&#\u001d,)'\u001b.ĉl·&)6 &\u001b \u001e\u001f& '#\u001f&)\u001c&\u001b-.)\n\"\u001b-.\u001b \u001f& \u001f-.\u001b\u001e#) \u001e\u001f '#\u001f&)\u001d#.) 3 &\u001b \u001e\u001f& ')()\u001c&\u001b-.) \"\u001b-.\u001b &\u001b \u001f.\u001b*\u001b \u001e\u001f *,)')()\u001d#.)8 \u0005& '\u001f!\u001b\u001d\u001b,#)\u001c&\u001b-.) () -\u001f\n\u001e#0#\u001e\u001f6 *\u001f,) '\u001b(.#\u001f(\u001f &\u001b \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e \u001e\u001f \u001e/*&#\u001d\u001b, -/ (Ě\u001d&\u001f) B\u001f(\u001e)\u001e/*&#\u001d\u001b\u001d#ĉ(C8 \u0005( \u001f-.\u001b\u001e) \u001e\u001f \u001f+/#&#\u001c,#)6 &)-\n'\u001f!\u001b\u001d\u001b,#)\u001d#.)- -)( *)&#*&)#\u001e\u001f-6 *,#(\u001d#*\u001b&'\u001f(.\u001f \u001d)( j6 n 3 gl 0\u001f\u001d\u001f- &\u001b \u001d\u001b(.#\u001e\u001b\u001e (),'\u001b& \u001e\u001f \u0004\u000e\u0001 \u001e#*&)#\u001e\u001f8\n\u0005& &#( )\u001c&\u001b-.) \u001d)(.#(Ě\u001b \u001e#0#\u001e#ï(\u001e)-\u001f \"\u001b-.\u001b \u001f& \u001f-.\u001b\u001e) \u001e\u001f *,)&#( )\u001d#.)8\n\nCOMPARTIMENTO TERMINAL","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":35,"lines":{"from":129,"to":143}}}}],["95",{"pageContent":"COMPARTIMENTO TERMINAL\n\n\u0005-.\u001f \u001d)'*\u001b,.#'\u001f(.) ,\u001f*,\u001f-\u001f(.\u001b \u001f& \u001f-.\u001b\u001e#) l·(\u001b& \u001e\u001f &)- \u001f(ĉ'\u001f()- \u001e\u001f \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( 3 '\u001b\u001e/,\u001b\u001d#ĉ( #(#\u001d#\u001b\u001e)-\n\u001b (#0\u001f& \u001e\u001f &\u001b \u0003\u0014\b8\n \n\u001b- \u001dï&/&\u001b- '\u001b\u001e/,\u001b- -)( ,\u001f.\u001f(#\u001e\u001b- \u001f( &\u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b \"\u001b-.\u001b +/\u001f \u001b&\u001d\u001b(4\u001b( \u001d#\u001f,.) !,\u001b\u001e)\n\u001e\u001f '\u001b\u001e/,\u001b\u001d#ĉ(6 \u001d)( \u001d\u001b,\u001b\u001d.\u001f,ù-.#\u001d\u001b- '), )&ĉ!#\u001d\u001b- 3\n \n/(\u001d#)(\u001b&\u001f- \u001e#-.#(.#0\u001b- 3 -#( *).\u001f(\u001d#\u001b& *,)&# \u001f,\u001b.#0)6 \u001b\n\u001f2\u001d\u001f*\u001d#ĉ( \u001e\u001f &)- &#( )\u001d#.)-6 *\u001b,\u001b \u001e\u001f-*/ï- -\u001f, &#\u001c\u001f,\u001b\u001e\u001b- \u001b& .),,\u001f(.\u001f -\u001b(!/ù(\u001f)8 \u0005-.\u001f *\u001b-) *)\u001e,ù\u001b \u001f-.\u001b, \u001b-)\u001d#\u001b\n-\n\n\u001e) \u001d)( &\u001b \u001f2*,\u001f-#ĉ( \u001e\u001f \u001e\u001f.\u001f,'#(\u001b(.\u001f- \u001b(.#!ï(#\u001d)- \u001f( -/ -/*\u001f,l·\u001d#\u001f6 &)- \u001d/\u001b&\u001f- ,\u001f!/&\u001b( \u001f& \u001f!,\u001f-) ) #(!,\u001f-) \u001b\n&\u001b\n \n\u000f8 \u0003/\u001b(\u001e) &\u001b- \u001dï&/&\u001b- '\u001b\u001e/,\u001b- ,\u001f.),(\u001b( \u001b &\u001b\n \n\u000f6 */\u001f\u001e\u001f( &#\u001c\u001f,\u001b, -/- *,)\u001e/\u001d.)-6 3 \u001f-.)- (/\u001f0\u001b'\u001f(.\u001f\n\u001f$\u001f,\u001d\u001f, ,\u001f!/&\u001b\u001d#ĉ( \u001f( &\u001b \"\u001f'\u001b.)*)3\u001f-#-8\n \n) \u001b(.\u001f,#), -\u001f \u001f$\u001f'*&#l·\u001d\u001b \u001d)( &\u001b &\u001b\u001d.) \u001f,,#(\u001b6 *,).\u001fù(\u001b .,\u001b(-*),.\u001b\n-\n\n\u001e),\u001b \u001e\u001f \"#\u001f,,) &#\u001c\u001f,\u001b\u001e\u001b *), &)- (\u001f/.,ĉl·&)-6 3 &\u001b \"\u001f'#(\u001b6 \u001d)(.\u001f(#\u001e\u001b \u001f( &)- \u001f&\u001f'\u001f(.)- \u001e\u001f &\u001b -\u001f,#\u001f \u001f,#.,)#\u001e\u001f8\n \n\u001b","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":35,"lines":{"from":143,"to":168}}}}],["96",{"pageContent":"\u001e),\u001b \u001e\u001f \"#\u001f,,) &#\u001c\u001f,\u001b\u001e\u001b *), &)- (\u001f/.,ĉl·&)-6 3 &\u001b \"\u001f'#(\u001b6 \u001d)(.\u001f(#\u001e\u001b \u001f( &)- \u001f&\u001f'\u001f(.)- \u001e\u001f &\u001b -\u001f,#\u001f \u001f,#.,)#\u001e\u001f8\n \n\u001b\n\nLa\n \nUFB\n \nmegacariocítica\n(Meg) antecede a la UFC-\nMeg y ambas tienen como\nprecursor común a la UFC-\nGEMM.\n \nQuizás\n \nalgunas\nUFB-Meg\n \ny\n \nUFC-Meg\nsean\n \ndescendientes\n \nde\n \nla\nUFC-EMeg.\nLas células maduras son rete-\nnidas en la médula ósea hasta\nque alcanzan cierto grado de\nmaduración, con característi-\ncas morfológicas y funcionales\ndistintivas y sin potencial pro-\nliferativo, a excepción de los\nlinfocitos, para después ser li-\nberadas al torrente sanguíneo.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":35,"lines":{"from":168,"to":206}}}}],["97",{"pageContent":"CAPÍTULO 1. HEMATOPOYESIS\n\n9\n\nCuadro 1-3.\n \nAcción de los factores de crecimiento\nen progenitores hematopoyéticos y células sanguíneas\n\nCélula diana\n \nFactor de crecimiento\n\n\u0015\u0006\u00037\u0002\n \n6 \u0015\u0006\u00037\n \n6 \u0014\u0010\u000f6\n \n7g6\n \n7i6\n \n7l6\n \n7gg6\n \n7gm\n\u0015\u0006\u00037\u0007\u0005\n \n6 \u0006\u0005\u00037\u0007\n \n6\n \n7i6\n \n7j6\n \n7o\n\u0015\u0006\u00037\n \nLK","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":36,"lines":{"from":1,"to":42}}}}],["98",{"pageContent":"\u0015\u0006\u00037\u0007\n \n6 \u0006\u0005\u00037\u00076 \u0006\u0005\u00037\u0007\n \n6\n \n7j6\n \n7o\n\u0015\u0006\u00027\u0005\n \n6 \u0005\u0010\u000f6\n \n7i6\n \n7o\n\u0015\u0006\u00037\u0005\n \n6 \u0005\u0010\u000f6\n \n7i6\n \n7j\n\u0015\u0006\u00037\n \n6 \u0006\u0005\u00037\u0007\n \n6 \u0006\u0005\u00037\n \n6\n \n7l\n\u0015\u0006\u00037\u0007\n \n6 \u0006\u0005\u00037\u00076 \u0006\u0005\u00037\u0007\n \n6 \u0006\u0005\u00037\n \n6\n \n7l6\n \n7o6\n \n7gm\n\u0015\u0006\u00027\n \n\u001f!\n \n6 \u0014\u0010\u000f6\n \n7i6\n \n7l6\n \n7gg\n\u0015\u0006\u00037\n \n\u001f!\n \n6 \u0014\u0010\u000f6\n \n7i6\n \n7j6\n \n7l6\n \n7gg\n\u0015\u0006\u00037\u0002\u001b-\n \n6\n \n7gf6\n \n7gg\n\u0015\u0006\u00037\u0005)\n \n\u0006\u0005\u00037\u0007\n \n6\n \n7k\n\u0015\u0006\u00037\n \n\u0002\n \n6\n \n7h6\n \n7j\n\u0015\u0006\u00037\n \n\u0014\n \n6\n \n7h6\n \n7m\n\u0010,)\u001f,#.,)\u001c&\u001b-.)\n \n\u0005\u0010\u000f\n#( )\u001c&\u001b-.) \u0002\n \n7h6\n \n7j6\n \n7gj\n#( )\u001c&\u001b-.) \u0014\n \n7h6\n \n7m\n)()\u001d#.)I'\u001b\u001d,ĉ \u001b!)\n \n\u0006\u0005\u00037\u00076 \u0006\u0005\u00037\n \n6\n \n7g6\n \n7m6\n \n7gm\n\u000e\u001f/.,ĉl·&)\n \n\u0006\u0005\u00037\u00076 \u0006\u0005\u00037\u0007\n \n6\n \n7g6\n \n7n\n#( )\u001d#.) \u0002 I\n\u001dï&/&\u001b *&\u001b-'á.#\u001d\u001b\n \n7h6\n \n7j6\n \n7k6\n \n7l6\n \n7gf6\n \n7gi6\n \n7gj6\n \n7gn\n#( )\u001d#.) \u0014\n \n7h6\n \n7j6\n \n7l6\n \n7m6\n \n7gf6\n \n7gh6\n \n7gi6\n \n7gk6\n \n7gl6\n7gm6\n \n7gn\n#( )\u001d#.) \u0007\u0007\n \n7h6\n \n7l6\n \n7gf6\n \n7gh6\n \n7gi6\n \n7gk6\n \n7gn\n\u0015\u0006\u0003  /(#\u001e\u001b\u001e ),'\u001b\u001e),\u001b \u001e\u001f \u001d)&)(#\u001b-: \u0015\u0006\u0002  /(#\u001e\u001b\u001e ),'\u001b\u001e),\u001b \u001e\u001f \u001c,).\u001f-: \u0002\n \n \u001c&\u001b-.)-:\n \n &#( )#\u001e\u001f7'#\u001f&)#\u001e\u001f: \u0007\u0005\n \n\n!,\u001b(/&)\u001d#.)-6 \u001f,#.,)\u001d#.)-6 ')()\u001d#.)-6 '\u001f!\u001b\u001d\u001b,#)\u001d#.)-:\n \n &#( )#\u001e\u001f: \u0007\n \n !,\u001b(/&)\u001d#.)-6 ')()\u001d#.)-: \u0005  \u001f,#.,)#\u001e\u001f:\n \n ')()\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":36,"lines":{"from":44,"to":249}}}}],["99",{"pageContent":"\u001d#.)-: \u0007  !,\u001b(/&)\u001d#.)-:\n \n\u001f!  '\u001f!\u001b\u001d\u001b,#)\u001d#.)-: \u0002\u001b-  \u001c\u001b-ĉl·&)-: \u0005)  \u001f)-#(ĉl·&)-:\n \n\u0002  &#( )\u001d#.)- \u0002:\n \n\u0014  &#( )\u001d#.)- \u0014: \u0007\u0007 \n!,\u001b(\u001e\u001f !,\u001b(/&\u001b,:\n \n &#!\u001b(\u001e) \u001d7%#.:\n \n #(.\u001f,&\u001f/\u001d#(\u001b: \u0006\u0005\u0003  \u001b\u001d.), \u001f-.#'/&\u001b(.\u001f \u001e\u001f \u001d)&)(#\u001b-: \u0014\u0010\u000f  .,)'\u001c)*)3\u001f.#(\u001b: \u0005\u0010\u000f\n \u001f,#.,)*)3\u001f.#(\u001b8\n*,#'\u001f,\u001b #(\"#\u001c\u001f \u001f& \u001d,\u001f\u001d#'#\u001f(.) \u001e\u001f &\u001b \u0015\u0006\u00037\u0007\n \n3 &\u001b -\u001f!/(\u001e\u001b *).\u001f(\u001d#\u001b \u001f& \u001f \u001f\u001d.) \u001e\u001f &\u001b\n \n7i \u001f( &\u001b ),'\u001b\u001d#ĉ(\n\u001e\u001f \u0015\u0006\u00037\u0007\u0005\n \n3 \u001e\u001f \u0015\u0006\u00027\u00058\n\nREGULACIÓN\n\n)-\n \n\u001b\u001d.),\u001f- \u001e\u001f \u001d,\u001f\u001d#'#\u001f(.) \"\u001f')&#( )*)3ï.#\u001d)- -)( #(\u001e#-*\u001f(-\u001b\u001c&\u001f- \u001f( \u001f& *,)\u001d\u001f-) \u001e\u001f\n \n),'\u001b\u001d#ĉ( \u001e\u001f \u001dï&/&\u001b-\n-\u001b(!/ù(\u001f\u001b-6 3 -\u001f \u001e#0#\u001e\u001f( \u001f( \u001b\u001d.),\u001f- \u001f-.#'/&\u001b(.\u001f- \u001e\u001f \u001d)&)(#\u001b- B\u0006\u0005\u0003C \u001f\n \n8 \u0013)( 0\u001b,#\u001b- &\u001b- \u001d#.)\u001d#(\u001b- \u001e\u001f \u001d,\u001f\u001d#\n-\n\n'#\u001f(.) \u001d\u001f&/&\u001b, \u001d\u001b,\u001b\u001d.\u001f,#4\u001b\u001e\u001b- \u001c#)+/ù'#\u001d\u001b'\u001f(.\u001f 3 \u001d&)(\u001b\u001e\u001b- \u001b .,\u001b0ï- \u001e\u001f \u001d)*#\u001b- \u001d)'*&\u001f'\u001f(.\u001b,#\u001b- \u001e\u001f \u0004\u000e\u00018\n \n\u001b-\n\u001d\u001b,\u001b\u001d.\u001f,ù-.#\u001d\u001b- !\u001f(\u001f,\u001b&\u001f- \u001e\u001f \u001f-.\u001b- \u001d#.)\u001d#(\u001b- #(\u001d&/3\u001f(9 \u001f-.,/\u001d./,\u001b !&/\u001d)*,).\u001f#\u001d\u001b6 \u001b\u001d.#0#\u001e\u001b\u001e #( 0#.,) \u001f #( 0#0) \u001b","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":36,"lines":{"from":251,"to":288}}}}],["100",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n10\n\nLa eritropoyetina (EPO) es\nquizás el factor de crecimiento\nhematopoyético más estudia-\ndo, por lo que se conoce que el\nácido siálico terminal de esta\nalfaglobulina es indispensa-\nble para que exprese su acción\nbiológica\nLa TPO ejerce su actividad\nbiológica al unirse a un recep-\ntor codificado por el oncogén\n\n\u001d7'*&6\n \nque está presente solo\nen la CTH, megacariocitos y\nplaquetas. Es entonces cuan-\ndo la TPO o ligando c-mpl\nestimula la megacariopoyesis\ny por ende la producción de\nplaquetas.\n\n\u001c\u001b$\u001b- \u001d)(\u001d\u001f(.,\u001b\u001d#)(\u001f-6 +/\u001f -)( *,)\u001e/\u001d#\u001e\u001b- *), \u001e# \u001f,\u001f(.\u001f- .#*)- \u001e\u001f \u001dï&/&\u001b-6 !\u001f(\u001f,\u001b&'\u001f(.\u001f ,\u001f!/&\u001b( 'á- \u001e\u001f /(\u001b\n&ù(\u001f\u001b \u001d\u001f&/&\u001b, 3 '/\u001f-.,\u001b( \u001f \u001f\u001d.) \u001b\u001e#.#0) ) -#(ï,!#\u001d) \u001d)( ).,)- \u001b\u001d.),\u001f- \u001e\u001f \u001d,\u001f\u001d#'#\u001f(.) B0ï\u001b-\u001f \u001d/\u001b\u001e,) g7iC6 ')\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":37,"lines":{"from":1,"to":29}}}}],["101",{"pageContent":"\u001e/&\u001b( &\u001b \u001f2*,\u001f-#ĉ( \u001e\u001f !\u001f(\u001f- ,\u001f!/&\u001b\u001e),\u001f- *,)\u001e/\u001d.),\u001f- \u001e\u001f \u001d#.)\u001d#(\u001b- 3 \u001d)( ,\u001f\u001d/\u001f(\u001d#\u001b \u001b\u001d.Ě\u001b( \u001f( &\u001b \u001d)(.,\u001b*\u001b,.\u001f\n(\u001f)*&á-#\u001d\u001b \u001e\u001f &\u001b- \u001dï&/&\u001b- (),'\u001b&\u001f-8\n\u0013\u001f \u001d)()\u001d\u001f +/\u001f \u001f& á\u001d#\u001e) -#á&#\u001d) .\u001f,'#(\u001b& \u001e\u001f &\u001b \u001f,#.,)*)3\u001f.#(\u001b B\u0005\u0010\u000fC \u001f- #(\u001e#-*\u001f(-\u001b\u001c&\u001f *\u001b,\u001b +/\u001f \u001f2*,\u001f-\u001f -/\n\u001b\u001d\u001d#ĉ( \u001c#)&ĉ!#\u001d\u001b8\n \n\u001b \u0005\u0010\u000f \u001f- /(\u001b \u001b& \u001b!&)\u001c/&#(\u001b \u001d)( /( *\u001f-) ')&\u001f\u001d/&\u001b, \u001e\u001f if6j %\u0004\u001b6 \u001f& !\u001f( +/\u001f \u001d)\u001e#l·\u001d\u001b -/ -ù(\n-\n\n.\u001f-#- -\u001f &)\u001d\u001b&#4\u001b \u001f( \u001f& \u001d,)')-)'\u001b m 3 \u001f& '\u0012\u000e\u0001 -\u001f \u001f2*,\u001f-\u001b Ě(#\u001d\u001b'\u001f(.\u001f \u001f( ,#Ą)(\u001f- 3 \u001f( \"ù!\u001b\u001e)8\n \n\u001b *,)\u001e/\u001d\u001d#ĉ(\n\u001e\u001f \u0005\u0010\u000f \u001f- '\u001f\u001e#\u001b\u001e\u001b *), &\u001b .\u001f(-#ĉ( \u001e\u001f )2ù!\u001f() .#-/&\u001b,6 *\u001f,) -\u001f #!(),\u001b \u001f& '\u001f\u001d\u001b(#-') \u001f2\u001b\u001d.) *), \u001f& \u001d/\u001b& &\u001b- \u001dï&/&\u001b-\n*\u001f,#./\u001c/&\u001b,\u001f- ,\u001f(\u001b&\u001f- ,\u001f-*)(\u001e\u001f( \u001b &\u001b \"#*)2#\u001b8\n \n\u001b \u0005\u0010\u000f \u001b\u001d.Ě\u001b \u001e#,\u001f\u001d.\u001b'\u001f(.\u001f \u001b (#0\u001f& \u001e\u001f &\u001b \u0015\u0006\u00027\u0005 3 \u0015\u0006\u00037\u00056 \u001b-ù\n\u001d)') \u001e\u001f& *,)\u001f,#.,)\u001c&\u001b-.) 3 \u001f,#.,)\u001c&\u001b-.) \u001c\u001b-ĉl·&)8 \u0013\u001f -\u001b\u001c\u001f +/\u001f &\u001b \u0015\u0006\u00037\u0005 .#\u001f(\u001f ,\u001f\u001d\u001f*.),\u001f- *\u001b,\u001b &\u001b \u0005\u0010\u000f 3 +/\u001f \u001f-\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":37,"lines":{"from":31,"to":47}}}}],["102",{"pageContent":".)- \u001f-.á( ),'\u001b\u001e)- *), \u001e)- \u001d\u001b\u001e\u001f(\u001b- *,).\u001f#\u001d\u001b- \u001d)( *\u001f-)- ')&\u001f\u001d/&\u001b,\u001f- \u001e\u001f gff 3 of %\u0004\u001b8\n \n\u001b \u001dï&/&\u001b +/\u001f \u001e\u001b ),#!\u001f(\n\u001b &\u001b \u0015\u0006\u00037\u0005 \u001d)(.#\u001f(\u001f \u001b*,)2#'\u001b\u001e\u001b'\u001f(.\u001f g fkf ,\u001f\u001d\u001f*.),\u001f- *\u001b,\u001b &\u001b \"),')(\u001b 3 \u001f-.)- -)( \u001e\u001f \u001b&.\u001b 3 \u001c\u001b$\u001b \u001e\u001f(-#\u001e\u001b\u001e8\n\u0005( \u001f& \u001d,)')-)'\u001b gm -\u001f &)\u001d\u001b&#4\u001b( &)- !\u001f(\u001f- +/\u001f \u001d)\u001e#l·\u001d\u001b( &\u001b -ù(.\u001f-#- \u001e\u001f \u0006\u0005\u0003 \u001e\u001f !,\u001b(/&)\u001d#.)- B\u0007C 3 \u001e\u001f\n'#\u001f&)*\u001f,)2#\u001e\u001b-\u001b6 \u001d)'*)(\u001f(.\u001f #'*),.\u001b(.\u001f \u001e\u001f &)- !,á(/&)- *,#'\u001b,#)- \u001e\u001f &)- (\u001f/.,ĉl·&)-8 \u0005-.\u001f \u0006\u0005\u00036 \u001d)(\n/( *\u001f-) ')&\u001f\u001d/&\u001b, \u001e\u001f gn6n %\u0004\u001b6 \u001f-.#'/&\u001b &\u001b !,\u001b(/&)*)3\u001f-#- #( 0#0) 3 &\u001b \u0015\u0006\u00037\u0007\n \n#( 0#.,)8 \u0001\u001e\u001f'á-6 \u001f&\n\u0006\u0005\u00037\u0007 \u001f$\u001f,\u001d\u001f \u001b\u001d.#0#\u001e\u001b\u001e +/#'#).á\u001d.#\u001d\u001b -)\u001c,\u001f &)- (\u001f/.,ĉl·&)- 3 ')()\u001d#.)- \u001f #(\u001d,\u001f'\u001f(.\u001b &\u001b \u001b\u001d.#0#\u001e\u001b\u001e \u001b!)\u001dù\n-\n\n.#\u001d\u001b 3 \u001d#.).ĉ2#\u001d\u001b \u001e\u001f*\u001f(\u001e#\u001f(.\u001f \u001e\u001f \u001b(.#\u001d/\u001f,*)- \u001e\u001f &)- (\u001f/.,ĉl·&)-8\n( 0#0)6 \u001f& \u0006\u0005\u0003 \u001e\u001f !,\u001b(/&)\u001d#.)- 3 ')()\u001d#.)- B\u0007\n \nC \u001f-.#'/&\u001b &\u001b !,\u001b(/&)')()*)3\u001f-#-6 #(\u001d,\u001f'\u001f(.\u001b &\u001b\n\u001b\u001d.#0#\u001e\u001b\u001e \u001d#.).ĉ2#\u001d\u001b 3\n \n\u001b!)\u001dù.#\u001d\u001b \u001e\u001f &)- (\u001f/.,ĉl·&)- \u001f #(\"#\u001c\u001f &\u001b ').#&#\u001e\u001b\u001e \u001e\u001f &)- (\u001f/.,ĉl·&)-8\n \n( 0#.,)6 \u001f-.#\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":37,"lines":{"from":49,"to":70}}}}],["103",{"pageContent":"'/&\u001b \u001e#,\u001f\u001d.\u001b'\u001f(.\u001f \u001b &\u001b \u0015\u0006\u00037\u0007\n \n6 \u0015\u0006\u00037\u0007 3 \u0015\u0006\u00037\n \n\u001f #(\u001e#,\u001f\u001d.\u001b'\u001f(.\u001f #(\u001d,\u001f'\u001f(.\u001b &\u001b -/*\u001f,0#0\u001f(\u001d#\u001b \u001e\u001f\n&)- (\u001f/.,ĉl·&)- 3 \u001e\u001f &)- \u001f)-#(ĉl·&)-6 \u001b-ù \u001d)') &\u001b \u001b\u001e\"\u001f-#ĉ( \u001dï&/&\u001b7\u001dï&/&\u001b \u001e\u001f &)- (\u001f/.,ĉl·&)- 3 &\u001b &#\u001c\u001f,\u001b\u001d#ĉ(\n\u001e\u001f \"#-.\u001b'#(\u001b *), &)- \u001c\u001b-ĉl·&)-8 \u0005& !\u001f( ,\u001f-*)(-\u001b\u001c&\u001f \u001e\u001f &\u001b -ù(.\u001f-#- \u001e\u001f \u001f-.\u001f \u0006\u0005\u0003 +/\u001f \u001b\u001d.Ě\u001b \u001f( &\u001b \u001b-\u001f \u0007g \u001e\u001f&\n\u001d#\u001d&) \u001d\u001f&/&\u001b, -\u001f &)\u001d\u001b&#4\u001b \u001f( \u001f& \u001d,)')-)'\u001b k8\n\u0005& \u0006\u0005\u0003 \u001e\u001f ')()\u001d#.)- B\n \nC ) \u0006\u0005\u00037g \u001f-.#'/&\u001b &\u001b \u0015\u0006\u00037\n \n3 &\u001b \u0015\u0006\u00037\u00078 \u0005( \u001f& \u001d,)')-)'\u001b k6 -\u001f &)\u001d\u001b&#4\u001b\n\u001f& !\u001f( +/\u001f \u001d)\u001e#l·\u001d\u001b &\u001b -ù(.\u001f-#- \u001e\u001f& \u0006\u0005\u00037\n \n3 &\u001b \u001e\u001f -/ ,\u001f-*\u001f\u001d.#0) ,\u001f\u001d\u001f*.),6 +/\u001f \u001f- *,)\u001e/\u001d.) \u001e\u001f& *,).))(\u001d)!ï(\n\nc-fms\n8 \u0005-.\u001f \u0006\u0005\u0003 #(\u001e/\u001d\u001f &\u001b -ù(.\u001f-#- \u001e\u001f \u0006\u0005\u00037\u0007 3 &\u001b &#\u001c\u001f,\u001b\u001d#ĉ( \u001e\u001f\n \n7g *), ')()\u001d#.)-I'\u001b\u001d,ĉ \u001b!)- 3 \u001b0),\u001f\u001d\u001f\n-/ '#!,\u001b\u001d#ĉ(8\n\u0005( gooj6 \u001f( ),'\u001b -#'/&.á(\u001f\u001b6 0\u001b,#)- !,/*)- \u001e\u001f #(0\u001f-.#!\u001b\u001d#ĉ( \u001b#-&\u001b,)( \u001f( *&\u001b-'\u001b 3 ),#(\u001b \u001e\u001f \u001b(#'\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":37,"lines":{"from":72,"to":95}}}}],["104",{"pageContent":"&\u001f- \u001d)( \u001b*&\u001b-#\u001b '\u001f\u001e/&\u001b, #(\u001e/\u001d#\u001e\u001b *), ,\u001b\u001e#\u001b\u001d#ĉ(6 /(\n \n\u001b\u001d.), \u001d\u001b*\u001b4 \u001e\u001f \u001f-.#'/&\u001b, \u001f& \u001d,\u001f\u001d#'#\u001f(.) #( 0#.,) \u001e\u001f\n'\u001f!\u001b\u001d\u001b,#)\u001d#.)- \"/'\u001b()-8 \u0005-.\u001f\n \n\u001b\u001d.),6 \u001e\u001f()'#(\u001b\u001e) \u0014\u0010\u000f6 \u001f$\u001f,\u001d\u001f -/ \u001b\u001d.#0#\u001e\u001b\u001e \u001c#)&ĉ!#\u001d\u001b \u001b& /(#,-\u001f \u001b /(\n,\u001f\u001d\u001f*.), \u001d)\u001e#l·\u001d\u001b\u001e) *), \u001f& )(\u001d)!ï(\n \nc-mpl\n6 +/\u001f \u001f-.á *,\u001f-\u001f(.\u001f -)&) \u001f( \u0003\u0014\b6 '\u001f!\u001b\u001d\u001b,#)\u001d#.)- 3 *&\u001b+/\u001f.\u001b-8\n\u0005- \u001f(.)(\u001d\u001f- +/\u001f &\u001b \u0014\u0010\u000f ) &#!\u001b(\u001e) \u001d7'*& \u001f-.#'/&\u001b &\u001b '\u001f!\u001b\u001d\u001b,#)*)3\u001f-#- 3 *), \u001f(\u001e\u001f &\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f\n*&\u001b+/\u001f.\u001b-6 3 -\u001f -\u001b\u001c\u001f +/\u001f &\u001b \u0014\u0010\u000f .\u001b'\u001c#ï( \u001f-.#'/&\u001b &\u001b \u0015\u0006\u00037\u0002\n \n3 &\u001b \u0015\u0006\u00037\n \n8\n\u0005( \u001f& \u001d,)')-)'\u001b h -\u001f /\u001c#\u001d\u001b \u001f& !\u001f( +/\u001f \u001d)\u001e#l·\u001d\u001b &\u001b -ù(.\u001f-#- \u001e\u001f\n \n7g B\nα\n \n3\n \nβ\nC ) *#,ĉ!\u001f() \u001f(\u001eĉ!\u001f()6 \u001d)( *\u001f-)-\n')&\u001f\u001d/&\u001b,\u001f- \u001e\u001f gk 3 gm %\u0004\u001b6 ,\u001f-*\u001f\u001d.#0\u001b'\u001f(.\u001f8\n \n\u001b\n \n7g \u001f-.#'/&\u001b &\u001b \u0015\u0006\u00037\u0002\n \n6 &)- l·\u001c,)\u001c&\u001b-.)-6 )-.\u001f)\u001c&\u001b-.)- 3\n&\u001b- \u001dï&/&\u001b- -#()0#\u001b&\u001f-6 '\u001f-\u001b(!#\u001b&\u001f- 3 \u001e\u001f &\u001b !&ù\u001b8 \u0005-.\u001b\n \n*,)\u001e/\u001d\u001f (\u001f/.,)l·&#\u001b6 \u001f- +/#'#).á\u001d.#\u001d\u001b *\u001b,\u001b &)- ')()\u001d#\n-\n\n.)- 3 (\u001f/.,ĉl·&)-6 3 \u001f-.#'/&\u001b &\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f *,)-.\u001b!&\u001b(\u001e#(\u001b- *), \u001e# \u001f,\u001f(.\u001f- \u001dï&/&\u001b-8 \u0001\u001e\u001f'á-6 #(\u001e/\u001d\u001f &\u001b *,)\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":37,"lines":{"from":97,"to":135}}}}],["105",{"pageContent":".)- 3 (\u001f/.,ĉl·&)-6 3 \u001f-.#'/&\u001b &\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f *,)-.\u001b!&\u001b(\u001e#(\u001b- *), \u001e# \u001f,\u001f(.\u001f- \u001dï&/&\u001b-8 \u0001\u001e\u001f'á-6 #(\u001e/\u001d\u001f &\u001b *,)\n-\n\n\u001e/\u001d\u001d#ĉ( \u001e\u001f #(.\u001f, \u001f,ĉ( B \u0006\u000eC6 \u0006\u0005\u00037\u0007\n \n6 \u0006\u0005\u00037\u00076 \u0006\u0005\u00037\n \n6\n \n7l \u001f\n \n7h6 \u001b-ù \u001d)') &\u001b \u001f2*,\u001f-#ĉ( \u001e\u001f& ,\u001f\u001d\u001f*.),\n*\u001b,\u001b\n \n7h8 \u0012\u001f\u001d#\u001f(.\u001f'\u001f(.\u001f -\u001f \"\u001b \u001e\u001f')-.,\u001b\u001e) +/\u001f &\u001b- *&\u001b+/\u001f.\u001b- \u001b\u001d.#0\u001b\u001e\u001b- \u001f2*,\u001f-\u001b( \u001f( -/ -/*\u001f,l·\u001d#\u001f\n \n7g8\n\u000f,#!#(\u001b&'\u001f(.\u001f -\u001f \u001e\u001f-\u001d,#\u001c#ĉ +/\u001f &\u001b\n \n7h \u001f-.#'/&\u001b\u001c\u001b \u001f& \u001d,\u001f\u001d#'#\u001f(.) \u001e\u001f &#( )\u001d#.)- \u00148 \u0005( &\u001b \u001b\u001d./\u001b&#\u001e\u001b\u001e\n-\u001f \u001d)()\u001d\u001f +/\u001f \u001f-.\u001b \u001d#.)\u001d#(\u001b6 \u001d)( *\u001f-) ')&\u001f\u001d/&\u001b, \u001e\u001f gk %\u0004\u001b6 \u001f-.#'/&\u001b () -)&) \u001b &\u001b \u0015\u0006\u00037\n \n\u00146 -#() \u001b\u001e\u001f'á-\n\u001b &)- &#( )\u001d#.)- \u0002 \u001b\u001d.#0\u001b\u001e)- 3 *,)\u001c\u001b\u001c&\u001f'\u001f(.\u001f .\u001b'\u001c#ï( \u001b &\u001b \u0015\u0006\u00037\n \n\u00028 \u0005& ,\u001f\u001d\u001f*.), \u001e\u001f \u001f-.\u001b \u001d#.)\u001d#(\u001b \u001d),,\u001f-\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":37,"lines":{"from":135,"to":161}}}}],["106",{"pageContent":"*)(\u001e\u001f \u001b& \u001b(.ù!\u001f() \u0003\u0004hk6 '#-') +/\u001f -\u001f \"\u001b \u001e\u001f-\u001d,#.) \u001f( &)- \u001c&\u001b-.)- \u001e\u001f \u001b&!/()- *\u001b\u001d#\u001f(.\u001f- \u001d)( &\u001f/\u001d\u001f'#\u001b-\n\u001b!/\u001e\u001b- '#\u001f&)#\u001e\u001f-6 &) +/\u001f \"\u001b\u001d\u001f -/*)(\u001f, +/\u001f &\u001b\n \n7h */\u001f\u001e\u001f .\u001f(\u001f, \u001f \u001f\u001d.) \u001f( &\u001b '#\u001f&)*)3\u001f-#- \u001b(),'\u001b&8\n \n\u001b\n7h #(\"#\u001c\u001f \u001f& \u001d,\u001f\u001d#'#\u001f(.) \u001e\u001f &\u001b \u0015\u0006\u00037\u00076 &\u001b \u0015\u0006\u00037\n \n3 &\u001b \u0015\u0006\u00037\u0007\n \n6 #(\u001e/\u001d\u001f &\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f\n \n\u0006\u000e7\nγ\n6\n\u001b/'\u001f(.\u001b &\u001b \u001b\u001d.#0#\u001e\u001b\u001e \u001d#.).ĉ2#\u001d\u001b \u001e\u001f &)- &#( )\u001d#.)- ^\u001b-\u001f-#()-_ \u001b\u001d.#0\u001b\u001e)-6 3 ')\u001e/&\u001b &\u001b \u001f2*,\u001f-#ĉ( \u001e\u001f &\u001b- ')\n-\n\n&ï\u001d/&\u001b- \u001d&\u001b-\u001f\n \n\u001e\u001f& \u001d)'*&\u001f$) *,#(\u001d#*\u001b& \u001e\u001f \"#-.)\u001d)'*\u001b.#\u001c#&#\u001e\u001b\u001e B\b\n \n\u0001C8\n\u001b\n \n7i \u001f-.#'/&\u001b 'Ě&.#*&\u001f- &ù(\u001f\u001b- \u001d\u001f&/&\u001b,\u001f- B0ï\u001b-\u001f \u001d/\u001b\u001e,) g7iC6 \u001b-ù \u001d)') &\u001b -ù(.\u001f-#- \u001e\u001f #('/()!&)\u001c/\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":37,"lines":{"from":163,"to":189}}}}],["107",{"pageContent":"&ï\u001d/&\u001b- \u001d&\u001b-\u001f\n \n\u001e\u001f& \u001d)'*&\u001f$) *,#(\u001d#*\u001b& \u001e\u001f \"#-.)\u001d)'*\u001b.#\u001c#&#\u001e\u001b\u001e B\b\n \n\u0001C8\n\u001b\n \n7i \u001f-.#'/&\u001b 'Ě&.#*&\u001f- &ù(\u001f\u001b- \u001d\u001f&/&\u001b,\u001f- B0ï\u001b-\u001f \u001d/\u001b\u001e,) g7iC6 \u001b-ù \u001d)') &\u001b -ù(.\u001f-#- \u001e\u001f #('/()!&)\u001c/\n-\n\n&#(\u001b- B !C8\n \n\u001b\n \n7i .#\u001f(\u001f /( *\u001f-) ')&\u001f\u001d/&\u001b, \u001e\u001f hn %\u0004\u001b 3 -/ -ù(.\u001f-#- \u001f- ,\u001f!/&\u001b\u001e\u001b *), /( !\u001f( &)\u001d\u001b&#4\u001b\u001e)\n\u001f( \u001f& \u001d,)')-)'\u001b k8\n \n\u001b \u001b\u001e'#(#-.,\u001b\u001d#ĉ( \u001e#\u001b,#\u001b \u001e\u001f\n \n7i \u001f( *,#'\u001b.\u001f- *,)\u001e/\u001d\u001f #(\u001d,\u001f'\u001f(.) \u001f( \u001f& (Ě'\u001f,) \u001e\u001f\n\u0015\u0006\u00037\n \n\u001f!6 ,\u001f.#\u001d/&)\u001d#.)- 3 *&\u001b+/\u001f.\u001b- \u001d#,\u001d/&\u001b(.\u001f-8 \u0005( *\u001b\u001d#\u001f(.\u001f- \u001d)( \u001b(\u001f'#\u001b \u001b*&á-#\u001d\u001b6 &\u001b \u001b\u001e'#(#-.,\u001b\u001d#ĉ(\n\u001d,ĉ(#\u001d\u001b \u001e\u001f\n \n7i \u001b/'\u001f(.ĉ \u001f& (Ě'\u001f,) \u001e\u001f !,\u001b(/&)\u001d#.)-6 ')()\u001d#.)-6 &#( )\u001d#.)- 3 ,\u001f.#\u001d/&)\u001d#.)-6 *\u001f,) () *,)\u001e/$)\n#(\u001d,\u001f'\u001f(.) \u001f( &\u001b \u001d# ,\u001b \u001e\u001f *&\u001b+/\u001f.\u001b-8\n\u001b\n \n7j \u001f- *,)\u001e/\u001d#\u001e\u001b *), &)- &#( )\u001d#.)- \u00146 .#\u001f(\u001f /( *\u001f-) ')&\u001f\u001d/&\u001b, \u001e\u001f hf %\u0004\u001b 3 \u001f& !\u001f( +/\u001f ,\u001f!/&\u001b -/ -ù(.\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":37,"lines":{"from":189,"to":219}}}}],["108",{"pageContent":"-#- -\u001f &)\u001d\u001b&#4\u001b \u001f( \u001f& \u001d,)')-)'\u001b k8 \u0005-.#'/&\u001b &\u001b ),'\u001b\u001d#ĉ( \u001e\u001f \u0015\u0006\u00037\n \n\u0002 3 \u001b\u001d.#0\u001b \u001b &)- &#( )\u001d#.)- \u0014 \u001d))*\u001f,\u001b\u001e),\u001f-\n3 \u00028 \u0005( \u001d)(\u001d#\u001f,.) \u001d)( &\u001b\n \n7i6 \u001b/'\u001f(.\u001b \u001f& \u001d,\u001f\u001d#'#\u001f(.) \u001e\u001f '\u001b-.)\u001d#.)-: \u001d)( \u0006\u0005\u00037\u00076 &\u001b ),'\u001b\u001d#ĉ( \u001e\u001f \u0015\u0006\u00037\n\u0007\n \n: \u001d)( \u0005\u0010\u000f6 &\u001b \u001d,\u001f\u001b\u001d#ĉ( \u001e\u001f \u0015\u0006\u00037\u0005 3 \u0015\u0006\u00037\u0007\u0005\n \n: 3 \u001d)( \u0005\u0010\u000f \u001f\n \n7g6&\u001b ),'\u001b\u001d#ĉ( \u001e\u001f \u0015\u0006\u00037\n \n\u001f!8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":37,"lines":{"from":221,"to":235}}}}],["109",{"pageContent":"CAPÍTULO 1. HEMATOPOYESIS\n\n11","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":38,"lines":{"from":1,"to":3}}}}],["110",{"pageContent":"\u0005& \u001e\u001f-\u001d/\u001c,#'#\u001f(.) \u001e\u001f &\u001b\n \n7k6 \u001d)( *\u001f-) ')&\u001f\u001d/&\u001b, \u001e\u001f jk %\u0004\u001b6 ,\u001f*,\u001f-\u001f(.\u001b /( \u001b0\u001b(\u001d\u001f -#!(#l·\u001d\u001b.#0)\n\u001f( \u001f& \u001d)()\u001d#'#\u001f(.) \u001e\u001f &\u001b \"\u001f'\u001b.)*)3\u001f-#-6 3\u001b +/\u001f \u001b+/\u001f&&\u001b \u001f- &\u001b *,#'\u001f,\u001b \u001d#.)\u001d#(\u001b ,\u001f\u001d)()\u001d#\u001e\u001b +/\u001f \u001f$\u001f,\u001d\u001f\n\u001b\u001d\u001d#ĉ( \u001e#,\u001f\u001d.\u001b \u001f( &\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f \u001f)-#(ĉl·&)-8\n \n\u001b\n \n7i 3 \u001f& \u0006\u0005\u00037\u0007\n \n.#\u001f(\u001f( \u001f \u001f\u001d.) -#(ï,!#\u001d) \u001d)( &\u001b\n7k8 \u0001\u001e\u001f'á-6 &\u001b\n \n7k \u001b\u001d.Ě\u001b \u001f( &)- &#( )\u001d#.)- \u0002 *,)')0#\u001f(\u001e) -/ \u001d,\u001f\u001d#'#\u001f(.) 3 \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( \u001b \u001dï&/&\u001b-\n*,)\u001e/\u001d.),\u001b- \u001e\u001f\n \n!8\n(#\u001d#\u001b&'\u001f(.\u001f6 &\u001b\n \n7l !\u001b(ĉ #'*),.\u001b(\u001d#\u001b \u001c#)&ĉ!#\u001d\u001b \u001d)') \u001b\u001d.), \u001f-\u001f(\u001d#\u001b& \u001f( &\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f \"#\u001c,#\u001e)'\u001b-:\n\u001b\"),\u001b -\u001f -\u001b\u001c\u001f +/\u001f \u001f& \u001d,\u001f\u001d#'#\u001f(.) \u001d\u001f&/&\u001b, \u001e\u001f& '#\u001f&)'\u001b 'Ě&.#*&\u001f B*\u001b\u001e\u001f\u001d#'#\u001f(.) (\u001f)*&á-#\u001d) '\u001b&#!() +/\u001f\n#(0)&/\u001d,\u001b \u001b &\u001b \u001dï&/&\u001b *&\u001b-'á.#\u001d\u001bC \"/'\u001b() \u001e\u001f*\u001f(\u001e\u001f \u001e\u001f \u001f-.\u001b\n \n8 \u0005( \u001d)(\u001e#\u001d#)(\u001f- (),'\u001b&\u001f-6 &\u001b\n \n7l6 \u001d)( *\u001f-)\n')&\u001f\u001d/&\u001b, \u001e\u001f hg \u001b hk %\u0004\u001b 3 \u001d/3) !\u001f( -\u001f /\u001c#\u001d\u001b \u001f( \u001f& \u001d,)')-)'\u001b m6 \u001f-.#'/&\u001b \u001e\u001f '\u001b(\u001f,\u001b \u001e#,\u001f\u001d.\u001b &\u001b ),'\u001b\u001d#ĉ(\n\u001e\u001f \u0015\u0006\u00027\n \n\u001f!6 \u0015\u0006\u00037\n \n\u001f!6 \u0015\u0006\u00037\u0007 3 \u0015\u0006\u00037\n \n: 3 \u001e\u001f '\u001b(\u001f,\u001b -#(ï,!#\u001d\u001b \u001d)( &\u001b\n \n7i6 \u001f& \u001d,\u001f\u001d#'#\u001f(.) \u001e\u001f &\u001b\n\u0015\u0006\u00037\u0002\n \n3 &\u001b \u0015\u0006\u00037\n \n8 \u0001-#'#-')6 &\u001b\n \n7l -#,0\u001f \u001e\u001f \u001f-.ù'/&) *,)&# \u001f,\u001b.#0) 3 \u001e# \u001f,\u001f(\u001d#\u001b\u001e), \u001e\u001f &)- \"\u001f*\u001b.)\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":38,"lines":{"from":5,"to":48}}}}],["111",{"pageContent":"\u001d#.)-6 &) +/\u001f \"\u001b\u001d\u001f +/\u001f \u001f-.\u001b\n \n\u001f-.ï #'*&#\u001d\u001b\u001e\u001b \u001f( &\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f ,\u001f\u001b\u001d.#0)- \u001e\u001f \u001b-\u001f \u001b!/\u001e\u001b \u001d)') &\u001b *,).\u001fù(\u001b\n\u0003 ,\u001f\u001b\u001d.#0\u001b8 \u0001-#'#-')6 &\u001b\n \n7l #(\u001e/\u001d\u001f &\u001b \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( .\u001f,'#(\u001b& \u001e\u001f &#( )\u001d#.)- \u0002 \u001b \u001dï&/&\u001b- *&\u001b-'á.#\u001d\u001b-\n*,)\u001e/\u001d.),\u001b- \u001e\u001f\n \n! 3 &\u001b \u001e\u001f &)- &#( )\u001d#.)- \u0014 \u001d#.).ĉ2#\u001d)-6 \u001b-ù \u001d)') &\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f\n \n7h *), \u001dï&/&\u001b- \u00148\n \n\u001b\n7l #(\"#\u001c\u001f \u001f& \u001d,\u001f\u001d#'#\u001f(.) \u001e\u001f l·\u001c,)\u001c&\u001b-.)- \"/'\u001b()- 3 -/ \u001b\u001e'#(#-.,\u001b\u001d#ĉ( \u001f( ,\u001b.)(\u001f- #(\u001e/\u001d\u001f .,)'\u001c)\u001d#.)-#- 3\n-/*,#'\u001f &\u001b #(\"#\u001c#\u001d#ĉ( \"\u001f'\u001b.)*)3ï.#\u001d\u001b '\u001f\u001e#\u001b\u001e\u001b *), \u001f& \u001b\u001d.), .,\u001b(- ),'\u001b\u001e), \u001e\u001f \u001d,\u001f\u001d#'#\u001f(.) \u001cá-#\u001d)8\n\u0005( \u001f& \u001d,)')-)'\u001b n -\u001f &)\u001d\u001b&#4\u001b \u001f& !\u001f( +/\u001f \u001d)\u001e#l·\u001d\u001b &\u001b -ù(.\u001f-#- \u001e\u001f\n \n7m6 +/\u001f \u001f- /(\u001b !&/\u001d)*,).\u001fù(\u001b \u001e\u001f\nhk %\u0004\u001b +/\u001f \u001f-.#'/&\u001b &\u001b *,)&# \u001f,\u001b\u001d#ĉ( \u001e\u001f \u001dï&/&\u001b- *,\u001f7\u00026 *\u001f,) () &\u001b \u001e\u001f &#( )\u001d#.)- \u0002 '\u001b\u001e/,)-8 \u0005-.\u001b\n\u001e\u001f-\u001f'*\u001fĄ\u001b /(\u001b\n \n/(\u001d#ĉ( ,\u001f&\u001f0\u001b(.\u001f \u001f( &\u001b *,)&# \u001f,\u001b\u001d#ĉ( 3 \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( \u001e\u001f &)- .#')\u001d#.)- 3 \u001b\u001d.Ě\u001b \u001d)')\n'#.ĉ!\u001f() 3 \u001d)'#.ĉ!\u001f() \u001f( &)- &#( )\u001d#.)- \u0014 '\u001b\u001e/,)-8 \u0003)( \u001f& \u001f'*&\u001f) \u001e\u001f &\u001b\n \n7m '\u001b,\u001d\u001b\u001e\u001b ,\u001b\u001e#)#-).ĉ*#\u001d\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":38,"lines":{"from":50,"to":75}}}}],["112",{"pageContent":"'\u001f(.\u001f6 -\u001f \u001e\u001f'/\u001f-.,\u001b +/\u001f &\u001b- \u001dï&/&\u001b- *,\u001f7\u00026 &)- .#')\u001d#.)-6 &)- &#( )\u001d#.)- \u0014 3 &)- '\u001b\u001d,ĉ \u001b!)- \u001e\u001f\n \n\u000f \u001f2\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":38,"lines":{"from":77,"to":80}}}}],["113",{"pageContent":"*,\u001f-\u001b( ,\u001f\u001d\u001f*.),\u001f- *\u001b,\u001b &\u001b\n \n7m8\n \n\u001b\n \n7h *).\u001f(\u001d#\u001b &\u001b \u001b\u001d\u001d#ĉ( \u001c#)&ĉ!#\u001d\u001b \u001e\u001f &\u001b\n \n7m6 3 \u001f-.\u001b \u001b -/ 0\u001f4 ,\u001f!/&\u001b &\u001b\n*,)\u001e/\u001d\u001d#ĉ( \u001e\u001f\n \n7h 3 &\u001b \u001f2*,\u001f-#ĉ( \u001e\u001f& ,\u001f\u001d\u001f*.), *\u001b,\u001b\n \n7h \u001f( \u001dï&/&\u001b- \u0014 '\u001b\u001e/,\u001b-8 \u0005( ,\u001b.)(\u001f- ,\u001b\u001e#\u001b\u001e)-6\n&\u001b\n \n7m \u001b0),\u001f\u001d\u001f &\u001b ,\u001f\u001d/*\u001f,\u001b\u001d#ĉ( \u001e\u001f *&\u001b+/\u001f.\u001b-8\n\u001b\n \n7n6 ) *ï*.#\u001e) \u001b\u001d.#0\u001b\u001e), \u001e\u001f (\u001f/.,ĉl·&)- B\u0010\u0001\u000e7gC6 \u001f- -\u001f\u001d,\u001f.\u001b\u001e\u001b *), \u001e# \u001f,\u001f(.\u001f- .#*)- \u001e\u001f \u001dï&/&\u001b- \u001f(\n,\u001f-*/\u001f-.\u001b \u001b /( \u001f-.ù'/&) #(ł\u001b'\u001b.),#)6 \u001f- \u001e\u001f\u001d#,6 #-+/\u001f'#\u001b6 .,\u001b/'\u001b.#-')6 #( \u001f\u001d\u001d#ĉ( ) \u001dá(\u001d\u001f,8 \u0005-.\u001b\n \n()\n!/\u001b,\u001e\u001b \")')&)!ù\u001b \u001d)( ).,\u001b- \u001d#.)\u001d#(\u001b- *,)\u001e/\u001d#\u001e\u001b- *), \u001dï&/&\u001b- ')()(/\u001d&\u001f\u001b,\u001f-\n \n\u001b!)\u001dù.#\u001d\u001b-6 *\u001f,) -ù \u001d)( &)-\n*ï*.#\u001e)- \u001e\u001f &)- !,á(/&)-\n \nα\n \n\u001e\u001f &\u001b- *&\u001b+/\u001f.\u001b-8 \u0005& *\u001f,l·& \u001c#)&ĉ!#\u001d) \u001e\u001f& \u0010\u0001\u000e7g -\u001f \u001b-\u001f'\u001f$\u001b \u001b& \u001e\u001f ).,)- *ï*.#\u001e)-\n+/#'#).á\u001d.#\u001d)- \u001d)') \u001f& \u0003k\u001b6 &) +/\u001f -/!#\u001f,\u001f +/\u001f &\u001b\n \n7n \u001f- /( '\u001f\u001e#\u001b\u001e), \u001e\u001f &\u001b ,\u001f-*/\u001f-.\u001b #(ł\u001b'\u001b.),#\u001b \u001d)(\n\u001b\u001d.#0#\u001e\u001b\u001e +/#'#).á\u001d.#\u001d\u001b8\n \n\u001b\n \n7g 3 \u001f&\n \n\u001b\u001d.), \u001e\u001f (\u001f\u001d,)-#- ./'),\u001b& #(\u001d,\u001f'\u001f(.\u001b( &\u001b \u001f2*,\u001f-#ĉ( \u001e\u001f &\u001b\n \n7n \u001f(\n&)- (\u001f/.,ĉl·&)-8\n\u001b\n \n7o '\u001b(.#\u001f(\u001f \u001f& \u001d,\u001f\u001d#'#\u001f(.) \u001e\u001f &\u001b \u0015\u0006\u00027\u0005 \u001f( *,\u001f-\u001f(\u001d#\u001b \u001e\u001f \u0005\u0010\u000f 3 \u001f-.#'/&\u001b &\u001b *,)&# \u001f,\u001b\u001d#ĉ( \u001e\u001f &ù\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":38,"lines":{"from":82,"to":129}}}}],["114",{"pageContent":"(\u001f\u001b- \u001d\u001f&/&\u001b,\u001f- '\u001f!\u001b\u001d\u001b,#)\u001dù.#\u001d\u001b-8 \u0005( \u001dï&/&\u001b- \u001f.\u001b&\u001f-6 \u001f-.\u001b \u001d#.)\u001d#(\u001b \u001b0),\u001f\u001d\u001f &\u001b '\u001b\u001e/,\u001b\u001d#ĉ( \u001e\u001f \u0015\u0006\u00037\u0007\u0005\n \n6\n\u0015\u0006\u00037\u0007\n \n3 \u0015\u0006\u00037\u00078 \u0005& !\u001f( ,\u001f-*)(-\u001b\u001c&\u001f \u001e\u001f &\u001b -ù(.\u001f-#- \u001e\u001f\n \n7o -\u001f &)\u001d\u001b&#4\u001b \u001f( \u001f& \u001d,)')-)'\u001b k8\n\u0005( \u001f& \u001d,)')-)'\u001b g -\u001f \u001f(\u001d/\u001f(.,\u001b \u001f& !\u001f( +/\u001f ,\u001f!/&\u001b &\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f\n \n7gf8 \u0005-.\u001b\n \n\u001f-.#'/&\u001b &\u001b ),'\u001b\n-\n\n\u001d#ĉ( \u001e\u001f \u0015\u0006\u00037\n \n\u0007\u0007 \u001f #(\u001d,\u001f'\u001f(.\u001b &\u001b \u001b\u001d.#0#\u001e\u001b\u001e \u001d#.).ĉ2#\u001d\u001b \u001e\u001f &\u001b- \u001dï&/&\u001b- \u00146 '\u001b(.#\u001f(\u001f 0#\u001b\u001c&\u001f- \u001b &)- &#( )\u001d#.)-\n\u00026 \u001b0),\u001f\u001d\u001f &\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f '\u001b-.)\u001d#.)- \u001f #(\"#\u001c\u001f &\u001b \u001e\u001f\n \n\u0006\u000e7!\u001b''\u001b *), &#( )\u001d#.)- \u0014 \u001b\u001d.#0\u001b\u001e)-8\n\u001b\n \n7gg \u001d)'*\u001b,.\u001f \u001b&!/()- \u001e\u001f &)- \u001f \u001f\u001d.)- \u001c#)&ĉ!#\u001d)- \u001e\u001f &\u001b\n \n7l9 \u001f-.#'/&\u001b &ù(\u001f\u001b- \u001d\u001f&/&\u001b,\u001f- \u001e\u001f &#( )\u001d#.)-\n\u0002 3 &\u001b ),'\u001b\u001d#ĉ( \u001e\u001f \u0015\u0006\u00037\u0002\n \n6 \u0015\u0006\u00027\n \n\u001f! 3 \u0015\u0006\u00037\n \n\u001f!: \u001b\u001e\u001f'á-6 #(\u001e/\u001d\u001f &ù(\u001f\u001b- \u001d\u001f&/&\u001b,\u001f- \u001e\u001f '\u001b-.)\u001d#.)-8 \u0005&\n!\u001f( ,\u001f-*)(-\u001b\u001c&\u001f \u001e\u001f &\u001b -ù(.\u001f-#- \u001e\u001f\n \n7gg -\u001f /\u001c#\u001d\u001b \u001f( \u001f& \u001d,)')-)'\u001b g8\n \n\u001b \u001b*&#\u001d\u001b\u001d#ĉ( \u001e\u001f \u001f-.\u001b\n \n\u001f( \"/'\u001b()-\n#(\u001d,\u001f'\u001f(.\u001b &\u001b \u001d/\u001f(.\u001b *&\u001b+/\u001f.\u001b,#\u001b 3 \u001f-.á \u001e#-*)(#\u001c&\u001f \u001d)'\u001f,\u001d#\u001b&'\u001f(.\u001f8\n\u001b\n \n7gh \u001f- /( \u001eù'\u001f,) \u001d)( *\u001f-)- ')&\u001f\u001d/&\u001b,\u001f- \u001e\u001f ik 3 jf %\u0004\u001b8 \u0005-.\u001b\n \n6 .\u001b'\u001c#ï( \u001d)()\u001d#\u001e\u001b \u001d)')","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":38,"lines":{"from":131,"to":176}}}}],["115",{"pageContent":"factor estimulante de células asesinas naturales\n \nB\u000e\n \nC6 \u001b\u001d.Ě\u001b -#(ï,!#\u001d\u001b'\u001f(.\u001f \u001d)( &\u001b\n \n7h \u001f-.#'/&\u001b(\u001e) \u001f&\n\u001d,\u001f\u001d#'#\u001f(.) 3 &\u001b \u001b\u001d.#0#\u001e\u001b\u001e \u001d#.).ĉ2#\u001d\u001b \u001e\u001f \u001f-.\u001b- \u001dï&/&\u001b-8 \u0001\u001e\u001f'á-6 &\u001b\n \n7gh #(\u001e/\u001d\u001f &\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f\n \n\u0006\u000e7\nγ\n\n*), \u001dï&/&\u001b- \u0014 3 \u000e\n \n8\n\u001b\n \n7gi6 /(\u001b \u001d#.)\u001d#(\u001b *,)\u001e/\u001d#\u001e\u001b *), \u001dï&/&\u001b- \u00146 \u001d)'*\u001b,.\u001f \u001b&!/(\u001b- \u001e\u001f &\u001b- \u001b\u001d.#0#\u001e\u001b\u001e\u001f- \u001c#)&ĉ!#\u001d\u001b- \u001e\u001f &\u001b\n7j8\n \n\u001b\n \n7gi6\u001b \u001e# \u001f,\u001f(\u001d#\u001b \u001e\u001f &\u001b\n \n7j6 #(\u001e/\u001d\u001f &\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f\n \n\u0006\u000e7\nγ\n \n*),\n \n\u0007\u0007 3 \u001b0),\u001f\u001d\u001f \u001f& \u001d,\u001f\u001d#'#\u001f(\n-\n\n.) \u001e\u001f &#( )\u001d#.)- \u0014 \u001b\u001d.#0\u001b\u001e)-8\n)- &#( )\u001d#.)- \u0014 (),'\u001b&\u001f- 3 &\u001b- \u001dï&/&\u001b- \u0002 \u001e\u001f *\u001b\u001d#\u001f(.\u001f- \u001d)( &\u001f/\u001d\u001f'#\u001b \u001b!/\u001e\u001b &#( )\u001c&á-.#\u001d\u001b \u001e\u001f \u001f-.#,*\u001f \u00026\n&#( )'\u001b- \u001e\u001f \u001dï&/&\u001b- \u0002 3 &\u001f/\u001d\u001f'#\u001b &#( )\u001dù.#\u001d\u001b \u001d,ĉ(#\u001d\u001b *,)\u001e/\u001d\u001f(\n \n7gj8 \u0005-.\u001b \u001d#.)\u001d#(\u001b #(\u001e/\u001d\u001f &\u001b *,)&# \u001f,\u001b\u001d#ĉ(\n\u001e\u001f &#( )\u001d#.)- \u0002 \u001f #(\"#\u001c\u001f &\u001b -ù(.\u001f-#- 3 \u001f2\u001d,\u001f\u001d#ĉ( \u001e\u001f\n \n!8\n\u001b\n \n7gk \u001d)'*\u001b,.\u001f \u001b\u001d.#0#\u001e\u001b\u001e\u001f- \u001c#)&ĉ!#\u001d\u001b- \u001d)( &\u001b\n \n7h8 \u0005-.\u001b \u001d#.)\u001d#(\u001b \u001f-.#'/&\u001b &\u001b *,)&# \u001f,\u001b\u001d#ĉ( \u001e\u001f \u001dï\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":38,"lines":{"from":178,"to":227}}}}],["116",{"pageContent":"&/&\u001b- \u0003\u0004j 3 \u0003\u0004n \u001b\u001d.#0\u001b\u001e\u001b-6 &#( )\u001d#.)- (\u001b./,\u001b&\u001f- \u001d#.).ĉ2#\u001d)- 3 '\u001b-.)\u001d#.)-6 3 \u001f- /( *).\u001f(.\u001f +/#'#).á\u001d.#\u001d)\n\u001e\u001f &#( )\u001d#.)- \u00148\n \n\u001b\n \n7gk \u001b\u001d.Ě\u001b \u001d)') \u001d)\u001f-.#'/&\u001b\u001e), \u001d)( &\u001b\n \n7gh *\u001b,\u001b\n \n\u001b\u001d#&#.\u001b, &\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f\n \n\u0006\u000e7\nγ\n\n3\n \n\u001b\u001d.), \u001e\u001f (\u001f\u001d,)-#- ./'),\u001b& B\u0006\u000e\u0014C\n \nα\n8 \u0005-.\u001b \u001d#.)\u001d#(\u001b .#\u001f(\u001f \u001f \u001f\u001d.) \u001b(\u001b\u001cĉ&#\u001d)6 3\u001b +/\u001f #(\u001d,\u001f'\u001f(.\u001b &\u001b '\u001b-\u001b\n'/-\u001d/&\u001b, 3 \u001b\u001e\u001f'á- \u001b3/\u001e\u001b \u001b &\u001b \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( 3 '\u001b\u001e/,\u001b\u001d#ĉ( \u001e\u001f& -#-.\u001f'\u001b #('/(#.\u001b,#)8 \u0001& *\u001b,\u001f\u001d\u001f,6 &\u001b\n \n7gk\n*\u001b,.#\u001d#*\u001b \u001f( &\u001b l·-#)*\u001b.)&)!ù\u001b \u001e\u001f &\u001b '\u001b-.)\u001d#.)-#- -#-.ï'#\u001d\u001b8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":38,"lines":{"from":229,"to":252}}}}],["117",{"pageContent":"La\n \nIL-6\n \nganó\n \nimportancia\nbiológica como factor esencial\nen la producción de hibrido-\nmas; ahora se conoce que el cre-\ncimiento celular del mieloma\nmúltiple depende de esta IL.\nLa IL-11 estimula líneas celu-\nlares de linfocitos B y la forma\n-\nción de UFC-BL UFB-Meg y\nUFC-Meg; además, estimula\nlíneas celulares de mastocitos.\nLos linfocitos T normales y las\ncélulas B de pacientes con leu-\ncemia aguda linfoblástica de\nestirpe B, linfomas de células\nB y leucemia linfocítica cróni-\nca producen IL-14. Esta cito-\ncina induce la proliferación de\nlinfocitos B e inhibe la síntesis\ny excreción de Ig.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":38,"lines":{"from":254,"to":280}}}}],["118",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n12\n\n\u0005& !\u001f( +/\u001f \u001d)\u001e#l·\u001d\u001b &\u001b -ù(.\u001f-#- \u001e\u001f\n \n7gl -\u001f &)\u001d\u001b&#4\u001b \u001f( \u001f& \u001d,)')-)'\u001b gk8 \u0005-.\u001b #(.\u001f,&\u001f/\u001d#(\u001b \u001f- -#(.\u001f.#4\u001b\u001e\u001b\n\u001d)') /( *ï*.#\u001e) \u001d)( *\u001f-) ')&\u001f\u001d/&\u001b, \u001e\u001f nf %\u0004\u001b6 +/\u001f \u001b& -\u001f, *,)\u001d\u001f-\u001b\u001e\u001b \u001b -/\n \n),'\u001b \u001c#)&ĉ!#\u001d\u001b'\u001f(.\u001f \u001b\u001d.#0\u001b\n\u001b&\u001d\u001b(4\u001b /( *\u001f-) ')&\u001f\u001d/&\u001b, \u001f(.,\u001f gj 3 gm %\u0004\u001b8 \u0005-.\u001b \u001d#.)\u001d#(\u001b \u001f- *,)\u001e/\u001d#\u001e\u001b *), \u001dï&/&\u001b- \u0003\u0004j 3 \u0003\u0004n \u001b\u001d.#0\u001b\n-\n\n\u001e\u001b-6 \u001f)-#(ĉl·&)-6 '\u001b-.)\u001d#.)- 3 *), \u001dï&/&\u001b- \u001f*#.\u001f&#\u001b&\u001f- */&')(\u001b,\u001f- \u001e\u001f *\u001b\u001d#\u001f(.\u001f- \u001d)( \u001b-'\u001b8 \u0013/- *,#(\u001d#*\u001b&\u001f-\n/(\u001d#)(\u001f- -)( *,)#(ł\u001b'\u001b.),#\u001b- \u001f #('/()')\u001e/&\u001b\u001e),\u001b-6 \u001b& \u001b\u001d./\u001b, \u001d)') +/#'#).á\u001d.#\u001d)- \u001e\u001f &#( )\u001d#.)- \u0003\u0004j8\n\u001b\n \n7gm \u001f- /(\u001b !&/\u001d)*,).\u001fù(\u001b *,)\u001e/\u001d#\u001e\u001b *), &#( )\u001d#.)- \u0014 +/\u001f \u001f-.#'/&\u001b '\u001b\u001d,ĉ \u001b!)-6 \u001dï&/&\u001b- \u001f(\u001e).\u001f&#\u001b&\u001f- 3\n\u001f*#.\u001f&#\u001b&\u001f-6 +/\u001f,\u001b.#()\u001d#.)- 3 l·\u001c,)\u001c&\u001b-.)- *\u001b,\u001b +/\u001f *,)\u001e/4\u001d\u001b(\n \n7g6\n \n7l6\n \n7n6\n \n7gf6\n \n7gh6\u0006\u0005\u00037\u00076 \u0006\u000e\u00147\nα","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":39,"lines":{"from":1,"to":30}}}}],["119",{"pageContent":"3 \u001b\u001d.), #(\"#\u001c#\u001e), \u001e\u001f &\u001b &\u001f/\u001d\u001f'#\u001b8\n \n(\u001e/\u001d\u001f &\u001b \u001f2*,\u001f-#ĉ( \u001e\u001f ')&ï\u001d/&\u001b- \u001e\u001f \u001d#.)\u001b\u001e\"\u001f-#ĉ(6 \u001b0),\u001f\u001d\u001f &\u001b *,)&# \u001f,\u001b\u001d#ĉ(\n\u001e\u001f &#( )\u001d#.)- \u00146 *,)'/\u001f0\u001f &\u001b \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( 3 *,)&# \u001f,\u001b\u001d#ĉ( \u001e\u001f &\u001b \u0003\u0014\b \u001f #( 0#0) \u001f-.#'/&\u001b &\u001b !,\u001b(/&)*)3\u001f-#-8\n\u001b- *,)*#\u001f\u001e\u001b\u001e\u001f-\n \n/(\u001d#)(\u001b&\u001f- \u001e\u001f &\u001b\n \n7gn -)( -\u001f'\u001f$\u001b(.\u001f- \u001b &\u001b- \u001e\u001f &\u001b\n \n7gh8 \u0005- *,)\u001e/\u001d#\u001e\u001b *), /(\u001b !,\u001b(\n0\u001b,#\u001f\u001e\u001b\u001e \u001e\u001f \u001dï&/&\u001b-6 #(\u001d,\u001f'\u001f(.\u001b &\u001b #('/(#\u001e\u001b\u001e \u001d\u001f&/&\u001b, 3 ')\u001e/&\u001b &\u001b\n \n/(\u001d#ĉ( \u001e\u001f &)- &#( )\u001d#.)- \u00146 \u0002 3 \u001dï&/&\u001b-\n\u001d)( \u001b\u001d.#0#\u001e\u001b\u001e \u001d#.).ĉ2#\u001d\u001b (\u001b./,\u001b&8\n\u0005& &#!\u001b(\u001e) \u001e\u001f \u001d7%#. B\n \nC6 .\u001b'\u001c#ï( \u001d)()\u001d#\u001e) \u001d)')\n \nfactor de mastocitos\n6\n \nfactor de células estaminales\n6\n \nfactor\nhemolinfopoyético 1\n \n)\n \nfactor de células troncales\n6 \u001f- \u001d)\u001e#l·\u001d\u001b\u001e) *), \u001f& \u001d,)')-)'\u001b gf6 3 -/ ,\u001f\u001d\u001f*.), \u001f- /(\u001b\n\u001d#(\u001b-\u001b \u001e\u001f .#,)-#(\u001b *,)\u001e/\u001d.) \u001e\u001f& )(\u001d)!ï(\n \nc-kit\n \nB\u0003\u0004ggmC8 \u0005-.\u001f\n \n\u001b\u001d.), \u001f-.#'/&\u001b \u001e# \u001f,\u001f(.\u001f- &ù(\u001f\u001b- \u001d\u001f&/&\u001b,\u001f-\n\"\u001f'\u001b.)*)3ï.#\u001d\u001b-6 #(\u001d&/3\u001f(\u001e) \u001b &\u001b \u0015\u0006\u00037\u0002\n \n6 3 \u001d),,#!\u001f \u001f& \u001e\u001f \u001f\u001d.) \u001e\u001f&\n \n\b \u001f( &\u001b \u001d\u001f*\u001b '/,#(\u001b \u0013gI\u0013gg8 \u0005&\n*\u001f, -\u001f \u001f- #(\u001d\u001b*\u001b4 \u001e\u001f #(\u001e/\u001d#, &\u001b *,)&# \u001f,\u001b\u001d#ĉ( 3 \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( \u001d\u001f&/&\u001b,: -#( \u001f'\u001c\u001b,!)6 \u001b \u001e)-#- '/3 \u001c\u001b$\u001b-6","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":39,"lines":{"from":32,"to":76}}}}],["120",{"pageContent":"\"\u001f'\u001b.)*)3ï.#\u001d\u001b-6 #(\u001d&/3\u001f(\u001e) \u001b &\u001b \u0015\u0006\u00037\u0002\n \n6 3 \u001d),,#!\u001f \u001f& \u001e\u001f \u001f\u001d.) \u001e\u001f&\n \n\b \u001f( &\u001b \u001d\u001f*\u001b '/,#(\u001b \u0013gI\u0013gg8 \u0005&\n*\u001f, -\u001f \u001f- #(\u001d\u001b*\u001b4 \u001e\u001f #(\u001e/\u001d#, &\u001b *,)&# \u001f,\u001b\u001d#ĉ( 3 \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( \u001d\u001f&/&\u001b,: -#( \u001f'\u001c\u001b,!)6 \u001b \u001e)-#- '/3 \u001c\u001b$\u001b-6\n*).\u001f(\u001d#\u001b \u001f& \u001f \u001f\u001d.) \u001e\u001f .)\u001e)- &)- \u001b\u001d.),\u001f- \u001e\u001f \u001d,\u001f\u001d#'#\u001f(.) \"\u001f'\u001b.)*)3ï.#\u001d) \"\u001b-.\u001b \u001b\"),\u001b \u001f-./\u001e#\u001b\u001e)-8 \u0005- *)-#\u001c&\u001f\n+/\u001f \u001f&\n \n-\u001f\u001b \u001f& \u001b\u001d.), +/\u001f ^\u001b\u001d)(\u001e#\u001d#)(\u001b_ \u001b &\u001b- \u0003\u0014\b 3 \u001b &\u001b- \u001dï&/&\u001b- *,)!\u001f(#.),\u001b- *\u001b,\u001b +/\u001f \u001b\u001d.Ě\u001f( \u001f( \u001f&&\u001b-\n).,\u001b- \u001d#.)\u001d#(\u001b- \"\u001f')&#( )*)3ï.#\u001d\u001b-8\n\u0004ù\u001b \u001b \u001eù\u001b -\u001f \u001d)()\u001d\u001f 'á- \u001e\u001f &\u001b ,\u001f!/&\u001b\u001d#ĉ( \u001f*#!\u001f(ï.#\u001d\u001b8 \u0005-.\u001b -\u001f \u001e\u001fl·(\u001f \u001d)') &)- '\u001f\u001d\u001b(#-')- +/\u001f '\u001b(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":39,"lines":{"from":76,"to":88}}}}],["121",{"pageContent":".#\u001f(\u001f( &)- *\u001b.,)(\u001f- \u001e\u001f \u001f2*,\u001f-#ĉ( !ï(#\u001d\u001b \u001f-*\u001f\u001dùl·\u001d)- \u001e\u001f \u001d\u001b\u001e\u001b .#*) \u001e\u001f \u001dï&/&\u001b \u001f( &\u001b- \u001dï&/&\u001b- \"#$\u001b- \u001b .,\u001b0ï- \u001e\u001f\n&\u001b \u001e#0#-#ĉ( \u001d\u001f&/&\u001b,6 #(\u001e\u001f*\u001f(\u001e#\u001f(.\u001f'\u001f(.\u001f \u001e\u001f &\u001b -\u001f\u001d/\u001f(\u001d#\u001b \u001e\u001f \u0004\u000e\u0001 *,#'\u001b,#\u001b8\n \n)- '\u001f\u001d\u001b(#-')- \u001f*#!\u001f(ï.#\u001d)-\n#'*&#\u001d\u001b( &\u001b '\u001f.#&\u001b\u001d#ĉ( \u001e\u001f& \u0004\u000e\u0001 3 ')\u001e#l·\u001d\u001b\u001d#)(\u001f- \u001f( &\u001b \"#-.)(\u001b 3 ,\u001f!/&\u001b\u001d#ĉ( \u001f-.,/\u001d./,\u001b& \u001e\u001f &\u001b \u001d,)'\u001b.#(\u001b8\n§-.)- \u001e\u001f-\u001f'*\u001fĄ\u001b( /( *\u001b*\u001f& \u001d\u001f(.,\u001b& \u001f( &\u001b '\u001f'),#\u001b \u001d\u001f&/&\u001b,6 \u001f- \u001e\u001f\u001d#,6 '\u001b(.#\u001f(\u001f( &\u001b \"\u001b\u001c#&#\u001e\u001b\u001e \u001e\u001f &\u001b- \u001dï&/&\u001b-\n\u001e\u001f ^,\u001f\u001d),\u001e\u001b,_ \u001e/,\u001b(.\u001f &\u001b \u001e#0#-#ĉ( \u001d\u001f&/&\u001b, -/- *\u001b.,)(\u001f- \u001e\u001f \u001f2*,\u001f-#ĉ( !ï(#\u001d\u001b8 \u0005-.\u001f -#-.\u001f'\u001b \u001e\u001f '\u001f'),#\u001b \u001d\u001f&/&\u001b,\n\u001f- \u001f-\u001f(\u001d#\u001b& .\u001b(.) *\u001b,\u001b \u001f& \u001e\u001f-\u001b,,)&&) (),'\u001b& \u001d)') *\u001b,\u001b \u001f& '\u001b(.\u001f(#'#\u001f(.) \u001e\u001f &\u001b \")'\u001f)-.\u001b-#- \u001b &) &\u001b,!) \u001e\u001f\n&\u001b 0#\u001e\u001b \u001e\u001f& #(\u001e#0#\u001e/) 0ù\u001b &\u001b \u001b/.),,\u001f()0\u001b\u001d#ĉ( 3 &\u001b \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( \u001e\u001f &\u001b- \u001dï&/&\u001b- .,)(\u001d\u001b&\u001f- \u001e\u001f \u001d\u001b\u001e\u001b .\u001f$#\u001e)8\n \n\u001b-\n*,).\u001fù(\u001b- \u001e\u001f& !,/*) *)&3\u001d)'\u001c B\u0010\u001d\u0007C 3 &)- !\u001f(\u001f- +/\u001f ,\u001f!/&\u001b( -/ \u001f2*,\u001f-#ĉ( B!\u001f(\u001f-\n \nPcG\nC \u001e\u001f-\u001f'*\u001fĄ\u001b( /(\n*\u001b*\u001f& \u001d,/\u001d#\u001b& \u001f( &\u001b \u001b/.),,\u001f()0\u001b\u001d#ĉ( 3 \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( \u001e\u001f &\u001b- \u0003\u0014\b6 ,\u001f*,#'#\u001f(\u001e) !\u001f(\u001f- -/*,\u001f-),\u001f- \u001e\u001f ./'),","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":39,"lines":{"from":90,"to":105}}}}],["122",{"pageContent":"*,).\u001fù(\u001b- \u001e\u001f& !,/*) *)&3\u001d)'\u001c B\u0010\u001d\u0007C 3 &)- !\u001f(\u001f- +/\u001f ,\u001f!/&\u001b( -/ \u001f2*,\u001f-#ĉ( B!\u001f(\u001f-\n \nPcG\nC \u001e\u001f-\u001f'*\u001fĄ\u001b( /(\n*\u001b*\u001f& \u001d,/\u001d#\u001b& \u001f( &\u001b \u001b/.),,\u001f()0\u001b\u001d#ĉ( 3 \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( \u001e\u001f &\u001b- \u0003\u0014\b6 ,\u001f*,#'#\u001f(\u001e) !\u001f(\u001f- -/*,\u001f-),\u001f- \u001e\u001f ./'),\n3 \u001f( &\u001b ,\u001f!/&\u001b\u001d#ĉ( \")'\u001f)-.á.#\u001d\u001b \u001e\u001f ,\u001f\u001e)26 \u001f0#.\u001b(\u001e) \u001b-ù \u001f& \u001e\u001f-\u001b,,)&&) \u001e\u001f &\u001f/\u001d\u001f'#\u001b 3 *,\u001f0#(#\u001f(\u001e) &\u001b *ï,\u001e#\u001e\u001b\n*,\u001f'\u001b./,\u001b \u001e\u001f \u0003\u0014\b +/\u001f &&\u001f0\u001b \u001b \u001b*&\u001b-#\u001b ) \u001e#-*&\u001b-#\u001b \u001e\u001f &\u001b\n \n\u000f6 ,\u001f-*\u001f\u001d.#0\u001b'\u001f(.\u001f8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":39,"lines":{"from":105,"to":113}}}}],["123",{"pageContent":"COROLARIO\n\n\u0005& \u001f-+/\u001f'\u001b $\u001f,á,+/#\u001d) \u001d&á-#\u001d) \u001e\u001f &\u001b \"\u001f'\u001b.)*)3\u001f-#- \u001f( \u001f& +/\u001f -\u001f *,\u001f-\u001f(.\u001b( \u001f( ),'\u001b ),\u001e\u001f(\u001b\u001e\u001b &)- *,)!\u001f(#.)\n-\n\n,\u001f- \"\u001f'\u001b.)*)3ï.#\u001d)- \u001b *\u001b,.#, \u001e\u001f &\u001b \u0003\u0014\b \u001f- \u001b.,\u001b\u001d.#0) *\u001f,) -#'*&#-.\u001b8\n \n\u001b- \u0003\u0014\b */\u001f\u001e\u001f( -\u001f, \u001e\u001f-\u001d,#.\u001b- \u001e\u001f '\u001b\n-\n\n(\u001f,\u001b 'á- \u001f2\u001b\u001d.\u001b \u001d)') !,/*)- \u001e\u001f \u001dï&/&\u001b- \u001d)( *).\u001f(\u001d#\u001b&\u001f- \u001e\u001f \u001e\u001f-\u001b,,)&&) \u001c\u001b-\u001b\u001e)- \u001f( ,\u001f\u001e\u001f- \u001e\u001f \u001d)'/(#\u001d\u001b\u001d#ĉ(\n'\u001f\u001e#\u001b\u001e)- *),\n \n\u001b\u001d.),\u001f- !\u001f(ï.#\u001d)- 3 \u001f*#!\u001f(ï.#\u001d)- 3 \u001d#.)\u001d#(\u001b- \u001e\u001f(.,) \u001e\u001f& (#\u001d\") \"\u001f'\u001b.)*)3ï.#\u001d)8 \u0001\u001e\u001f'á-6 &\u001b\n*).\u001f(\u001d#\u001b&#\u001e\u001b\u001e \u001e\u001f &\u001b- \u0003\u0014\b \u001d\u001b'\u001c#\u001b \u001e\u001f*\u001f(\u001e#\u001f(\u001e) \u001e\u001f -/ &)\u001d\u001b&#4\u001b\u001d#ĉ( B\n \n\u000f6 \"ù!\u001b\u001e)6 -\u001b(!,\u001f6 \u001d),\u001eĉ( /'\u001c#&#\n-\n\n\u001d\u001b&6 *&\u001b\u001d\u001f(.\u001bC 3 \u001e\u001f &\u001b \u001f\u001e\u001b\u001e \u001e\u001f& #(\u001e#0#\u001e/)8\n\nCONCLUSIONES","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":39,"lines":{"from":115,"to":136}}}}],["124",{"pageContent":"\u001d\u001b&6 *&\u001b\u001d\u001f(.\u001bC 3 \u001e\u001f &\u001b \u001f\u001e\u001b\u001e \u001e\u001f& #(\u001e#0#\u001e/)8\n\nCONCLUSIONES\n\n•\n \n\u001b \"\u001f'\u001b.)*)3\u001f-#- \u001f- \u001f& \u001d)($/(.) \u001e\u001f *,)\u001d\u001f-)- *\u001b,\u001b &\u001b ),'\u001b\u001d#ĉ( ) *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f &)- \u001f&\u001f'\u001f(.)- \u001d\u001f&/&\u001b,\u001f-\n-\u001b(!/ù(\u001f)-8\n•\n \n\u001b *,)!,\u001f-#ĉ( ),\u001e\u001f(\u001b\u001e\u001b \u001e\u001f &\u001b \u001f0)&/\u001d#ĉ( \u001e\u001f &\u001b- \u001e#-.#(.\u001b- \u001dï&/&\u001b- \u001e\u001f &\u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b -\u001f \u001f(\u001d/\u001f(.,\u001b \u001c\u001b$)\n\u001f& \u001d)(.,)& \u001e\u001f /(\u001b 0\u001b,#\u001f\u001e\u001b\u001e \u001e\u001f\n \n\u001b\u001d.),\u001f- \u001d\u001f&/&\u001b,\u001f- 3 \"/'),\u001b&\u001f-6 &)- \u001d/\u001b&\u001f- ,\u001f-*)(\u001e\u001f( \u001b &\u001b \u001e\u001f'\u001b(\u001e\u001b \u001e\u001f &\u001b\n\")'\u001f)-.\u001b-#\u001b \u001e\u001f& ),!\u001b(#-')8\n•\n \n\u001b \"\u001f'\u001b.)*)3\u001f-#- #(#\u001d#\u001b \u001b (#0\u001f& /(#\u001d\u001f&/&\u001b, \u001d)( &\u001b \u001b/.)\u001e/*&#\u001d\u001b\u001d#ĉ( 3 '\u001b\u001e/,\u001b\u001d#ĉ( 3 \u001d/&'#(\u001b \u001d)( &\u001b *,)\n-\n\n\u001e/\u001d\u001d#ĉ( \u001e\u001f &)- \u001f&\u001f'\u001f(.)- ),'\u001f- -\u001b(!/ù(\u001f)-\n \n/(\u001d#)(\u001b&\u001f-8\n\nRECONOCIMIENTO\n\n\u0001!,\u001b\u001e\u001f4\u001d) \u001b &\u001b +/ù'#\u001d\u001b\n \n)-\u001f \u001b \u0010#\u001f\u001e,\u001b- -/ *\u001b,.#\u001d#*\u001b\u001d#ĉ( \u001f( &\u001b \u001f&\u001b\u001c),\u001b\u001d#ĉ( \u001e\u001f &\u001b- l·!/,\u001b-8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":39,"lines":{"from":136,"to":164}}}}],["125",{"pageContent":"\u001e/\u001d\u001d#ĉ( \u001e\u001f &)- \u001f&\u001f'\u001f(.)- ),'\u001f- -\u001b(!/ù(\u001f)-\n \n/(\u001d#)(\u001b&\u001f-8\n\nRECONOCIMIENTO\n\n\u0001!,\u001b\u001e\u001f4\u001d) \u001b &\u001b +/ù'#\u001d\u001b\n \n)-\u001f \u001b \u0010#\u001f\u001e,\u001b- -/ *\u001b,.#\u001d#*\u001b\u001d#ĉ( \u001f( &\u001b \u001f&\u001b\u001c),\u001b\u001d#ĉ( \u001e\u001f &\u001b- l·!/,\u001b-8\n\nLa administración de LK a\nprimates y ratones incrementa\nel número de células progenito-\nras pluripotenciales circulantes\ny el de sus respectivas cohortes\ncelulares con excepción de pla-\nquetas. Es posible que el LK\nsea el factor que “acondiciona”\na las células progenitoras para\nque actúen en ellas otras citoci-\nnas hemolinfopoyéticas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":39,"lines":{"from":164,"to":184}}}}],["126",{"pageContent":"CAPÍTULO 1. HEMATOPOYESIS\n\n13\n\nPREGUNTAS DE AUTOEVALUACIÓN\n\ng8\n \n(\u001e#+/\u001f \u001f& *),\u001d\u001f(.\u001b$\u001f +/\u001f )\u001d/*\u001b( &\u001b- \u001dï&/&\u001b- '\u001b\u001e,\u001f \u001f( &\u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b9\n\u001b8\n \ngz\n\u001c8 gfz\n\u001d8\n \nf6gz\nh8 \u0005& \u001b(.ù!\u001f() 'á- /.#&#4\u001b\u001e) *\u001b,\u001b #\u001e\u001f(.#l·\u001d\u001b, \u001b &\u001b- \u001dï&/&\u001b- '\u001b\u001e,\u001f \u001f-9\n\u001b8\n \n\u0003\u0004go\n+\n\n\u001c8 \u0003\u0004ij\n+\n\n\u001d8\n \n\u0003\u0004ggo\n+\n\ni8 ?\u0003/á&\u001f- -)( &\u001b- \u001e)- \u001d\u001b,\u001b\u001d.\u001f,ù-.#\u001d\u001b- \u001e\u001f &\u001b \u001dï&/&\u001b .,)(\u001d\u001b& \"\u001f'\u001b.)*)3ï.#\u001d\u001b B\u0003\u0014\bC>\n\u001b8\n \n\u0001/.),,\u001f()0\u001b\u001d#ĉ(\n\u001c8 \u0004# \u001f,\u001f(\u001d#\u001b\u001d#ĉ(\n\u001d8\n \n\u0005-*\u001f\u001d#l·\u001d#\u001e\u001b\u001e\nj8\n \n\u001b- *&\u001b+/\u001f.\u001b- ,\u001f-*)(\u001e\u001f( \u001b& -#!/#\u001f(.\u001f \u001b\u001d.), \u001e\u001f \u001d,\u001f\u001d#'#\u001f(.)9\n\u001b8\n \n\u0005,#.,)*)3\u001f.#(\u001b\n\u001c8\n \n7j\n\u001d8\n \n\u0014,)'\u001c)*)3\u001f.#(\u001b\nk8 ?\u0003/á& \u001f- &\u001b #(.\u001f,&\u001f/\u001d#(\u001b \u001e\u001f &\u001b \u001d/\u001b& \u001e\u001f*\u001f(\u001e\u001f \u001f& \u001d,\u001f\u001d#'#\u001f(.) \u001d\u001f&/&\u001b, \u001e\u001f& '#\u001f&)'\u001b 'Ě&.#*&\u001f>\n\u001b8\n \n7h\n\u001c8\n \n7j\n\u001d8\n \n7l\n\nBIBLIOGRAFÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":40,"lines":{"from":1,"to":62}}}}],["127",{"pageContent":"\b) \u0001\u00048\n \n#(\u001f.#\u001d- \u001b(\u001e -3''\u001f.,3 ) \u001e#0#-#)(- ) \"\u001f'\u001b.)*)#\u001f.#\u001d -.\u001f' \u001d\u001f&&-8 \u00052* \b\u001f'\u001b.)&8 hffk: ii9 g7n8\n()\u001c&#\u001d\" \u00018\n \n\u001f\u001d\"\u001b(#-'- ) \u001b-3''\u001f.,#\u001d -.\u001f' \u001d\u001f&& \u001e#0#-#)(8 \u0003\u001f&&8 hffn: gih9 kni7kom8\n)(/'\u001b \u00148 \u0012)&\u001f ) .\"\u001f *)&3\u001d)'\u001c !,)/* *,).\u001f#(- #( \"\u001f'\u001b.)*)#\u001f.#\u001d -.\u001f' \u001d\u001f&&-8 \u0004\u001f0\u001f&)* \u0007,)1.\" \u0004#L·\u001f,8 hfgf: kh9 kfk7kgl8\n# \u001a6\n \n#\n \n8 \u0015(\u001e\u001f,-.\u001b(\u001e#(! \"\u001f'\u001b.)*)#\u001f.#\u001d -.\u001f'7\u001d\u001f&& '#\u001d,)\u001f(0#,)('\u001f(.-8 \u0014,\u001f(\u001e- \u0002#)\u001d\"\u001f' \u0013\u001d#8 hffl: ig9 kno7kok8\n\u001f((\u001b,.--)( 8 \u0013.\u001f' \u001d\u001f&& \u001b\u001d.), ,\u001f\u001d\u001f*.),I\u001d7%#.9 ,)' \u001c\u001b-#\u001d -\u001d#\u001f(\u001d\u001f .) \u001d&#(#\u001d\u001b& #'*&#\u001d\u001b.#)(-8 \u0010\"3-#)& \u0012\u001f08 hfgh: oh9 glgo7gljo8\n\u001f\u001e0#(-%3 \u00018 \u0005'\u001c,3)(#\u001d ),#!#( ) .\"\u001f \u001b\u001e/&. \"\u001f'\u001b.)*)#\u001f.#\u001d -3-.\u001f'9 \u001b\u001e0\u001b(\u001d\u001f- \u001b(\u001e +/\u001f-.#)(-8 \u0004\u001f0\u001f&)*'\u001f(.8 hfgg: gin9 gfgm7gfig8\n\u000fL·\u001f,-\u001c\u001b\u001d\"\n \n8 \u000f(.)!\u001f(3 ) \"\u001b\u001f'\u001b.)*)#\u001f-#-9 ,\u001f\u001d\u001f(. \u001b\u001e0\u001b(\u001d\u001f- \u001b(\u001e )*\u001f( +/\u001f-.#)(-8 \u0002,\n \n\b\u001b\u001f'\u001b.)&8 hfgf: gjn9 iji7ikk8\n\u000f!/,) \b6\n \n1\u001b'\u001b \u00018\n \n# \u001f \u001b(\u001e \u001e\u001f\u001b.\" #( \"\u001f'\u001b.)*)#\u001f.#\u001d -.\u001f' \u001d\u001f&&-8 \u0003/,, \u000f*#(\n \n''/()&8 hffm: go9 kfi7kfo8 \u000f,%#( \u0013\b8\n\b\u001f'\u001b.)*)#\u001f-#-9 \u001b( \u001f0)&0#(! *\u001b,\u001b\u001e#!' ), -.\u001f' \u001d\u001f&& \u001c#)&)!38 \u0003\u001f&&8 hffn: gih9 lig7ljj8\n\u0011/\u001f-\u001f(\u001c\u001f,,3 \u0010 6 \u0003)&0#( \u00076 \u0001\u001c\u001f\u001e#","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":40,"lines":{"from":64,"to":91}}}}],["128",{"pageContent":"''/()&8 hffm: go9 kfi7kfo8 \u000f,%#( \u0013\b8\n\b\u001f'\u001b.)*)#\u001f-#-9 \u001b( \u001f0)&0#(! *\u001b,\u001b\u001e#!' ), -.\u001f' \u001d\u001f&& \u001c#)&)!38 \u0003\u001f&&8 hffn: gih9 lig7ljj8\n\u0011/\u001f-\u001f(\u001c\u001f,,3 \u0010 6 \u0003)&0#( \u00076 \u0001\u001c\u001f\u001e#\n \n8 \u0010\u001f,-*\u001f\u001d.#0\u001f9 \u0006/(\u001e\u001b'\u001f(.\u001b& \u001b(\u001e \u001d&#(#\u001d\u001b& \u001d)(\u001d\u001f*.- )( -.\u001f' \u001d\u001f&& \")'#(! \u001b(\u001e \u001f(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":40,"lines":{"from":91,"to":96}}}}],["129",{"pageContent":"!,\u001b '\u001f(.9 \u0001 $)/,(\u001f3 .) (#\u001d\"\u001f- \u001b(\u001e \u001c\u001f3)(\u001e8 \u00052* \b\u001f'\u001b.)&8 hffk: iiBgC9 o7go8\n\u0013\u001b-\"#\u001e\u001b \u00078 \u0005*#!\u001f(\u001f.#\u001d ,\u001f!/&\u001b.#)( ) \"\u001f'\u001b.)*)#\u001f-#-8\n \n(.\n \n\b\u001f'\u001b.)&8 hfgh: ol9 jfk7jgh8\n\u0011/\u001f-\u001f(\u001c\u001f,,3 \u0010 8 \u00052*,\u001f--#)( )\n \n\u001d\u001f&& \u001d3\u001d&\u001f7,\u001f&\u001b.\u001f\u001e !\u001f(\u001f- 1#.\" \u001d3.)%#(\u001f7#(\u001e/\u001d\u001f\u001e \u001d\u001f&& \u001d3\u001d&\u001f *,)!,\u001f--#)( )\n \n*,#'#.#0\u001f\n\"\u001f'\u001b.)*)#\u001f.#\u001d -.\u001f' \u001d\u001f&&-8 \u0013.\u001f' \u0003\u001f&&- \u0004\u001f08 hfgf: go9 jki7jlf8\n\nRESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\ng8\n \n\u001b\nh8\n \n\u001c\ni8\n \n\u001b 3 \u001c\nj8\n \n\u001d\nk8\n \n\u001d","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":40,"lines":{"from":98,"to":127}}}}],["130",{"pageContent":"15\n\nObjetivos de aprendizaje\n\n•\n \n\u0003)'*,\u001f(\u001e\u001f, &\u001b #(.\u001f,*,\u001f.\u001b\u001d#ĉ( \u001e\u001f &\u001b \u001d#.)'\u001f.,ù\u001b \"\u001f'á.#\u001d\u001b8\n•\n \n\u0004#-.#(!/#, &\u001b- \u001e# \u001f,\u001f(.\u001f- -\u001f,#\u001f- \u001d\u001f&/&\u001b,\u001f- 3 -/- ,\u001f-*\u001f\u001d.#0)- 0\u001b&),\u001f- \u001e\u001f ,\u001f \u001f,\u001f(\u001d#\u001b8\n•\n \n\u0005(.\u001f(\u001e\u001f, &)- .#*)- 3 \u001d\u001b/-\u001b- \u001e\u001f \u001b(\u001f'#\u001b8\n•\n \n\u0012\u001f\u001d)()\u001d\u001f, &\u001b- \u001e#0\u001f,-\u001b- \u001d\u001b/-\u001b- \u001e\u001f &\u001f/\u001d)\u001d#.)-#-8\n•\n \n\u0003)()\u001d\u001f, &\u001b- \u001d\u001b/-\u001b- \u001e\u001f .,)'\u001c)\u001d#.)-#- 3 .,)'\u001c)\u001d#.)*\u001f(#\u001b\n\nINTRODUCCIÓN\n\n\u0005& .ï,'#()\n \ncitometría hemática\n \n*\u001b,\u001f\u001d\u001f -\u001f, \u001f& 'á- \u001b\u001e\u001f\u001d/\u001b\u001e) *\u001b,\u001b ,\u001f \u001f,#,-\u001f \u001b &\u001b '\u001f\u001e#\u001d#ĉ( \u001e\u001f &\u001b- \u001dï\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":42,"lines":{"from":1,"to":28}}}}],["131",{"pageContent":"&/&\u001b- \u001e\u001f &\u001b -\u001b(!,\u001f B\ncitos\n \n \u001dï&/&\u001b6\n \nmetros\n \n '\u001f\u001e#\u001e\u001b6\n \nhaema, haematos\n \n -\u001b(!,\u001fC8 \u0005& \u001d&á-#\u001d) .ï,'#()\n\u001e\u001f ^\u001c#)'\u001f.,ù\u001b \"\u001f'á.#\u001d\u001b_ B\nbios\n \n 0#\u001e\u001b6\n \nmetros\n \n '\u001f\u001e#\u001e\u001bC \u001f- #(\u001d),,\u001f\u001d.) \u001f( .\u001b(.) +/\u001f \u001f& \u001f-./\u001e#) () -\u001f\n,\u001fl·\u001f,\u001f \u001b &\u001b '\u001f\u001e#\u001e\u001b \u001e\u001f &\u001b 0#\u001e\u001b6 *), &) +/\u001f \u001e\u001f\u001c#\u001f,\u001b \u001b\u001c\u001b(\u001e)(\u001b,-\u001f8 \u000f.,\u001b \u001f2*,\u001f-#ĉ( \u001f'*&\u001f\u001b\u001e\u001b6 &\u001b \u001e\u001f\n^\u001d#.)&)!ù\u001b \"\u001f'á.#\u001d\u001b_ B\ncitos\n \n \u001dï&/&\u001b6\n \nlogos\n \n .,\u001b.\u001b\u001e)C6 \u001f- '\u001f()- #(\u001d),,\u001f\u001d.\u001b8 \u0005& .ï,'#()\n \ncitometría\nhemática\n \nB\u0003\bC \u001f- \u001f& +/\u001f '\u001f$), \u001e\u001f-\u001d,#\u001c\u001f \u001b& \u001f-./\u001e#) \u001e\u001f &\u001b\u001c),\u001b.),#) \u001e\u001f-.#(\u001b\u001e) \u001b #( ),'\u001b, -)\u001c,\u001f \u001f&\n(Ě'\u001f,) 3 &\u001b- \u001d\u001b,\u001b\u001d.\u001f,ù-.#\u001d\u001b- \u001e\u001f &\u001b- \u001dï&/&\u001b- \u001e\u001f &\u001b -\u001b(!,\u001f: \u001f-.\u001f Ě&.#') -\u001f,á \u001f( \u001b\u001e\u001f&\u001b(.\u001f \u001f& Ě(#\u001d) +/\u001f\n-\u001f \u001f'*&\u001f\u001f8\n \n\u001b \u0003\b \u001f- *,)\u001c\u001b\u001c&\u001f'\u001f(.\u001f \u001f& \u001f-./\u001e#) \u001e\u001f &\u001b\u001c),\u001b.),#) 'á- -)&#\u001d#.\u001b\u001e)6 $/(.) \u001d)( \u001f& \u001f2\u001b'\u001f(\n!\u001f(\u001f,\u001b& \u001e\u001f ),#(\u001b 3 &\u001b &&\u001b'\u001b\u001e\u001b ^+/ù'#\u001d\u001b -\u001b(!/ù(\u001f\u001b_8 \u0004\u001f-\u001b ),./(\u001b\u001e\u001b'\u001f(.\u001f6 \u001f- -/\u001c/.#&#4\u001b\u001e\u001b6 */\u001f-\n'/\u001d\")- 'ï\u001e#\u001d)- -\u001f &#'#.\u001b( \u001b /-\u001b, -)&) &\u001b- \u001d# ,\u001b- \u001e\u001f \"\u001f')!&)\u001c#(\u001b6 &\u001b \u001d/\u001f(.\u001b \u001e\u001f &\u001f/\u001d)\u001d#.)-6 \u001f& (Ě\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":42,"lines":{"from":30,"to":70}}}}],["132",{"pageContent":"'\u001f,) \u001e\u001f ^\u001c\u001b(\u001e\u001b-_ 36 \u001f( )\u001d\u001b-#)(\u001f-6 &\u001b \u001b*,\u001f\u001d#\u001b\u001d#ĉ( \u001e\u001f &\u001b- *&\u001b+/\u001f.\u001b-8\n \n\u001b #(.\u001f,*,\u001f.\u001b\u001d#ĉ( \u001d),,\u001f\u001d.\u001b \u001e\u001f\n.)\u001e\u001b &\u001b #( ),'\u001b\u001d#ĉ( +/\u001f ) ,\u001f\u001d\u001f /(\u001b \u0003\b *\u001f,'#.\u001f \u001f-.\u001b\u001c&\u001f\u001d\u001f, -)-*\u001f\u001d\"\u001b- \u001e#\u001b!(ĉ-.#\u001d\u001b- \u001e\u001fl·(#\u001e\u001b- -)\u001c,\u001f\n&\u001b \u001f( \u001f,'\u001f\u001e\u001b\u001e +/\u001f \u001d\u001b/-\u001b &\u001b- \u001b&.\u001f,\u001b\u001d#)(\u001f- \u001e\u001f& \u001f( \u001f,') 3 \u001b\"),,\u001b, \u001b& 'ï\u001e#\u001d) 3 \u001b& *\u001b\u001d#\u001f(.\u001f .#\u001f'*)6\n\u001f- /\u001f,4)- \u001f #(\u001d&/-) \u001f,)!\u001b\u001d#)(\u001f- \u001f\u001d)(ĉ'#\u001d\u001b-8\n \n\u001b #(.\u001f,*,\u001f.\u001b\u001d#ĉ( \u001d),,\u001f\u001d.\u001b \u001e\u001f &\u001b \u0003\b -/*)(\u001f \u001f& \u001b(á\n-\n\n&#-#- \u001e\u001f.\u001b&&\u001b\u001e) \u001e\u001f \u001d\u001b\u001e\u001b /() \u001e\u001f &)- \u001e\u001b.)- +/\u001f #( ),'\u001b6 &)- \u001d/\u001b&\u001f- */\u001f\u001e\u001f( \u001e#0#\u001e#,-\u001f \u001f( .,\u001f- !,\u001b(\u001e\u001f-\n!,/*)-9 \u001e\u001b.)- \u001e\u001f &\u001b -\u001f,#\u001f ,)$\u001b6 \u001e\u001f &\u001b -\u001f,#\u001f \u001c&\u001b(\u001d\u001b 3 \u001e\u001f &\u001b -\u001f,#\u001f .,)'\u001c)\u001dù.#\u001d\u001b8\n \n\u001e\u001f\u001b&'\u001f(.\u001f6 &\u001b '\u001f\u001e#\u001d#ĉ(\n\u001e\u001f .)\u001e)- &)- *\u001b,á'\u001f.,)- \u001f ù(\u001e#\u001d\u001f- \u001f,#.,)\u001dù.#\u001d)- \u001e\u001f\u001c\u001f \"\u001b\u001d\u001f,-\u001f \u001f'*&\u001f\u001b(\u001e) \u001d)(.\u001b\u001e),\u001f- \u001e\u001f *\u001b,.ù\u001d/&\u001b-\n*), \u001d#.)'\u001f.,ù\u001b \u001e\u001f ł/$)8\n\nSERIE ROJA\n\n)- \u001e\u001b.)- +/\u001f &\u001b \u0003\b #( ),'\u001b *\u001b,\u001b &\u001b -\u001f,#\u001f ,)$\u001b -)( &)- -#!/#\u001f(.\u001f-9\n\nCAPÍTULO 2\n\nGuillermo J. Ruiz Argüelles\nGuillermo Ruiz Reyes\nGuillermo J. Ruiz Delgado\nEl término\n \n\u001d#.)'\u001f.,ù\u001b \"\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":42,"lines":{"from":72,"to":101}}}}],["133",{"pageContent":"SERIE ROJA\n\n)- \u001e\u001b.)- +/\u001f &\u001b \u0003\b #( ),'\u001b *\u001b,\u001b &\u001b -\u001f,#\u001f ,)$\u001b -)( &)- -#!/#\u001f(.\u001f-9\n\nCAPÍTULO 2\n\nGuillermo J. Ruiz Argüelles\nGuillermo Ruiz Reyes\nGuillermo J. Ruiz Delgado\nEl término\n \n\u001d#.)'\u001f.,ù\u001b \"\u001f\n-\n\n'á.#\u001d\u001b\n \nparece ser el más\nadecuado para referirse a la\nmedición\n \nde\n \nlas\n \ncélulas\n \nde\nla sangre\n \nB\u001d#.)-\n \n= célula;\n \nme-\n\n.,)-\n \n= medida;\n \n\"\u001b\u001f'\u001b6 \"\u001b\u001f\n-\n\n'\u001b.)-\n \n= sangre).\n\nCITOMETRÍA HEMÁTICA\nY SU INTERPRETACIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":42,"lines":{"from":101,"to":148}}}}],["134",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n16\n\nHemoglobina y definición de anemia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":43,"lines":{"from":1,"to":5}}}}],["135",{"pageContent":"\u001b \"\u001f')!&)\u001c#(\u001b B\b\u001cC -\u001f '#\u001e\u001f \u001f( !,\u001b')- *), \u001e\u001f\u001d#&#.,) B!I\u001e\n \nC 3 ,\u001f*,\u001f-\u001f(.\u001b &\u001b \u001d\u001b(.#\u001e\u001b\u001e \u001e\u001f \u001f-.\u001b *,).\u001fù(\u001b\n*), /(#\u001e\u001b\u001e \u001e\u001f 0)&/'\u001f(8 \u0005-.\u001f *\u001b,á'\u001f.,) \u001e\u001f\u001c\u001f -\u001f, \u001f& Ě(#\u001d) /.#&#4\u001b\u001e) *\u001b,\u001b \u001e\u001fl·(#, -# \"\u001b3 ) () \u001b(\u001f'#\u001b6 \u001f-\n\u001e\u001f\u001d#,6 -)&) -# &\u001b- \u001d# ,\u001b- \u001e\u001f \"\u001f')!&)\u001c#(\u001b -)( #( \u001f,#),\u001f- \u001b &)- 0\u001b&),\u001f- (),'\u001b&\u001f- */\u001f\u001e\u001f \u001b-\u001f!/,\u001b,-\u001f +/\u001f \u001f2#-.\u001f\n\u001b(\u001f'#\u001b8\n \n\u001b- \u001d# ,\u001b- ^(),'\u001b&\u001f-_ ) ^\u001e\u001f ,\u001f \u001f,\u001f(\u001d#\u001b_ \u001e\u001f &\u001b \"\u001f')!&)\u001c#(\u001b -)( 0\u001b,#\u001b\u001c&\u001f- 3 \u001e\u001f*\u001f(\u001e\u001f( \u001e\u001f9 \u001f\u001e\u001b\u001e6\n-\u001f2)6 \u001b&./,\u001b \u001e\u001f& -#.#) \u001e\u001f ,\u001f-#\u001e\u001f(\u001d#\u001b6 \u001f.\u001dï.\u001f,\u001b8 \u0001 &\u001b \u001b&./,\u001b \u001e\u001f &\u001b \u0003#/\u001e\u001b\u001e \u001e\u001f\n \nï2#\u001d) Bh̓hjf̓'\n \n-)\u001c,\u001f \u001f& (#0\u001f&\n\u001e\u001f& '\u001b,C6 &\u001b- \u001d# ,\u001b- #( \u001f,#),\u001f- (),'\u001b&\u001f- \u001e\u001f \"\u001f')!&)\u001c#(\u001b \u001f( \u001b\u001e/&.)- -\u001b()- \u001b-\u001d#\u001f(\u001e\u001f( \u001b gh6k̓!I\u001e\n \n*\u001b,\u001b\n'/$\u001f,\u001f- 3 \u001b gk6k̓!I\u001e\n \n*\u001b,\u001b 0\u001b,)(\u001f-8\n \n\u001b- \u001d/\u001b(.#l·\u001d\u001b\u001d#)(\u001f- \u001e\u001f \b\u001c #( \u001f,#),\u001f- \u001b &\u001b- '\u001f(\u001d#)(\u001b\u001e\u001b- *\u001f,'#.\u001f(\n\u001f-.\u001b\u001c&\u001f\u001d\u001f, \u001f& \u001e#\u001b!(ĉ-.#\u001d) \u001e\u001f \u001b(\u001f'#\u001b8\n \n\u001b- \u001d# ,\u001b- \u001e\u001f \"\u001f')!&)\u001c#(\u001b -/*\u001f,#),\u001f- \u001b gl6l̓ !I\u001e\n \n*\u001b,\u001b '/$\u001f,\u001f-\n3 go6k̓!I\u001e\n \n*\u001b,\u001b 0\u001b,)(\u001f- *\u001f,'#.\u001f( \u001f-.\u001b\u001c&\u001f\u001d\u001f, \u001f& \u001e#\u001b!(ĉ-.#\u001d) \u001e\u001f \u001f,#.,)\u001d#.)-#-6 \u001b &\u001b \u001b&./,\u001b \u001e\u001f &\u001b \u0003#/\u001e\u001b\u001e\n\u001e\u001f\n \nï2#\u001d)8 \u0005& .ï,'#() \u001e\u001f\n \npolicitemia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":43,"lines":{"from":7,"to":40}}}}],["136",{"pageContent":"\u001b- \u001d# ,\u001b- \u001e\u001f \"\u001f')!&)\u001c#(\u001b -/*\u001f,#),\u001f- \u001b gl6l̓ !I\u001e\n \n*\u001b,\u001b '/$\u001f,\u001f-\n3 go6k̓!I\u001e\n \n*\u001b,\u001b 0\u001b,)(\u001f- *\u001f,'#.\u001f( \u001f-.\u001b\u001c&\u001f\u001d\u001f, \u001f& \u001e#\u001b!(ĉ-.#\u001d) \u001e\u001f \u001f,#.,)\u001d#.)-#-6 \u001b &\u001b \u001b&./,\u001b \u001e\u001f &\u001b \u0003#/\u001e\u001b\u001e\n\u001e\u001f\n \nï2#\u001d)8 \u0005& .ï,'#() \u001e\u001f\n \npolicitemia\n \n\u001e\u001f\u001c\u001f ,\u001f-\u001f,0\u001b,-\u001f *\u001b,\u001b -#./\u001b\u001d#)(\u001f- \u001f( &\u001b- +/\u001f6 \u001b\u001e\u001f'á- \u001e\u001f \u001f,#.,)\u001d#\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":43,"lines":{"from":40,"to":53}}}}],["137",{"pageContent":".)-#-6 \"\u001b3 &\u001f/\u001d)\u001d#.)-#- ) .,)'\u001c)\u001d#.)-#-: *), &) .\u001b(.)6 \u001f& .ï,'#() \u001e\u001f ^*)&#\u001d#.\u001f'#\u001b -\u001f\u001d/(\u001e\u001b,#\u001b \u001b \"#*)2\u001f'#\u001b\n\u001d,ĉ(#\u001d\u001b_ \u001f- #(\u001d),,\u001f\u001d.) 3 \u001e\u001f\u001c\u001f -/-.#./#,-\u001f *), \u001f& \u001e\u001f\n \neritrocitosis secundaria a hipoxemia crónica\n8\n \n\u001b \b\u001c -\u001f\n'#\u001e\u001f \u001e#,\u001f\u001d.\u001b'\u001f(.\u001f *), '\u001f\u001e#) \u001e\u001f &)- \u001d#.ĉ'\u001f.,)- \u001e\u001f ł/$) 3 \u001f- (\u001f\u001d\u001f-\u001b,#) \u001f-.\u001b\u001c&\u001f\u001d\u001f, &)- 0\u001b&),\u001f- \u001e\u001f ,\u001f \u001f,\u001f(\n-\n\n\u001d#\u001b6 .)'\u001b(\u001e) \u001f( \u001d/\u001f(.\u001b &\u001b- 0\u001b,#\u001b\u001c&\u001f- \u001b(.\u001f- \u001b().\u001b\u001e\u001b-8 \u0010\u001b,\u001b \u001f& \u001d\u001b-) \u001f-*\u001f\u001dùl·\u001d) \u001e\u001f &\u001b 0\u001b,#\u001b\u001c&\u001f \u001b&./,\u001b6 \u001f2#-.\u001f(\n\u001f\u001d/\u001b\u001d#)(\u001f- \u001b&!\u001f\u001c,\u001b#\u001d\u001b- +/\u001f *\u001f,'#.\u001f( \u001d\u001b&\u001d/&\u001b, &)- 0\u001b&),\u001f- \u001e\u001f ,\u001f \u001f,\u001f(\u001d#\u001b \u001e\u001f \u001d\u001b\u001e\u001b /() \u001e\u001f &)- *\u001b,á'\u001f.,)- \u001f\nù(\u001e#\u001d\u001f- \u001f,#.,)\u001dù.#\u001d)-8\n\nHematocrito\n\n\u0005& \"\u001f'\u001b.)\u001d,#.) B\b.\u001dC -\u001f '#\u001e\u001f \u001f( *),\u001d\u001f(.\u001b$\u001f BzC 3 ,\u001f*,\u001f-\u001f(.\u001b &\u001b *,)*),\u001d#ĉ( \u001e\u001f \u001f,#.,)\u001d#.)- \u001f( \u001f& .).\u001b& \u001e\u001f\n&\u001b -\u001b(!,\u001f8 \u0005-.\u001f *\u001b,á'\u001f.,) () \u001e\u001f\u001c\u001f \u001f'*&\u001f\u001b,-\u001f *\u001b,\u001b \u001f-.\u001b\u001c&\u001f\u001d\u001f, &\u001b \u001f2#-.\u001f(\u001d#\u001b \u001e\u001f \u001b(\u001f'#\u001b8\n \n)- 0\u001b&),\u001f- (),\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":43,"lines":{"from":55,"to":75}}}}],["138",{"pageContent":"'\u001b&\u001f- \u001e\u001f& \"\u001f'\u001b.)\u001d,#.) \u001e\u001f*\u001f(\u001e\u001f( .\u001b'\u001c#ï( \u001e\u001f& -\u001f2)6 &\u001b \u001f\u001e\u001b\u001e 3 &\u001b \u001b&./,\u001b \u001e\u001f& -#.#) \u001e\u001f ,\u001f-#\u001e\u001f(\u001d#\u001b8 \u0001 (#0\u001f& \u001e\u001f\n&\u001b \u0003#/\u001e\u001b\u001e \u001e\u001f\n \nï2#\u001d)6 \u001f& \"\u001f'\u001b.)\u001d,#.) \u001e\u001f ,\u001f \u001f,\u001f(\u001d#\u001b )-\u001d#&\u001b \u001f(.,\u001f jl 3 klz *\u001b,\u001b 0\u001b,)(\u001f- 3 \u001f(.,\u001f io 3 kfz\n*\u001b,\u001b '/$\u001f,\u001f-8 \u0005-.\u001f *\u001b,á'\u001f.,) \u001f,#.,)\u001dù.#\u001d) () -\u001f '#\u001e\u001f \u001e#,\u001f\u001d.\u001b'\u001f(.\u001f \u001d)( &)- \u001d#.ĉ'\u001f.,)- \u001e\u001f ł/$)6 -#() +/\u001f\n-\u001f \u001d\u001b&\u001d/&\u001b \u001b *\u001b,.#, \u001e\u001f &\u001b '\u001f\u001e#\u001d#ĉ( \u001e\u001f& (Ě'\u001f,) \u001e\u001f \u001f,#.,)\u001d#.)- 3 \u001e\u001f& 0)&/'\u001f( !&)\u001c/&\u001b, '\u001f\u001e#): *), &) .\u001b(.)6\n\u001f- /( *\u001b,á'\u001f.,) \u001d)( '\u001f(), *,\u001f\u001d#-#ĉ( 3 \u001f2\u001b\u001d.#./\u001e +/\u001f &)- ).,)- \u001e)- B\b\u001c 3 \u0007\u0012C8\n\nNúmero de eritrocitos o glóbulos rojos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":43,"lines":{"from":77,"to":85}}}}],["139",{"pageContent":"Número de eritrocitos o glóbulos rojos\n\n\u0005& (Ě'\u001f,) \u001e\u001f \u001f,#.,)\u001d#.)- B\u0007\u0012C -\u001f '#\u001e\u001f \u001f( '#&&)(\u001f- *), '#\u001d,)&#.,) B'#&&)(\u001f-I\n \nC8 \u0013/ 0\u001b&), (),'\u001b& \u001e\u001f*\u001f(\u001e\u001f\n.\u001b'\u001c#ï( \u001e\u001f &)- \u001b\u001d.),\u001f- -\u001fĄ\u001b&\u001b\u001e)- *\u001b,\u001b &)- ).,)- \u001e)- *\u001b,á'\u001f.,)- \u001f,#.,)\u001dù.#\u001d)- B\b\u001c 3 \b.\u001dC8 \u0010\u001b,\u001b &\u001b \u001b&./,\u001b \u001e\u001f&\n\u001b&.#*&\u001b() '\u001f2#\u001d\u001b()6 &)- 0\u001b&),\u001f- \u001e\u001f ,\u001f \u001f,\u001f(\u001d#\u001b \u001f( \u001b\u001e/&.)- -)(9 0\u001b,)(\u001f- k6f \u001b l6i '#&&)(\u001f-I\n \n3 '/$\u001f,\u001f- j6g\n\u001b k6m '#&&)(\u001f-I\n \n8 \u0005& \u001f'*&\u001f) \u001b\u001d./\u001b& \u001e\u001f \u001d)(.\u001b\u001e),\u001f- \u001e\u001f *\u001b,.ù\u001d/&\u001b- *), \u001d#.)'\u001f.,ù\u001b \u001e\u001f ł/$) *\u001f,'#.\u001f \u001d\u001b&\u001d/&\u001b,\n\u001d)( !,\u001b( \u001f2\u001b\u001d.#./\u001e \u001f-.\u001f *\u001b,á'\u001f.,) \u001f,#.,)\u001dù.#\u001d)8 \u0003/\u001b(\u001e) () -\u001f \u001d/\u001f(.\u001b \u001d)( \u001d#.ĉ'\u001f.,) \u001e\u001f ł/$) *\u001b,\u001b \"\u001b\u001d\u001f, &\u001b\n'\u001f\u001e#\u001d#ĉ( \u001e\u001f& (Ě'\u001f,) \u001e\u001f \u0007\u00126 \u001f- *,\u001f \u001f,#\u001c&\u001f () *,)*),\u001d#)(\u001b, \u001f-.\u001f \u001e\u001b.)6 \u001e\u001b\u001e) \u001f& '\u001b,!\u001f( \u001e\u001f \u001f,,), .\u001b( !,\u001b(\u001e\u001f\n\u001e\u001f &\u001b \u001d/\u001b(.#l·\u001d\u001b\u001d#ĉ( \u001d)( 'ï.)\u001e)- '\u001b(/\u001b&\u001f-8\n\nVolumen globular medio","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":43,"lines":{"from":85,"to":101}}}}],["140",{"pageContent":"Volumen globular medio\n\n\u0005& 0)&/'\u001f( !&)\u001c/&\u001b, '\u001f\u001e#) B\u0016\u0007\n \nC -\u001f '#\u001e\u001f \u001f( \u001f'.)&#.,)- B\n \nC ) '#\u001d,\u001b- \u001dĚ\u001c#\u001d\u001b-8 \u0005-.\u001f ù(\u001e#\u001d\u001f \u001f,#.,)\u001dù.#\u001d)6\n'\u001f\u001e#\u001e) \u001e#,\u001f\u001d.\u001b'\u001f(.\u001f \u001d)( \u001d#.)'\u001f.,ù\u001b \u001e\u001f ł/$)6 \u001f- \u001e\u001f !,\u001b( 0\u001b&), \u001f( \u001f& \u001f-\u001d&\u001b,\u001f\u001d#'#\u001f(.) \u001e\u001f &\u001b \u001d\u001b/-\u001b \u001e\u001f /(\u001b\n\u001b(\u001f'#\u001b8\n \n)- 0\u001b&),\u001f- \u001e\u001f& \u0016\u0007\n \n*\u001f,'#.\u001f( -\u001b\u001c\u001f, -# /(\u001b \u001b(\u001f'#\u001b \u001f- '\u001b\u001d,)\u001dù.#\u001d\u001b B\u0016\u0007\n \n'\u001b3), \u001b &)- &ù'#.\u001f-\n(),'\u001b&\u001f-C ) '#\u001d,)\u001dù.#\u001d\u001b B\u0016\u0007\n \n'\u001f(), \u001b &)- &ù'#.\u001f- (),'\u001b&\u001f-6 +/\u001f \u001b &\u001b \u001b&./,\u001b \u001e\u001f& \u001b&.#*&\u001b() '\u001f2#\u001d\u001b() -)(\n\u001e\u001f ni \u001b on\n \n*\u001b,\u001b 0\u001b,)(\u001f- 3 \u001e\u001f mn \u001b gfi\n \n*\u001b,\u001b '/$\u001f,\u001f-C8\n \ná- \u001e\u001f& nfz \u001e\u001f &)- \u001d\u001b-)- \u001e\u001f \u001b(\u001f'#\u001b \u001f(\n \nï2#\u001d)\n\u001f-.á( \u001e\u001b\u001e)- *), \u001b(\u001f'#\u001b- '#\u001d,)\u001dù.#\u001d\u001b- B\u0016\u0007\n \n\u001c\u001b$)C6 3 \u001e\u001f \u001f&&\u001b-6 &\u001b 'á- ,\u001f\u001d/\u001f(.\u001f \u001f- &\u001b \u001b(\u001f'#\u001b *), \u001e\u001fl·\u001d#\u001f(\u001d#\u001b\n\u001e\u001f \"#\u001f,,)6 -# \u001c#\u001f( () -\u001f \u001e\u001f\u001c\u001f( )&0#\u001e\u001b, &\u001b- .\u001b&\u001b-\u001f'#\u001b- \u001d)') \u001d\u001b/-\u001b \u001e\u001f \u001b(\u001f'#\u001b '#\u001d,)\u001dù.#\u001d\u001b8 \u0005( \u001b&!/(\u001b- \u001d)'/\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":43,"lines":{"from":101,"to":132}}}}],["141",{"pageContent":"(#\u001e\u001b\u001e\u001f- \u001e\u001f &\u001b \u001d)-.\u001b \u001e\u001f& \u0007)& ) \u001e\u001f\n \nï2#\u001d)6 \"\u001b-.\u001b \u001f& gkz \u001e\u001f &)- \"\u001b\u001c#.\u001b(.\u001f- -)( *),.\u001b\u001e),\u001f- \u001e\u001f .\u001b&\u001b-\u001f'#\u001b6 \u001f( &\u001b\n'\u001b3),ù\u001b \u001e\u001f &)- \u001d\u001b-)- .\u001b&\u001b-\u001f'#\u001b\n \nβ\n8\n \n)- 0\u001b&),\u001f- \u001e\u001f \u0016\u0007\n \n-)( \"\u001b\u001c#./\u001b&'\u001f(.\u001f 'á- \u001c\u001b$)- \u001f( \u001d\u001b-)- \u001e\u001f .\u001b&\u001b-\u001f'#\u001b\n+/\u001f \u001f( &)- \u001e\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)6 \u001b\u001e\u001f'á- \u001e\u001f +/\u001f &\u001b \u001e#-.,#\u001c/\u001d#ĉ( !\u001b/--#\u001b(\u001b \u001e\u001f& .\u001b'\u001bĄ) \u001e\u001f &)- \u001f,#.,)\u001d#.)-\n\u001f-.á 'á- \u001e#-*\u001f,-\u001b \u001f( &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) +/\u001f \u001f( &\u001b .\u001b&\u001b-\u001f'#\u001b B0ï\u001b-\u001f 'á- \u001b\u001e\u001f&\u001b(.\u001fC8\n \n\u001b- \u001b(\u001f'#\u001b- +/\u001f\n\u001d/,-\u001b( \u001d)( \u001d# ,\u001b- \u001b(),'\u001b&'\u001f(.\u001f \u001b&.\u001b- \u001e\u001f \u0016\u0007\n \n6 .\u001b'\u001c#ï( &&\u001b'\u001b\u001e\u001b-\n \nanemias macrocíticas\n6 */\u001f\u001e\u001f( \u001e\u001f\u001c\u001f,-\u001f \u001b\n\u001f,#.,)*)3\u001f-#- \u001b\u001d\u001f&\u001f,\u001b\u001e\u001b B*8 \u001f$86 \"\u001f'ĉ&#-#-C6 \u001f,#.,)*)3\u001f-#- '\u001f!\u001b&)\u001c&á-.#\u001d\u001b B\u001d\u001b,\u001f(\u001d#\u001b \u001e\u001f )&\u001b.)- ) \u001e\u001f 0#.\u001b'#(\u001b\n\u0002ghC6 '#\u001f&)\u001e#-*&\u001b-#\u001b-6 \u001b(\u001f'#\u001b \u001b*&á-#\u001d\u001b6 \u001f.\u001dï.\u001f,\u001b8 \u0005-.\u001f ù(\u001e#\u001d\u001f \u001f,#.,)\u001dù.#\u001d)6 \u001e\u001f !,\u001b( \u001d)(l·\u001b\u001c#&#\u001e\u001b\u001e \u001d/\u001b(\u001e) -\u001f\n/-\u001b( \u001d#.ĉ'\u001f.,)- \u001e\u001f ł/$)6 \u001e\u001f\u001c\u001f -\u001f, \u001f& Ě(#\u001d) \u001f'*&\u001f\u001b\u001e) *\u001b,\u001b \u001e\u001fl·(#, -# /(\u001b \u001b(\u001f'#\u001b \u001f- '#\u001d,)\u001dù.#\u001d\u001b6 (),')\u001dù.#\u001d\u001b\n) '\u001b\u001d,)\u001dù.#\u001d\u001b8 \u0003/\u001b(\u001e) () -\u001f \u001d/\u001f(.\u001f \u001d)( \u001d#.ĉ'\u001f.,)- \u001e\u001f ł/$) \u001f- *,\u001f \u001f,#\u001c&\u001f () \u001e\u001b, \u001d,ï\u001e#.) \u001b& 0\u001b&), \u001e\u001f& \u0016\u0007\n \n6","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":43,"lines":{"from":134,"to":160}}}}],["142",{"pageContent":"La Hb se mide en gramos por\ndecilitro (g/dL) y representa\nla cantidad de esta proteína\npor unidad de volumen. Este\nparámetro debe ser el único que\nse emplee para definir si hay o\nno anemia, es decir, solo si las\ncifras de hemoglobina son in-\nferiores a los valores normales\npuede\n \nasegurarse\n \nque\n \nexiste\nanemia.\nLos valores del VGM per-\nmiten saber si una anemia\nes macrocítica (VGM mayor\na los límites normales) o mi-\ncrocítica (VGM menor a los\nlímites normales).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":43,"lines":{"from":162,"to":184}}}}],["143",{"pageContent":"CAPÍTULO 2. CITOMETRÍA HEMÁTICA Y SU INTERPRETACIÓN\n\n17\n\n+/\u001f -\u001f \u001d\u001b&\u001d/&\u001b *), \u001f& \u001d)\u001d#\u001f(.\u001f \u001f(.,\u001f \u001f& \b.\u001d '/&.#*&#\u001d\u001b\u001e) *), gf 3 \u001f& (Ě'\u001f,) \u001e\u001f \u0007\u0012 \u001f( '#&&)(\u001f-8 \u0015(\u001b \u001d# ,\u001b\n\u001e\u001f \u0016\u0007\n \n-/*\u001f,#), \u001b ghf̓\n \n\u001f- *\u001b.)!()'ĉ(#\u001d\u001b \u001e\u001f \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8\n\nHemoglobina corpuscular media\n\n\u001b \"\u001f')!&)\u001c#(\u001b \u001d),*/-\u001d/&\u001b, '\u001f\u001e#\u001b B\b\u0003\n \nC -\u001f \u001f2*,\u001f-\u001b \u001f( *#\u001d)!,\u001b')- B*!C 3 ,\u001f*,\u001f-\u001f(.\u001b &\u001b \u001d\u001b(.#\u001e\u001b\u001e *,)\n-\n\n'\u001f\u001e#) \u001e\u001f \"\u001f')!&)\u001c#(\u001b \u001f( \u001d\u001b\u001e\u001b \u001f,#.,)\u001d#.)8\n \n)- \u001d#.ĉ'\u001f.,)- \u001e\u001f ł/$) \u001e\u001f.\u001f,'#(\u001b( \u001f-.\u001f ù(\u001e#\u001d\u001f \u001e#0#\u001e#\u001f(\u001e) &\u001b\n\b\u001c \u001f(.,\u001f \u001f& (Ě'\u001f,) \u001e\u001f \u0007\u0012 3 '/&.#*&#\u001d\u001b(\u001e) \u001f& \u001d)\u001d#\u001f(.\u001f *), gf8 \u0005( 0#,./\u001e \u001e\u001f +/\u001f \u001f-.\u001f ù(\u001e#\u001d\u001f -\u001f \u001d\u001b&\u001d/&\u001b \u001b\n*\u001b,.#, \u001e\u001f \u001e)- \u001e\u001b.)- )\u001c.\u001f(#\u001e)- \u001e#,\u001f\u001d.\u001b'\u001f(.\u001f \u001e\u001f &\u001b \u001d#.)'\u001f.,ù\u001b \u001e\u001f ł/$)6 -\u001f .,\u001b.\u001b \u001e\u001f /( ù(\u001e#\u001d\u001f '/3 \u001d)(l·\u001b\u001c&\u001f8\n\u0001 &\u001b \u001b&./,\u001b \u001e\u001f &\u001b \u0003#/\u001e\u001b\u001e \u001e\u001f\n \nï2#\u001d)6 &)- 0\u001b&),\u001f- \u001e\u001f ,\u001f \u001f,\u001f(\u001d#\u001b \u001e\u001f &\u001b \b\u0003\n \n-)( \u001e\u001f hm \u001b ij *!8 \u0005-.\u001f ù(\u001e#\u001d\u001f\n\u001e\u001f\u001c\u001f -\u001f, \u001f& Ě(#\u001d) +/\u001f -\u001f \u001f'*&\u001f\u001f *\u001b,\u001b ,\u001f \u001f,#,-\u001f \u001b &\u001b \u001d\u001b(.#\u001e\u001b\u001e \u001e\u001f \"\u001f')!&)\u001c#(\u001b \u001d)(.\u001f(#\u001e\u001b \u001f( \u001d\u001b\u001e\u001b \u001f,#.,)\u001d#\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":44,"lines":{"from":1,"to":30}}}}],["144",{"pageContent":".)6 \u001f- \u001e\u001f\u001d#,6 -\u001f \"\u001b\u001c&\u001b,á \u001e\u001f\n \nhipocromía\n \n3\n \nnormocromía\n \n\u001d/\u001b(\u001e) \u001f& 0\u001b&), \u001e\u001f \b\u0003\n \n-\u001f\u001b -/\u001c(),'\u001b& ) (),'\u001b&6\n,\u001f-*\u001f\u001d.#0\u001b'\u001f(.\u001f8\n \n\u001b \u001b-)\u001d#\u001b\u001d#ĉ( \u001e\u001f /( 0\u001b&), -/\u001c(),'\u001b& \u001e\u001f \b\u0003\n \nB\"#*)\u001d,)'ù\u001bC \u001d)( /( 0\u001b&), -/\u001c(),'\u001b&\n\u001e\u001f \u0016\u0007\n \nB'#\u001d,)\u001d#.)-#-C *\u001f,'#.\u001f \u001f-.\u001b\u001c&\u001f\u001d\u001f, &\u001b \u001f(.#\u001e\u001b\u001e \u001e\u001f '#\u001d,)\u001d#.)-#- \u001f \"#*)\u001d,)'ù\u001b6 +/\u001f */\u001f\u001e\u001f \u001b\u001d)'\n-\n\n*\u001bĄ\u001b,-\u001f ) () \u001e\u001f \u001b(\u001f'#\u001b8 \u0005(\n \nï2#\u001d)6 &\u001b \u001d\u001b/-\u001b 'á-\n \n,\u001f\u001d/\u001f(.\u001f \u001e\u001f \u001b(\u001f'#\u001b '#\u001d,)\u001dù.#\u001d\u001b \"#*)\u001d,ĉ'#\u001d\u001b \u001f- &\u001b\n\u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)6 -\u001f!/#\u001e\u001b \u001e\u001f &\u001b .\u001b&\u001b-\u001f'#\u001b8\n \n\u001b /.#&#\u001e\u001b\u001e \u001e\u001f &\u001b \b\u0003\n \n*\u001b,\u001b \u001f-.\u001b- \u001d)(-#\u001e\u001f,\u001b\u001d#)(\u001f- -)&)\n\u001f- 0á&#\u001e\u001b \u001d/\u001b(\u001e) &\u001b \u0003\b -\u001f \"\u001b &&\u001f0\u001b\u001e) \u001b \u001d\u001b\u001c) *), '\u001f\u001e#) \u001e\u001f \u001d#.)'\u001f.,ù\u001b \u001e\u001f ł/$): &\u001b \b\u0003\n \n() \u001f- \u001d)(l·\u001b\u001c&\u001f\n\u001d/\u001b(\u001e) -\u001f \u001f'*&\u001f\u001b( 'ï.)\u001e)- '\u001b(/\u001b&\u001f- *\u001b,\u001b -/ \u001e\u001f.\u001f,'#(\u001b\u001d#ĉ(8\n\nConcentración media de hemoglobina globular","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":44,"lines":{"from":32,"to":68}}}}],["145",{"pageContent":"Concentración media de hemoglobina globular\n\n\u0005& ù(\u001e#\u001d\u001f \u001f,#.,)\u001dù.#\u001d) \u001d)()\u001d#\u001e) \u001d)')\n \nconcentración media de hemoglobina globular\n \nB\u0003'\b\u001cC6 '\u001f\u001e#\u001e) \u001d)')\n*),\u001d\u001f(.\u001b$\u001f BzC6 -\u001f \u001e\u001f.\u001f,'#(\u001b \u001e#0#\u001e#\u001f(\u001e) &\u001b \b\u001c '/&.#*&#\u001d\u001b\u001e\u001b *), gff \u001f(.,\u001f \u001f& \b.\u001d8 \u0003)') \u001f& \b.\u001d \u001f- /(\n*\u001b,á'\u001f.,) \u001f,#.,)\u001dù.#\u001d) \u001d\u001b&\u001d/&\u001b\u001e) \u001b *\u001b,.#, \u001e\u001f& \u0007\u0012 3 \u001e\u001f& \u0016\u0007\n \n\u001d)( &)- \u001d#.ĉ'\u001f.,)- \u001e\u001f ł/$)6 &\u001b \u0003'\b\u001c \u001f-\n/( \u001e\u001b.) \u001e\u001f ,\u001f \u001f,\u001f(\u001d#\u001b '\u001f()- Ě.#& \u001f #(\u001f2\u001b\u001d.)8\n \n)- 0\u001b&),\u001f- \u001e\u001f ,\u001f \u001f,\u001f(\u001d#\u001b \u001e\u001f &\u001b \u0003'\b\u001c -)( \u001e\u001f ih \u001b ijz\n*\u001b,\u001b 0\u001b,)(\u001f- 3 \u001e\u001f if \u001b ijz *\u001b,\u001b '/$\u001f,\u001f- B\u001b\u001e/&.)- \u001f( \u001f& \u001b&.#*&\u001b() '\u001f2#\u001d\u001b()C8 \u000e) \"\u001b\u001d\u001f '/\u001d\")- \u001bĄ)-6 &\u001b\n\u001e\u001f.\u001f,'#(\u001b\u001d#ĉ( \u001e\u001f \u0003'\b\u001c -\u001f /-\u001b\u001c\u001b *\u001b,\u001b #(\u001e#\u001d\u001b, &\u001b \u001d)(\u001d\u001f(.,\u001b\u001d#ĉ( \u001e\u001f \b\u001c \u001f( &)- \u001f,#.,)\u001d#.)-8 \u0005-.\u001b \u001d)-./'\u001c,\u001f\n() \u001f- \u001b\u001d)(-\u001f$\u001b\u001c&\u001f 3\u001b +/\u001f \u001f- '\u001f()- \u001d)(l·\u001b\u001c&\u001f \u001e\u001f &) +/\u001f -\u001f -/*)(ù\u001b: -#( \u001f'\u001c\u001b,!)6 */\u001f\u001e\u001f \u001d\u001b&\u001d/&\u001b,-\u001f \u001f( \u0003\b\n,\u001f\u001b&#4\u001b\u001e\u001b- \u001d)( 'ï.)\u001e)- '\u001b(/\u001b&\u001f-6 *\u001f,) .\u001f(#\u001f(\u001e) \u001f( \u001d/\u001f(.\u001b +/\u001f -)&) \u001f( \u001d)(\u001e#\u001d#)(\u001f- \u001f2.,\u001f'\u001b- -\u001f \u001b&.\u001f,\u001b(\n-/- 0\u001b&),\u001f- (),'\u001b&\u001f-8 \u0005( &\u001b- \u001d#.)'\u001f.,ù\u001b- \"\u001f'á.#\u001d\u001b- &&\u001f0\u001b\u001e\u001b- \u001b \u001d\u001b\u001c) \u001d)( \u001d)(.\u001b\u001e),\u001f- \u001e\u001f *\u001b,.ù\u001d/&\u001b- *), \u001d#.)\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":44,"lines":{"from":68,"to":87}}}}],["146",{"pageContent":"'\u001f.,ù\u001b \u001e\u001f ł/$) \u001e\u001f\u001c\u001f \u001b\u001c\u001b(\u001e)(\u001b,-\u001f \u001f& \u001f'*&\u001f) \u001e\u001f \u001f-.\u001f ù(\u001e#\u001d\u001f8\n\u001b \"#-.),#\u001b (\u001b./,\u001b& \u001e\u001f &\u001b\n \n\u001f,,)*\u001f(#\u001b \u001f( /( #(\u001e#0#\u001e/) \u001f- &\u001b -#!/#\u001f(.\u001f9 #(#\u001d#\u001b&'\u001f(.\u001f \"\u001b3 \u001eïl·\u001d#. \u001e\u001f&\n\"#\u001f,,) \u001e\u001f ,\u001f-\u001f,0\u001b B\"#*) \u001f,,#.#(\u001f'#\u001bC6 -\u001f!/#\u001e) \u001e\u001f \u001e#-'#(/\u001d#ĉ( \u001e\u001f& \"#\u001f,,) -ï,#\u001d) 3 \u001e\u001f &\u001b -\u001b./,\u001b\u001d#ĉ( \u001e\u001f &\u001b\n.,\u001b(- \u001f,,#(\u001b B\"#*) \u001f,,\u001f'#\u001bC8 \u0004\u001f-*/ï- \u001e#-'#(/3\u001f &\u001b \b\u0003\n \nB\"#*)\u001d,)'ù\u001bC6 'á- .\u001b,\u001e\u001f \u001f& \u0016\u0007\n \nB'#\u001d,)\u001d#.)\n-\n\n-#-C6 *)-.\u001f,#),'\u001f(.\u001f &\u001b \b\u001c B\u001b(\u001f'#\u001bC 36 -)&) .\u001b,\u001eù\u001b'\u001f(.\u001f6 &\u001b \u0003'\b\u001c8 \u0005-.\u001b -\u001f\u001d/\u001f(\u001d#\u001b \u001e\u001f\n \n\u001f(ĉ'\u001f()- *\u001f,\n-\n\n'#.\u001f \u001d)()\u001d\u001f, &\u001b /.#&#\u001e\u001b\u001e \u001e\u001f &\u001b- \u001b&.\u001f,\u001b\u001d#)(\u001f- \u001e\u001f &)- ù(\u001e#\u001d\u001f- B\b\u001c6 \b.\u001d6 \u0007\u0012C 3 *\u001b,á'\u001f.,)- B\u0016\u0007\n \n6 \b\u0003\n \n6\n\u0003'\b\u001cC \u001f,#.,)\u001dù.#\u001d)- \u001f( \u001f& \u001e#\u001b!(ĉ-.#\u001d) .\u001f'*,\u001b() \u001e\u001f &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)6 \u001d\u001b/-\u001b '/3\n \n,\u001f\u001d/\u001f(.\u001f \u001e\u001f\n\u001b(\u001f'#\u001b \u001f( (/\u001f-.,) '\u001f\u001e#)8\n\nCoeficiente de variación del VGM\n\n\u0005& \u001d)\u001fl·\u001d#\u001f(.\u001f \u001e\u001f 0\u001b,#\u001b\u001d#ĉ( \u001e\u001f& \u0016\u0007\n \nB\u0003\u00167\u0016\u0007\n \nC -\u001f '#\u001e\u001f \u001d)') *),\u001d\u001f(.\u001b$\u001f BzC 3 -)&) */\u001f\u001e\u001f \u001d\u001b&\u001d/&\u001b,-\u001f\n\u001d)( \u001d#.ĉ'\u001f.,)- \u001e\u001f ł/$)6 +/\u001f \"\u001b\u001d\u001f( \"#-.)!,\u001b'\u001b- \u001e\u001f \u001e#-.,#\u001c/\u001d#ĉ( \u001e\u001f ,\u001f\u001d/\u001f(\u001d#\u001b- \u001e\u001f &)- 0)&Ě'\u001f(\u001f- \u001f,#.,)\u001dù.#\u001d)-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":44,"lines":{"from":89,"to":123}}}}],["147",{"pageContent":"(fig. 2-1)\n8 \u0005-.\u001f ù(\u001e#\u001d\u001f .\u001b'\u001c#ï( -\u001f \u001d)()\u001d\u001f \u001d)( \u001f& ()'\u001c,\u001f \u001e\u001f ^\u001b(\u001d\"/,\u001b \u001e\u001f &\u001b \u001e#-.,#\u001c/\u001d#ĉ( \u001e\u001f &)- \u001f,#.,)\u001d#.)-_\nB\u0012\u0004\u00176 \u001e\u001f\n \nred cell distribution width\nC8 \u0005& \u001f+/#*) \u001e\u001f \u001d#.)'\u001f.,ù\u001b \u001e\u001f ł/$) \"\u001b\u001d\u001f /(\u001b \u001d/,0\u001b \u001e\u001f \u001e#-.,#\u001c/\u001d#ĉ( \u001e\u001f&\n.\u001b'\u001bĄ) B\u0016\u0007\n \nC \u001e\u001f &)- \u001f,#.,)\u001d#.)-6 \u001e)(\u001e\u001f !,\u001bl·\u001d\u001b \u001f( &\u001b- \u001b\u001c-\u001d#-\u001b- \u001f& \u0016\u0007\n \n'\u001f\u001e#\u001e) \u001f( \u001f'.)&#.,)- 3 \u001f( &\u001b- ),\u001e\u001f\n-\n\n(\u001b\u001e\u001b- &\u001b ,\u001f\u001d/\u001f(\u001d#\u001b ,\u001f&\u001b.#0\u001b \u001e\u001f &)- 0)&Ě'\u001f(\u001f-6 \u001f2*,\u001f-\u001b\u001e\u001b \u001d)') *),\u001d\u001f(.\u001b$\u001f BzC8 \u0005& \u0003\u00167\u0016\u0007\n \n\u001f-6 \u001b*,)2#'\u001b\u001e\u001b\n-\n\n'\u001f(.\u001f6 \u001e\u001f gh \u001b giz \u001f( \u001d)(\u001e#\u001d#)(\u001f- (),'\u001b&\u001f-8 \u0005( \u001f& \u001d\u001b-) \u001e\u001f &\u001b- \u001b(\u001f'#\u001b- \u001f,,)*ï(#\u001d\u001b-6 +/\u001f \u001d/,-\u001b( \u001d)( \u0016\u0007\n \n3\n\b\u0003\n \n\u001c\u001b$)-6 \u001f& \u0003\u00167\u0016\u0007\n \n\u001b*\u001b,\u001f\u001d\u001f \u001d\u001b,\u001b\u001d.\u001f,ù-.#\u001d\u001b'\u001f(.\u001f \u001b/'\u001f(.\u001b\u001e) Bgk \u001b gnzC6 \u001f( .\u001b(.) +/\u001f \u001f( &\u001b- .\u001b&\u001b-\u001f'#\u001b-6\n+/\u001f \u001d/,-\u001b( .\u001b'\u001c#ï( \u001d)( \u0016\u0007\n \n3 \b\u0003\n \n\u001e#-'#(/#\u001e)-6 \u001f& \u0003\u00167\u0016\u0007\n \n\u001f- (),'\u001b& Bgh \u001b gizC8\n\nCurvas de distribución de frecuencias del VGM","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":44,"lines":{"from":125,"to":159}}}}],["148",{"pageContent":"Curvas de distribución de frecuencias del VGM\n\n\u0001& \u001d)'\u001f(.\u001b, -)\u001c,\u001f \u001f& \u0003\u00167\u0016\u0007\n \n6 -\u001f #(\u001e#\u001dĉ +/\u001f \u001f-.\u001f ù(\u001e#\u001d\u001f -)&) */\u001f\u001e\u001f \u001d\u001b&\u001d/&\u001b,-\u001f \u001b *\u001b,.#, \u001e\u001f \u001d/,0\u001b- \u001e\u001f\n\u001e#-.,#\u001c/\u001d#ĉ( \u001e\u001f\n \n,\u001f\u001d/\u001f(\u001d#\u001b- \u001e\u001f& \u0016\u0007\n \n8 \u0005-.\u001b- \u001d/,0\u001b- *,)*),\u001d#)(\u001b( #( ),'\u001b\u001d#ĉ( 0\u001b&#)-\u001b -)\u001c,\u001f &)- 0\u001b&),\u001f-\n*,)'\u001f\u001e#) \u001e\u001f \u0016\u0007\n \n3 \u001e\u001f &\u001b \u001e#-.,#\u001c/\u001d#ĉ( \u001e\u001f .)\u001e\u001b- &\u001b- \u001d# ,\u001b- \u001e\u001f& \u0016\u0007\n \n\u001e\u001f &)- \u001f,#.,)\u001d#.)- \u001f-./\u001e#\u001b\u001e)-8 \u0015(\u001b \u0003\b\n*/\u001f\u001e\u001f .\u001f(\u001f, /( \u0016\u0007\n \n*,)'\u001f\u001e#) (),'\u001b&6 *\u001f,) &\u001b \u001d/,0\u001b \u001e\u001f \u001e#-.,#\u001c/\u001d#ĉ( \u001e\u001f& \u0016\u0007\n \n\u001b(),'\u001b&8\n\nEste índice debe ser el único\nque se emplee para referirse a la\ncantidad de hemoglobina con-\ntenida en cada eritrocito, es de-\ncir, se hablará de\n \n\"#*)\u001d,)'ù\u001b\n \ny\n\n(),')\u001d,)'ù\u001b\n \ncuando el valor\nde la HCM sea subnormal o\nnormal, respectivamente.\nInicialmente hay déficit del\nhierro de reserva (hipoferri-\ntinemia), seguido de dismi-\nnución del hierro sérico y de\nla saturación de la transferri-\nna\n \n(hipoferremia).\n \nDespués\ndisminuye\n \nla\n \nHCM\n \n(hipo-\ncromía), más tarde el VGM\n(microcitosis), posteriormente\nla Hb (anemia) y, solo tardía-\nmente, la CmHb.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":44,"lines":{"from":159,"to":215}}}}],["149",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n18\n\n\u001b\n \nfigura 2-2\n \n'/\u001f-.,\u001b &\u001b \u001d/,0\u001b (),'\u001b& \u001e\u001f \u001e#-.,#\u001c/\u001d#ĉ( \u001e\u001f& \u0016\u0007\n \n\u001e\u001f &)- \u001f,#.,)\u001d#.)-8\n\u0005( &\u001b\n \nfigura 2-3\n \n\u001b*\u001b,\u001f\u001d\u001f /(\u001b \u001d/,0\u001b \u001b(),'\u001b& \u001e\u001f \u001e#-.,#\u001c/\u001d#ĉ( \u001e\u001f& \u0016\u0007\n \n\u001f( /( *\u001b\u001d#\u001f(.\u001f \u001d)( \u001b(\u001f'#\u001b *),\n\u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)6 \u001f( +/#\u001f( \u001f& \u0016\u0007\n \n\u001f-.á \u001e#-'#(/#\u001e) 3 \u001f& \u0003\u00167\u0016\u0007\n \n\u001f&\u001f0\u001b\u001e)8\n\u001b\n \nfigura 2-4\n \n'/\u001f-.,\u001b .\u001b'\u001c#ï( /(\u001b '#\u001d,)\u001d#.)-#- B\u0016\u0007\n \n\u001c\u001b$)C -#( \u001b(\u001f'#\u001b6 *\u001f,) \u001d)( \u0003\u00167\u0016\u0007\n \n(),'\u001b&6\n\u001d\u001b,\u001b\u001d.\u001f,ù-.#\u001d\u001b \u001e\u001f /( *\u001b\u001d#\u001f(.\u001f \u001d)( \u001f-.\u001b\u001e) \"\u001f.\u001f,)\u001d#!).) *\u001b,\u001b .\u001b&\u001b-\u001f'#\u001b\n \nβ\n8\n \n\u001b \u001d/\u001b(.#l·\u001d\u001b\u001d#ĉ( \u001e\u001f &\u001b \"\u001f')!&)\u001c#(\u001b\n\u0001h B#(\u001d,\u001f'\u001f(.\u001b\u001e\u001b \u001f( .\u001b&\u001b-\u001f'#\u001bC 3 &\u001b '\u001f\u001e#\u001d#ĉ( \u001e\u001f& \"#\u001f,,) -ï,#\u001d)6 .,\u001b(- \u001f,,#(\u001b 3 \u001f,,#.#(\u001b -)( &)- Ě(#\u001d)- *\u001b,á\n-\n\n'\u001f.,)- \u001f( &)- +/\u001f \u001f- *)-#\u001c&\u001f \u001c\u001b-\u001b, \u001f& \u001e#\u001b!(ĉ-.#\u001d) \u001f(.,\u001f \u001f-.\u001b- \u001e)- ),'\u001b- \u001e\u001f \u001b(\u001f'#\u001b '#\u001d,)\u001dù.#\u001d\u001b \"#*)\u001d,ĉ'#\u001d\u001b8\n\u0005( &\u001b\n \nfigura 2-5\n \n-\u001f )\u001c-\u001f,0\u001b \u001f& \"#-.)!,\u001b'\u001b \u001e\u001f \u001f,#.,)\u001d#.)- \u001e\u001f /( -/$\u001f.) \u001d)( \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) B*#\u001d) \u001e\u001f\n&\u001b #4+/#\u001f,\u001e\u001b6 '#\u001d,)\u001dù.#\u001d)C \u001b +/#\u001f( -\u001f &\u001f \"\u001b( \u001b\u001e'#(#-.,\u001b\u001e) -\u001b&\u001f- \u001e\u001f \"#\u001f,,) 3 \u001f'*#\u001f4\u001b \u001b *,)\u001e/\u001d#, /(\u001b *)\u001c&\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":45,"lines":{"from":1,"to":49}}}}],["150",{"pageContent":"\u001d#ĉ( \u001e\u001f \u001f,#.,)\u001d#.)- \u001e\u001f '\u001b3), .\u001b'\u001bĄ) B*#\u001d) \u001e\u001f &\u001b \u001e\u001f,\u001f\u001d\"\u001b6 '\u001b\u001d,)\u001dù.#\u001d)C6 *), &) +/\u001f */\u001f\u001e\u001f -\u001fĄ\u001b&\u001b,-\u001f +/\u001f -\u001f\n.,\u001b.\u001b \u001e\u001f /(\u001b *)\u001c&\u001b\u001d#ĉ( \u001f,#.,)\u001dù.#\u001d\u001b \u001e#'ĉ,l·\u001d\u001b8\n\u001b\n \nfigura 2-6\n \n\u001d),,\u001f-*)(\u001e\u001f \u001b /( \u001d\u001b-) \u001e\u001f \u001b(\u001f'#\u001b '\u001b\u001d,)\u001dù.#\u001d\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8 \u000eĉ.\u001f-\u001f \u001dĉ') \u001f& 0\u001b&),\n'\u001f\u001e#) \u001e\u001f& \u0016\u0007\n \n-\u001f \u001f(\u001d/\u001f(.,\u001b #(\u001d,\u001f'\u001f(.\u001b\u001e) B'\u001b\u001d,)\u001d#.)-#-6 \u001e\u001f-*&\u001b4\u001b'#\u001f(.) \u001e\u001f& *#\u001d) \u001e\u001f \"#-.)!,\u001b'\u001b \u001b &\u001b\n\u001e\u001f,\u001f\u001d\"\u001bC6 \u001b\u001e\u001f'á- \u001e\u001f +/\u001f \u001f& \u0003\u00167\u0016\u0007\n \n\u001f- \u001b&.)6 \u001f( .\u001b(.) +/\u001f &\u001b \u001c\u001b-\u001f \u001e\u001f& \"#-.)!,\u001b'\u001b \u001f- \u001b(\u001d\"\u001b8\n\nCuenta corregida de reticulocitos\n\n\u001b \u001d/\u001f(.\u001b \u001d),,\u001f!#\u001e\u001b \u001e\u001f ,\u001f.#\u001d/&)\u001d#.)- B\u0003\u0003\u0012C -\u001f \u001f2*,\u001f-\u001b \u001d)') *),\u001d\u001f(.\u001b$\u001f BzC 3 -\u001f ,\u001fl·\u001f,\u001f \u001b &\u001b *,)*),\u001d#ĉ(\n*),\u001d\u001f(./\u001b& \u001e\u001f \u001f,#.,)\u001d#.)- #('\u001b\u001e/,)-6 ,\u001f\u001d#\u001f(.\u001f'\u001f(.\u001f \u001e\u001f-*,)0#-.)- \u001e\u001f& (Ě\u001d&\u001f)6 +/\u001f \"\u001b( -#\u001e) \u001f'#.#\u001e)- \u001b &\u001b\n-\u001b(!,\u001f *\u001f,# ï,#\u001d\u001b *,\u001f'\u001b./,\u001b'\u001f(.\u001f *), &\u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b8 \u0013\u001f \u001e\u001f()'#(\u001b(\n \nreticulocitos\n \n*),+/\u001f6 \u001b& .\u001fĄ#, &)- \u001f,#\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":45,"lines":{"from":51,"to":74}}}}],["151",{"pageContent":".,)\u001d#.)- \u001d)( .#(\u001d#)(\u001f- -/*,\u001b0#.\u001b&\u001f-6 &)- ,\u001f-.)- \u001e\u001f á\u001d#\u001e)- (/\u001d&\u001f#\u001d)- -\u001f \u001e#-*)(\u001f( \u001f( \u001f& \u001d#.)*&\u001b-'\u001b \u001b '\u001b(\u001f,\u001b \u001e\u001f\n/(\u001b ,\u001f\u001e8\n \n\u001b \u0003\u0003\u0012 -\u001f \u001d\u001b&\u001d/&\u001b \u001e\u001f &\u001b -#!/#\u001f(.\u001f '\u001b(\u001f,\u001b9\n\u001e)(\u001e\u001f\n \nCR (%)\n \n\u001f- &\u001b \u001d/\u001f(.\u001b *),\u001d\u001f(./\u001b& \u001e\u001f ,\u001f.#\u001d/&)\u001d#.)- \u001f( /( \u001f2.\u001f(\u001e#\u001e) \u001e\u001f -\u001b(!,\u001f *\u001f,# ï,#\u001d\u001b8\n\u001b \u0003\u0003\u0012 \u001d)(-.#./3\u001f /( ù(\u001e#\u001d\u001f #(\u001e#,\u001f\u001d.) \u001e\u001f &\u001b '\u001b!(#./\u001e \u001e\u001f &\u001b \u001f,#.,)*)3\u001f-#- \u001f( &\u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b8 \u0003/\u001b(\u001e)\n&\u001b 0\u001f&)\u001d#\u001e\u001b\u001e \u001e\u001f *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f &)- \u001f,#.,)\u001d#.)- -\u001f #(\u001d,\u001f'\u001f(.\u001b6 -\u001f \u001f(0ù\u001b( \u001b &\u001b -\u001b(!,\u001f *\u001f,# ï,#\u001d\u001b ),'\u001b- #('\u001b\n-\n\n\u001e/,\u001b- \u001e\u001f \u001f-.)-6 3 &\u001b \u0003\u0003\u0012 -\u001f \u001f(\u001d/\u001f(.,\u001b \u001f&\u001f0\u001b\u001e\u001b \u001e\u001f '\u001b(\u001f,\u001b \u001d\u001b,\u001b\u001d.\u001f,ù-.#\u001d\u001b8 \u0005( \u001b(\u001f'#\u001b- \"#*)*&á-#\u001d\u001b-6 \u001e)(\u001e\u001f\n\"\u001b3 \u001e#-'#(/\u001d#ĉ( \u001b\u001c-)&/.\u001b \u001e\u001f& .\u001f$#\u001e) \"\u001f'\u001b.)*)3ï.#\u001d) \u001f( &\u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b6 &\u001b \u0003\u0003\u0012 -\u001f \u001f(\u001d/\u001f(.,\u001b \u001e#-'#(/#\u001e\u001b8\n\nFigura 2-1.\n \n'\u001b!\u001f( \u001e\u001f &\u001b *\u001b(.\u001b&&\u001b \u001e\u001f /() \u001e\u001f &)- \u001d#.ĉ'\u001f.,)- \u001e\u001f ł/$)8 \u0001 &\u001b #4+/#\u001f,\u001e\u001b \u001b*\u001b,\u001f\u001d\u001f( &\u001b- \u001e#-.,#\u001c/\u001d#)(\u001f- \u001e\u001f &)- &\u001f/\u001d)\u001d#.)-\nB\n \n &#( )\u001d#.)-:\n \n ')()\u001d#.)-: \u000e  (\u001f/.,ĉl·&)-: \u0005  \u001f)-#(ĉl·&)-C6 \u001e\u001f \u001b\u001d/\u001f,\u001e) \u001b -/ .\u001b'\u001bĄ) B0)&/'\u001f( 3 !,\u001b(/&\u001b,#\u001e\u001b\u001eC6 3 \u001b &\u001b \u001e\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":45,"lines":{"from":76,"to":100}}}}],["152",{"pageContent":",\u001f\u001d\"\u001b \u001b*\u001b,\u001f\u001d\u001f(6 \u001b,,#\u001c\u001b6 &\u001b \u001d/,0\u001b \u001e\u001f \u001e#-.,#\u001c/\u001d#ĉ( \u001e\u001f &)- \u001f,#.,)\u001d#.)- B\u0007\u0012C 3 \u001b\u001c\u001b$) &\u001b \u001d/,0\u001b \u001e\u001f \u001e#-.,#\u001c/\u001d#ĉ( \u001e\u001f &\u001b- *&\u001b+/\u001f.\u001b- B\u0010\n \n\u0014C8\n\nCCR= CR(%)\n \nx\n \nHematocrito del paciente\n45","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":45,"lines":{"from":102,"to":111}}}}],["153",{"pageContent":"CAPÍTULO 2. Ci\nTO\nme\nT\nr\nÍA\n \nhemá\nT\ni\nCA\n \ny s\nU\n \nin\nT\ner\nP\nre\nTAC\nión\n19\n\nFigura 2-2.\n \nHistograma\n \nde\n \nlos\n \neritrocitos\n \nde\n \nun\n \nindividuo\n \nsano.\n\nFigura 2-3.\n \nHistograma\n \nde\n \nlos\n \neritrocitos\n \nde\n \nun\n \nindividuo\n \ncon\n \nanemia\n \npor\n \ndeficiencia\n \nde\n \nhierro.\n \nNótese\n \ncómo\n\nla\n \nHb\n \nestá\n \nbaja,\n \nel\n \nVGM\n \ndisminuido\n \ny\n \nel\n \nCV-VGM\n \naumentado.\n \nLa\n \ncurva\n \nde\n \nVGM\n \nestá\n \ndesplazada\n \na\n \nla\n \niz\n-\n\nquierda\n \n(microcitosis).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":46,"lines":{"from":1,"to":118}}}}],["154",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n20\n\nFigura 2-5.\n \nHistograma\n \nde\n \nlos\n \neritrocitos\n \nde\n \nun\n \nindividuo\n \ncon\n \nanemia\n \npor\n \ndeficiencia\n \nde\n \nhierro\n \na\n \nquien\n \nse\n \nle\n\nhan\n \nadministrado\n \nsales\n \nde\n \nhierro.\n \nNótese\n \ncómo\n \nla\n \nHb\n \nse\n \nencuentra\n \ndisminuida,\n \nel\n \nVGM\n \nbajo\n \ny\n \nel\n \nCV-VGM\n\nmuy\n \nalto.\n \nLa\n \ncurva\n \ndel\n \nVGM\n \nes\n \nbimodal\n \ny\n \ncorresponde\n \na\n \ndos\n \npoblaciones\n \neritrocíticas:\n \nuna\n \nmicrocítica\n\ndesplazada\n \na\n \nla\n \nizquierda,\n \ny\n \notra\n \nmacrocítica\n \ndesplazada\n \na\n \nla\n \nderecha;\n \nesta\n \núltima\n \ncorresponda\n \na\n \nla\n \npoblación\n\neritrocitaria\n \n“nueva”\n \nque\n \nse\n \nha\n \nproducido\n \nen\n \nrespuesta\n \na\n \nla\n \nadministración\n \nde\n \nhierro.\n\nFigura 2-4.\n \nHistograma\n \nde\n \nlos\n \neritrocitos\n \nde\n \nun\n \nindividuo\n \ncon\n \ntalasemia\n \nβ\n.\n \nNótese\n \ncómo\n \nel\n \nVGM\n \ndisminuido\n\ny\n \nel\n \nCV-VGM,\n \na\n \ndiferencia\n \nde\n \nlo\n \nque\n \nocurre\n \nen\n \nla\n \ndeficiencia\n \nde\n \nhierro,\n \nson\n \nnormales.\n \nLa\n \ncurva\n \ndel\n \nVGM\n \nestá","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":47,"lines":{"from":1,"to":241}}}}],["155",{"pageContent":"y\n \nel\n \nCV-VGM,\n \na\n \ndiferencia\n \nde\n \nlo\n \nque\n \nocurre\n \nen\n \nla\n \ndeficiencia\n \nde\n \nhierro,\n \nson\n \nnormales.\n \nLa\n \ncurva\n \ndel\n \nVGM\n \nestá\n\ndesplazada\n \na\n \nla\n \nizquierda\n \n(microcitosis).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":47,"lines":{"from":241,"to":291}}}}],["156",{"pageContent":"CAPÍTULO 2. CITOMETRÍA HEMÁTICA Y SU INTERPRETACIÓN\n\n21\n\nFigura 2-6.\n \n\b#-.)!,\u001b'\u001b \u001e\u001f &)- \u001f,#.,)\u001d#.)- \u001e\u001f /( #(\u001e#0#\u001e/) \u001d)( \u001b(\u001f'#\u001b '\u001b\u001d,)\u001dù.#\u001d\u001b *), \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f 0#.\u001b'#(\u001b\n\u0002gh8 \u000eĉ.\u001f-\u001f \u001dĉ') &\u001b \b\u001c \u001f-.á \u001c\u001b$\u001b6 \u001f& \u0016\u0007\n \n'/3 \u001b&.) 3 \u001f& \u0003\u00167\u0016\u0007\n \n.\u001b'\u001c#ï( '/3 \u001b/'\u001f(.\u001b\u001e)8\n \n\u001b \u001d/,0\u001b \u001e\u001f&\n\u0016\u0007\n \n\u001f-.á \u001e\u001f-*&\u001b4\u001b\u001e\u001b \u001b &\u001b \u001e\u001f,\u001f\u001d\"\u001b B'\u001b\u001d,)\u001d#.)-#-C8\n\u0005& \u001f'*&\u001f) ,\u001b\u001d#)(\u001b& \u001e\u001f &\u001b #( ),'\u001b\u001d#ĉ( !\u001f(\u001f,\u001b\u001e\u001b *), &)- \u001d)(.\u001b\u001e),\u001f- \u001e\u001f *\u001b,.ù\u001d/&\u001b- \u001b .,\u001b0ï- \u001e\u001f \u001d#.)'\u001f.,ù\u001b\n\u001e\u001f ł/$) *\u001f,'#.\u001f \u001b& \u001d&ù(#\u001d) ),#\u001f(.\u001b,-\u001f \u001b\u001e\u001f\u001d/\u001b\u001e\u001b'\u001f(.\u001f -)\u001c,\u001f \u001f& ),#!\u001f( \u001e\u001f &\u001b- \u001b&.\u001f,\u001b\u001d#)(\u001f- \u001f,#.,)\u001dù.#\u001d\u001b- 3 \u001e\u001f\n&\u001b- \u001b(\u001f'#\u001b-8 \u0004\u001f\u001c\u001f #(-#-.#,-\u001f \u001f( &\u001b \u001d)(0\u001f(#\u001f(\u001d#\u001b \u001e\u001f \u001f'*&\u001f\u001b, \u001d)(.\u001b\u001e),\u001f- \u001f&\u001f\u001d.,ĉ(#\u001d)- \u001e\u001f *\u001b,.ù\u001d/&\u001b- *\u001b,\u001b &\u001b\n'\u001f\u001e#\u001d#ĉ( \u001e\u001f &)- *\u001b,á'\u001f.,)- \u001f ù(\u001e#\u001d\u001f- \u001f,#.,)\u001dù.#\u001d)-8\n \n)- \u001d)(\u001d\u001f*.)- \u001b(.\u001f- -\u001fĄ\u001b&\u001b\u001e)- -)\u001c,\u001f &)- ù(\u001e#\u001d\u001f- 3 *\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":48,"lines":{"from":1,"to":24}}}}],["157",{"pageContent":",á'\u001f.,)- \u001f,#.,)\u001dù.#\u001d)- *#\u001f,\u001e\u001f( 0\u001b&#\u001e\u001f4 \u001d/\u001b(\u001e) -\u001f /-\u001b( 'ï.)\u001e)- '\u001b(/\u001b&\u001f- *\u001b,\u001b \u001e\u001f.\u001f,'#(\u001b,&)-8\n \n!/\u001b&'\u001f(.\u001f6\n&\u001b- '\u001f\u001e#\u001d#)(\u001f- \"\u001f\u001d\"\u001b- \u001d)( &)- \u001d)(.\u001b\u001e),\u001f- \u001f&\u001f\u001d.,ĉ(#\u001d)- \u001e\u001f *\u001b,.ù\u001d/&\u001b- *#\u001f,\u001e\u001f( 0\u001b&), -# () -\u001f \u001d)(l·,'\u001b( \u001d)( &\u001b\n)\u001c-\u001f,0\u001b\u001d#ĉ( \u001b& '#\u001d,)-\u001d)*#) \u001e\u001f \u001f2.\u001f(\u001e#\u001e)- \u001e\u001f -\u001b(!,\u001f .\u001fĄ#\u001e)- \u001d)( .#(\u001d#)(\u001f- *\u001b(\u001d,)'á.#\u001d\u001b-8 \u0005( \u001d)(\u001e#\u001d#)(\u001f-\n#\u001e\u001f\u001b&\u001f-6 \u001e\u001f\u001c\u001f \u001d)(l·,'\u001b,-\u001f '\u001f\u001e#\u001b(.\u001f '#\u001d,)-\u001d)*#) &\u001b \u001f2#-.\u001f(\u001d#\u001b \u001e\u001f '#\u001d,)\u001d#.)-#-6 \"#*)\u001d,)'ù\u001b6 \u001b(#-)\u001d,)'ù\u001b6\n'\u001b\u001d,)\u001d#.)-#-6 \u001f.\u001dï.\u001f,\u001b8 \u0001\u001e\u001f'á-6 ).,\u001b- \u001b&.\u001f,\u001b\u001d#)(\u001f- \u001f,#.,)\u001dù.#\u001d\u001b- () */\u001f\u001e\u001f( \u001f0\u001b&/\u001b,-\u001f \u001d)( \u001d#.)'\u001f.,ù\u001b \u001e\u001f\nł/$)6 \u001d)') &\u001b *,\u001f-\u001f(\u001d#\u001b \u001e\u001f \u001c\u001b-)l·&#\u001b \u001e# /-\u001b ) \u001e\u001f */(.\u001f\u001b\u001e) \u001c\u001b-ĉl·&)6 +/\u001f ,\u001f0\u001f&\u001b( \u001f,#.,)*)3\u001f-#- \u001b\u001d\u001f&\u001f,\u001b\u001e\u001b 3\n+/\u001f \"\u001b\u001c#./\u001b&'\u001f(.\u001f \u001d)\u001f2#-.\u001f( \u001d)( \u001d# ,\u001b- \u001f&\u001f0\u001b\u001e\u001b- \u001e\u001f \u0003\u0003\u00128\n \n\u001b *,\u001f-\u001f(\u001d#\u001b \u001e\u001f *\u001b,á-#.)- \u001f,#.,)\u001dù.#\u001d)- B*8 \u001f$86\n\nPlasmodium\nC () */\u001f\u001e\u001f \u001f-.\u001b\u001c&\u001f\u001d\u001f,-\u001f \u001d)( \u001d#.)'\u001f.,ù\u001b \u001e\u001f ł/$)6 \u001e\u001f \u001b\"ù +/\u001f \u001d)(.#(Ě\u001b -#\u001f(\u001e) '/3 #'*),.\u001b(.\u001f\n\"\u001b\u001d\u001f,6 \u001b\u001e\u001f'á- \u001e\u001f &\u001b '\u001f\u001e#\u001d#ĉ( \u001e\u001f &)- \u001f,#.,)\u001d#.)- *), \u001d#.)'\u001f.,ù\u001b \u001e\u001f ł/$)6 &\u001b )\u001c-\u001f,0\u001b\u001d#ĉ( '#\u001d,)-\u001dĉ*#\u001d\u001b \u001e\u001f\n\u001f-.\u001b- \u001dï&/&\u001b-8\n\nSERIE BLANCA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":48,"lines":{"from":26,"to":43}}}}],["158",{"pageContent":"SERIE BLANCA\n\n)- \u001e\u001b.)- +/\u001f &\u001b \u0003\b *,)*),\u001d#)(\u001b -)(9 (Ě'\u001f,) \u001e\u001f !&ĉ\u001c/&)- \u001c&\u001b(\u001d)-6 \u001d/\u001f(.\u001b \u001e# \u001f,\u001f(\u001d#\u001b& 3 \u001b&.\u001f,\u001b\u001d#)(\u001f-\n\u001e\u001f &)- &\u001f/\u001d)\u001d#.)-8\n\nNúmero de leucocitos\n\n\u0005& (Ě'\u001f,) \u001e\u001f &\u001f/\u001d)\u001d#.)- ) !&ĉ\u001c/&)- \u001c&\u001b(\u001d)- B\u0007\u0002C -\u001f '#\u001e\u001f \u001f( '#&\u001f- \u001e\u001f '#&&)(\u001f- *), &#.,) B̓gf\n \no\n \nI\n \nC8\n \n)-\n\u001d#.ĉ'\u001f.,)- \u001e\u001f ł/$) *\u001f,'#.\u001f( \u001e\u001f.\u001f,'#(\u001b, \u001d)( !,\u001b( \u001f2\u001b\u001d.#./\u001e \u001f-.\u001f *\u001b,á'\u001f.,)8 \u0005& (Ě'\u001f,) \u001e\u001f &\u001f/\u001d)\u001d#.)-\n\u001e\u001f*\u001f(\u001e\u001f \u001e\u001f '/\u001d\")- \u001b\u001d.),\u001f-6 \u001d)') \u001f\u001e\u001b\u001e6 *\u001f-)6 \"á\u001c#.) .\u001b\u001cá+/#\u001d)6 \u001d)(-/') \u001e\u001f \"),')(\u001b- \u001b(.#\u001d)(\u001d\u001f*.#0\u001b-6\n\u001f.\u001dï.\u001f,\u001b8 \u0010\u001b,\u001b &)- \u001b\u001e/&.)-6 &)- 0\u001b&),\u001f- \u001e\u001f ,\u001f \u001f,\u001f(\u001d#\u001b )-\u001d#&\u001b( \u001f(.,\u001f j 3 gh̓̓gf\n \no\n \nI\n \nBj̓fff \u001b gh̓fffI\n \nC8 \u0003/\u001b(\n-\n\n\u001e) &\u001b \u001d/\u001f(.\u001b \u001e\u001f \u0007\u0002 -\u001f \u001f(\u001d/\u001f(.,\u001b *), \u001b,,#\u001c\u001b \u001e\u001f gh̓̓gf\n \no\n \nI\n \n6 -\u001f \"\u001b\u001c&\u001b \u001e\u001f\n \nleucocitosis\n6 3 \u001d/\u001b(\u001e) -\u001f \u001f(\u001d/\u001f(.,\u001b\n*), \u001b\u001c\u001b$) \u001e\u001f j̓̓gf\n \no\n \nI\n \n6 \u001e\u001f\n \nleucopenia\n8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":48,"lines":{"from":43,"to":91}}}}],["159",{"pageContent":"\u001e) &\u001b \u001d/\u001f(.\u001b \u001e\u001f \u0007\u0002 -\u001f \u001f(\u001d/\u001f(.,\u001b *), \u001b,,#\u001c\u001b \u001e\u001f gh̓̓gf\n \no\n \nI\n \n6 -\u001f \"\u001b\u001c&\u001b \u001e\u001f\n \nleucocitosis\n6 3 \u001d/\u001b(\u001e) -\u001f \u001f(\u001d/\u001f(.,\u001b\n*), \u001b\u001c\u001b$) \u001e\u001f j̓̓gf\n \no\n \nI\n \n6 \u001e\u001f\n \nleucopenia\n8\n\nEn condiciones ideales, debe\nconfirmarse\n \nmediante\n \nmi-\ncroscopio\n \nla\n \nexistencia\n \nde\nmicrocitosis, hipocromía, ani-\nsocromía, macrocitosis, etcéte-\nra. Además, otras alteraciones\neritrocíticas no pueden eva-\nluarse con citometría de flujo,\ncomo la presencia de basofilia\ndifusa o de punteado basófilo.\nEl número de leucocitos de-\npende\n \nde\n \nmuchos\n \nfactores,\ncomo edad, peso, hábito ta-\nbáquico, consumo de hormo-\nnas anticonceptivas, etcétera.\nPara adultos, los valores de\nreferencia oscilan entre 4 y\n12 × 10\n \n9\n \n/L.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":48,"lines":{"from":91,"to":149}}}}],["160",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n22\n\n\b\u001b3 '/\u001d\"\u001b- \u001d\u001b/-\u001b- \u001e\u001f &\u001f/\u001d)\u001d#.)-#-: \u001f&\n \ncuadro 2-1\n \n&\u001b- ,\u001f-/'\u001f8 \u0004\u001f(.,) \u001e\u001f &\u001b- \u001d\u001b/-\u001b- \u001e\u001f &\u001f/\u001d)*\u001f(#\u001b6 */\u001f\n-\n\n\u001e\u001f( -\u001fĄ\u001b&\u001b,-\u001f &\u001b- #( \u001f\u001d\u001d#)(\u001f- \u001c\u001b\u001d.\u001f,#\u001b(\u001b- B-\u001f*.#\u001d\u001f'#\u001b6 ./\u001c\u001f,\u001d/&)-#- '#&#\u001b,6 .# )#\u001e\u001f\u001b6 \u001c,/\u001d\u001f&)-#-6 ./&\u001b,\u001f'#\u001bC:\n#( \u001f\u001d\u001d#)(\u001f- 0#,\u001b&\u001f- B')()(/\u001d&\u001f)-#- #( \u001f\u001d\u001d#)-\u001b6 \"\u001f*\u001b.#.#-6 #(ł/\u001f(4\u001b6 *\u001b,).#\u001e#.#-6 *-#.\u001b\u001d)-#-C: #( \u001f\u001d\u001d#)(\u001f-\n*), ,#\u001d%\u001f..-#\u001b- B.# )C 3 ).,\u001b- #( \u001f\u001d\u001d#)(\u001f- B*\u001b&/\u001e#-')6\n \nkala-azar\nC8 \u0001&!/()- '\u001f\u001e#\u001d\u001b'\u001f(.)- */\u001f\u001e\u001f( ),#!#(\u001b,\n.\u001b'\u001c#ï( &\u001f/\u001d)*\u001f(#\u001b B-/& )(\u001b'#\u001e\u001b-6 \u001b(.#\u001c#ĉ.#\u001d)-6 \u001b(\u001b&!ï-#\u001d)-6 '#\u001f&)-/*,\u001f-),\u001f-6 \u001b,-\u001f(#\u001d\u001b&\u001f-6\n \ná,'\u001b\u001d)- \u001b(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":49,"lines":{"from":1,"to":21}}}}],["161",{"pageContent":".#.#,)#\u001e\u001f)-C6 \u001b-ù \u001d)') &\u001b- ,\u001b\u001e#\u001b\u001d#)(\u001f- #)(#4\u001b(.\u001f-6 \u001b&!/()- *\u001b\u001e\u001f\u001d#'#\u001f(.)- \"\u001f'\u001b.)&ĉ!#\u001d)- \u001d)') &\u001b \u001b(\u001f'#\u001b\n*\u001f,(#\u001d#)-\u001b6 \u001d#\u001f,.\u001b- &\u001f/\u001d\u001f'#\u001b- \u001b!/\u001e\u001b-6 &\u001b \u001b*&\u001b-#\u001b '\u001f\u001e/&\u001b,6 \u001f& \"#*\u001f,\u001f-*&\u001f(#-')6 &\u001b \u001f( \u001f,'\u001f\u001e\u001b\u001e \u001e\u001f \u0007\u001b/\u001d\"\u001f,6\n\u001f& -ù(\u001e,)'\u001f \u001e\u001f \u0006\u001f&.36 \u001f.\u001dï.\u001f,\u001b8 \u0014\u001b'\u001c#ï( -\u001f \u001b\u001d)'*\u001bĄ\u001b \u001e\u001f &\u001f/\u001d)*\u001f(#\u001b \u001f& \u001d\")+/\u001f \u001b(\u001bl·&á\u001d.#\u001d)6 &\u001b \u001d\u001b+/\u001f2#\u001b6 \u001f&\n&/*/- \u001f,#.\u001f'\u001b.)-) !\u001f(\u001f,\u001b&#4\u001b\u001e)6 &\u001b \u001b,.,#.#- ,\u001f/'\u001b.)#\u001e\u001f 3 &\u001b #(-/l·\u001d#\u001f(\u001d#\u001b ,\u001f(\u001b&8\n\u0005( &)- \u001d)(.\u001b\u001e),\u001f- \u001f&\u001f\u001d.,ĉ(#\u001d)- \u001e\u001f *\u001b,.ù\u001d/&\u001b- *), \u001d#.)'\u001f.,ù\u001b \u001e\u001f ł/$) \u001f- (\u001f\u001d\u001f-\u001b,#) .\u001f(\u001f, \u001f( \u001d/\u001f(.\u001b\n+/\u001f \u001b&!/(\u001b- (\u001f/.,)*\u001f(#\u001b- */\u001f\u001e\u001f( \u001e\u001f\u001c\u001f,-\u001f \u001b &)- -#!/#\u001f(.\u001f- \u001f(ĉ'\u001f()-9\n \n,\u001b!#&#\u001e\u001b\u001e &\u001f/\u001d)\u001d#.\u001b,#\u001b \u001f2\u001b!\u001f,\u001b\u001e\u001b\n*,)\u001e/\u001d#\u001e\u001b *),\n \ná,'\u001b\u001d)- B#('/()-/*,\u001f-),\u001f- ) \u001d#.).ĉ2#\u001d)-C6\n \n,\u001b!#&#\u001e\u001b\u001e &#( )\u001d#.\u001b,#\u001b \u001f2\u001b!\u001f,\u001b\u001e\u001b B&\u001f/\u001d\u001f'#\u001b\n&#( á.#\u001d\u001b \u001d,ĉ(#\u001d\u001bC6\n \n),'\u001b\u001d#ĉ( \u001e\u001f \u001dĚ'/&)- B\u001b!,\u001f!\u001b\u001e)-C \u001e\u001f &\u001f/\u001d)\u001d#.)- -\u001f\u001d/(\u001e\u001b,#)- \u001b !\u001b''\u001b*\u001b.ù\u001b- ')()\n-\n\n\u001d&)(\u001b&\u001f-6 3 \u001d,#)\u001b!&/.#(#(\u001f'#\u001b ) \u001d,#)l·\u001c,#()!\u001f(\u001f'#\u001b8 \u0005( \u001f-.\u001b- \u001d)(\u001e#\u001d#)(\u001f-6 &)- \u001d)(.\u001b\u001e),\u001f- \u001f&\u001f\u001d.,ĉ(#\u001d)-\n\u001e\u001f *\u001b,.ù\u001d/&\u001b- ,\u001f!#-.,\u001b( \u001d/\u001f(.\u001b- \u001f+/#0)\u001d\u001b\u001e\u001b-6 *), &) +/\u001f6 \u001d\u001b\u001c\u001f #(-#-.#,6 \u001f- #(\u001e#-*\u001f(-\u001b\u001c&\u001f \u001d),,)\u001c),\u001b, \u001f(","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":49,"lines":{"from":23,"to":42}}}}],["162",{"pageContent":"Cuadro 2-1.\n \nCausas de leucocitosis (más de 12 × 10\n \n9\n \n/L leucocitos)\n\nInfecciones agudas\n\n)\u001d\u001b&#4\u001b\u001e\u001b-9\n(\u001f/')(ù\u001b-6 '\u001f(#(!#.#-6 \u001b\u001c-\u001d\u001f-)-6 \u001b'#!\u001e\u001b&#.#-6 \u001b*\u001f(\u001e#\u001d#.#-\n\u0007\u001f(\u001f,\u001b&#4\u001b\u001e\u001b-9\nl·\u001f\u001c,\u001f ,\u001f/'á.#\u001d\u001b \u001b!/\u001e\u001b6 -\u001f*.#\u001d\u001f'#\u001b6 \u001dĉ&\u001f,\u001b6 \u001f(\u001e)\u001d\u001b,\u001e#.#- #( \u001f\u001d\u001d#)-\u001b\n\nIntoxicaciones\n\n\u001f.\u001b\u001cĉ&#\u001d\u001b-9\n/,\u001f'#\u001b6 \u001b\u001d#\u001e)-#-6 .)2\u001f'#\u001b !,\u001b0ù\u001e#\u001d\u001b6 !).\u001b \u001b!/\u001e\u001b\n\u000f.,\u001b-9\n\u001f(0\u001f(\u001f(\u001b'#\u001f(.) *), +/ù'#\u001d)- ) 0\u001f(\u001f()- B'\u001f,\u001d/,#)6 0\u001f(\u001f() \u001e\u001f \u001b,á\u001d(#\u001e)6\n\u001b\u001e,\u001f(\u001b&#(\u001bC\n\nHemorragia aguda\nHemólisis aguda\nPadecimientos\nmieloproliferativos\no linfoproliferativos\nLeucemias\ncrónicas\n\n\u001f/\u001d\u001f'#\u001b- \u001b!/\u001e\u001b-\n\u0010)&#\u001d#.\u001f'#\u001b 0\u001f,\u001b\n#\u001f&)l·\u001c,)-#- I '\u001f.\u001b*&\u001b-#\u001b '#\u001f&)#\u001e\u001f \u001b!()!ï(#\u001d\u001b\n\u000f.,)-\n\nNecrosis tisular\n\n( \u001b,.) \u001e\u001f& '#)\u001d\u001b,\u001e#)\n\u000e\u001f\u001d,)-#- \u001e\u001f ./'),\u001f-\n\u0011/\u001f'\u001b\u001e/,\u001b-\n\u0007\u001b(!,\u001f(\u001b\n\u000e\u001f\u001d,)-#- \u001c\u001b\u001d.\u001f,#\u001b(\u001b\n\nCondiciones\nfisiológicas\n\n\u0005$\u001f,\u001d#\u001d#)\n\u0014\u001f(-#ĉ( \u001f')\u001d#)(\u001b&\n\u0014,\u001b\u001c\u001b$) \u001e\u001f *\u001b,.)\n\u001f(-.,/\u001b\u001d#ĉ(","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":49,"lines":{"from":44,"to":94}}}}],["163",{"pageContent":"CAPÍTULO 2. CITOMETRÍA HEMÁTICA Y SU INTERPRETACIÓN\n\n23\n\n\u001f2.\u001f(\u001e#\u001e)- \u001e\u001f -\u001b(!,\u001f .\u001fĄ#\u001e)- \u001d)( .#(\u001d#)(\u001f- *\u001b(\u001d,)'á.#\u001d\u001b-6 \u001d)') &\u001b- \u001e\u001f\n \n\u001b37\u0007,\u001f\u001f(1\u001b&\u001e7\u0007#\u001f'-\u001b )\n\u0017,#!\".6 &\u001b #( ),'\u001b\u001d#ĉ( *,)*),\u001d#)(\u001b\u001e\u001b *), \u001f& \u001d)(.\u001b\u001e), \u001e\u001f *\u001b,.ù\u001d/&\u001b-8\n\nCuenta diferencial de glóbulos blancos\n\n\b\u001b\u001d\u001f, &\u001b \u001d/\u001f(.\u001b \u001e# \u001f,\u001f(\u001d#\u001b& \u001e\u001f &\u001b- 0\u001b,#\u001f\u001e\u001b\u001e\u001f- \u001e\u001f &\u001f/\u001d)\u001d#.)- \u001f- \u001e\u001f !,\u001b( #'*),.\u001b(\u001d#\u001b \u001f( &\u001b \u0003\b8 \u000e),'\u001b&\n-\n\n'\u001f(.\u001f6 \u001f( -\u001b(!,\u001f *\u001f,# ï,#\u001d\u001b */\u001f\u001e\u001f( \u001f(\u001d)(.,\u001b,-\u001f &)- -#!/#\u001f(.\u001f- .#*)- \u001e\u001f &\u001f/\u001d)\u001d#.)-9 (\u001f/.,ĉl·&)- ) *)&#'),\n-\n\n)(/\u001d&\u001f\u001b,\u001f- B#(\u001d&/3\u001f &\u001b- ),'\u001b- \u001d)( (Ě\u001d&\u001f) -\u001f!'\u001f(.\u001b\u001e)6 &\u001b- \u001e\u001f (Ě\u001d&\u001f) ^\u001f( \u001c\u001b(\u001e\u001b_ 3 &)- '\u001f.\u001b'#\u001f&)\u001d#.)-C6\n\u001f)-#(ĉl·&)-6 \u001c\u001b-ĉl·&)-6 &#( )\u001d#.)- 3 ')()\u001d#.)-8 \u0005( \u001f& \u001b\u001e/&.)6 &\u001b *,)*),\u001d#ĉ( (),'\u001b& \u001f- &\u001b +/\u001f \u001b*\u001b,\u001f\u001d\u001f \u001f(\n\u001f&\n \ncuadro 2-2\n8\n\nNeutrófilos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":50,"lines":{"from":1,"to":25}}}}],["164",{"pageContent":"\u0003/\u001b(\u001e) &\u001b \u001d# ,\u001b \u001e\u001f (\u001f/.,ĉl·&)- \u001b\u001c-)&/.)- \u001f- \u001e\u001f g6k̓̓gf\n \no\nI\n \n6 -\u001f \"\u001b\u001c&\u001b \u001e\u001f (\u001f/.,)*\u001f(#\u001b: \u001d/\u001b(\u001e) &\u001b \u001d\u001b(.#\u001e\u001b\u001e \u001f-\n'\u001b3), \u001e\u001f m6f̓̓gf\n \no\nI\n \n6 -\u001f .,\u001b.\u001b \u001f(.)(\u001d\u001f- \u001e\u001f (\u001f/.,)l·&#\u001b8\n \n\u001b- \u001d\u001b/-\u001b- \u001e\u001f (\u001f/.,)*\u001f(#\u001b 3 (\u001f/.,)l·&#\u001b -)( &\u001b- '#-'\u001b-\n+/\u001f -\u001f -\u001fĄ\u001b&\u001b,)( *\u001b,\u001b &\u001f/\u001d)*\u001f(#\u001b 3 &\u001f/\u001d)\u001d#.)-#-6 *\u001f,) -\u001f ,\u001fl·\u001f,\u001f( \u001f-*\u001f\u001dùl·\u001d\u001b'\u001f(.\u001f \u001b &\u001b -\u001f,#\u001f !,\u001b(/&)\u001dù.#\u001d\u001b8\n\u0005( &\u001b- (\u001f/.,)l·&#\u001b- -\u001f\u001d/(\u001e\u001b,#\u001b- ) *,)\u001d\u001f-)- #( \u001f\u001d\u001d#)-)- ) #(ł\u001b'\u001b.),#)-6 -\u001f #(\u001d,\u001f'\u001f(.\u001b \u001f& (Ě'\u001f,) \u001e\u001f ),'\u001b-\n^\u001f( \u001c\u001b(\u001e\u001b_: /(\u001b \u001d# ,\u001b \u001b\u001c-)&/.\u001b \u001e\u001f 'á- \u001e\u001f nff Bf6n̓ ̓ gf\n \no\nI\n \nC (\u001f/.,ĉl·&)- ^\u001f( \u001c\u001b(\u001e\u001b_ *\u001f,'#.\u001f \u001f-.\u001b\u001c&\u001f\u001d\u001f, &\u001b\n*,\u001f-\u001f(\u001d#\u001b \u001e\u001f \u001c\u001b(\u001e\u001f'#\u001b8 \u0003)( \u001b(.\u001f,#),#\u001e\u001b\u001e -\u001f \u001f'*&\u001f\u001b\u001c\u001b \u001f& .ï,'#() \u001e\u001f ^,\u001f\u001b\u001d\u001d#ĉ( &\u001f/\u001d\u001f')#\u001e\u001f_ *\u001b,\u001b ,\u001f \u001f,#,-\u001f\n\u001b &\u001b- &\u001f/\u001d)\u001d#.)-#- !,\u001b0\u001f- \u001d)(\n \n),'\u001b- $ĉ0\u001f(\u001f- ) #('\u001b\u001e/,\u001b- \u001e\u001f \u001f&\u001f'\u001f(.)- \u001e\u001f &\u001b -\u001f,#\u001f !,\u001b(/&)\u001dù.#\u001d\u001b B^\u001c\u001b(\u001e\u001b-_6\n'\u001f.\u001b'#\u001f&)\u001d#.)-6 '#\u001f&)\u001d#.)-6 \u001f.\u001d8C6 \u001f( \u001b/-\u001f(\u001d#\u001b \u001e\u001f &\u001f/\u001d\u001f'#\u001b: \u001f& .ï,'#() \u001e\u001f\u001c\u001f \u001b\u001c\u001b(\u001e)(\u001b,-\u001f 3 \u001f( -/ &/!\u001b, \"\u001b \u001e\u001f\n/-\u001b,-\u001f \u001f& \u001e\u001f\n \nleucoblastosis\n6 +/\u001f */\u001f\u001e\u001f -\u001f,\n \nleucoeritroblastosis\n \n\u001d/\u001b(\u001e) -\u001f \u001b\u001d)'*\u001bĄ\u001b \u001e\u001f ),'\u001b- #('\u001b\u001e/,\u001b- \u001e\u001f \u001f&\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":50,"lines":{"from":27,"to":62}}}}],["165",{"pageContent":"'\u001f(.)- \u001e\u001f -\u001f,#\u001f ,)$\u001b B(),')\u001c&\u001b-.)-C \u001f( -\u001b(!,\u001f *\u001f,# ï,#\u001d\u001b8\n \n\u001b- &\u001f/\u001d)\u001c&\u001b-.)-#- */\u001f\u001e\u001f( \u001d)(-.#./#,-\u001f \u001b \u001f2*\u001f(-\u001b-\n\u001e\u001f !,\u001b(/&)\u001d#.)- B'#\u001f&)\u001dù.#\u001d\u001b-C6 \u001e\u001f &#( )\u001d#.)- ) \u001e\u001f ')()\u001d#.)-8\n \n\u001b- \u001d\u001b/-\u001b- \u001e\u001f &\u001f/\u001d)\u001c&\u001b-.)-#- ) &\u001f/\u001d)\u001f,#.,)\u001c&\u001b-\n-\n\n.)-#- '#\u001f&)\u001dù.#\u001d\u001b- \u001d)'*,\u001f(\u001e\u001f( \u001f(\u001e)\u001d\u001b,\u001e#.#- #( \u001f\u001d\u001d#)-\u001b6 (\u001f/')(ù\u001b6 -\u001f*.#\u001d\u001f'#\u001b6 &\u001f*.)-*#,)-#-6 +/\u001f'\u001b\u001e/,\u001b-6\n\u001f\u001d&\u001b'*-#\u001b6 \u001f(0\u001f(\u001f(\u001b'#\u001f(.)-6 \u001d\u001b,\u001d#()'\u001b- '\u001f.\u001b-.á-#\u001d)- \u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b6 \"\u001f'),,\u001b!#\u001b \u001b!/\u001e\u001b6 \"\u001f'ĉ&#-#- \u001b!/\u001e\u001b6\n,\u001f\u001d/*\u001f,\u001b\u001d#ĉ( \u001e\u001f \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b ) \u001e\u001f !,\u001b(/&)\u001d#.)-#-6 \u001f.\u001dï.\u001f,\u001b8\n\nEosinófilos\n\n\u00052#-.\u001f( 0\u001b,#\u001b- \u001d\u001b/-\u001b- \u001e\u001f \u001f)-#()l·&#\u001b\n \n(cuadro 2-3)\n8 \u0013\u001f \u001e#\u001d\u001f +/\u001f &)- *\u001b\u001d#\u001f(.\u001f- \u001d)( -ù(\u001e,)'\u001f \u001e\u001f \u0003/-\"#(! .#\u001f\n-\n\n(\u001f( \u001f)-#()*\u001f(#\u001b6 *\u001f,) -# -\u001f \u001b\u001d\u001f*.\u001b +/\u001f \u001f- (),'\u001b& +/\u001f \u001f( /(\u001b \u001d/\u001f(.\u001b \u001e# \u001f,\u001f(\u001d#\u001b& () \"\u001b3\u001b \u001f)-#(ĉl·&)-6 ,\u001f-/&.\u001b\n\u001e# ù\u001d#& \u001e\u001fl·(#, \u001f(.)(\u001d\u001f- \u001b &\u001b \u001f)-#()*\u001f(#\u001b8\n\nBasófilos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":50,"lines":{"from":64,"to":87}}}}],["166",{"pageContent":"(\u001f( \u001f)-#()*\u001f(#\u001b6 *\u001f,) -# -\u001f \u001b\u001d\u001f*.\u001b +/\u001f \u001f- (),'\u001b& +/\u001f \u001f( /(\u001b \u001d/\u001f(.\u001b \u001e# \u001f,\u001f(\u001d#\u001b& () \"\u001b3\u001b \u001f)-#(ĉl·&)-6 ,\u001f-/&.\u001b\n\u001e# ù\u001d#& \u001e\u001fl·(#, \u001f(.)(\u001d\u001f- \u001b &\u001b \u001f)-#()*\u001f(#\u001b8\n\nBasófilos\n\n\u001b- \u001d\u001b/-\u001b- \u001e\u001f \u001c\u001b-)l·&#\u001b -)(9 &\u001f/\u001d\u001f'#\u001b '#\u001f&)#\u001e\u001f \u001d,ĉ(#\u001d\u001b6 *)&#\u001d#.\u001f'#\u001b 0\u001f,\u001b6 '\u001f.\u001b*&\u001b-#\u001b '#\u001f&)#\u001e\u001f6 \u001f( \u001f,'\u001f\u001e\u001b\u001e\n\u001e\u001f \b)\u001e!%#(6 \u001b(\u001f'#\u001b \"\u001f')&ù.#\u001d\u001b \u001d,ĉ(#\u001d\u001b6 -#(/-#.#- \u001d,ĉ(#\u001d\u001b6 0\u001b,#\u001d\u001f&\u001b6 '#2\u001f\u001e\u001f'\u001b6 -ù(\u001e,)'\u001f (\u001f ,ĉ.#\u001d)6 \u001f&\n*)-)*\u001f,\u001b.),#) \u001b \u001f-*&\u001f(\u001f\u001d.)'ù\u001b6 \u001f(.,\u001f ).,\u001b-8 \u0004\u001b\u001e) +/\u001f (),'\u001b&'\u001f(.\u001f */\u001f\u001e\u001f () \"\u001b\u001c\u001f, \u001c\u001b-ĉl·&)- \u001f( -\u001b(!,\u001f\n\nNormalmente en sangre peri-\nférica pueden encontrarse los\nsiguientes tipos de leucocitos:\nneutrófilos\n \no\n \npolimorfonu-\ncleares (incluye las formas con\nnúcleo segmentado, las de nú-\ncleo “en banda” y los metamie-\nlocitos), eosinófilos, basófilos,\nlinfocitos y monocitos.\n\nCuadro 2-2.\n \nCausas de leucocitosis (más de 12 × 10\n \n9\n \n/L leucocitos)\n\nCélula\n \nPorcentaje (%)\n \nLímites absolutos (/μL)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":50,"lines":{"from":87,"to":122}}}}],["167",{"pageContent":"Cuadro 2-2.\n \nCausas de leucocitosis (más de 12 × 10\n \n9\n \n/L leucocitos)\n\nCélula\n \nPorcentaje (%)\n \nLímites absolutos (/μL)\n\n\u000e\u001f/.,ĉl·&)- .).\u001b&\u001f-\n \njf7nk\n \ng̓kff7m̓fff\n\u001f.\u001b'#\u001f&)\u001d#.)-\n \nf7h\n \n̓gf7kff\n^\u0005( \u001c\u001b(\u001e\u001b_\n \nf7gg\n \ngff7nff\n\u0013\u001f!'\u001f(.\u001b\u001e)-\n \njf7mj\n \nh̓fff7l̓fff\n\u0005)-#(ĉl·&)-\n \nf7m\n \n̓gff7hff\n\u0002\u001b-ĉl·&)-\n \n̓gf7hf\n \n̓gf7hf\n)()\u001d#.)-\n \ng7gi\n \ngff7nff\n#( )\u001d#.)-\n \ngh7jl\n \ng̓fff7j̓hff\n\nCon anterioridad se emplea-\nba\n \nel\n \ntérmino\n \nde\n \n“reacción\nleucemoide” para referirse a\nleucocitosis grave con formas\njóvenes o inmaduras de ele-\nmentos de la serie granulocíti-\nca (“ bandas”, metamielocitos,\nmielocitos, etc.), en ausencia\nde leucemia; el término debe\nabandonarse y en su lugar ha\nde usarse el de\n \n&\u001f/\u001d)\u001c&\u001b-.)-#-\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":50,"lines":{"from":122,"to":198}}}}],["168",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n24\n\n*\u001f,# ï,#\u001d\u001b6 (/\u001f0\u001b'\u001f(.\u001f \u001f- #'*)-#\u001c&\u001f \u001e\u001fl·(#, &\u001b \u001c\u001b-)*\u001f(#\u001b +/\u001f6 () )\u001c-.\u001b(.\u001f6 -\u001f \"\u001b \u001e\u001f-\u001d,#.) \u001f( .#,).)2#\u001d)-#-6\n-ù(\u001e,)'\u001f \u001e\u001f \u0003/-\"#(!6 \u001f.\u001dï.\u001f,\u001b8\n\nLinfocitos\n\n\u001b- \u001d\u001b/-\u001b- \u001e\u001f &#( )\u001d#.)-#- -)( 0\u001b,#\u001b-6 \u001d\u001b-# .)\u001e\u001b- #( \u001f\u001d\u001d#)-\u001b-\n \n(cuadro 2-4)\n8\n \n\u001b-\n \n),'\u001b- \u001f2.,\u001f'\u001b- \u001e\u001f &#(\n-\n\n)\u001d#.)-#- () &\u001f/\u001dï'#\u001d\u001b- \u001d)(-.#./3\u001f( *\u001b,.\u001f \u001e\u001f &\u001b- ,\u001f\u001b\u001d\u001d#)(\u001f- &\u001f/\u001d)\u001c&á-.#\u001d\u001b-I&\u001f/\u001d)\u001f,#.,)\u001c&á-.#\u001d\u001b- &#( )#\u001e\u001f-8\n\u0001&!/(\u001b- #( \u001f\u001d\u001d#)(\u001f- 0#,\u001b&\u001f- +/\u001f \u001d\u001b/-\u001b( &#( )\u001d#.)-#- */\u001f\u001e\u001f( \"\u001b\u001d\u001f, \u001b*\u001b,\u001f\u001d\u001f, \u001f( &\u001b -\u001b(!,\u001f *\u001f,# ï,#\u001d\u001b &#( )\u001d#.)-\n^\u001b.ù*#\u001d)-_6 ^#,,#.\u001b.#0)-_6 ^0#,)\u001d#.)-_6 \u001f.\u001dï.\u001f,\u001b8\n \n\u001b '\u001b3),ù\u001b \u001e\u001f \u001f-.)- &#( )\u001d#.)- ^\u001b.ù*#\u001d)-_ ) ^0#,)\u001d#.)-_ -)( &#(\n-\n\n)\u001d#.)- \u00026 \u001f-.#'/&\u001b\u001e)- \"\u001b\u001c#./\u001b&'\u001f(.\u001f *), \u001f& *,)\u001d\u001f-) #( \u001f\u001d\u001d#)-) 0#,\u001b& ) *), &\u001b ,\u001f-*/\u001f-.\u001b #('/(#.\u001b,#\u001b -\u001f\u001d/(\n-\n\n\u001e\u001b,#\u001b8 \u0005- #'*),.\u001b(.\u001f \u001f-.\u001b\u001c&\u001f\u001d\u001f, &\u001b \u001e# \u001f,\u001f(\u001d#\u001b \u001f(.,\u001f \u001f-.\u001b- \u001dï&/&\u001b- ,\u001f\u001b\u001d.#0\u001b- 3 &)- \u001c&\u001b-.)-6 3\u001b +/\u001f &\u001b *,\u001f-\u001f(\u001d#\u001b\n\u001e\u001f \u001f-.)- Ě&.#')- \u001f( &\u001b -\u001b(!,\u001f *\u001f,# ï,#\u001d\u001b \u001f- \u001d\u001b-# *\u001b.)!()'ĉ(#\u001d\u001b \u001e\u001f &\u001f/\u001d\u001f'#\u001b \u001b!/\u001e\u001b B0ï\u001b-\u001f 'á- \u001b\u001e\u001f&\u001b(.\u001fC8\n\nMonocitos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":51,"lines":{"from":1,"to":33}}}}],["169",{"pageContent":"Monocitos\n\n\u0003/\u001b(\u001e) &\u001b \u001d/\u001f(.\u001b \u001b\u001c-)&/.\u001b \u001e\u001f ')()\u001d#.)- \u001f2\u001d\u001f\u001e\u001f kffI\n \nBf6k̓̓gf\n \no\n \nI\n \nC -\u001f \"\u001b\u001c&\u001b \u001e\u001f\n \nmonocitosis\n6 \u001d/3\u001b- \u001d\u001b/-\u001b-\n-)(9 &\u001f/\u001d\u001f'#\u001b-6 ./\u001c\u001f,\u001d/&)-#-6 '\u001f.\u001b*&\u001b-#\u001b '#\u001f&)#\u001e\u001f \u001b!()!ï(#\u001d\u001b6 *)&#\u001d#.\u001f'#\u001b0\u001f,\u001b6 \u001f( \u001f,'\u001f\u001e\u001b\u001e \u001e\u001f \b)\u001e!%#(6\n&#( )'\u001b- '\u001b&#!()-6 .\u001f-\u001b/,#-')-#-6 ,\u001f\u001d/*\u001f,\u001b\u001d#ĉ( \u001e\u001f \u001e\u001bĄ) '\u001f\u001e/&\u001b, *), ,\u001b\u001e#\u001b\u001d#)(\u001f- ) *), '\u001f\u001e#\u001d\u001b'\u001f(.)-6\n*\u001b&/\u001e#-')6\n \nkala-azar\n6 .,#*\u001b()-)'#\u001b-#-6 ,#\u001d%\u001f..-#)-#-6 \u001f(\u001e)\u001d\u001b,\u001e#.#- #( \u001f\u001d\u001d#)-\u001b6 \u001c,/\u001d\u001f&)-#-6 \u001d)&#.#- /&\u001d\u001f,)-\u001b6\n\u001f(.\u001f,#.#- ,\u001f!#)(\u001b&6 -\u001b,\u001d)#\u001e)-#-6 *\u001b\u001e\u001f\u001d#'#\u001f(.)- \u001b/.)#('/(#.\u001b,#)-6 \u001f(.,\u001f ).,\u001b-8\n \n\u001b ./\u001c\u001f,\u001d/&)-#- \u001f- *,)\u001c\u001b\u001c&\u001f\n-\n\n'\u001f(.\u001f &\u001b Ě(#\u001d\u001b \u001d\u001b/-\u001b \u001e\u001f &\u001f/\u001d)\u001c&\u001b-.)-#-I&\u001f/\u001d)\u001f,#.,)\u001c&\u001b-.)-#- ')()\u001dù.#\u001d\u001b8\n\nOTRAS CÉLULAS EN SANGRE PERIFÉRICA\n\nPlasmocitos\n\n\u0004\u001f '\u001b(\u001f,\u001b \u001f2\u001d\u001f*\u001d#)(\u001b&6 &)- *&\u001b-')\u001d#.)- -\u001f \u001f(\u001d/\u001f(.,\u001b( \u001f( \u001b&!/(\u001b- 0#,)-#- \u001d)') ')()(/\u001d&\u001f)-#- #( \u001f\u001d\u001d#)-\u001b6\n,/\u001cï)&\u001b6 0\u001b,#\u001d\u001f&\u001b6 -\u001b,\u001b'*#ĉ( 3 '\u001f(#(!#.#- &#( )\u001dù.#\u001d\u001b \u001c\u001f(#!(\u001b8 \u0001*\u001b,\u001f\u001d\u001f( .\u001b'\u001c#ï( *&\u001b-')\u001d#.)- \u001f( -\u001b(!,\u001f\n*\u001f,# ï,#\u001d\u001b \u001f( '#\u001f&)'\u001b 'Ě&.#*&\u001f 3 \u001f( &\u001f/\u001d\u001f'#\u001b \u001e\u001f \u001dï&/&\u001b- *&\u001b-'á.#\u001d\u001b-8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":51,"lines":{"from":33,"to":66}}}}],["170",{"pageContent":"Cuadro 2-3.\n \nCausas de eosinofilia (más de 0,5 × 10\n \n9\n \n/L eosinófilos)\n\nEnfermedades alérgicas\n \nEnfermedades gastrointestinales\n\n\u0001-'\u001b \u001c,)(+/#\u001b&\n\u0006#\u001f\u001c,\u001f \u001e\u001f& \"\u001f()\n\u0015,.#\u001d\u001b,#\u001b\n\u0007\u001b-.,)\u001f(.\u001f,#.#- \u001f)-#() ù&#\u001d\u001b\n\u0005(.\u001f,#.#- ,\u001f!#)(\u001b&\n\u0003)&#.#- /&\u001d\u001f,)-\u001b \u001d,ĉ(#\u001d\u001b #(\u001f-*\u001f\u001dùl·\u001d\u001b\n\nInfestaciones por parásitos\n \nEnfermedades hemáticas\n\n\u0014,#+/#()-#-\n\b#\u001e\u001b.#\u001e)-#-\n\u001b,0\u001b '#!,\u001b.),#\u001b\n\u0013ù(\u001e,)'\u001f \"#*\u001f,\u001f)-#() ù&#\u001d)\n\u001f/\u001d\u001f'#\u001b '#\u001f&)#\u001e\u001f \u001d,ĉ(#\u001d\u001b\n\u0010)&#\u001d#.\u001f'#\u001b 0\u001f,\u001b\n\u0005( \u001f,'\u001f\u001e\u001b\u001e \u001e\u001f \b)\u001e!%#(\n\u0001(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b\n\nEnfermedades infecciosas\n \nOtras\n\n\u0005-\u001d\u001b,&\u001b.#(\u001b\n\u0010\u001b\u001e\u001f\u001d#'#\u001f(.)- \u001d/.á(\u001f)-\n\u0010ï(l·!)\n\u0004\u001f,'\u001b.#.#- \"\u001f,*\u001f.# ),'\u001f\n\u0010)&#\u001b,.\u001f,#.#- ()\u001e)-\u001b\n\u0014/'),\u001f- )0á,#\u001d)-\n\u0013\u001b,\u001d)#\u001e)-#-\n\u0005(\u001e)\u001d\u001b,\u001e#.#- l·\u001c,)*&á-#\u001d\u001b \u001e\u001f\n \nČń\u001f,\n(.)2#\u001d\u001b\u001d#ĉ( *), ĉ- ),)\n),\u001e\u001f\u001e/,\u001b \u001e\u001f \u001b,á\u001d(#\u001e)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":51,"lines":{"from":68,"to":115}}}}],["171",{"pageContent":"\u0005-\u001d\u001b,&\u001b.#(\u001b\n\u0010\u001b\u001e\u001f\u001d#'#\u001f(.)- \u001d/.á(\u001f)-\n\u0010ï(l·!)\n\u0004\u001f,'\u001b.#.#- \"\u001f,*\u001f.# ),'\u001f\n\u0010)&#\u001b,.\u001f,#.#- ()\u001e)-\u001b\n\u0014/'),\u001f- )0á,#\u001d)-\n\u0013\u001b,\u001d)#\u001e)-#-\n\u0005(\u001e)\u001d\u001b,\u001e#.#- l·\u001c,)*&á-#\u001d\u001b \u001e\u001f\n \nČń\u001f,\n(.)2#\u001d\u001b\u001d#ĉ( *), ĉ- ),)\n),\u001e\u001f\u001e/,\u001b \u001e\u001f \u001b,á\u001d(#\u001e)\n\nAlgunas\n \ninfecciones\n \nvirales\nque causan linfocitosis pueden\nhacer aparecer en la sangre\nperiférica\n \nlinfocitos\n \n“atípi-\ncos”, “ irritativos”, “virocitos”,\netcétera. La mayoría de estos\nlinfocitos “atípicos” o “viroci-\ntos” son linfocitos B, estimu-\nlados\n \nhabitualmente\n \npor\n \nel\nproceso infeccioso viral o por\nla respuesta inmunitaria se-\ncundaria.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":51,"lines":{"from":115,"to":153}}}}],["172",{"pageContent":"CAPÍTULO 2. CITOMETRÍA HEMÁTICA Y SU INTERPRETACIÓN\n\n25\n\nBlastos\n\n\u001b *,\u001f-\u001f(\u001d#\u001b \u001e\u001f \u001c&\u001b-.)-6 3\u001b -\u001f\u001b \u001e\u001f -\u001f,#\u001f '#\u001f&)#\u001e\u001f ) &#( )#\u001e\u001f6 \u001f- \u001b&.\u001b'\u001f(.\u001f -/!\u001f-.#0\u001b \u001e\u001f &\u001f/\u001d\u001f'#\u001b \u001b!/\u001e\u001b8\n \n)-\n\u001d/\u001b\u001e,)- &\u001f/\u001d)\u001c&á-.#\u001d)-I&\u001f/\u001d)\u001f,#.,)\u001c&á-.#\u001d)- */\u001f\u001e\u001f( \u001b\u001d)'*\u001bĄ\u001b,-\u001f \u001e\u001f \u001f-.\u001f .#*) \u001e\u001f \u001dï&/&\u001b- \u001f( -\u001b(!,\u001f *\u001f,# ï\n-\n\n,#\u001d\u001b8\n \n\u001b *,\u001f-\u001f(\u001d#\u001b \u001e\u001f \u001c&\u001b-.)- \u001d)( \u001d/\u001f,*)- ) \u001c\u001b-.)(\u001f- \u001e\u001f \u0001/\u001f, \u001f- \u001e#\u001b!(ĉ-.#\u001d\u001b \u001e\u001f &\u001f/\u001d\u001f'#\u001b \u001b!/\u001e\u001b \u001e\u001f \u001f-.#,*\u001f\n'#\u001f&)#\u001e\u001f8\n \n\u001b \u001f2#-.\u001f(\u001d#\u001b \u001e\u001f \u001c&\u001b-.)- \u001f( -\u001b(!,\u001f *\u001f,# ï,#\u001d\u001b )\u001c&#!\u001b \u001b \u001f \u001f\u001d./\u001b, /(\u001b #(0\u001f-.#!\u001b\u001d#ĉ( \"\u001f'\u001b.)&ĉ!#\u001d\u001b\n\u001e\u001f.\u001b&&\u001b\u001e\u001b \u001e\u001f #('\u001f\u001e#\u001b.)8\n\nSERIE TROMBOCÍTICA\n\n\u0005( &\u001b \u0003\b6 -)( .,\u001f- &)- \u001e\u001b.)- +/\u001f -\u001f #( ),'\u001b( *\u001b,\u001b &\u001b -\u001f,#\u001f .,)'\u001c)\u001dù.#\u001d\u001b9 (Ě'\u001f,) \u001e\u001f *&\u001b+/\u001f.\u001b-6 \"#-.)!,\u001b'\u001b-\n\u001e\u001f \u001e#-.,#\u001c/\u001d#ĉ( \u001e\u001f &)- 0)&Ě'\u001f(\u001f- *&\u001b+/\u001f.\u001b,#)- 3 '), )&)!ù\u001b *&\u001b+/\u001f.\u001b,#\u001b8\n\nNúmero de plaquetas\n\n\u001b- \u001d# ,\u001b- \u001e\u001f ,\u001f \u001f,\u001f(\u001d#\u001b \u001e\u001f &\u001b \u001d/\u001f(.\u001b *&\u001b+/\u001f.\u001b,#\u001b B\u0010\n \n\u0014C -\u001f \"\u001b&&\u001b( \u001f(.,\u001f gkf 3 kff̓ ̓ gf\n \no\n \nI\n \nBgkf̓ fff\n\u001b kff̓ fffI\n \nC8\n \n\u001b- \u001d\u001b/-\u001b- \u001e\u001f .,)'\u001c)\u001d#.)*\u001f(#\u001b -)(9 *Ě,*/,\u001b \u001b/.)#('/(#.\u001b,#\u001b6 &\u001f/\u001d\u001f'#\u001b \u001b!/\u001e\u001b6 \u001b(\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":52,"lines":{"from":1,"to":42}}}}],["173",{"pageContent":"'#\u001b \u001b*&á-#\u001d\u001b6 '#\u001f&)*.#-#-6 \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b6 \"#*\u001f,\u001f-*&\u001f(#-')6 *Ě,*/,\u001b .,)'\u001cĉ.#\u001d\u001b .,)'\u001c)\u001d#.)*ï(#\u001d\u001b6\n.,\u001b(- /-#)(\u001f- -\u001b(!/ù(\u001f\u001b-6 \u001f(\u001e)\u001d\u001b,\u001e#.#- #( \u001f\u001d\u001d#)-\u001b6 -\u001f*.#\u001d\u001f'#\u001b6 .# )6 &/*/- \u001f,#.\u001f'\u001b.)-) !\u001f(\u001f,\u001b&#4\u001b\u001e)6 ,\u001b\n-\n\n\u001e#\u001b\u001d#)(\u001f- #)(#4\u001b(.\u001f-6 '\u001f\u001e#\u001d\u001b'\u001f(.)- \u001d#.).ĉ2#\u001d)-6 \u001f(.,\u001f ).,\u001b-8 \u0003/\u001b(\u001e) &\u001b \u001d/\u001f(.\u001b *&\u001b+/\u001f.\u001b,#\u001b -\u001f \u001f(\u001d/\u001f(.,\u001b\n*), \u001f(\u001d#'\u001b \u001e\u001f kff̓̓gf\n \no\n \nI\n \n6 -\u001f \"\u001b\u001c&\u001b \u001e\u001f\n \ntrombocitosis\n6 \u001d/3\u001b- \u001d\u001b/-\u001b- -)( .\u001b'\u001c#ï( 'Ě&.#*&\u001f-9 *\u001b\u001e\u001f\u001d#'#\u001f(.)-\n'\u001b&#!()-6 -ù(\u001e,)'\u001f- '#\u001f&)*,)&# \u001f,\u001b.#0)- B*)&#\u001d#.\u001f'#\u001b 0\u001f,\u001b6 &\u001f/\u001d\u001f'#\u001b '#\u001f&)#\u001e\u001f \u001d,ĉ(#\u001d\u001b6 .,)'\u001c)\u001d#.)-#-\n*,#'\u001b,#\u001bC6 \u001f-.\u001b\u001e) *)-\u001f-*&\u001f(\u001f\u001d.)'ù\u001b6 *\u001b\u001e\u001f\u001d#'#\u001f(.)- \u001b/.)#('/(#.\u001b,#)- B\u001b,.,#.#- ,\u001f/'\u001b.)#\u001e\u001fC6 \u001b(\u001f'#\u001b *),\n\u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)6 #( \u001f\u001d\u001d#)(\u001f- \u001b!/\u001e\u001b-6 *\u001b(\u001d,\u001f\u001b.#.#- \u001d,ĉ(#\u001d\u001b6 \u001d#,,)-#- \"\u001f*á.#\u001d\u001b6 \u001f.\u001dï.\u001f,\u001b8 \u0005- '/3 #'\n-\n\n*),.\u001b(.\u001f () \u001e\u001f$\u001b, *\u001b-\u001b, #(\u001b\u001e0\u001f,.#\u001e\u001b /(\u001b .,)'\u001c)\u001d#.)-#- #(\u001f2*&#\u001d\u001b\u001c&\u001f6 \u001e\u001b\u001e) +/\u001f */\u001f\u001e\u001f -\u001f, /(\u001b '\u001b(# \u001f-.\u001b\n-\n\n\u001d#ĉ( #(#\u001d#\u001b& \u001e\u001f /(\u001b (\u001f)*&\u001b-#\u001b '\u001b&#!(\u001b8\n\nVolumen plaquetario medio","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":52,"lines":{"from":44,"to":69}}}}],["174",{"pageContent":"*),.\u001b(.\u001f () \u001e\u001f$\u001b, *\u001b-\u001b, #(\u001b\u001e0\u001f,.#\u001e\u001b /(\u001b .,)'\u001c)\u001d#.)-#- #(\u001f2*&#\u001d\u001b\u001c&\u001f6 \u001e\u001b\u001e) +/\u001f */\u001f\u001e\u001f -\u001f, /(\u001b '\u001b(# \u001f-.\u001b\n-\n\n\u001d#ĉ( #(#\u001d#\u001b& \u001e\u001f /(\u001b (\u001f)*&\u001b-#\u001b '\u001b&#!(\u001b8\n\nVolumen plaquetario medio\n\n)- 0\u001b&),\u001f- (),'\u001b&\u001f- \u001e\u001f& 0)&/'\u001f( *&\u001b+/\u001f.\u001b,#) '\u001f\u001e#) B\u0016\u0010\n \nC -\u001f \"\u001b&&\u001b( \u001f(.,\u001f n 3 gh\n \n: \u001f& \u0016\u0010\n \n\u001f-\n#(0\u001f,-\u001b'\u001f(.\u001f *,)*),\u001d#)(\u001b& \u001b &\u001b \u001d/\u001f(.\u001b \u001e\u001f *&\u001b+/\u001f.\u001b-8 \u0014\u001f(#\u001f(\u001e) \u001f( \u001d/\u001f(.\u001b \u001f& \u0016\u0010\n \n3 &\u001b \u0010\n \n\u00146 \u001f- *)-#\u001c&\u001f\n\"\u001b\u001d\u001f, \u001d#(\u001d) \u001d\u001b.\u001f!),ù\u001b- \u001e\u001f .,\u001b-.),()- *&\u001b+/\u001f.\u001b,#)-9 \u001bC \u0010\n \n\u0014 \u001e#-'#(/#\u001e\u001b \u001d)( \u0016\u0010\n \n\u001b&.)9 .,)'\u001c)\u001d#.)*\u001f(#\u001b\n\nCuadro 2-4.\n \nCausas de linfocitosis (más de 5 × 10\n \n9\n \n/L linfocitos)\n\nInfecciosas\nPor virus:\n\n\u0016\u001b,#\u001d\u001f&\u001b\n\u0014)- \u001f,#(\u001b\n)()(/\u001d&\u001f)-#- #( \u001f\u001d\u001d#)-\u001b\n\b\u001f*\u001b.#.#-\n\u0010\u001b,).#\u001e#.#-\n\u0012/\u001cï)&\u001b\n\nPor otros agentes:\n\n\u0014/\u001c\u001f,\u001d/&)-#-\n\u0002,/\u001d\u001f&)-#-\n\u0013ùl·&#-\n\u0014)2)*&\u001b-')-#-\n\nOtras\n\n\u001f/\u001d\u001f'#\u001b &#( á.#\u001d\u001b \u001d,ĉ(#\u001d\u001b\n\u0014#,).)2#\u001d)-#-\n\u000e\u001f/.,)*\u001f(#\u001b \u001d)( &#( )\u001d#.)-#- ,\u001f&\u001b.#0\u001b","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":52,"lines":{"from":69,"to":123}}}}],["175",{"pageContent":"Por otros agentes:\n\n\u0014/\u001c\u001f,\u001d/&)-#-\n\u0002,/\u001d\u001f&)-#-\n\u0013ùl·&#-\n\u0014)2)*&\u001b-')-#-\n\nOtras\n\n\u001f/\u001d\u001f'#\u001b &#( á.#\u001d\u001b \u001d,ĉ(#\u001d\u001b\n\u0014#,).)2#\u001d)-#-\n\u000e\u001f/.,)*\u001f(#\u001b \u001d)( &#( )\u001d#.)-#- ,\u001f&\u001b.#0\u001b\n\nLa presencia de blastos, ya sea\nde serie mieloide o linfoide,\nes muy sugestiva de leucemia\naguda. Los cuadros leucoblás-\nticos/leucoeritroblásticos\n \npue-\nden acompañarse de este tipo\nde células en sangre periférica.\nLas cifras de referencia de la\ncuenta plaquetaria se hallan\nentre 150 y 500 × 10\n \n9\n \n/L.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":52,"lines":{"from":123,"to":151}}}}],["176",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n26\n\n\u001b/.)#('/(#.\u001b,#\u001b6 .)2\u001f'#\u001b !,\u001b0ù\u001e#\u001d\u001b6 -ù(\u001e,)'\u001f \u001e\u001f \u0002\u001f,(\u001b,\u001e \u0013)/&#\u001f,: \u001cC \u0010\n \n\u0014 \u001e#-'#(/#\u001e\u001b \u001d)( \u0016\u0010\n \n\u001c\u001b$)9\n\u001b(\u001f'#\u001b \u001b*&á-#\u001d\u001b6 \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b6 .,\u001b.\u001b'#\u001f(.) \u001d)( +/#'#).\u001f,\u001b*#\u001b6 \"#*\u001f,\u001f-*&\u001f(#-')6 -ù(\u001e,)'\u001f\n\u001e\u001f \u0017#-%)..7\u0001&\u001e,#\u001d\": \u001dC \u0010\n \n\u0014 (),'\u001b& \u001d)( \u0016\u0010\n \n\u001b/'\u001f(.\u001b\u001e)9 .\u001b&\u001b-\u001f'#\u001b6 '#\u001f&)l·\u001c,)-#-6 '#\u001f&)\u001e#-*&\u001b-#\u001b:\n\u001eC \u0010\n \n\u0014 \u001b&.\u001b \u001d)( \u0016\u0010\n \n(),'\u001b&9 .,)'\u001c)\u001d#.)-#- ,\u001f\u001b\u001d.#0\u001b: \u001fC \u0010\n \n\u0014 \u001b&.\u001b \u001d)( \u0016\u0010\n \n\u001b&.)9 &\u001f/\u001d\u001f'#\u001b '#\u001f&)#\u001e\u001f\n\u001d,ĉ(#\u001d\u001b6 \u001f-*&\u001f(\u001f\u001d.)'ù\u001b8\n\nMorfología de las plaquetas\n\n\u0001\u001e\u001f'á- \u001e\u001f& ,\u001f\u001d/\u001f(.) \u001e\u001f *&\u001b+/\u001f.\u001b- 3 \u001e\u001f &\u001b )\u001c.\u001f(\u001d#ĉ( \u001e\u001f& \"#-.)!,\u001b'\u001b \u001e\u001f \u001e#-.,#\u001c/\u001d#ĉ( \u001e\u001f &)- 0)&Ě\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":53,"lines":{"from":1,"to":30}}}}],["177",{"pageContent":"Morfología de las plaquetas\n\n\u0001\u001e\u001f'á- \u001e\u001f& ,\u001f\u001d/\u001f(.) \u001e\u001f *&\u001b+/\u001f.\u001b- 3 \u001e\u001f &\u001b )\u001c.\u001f(\u001d#ĉ( \u001e\u001f& \"#-.)!,\u001b'\u001b \u001e\u001f \u001e#-.,#\u001c/\u001d#ĉ( \u001e\u001f &)- 0)&Ě\n-\n\n'\u001f(\u001f- \u001e\u001f \u001f-.\u001b-6 \u001f- (\u001f\u001d\u001f-\u001b,#) \"\u001b\u001d\u001f, &\u001b )\u001c-\u001f,0\u001b\u001d#ĉ( '#\u001d,)-\u001dĉ*#\u001d\u001b \u001e\u001f \u001e#\u001d\"\u001b- \u001dï&/&\u001b- \u001f( \u001f2.\u001f(\u001e#\u001e)- \u001e\u001f\n-\u001b(!,\u001f *\u001f,# ï,#\u001d\u001b8\n \n)- \u001d#.ĉ'\u001f.,)- \u001e\u001f\n \n&/$) */\u001f\u001e\u001f( \u001e\u001b, \u001e\u001b.)- \u001f+/#0)\u001d\u001b\u001e)- \u001d/\u001b(\u001e) -\u001f\n \n),'\u001b( !,/')-\n\u001e\u001f *&\u001b+/\u001f.\u001b-6 *), \u001f$\u001f'*&)9 \u001e\u001b\u001e) +/\u001f \u001f& 0)&/'\u001f( \u001e\u001f /( !,/') \u001e\u001f *&\u001b+/\u001f.\u001b- \u001f- \u001b&.)6 \u001f& \u001d#.ĉ'\u001f.,) &)\n,\u001f!#-.,\u001b \u001d)') /(\u001b \u001dï&/&\u001b \u001e\u001f '\u001b3), .\u001b'\u001bĄ) 3 +/\u001f */\u001f\u001e\u001f ),#!#(\u001b, /(\u001b \u0010\n \n\u0014\n \n\u001b&-\u001b'\u001f(.\u001f \u001e#-'#(/#\u001e\u001b8\n \n\u001b\n)\u001c-\u001f,0\u001b\u001d#ĉ( \u001e\u001f&\n \n,).#- *\u001f,'#.\u001f \u001f-.\u001b\u001c&\u001f\u001d\u001f, &\u001b *,\u001f-\u001f(\u001d#\u001b \u001e\u001f !,/')- *&\u001b+/\u001f.\u001b,#)-8 \u0005( &)- *\u001b\u001e\u001f\u001d#'#\u001f(.)-\n\u001f( \u001e)(\u001e\u001f -\u001f *,)\u001e/\u001d\u001f\n \n,\u001b!'\u001f(.\u001b\u001d#ĉ( \u001f,#.,)\u001dù.#\u001d\u001b6 &\u001b- *),\u001d#)(\u001f- '\u001f(),\u001f- \u001b hf̓\n \n-)( \u001d&\u001b-# #\u001d\u001b\u001e\u001b- *),\n\u001f& \u001d#.ĉ'\u001f.,) \u001e\u001f\n \n&/$) \u001d)') *&\u001b+/\u001f.\u001b-6 *,)\u001e/\u001d#ï(\u001e)-\u001f \u001b-ù \u0010\n \n\u0014\n \n\u001b&-\u001b'\u001f(.\u001f \u001f&\u001f0\u001b\u001e\u001b-: -)&) &\u001b )\u001c-\u001f,0\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":53,"lines":{"from":30,"to":66}}}}],["178",{"pageContent":"\u001d#ĉ( '#\u001d,)-\u001dĉ*#\u001d\u001b \u001e\u001f& \u001f2.\u001f(\u001e#\u001e) \u001e\u001f -\u001b(!,\u001f *\u001f,'#.\u001f \u001f-.\u001b\u001c&\u001f\u001d\u001f, &\u001b \u001f2#-.\u001f(\u001d#\u001b \u001e\u001f \u001f-.\u001b -#./\u001b\u001d#ĉ(8\n \n)-\n,\u001b!'\u001f(.)- \u001e\u001f &)- \u001c&\u001b-.)- \u001f( &\u001b- &\u001f/\u001d\u001f'#\u001b- \u001b!/\u001e\u001b- ) \u001d,ĉ(#\u001d\u001b- */\u001f\u001e\u001f( \u001d\u001b/-\u001b, /( \u001f \u001f\u001d.) -#'#&\u001b,8\n \n\u001b\n)\u001c-\u001f,0\u001b\u001d#ĉ( \u001e\u001f &\u001b- *&\u001b+/\u001f.\u001b- \u001f( \u001f& \u001f2.\u001f(\u001e#\u001e) \u001e\u001f -\u001b(!,\u001f *\u001f,'#.\u001f \u001d)( #,'\u001b, .\u001b'\u001c#ï( &\u001b \u001f2#-.\u001f(\u001d#\u001b \u001e\u001f\n'#\u001d,) ) '\u001b\u001d,).,)'\u001c)\u001d#.)-8\n\nCONCLUSIONES\n\n•\n \n\u001b \u001d#.)'\u001f.,ù\u001b \"\u001f'á.#\u001d\u001b \u001f- \u001f& \u001f-./\u001e#) \u001e\u001f &\u001b\u001c),\u001b.),#) +/\u001f #( ),'\u001b -)\u001c,\u001f \u001f& (Ě'\u001f,) 3 &\u001b- \u001d\u001b,\u001b\u001d.\u001f,ù-.#\u001d\u001b-\n\u001e\u001f &\u001b- \u001dï&/&\u001b- \u001e\u001f &\u001b -\u001b(!,\u001f8\n•\n \n\u0005& \u001f-./\u001e#) \u001b\u001e\u001f\u001d/\u001b\u001e) \u001e\u001f &\u001b \u001d#.)'\u001f.,ù\u001b \u001f-.á \u001f( )\u001d\u001b\u001e) \u001b& \u001b(á&#-#- \u001e\u001f.\u001b&&\u001b\u001e) \u001e\u001f \u001d\u001b\u001e\u001b /() \u001e\u001f &)- \u001e\u001b.)- \u001e\u001f &\u001b\n-\u001f,#\u001f ,)$\u001b6 \u001e\u001f &\u001b -\u001f,#\u001f \u001c&\u001b(\u001d\u001b 3 \u001e\u001f &\u001b -\u001f,#\u001f .,)'\u001c)\u001dù.#\u001d\u001b8\n•\n \n\u001b \u001d),,\u001f\u001d.\u001b #(.\u001f,*,\u001f.\u001b\u001d#ĉ( \u001e\u001f &\u001b \u001d#.)'\u001f.,ù\u001b \u001f-\n \n/(\u001e\u001b'\u001f(.\u001b& *\u001b,\u001b \u001f& \u001e#\u001b!(ĉ-.#\u001d) 3 -\u001f!/#'#\u001f(.) \u001e\u001f \u001e#0\u001f,\n-\n\n-\u001b- \u001f(.#\u001e\u001b\u001e\u001f- \"\u001f'\u001b.)&ĉ!#\u001d\u001b-8\n\nPREGUNTAS DE AUTOEVALUACIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":53,"lines":{"from":68,"to":96}}}}],["179",{"pageContent":"-\u001b- \u001f(.#\u001e\u001b\u001e\u001f- \"\u001f'\u001b.)&ĉ!#\u001d\u001b-8\n\nPREGUNTAS DE AUTOEVALUACIÓN\n\ng8 ?\u0003/á& \u001f- \u001f& ù(\u001e#\u001d\u001f +/\u001f \u001e\u001fl·(\u001f &\u001b \u001f2#-.\u001f(\u001d#\u001b \u001e\u001f \u001b(\u001f'#\u001b>\n\u001b8\n \n\b\u001f')!&)\u001c#(\u001b\n\u001c8 \b\u001f'\u001b.)\u001d,#.)\n\u001d8\n \n\u0016\u0007\nh8 \u0004\u001f \u001b\u001d/\u001f,\u001e) \u001d)( \u001f& 0\u001b&), \u001e\u001f& \u0016\u0007\n \n6 ?\u001dĉ') -\u001f \u001d&\u001b-#l·\u001d\u001b( &\u001b- \u001b(\u001f'#\u001b->\n\u001b8\n \n\u001f/\u001d)\u001dù.#\u001d\u001b6 \u001f,#.,)\u001dù.#\u001d\u001b 3 .,)'\u001cĉ.#\u001d\u001b\n\u001c8 \u000e),')\u001dù.#\u001d\u001b6 '\u001b\u001d,)\u001dù.#\u001d\u001b 3 '#\u001d,)\u001dù.#\u001d\u001b\n\u001d8\n \n\b#*\u001f, ï,,#\u001d\u001b6 (),') ï,,#\u001d\u001b \u001f \"#*) ï,,#\u001d\u001b\ni8 ?\u0011/ï ù(\u001e#\u001d\u001f \u001f,#.,)\u001dù.#\u001d) \u001e\u001fl·(\u001f &\u001b (),')\u001d,)'ù\u001b ) &\u001b \"#*)\u001d,)'ù\u001b>\n\u001b8\n \n\u0016\u0007\n\u001c8 \u0003'\b\u001c\n\u001d8\n \n\b\u0003\nj8 ?\u0003ĉ') -\u001f \u001e\u001fl·(\u001f &\u001b \u001f2#-.\u001f(\u001d#\u001b \u001e\u001f &\u001f/\u001d)\u001d#.)-#->\n\u001b8\n \n\u0003# ,\u001b \u001e\u001f &\u001f/\u001d)\u001d#.)- #( \u001f,#), \u001b gh̓̓gf\n \no\n \nI\n\u001c8 \u0003# ,\u001b \u001e\u001f &\u001f/\u001d)\u001d#.)- -/*\u001f,#), \u001b gh̓̓gf\n \no\n \nI\n\u001d8\n \n\u0003# ,\u001b \u001e\u001f &\u001f/\u001d)\u001d#.)- -/*\u001f,#), \u001b gk̓̓gf\n \no\n \nI\n\nLa observación de las plaque-\ntas en el extendido de sangre\npermite confirmar también la\nexistencia de micro o macro-\ntrombocitos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":53,"lines":{"from":96,"to":151}}}}],["180",{"pageContent":"CAPÍTULO 2. CITOMETRÍA HEMÁTICA Y SU INTERPRETACIÓN\n\n27\n\nk8 ?\u0003ĉ') -\u001f \u001e\u001fl·(\u001f &\u001b \u001f2#-.\u001f(\u001d#\u001b \u001e\u001f .,)'\u001c)\u001d#.)-#->\n\u001b8\n \n\u0003# ,\u001b \u001e\u001f *&\u001b+/\u001f.\u001b- #( \u001f,#), \u001b jff̓̓gf\n \no\n \nI\n\u001c8 \u0003# ,\u001b \u001e\u001f *&\u001b+/\u001f.\u001b- -/*\u001f,#), \u001b jkf̓̓gf\n \no\n \nI\n\u001d8\n \n\u0003# ,\u001b \u001e\u001f *&\u001b+/\u001f.\u001b- -/*\u001f,#), \u001b lff̓̓gf\n \no\n \nI\n\nBIBLIOGRAFÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":54,"lines":{"from":1,"to":26}}}}],["181",{"pageContent":"\u0002\u001f--'\u001b( \u0004 8 \u0001/.)'\u001b.\u001f\u001e \u001c&))\u001e \u001d)/(.- \u001b(\u001e \u001e#L·\u001f,\u001f(.#\u001b&-8 \u0002\u001b&.#'),\u001f9\n \n)\"(- \b)*%#(- \u0015(#0\u001f,-#.3 \u0010,\u001f--: gonl8 *8 gg8\n\b)L· \u001c,\u001b(\u001e \u0001\u00166 \u0010\u001f..#.\n \n\u00058 \u0005--\u001f(.#\u001b& \"\u001b\u001f'\u001b.)&)!38 i.\" \u001f\u001e8\n \n)(\u001e)(9 \u0002&\u001b\u001d%1\u001f&& \u0013\u001d#\u001f(.#l·\u001d \u0010/\u001c&#\u001d\u001b.#)(-6 gooi8\n\u001b(\u001e&\n \n\b8 \u0002&))\u001e8 \u0014\u001f2.\u001c))% ) \"\u001f'\u001b.)&)!38 \u0002)-.)(9\n \n#..&\u001f \u0002,)1(: gonn8 *8 g8\n\u0012/#47\u0001,!Ĝ\u001f&&\u001f- \u0007 6 \u0013á(\u001d\"\u001f47\n \n\u001f\u001e\u001b&\n \n6 \u001f. \u001b&8 \u0012\u001f\u001e \u001d\u001f&& #(\u001e#\u001d\u001f- #( (),'\u001b& \u001b\u001e/&.- ,\u001f-#\u001e#(! \u001b. \u001b&.#./\u001e\u001f-\n \n,)' -\u001f\u001b &\u001f0\u001f& .) h\nlmf '\u001f.\u001f,-8 \u0001'\n \n\b\u001f'\u001b.)&8 gonf: n9 hlk8\n\u0012/#47\u0001,!Ĝ\u001f&&\u001f- \u0007 6\n \n&),\u001f(.\u001f \u0010\u001f.\u001f,- \u00018 \u0010,\u001f\u001e#\u001d.#0\u001f \u001f+/\u001b.#)(- ), (),'\u001b& ,\u001f\u001e \u001d\u001f&& 0\u001b&/\u001f- \u001b. \u001b&.#./\u001e\u001f-\n \n,)' -\u001f\u001b &\u001f0\u001f& .) h\nlmf '\u001f.\u001f,-8 \u0012\u001f0\n \n(0\u001f-. \u0003&ù(\n \nï28 gong: ii9 gog8\n\u0012/#47\u0001,!Ĝ\u001f&&\u001f- \u0007 6 \u0013á(\u001d\"\u001f47\n \n\u001f\u001e\u001b&\n \n8 \u0001(\u001f'#\u001b8 \u0005(9 #(#\u001d\" \b6 \u001f\u001e8 \u0014,\u001b.\u001b\u001e) \u001e\u001f '\u001f\u001e#\u001d#(\u001b #(.\u001f,(\u001b8 \u0001\u001d\u001b\u001e\u001f'#\u001b \u000e\u001b\u001d#)(\u001b&\n\u001e\u001f\n \n\u001f\u001e#\u001d#(\u001b8\n \nï2#\u001d)9 \u0005\u001e#.),#\u001b& \u0005&\n \n\u001b(/\u001b&\n \n)\u001e\u001f,(): gonn8 *8 jfi8\n\u0012/#47\u0001,!Ĝ\u001f&&\u001f- \u0007 8 \u0001(\u001f'#\u001b *), \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)8 \u0005(9 \u0015,#\u001c\u001f\n \n6 \u001f\u001e8 \u0014,\u001b.\u001b\u001e) \u001e\u001f '\u001f\u001e#\u001d#(\u001b #(.\u001f,(\u001b8 \u0016)&8\n \n8\n \nï2#\u001d)9\n\u0005\u001e#.),#\u001b&\n \nï\u001e#\u001d\u001b \u0010\u001b(\u001b'\u001f,#\u001d\u001b(\u001b6 h\u001b \u001f\u001e8 gook: *8 ggmi8\n\u0012/#47\u0001,!Ĝ\u001f&&\u001f- \u0007 8 \u0013ù(\u001e,)'\u001f- \"#*\u001f,\u001f)-#() ù&#\u001d)-8\n \n\u001f\u001e#\u001d#(\u001f B","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":54,"lines":{"from":28,"to":87}}}}],["182",{"pageContent":"6 \u001f\u001e8 \u0014,\u001b.\u001b\u001e) \u001e\u001f '\u001f\u001e#\u001d#(\u001b #(.\u001f,(\u001b8 \u0016)&8\n \n8\n \nï2#\u001d)9\n\u0005\u001e#.),#\u001b&\n \nï\u001e#\u001d\u001b \u0010\u001b(\u001b'\u001f,#\u001d\u001b(\u001b6 h\u001b \u001f\u001e8 gook: *8 ggmi8\n\u0012/#47\u0001,!Ĝ\u001f&&\u001f- \u0007 8 \u0013ù(\u001e,)'\u001f- \"#*\u001f,\u001f)-#() ù&#\u001d)-8\n \n\u001f\u001e#\u001d#(\u001f B\n \n\u001b\u001e,#\u001eC8 gool: ig9 gilh7gilm8\n\u0012/#47\u0001,!Ĝ\u001f&&\u001f- \u0007 8 \u0001&.#./\u001e\u001f \u001b\u001c)0\u001f -\u001f\u001b &\u001f0\u001f& \u001b- \u001b 0\u001b,#\u001b\u001c&\u001f ), \u001e\u001fl·(#.#)( ) \u001b(\u001f'#\u001b8 \u0002&))\u001e8 hffl9 gfn9 hgig8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":54,"lines":{"from":87,"to":100}}}}],["183",{"pageContent":"RESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\ng8\n \n\u001b\nh8\n \n\u001c\ni8\n \n\u001d\nj8\n \n\u001c\nk8\n \n\u001c","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":54,"lines":{"from":102,"to":118}}}}],["184",{"pageContent":"PARTE 2\nAnemias\n\n03\n\nAnemi\nA\n \npor deficienci\nA\n \nde hierro\n\n04\n\nAnemi\nA\ns meg\nA\nloblástic\nA\ns\n\n05\n\nAnemi\nA\ns hemolític\nA\ns.\nAspectos gener\nA\nles\n\n06\n\nAnemi\nA\ns hemolític\nA\ns c\nA\nus\nA\nd\nA\ns por tr\nA\nstornos\nde l\nA\n \nmembr\nA\nn\nA\n \neritrocític\nA\n\n07\n\nh\nemoglobinop\nA\ntí\nA\ns y t\nA\nl\nA\nsemi\nA\ns\n\n08\n\nAnemi\nA\ns hemolític\nA\ns por\n \nA\nlter\nA\nciones\nde enzim\nA\ns eritrocit\nA\nri\nA\ns\n\n09\n\nAnemi\nA\ns hemolític\nA\ns inmunit\nA\nri\nA\ns\n\n10\n\nh\nipopl\nA\nsi\nA\ns y displ\nA\nsi\nA\ns medul\nA\nres\n\n11\n\nAnemi\nA\ns secund\nA\nri\nA\ns\n \nA\n \np\nA\ndecimientos no hemáticos\n\n137\n115\n99\n77\n67\n45\n31\n151\n127","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":56,"lines":{"from":1,"to":147}}}}],["185",{"pageContent":"31\n\nObjetivos de aprendizaje\n\n•\n \n\u0012\u001f\u001d)()\u001d\u001f, \u001b &\u001b \u001b(\u001f'#\u001b\n \n\u001f,,)*ï(#\u001d\u001b \u001d)') &\u001b \u001d\u001b/-\u001b 'á-\n \n,\u001f\u001d/\u001f(.\u001f \u001e\u001f \u001b(\u001f'#\u001b \u001f( \u001f& '/(\u001e)8\n•\n \n\u0003)'*,\u001f(\u001e\u001f, \u001f& '\u001f.\u001b\u001c)&#-') \u001e\u001f& \"#\u001f,,) 3 &\u001b l·-#)*\u001b.)&)!ù\u001b \u001e\u001f -/ \u001e\u001fl·\u001d#\u001f(\u001d#\u001b8\n•\n \n\u0015.#&#4\u001b, \u001e\u001f ),'\u001b \u001b\u001e\u001f\u001d/\u001b\u001e\u001b &\u001b- *,/\u001f\u001c\u001b- \u001e\u001f &\u001b\u001c),\u001b.),#) *\u001b,\u001b \u001f& \u001e#\u001b!(ĉ-.#\u001d) \u001e\u001f &\u001b \u001b(\u001f'#\u001b \u001f,,)*ï(#\u001d\u001b8\n•\n \n\u001e\u001f(.#l·\u001d\u001b, 3 \u001d),,\u001f!#, &\u001b \u001d\u001b/-\u001b \u001e\u001f &\u001b \u001b(\u001f'#\u001b *\u001b,\u001b #(\u001e#\u001d\u001b, \u001f& .,\u001b.\u001b'#\u001f(.) \u001b\u001e\u001f\u001d/\u001b\u001e)8\n\nINTRODUCCIÓN\n\n\u0005& \"#\u001f,,) \u001f- /( '#(\u001f,\u001b& \u001f-\u001f(\u001d#\u001b& ,\u001f+/\u001f,#\u001e) *), \u001d\u001b\u001e\u001b -\u001f, 0#0#\u001f(.\u001f *\u001b,\u001b &\u001b -ù(.\u001f-#- \u001e\u001f& \u0004\u000e\u00016 \u001f& .,\u001b(-*),.\u001f\n\u001e\u001f )2ù!\u001f() 3 &\u001b ,\u001f-*#,\u001b\u001d#ĉ(8 \u0014#\u001f(\u001f \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e *\u001b,\u001b \u001b\u001d\u001f*.\u001b, 3 \u001e)(\u001b, \u001f&\u001f\u001d.,)(\u001f-6 &) \u001d/\u001b& \u001e\u001f-\u001f'*\u001fĄ\u001b /( *\u001b\n-\n\n*\u001f&\n \n/(\u001e\u001b'\u001f(.\u001b& \u001f( \u001e# \u001f,\u001f(.\u001f- ,\u001f\u001b\u001d\u001d#)(\u001f- \u001f(4#'á.#\u001d\u001b-8 \u0013/ \u001f2\u001d\u001f-) */\u001f\u001e\u001f .\u001f(\u001f, \u001d)(-\u001f\u001d/\u001f(\u001d#\u001b- \u001b\u001e0\u001f,-\u001b-\n*\u001b,\u001b \u001f& ),!\u001b(#-')6 \u001d)') &\u001b- )\u001c-\u001f,0\u001b\u001e\u001b- \u001f( &\u001b \"\u001f')\u001d,)'\u001b.)-#- ) &\u001b \"\u001f')-#\u001e\u001f,)-#- B\u001e#- /(\u001d#ĉ( \u001d\u001b,\u001eù\u001b\u001d\u001b6\n\"\u001f*á.#\u001d\u001b6 \u001f(.,\u001f ).,\u001b-C8\n\nMETABOLISMO Y REGULACIÓN DE LA HOMEOSTASIS DEL HIERRO\n\n\u0003)') -\u001f \"\u001b '\u001f(\u001d#)(\u001b\u001e)6 &\u001b \u001d\u001b(.#\u001e\u001b\u001e \u001e\u001f \"#\u001f,,) \u001f( \u001f& \u001d/\u001f,*) \u001e\u001f-\u001f'*\u001fĄ\u001b /( *\u001b*\u001f& #'*),.\u001b(.\u001f \u001f( \u001f&\n \n/(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":58,"lines":{"from":1,"to":39}}}}],["186",{"pageContent":"METABOLISMO Y REGULACIÓN DE LA HOMEOSTASIS DEL HIERRO\n\n\u0003)') -\u001f \"\u001b '\u001f(\u001d#)(\u001b\u001e)6 &\u001b \u001d\u001b(.#\u001e\u001b\u001e \u001e\u001f \"#\u001f,,) \u001f( \u001f& \u001d/\u001f,*) \u001e\u001f-\u001f'*\u001fĄ\u001b /( *\u001b*\u001f& #'*),.\u001b(.\u001f \u001f( \u001f&\n \n/(\n-\n\n\u001d#)(\u001b'#\u001f(.) (),'\u001b& 3 *\u001b.)&ĉ!#\u001d) \u001e\u001f& ),!\u001b(#-')8 \u0005& \u001d)(.\u001f(#\u001e) \u001e\u001f \"#\u001f,,) \u001d),*),\u001b& *,)'\u001f\u001e#) \u001e\u001f& \")'\u001c,\u001f\n\u001b\u001e/&.) 3 &\u001b- '/$\u001f,\u001f- *)-'\u001f()*\u001bĚ-#\u001d\u001b- -\u001f \u001f-.#'\u001b \u001f( ik̓ '!I%!6 \u001b/(+/\u001f \u001f- '\u001f(), \u001f( &\u001b- '/$\u001f,\u001f- +/\u001f '\u001f(-\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":58,"lines":{"from":39,"to":48}}}}],["187",{"pageContent":".,Ě\u001b(8\n \n\u001b '\u001b3), *\u001b,.\u001f \u001e\u001f& \"#\u001f,,) \u001d),*),\u001b& \u001f-.á \u001d)(.\u001f(#\u001e) \u001f( &)- \u001f,#.,)\u001d#.)-6 \u001d\u001b\u001e\u001b /() \u001e\u001f &)- \u001d/\u001b&\u001f- \u001d/\u001f(.\u001b\n\u001d)( \u001b*,)2#'\u001b\u001e\u001b'\u001f(.\u001f g6f̓'! \u001e\u001f \"#\u001f,,) \u001f&\u001f'\u001f(.\u001b&: *), &) .\u001b(.)6 \u001f& \u001d)(.\u001f(#\u001e) \u001e\u001f \"#\u001f,,) \u001f,#.,)\u001d#.\u001b,#) \u001e\u001f\n/( \")'\u001c,\u001f 3 /(\u001b '/$\u001f, \u001b\u001e/&.)- -\u001f \u001f-.#'\u001b \u001f( h 3 g6k̓!6 ,\u001f-*\u001f\u001d.#0\u001b'\u001f(.\u001f8 \u0004\u001f(.,) \u001e\u001f& \u001f,#.,)\u001d#.)6 \u001f& \"#\u001f,,)\n\u001f( \u001f2\u001d\u001f-) +/\u001f () \u001f- ,\u001f+/\u001f,#\u001e) *\u001b,\u001b &\u001b -ù(.\u001f-#- \u001e\u001f \"\u001f')!&)\u001c#(\u001b -\u001f l·$\u001b \u001b /(\u001b *,).\u001fù(\u001b \u001e\u001f \u001b&'\u001b\u001d\u001f(\u001b'#\u001f(.)6\n&\u001b \u001b*) \u001f,,#.#(\u001b6 *\u001b,\u001b ),'\u001b, &\u001b \u001f,,#.#(\u001b8 \u0005-.\u001b Ě&.#'\u001b ,\u001f*,\u001f-\u001f(.\u001b &)- \u001e\u001f*ĉ-#.)- \u001d),*),\u001b&\u001f- \u001e\u001f \"#\u001f,,)6 \u001d/3)-\n0\u001b&),\u001f- (),'\u001b&\u001f- \u001f( '/$\u001f,\u001f- 3 \")'\u001c,\u001f- \u001b\u001e/&.)- )-\u001d#&\u001b( \u001f(.,\u001f gk 3 iff̓(!I'\n \n8\n \n\u001b \"\u001f')-#\u001e\u001f,#(\u001b6 +/\u001f \u001f-\n/( *,)\u001e/\u001d.) \u001e\u001f \u001e\u001f!,\u001b\u001e\u001b\u001d#ĉ( \u001e\u001f &\u001b \"\u001f')!&)\u001c#(\u001b +/\u001f ),'\u001b *\u001b,.\u001f \u001e\u001f &\u001b- ,\u001f-\u001f,0\u001b- \u001d),*),\u001b&\u001f- \u001e\u001f& \"#\u001f,,)6 -\u001f\n\u001f(\u001d/\u001f(.,\u001b *,#(\u001d#*\u001b&'\u001f(.\u001f \u001f( &)- '\u001b\u001d,ĉ \u001b!)- \u001e\u001f &\u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b6 \u001f& \"ù!\u001b\u001e) 3 \u001f& \u001c\u001b4)8 \u0003\u001b(.#\u001e\u001b\u001e\u001f- '\u001f(),\u001f-\n\u001e\u001f \"#\u001f,,) -\u001f /\u001c#\u001d\u001b( \u001f( &)- 'Ě-\u001d/&)- \u001f( ),'\u001b \u001e\u001f '#)!&)\u001c#(\u001b 3 \u001f( &)- .\u001f$#\u001e)- \u001d)') \u001d#.)\u001d,)')- 3 \u001f(4#'\u001b-8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":58,"lines":{"from":50,"to":64}}}}],["188",{"pageContent":"\u001e\u001f \"#\u001f,,) -\u001f /\u001c#\u001d\u001b( \u001f( &)- 'Ě-\u001d/&)- \u001f( ),'\u001b \u001e\u001f '#)!&)\u001c#(\u001b 3 \u001f( &)- .\u001f$#\u001e)- \u001d)') \u001d#.)\u001d,)')- 3 \u001f(4#'\u001b-8\n\u0015(\u001b \u001d\u001b(.#\u001e\u001b\u001e '/3 *\u001f+/\u001fĄ\u001b \u001e\u001f \"#\u001f,,) -\u001f -#.Ě\u001b \u001f( \u001f& *&\u001b-'\u001b /(#\u001e\u001b \u001b &\u001b .,\u001b(- \u001f,,#(\u001b 3 \u001b &\u001b &\u001b\u001d.) \u001f,,#(\u001b8 \u0003\u001b\u001e\u001b","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":58,"lines":{"from":64,"to":65}}}}],["189",{"pageContent":"CAPÍTULO 3\n\nJosé Carlos Jaime Pérez\nJorge Cuervo Sierra\nLa mayor parte del hierro cor-\nporal está contenido en los eri-\ntrocitos, cada uno de los cuales\ncuenta con aproximadamente\n1,0 mg de hierro elemental; por\nlo tanto, el contenido de hierro\neritrocitario de un hombre y\nuna mujer adultos se estima en\n2 y 1,5 g, respectivamente.\n\nANEMIA\nPOR DEFICIENCIA\nDE HIERRO","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":58,"lines":{"from":67,"to":83}}}}],["190",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n32\n\n')&ï\u001d/&\u001b \u001e\u001f .,\u001b(- \u001f,,#(\u001b ) &\u001b\u001d.) \u001f,,#(\u001b /(\u001f \u001e)- ')&ï\u001d/&\u001b- \u001e\u001f \"#\u001f,,) ï,,#\u001d)8 \u0005& \"#\u001f,,) /(#\u001e) \u001b &\u001b .,\u001b(- \u001f,,#(\u001b\n\u001f-.á \u001f( \u001d)(-.\u001b(.\u001f ,\u001f\u001d\u001b'\u001c#) \u001f( &\u001b '\u001f\u001e#\u001e\u001b \u001f( +/\u001f \u001f- /-\u001b\u001e) *), &)- .\u001f$#\u001e)- \u001d),*),\u001b&\u001f-8\n\u0005& \"#\u001f,,) \u001b\u001c-),\u001c#\u001e) \u001e\u001f &\u001b \u001e#\u001f.\u001b ) &#\u001c\u001f,\u001b\u001e) \u001e\u001f &)- \u001e\u001f*ĉ-#.)- \u001d#,\u001d/&\u001b \u001f( \u001f& *&\u001b-'\u001b /(#\u001e) \u001b &\u001b .,\u001b(- \u001f,,#(\u001b6 +/\u001f\n\u001f- &\u001b *,).\u001fù(\u001b .,\u001b(-*),.\u001b\u001e),\u001b \u001e\u001f \"#\u001f,,)8\n \n\u001b .,\u001b(- \u001f,,#(\u001b \u001f- /(\u001b !&#\u001d)*,).\u001fù(\u001b \u001d)( \u001e)- -#.#)- \u001e\u001f /(#ĉ( *\u001b,\u001b \u001f&\n\"#\u001f,,) 3 .#\u001f(\u001f \u001e)- ),'\u001b- \u001cá-#\u001d\u001b-9 ')() ï,,#\u001d\u001b 3 \u001e# ï,,#\u001d\u001b6 -\u001f!Ě( \u001f& (Ě'\u001f,) \u001e\u001f á.)')- \u001e\u001f \"#\u001f,,) +/\u001f \u001d)(.#\u001f(\u001f8\n\u001b .\u001b-\u001b \u001e\u001f ,\u001f\u001d\u001b'\u001c#) \u001e\u001f& \"#\u001f,,) /(#\u001e) \u001b &\u001b .,\u001b(- \u001f,,#(\u001b \u001f- '/3 ,á*#\u001e\u001b6 \u001f( *,)'\u001f\u001e#) \u001e\u001f lf \u001b of '#(/.)-8 \u0004\u001f\u001c#\u001e)\n\u001b +/\u001f &\u001b !,\u001b( '\u001b3),ù\u001b \u001e\u001f& \"#\u001f,,) .,\u001b(-*),.\u001b\u001e) *), &\u001b .,\u001b(- \u001f,,#(\u001b \u001f- /.#&#4\u001b\u001e) *\u001b,\u001b &\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f \u001f,#.,)\u001d#.)-\n\u001f( &\u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b6 \u001f& .#\u001f'*) \u001e\u001f \u001e\u001f*/,\u001b\u001d#ĉ( \u001e\u001f& \"#\u001f,,) /(#\u001e) \u001b &\u001b .,\u001b(- \u001f,,#(\u001b \u001e\u001f-\u001e\u001f &\u001b \u001d#,\u001d/&\u001b\u001d#ĉ( -\u001f 0\u001f \u001b \u001f\u001d.\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":59,"lines":{"from":1,"to":15}}}}],["191",{"pageContent":"\u001e) *,#(\u001d#*\u001b&'\u001f(.\u001f *), &)- (#0\u001f&\u001f- \u001e\u001f \"#\u001f,,) *&\u001b-'á.#\u001d) 3 *), &\u001b \u001b\u001d.#0#\u001e\u001b\u001e \u001f,#.,)#\u001e\u001f \u001e\u001f &\u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b8 \u0003/\u001b(\u001e)\n&\u001b \u001f,#.,)*)3\u001f-#- -\u001f \u001f-.#'/&\u001b \u001e\u001f'\u001b-#\u001b\u001e)6 \u001d)') \u001f( \u001f& -\u001b(!,\u001b\u001e) \u001b!/\u001e)6 \u001b/'\u001f(.\u001b( &\u001b- \u001e\u001f'\u001b(\u001e\u001b- \u001e\u001f \"#\u001f,,) 3 \u001f&\n.#\u001f'*) \u001e\u001f \u001e\u001f*/,\u001b\u001d#ĉ( \u001e\u001f& \"#\u001f,,) \u001d#,\u001d/&\u001b(.\u001f \u001e#-'#(/3\u001f8 \u0003/\u001b(\u001e) \"\u001b3 -/*,\u001f-#ĉ( \u001e\u001f &\u001b \u001f,#.,)*)3\u001f-#- \u001f( &\u001b 'ï\u001e/&\u001b\nĉ-\u001f\u001b6 &)- (#0\u001f&\u001f- -ï,#\u001d)- \u001e\u001f \"#\u001f,,) \u001b/'\u001f(.\u001b( 3 \u001f& .#\u001f'*) \u001e\u001f \u001e\u001f*/,\u001b\u001d#ĉ( -\u001f *,)&)(!\u001b *), 0\u001b,#\u001b- \"),\u001b-8\n\u001b \u001e#\u001f.\u001b )\u001d\u001d#\u001e\u001f(.\u001b& *,)*),\u001d#)(\u001b \u001f( *,)'\u001f\u001e#) \u001f(.,\u001f gf 3 hf̓ '! \u001e\u001f \"#\u001f,,) *), \u001eù\u001b6 \u001e\u001f &)- \u001d/\u001b&\u001f- -\u001f \u001b\u001c-),\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":59,"lines":{"from":17,"to":22}}}}],["192",{"pageContent":"\u001c\u001f -)&) \u001f& k \u001b gfz8 \u0004#\u001d\"\u001b \u001b\u001c-),\u001d#ĉ( -\u001f */\u001f\u001e\u001f #(\u001d,\u001f'\u001f(.\u001b, \u001f( &)- \u001f-.\u001b\u001e)- \u001e\u001f \u001f,,)*\u001f(#\u001b \"\u001b-.\u001b *), k 0\u001f\u001d\u001f-8\n\u000e),'\u001b&'\u001f(.\u001f \u001f& ),!\u001b(#-') ,\u001f+/#\u001f,\u001f g '!I\u001eù\u001b \u001e\u001f \"#\u001f,,) *\u001b,\u001b \u001d)'*\u001f(-\u001b, &\u001b- *ï,\u001e#\u001e\u001b- *), \"\u001f\u001d\u001f-8\n \n\u001b .\u001b-\u001b\n\u001e\u001f \u001b\u001c-),\u001d#ĉ( \u001e\u001f \"#\u001f,,) \u001f-.á #(ł/\u001f(\u001d#\u001b\u001e\u001b *), 0\u001b,#)- \u001b\u001d.),\u001f-6 \u001b -\u001b\u001c\u001f,9 \u001e\u001f*ĉ-#.)- \u001e\u001f \"#\u001f,,) \u001d),*),\u001b&6 \u001f& !,\u001b\u001e) \u001e\u001f\n\u001f,#.,)*)3\u001f-#- \u001f( &\u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b6 &\u001b \u001d)(\u001d\u001f(.,\u001b\u001d#ĉ( \u001e\u001f \"\u001f')!&)\u001c#(\u001b \u001f( *&\u001b-'\u001b6 \u001f& \u001d)(.\u001f(#\u001e) \u001e\u001f )2ù!\u001f()\n-\u001b(!/ù(\u001f) 3 &\u001b *,\u001f-\u001f(\u001d#\u001b \u001e\u001f \u001d#.)\u001d#(\u001b- #(ł\u001b'\u001b.),#\u001b-8 \u0005& \"#\u001f,,) -\u001f \u001b\u001c-),\u001c\u001f \u001f( \u001f& \u001e/)\u001e\u001f() \u001b .,\u001b0ï- \u001e\u001f \u001e)- 0ù\u001b-6\n/(\u001b +/\u001f *\u001f,'#.\u001f &\u001b \u001b\u001c-),\u001d#ĉ( \u001e\u001f& \"#\u001f,,) \"\u001f') 3 &\u001b -\u001f!/(\u001e\u001b *\u001b,\u001b &\u001b \u001b\u001c-),\u001d#ĉ( \u001e\u001f& \"#\u001f,,) \u001f&\u001f'\u001f(.\u001b&8 \u0010\u001b,\u001b &\u001b\n\u001b\u001c-),\u001d#ĉ( \u001e\u001f& \"#\u001f,,) \"\u001f') \u001f-\n \n/(\u001e\u001b'\u001f(.\u001b& +/\u001f \u001f2#-.\u001b \u001b\u001d#\u001e\u001f4 !á-.,#\u001d\u001b6 &\u001b \u001d/\u001b& *\u001f,'#.\u001f &#\u001c\u001f,\u001b, \u001b& \"\u001f') \u001e\u001f -/\n\u001b*)*,).\u001fù(\u001b8 \u0005& \"#\u001f,,) \"\u001f') *)-.\u001f,#),'\u001f(.\u001f \u001f- )2#\u001e\u001b\u001e) \u001b -/ \u001f-.\u001b\u001e) ï,,#\u001d)6 ),'\u001b(\u001e) \"\u001f'#(\u001b6 3 -\u001f \u001b\u001c-),\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":59,"lines":{"from":24,"to":36}}}}],["193",{"pageContent":"\u001c\u001f \u001b .,\u001b0ï- \u001e\u001f /( '\u001f\u001d\u001b(#-') *)\u001d) \u001d&\u001b,)8 \u0005- ,\u001f\u001d/\u001f(.\u001f )\u001c-\u001f,0\u001b, \u001d/\u001b\u001e,)- \u001e\u001f \u001f,,)*\u001f(#\u001b ) \u001b(\u001f'#\u001b \u001f,,)*ï(#\u001d\u001b\n\u001f( *\u001b\u001d#\u001f(.\u001f- \u001b(\u001d#\u001b()- +/\u001f \u001d/,-\u001b( \u001d)( \u001b.,)l·\u001b !á-.,#\u001d\u001b 3 \u001d)( &\u001b \u001d)(-#!/#\u001f(.\u001f \u001b\u001d&),\"#\u001e,#\u001b8\n\u0005& \"#\u001f,,) () \"\u001f') ,\u001f+/#\u001f,\u001f -\u001f, ,\u001f\u001e/\u001d#\u001e) \u001b &\u001b\n \n),'\u001b\n \n\u001f,,)-\u001b *\u001b,\u001b *)\u001e\u001f, -\u001f, \u001b\u001c-),\u001c#\u001e)6 -#\u001f(\u001e)\n \n/(\n-\n\n\u001e\u001b'\u001f(.\u001b& \u001f( \u001f-.\u001f Ě&.#') *\u001b-) &\u001b \u001f(4#'\u001b \u001d#.)\u001d,)') \u001c \u001e/)\u001e\u001f(\u001b& B\u0004\u001d3.\u001cC8 \u0005( &\u001b \u001b\u001c-),\u001d#ĉ( #(.\u001f-.#(\u001b& \u001e\u001f&\n\"#\u001f,,) \u001f2#-.\u001f( .,\u001b(-*),.\u001b\u001e),\u001f-6 \u001d)') \u001f& .,\u001b(-*),.\u001b\u001e), \u001e\u001f '\u001f.\u001b&\u001f- \u001e#0\u001b&\u001f(.\u001f B\u0004\n \n\u0014gC6 +/\u001f -\u001f \u001f(\u001d\u001b,!\u001b\n\u001e\u001f& .,\u001b(-*),.\u001f \u001f( &\u001b '\u001f'\u001c,\u001b(\u001b \u001b*#\u001d\u001b& \u001e\u001f& \u001f(.\u001f,)\u001d#.)8 \u0015(\u001b 0\u001f4 \u001e\u001f(.,) \u001e\u001f& \u001f(.\u001f,)\u001d#.)6 \u001f& \"#\u001f,,) */\u001f\u001e\u001f\n.)'\u001b, \u001e)- 0ù\u001b-9 -\u001f, &#\u001c\u001f,\u001b\u001e) *), \u001e\u001f-\u001d\u001b'\u001b\u001d#ĉ( #(.\u001f-.#(\u001b& ) -\u001f, .,\u001b(-*),.\u001b\u001e) \u001f( \u001f& *&\u001b-'\u001b *), &\u001b *,).\u001fù(\u001b\n\u001f,,)*),.#(\u001b6 &\u001b \u001d/\u001b& \u001f-.á /\u001c#\u001d\u001b\u001e\u001b \u001f( &\u001b '\u001f'\u001c,\u001b(\u001b \u001c\u001b-)&\u001b.\u001f,\u001b& \u001e\u001f& \u001f(.\u001f,)\u001d#.)8\n \n\u001b\n \n\u001f,,)*),.#(\u001b \u001b -/ 0\u001f4 \u001f-\n\u001f-.#'/&\u001b\u001e\u001b *), &\u001b \"\u001f \u001b-.#(\u001b8 \u0005& \"#\u001f,,) +/\u001f -\u001f &#\u001c\u001f,\u001b \u001b &\u001b \u001d#,\u001d/&\u001b\u001d#ĉ( -\u001f /(\u001f \u001b &\u001b .,\u001b(- \u001f,,#(\u001b 3 \u001f- .,\u001b(-\n-\n\n*),.\u001b\u001e) \u001b &)- -#.#)- \u001e\u001f /.#&#4\u001b\u001d#ĉ( 3 \u001b&'\u001b\u001d\u001f(\u001b'#\u001f(.) \u001e\u001f& \"#\u001f,,)\n \n(fig. 3-1)\n8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":59,"lines":{"from":38,"to":66}}}}],["194",{"pageContent":"*),.\u001b\u001e) \u001b &)- -#.#)- \u001e\u001f /.#&#4\u001b\u001d#ĉ( 3 \u001b&'\u001b\u001d\u001f(\u001b'#\u001f(.) \u001e\u001f& \"#\u001f,,)\n \n(fig. 3-1)\n8\n\nLa dieta occidental propor-\nciona en promedio entre 10 y\n20 mg de hierro por día, de\nlos cuales se absorbe solo el 5\na 10%.\n\nFigura 3-1.\n \n\u0003#\u001d&) 0#.\u001b& \u001e\u001f& \u001f(.\u001f,)\u001d#.) \u001e/)\u001e\u001f(\u001b&8 B\u0012)3 \u00036 \u0005((- \u00038\n \n,)( \")'\u001f)-.\u001b-#-9 \u000e\u001f1 .\u001b&\u001f-\n \n,)' .\"\u001f\n\u001d,3*.8 \u0002&))\u001e8 hfffC8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":59,"lines":{"from":66,"to":84}}}}],["195",{"pageContent":"CAPÍTULO 3. ANEMIA POR DEFICIENCIA DE HIERRO\n\n33\n\n\u001b *,).\u001fù(\u001b \u001e\u001f &\u001b \"\u001f')\u001d,)'\u001b.)-#- \"\u001f,\u001f\u001e#.\u001b,#\u001b B\b\u0006\u0005C -\u001f /(\u001f \u001b& ,\u001f\u001d\u001f*.), \u001e\u001f &\u001b .,\u001b(- \u001f,,#(\u001b \u001f( &\u001b '\u001f'\n-\n\n\u001c,\u001b(\u001b \u001c\u001b-)&\u001b.\u001f,\u001b& 3 -\u001f #(\u001d),*),\u001b \u001b &\u001b \u001dï&/&\u001b $/(.) \u001d)( \u001f& ,\u001f\u001d\u001f*.), \u001e\u001f &\u001b .,\u001b(- \u001f,,#(\u001b8 \u0005-.) \"\u001b\u001d\u001f +/\u001f )\u001d/,,\u001b\n/(\u001b \u001e#-'#(/\u001d#ĉ( \u001f( &\u001b \u001bl·(#\u001e\u001b\u001e \u001e\u001f& ,\u001f\u001d\u001f*.), \u001e\u001f &\u001b .,\u001b(- \u001f,,#(\u001b \u001d)( -/ &#!\u001b(\u001e) B&\u001b .,\u001b(- \u001f,,#(\u001b \u001e# ï,,#\u001d\u001bC6\n,\u001f\u001e/\u001d#\u001f(\u001e) \u001b-ù &\u001b &#\u001c\u001f,\u001b\u001d#ĉ( \u001e\u001f& \"#\u001f,,) \u001e\u001f& \u001d)'*&\u001f$) \"#\u001f,,)7.,\u001b(- \u001f,,#(\u001b8 \u0010), &) .\u001b(.)6 &\u001b \b\u0006\u0005 ,\u001f!/&\u001b\n3 &#'#.\u001b &\u001b \u001d\u001b(.#\u001e\u001b\u001e \u001e\u001f \"#\u001f,,) \u001b\u001c-),\u001c#\u001e) *), &\u001b 0ù\u001b #(.\u001f-.#(\u001b&8 \u0005( &)- \u001d\u001b-)- \u001e)(\u001e\u001f \"\u001b3 '/.\u001b\u001d#)(\u001f- \u001e\u001f &\u001b\n\b\u0006\u00056 )\u001d/,,\u001f -)\u001c,\u001f\u001d\u001b,!\u001b \u001e\u001f \"#\u001f,,) *), \u001b\u001c-),\u001d#ĉ( () \u001d)(.,)&\u001b\u001e\u001b \u001e\u001f-\u001e\u001f \u001f& #(.\u001f-.#()8\n\u0005& \"#\u001f,,) /(#\u001e) \u001b &\u001b .,\u001b(- \u001f,,#(\u001b \u001f- .,\u001b(-*),.\u001b\u001e) \u001b &)- \u001f,#.,)\u001c&\u001b-.)-6 \u001e)(\u001e\u001f -\u001f /(\u001f \u001b& ,\u001f\u001d\u001f*.), \u001e\u001f &\u001b\n.,\u001b(- \u001f,,#(\u001b 3 \u001f(.,\u001b *), \u001f(\u001e)\u001d#.)-#-8 \u0003/\u001b(\u001e) &)- \u001e\u001f*ĉ-#.)- \u001e\u001f \"#\u001f,,) -)( \u001c\u001b$)-6 \u001e#-'#(/3\u001f &\u001b -ù(.\u001f-#- \u001e\u001f\n\u001b*) \u001f,,#.#(\u001b 3 \u001b/'\u001f(.\u001b &\u001b -ù(.\u001f-#- \u001e\u001f ,\u001f\u001d\u001f*.),\u001f- \u001e\u001f .,\u001b(- \u001f,,#(\u001b6 +/\u001f -\u001f &)\u001d\u001b&#4\u001b( \u001f( &\u001b '\u001f'\u001c,\u001b(\u001b \u001e\u001f& \u001f,#.,)\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":60,"lines":{"from":1,"to":16}}}}],["196",{"pageContent":"\u001d#.)8 \u0010), &) .\u001b(.)6 \u001f& ,\u001f\u001d\u001f*.), \u001e\u001f &\u001b .,\u001b(- \u001f,,#(\u001b \u001e\u001f.\u001f\u001d.\u001b \u001f,,)*\u001f(#\u001b \u001b/( \u001f( &)- \u001f-.\u001b\u001e)- #(ł\u001b'\u001b.),#)- \u001b!/\u001e)-\n+/\u001f \u001d/,-\u001b( \u001d)( (#0\u001f&\u001f- \u001e\u001f\n \n\u001f,,#.#(\u001b \u001b&.)- +/\u001f \u001e#l·\u001d/&.\u001b( \"\u001b\u001d\u001f, /( \u001e#\u001b!(ĉ-.#\u001d) \u001e\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)6\n\u001d)(.\u001b(\u001e) -)&\u001b'\u001f(.\u001f \u001d)( &\u001b \u001d)(\u001d\u001f(.,\u001b\u001d#ĉ( \u001e\u001f \u001f,,#.#(\u001b8\n\u001b '\u001b3), *\u001b,.\u001f \u001e\u001f& \"#\u001f,,) \u001f( \u001f& \u001f,#.,ĉ( -\u001f /(\u001f \u001d)( &\u001b *,).)*),l·,#(\u001b *\u001b,\u001b ),'\u001b, &\u001b ')&ï\u001d/&\u001b \u001e\u001f& \"\u001f')6 +/\u001f\n\u001d)(-.\u001b \u001e\u001f /( \u001b(#&&) .\u001f.,\u001b*#,,ĉ&#\u001d) \u001b& +/\u001f -\u001f #(\u001d),*),\u001b \u001f& \"#\u001f,,) *), &\u001b \u001b\u001d\u001d#ĉ( \u001e\u001f &\u001b \u001f(4#'\u001b \u001f,,)+/\u001f&\u001b.\u001b-\u001b6 &\u001b \u001d/\u001b&\n-\u001f \u001f(\u001d/\u001f(.,\u001b \u001f&\u001f0\u001b\u001e\u001b \u001f( \u001f& \u001f,#.,)\u001d#.) \u001f( &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)8 \u0005& \"\u001f') -\u001f /(\u001f \u001d)( &\u001b- \u001d\u001b\u001e\u001f(\u001b- \u001e\u001f !&)\u001c#(\u001b\n \nα\n \n3\n \nβ","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":60,"lines":{"from":18,"to":31}}}}],["197",{"pageContent":"*\u001b,\u001b ),'\u001b, &\u001b ')&ï\u001d/&\u001b \u001e\u001f &\u001b \"\u001f')!&)\u001c#(\u001b8 \u0015(\u001b 0\u001f4 \u001d/'*&#\u001e\u001b &\u001b 0#\u001e\u001b '\u001f\u001e#\u001b \u001f,#.,)\u001d#.\u001b,#\u001b Bghf \u001eù\u001b-C6 \u001f& \u001f,#.,)\u001d#.)\n-\u001f(\u001f-\u001d\u001f(.\u001f \u001f- \u001b!)\u001d#.\u001b\u001e) *), &)- '\u001b\u001d,ĉ \u001b!)- \u001f( \u001f& -#-.\u001f'\u001b ,\u001f.#\u001d/&)\u001f(\u001e).\u001f&#\u001b&8\n \n\u001b \"\u001f')!&)\u001c#(\u001b -\u001f ,)'*\u001f6 \u001f& \u001b(#&&)\n\"\u001f') -\u001f \u001f-\u001d#(\u001e\u001f 3 -\u001f &#\u001c\u001f,\u001b \u001f& \"#\u001f,,)8 \u0010\u001b,.\u001f \u001e\u001f \u001f-.\u001f \"#\u001f,,) -\u001f \u001b&'\u001b\u001d\u001f(\u001b \u001d)') \u001f,,#.#(\u001b ) \"\u001f')-#\u001e\u001f,#(\u001b6 3 \u001f& ,\u001f-.)\n\u001f- .,\u001b(-*),.\u001b\u001e) /\u001f,\u001b \u001e\u001f &\u001b \u001dï&/&\u001b *), &\u001b \u001f,,)*),.#(\u001b6 *\u001b,\u001b -\u001f, *)-.\u001f,#),'\u001f(.\u001f .,\u001b(-*),.\u001b\u001e) *), &\u001b .,\u001b(- \u001f,,#(\u001b8\n\u0005& \u001f+/#&#\u001c,#) \u001e\u001f& \"#\u001f,,) \u001d),*),\u001b& .\u001b'\u001c#ï( &) ,\u001f!/&\u001b \u001f& \"\u001f*\u001b.)\u001d#.)6 \u001f& \u001d/\u001b& /(!\u001f \u001d)') ,\u001f-\u001f,0),#)6 \u001d\u001b*.\u001b(\u001e)\n\"#\u001f,,) \u001e\u001f& -#-.\u001f'\u001b *),.\u001b& 3 &#\u001c\u001f,\u001b(\u001e) \"#\u001f,,) \u001e\u001f ,\u001f!,\u001f-) \u001b& *&\u001b-'\u001b8\n \n\u001b \"\u001f*\u001d#\u001e#(\u001b \u001f- /( *ï*.#\u001e) \u001d)( *,)*#\u001f\u001e\u001b\u001e\u001f-\n\u001c\u001b\u001d.\u001f,#\u001d#\u001e\u001b- 3 \u001f- /( ,\u001f!/&\u001b\u001e), \u001e\u001f &\u001b \u001b\u001c-),\u001d#ĉ( \u001e\u001f& \"#\u001f,,) 3 \u001e\u001f -/ \u001b&'\u001b\u001d\u001f(\u001b'#\u001f(.)8 \u0013\u001f /(\u001f \u001b &\u001b \u001f,,)*),.#(\u001b6\n#(.\u001f,(\u001b&#4á(\u001e)&\u001b 3 \u001e\u001f!,\u001b\u001eá(\u001e)&\u001b6 #'*#\u001e#\u001f(\u001e) \u001b-ù &\u001b -\u001b&#\u001e\u001b \u001e\u001f& \"#\u001f,,) \u001e\u001f-\u001e\u001f &\u001b- \u001dï&/&\u001b-8\n \n)- (#0\u001f&\u001f- \u001f&\u001f0\u001b\u001e)-\n\u001e\u001f \"\u001f*\u001d#\u001e#(\u001b #'*#\u001e\u001f( &\u001b \u001b\u001c-),\u001d#ĉ( \u001e\u001f \"#\u001f,,) 3 \u001e#-'#(/3\u001f( -/ &#\u001c\u001f,\u001b\u001d#ĉ( \u001e\u001f-\u001e\u001f \u001f& \"\u001f*\u001b.)\u001d#.) 3 &)- '\u001b\u001d,ĉ \u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":60,"lines":{"from":33,"to":48}}}}],["198",{"pageContent":"!)-8\n \n\u001b \"\u001f*\u001d#\u001e#(\u001b -\u001f \u001f&\u001f0\u001b ().),#\u001b'\u001f(.\u001f \u001f( &\u001b- \u001b(\u001f'#\u001b- #( \u001b'\u001b.),#\u001b-6 3 \u001e#-'#(/3\u001f \u001d/\u001b(\u001e) \u001f2#-.\u001f \u001b(\u001f'#\u001b 3\n\u001f( &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) -#( \u001b(\u001f'#\u001b8\n \n)- (#0\u001f&\u001f- \u001e\u001f \"\u001f*\u001d#\u001e#(\u001b -)( ,\u001f!/&\u001b\u001e)- *), &\u001b \"\u001f')$/0\u001f&#(\u001b 3 *), &\u001b\n*,).\u001fù(\u001b \u001e\u001f &\u001b \"\u001f')\u001d,)'\u001b.)-#- B\b\u0006\u0005C6 *\u001f,) &\u001b ),'\u001b \u001f( +/\u001f ,\u001f!/&\u001b( -/ \u001f2*,\u001f-#ĉ( () -\u001f \u001d)()\u001d\u001f\n \n(fig. 3-2)\n8\n\u0005( &\u001b !ï(\u001f-#- \u001e\u001f &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) 3 \u001e\u001f &\u001b \u001b(\u001f'#\u001b *), \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) \u001f2#-.\u001f( \u001e# \u001f,\u001f(.\u001f- \u001f-\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":60,"lines":{"from":50,"to":61}}}}],["199",{"pageContent":".\u001b\u001e#)- +/\u001f ,\u001fł\u001f$\u001b( &)- \u001b\u001d)(.\u001f\u001d#'#\u001f(.)- *,)!,\u001f-#0)- \u001e\u001f \u001e\u001f*&\u001f\u001d#ĉ( \u001e\u001f \u001e#\u001d\") '\u001f.\u001b&8\n \n) *,#'\u001f,) +/\u001f )\u001d/,,\u001f \u001f-\n/(\u001b \u001e#-'#(/\u001d#ĉ( \u001e\u001f &)- \u001e\u001f*ĉ-#.)- \u001e\u001f \"#\u001f,,) \u001f( &\u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b6 \u001f& \"ù!\u001b\u001e) 3 \u001f& \u001c\u001b4)6 +/\u001f -\u001f 0\u001f ,\u001fł\u001f$\u001b\u001e) *),\n&\u001b \u001d)(\u001d\u001f(.,\u001b\u001d#ĉ( \u001e\u001f \u001f,,#.#(\u001b \u001c\u001b$\u001b6 !\u001f(\u001f,\u001b&'\u001f(.\u001f *), \u001e\u001f\u001c\u001b$) \u001e\u001f gk̓(!I'\n \n8 \u0010)-.\u001f,#),'\u001f(.\u001f6 &\u001b \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e \u001e\u001f\nl·$\u001b\u001d#ĉ( \u001e\u001f& \"#\u001f,,) .).\u001b& B\u0014 \u0002\u0003C \u001b/'\u001f(.\u001b 3 &)- (#0\u001f&\u001f- -ï,#\u001d)- \u001e\u001f& \"#\u001f,,) \u001e\u001f-\u001d#\u001f(\u001e\u001f(8\n \n\u001b \u001e#-'#(/\u001d#ĉ( \u001e\u001f &\u001b\n\"\u001f')!&)\u001c#(\u001b 3 &\u001b '#\u001d,)\u001d#.)-#- -\u001f )\u001c-\u001f,0\u001b( \u001f( &)- \u001f-.\u001b\u001e#)- .\u001b,\u001eù)- \u001f( \u001f& \u001e\u001f-\u001b,,)&&) \u001e\u001f &\u001b \u001b(\u001f'#\u001b \u001f,,)*ï(#\u001d\u001b8\n\u001b \u001f,#.,)*)3\u001f-#- \u001e\u001fl·\u001d#\u001f(.\u001f \u001e\u001f \"#\u001f,,) -\u001f \u001e\u001f-\u001b,,)&&\u001b \u001f( 0\u001b,#)- \u001f-.\u001b\u001e#)-6 \u001d)') -\u001f #(\u001e#\u001d\u001b \u001f( \u001f&\n \ncuadro 3-1\n8\n\nFigura 3-2.\n \n)\u001e\u001f&) *\u001b,\u001b \u001f& \u001f-.\u001b\u001c&\u001f\u001d#'#\u001f(.) \u001e\u001f& -#.#) \u001e\u001f \u001b\u001c-),\u001d#ĉ( \u001e\u001f \"#\u001f,,) \u001f( &\u001b \u001d,#*.\u001b \u001e\u001f& \u001f(.\u001f,)\u001d#.)8\n\u0004)(\u001e\u001f9 \u0014 \u0012  ,\u001f\u001d\u001f*.), \u001e\u001f .,\u001b(- \u001f,,#(\u001b: \b\u0006\u0005  *,).\u001fù(\u001b \u001e\u001f &\u001b \"\u001f')\u001d,)'\u001b.)-#- \"\u001f,\u001f\u001e#.\u001b,#\u001b: \u0014  .,\u001b(-\n-\n\n\u001f,,#(\u001b: \u0006I&I\n \n .,\u001b(-*),.\u001b\u001e), \u001c\u001b-)&\u001b.\u001f,\u001b& \u001e\u001f \"#\u001f,,) \u001f,,)*),.#(\u001bI&,\u001f!gI\n \n\u0014\u0010g: \u0004\n \n\u0014g  .,\u001b(-*),.\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":60,"lines":{"from":63,"to":92}}}}],["200",{"pageContent":"\u001f,,#(\u001b: \u0006I&I\n \n .,\u001b(-*),.\u001b\u001e), \u001c\u001b-)&\u001b.\u001f,\u001b& \u001e\u001f \"#\u001f,,) \u001f,,)*),.#(\u001bI&,\u001f!gI\n \n\u0014\u0010g: \u0004\n \n\u0014g  .,\u001b(-*),.\u001b\n-\n\n\u001e), \u001e\u001f '\u001f.\u001b& \u001e#0\u001b&\u001f(.\u001f8 B\u0012)3 \u00036 \u0005((- \u00038\n \n,)( \")'\u001f)-.\u001b-#-9 \u000e\u001f1 .\u001b&\u001f-\n \n,)' .\"\u001f \u001d,3*.8 \u0002&))\u001e8 hfffC8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":60,"lines":{"from":92,"to":105}}}}],["201",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n34\n\nEPIDEMIOLOGÍA\n\n\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) \u001f- &\u001b \u001d\u001b/-\u001b 'á-\n \n,\u001f\u001d/\u001f(.\u001f \u001e\u001f \u001b(\u001f'#\u001b \u001f( .)\u001e) \u001f& '/(\u001e)6 \u001b/( *), \u001f(\u001d#'\u001b \u001e\u001f &\u001b \u001b(\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":61,"lines":{"from":1,"to":10}}}}],["202",{"pageContent":"'#\u001b \u001e\u001f &\u001b \u001f( \u001f,'\u001f\u001e\u001b\u001e \u001d,ĉ(#\u001d\u001b8 \u0001 (#0\u001f& '/(\u001e#\u001b&6 \"\u001b-.\u001b \u001f& kfz \u001e\u001f &)- (#Ą)- '\u001f(),\u001f- \u001e\u001f k \u001bĄ)- 3 \u001f& hkz \u001e\u001f\n&\u001b- '/$\u001f,\u001f- \u001b\u001e/&.\u001b- .#\u001f(\u001f( \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)8 \u0005( &)- *\u001bù-\u001f- \u001f( 0ù\u001b- \u001e\u001f \u001e\u001f-\u001b,,)&&)6 &\u001b \u001b(\u001f'#\u001b \u001f,,)*ï(#\u001d\u001b\n\u001f( &\u001b \u001f\u001e\u001b\u001e *\u001f\u001e#á.,#\u001d\u001b !/\u001b,\u001e\u001b \u001f-.,\u001f\u001d\"\u001b ,\u001f&\u001b\u001d#ĉ( \u001d)( &\u001b '\u001b&(/.,#\u001d#ĉ(: *), \u001f& \u001d)(.,\u001b,#)6 \u001f( &\u001b- '/$\u001f,\u001f- \u001f(\n\u001f\u001e\u001b\u001e ,\u001f*,)\u001e/\u001d.#0\u001b &\u001b \u001d\u001b/-\u001b 'á-\n \n,\u001f\u001d/\u001f(.\u001f \u001e\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) 3 \u001b(\u001f'#\u001b\n \n\u001f,,)*ï(#\u001d\u001b -)( &\u001b- *ï,\u001e#\u001e\u001b-\n'\u001f(-.,/\u001b&\u001f- \u001f2\u001d\u001f-#0\u001b-8 \u0003)( \u001d\u001b\u001e\u001b \u001d#\u001d&) '\u001f(-.,/\u001b& *,)'\u001f\u001e#) &\u001b '/$\u001f, *#\u001f,\u001e\u001f \u001f(.,\u001f gf 3 gk̓ '! \u001e\u001f \"#\u001f,,)8\n\u0005( &)- \u001b\u001e/&.)- \u001e\u001f \u001b'\u001c)- !ï(\u001f,)- \u001f& -\u001b(!,\u001b\u001e) \u001e\u001f& ./\u001c) \u001e#!\u001f-.#0) )\u001d/*\u001b &)- *,#'\u001f,)- &/!\u001b,\u001f- \u001d)') \u001d\u001b/-\u001b \u001e\u001f\n*ï,\u001e#\u001e\u001b \u001e\u001f \"#\u001f,,) 3 \u001b(\u001f'#\u001b \u001f,,)*ï(#\u001d\u001b8 \u0005( &)- *\u001bù-\u001f- \u001f( \u001e\u001f-\u001b,,)&&) -\u001f \u001d\u001b&\u001d/&\u001b +/\u001f \u001f& ilz \u001e\u001f &\u001b *)\u001c&\u001b\u001d#ĉ(\n-/ ,\u001f \u001e\u001f \u001b(\u001f'#\u001b (/.,#\u001d#)(\u001b&6 3 &\u001b *,\u001f0\u001b&\u001f(\u001d#\u001b \u001f( \u001f-\u001d)&\u001b,\u001f- 3 \u001b\u001e)&\u001f-\u001d\u001f(.\u001f- \u001e\u001f k \u001b gj \u001bĄ)- \u001f- \u001e\u001f& hg6nz8\n \n)-\n\u001b\u001d.),\u001f- +/\u001f \u001d)(.,#\u001c/3\u001f( \u001b &\u001b \u001b*\u001b,#\u001d#ĉ( \u001e\u001f &\u001b \u001b(\u001f'#\u001b \u001f,,)*ï(#\u001d\u001b \u001f( \u001f-\u001d)&\u001b,\u001f- 3 \u001b\u001e)&\u001f-\u001d\u001f(.\u001f- */\u001f\u001e\u001f( -\u001f, \u001f&","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":61,"lines":{"from":12,"to":26}}}}],["203",{"pageContent":")-\n\u001b\u001d.),\u001f- +/\u001f \u001d)(.,#\u001c/3\u001f( \u001b &\u001b \u001b*\u001b,#\u001d#ĉ( \u001e\u001f &\u001b \u001b(\u001f'#\u001b \u001f,,)*ï(#\u001d\u001b \u001f( \u001f-\u001d)&\u001b,\u001f- 3 \u001b\u001e)&\u001f-\u001d\u001f(.\u001f- */\u001f\u001e\u001f( -\u001f, \u001f&\n\u001d,\u001f\u001d#'#\u001f(.) ,á*#\u001e)6 \u001f& \u001c\u001b$) \u001d)(-/') \u001e\u001f \"#\u001f,,) \u001f( &\u001b \u001b&#'\u001f(.\u001b\u001d#ĉ( 3 &\u001b- *ï,\u001e#\u001e\u001b- -\u001b(!/ù(\u001f\u001b-: &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b\n*/\u001f\u001e\u001f -\u001f, /(# \u001b\u001d.),#\u001b& ) '/&.# \u001b\u001d.),#\u001b&8 \u0013\u001f \"\u001b( \u001f(\u001d)(.,\u001b\u001e) \u001e# \u001f,\u001f(.\u001f- *,\u001f0\u001b&\u001f(\u001d#\u001b- \u001e\u001f \u001f,,)*\u001f(#\u001b 3 \u001b(\u001f'#\u001b\n\u001f,,)*ï(#\u001d\u001b \u001f( &\u001b \u001f\u001e\u001b\u001e *\u001f\u001e#á.,#\u001d\u001b \u001f( &\u001b- *)\u001c&\u001b\u001d#)(\u001f- &\u001b.#()\u001b'\u001f,#\u001d\u001b(\u001b-\n \n(cuadro 3-2)\n8 \u0005( &\u001b *)\u001c&\u001b\u001d#ĉ( \u001b\u001e/&\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":61,"lines":{"from":26,"to":34}}}}],["204",{"pageContent":".\u001b '\u001f2#\u001d\u001b(\u001b -\u001f .#\u001f(\u001f( *,\u001f0\u001b&\u001f(\u001d#\u001b- \u001e\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) \u001f(.,\u001f i6l 3 lfz6 \u001d),,\u001f-*)(\u001e#\u001f(\u001e) &\u001b- \u001d# ,\u001b-\n'á- \u001b&.\u001b- \u001b &\u001b- '/$\u001f,\u001f- \u001f'\u001c\u001b,\u001b4\u001b\u001e\u001b-6 3 *,\u001f0\u001b&\u001f(\u001d#\u001b- \u001e\u001f \u001b(\u001f'#\u001b\n \n\u001f,,)*ï(#\u001d\u001b \u001f(.,\u001f f6o 3 hmz6 #!/\u001b&'\u001f(.\u001f\n,\u001f-/&.\u001b(\u001e) &\u001b- \u001f'\u001c\u001b,\u001b4\u001b\u001e\u001b- &\u001b- 'á- \u001b \u001f\u001d.\u001b\u001e\u001b-8\n\nCuadro 3-1.\n \nEstadios de la deficiencia de hierro\n\nEstadio\n \nManifestación\nPrelatente\n\n•\n \n\u0004\u001f*&\u001f\u001d#ĉ( \u001e\u001f &)- \u001e\u001f*ĉ-#.)- \u001e\u001f \"#\u001f,,) B \u001f,,#.#(\u001b \u001c\u001b$\u001bC\n•\n \n\b#\u001f,,) -ï,#\u001d) (),'\u001b&\n•\n \n\b\u001f')!&)\u001c#(\u001b (),'\u001b&\n\nLatente\n\n•\n \n\u0004\u001f*&\u001f\u001d#ĉ( \u001e\u001f &)- \u001e\u001f*ĉ-#.)- \u001e\u001f \"#\u001f,,) B \u001f,,#.#(\u001b \u001c\u001b$\u001bC\n•\n \n\b#\u001f,,) -ï,#\u001d) \u001c\u001b$)\n•\n \n\b\u001f')!&)\u001c#(\u001b (),'\u001b&\n\nManifiesta\n\n•\n \n\u0004\u001f*&\u001f\u001d#ĉ( \u001e\u001f &)- \u001e\u001f*ĉ-#.)- \u001e\u001f \"#\u001f,,) B \u001f,,#.#(\u001b \u001c\u001b$\u001bC\n•\n \n\b#\u001f,,) -ï,#\u001d) \u001c\u001b$)\n•\n \n\b\u001f')!&)\u001c#(\u001b \u001c\u001b$\u001b\n\nCuadro 3-2.\n \nPrevalencia de la deficiencia de hierro y la anemia ferropénica en Latinoamérica\n\nPaís\n \nGrupo de edad (años)\n \nAnemia (%)\n \nDeficiencia\nde hierro (%)\nAnemia\nferropénica (%)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":61,"lines":{"from":36,"to":98}}}}],["205",{"pageContent":"Cuadro 3-2.\n \nPrevalencia de la deficiencia de hierro y la anemia ferropénica en Latinoamérica\n\nPaís\n \nGrupo de edad (años)\n \nAnemia (%)\n \nDeficiencia\nde hierro (%)\nAnemia\nferropénica (%)\n\n\u0017\b\u000f gook\n \nk7gj\n \njl\n \n\u000e\u0005\n \n\u000e\u0005\n\u0003/\u001c\u001b\n \n\u0005-\u001d)&\u001b,\u001f- Bl7ggC\n \ngh6o\n \n\u000e\u0005\n \n\u000e\u0005\n\u0001,!\u001f(.#(\u001b\n \n\u0001\u001e)&\u001f-\u001d\u001f(.\u001f- Bgh7gnC\n \ngn\n \n\u000e\u0005\n \n\u000e\u0005\n\u0010\u001f,Ě\n \n\u0001\u001e)&\u001f-\u001d\u001f(.\u001f- Bgh7gnC\n \no6o\n \n\u000e\u0005\n \n\u000e\u0005\n\u0016\u001f(\u001f4/\u001f&\u001b\n \nm 3 gk\n \ngi6h\n \nif6k\n \nk6k\n\u0003)&)'\u001c#\u001b\n \ngh7gn\n \nk6o\n \ngj\n \nh6g\nï2#\u001d)\n \n\u0001\u001e/&.)- B\")'\u001c,\u001f-I'/$\u001f,\u001f-C\n \ni6lIhn\n \nf6oIgh\nï2#\u001d)\n \n\u0001\u001e)&\u001f-\u001d\u001f(.\u001f- Bgh7goC \bI\n \nj6lIgg6n\n \nm6oIgn6h\n \n\u000e\u0005\n\u000e\u0005  () \u001f0\u001b&/\u001b\u001e)8\n\nLa deficiencia de hierro es la\ncausa más frecuente de ane-\nmia en todo el mundo, aun\npor encima de la anemia de la\nenfermedad crónica.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":61,"lines":{"from":98,"to":189}}}}],["206",{"pageContent":"CAPÍTULO 3. ANEMIA POR DEFICIENCIA DE HIERRO\n\n35\n\nETIOLOGÍA DE LA DEFICIENCIA DE HIERRO\n\n\u0003)( &\u001b \u001f2\u001d\u001f*\u001d#ĉ( \u001e\u001f& \u001e\u001f-\u001b,,)&&)\n \n\u001f.\u001b&6 \u001f( \u001f& \u001d/\u001b& &\u001b *&\u001b\u001d\u001f(.\u001b \u001d)(.,)&\u001b &\u001b .,\u001b(- \u001f,\u001f(\u001d#\u001b \u001e\u001f& \"#\u001f,,) \u001e\u001f &\u001b\n'\u001b\u001e,\u001f \"\u001b\u001d#\u001b \u001f&\n \n\u001f.)6 \u001f& .,\u001b\u001d.) !\u001b-.,)#(.\u001f-.#(\u001b& \u001f- \u001f& *,#(\u001d#*\u001b& -#.#) \u001e\u001f &\u001b \u001f(.,\u001b\u001e\u001b \u001d),*),\u001b& \u001e\u001f& \"#\u001f,,)8\n\u0005& \u001c\u001b&\u001b(\u001d\u001f \u001f(.,\u001f &\u001b \u001d\u001b*.\u001b\u001d#ĉ( \u001e\u001f& \"#\u001f,,) 3 &\u001b- *ï,\u001e#\u001e\u001b- -\u001f '\u001b(.#\u001f(\u001f \u001f( *\u001f, \u001f\u001d.) \u001f+/#&#\u001c,#)8 \u0003/\u001b&+/#\u001f,\n\u001b\u001d.), +/\u001f \u001b&.\u001f,\u001f \u001f-.\u001f \u001f+/#&#\u001c,#) &&\u001f0\u001b,á \u001b &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)8\n \n\u001b \u001d\u001b*.\u001b\u001d#ĉ( \u001b&.\u001f,\u001b\u001e\u001b \u001e\u001f& \"#\u001f,,) ,\u001fł\u001f$\u001b\n*,)\u001c&\u001f'\u001b- \u001f( \u001f& .,\u001b\u001d.) !\u001b-.,)#(.\u001f-.#(\u001b& -/*\u001f,#),8 \u0005& -\u001b(!,\u001b\u001e) \u001f- &\u001b *,#(\u001d#*\u001b& \u001d\u001b/-\u001b \u001e\u001f *ï,\u001e#\u001e\u001b- \u001e\u001f \"#\u001f,,)\n3 */\u001f\u001e\u001f )\u001d/,,#, \u001f( \u001d/\u001b&+/#\u001f, -#.#) \u001b &) &\u001b,!) \u001e\u001f& \u001b*\u001b,\u001b.) \u001e#!\u001f-.#0)\n \n(cuadro 3-3)\n8\n\nCaptación alterada de hierro desde el tracto gastrointestinal\nPobre biodisponibilidad","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":62,"lines":{"from":1,"to":24}}}}],["207",{"pageContent":"Captación alterada de hierro desde el tracto gastrointestinal\nPobre biodisponibilidad\n\n\u0005& \"#\u001f,,) -\u001f \u001b\u001c-),\u001c\u001f *,#(\u001d#*\u001b&'\u001f(.\u001f \u001f( \u001f& \u001e/)\u001e\u001f() 3 \u001f( \u001f& 3\u001f3/() -/*\u001f,#),8\n \n\u001b \u001b\u001d#\u001e\u001f4 !á-.,#\u001d\u001b \u001d)(.,#\u001c/3\u001f\n\u001b &\u001b \u001d)(0\u001f,-#ĉ( \u001e\u001f &\u001b- -\u001b&\u001f- \u001e\u001f \"#\u001f,,) \u001b &\u001b- ),'\u001b- \u001b\u001c-),\u001c#\u001c&\u001f-8\n \n/\u001d\"\u001b- *&\u001b(.\u001b- *,)\u001e/\u001d\u001f( +/\u001f&\u001b(.\u001f- /\u001f,.\u001f-6\n\u001d)') &)- l·.\u001b.)- B*)&# )- \u001b.)- ),!á(#\u001d)-C6 +/\u001f \u001f-.á( \u001d)(.\u001f(#\u001e)- \u001f( &)- \u001d\u001f,\u001f\u001b&\u001f- \u001d)') \u001f& .,#!) 3 +/\u001f \u001b&.\u001f,\u001b( &\u001b\n\u001b\u001c-),\u001d#ĉ( \u001e\u001f& \"#\u001f,,)8\n \n\u001b- \u001d)(\u001e#\u001d#)(\u001f- +/\u001f \u001b/'\u001f(.\u001b( \u001f& *\b !á-.,#\u001d) #'*#\u001e\u001f( -/ \u001b\u001c-),\u001d#ĉ(8 \u0003#,/!ù\u001b- \u001d)')\n&\u001b 0\u001b!).)'ù\u001b ) \"\u001f'#!\u001b-.,\u001f\u001d.)'ù\u001b *\u001b,\u001b &\u001b Ě&\u001d\u001f,\u001b *ï*.#\u001d\u001b \u001f,\u001b( \u001d\u001b/-\u001b-\n \n,\u001f\u001d/\u001f(.\u001f- \u001e\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)6\n*\u001f,) \u001f( &\u001b \u001b\u001d./\u001b&#\u001e\u001b\u001e \u001f& \u001f'*&\u001f) \u001e\u001f á,'\u001b\u001d)- \u001c&)+/\u001f\u001b\u001e),\u001f- \u001e\u001f &)- ,\u001f\u001d\u001f*.),\u001f- \bh \u001d)(-.#./3\u001f /(\u001b \u001d\u001b/-\u001b \"\u001b\u001c#\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":62,"lines":{"from":24,"to":41}}}}],["208",{"pageContent":"./\u001b& \u001e\u001f \u001b\u001c-),\u001d#ĉ( \u001e\u001f \u001f\u001d./)-\u001b \u001e\u001f \u001f-.\u001f \u001f&\u001f'\u001f(.)8\n \n\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) \u001b '\u001f(/\u001e) \u001b\u001d)'*\u001bĄ\u001b 3 \u001f2\u001b\u001d\u001f,\u001c\u001b \u001b &\u001b\n\u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b8\n \n\u001b /(\u001d#ĉ( \u001b&.\u001f,\u001b\u001e\u001b \u001e\u001f &\u001b- \u001dï&/&\u001b- *\u001b,#\u001f.\u001b&\u001f- ,\u001f\u001e/\u001d\u001f &\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f& \u001b\u001d.), #(.,ù(-\u001f\u001d)\n36 *), \u001f(\u001e\u001f6 \u001e#-'#(/3\u001f &\u001b \u001b\u001d#\u001e\u001f4 !á-.,#\u001d\u001b #'*#\u001e#\u001f(\u001e) /(\u001b \u001b\u001c-),\u001d#ĉ( \u001b\u001e\u001f\u001d/\u001b\u001e\u001b \u001e\u001f& '\u001f.\u001b&8\n\nInhibición de la absorción del hierro\n\n\u0014\u001b(.) \u001f& \u001d\u001b ï \u001d)') \u001f& .ï \u001d)(.#\u001f(\u001f( \u001d)'*/\u001f-.)- +/\u001f #(\"#\u001c\u001f( &\u001b \u001b\u001c-),\u001d#ĉ( \u001e\u001f& \"#\u001f,,)8\n \n)- .\u001b(#()- \u001e\u001f& .ï\n\u001d)(-.#./3\u001f( +/\u001f&\u001b(.\u001f- *)\u001e\u001f,)-)- +/\u001f\n \n),'\u001b( \u001d)'*&\u001f$)- \u001f-.,\u001f\u001d\")- \u001d)( \u001f& \"#\u001f,,) #ĉ(#\u001d) 36 \u001e\u001f \u001f-.\u001b\n \n),'\u001b6\n\u001f&/\u001e\u001f( \u001f& \u001b*\u001b,\u001b.) \u001e\u001f \u001b\u001c-),\u001d#ĉ( \u001e\u001f \u001f-.\u001f \u001f&\u001f'\u001f(.)8 \u0005& \u001d)(-/') \u001e\u001f .ï \u001d)( &)- \u001b&#'\u001f(.)- \u001b&.\u001f,\u001b &\u001b \u001b\u001c-),\u001d#ĉ(\n\u001e\u001f& \"#\u001f,,) 'á- '\u001b,\u001d\u001b\u001e\u001b'\u001f(.\u001f +/\u001f \u001d/\u001b(\u001e) -\u001f \u001d)(-/'\u001f \u001f(.,\u001f &\u001b- \u001d)'#\u001e\u001b-\n \n8\n \n)- +/\u001f&\u001b(.\u001f- \u001e\u001f& \"#\u001f,,) \u001e\u001f&\n\u001d\u001b ï \u001f(.,\u001b( \u001b &)- ł/#\u001e)- \u001d),*),\u001b&\u001f-6 #(\u001d&/3\u001f(\u001e) &\u001b &\u001f\u001d\"\u001f '\u001b.\u001f,(\u001b6 &) \u001d/\u001b& */\u001f\u001e\u001f \u001f2\u001b\u001d\u001f,\u001c\u001b, &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f\n\"#\u001f,,) (\u001f)(\u001b.\u001b&8\n\nCuadro 3-3.\n \nCausas de deficiencia de hierro\n\nMecanismo\n \nCausa\n \nEjemplo\nCaptación\nde hierro alterada","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":62,"lines":{"from":43,"to":80}}}}],["209",{"pageContent":"Cuadro 3-3.\n \nCausas de deficiencia de hierro\n\nMecanismo\n \nCausa\n \nEjemplo\nCaptación\nde hierro alterada\n\n\u0010)\u001c,\u001f \u001e#-*)(#\u001c#&#\u001e\u001b\u001e \u001e\u001f \"#\u001f,,)\n\u0001\u001c-),\u001d#ĉ( \u001e\u001f \"#\u001f,,) \u001b&.\u001f,\u001b\u001e\u001b\n\u0004#\u001f.\u001b- \u001c\u001b$\u001b- \u001f( *,).\u001fù(\u001b \u001b(#'\u001b&\n\u0011/\u001f&\u001b(.\u001f- \u001e\u001f& \"#\u001f,,) \u001f( &\u001b \u001e#\u001f.\u001b\n\u001b(.#7\bh\n\u0004#-,/*\u001d#ĉ( \u001e\u001f &\u001b '/\u001d)-\u001b\n!\u001b-.,)#(.\u001f-.#(\u001b&\n\u0010ï,\u001e#\u001e\u001b\n \n/(\u001d#)(\u001b& \u001e\u001f #(.\u001f-.#()\n\u0005( \u001f,'\u001f\u001e\u001b\u001e \u001d\u001f&ù\u001b\u001d\u001b\n\u0005( \u001f,'\u001f\u001e\u001b\u001e \u001e\u001f \u0003,)\"(\n\u0012\u001f-\u001f\u001d\u001d#ĉ( +/#,Ě,!#\u001d\u001b\nÒ&\u001d\u001f,\u001b *ï*.#\u001d\u001b\n\nPérdidas sanguíneas\n\n\u0013\u001b(!,\u001b\u001e) \u001e\u001f .,\u001b\u001d.)\n!\u001b-.,)#(.\u001f-.#(\u001b&\n(!\u001f-.#ĉ( \u001e\u001f \u001b-*#,#(\u001b\n\u0004#0\u001f,.ù\u001d/&)- \u001d)&ĉ(#\u001d)-\n\u001b& ),'\u001b\u001d#)(\u001f- 0\u001b-\u001d/&\u001b,\u001f-\n\u001d)&ĉ(#\u001d\u001b-\n\u0013\u001b(!,\u001b\u001e) !\u001f(#.)/,#(\u001b,#)\n \n\u0003á&\u001d/&)- ,\u001f(\u001b&\u001f-\n\u001f(-.,/\u001b\u001d#)(\u001f-\n\u0013#-.\u001f'\u001b ,\u001f*,)\u001e/\u001d.),\n \n\u0010)-*\u001b,.)\n\u0005(\u001e)'\u001f.,#)-#-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":62,"lines":{"from":80,"to":122}}}}],["210",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n36\n\nDisrupción de la mucosa entérica\n\n\u0005& \u001f-*,Ě\u001f6 .\u001b(.) .,)*#\u001d\u001b& \u001d)') () .,)*#\u001d\u001b& B\u001f( \u001f,'\u001f\u001e\u001b\u001e \u001d\u001f&ù\u001b\u001d\u001bC6 */\u001f\u001e\u001f \u001b&.\u001f,\u001b, &\u001b \u001b\u001c-),\u001d#ĉ( \u001e\u001f& \"#\u001f,,)8 \u0005(\n\u001f-.\u001b \u001f( \u001f,'\u001f\u001e\u001b\u001e )\u001d/,,\u001f \u001e\u001f!\u001f(\u001f,\u001b\u001d#ĉ( \u001e\u001f& \u001f*#.\u001f&#) #(.\u001f-.#(\u001b& \u001f #(ł\u001b'\u001b\u001d#ĉ( \u001d,ĉ(#\u001d\u001b +/\u001f &&\u001f0\u001b( \u001b /(\u001b *,)\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":63,"lines":{"from":1,"to":9}}}}],["211",{"pageContent":"/(\u001e\u001b '\u001b&\u001b\u001c-),\u001d#ĉ(8 \u0001&!/()- *\u001b\u001d#\u001f(.\u001f- *,\u001f-\u001f(.\u001b( *#\u001d\u001b ) -ù(\u001e,)'\u001f \u001e\u001f \u0010&/''\u001f,7\u0016#(-)( *), \u001bĄ)-6 \u001b(.\u001f-\n\u001e\u001f \u001e#\u001b!()-.#\u001d\u001b, &\u001b \u001f( \u001f,'\u001f\u001e\u001b\u001e \u001d\u001f&ù\u001b\u001d\u001b8\n \n\u001b &\u001f\u001d\"\u001f \u001f(.\u001f,\u001b \u001e\u001f 0\u001b\u001d\u001b .#\u001f(\u001f *,).\u001fù(\u001b- +/\u001f */\u001f\u001e\u001f( #(ł\u001b'\u001b, \u001f&\n\u001f*#.\u001f&#) #(.\u001f-.#(\u001b& \u001f( &)- &\u001b\u001d.\u001b(.\u001f-6 \u001d)(\u001e/\u001d#\u001f(\u001e) \u001b /(\u001b \u001b\u001c-),\u001d#ĉ( \u001e\u001f \"#\u001f,,) \u001b&.\u001f,\u001b\u001e\u001b \u001d)( /(\u001b \"\u001f'),,\u001b!#\u001b \u001e\u001f\n\u001c\u001b$) !,\u001b\u001e) \u001b-)\u001d#\u001b\u001e\u001b8\n \n\u001b &\u001f\u001d\"\u001f \u001e\u001f 0\u001b\u001d\u001b .#\u001f(\u001f \u001c\u001b$) \u001d)(.\u001f(#\u001e) \u001f( \"#\u001f,,) Bf6k̓'!I\n \nC 3 -/ \u001b\u001c-),\u001d#ĉ( \u001f- *)\u001c,\u001f8\n\u0001\u001e#\u001d#)(\u001b&'\u001f(.\u001f6 */\u001f\u001e\u001f( )\u001d/,,#, -\u001b(!,\u001b\u001e)- \u001e#!\u001f-.#0)- \u001f( \u001f-.)- (#Ą)- \u001d\u001b/-\u001b\u001e)- *), /(\u001b *,).\u001fù(\u001b &á\u001c#& \u001b&\n\u001d\u001b&), +/\u001f &\u001f-#)(\u001b &\u001b '/\u001d)-\u001b #(.\u001f-.#(\u001b&8 \u000f.,)- .,\u001b-.),()- \u001b&.\u001f,\u001b( &\u001b \u001b\u001c-),\u001d#ĉ( \u001e\u001f& \"#\u001f,,) \u001b& *,)\u001e/\u001d#, /(\u001b\n\u001e#-,/*\u001d#ĉ( \u001e\u001f &\u001b '/\u001d)-\u001b \u001f(.ï,#\u001d\u001b6 \u001d)') \u001f( \u001f& \u001d\u001b-) \u001e\u001f &\u001b \u001f( \u001f,'\u001f\u001e\u001b\u001e #(ł\u001b'\u001b.),#\u001b #(.\u001f-.#(\u001b& B\u001f( \u001f,'\u001f\u001e\u001b\u001e\n\u001e\u001f \u0003,)\"(C6 +/\u001f */\u001f\u001e\u001f \u001d)'*,)'\u001f.\u001f, \u001b& 3\u001f3/() 3 \u001f& \u001e/)\u001e\u001f()8\n\nPérdida de intestino funcional","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":63,"lines":{"from":11,"to":26}}}}],["212",{"pageContent":"Pérdida de intestino funcional\n\n\u0003/\u001b(\u001e) -\u001f ,\u001f-\u001f\u001d\u001b( !,\u001b(\u001e\u001f- -\u001f!'\u001f(.)- \u001e\u001f& #(.\u001f-.#()6 */\u001f\u001e\u001f \"\u001b\u001c\u001f, \u001e#-,/*\u001d#ĉ( \u001e\u001f &\u001b \u001b\u001c-),\u001d#ĉ( \u001e\u001f& \"#\u001f,,)8\n \n\u001b\n\u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) *)-+/#,Ě,!#\u001d\u001b -\u001f \u001e\u001f-\u001b,,)&&\u001b &\u001f(.\u001b'\u001f(.\u001f 3 \u001b 0\u001f\u001d\u001f- *\u001b-\u001b \u001e\u001f-\u001b*\u001f,\u001d#\u001c#\u001e\u001b *), 0\u001b,#)- \u001bĄ)-8\n\nPérdidas sanguíneas\nPérdidas sanguíneas fisiológicas\n\n\u0005& -\u001b(!,\u001b\u001e) '\u001f(-.,/\u001b& \u001f- &\u001b \u001d\u001b/-\u001b 'á- \u001d)'Ě( \u001e\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) \u001f( &\u001b- '/$\u001f,\u001f- \u001f( \u001f\u001e\u001b\u001e ,\u001f*,)\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":63,"lines":{"from":26,"to":37}}}}],["213",{"pageContent":"Pérdidas sanguíneas\nPérdidas sanguíneas fisiológicas\n\n\u0005& -\u001b(!,\u001b\u001e) '\u001f(-.,/\u001b& \u001f- &\u001b \u001d\u001b/-\u001b 'á- \u001d)'Ě( \u001e\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) \u001f( &\u001b- '/$\u001f,\u001f- \u001f( \u001f\u001e\u001b\u001e ,\u001f*,)\n-\n\n\u001e/\u001d.#0\u001b8 \u0013\u001f \u001d)(-#\u001e\u001f,\u001b \u001d)') \"\u001f'),,\u001b!#\u001b '\u001f(-.,/\u001b& *,)'\u001f\u001e#) ik̓ '\n \n*), \u001d#\u001d&)6 \u001d)( /( &ù'#.\u001f -/*\u001f,#),\n(),'\u001b& \u001e\u001f nf̓ '\n \n*), *\u001f,ù)\u001e)8 \u0013\u001f \"\u001b( \u001e#-\u001fĄ\u001b\u001e) #(\u001e#\u001d\u001b\u001e),\u001f- 0#-/\u001b&\u001f- \u001e\u001f &\u001b '\u001b!(#./\u001e \u001e\u001f& -\u001b(!,\u001b\u001e)6 \u001d)')\n\u001f& (Ě'\u001f,) \u001e\u001f .)\u001b&&\u001b- \"#!#ï(#\u001d\u001b- ) .\u001b'*)(\u001f- /.#&#4\u001b\u001e)- \u001f( \u001d\u001b\u001e\u001b \u001eù\u001b \u001e\u001f& \u001d#\u001d&) '\u001f(-.,/\u001b&8 \u0005- #'*),.\u001b(.\u001f\n\u001e\u001fl·(#, -# )\u001d/,,\u001f( -\u001b(!,\u001b\u001e)- #(.\u001f,'\u001f(-.,/\u001b&\u001f- B'\u001f()'\u001f.,),,\u001b!#\u001b-C8 \u0015() \u001e\u001f &)- \u001b\u001d.),\u001f- +/\u001f \u001b/'\u001f(.\u001b( &\u001b\n\u001d\u001b(.#\u001e\u001b\u001e \u001e\u001f -\u001b(!,\u001b\u001e) &) \u001d)(-.#./3\u001f &\u001b #(-\u001f,\u001d#ĉ( \u001e\u001f \u001e#-*)-#.#0)- #(.,\u001b/.\u001f,#()- B\u0004 \u0015C6 3 \"\u001b-.\u001b \u001f& giz \u001e\u001f\n&\u001b- '/$\u001f,\u001f- \u001d)( \u0004 \u0015 \u001e\u001f-\u001b,,)&&\u001b( \u001b(\u001f'#\u001b /( \u001bĄ) \u001e\u001f-*/ï- \u001e\u001f \"\u001b\u001c\u001f,-\u001f #(-\u001f,.\u001b\u001e) \u001f& \u001e#-*)-#.#0) #(.,\u001b/.\u001f,#\n-\n\n()8\n \n\u001b- '/$\u001f,\u001f- *)-'\u001f()*á/-#\u001d\u001b- \u001d)( \u001b(\u001f'#\u001b \u001f,,)*ï(#\u001d\u001b !\u001f(\u001f,\u001b&'\u001f(.\u001f ,\u001f+/#\u001f,\u001f( &\u001b \u001cĚ-+/\u001f\u001e\u001b \u001e\u001f ).,)-\n-#.#)- \u001e\u001f -\u001b(!,\u001b\u001e)6 *,#(\u001d#*\u001b&'\u001f(.\u001f \u001f& ./\u001c) \u001e#!\u001f-.#0)8\n\nDefectos estructurales","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":63,"lines":{"from":37,"to":60}}}}],["214",{"pageContent":"\u001b- *ï,\u001e#\u001e\u001b- -\u001b(!/ù(\u001f\u001b- \u001e\u001f\u001c#\u001e\u001b- \u001b &\u001f-#)(\u001f- \u001f-.,/\u001d./,\u001b&\u001f- -)( /(\u001b \u001d\u001b/-\u001b ,\u001f\u001d/\u001f(.\u001f \u001e\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)8\n \n)-\n\u001e#0\u001f,.ù\u001d/&)- \u001e\u001f\n \n\u001f\u001d%\u001f& -)( &\u001b &\u001f-#ĉ( \u001d)(!ï(#.\u001b 'á-\n \n,\u001f\u001d/\u001f(.\u001f8 \u0005( &)- \u001b\u001e/&.)- &\u001b Ě&\u001d\u001f,\u001b *ï*.#\u001d\u001b \u001f- /(\u001b \u001d\u001b/-\u001b\n,\u001f\u001d/\u001f(.\u001f \u001e\u001f -\u001b(!,\u001b\u001e) \u001e#!\u001f-.#0)8\n \n\u001b #( \u001f\u001d\u001d#ĉ( *),\n \nHelicobacter pylori\n \n-\u001f \u001b-)\u001d#\u001b \u001d)( &\u001b \u001f( \u001f,'\u001f\u001e\u001b\u001e á\u001d#\u001e)7*ï*.#\u001d\u001b\n3 \u001b \u001f\u001d.\u001b &)- (#0\u001f&\u001f- \u001e\u001f \"#\u001f,,) 3 \u001e\u001f \u001f,,#.#(\u001b8 \u0013\u001f \"\u001b 0#-.) +/\u001f &\u001b #( \u001f\u001d\u001d#ĉ( \u001e\u001f& \u001b(.,) *),\n \nH. pylori\n \n-#,0\u001f \u001d)') -#.#)\n\u001e\u001f -\u001f\u001d/\u001f-.,) \u001e\u001f& '\u001f.\u001b& \u001b .,\u001b0ï- \u001e\u001f &)- ,\u001f\u001d\u001f*.),\u001f- \u001e\u001f '\u001f'\u001c,\u001b(\u001b \u001c\u001b\u001d.\u001f,#\u001b(\u001b +/\u001f \u001d\u001b*./,\u001b( 3 /-\u001b( \u001f& \"#\u001f,,) \u001e\u001f &\u001b\n&\u001b\u001d.) \u001f,,#(\u001b \"/'\u001b(\u001b8 \u0003)( &\u001b \u001f,,\u001b\u001e#\u001d\u001b\u001d#ĉ( \u001e\u001f&\n \nH. pylori\n \n-\u001f )\u001c-\u001f,0\u001b /(\u001b ,\u001f-*/\u001f-.\u001b \u001b\u001e\u001f\u001d/\u001b\u001e\u001b .,\u001b- &\u001b .\u001f,\u001b*#\u001b \u001d)(\n\"#\u001f,,) ),\u001b&8\n \n\u001b- \"\u001f'),,)#\u001e\u001f- -\u001b(!,\u001b(.\u001f- -)( ).,\u001b \u001d\u001b/-\u001b ,\u001f\u001d/\u001f(.\u001f \u001e\u001f -\u001b(!,\u001b\u001e) !\u001b-.,)#(.\u001f-.#(\u001b& \u001f( \u001b\u001e/&.)-8\n \n)-\n\u001e#0\u001f,.ù\u001d/&)- \u001d)&ĉ(#\u001d)- \u001d)') \u001d\u001b/-\u001b \u001e\u001f -\u001b(!,\u001b\u001e) -)( 'á- ,\u001f\u001d/\u001f(.\u001f- \u001f( \u001b\u001e/&.)- '\u001b3),\u001f-8\n\u000f.,)- \u001e\u001f \u001f\u001d.)- \u001f-.,/\u001d./,\u001b&\u001f- '\u001f()-\n \n,\u001f\u001d/\u001f(.\u001f- -)( \u001f& -ù(\u001e,)'\u001f \u001e\u001f \u000f-&\u001f,7\u0017\u001f\u001c\u001f,7\u0012\u001f(\u001e/6 \u001d\u001b,\u001b\u001d.\u001f,#4\u001b\u001e)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":63,"lines":{"from":62,"to":96}}}}],["215",{"pageContent":")-\n\u001e#0\u001f,.ù\u001d/&)- \u001d)&ĉ(#\u001d)- \u001d)') \u001d\u001b/-\u001b \u001e\u001f -\u001b(!,\u001b\u001e) -)( 'á- ,\u001f\u001d/\u001f(.\u001f- \u001f( \u001b\u001e/&.)- '\u001b3),\u001f-8\n\u000f.,)- \u001e\u001f \u001f\u001d.)- \u001f-.,/\u001d./,\u001b&\u001f- '\u001f()-\n \n,\u001f\u001d/\u001f(.\u001f- -)( \u001f& -ù(\u001e,)'\u001f \u001e\u001f \u000f-&\u001f,7\u0017\u001f\u001c\u001f,7\u0012\u001f(\u001e/6 \u001d\u001b,\u001b\u001d.\u001f,#4\u001b\u001e)\n*), '\u001b& ),'\u001b\u001d#)(\u001f- \u001b,.\u001f,#)0\u001f()-\u001b- \u001e\u001f &)- 0\u001b-)- -\u001b(!/ù(\u001f)- -/*\u001f,l·\u001d#\u001b&\u001f- 3 \u001d/3\u001b '\u001b(# \u001f-.\u001b\u001d#ĉ( \u001d\u001b,\u001e#(\u001b& \u001f- &\u001b\n\u001b(\u001f'#\u001b *), -\u001b(!,\u001b\u001e) \u001d,ĉ(#\u001d)8 \u0005-.)- *\u001b\u001d#\u001f(.\u001f- .#\u001f(\u001f( .\u001f&\u001b(!#\u001f\u001d.\u001b-#\u001b- \u001f( ),) \u001b,#(!\u001f6 \u001d\u001b0#\u001e\u001b\u001e (\u001b-\u001b& 3 &\u001f(!/\u001b8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":63,"lines":{"from":96,"to":102}}}}],["216",{"pageContent":"Sangrado uterino disfuncional\n\n\u0005& -\u001b(!,\u001b\u001e) /.\u001f,#() \u001e#- /(\u001d#)(\u001b& \u001f- &\u001b \u001d\u001b/-\u001b 'á-\n \n,\u001f\u001d/\u001f(.\u001f \u001e\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) \u001f( &\u001b- '/$\u001f,\u001f- *)-'\u001f\n-\n\n()*á/-#\u001d\u001b-8 \u0003\u001b-# -#\u001f'*,\u001f -\u001f \u001b\u001d)'*\u001bĄ\u001b \u001e\u001f \u001f(\u001e)'\u001f.,#)-#-8 \u0005& -\u001b(!,\u001b\u001e) \u001f- 0\u001b,#\u001b\u001c&\u001f6 \u001e\u001f '\u001b(\u001f,\u001b +/\u001f \u001b&!/(\u001b-\n'/$\u001f,\u001f- .#\u001f(\u001f( -\u001b(!,\u001b\u001e) #(.\u001f(-) #(.\u001f,'#.\u001f(.\u001f 3 ).,\u001b- \u001d/,-\u001b( \u001d)( -\u001b(!,\u001b\u001e) \u001e#\u001b,#)8\n\nParásitos\n\n\u001b *,#(\u001d#*\u001b& \u001d\u001b/-\u001b \u001e\u001f -\u001b(!,\u001b\u001e) !\u001b-.,)#(.\u001f-.#(\u001b& \u001f( \u001f& '/(\u001e) -)( &\u001b- #( \u001f\u001d\u001d#)(\u001f- *\u001b,\u001b-#.\u001b,#\u001b-8\n \nNecator\namericanus\n \n3\n \nAncylostoma duodenale\n \nB/(\u001d#(\u001b,#\u001b-C -)( \u001f(\u001eï'#\u001d)- 3 */\u001f\u001e\u001f( -\u001f, \u001b-#(.)'á.#\u001d)-8 \u0005& -\u001b(!,\u001b\u001e) \u001f-\n'#\u001d,)-\u001dĉ*#\u001d) 3 \u001d)(\u001e/\u001d\u001f \u001b !,\u001b(\u001e\u001f- *ï,\u001e#\u001e\u001b- -\u001b(!/ù(\u001f\u001b- \u001f( -\u001f'\u001b(\u001b- \u001b '\u001f-\u001f-8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":63,"lines":{"from":104,"to":126}}}}],["217",{"pageContent":"CAPÍTULO 3. ANEMIA POR DEFICIENCIA DE HIERRO\n\n37\n\nSituación de México frente a la anemia ferropénica\n\n\u0005(\n \nï2#\u001d)6 &\u001b \u001e#\u001f.\u001b \u001d)(.#\u001f(\u001f \u001b&,\u001f\u001e\u001f\u001e), \u001e\u001f l̓ '! \u001e\u001f \"#\u001f,,) *), g̓ fff̓%\u001d\u001b&6 *\u001f,) -/ \u001c#)\u001e#-*)(#\u001c#&#\u001e\u001b\u001e \u001f( &\u001b\n\u001e#\u001f.\u001b 0\u001b,ù\u001b \u001d)(-#\u001e\u001f,\u001b\u001c&\u001f'\u001f(.\u001f8 \u0005( !,\u001b( *\u001b,.\u001f \u001e\u001f &\u001b *)\u001c&\u001b\u001d#ĉ( ,/,\u001b& 3 -/\u001c/,\u001c\u001b(\u001b \u001e\u001f\n \nï2#\u001d) &\u001b \u001e#\u001f.\u001b \u001cá-#\u001d\u001b\n\u001f-.á \u001d)(-.#./#\u001e\u001b *), !,\u001b()- 3 0\u001f!\u001f.\u001b&\u001f-6 \u001f( \u001d/3) \u001d\u001b-) &\u001b /\u001f(.\u001f \u001e\u001f \"#\u001f,,) .#\u001f(\u001f +/\u001f -\u001f, .,\u001b(- ),'\u001b\u001e\u001b *\u001b,\u001b -/\n\u001b\u001c-),\u001d#ĉ(6 3 \u001f& \"#\u001f,,) \"\u001f'ù(#\u001d) \u001f-.á *,á\u001d.#\u001d\u001b'\u001f(.\u001f \u001b/-\u001f(.\u001f \u001e\u001f &\u001b \u001e#\u001f.\u001b8 \u0005-.)- \u001b\u001d.),\u001f- \u001b0),\u001f\u001d\u001f( \u001f& \u001b/'\u001f(.) \u001f(\n&\u001b *,\u001f0\u001b&\u001f(\u001d#\u001b \u001e\u001f &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)8 \u0004\u001f &\u001b \u0003,/4 \u0007ĉ(!),\u001b 3 \u001d)&-8 \u001f(\u001d)(.,\u001b,)( \u001f( /(\u001b *)\u001c&\u001b\u001d#ĉ( \u001e\u001f h̓ jjm\n\u001b\u001e)&\u001f-\u001d\u001f(.\u001f- \u001f( &\u001b \u001f(\u001d/\u001f-.\u001b *,)\u001c\u001b\u001c#&ù-.#\u001d\u001b \u0005\u000e\u0013\u0001\u000e\u0015\u0014 hffl +/\u001f &\u001b '\u001f\u001e#\u001b(\u001b \u001e\u001f& \u001d)(-/') \u001e\u001f \"#\u001f,,) \"\u001f') \u001f,\u001b\n\u001e\u001f f6hl̓'!I\u001eù\u001b 3 &\u001b \u001e\u001f& \"#\u001f,,) () \"\u001f') \u001e\u001f gf6nn̓'!I\u001eù\u001b6 0\u001b&),\u001f- +/\u001f \u001f-.\u001b\u001c\u001b( *), \u001f(\u001d#'\u001b \u001e\u001f &\u001b #(!\u001f-.\u001b ,\u001f\u001d)\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":64,"lines":{"from":1,"to":18}}}}],["218",{"pageContent":"'\u001f(\u001e\u001b\u001e\u001b6 \u001b/(+/\u001f -\u001f \u001f(\u001d)(.,ĉ +/\u001f &\u001b #(!\u001f-.\u001b \u001e\u001f +/\u001f&\u001b(.\u001f- \u001d)') &)- l·.\u001b.)- \u001f,\u001b \u001e\u001f g̓ hjf̓'!I\u001eù\u001b8 \u0013\u001f \u001f(\u001d)(.,ĉ\n/(\u001b *,\u001f0\u001b&\u001f(\u001d#\u001b \u001e\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) B\u001f-.#'\u001b\u001e\u001b *), /(\u001b \u001d)(\u001d\u001f(.,\u001b\u001d#ĉ( \u001e\u001f \u001f,,#.#(\u001b '\u001f(), \u001e\u001f̓gh̓(!I'\n \nC\n\u001e\u001f& gn6h 3 m6oz \u001f( '/$\u001f,\u001f- 3 \")'\u001c,\u001f-6 ,\u001f-*\u001f\u001d.#0\u001b'\u001f(.\u001f8\n \n)- \u001e\u001b.)- 'á- ,\u001f\u001d#\u001f(.\u001f- \u001e\u001f \u0005\u000e\u0013\u0001\u000e\u0015\u0014 hfgh '/\u001f-\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":64,"lines":{"from":20,"to":27}}}}],["219",{"pageContent":".,\u001b( /(\u001b \u001e#-'#(/\u001d#ĉ( \u001f( &\u001b *,\u001f0\u001b&\u001f(\u001d#\u001b \u001e\u001f &\u001b \u001b(\u001f'#\u001b \u001f( &\u001b *)\u001c&\u001b\u001d#ĉ( #( \u001b(.#&6 ,\u001f&\u001b\u001d#)(\u001b\u001e) '/3 *,)\u001c\u001b\u001c&\u001f'\u001f(.\u001f\n\u001d)( &\u001b '\u001f$),ù\u001b \u001f( &)- \"á\u001c#.)- \u001b&#'\u001f(.\u001b,#)-8 \u0005( &)- \u001b\u001e)&\u001f-\u001d\u001f(.\u001f- -\u001f -#!/\u001f )\u001c-\u001f,0\u001b(\u001e) /(\u001b '\u001b3), *,\u001f0\u001b&\u001f(\u001d#\u001b\n\u001e\u001f \u001b(\u001f'#\u001b \u001f( &\u001b- '/$\u001f,\u001f- \u001e\u001f gh \u001bĄ)- Bm6mz \u001d)(.,\u001b i6lzC6 *)-#\u001c&\u001f'\u001f(.\u001f \u001f2*&#\u001d\u001b\u001e) *), \u001f& #(#\u001d#) \u001e\u001f &)- \u001d#\u001d&)-\n'\u001f(-.,/\u001b&\u001f- +/\u001f \u001b0),\u001f\u001d\u001f( &\u001b \u001e\u001f*&\u001f\u001d#ĉ( \u001e\u001f &)- \u001e\u001f*ĉ-#.)- \u001e\u001f \"#\u001f,,)8 \u0005( &)- \u001b\u001e/&.)-6 &\u001b *,\u001f0\u001b&\u001f(\u001d#\u001b \u001e\u001f \u001b(\u001f'#\u001b\n-#!/\u001f -#\u001f(\u001e) 'á- \u001b&.\u001b \u001f( &\u001b- '/$\u001f,\u001f- \u001f'\u001c\u001b,\u001b4\u001b\u001e\u001b- Bgm6oz \u001d)(.,\u001b gg6lzC6 &) \u001d/\u001b& #(\u001e#\u001d\u001b +/\u001f -\u001f \u001e\u001f\u001c\u001f '\u001f$),\u001b, \u001f&\n\u001d)(.,)& \u001e\u001f& \u001f'\u001c\u001b,\u001b4) !\u001b,\u001b(.#4\u001b(\u001e) /(\u001b \u001b\u001e\u001f\u001d/\u001b\u001e\u001b -/*&\u001f'\u001f(.\u001b\u001d#ĉ( \u001e\u001f \"#\u001f,,) 3 á\u001d#\u001e) ĉ&#\u001d)8 \u0005( &\u001b *)\u001c&\u001b\u001d#ĉ(\n'\u001b3), \u001e\u001f lf \u001bĄ)-6 &\u001b *,\u001f0\u001b&\u001f(\u001d#\u001b \u001e\u001f \u001b(\u001f'#\u001b \u001f- '\u001b3), \u001f( &)- \")'\u001c,\u001f- Bgm6nz \u001d)(.,\u001b gk6jzC8\n\u0005(\n \nï2#\u001d)6 &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b 3 &\u001b \u001b(\u001f'#\u001b *), \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) \u001f( \u001f& \u001b\u001e/&.) -\u001f *,\u001f-\u001f(.\u001b( 'á-\n \n,\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":64,"lines":{"from":29,"to":41}}}}],["220",{"pageContent":"\u001d/\u001f(.\u001f'\u001f(.\u001f *), \"\u001f'),,\u001b!#\u001b \u001d,ĉ(#\u001d\u001b6 3 \u001f( &)- 0\u001b,)(\u001f- \u001b\u001e/&.)- \u001f- !\u001f(\u001f,\u001b&'\u001f(.\u001f -\u001f\u001d/(\u001e\u001b,#\u001b \u001b 0á,#\u001d\u001f-\n\u001f-) á!#\u001d\u001b- 3 (\u001f)*&\u001b-#\u001b- \u001e\u001f ./\u001c) \u001e#!\u001f-.#0)8 \u0005( &\u001b- '/$\u001f,\u001f- &\u001b \u001d\u001b/-\u001b 'á-\n \n,\u001f\u001d/\u001f(.\u001f \u001f- \u001f& -\u001b(!,\u001b\u001e) !#(\u001f\n-\n\n\u001d)&ĉ!#\u001d)8 \u0005(.,\u001f &)- '\u001f\u001e#\u001d\u001b'\u001f(.)- +/\u001f 'á- -\u001f \u001b-)\u001d#\u001b( \u001d)( \"\u001f'),,\u001b!#\u001b !\u001b-.,)#(.\u001f-.#(\u001b& -\u001f .#\u001f(\u001f( \u001b &)-\n\u0001 \u000e\u00056 &\u001b \u001b-*#,#(\u001b6 &)- \u001d/'\u001b,ù(#\u001d)- 3 &)- !&/\u001d)\u001d),.#\u001d)#\u001e\u001f-8 \u0005( \u001d/\u001b(.) \u001b &\u001b- (\u001f)*&\u001b-#\u001b- \u001e\u001f& ./\u001c) \u001e#!\u001f-.#0)6\n&\u001b \u001b(\u001f'#\u001b \u001f,,)*ï(#\u001d\u001b */\u001f\u001e\u001f -\u001f, \u001f& *,#'\u001f, -#!() \u001e\u001f -/ *,\u001f-\u001f(\u001d#\u001b8\n\nEmbarazo, recién nacido y lactancia\n\n\u0004/,\u001b(.\u001f \u001f& \u001f'\u001c\u001b,\u001b4) -\u001f *#\u001f,\u001e\u001f( \u001d\u001b-# g̓ hff̓'! \u001e\u001f \"#\u001f,,)6 \u001d)'*,\u001f(\u001e#\u001f(\u001e) hmf̓'! \u001f( \u001f& \u001f.)6 of̓'! \u001f( &\u001b *&\u001b\u001d\u001f(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":64,"lines":{"from":43,"to":56}}}}],["221",{"pageContent":"Embarazo, recién nacido y lactancia\n\n\u0004/,\u001b(.\u001f \u001f& \u001f'\u001c\u001b,\u001b4) -\u001f *#\u001f,\u001e\u001f( \u001d\u001b-# g̓ hff̓'! \u001e\u001f \"#\u001f,,)6 \u001d)'*,\u001f(\u001e#\u001f(\u001e) hmf̓'! \u001f( \u001f& \u001f.)6 of̓'! \u001f( &\u001b *&\u001b\u001d\u001f(\n-\n\n.\u001b6 jkf̓'! \u001f( &\u001b \u001f2*\u001b(-#ĉ( \u001f,#.,)\u001d#.\u001b,#\u001b '\u001b.\u001f,(\u001b 3 hif̓'! \u001f( &\u001b- *ï,\u001e#\u001e\u001b- \u001c\u001b-\u001b&\u001f-6 *), &) +/\u001f &)- ,\u001f+/\u001f,#'#\u001f(.)-\n-\u001f \u001f&\u001f0\u001b( ().),#\u001b'\u001f(.\u001f6 \u001e\u001f$\u001b(\u001e) \u001b &\u001b \u001f'\u001c\u001b,\u001b4\u001b\u001e\u001b -/-\u001d\u001f*.#\u001c&\u001f \u001b \u001e\u001f-\u001b,,)&&\u001b, \u001b(\u001f'#\u001b\n \n\u001f,,)*ï(#\u001d\u001b -# () ,\u001f\u001d#\u001c\u001f\n-/*&\u001f'\u001f(.\u001b\u001d#ĉ(8 \u0004/,\u001b(.\u001f &\u001b &\u001b\u001d.\u001b(\u001d#\u001b6 &\u001b '/$\u001f, *#\u001f,\u001e\u001f \u001e\u001f f6k \u001b g̓ '!I\u001eù\u001b \u001e\u001f \"#\u001f,,)8 \u0003)( &\u001b *ï,\u001e#\u001e\u001b -\u001b(!/ù(\u001f\u001b\n\u001b-)\u001d#\u001b\u001e\u001b \u001b& *\u001b,.) -\u001f ,\u001f\u001e/\u001d\u001f( \u001bĚ( 'á- &\u001b- ,\u001f-\u001f,0\u001b-6\n \n\u001b0),\u001f\u001d#\u001f(\u001e) &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)8 \u0003)( &\u001b &\u001b\u001d.\u001b(\u001d#\u001b -\u001f\n-\u001f\u001d,\u001f.\u001b \"#\u001f,,) \u001f( &\u001b &\u001f\u001d\"\u001f '\u001b.\u001f,(\u001b6 *), &) +/\u001f ,\u001f-/&.\u001b '/3 *,)\u001c\u001b\u001c&\u001f +/\u001f -# /(\u001b '/$\u001f, +/\u001f \u001f-.á &\u001b\u001d.\u001b(\u001e) () ,\u001f\u001d#\u001c\u001f\n-/*&\u001f'\u001f(.\u001b\u001d#ĉ( \u001d)( \"#\u001f,,) \u001e\u001f-\u001b,,)&&\u001b,á /(\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \u001f-.\u001f '\u001f.\u001b&8\n \n\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) \u001e/,\u001b(.\u001f \u001f& \u001f'\u001c\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":64,"lines":{"from":56,"to":73}}}}],["222",{"pageContent":",\u001b4) \u001f- /( \u001b\u001d.), \u001e\u001f ,#\u001f-!) *\u001b,\u001b *\u001b,.) *,\u001f'\u001b./,) 3 \u001c\u001b$) *\u001f-) \u001b& (\u001b\u001d#'#\u001f(.)8\n \n)- ,\u001f+/\u001f,#'#\u001f(.)- l·-#)&ĉ!#\u001d)- \u001f( &\u001b\n-\u001f!/(\u001e\u001b '#.\u001b\u001e \u001e\u001f &\u001b !\u001f-.\u001b\u001d#ĉ( () */\u001f\u001e\u001f( -\u001f, \u001d)'*&\u001f.\u001b'\u001f(.\u001f \u001d/\u001c#\u001f,.)- \u001d)( \u001f& \"#\u001f,,) \u001e\u001f &\u001b \u001e#\u001f.\u001b6 \u001b '\u001f()- +/\u001f &\u001b-\n,\u001f-\u001f,0\u001b- -\u001f\u001b( \u001e\u001f \u001b&,\u001f\u001e\u001f\u001e), \u001e\u001f kff̓'!8 \u0004\u001f \u001b\"ù &\u001b #'*),.\u001b(\u001d#\u001b \u001e\u001f -/*&\u001f'\u001f(.\u001b, \u001d)( \"#\u001f,,) \u001b &\u001b- \u001f'\u001c\u001b,\u001b4\u001b\u001e\u001b-6 *\u001b,\u001b\n,\u001f\u001e/\u001d#, &\u001b *,\u001f0\u001b&\u001f(\u001d#\u001b \u001e\u001f -/ \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001f( ,\u001f\u001d#ï( (\u001b\u001d#\u001e)-8 \u0005( &)- &\u001b\u001d.\u001b(.\u001f-6 \u001f& \"#\u001f,,) \u001d),*),\u001b& .).\u001b& \u001b& (\u001b\u001d#'#\u001f(.)\n\u001e\u001f*\u001f(\u001e\u001f \u001e\u001f& *\u001f-) \u001b& (\u001b\u001d\u001f, 3 \u001e\u001f &\u001b \u001d)(\u001d\u001f(.,\u001b\u001d#ĉ( \u001e\u001f &\u001b \"\u001f')!&)\u001c#(\u001b8\n \n)- (#Ą)- (\u001b\u001d#\u001e)- \u001b(.\u001f- \u001e\u001f .ï,'#() 3 &)- +/\u001f\n\u001f2*\u001f,#'\u001f(.\u001b( -\u001b(!,\u001b\u001e) *\u001f,#(\u001b.\u001b& -)( '/3 -/-\u001d\u001f*.#\u001c&\u001f- \u001b \u001e\u001f-\u001b,,)&&\u001b, \u001b(\u001f'#\u001b \u001f,,)*ï(#\u001d\u001b \u001e\u001f ),'\u001b .\u001f'*,\u001b(\u001b8\n\nMANIFESTACIONES CLÍNICAS\n\nDeficiencia de hierro durante la niñez\n\n\u001b \u001b(\u001f'#\u001b \u001f,,)*ï(#\u001d\u001b \u001f( (\u001f)(\u001b.)- \u001f- '/3 ,\u001b,\u001b6 3\u001b +/\u001f &\u001b *&\u001b\u001d\u001f(.\u001b &\u001f *,)*),\u001d#)(\u001b \u001b& \u001f.) \u001f& \"#\u001f,,) (\u001f\u001d\u001f-\u001b,#)\n*\u001b,\u001b /(\u001b \u001b\u001e\u001f\u001d/\u001b\u001e\u001b \"\u001f'\u001b.)*)3\u001f-#-8 \u00052\u001d\u001f*.) \u001f( &)- (\u001f)(\u001b.)- (\u001b\u001d#\u001e)- \u001e\u001f '\u001b\u001e,\u001f- \u001d)( \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) '\u001b,\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":64,"lines":{"from":75,"to":92}}}}],["223",{"pageContent":"\u001d\u001b\u001e\u001b6 &\u001b *&\u001b\u001d\u001f(.\u001b \u001b*),.\u001b &\u001b \u001d\u001b(.#\u001e\u001b\u001e (\u001f\u001d\u001f-\u001b,#\u001b *\u001b,\u001b '\u001b(.\u001f(\u001f, &\u001b \"\u001f')!&)\u001c#(\u001b \u001f( 0\u001b&),\u001f- (),'\u001b&\u001f-8 \u0003/\u001b(\u001e)\n\"\u001b3 \u001e\u001f*ĉ-#.)- \u001c\u001b$)- ) \u001b/-\u001f(.\u001f- \u001e\u001f \"#\u001f,,)6 () -\u001f )\u001c-\u001f,0\u001b \u001f& \u001b/'\u001f(.) \u001f-*\u001f,\u001b\u001e) \u001e\u001f &\u001b \"\u001f')!&)\u001c#(\u001b \u001e\u001f-*/ï- \u001e\u001f&\n(\u001b\u001d#'#\u001f(.)8 \u0005& *,#'\u001f, -#!() \u001e\u001f \u001e\u001f*ĉ-#.)- \u001e\u001f \"#\u001f,,) \u001b/-\u001f(.\u001f- &) \u001d)(-.#./3\u001f /(\u001b \u001d\u001bù\u001e\u001b '\u001b3), \u001e\u001f &\u001b \u001f-*\u001f,\u001b\u001e\u001b\n\u001f( &\u001b \"\u001f')!&)\u001c#(\u001b \u001e/,\u001b(.\u001f &\u001b- *,#'\u001f,\u001b- l \u001b n -\u001f'\u001b(\u001b- \u001e\u001f 0#\u001e\u001b8 \u0005( \u001b&!/()- (#Ą)- \u001d/3)- \u001e\u001f*ĉ-#.)- () \u001f-.á(\n.\u001b( \u001c\u001b$)-6 &\u001b \u001b(\u001f'#\u001b */\u001f\u001e\u001f '\u001b(# \u001f-.\u001b,-\u001f \"\u001b-.\u001b &\u001b (#Ą\u001f4 .\u001f'*,\u001b(\u001b8 \u000f.,)- '\u001b(#l·\u001f-.\u001b( &\u001b \u001b(\u001f'#\u001b \"\u001b-.\u001b +/\u001f\n)\u001d/,,\u001f &\u001b \u001b-\u001f \u001b\u001d\u001f&\u001f,\u001b\u001e\u001b \u001e\u001f& \u001d,\u001f\u001d#'#\u001f(.) B^\u001f-.#,ĉ(_C8 \u0005( &\u001b- \u001b\u001e)&\u001f-\u001d\u001f(.\u001f-6 \u001f-.\u001f \u001d\u001b'\u001c#) \u001e\u001f& \u001d,\u001f\u001d#'#\u001f(.)6 $/(.)\n\u001d)( \u001f& #(#\u001d#) \u001e\u001f &\u001b- '\u001f(-.,/\u001b\u001d#)(\u001f-6 \u001b0),\u001f\u001d\u001f &\u001b \u001b*\u001b,#\u001d#ĉ( \u001e\u001f &\u001b \u001b(\u001f'#\u001b \u001f,,)*ï(#\u001d\u001b8\n \n)- (#Ą)- \u001d)( \u001e\u001fl·\u001d#\u001f(\u001d#\u001b\n'\u001b,\u001d\u001b\u001e\u001b -\u001f +/\u001f$\u001b( \u001e\u001f\n \n\u001b.#!\u001b \u001d)( *\u001f+/\u001fĄ)- \u001f- /\u001f,4)-8\n \n\u001b- '\u001b(# \u001f-.\u001b\u001d#)(\u001f- !,\u001b0\u001f- \u001e\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)6\n\u001d)') \u001d)#&)(#+/#\u001b ) !&)-#.#-6 () -)( ,\u001f\u001d/\u001f(.\u001f- *\u001f,) */\u001f\u001e\u001f( )\u001d/,,#, \u001f( \u001d\u001b-)- \u001e\u001f \u001f,,)*\u001f(#\u001b \u001e\u001f &\u001b,!\u001b \u001e/,\u001b\u001d#ĉ(8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":64,"lines":{"from":94,"to":108}}}}],["224",{"pageContent":"Durante el embarazo se pier-\nden casi 1 200 mg de hierro,\ncomprendiendo\n \n270\n \nmg\n \nen\nel feto, 90 mg en la placenta,\n450 mg en la expansión eritro-\ncitaria materna y 230 mg en\nlas pérdidas basales, por lo que\nlos requerimientos se elevan no\n-\ntoriamente, dejando a la emba-\nrazada susceptible a desarrollar\nanemia ferropénica si no recibe\nsuplementación.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":64,"lines":{"from":110,"to":128}}}}],["225",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n38\n\n\u0004\u001f(.,) \u001e\u001f &)- \u001f \u001f\u001d.)- \u001d)!(#.#0)- \u001e\u001f &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) -\u001f #(\u001d&/3\u001f /(\u001b \u001e#-'#(/\u001d#ĉ( \u001f( &\u001b \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e \u001e\u001f\n\u001b.\u001f(\u001d#ĉ( 3 \u001d)(\u001d\u001f(.,\u001b\u001d#ĉ(6 \u001d)( \u001f& \u001d)(-\u001f\u001d/\u001f(.\u001f \u001c\u001b$) ,\u001f(\u001e#'#\u001f(.) \u001f-\u001d)&\u001b, \u001d)') \u001f \u001f\u001d.)- \u001f2.,\u001b\"\u001f'\u001b.)*)3ï.#\u001d)-\n\u001e\u001f &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \u001f-.\u001f '\u001f.\u001b&6 *), &) +/\u001f ,\u001f-/&.\u001b \u001d&\u001b,) +/\u001f &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) */\u001f\u001e\u001f \u001b \u001f\u001d.\u001b, \u001f& \u001e\u001f-\u001b,,)&&)\nù-#\u001d) B\u001d,\u001f\u001d#'#\u001f(.)C \u001f #(.\u001f&\u001f\u001d./\u001b& \u001e\u001f &)- (#Ą)-8\n\nDeficiencia de hierro en adultos\n\n)- \u001b\u001e/&.)- .#\u001f(\u001e\u001f( \u001b \u001d)(-/&.\u001b, 'á- ,á*#\u001e\u001b'\u001f(.\u001f +/\u001f &)- (#Ą)- \u001d/\u001b(\u001e) *\u001b\u001e\u001f\u001d\u001f( \u001e\u001f \u001b(\u001f'#\u001b \u001f,,)*ï(#\u001d\u001b8 \u0005(.,\u001f\n&)- -ù(.)'\u001b- 'á- ,\u001f\u001d/\u001f(.\u001f- -\u001f \u001d/\u001f(.\u001b( \u001e#-(\u001f\u001b6 \u001b.#!\u001b 3 &\u001f.\u001b,!#\u001b8 \u0005-.)- -ù(.)'\u001b- () -)( \u001f-*\u001f\u001dùl·\u001d)- \u001e\u001f &\u001b \u001e\u001fl·\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":65,"lines":{"from":1,"to":14}}}}],["226",{"pageContent":"\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) 3 */\u001f\u001e\u001f( 0\u001f,-\u001f \u001f( ).,)- \u001f-.\u001b\u001e)- \u001d\u001b,\u001f(\u001d#\u001b&\u001f-8 \u0003)') &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) \u001f( \u001b\u001e/&.)- -\u001f \u001b-)\u001d#\u001b\n\u001d\u001b-# #(0\u001b,#\u001b\u001c&\u001f'\u001f(.\u001f \u001b *ï,\u001e#\u001e\u001b- -\u001b(!/ù(\u001f\u001b-6 -\u001f \u001e\u001f\u001c\u001f #(\u001e\u001b!\u001b, \u001b\u001d\u001f,\u001d\u001b \u001e\u001f &\u001b *,\u001f-\u001f(\u001d#\u001b \u001e\u001f \u001f0\u001b\u001d/\u001b\u001d#)(\u001f- '\u001f&ï(#\u001d\u001b-\n+/\u001f ),#\u001f(.\u001f( \"\u001b\u001d#\u001b /( -\u001b(!,\u001b\u001e) \u001e#!\u001f-.#0) \u001b&.)8 \u0013\u001f \u001e\u001f\u001c\u001f( \u001c/-\u001d\u001b, -ù(.)'\u001b- \u001b-)\u001d#\u001b\u001e)- \u001d)( \u001f( \u001f,'\u001f\u001e\u001b\u001e á\u001d#\u001e)7\n*ï*.#\u001d\u001b6 \u001d)') \u001e)&), \u001f*#!á-.,#\u001d)6 *#,)-#- 3 -\u001b\u001d#\u001f\u001e\u001b\u001e *)-*,\u001b(\u001e#\u001b&8 \u0001\u001e#\u001d#)(\u001b&'\u001f(.\u001f6 &)- *\u001b\u001d#\u001f(.\u001f- \u001d)( \"#-.),#\u001b \u001e\u001f\n\u001e#\u001b,,\u001f\u001b \u001d,ĉ(#\u001d\u001b 3 \u001e)&), \u001b\u001c\u001e)'#(\u001b& */\u001f\u001e\u001f( .\u001f(\u001f, \u001d)') \u001d\u001b/-\u001b \u001e\u001f -/ \u001f,,)*\u001f(#\u001b &\u001b \u001f( \u001f,'\u001f\u001e\u001b\u001e #(ł\u001b'\u001b.),#\u001b \u001d,ĉ(#\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":65,"lines":{"from":16,"to":21}}}}],["227",{"pageContent":"\u001d\u001b #(.\u001f-.#(\u001b& B\u001f( \u001f,'\u001f\u001e\u001b\u001e \u001e\u001f \u0003,)\"(C6 +/\u001f \u001f( )\u001d\u001b-#)(\u001f- -\u001f \u001b-)\u001d#\u001b \u001b -ù(.)'\u001b- -#-.ï'#\u001d)- B*ï,\u001e#\u001e\u001b \u001e\u001f *\u001f-)6 l·\u001f\u001c,\u001fC8\n\u001b ,\u001f\u001d.),,\u001b!#\u001b -/!#\u001f,\u001f /( -\u001b(!,\u001b\u001e) \u001e\u001f& ./\u001c) \u001e#!\u001f-.#0) \u001c\u001b$)6 3 &\u001b- \"\u001f'),,)#\u001e\u001f- */\u001f\u001e\u001f( -\u001f, &\u001b \u001f.#)&)!ù\u001b\n-/\u001c3\u001b\u001d\u001f(.\u001f6 \u001b/(+/\u001f -#\u001f'*,\u001f \u001f- (\u001f\u001d\u001f-\u001b,#) \u001f-./\u001e#\u001b, \u001b )(\u001e) \u001b \u001f-.)- *\u001b\u001d#\u001f(.\u001f- *\u001b,\u001b \u001e\u001f-\u001d\u001b,.\u001b, &\u001b *,\u001f-\u001f(\u001d#\u001b \u001e\u001f /(\u001b\n'\u001b&#!(#\u001e\u001b\u001e \u001d)&),,\u001f\u001d.\u001b&8 \u0001&!/()- *\u001b\u001d#\u001f(.\u001f- *,\u001f-\u001f(.\u001b( \u001e)&), \u001f( &\u001b &\u001f(!/\u001b 3 \u001f( &\u001b \u001c)\u001d\u001b -\u001f\u001d/(\u001e\u001b,#) \u001b !&)-#.#- 3\n+/\u001f#&#.#- \u001b(!/&\u001b, *), \u001f,,)*\u001f(#\u001b8\n \n\u001b \u001d)#&)(#+/#\u001b -/!#\u001f,\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)6 */\u001f- \u001f& &\u001f\u001d\") /(!/\u001f\u001b& ,\u001f+/#\u001f,\u001f\n\"#\u001f,,) *\u001b,\u001b !\u001f(\u001f,\u001b, +/\u001f,\u001b.#(\u001b: *), &) .\u001b(.)6 &)- *\u001b\u001d#\u001f(.\u001f- \u001e\u001fl·\u001d#\u001f(.\u001f- \u001e\u001f \"#\u001f,,) */\u001f\u001e\u001f( .\u001f(\u001f, /(\u001b \u001f-.,/\u001d./,\u001b\n/(!/\u001f\u001b& \u001eï\u001c#& +/\u001f -\u001f .),(\u001b \u001dĉ(\u001d\u001b0\u001b .,\u001b- &\u001b *,\u001f-#ĉ( \u001e/,\u001b(.\u001f &\u001b- \u001b\u001d.#0#\u001e\u001b\u001e\u001f- \u001e\u001f &\u001b 0#\u001e\u001b \u001e#\u001b,#\u001b8 \u0003)') \"\u001b3 \u001c&)+/\u001f)\n\u001e\u001f &\u001b\n \n),'\u001b\u001d#ĉ( \u001e\u001f +/\u001f,\u001b.#(\u001b \u001f( &)-\n \n)&ù\u001d/&)- *#&)-)-6 \u001e#\u001d\")- *\u001b\u001d#\u001f(.\u001f- .\u001f(\u001e,á( \u001d\u001b\u001c\u001f&&)\n \n,á!#&6 +/\u001f\u001c,\u001b\u001e#4)8\n\u000f\u001d/,,\u001f \u001b\u001e\u001f'á- /(\u001b \u001e#-'#(/\u001d#ĉ( \u001e\u001f &\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f \u001d\u001b\u001c\u001f&&)8\n \n\u001b- \u001f-\u001d&\u001f,ĉ.#\u001d\u001b- \u001b4/&\u001f- -\u001f \u001b-)\u001d#\u001b( \u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":65,"lines":{"from":23,"to":41}}}}],["228",{"pageContent":")&ù\u001d/&)- *#&)-)-6 \u001e#\u001d\")- *\u001b\u001d#\u001f(.\u001f- .\u001f(\u001e,á( \u001d\u001b\u001c\u001f&&)\n \n,á!#&6 +/\u001f\u001c,\u001b\u001e#4)8\n\u000f\u001d/,,\u001f \u001b\u001e\u001f'á- /(\u001b \u001e#-'#(/\u001d#ĉ( \u001e\u001f &\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f \u001d\u001b\u001c\u001f&&)8\n \n\u001b- \u001f-\u001d&\u001f,ĉ.#\u001d\u001b- \u001b4/&\u001f- -\u001f \u001b-)\u001d#\u001b( \u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b-\n\u001e\u001f \"#\u001f,,) !,\u001b0\u001f- 3 )\u001d/,,\u001f( *), \u001b\u001e\u001f&!\u001b4\u001b'#\u001f(.) \u001e\u001f& \u001f*#.\u001f&#)6 &) \u001d/\u001b& ,\u001f-\u001b&.\u001b &\u001b \u001d)&),\u001b\u001d#ĉ( \u001b4/&\u001b\u001e\u001b \u001e\u001f &\u001b -/*\u001f,\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":65,"lines":{"from":41,"to":48}}}}],["229",{"pageContent":"l·\u001d#\u001f -/\u001c\u001f*#.\u001f&#\u001b& \u001e\u001f &\u001b \u001f-\u001d&\u001f,\u001b: \u001b\u001e\u001f'á-6 \u001f& \u001c\u001b$) \u001d)(.\u001f(#\u001e) \u001e\u001f )2ù!\u001f() \u001b-)\u001d#\u001b\u001e) \u001b &\u001b \u001b(\u001f'#\u001b '\u001b!(#l·\u001d\u001b \u001f& \u001d)&),\n\u001b4/& \u001e\u001f \u001f-.\u001b-8 \u0001&!/()- *\u001b\u001d#\u001f(.\u001f- */\u001f\u001e\u001f( +/\u001f$\u001b,-\u001f \u001e\u001f \u001e#- \u001b!#\u001b \u001b-)\u001d#\u001b\u001e\u001b \u001b &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b !,\u001b0\u001f \u001e\u001f \"#\u001f,,)6 '#-'\u001b\n+/\u001f */\u001f\u001e\u001f \u001e\u001f\u001c\u001f,-\u001f \u001b& -ù(\u001e,)'\u001f \u001e\u001f \u0010&/''\u001f,7\u0016#(-)(6 +/\u001f -\u001f 0#(\u001d/&\u001b \u001b& \u001e\u001f-\u001b,,)&&) \u001e\u001f \u001b(#&&)- *)-\u001d,#\u001d)#\u001e\u001f- +/\u001f\n\u001d)(\u001e#\u001d#)(\u001b( /(\u001b \u001d)(-.,#\u001d\u001d#ĉ( \u001f-) á!#\u001d\u001b8\n \n\u001b *#\u001d\u001b )\u001d/,,\u001f \u001e\u001f ),'\u001b 0\u001b,#\u001b\u001c&\u001f \u001f( &)- *\u001b\u001d#\u001f(.\u001f- \u001d)(\n \n\u001f,,)*\u001f(#\u001b8\n\u0007\u001f(\u001f,\u001b&'\u001f(.\u001f -\u001f \u001d\u001b,\u001b\u001d.\u001f,#4\u001b *), \u001f& \u001d)(-/') \u001e\u001f -/-.\u001b(\u001d#\u001b- \u001d)') \u001b&'#\u001eĉ(6 \"#\u001f&) B*\u001b!) \u001b!#\u001bC 3 .#\u001f,,\u001b8\n\nFrotis de sangre periférica\n\n\u0005&\n \n,).#- \u001e\u001f -\u001b(!,\u001f *\u001f,# ï,#\u001d\u001b \u001f- /( #(-.,/'\u001f(.) 0\u001b&#)-) \u001f( &\u001b \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( \u001e\u001f &)- \u001f-.\u001b\u001e)- \u001b-)\u001d#\u001b\u001e)- \u001b\n\u001e\u001fl·\u001d#\u001f(\u001d#\u001b- (/.,#\u001d#)(\u001b&\u001f- 3 *\u001f,'#.\u001f ),#\u001f(.\u001b, ) -/!\u001f,#, /(\u001b \u001f.#)&)!ù\u001b \u001f( \u001f-*\u001f\u001d#\u001b&6 \u001f #(\u001d&/-) */\u001f\u001e\u001f -/!\u001f,#,\n\u001f-.\u001b\u001e)- \u001e\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b- '#2.\u001b- B\u001eïl·\u001d#. \u001e\u001f )&\u001b.)- ) 0#.\u001b'#(\u001b \u0002gh $/(.) \u001d)( \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)C8\n \n\u001b \u001e\u001fl·\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":65,"lines":{"from":50,"to":69}}}}],["230",{"pageContent":"\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) *,)\u001e/\u001d\u001f \u001f,#.,)\u001d#.)- '#\u001d,)\u001dù.#\u001d)- \u001f \"#*)\u001d,ĉ'#\u001d)-6 \u001d)( &\u001b *\u001b&#\u001e\u001f4 \u001d\u001f(.,\u001b& \u001b\u001c\u001b,\u001d\u001b(\u001e) \"\u001b-.\u001b \u001f&\nofz \u001e\u001f& \u001e#á'\u001f.,) \u001e\u001f &\u001b \u001dï&/&\u001b8 \u0005& \u001b(\u001d\") \u001e\u001f \u001e#-.,#\u001c/\u001d#ĉ( \u001f,#.,)\u001d#.\u001b,#\u001b B\u0012\u0004\u00176 \u001e\u001f\n \nred cell distribution width\nC\n\u001f-.á \u001b/'\u001f(.\u001b\u001e)8 \u0005( \u001f-.\u001b\u001e)- \u001b0\u001b(4\u001b\u001e)- \u001e\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) -\u001f 0\u001f( \u001f,#.,)\u001d#.)- \u001e\u001f ),'\u001b- \u001c#4\u001b,,\u001b-6 #(\n-\n\n\u001d&/3\u001f(\u001e) \u001dï&/&\u001b- \u001f( ),'\u001b \u001e\u001f &á*#4 ) \u001e\u001f \u001d#!\u001b,,)8\n \n\u001b \u001f,,)*\u001f(#\u001b \u001f- /(\u001b \u001d\u001b/-\u001b \u001e\u001f .,)'\u001c)\u001d#.)-#- 3 \u001f& )\u001c-\u001f,0\u001b,\n/( \u001b/'\u001f(.) \u001e\u001f& (Ě'\u001f,) \u001e\u001f *&\u001b+/\u001f.\u001b- \u001f( \u001f&\n \n,).#- \u001b*)3\u001b \u001f& \u001e#\u001b!(ĉ-.#\u001d)8\n\nPRUEBAS DE LABORATORIO\n\nCitometría hemática\n\n\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) \u001e#-'#(/3\u001f '\u001b,\u001d\u001b\u001e\u001b'\u001f(.\u001f \u001f& 0)&/'\u001f( \u001d),*/-\u001d/&\u001b, '\u001f\u001e#) B\u0016\u0003\n \nC8 \u0007\u001f(\u001f,\u001b&'\u001f(.\u001f6\n\u001f& \u0016\u0003\n \n-\u001f \u001f(\u001d/\u001f(.,\u001b \u001f( \u001f& ,\u001b(!) \u001e\u001f lf \u001b mf̓\n \n6 3 0\u001b&),\u001f- '\u001f(),\u001f- -/!#\u001f,\u001f( .\u001b&\u001b-\u001f'#\u001b8 \u0005( \u001f-.)- \u001d\u001b-)- &\u001b \u001e\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":65,"lines":{"from":71,"to":98}}}}],["231",{"pageContent":".\u001f,'#(\u001b\u001d#ĉ( \u001e\u001f &\u001b \u001f,,#.#(\u001b -ï,#\u001d\u001b -#,0\u001f *\u001b,\u001b \u001d)(l·,'\u001b, \u001f& \u001e#\u001b!(ĉ-.#\u001d) \u001e\u001f \u001f,,)*\u001f(#\u001b ) -/!\u001f,#, &\u001b *)-#\u001c#&#\u001e\u001b\u001e\n\u001e\u001f /(\u001b .\u001b&\u001b-\u001f'#\u001b8 \u0005& .\u001b'\u001bĄ) \u001e\u001f &\u001b \u001dï&/&\u001b 3 &\u001b \"\u001f')!&)\u001c#(\u001b '\u001f\u001e#\u001b \u001e\u001f &\u001b \u001dï&/&\u001b \u001e\u001fl·(\u001f( &\u001b \u001d)(\u001d\u001f(.,\u001b\u001d#ĉ( \u001e\u001f\n\"\u001f')!&)\u001c#(\u001b \u001d),*/-\u001d/&\u001b, '\u001f\u001e#\u001b B\u0003\b\u0003\n \nC6 &\u001b \u001d/\u001b& \u001f-.\u001b,á \u001c\u001b$\u001b */\u001f- &\u001b \u001f,,)*\u001f(#\u001b \u001e#-'#(/3\u001f \u001f& \u001d)(.\u001f(#\u001e)\n\u001e\u001f \"\u001f')!&)\u001c#(\u001b \u001d\u001f&/&\u001b, \u001e\u001f ),'\u001b 'á- #'*),.\u001b(.\u001f +/\u001f &\u001b \u001e#-'#(/\u001d#ĉ( \u001e\u001f& .\u001b'\u001bĄ) \u001e\u001f &\u001b \u001dï&/&\u001b8\n\nMedición de hierro medular\n\n\u001b \u001b/-\u001f(\u001d#\u001b \u001e\u001f \u001e\u001f*ĉ-#.)- \u001e\u001f \"#\u001f,,) \u001f( \u001f& \u001b-*#,\u001b\u001e) \u001e\u001f 'ï\u001e/&\u001b ĉ-\u001f\u001b \u001f- \u001f& *\u001b.,ĉ( \u001e\u001f ,\u001f \u001f,\u001f(\u001d#\u001b *\u001b,\u001b \u001f& \u001e#\u001b!\n-\n\n(ĉ-.#\u001d) \u001e\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)6 3 \u001b\u001d./\u001b&'\u001f(.\u001f .#\u001f(\u001f *)\u001d\u001b /.#&#\u001e\u001b\u001e \u001d)') \"\u001f,,\u001b'#\u001f(.\u001b \u001e#\u001b!(ĉ-.#\u001d\u001b \u001e\u001f\u001c#\u001e)\n\u001b +/\u001f \u001f- /( *,)\u001d\u001f\u001e#'#\u001f(.) #(\u001dĉ')\u001e) \u001f #(0\u001b-#0)8\n\nLos adultos tienden a con-\nsultar más rápidamente que\nlos\n \nniños\n \ncuando\n \npadecen\nde anemia ferropénica. Entre\nlos síntomas más frecuentes se\ncuentan disnea, fatiga y le-\ntargia. Estos síntomas no son\nespecíficos de la deficiencia de\nhierro y pueden verse en otros\nestados carenciales.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":65,"lines":{"from":100,"to":130}}}}],["232",{"pageContent":"CAPÍTULO 3. ANEMIA POR DEFICIENCIA DE HIERRO\n\n39\n\nPerfil de hierro\n\n\u0005& \"#\u001f,,) -ï,#\u001d) \u001f- /( *)\u001c,\u001f #(\u001e#\u001d\u001b\u001e), \u001e\u001f &)- \u001e\u001f*ĉ-#.)- \u001e\u001f \"#\u001f,,) 3 -\u001f \u001f(\u001d/\u001f(.,\u001b \u001c\u001b$) ) (),'\u001b& \u001f( &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b\n\u001e\u001f \"#\u001f,,)8 \u0005-.\u001f 0\u001b&), .#\u001f(\u001f 0\u001b,#\u001b\u001d#ĉ( \u001e#/,(\u001b6 *,\u001f-\u001f(.\u001b(\u001e) 0\u001b&),\u001f- 'á- \u001b&.)- \u001b& l·(\u001b& \u001e\u001f& \u001eù\u001b8\n \n\u001b \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e \u001e\u001f\nl·$\u001b\u001d#ĉ( \u001e\u001f \"#\u001f,,) .).\u001b& B\u0014 \u0002\u0003C ,\u001fł\u001f$\u001b &\u001b 'á2#'\u001b \u001d\u001b(.#\u001e\u001b\u001e \u001e\u001f \"#\u001f,,) +/\u001f &\u001b .,\u001b(- \u001f,,#(\u001b */\u001f\u001e\u001f /(#,6 3 /-/\u001b&\n-\n\n'\u001f(.\u001f \u001f-.á \u001f&\u001f0\u001b\u001e\u001b ) \u001f( \u001f& ,\u001b(!) -/*\u001f,#), \u001e\u001f &) (),'\u001b& \u001f( &)- \u001f-.\u001b\u001e)- \u001e\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)8\n \n\u001b -\u001b./,\u001b\u001d#ĉ(\n\u001e\u001f \"#\u001f,,) B,\u001f&\u001b\u001d#ĉ( \u001e\u001f \"#\u001f,,) -ï,#\u001d) \u001b \u0014 \u0002\u0003C (),'\u001b&'\u001f(.\u001f 0\u001b,ù\u001b \u001f(.,\u001f hf 3 kfz6 3 \u001f( &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)\n-/\u001f&\u001f \u001f-.\u001b, \u001c\u001b$\u001b B̓gfzC\n \n(cuadro 3-4)\n8 \u0015(\u001b \u001f,,#.#(\u001b -ï,#\u001d\u001b '\u001f(), \u001e\u001f̓gh̓(!I'\n \n\u001f- \u001e#\u001b!(ĉ-.#\u001d\u001b \u001e\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b\n\u001e\u001f \"#\u001f,,)8 \u0005( *,)\u001d\u001f-)- #(ł\u001b'\u001b.),#)- B*8 \u001f$86 \u001b,.,#.#- ,\u001f/'\u001b.)#\u001e\u001fC6 \u001d/\u001b(\u001e) \u001d)\u001f2#-.\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)6 &\u001b\n\u001d)(\u001d\u001f(.,\u001b\u001d#ĉ( \u001e\u001f \u001f,,#.#(\u001b */\u001f\u001e\u001f -\u001f, (),'\u001b&: -#( \u001f'\u001c\u001b,!)6 \u001f- ,\u001b,) +/\u001f -\u001f\u001b '\u001b3), \u001e\u001f kf̓(!I'\n \n(cuadro 3-5)\n8\n\nOtros marcadores de deficiencia de hierro","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":66,"lines":{"from":1,"to":30}}}}],["233",{"pageContent":"Otros marcadores de deficiencia de hierro\n\n\u001b *,).)*),l·,#(\u001b \u001d#(\u001d \u001e\u001f& \u001f,#.,)\u001d#.) \u001f-.á \u001f&\u001f0\u001b\u001e\u001b \u001f( &\u001b #(.)2#\u001d\u001b\u001d#ĉ( *), *&)') 3 \u001f( &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)6\n*/\u001f- &)- (#0\u001f&\u001f- \u001b/'\u001f(.\u001b( \u001d)( &\u001b \u001e#-,/*\u001d#ĉ( \u001e\u001f &\u001b -ù(.\u001f-#- \u001e\u001f \"\u001f')8 \u0005-.\u001f \u001f2\u001b'\u001f( .#\u001f(\u001f *)\u001d\u001b \u001f-*\u001f\u001d#l·\u001d#\u001e\u001b\u001e\n*\u001f,) \u001b&.\u001b -\u001f(-#\u001c#&#\u001e\u001b\u001e8\n \n\u001b '\u001f\u001e#\u001d#ĉ( \u001e\u001f& ,\u001f\u001d\u001f*.), -)&/\u001c&\u001f \u001e\u001f &\u001b .,\u001b(- \u001f,,#(\u001b B-\u0014 \u0012C\u001f-.á \u001f&\u001f0\u001b\u001e\u001b \u001f( *\u001b\u001d#\u001f(.\u001f-\n\u001d)( \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) 3 \u001f- (),'\u001b& \u001f( &\u001b \u001b(\u001f'#\u001b \u001e\u001f &\u001b \u001f( \u001f,'\u001f\u001e\u001b\u001e \u001d,ĉ(#\u001d\u001b8\n\nTRATAMIENTO\n\nSuplementación con hierro oral","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":66,"lines":{"from":30,"to":41}}}}],["234",{"pageContent":"TRATAMIENTO\n\nSuplementación con hierro oral\n\n\u001b \u001b\u001e'#(#-.,\u001b\u001d#ĉ( \u001e\u001f& \"#\u001f,,) *), 0ù\u001b ),\u001b& \u001f- &\u001b ),'\u001b ĉ*.#'\u001b *\u001b,\u001b &\u001b \u001d),,\u001f\u001d\u001d#ĉ( \u001e\u001f &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)8\n\u0005( &)- \u001f-.\u001b\u001e)- \u001e\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b -\u001f \u001b/'\u001f(.\u001b &\u001b \u001b\u001c-),\u001d#ĉ( \u001e\u001f& \"#\u001f,,) \"\u001b-.\u001b j \u001b l̓ '!I\u001eù\u001b8 \u0013#( \u001f'\u001c\u001b,!)6 \u001f-.\u001b\n\u001d\u001b(.#\u001e\u001b\u001e \u001f- #(-/l·\u001d#\u001f(.\u001f *\u001b,\u001b \u001d/\u001c,#, \u001f& \u001eïl·\u001d#. .).\u001b& \u001e\u001f \"#\u001f,,)6 +/\u001f -\u001f \u001f-.#'\u001b \u001f( h \u001b j̓! \u001f( &\u001b \u001e \u001fl·\u001d#\u001f(\u001d#\u001b !,\u001b0\u001f8\n\u0004\u001f \"\u001f\u001d\")6 \u001f& \u001d)(.\u001f(#\u001e) \u001e\u001f \"#\u001f,,) \u001e\u001f &\u001b- .\u001b\u001c&\u001f.\u001b-6 +/\u001f *,)'\u001f\u001e#\u001b &)- kf̓ '!6\n \n\u001f2\u001d\u001f\u001e\u001f &\u001b \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e \u001e\u001f\n\u001b\u001c-),\u001d#ĉ( !\u001b-.,)#(.\u001f-.#(\u001b&6 *), &) +/\u001f /-\u001b, 'á- \u001e\u001f /(\u001b .\u001b\u001c&\u001f.\u001b \u001b& \u001eù\u001b \u001f( .\u001f),ù\u001b *)\u001e,ù\u001b \u001b/'\u001f(.\u001b, &)- \u001f \u001f\u001d.)-\n\u001b\u001e0\u001f,-)- -#( '\u001f$),\u001b, -/ \u001b\u001c-),\u001d#ĉ(8\n \n\u001b \u001d)&),\u001b\u001d#ĉ( )-\u001d/,\u001b \u001e\u001f &\u001b- \"\u001f\u001d\u001f- \u001b-)\u001d#\u001b\u001e\u001b \u001b& \u001d)(-/') \u001e\u001f \"#\u001f,,) ),\u001b& \u001e\u001f\n\"\u001f\u001d\") \u001e\u001f*\u001f(\u001e\u001f \u001e\u001f& \"#\u001f,,) () \u001b\u001c-),\u001c#\u001e)8\n\u0004\u001f(.,) \u001e\u001f &\u001b-\n \n),'/&\u001b\u001d#)(\u001f- /-\u001b\u001e\u001b-6 \u001f& -/& \u001b.)\n \n\u001f,,)-) *,)*),\u001d#)(\u001b \u001f(.,\u001f lk 3 nf̓'! \u001e\u001f \"#\u001f,,) \u001f&\u001f\n-\n\n'\u001f(.\u001b& *), .\u001b\u001c&\u001f.\u001b8 \u0003)') 0\u001f(.\u001b$\u001b \u001f-.á -/ \u001c\u001b$) \u001d)-.)6 *\u001f,) .#\u001f(\u001f \u001f \u001f\u001d.)- \u001b\u001e0\u001f,-)-\n \n,\u001f\u001d/\u001f(.\u001f- \u001d)') *)\u001c,\u001f","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":66,"lines":{"from":41,"to":65}}}}],["235",{"pageContent":"'\u001f(.\u001b& *), .\u001b\u001c&\u001f.\u001b8 \u0003)') 0\u001f(.\u001b$\u001b \u001f-.á -/ \u001c\u001b$) \u001d)-.)6 *\u001f,) .#\u001f(\u001f \u001f \u001f\u001d.)- \u001b\u001e0\u001f,-)-\n \n,\u001f\u001d/\u001f(.\u001f- \u001d)') *)\u001c,\u001f\n\nCuadro 3-4.\n \nValores normales de hierro sérico y saturación de transferrina\n\nValores normales\n\n\b)'\u001c,\u001f-9\n \nmk7gmk !I\u001e\n/$\u001f,\u001f-9\n \nlk7glk !I\u001e\n\u000e#Ą)-9\n \nkf7ghf !I\u001e\n\u0012\u001f\u001d#ï( (\u001b\u001d#\u001e)-9\n \ngff7hkf !I\u001e\n\nSaturación de transferrina\n \n\b)'\u001c,\u001f-9\n \ngf7kfz\n/$\u001f,\u001f-9\n \ngk7kfz\n\nCuadro 3-5.\n \nValores normales de la ferritina en suero\n\nHierro sérico\n\n\b)'\u001c,\u001f-9\n \ngn7hmf (!I'\n \n) !I\n/$\u001f,\u001f-9\n \ngn7glf (!I'\n \n) !I\n\u000e#Ą)-9\n \nm7gjf (!I'\n \n) !I\n\u0012\u001f\u001d#ï( (\u001b\u001d#\u001e)-9\n \nhk7hff (!I'\n \n) !I\n\nSignificado\n\n\u001b \u001f,,#.#(\u001b -ï,#\u001d\u001b ,\u001fł\u001f$\u001b &)- \u001b&'\u001b\u001d\u001f(\u001f- \u001d),*),\u001b&\u001f- \u001e\u001f \"#\u001f\n-\n\n,,) 3 -\u001f \u001d),,\u001f-*)(\u001e\u001f \u001d)( \u001f& \"#\u001f,,) \u001d),*),\u001b& .).\u001b& \u001b ,\u001b4ĉ(\n\u001e\u001f g̓!  gf̓'!\n \n\u001e\u001f \"#\u001f,,) \u001b&'\u001b\u001d\u001f(\u001b\u001e)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":66,"lines":{"from":65,"to":132}}}}],["236",{"pageContent":"Significado\n\n\u001b \u001f,,#.#(\u001b -ï,#\u001d\u001b ,\u001fł\u001f$\u001b &)- \u001b&'\u001b\u001d\u001f(\u001f- \u001d),*),\u001b&\u001f- \u001e\u001f \"#\u001f\n-\n\n,,) 3 -\u001f \u001d),,\u001f-*)(\u001e\u001f \u001d)( \u001f& \"#\u001f,,) \u001d),*),\u001b& .).\u001b& \u001b ,\u001b4ĉ(\n\u001e\u001f g̓!  gf̓'!\n \n\u001e\u001f \"#\u001f,,) \u001b&'\u001b\u001d\u001f(\u001b\u001e)\n\nLa administración del hierro\npor vía oral es la forma óp-\ntima para la corrección de la\ndeficiencia de hierro. En los\nestados de deficiencia se au-\nmenta la absorción del hierro\nhasta 4 a 6 mg/día. Sin em-\nbargo, esta cantidad es insu-\nficiente para cubrir el déficit\ntotal de hierro, que se estima\nen 2 a 4 g en la deficiencia\ngrave.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":66,"lines":{"from":132,"to":153}}}}],["237",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n40\n\n.)&\u001f,\u001b(\u001d#\u001b !\u001b-.,)#(.\u001f-.#(\u001b&8 \u0005& !&/\u001d)(\u001b.)\n \n\u001f,,)-) 3 \u001f&\n \n/'\u001b,\u001b.)\n \n\u001f,,)-) -)( \u001c/\u001f(\u001b- \u001b&.\u001f,(\u001b.#0\u001b-6 \u001d)( /(\n\u001d)-.) -#'#&\u001b, \u001b& \u001e\u001f& -/& \u001b.) \u001f,,)-) 3 \u001c/\u001f(\u001b .)&\u001f,\u001b(\u001d#\u001b \u001f( !\u001f(\u001f,\u001b&8\n\u000f.,\u001b\n \n),'/&\u001b\u001d#ĉ( \u001e\u001f ,\u001f\u001f'*&\u001b4) \u001e\u001f \"#\u001f,,) \u001f- \u001f& \u001d)'*&\u001f$) \u001e\u001f \"#\u001f,,)7*)&#-\u001b\u001dá,#\u001e)6 +/\u001f .#\u001f(\u001f \"#\u001f,,) #ĉ\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":67,"lines":{"from":1,"to":16}}}}],["238",{"pageContent":"(#\u001d) \u001f( /( \u001d)'*&\u001f$) \u001d)),\u001e#(\u001b\u001e) \u001d)( !,/*)- \u001e\u001f )2ù!\u001f() *)&\u001b, \u001f( \u001f& *)&#-\u001b\u001dá,#\u001e)8 \u0005-.\u001f \"#\u001f,,) *)&#-\u001b\u001dá,#\u001e)\n.#\u001f(\u001f '#\u001d,)\u001f- \u001f,\u001b- \u001c#\u001f( \"#\u001e,\u001b.\u001b\u001e\u001b- +/\u001f *\u001f,'\u001b(\u001f\u001d\u001f( \u001f( -)&/\u001d#ĉ( \u001f( /( \u001b'*&#) ,\u001b(!) \u001e\u001f *\b8 \u0005- '/3 \u001c#\u001f(\n.)&\u001f,\u001b\u001e)6 #(\u001d&/-#0\u001f '\u001f$), +/\u001f \u001f& -/& \u001b.)\n \n\u001f,,)-)6 \u001b/(+/\u001f -/ *,#(\u001d#*\u001b& \u001e\u001f-0\u001f(.\u001b$\u001b \u001f- /( \u001d)-.) 'á- \u001f&\u001f0\u001b\u001e)8\nĚ&.#*&\u001f- \u001f-./\u001e#)- \"\u001b( \u001d/\u001f-.#)(\u001b\u001e) -/ \u001fl·\u001d\u001b\u001d#\u001b \u001b& \u001d)'*\u001b,\u001b,&) \u001d)( \u001f& -/& \u001b.)\n \n\u001f,,)-) ) \u001d)( \u001f&\n \n/'\u001b,\u001b.)\n\u001f,,)-)6 3 -\u001f \"\u001b -/!\u001f,#\u001e) +/\u001f \u001f- '\u001f$), 3 'á- \u001f\u001d)(ĉ'#\u001d) \u001f& \u001f'*&\u001f\u001b, \u001f-.\u001b- Ě&.#'\u001b- *,\u001f-\u001f(.\u001b\u001d#)(\u001f- $/(.) \u001d)(\n/( '\u001f\u001e#\u001d\u001b'\u001f(.) +/\u001f '\u001f$),\u001f &\u001b .)&\u001f,\u001b(\u001d#\u001b !\u001b-.,)#(.\u001f-.#(\u001b&6 \u001d)') /( #(\"#\u001c#\u001e), \u001e\u001f &\u001b \u001c)'\u001c\u001b \u001e\u001f *,).)(\u001f-8\n\u0005& \"#\u001f,,) \u001d\u001b,\u001c)(#& \u001f- /(\u001b ),'/&\u001b\u001d#ĉ( +/\u001f *,)*),\u001d#)(\u001b \u001f& \"#\u001f,,) \u001f( /(\u001b ),'\u001b () #ĉ(#\u001d\u001b \u001d)') *\u001b,.\u001f \u001e\u001f\n/( \u001d)'*&\u001f$) '\u001b\u001d,)')&\u001f\u001d/&\u001b,6 \u001f- \u001c#\u001f( .)&\u001f,\u001b\u001e)6 \u001b/( \u001f( !,\u001b(\u001e\u001f- \u001e)-#-6 3 .#\u001f(\u001f /( \u001d)(.\u001f(#\u001e) \u001e\u001f \"#\u001f,,) \u001e\u001f&\nonz8 \u0014#\u001f(\u001f ),'\u001b \u001f- ï,#\u001d\u001b \u001e\u001f h̓ '6 &) +/\u001f &) \"\u001b\u001d\u001f -#!(#l·\u001d\u001b.#0\u001b'\u001f(.\u001f 'á- *\u001f+/\u001fĄ) +/\u001f &\u001b- ).,\u001b- ),'/&\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":67,"lines":{"from":18,"to":33}}}}],["239",{"pageContent":"\u001d#)(\u001f-6 3 \u001f- /(\u001b *,\u001f-\u001f(.\u001b\u001d#ĉ( '/3 \u001c#\u001f( .)&\u001f,\u001b\u001e\u001b8\n\u0005& '\u001f\u001d\u001b(#-') \u001e\u001f \u001d\u001b*.\u001b\u001d#ĉ( !\u001b-.,)#(.\u001f-.#(\u001b& .#\u001f(\u001f '\u001b3), \u001b0#\u001e\u001f4 *), \u001f& \"#\u001f,,) #ĉ(#\u001d) \u0006\u001f B\n \nC +/\u001f *), \u001f&\n\"#\u001f,,)\n \n\u001f,,)-) \u0006\u001f B\n \nC: *), &) .\u001b(.)6 &)- \u001d)'*)(\u001f(.\u001f- )2#\u001e\u001b(.\u001f- +/\u001f \u001d)(0#\u001f,.\u001f( \u001f& \"#\u001f,,)\n \n\u001f,,)-) \u001b\n \nï,,#\u001d)\n\u001b/'\u001f(.\u001b( -/ \u001b\u001c-),\u001d#ĉ( !\u001b-.,)#(.\u001f-.#(\u001b&8\n \n\u001b- -\u001b&\u001f- \u001e\u001f \"#\u001f,,) -\u001f \u001b\u001c-),\u001c\u001f( '\u001f$), \u001d/\u001b(\u001e) -\u001f .)'\u001b( \u001d)( \u001f&\n\u001f-.ĉ'\u001b!) 0\u001b\u001dù) \u001b *,#'\u001f,\u001b \"),\u001b \u001e\u001f &\u001b '\u001bĄ\u001b(\u001b6 \u001d/\u001b(\u001e) \u001f& *\b \u001f- 'á- \u001c\u001b$)8 \u0003/\u001b(\u001e) \"\u001b3 -)-*\u001f\u001d\"\u001b \u001e\u001f \u001b&&\u001b \u001b&\n.,\u001b.\u001b'#\u001f(.) ),\u001b&6 -\u001f \u001e\u001f\u001c\u001f 0\u001f,#l·\u001d\u001b, *,#'\u001f,) +/\u001f \u001f& *\u001b\u001d#\u001f(.\u001f .\u001f(!\u001b /(\u001b \u001b\u001e\u001f\u001d/\u001b\u001e\u001b \u001b\u001e\"\u001f,\u001f(\u001d#\u001b6 */\u001f- &)- \u001f \u001f\u001d.)-\n\u001b\u001e0\u001f,-)- !\u001b-.,)#(.\u001f-.#(\u001b&\u001f- -)( \u001d\u001b/-\u001b ,\u001f\u001d/\u001f(.\u001f \u001e\u001f '\u001b&\u001b \u001b\u001e\"\u001f,\u001f(\u001d#\u001b \u001b &\u001b .\u001f,\u001b*#\u001b \u001d)( \"#\u001f,,) ),\u001b&8\n\u0005& á\u001d#\u001e) \u001b-\u001dĉ,\u001c#\u001d) \u001f- /( +/\u001f&\u001b(.\u001f \u001eï\u001c#& \u001e\u001f& \"#\u001f,,) +/\u001f *,\u001f0#\u001f(\u001f &\u001b ),'\u001b\u001d#ĉ( \u001e\u001f -\u001b&\u001f- \u001e\u001f \"#\u001f,,) #(-)&/\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":67,"lines":{"from":35,"to":55}}}}],["240",{"pageContent":"\u001c&\u001f- \u001f( \u001f& .,\u001b\u001d.) !\u001b-.,)#(.\u001f-.#(\u001b&6 '\u001b(.\u001f(#\u001f(\u001e) \u001f& \"#\u001f,,) \u001f( /(\u001b ),'\u001b -)&/\u001c&\u001f +/\u001f \u001f- á\u001d#&'\u001f(.\u001f \u001b\u001c-),\u001c#\u001e\u001b8\n\u0013\u001f ,\u001f\u001d)'#\u001f(\u001e\u001b .)'\u001b, &\u001b- .\u001b\u001c&\u001f.\u001b- \u001e\u001f& \"#\u001f,,) \u001f( \u001d)($/(.) \u001d)( á\u001d#\u001e) \u001b-\u001dĉ,\u001c#\u001d) *\u001b,\u001b \u001f-.#'/&\u001b, -/ \u001b\u001c-),\u001d#ĉ(\n!\u001b-.,)#(.\u001f-.#(\u001b&6 3 -# \u001f-.\u001f \u001f- \u001f& \u001d\u001b-)6 -\u001f *,\u001fl·\u001f,\u001f .)'\u001b,&\u001b- \u001f( &\u001b ()\u001d\"\u001f6 ')'\u001f(.) \u001f( \u001f& \u001d/\u001b& \"\u001b3 /(\u001b ,\u001f\u001e/\u001d\u001d#ĉ(\n\u001f( &\u001b ').#&#\u001e\u001b\u001e !\u001b-.,)#(.\u001f-.#(\u001b& +/\u001f \u001b/'\u001f(.\u001b \u001f& .#\u001f'*) \u001e\u001f *\u001f,'\u001b(\u001f(\u001d#\u001b \u001e\u001f& \"#\u001f,,) \u001f( &\u001b *),\u001d#ĉ( -/*\u001f,#),\n\u001e\u001f& #(.\u001f-.#()6 \u001b3/\u001e\u001b(\u001e) \u001b -/ \u001b\u001c-),\u001d#ĉ( \u001d)( /(\u001b '\u001f$), .)&\u001f,\u001b(\u001d#\u001b8\n\u0005& \"\u001f\u001d\") \u001e\u001f \u001d\u001b'\u001c#\u001b, &\u001b ),'/&\u001b\u001d#ĉ( \u001e\u001f \"#\u001f,,) ) \u001f& /-\u001b,&) \u001e\u001f ()\u001d\"\u001f $/(.) \u001d)( á\u001d#\u001e) \u001b-\u001dĉ,\u001c#\u001d) ,\u001f-/\u001f&0\u001f '/\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":67,"lines":{"from":57,"to":63}}}}],["241",{"pageContent":"\u001d\")- \u001e\u001f &)- #(\u001d)(0\u001f(#\u001f(.\u001f- ,\u001f&\u001b\u001d#)(\u001b\u001e)- \u001d)( &\u001b *)\u001c,\u001f .)&\u001f,\u001b(\u001d#\u001b \u001e\u001f& *\u001b\u001d#\u001f(.\u001f8 \u0005& \"\u001f') \u001f- &\u001b ),'\u001b \u001e\u001f \"#\u001f,,)\n+/\u001f 'á- á\u001d#&'\u001f(.\u001f -\u001f \u001b\u001c-),\u001c\u001f 3 -/ \u001b\u001c-),\u001d#ĉ( () \u001e\u001f*\u001f(\u001e\u001f \u001e\u001f& '\u001f\u001d\u001b(#-') *\u001b,\u001b &\u001b \u001d\u001b*.\u001b\u001d#ĉ( \u001e\u001f& \"#\u001f,,) #ĉ(#\u001d):\n*), &) .\u001b(.)6 () -\u001f 0\u001f \u001b \u001f\u001d.\u001b\u001e) *), &)- &ù'#.\u001f- \u001e#\u001b,#)- \u001e\u001f \u001b\u001c-),\u001d#ĉ( ï,,#\u001d\u001b )\u001c-\u001f,0\u001b\u001e) \u001d)( &\u001b- -\u001b&\u001f- \u001e\u001f \"#\u001f,,)8\n\u001b- \u001d\u001b,(\u001f- ,)$\u001b- -)( &\u001b /\u001f(.\u001f 'á- \u001b\u001c/(\u001e\u001b(.\u001f \u001e\u001f \"#\u001f,,) \"\u001f') \u001e\u001f &\u001b \u001e#\u001f.\u001b6 *\u001f,) \u001e\u001f-\u001b ),./(\u001b\u001e\u001b'\u001f(.\u001f &\u001b \u001d\u001b,(\u001f\n\u001b 0\u001f\u001d\u001f- () \u001f- /(\u001b )*\u001d#ĉ(6 3\u001b -\u001f\u001b *), *,\u001f \u001f,\u001f(\u001d#\u001b- \u001f( &\u001b \u001e#\u001f.\u001b ) *), ,\u001b4)(\u001f- \u001f\u001d)(ĉ'#\u001d\u001b-8\n\nSuplementación parenteral de hierro\n\n\u0005& ,\u001f\u001f'*&\u001b4) \u001e\u001f& \"#\u001f,,) \u001e\u001f ),'\u001b *\u001b,\u001f(.\u001f,\u001b& *\u001f,'#.\u001f -/*\u001f,\u001b, \u001f& *,)\u001c&\u001f'\u001b \u001e\u001f &\u001b \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e &#'#.\u001b\u001e\u001b \u001e\u001f \u001b\u001c-),\n-\n\n\u001d#ĉ( \u001e\u001f& \"#\u001f,,) \u001b (#0\u001f& !\u001b-.,)#(.\u001f-.#(\u001b&8\n \n\u001b- ),'/&\u001b\u001d#)(\u001f- *\u001b,\u001f(.\u001f,\u001b&\u001f- */\u001f\u001e\u001f( \u001d),,\u001f!#, ,á*#\u001e\u001b'\u001f(.\u001f &\u001b- \u001e\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":67,"lines":{"from":65,"to":79}}}}],["242",{"pageContent":"\u001d#ĉ( \u001e\u001f& \"#\u001f,,) \u001b (#0\u001f& !\u001b-.,)#(.\u001f-.#(\u001b&8\n \n\u001b- ),'/&\u001b\u001d#)(\u001f- *\u001b,\u001f(.\u001f,\u001b&\u001f- */\u001f\u001e\u001f( \u001d),,\u001f!#, ,á*#\u001e\u001b'\u001f(.\u001f &\u001b- \u001e\u001f\n-\n\nl·\u001d#\u001f(\u001d#\u001b- \u001f2.,\u001f'\u001b\u001e\u001b'\u001f(.\u001f !,\u001b0\u001f- \u001e\u001f \"#\u001f,,)8 \u0005& \"#\u001f,,) *\u001b,\u001f(.\u001f,\u001b& \u001f- &\u001b Ě(#\u001d\u001b )*\u001d#ĉ( \u001e#-*)(#\u001c&\u001f *\u001b,\u001b \u001d),,\u001f!#,\n&)- \u001eïl·\u001d#.- \u001e\u001f \"#\u001f,,) \u001f( *\u001f,-)(\u001b- +/\u001f \u001d\u001b,\u001f\u001d\u001f( \u001e\u001f &\u001b /(\u001d#ĉ( \u001e\u001f& #(.\u001f-.#() \u001e\u001f&!\u001b\u001e) *), \u001f( \u001f,'\u001f\u001e\u001b\u001e ) ,\u001f-\u001f\u001d\u001d#ĉ(\n+/#,Ě,!#\u001d\u001b8 \u0004#\u001d\"\u001b *,\u001f-\u001f(.\u001b\u001d#ĉ( -\u001f */\u001f\u001e\u001f /-\u001b, \u001e\u001f ),'\u001b #(.,\u001b0\u001f()-\u001b ) #(.,\u001b'/-\u001d/&\u001b,8\n\u001b- \u001e)- \u001d&\u001b-\u001f- 'á- \u001d)'/(\u001f- /-\u001b\u001e\u001b- *\u001b,\u001b ,\u001f\u001f'*&\u001b4) *\u001b,\u001f(.\u001f,\u001b& -)( \u001f& \"#\u001f,,) \u001e\u001f2.,á( 3 /(\u001b 0\u001b,#\u001f\u001e\u001b\u001e \u001e\u001f ),\n-\n\n'/&\u001b\u001d#)(\u001f- \u001e)(\u001e\u001f &\u001b- #(.\u001f,\u001b\u001d\u001d#)(\u001f- *)&\u001b,\u001f- \u001d)( &)- !,/*)- \u001e\u001f )2ù!\u001f() \u001f( &)- \u001d)'*)(\u001f(.\u001f- \u001e\u001f -\u001b\u001d\u001b,\u001b.) \u001f-.\u001b\u001c#&#4\u001b(\n\u001b& \"#\u001f,,) #ĉ(#\u001d)8 \u0003\u001b\u001e\u001b \u001d&\u001b-\u001f .#\u001f(\u001f -/- 0\u001f(.\u001b$\u001b- 3 \u001e\u001f-0\u001f(.\u001b$\u001b-8 \u0005& \"#\u001f,,) \u001e\u001f2.,á( /\u001f &\u001b *,#'\u001f,\u001b ),'/&\u001b\u001d#ĉ( \u001e#-*)\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":67,"lines":{"from":79,"to":92}}}}],["243",{"pageContent":"(#\u001c&\u001f *\u001b,\u001b ,\u001f*)-#\u001d#ĉ( \u001e\u001f \"#\u001f,,) \u001e\u001f ),'\u001b *\u001b,\u001f(.\u001f,\u001b&: -\u001f */\u001f\u001e\u001f \u001b\u001e'#(#-.,\u001b, 0ù\u001b #(.,\u001b0\u001f()-\u001b \u001f( \u001e)-#- \u001e\u001f \"\u001b-.\u001b l̓!\n\u001f( /(\u001b -)&\u001b \u001b*&#\u001d\u001b\u001d#ĉ(6 \u001b\u001e\u001f'á- \u001e\u001f -/ \u001c\u001b$) \u001d)-.)8 \u0013\u001f (\u001f\u001d\u001f-#.\u001b \u001b*&#\u001d\u001b, /(\u001b \u001e)-#- \u001e\u001f *,/\u001f\u001c\u001b *\u001b,\u001b \u001e\u001f-\u001d\u001b,.\u001b, *)-#\u001c&\u001f-\n,\u001f\u001b\u001d\u001d#)(\u001f- \u001b(\u001bl·&á\u001d.#\u001d\u001b- \u001d)( &\u001b #( /-#ĉ( .\u001f,\u001b*ï/.#\u001d\u001b8 \u0013#( \u001f'\u001c\u001b,!)6 \u001f& ,#\u001f-!) \u001e\u001f \u001b(\u001bl·&\u001b2#- \u001d)( \u001f& \"#\u001f,,) \u001e\u001f2.,á( \u001f-\n\u001c\u001b$)6 \u001d)(.,\u001b,#) \u001b &\u001b \u001d,\u001f\u001f(\u001d#\u001b !\u001f(\u001f,\u001b& B'\u001f(), \u001e\u001f& gzC8 \u0005( \u001d\u001b-) \u001e\u001f /-\u001b, &\u001b 0ù\u001b #(.,\u001b'/-\u001d/&\u001b, *\u001b,\u001b \u001b*&#\u001d\u001b, \u001f& \"#\u001f,,)\n\u001e\u001f2.,á(6 () -\u001f \u001e\u001f\u001c\u001f \u001f2\u001d\u001f\u001e\u001f, &\u001b \u001e)-#- \u001e\u001f g̓! *), \u001b*&#\u001d\u001b\u001d#ĉ(8 \u0013\u001f */\u001f\u001e\u001f( *,\u001f-\u001f(.\u001b, á,\u001f\u001b- \u001e\u001f \u001e\u001f\u001d)&),\u001b\u001d#ĉ( \u001f( \u001f& -#.#) \u001e\u001f\n\u001b*&#\u001d\u001b\u001d#ĉ( \u001e\u001f& \"#\u001f,,) +/\u001f */\u001f\u001e\u001f( *\u001f,-#-.#, *), \u001bĄ)-6 *), &) +/\u001f -\u001f \u001e\u001f\u001c\u001f /.#&#4\u001b, &\u001b .ï\u001d(#\u001d\u001b \u001f( 4\u001f.\u001b \u001f( \u001f& \u001d/\u001b\u001e,\u001b(.\u001f\n-/*\u001f,#), 3 \u001f2.\u001f,() \u001e\u001f &)- !&Ě.\u001f)-8 \u0005& \u001e)&), \u001f( \u001f& -#.#) \u001e\u001f &\u001b #(3\u001f\u001d\u001d#ĉ( \u001f- /( \u001f \u001f\u001d.) ,\u001f\u001d/\u001f(.\u001f 3 .\u001b'\u001c#ï( -\u001f \"\u001b \u001e\u001f-\u001d,#\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":67,"lines":{"from":94,"to":101}}}}],["244",{"pageContent":".) &\u001b \u001b*\u001b,#\u001d#ĉ( \u001e\u001f -\u001b,\u001d)'\u001b- \u001e\u001f .\u001f$#\u001e)- \u001c&\u001b(\u001e)-8\n \n)- *,)\u001c&\u001f'\u001b- -#-.ï'#\u001d)- 'á- ,\u001f\u001d/\u001f(.\u001f- \u001b& /-\u001b, \u001f& \"#\u001f,,) \u001e\u001f2.,á(\n*\u001b,\u001f(.\u001f,\u001b& #(\u001d&/3\u001f( l·\u001f\u001c,\u001f6 '#\u001b&!#\u001b- 3 \u001b,.,\u001b&!#\u001b- \"\u001b-.\u001b gh \u001b hj \"),\u001b- *)-.\u001f,#),\u001f- \u001b -/ \u001b\u001e'#(#-.,\u001b\u001d#ĉ(8 \u0005-.\u001b- )\u001d/\n-\n\n,,\u001f( \"\u001b-.\u001b \u001f( \u001f& hfz \u001e\u001f &)- \u001d\u001b-)- 3 */\u001f\u001e\u001f( -\u001f, \u001d)(.,)&\u001b\u001e\u001b- \u001d)( \u001f-.\u001f,)#\u001e\u001f- *\u001b,\u001f(.\u001f,\u001b&\u001f-8 \u0005& \"#\u001f,,) \u001e\u001f2.,á( \u001f- /(\u001b\n'\u001f4\u001d&\u001b \u001e\u001f \"#\u001f,,) 3 \u001e\u001f2.,á( +/\u001f &\u001b- \u001dï&/&\u001b- ,\u001f.#\u001d/&)\u001f(\u001e).\u001f&#\u001b&\u001f- \u001e\u001f*/,\u001b( \u001e\u001f &\u001b \u001d#,\u001d/&\u001b\u001d#ĉ( \u001d)( /(\u001b 0#\u001e\u001b '\u001f\u001e#\u001b \u001e\u001f h\n\u001eù\u001b-8\n \n\u001b '\u001b+/#(\u001b,#\u001b \u001d\u001f&/&\u001b, \u001e\u001f& '\u001b\u001d,ĉ \u001b!) &#\u001c\u001f,\u001b \u001f& \"#\u001f,,) \u001e\u001f& *)&ù'\u001f,) \u001e\u001f2.,á( 3 &) \u001d)&)\u001d\u001b \u001e\u001f(.,) \u001e\u001f &\u001b .,\u001b(- \u001f\n-\n\n,,#(\u001b \u001d#,\u001d/&\u001b(.\u001f8 \u0005& \"#\u001f,,) .,\u001b(- \u001f,,#(\u001b */\u001f\u001e\u001f \u001f(.)(\u001d\u001f- -\u001f, /-\u001b\u001e) *\u001b,\u001b &\u001b \u001f,#.,)*)3\u001f-#-6 */\u001f- &\u001b 0\u001b,#\u001b(.\u001f \u001e\u001f2.,á( ()\n*,)*),\u001d#)(\u001b &\u001b \u001d\u001b(.#\u001e\u001b\u001e (\u001f\u001d\u001f-\u001b,#\u001b *\u001b,\u001b &\u001b \u001f,#.,)*)3\u001f-#-8 \u0005& \"#\u001f,,) \u001e\u001f2.,á( -\u001f */\u001f\u001e\u001f \u001e\u001f.\u001f\u001d.\u001b, \u001f( &\u001b \u001d#,\u001d/&\u001b\u001d#ĉ( \u001d)(\n&\u001b- *,/\u001f\u001c\u001b- \u001e\u001f &\u001b\u001c),\u001b.),#) \u001e\u001f ,/.#(\u001b6 \u001e\u001b(\u001e) \u001d)') ,\u001f-/&.\u001b\u001e) /(\u001b -\u001b./,\u001b\u001d#ĉ( \u001e\u001f .,\u001b(- \u001f,,#(\u001b \u001f( \u001f2\u001d\u001f-) \u001e\u001f gffz6","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":67,"lines":{"from":103,"to":118}}}}],["245",{"pageContent":"CAPÍTULO 3. ANEMIA POR DEFICIENCIA DE HIERRO\n\n41\n\n\"\u001b\u001d#\u001f(\u001e) +/\u001f &)- (#0\u001f&\u001f- \u001e\u001f \"#\u001f,,) -ï,#\u001d) *#\u001f,\u001e\u001b( 0\u001b&), *), /( *\u001b, \u001e\u001f -\u001f'\u001b(\u001b- .,\u001b- \u001f& /-) \u001e\u001f& '\u001f\u001e#\u001d\u001b'\u001f(.)8 \u0005(\n\u0005/,)*\u001b -\u001f \"\u001b /-\u001b\u001e) *), 0\u001b,#\u001b- \u001eï\u001d\u001b\u001e\u001b- \u001f& \"#\u001f,,) \u001e\u001f2.,á( \u001e\u001f ),'\u001b *\u001b,\u001f(.\u001f,\u001b& \u001d)( *)\u001d)- \u001f \u001f\u001d.)- \u001b\u001e0\u001f,-)-8\n\u0003)( \u001f& \"#\u001f,,) -\u001b\u001d\u001b,\u001b.) \u001f& *,)\u001c&\u001f'\u001b *,#(\u001d#*\u001b& \u001f- &\u001b &#'#.\u001b\u001e\u001b \u001d\u001b(.#\u001e\u001b\u001e \u001e\u001f \"#\u001f,,) +/\u001f */\u001f\u001e\u001f -\u001f, \u001b\u001e'#(#-.,\u001b\u001e\u001b\n#(.,\u001b0\u001f()-\u001b'\u001f(.\u001f \u001e/,\u001b(.\u001f /(\u001b -\u001f-#ĉ( Ě(#\u001d\u001b6 +/\u001f !\u001f(\u001f,\u001b&'\u001f(.\u001f \u001f- \u001e\u001f hkf̓'!6 #'*#\u001e#\u001f(\u001e) \u001b-ù &\u001b \u001d),,\u001f\u001d\u001d#ĉ(\n\u001e\u001f /(\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b !,\u001b0\u001f \u001e\u001f \"#\u001f,,) \u001d)( /(\u001b -)&\u001b \u001b\u001e'#(#-.,\u001b\u001d#ĉ(8\n \n\u001b- 0\u001f(.\u001b$\u001b- \u001e\u001f& \"#\u001f,,) -\u001b\u001d\u001b,\u001b.) 3 \u001e\u001f& \"#\u001f,,)\n!&/\u001d)(\u001b.) #(\u001d&/3\u001f( &\u001b \u001c\u001b$\u001b #(\u001d#\u001e\u001f(\u001d#\u001b \u001e\u001f \u001b(\u001bl·&\u001b2#\u001b6 -#( \"\u001b\u001c\u001f,-\u001f ,\u001f*),.\u001b\u001e) \u001d\u001b-)- \u001b.\u001b&\u001f-8 \u0004\u001f(.,) \u001e\u001f &\u001b- \u001e\u001f-0\u001f(\n-\n\n.\u001b$\u001b- -\u001f .#\u001f(\u001f -/ \u001d)-.) 3 &\u001b #(\u001d\u001b*\u001b\u001d#\u001e\u001b\u001e \u001e\u001f \u001d),,\u001f!#, \u001f& \u001eïl·\u001d#. \u001d)( /(\u001b -)&\u001b #( /-#ĉ(8\n\u001b ĉ,'/&\u001b \u001d&á-#\u001d\u001b *\u001b,\u001b \u001d\u001b&\u001d/&\u001b, &\u001b \u001e)-#- \u001e\u001f \"#\u001f,,) #(.,\u001b0\u001f()-) B ĉ,'/&\u001b \u001e\u001f \u0007\u001b(4)(#C -\u001f \u001f2*,\u001f-\u001b \u001b-ù9\n\nDéficit de hierro (mg) = peso (kg) × [(Hemoglobina ideal (g/dL) – Hemoglobina actual)] × 2,4 + 500","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":68,"lines":{"from":1,"to":18}}}}],["246",{"pageContent":"Déficit de hierro (mg) = peso (kg) × [(Hemoglobina ideal (g/dL) – Hemoglobina actual)] × 2,4 + 500\n\n\u0013\u001f \u001f-.#'\u001b /( #(\u001d,\u001f'\u001f(.) \u001e\u001f g̓! I\u001e\n \n\u001f( &\u001b \"\u001f')!&)\u001c#(\u001b *), \u001d\u001b\u001e\u001b hff '! \u001e\u001f \"#\u001f,,) \u001b\u001e'#(#-.,\u001b\u001e)8 \u0013\u001f\n)\u001c-\u001f,0\u001b \u001f \u001f\u001d.) -)\u001c,\u001f &\u001b \u001f,#.,)*)3\u001f-#- \u001b *\u001b,.#, \u001e\u001f& -ï*.#') \u001b \u001eï\u001d#') \u001eù\u001b 3 /( \u001b/'\u001f(.) \u001e\u001f &\u001b \"\u001f')!&)\u001c#(\u001b\n\u001e\u001f h !I\u001e\n \n\u001f( h7j -\u001f'\u001b(\u001b-8 \u0003)') *\u001b/.\u001b \u001cá-#\u001d\u001b *)\u001e\u001f')- /-\u001b, \u001f& \"#\u001f,,) -\u001b\u001d\u001b,\u001b.) \u001e#&/3\u001f(\u001e) gff7hff̓'! \u001f(\ngff7hkf̓\u001d\u001d \u001e\u001f -/\u001f,) l·-#)&ĉ!#\u001d) *\u001b,\u001b *\u001b-\u001b,&) \u001f( if̓ '#(/.)-6 \u001d)( /(\u001b \u001e)-#- 'á2#'\u001b \u001e\u001f lff̓'!I-\u001f'\u001b(\u001b8 \u0012\u001f\n-\n\n-/&.\u001b (\u001f\u001d\u001f-\u001b,#) \u001b\u001e'#(#-.,\u001b, /(\u001b *\u001f+/\u001fĄ\u001b \u001e)-#- #(#\u001d#\u001b& \u001e\u001f *,/\u001f\u001c\u001b *\u001b,\u001b \u001e\u001f-\u001d\u001b,.\u001b, \u001f& \u001e\u001f-\u001b,,)&&) \u001e\u001f ,\u001f\u001b\u001d\u001d#)(\u001f-\n\u001b(\u001bl·&á\u001d.#\u001d\u001b-8 \u0013\u001f \"\u001b( /-\u001b\u001e) \u001e)-#- \u001b&.\u001b- \u001e\u001f \"#\u001f,,) -\u001b\u001d\u001b,\u001b.) \u001b*&#\u001dá(\u001e)&) \u001f( \u001e)-#- \u001e\u001f kff̓'! *), \u001eù\u001b6 \u001e#&/#\u001e)\n\u001f( hkf̓\u001d\u001d \u001e\u001f - /\u001f,) l·-#)&ĉ!#\u001d) *\u001b,\u001b *\u001b-\u001b,&) \u001f( i \"),\u001b-6 *), \u001e)- \u001e)-#-8\n\u0005& \"#\u001f,,) \u001e\u001f2.,á( \u001f- \u001f& Ě(#\u001d) *,)\u001e/\u001d.) \u001e\u001f \"#\u001f,,) *\u001b,\u001f(.\u001f,\u001b& +/\u001f */\u001f\u001e\u001f \u001b\u001e'#(#-.,\u001b,-\u001f *), 0ù\u001b #(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":68,"lines":{"from":18,"to":34}}}}],["247",{"pageContent":".,\u001b'/-\u001d/&\u001b,8 \u0013#( \u001f'\u001c\u001b,!)6 \u001f& \u001e)&), \u001f( \u001f& -#.#) \u001e\u001f &\u001b #(3\u001f\u001d\u001d#ĉ(6 &\u001b .#(\u001d#ĉ( \u001e\u001f &\u001b *#\u001f& 3 -/ ')0#&#4\u001b\u001d#ĉ( 3\n\u001b\u001c-),\u001d#ĉ( #'*,\u001f\u001e\u001f\u001d#\u001c&\u001f- \"\u001b\u001d\u001f( +/\u001f \u001d\u001b\u001e\u001b 0\u001f4 -\u001f /-\u001f '\u001f()- \u001f-.\u001b 0ù\u001b8\n\nEvaluación de la respuesta\n\n\u0003)') \u001e\u001b.) \u001e\u001f \u001b\u001e\u001f\u001d/\u001b\u001e\u001b ,\u001f-*/\u001f-.\u001b \u001b &\u001b .\u001f,\u001b*#\u001b \u001e\u001f ,\u001f\u001f'*&\u001b4) \u001e\u001f \"#\u001f,,) \u001e\u001f\u001c\u001f )\u001c-\u001f,0\u001b,-\u001f ,\u001f.#\u001d/&)\u001d#.)-#- .,\u001b- j\n\u001b m̓\u001e ù\u001b- \u001e\u001f \"\u001b\u001c\u001f, #(#\u001d#\u001b\u001e) &\u001b ,\u001f*)-#\u001d#ĉ(8\n \n\u001b \u001d)(\u001d\u001f(.,\u001b\u001d#ĉ( \u001e\u001f &\u001b \"\u001f')!&)\u001c#(\u001b \u001e\u001f& ,\u001f.#\u001d/&)\u001d#.) B\b\u0003,C \u001d)')\n'\u001b,\u001d\u001b\u001e), .\u001f'*,\u001b() \u001e\u001f &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) */\u001f\u001e\u001f -\u001f, \u001e\u001f /.#&#\u001e\u001b\u001e6 3\u001b +/\u001f -\u001f )\u001c-\u001f,0\u001b /(\u001b ,á*#\u001e\u001b (),'\u001b&#\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":68,"lines":{"from":36,"to":46}}}}],["248",{"pageContent":"4\u001b\u001d#ĉ( \u001e\u001f -/ 0\u001b&), +/\u001f \u001d)#(\u001d#\u001e\u001f \u001d)( &\u001b ,\u001f-*/\u001f-.\u001b \u001b& .,\u001b.\u001b'#\u001f(.)8 \u0003)( \u001f& \"#\u001f,,) *\u001b,\u001f(.\u001f,\u001b& -\u001f */\u001f\u001e\u001f )\u001c-\u001f,0\u001b,\n/(\u001b ,\u001f-*/\u001f-.\u001b \u001f( \u001f& (#0\u001f& \u001e\u001f \"\u001f')!&)\u001c#(\u001b \u001e\u001f-*/ï- \u001e\u001f g \u001b h -\u001f'\u001b(\u001b- \u001e\u001f .,\u001b.\u001b'#\u001f(.)6 \u001b/(+/\u001f \u001b&!/()- *\u001b\u001d#\u001f(.\u001f-\n*/\u001f\u001e\u001f( .\u001b,\u001e\u001b,-\u001f 0\u001b,#\u001b- -\u001f'\u001b(\u001b- *\u001b,\u001b \u001b&\u001d\u001b(4\u001b, ,\u001f-*/\u001f-.\u001b8 \u0013\u001f )\u001c-\u001f,0\u001b /( \u001b/'\u001f(.) \u001e\u001f& (#0\u001f& \u001e\u001f \"\u001f')!&)\u001c#(\u001b\n\u001f( &\u001b- *,#'\u001f,\u001b- j̓-\u001f'\u001b(\u001b- \u001e\u001f& #(#\u001d#) \u001e\u001f& \"#\u001f,,) ),\u001b&: *\u001b,\u001b \u001d),,\u001f!#, &\u001b \u001b(\u001f'#\u001b6 -\u001f */\u001f\u001e\u001f( (\u001f\u001d\u001f-#.\u001b, \u001f(.,\u001f j 3 l\n'\u001f-\u001f- \u001e\u001f -/ #(!\u001f-.#ĉ( \u001d)( \u001f-.,#\u001d.) \u001b*\u001f!) 3 \u001e\u001f\u001c\u001f \u001d)(.#(/\u001b,-\u001f *), 0\u001b,#)- '\u001f-\u001f- *\u001b,\u001b *)\u001e\u001f, ,\u001f*)(\u001f, &)- \u001e\u001f*ĉ\n-\n\n-#.)- .#-/&\u001b,\u001f-8 \u0013\u001f */\u001f\u001e\u001f /-\u001b, &\u001b \u001e\u001f.\u001f,'#(\u001b\u001d#ĉ( \u001e\u001f \u001f,,#.#(\u001b -ï,#\u001d\u001b \u001d)') #(\u001e#\u001d\u001b\u001e), \u001e\u001f& \u001f-.\u001b\u001e) \u001e\u001f &)- \u001e\u001f*ĉ-#.)-\n\u001e\u001f \"#\u001f,,) 3 ),#\u001f(.\u001b,()- -)\u001c,\u001f &\u001b \u001e/,\u001b\u001d#ĉ( \u001e\u001f& .,\u001b.\u001b'#\u001f(.)8\n\nDEFICIENCIA GENÉTICA DE HIERRO\n\n\u0005-.\u001b 0\u001b,#\u001b(.\u001f -\u001f \u001f(\u001d/\u001f(.,\u001b ,\u001f*,\u001f-\u001f(.\u001b\u001e\u001b *), &\u001b \u001b(\u001f'#\u001b *), \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) ,\u001f ,\u001b\u001d.\u001b,#\u001b6 .,\u001b-.),() \u001b/.)\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":68,"lines":{"from":48,"to":61}}}}],["249",{"pageContent":"DEFICIENCIA GENÉTICA DE HIERRO\n\n\u0005-.\u001b 0\u001b,#\u001b(.\u001f -\u001f \u001f(\u001d/\u001f(.,\u001b ,\u001f*,\u001f-\u001f(.\u001b\u001e\u001b *), &\u001b \u001b(\u001f'#\u001b *), \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) ,\u001f ,\u001b\u001d.\u001b,#\u001b6 .,\u001b-.),() \u001b/.)\n-\n\n-ĉ'#\u001d) ,\u001f\u001d\u001f-#0) \u001e\u001f\u001c#\u001e) \u001b '/.\u001b\u001d#)(\u001f- \u001e\u001f& !\u001f(\n \nTMPRSS6\n6 \u001f& \u001d/\u001b& \u001d)\u001e#l·\u001d\u001b &\u001b \u001f(4#'\u001b '\u001b.,#*.\u001b-\u001b7h8 \u0004#\u001d\"\u001b-\n'/.\u001b\u001d#)(\u001f- \u001e\u001b( &/!\u001b, \u001b /(\u001b \u001f&\u001f0\u001b\u001d#ĉ( \u001d,ĉ(#\u001d\u001b \u001e\u001f &)- (#0\u001f&\u001f- \u001e\u001f \"\u001f*\u001d#\u001e#(\u001b *&\u001b-'á.#\u001d\u001b6 *), &) .\u001b(.) \u001b&.\u001f,\u001b(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":68,"lines":{"from":61,"to":71}}}}],["250",{"pageContent":"\u001e) &\u001b \u001b\u001c-),\u001d#ĉ( \u001e/)\u001e\u001f(\u001b& \u001e\u001f \"#\u001f,,) 3 &\u001b &#\u001c\u001f,\u001b\u001d#ĉ( \u001e\u001f \"#\u001f,,) \u001e\u001f-\u001e\u001f \u001f& \u001c\u001b4)8 \u0005-.\u001b *\u001b.)&)!ù\u001b -\u001f \u001d\u001b,\u001b\u001d.\u001f,#4\u001b\n*), /(\u001b \u001b(\u001f'#\u001b '#\u001d,)\u001dù.#\u001d\u001b !,\u001b0\u001f \u001d)( /(\u001b -\u001b./,\u001b\u001d#ĉ( \u001e\u001f .,\u001b(- \u001f,,#(\u001b '/3 \u001c\u001b$\u001b 3 /(\u001b \u001f,,#.#(\u001b *&\u001b-'á.#\u001d\u001b\n(),'\u001b& ) \u001b&.\u001b8\n \n)- (#0\u001f&\u001f- \u001e\u001f \"\u001f*\u001d#\u001e#(\u001b \u001f-.á( ^\u001b(),'\u001b&'\u001f(.\u001f (),'\u001b&\u001f-_ ) \u001f&\u001f0\u001b\u001e)-6 3\u001b +/\u001f &\u001b ,\u001f-*/\u001f-.\u001b\nl·-#)&ĉ!#\u001d\u001b \u001f-*\u001f,\u001b\u001e\u001b \u001e\u001f\u001c\u001f,ù\u001b -\u001f, /(\u001b \"\u001f*\u001d#\u001e#(\u001b \u001c\u001b$\u001b8\n \n\u001b \u001b(\u001f'#\u001b \u001f- 'á- *,)(/(\u001d#\u001b\u001e\u001b \u001f( &)- (#Ą)- +/\u001f \u001f(\n&)- \u001b\u001e/&.)-8\n \n\u001b -/*&\u001f'\u001f(.\u001b\u001d#ĉ( \u001d)( \"#\u001f,,) \u001f- #(\u001fl·\u001d\u001b4 3 \u001f& /-) \u001e\u001f& \"#\u001f,,) *\u001b,\u001f(.\u001f,\u001b& -)&) *,)\u001e/\u001d\u001f '\u001f$),ù\u001b\n*\u001b,\u001d#\u001b&6 */\u001f- \u001f& *,)\u001d\u001f-) \u001e\u001f ,\u001f\u001d#\u001d&\u001b$\u001f \u001e\u001f& \"#\u001f,,) *), &)- '\u001b\u001d,ĉ \u001b!)- -\u001f 0\u001f )\u001c-.\u001b\u001d/&#4\u001b\u001e) *), &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f\n&\u001b \u001f,,)*),.#(\u001b6 +/\u001f \u001b -/ 0\u001f4 \u001f- *,)\u001e/\u001d.) \u001e\u001f &)- (#0\u001f&\u001f- #(\u001d,\u001f'\u001f(.\u001b\u001e)- \u001e\u001f \"\u001f*\u001d#\u001e#(\u001b8 \u0005& /-) \u001e\u001f \u001b!\u001f(.\u001f- +/\u001f\n\u001c&)+/\u001f\u001f( &\u001b \"\u001f*\u001d#\u001e#(\u001b \u001f- /( á,\u001f\u001b #'*),.\u001b(.\u001f \u001e\u001f #(0\u001f-.#!\u001b\u001d#ĉ( \u001f( \u001f-.\u001f *\u001b\u001e\u001f\u001d#'#\u001f(.)8\n\nCONCLUSIONES","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":68,"lines":{"from":73,"to":88}}}}],["251",{"pageContent":"CONCLUSIONES\n\n•\n \n\u001b \u001b(\u001f'#\u001b *), \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) \u001f- &\u001b \u001d\u001b/-\u001b 'á- ,\u001f\u001d/\u001f(.\u001f \u001e\u001f \u001b(\u001f'#\u001b \u001f( \u001f& '/(\u001e) 3 \u001f- /(\u001b *\u001b.)&)!ù\u001b\n,\u001f&\u001b.#0\u001b'\u001f(.\u001f á\u001d#& \u001e\u001f \u001e#\u001b!()-.#\u001d\u001b, 3 .,\u001b.\u001b,8\n•\n \n\u0005- #'*),.\u001b(.\u001f ,\u001f\u001d)()\u001d\u001f, -/- '\u001b(# \u001f-.\u001b\u001d#)(\u001f- \u001d&ù(#\u001d\u001b- *\u001b,\u001b .,\u001b.\u001b, &\u001b \u001d\u001b/-\u001b \u001e\u001f \u001c\u001b-\u001f +/\u001f !\u001f(\u001f,\u001b \u001e#\u001d\")\n*\u001b\u001e\u001f\u001d#'#\u001f(.)6 \u001b l·( \u001e\u001f \u001f0#.\u001b, -/ \u001d,)(#\u001d#\u001e\u001b\u001e 3 \u001e# ù\u001d#& \u001d)(.,)&8\n•\n \n\u0005& .,\u001b.\u001b'#\u001f(.) \u001e\u001f\u001c\u001f -\u001f, #(\u001e#0#\u001e/\u001b&#4\u001b\u001e) *\u001b,\u001b -/ \u001b\u001e\u001f\u001d/\u001b\u001e\u001b ,\u001f-)&/\u001d#ĉ(8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":68,"lines":{"from":88,"to":100}}}}],["252",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n42\n\nPREGUNTAS DE AUTOEVALUACIÓN\n\ng8 \u0005- /( -#!() .\u001f'*,\u001b() \u001f( &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) 3 */\u001f\u001e\u001f -\u001f, \u001e\u001f 0\u001b&), \u001f( \u001f& \u001e#\u001b!(ĉ-.#\u001d) \u001e# \u001f,\u001f(\u001d#\u001b& \u001d)(\n,\u001f-*\u001f\u001d.) \u001b ).,\u001b- \u001f(.#\u001e\u001b\u001e\u001f- \u001d&ù(#\u001d\u001b-9\n\u001b8\n \n\u0001(#-)\u001d#.)-#-\n\u001c8 \u0010)#+/#&)\u001d#.)-#-\n\u001d8\n \n#\u001d,)\u001d#.)-#-\nh8 ?\u0003/á& \u001f- \u001f& *,#'\u001f, ù(\u001e#\u001d\u001f \"\u001f'\u001b.)&ĉ!#\u001d) +/\u001f -\u001f \u001b&.\u001f,\u001b \u001f( /(\u001b \u001b(\u001f'#\u001b *), \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)>\n\u001b8\n \n\u0006\u001f,,#.#(\u001b\n\u001c8 \u0016\u0003\n\u001d8\n \n\b\u0003\ni8 \u0005(\n \nï2#\u001d)6 &\u001b \u001b(\u001f'#\u001b *), \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) -\u001f *,\u001f-\u001f(.\u001b 'á- ,\u001f\u001d/\u001f(.\u001f'\u001f(.\u001f *),9\n\u001b8\n \n\u0004\u001f-(/.,#\u001d#ĉ(\n\u001c8 \b\u001f'),,\u001b!#\u001b \u001d,ĉ(#\u001d\u001b\n\u001d8\n \n\u0010#\u001d\u001b\nj8 ?\u0003/á& \u001f- &\u001b *,#'\u001f,\u001b )*\u001d#ĉ( *\u001b,\u001b &\u001b \u001b\u001e'#(#-.,\u001b\u001d#ĉ( \u001e\u001f \"#\u001f,,)>\n\u001b8\n \n\u0016ù\u001b *\u001b,\u001f(.\u001f,\u001b&\n\u001c8 \u0016ù\u001b ),\u001b&\n\u001d8\n \n\u0016ù\u001b #(.,\u001b'/-\u001d/&\u001b,\nk8 \u0005( &\u001b \u001b(\u001f'#\u001b \u001b-)\u001d#\u001b\u001e\u001b \u001b *\u001b,\u001b-#.)-#-6 \u001f- ,\u001f\u001d/\u001f(.\u001f \u001f(\u001d)(.,\u001b,9\n\u001b8\n \n#( )\u001d#.)-#-\n\u001c8\n \n#( )*\u001f(#\u001b\n\u001d8\n \n\u0005)-#()l·&#\u001b\n\nBIBLIOGRAFÍA\n\n\u0001!/\u001e\u001f&) \u00076 \u0003\u001b,\u001e)(\u001b \u000f6 \u0010)-\u001b\u001e\u001b\n \n8 \u0010,\u001f0\u001b&\u001f(\u001d#\u001b \u001e\u001f \u001b(\u001f'#\u001b \u001f,,)*ï(#\u001d\u001b \u001f( \u001f-\u001d)&\u001b,\u001f- 3 \u001b\u001e)&\u001f-\u001d\u001f(.\u001f-6\n \n\u001f\u001e\u001f&&ù(6 \u0003)&)'\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":69,"lines":{"from":1,"to":60}}}}],["253",{"pageContent":"BIBLIOGRAFÍA\n\n\u0001!/\u001e\u001f&) \u00076 \u0003\u001b,\u001e)(\u001b \u000f6 \u0010)-\u001b\u001e\u001b\n \n8 \u0010,\u001f0\u001b&\u001f(\u001d#\u001b \u001e\u001f \u001b(\u001f'#\u001b \u001f,,)*ï(#\u001d\u001b \u001f( \u001f-\u001d)&\u001b,\u001f- 3 \u001b\u001e)&\u001f-\u001d\u001f(.\u001f-6\n \n\u001f\u001e\u001f&&ù(6 \u0003)&)'\n-\n\n\u001c#\u001b6 gooo8 \u0012\u001f0 \u0010\u001b(\u001b' \u0013\u001b&/\u001e \u0010/\u001c&#\u001d\u001bI\u0010\u001b( \u0001'\n \n\u0010/\u001c&#\u001d \b\u001f\u001b&.\"8 hffh: giBlC8\n\u0001/\u001f,\u001c\u001b\u001d\"\n \n6 \u0017#.. \u00046 \u0014)&\u001f, \u00176 \u0006#\u001f,-.\u001f#(\n \n6\n \n\u001f,(\u001f, \u00126 \u0002\u001b&&\u001b,\u001e \b8 \u0003&#(#\u001d\u001b& /-\u001f ) .\"\u001f .).\u001b& \u001e)-\u001f #(.,\u001b0\u001f()/- #( /-#)(\n) #,)( \u001e\u001f2.,\u001b(8\n \n\u001b\u001c \u0003&#(\n \n\u001f\u001e8 gonn: ggg9 kll7kmf8\n\u0002,#\u001e!\u001f-\n \n6 \u0010\u001f\u001b,-)( \b8\n \n,)( \u001e\u001fl·\u001d#\u001f(\u001d38 \u0005(9 \u0002,#\u001e!\u001f-\n \n6 \u0010\u001f\u001b,-)( \b8 \u0001(\u001f'#\u001b- \u001b(\u001e ).\"\u001f, ,\u001f\u001e \u001d\u001f&& \u001e#-),\u001e\u001f,-8 \u000e\u001f1 \u0019),%9\n\u001d\u0007,\u001b17\b#&&: hffn8 *8 oo7ghf8\n\u0002,#..\u001f(\"\u001b' \u00078 \u0004#-),\u001e\u001f,- ) #,)( '\u001f.\u001b\u001c)&#-'9\n \n,)( \u001e\u001fl·\u001d#\u001f(\u001d3 \u001b(\u001e )0\u001f,&)\u001b\u001e8 \u0005(9 \b)L·'\u001b( \u00126 \u0002\u001f(4 \u00056 \u0013\"\u001b..#& \u00138 \b\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":69,"lines":{"from":60,"to":95}}}}],["254",{"pageContent":"'\u001b.)&)!38 \u0002\u001b-#\u001d *,#(\u001d#*&\u001f- \u001b(\u001e *,\u001b\u001d.#\u001d\u001f8 j.\" \u001f\u001e8 \u0010\"#&\u001b\u001e\u001f&*\"#\u001b9 \u0005&-\u001f0#\u001f,: hffk8 *8 jng7jnm8\n\u0003))%\n \n\u00048 \u0004#\u001b!()-#- \u001b(\u001e '\u001b(\u001b!\u001f'\u001f(. ) #,)(7\u001e\u001fl·\u001d#\u001f(.7\u001b(\u001f'#\u001b8 \u0002\u001f-. \u0010,\u001b\u001d. \u0012\u001f- \u0003&#( \b\u001f'\u001b.)&8 hffk: gn9 igo7ih8\n\u0003),\u001b44\u001b \u00076 \u0016\u001b&\u001f(.#(# \u00126 \u0001(\u001e,\u001f\u001b(#\n \n6 \u001f. \u001b&8 \u0013/\u001c\u001d&#(#\u001d\u001b& \u001d)\u001f&#\u001b\u001d \u001e#-\u001f\u001b-\u001f #- \u001b ,\u001f+/\u001f(. \u001d\u001b/-\u001f ) #,)(7\u001e\u001fl·\u001d#\u001f(\u001d3 \u001b(\u001b\u001f'#\u001b8\n\u0013\u001d\u001b(\u001e\n \n\u0007\u001b-.,)\u001f(.\u001f,)&8 gook: if9 gki7gkl8\n\u0003,\u001f\u001f\u001e7\n \n\u001b(\u001b-\"#,) \b\n \n6 \u0015,#\u001c\u001f \u0014\u00076 \u0002\u001b,.)&#(# \u0012\n \n6 \u0006/%/').)\n \n\u000e6\n \nĉ*\u001f4 \u0014\u00146 \u001a\u001b\u001c\u001b&\u001f.\u001b \u000e\n \n6 \u001f. \u001b&8 '*,)0#(! \u001e#\u001f.\u001b,3\n#(.\u001b%\u001f .) *,\u001f0\u001f(. \u001b(\u001f'#\u001b #( \u001b\u001e)&\u001f-\u001d\u001f(. !#,&- .\",)/!\" \u001d)''/(#.3 %#.\u001d\"\u001f(- #( \u001b *\u001f,#/,\u001c\u001b( *)*/&\u001b.#)( )\n \n#'\u001b6 \u0010\u001f,/8\n\u000e/.,8 hfff: gif9 jko\u00137jlg\u00138\n\u0004\u001f &\u001b \u0003,/47\u0007ĉ(!),\u001b \u00166 \u0007\u001b)(\u001b \u00026 \u0016#&&\u001b&*\u001b(\u001e) \u00136 \u001f. \u001b&8 \u0001(\u001f'#\u001b \u001b(\u001e #,)(6 4#(\u001d6 \u001d)**\u001f, \u001b(\u001e '\u001b!(\u001f-#/' \u001e\u001fl·\u001d#\u001f(\u001d3 #(\n\u001f2#\u001d\u001b( \u001b\u001e)&\u001f-\u001d\u001f(.-9 \u000e\u001b.#)(\u001b& \b\u001f\u001b&.\" \u001b(\u001e \u000e/.,#.#)( \u0013/,0\u001f3 hffl8 \u0013\u001b&/\u001e \u0010Ě\u001c&#\u001d\u001b\n \nï28 hfgh: kj BhC9 gik7gjk8\n\u0005(\u001d/\u001f-.\u001b \u000e\u001b\u001d#)(\u001b& \u001e\u001f \u0013\u001b&/\u001e 3 \u000e/.,#\u001d#ĉ( B\u0005\u000e\u0013\u0001\u000e\u0015\u0014C hfgh8 \u0012\u001f-/&.\u001b\u001e)- \u000e\u001b\u001d#)(\u001b&\u001f-8\n \n(-.#./.) \u000e\u001b\u001d#)(\u001b& \u001e\u001f \u0013\u001b&/\u001e\n\u0010Ě\u001c&#\u001d\u001b8\n \nï2#\u001d)9 \u0013\u0013\u0001: hfgi8\n\u0007\u001b'\u001c&#(!\n \n6\n \n\u001b(! \u00036","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":69,"lines":{"from":97,"to":138}}}}],["255",{"pageContent":"ï28 hfgh: kj BhC9 gik7gjk8\n\u0005(\u001d/\u001f-.\u001b \u000e\u001b\u001d#)(\u001b& \u001e\u001f \u0013\u001b&/\u001e 3 \u000e/.,#\u001d#ĉ( B\u0005\u000e\u0013\u0001\u000e\u0015\u0014C hfgh8 \u0012\u001f-/&.\u001b\u001e)- \u000e\u001b\u001d#)(\u001b&\u001f-8\n \n(-.#./.) \u000e\u001b\u001d#)(\u001b& \u001e\u001f \u0013\u001b&/\u001e\n\u0010Ě\u001c&#\u001d\u001b8\n \nï2#\u001d)9 \u0013\u0013\u0001: hfgi8\n\u0007\u001b'\u001c&#(!\n \n6\n \n\u001b(! \u00036\n \n\u001d\u0001,\u001e&\u001f \b 8 \u0006\u001f.\u001b& ,\u001f!/&\u001b.#)( ) #,)( .,\u001b(-*),. \u001e/,#(! *,\u001f!(\u001b(\u001d38 \u0001'\n \n\u0003&#( \u000e/.,8 hfgg8\n\u0007\u001b(4 \u00148 \b\u001f*\u001d#\u001e#(6 \u001b %\u001f3 ,\u001f!/&\u001b.), ) #,)( '\u001f.\u001b\u001c)&#-' \u001b(\u001e '\u001f\u001e#\u001b.), ) \u001b(\u001f'#\u001b ) #(ł\u001b''\u001b.#)(8 \u0002&))\u001e8 hffi: gfh9 mni7n8\n\u0007\u001b(4)(# \u0001\n \n8 (.,\u001b0\u001f()/- #,)(7\u001e\u001f2.,\u001b(9 Ļ\u001f,\u001b*\u001f/.#\u001d \u001b(\u001e \u001f2*\u001f,#'\u001f(.\u001b& *)--#\u001c#&#.#\u001f-8 \u0013\u001d\"1\u001f#4-\n \n\u001f\u001e \u0017)\u001d\"\u001f(-\u001d\",8 gomf: gff9 ifg7i8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":69,"lines":{"from":138,"to":159}}}}],["256",{"pageContent":"CAPÍTULO 3. ANEMIA POR DEFICIENCIA DE HIERRO\n\n43","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":70,"lines":{"from":1,"to":3}}}}],["257",{"pageContent":"\u0007#&&))&3\n \n6 \u0002).\"1\u001f&& \u00146 \u0003\"\u001b,&.)( \u00126 \u001f. \u001b&8 \u0006\u001b\u001d.),- \u001bL·\u001f\u001d.#(! .\"\u001f \u001b\u001c-),*.#)( ) #,)( ,)' \u001d\u001f,\u001f\u001b&-8 \u0002,\n \n\u000e/.,8 gonj: kg9 im7jl8\n\u0007)(4á&\u001f47\n \n&\u001b() \u000f8 \u0001(\u001f'#\u001b\n \n\u001f,,)*ï(#\u001d\u001b8 \u0005(9\n \n\u001b#'\u001f7\u0010ï,\u001f4\n \n\u00036 \u0007ĉ'\u001f47\u0001&'\u001b!/\u001f, \u00048 \b\u001f'\u001b.)&)!ù\u001b8\n \n\u001b -\u001b(!,\u001f 3 -/-\n\u001f( \u001f,'\u001f\u001e\u001b\u001e\u001f-8 i\u001b \u001f\u001e8\n \n\u001d\u0007,\u001b17\b#&&: hfgh8 *8 hh7hk8\n\u0007,\u001b\u001d#\u001b \u00026 \u0010,\u001b\u001e#&&\u001b \u00018 \b\u001f')!&)\u001c#(\u001b 3 \u001f,,#.#(\u001b \u001f( &\u001b *)\u001c&\u001b\u001d#ĉ( \u001f-\u001d)&\u001b, \u001e\u001f (#0\u001f& -)\u001d#)\u001f\u001d)(ĉ'#\u001d) \u001c\u001b$)8 \u0003\u001b&#9 \u0015(#0\u001f,-#\u001e\u001b\u001e\n\u001e\u001f& \u0016\u001b&&\u001f6 \u0013\u001f\u001d,\u001f.\u001b,ù\u001b \u001e\u001f \u0013\u001b&/\u001e \u001e\u001f \u0003\u001b&#: hfff8\n\b/(!\u001f, ),\u001e \u0004 ,6\n \n#(\u001e\u001f,\n \n8 (.\u001f,\u001b\u001d.#)(- ) *\b \u001b(\u001e \u001b-\u001d),\u001c\u001b.\u001f #( #(.\u001f-.#(\u001b& #,)( \u001b\u001c-),*.#)(8\n \n\u000e/.,8 goni: ggi9 hlgk7hlhh8\n\u001b(\u001b%\u001b%),(\n \n6 \u0003\u001b0#&&\n \n6 \u001b\u001d)\u001c- \u00018 Ļ\u001f '\u001f.\u001b\u001c)&#-' ) #(.,\u001b0\u001f()/-&3 \u001b\u001e'#(#-.\u001f,\u001f\u001e #,)(7\u001e\u001f2.,\u001b(8 \u0002,\n \n\b\u001b\u001f'\u001b.)&8 gomi:\nhk9 lim7lji8\n\u001b3,#--\u001f\n \n6 \u0003\"á0\u001f4\n \n\u00066 \u0003\u001b-.\u001f&&\u001b()\n \n\b6 \u0002)-\u001d\" \u00166 \u0014,)**\u001f, \u00056 \u0002\u001b-.\u001b,\u001e) \u00026 \u001f. \u001b&8 \u0005\u001b,&3 ,\u001f-*)(-\u001f .) .\"\u001f \u001fL·\u001f\u001d. ) #,)(\n),.#l·\u001d\u001b.#)( #( .\"\u001f \u0016\u001f(\u001f4/\u001f&\u001b( *)*/&\u001b.#)(8 \u0001'\n \n\u0003&#( \u000e/.,8 gool: lj9 ofi7ofm8\n)4)L· \u00026\n \n#'ï(\u001f4 \u00056 \u0017)&\n \n\u00018\n \n)(!7.\u001f,' \u001e\u001f0\u001f&)*'\u001f(.\u001b& )/.\u001d)'\u001f )\n \n#( \u001b(.- 1#.\" #,)( \u001e\u001fl·\u001d#\u001f(\u001d38 \u000e \u0005(!&\n \n\u001f\u001e8\ngoog: ihk9 lnm7loj8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":70,"lines":{"from":5,"to":62}}}}],["258",{"pageContent":"),.#l·\u001d\u001b.#)( #( .\"\u001f \u0016\u001f(\u001f4/\u001f&\u001b( *)*/&\u001b.#)(8 \u0001'\n \n\u0003&#( \u000e/.,8 gool: lj9 ofi7ofm8\n)4)L· \u00026\n \n#'ï(\u001f4 \u00056 \u0017)&\n \n\u00018\n \n)(!7.\u001f,' \u001e\u001f0\u001f&)*'\u001f(.\u001b& )/.\u001d)'\u001f )\n \n#( \u001b(.- 1#.\" #,)( \u001e\u001fl·\u001d#\u001f(\u001d38 \u000e \u0005(!&\n \n\u001f\u001e8\ngoog: ihk9 lnm7loj8\n\u001b\"&%(\u001f\u001d\". \u00156 \u0017\u001f#\u001e'\u001b(( \u00056 \u0013\u001f#*\u001f&. \u00078 Ļ\u001f #,,\u001f*&\u001b\u001d\u001f\u001b\u001c&\u001f #'\u001b!\u001f9 \u0002&\u001b\u001d% .\u001f\u001b \u001e\u001f&\u001b3- ,\u001f\u001d)0\u001f,3\n \n,)' #,)(7\u001e\u001fl·\u001d#\u001f(\u001d3\n\u001b(\u001f'#\u001b8 \b\u001b\u001f'\u001b.)&)!#\u001d\u001b8 hffg: nl9 kko8\n\u001b,#!(\u001b(#\n \n6 \u0001(!\u001f&\u001f..# \u00136 \u0002),\u001e# \u00036 \u001f. \u001b&8 \u0012\u001f0\u001f,-\u001b& )\n \n&)(!7-.\u001b(\u001e#(! #,)( \u001e\u001fl·\u001d#\u001f(\u001d3 \u001b(\u001b\u001f'#\u001b \u001b .\u001f, \u001f,\u001b\u001e#\u001d\u001b.#)( )","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":70,"lines":{"from":62,"to":85}}}}],["259",{"pageContent":"Helicobacter pylori\n \n#( \u001f\u001d.#)(8 \u0013\u001d\u001b(\u001e\n \n\u0007\u001b-.,)\u001f(.\u001f,)& goom: ih9 lgm7lhh8\n\u001b-. \u0001\u00056 \u0002&#(\u001e\u001f,\n \n\u00016\n \n/ \u0011 6 \u0006&\u001b2 \u00136 \u0004#\u001f.4\u001f( \u0004 8 \u0003&#(#\u001d\u001b& /.#&#.3 )\n \n.\"\u001f ,\u001f.#\u001d/&)\u001d3.\u001f \"\u001f')!&)\u001c#( \u001d)(.\u001f(. #( .\"\u001f\n\u001e#\u001b!()-#- ) #,)( \u001e\u001fl·\u001d#\u001f(\u001d38 \u0002&))\u001e8 hffh: ooBjC9 gjno7gjog8\n),\u001b \u000f6\n \n),\u001b \u000f\n \n8 \u0004\u001fl·\u001d#\u001f(\u001d#\u001b- \u001e\u001f '#\u001d,)(/.,#\u001f(.\u001f- \u001f( \u0001'ï,#\u001d\u001b\n \n\u001b.#(\u001b 3 \u001f& \u0003\u001b,#\u001c\u001f9 \u0001(\u001f'#\u001b \u001f,,)*,#0\u001b8 \u0017\u001b-\"#(!.)(6\n\u00048\u000389 \u000f,!\u001b(#4\u001b\u001d#ĉ( \u0010\u001b(\u001b'\u001f,#\u001d\u001b(\u001b \u001e\u001f &\u001b \u0013\u001b&/\u001e6 \u0001!\u001f(\u001d#\u001b \u001e\u001f &\u001b- \u000e\u001b\u001d#)(\u001f- \u0015(#\u001e\u001b- *\u001b,\u001b \u001f& \u0004\u001f-\u001b,,)&&)6 \u0012)\u001d\"\u001f \u0012\u001f!#)\n-\n\n(\u001b& \u0001'ï,#\u001d\u001b\n \n\u001b.#(\u001b6 \u000f**),./(#.#\u001f- ),\n \n#\u001d,)(/.,#\u001f(.\n \n(.\u001f,0\u001f(.#)(- \u0010,)$\u001f\u001d. B\u000f\n \n\u000e C: goon8\n\u000f]\u0004)((\u001f&&\n \n\u00016 \u0003\u001b,'/\u001f!\u001b \u0013\u00056 \u0004/,á( \u00108 \u0010,\u001f0\u001f(.#(! #,)( \u001e\u001fl·\u001d#\u001f(\u001d3 #( #( \u001b(.- \u001b(\u001e *,\u001f-\u001d\"))& \u001d\"#&\u001e,\u001f( #( \u0001,!\u001f(.#(\u001b8\n\u000e/., \u0012\u001f08 goom: kk9 gno7goj8\n\u000f,!\u001b(#4\u001b\u001d#ĉ( \u001e\u001f &\u001b- \u000e\u001b\u001d#)(\u001f- \u0015(#\u001e\u001b- *\u001b,\u001b &\u001b \u0001!,#\u001d/&./,\u001b 3 &\u001b \u0001&#'\u001f(.\u001b\u001d#ĉ(6 \u000f,!\u001b(#4\u001b\u001d#ĉ(\n \n/(\u001e#\u001b& \u001e\u001f &\u001b \u0013\u001b&/\u001e8 \u000e\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":70,"lines":{"from":87,"to":126}}}}],["260",{"pageContent":"\u001d\u001f-#\u001e\u001b\u001e\u001f- \u001e\u001f 0#.\u001b'#(\u001b \u00016 \"#\u001f,,)6 )&\u001b.)- 3 0#.\u001b'#(\u001b \u0002gh9\n \n( ),'\u001f \u001e\u001f /(\u001b \u001d)(-/&.\u001b '#2.\u001b \u0006\u0001\u000fI\u000f\n \n\u0013 \u001e\u001f \u001f2*\u001f,.)-8\n\u0012)'\u001b9 \u0006\u0001\u000f: goog8\n\u000f-\u001b%# \u00146 \u0015\u001f.\u001b \u00056 \u0001,#-\u001b1\u001b\n \n6\n \n#.\u001b'/,\u001b \u00196\n \n\u001b.-/!# \u000e8 Ļ\u001f *\u001b.\")*\"3-#)&)!3 ) !&)--\u001b& *\u001b#( #( *\u001b.#\u001f(.- 1#.\" #,)( \u001e\u001fl·\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":70,"lines":{"from":128,"to":141}}}}],["261",{"pageContent":"\u001d#\u001f(\u001d3 \u001b(\u001e \u001b(\u001f'#\u001b8 \u0001'\n \n\u001f\u001e \u0013\u001d#8 gooo: ign9 ihj7iho8\n\u0010ï,\u001f47\u00052*)-#.) \u0001\u00028 \u0001(\u001f'#\u001b 3 \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f '#\u001d,)(/.,#\u001f(.\u001f- \u001f( '/$\u001f,\u001f- '\u001f2#\u001d\u001b(\u001b- \u001e\u001f gh7jo \u001bĄ)- \u001e\u001f \u001f\u001e\u001b\u001e B.\u001f-#- \u001e\u001f\n'\u001b\u001f-.,ù\u001bC8\n \n\u001b\u001e,#\u001e9\n \n(-.#./.) \u001e\u001f \u0013\u001b&/\u001e \u0010Ě\u001c&#\u001d\u001b \u0003\u001b,&)-\n \n: hffg8\n\u0010#\u001f\u001e,\u001b-7\u0012ù)-\n \n6 \u0003ĉ,\u001e)0\u001b7\u0003\u001b\u001c\u001b&&\u001f,)\n \n6 &0\u001b,\u001f47\b\u001f,(á(\u001e\u001f4 \u00188 \u0015.#&#\u001e\u001b\u001e \u001e\u001f \u001b&!/()- *\u001b,á'\u001f.,)- \"\u001f'\u001b.)&ĉ!#\u001d)- \u001f( \u001f&\n\u001e#\u001b!(ĉ-.#\u001d) \u001e\u001f \u001b(\u001f'#\u001b *), \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) \u001f( (#Ą)- 3 '/$\u001f,\u001f-8 \u0002)&\n \n\u001f\u001e \b)-*\n \n( \u001b(.\n \nï28 gong: in9 ogg7ohh8\n\u0010,#.\u001d\"\u001b,\u001e \u00046 \u0011/#((\u001f&& \u00126\n \n)/-.\u001b \u001b\n \n6 \u001f. \u001b&8 \b))%1),' B\nNecator americanus\nC #( \u001f\u001d.#)( \u001b(\u001e -.),\u001b!\u001f #,)( \u001e\u001f*&\u001f.#)(8\n\u0014,\u001b(- \u0012 \u0013)\u001d \u0014,)*\n \n\u001f\u001e \b3!8 goog: nk9 hik7hin8\n\u0012)\u001e,ù!/\u001f4 \u00076 \u0003\u001b\u001c,\u001f,\u001b \b\u00016 \u0003\u001b&\u001e\u001f,ĉ( \u0016\n \n6 \u0012)\u001e,ù!/\u001f4 \u0013\u00016 \u0012)'\u001f,)\n \n\u00036 \u0013á(\u001d\"\u001f4 \u0005\n \n8 \u0001&#'\u001f(.\u001b\u001d#ĉ( 3 \u001b(\u001f'#\u001b \u001f(\n/( !,/*) \u001e\u001f \u001f-\u001d)&\u001b,\u001f- \u001e\u001f *,#'\u001b,#\u001b8 \u0012\u001f0 \u0003/\u001c \u0001&#'\u001f(. \u000e/.8 goom: gg9 hl7ij8\n\u0012/#47\u0001,!Ĝ\u001f&&\u001f- \u0007 8\n \n(\u001f \u001f\u001d.#0\u001f(\u001f-- ) ),\u001b& #,)( \"3\u001e,)2#\u001e\u001f *)&3'\u001b&.)-\u001f #( #,)(7\u001e\u001fl·\u001d#\u001f(\u001d3 \u001b(\u001f'#\u001b8 \b\u001f'\u001b.)&)!38 hffm:\nghBiC9 hkk7hkl8\n\u0012/#47\u0001,!Ĝ\u001f&&\u001f- \u0007 8\n \n,)( \u001e\u001fl·\u001d#\u001f(\u001d3 \u001b(\u001f'#\u001b #( &)1 \u001b(\u001e '#\u001e\u001e&\u001f #(\u001d)'\u001f \u001d)/(.,#\u001f-8 \u0002&))\u001e hfgi: ghh9 hhno8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":70,"lines":{"from":143,"to":190}}}}],["262",{"pageContent":"ghBiC9 hkk7hkl8\n\u0012/#47\u0001,!Ĝ\u001f&&\u001f- \u0007 8\n \n,)( \u001e\u001fl·\u001d#\u001f(\u001d3 \u001b(\u001f'#\u001b #( &)1 \u001b(\u001e '#\u001e\u001e&\u001f #(\u001d)'\u001f \u001d)/(.,#\u001f-8 \u0002&))\u001e hfgi: ghh9 hhno8\n\u0013#&0\u001f,-.\u001f#( \u0013\u00026 \u0012)\u001e!\u001f,- \u0007\n \n8 \u0010\u001b,\u001f(.\u001f,\u001b& #,)( .\"\u001f,\u001b*3 )*.#)(-8 \u0001'\n \n\b\u001f'\u001b.8 hffj: ml9 mj7n8\n\u0015'\u001c,#\u001f. 8\n \n,)( \u001e\u001fl·\u001d#\u001f(\u001d39 \u0001 \u001d)(\u001d#-\u001f ,\u001f0#\u001f18 \u0001'\n \n\b\u001f'\u001b.8 hffk: mn9 hhk7ig8\n\u0015(#.\u001f\u001e \u000e\u001b.#)(- \u0003\"#&\u001e,\u001f(]- \u0006/(\u001e6 \u0017),&\u001e \b\u001f\u001b&.\" \u000f,!\u001b(#4\u001b.#)(8 )#(. \u0003)''#..\u001f\u001f )( \b\u001f\u001b&.\" \u0010)&#\u001d39 \u0017),&\u001e -/''#. ),\n\u001d\"#&\u001e,\u001f(8 \u0007\u001f(\u001f0\u001b9 \u0017\b\u000f: gook8\n\u00154\u001f& \u00036 \u0003)(,\u001b\u001e\n \n8 \u0001\u001c-),*.#)( ) \"\u001f'\u001f #,)(8 \u0013\u001f'#( \b\u001f'\u001b.)&8 goon: ik9 hm7ij8\n\u0016\u001b( \u00173\u001d% \u00046 \u0003\u001b0\u001b&&) \u00076 \u0013*#()1#.4 \u00026 \u001f. \u001b&8 \u0013\u001b \u001f.3 \u001b(\u001e \u001fŃ\u001d\u001b\u001d3 ) #,)( -/\u001d,)-\u001f #( *\u001b.#\u001f(.- -\u001f(-#.#0\u001f .) #,)( \u001e\u001f2.,\u001b(9\n\u000e),.\" \u0001'\u001f,#\u001d\u001b( \u001d&#(#\u001d\u001b& .,#\u001b&8 \u0001'\n \n#\u001e(\u001f3 \u0004#-8 hfff: il9 nn7om8\n\u001a/'\u001c\u001f,!\n \n6\n \n\u001f#--#(!\u001f, \u00038 \u0001\u001d+/#,\u001f\u001e /(\u001e\u001f,*,)\u001e/\u001d.#)( \u001b(\u001f'#\u001b-8 \u0001'\u001f,#\u001d\u001b( \u0013)\u001d#\u001f.3 )\n \n\b\u001f'\u001b.)&)!3 \u0013\u001f&\n \n\u0001--\u001f--'\u001f(.\n\u0010,)!,\u001b'8 i,\u001e \u001f\u001e#.#)(8 \u0017\u001b-\"#(!.)(6 \u00048\u000389 \u0001\u0013\b: hffm8 *8 mo 7ni8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":70,"lines":{"from":190,"to":222}}}}],["263",{"pageContent":"RESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\ng8\n \n\u001b\nh8\n \nc\n\ni8\n \n\u001c\nj8\n \n\u001c\nk8\n \nc","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":70,"lines":{"from":224,"to":241}}}}],["264",{"pageContent":"45\n\nObjetivos de aprendizaje\n\n•\n \n\u0013\u001fĄ\u001b&\u001b, &\u001b #(\u001d#\u001e\u001f(\u001d#\u001b 3 \u001f.#)*\u001b.)!\u001f(#\u001b \u001e\u001f &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8\n•\n \n\u0003)()\u001d\u001f, \u001f& \u001d/\u001b\u001e,) \u001d&ù(#\u001d) 3 \"\u001f'\u001b.)&ĉ!#\u001d) \u001e\u001f &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8\n•\n \n\u001e\u001f(.#l·\u001d\u001b, &)- !,/*)- \u001e\u001f ,#\u001f-!) *\u001b,\u001b \u001e\u001f-\u001b,,)&&\u001b, \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8\n•\n \n\u0004\u001f-\u001d,#\u001c#, \u001f& \u001e#\u001b!(ĉ-.#\u001d) \u001e# \u001f,\u001f(\u001d#\u001b& \u001e\u001f &\u001b- \u001b(\u001f'#\u001b- '\u001b\u001d,)\u001dù.#\u001d\u001b-8\n•\n \n\u0005(.\u001f(\u001e\u001f, &\u001b #'*),.\u001b(\u001d#\u001b \u001e\u001f& .,\u001b.\u001b'#\u001f(.) \u001c\u001b-\u001b\u001e) \u001f( \u001f& ),#!\u001f( \u001e\u001f &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b (/.,#'\u001f(.\u001b& 3 \u001d)()\n-\n\n\u001d\u001f, &\u001b- \u001d)(-\u001f\u001d/\u001f(\u001d#\u001b- (\u001f/,)&ĉ!#\u001d\u001b- \u001e\u001f /( .,\u001b.\u001b'#\u001f(.) #(-/l·\u001d#\u001f(.\u001f8\n\nINTRODUCCIÓN\n\n\u001b- \u001b(\u001f'#\u001b- '\u001f!\u001b&)\u001c&á-.#\u001d\u001b- -)( \u001f(.#\u001e\u001b\u001e\u001f- \"\u001f'á.#\u001d\u001b- +/\u001f -\u001f *,\u001f-\u001f(.\u001b( \u001b \u001d)(-\u001f\u001d/\u001f(\u001d#\u001b \u001e\u001f /( .,\u001b-\n-\n\n.),() '\u001b\u001e/,\u001b.#0) \u001e\u001f &)- *,\u001f\u001d/,-),\u001f- \u001f,#.,)#\u001e\u001f- 3 '#\u001f&)#\u001e\u001f- \u001e\u001f(.,) \u001e\u001f &\u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b8 \u0005& okz \u001e\u001f &)-\n\u001d\u001b-)- \u001d/,-\u001b( \u001d)( \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f 0#.\u001b'#(\u001b \u0002gh ) á\u001d#\u001e)\n \nĉ&#\u001d)8\n \n\u001b \u001d\u001b,\u001f(\u001d#\u001b \u001e\u001f \u001f-.)- \u001f&\u001f'\u001f(.)- #(\u001e/\u001d\u001f\n/(\u001b -ù(.\u001f-#- \u001e\u001f \u001f\u001d./)-\u001b \u001e\u001f &)- á\u001d#\u001e)- (/\u001d&\u001f#\u001d)-8\n \n\u001b- \u001dï&/&\u001b- '), )&ĉ!#\u001d\u001b'\u001f(.\u001f -)( ,\u001f\u001d)()\u001d#\u001e\u001b- \u001d)')\n'\u001f!\u001b&)\u001c&\u001b-.)-6 *), *,\u001f-\u001f(.\u001b, /(\u001b '\u001b\u001e/,\u001b\u001d#ĉ( \u001b-#(\u001d,ĉ(#\u001d\u001b8 \u0005& \u001d#.)*&\u001b-'\u001b .#\u001f(\u001f '\u001b3), '\u001b-\u001b 3 '\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":72,"lines":{"from":1,"to":39}}}}],["265",{"pageContent":"\u001e/,\u001b\u001d#ĉ( +/\u001f \u001f& (Ě\u001d&\u001f)8 \u0005-.\u001b \u001b&.\u001f,\u001b\u001d#ĉ( -\u001f \u001f(\u001d/\u001f(.,\u001b *,\u001f-\u001f(.\u001f \u001f( &\u001b- .,\u001f- &ù(\u001f\u001b- \u001d\u001f&/&\u001b,\u001f-9 \u001f,#.,)\u001d#.)-6\n&\u001f/\u001d)\u001d#.)- 3 *&\u001b+/\u001f.\u001b-6 \u001b-ù \u001d)') \u001f( &\u001b- \u001dï&/&\u001b- () \"\u001f'\u001b.)*)3ï.#\u001d\u001b- \u001d)( \u001f&\u001f0\u001b\u001e) ,\u001f\u001d\u001b'\u001c#) \u001d\u001f&/&\u001b,6\n\u001d)') *#\u001f&6 '/\u001d)-\u001b- 3 \u001f*#.\u001f&#) !\u001b-.,)#(.\u001f-.#(\u001b&8\n \n\u001b- '\u001b(# \u001f-.\u001b\u001d#)(\u001f- \u001d&ù(#\u001d\u001b- -)( .ù*#\u001d\u001b-6 \u001d)( \u001b(),\n-\n\n'\u001b&#\u001e\u001b\u001e\u001f- \u001d\u001b,\u001b\u001d.\u001f,ù-.#\u001d\u001b- \u001f( &\u001b \u001d#.)'\u001f.,ù\u001b \"\u001f'á.#\u001d\u001b 3 &\u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b8\n\u001e\u001f(.#l·\u001d\u001b, &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001f-*\u001f\u001dùl·\u001d\u001b ,\u001f-/&.\u001b 0#.\u001b&6 *),+/\u001f &\u001b- \u001b(\u001f'#\u001b- '\u001f!\u001b&)\u001c&á-.#\u001d\u001b- *), \u001e\u001f\n-\n\nl·\u001d#\u001f(\u001d#\u001b \u001e\u001f 0#.\u001b'#(\u001b \u0002gh -)( /(\u001b \u001d\u001b/-\u001b ,\u001f0\u001f,-#\u001c&\u001f \u001e\u001f& -ù(\u001e,)'\u001f \u001e\u001f\n \n\u001b&&\u001b '\u001f\u001e/&\u001b, 3 \u001e\u001f &\u001b \u001f( \u001f,\n-\n\n'\u001f\u001e\u001b\u001e \u001e\u001f-'#\u001f&#(#4\u001b(.\u001f \u001e\u001f& -#-.\u001f'\u001b (\u001f,0#)-)8 \u0005( \u001d)(-\u001f\u001d/\u001f(\u001d#\u001b6 \u001f& .,\u001b.\u001b'#\u001f(.) \u001e\u001f\u001c\u001f \u001f-.\u001b, &#!\u001b\u001e)\n\u001b &\u001b \u001d\u001b/-\u001b +/\u001f &\u001b *,)\u001e/\u001d\u001f8 \u0014,\u001b.\u001b, \u001b /( \u001f( \u001f,') \u001b(ï'#\u001d) \u001d)( *,\u001f*\u001b,\u001b\u001e)- \u001e\u001f '/&.#0#.\u001b'ù(#\u001d)- -#(\n\u001d)()\u001d\u001f, &\u001b \u001f.#)*\u001b.)!\u001f(#\u001b */\u001f\u001e\u001f )\u001d\u001b-#)(\u001b,\n \n\u001e\u001bĄ)- \u001b &\u001b -\u001b&/\u001e6 \u001b \u001f\u001d.\u001b\u001d#ĉ( \u001e\u001f& *\u001b.,#')(#) *\u001f,-)(\u001b&\n3 ,\u001f*\u001f,\u001d/-#)(\u001f- &\u001b\u001c),\u001b&\u001f- *),+/\u001f6 \u001b/(+/\u001f ,\u001b,)6 &\u001b- -\u001f\u001d/\u001f&\u001b- (\u001f/,)&ĉ!#\u001d\u001b- \u001e\u001f /(\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":72,"lines":{"from":41,"to":63}}}}],["266",{"pageContent":"\u001c&á-.#\u001d\u001b *), \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f 0#.\u001b'#(\u001b \u0002gh */\u001f\u001e\u001f( )\u001d\u001b-#)(\u001b, \u001e#l·\u001d/&.\u001b\u001e\u001f- *\u001b,\u001b ,\u001f#(.\u001f!,\u001b,-\u001f \u001b &\u001b 0#\u001e\u001b\n*,)\u001e/\u001d.#0\u001b8\n\nCAPÍTULO 4\n\nFernando Romero García\nJosé Rodríguez Carrillo\nIdentificar la deficiencia es-\npecífica resulta vital, porque\nlas anemias megaloblásticas\npor deficiencia de vitamina\nB12 son una causa reversible\ndel síndrome de falla medular\ny de la enfermedad desmieli-\nnizante del sistema nervioso.\n\nANEMIAS\nMEGALOBLÁSTICAS\n\n“Hombre de 62 años, con antecedentes de diabetes mellitus tipo 1,\nhipotiroidismo, consulta por fatiga, anemia macrocítica y dificultad para\ncaminar. Se diagnostica anemia perniciosa.”","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":72,"lines":{"from":65,"to":86}}}}],["267",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n46\n\n\u0005& .ï,'#()\n \nmegaloblástica\n \n/\u001f #(.,)\u001e/\u001d#\u001e) *), \u0005\",&#\u001d\" \u001f( gnnf 3 -\u001f /-ĉ *\u001b,\u001b \u001e\u001f-\u001d,#\u001c#, \u001b &)- (),')\u001c&\u001b-\n-\n\n.)- )\u001c-\u001f,0\u001b\u001e)- \u001f( \u001f-\u001f *\u001b\u001e\u001f\u001d#'#\u001f(.)8 \u0013#( \u001f'\u001c\u001b,!)6 &)- \u001b0\u001b(\u001d\u001f- \u001f( \u001f& \u001d)()\u001d#'#\u001f(.) \u001e\u001f &\u001b \u001f( \u001f,'\u001f\u001e\u001b\u001e -\u001f\n,\u001f\u001b&#4\u001b,)( \u001b *,#(\u001d#*#)- \u001e\u001f& -#!&) \u0018\u00188 \u0005( gohl6 \u0007\u001f),!\u001f \u00128\n \n#(). 3 \u0017#&&#\u001b' \u00108\n \n/,*\"3 \u001d)'/(#\u001d\u001b,)( &\u001b\n\u001d/,\u001b\u001d#ĉ( \u001e\u001f &\u001b \u001b(\u001f'#\u001b \u001d)( /(\u001b \u001e#\u001f.\u001b ,#\u001d\u001b \u001f( \"ù!\u001b\u001e)8 \u0014,\u001f- \u001bĄ)- \u001e\u001f-*/ï- BgohoC6 \u0017#&&#\u001b' \u0002)-1),.\" \u0003\u001b-.&\u001f\n3 \u001d)&\u001b\u001c),\u001b\u001e),\u001f- \u001e\u001f-\u001d,#\u001c#\u001f,)( \u001f& \u001b\u001d.), #(.,ù(-\u001f\u001d)8 \u0005& á\u001d#\u001e) ĉ&#\u001d)6 \u001e\u001f& &\u001b.ù(\n \nfolium\n \nB\")$\u001bC6 /\u001f \u001e\u001f-\u001d/\u001c#\u001f,.) \u001f(\n&\u001b\n \n(\u001e#\u001b \u001f( goig *),\n \n8 \u0017#&&- B \u001b\u001d.), \u001e\u001f \u0017#&&-C6 3 /\u001f \u001b#-&\u001b\u001e) \u001f( gojg \u001e\u001f &\u001b- \")$\u001b- \u001e\u001f &\u001b \u001f-*#(\u001b\u001d\u001b8 \u0006/\u001f \"\u001b-.\u001b\ngojn \u001d/\u001b(\u001e) \u00078 \u0006\u001b&%\u001f, 3\n \n8 \u0013'#.\" \u001b#-&\u001b,)( &\u001b 0#.\u001b'#(\u001b \u0002gh8\n\nINCIDENCIA Y ETIOPATOGENIA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":73,"lines":{"from":1,"to":33}}}}],["268",{"pageContent":"INCIDENCIA Y ETIOPATOGENIA\n\n\u0003# ,\u001b- \u001e\u001f &\u001b \u000f,!\u001b(#4\u001b\u001d#ĉ(\n \n/(\u001e#\u001b& \u001e\u001f &\u001b \u0013\u001b&/\u001e B\u000f\n \n\u0013C -\u001fĄ\u001b&\u001b( +/\u001f \u001f( \u001f& '/(\u001e) 0#0\u001f( h '#& '#&&)(\u001f-\n\u001e\u001f *\u001f,-)(\u001b- \u001b(ï'#\u001d\u001b- 3 +/\u001f \u001b*,)2#'\u001b\u001e\u001b'\u001f(.\u001f \u001f& kfz \u001e\u001f &)- \u001d\u001b-)- -\u001f \u001b.,#\u001c/3\u001f( \u001b &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)8\n\u0005& \u001eïl·\u001d#. \u001e\u001f 0#.\u001b'#(\u001b \u0002gh 3 á\u001d#\u001e)\n \nĉ&#\u001d) \u001d)(\u001e#\u001d#)(\u001b \u001b &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b6 \u001b/(+/\u001f -\u001f \u001e\u001f-\u001d)()\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":73,"lines":{"from":33,"to":44}}}}],["269",{"pageContent":"\u001d\u001f \u001f& #'*\u001b\u001d.) *,\u001f\u001d#-) \u001f( \u001d# ,\u001b-8 \u0013#( \u001f'\u001c\u001b,!)6 -\u001f \u001f-.#'\u001b +/\u001f &\u001b- \u001b(\u001f'#\u001b- '\u001f!\u001b&)\u001c&á-.#\u001d\u001b- \u001d)(-.#./3\u001f(\n\u001e\u001f& h \u001b& kz \u001e\u001f& .).\u001b& \u001e\u001f &\u001b- \u001b(\u001f'#\u001b-8 \u0005( !\u001f(\u001f,\u001b&6 \u001f(\n \n\u001c\u001f,)\u001b'ï,#\u001d\u001b -)( *\u001b\u001e\u001f\u001d#'#\u001f(.)- *)\u001d)\n \n,\u001f\u001d/\u001f(.\u001f-6 3\n&)- #( ),'\u001f- \u001f*#\u001e\u001f'#)&ĉ!#\u001d)- -)( \u001f-\u001d\u001b-)-8 \u0003\u001b,'\u001f&6 \u001e\u001f &\u001b \u0015(#0\u001f,-#\u001e\u001b\u001e \u001e\u001f& \u0013/, \u001e\u001f \u0003\u001b&# ),(#\u001b6 #(0\u001f-.#!ĉ\n&\u001b \u001f\u001e\u001b\u001e \u001e\u001f *,\u001f-\u001f(.\u001b\u001d#ĉ( \u001e\u001f &\u001b \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b \u001f(.,\u001f oh *\u001b\u001d#\u001f(.\u001f- &\u001b.#()\u001b'\u001f,#\u001d\u001b()-6 ggk \u001c&\u001b(\u001d)- 3 gff\n\u001b ,)\u001b'\u001f,#\u001d\u001b()- \u001d)( \u001f-.\u001b \u001f( \u001f,'\u001f\u001e\u001b\u001e8\n \n)- &\u001b.#()\u001b'\u001f,#\u001d\u001b()- \")'\u001c,\u001f- 3 '/$\u001f,\u001f-\n \n/\u001f,)( 'á- $ĉ0\u001f(\u001f-6 3\nĚ(#\u001d\u001b'\u001f(.\u001f \u001f& hgz .\u001f(ù\u001b mf ) 'á- \u001bĄ)-6 \u001d)'*\u001b,\u001b\u001e)- \u001d)(.,\u001b \u001f& joz \u001e\u001f &)- \u001c&\u001b(\u001d)-8\n\u0013\u001f \u001e\u001f\u001c\u001f \u001e\u001f-.\u001b\u001d\u001b, +/\u001f *), '/\u001d\")- \u001bĄ)- -\u001f \u001e#$) +/\u001f &\u001b \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b () -\u001f )\u001c-\u001f,0\u001b\u001c\u001b \u001f( &\u001b *)\u001c&\u001b\u001d#ĉ(\n'\u001f-.#4\u001b \u001e\u001f\n \nï2#\u001d)8 \u0013#( \u001f'\u001c\u001b,!)6 \u001f-./\u001e#)- ,\u001f\u001b&#4\u001b\u001e)- \u001f( \u001f-.\u001f *\u001bù- \u001e\u001f'/\u001f-.,\u001b( +/\u001f &\u001b \u001b(\u001f'#\u001b *), \u001e\u001fl·\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":73,"lines":{"from":46,"to":64}}}}],["270",{"pageContent":"\u001d#\u001f(\u001d#\u001b \u001e\u001f 0#.\u001b'#(\u001b \u0002gh () \u001f- .\u001b( ,\u001b,\u001b \u001d)') -\u001f *\u001f(-\u001b\u001c\u001b8 \u0004\u001f m̓ gil *\u001b\u001d#\u001f(.\u001f- \u001b.\u001f(\u001e#\u001e)- \u001f( /( &\u001b*-) \u001e\u001f gm\n\u001bĄ)- \u001f( &\u001b \u0003&ù(#\u001d\u001b \u0012/#4 \u001e\u001f &\u001b \u001d#/\u001e\u001b\u001e \u001e\u001f \u0010/\u001f\u001c&\u001b6\n \nï2#\u001d)6 lgh *,\u001f-\u001f(.\u001b,)( -ù(\u001e,)'\u001f \u001b(ï'#\u001d)6 \u001e\u001f &)- \u001d/\u001b&\u001f-\n\u001f& mj6nz \u001d),,\u001f-*)(\u001e#\u001f,)( \u001b \u001b(\u001f'#\u001b- \u001d\u001b,\u001f(\u001d#\u001b&\u001f- 3 \u001e\u001f \u001f-.\u001b- oi6hz\n \n/\u001f,)( \u001d&\u001b-#l·\u001d\u001b\u001e\u001b- \u001d)') \u001e\u001fl·\u001d#\u001f(.\u001f- \u001f(\n\"#\u001f,,)8 \u0004\u001f \u001b+/ù6 ho *\u001b\u001d#\u001f(.\u001f-6 \u001f- \u001e\u001f\u001d#,6 \u001f& jz6 \u001d/'*&#\u001f,)( \u001d)( \u001f& \u001d,#.\u001f,#) \"\u001f'\u001b.)&ĉ!#\u001d) \u001e\u001f \u001b(\u001f'#\u001b '\u001f!\u001b&)\n-\n\n\u001c&á-.#\u001d\u001b6 \u001e\u001f')-.,\u001b(\u001e) \u001f( \u001d/\u001b.,) \u001e\u001f \u001f&&)- \u001d\u001b,\u001f(\u001d#\u001b \u001e\u001f á\u001d#\u001e) ĉ&#\u001d) 3 &)- hk ,\u001f-.\u001b(.\u001f- \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f 0#.\u001b'#(\u001b\n\u0002gh8 \u000f.,)- \u001f-./\u001e#)-6 \u001d)') \u001f& ,\u001f\u001b&#4\u001b\u001e) \u001f( \u001f& (-.#./.) \u000e\u001b\u001d#)(\u001b& \u001e\u001f \u0003#\u001f(\u001d#\u001b-\n \nï\u001e#\u001d\u001b- 3 \u000e/.,#\u001d#ĉ( \u0013\u001b&0\u001b\u001e),\n\u001a/\u001c#,á( B \u000e\u0003\n \n\u000e\u0013\u001aC6 \u001e\u001f.\u001f\u001d.\u001b,)( f6ghz *\u001b\u001d#\u001f(.\u001f- \u001d)( \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b B\u001f( mi̓fff \u001f!,\u001f-)- oi \u001d\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":73,"lines":{"from":66,"to":83}}}}],["271",{"pageContent":"-)-C6 3 \u001e\u001f g̓ hff *\u001b\u001d#\u001f(.\u001f- \u001d)( *,)\u001c&\u001f'\u001b- \"\u001f'á.#\u001d)- \u001b.\u001f(\u001e#\u001e)- \u001f( &\u001b '\u001f\u001e#\u001d#(\u001b *,#0\u001b\u001e\u001b6 gh *\u001b\u001e\u001f\u001dù\u001b( \u001b(\u001f'#\u001b\n'\u001f!\u001b&)\u001c&á-.#\u001d\u001b6 ) -\u001f\u001b6 \u001f& g6fz8 \u000f.,\u001b */\u001c&#\u001d\u001b\u001d#ĉ( \u001e\u001f&\n \n\u000e\u0003\n \n\u000e\u0013\u001a \u001f(\u001d/\u001f(.,\u001b hi \u001b(\u001f'#\u001b- *\u001f,(#\u001d#)-\u001b- \u001f( gfk\n\u001d\u001b-)- \u001e\u001f \u001b(\u001f'#\u001b- '\u001f!\u001b&)\u001c&á-.#\u001d\u001b-8\n\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b *), \u001e\u001fl·\u001d#\u001f(.\u001f \u001b*),.\u001f (/.,#'\u001f(.\u001b& \u001e\u001f 0#.\u001b'#(\u001b \u0002gh \u001f- #( ,\u001f\u001d/\u001f(.\u001f \u001f( &)-\n*\u001bù-\u001f- \u001d)( \u001f\u001d)()'ù\u001b- /\u001f,.\u001f-8\n \n\u001b'\u001f(.\u001b\u001c&\u001f'\u001f(.\u001f6 -\u001f -#!/\u001f )\u001c-\u001f,0\u001b(\u001e) \u001f( \u001b&!/(\u001b- á,\u001f\u001b- !\u001f)!,ál·\u001d\u001b- \u001e\u001f ,\u001f\n-\n\n!#)(\u001f- \u001f'\u001f,!\u001f(.\u001f- \u001d)')  ,#\u001d\u001b6 \u0003\u001f(.,)\u001b'ï,#\u001d\u001b 3 \u0013/\u001e\u001b'ï,#\u001d\u001b8 \u0013\u001f!/#, /(\u001b \u001e#\u001f.\u001b \u001f-.,#\u001d.\u001b'\u001f(.\u001f 0\u001f!\u001f.\u001b,#\u001b(\u001b\n*), \u001bĄ)- \u001b!).\u001b &\u001b- ,\u001f-\u001f,0\u001b- \u001e\u001f 0#.\u001b'#(\u001b \u0002gh +/\u001f6 \u001f( \u001d\u001b-) \u001e\u001f () -\u001f, -/*&\u001f'\u001f(.\u001b\u001e\u001b6 -\u001f \u001d),,\u001f \u001f& ,#\u001f-!) \u001e\u001f\n-/ ,#, \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b6 +/\u001f \u001f- \u001d\u001b/-\u001b \u001e\u001f \"#*\u001f,\")')\u001d#-.\u001f#(\u001f'#\u001b 3 \u001f&\u001f0\u001b\u001d#ĉ( \u001e\u001f á\u001d#\u001e) '\u001f.#&'\u001b&ĉ(#\u001d)8\n\u0005& .ï,'#()\n \nanemia perniciosa\n \n-\u001f ,\u001fl·\u001f,\u001f \u001b &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b \u001f( &\u001b +/\u001f \u001f2#-.\u001f /(\u001b !\u001b-.,#.#-\n\u001b/.)#('/(#.\u001b,#\u001b 3 \u001e\u001f-.,/\u001d\u001d#ĉ( \u001e\u001f &\u001b- \u001dï&/&\u001b- *\u001b,#\u001f.\u001b&\u001f- \u001e\u001f& \u001f-.ĉ'\u001b!)6 \u001d)( *ï,\u001e#\u001e\u001b \u001e\u001f&\n \n\u001b\u001d.), #(.,ù(-\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":73,"lines":{"from":85,"to":109}}}}],["272",{"pageContent":"\u001d) +/\u001f -\u001f /(\u001f \u001b &\u001b 0#.\u001b'#(\u001b \u0002gh #(!\u001f,#\u001e\u001b *), &\u001b \u001e#\u001f.\u001b8\n \n\u001b ,\u001f-*/\u001f-.\u001b #('/(#.\u001b,#\u001b 0\u001b \u001e#,#!#\u001e\u001b \u001d)(.,\u001b &\u001b\n\bI\n \n7\u0001\u0014\u0010\u001b-\u001b !á-.,#\u001d\u001b6 *,)0)\u001d\u001b(\u001e) \u001b\u001d&),\"#\u001e,#\u001b8 \u000f.,\u001b- \u001f( \u001f,'\u001f\u001e\u001b\u001e\u001f- \u001b/.)#('/(#.\u001b,#\u001b- -\u001f \u001b-)\u001d#\u001b( \u001d)(\n\u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b6 \u001f-*\u001f\u001d#\u001b&'\u001f(.\u001f &\u001b \u001f( \u001f,'\u001f\u001e\u001b\u001e .#,)#\u001e\u001f\u001b6 &\u001b \u001e#\u001b\u001c\u001f.\u001f- '\u001f&&#./- .#*) g 3 \u001f& 0#.ù&#!)8\n \n\u001b\n!\u001b-.,#.#- \u001b/.)#('/(#.\u001b,#\u001b */\u001f\u001e\u001f \u001d\u001b/-\u001b, \u001b\u001c-),\u001d#ĉ( \u001e\u001fl·\u001d#\u001f(.\u001f \u001e\u001f \"#\u001f,,)6 \u001d)( \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001d&ù(#\u001d\u001b \u001e\u001f \"#\u001f,,)\n+/\u001f -\u001f *,\u001f-\u001f(.\u001b \u001f( \u001f.\u001b*\u001b- .\u001f'*,\u001b(\u001b- \u001e\u001f &\u001b 0#\u001e\u001b6 *,)!,\u001f-\u001b(\u001e) \u001f0\u001f(./\u001b&'\u001f(.\u001f \u001b \u001b\u001c-),\u001d#ĉ( #(-/l·\u001d#\u001f(.\u001f \u001e\u001f\n&\u001b 0#.\u001b'#(\u001b \u0002gh8\n\u001b \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b .#\u001f(\u001f /(\u001b #(\u001d#\u001e\u001f(\u001d#\u001b \u001e\u001f kf \u001b j̓ fff \u001d\u001b-)- *), \u001d\u001b\u001e\u001b gff̓fff \"\u001b\u001c#.\u001b(.\u001f- 3 -\u001f *,\u001f-\u001f(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":73,"lines":{"from":111,"to":124}}}}],["273",{"pageContent":".\u001b \u001b \u001d/\u001b&+/#\u001f, \u001f\u001e\u001b\u001e6 *\u001f,) -\u001f,#\u001f- !,\u001b(\u001e\u001f- #( ),'\u001b( /(\u001b \u001f\u001e\u001b\u001e \u001e\u001f *,\u001f-\u001f(.\u001b\u001d#ĉ( \u001f(.,\u001f mf 3 nf \u001bĄ)-8\n \n\u001b \u001b(\u001f'#\u001b\n*\u001f,(#\u001d#)-\u001b \u001f- 'á- \u001d)'Ě( \u001f( *\u001f,-)(\u001b- \u001d)( \u001b(\u001d\u001f-.,)- \u001e\u001f  ,#\u001d\u001b ) \u001e\u001f \u0005/,)*\u001b -\u001f*.\u001f(.,#)(\u001b& B*,\u001f0\u001b&\u001f(\u001d#\u001b \u001f(.,\u001f\n\u001b\u001e/&.)- '\u001b3),\u001f- \u001e\u001f j6iz 3 j6fz6 ,\u001f-*\u001f\u001d.#0\u001b'\u001f(.\u001fC8 \u0005( \u0001-#\u001b \u001f- #( ,\u001f\u001d/\u001f(.\u001f8 \u00052#-.\u001f(\n \n),'\u001b- \u001e\u001f !\u001b-.,#.#-\n\u001b.,ĉl·\u001d\u001b \u001d)( \"#*)\u001d&),\"#\u001e,#\u001b6 +/\u001f *,)0)\u001d\u001b #(\u001d\u001b*\u001b\u001d#\u001e\u001b\u001e *\u001b,\u001b &#\u001c\u001f,\u001b, &\u001b 0#.\u001b'#(\u001b \u0002gh /(#\u001e\u001b \u001b *,).\u001fù(\u001b- \u001e\u001f &\u001b\n\u001e#\u001f.\u001b6 \u001b \u001f\u001d.\u001b(\u001e) \u001b& hfz \u001e\u001f &)- \u001b\u001e/&.)-8 \u0005( \u001f& *\u001f,ù)\u001e) \u001e\u001f gono \u001b gooj6 \u001f( ).,\u001b- &\u001b.#./\u001e\u001f-6 \u001d)') \u0010\u001f,Ě6\n \n/\u001f\n\u001d)'/(#\u001d\u001b\u001e\u001b &\u001b \u001f2*\u001f,#\u001f(\u001d#\u001b \u001e\u001f& \b)-*#.\u001b& \u000e\u001b\u001d#)(\u001b& \u0004\u001b(#\u001f& \u0001&\u001d#\u001e\u001f-6 \u001f(\u001d)(.,\u001b(\u001e) mf \u001d\u001b-)- \u001e\u001f \u001b(\u001f'#\u001b '\u001f!\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":73,"lines":{"from":126,"to":138}}}}],["274",{"pageContent":"&)\u001c&á-.#\u001d\u001b6 hl \u001e\u001f &)- \u001d/\u001b&\u001f- \u001d),,\u001f-*)(\u001eù\u001b( \u001b &\u001b 0\u001b,#\u001f\u001e\u001b\u001e \u001e\u001f \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b8\n\u001b- '/$\u001f,\u001f- \u001f'\u001c\u001b,\u001b4\u001b\u001e\u001b- \u001d)(-.#./3\u001f( /( !,/*) \u001e\u001f ,#\u001f-!) *\u001b,\u001b \u001e\u001f-\u001b,,)&&\u001b, \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f á\u001d#\u001e) ĉ&#\u001d)\n3 0#.\u001b'#(\u001b \u0002gh8 \u0004/,\u001b(.\u001f \u001f& \u001f'\u001c\u001b,\u001b4)6 &\u001b- (\u001f\u001d\u001f-#\u001e\u001b\u001e\u001f- \u001e\u001f á\u001d#\u001e) ĉ&#\u001d) -\u001f #(\u001d,\u001f'\u001f(.\u001b( *), \u001f& \u001d,\u001f\u001d#'#\u001f(.)\n\u001e\u001f& Ě.\u001f,) 3 \u001e\u001f& \u001f.)6 ,\u001f+/#,#\u001f(\u001e) \u001e/,\u001b(.\u001f &\u001b !\u001f-.\u001b\u001d#ĉ( \"\u001b-.\u001b lff̓! \u001e#\u001b,#)- \u001e\u001f á\u001d#\u001e) ĉ&#\u001d)8 \u0005( &)- -#!/#\u001f(\n-\n\n.\u001f- \u001d\u001b-)- \u001f- (\u001f\u001d\u001f-\u001b,#) /( \u001b*),.\u001f \u001b\u001e#\u001d#)(\u001b&9 -# \u001f& \u001f'\u001c\u001b,\u001b4) \u001f- 'Ě&.#*&\u001f6 \u001b(.\u001f\u001d\u001f\u001e\u001f(.\u001f \u001e\u001f \u001f'\u001c\u001b,\u001b4) ,\u001f\u001d#\u001f(.\u001f6\n\u001e#\u001f.\u001b \u001f-.,#\u001d.\u001b'\u001f(.\u001f 0\u001f!\u001f.\u001b,#\u001b(\u001b6 !\u001b-.,#.#-6 !\u001b-.,\u001f\u001d.)'ù\u001b6 \u001d#,/!ù\u001b \u001c\u001b,#á.,#\u001d\u001b6 \u001f( \u001f,'\u001f\u001e\u001b\u001e \u001e\u001f \u0003,)\"( ) \u001f-\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":73,"lines":{"from":140,"to":148}}}}],["275",{"pageContent":"CAPÍTULO 4. ANEMIAS MEGALOBLÁSTICAS\n\n47\n\n*,Ě\u001f .,)*#\u001d\u001b& 3 /-) \u001d,ĉ(#\u001d) \u001e\u001f '\u001f\u001e#\u001d\u001b'\u001f(.)- \u001b(.#\u001d)(0/&-#0\u001b(.\u001f- \u001f #(\"#\u001c#\u001e),\u001f- \u001e\u001f &\u001b \u001c)'\u001c\u001b \u001e\u001f *,).)(\u001f-8\n\u0003/\u001b(\u001e) \u001d)\u001f2#-.\u001f \u001b&!/(\u001b \"\u001f')!&)\u001c#()*\u001b.ù\u001b6 &\u001b '\u001b\u001d,)\u001d#.)-#- \u001e\u001f &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b -\u001f *#\u001f,\u001e\u001f8\n\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b \u001e\u001f& \u001f'\u001c\u001b,\u001b4)\n \n/\u001f \u001e\u001f-\u001d,#.\u001b *), *,#'\u001f,\u001b 0\u001f4 *), \u0017\u001b&.\u001f, \u0003\"\u001b((#(! \u001f( gnjh6\n\u001d)'/(#\u001d\u001b(\u001e) \u001b(\u001f'#\u001b- +/\u001f )\u001d/,,ù\u001b( \u001e/,\u001b(.\u001f \u001f& \u001f'\u001c\u001b,\u001b4) ) */\u001f,*\u001f,#) -#( \u001f2#-.#, *ï,\u001e#\u001e\u001b \u001e\u001f -\u001b(!,\u001f8 \u0005&\n.ï,'#()\n \nanemia perniciosa del embarazo y del puerperio\n \n\u001e/,ĉ '/\u001d\")- \u001bĄ)-8 \u0005( gogo6 \u0013#, \u0017#&&#\u001b' \u000f-&\u001f,\n\u001e\u001f-\u001d,#\u001c#ĉ +/\u001f \"\u001b\u001cù\u001b \u001e# \u001f,\u001f(\u001d#\u001b- \u001d)( &\u001b \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b \u001b\u001e\u001e#-)(#\u001b(\u001b8\n \n\u001b- \u001f'\u001c\u001b,\u001b4\u001b\u001e\u001b- +/\u001f *,\u001f-\u001f(.\u001b\u001c\u001b(\n\u001b(\u001f'#\u001b () ,\u001f&\u001b\u001d#)(\u001b\u001e\u001b \u001b \"\u001f'),,\u001b!#\u001b ')-.,\u001b\u001c\u001b( /(\u001b ,\u001f\u001d/*\u001f,\u001b\u001d#ĉ( *\u001f,'\u001b(\u001f(.\u001f6 3 &\u001b ,\u001f\u001d/,,\u001f(\u001d#\u001b -\u001f *,\u001f-\u001f(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":74,"lines":{"from":1,"to":20}}}}],["276",{"pageContent":".\u001b\u001c\u001b \u001d/\u001b(\u001e) \u001f2#-.ù\u001b /( \u001f'\u001c\u001b,\u001b4) *)-.\u001f,#),8 \u0005( gojh6 \u0004\u001b0#-)( -/-.#./3\u001f \u001f& .ï,'#() \u001e\u001f ^\u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b\n\u001e\u001f& \u001f'\u001c\u001b,\u001b4)_ *), \u001f& \u001e\u001f\n \nanemia megaloblástica del embarazo\n8\n\u0005(\n \nï2#\u001d)6 /( !,/*) \u001e\u001f \u001f2*\u001f,.)- *\u001f,.\u001f(\u001f\u001d#\u001f(.\u001f- \u001b &\u001b \u0006\u001f\u001e\u001f,\u001b\u001d#ĉ(\n \n\u001f2#\u001d\u001b(\u001b \u001e\u001f \u0003)&\u001f!#)- \u001e\u001f \u000f\u001c-.\u001f.,#\u001d#\u001b\n3 \u0007#(\u001f\u001d)&)!ù\u001b6 \u00018\u00038 */\u001c&#\u001d\u001b,)( ,\u001f\u001d#\u001f(.\u001f'\u001f(.\u001f +/\u001f \u001f& hf6lz \u001e\u001f &\u001b- '/$\u001f,\u001f- \u001f'\u001c\u001b,\u001b4\u001b\u001e\u001b- \u001f(\n \nï2#\u001d) \u001d/,-\u001b(\n\u001d)( \u001b(\u001f'#\u001b8\n \n\u001b !,\u001b( '\u001b3),ù\u001b \u001e\u001f &)- \u001d\u001b-)- -\u001f ),#!#(\u001b( *), \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)6 -#( '\u001f(\u001d#)(\u001b, \u001f& *),\u001d\u001f(\n-\n\n.\u001b$\u001f \u001e\u001f &\u001b- \u001b(\u001f'#\u001b- '\u001f!\u001b&)\u001c&á-.#\u001d\u001b- +/\u001f \u001f(\u001d)(.,\u001b,)(8 \u0005-./\u001e#)- \u001f( \u0014/,+/ù\u001b \u001f(\u001d)(.,\u001b,)( +/\u001f \u001f& gz \u001e\u001f &\u001b-\n\u001b(\u001f'#\u001b- \u001d\u001b,\u001f(\u001d#\u001b&\u001f- \u001f( \u001f'\u001c\u001b,\u001b4\u001b\u001e\u001b- \u001d),,\u001f-*)(\u001eù\u001b( \u001b &\u001b 0\u001b,#\u001f\u001e\u001b\u001e '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8\n\u0005& gkz \u001e\u001f &)- \u001b\u001e/&.)- \u001f( *&\u001f(#./\u001e \u001d/,-\u001b( \u001d)( \u001eïl·\u001d#. \u001e\u001f 0#.\u001b'#(\u001b \u0002gh6 '\u001f,\u001d\u001f\u001e \u001b \u001eïl·\u001d#. (/.,#\u001d#)(\u001b& 3\n\u001e#l·\u001d/&.\u001b\u001e *\u001b,\u001b &\u001b \u001b\u001c-),\u001d#ĉ( \u001e\u001f (/.,#'\u001f(.)- *), \u001f( \u001f,'\u001f\u001e\u001b\u001e\u001f- \u001e#!\u001f-.#0\u001b- ) #(!\u001f-.\u001b \u001d,ĉ(#\u001d\u001b \u001e\u001f '\u001f\u001e#\u001d\u001b'\u001f(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":74,"lines":{"from":22,"to":44}}}}],["277",{"pageContent":".)-8 \u000e) ,\u001f-/&.\u001b \u001d&\u001b,) \u001f& *\u001b*\u001f& \u001e\u001f &\u001b #( \u001f\u001d\u001d#ĉ( *),\n \nHelicobacter pylori\n \n\u001f( &\u001b !ï(\u001f-#- \u001e\u001f &\u001b \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b8\n\u0004\u001f () ,\u001f\u001d#\u001c#, -/*&\u001f'\u001f(.\u001b\u001d#ĉ( \u001b\u001e\u001f\u001d/\u001b\u001e\u001b6 &)- *\u001b\u001d#\u001f(.\u001f- -)'\u001f.#\u001e)- \u001b \u001d#,/!ù\u001b \u001c\u001b,#á.,#\u001d\u001b \u001d),,\u001f( \u001f& ,#\u001f-!) \u001e\u001f\n*\u001b\u001e\u001f\u001d\u001f, \u001eïl·\u001d#. \u001e\u001f 0#.\u001b'#(\u001b \u0002gh 3 \u001f0\u001f(./\u001b&'\u001f(.\u001f \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8\n \n\u001b- \u001f( \u001f,'\u001f\u001e\u001b\u001e\u001f- \"\u001f')&ù.#\u001d\u001b-\n\u001d,ĉ(#\u001d\u001b-6 \u001d)') .\u001b&\u001b-\u001f'#\u001b-6 \"\u001f')!&)\u001c#(/,#\u001b *\u001b,)2ù-.#\u001d\u001b ()\u001d./,(\u001b6 \u001b(\u001f'#\u001b \"\u001f')&ù.#\u001d\u001b \u001b/.)#('/(#.\u001b,#\u001b6 *),\n\u001f& \u001d)(-/') \u001f2\u001b!\u001f,\u001b\u001e) \u001e\u001f á\u001d#\u001e)\n \nĉ&#\u001d)6 */\u001f\u001e\u001f( \u001e\u001f-\u001b,,)&&\u001b, '\u001b\u001d,)\u001d#.)-#- 3 *\u001b(\u001d#.)*\u001f(#\u001b6 \u001d)( '), )&)!ù\u001b\n'\u001f!\u001b&)\u001c&á-.#\u001d\u001b \u001f( -\u001b(!,\u001f *\u001f,# ï,#\u001d\u001b 3 'ï\u001e/&\u001b ĉ-\u001f\u001b8\n \n)- ù(\u001e#\u001d\u001f- \u001f,#.,)\u001d#.\u001b,#)- \u001e\u001f\u001c\u001f( -\u001f, \u001d/#\u001e\u001b\u001e)-\u001b'\u001f(.\u001f\n\u001f0\u001b&/\u001b\u001e)- \u001d/\u001b(\u001e) -\u001f \u001b!,\u001f!\u001b '\u001b\u001e/,\u001b\u001d#ĉ( '\u001f!\u001b&)\u001c&á-.#\u001d\u001b \u001f( &)- \u001d\u001b-)- \u001e\u001f .\u001b&\u001b-\u001f'#\u001b8\n\u0005( &\u001b *)\u001c&\u001b\u001d#ĉ( #( \u001b(.#&6 \u001b/(+/\u001f #( ,\u001f\u001d/\u001f(.\u001f6 .\u001b'\u001c#ï( */\u001f\u001e\u001f *,\u001f-\u001f(.\u001b,-\u001f &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8\n\u00052#-.\u001f( #( ),'\u001f- -)\u001c,\u001f ,\u001f\u001d#ï( (\u001b\u001d#\u001e)- \u001d)( \u001b(\u001f'#\u001b- '\u001b\u001d,)\u001dù.#\u001d\u001b- +/\u001f -\u001f '\u001b(#l·\u001f-.\u001b( \u001d)') *\u001b(\u001d#.)*\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":74,"lines":{"from":46,"to":65}}}}],["278",{"pageContent":"(#\u001b *\u001f,# ï,#\u001d\u001b 3 \u001e\u001bĄ) (\u001f/,)&ĉ!#\u001d)8 \u0003/\u001f(.\u001b( \u001d)( \u001b(.\u001f\u001d\u001f\u001e\u001f(.\u001f- \u001e\u001f -\u001f, \u001b&#'\u001f(.\u001b\u001e)- \u001b& -\u001f() '\u001b.\u001f,() *),\n'\u001b\u001e,\u001f- \u001e\u001fl·\u001d#\u001f(.\u001f- \u001f( 0#.\u001b'#(\u001b \u0002gh ) -/$\u001f.\u001b- \u001b \u001e#\u001f.\u001b- \u001f-.,#\u001d.\u001b'\u001f(.\u001f 0\u001f!\u001f.\u001b,#\u001b(\u001b- ) \u001b \u001f,,),\u001f- \u001d)(!ï(#.)-\n\u001e\u001f& '\u001f.\u001b\u001c)&#-')8 \u0005( \u0014/,+/ù\u001b6 \b\u001b&#\u001d#)!&/ \u001f(\u001d)(.,ĉ \u001f(.,\u001f hffi 3 hfgf \u001b if (#Ą)- \u001e\u001f g \u001b hg '\u001f-\u001f- \u001d)(\n\u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8 \u0014)\u001e\u001b- &\u001b- '\u001b\u001e,\u001f- *,\u001f-\u001f(.\u001b,)( (#0\u001f&\u001f- -ï,#\u001d)- \u001c\u001b$)- \u001e\u001f 0#.\u001b'#(\u001b \u0002gh 3 )\u001d\") \u001d/,\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":74,"lines":{"from":67,"to":71}}}}],["279",{"pageContent":"-\u001b\u001c\u001b( \u001d)( \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8 \u0004\u001f&\n \n(-.#./.) \u000e\u001b\u001d#)(\u001b& \u001e\u001f \u0013\u001b&/\u001e \u0010Ě\u001c&#\u001d\u001b \u001f( \u0003/\u001f,(\u001b0\u001b\u001d\u001b6\n \nï2#\u001d)6 \u001e\u001f &\u001b\n\u0003,/47\u0007ĉ(!),\u001b 3 \u001d)&\u001b\u001c),\u001b\u001e),\u001f- \u001f-./\u001e#\u001b,)( \u001b ong (#Ą)-6 \u001f(\u001d)(.,\u001b(\u001e) +/\u001f \u001f& hf6lz -/ ,ù\u001b \u001b(\u001f'#\u001b 3 +/\u001f \u001b\n&\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f 0#.\u001b'#(\u001b \u0002gh ) )&\u001b.)- \u001d),,\u001f-*)(\u001eù\u001b \u001f& hz8\n\u0005( &\u001b \u0003&ù(#\u001d\u001b hk \u001e\u001f&\n \n(-.#./.)\n \n\u001f2#\u001d\u001b() \u001e\u001f& \u0013\u001f!/,) \u0013)\u001d#\u001b& B\n \n\u0013\u0013C6 \u001f(\n \n)(.\u001f,,\u001f36\n \nï2#\u001d)6 \u001b.\u001f(\u001e#\u001f,)(\n\u001b \u001e)- &\u001b\u001d.\u001b(.\u001f- \u001e\u001f l 3 m '\u001f-\u001f- \u001e\u001f \u001f\u001e\u001b\u001e8 \u0015() \u001e\u001f \u001f&&)- *,\u001f-\u001f(.\u001b\u001c\u001b ')0#'#\u001f(.)- '#)\u001d&ĉ(#\u001d)-6 -)\u001c,\u001f .)\u001e)\n\u001f( \u001d\u001b,\u001b 3 \u001f2.,\u001f'#\u001e\u001b\u001e\u001f-6 \u001b\u001e\u001f'á- \u001e\u001f \"#*).)(ù\u001b !\u001f(\u001f,\u001b&#4\u001b\u001e\u001b8\n \n\u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b *,\u001f-\u001f(.\u001b\u001c\u001b \u001d\u001b,\u001b\u001d.\u001f,ù-.#\u001d\u001b-\n\u001e#\u001b!(ĉ-.#\u001d\u001b- \u001e\u001f \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b 3 \u001f& (#0\u001f& -ï,#\u001d) \u001e\u001f 0#.\u001b'#(\u001b \u0002gh \u001f,\u001b #(\u001e\u001f.\u001f\u001d.\u001b\u001c&\u001f8\n \n\u001b .)')!,\u001b ù\u001b\n\u001d)'*/.\u001b,#4\u001b\u001e\u001b ')-.,\u001b\u001c\u001b \u001b.,)l·\u001b \u001d),.#\u001d)-/\u001c\u001d),.#\u001d\u001b& !,\u001b0\u001f 3 &\u001b *,\u001f-\u001f(\u001d#\u001b \u001e\u001f \"#!,)'\u001b-\n \n,)(.)*\u001b,#\u001f.\u001b&\u001f-8 \u0005(\n\u001f& -\u001f!/(\u001e) \u001d\u001b-)6 &\u001b &\u001b\u001d.\u001b(.\u001f \u001d/,-\u001b\u001c\u001b \u001d)( \"#*).)(ù\u001b !\u001f(\u001f,\u001b&#4\u001b\u001e\u001b6 '#,\u001b\u001e\u001b l·$\u001b6 \u001d)( ')0#'#\u001f(.)- \u001e\u001f \u001d\"/*\u001f.\u001f)\n\u001d)(.#(/) 3 \u001d)( /( -\u001f0\u001f,) ,\u001f.,\u001b-) *-#\u001d)').),8\n \n)- (#0\u001f&\u001f- \u001e\u001f \u0002gh () \u001f,\u001b( *\u001f,\u001d\u001f*.#\u001c&\u001f- 3 \u001f& á\u001d#\u001e) ĉ&#\u001d) \u001f,\u001b","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":74,"lines":{"from":73,"to":104}}}}],["280",{"pageContent":"\u001d)(.#(/) 3 \u001d)( /( -\u001f0\u001f,) ,\u001f.,\u001b-) *-#\u001d)').),8\n \n)- (#0\u001f&\u001f- \u001e\u001f \u0002gh () \u001f,\u001b( *\u001f,\u001d\u001f*.#\u001c&\u001f- 3 \u001f& á\u001d#\u001e) ĉ&#\u001d) \u001f,\u001b\n(),'\u001b&8 \u0005( &\u001b '\u001b\u001e,\u001f \u001e\u001f& -\u001f!/(\u001e) \u001d\u001b-) -\u001f \u001f(\u001d)(.,\u001b,)( (#0\u001f&\u001f- -/\u001c(),'\u001b&\u001f- \u001e\u001f 0#.\u001b'#(\u001b \u0002gh8 \u0001'\u001c)- \u001d\u001b-)-\n')-.,\u001b,)( ,\u001f\u001d/*\u001f,\u001b\u001d#ĉ( \u001d)( &\u001b \u001b\u001e'#(#-.,\u001b\u001d#ĉ( *\u001b,\u001f(.\u001f,\u001b& \u001e\u001f 0#.\u001b'#(\u001b \u0002gh8\n\u0005( ,\u001f-/'\u001f(9 &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b6 \u001f2\u001d&/3\u001f(\u001e) &\u001b ,\u001f&\u001b\u001d#)(\u001b\u001e\u001b \u001d)( \u001f& \u001f'\u001c\u001b,\u001b4) *), \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f\ná\u001d#\u001e) ĉ&#\u001d)6 \u001f- /( *,)\u001c&\u001f'\u001b *\u001b,.#\u001d/&\u001b,'\u001f(.\u001f \u001e\u001f \u001b\u001e/&.)- \u001e\u001f '\u001f\u001e#\u001b(\u001b \u001f\u001e\u001b\u001e6 3 \u001f( (#Ą)- \u001f- \u001f2\u001d\u001f*\u001d#)(\u001b& \u001f(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":74,"lines":{"from":104,"to":111}}}}],["281",{"pageContent":"\u001d)(.,\u001b,&\u001b8 \u0005( \u0010/\u001f\u001c&\u001b6\n \nï2#\u001d)6 -\u001f )\u001c-\u001f,0ĉ g \u001d\u001b-) *), \u001d\u001b\u001e\u001b hjl *\u001f,-)(\u001b- \u001b(ï'#\u001d\u001b-: \u001f( \u001f&\n \n\u000e\u0003\n \n\u000e\u0013\u001a6 g *),\n\u001d\u001b\u001e\u001b ngm6 3 \u001f( &\u001b *,á\u001d.#\u001d\u001b \"\u001f'\u001b.)&ĉ!#\u001d\u001b *,#0\u001b\u001e\u001b \u001e\u001f& \u0004,8 \u0013á(\u001d\"\u001f4\n \n\u001f\u001e\u001b&6 g \u001e\u001f gho *\u001b\u001d#\u001f(.\u001f-8 \u0005-.\u001b- \u001e# \u001f,\u001f(\n-\n\n\u001d#\u001b- '\u001f,\u001f\u001d\u001f( &)- -#!/#\u001f(.\u001f- \u001d)'\u001f(.\u001b,#)-9 &)- \u001d\u001b-)- \u001e\u001f &\u001b \u001d#/\u001e\u001b\u001e \u001e\u001f \u0010/\u001f\u001c&\u001b \u001d),,\u001f-*)(\u001e\u001f( \u001b /(\u001b \u001d)(-/&.\u001b \u001e\u001f\n'\u001f\u001e#\u001d#(\u001b #(.\u001f,(\u001b 3 \"\u001f'\u001b.)&)!ù\u001b: \u001f&\n \n\u000e\u0003\n \n\u000e\u0013\u001a \u001f- /( \u001d\u001f(.,) \u001e\u001f \u001d)(\u001d\u001f(.,\u001b\u001d#ĉ( -\u001f&\u001f\u001d.#0\u001b \u001e\u001f *\u001b\u001d#\u001f(.\u001f-6 3 &\u001b\n*,á\u001d.#\u001d\u001b *,#0\u001b\u001e\u001b \u001e\u001f& '\u001b\u001f-.,) \u0013á(\u001d\"\u001f4\n \n\u001f\u001e\u001b& \u001d),,\u001f-*)(\u001e\u001f \u001b \u001d)(-/&.\u001b */,\u001b'\u001f(.\u001f \"\u001f'\u001b.)&ĉ!#\u001d\u001b8\n\u0001-#'#-')6 \u001f- ,\u001f&\u001f0\u001b(.\u001f -\u001fĄ\u001b&\u001b, +/\u001f &)- \u001e)- Ě&.#')- \u001f-./\u001e#)- /\u001f,)( ,\u001f\u001b&#4\u001b\u001e)- \u001f( &\u001b \u001eï\u001d\u001b\u001e\u001b \u001e\u001f gomf:\n\u001d)'*\u001b,\u001b.#0\u001b'\u001f(.\u001f \u001d)( &\u001b ï*)\u001d\u001b \u001b\u001d./\u001b&6 &\u001b *)\u001c&\u001b\u001d#ĉ( \"\u001b '\u001f$),\u001b\u001e) -/- \"á\u001c#.)- \u001b&#'\u001f(.\u001b,#)- 3\n \nï2#\u001d)\n-\u001f \"\u001b -/'\u001b\u001e) \u001b &\u001b- *)&ù.#\u001d\u001b- #(.\u001f,(\u001b\u001d#)(\u001b&\u001f- \u001e\u001f -/*&\u001f'\u001f(.\u001b, \u001d)( á\u001d#\u001e)\n \nĉ&#\u001d) \u001b &\u001b- \u001f'\u001c\u001b,\u001b4\u001b\u001e\u001b-6 #'\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":74,"lines":{"from":113,"to":141}}}}],["282",{"pageContent":"*\u001b\u001d.\u001b(\u001e)\n \n\u001b0),\u001b\u001c&\u001f'\u001f(.\u001f \u001f( \u001f& *,)\u001c&\u001f'\u001b8\n \n\u001b \u000e),'\u001b \u000fl·\u001d#\u001b&\n \n\u001f2#\u001d\u001b(\u001b \u000e\u000f\n \n7fij7\u0013\u0013\u0001h7hffh *\u001b,\u001b\n&\u001b *,\u001f0\u001f(\u001d#ĉ( 3 \u001d)(.,)& \u001e\u001f &)- \u001e\u001f \u001f\u001d.)- \u001b& (\u001b\u001d#'#\u001f(.) B\u001b\u001c),.)6 *,\u001f'\u001b./,\u001f46 \u001e\u001f \u001f\u001d.)- \u001e\u001f& ./\u001c) (\u001f/,\u001b&C\n-\u001fĄ\u001b&\u001b +/\u001f \u001b .)\u001e\u001b '/$\u001f, \u001f( \u001f\u001e\u001b\u001e ,\u001f*,)\u001e/\u001d.#0\u001b -\u001f &\u001f ,\u001f\u001d)'#\u001f(\u001e\u001b /(\u001b #(!\u001f-.\u001b \u001e#\u001b,#\u001b \u001e\u001f á\u001d#\u001e)\n \nĉ&#\u001d) \u001e\u001f\njff̓! ) f6j̓'! \u001b& \u001eù\u001b6 \u001f-*\u001f\u001d#\u001b&'\u001f(.\u001f \u001e/,\u001b(.\u001f &\u001b \u001f.\u001b*\u001b *\u001f,#\u001d)(\u001d\u001f*\u001d#)(\u001b& Bi̓'\u001f-\u001f- *,\u001f0#)- \u001b& \u001f'\u001c\u001b,\u001b4)\n3 \"\u001b-.\u001b &\u001b -\u001f'\u001b(\u001b gh \u001e\u001f &\u001b !\u001f-.\u001b\u001d#ĉ(C6 \u001b-ù \u001d)') \u001b '/$\u001f,\u001f- \u001f( &\u001b- +/\u001f6 *), \u001b(.\u001f\u001d\u001f\u001e\u001f(.\u001f- ) \u001d)(\u001e#\u001d#ĉ( -)\n-\n\n\u001d#\u001b& ) !\u001f)!,ál·\u001d\u001b6 -\u001f #\u001e\u001f(.#l·+/\u001f ,#\u001f-!) \u001b&.) *\u001b,\u001b \u001e\u001f \u001f\u001d.)- \u001e\u001f& ./\u001c) (\u001f/,\u001b&6 \u001e\u001f\u001c#\u001f(\u001e) #(!\u001f,#, á\u001d#\u001e) ĉ&#\u001d)\n\nLa\n \nanemia\n \nmegaloblástica,\nexcluyendo la relacionada con\nel embarazo por deficiencia de\nácido fólico, es un problema\nparticularmente de adultos de\nmediana edad, y en niños es\nexcepcional encontrarla.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":74,"lines":{"from":143,"to":172}}}}],["283",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n48\n\nBj̓'! \u001b& \u001eù\u001b &)- i̓'\u001f-\u001f- *,\u001f0#)- \u001b& \u001f'\u001c\u001b,\u001b4) 3 &\u001b- *,#'\u001f,\u001b- gh -\u001f'\u001b(\u001b- \u001e\u001f& \u001e\u001f-\u001b,,)&&)\n \n\u001f.\u001b&C8 \u0003)( \u001f-.)\n-\u001f *,\u001f.\u001f(\u001e\u001f \u001f2*&#\u001d\u001b, &\u001b- \u001e# \u001f,\u001f(\u001d#\u001b- \u001e\u001f &)- \u001e\u001b.)- 3 &\u001b\n \n,\u001b(\u001d\u001b .\u001f(\u001e\u001f(\u001d#\u001b \u001b &\u001b \u001c\u001b$\u001b \u001e\u001f \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b\n*), \u001eïl·\u001d#. \u001e\u001f á\u001d#\u001e)\n \nĉ&#\u001d)8\n\nCÁNCER, ENFERMEDAD TROMBÓTICA\nY ENFERMEDAD NEURODEGENERATIVA\n\n\u0001&!/()- *\u001bù-\u001f- ),.#l·\u001d\u001b( &\u001b \"\u001b,#(\u001b \u001d)( á\u001d#\u001e) ĉ&#\u001d) *\u001b,\u001b *,\u001f0\u001f(#, &)- \u001e\u001f \u001f\u001d.)- \u001e\u001f& ./\u001c) (\u001f/,\u001b&6 *\u001f,) ).,)-\n() &) \"\u001b\u001d\u001f( *), &\u001b *,\u001f)\u001d/*\u001b\u001d#ĉ( \u001e\u001f& ,#\u001f-!) \u001b/'\u001f(.\u001b\u001e) \u001e\u001f -/ ,#, \u001dá(\u001d\u001f,8 \u0015( \u001f-./\u001e#) (),/\u001f!) #( ),'ĉ /(\n&\u001f0\u001f \u001b/'\u001f(.) \u001f( &\u001b #(\u001d#\u001e\u001f(\u001d#\u001b \u001e\u001f \u001dá(\u001d\u001f, \u001e\u001f */&'ĉ( \u001f(.,\u001f l̓ nim #(\u001e#0#\u001e/)- \u001d)( \u001f( \u001f,'\u001f\u001e\u001b\u001e \u001d),)(\u001b,#\u001b +/\u001f\n/\u001f,)( -/*&\u001f'\u001f(.\u001b\u001e)- \u001d)( á\u001d#\u001e) ĉ&#\u001d) 3 0#.\u001b'#(\u001b \u0002gh8 \u0005-.) () \"\u001b -#\u001e) ,\u001f*,)\u001e/\u001d#\u001e)8\n\u0012\u001f\u001d#\u001f(.\u001f'\u001f(.\u001f\n \n/\u001f */\u001c&#\u001d\u001b\u001e) /( '\u001f.\u001b(á&#-#- +/\u001f #(\u001d&/3ĉ jo̓lhg * \u001b,.#\u001d#*\u001b(.\u001f- \u001f( gi \u001f(-\u001b3)- \u001d&ù(#\u001d)-6\n.)\u001e)- .\u001f,'#(\u001b\u001e)- \u001b(.\u001f- \u001e\u001f hfgg8 \u0005& \u001f-./\u001e#) \u001d)'*\u001b,ĉ -/$\u001f.)- +/\u001f ,\u001f\u001d#\u001c#\u001f,)( *&\u001b\u001d\u001f\u001c) \u001d)(.,\u001b &)- +/\u001f ,\u001f\u001d#\u001c#\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":75,"lines":{"from":1,"to":26}}}}],["284",{"pageContent":",)( á\u001d#\u001e) ĉ&#\u001d) \u001b \u001e)-#- 'á- \u001b&.\u001b- +/\u001f &\u001b- /.#&#4\u001b\u001e\u001b- \u001f( &\u001b -/*&\u001f'\u001f(.\u001b\u001d#ĉ( \u001e\u001f &)- \u001b&#'\u001f(.)-6 *\u001b,\u001b *,\u001f0\u001f(#,\n\u001f( \u001f,'\u001f\u001e\u001b\u001e \u001d\u001b,\u001e#)0\u001b-\u001d/&\u001b,8 \u0001 k̓ \u001bĄ)- \u001e\u001f .,\u001b.\u001b'#\u001f(.) \u001d)( á\u001d#\u001e)\n \nĉ&#\u001d)6 \u001f2\u001d&/3\u001f(\u001e) \u001f& \u001dá(\u001d\u001f, \u001e\u001f *#\u001f& ()\n'\u001f&\u001b()'\u001b.)-)6 () -\u001f )\u001c-\u001f,0ĉ /( \u001b/'\u001f(.) \u001f( &\u001b #(\u001d#\u001e\u001f(\u001d#\u001b \u001e\u001f \u001dá(\u001d\u001f, B\u001d)&)(6 *,ĉ-.\u001b.\u001b6 */&'ĉ(6 '\u001b'\u001b )\n\u001b&!/() ).,)C \u001f(.,\u001f &)- #(\u001e#0#\u001e/)- +/\u001f ,\u001f\u001d#\u001c#\u001f,)( á\u001d#\u001e) ĉ&#\u001d)8\n \n\u001b *,)!,\u001f-#ĉ( \u001e\u001f& \u001dá(\u001d\u001f, \u001d\u001f,0#\u001d)/.\u001f,#() \"\u001b\n-#\u001e) ,\u001f&\u001b\u001d#)(\u001b\u001e\u001b \u001d)( (#0\u001f&\u001f- \u001c\u001b$)- \u001e\u001f 0#.\u001b'#(\u001b \u0002gh6 \u001b/(+/\u001f \u001f-.\u001b \u001b-)\u001d#\u001b\u001d#ĉ( () \"\u001b -#\u001e) \u001e\u001f')-.,\u001b\u001e\u001b8\n\u0005( *\u001bù-\u001f- \u001d)') \u0003\u001b(\u001b\u001eá 3 \u0005-.\u001b\u001e)- \u0015(#\u001e)-6 \u001e)(\u001e\u001f -\u001f ),.#l·\u001d\u001b &)- \u001b&#'\u001f(.)- \u001d)( á\u001d#\u001e) ĉ&#\u001d)6 &\u001b \u001d\u001b/-\u001b\n'á- \u001d)'Ě( \u001e\u001f \"#*\u001f,\")')\u001d#-.\u001f#(\u001f'#\u001b \u001f- &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f 0#.\u001b'#(\u001b \u0002gh8 \u0005-./\u001e#)- \u001f*#\u001e\u001f'#)&ĉ!#\u001d)- \"\u001b(\n')-.,\u001b\u001e) /(\u001b -#!(#l·\u001d\u001b.#0\u001b \u001b-)\u001d#\u001b\u001d#ĉ( \u001f(.,\u001f (#0\u001f&\u001f- \u001f&\u001f0\u001b\u001e)- \u001e\u001f \")')\u001d#-.\u001fù(\u001b 3 \u001f( \u001f,'\u001f\u001e\u001b\u001e 0\u001b-\u001d/&\u001b, 3\n.,)'\u001c)-#-8 \u000e) -\u001f \"\u001b \u001e\u001f')-.,\u001b\u001e) +/\u001f &\u001b- \u001e)-#- \u001b&.\u001b- \u001e\u001f 0#.\u001b'#(\u001b \u0002gh \u001f( *\u001b\u001d#\u001f(.\u001f- \u001d)( \u001f( \u001f,'\u001f\u001e\u001b\u001e 0\u001b-\u001d/&\u001b,\n,\u001f\u001e/4\u001d\u001b( &)- \u001f0\u001f(.)- .,)'\u001cĉ.#\u001d)-6 3 .\u001b'*)\u001d) -\u001f \"\u001b \u001d)'*,)\u001c\u001b\u001e) /( \u001b/'\u001f(.) \u001f( &\u001b #(\u001d#\u001e\u001f(\u001d#\u001b \u001e\u001f .,)'\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":75,"lines":{"from":28,"to":42}}}}],["285",{"pageContent":"\u001c)-#- \u001f( &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8 \u0005- (\u001f\u001d\u001f-\u001b,#) #(0\u001f-.#!\u001b, \u001f& \u001f-.\u001b\u001e) \u001e\u001f &\u001b 0#.\u001b'#(\u001b \u0002gh \u001f( *\u001b\u001d#\u001f(.\u001f- \u001d)(\n\"#*\u001f,\")')\u001d#-.\u001f#(\u001f'#\u001b \u001b(.\u001f- \u001e\u001f #(#\u001d#\u001b, \u001d)( &\u001b .\u001f,\u001b*#\u001b \u001d)( á\u001d#\u001e)\n \nĉ&#\u001d)6 *\u001b,\u001b () \u001e\u001f$\u001b, -#( .,\u001b.\u001b'#\u001f(.) /(\u001b\n\u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f 0#.\u001b'#(\u001b \u0002gh8\n\u0005& *\u001b*\u001f& *).\u001f(\u001d#\u001b& \u001e\u001f &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b &\u001f0\u001f \u001e\u001f 0#.\u001b'#(\u001b \u0002gh \u001f( \u001f& \u001e\u001f.\u001f,#),) \u001d)!(#.#0) () \u001f-.á \u001d&\u001b,)8\n \n)-\n\u001f-./\u001e#)- #(\u001e#\u001d\u001b( +/\u001f &\u001b -/*&\u001f'\u001f(.\u001b\u001d#ĉ( \u001d)( 0#.\u001b'#(\u001b \u0002gh () ')\u001e#l·\u001d\u001b \u001f& \u001d/,-) \u001e\u001f &\u001b \u001f( \u001f,'\u001f\u001e\u001b\u001e (\u001f/,)\n-\n\n\u001e\u001f!\u001f(\u001f,\u001b.#0\u001b8\n\u0003)( &\u001b- \u001f0#\u001e\u001f(\u001d#\u001b- *,\u001f-\u001f(.\u001b\u001e\u001b- -\u001f \u001d)(\u001d&/3\u001f +/\u001f &\u001b -/*&\u001f'\u001f(.\u001b\u001d#ĉ( \u001d)( á\u001d#\u001e) ĉ&#\u001d) 3 0#.\u001b'#(\u001b \u0002gh ()\n*,\u001f0#\u001f(\u001f &\u001b \u001f( \u001f,'\u001f\u001e\u001b\u001e \u001d\u001b,\u001e#)0\u001b-\u001d/&\u001b, (# \u001b/'\u001f(.\u001b \u001f& ,#\u001f-!) \u001e\u001f \u001dá(\u001d\u001f,8\n\nBIOQUÍMICA Y ETIOPATOGENIA\n\n\u001b 0#.\u001b'#(\u001b \u0002gh 3 \u001f&\n \n)&\u001b.) *\u001b,.#\u001d#*\u001b( \u001f( &\u001b ')\u001e/&\u001b\u001d#ĉ( \u001e\u001f &\u001b \u001f2*,\u001f-#ĉ( !ï(#\u001d\u001b 3 \u001e\u001f.)2#l·\u001d\u001b\u001d#ĉ( \u001e\u001f &\u001b\n\")')\u001d#-.\u001fù(\u001b 3 &\u001b -ù(.\u001f-#- \u001e\u001f (\u001f/,).,\u001b(-'#-),\u001f- #'*,\u001f-\u001d#(\u001e#\u001c&\u001f- *\u001b,\u001b \u001f& '\u001b(.\u001f(#'#\u001f(.) \u001e\u001f &\u001b\n \n/(\u001d#ĉ(\n\u001d)!(#.#0\u001b 3 \u001f( ).,\u001b- ,\u001f\u001b\u001d\u001d#)(\u001f- \u001c#)+/ù'#\u001d\u001b-8 \u0013/ *\u001b*\u001f& \u001f-\u001f(\u001d#\u001b& ,\u001b\u001e#\u001d\u001b \u001f( &\u001b -ù(.\u001f-#- \u001e\u001f& \u0004\u000e\u00018\n \n\u001b \u001e\u001fl·\u001d#\u001f(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":75,"lines":{"from":44,"to":70}}}}],["286",{"pageContent":"\u001d#\u001b \u001e\u001f /(\u001b \u001e\u001f \u001f&&\u001b- *,)\u001e/\u001d\u001f .,\u001b-.),()- \u001f( &\u001b \u001e#0#-#ĉ( ) '\u001b\u001e/,\u001b\u001d#ĉ( \u001d\u001f&/&\u001b, \u001f( &)- .\u001f$#\u001e)- +/\u001f *,\u001f-\u001f(.\u001b(\n\u001d)(-.\u001b(.\u001f ,\u001f()0\u001b\u001d#ĉ(6 \u001d)') -)( \u001f& .\u001f$#\u001e) \"\u001f'\u001b.)*)3ï.#\u001d) 3 &)- \u001f*#.\u001f&#)-8\n \n)- .,\u001b-.),()- \u001f( &\u001b -ù(.\u001f-#- \u001e\u001f&\n\u0004\u000e\u0001 +/\u001f \u001d)(\u001e/\u001d\u001f( \u001b &\u001b '\u001f!\u001b&)\u001c&\u001b-.)-#- -)( *,)\u001e/\u001d#\u001e)- \u001f-\u001f(\u001d#\u001b&'\u001f(.\u001f *), \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f á\u001d#\u001e) ĉ&#\u001d) )\n0#.\u001b'#(\u001b \u0002gh ),#!#(\u001b\u001e\u001b *), /( \u001b*),.\u001f \u001f2ĉ!\u001f() \u001e\u001fl·\u001d#\u001f(.\u001f ) *), *,)\u001c&\u001f'\u001b- \u001f( &\u001b \u001b\u001c-),\u001d#ĉ( ) \u001f( -/ /.#&#4\u001b\n-\n\n\u001d#ĉ( \u001b (#0\u001f& \u001d\u001f&/&\u001b,8 \u0005& á\u001d#\u001e) ĉ&#\u001d)6 )&\u001b\u001d#(\u001b ) á\u001d#\u001e) *.\u001f,)#&7\n \n7!&/.á'#\u001d) /\u001f \u001d)()\u001d#\u001e) \"\u001b\u001d\u001f .#\u001f'*) \u001d)')\n\nvitamina B9\n8 \u0005- \u001f& \u001d)'*/\u001f-.) \u001e\u001f ),#!\u001f( \u001e\u001f /( !,/*) \u001e\u001f -/-.\u001b(\u001d#\u001b- ,\u001f&\u001b\u001d#)(\u001b\u001e\u001b- *), -/ \u001f-.,/\u001d./,\u001b +/\u001f -\u001f\n\u001f(\u001d/\u001f(.,\u001b( \u001b'*&#\u001b'\u001f(.\u001f \u001e#-.,#\u001c/#\u001e\u001b- \u001f( &\u001b (\u001b./,\u001b&\u001f4\u001b 3 -\u001f \u001e\u001f()'#(\u001b(\n \nfolatos\n8 \u0005-.\u001b ')&ï\u001d/&\u001b \u001f-.á ),'\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":75,"lines":{"from":72,"to":90}}}}],["287",{"pageContent":"\u001e\u001b *), .,\u001f- /(#\u001e\u001b\u001e\u001f- \u001d\u001b,\u001b\u001d.\u001f,ù-.#\u001d\u001b-9 /(\u001b *.\u001f,#\u001e#(\u001b \u001d)( /(\u001b -/-.#./\u001d#ĉ( \u001f( -/ \u001f-.,/\u001d./,\u001b6 /(\u001b ')&ï\u001d/&\u001b \u001e\u001f\ná\u001d#\u001e) *\u001b,\u001b\u001b'#()\u001c\u001f(4)#\u001d) 3 /() ) 'á- ,\u001f-#\u001e/)- \u001e\u001f á\u001d#\u001e)\n \n7!&/.á'#\u001d) 3 *\u001f*.ù\u001e#\u001d)-8 \u0005& \u001b(#&&) \u001e\u001f *.\u001f,#\u001e#(\u001b\n*/\u001f\u001e\u001f \u001f(\u001d)(.,\u001b,-\u001f \u001f( ),'\u001b () ,\u001f\u001e/\u001d#\u001e\u001b6 *\u001b,\u001d#\u001b&'\u001f(.\u001f ,\u001f\u001e/\u001d#\u001e\u001b \u001d)') \u001e#\"#\u001e,) )&\u001b.) B\u0006\b\n \nh\n \nC ) .).\u001b&'\u001f(.\u001f\n,\u001f\u001e/\u001d#\u001e\u001b \u001d)') .\u001f.,\u001b\"#\u001e,) )&\u001b.) B\u0006\b\nj\nC: \u001f-.\u001b Ě&.#'\u001b \u001f- &\u001b\n \n),'\u001b \u001c#)&ĉ!#\u001d\u001b'\u001f(.\u001f \u001b\u001d.#0\u001b6 \u001d\u001b*\u001b4 \u001e\u001f \u001b\u001d\u001f*.\u001b,\n\u001e# \u001f,\u001f(.\u001f-\n \n,\u001b!'\u001f(.)- \u001e\u001f /( \u001d\u001b,\u001c)()8 \u0005-.)-\n \n,\u001b!'\u001f(.)- -\u001f \u001f(\u001d/\u001f(.,\u001b( /(#\u001e)- \u001b& \u000ek6 \u001b& \u000egf ) \u001d)($/(.\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":75,"lines":{"from":92,"to":111}}}}],["288",{"pageContent":"'\u001f(.\u001f \u001b \u001b'\u001c)-6 ),'\u001b(\u001e) &\u001b- \u001d)\u001f(4#'\u001b- \u001e\u001f& á\u001d#\u001e) ĉ&#\u001d)6 &\u001b- \u001d/\u001b&\u001f- */\u001f\u001e\u001f( -/ ,#, #(.\u001f,\u001d)(0\u001f,-#)(\u001f- \u001f( \u001f&\n#(.\u001f,#), \u001e\u001f &\u001b- \u001dï&/&\u001b- '\u001f\u001e#\u001b(.\u001f \u001d\u001b'\u001c#)- \u001f( &\u001b \u001d\u001b\u001e\u001f(\u001b &\u001b.\u001f,\u001b&8\n)- )&\u001b.)- -)( -#(.\u001f.#4\u001b\u001e)- -)&\u001b'\u001f(.\u001f *), &\u001b- \u001c\u001b\u001d.\u001f,#\u001b- 3 &\u001b- *&\u001b(.\u001b-6 *), &) +/\u001f \u001f& \")'\u001c,\u001f ,\u001f+/#\u001f,\u001f /(\u001b\n\u001e#\u001f.\u001b *\u001b,\u001b \u001d/\u001c,#, -/- (\u001f\u001d\u001f-#\u001e\u001b\u001e\u001f- \u001e#\u001b,#\u001b- \u001e\u001f \u001f-.\u001b 0#.\u001b'#(\u001b8 \u0013)( ,#\u001d)- \u001f( )&\u001b.)- &)- 0\u001f!\u001f.\u001b&\u001f- ,\u001f-\u001d)- \u001e\u001f \")$\u001b-\n0\u001f,\u001e\u001f- 3 \u001b'\u001b,#&&\u001b-6 &\u001b- &\u001f!/'\u001c,\u001f-6 &)- \u001d\u001f,\u001f\u001b&\u001f- 3 &\u001b-\n \n,/.\u001b- \u001dù.,#\u001d\u001b-: \u001f(.,\u001f &)- \u001b&#'\u001f(.)- \u001e\u001f ),#!\u001f( \u001b(#'\u001b&\n-\u001f \u001e\u001f-.\u001b\u001d\u001b( *), -/ \u001b&.) \u001d)(.\u001f(#\u001e) \u001e\u001f \u001f-.\u001b 0#.\u001b'#(\u001b &)- ĉ,!\u001b()- .\u001b&\u001f- \u001d)') \u001f& \"ù!\u001b\u001e) 3 \u001f& ,#Ąĉ(8 \u0005( \u001f& .ï -\u001f\n\u001f(\u001d/\u001f(.,\u001b( \u001d\u001b(.#\u001e\u001b\u001e\u001f- -#!(#l·\u001d\u001b.#0\u001b- \u001e\u001f )&\u001b.)6 '#\u001f(.,\u001b- +/\u001f -/ \u001d)(.\u001f(#\u001e) \u001f( &\u001b &\u001f\u001d\"\u001f \u001e\u001f 0\u001b\u001d\u001b \u001f- \u001f-\u001d\u001b-) 3 \u001f(\n&\u001b \u001e\u001f \u001d\u001b\u001c,\u001b (/&)8 \u0013#( \u001f'\u001c\u001b,!)6 &\u001b &\u001f\u001d\"\u001f '\u001b.\u001f,(\u001b *)-\u001f\u001f \u001d\u001b(.#\u001e\u001b\u001e\u001f- -/l·\u001d#\u001f(.\u001f- *\u001b,\u001b \u001f& &\u001b\u001d.\u001b(.\u001f8\n \n)- )&\u001b.)-\n\nCon las evidencias presenta-\ndas se concluye que la suple-\nmentación con ácido fólico y\nvitamina B12 no previene la\nenfermedad cardiovascular ni\naumenta el riesgo de cáncer.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":75,"lines":{"from":113,"to":131}}}}],["289",{"pageContent":"CAPÍTULO 4. ANEMIAS MEGALOBLÁSTICAS\n\n49\n\n-)( \u001e\u001f-.,/#\u001e)- *), \u001f& \u001d\u001b&), 3 &\u001b &/46 3 -\u001f *#\u001f,\u001e\u001f( *), &\u001b \u001d)\u001d\u001d#ĉ( \u001f(.,\u001f \u001f& kf 3 okz6 \u001f-*\u001f\u001d#\u001b&'\u001f(.\u001f \u001d/\u001b(\u001e) &)-\n\u001b&#'\u001f(.)- -\u001f \"#\u001f,0\u001f( \u001f( !,\u001b(\u001e\u001f- 0)&Ě'\u001f(\u001f- \u001e\u001f \u001b!/\u001b *), /( .#\u001f'*) *,)&)(!\u001b\u001e)8 \u0005-.)- \u001f \u001f\u001d.)- (\u001f!\u001b.#0)-\n*/\u001f\u001e\u001f( *,\u001f0\u001f(#,-\u001f '\u001f\u001e#\u001b(.\u001f &\u001b \u001b\u001e#\u001d#ĉ( \u001e\u001f \u001b-\u001d),\u001c\u001b.)8\n\u001b \u001c#)\u001e#-*)(#\u001c#&#\u001e\u001b\u001e \u001f( &\u001b '\u001b3),ù\u001b \u001e\u001f &)- \u001b&#'\u001f(.)- \u001f- \u001e\u001f& im \u001b& mhz6 *\u001f,) */\u001f\u001e\u001f -\u001f, .\u001b( *)\u001c,\u001f \u001d)')\n\u001e\u001f& gfz8\n \n)- ,\u001f+/\u001f,#'#\u001f(.)- \u001e#\u001b,#)- \u001f( \u001f& \")'\u001c,\u001f \u001b\u001e/&.) -)( \u001e\u001f hff̓'!I\u001eù\u001b 3 \u001f( &\u001b '/$\u001f, \u001e\u001f gnf̓'!I\u001eù\u001b:\n\u001e/,\u001b(.\u001f \u001f& \u001f'\u001c\u001b,\u001b4) 3 &\u001b &\u001b\u001d.\u001b(\u001d#\u001b \u001f-.)- \u001b/'\u001f(.\u001b( \u001b jff 3 hnf̓'!I\u001eù\u001b6 ,\u001f-*\u001f\u001d.#0\u001b'\u001f(.\u001f6 3 \u001e/,\u001b(.\u001f \u001f& *,#'\u001f,\n\u001bĄ) \u001e\u001f 0#\u001e\u001b -)( \u001e\u001f i6l̓'!I%!I\u001eù\u001b8\n\u001b- \u001e\u001f'\u001b(\u001e\u001b- \u001e#\u001b,#\u001b- \u001e\u001f\n \n)&\u001b.) -\u001f #(\u001d,\u001f'\u001f(.\u001b( \u001d)( &\u001b- \u001f( \u001f,'\u001f\u001e\u001b\u001e\u001f- '\u001b&#!(\u001b-6 \u001b&\u001d)\")&#-')6 \"#*\u001f,\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":76,"lines":{"from":1,"to":17}}}}],["290",{"pageContent":".#,)#\u001e#-') 3 (\u001f)*&\u001b-#\u001b- '#\u001f&)*,)&# \u001f,\u001b.#0\u001b-8 \u0005( \u001f& \u001d\u001b-) \u001e\u001f &\u001b- \u001b(\u001f'#\u001b- \"\u001f')&ù.#\u001d\u001b-6 &)- ,\u001f+/\u001f,#'#\u001f(.)-\n*/\u001f\u001e\u001f( &&\u001f!\u001b, \u001b -\u001f, \u001e\u001f i \u001b l 0\u001f\u001d\u001f- '\u001b3),\u001f-8\n\u001b \u001b\u001c-),\u001d#ĉ( -\u001f *,)\u001e/\u001d\u001f /(\u001e\u001b'\u001f(.\u001b&'\u001f(.\u001f \u001f( \u001f& 3\u001f3/()8\n \n)- *)&#!&/.\u001b'\u001b.)- \u001e\u001f\u001c\u001f( \u001d)(0\u001f,.#,-\u001f *,#'\u001f,)\n\u001f( ')()!&/.\u001b'\u001b.)-6 \u001d)(0\u001f,-#ĉ( \u001d\u001b.\u001b&#4\u001b\u001e\u001b *), &\u001b \u001f(4#'\u001b )&\u001b.) \"#\u001e,)&\u001b-\u001b6 \u001b\u001d.#0\u001b\u001e\u001b *), \u001d#(\u001d6 +/\u001f -\u001f \u001f(\u001d/\u001f(\n-\n\n.,\u001b \u001f( &)- \u001c),\u001e\u001f- \u001f( \u001d\u001f*#&&) \u001e\u001f &\u001b '/\u001d)-\u001b #(.\u001f-.#(\u001b&8\n \n)- ')()!&/.\u001b'\u001b.)- -)( \u001b\u001c-),\u001c#\u001e)- ,á*#\u001e\u001b'\u001f(.\u001f6 \u001f&\n'\u001f.#&7\u0006\b\nj\n \n*), -#'*&\u001f \u001e# /-#ĉ( 3 \u001f( \u001f& \u001d\u001b-) \u001e\u001f &)- ,\u001f-.\u001b(.\u001f- ')()!&/.\u001b'\u001b.)- '\u001f\u001e#\u001b(.\u001f /( .,\u001b(-*),.\u001f \u001b\u001d.#0)8\n\u001b '\u001b3), *\u001b,.\u001f \u001e\u001f&\n \n)&\u001b.) *,\u001f-\u001f(.\u001f \u001f( \u001f& -/\u001f,) -\u001f \u001f(\u001d/\u001f(.,\u001b \u001f(\n \n),'\u001b &#\u001c,\u001f 3 -)&\u001b'\u001f(.\u001f /(\u001b *\u001f+/\u001fĄ\u001b *),\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":76,"lines":{"from":19,"to":39}}}}],["291",{"pageContent":"\u001d#ĉ( \u001f-.á /(#\u001e\u001b \u001b *,).\u001fù(\u001b- -ï,#\u001d\u001b- \u001d)') &\u001b \u001b&\u001cĚ'#(\u001b: -#( \u001f'\u001c\u001b,!)6 -\u001f ,\u001f*),.\u001b( \u001d\u001b(.#\u001e\u001b\u001e\u001f- 'ù(#'\u001b- \u001e\u001f /(\u001b\n*,).\u001fù(\u001b \u001f-*\u001f\u001dùl·\u001d\u001b \u001e\u001f /(#ĉ(6 &\u001b \u001d/\u001b& *,)\u001c\u001b\u001c&\u001f'\u001f(.\u001f -\u001f \u001e\u001f,#0\u001b \u001e\u001f /(\u001b *,).\u001fù(\u001b \u001d\u001b*.\u001b\u001e),\u001b \u001e\u001f )&\u001b.) \u001b-)\u001d#\u001b\u001e\u001b \u001b\n'\u001f'\u001c,\u001b(\u001b +/\u001f /(\u001d#)(\u001b \u001d)') ,\u001f\u001d\u001f*.), \u001d\u001f&/&\u001b, \u001e\u001f \u001f-.\u001b 0#.\u001b'#(\u001b8 \u0013/ /(\u001d#ĉ( \u001bĚ( () \u001f-.á \u001e\u001f& .)\u001e) \u001f-\u001d&\u001b,\u001f\u001d#\u001e\u001b6\n*\u001f,) -\u001f -\u001fĄ\u001b&\u001b( 0\u001b,#\u001b\u001d#)(\u001f- \u001e\u001f -/ \u001d)(\u001d\u001f(.,\u001b\u001d#ĉ( \u001f( \u001e# \u001f,\u001f(.\u001f- \u001f-.\u001b\u001e)-6 \u001d)') \u001f( \u001f& \u001f'\u001c\u001b,\u001b4)6 3 \u001f( \u001b&!/(\u001b-\n-#./\u001b\u001d#)(\u001f-6 \u001d)') \u001f( &\u001b &\u001f/\u001d\u001f'#\u001b '#\u001f&)#\u001e\u001f \u001d,ĉ(#\u001d\u001b6 &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f )&\u001b.)-6 &\u001b \u001d#,,)-#- \"\u001f*á.#\u001d\u001b6 &\u001b /,\u001f'#\u001b6 \u001f&\n\u001dá(\u001d\u001f,6 \u001f( \u001b&!/()- .#*)- \u001e\u001f \u001b&.\u001f,\u001b\u001d#)(\u001f- #(ł\u001b'\u001b.),#\u001b- 3 \u001b-)\u001d#\u001b\u001e\u001b \u001d)( &\u001b #(!\u001f-.#ĉ( \u001e\u001f \u001b(.#\u001d)(\u001d\u001f*.#0)- ),\u001b&\u001f-8\n\u0005-.\u001b *,).\u001fù(\u001b \u001f-.á *,\u001f-\u001f(.\u001f \u001f( &\u001b &\u001f\u001d\"\u001f 3 */\u001f\u001e\u001f '\u001f$),\u001b, &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f& )&\u001b.) \u001f( \u001f& ,\u001f\u001d#ï( (\u001b\u001d#\u001e)8\n\u0004\u001f(.,) \u001e\u001f &\u001b- \u001dï&/&\u001b-6 &)- )&\u001b.)- -)( \u001d)(0\u001f,.#\u001e)- \u001f( *)&#!&/.\u001b'\u001b.)-6 &) +/\u001f !\u001b,\u001b(.#4\u001b -/ *\u001f,'\u001b(\u001f(\u001d#\u001b\n\u001f( \u001f& #(.\u001f,#), \u001e\u001f \u001f-.\u001b8 \u0005-.\u001f *,)\u001d\u001f-) \u001f- &&\u001f0\u001b\u001e) \u001b \u001d\u001b\u001c) *), *\u001b,.\u001f \u001e\u001f &\u001b \u001f(4#'\u001b )&#&7*)&#!&/.\u001b'\u001b.) -#(.\u001f.\u001b-\u001b6\n\u001d/3) '\u001f$), -/-.,\u001b.) \u001f- \u001f& \u0006\b\nj","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":76,"lines":{"from":41,"to":51}}}}],["292",{"pageContent":"\u001f( \u001f& #(.\u001f,#), \u001e\u001f \u001f-.\u001b8 \u0005-.\u001f *,)\u001d\u001f-) \u001f- &&\u001f0\u001b\u001e) \u001b \u001d\u001b\u001c) *), *\u001b,.\u001f \u001e\u001f &\u001b \u001f(4#'\u001b )&#&7*)&#!&/.\u001b'\u001b.) -#(.\u001f.\u001b-\u001b6\n\u001d/3) '\u001f$), -/-.,\u001b.) \u001f- \u001f& \u0006\b\nj\n \n6 +/\u001f *)-#\u001c&\u001f'\u001f(.\u001f -\u001f\u001b \u001f& -/-.,\u001b.) l·-#)&ĉ!#\u001d)8 \u0005&\n \n)&\u001b.) \u001b\u001c-),\u001c#\u001e) -\u001f \u001d)(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":76,"lines":{"from":51,"to":58}}}}],["293",{"pageContent":"0#\u001f,.\u001f \u001f( '\u001f.#&7\u0006\b\nj\n \n\u001f( \u001f& #(.\u001f-.#() 3 \u001f( \u001f& \"ù!\u001b\u001e)6 3 /(\u001b *),\u001d#ĉ( \u001f- *)&#!&/.\u001b'\u001b\u001e\u001b \u001e\u001f(.,) \u001e\u001f& \"\u001f*\u001b.)\u001d#.)8\n\u0013#( \u001f'\u001c\u001b,!)6 !,\u001b( *\u001b,.\u001f \u001e\u001f& ')()!&/.\u001b'\u001b.) \u001f- \u001f2\u001d,\u001f.\u001b\u001e) \u001d)( &\u001b \u001c#&#- \u001b& #(.\u001f-.#()6 \u001e\u001f-\u001e\u001f \u001e)(\u001e\u001f */\u001f\u001e\u001f\n-\u001f, ,\u001f\u001b\u001c-),\u001c#\u001e)8\n \n\u001b ,\u001f\u001e#-.,#\u001c/\u001d#ĉ( \u001e\u001f &\u001b- ,\u001f-\u001f,0\u001b- \"\u001f*á.#\u001d\u001b- \u001b &)- .\u001f$#\u001e)- \u001e\u001f*\u001f(\u001e\u001f \u001f( !,\u001b( '\u001f\u001e#\u001e\u001b \u001e\u001f \u001f-.\u001b\n\u001d#,\u001d/&\u001b\u001d#ĉ( \u001f(.\u001f,)\"\u001f*á.#\u001d\u001b8 \u0005( &\u001b '\u001b3),ù\u001b \u001e\u001f &)- .\u001f$#\u001e)- \u001f&\n \n)&\u001b.) *)&#!&/.\u001b'\u001b\u001e) *\u001f,'\u001b(\u001f\u001d\u001f \u001e\u001f(.,) \u001e\u001f &\u001b\n\u001dï&/&\u001b6 \u001f( \u001d)(.,\u001b-.\u001f \u001d)( \u001f& )&\u001b.) \"\u001f*á.#\u001d)6 +/\u001f \u001f- ')0#&#4\u001b\u001e) ,á*#\u001e\u001b'\u001f(.\u001f \u001e/,\u001b(.\u001f &\u001b \u001e\u001f*,#0\u001b\u001d#ĉ( \u001e\u001f )&\u001b.)8\n\u0005( \u001f& \u001f,#.,)\u001d#.) '\u001b\u001e/,) -\u001f \u001f(\u001d/\u001f(.,\u001b( \u001d\u001b(.#\u001e\u001b\u001e\u001f- -/-.\u001b(\u001d#\u001b&\u001f- \u001e\u001f )&\u001b.) *)&#!&/.\u001b'\u001b\u001e)6 \u001d/3\u001b\n \n/(\u001d#ĉ(\n() \u001f- \u001c#\u001f( \u001d)()\u001d#\u001e\u001b6 3 +/\u001f \u001b*\u001b,\u001f(.\u001f'\u001f(.\u001f ,\u001f*,\u001f-\u001f(.\u001b \u001f& )&\u001b.) \u001b\u001e+/#,#\u001e) #(#\u001d#\u001b&'\u001f(.\u001f \u001e/,\u001b(.\u001f &\u001b \u001f,#.,)*)\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":76,"lines":{"from":60,"to":76}}}}],["294",{"pageContent":"3\u001f-#-6 *\u001f,) +/\u001f \u001b& -\u001f, *)&#!&/.\u001b'\u001b\u001e)6 \u001f- #(\u001d\u001b*\u001b4 \u001e\u001f \u001b.,\u001b0\u001f-\u001b, &\u001b '\u001f'\u001c,\u001b(\u001b 3 *\u001f,'\u001b(\u001f\u001d\u001f \u001e\u001f(.,) \u001e\u001f &\u001b \u001dï&/&\u001b\n\u001e/,\u001b(.\u001f .)\u001e\u001b -/ 0#\u001e\u001b6 *), &) +/\u001f -/ \u001d)(\u001d\u001f(.,\u001b\u001d#ĉ( #(.,\u001b\u001f,#.,)\u001d#.\u001b,#\u001b ,\u001fł\u001f$\u001b \u001f& \u001f-.\u001b\u001e) \u001e\u001f &\u001b- ,\u001f-\u001f,0\u001b- \"ù-.#\u001d\u001b-\n\u001e\u001f \u001f-.\u001f (/.,#'\u001f(.)8 \u0005& (#0\u001f& -ï,#\u001d) \u001e\u001f )&\u001b.) .,\u001b\u001e/\u001d\u001f &\u001b #(!\u001f-.\u001b \u001e\u001f &\u001b Ě&.#'\u001b -\u001f'\u001b(\u001b8\n\b\u001b3 +/\u001f -\u001fĄ\u001b&\u001b, +/\u001f &)- #(\u001e#\u001d\u001b\u001e),\u001f- \u001c#)+/ù'#\u001d)- \u001e\u001f& \u001eïl·\u001d#. \u001e\u001f )&\u001b.) B(#0\u001f& -ï,#\u001d) \u001f #(.,\u001b\u001f,#.,)\u001d#.\u001b,#)C\n\u001b '\u001f(/\u001e) \u001b*\u001b,\u001f\u001d\u001f( \u001f( \u001b/-\u001f(\u001d#\u001b \u001e\u001f \u001b&.\u001f,\u001b\u001d#)(\u001f- \"\u001f'á.#\u001d\u001b-8 \u0015( *),\u001d\u001f(.\u001b$\u001f #'*),.\u001b(.\u001f \u001e\u001f *\u001b\u001d#\u001f(.\u001f- \u001d)(\n\u001eïl·\u001d#. \u001e\u001f\n \n)&\u001b.) () -)( \u001e\u001f.\u001f\u001d.\u001b\u001e)- -# -)&) -\u001f /.#&#4\u001b \u001f& \u001d,#.\u001f,#) \u001e\u001f \u001b(\u001f'#\u001b '\u001b\u001d,)\u001dù.#\u001d\u001b \u001d)') #(\u001e#\u001d\u001b\u001e),\n\u001e\u001f \u001eïl·\u001d#. \u001e\u001f\n \n)&\u001b.)8 \u0005( \u0005-*\u001bĄ\u001b '#\u001e#\u001f,)( \u001f&\n \n)&\u001b.) -ï,#\u001d) \u001f #(.,\u001b\u001f,#.,)\u001d#.\u001b,#) \u001f( gko -/$\u001f.)- -\u001b()- \u001e\u001f\ng '\u001f- \u001b nj \u001bĄ)- \u001e\u001f \u001f\u001e\u001b\u001e8 \u0005(\u001d)(.,\u001b,)( /( \u001eïl·\u001d#. '\u001b,!#(\u001b& \u001f( \u001f& gmz6 3 \u001f( \u001f& hkz /( \u001eïl·\u001d#. #'*),.\u001b(.\u001f8\n\u0005( \u001f& !,/*) \u001e\u001f gk \u001b jo \u001bĄ)- \u001f& \u001eïl·\u001d#. \u001e\u001f\n \n)&\u001b.) \u001b-\u001d#\u001f(\u001e\u001f \u001b& inz \u001f( '/$\u001f,\u001f- 3 koz \u001f( \")'\u001c,\u001f-: -)&) \u001f&\ng6iz ')-.,ĉ \u001eïl·\u001d#. '\u001b,!#(\u001b& \u001e\u001f \u001d)\u001c\u001b&\u001b'#(\u001b8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":76,"lines":{"from":78,"to":95}}}}],["295",{"pageContent":"\u0005( \u001f& !,/*) \u001e\u001f gk \u001b jo \u001bĄ)- \u001f& \u001eïl·\u001d#. \u001e\u001f\n \n)&\u001b.) \u001b-\u001d#\u001f(\u001e\u001f \u001b& inz \u001f( '/$\u001f,\u001f- 3 koz \u001f( \")'\u001c,\u001f-: -)&) \u001f&\ng6iz ')-.,ĉ \u001eïl·\u001d#. '\u001b,!#(\u001b& \u001e\u001f \u001d)\u001c\u001b&\u001b'#(\u001b8\n\u001b /(\u001d#ĉ( '\u001f.\u001b\u001cĉ&#\u001d\u001b \u001e\u001f &)- )&\u001b.)- \u001f- #'*),.\u001b(.\u001f *\u001b,\u001b \u001f& /(\u001d#)(\u001b'#\u001f(.) \u001e\u001f& ),!\u001b(#-')8 \u0005& \u0006\b\nj\n \n.#\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":76,"lines":{"from":95,"to":103}}}}],["296",{"pageContent":"(\u001f &\u001b \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e \u001e\u001f .,\u001b(- \u001f,#,\n \n,\u001b!'\u001f(.)- \u001e\u001f /( á.)') \u001e\u001f \u001d\u001b,\u001c)() \u001e\u001f /(\u001b ')&ï\u001d/&\u001b \u001b ).,\u001b \u001b\u001d./\u001b(\u001e) \u001d)')\n\u001d)\u001f(4#'\u001b \u001f( .)\u001e)- &)- -#-.\u001f'\u001b- '\u001f.\u001b\u001cĉ&#\u001d)- \u001e\u001f &)- '\u001b'ù \u001f,)- \u001e)(\u001e\u001f -\u001f *,)\u001e/4\u001d\u001b \u001f-.\u001f .#*) \u001e\u001f ,\u001f\u001b\u001d\u001d#ĉ(8\n \n\u001b\n\u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f á\u001d#\u001e) ĉ&#\u001d) -\u001f \u001e\u001f\u001c\u001f \u001b /( \u001b*),.\u001f \u001e#\u001f.ï.#\u001d) #(-/l·\u001d#\u001f(.\u001f6 \u001b \u001e\u001f \u001f\u001d.)- \u001f( &\u001b \u001b\u001c-),\u001d#ĉ( ) \u001b #(\u001d,\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":76,"lines":{"from":105,"to":112}}}}],["297",{"pageContent":"'\u001f(.)- \u001f( &)- ,\u001f+/\u001f,#'#\u001f(.)-6 \u001d)') \u001f& \u001f'\u001c\u001b,\u001b4)6 &\u001b &\u001b\u001d.\u001b(\u001d#\u001b ) \u001f& \u001d,\u001f\u001d#'#\u001f(.)6 \u001b\u001e\u001f'á- \u001e\u001f &\u001b #(.\u001f,\u001b\u001d\u001d#ĉ(\n'\u001f\u001e#\u001d\u001b'\u001f(.)-\u001b \u001d)( á,'\u001b\u001d)- \u001d)') '\u001f.).,\u001f2\u001b.)6 -/& \u001b-6 \u001b(.#\u001d)(0/&-#0\u001b(.\u001f- 3 \u001b(.#\u001d)(\u001d\u001f*.#0)- ),\u001b&\u001f-8\n\u001b- ,\u001f-\u001f,0\u001b- \u001e\u001f )&\u001b.) \u001f( /( \u001b\u001e/&.) -\u001b() -)( *\u001f+/\u001fĄ\u001b-6 3 \u001b &\u001b- i -\u001f'\u001b(\u001b- \u001e\u001f /( ,ï!#'\u001f( \u001e\u001fl·\u001d#\u001f(.\u001f -\u001f\n*,)\u001e/\u001d\u001f /(\u001b \u001d\u001bù\u001e\u001b \u001e\u001f&\n \n)&\u001b.) -ï,#\u001d)8\n \n\u001b \u001e#-'#(/\u001d#ĉ( \u001f( &\u001b- ,\u001f-\u001f,0\u001b- *,)0)\u001d\u001b &\u001b \"#*\u001f,-\u001f!'\u001f(.\u001b\u001d#ĉ( \u001e\u001f &)-\n(\u001f/.,ĉl·&)-6 \"\u001b&&\u001b4!)\n \n,\u001f\u001d/\u001f(.\u001f \u001f( *\u001b\u001d#\u001f(.\u001f- \")-*#.\u001b&#4\u001b\u001e)-: \u001b\u001e\u001f'á-6 \u001b/'\u001f(.\u001b &\u001b \u001f2\u001d,\u001f\u001d#ĉ( /,#(\u001b,#\u001b \u001e\u001f\ná\u001d#\u001e) ),'#'#()!&/.á'#\u001d) B\u0006 \u0007\n \n\u0015C .,\u001b- &\u001b -)\u001c,\u001f\u001d\u001b,!\u001b \u001e\u001f \"#-.#\u001e#(\u001b 3 \u001b*\u001b,\u001f\u001d\u001f '\u001b\u001d,)\u001d#.)-#- \u001f( &\u001b -\u001f,#\u001f ,)$\u001b6\n\u001d)( \u001d\u001b'\u001c#)- '\u001f!\u001b&)\u001c&á-.#\u001d)- \u001f( &\u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b8\n \n\u001b \u001b(\u001f'#\u001b \u001b*\u001b,\u001f\u001d\u001f \u001e\u001f-*/ï- \u001e\u001f& \u001d/\u001b,.) '\u001f- \u001e\u001f &\u001b -/*,\u001f-#ĉ(\n\u001e\u001f )&\u001b.)-6 *), &\u001b \u001d\u001b,\u001f(\u001d#\u001b \u001e\u001f á\u001d#\u001e) ĉ&#\u001d): -#( \u001f'\u001c\u001b,!)6 \u001f( \u001e#0\u001f,-)- *\u001b-)- \u001e\u001f& '\u001f.\u001b\u001c)&#-') +/\u001f \u001d)(\u001e/\u001d\u001f \u001b\n&\u001b -ù(.\u001f-#- \u001e\u001f á\u001d#\u001e)- (/\u001d&\u001f#\u001d)- #(.\u001f,0#\u001f(\u001f &\u001b 0#.\u001b'#(\u001b \u0002gh \u001d)') \u001d) \u001b\u001d.), \u001f(4#'á.#\u001d)6 \u001e\u001f \u001b\"ù +/\u001f -/ \u001d\u001b,\u001f(\u001d#\u001b","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":76,"lines":{"from":114,"to":132}}}}],["298",{"pageContent":"&\u001b -ù(.\u001f-#- \u001e\u001f á\u001d#\u001e)- (/\u001d&\u001f#\u001d)- #(.\u001f,0#\u001f(\u001f &\u001b 0#.\u001b'#(\u001b \u0002gh \u001d)') \u001d) \u001b\u001d.), \u001f(4#'á.#\u001d)6 \u001e\u001f \u001b\"ù +/\u001f -/ \u001d\u001b,\u001f(\u001d#\u001b\n\u001d)(\u001e/4\u001d\u001b \u001b& '#-') ,\u001f-/&.\u001b\u001e)8 \u0005& .\u001f$#\u001e) (\u001f,0#)-) +/\u001f () -\u001f \"\u001b&&\u001b \u001f( \u001f-.\u001b\u001e) \u001e\u001f *,)&# \u001f,\u001b\u001d#ĉ( .#\u001f(\u001f (\u001f\u001d\u001f-#\u001e\u001b\u001e\n\u001e\u001f 0#.\u001b'#(\u001b \u0002gh6 \u001e\u001b\u001e) +/\u001f \u001f-.\u001b -\u001f ,\u001f+/#\u001f,\u001f *\u001b,\u001b &\u001b -ù(.\u001f-#- \u001e\u001f &\u001b '#\u001f&#(\u001b8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":76,"lines":{"from":132,"to":134}}}}],["299",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n50\n\n\u001b 0#.\u001b'#(\u001b \u0002gh6 \u001d)( /( *\u001f-) ')&\u001f\u001d/&\u001b, \u001e\u001f g̓ ikk \u0004\u001b6 \u001f-.á \u001d)(-.#./#\u001e\u001b \u001b-#'ï.,#\u001d\u001b'\u001f(.\u001f \u001b&,\u001f\u001e\u001f\u001e),\n\u001e\u001f& \u001d)\u001c\u001b&.)6 \u001e\u001f '\u001b(\u001f,\u001b -#'#&\u001b, \u001b \u001d)') &) \"\u001b\u001d\u001f \u001f& \"\u001f') \u001b&,\u001f\u001e\u001f\u001e), \u001e\u001f& \"#\u001f,,)8 \u0005& \u001d)\u001c\u001b&.) .#\u001f(\u001f -\u001f#- *)-#\n-\n\n\u001d#)(\u001f- \u001d)),\u001e#(\u001b\u001e\u001b-6 3 \u001d/\u001b.,) \u001e\u001f \u001f&&\u001b- -\u001f /(\u001f( \u001b á.)')- \u001e\u001f (#.,ĉ!\u001f() \u001f( /( \u001b(#&&) .\u001f.,\u001b*#,,ĉ&#\u001d) *&\u001b(\u001b,8\n\u0004\u001f\u001c\u001b$) 3 \u001d\u001b-# *\u001f,*\u001f(\u001e#\u001d/&\u001b, \u001b& *&\u001b() \u001e\u001f& \u001b(#&&)6 /( (/\u001d&\u001fĉ.#\u001e) \u001c\u001f(\u001d#'#\u001e\u001b4ĉ&#\u001d) )\u001d/*\u001b &\u001b +/#(.\u001b *)-#\u001d#ĉ(\n\u001d)),\u001e#(\u001b\u001e\u001b6 .\u001b'\u001c#ï( \u001f( &\u001b /(#ĉ( (#.,ĉ!\u001f()8\n \n\u001b -\u001f2.\u001b *)-#\u001d#ĉ( \u001f- #ĉ(#\u001d\u001b 3 \u001f-.á )\u001d/*\u001b\u001e\u001b *), \u001d#\u001b(/,) \u001f( &\u001b\n\u001d#\u001b()\u001d)\u001c\u001b&\u001b'#(\u001b8\n\u001b\n \n),'\u001b \u001b\u001d.#0\u001b \u001e\u001f &\u001b 0#.\u001b'#(\u001b -\u001f \u001d\u001b,\u001b\u001d.\u001f,#4\u001b *), &\u001b *,\u001f-\u001f(\u001d#\u001b \u001e\u001f& !,/*) '\u001f.#&) ) /( !,/*) \u001e\u001f-)2#\u001b\n-\n\n\u001e\u001f()\u001dù\u001d&#\u001d)8\n \n\u001b \u001b\u001c-),\u001d#ĉ( \u001e\u001f &\u001b 0#.\u001b'#(\u001b \u0002gh \u001e\u001f*\u001f(\u001e\u001f \u001e\u001f /( '\u001f\u001d\u001b(#-') Ě(#\u001d) +/\u001f () \u001f- \u001d)'*\u001b,.#\u001e) *),\n(#(!Ě( ).,) \u001f&\u001f'\u001f(.) (/.,#.#0)8\n \n\u001b- \u001dï&/&\u001b- *\u001b,#\u001f.\u001b&\u001f- \u001e\u001f& \u001f-.ĉ'\u001b!) *,)\u001e/\u001d\u001f( /(\u001b !&/\u001d)*,).\u001fù(\u001b \u001d)()\u001d#\u001e\u001b\n\u001d)') \u001f&\n \n\u001b\u001d.), #(.,ù(-\u001f\u001d) B\u0006 C6 +/\u001f l·$\u001b \u001e\u001f '\u001b(\u001f,\u001b \u001f-*\u001f\u001dùl·\u001d\u001b \u001b &\u001b 0#.\u001b'#(\u001b \u0002gh8 \u0005& \u0006\n \n.#\u001f(\u001f /( *\u001f-) ')\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":77,"lines":{"from":1,"to":31}}}}],["300",{"pageContent":"&\u001f\u001d/&\u001b, \u001e\u001f jj̓fff̓\u0004\u001b 3\n \n\u001d\u001b\u001e\u001b '#&#!,\u001b') -\u001f /(\u001f \u001b if6g̓'! \u001e\u001f 0#.\u001b'#(\u001b \u0002gh8 \u0005& \u001d)'*&\u001f$) \u0006\n \n'á- \u0002gh 0#\u001b$\u001b\n\u001b &) &\u001b,!) \u001e\u001f &\u001b &/4 \u001e\u001f& ./\u001c) \u001e#!\u001f-.#0) 3 \u001f& \u0006\n \n*,).\u001f!\u001f \u001b &\u001b 0#.\u001b'#(\u001b \u001e\u001f &\u001b \u001b\u001d\u001d#ĉ( \u001e\u001f &\u001b- \u001f(4#'\u001b- \u001e#!\u001f-.#0\u001b-8\n&\u001f!\u001b( \u001b& ù&\u001f)( .\u001f,'#(\u001b& 3 \u001b& \u001d#\u001f!)6 \u001f( \u001e)(\u001e\u001f \u001f2#-.\u001f( ,\u001f\u001d\u001f*.),\u001f- \u001f-*\u001f\u001dùl·\u001d)- \u001d)&)\u001d\u001b\u001e)- \u001f( &\u001b -/*\u001f,l·\u001d#\u001f \u001e\u001f\n&\u001b- '#\u001d,)0\u001f&&)-#\u001e\u001b\u001e\u001f-6 3 \u001b *\b '\u001b3), \u001e\u001f l6k 3 \u001f( *,\u001f-\u001f(\u001d#\u001b \u001e\u001f \u001d\u001b&\u001d#) 3 '\u001b!(\u001f-#)6 &\u001b 0#.\u001b'#(\u001b \u0002gh *\u001f(\u001f.,\u001b\n\u001f& #(.\u001f,#), \u001e\u001f &\u001b- \u001dï&/&\u001b-8\n\u0004\u001f-*/ï- \u001e\u001f /(\u001b *\u001f+/\u001fĄ\u001b \u001e)-#- \u001e\u001f g̓ '! \u001e\u001f 0#.\u001b'#(\u001b \u0002gh6 -\u001f \u001b\u001c-),\u001c\u001f \u001f& lf \u001b nfz \u001e\u001f &\u001b \u001e)-#- \u001b\u001e'#(#-\n-\n\n.,\u001b\u001e\u001b8\n \n\u001b *,)*),\u001d#ĉ( \u001b\u001c-),\u001c#\u001e\u001b \u001e#-'#(/3\u001f \u001d/\u001b(\u001e) &\u001b \u001d\u001b(.#\u001e\u001b\u001e \u001e\u001f 0#.\u001b'#(\u001b \u0002gh *,\u001f-\u001f(.\u001f \u001f( \u001f& #(.\u001f-.#()\n\u001b/'\u001f(.\u001b8 \u0013\u001f \u001b\u001c-),\u001c\u001f( \u001b*,)2#'\u001b\u001e\u001b'\u001f(.\u001f \u001e\u001f g \u001b k '! \u001e\u001f &\u001b \u001e)-#- #(!\u001f,#\u001e\u001b \u001d)( &)- \u001b&#'\u001f(.)- B\u001b&,\u001f\u001e\u001f\u001e),\n\u001e\u001f k \u001b if̓ '!I\u001eù\u001bC8\n \n\u001b \u001b\u001c-),\u001d#ĉ( \u001e\u001f &\u001b 0#.\u001b'#(\u001b \u0002gh 0\u001b -\u001f!/#\u001e\u001b \u001e\u001f -/ \u001e#-.,#\u001c/\u001d#ĉ( \u001f( \u001f& ),!\u001b(#-')6\n,\u001f+/#,#\u001f(\u001e) \u001e\u001f *,).\u001fù(\u001b- .,\u001b(-*),.\u001b\u001e),\u001b- *\u001b,\u001b \u001f-.\u001f l·(8\n \n\u001b- .,\u001b(-\u001d)\u001c\u001b&\u001b'#(\u001b- -)( !&/\u001d)*,).\u001fù(\u001b- \u001f(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":77,"lines":{"from":33,"to":57}}}}],["301",{"pageContent":"\u001d\u001b,!\u001b\u001e\u001b- \u001e\u001f \u001f-.\u001b\n \n/(\u001d#ĉ(8\n \n\u001b .,\u001b(-\u001d)\u001c\u001b&\u001b'#(\u001b\n \nB\u0014\u0003 C 3 &\u001b .,\u001b(-\u001d)\u001c\u001b&\u001b'#(\u001b\n \nB\u0014\u0003\n \nC -\u001f \u001f(\u001d/\u001f(.,\u001b(\n\u001f( \u001f& *&\u001b-'\u001b8\n \n\u001b .,\u001b(-\u001d)\u001c\u001b&\u001b'#(\u001b\n \nB\u0014\u0003\n \nC \u001e#l·\u001f,\u001f \u001e\u001f &\u001b- ).,\u001b-6 */\u001f- *)-\u001f\u001f '\u001f()- \u001d\u001b,\u001c)\"#\u001e,\u001b.)- 3 \u001f&&)\n*\u001f,'#.\u001f #(\u001d,\u001f'\u001f(.\u001b, -/ *)\u001e\u001f, \u001b\u001d)*&\u001b\u001e), \u001b &\u001b 0#.\u001b'#(\u001b \u0002gh 3 .\u001f(\u001f, !,\u001b( \u001b\u001d#&#\u001e\u001b\u001e *\u001b,\u001b \u001e\u001f-\u001b\u001d)*&\u001b,-\u001f \u001e\u001f &\u001b\n0#.\u001b'#(\u001b \u001f( &)- .\u001f$#\u001e)-8\n \n\u001b \u0014\u0003\n \n3 &\u001b \u0014\u0003\n \n-)( -#(.\u001f.#4\u001b\u001e\u001b- *), 0\u001b,#)- .\u001f$#\u001e)-6 *,#(\u001d#*\u001b&'\u001f(.\u001f &)- !,\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":77,"lines":{"from":59,"to":85}}}}],["302",{"pageContent":"(/&)\u001d#.)-6 3 .#\u001f(\u001f( \u001d)') /(\u001d#ĉ( -\u001f, ,\u001f-\u001f,0),#)- \u001e\u001f &\u001b 0#.\u001b'#(\u001b \u0002gh8\n \n\u001b \u0014\u0003\n \n(),'\u001b&'\u001f(.\u001f \u001f-.á -\u001b./,\u001b\u001e\u001b\n\u001f( nf \u001b gffz \u001d)( \u001d)\u001c\u001b&\u001b'#(\u001b- 3 ,\u001f*,\u001f-\u001f(.\u001b &\u001b '\u001b3), *\u001b,.\u001f \u001e\u001f &\u001b 0#.\u001b'#(\u001b \u0002gh *&\u001b-'á.#\u001d\u001b8\n \n\u001b \u0014\u0003\n\u001d)(.#\u001f(\u001f *)\u001d\u001b ) (#(!/(\u001b 0#.\u001b'#(\u001b 3 \u001d)(.,#\u001c/3\u001f \u001b &\u001b \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e -ï,#\u001d\u001b \u001e\u001f &\u001b \u001d)\u001c\u001b&\u001b'#(\u001b () -\u001b./,\u001b\u001e\u001b8\n \n\u001b\n\u001b/-\u001f(\u001d#\u001b \u001d)(!ï(#.\u001b \u001e\u001f \u0014\u0003\n \n3 \u0014\u0003\n \n.#\u001f(\u001f \u001f-\u001d\u001b-) -#!(#l·\u001d\u001b\u001e) \u001d&ù(#\u001d): \u001f( \u001d\u001b'\u001c#)6 &\u001b \u001b/-\u001f(\u001d#\u001b \u001e\u001f \u0014\u0003\n#(\u001e/\u001d\u001f \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8\n\u0005& á\u001d#\u001e)\n \nĉ&#\u001d) Bá\u001d#\u001e) *.\u001f,)#&')()!&/.á'#\u001d)C \u001f-.á \u001d)(-.#./#\u001e) *), \u001f& á\u001d#\u001e) *.ï,#\u001d) \u001f( \u001d)'\u001c#(\u001b\u001d#ĉ(\n\u001d)( \u001f& á\u001d#\u001e)\n \n7!&/.á'#\u001d)8 \u0003\u001b-# .)\u001e)- &)-\n \n)&\u001b.)- \u001e\u001f &)- \u001b&#'\u001f(.)- B0\u001f!\u001f.\u001b&\u001f- 0\u001f,\u001e\u001f-6\n \n,/.\u001b-6 ĉ,!\u001b()-\n*\u001b,\u001f(+/#'\u001b.)-)- 3 \u001b&!/()- \u001d\u001f,\u001f\u001b&\u001f-C -\u001f \u001f(\u001d/\u001f(.,\u001b( \u001f( ),'\u001b \u001e\u001f *)&#!&/.\u001b'\u001b.) 3 -\u001f \u001e\u001f\u001c\u001f( \u001e\u001f-\u001e)\u001c&\u001b, \u001f(\n\u001f& #(.\u001f-.#() \"\u001b-.\u001b ')()!&/.\u001b'\u001b.) *\u001b,\u001b +/\u001f */\u001f\u001e\u001b( -\u001f, \u001b\u001c-),\u001c#\u001e)-8 \u0005-.) -\u001f &)!,\u001b '\u001f\u001e#\u001b(.\u001f /(\u001b \u001f(4#'\u001b\n\u001e\u001f& #(.\u001f-.#() B\u001d)($/!\u001b-\u001bC6 \u001b (#0\u001f& \u001e\u001f& 3\u001f3/()8 \u0004\u001f-*/ï- \u001e\u001f \u001b\u001c-),\u001c\u001f,-\u001f6 \u001f& á\u001d#\u001e)\n \nĉ&#\u001d) \u001f- ,\u001f\u001e/\u001d#\u001e) *), &\u001b","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":77,"lines":{"from":87,"to":118}}}}],["303",{"pageContent":"\u001e\u001f& #(.\u001f-.#() B\u001d)($/!\u001b-\u001bC6 \u001b (#0\u001f& \u001e\u001f& 3\u001f3/()8 \u0004\u001f-*/ï- \u001e\u001f \u001b\u001c-),\u001c\u001f,-\u001f6 \u001f& á\u001d#\u001e)\n \nĉ&#\u001d) \u001f- ,\u001f\u001e/\u001d#\u001e) *), &\u001b\n\u001f(4#'\u001b \u001e\u001f \"#\u001e,) )&\u001b.) ,\u001f\u001e/\u001d.\u001b-\u001b6 +/\u001f \u001b\u001e#\u001d#)(\u001b \u001e)- *\u001b,\u001f- \u001e\u001f á.)')- \u001e\u001f \"#\u001e,ĉ!\u001f() *,)\u001e/\u001d#\u001f(\u001e) \u001f& á\u001d#\u001e)\n.\u001f.,\u001b\"#\u001e,) ĉ&#\u001d) B\u0006\bC6 +/\u001f \u001f- \u001c#)+/ù'#\u001d\u001b'\u001f(.\u001f \u001b\u001d.#0)8\n \n\u001b \u001e\u001f\"#\u001e,) )&\u001b.) ,\u001f\u001e/\u001d.\u001b-\u001b \u001f- #(\"#\u001c#\u001e\u001b *), \u001f&\n'\u001f.).,\u001f2\u001b.)6\n \ná,'\u001b\u001d) \u001b(.#(\u001f)*&á-#\u001d)8 \u0001\u001e\u001f'á- \u001e\u001f& á\u001d#\u001e) \u0006\b\nj\n \n6 \u001f2#-.\u001f \u001f& \u001e\u001f,#0\u001b\u001e)\n \n),'#&) \u000ek ) á\u001d#\u001e)\n*)&ù(#\u001d)6 +/\u001f ,\u001f\u001e/\u001d\u001f &)- \u001f \u001f\u001d.)- .ĉ2#\u001d)- \u001e\u001f& '\u001f.).,\u001f2\u001b.)6 \u001d)(.,\u001b \u001f& \u001d/\u001b& \u001f& á\u001d#\u001e) ĉ&#\u001d) \u001f- #(\u001fl·\u001d\u001b48\n\u0003\u001b-# &\u001b .).\u001b&#\u001e\u001b\u001e \u001e\u001f&\n \n)&\u001b.) \u001e\u001f& *&\u001b-'\u001b -\u001f *,\u001f-\u001f(.\u001b \u001c\u001b$) &\u001b\n \n),'\u001b ')()!&/.\u001b'\u001b\u001e\u001b \u001e\u001f& \u0006\b\nj\n \n6 *\u001f,) /(\u001b\n0\u001f4 \u001e\u001f(.,) \u001e\u001f &\u001b- \u001dï&/&\u001b-6 \u001e\u001f (/\u001f0) \u001b/'\u001f(.\u001b -/ .\u001b'\u001bĄ) ')&\u001f\u001d/&\u001b, *), &\u001b \u001b\u001e#\u001d#ĉ( \u001e\u001f 'Ě&.#*&\u001f- ,\u001f-#\u001e/)- \u001e\u001f\ná\u001d#\u001e) !&/.á'#\u001d) 3 -\u001f \u001d)(-.#./3\u001f( (/\u001f0\u001b'\u001f(.\u001f *)&#!&/.\u001b'\u001b.)- +/\u001f6 ,\u001f\u001e/\u001d#\u001e)-6\n \n),'\u001b( &\u001b\n \n/\u001f(.\u001f *,#(\u001d#*\u001b&\n\u001e\u001f &\u001b \u001b\u001d.#0#\u001e\u001b\u001e \u001c#)&ĉ!#\u001d\u001b \u001e\u001f &)-\n \n)&\u001b.)-8 \u0001/(+/\u001f &\u001b 0#.\u001b'#(\u001b \u0002gh 3 \u001f&\n \n)&\u001b.) *\u001b,.#\u001d#*\u001b( \u001d)') \u001d)\u001f(4#'\u001b-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":77,"lines":{"from":118,"to":152}}}}],["304",{"pageContent":"á\u001d#\u001e) !&/.á'#\u001d) 3 -\u001f \u001d)(-.#./3\u001f( (/\u001f0\u001b'\u001f(.\u001f *)&#!&/.\u001b'\u001b.)- +/\u001f6 ,\u001f\u001e/\u001d#\u001e)-6\n \n),'\u001b( &\u001b\n \n/\u001f(.\u001f *,#(\u001d#*\u001b&\n\u001e\u001f &\u001b \u001b\u001d.#0#\u001e\u001b\u001e \u001c#)&ĉ!#\u001d\u001b \u001e\u001f &)-\n \n)&\u001b.)-8 \u0001/(+/\u001f &\u001b 0#.\u001b'#(\u001b \u0002gh 3 \u001f&\n \n)&\u001b.) *\u001b,.#\u001d#*\u001b( \u001d)') \u001d)\u001f(4#'\u001b-\n\u001b\u001d.#0\u001b- \u001f( &\u001b -ù(.\u001f-#- \u001e\u001f &)- á\u001d#\u001e)- (/\u001d&\u001f#\u001d)-6 -/ \u001e\u001fl·\u001d#\u001f(\u001d#\u001b -\u001f \u001d\u001b,\u001b\u001d.\u001f,#4\u001b *), /( \u001e\u001f \u001f\u001d.) \u001f( &\u001b -ù(.\u001f-#- \u001e\u001f&\n\u0004\u000e\u00016 3 \u001f&&) )\u001d\u001b-#)(\u001b /(\u001b \u001e#-'#(/\u001d#ĉ( \u001f( &\u001b *,)&# \u001f,\u001b\u001d#ĉ( 3 '\u001b\u001e/,\u001b\u001d#ĉ( \u001d\u001f&/&\u001b,\u001f-8\n \n)- .\u001f$#\u001e)- \u001e\u001f '\u001b3),\n,\u001f\u001d\u001b'\u001c#) -)( &)- +/\u001f -/ ,\u001f( &\u001b- \u001d)(-\u001f\u001d/\u001f(\u001d#\u001b- B-\u001b(!,\u001f 3 \u001f*#.\u001f&#)-C 36 *), &) .\u001b(.)6 -)( &)- .\u001f$#\u001e)- \u001b \u001f\u001d.\u001b\u001e)-\n+/\u001f \u001d\u001b/-\u001b( &)- -ù(.)'\u001b-8\n\u0010), ).,\u001b *\u001b,.\u001f6 \u001f& ,\u001f.,\u001b-) \u001f( &\u001b -ù(.\u001f-#- \u001e\u001f& \u0004\u000e\u0001 \u001e\u001b \u001d)') ,\u001f-/&.\u001b\u001e) /( \u001e\u001f-\u001f+/#&#\u001c,#) \u001f( \u001f& \u001d,\u001f\u001d#'#\u001f(.)\n\u001d\u001f&/&\u001b,8\n \n\u001b -ù(.\u001f-#- \u001e\u001f \u0012\u000e\u0001 *\u001f,'\u001b(\u001f\u001d\u001f -#( \u001d\u001b'\u001c#)- 3 \u001f&&) *,)0)\u001d\u001b +/\u001f &)- \u001d)'*)(\u001f(.\u001f- \u001e\u001f& \u001d#.)*&\u001b-'\u001b\n\u001d)(.#(Ě\u001f( \u001f( \u001b\u001d.#0#\u001e\u001b\u001e8 \u0001-ù6 &\u001b -ù(.\u001f-#- \u001e\u001f \"\u001f')!&)\u001c#(\u001b \u001b/'\u001f(.\u001b \u001b *\u001f-\u001b, \u001e\u001f& ,\u001f.,\u001b-) \u001f( &\u001b \u001e#0#-#ĉ( \u001d\u001f&/&\u001b,6\n&) +/\u001f \u001f2*&#\u001d\u001b \u001f& \u001b-#(\u001d,)(#-') \u001f( &\u001b '\u001b\u001e/,\u001b\u001d#ĉ( (Ě\u001d&\u001f)I\u001d#.)*&\u001b-'\u001b 3 &\u001b '\u001b\u001d,)\u001d#.)-#-6 +/\u001f -)( .\u001b( \u001d\u001b,\u001b\u001d\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":77,"lines":{"from":152,"to":174}}}}],["305",{"pageContent":".\u001f,ù-.#\u001d)- \u001f( &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8\n \n\u001b 0#.\u001b'#(\u001b \u0002gh \u001d)(.\u001f(#\u001e\u001b \u001f( &\u001b \u001e#\u001f.\u001b *,\u001f-\u001f(.\u001b \u001d)(\u001d\u001f(.,\u001b\u001d#)(\u001f-\n\u001e\u001f \u001f(.,\u001f k 3 if̓!6 3 \u001e\u001f \u001f-.\u001b \u001d\u001b(.#\u001e\u001b\u001e -\u001f \u001b\u001c-),\u001c\u001f( \u001e\u001f g \u001b k̓ !8 \u0005& \u001b\u001e/&.) .#\u001f(\u001f \u001f( -/ ),!\u001b(#-') \u001e\u001f i̓ fff \u001b\nk̓ fff̓!6 3 \u001e\u001f \u001f&&)- g̓ fff \u001b i̓ fff \u001f-.á( \u001d)(.\u001f(#\u001e)- \u001f( \u001f& \"ù!\u001b\u001e)8\n \n)- ,\u001f+/\u001f,#'#\u001f(.)- \u001e#\u001b,#)- 0\u001b,ù\u001b( \u001f(.,\u001f\nf6l 3 g6h̓!6 3 -\u001f \u001d )(-#\u001e\u001f,\u001b +/\u001f &\u001b- *ï,\u001e#\u001e\u001b- \u001e#\u001b,#\u001b- ,\u001f*,\u001f-\u001f(.\u001b( .\u001b( -)&) \u001f& f6gz \u001e\u001f &)- \u001e\u001f*ĉ-#.)- .).\u001b&\u001f-8\n\u0005- *), \u001f&&) +/\u001f &)- *\u001b\u001d#\u001f(.\u001f- \u001d)( \u001e\u001f \u001f\u001d.)- \u001e\u001f \u001b\u001c-),\u001d#ĉ( \u001e\u001f 0#.\u001b'#(\u001b \u0002gh B!\u001b-.,\u001f\u001d.)'ù\u001b- ) -ù(\u001e,)'\u001f- \u001e\u001f\n\u001b\u001c-),\u001d#ĉ( #(.\u001f-.#(\u001b& \u001e\u001fl·\u001d#\u001f(.\u001fC ,\u001f+/#\u001f,\u001f( '/\u001d\")- \u001bĄ)- *\u001b,\u001b +/\u001f \u001b*\u001b,\u001f4\u001d\u001b &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b: *),\n).,\u001b *\u001b,.\u001f6 \u001f- '/3 ,\u001b,) )\u001c-\u001f,0\u001b, \u001f-.\u001b \u001b(\u001f'#\u001b \u001f( \u001d\u001b-)- \u001e\u001f \u001e\u001f-(/.,#\u001d#ĉ( *,#'\u001b,#\u001b8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":77,"lines":{"from":176,"to":186}}}}],["306",{"pageContent":"La síntesis de RNA permanece\nsin cambios y ello provoca que\nlos componentes del citoplasma\ncontinúen en actividad. Así,\nla síntesis de hemoglobina au-\nmenta a pesar del retraso en la\ndivisión celular, lo que explica el\nasincronismo en la maduración\nnúcleo/citoplasma y la macroci-\ntosis, que son tan característicos\nen la anemia megaloblástica.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":77,"lines":{"from":188,"to":198}}}}],["307",{"pageContent":"CAPÍTULO 4. ANEMIAS MEGALOBLÁSTICAS\n\n51\n\nCONSIDERACIONES CLÍNICAS\n\n\u001b- *\u001f,-)(\u001b- \u001e\u001fl·\u001d#\u001f(.\u001f- \u001e\u001f á\u001d#\u001e) ĉ&#\u001d)6 0#.\u001b'#(\u001b \u0002gh6 ) \u001b'\u001c\u001b-6 \u001e\u001f-\u001b,,)&&\u001b( \u001b(\u001f'#\u001b &\u001f(.\u001b'\u001f(.\u001f 3 \u001b& *,#(\u001d#\n-\n\n*#) */\u001f\u001e\u001f *\u001b-\u001b, #(\u001b\u001e0\u001f,.#\u001e\u001b6 ,\u001f.,\u001b-\u001b(\u001e) &\u001b \u001b.\u001f(\u001d#ĉ( 'ï\u001e#\u001d\u001b6 3\u001b +/\u001f *), &) !\u001f(\u001f,\u001b& -)&#\u001d#.\u001b( \u001b.\u001f(\u001d#ĉ( \u001d/\u001b(\u001e)\n&\u001b \u001b(\u001f'#\u001b \u001e#l·\u001d/&.\u001b &\u001b ,\u001f\u001b&#4\u001b\u001d#ĉ( \u001e\u001f &\u001b- \u001b\u001d.#0#\u001e\u001b\u001e\u001f- \u001d).#\u001e#\u001b(\u001b-8\n \n\u001b \u001b.#!\u001b 3 &\u001b -#(.)'\u001b.)&)!ù\u001b \u001b\u001c\u001e)'#(\u001b& -)(\n\u001d)'/(\u001f-8\n \n)- \u001f( \u001f,')- -\u001f +/\u001f$\u001b( \u001e\u001f \u001e#\u001b,,\u001f\u001b \u001d,ĉ(#\u001d\u001b6 \u001b,\u001e), \u001f( &\u001b &\u001f(!/\u001b 3 */\u001f\u001e\u001f( &&\u001f!\u001b, \u001b *,\u001f-\u001f(.\u001b, +/\u001f#&#.#-\n3 Ě&\u001d\u001f,\u001b- ),\u001b&\u001f-8\n \n\u001b &\u001f(!/\u001b \u001f-.\u001b \u001f(,)$\u001f\u001d#\u001e\u001b6 &#-\u001b6 \u001c,#&&\u001b(.\u001f 3 \u001e)&),)-\u001b \u001e\u001f\u001c#\u001e) \u001b& \u001b\u001e\u001f&!\u001b4\u001b'#\u001f(.) \u001e\u001f& \u001f*#.\u001f&#)\n\n(fig. 4-1)\n8\n \n( ,\u001f\u001d/\u001f(.\u001f6 *\u001f,) */\u001f\u001e\u001f &&\u001f!\u001b, \u001b .)\u001d\u001b,-\u001f \u001f& \u001c\u001b4) \u001f( \u001f2á'\u001f(\u001f- ù-#\u001d)- \u001d/#\u001e\u001b\u001e)-)- 3 )\u001d\u001b-#)(\u001b&'\u001f(.\u001f\n*,\u001f-\u001f(.\u001b, \u001e)&), ĉ-\u001f) 3 l·\u001f\u001c,\u001f \u001f( \u001d/\u001b\u001e,)- \u001b0\u001b(4\u001b\u001e)-8\n \n\u001b *\u001b&#\u001e\u001f4 '/\u001d)\u001d/.á(\u001f\u001b \u001b-)\u001d#\u001b\u001e\u001b \u001b /(\u001b \u001d\u001b,\u001b \u001b\u001c).\u001b!\u001b\u001e\u001b )\n^ \u001b\u001d#\u001f- \u001e\u001f ,/.\u001b '\u001b\u001e/,\u001b_ \u001f- -/!\u001f-.#0\u001b \u001e\u001f \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b6 \"#*).#,)#\u001e#-') ) #(-/l·\u001d#\u001f(\u001d#\u001b ,\u001f(\u001b&8 \u0003)( ,\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":78,"lines":{"from":1,"to":29}}}}],["308",{"pageContent":"&\u001b\u001d#ĉ( \u001b &\u001b -#(.)'\u001b.)&)!ù\u001b ,\u001f&\u001b\u001d#)(\u001b\u001e\u001b \u001b &\u001b &\u001f/\u001d)*\u001f(#\u001b 3 .,)'\u001c)\u001d#.)*\u001f(#\u001b6 *), -/ \u001f-\u001d\u001b-\u001b !,\u001b0\u001f\u001e\u001b\u001e6 .,\u001b(-\u001d/,,\u001f(\n\u001b-#(.)'á.#\u001d\u001b-6 '\u001f()- \u001e\u001f& gfz *,\u001f-\u001f(.\u001b,á \"\u001f'),,\u001b!#\u001b \u001d&ù(#\u001d\u001b6 3 &\u001b l·\u001f\u001c,\u001f6 -# -\u001f *,\u001f-\u001f(.\u001b6 () !/\u001b,\u001e\u001b ,\u001f&\u001b\u001d#ĉ(\n\u001d)( #( \u001f\u001d\u001d#ĉ( \u001b!,\u001f!\u001b\u001e\u001b6 \u001b/(+/\u001f */\u001f\u001e\u001f *,\u001f-\u001f(.\u001b,-\u001f \u001e\u001f '\u001b(\u001f,\u001b #(\u001e\u001f*\u001f(\u001e#\u001f(.\u001f8\n\u001b '\u001f\u001e#\u001b \u001e\u001f \u001f\u001e\u001b\u001e \u001f(\u001d)(.,\u001b\u001e\u001b \u001f( \u001e# \u001f,\u001f(.\u001f- \u001f-./\u001e#)- \u001f- \u001e\u001f ki6 kn 3 jg6n \u001bĄ)-6 \u001f( *)\u001c&\u001b\u001d#)(\u001f- \u001e\u001f \u0010\u001f,Ě6\n\u0010/\u001f\u001c&\u001b B\n \nï2#\u001d)C 3 \u0004#-.,#.) \u0006\u001f\u001e\u001f,\u001b&8 \u0005( /(\u001b ,\u001f0#-#ĉ( -)\u001c,\u001f ggf *\u001b\u001d#\u001f(.\u001f- ,\u001f!#-.,\u001b\u001e)- \u001f( \u001f& \b)-*#.\u001b& \u001e\u001f \u0005-*\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":78,"lines":{"from":31,"to":38}}}}],["309",{"pageContent":"\u001d#\u001b&#\u001e\u001b\u001e\u001f- \u001e\u001f& \u0003\u001f(.,)\n \nï\u001e#\u001d) \u001e\u001f &\u001b \u0012\u001b4\u001b \u001e\u001f&\n \n\u0013\u00136 -\u001f \u001f(\u001d)(.,ĉ +/\u001f &)- \u001f( \u001f,')- .\u001f(ù\u001b( \u001f(.,\u001f gk 3 nk \u001bĄ)-\n\u001e\u001f \u001f\u001e\u001b\u001e Bjg6n \u001bĄ)- *,)'\u001f\u001e#)C 3 +/\u001f &\u001b ,\u001f&\u001b\u001d#ĉ( \")'\u001c,\u001fI'/$\u001f, /\u001f \u001e\u001f g9g6k8\n \n\u001b- '\u001b(# \u001f-.\u001b\u001d#)(\u001f- \u001d&ù(#\u001d\u001b- 3 -/\n,\u001f\u001d/\u001f(\u001d#\u001b -\u001f *,\u001f-\u001f(.\u001b( \u001f( \u001f&\n \ncuadro 4-1\n8\n \n)- \"\u001b&&\u001b4!)- \u001d&ù(#\u001d)- 0\u001b,ù\u001b(6 \u001e\u001f*\u001f(\u001e#\u001f(\u001e) \u001e\u001f& .#*) \u001e\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b8\n\u0005& \u001d)(\u001d\u001f*.) \u001d&á-#\u001d) \u001e\u001f-\u001d,#.) *), Ļ)'\u001b- \u0001\u001e\u001e#-)( Bgmoi7gnlfC \u001e\u001f \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b \u001f,\u001b9\n \n“en los pa-\ncientes el rostro se vuelve pálido, el blanco de los ojos toma un color perlado, toda la superficie corporal presenta un\ncolor blanquecino y apariencia encerada, los labios y la lengua parecen faltos de sangre, incrementa la flacidez de\nlo sólido, disminuye el apetito, se produce dificultad para respirar y taquicardia, aparecen ligeros edemas general-\nmente en los tobillos, la debilidad llega a ser extrema y el paciente llega a no poder levantarse de la cama, la mente\nocasionalmente ausente, y llega a entrar en un tórpido estado de un largo morir”.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":78,"lines":{"from":40,"to":61}}}}],["310",{"pageContent":"\u0004\u001f \u001f-.\u001b \u001e\u001f-\u001d,#*\u001d#ĉ( \u001d&ù(#\u001d\u001b -\u001f \u001e\u001f-.\u001b\u001d\u001b +/\u001f6 \u001d/\u001b(\u001e) &\u001b \u001b(\u001f'#\u001b -\u001f \u001e\u001f\u001c\u001f \u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f 0#.\u001b'#(\u001b \u0002gh6 \u001b*\u001b,\u001f\n-\n\n\u001d\u001f( \u001b(),'\u001b&#\u001e\u001b\u001e\u001f- (\u001f/,)&ĉ!#\u001d\u001b-8 \u0001 (#0\u001f& \u001d\u001f(.,\u001b& -\u001f ,\u001f!#-.,\u001b \u001b&.\u001f,\u001b\u001d#ĉ( \u001e\u001f& \u001f-.\u001b\u001e) '\u001f(.\u001b&6 \u001e\u001f \u001f\u001d.)- \u001d)!(#.#0)-\n\nFigura 4-1.\n \n\u001f(!/\u001b &#-\u001b 3 -\u001f(-#\u001c&\u001f \u001f( /(\u001b '/$\u001f, \u001e\u001f nm \u001bĄ)- \u001d)( \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b8 \u0003),.\u001f-ù\u001b \u001e\u001f& \u0004,8\n \n)-ï\n/#- \u0014),#4\n \n\u001f&\u001d\"),6 \u0001-)\u001d#\u001b\u001d#ĉ( \u001b&#-\u001d#\u001f(-\u001f \u001e\u001f\n \nï\u001e#\u001d)-\n \n(.\u001f,(#-.\u001b-8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":78,"lines":{"from":63,"to":79}}}}],["311",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n52\n\n3 ^&)\u001d/,\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b_6 '\u001b(# \u001f-.\u001b\u001e\u001b \u001d)') \u001e\u001f*,\u001f-#ĉ(6 \u001e\u001f-#&/-#ĉ(6 '\u001b(ù\u001b6 #,,#.\u001b\u001c#&#\u001e\u001b\u001e6 *\u001b,\u001b()#\u001b 3 &\u001b\u001c#&#\u001e\u001b\u001e\n\u001b \u001f\u001d.#0\u001b: \u001f( 'ï\u001e/&\u001b \u001f-*#(\u001b&6 '#\u001f&)*\u001b.ù\u001b \u001e\u001f& .#*) \u001e\u001f &\u001b \u001e\u001f!\u001f(\u001f,\u001b\u001d#ĉ( \u001d)'\u001c#(\u001b\u001e\u001b -/\u001c\u001b!/\u001e\u001b B\u001e\u001f-'#\u001f&#(#4\u001b\u001d#ĉ( \u001e\u001f\n&)- \u001d),\u001e)(\u001f- &\u001b.\u001f,\u001b&\u001f- 3 *)-.\u001f,#),\u001f- \u001e\u001f &\u001b 'ï\u001e/&\u001b \u001f-*#(\u001b&C6 +/\u001f -\u001f \u001d\u001b,\u001b\u001d.\u001f,#4\u001b( *), \u001e#-'#(/\u001d#ĉ( ) *ï,\u001e#\u001e\u001b \u001e\u001f &\u001b\n-\u001f(-#\u001c#&#\u001e\u001b\u001e 0#\u001c,\u001b.),#\u001b 3 \u001e\u001f& -\u001f(.#\u001e) \u001e\u001f &\u001b *,)*#)\u001d\u001f*\u001d#ĉ(6 \u001b-ù \u001d)') .,\u001b-.),()- \u001e\u001f &\u001b '\u001b,\u001d\"\u001b: -#!() \u001e\u001f \u0012)'\u001c\u001f,!\n*)-#.#0)6 -#!() \u001e\u001f\n \n\"\u001f,'#..\u001f 3 -\u001f \u001f(\u001d/\u001f(.,\u001b /( (#0\u001f& -\u001f(-#.#0) \u001d/.á(\u001f): 3 \u001b (#0\u001f& \u001e\u001f& -#-.\u001f'\u001b (\u001f,0#)-) \u001d\u001f(.,\u001b&\n\u001b/.ĉ()')6 \"#*).\u001f(-#ĉ( *)-./,\u001b&8 \u0005( &)- \u001d\u001b-)- \u001d,ĉ(#\u001d)-6 \"\u001b3 *ï,\u001e#\u001e\u001b \u001e\u001f& \u001d)(.,)& \u001e\u001f &)- \u001f- ù(.\u001f,\u001f- 0\u001f-#\u001d\u001b&7,\u001f\u001d.\u001b&\n3 \u001e#- /(\u001d#ĉ( \u001f,ï\u001d.#&8 \u0001 (#0\u001f& \u001e\u001f& -#-.\u001f'\u001b (\u001f,0#)-) *\u001f,# ï,#\u001d) -\u001f )\u001c-\u001f,0\u001b *ï,\u001e#\u001e\u001b \u001e\u001f &\u001b -\u001f(-#\u001c#&#\u001e\u001b\u001e \u001d/.á(\u001f\u001b6\n\"#*),,\u001fł\u001f2#\u001b6 \u001e\u001f\u001c#&#\u001e\u001b\u001e -#'ï.,#\u001d\u001b 3 *\u001b,\u001f-.\u001f-#\u001b-8 \u0005( \u001d\u001b'\u001c#)6 \u001f( &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b ,\u001f&\u001b\u001d#)(\u001b\u001e\u001b \u001b &\u001b \u001e\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":79,"lines":{"from":1,"to":15}}}}],["312",{"pageContent":"l·\u001d#\u001f(\u001d#\u001b \u001e\u001f á\u001d#\u001e) ĉ&#\u001d)6 () \u001f2#-.\u001f( &\u001b- '\u001b(# \u001f-.\u001b\u001d#)(\u001f- (\u001f/,)&ĉ!#\u001d\u001b- \u001e\u001b\u001e) +/\u001f \u001f& )&\u001b.) -)&) \u001b \u001f\u001d.\u001b &\u001b -ù(.\u001f-#-\n\u001e\u001f& á\u001d#\u001e) ,#\u001c)(/\u001d&\u001f#\u001d) 36 *), &) .\u001b(.)6 () #(.\u001f,0#\u001f(\u001f \u001f( &\u001b *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f '#\u001f&#(\u001b8\n\u001b \u001b(\u001f'#\u001b \u001e\u001f\u001c#\u001e\u001b \u001b \u001eïl·\u001d#. \u001e\u001f )&\u001b.)- \u001d/,-\u001b \u001d)( 0ĉ'#.) 3 \u001e#\u001b,,\u001f\u001b +/\u001f \u001d\u001f\u001e\u001f( ,á*#\u001e\u001b'\u001f(.\u001f \u001b& .,\u001b.\u001b'#\u001f(.)\n\u001d)( )&\u001b.)-8 \u0007\u001f(\u001f,\u001b&'\u001f(.\u001f &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f 0#.\u001b'#(\u001b \u0002gh ,\u001f-/&.\u001b \u001e\u001f /( \u001e\u001f \u001f\u001d.) \u001e\u001f \u001b\u001c-),\u001d#ĉ( #(.\u001f-.#(\u001b& *,)\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":79,"lines":{"from":17,"to":21}}}}],["313",{"pageContent":"&)(!\u001b\u001e)8 \u0005&&) -\u001f )\u001c-\u001f,0\u001b \u001d&\u001b,\u001b'\u001f(.\u001f \u001f( &\u001b \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b6 +/\u001f \u001f- &\u001b 0\u001b,#\u001f\u001e\u001b\u001e 'á- \u001d)'Ě( \u001e\u001f& \u001eïl·\u001d#. \u001e\u001f\n\u001d)\u001c\u001b&\u001b'#(\u001b-8 \u0005( \u001f-.\u001b \u001f(.#\u001e\u001b\u001e ()-)&ĉ!#\u001d\u001b \"\u001b3 \u001b.,)l·\u001b \u001e\u001f &\u001b- \u001dï&/&\u001b- *\u001b,#\u001f.\u001b&\u001f- \u001e\u001f &\u001b '/\u001d)-\u001b !á-.,#\u001d\u001b6 +/\u001f -)(\n&\u001b- \u001f(\u001d\u001b,!\u001b\u001e\u001b- \u001e\u001f -\u001f\u001d,\u001f.\u001b, \u001f& \u001b\u001d.), #(.,ù(-\u001f\u001d)6 \u001f& \u001d/\u001b& \u001f- #(\u001e#-*\u001f(-\u001b\u001c&\u001f *\u001b,\u001b &\u001b \u001b\u001c-),\u001d#ĉ( \u001e\u001f &\u001b 0#.\u001b'#(\u001b \u0002gh8\n\u001b \u001b.,)l·\u001b \u001e\u001f &\u001b- \u001dï&/&\u001b- *\u001b,#\u001f.\u001b&\u001f- ,\u001f-/&.\u001b \u001e\u001f /(\u001b \u001b!,\u001f-#ĉ( #('/(#.\u001b,#\u001b6 \u001d)') &) \u001e\u001f'/\u001f-.,\u001b &\u001b *,\u001f-\u001f(\u001d#\u001b \u001e\u001f\n\u001b(.#\u001d/\u001f,*)- \u001e#,#!#\u001e)- \u001d)(.,\u001b &\u001b '/\u001d)-\u001b !á-.,#\u001d\u001b6 +/\u001f -)( \u001e\u001f.\u001f\u001d.\u001b\u001e)- \u001f( \u001f& ofz \u001e\u001f &)- *\u001b\u001d#\u001f(.\u001f-8\n)- \u001b(.#\u001d/\u001f,*)- \u001b(.#7 \u001b\u001d.), #(.,ù(-\u001f\u001d) 3 &)- \u001e#,#!#\u001e)- \u001d)(.,\u001b \u001f& \u001d)'*&\u001f$) \u001b\u001d.), #(.,ù(-\u001f\u001d) 'á- 0#.\u001b'#(\u001b\n\u0002gh B\u0006 ̓ ̓\u0002ghC6\n \n&&\u001b'\u001b\u001e)- (\u001f/.,\u001b&#4\u001b(.\u001f 3 *,\u001f\u001d#*#.\u001b(.\u001f6 ,\u001f-*\u001f\u001d.#0\u001b'\u001f(.\u001f6 -)( .\u001b'\u001c#ï( \u001e\u001f.\u001f\u001d.\u001b\u001e)- \u001f( &\u001b '\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":79,"lines":{"from":23,"to":32}}}}],["314",{"pageContent":"3),ù\u001b \u001e\u001f &)- \u001f( \u001f,')- 3 -/ *,\u001f-\u001f(\u001d#\u001b \u001f- \u001b&.\u001b'\u001f(.\u001f \u001f-*\u001f\u001dùl·\u001d\u001b6 \u001f( \u001d)(.,\u001b-.\u001f \u001d)( &)- \u001b(.#\u001d/\u001f,*)- \u001b(.#7'/\u001d)-\u001b\n!á-.,#\u001d\u001b6 +/\u001f */\u001f\u001e\u001f( \u001b*\u001b,\u001f\u001d\u001f, \u001f( ).,\u001b- \u001f( \u001f,'\u001f\u001e\u001b\u001e\u001f- \u001b/.)#('/(#.\u001b,#\u001b- B.#,)#\u001e#.#-6 \u001e#\u001b\u001c\u001f.\u001f- '\u001f&&#./- .#*)\ng6 \u001d)&#.#- /&\u001d\u001f,)-\u001b6 \u001f.\u001d8C8\n\u0005( &)- \u001d\u001b-)- ,\u001f*),.\u001b\u001e)- \u001f( \u0010/\u001f\u001c&\u001b6 -)&) \u001f( h \u001e\u001f hk *\u001b\u001d#\u001f(.\u001f-\n \n/\u001f,)( \u001f(\u001d)(.,\u001b\u001e)- *)-#.#0)- &)- \u001b(.#\n-\n\n\u001d/\u001f,*)- \u001b(.#7'/\u001d)-\u001b !á-.,#\u001d\u001b8 \u0010), ).,\u001b *\u001b,.\u001f6 -\u001f \"\u001b \u001f(\u001d)(.,\u001b\u001e) /(\u001b \u001d&\u001b,\u001b *,\u001f\u001e#&\u001f\u001d\u001d#ĉ( \u001e\u001f& *\u001b\u001e\u001f\u001d#'#\u001f(.)\n*), *\u001f,-)(\u001b- \u001e\u001f !,/*) -\u001b(!/ù(\u001f) \u0001 3 \u001d)( \b\n \n\u0001 .#*) \u0001i6 \u0001m 3 \u0001gh8 \u0005( \u001d#\u001f,.)- !,/*)- \u001e\u001f *)\u001c&\u001b\u001d#ĉ( \u001e\u001f&\n(),.\u001f \u001e\u001f \u0005/,)*\u001b B\u0004#(\u001b'\u001b,\u001d\u001b6 \u000e),/\u001f!\u001b6 \u0013/\u001f\u001d#\u001b 3 \u0006#(&\u001b(\u001e#\u001bC6 &\u001b\n \n,\u001f\u001d/\u001f(\u001d#\u001b \u001e\u001f \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b \u001f- \u001b&.\u001b8\n\u0005(\n \n\u001b'#&#\u001b- \u001e)(\u001e\u001f \"\u001b3 /( \u001f( \u001f,')6 &\u001b #(\u001d#\u001e\u001f(\u001d#\u001b \u001b&\u001d\u001b(4\u001b \u001e\u001f hf \u001b ifz8 \u0005- \u001d)'Ě( +/\u001f &)- \u001f( \u001f,')- \u001d)(\n\nCuadro 4-1.\n \nCuadro clínico de la anemia megaloblástica\n\nSíntomas y signos\n \nIMSS = 110 (1981) (%)\n \nPerú = 70 (1989) (%)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":79,"lines":{"from":34,"to":61}}}}],["315",{"pageContent":"Cuadro 4-1.\n \nCuadro clínico de la anemia megaloblástica\n\nSíntomas y signos\n \nIMSS = 110 (1981) (%)\n \nPerú = 70 (1989) (%)\n\n\u0010\u001b&#\u001e\u001f46 \u001b-.\u001f(#\u001b \"#*)\u001e#(\u001b'#\u001b\n \ngff\n \nnf\n\u0010ï,\u001e#\u001e\u001b \u001e\u001f *\u001f-)\n \noi\n \nij\n\u0004#\u001b,,\u001f\u001b 3 0ĉ'#.)\n \nmh\n \nkg\n\u0004)&), \u001f*#!á-.,#\u001d)\n \nB @ C\n \nhn\n\u0005\u001e\u001f'\u001bI\u001b-\u001d#.#-\n \nB @ C\n \nhh\n\u0006#\u001f\u001c,\u001f\n \nki\n \nB @ C\n\u0007&)-#.#-\n \njf\n \nB @ C\n\u001d.\u001f,#\u001d#\u001b\n \nik\n \ngj\n\u0013ù(.)'\u001b- (\u001f/,)&ĉ!#\u001d)-\n \nif\n \ngg\n\u0001(\u001f'#\u001b\n \ngff\n \ngff\n\u0014,)'\u001c)\u001d#.)*\u001f(#\u001b\n \nlj\n \nB @ C\n\u001f/\u001d)*\u001f(#\u001b\n \nlh\n \nB @ C\n\u0010\u001b(\u001d#.)*\u001f(#\u001b\n \nB @ C\n \njk\n\u0002#\u001d#.)*\u001f(#\u001b\n \nB @ C\n \njh\n\u0004\b\n \nB kff \u0015 I\n \nC \u0015(#\u001e\u001b\u001e\u001f- BLC\n \nof\n \nB @ C\nBLC \u0004\b\n \n \u001e\u001f-\"#\u001e,)!\u001f(\u001b-\u001b &á\u001d.#\u001d\u001b8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":79,"lines":{"from":61,"to":152}}}}],["316",{"pageContent":"CAPÍTULO 4. ANEMIAS MEGALOBLÁSTICAS\n\n53\n\nCuadro 4-2.\n \nManifestaciones clínicas del déficit de vitamina B12\n\nNeuropsiquiátricas\nCerebro:\n \n\u001b&.\u001f,\u001b\u001d#ĉ( \u001e\u001f& \u001f-.\u001b\u001e) '\u001f(.\u001b&6 \u001e\u001f \u001f\u001d.)- \u001d)!(#.#0)-6 \u001b&.\u001f,\u001b\n-\n\n\u001d#ĉ( \u001f( &\u001b '\u001f$),ù\u001b6 \u001d\u001b'\u001c#)- \u001f( &\u001b *\u001f,-)(\u001b&#\u001e\u001b\u001e6 ^&)\u001d/,\u001b '\u001f!\u001b&)\u001c&\u001b-.#\n-\n\n\u001d\u001b_9 \u001e\u001f*,\u001f-#ĉ(6 '\u001b(ù\u001b6 #,,#.\u001b\u001c#&#\u001e\u001b\u001e6 *\u001b,\u001b()#\u001b6 \u001e\u001f-#&/-#)(\u001f-6 &\u001b\u001c#&#\u001e\u001b\u001e\n\u001b \u001f\u001d.#0\u001b8 \u0001.,)l·\u001b ĉ*.#\u001d\u001b6 \u001b()-'#\u001b6 *ï,\u001e#\u001e\u001b \u001e\u001f& !/-.)\n\nMédula espinal:\n \n'#\u001f&)*\u001b.ù\u001b6 \u001e\u001f!\u001f(\u001f,\u001b\u001d#ĉ( \u001d)'\u001c#(\u001b\u001e\u001b -/\u001c\u001b!/\u001e\u001b6\n*\u001b,\u001f-.\u001f-#\u001b-6 *ï,\u001e#\u001e\u001b \u001e\u001f &\u001b *,)*#)\u001d\u001f*\u001d#ĉ(9 0#\u001c,\u001b\u001d#)(\u001f-6 *)-#\u001d#)(\u001f-6\n'\u001b,\u001d\"\u001b \u001b.á2#\u001d\u001b6 \u001e\u001f\u001c#&#\u001e\u001b\u001e \u001e\u001f &)- '#\u001f'\u001c,)-6 \u001f-*\u001b-.#\u001d#\u001e\u001b\u001e6 \"#*\u001f,,\u001f\n-\n\nł\u001f2#\u001b6 -#!()- \u001e\u001f \u0012)'\u001c\u001f,! 3\n \n\"\u001f,'#..\u001f *)-#.#0)-6 (#0\u001f& -\u001f(-#.#0) \u001f(\n/( -\u001f!'\u001f(.) \u001d/.á(\u001f)\n\nSistema nervioso periférico:\n \n*ï,\u001e#\u001e\u001b \u001e\u001f &\u001b -\u001f(-#\u001c#&#\u001e\u001b\u001e \u001d/.á(\u001f\u001b6 \"#\n-\n\n*),,\u001fł\u001f2#\u001b6 \u001e\u001f\u001c#&#\u001e\u001b\u001e -#'ï.,#\u001d\u001b6 *\u001b,\u001f-.\u001f-#\u001b-\n\nHematológicas\nMédula ósea:\n \n\"#*\u001f,\u001d\u001f&/&\u001b,6 *,\u001f\u001d/,-),\u001f- \u001f,#.,)#\u001e\u001f- \u001b/'\u001f(.\u001b\u001e)-8\n \n),\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":80,"lines":{"from":1,"to":46}}}}],["317",{"pageContent":"Sistema nervioso periférico:\n \n*ï,\u001e#\u001e\u001b \u001e\u001f &\u001b -\u001f(-#\u001c#&#\u001e\u001b\u001e \u001d/.á(\u001f\u001b6 \"#\n-\n\n*),,\u001fł\u001f2#\u001b6 \u001e\u001f\u001c#&#\u001e\u001b\u001e -#'ï.,#\u001d\u001b6 *\u001b,\u001f-.\u001f-#\u001b-\n\nHematológicas\nMédula ósea:\n \n\"#*\u001f,\u001d\u001f&/&\u001b,6 *,\u001f\u001d/,-),\u001f- \u001f,#.,)#\u001e\u001f- \u001b/'\u001f(.\u001b\u001e)-8\n \n),\n-\n\n)&ĉ!#\u001d\u001b'\u001f(.\u001f6 \u001d,)'\u001b.#(\u001b (/\u001d&\u001f\u001b, #('\u001b\u001e/,\u001b6 \u001b-#(\u001d,)(ù\u001b '\u001b\u001e/,\u001b.#0\u001b\n(Ě\u001d&\u001f)7\u001d#.)*&\u001b-'\u001b6\n \n\u001c\u001b(\u001e\u001b-\n \n!#!\u001b(.\u001f-6\n \n'\u001f.\u001b'#\u001f&)\u001d#.)-6\n \n\u001d\u001b,#),,\u001f2#-6\n\u001e#-*&\u001b-#\u001b8 \u0012\u001f-/&.\u001b\u001e)- \u001b(),'\u001b&\u001f- \u001f( &\u001b \u001d#.)'\u001f.,ù\u001b \u001e\u001f ł/$) 3 \u001b(á&#-#-\n\u001d#.)!\u001f(ï.#\u001d)-\n\nSangre periférica:\n \n\u0005,#.,)\u001d#.)-9 '\u001b\u001d,)\u001d#.)-#-6 '\u001b\u001d,))0\u001b&)\u001d#.)-6 \u001b(#\n-\n\n-)\u001d#.)-#-6\n \n),'\u001b-\n \n,\u001b!'\u001f(.\u001b\u001e\u001b-6 (\u001f/.,ĉl·&)- \"#*\u001f,-\u001f!'\u001f(.\u001b\u001e)- Bgz\n\u001d)( l &ĉ\u001c/&)- ) kz \u001d)( k &ĉ\u001c/&)-C8\n \n\u001f/\u001d)*\u001f(#\u001b \u001d)( ),'\u001b- #('\u001b\u001e/\n-\n\n,\u001b-6 .,)'\u001c)\u001d#.)*\u001f(#\u001b6 *\u001b(\u001d#.)*\u001f(#\u001b6 \u001f&\u001f0\u001b\u001d#ĉ( \u001e\u001f &\u001b \u001e\u001f-\"#\u001e,)!\u001f(\u001b-\u001b\n&á\u001d.#\u001d\u001b B(#0\u001f&\u001f- \u001b&.)-C6 \u001c#&#,,/\u001c#(\u001b #(\u001e#,\u001f\u001d.\u001b \u001b/'\u001f(.\u001b\u001e\u001b6 \u001b'#().,\u001b(-\n-\n\n\u001f,\u001b-\u001b- \u001b&.\u001b-6 \u001e#-'#(/\u001d#ĉ( \u001e\u001f &\u001b \"\u001b*.)!&)\u001c#(\u001b \u001f #(\u001d,\u001f'\u001f(.) \u001e\u001f á\u001d#\u001e)\n'\u001f.#&'\u001b&ĉ(#\u001d)6 \")')\u001d#-.\u001fù(\u001b6 ) \u001b'\u001c)-\n\nDigestivas\n \n\u0007&)-#.#-6 Ě&\u001d\u001f,\u001b- '/\u001d)\u001d/.á(\u001f\u001b-6 \u001e#\u001b,,\u001f\u001b6 \u001b\u001c-),\u001d#ĉ( #(.\u001f-.#(\u001b& \u001e\u001fl·\u001d#\u001f(.\u001f\n\nGenitourinarias\n \n( \u001f,.#&#\u001e\u001b\u001e6 \u001e#- /(\u001d#ĉ( \u001f,ï\u001d.#&","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":80,"lines":{"from":46,"to":102}}}}],["318",{"pageContent":"Digestivas\n \n\u0007&)-#.#-6 Ě&\u001d\u001f,\u001b- '/\u001d)\u001d/.á(\u001f\u001b-6 \u001e#\u001b,,\u001f\u001b6 \u001b\u001c-),\u001d#ĉ( #(.\u001f-.#(\u001b& \u001e\u001fl·\u001d#\u001f(.\u001f\n\nGenitourinarias\n \n( \u001f,.#&#\u001e\u001b\u001e6 \u001e#- /(\u001d#ĉ( \u001f,ï\u001d.#&\n\nCardiovasculares\n \n\u00050\u001f(.)- .,)'\u001c)\u001f'\u001cĉ&#\u001d)-9 #( \u001b,.) \u001e\u001f& '#)\u001d\u001b,\u001e#)6 \u001b\u001d\u001d#\u001e\u001f(.\u001f \u001d\u001f,\u001f\u001c,)\n-\n\n0\u001b-\u001d/&\u001b,6 \u001f'\u001c)&#-') */&')(\u001b,\n\nNiños\n\n\u0012\u001f.,\u001b-) \u001f( \u001f& \u001d,\u001f\u001d#'#\u001f(.) ) ,\u001f!,\u001f-#ĉ(6 \u001e#-\u001d\u001b*\u001b\u001d#\u001e\u001b\u001e *\u001f,'\u001b(\u001f(.\u001f6 () -)(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":80,"lines":{"from":102,"to":120}}}}],["319",{"pageContent":",ù\u001f(6 \u001e#l·\u001d/&.\u001b\u001e *\u001b,\u001b \u001b&#'\u001f(.\u001b,-\u001f6 \"#*).)(ù\u001b6 &\u001f.\u001b,!#\u001b6 \u001d)'\u001b6 #,,#.\u001b\u001c#&#\u001e\u001b\u001e6\n\u001d)(0/&-#)(\u001f-6 .\u001f'\u001c&),\u001f-6 '#\u001d,)\u001d\u001f \u001b&#\u001b6 ')0#'#\u001f(.)- \u001d),#)\u001b.\u001f.)#\u001e\u001f-\n)\u001e#l·\u001d\u001b\u001e) \u001e\u001f9 \u000e\u0005\n \nhfgi: iln9 h8\n\u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b )\u001c-\u001f,0\u001b\u001e)- \u001f(\n \nï2#\u001d) -\u001f\u001b( \u001e\u001f *#\u001f& \u001c&\u001b(\u001d\u001b6 )$)- \u001b4/&\u001f-6 *\u001b\u001c\u001f&&)(\u001f- \u001b/,#\u001d/&\u001b,\u001f- !,\u001b(\u001e\u001f-6\n\")'\u001c,)- \u001b(\u001d\")- 3 \u001d\u001b(#\u001d#\u001f *,\u001f\u001d)46 .)\u001e) \u001f&&) ,\u001f0\u001f&\u001b\u001e), \u001e\u001f -/ \u001b-\u001d\u001f(\u001e\u001f(\u001d#\u001b -\u001b$)(\u001b8\n\u0005( &\u001b ,\u001f-\u001f\u001d\u001d#ĉ( !á-.,#\u001d\u001b \u001d)'*&\u001f.\u001b -\u001f \u001f&#'#(\u001b &\u001b *),\u001d#ĉ( \u001e\u001f '/\u001d)-\u001b -\u001f\u001d,\u001f.),\u001b \u001e\u001f\n \n\u001b\u001d.), #(.,ù(-\u001f\u001d)6 3\n\u001e\u001f-*/ï- \u001e\u001f k \u001b l \u001bĄ)- \u001e\u001f& *)-)*\u001f,\u001b.),#) \u001b*\u001b,\u001f\u001d\u001f &\u001b \u001b(\u001f'#\u001b8 \u0005( &\u001b !\u001b-.,\u001f\u001d.)'ù\u001b *\u001b,\u001d#\u001b&6 \u001e\u001f-*/ï- \u001e\u001f 0\u001b,#)-\n\u001bĄ)- -\u001f \u001b*,\u001f\u001d#\u001b &\u001b \u001e#-'#(/\u001d#ĉ( \u001e\u001f &)- (#0\u001f&\u001f- -ï,#\u001d)- \u001e\u001f &\u001b 0#.\u001b'#(\u001b \u0002gh6 *\u001f,) &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b\n-\u001f )\u001c-\u001f,0\u001b \u001f( '\u001f()- \u001e\u001f& kz \u001e\u001f \u001f&&)-8 \u0005( \u001f-.)- *\u001b\u001d#\u001f(.\u001f- -\u001f \u001e\u001f'/\u001f-.,\u001b \u001b.,)l·\u001b \u001e\u001f &\u001b '/\u001d)-\u001b \u001e\u001f &\u001b *),\u001d#ĉ(\n\u001e\u001f& \u001f-.ĉ'\u001b!) () ,\u001f-\u001f\u001d\u001b\u001e\u001b8 \u0005( \u001f( \u001f,'\u001f\u001e\u001b\u001e\u001f- #(.\u001f-.#(\u001b&\u001f- \u001d\u001b,\u001b\u001d.\u001f,#4\u001b\u001e\u001b- *), \u001e\u001f \u001f\u001d.) \u001e\u001f \u001b\u001c-),\u001d#ĉ(6 \u001d)')\n#&\u001fù.#-6 \u001b'#&)#\u001e)-#- #(.\u001f-.#(\u001b&6 \u001f-*,Ě\u001f .,)*#\u001d\u001b& 3 () .,)*#\u001d\u001b&6 ./\u001c\u001f,\u001d/&)-#- #(.\u001f-.#(\u001b& 3 \u001f( ,\u001f-\u001f\u001d\u001d#)(\u001f- +/#\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":80,"lines":{"from":122,"to":139}}}}],["320",{"pageContent":",Ě,!#\u001d\u001b- \u001b'*&#\u001b- \u001e\u001f& ù&\u001f)(6 \u001f-\n \n,\u001f\u001d/\u001f(.\u001f &\u001b \u001b*\u001b,#\u001d#ĉ( \u001e\u001f \u001b(\u001f'#\u001b )\u001d\u001b-#)(\u001b\u001e\u001b *), \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \u001b\u001c-),\u001d#ĉ(\n\u001e\u001f &\u001b 0#.\u001b'#(\u001b \u0002gh8 \u0014\u001b'\u001c#ï( -\u001f \"\u001b )\u001c-\u001f,0\u001b\u001e) \u001f-.\u001b 0\u001b,#\u001f\u001e\u001b\u001e \u001e\u001f \u001b(\u001f'#\u001b \u001f( \u001f& -ù(\u001e,)'\u001f \u001e\u001f& \u001b-\u001b \u001d#\u001f!\u001b6 \u001f(\n\u001e)(\u001e\u001f &\u001b \u001f-.\u001b-#- \u001e\u001f& \u001d)(.\u001f(#\u001e) #(.\u001f-.#(\u001b&\n \n\u001b0),\u001f\u001d\u001f &\u001b *,)&# \u001f,\u001b\u001d#ĉ( \u001e\u001f &\u001b ł),\u001b \u001c\u001b\u001d.\u001f,#\u001b(\u001b +/\u001f \u001d)(-/'\u001f\n0#.\u001b'#(\u001b \u0002gh8\n \nDiphyllobothrium latum\n \n\u001f- /( *\u001b,á-#.) +/\u001f #( \u001f-.\u001b \u001b& -\u001f, \"/'\u001b() 3 \u001d)(-/'\u001f \u001d)\u001c\u001b&\u001b'#(\u001b6\n)\u001d\u001b-#)(\u001b(\u001e) &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \u001f-\u001b 0#.\u001b'#(\u001b \u001f( \u001f& *),.\u001b\u001e),: -#( \u001f'\u001c\u001b,!)6 ,\u001f+/#\u001f,\u001f \u001d)') 0\u001f\u001d.), /( *\u001f4\n+/\u001f -)&) \u001f2#-.\u001f \u001f( &\u001b 4)(\u001b \u001e\u001f& '\u001b, \u0002á&.#\u001d)6 \u0001&\u001b-%\u001b 3 \u0003\u001b(\u001b\u001eá6 *), &) +/\u001f \u001f-.\u001b 0\u001b,#\u001f\u001e\u001b\u001e \u001e\u001f \u001b(\u001f'#\u001b \u001f- \u001e\u001f-\n-\n\n\u001d)()\u001d#\u001e\u001b \u001f(\n \nï2#\u001d) 3\n \n\u001b.#()\u001b'ï,#\u001d\u001b \u001f( !\u001f(\u001f,\u001b&\n \n(cuadro 4-2)\n8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":80,"lines":{"from":141,"to":164}}}}],["321",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n54\n\nCuadro 4-3.\n \nCausas de las anemias megaloblásticas\n\nFrecuentes\n \nRaras\nDéficit de cobalamina\n(B12)\n\n•\n \n\u0001\u001c-),\u001d#ĉ( \u001e\u001f̑\u001d#\u001f(.\u001f\n \n\u001e\u001f\n\u001d)\u001c\u001b&\u001b'#(\u001b\n•\n \n\u0007\u001b-.,\u001f\u001d.)'ù\u001b\n•\n \n\u0001\u001d&),\"#\u001e,#\u001b\n•\n \n\u0001(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b\n•\n \n\u0005( \u001f,'\u001f\u001e\u001b\u001e \u001e\u001f& ù&\u001f)(\n.\u001f,'#(\u001b&9 \u0003,)\"(6 \u001f-*,Ě\u001f6\n#(.)&\u001f,\u001b(\u001d#\u001b \u001b& !&/.\u001f(\n•\n \n\u0001'#&)#\u001e)-#-\n•\n \n\u0012\u001f-\u001f\u001d\u001d#ĉ( +/#,Ě,!#\u001d\u001b\n•\n \n\u0003)(-/') #(.\u001f-.#(\u001b& \u001e\u001f \u0002gh9\n\u001b-\u001b \u001d#\u001f!\u001b\n•\n \nDiphyllobothrium latum\n\n•\n \n\u0006á,'\u001b\u001d)-9 #(\"#\u001c#\u001e),\u001f- \u001e\u001f\n&\u001b -\u001f\u001d,\u001f\u001d#ĉ( á\u001d#\u001e\u001b !á-.,#\u001d\u001b\nB)'\u001f*,\u001b4)&6 ,\u001b(#.#\u001e#(\u001bC6\n\u001d)&\u001d\"#\u001d#(\u001b\n•\n \n\u0004#\u001f.\u001b 0\u001f!\u001f.\u001b,#\u001b(\u001b \u001f-.,#\u001d.\u001b\n•\n \n\u0001&.\u001f,\u001b\u001d#)(\u001f- \u001f(4#'á.#\u001d\u001b-9\n@\n \n\u0001/-\u001f(\u001d#\u001b \u001d)(!ï(#.\u001b \u001e\u001f\n\u001b\u001d.), #(.,ù(-\u001f\u001d)\n@\n \n\u0013ù(\u001e,)'\u001f \u001e\u001f\n \n'\u001f,-&/(\u001e\n@\n \n\u0004ï̑\u001d#.\n \n\u001e\u001f\n.,\u001b(-\u001d)\u001c\u001b&\u001b'#(\u001b\n@\n \n\u0004\u001f \u001f\u001d.) \u001e\u001f *,)\u001e/\u001d\u001d#ĉ( \u001e\u001f\n\u001b\u001d.), #(.,ù(-\u001f\u001d)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":81,"lines":{"from":1,"to":79}}}}],["322",{"pageContent":"Déficit de ácido fólico\n \n•\n \n\u0001/'\u001f(.) \u001e\u001f &\u001b- (\u001f\u001d\u001f-#\u001e\u001b\u001e\u001f-9\n\u001b(\u001f'#\u001b- \"\u001f')&ù.#\u001d\u001b-6\n\u001f'\u001c\u001b,\u001b4)6 ./'),\u001f-\n•\n \n\u0005-*,Ě\u001f\n•\n \n\u0004\u001f,'\u001b.#.#- \u001f2 )&#\u001b.#0\u001b-\n•\n \n\u0006á,'\u001b\u001d)-9 \u001f(#.)ù(\u001b6\n\u001c\u001b,\u001c#.Ě,#\u001d)-6 '\u001f.).,\u001f2\u001b.)6\n*#,#'\u001f.\u001b'#(\u001b6 .,#'\u001f.)*,#'\n\u001d)( -/& \u001b6 .,#\u001b'.\u001f,\u001f()6\n*\u001f(.\u001b'#\u001e#(\u001b\n•\n \n\u0001&\u001d)\")&\n•\n \n\u0004#\u001f.\u001b #(\u001b\u001e\u001f\u001d/\u001b\u001e\u001b\n•\n \n\u0004\u001f \u001f\u001d.)- \u001f(4#'á.#\u001d)-9\n\u001e#\"#\u001e,) )&\u001b.) ,\u001f\u001e/\u001d.\u001b-\u001b\n•\n \n\u0012\u001b\u001e#).\u001f,\u001b*#\u001b *), \u001dá(\u001d\u001f,\n\u001d\u001f,0#\u001d)/.\u001f,#() B\u001b \u001f\u001d.\u001b \u001f&\nù&\u001f)(C\n•\n \n\b \u0016 Bł),\u001b #(.\u001f-.#(\u001b&\n')\u001e#̑\u001d\u001b\u001e\u001b\n \n*),\n\u001b(.#'#\u001d,)\u001c#\u001b()-C\n•\n \n#( )'\u001b #(.\u001f-.#(\u001b&\n•\n \n\u0012\u001f-\u001f\u001d\u001d#)(\u001f- #(.\u001f-.#(\u001b&\u001f-\n•\n \n\u0001'#&)#\u001e)-#-\n•\n \n\u0014\u0002 #(.\u001f-.#(\u001b&\n•\n \n&\u001fù.#- ,\u001f!#)(\u001b&\n•\n \n(.)&\u001f,\u001b(\u001d#\u001b \u001b& !&/.\u001f(\n•\n \n\u0001&#'\u001f(.\u001b\u001d#ĉ( *\u001b,\u001f(.\u001f,\u001b&\n\u001b- ,\u001f-\u001f,0\u001b- \u001e\u001f 0#.\u001b'#(\u001b \u0002gh \u001f( &\u001b *\u001f,-)(\u001b \u001b\u001e/&.\u001b -)( '/3 !,\u001b(\u001e\u001f- B'á- \u001e\u001f k̓fff '!C 3 &)- ,\u001f+/\u001f\n-\n\n,#'#\u001f(.)- \u001e#\u001b,#)- -)( '\u001f(),\u001f- \u001e\u001f g '!8 \u0005-.) *\u001f,'#.\u001f -)*),.\u001b, *), \u001bĄ)- &\u001b\n \n\u001b&.\u001b \u001e\u001f \u001b*),.\u001f \u001b(.\u001f- \u001e\u001f +/\u001f\n\u001b*\u001b,\u001f4\u001d\u001b &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8 \u0005&&) \u001f2*&#\u001d\u001b *), +/ï &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b *), \u001e\u001fl·\u001d#\u001f(\u001d#\u001b (/.,#\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":81,"lines":{"from":81,"to":151}}}}],["323",{"pageContent":"\u001d#)(\u001b& \u001f- 0\u001f,\u001e\u001b\u001e\u001f,\u001b'\u001f(.\u001f \u001f2\u001d\u001f*\u001d#)(\u001b&6 -#./\u001b\u001d#ĉ( +/\u001f )\u001c&#!\u001b \u001b \u001c/-\u001d\u001b, *,)\u001c&\u001f'\u001b- \u001e\u001f \u001b\u001c-),\u001d#ĉ( \u001d)')\n \n\u001b\u001d.),\n\u001f.#)&ĉ!#\u001d) \u001e\u001f &\u001b \u001b(\u001f'#\u001b8\n \n\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f )&\u001b.)- -\u001f */\u001f\u001e\u001f \u001b\u001e+/#,#, *),9 gC \u001e#\u001f.\u001b #(-/l·\u001d#\u001f(.\u001f: hC \u001e\u001f \u001f\u001d.)-\n\u001e\u001f \u001b\u001c-),\u001d#ĉ( #(.\u001f-.#(\u001b&: 3 iC #(\u001d,\u001f'\u001f(.) \u001f( &)- ,\u001f+/\u001f,#'#\u001f(.)-\n \n(cuadro 4-3)\n8\n\u0004\u001f\u001c#\u001e) \u001b &)- \u001d\u001b'\u001c#)- \u001b&#'\u001f(.\u001b,#)- \u001f- (\u001f\u001d\u001f-\u001b,#) \u001b\u001e'#(#-.,\u001b, á\u001d#\u001e) ĉ&#\u001d) -/*&\u001f'\u001f(.\u001b,#) \u001b &\u001b- \u001f'\u001c\u001b,\u001b4\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":81,"lines":{"from":153,"to":164}}}}],["324",{"pageContent":"\u001e\u001b-6 *\u001b,\u001b \u001f0#.\u001b, \u001e\u001f \u001f\u001d.)- \u001e\u001f& ./\u001c) (\u001f/,\u001b& 3 \u001b\u001c),.)-8\n \n\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f á\u001d#\u001e) ĉ&#\u001d) \u001f- \u001d\u001b\u001e\u001b 0\u001f4 '\u001f()- ,\u001f\u001d/\u001f(.\u001f6\n*\u001f,) \u001e\u001f\u001c\u001f \u001d)(-#\u001e\u001f,\u001b,-\u001f \u001d)') *,#'\u001f,\u001b *)-#\u001c#&#\u001e\u001b\u001e \u001b(.\u001f \u001d/\u001b\u001e,)- \u001e\u001f \u001b(\u001f'#\u001b '\u001b\u001d,)\u001dù.#\u001d\u001b8\n \n\u001b- ,\u001f-\u001f,0\u001b- \u001e\u001f á\u001d#\u001e)\nĉ&#\u001d) \u001f( \u001f& -\u001f, \"/'\u001b() -)( ,\u001f&\u001b.#0\u001b'\u001f(.\u001f *\u001f+/\u001fĄ\u001b-6 \u001e\u001f '\u001b(\u001f,\u001b +/\u001f &\u001b- *\u001f,-)(\u001b- \u001d)( /(\u001b \u001e#\u001f.\u001b \u001f-\u001d\u001b-\u001b B.ï 3\n*\u001b(C 3 \u001b&#'\u001f(.)- -)'\u001f.#\u001e)- \u001b \u001d)\u001d\u001d#ĉ( *,)&)(!\u001b\u001e\u001b +/\u001f \u001e\u001f-.,/3\u001f &)- )&\u001b.)-6 */\u001f\u001e\u001f( *\u001b\u001e\u001f\u001d\u001f, \u001f-.\u001b 0\u001b,#\u001f\u001e\u001b\u001e \u001e\u001f\n\u001e\u001fl·\u001d#\u001f(\u001d#\u001b8\n \n)- \u001b(\u001d#\u001b()-6 \u001b&\u001d)\"ĉ&#\u001d)-6 &\u001b\u001d.\u001b(.\u001f- +/\u001f ,\u001f\u001d#\u001c\u001f( &\u001f\u001d\"\u001f- \"\u001f,0#\u001e\u001b- ) \u001e\u001f \u001d\u001b\u001c,\u001b B() \u001d)(.#\u001f(\u001f( )&\u001b.)-C6\n*\u001f,-)(\u001b- -)'\u001f.#\u001e\u001b- \u001b (/.,#\u001d#ĉ( *\u001b,\u001f(.\u001f,\u001b& ) \u001d)( \"\u001f')\u001e#á&#-#-6 -)( &)- -/$\u001f.)- \u001d)( '\u001b3), ,#\u001f-!) \u001e\u001f *,\u001f-\u001f(.\u001b,\n&\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \u001f-.\u001f (/.,#'\u001f(.)8 \u000e) )\u001c-.\u001b(.\u001f6 *\u001b,\u001b +/\u001f \u001b*\u001b,\u001f4\u001d\u001b &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b -\u001f ,\u001f+/#\u001f,\u001f \u001d\u001b-#\n-#\u001f'*,\u001f +/\u001f6 \u001b\u001e\u001f'á- \u001e\u001f &\u001b \u001f-\u001d\u001b-\u001b #(!\u001f-.#ĉ(6 \u001f2#-.\u001b #(\u001d,\u001f'\u001f(.) \u001f( &)- ,\u001f+/\u001f,#'#\u001f(.)-8 \u0005&&) */\u001f\u001e\u001f 0\u001f,-\u001f \u001f( \u001f&","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":81,"lines":{"from":166,"to":179}}}}],["325",{"pageContent":"Debido a los cambios alimen-\ntarios es necesario administrar\nácido fólico suplementario a las\nembarazadas, para evitar de-\nfectos del tubo neural y abortos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":81,"lines":{"from":181,"to":185}}}}],["326",{"pageContent":"CAPÍTULO 4. ANEMIAS MEGALOBLÁSTICAS\n\n55\n\n\u001f'\u001c\u001b,\u001b4) \u001f( \u001e)(\u001e\u001f &\u001b- (\u001f\u001d\u001f-#\u001e\u001b\u001e\u001f- \u001e\u001f )&\u001b.)- \u001b/'\u001f(.\u001b( \u001e\u001f n \u001b gf 0\u001f\u001d\u001f- \u001e\u001f\u001c#\u001e) \u001b& \u001e\u001f-\u001b,,)&&) 3 \u001d,\u001f\u001d#'#\u001f(.)\n\u001f.\u001b&6 \u001e\u001f '\u001b(\u001f,\u001b +/\u001f /(\u001b '/$\u001f, !\u001f-.\u001b(.\u001f \u001d)( \u001b*),.\u001f (/.,#'\u001f(.\u001b& #( \u001f,#), \u001b& ,\u001f\u001d)'\u001f(\u001e\u001b\u001e) \u001f- #(\u001d\u001b*\u001b4 \u001e\u001f\n-\u001b.#- \u001b\u001d\u001f, &\u001b- \u001e\u001f'\u001b(\u001e\u001b- \u001e\u001f )&\u001b.) 3 \u001b*\u001b,\u001f\u001d\u001f &\u001b \u001b(\u001f'#\u001b \u001f( &\u001b -\u001f!/(\u001e\u001b '#.\u001b\u001e \u001e\u001f& \u001f'\u001c\u001b,\u001b4)8\n\u0005( /( \u001f-./\u001e#) \u001d)&\u001b\u001c),\u001b.#0) &&\u001f0\u001b\u001e) \u001b \u001d\u001b\u001c) \u001f( 0\u001b,#)- *\u001bù-\u001f- \u001e\u001f\n \n\u001c\u001f,)\u001b'ï,#\u001d\u001b6 -\u001f )\u001c-\u001f,0ĉ \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f\n)&\u001b.) \u001f( \u001f& gfz \u001e\u001f &\u001b- '/$\u001f,\u001f- \u001f'\u001c\u001b,\u001b4\u001b\u001e\u001b-: -#( \u001f'\u001c\u001b,!)6 &\u001b \u001b(\u001f'#\u001b -)&) -\u001f \u001e\u001f.\u001f\u001d.ĉ \u001f( \u001f& gz \u001e\u001f \u001f&&\u001b-8 \u0005(\nï2#\u001d)6 &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b \u001f( \u001f& \u001f'\u001c\u001b,\u001b4) -\u001f \"\u001b ,\u001f!#-.,\u001b\u001e) \u001d)(\n \n,\u001f\u001d/\u001f(\u001d#\u001b 0\u001b,#\u001b\u001c&\u001f6 \u001e\u001f*\u001f(\u001e#\u001f(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":82,"lines":{"from":1,"to":15}}}}],["327",{"pageContent":"\u001e) \u001e\u001f &\u001b- \u001d)(\u001e#\u001d#)(\u001f- (/.,#\u001d#)(\u001b&\u001f- \u001e\u001f &\u001b *)\u001c&\u001b\u001d#ĉ( \u001f-./\u001e#\u001b\u001e\u001b8 \u0003/,#)-\u001b'\u001f(.\u001f6 \u001f-.\u001f\n \n\u001f(ĉ'\u001f() */\u001f\u001e\u001f -\u001f,\n\u001dù\u001d&#\u001d)6 3 &\u001b- *,)*#\u001b- *\u001b\u001d#\u001f(.\u001f- &) ,\u001f\u001d)()\u001d\u001f(8 \u0005- \u001e\u001f\u001d#,6 \u001d/\u001b(\u001e) -\u001f ,\u001f-/\u001f&0\u001f \u001f& \u001f'\u001c\u001b,\u001b4)6 \u001f& \u001d/\u001b\u001e,) \u001d&ù(#\u001d)\n\u001e\u001f-\u001b*\u001b,\u001f\u001d\u001f6 ,\u001f!,\u001f-\u001b(\u001e) \u001b(.\u001f &\u001b *,\u001f-\u001f(\u001d#\u001b \u001e\u001f (/\u001f0)- \u001f'\u001c\u001b,\u001b4)- -# () \u001f2#-.#ĉ #(.\u001f,0\u001f(\u001d#ĉ( .\u001f,\u001b*ï/.#\u001d\u001b 3\n\u001f\u001e/\u001d\u001b.#0\u001b \u001b\u001e\u001f\u001d/\u001b\u001e\u001b8\n\u0005( *,)\u001d\u001f-)- \"\u001f')&ù.#\u001d)-6 &\u001b- (\u001f\u001d\u001f-#\u001e\u001b\u001e\u001f- \u001e\u001f )&\u001b.)- \u001b/'\u001f(.\u001b( \u001d)(-#\u001e\u001f,\u001b\u001c&\u001f'\u001f(.\u001f8\n \n)- \u001d/\u001b\u001e,)- \"\u001f')\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":82,"lines":{"from":17,"to":26}}}}],["328",{"pageContent":"&ù.#\u001d)- #(.\u001f(-)- 3 \u001d,ĉ(#\u001d)- */\u001f\u001e\u001f( &&\u001f!\u001b, \u001b \u001d)(-/'#, &\u001b- ,\u001f-\u001f,0\u001b- 3 *,)\u001e/\u001d#, \u001b&.\u001f,\u001b\u001d#)(\u001f- \"\u001f'á.#\u001d\u001b- !,\u001b0\u001f-\n'\u001b(# \u001f-.\u001b\u001e\u001b- \u001d)') *\u001b(\u001d#.)*\u001f(#\u001b *\u001f,# ï,#\u001d\u001b6 \u001d)( 'ï\u001e/&\u001b- \"#*)*&á-#\u001d\u001b- *\u001f,) +/\u001f !/\u001b,\u001e\u001b( &\u001b '), )&)!ù\u001b\n.ù*#\u001d\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b6 .\u001b(.) \u001f( -\u001b(!,\u001f \u001d)') \u001f( 'ï\u001e/&\u001b ĉ-\u001f\u001b8\n \n) '#-') */\u001f\u001e\u001f )\u001d/,,#, \u001f( &\u001b- \u001e\u001f,'\u001b.)-#-\n\u001f2 )&#\u001b.#0\u001b-6 3 \u001e/,\u001b(.\u001f &\u001b +/#'#).\u001f,\u001b*#\u001b \u001d)( \u001e)-#- \u001b&.\u001b- \u001e\u001f '\u001f.).,\u001f2\u001b.) *\u001b,\u001b &\u001f/\u001d\u001f'#\u001b-6 &#( )'\u001b- ) \u001b&!/()-\n./'),\u001f- -ĉ&#\u001e)-8 \u0004\u001f .\u001b& '\u001b(\u001f,\u001b6 \u001f( \u001f-.\u001b- \u001d)(\u001e#\u001d#)(\u001f- *\u001b.)&ĉ!#\u001d\u001b-6 \u001d/\u001b(\u001e) -)( \u001d,ĉ(#\u001d\u001b- 3 \u001b*\u001b,\u001f\u001d\u001f( \u001f(\n*\u001f,-)(\u001b- \u001d)( \u001f-\u001d\u001b-\u001b #(!\u001f-.#ĉ( \u001e\u001f\n \n)&\u001b.)-6 \u001f2#-.\u001f(\n \n\u001b\u001d.),\u001f- \u001e\u001f ,#\u001f-!) *\u001b,\u001b \u001f& \u001e\u001f-\u001b,,)&&) \u001e\u001f &\u001b \u001b(\u001f'#\u001b8\n \n\u001b\n'\u001b\u001d,)\u001d#.)-#- #(#\u001d#\u001b& \u001f- -/!\u001f,\u001f(.\u001f \u001e\u001f& *,)\u001c&\u001f'\u001b6 \u001b3/\u001e\u001b(\u001e) \u001b ,\u001f\u001d)()\u001d\u001f, &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b *,\u001f\u001d)4'\u001f(.\u001f8\n\u0005( &)- \u001e\u001f \u001f\u001d.)- \u001e\u001f \u001b\u001c-),\u001d#ĉ( #(.\u001f-.#(\u001b& *), ./\u001c\u001f,\u001d/&)-#-6 \u001b'#&)#\u001e)-#-6 &#( )'\u001b \u001e\u001f& #(.\u001f-.#()6 \u001b-ù \u001d)') \u001f(\n\u001f-*,Ě\u001f6 &\u001b #(.)&\u001f,\u001b(\u001d#\u001b \u001b& !&/.\u001f( B\u001f-*,Ě\u001f () .,)*#\u001d\u001b&C 3 &\u001b- ,\u001f-\u001f\u001d\u001d#)(\u001f- #(.\u001f-.#(\u001b&\u001f- \u001b'*&#\u001b-6 */\u001f\u001e\u001f 0\u001f,-\u001f \u001e\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":82,"lines":{"from":28,"to":45}}}}],["329",{"pageContent":"l·\u001d#\u001f(\u001d#\u001b \u001e\u001f )&\u001b.)- 3 \u001b*\u001b,#\u001d#ĉ( \u001e\u001f &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b '\u001f-\u001f- ) \u001bĄ)- \u001e\u001f-*/ï- \u001e\u001f *,\u001b\u001d.#\u001d\u001b\u001e\u001b &\u001b \u001d#,/!ù\u001b8\n\u0001\u001e#\u001d#)(\u001b& \u001b& ,\u001f\u001d)()\u001d#'#\u001f(.) \u001e\u001f& \u001d/\u001b\u001e,) \u001d&ù(#\u001d) 3\u001b \u001d)'\u001f(.\u001b\u001e)6 \u001f-\n \n/(\u001e\u001b'\u001f(.\u001b& \u001b0\u001f,#!/\u001b, *), \u001d/\u001b&\n-\n\n+/#\u001f, *\u001b.)&)!ù\u001b -/\u001c3\u001b\u001d\u001f(.\u001f8\n \n\u001b \u001f-.\u001b\u001eù-.#\u001d\u001b *\u001f,/\u001b(\u001b ,\u001f*),.\u001b +/\u001f il \u001e\u001f &)- mf \u001d\u001b-)- *,\u001f-\u001f(.\u001b\u001c\u001b( *\u001b.)&)!ù\u001b\n!\u001b-.,)#(.\u001f-.#(\u001b&6 \u001d),,\u001f-*)(\u001e#\u001f(\u001e) \u001b !\u001b-.,#.#- \u001d,ĉ(#\u001d\u001b /(\u001b .\u001f,\u001d\u001f,\u001b *\u001b,.\u001f8 \u0015(\u001b \u001d/\u001b,.\u001b *\u001b,.\u001f -/ ,ù\u001b \u001e\u001f \u001b&\u001d)\n-\n\n\")&#-')9 -\u001f#- \u001d)( \u001e#\u001b\u001c\u001f.\u001f- '\u001f&&#./- 3 -\u001f#- \u001d)( ./\u001c\u001f,\u001d/&)-#- */&')(\u001b,: \u001e)- *\u001b\u001d#\u001f(.\u001f- \u001d)( 0#.ù&#!)6 \u001e)- \u001d)(\n*\u001b,\u001b-#.)-#- 3 \u001e)- \u001d)( #(!\u001f-.\u001b \u001d,ĉ(#\u001d\u001b \u001e\u001f \u001b(.#\u001d)(0/&-#0\u001b(.\u001f-\n \n(cuadro 4-4)\n8 \u0013)&) \u001e#\u001f4 \u001e\u001f &)- mf \u001f( \u001f,')-\n\u001d\u001b,\u001f\u001dù\u001b( \u001e\u001f \u001b(.\u001f\u001d\u001f\u001e\u001f(.\u001f- ) *\u001b.)&)!ù\u001b \u001b-)\u001d#\u001b\u001e\u001b8\n\nCuadro 4-4.\n \nFármacos que causan anemia megaloblástica\n\nInhibidores de la hidrofolatorreductasa\n\n\u001f.).,\u001f2\u001b.)\n\u0010#,#'\u001f.\u001b'#(\u001b\n\u0014,#'\u001f.)*,#'\n\u0013/& \u001b-\u001b&\u001b4#(\u001b\n\u0014,#\u001b'.\u001f,\u001f()\n\nInhibidores de ribonucleótidos\n \n\u0003#.\u001b,\u001b\u001c#(\u001b\n\b#\u001e,)2#\u001d\u001b,\u001c\u001b'#\u001e\u001b\n\nAntimetabolitos análogos a las purinas\n\nl7'\u001f,\u001d\u001b*.)*/,#(\u001b\nl7.#)!/\u001b(#(\u001b\n\u00014\u001b.#)*,#(\u001b\n\u0001\u001d#\u001d&)0#,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":82,"lines":{"from":47,"to":88}}}}],["330",{"pageContent":"Inhibidores de ribonucleótidos\n \n\u0003#.\u001b,\u001b\u001c#(\u001b\n\b#\u001e,)2#\u001d\u001b,\u001c\u001b'#\u001e\u001b\n\nAntimetabolitos análogos a las purinas\n\nl7'\u001f,\u001d\u001b*.)*/,#(\u001b\nl7.#)!/\u001b(#(\u001b\n\u00014\u001b.#)*,#(\u001b\n\u0001\u001d#\u001d&)0#,\n\nAnálogos de la pirimidina\n\nk7ł/),/,\u001b\u001d#&)\nk7ł/),\u001e\u001f)2#/,#\u001e#(\u001b\n\u001a#\u001e)0/\u001e#(\u001b B\u0001\u001a\u0014C\n\nInterfieren con la absorción de ácido fólico\n\n\u0001(.#\u001d)(0/&-#0\u001b(.\u001f-9 \u001e# \u001f(#&\"#\u001e\u001b(.)ù(\u001b6\n\u001f()\u001c\u001b,\u001c#.\u001b&\nÁ2#\u001e) (#.,)-)\n\u0001(.#\u001d)(\u001d\u001f*.#0)-\n\nFármacos que interfieren con la absorción\nde cobalaminas\n\n\u000e\u001f)'#\u001d#(\u001b\n\u0003)&\u001d\"#\u001d#(\u001b\n\u0001,-ï(#\u001d)\n\u001f. ),'#(\u001b","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":82,"lines":{"from":88,"to":119}}}}],["331",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n56\n\nCUADRO HEMATOLÓGICO\n\n\u001b- \u001b(\u001f'#\u001b- '\u001b\u001d,)\u001dù.#\u001d\u001b- -\u001f \u001d\u001b,\u001b\u001d.\u001f,#4\u001b( *), &\u001b \u001b&.\u001f,\u001b\u001d#ĉ( \u001e\u001f &\u001b '), )&)!ù\u001b 3 '\u001b\u001e/,\u001b\u001d#ĉ( \u001e\u001f &)-\n\u001f,#.,)\u001d#.)-8\n \n\u001b- \u001dï&/&\u001b- \u001e\u001f &\u001b -\u001f,#\u001f ,)$\u001b -)( 'á- !,\u001b(\u001e\u001f- \u001f( \u001d/\u001b&+/#\u001f, ')'\u001f(.) \u001e\u001f -/ \u001e\u001f-\u001b,,)&&) 3 -/\n\u001d,)'\u001b.#(\u001b (/\u001d&\u001f\u001b, \u001f- &\u001b2\u001b 3 \u001e#-*\u001f,-\u001b6 \u001d)( /(\u001b 0\u001f,\u001e\u001b\u001e\u001f,\u001b \u001b-#(\u001d,)(ù\u001b \u001f(.,\u001f &\u001b '\u001b\u001e/,\u001b\u001d#ĉ( \u001e\u001f& (Ě\u001d&\u001f) 3\n\u001f& \u001d#.)*&\u001b-'\u001b8 \u0005( ).,\u001b- *\u001b&\u001b\u001c,\u001b-6 &\u001b \u001d\u001f&/&\u001b,#\u001e\u001b\u001e \u001f-.á \u001b/'\u001f(.\u001b\u001e\u001b \u001d)( '\u001b,\u001d\u001b\u001e\u001b \"#*\u001f,*&\u001b-#\u001b \u001e\u001f &\u001b -\u001f,#\u001f\n,)$\u001b6 \u001f( \u001e)(\u001e\u001f -)( '/3 \u001f0#\u001e\u001f(.\u001f- &)- '\u001f!\u001b&)\u001c&\u001b-.)-6 \u001f( *\u001b,.#\u001d/&\u001b, -/-\n \n),'\u001b- .\u001f'*,\u001b(\u001b- B*,)(),')\n-\n\n\u001c&\u001b-.)- 3 (),')\u001c&\u001b-.)- \u001c\u001b-ĉl·&)-C6 +/\u001f \u001e\u001f-.\u001b\u001d\u001b( *), -/ !,\u001b( .\u001b'\u001bĄ)6 &\u001b \u001c\u001b-)l·&#\u001b \u001e\u001f& \u001d#.)*&\u001b-'\u001b \u001d)( /(\n\"\u001b&) \u001d&\u001b,) *\u001f,#(/\u001d&\u001f\u001b, 36 -)\u001c,\u001f .)\u001e)6 &\u001b \u001d\u001b,\u001b\u001d.\u001f,ù-.#\u001d\u001b \u001e#-.,#\u001c/\u001d#ĉ( \u001e\u001f &\u001b \u001d,)'\u001b.#(\u001b8 \u0005( &\u001b- ),'\u001b- 'á-\n.\u001b,\u001eù\u001b- B(),')\u001c&\u001b-.)- *)&#\u001d,)'á.#\u001d)- 3 ),.)\u001d,)'á.#\u001d)-C6 -\u001f )\u001c-\u001f,0\u001b \u001f& \u001b-#(\u001d,)(#-') \u001f( &\u001b '\u001b\u001e/,\u001b\u001d#ĉ(\n\u001e\u001f& (Ě\u001d&\u001f) 3 \u001e\u001f& \u001d#.)*&\u001b-'\u001b8\n\u001b -\u001f,#\u001f \u001c&\u001b(\u001d\u001b \u001f- .\u001b'\u001c#ï( \u001f2/\u001c\u001f,\u001b(.\u001f 3 &)- !,\u001b(/&)\u001d#.)- '/\u001f-.,\u001b( '\u001f.\u001b'#\u001f&)\u001d#.)- 3 \u001c\u001b(\u001e\u001b- !#\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":83,"lines":{"from":1,"to":23}}}}],["332",{"pageContent":"!\u001b(.\u001f-6 \u001b-ù \u001d)') (\u001f/.,ĉl·&)- *)&#-\u001f!'\u001f(.\u001b\u001e)-8 \u0001-#'#-')6 &)- '\u001f!\u001b\u001d\u001b,#)\u001d#.)- *,\u001f-\u001f(.\u001b( (Ě\u001d&\u001f)- *)\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":83,"lines":{"from":25,"to":26}}}}],["333",{"pageContent":"&#-\u001f!'\u001f(.\u001b\u001e)-6 ,\u001f-/&.\u001b(\u001e) '/3 \u001f0#\u001e\u001f(.\u001f &\u001b /(#ĉ( \u001e\u001f &)- -\u001f!'\u001f(.)- '\u001f\u001e#\u001b(.\u001f \"#&)- \u001e\u001f \u001d,)'\u001b.#(\u001b: -)(\n\u001d)'/(\u001f- &)- '\u001f!\u001b\u001d\u001b,#)\u001d#.)- ()\n \n),'\u001b\u001e),\u001f- \u001e\u001f *&\u001b+/\u001f.\u001b-8 \u0012\u001b,\u001b 0\u001f4 -\u001f \u001f(\u001d/\u001f(.,\u001b \"#*)*&\u001b-#\u001b \u001f,#.,)#\u001e\u001f6\n\u001d)( /(\u001b *,\u001f*)(\u001e\u001f,\u001b(\u001d#\u001b \u001e\u001f &)- *,\u001f\u001d/,-),\u001f- '#\u001f&)#\u001e\u001f- 3 /(\u001b \u001f-\u001d\u001b-\u001f4 \u001e\u001f '\u001f!\u001b&)\u001c&\u001b-.)-8\n \n) \u001b(.\u001f,#), */\u001f\u001e\u001f\n\u001b\u001e0\u001f,.#,-\u001f \u001f( \u001f'\u001c\u001b,\u001b4)- \u001d)'*&#\u001d\u001b\u001e)- 3 &&\u001f!\u001b, \u001b \u001e#\u001b!()-.#\u001d\u001b,-\u001f \u001f,,ĉ(\u001f\u001b'\u001f(.\u001f \u001d)') &\u001f/\u001d\u001f'#\u001b \u001b!/\u001e\u001b6\n\u001d)(-#\u001e\u001f,\u001b(\u001e) +/\u001f \u001b&!/()- \u001d\u001b-)- \u001d)( \u001e\u001fl·\u001d#\u001f(\u001d#\u001b !,\u001b0\u001f \u001d/,-\u001b( \u001d)( \u001f-*&\u001f()'\u001f!\u001b&#\u001b 3 .,)'\u001c)\u001d#.)*\u001f(#\u001b\n-#(.)'á.#\u001d\u001b8 \u0005( \u001f-.)- \u001d\u001b-)-6 \u001b& ')'\u001f(.) \u001e\u001f *,\u001b\u001d.#\u001d\u001b, \u001f& \u001b-*#,\u001b\u001e) \u001e\u001f 'ï\u001e/&\u001b ĉ-\u001f\u001b6 &\u001b \u001d\u001b(.#\u001e\u001b\u001e \u001e\u001f !,/')-\n\u001e\u001f &\u001b 'ï\u001e/&\u001b \u001f- #'*,\u001f-#)(\u001b(.\u001f8\n\u0003/\u001b(\u001e) &)- \u001f( \u001f,')- -)( .,\u001b.\u001b\u001e)- \u001e\u001f '\u001b(\u001f,\u001b #(-/l·\u001d#\u001f(.\u001f6 */\u001f\u001e\u001f( \u001e\u001f-\u001b*\u001b,\u001f\u001d\u001f, &)- '\u001f!\u001b&)\u001c&\u001b-.)- 3\n*\u001f,-#-.#, &)- ).,)- \u001d\u001b'\u001c#)- '\u001f!\u001b&)\u001c&á-.#\u001d)- \u001f( &\u001b- -\u001f,#\u001f- \u001c&\u001b(\u001d\u001b 3 '\u001f!\u001b\u001d\u001b,#)\u001dù.#\u001d\u001b: \u001f-.)- \"\u001b&&\u001b4!)- -)(\n-/l·\u001d#\u001f(.\u001f- *\u001b,\u001b -)*),.\u001b, \u001f& \u001e#\u001b!(ĉ-.#\u001d)8 \u0001\u001e\u001f'á-6 &)- 0\u001b&),\u001f- -ï,#\u001d)- \u001e\u001f \u001c#&#,,/\u001c#(\u001b-6 \"#\u001f,,) 3\n \n\u001f,,#.#(\u001b\n\u001f-.á( &#!\u001f,\u001b'\u001f(.\u001f \u001b/'\u001f(.\u001b\u001e)-8\n \n\u001b \u001e\u001f-\"#\u001e,)!\u001f(\u001b-\u001b &á\u001d.#\u001d\u001b B\u0004\b","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":83,"lines":{"from":28,"to":46}}}}],["334",{"pageContent":"-/l·\u001d#\u001f(.\u001f- *\u001b,\u001b -)*),.\u001b, \u001f& \u001e#\u001b!(ĉ-.#\u001d)8 \u0001\u001e\u001f'á-6 &)- 0\u001b&),\u001f- -ï,#\u001d)- \u001e\u001f \u001c#&#,,/\u001c#(\u001b-6 \"#\u001f,,) 3\n \n\u001f,,#.#(\u001b\n\u001f-.á( &#!\u001f,\u001b'\u001f(.\u001f \u001b/'\u001f(.\u001b\u001e)-8\n \n\u001b \u001e\u001f-\"#\u001e,)!\u001f(\u001b-\u001b &á\u001d.#\u001d\u001b B\u0004\b\n \nC -\u001f \u001f&\u001f0\u001b \u001d)(-#\u001e\u001f,\u001b\u001c&\u001f'\u001f(.\u001f 3 \u001f-\n \n,\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":83,"lines":{"from":46,"to":56}}}}],["335",{"pageContent":"\u001d/\u001f(.\u001f \u001f& \"\u001b&&\u001b4!) \u001e\u001f 0\u001b,#)- '#&\u001f- \u001e\u001f /(#\u001e\u001b\u001e\u001f-8\n\u0005( &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b \u001b-)\u001d#\u001b\u001e\u001b \u001d)( \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \u001d)\u001c\u001b&\u001b'#(\u001b-6 \"\u001b3 \u001c\u001b$)- (#0\u001f&\u001f- -ï,#\u001d)- \u001f #(\n-\n\n.,\u001b\u001f,#.,)\u001dù.#\u001d)- \u001e\u001f \u001f-.\u001b 0#.\u001b'#(\u001b B'\u001f()- \u001e\u001f nf̓*!I'\n \n\u001f( -/\u001f,)C8 \u0005( &\u001b \u001f( \u001f,'\u001f\u001e\u001b\u001e *,)\u001e/\u001d#\u001e\u001b *), \u001f& \u001eïl·\u001d#.\n\u001e\u001f )&\u001b.)-6 &\u001b- \u001d)(\u001d\u001f(.,\u001b\u001d#)(\u001f- -ï,#\u001d\u001b- -)( '\u001f(),\u001f- \u001e\u001f j̓ '!I'\n \n3 '\u001f()- \u001e\u001f glf̓'!I'\n \n\u001f( &\u001b '\u001f\u001e#\u001d#ĉ(\n#(.,\u001b\u001f,#.,)\u001dù.#\u001d\u001b8 \u0005-.\u001b Ě&.#'\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001b*\u001b,\u001f\u001d\u001f .\u001b,\u001eù\u001b'\u001f(.\u001f8\n\nOTRAS CAUSAS DE ANEMIAS MEGALOBLÁSTICAS\n\nDeficiencias congénitas\n\n\u001b\n \n),'\u001b 'á- ,\u001f*,\u001f-\u001f(.\u001b.#0\u001b \u001e\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001d)(!ï(#.\u001b \u001f- &\u001b \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b $/0\u001f(#&6 \u001e\u001f &\u001b \u001d/\u001b& \u001f2#-.\u001f(\n.,\u001f- 0\u001b,#\u001f\u001e\u001b\u001e\u001f-9 \u001bC \u001e\u001fl·\u001d#\u001f(.\u001f \u001b\u001c-),\u001d#ĉ( \u001e\u001f 0#.\u001b'#(\u001b \u0002gh \u001d)( -\u001f\u001d,\u001f\u001d#ĉ( \u001e\u001f á\u001d#\u001e) \u001d&),\"ù\u001e,#\u001d) 3 \u001b\u001d.), #(.,ù(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":83,"lines":{"from":58,"to":80}}}}],["336",{"pageContent":"-\u001f\u001d) (),'\u001b&: \u001cC -\u001f\u001d,\u001f\u001d#ĉ( \u001b(),'\u001b& \u001e\u001f \u001b\u001d.), #(.,ù(-\u001f\u001d): 3 \u001dC \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f .,\u001b(-\u001d)\u001c\u001b&\u001b'#(\u001b\n \n8\n\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001d)(!ï(#.\u001b \u001e\u001f \u001b\u001c-),\u001d#ĉ( \u001e\u001f \u001d)\u001c\u001b&\u001b'#(\u001b -\u001f \"\u001b \u001e\u001f.\u001f\u001d.\u001b\u001e) \u001f(\n \n-,\u001b\u001f& 3 -\u001f \u001d\u001b,\u001b\u001d.\u001f,#4\u001b *),\n/( \u001e\u001f \u001f\u001d.) \u001e\u001f \u001b\u001c-),\u001d#ĉ( \u001b (#0\u001f& \u001e\u001f &\u001b '/\u001d)-\u001b #&\u001f\u001b& \u001b-)\u001d#\u001b\u001e\u001b \u001d)( *,).\u001f#(/,#\u001b8\n \n\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001d)(!ï(#.\u001b \u001e\u001f\n\u001b\u001d.), #(.,ù(-\u001f\u001d) -\u001f )\u001c-\u001f,0\u001b \u001f( (#Ą)- \u001e\u001f l̓ '\u001f-\u001f- \u001b h̓ \u001bĄ)- \u001e\u001f \u001f\u001e\u001b\u001e \u001d)( \u001e\u001fl·\u001d#\u001f(.\u001f -\u001f\u001d,\u001f\u001d#ĉ( \u001e\u001f \u0006 6 *\u001f,) \u001d)(\n\u001b/-\u001f(\u001d#\u001b \u001e\u001f \u001b(.#\u001d/\u001f,*)- \u001e#,#!#\u001e)- \u001d)(.,\u001b \u001dï&/&\u001b- *\u001b,#\u001f.\u001b&\u001f- ) \u001d)(.,\u001b \u001f& \u001d)'*&\u001f$) \u0006 ̓ ̓\u0002gh8\n \n\u001b \u001e \u001fl·\u001d#\u001f(\u001d#\u001b\n\u001e\u001f .,\u001b(-\u001d)\u001c\u001b&\u001b'#(\u001b\n \n\u001b*\u001b,\u001f\u001d\u001f \u001f( &\u001b #( \u001b(\u001d#\u001b6 \u001e\u001f-\u001e\u001f &\u001b ï*)\u001d\u001b \u001e\u001f ,\u001f\u001d#ï( (\u001b\u001d#\u001e)6 3 -\u001f \u001d\u001b,\u001b\u001d.\u001f,#4\u001b *), *\u001b(\u001d#\n-\n\n.)*\u001f(#\u001b6 Ě&\u001d\u001f,\u001b- ),\u001b&\u001f-6 0ĉ'#.)- 3 \u001e#\u001b,,\u001f\u001b6 \u001d)( '\u001b(# \u001f-.\u001b\u001d#)(\u001f- \"\u001f'\u001b.)&ĉ!#\u001d\u001b- .\u001b,\u001eù\u001b-8 \u0005& \u001e#\u001b!(ĉ-.#\u001d) -\u001f\n\"\u001b\u001d\u001f '#\u001e#\u001f(\u001e) &\u001b .,\u001b(-\u001d)\u001c\u001b&\u001b'#(\u001b\n \n8\n\nEnfermedad pancreática\n\n\u0005( \u001f& kf \u001b mfz \u001e\u001f &)- *\u001b\u001d#\u001f(.\u001f- +/\u001f *,\u001f-\u001f(.\u001b( #(-/l·\u001d#\u001f(\u001d#\u001b *\u001b(\u001d,\u001fá.#\u001d\u001b \u001d)') \u001d)(-\u001f\u001d/\u001f(\u001d#\u001b \u001e\u001f *\u001b(\u001d,\u001f\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":83,"lines":{"from":82,"to":108}}}}],["337",{"pageContent":"Enfermedad pancreática\n\n\u0005( \u001f& kf \u001b mfz \u001e\u001f &)- *\u001b\u001d#\u001f(.\u001f- +/\u001f *,\u001f-\u001f(.\u001b( #(-/l·\u001d#\u001f(\u001d#\u001b *\u001b(\u001d,\u001fá.#\u001d\u001b \u001d)') \u001d)(-\u001f\u001d/\u001f(\u001d#\u001b \u001e\u001f *\u001b(\u001d,\u001f\u001b\n-\n\n.#.#- \u001d,ĉ(#\u001d\u001b ) \u001e\u001f *\u001b(\u001d,\u001f\u001b.\u001f\u001d.)'ù\u001b6 \u001b*\u001b,\u001f\u001d\u001f( \u001e\u001f \u001f\u001d.)- \u001e\u001f \u001b\u001c-),\u001d#ĉ( \u001e\u001f \u001d)\u001c\u001b&\u001b'#(\u001b8 \u000e) )\u001c-.\u001b(.\u001f6 -)&) \"\u001b3\n\u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f 0#.\u001b'#(\u001b \u0002gh 3 () -\u001f )\u001c-\u001f,0\u001b &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8\n\nDeficiencia en la dieta\n\n\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001f( &\u001b \u001e#\u001f.\u001b \u001f- '/3 ,\u001b,\u001b: -#( \u001f'\u001c\u001b,!)6 -\u001f \"\u001b \u001e\u001f.\u001f\u001d.\u001b\u001e) \u001f( *\u001f,-)(\u001b- +/\u001f -/ ,\u001f( \u001e\u001f \u001b&\u001d)\")\n-\n\n&#-')6 \u001f( \u001f,'\u001f\u001e\u001b\u001e\u001f- '\u001f(.\u001b&\u001f- \u001d,ĉ(#\u001d\u001b- 3 \u001b&#'\u001f(.\u001b\u001d#ĉ( 0\u001f!\u001f.\u001b,#\u001b(\u001b \u001f-.,#\u001d.\u001b6 .)\u001e)- \u001f&&)- \u001d)( \u001e\u001fl·\u001d#\u001f(\u001d#\u001b\n(/.,#'\u001f(.\u001b& !,\u001b0\u001f8 \b\u001b3 \u001b(\u001f'#\u001b- '\u001f!\u001b&)\u001c&á-.#\u001d\u001b- ,\u001f*),.\u001b\u001e\u001b- \u001f( &\u001b\u001d.\u001b(.\u001f- '\u001f(),\u001f- \u001d)( '\u001b(# \u001f-.\u001b\u001d#)(\u001f-\n(\u001f/,)&ĉ!#\u001d\u001b- \u001d)( \u001b(.\u001f\u001d\u001f\u001e\u001f(.\u001f \u001e\u001f \"\u001b\u001c\u001f, -#\u001e) \u001b&#'\u001f(.\u001b\u001e)- \u001b& -\u001f() '\u001b.\u001f,() \u001e\u001f '\u001b(\u001f,\u001b *,)&)(!\u001b\u001e\u001b *),","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":83,"lines":{"from":108,"to":123}}}}],["338",{"pageContent":"La forma más representativa\nde deficiencia congénita es la\nanemia perniciosa juvenil, de\nla cual existen tres variedades:\na) deficiente absorción de vita-\nmina B12 con secreción de áci-\ndo clorhídrico y factor intrínseco\nnormal; b) secreción anormal\nde factor intrínseco; y c) defi-\nciencia de transcobalamina II.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":83,"lines":{"from":125,"to":134}}}}],["339",{"pageContent":"CAPÍTULO 4. ANEMIAS MEGALOBLÁSTICAS\n\n57\n\n'\u001b\u001e,\u001f- 0\u001f!\u001f.\u001b,#\u001b(\u001b-8\n \n\u001b \u001f0#\u001e\u001f(\u001d#\u001b -/!#\u001f,\u001f +/\u001f &\u001b 0#.\u001b'#(\u001b \u0002gh () -\u001f .,\u001b(-l·\u001f,\u001f \u001b .,\u001b0ï- \u001e\u001f &\u001b &\u001f\u001d\"\u001f '\u001b.\u001f,\n-\n\n(\u001b6 \u001e\u001f& \u001b&'\u001b\u001dï( \u001e\u001f 0#.\u001b'#(\u001b \u0002gh \u001e\u001f &\u001b '\u001b\u001e,\u001f: &) +/\u001f -/\u001d\u001f\u001e\u001f \u001f- +/\u001f \u001f& '\u001f(),6 \u001b& (\u001b\u001d\u001f,6 \u001d\u001b,\u001f\u001d\u001f \u001e\u001f ,\u001f-\u001f,0\u001b-\n3 \u001f- \u001b\u001c&\u001b\u001d.\u001b\u001e) .\u001b,\u001eù\u001b'\u001f(.\u001f ) \u001c#\u001f( () ,\u001f\u001d#\u001c\u001f -/*&\u001f'\u001f(.\u001b\u001d#ĉ( ,#\u001d\u001b \u001f( 0#.\u001b'#(\u001b \u0002gh8\n\nANEMIA MEGALOBLÁSTICA AGUDA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":84,"lines":{"from":1,"to":13}}}}],["340",{"pageContent":"ANEMIA MEGALOBLÁSTICA AGUDA\n\n\u0005-.\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b -\u001f *,\u001f-\u001f(.\u001b \u001f( *)\u001d)- \u001eù\u001b- 3 -\u001f \u001d\u001b,\u001b\u001d.\u001f,#4\u001b *), &\u001f/\u001d)*\u001f(#\u001b 3 .,)'\u001c)\u001d#.)*\u001f(#\u001b \u001d)( &\u001f0\u001f\n\u001e\u001f-\u001d\u001f(-) \u001e\u001f &)- 0\u001b&),\u001f- \u001e\u001f &\u001b -\u001f,#\u001f ,)$\u001b8 \u0005& \u001d/\u001b\u001e,) -/!#\u001f,\u001f /(\u001b \u001d#.)*\u001f(#\u001b #('/(#.\u001b,#\u001b6 *\u001f,) \u001f& \u001b-*#,\u001b\u001e) \u001e\u001f &\u001b\n'ï\u001e/&\u001b ĉ-\u001f\u001b '/\u001f-.,\u001b &)- \u001e\u001b.)- .ù*#\u001d)- \u001e\u001f &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8\n \n\u001b \u001f2*)-#\u001d#ĉ( \u001b& ĉ2#\u001e) (#.,)-) B\u000e\n \nh\n \n\u000fC\n\u001f- &\u001b \u001d\u001b/-\u001b 'á- \u001d)'Ě( \u001e\u001f \u001f-.\u001b 0\u001b,#\u001f\u001e\u001b\u001e \u001e\u001f \u001b(\u001f'#\u001b8 \u0005& ĉ2#\u001e) (#.,)-) *,)\u001e/\u001d\u001f /(\u001b ,á*#\u001e\u001b \u001e\u001f-.,/\u001d\u001d#ĉ( \u001e\u001f &\u001b\n'\u001f.#)(#(\u001b -#(.\u001f.\u001b-\u001b 3 \u001e#-'#(/\u001d#ĉ( \u001e\u001f &\u001b \u001b\u001d.#0#\u001e\u001b\u001e \u001e\u001f &\u001b \u000ek'\u001f.7\u0006\bj6 \"\u001f')\u001d#-.\u001fù(\u001b '\u001f.#&.,\u001b(- \u001f,\u001b-\u001b6 \u001d)(\n\u001f& \u001d)(-#!/#\u001f(.\u001f \u001e\u001f-\u001b,,)&&) \u001e\u001f \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8 \u0001*\u001b,\u001f\u001d\u001f \u001e\u001f-*/ï- \u001e\u001f /(\u001b \u001f2*)-#\u001d#ĉ( *,)&)(!\u001b\u001e\u001b B'á-\n\u001e\u001f l̓\"),\u001b-C 3 &)- \u001d\u001b'\u001c#)- '\u001f!\u001b&)\u001c&á-.#\u001d)- -)( )\u001c-\u001f,0\u001b\u001e)- hj̓\"),\u001b- \u001e\u001f-*/ï-8\n\nDIAGNÓSTICO\n\n\u0013\u001f \u001e\u001f\u001c\u001f \u001d)(-#\u001e\u001f,\u001b, \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b \u001f( \u001d\u001b-)- \u001e\u001f \u001b(\u001f'#\u001b '\u001b\u001d,)\u001dù.#\u001d\u001b -#(.)'á.#\u001d\u001b6 \u001b(.\u001f\u001d\u001f\u001e\u001f(.\u001f- \u001e\u001f\n\u001e#\u001b,,\u001f\u001b6 \u001f'\u001c\u001b,\u001b4)6 \u001b&\u001d)\")&#-') ) \u001e\u001f-(/.,#\u001d#ĉ(6 *,\u001f-\u001f(\u001d#\u001b \u001e\u001f !&)-#.#- 3 \u001f-*&\u001f()'\u001f!\u001b&#\u001b 'ù(#'\u001b8 \u000f\u001d\u001b-#)\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":84,"lines":{"from":13,"to":33}}}}],["341",{"pageContent":"(\u001b&'\u001f(.\u001f \u001f2#-.\u001f \u001e)&), ĉ-\u001f) 3 l·\u001f\u001c,\u001f8 \u0001&!/()- \u001f-./\u001e#)- \u001e\u001f &\u001b\u001c),\u001b.),#) -\u001f(\u001d#&&)-6 \u001d)') &\u001b \u001d#.)'\u001f.,ù\u001b \"\u001f\n-\n\n'á.#\u001d\u001b 3 &\u001b \u001e\u001f.\u001f,'#(\u001b\u001d#ĉ( -ï,#\u001d\u001b \u001e\u001f &\u001b \u001f(4#'\u001b \u001e\u001f-\"#\u001e,)!\u001f(\u001b-\u001b &á\u001d.#\u001d\u001b6 ),#\u001f(.\u001b( \u001c\u001b-.\u001b(.\u001f \u001b& \u001e#\u001b!(ĉ-.#\u001d)8\n\u0005( &\u001b \u001d#.)'\u001f.,ù\u001b \"\u001f'á.#\u001d\u001b -\u001f \u001f(\u001d/\u001f(.,\u001b '\u001b\u001d,)\u001d#.)-#-6 (\u001f/.,ĉl·&)- '/&.#-\u001f!'\u001f(.\u001b\u001e)- 3 *&\u001b+/\u001f.\u001b- !#!\u001b(\n-\n\n.\u001f-6 */\u001e#\u001f(\u001e) \u001f(\u001d)(.,\u001b, ),'\u001b- $ĉ0\u001f(\u001f- \u001e\u001f -\u001f,#\u001f \u001c&\u001b(\u001d\u001b 3 (),')\u001c&\u001b-.)- B\u001d/\u001b\u001e,) &\u001f/\u001d)\u001f,#.,)\u001c&á-.#\u001d)C8 \u0005-\n#'*),.\u001b(.\u001f -\u001fĄ\u001b&\u001b, +/\u001f &)-\n \n,).#- \u001e\u001f -\u001b(!,\u001f *\u001f,# ï,#\u001d\u001b \u001e\u001f\u001c\u001f( -\u001f, \u001f-./\u001e#\u001b\u001e)- *), *\u001f,-)(\u001b& \u001e\u001f &\u001b\u001c),\u001b.),#)\n\u001d)( \u001f2*\u001f,#\u001f(\u001d#\u001b \u001f( \u001d#.)'), )&)!ù\u001b8\n)- \"\u001b&&\u001b4!)- \u001f( &\u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b -)( \u001d\u001b,\u001b\u001d.\u001f,ù-.#\u001d)-8 \u0005& .\u001f$#\u001e) \u001f- \"#*\u001f,\u001d\u001f&/&\u001b,6 \u001f(\u001d)(.,\u001b(\u001e) *)\u001d\u001b !,\u001b-\u001b\n\n(fig. 4-2)\n \n3\n \n,\u001b(\u001d) *,\u001f\u001e)'#(#) \u001e\u001f &\u001b -\u001f,#\u001f ,)$\u001b6 \u001d)( \u001b-#(\u001d,)(#-') \u001f( &\u001b '\u001b\u001e/,\u001b\u001d#ĉ(6 3 )\u001d\u001b-#)(\u001b&'\u001f(.\u001f -\u001f\n)\u001c-\u001f,0\u001b( \u001d),*Ě-\u001d/&)- \u001e\u001f \b)1\u001f&&7 )&&3 \u001f( &)- (),')\u001c&\u001b-.)- .\u001b,\u001eù)-8\n \n)- '\u001f!\u001b\u001d\u001b,#)\u001d#.)- -)( '/&.#&)\u001c/&\u001b\n-\n\n\u001e)- 3 \u001f( &\u001b -\u001f,#\u001f \u001c&\u001b(\u001d\u001b -\u001f \u001f(\u001d/\u001f(.,\u001b( \u001c\u001b(\u001e\u001b- !#!\u001b(.\u001f- 3 '\u001b\u001d,)*)&#\u001d#.)-8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":84,"lines":{"from":35,"to":59}}}}],["342",{"pageContent":"\u001e)- 3 \u001f( &\u001b -\u001f,#\u001f \u001c&\u001b(\u001d\u001b -\u001f \u001f(\u001d/\u001f(.,\u001b( \u001c\u001b(\u001e\u001b- !#!\u001b(.\u001f- 3 '\u001b\u001d,)*)&#\u001d#.)-8\n\nFigura 4-2.\n \n\u0002#)*-#\u001b \u001e\u001f \"/\u001f-)9 '/\u001f-.,\u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b \"#*\u001f,\u001d\u001f&/&\u001b, \u001d)( *,\u001f\u001e)'#(#) \u001e\u001f &\u001b -\u001f,#\u001f ,)$\u001b6 \u001d\u001b,\u001b\u001d.\u001f\n-\n\n,ù-.#\u001d) \u001e\u001f \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8\n \n#\u001d,) ).)!,\u001b ù\u001b \u001d),.\u001f-ù\u001b \u001e\u001f &\u001b \u0004,\u001b8 \u0001&\u001f$\u001b(\u001e,\u001b \u001aá,\u001b.\u001f \u000f-),()8 \b)-*#.\u001b&\n\u0005-*\u001bĄ)& \u001e\u001f\n \nï2#\u001d)8\n \nï2#\u001d)6 \u00048\u00068","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":84,"lines":{"from":59,"to":73}}}}],["343",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n58\n\nï2#\u001d) \u001d/\u001f(.\u001b \u001d)( \u001b&,\u001f\u001e\u001f\u001e), \u001e\u001f kff \"\u001f'\u001b.ĉ&)!)- *\u001b,\u001b 'á- \u001e\u001f ggj '#&&)(\u001f- \u001e\u001f \"\u001b\u001c#.\u001b(.\u001f- 3 \u0003)&)'\u001c#\u001b\n.#\u001f(\u001f nf \"\u001f'\u001b.ĉ&)!)- 3 mk )(\u001d)\"\u001f'\u001b.ĉ&)!)-: \u001f-.)- Ě&.#')- .,\u001b.\u001b( ./'),\u001f- -ĉ&#\u001e)- 3 \u001b&!/()- \u001b.#\u001f(\u001e\u001f( \"\u001f'\u001b\n-\n\n.)&)!ù\u001b \u001c\u001f(#!(\u001b8 \u0005(\n \nï2#\u001d) () -)( '/\u001d\")- &)- *\u001b.ĉ&)!)- \u001d&ù(#\u001d)- \u001d\u001b*\u001b\u001d#.\u001b\u001e)- \u001f( \u001d#.)'), )&)!ù\u001b \u001e\u001f 'ï\u001e/&\u001b\nĉ-\u001f\u001b 3 &)- \"\u001f'\u001b.)*\u001b.ĉ&)!)- \u001e\u001f \u001d\u001b,,\u001f,\u001b -)( \u001f-\u001d\u001b-)-8 \u0010), &) .\u001b(.)6 &\u001b #(.\u001f,*,\u001f.\u001b\u001d#ĉ( \u001e\u001f& \u001b-*#,\u001b\u001e) \u001e\u001f 'ï\u001e/&\u001b ĉ-\u001f\u001b\n,\u001f\u001d\u001b\u001f *), &) !\u001f(\u001f,\u001b& \u001f( &)- \"\u001f'\u001b.ĉ&)!)-8\n\u0004\u001f\u001c\u001f +/\u001f\u001e\u001b, \u001d&\u001b,) +/\u001f \u001f& \u001b-*#,\u001b\u001e) \u001e\u001f 'ï\u001e/&\u001b ĉ-\u001f\u001b () \u001f- #(\u001e#-*\u001f(-\u001b\u001c&\u001f *\u001b,\u001b \u001f-.\u001b\u001c&\u001f\u001d\u001f, \u001f& \u001e#\u001b!(ĉ-.#\u001d) \u001e\u001f\n\u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8 \u0010), \u001f$\u001f'*&)6 \u001f( \u001d\u001b-)- \u001e\u001f '/$\u001f,\u001f- \u001f'\u001c\u001b,\u001b4\u001b\u001e\u001b- \u001d)( /( \u001d/\u001b\u001e,) \u001d&ù(#\u001d) 3 \"\u001f'á.#\u001d)\n.ù*#\u001d) 3 \u001f2\u001d\u001f&\u001f(.\u001f ,\u001f-*/\u001f-.\u001b .\u001f,\u001b*ï/.#\u001d\u001b6 .,\u001b(+/#&\u001b'\u001f(.\u001f */\u001f\u001e\u001f \u001f0#.\u001b,-\u001f &\u001b */(\u001d#ĉ(8 \u0013#( \u001f'\u001c\u001b,!)6 \u001d/\u001b(\u001e)\n\u001f2#-.\u001f &\u001b \u001d)( /-#ĉ( \u001f(.,\u001f \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b 3 -ù(\u001e,)'\u001f '#\u001f&)\u001e#-*&á-#\u001d)6 *), -\u001f, \u001f-.\u001f Ě&.#') /(\u001b \u001f(.#\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":85,"lines":{"from":1,"to":18}}}}],["344",{"pageContent":"\u001e\u001b\u001e +/\u001f -\u001f \u001e#\u001b!()-.#\u001d\u001b *), \u001f2\u001d&/-#ĉ(6 \u001e\u001f\u001c\u001f ,\u001f\u001b&#4\u001b,-\u001f \u001b-*#,\u001b\u001e) 3 \u001c#)*-#\u001b \u001e\u001f 'ï\u001e/&\u001b ĉ-\u001f\u001b 3 \u001b*)3\u001b,-\u001f \u001f( /(\n\"\u001f'\u001b.)*\u001b.ĉ&)!)8\n \n)- -ù(\u001e,)'\u001f- '#\u001f&)\u001e#-*&á-#\u001d)- */\u001f\u001e\u001f( \u001b \u001f\u001d.\u001b, &\u001b -\u001f,#\u001f ,)$\u001b ) -\u001f, '/&.#&#(\u001f\u001b&\u001f-: &\u001b \u001b(\u001f'#\u001b\n*/\u001f\u001e\u001f -\u001f, '\u001b\u001d,)\u001dù.#\u001d\u001b 3 () ,\u001f-*)(\u001e\u001f \u001b .,\u001b.\u001b'#\u001f(.)- \u001d)( \"\u001f'\u001b.ù(#\u001d)-6 3 \u001f& \u001c\u001b4) &&\u001f!\u001b \u001b *\u001b&*\u001b,-\u001f8\n)- \u001c&\u001b-.)- \u001f( 'ï\u001e/&\u001b ĉ-\u001f\u001b ,\u001f-/&.\u001b( *)-#.#0)- *\u001b,\u001b \u0003\u0004ij8 \u000f\u001d\u001b-#)(\u001b&'\u001f(.\u001f -\u001f )\u001c-\u001f,0\u001b(\n \n),'\u001b- #(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":85,"lines":{"from":20,"to":28}}}}],["345",{"pageContent":"'\u001b\u001e/,\u001b- -/!\u001f-.#0\u001b- \u001e\u001f \u001c&\u001b-.)- +/\u001f () -)( \u0003\u0004ij\n \n\n8 \u0005( \u001f-.)- \u001d\u001b-)-6 &\u001b- '\u001b,\u001d\u001b\u001d#)(\u001f- *\u001b,\u001b \u001b(.ù!\u001f()- \u001e\u001f\n&#(\u001b$\u001f6 '#\u001f&)*\u001f,)2#\u001e\u001b-\u001b6 \u0003\u0004ggm 3 !&#\u001d) ),#(\u001b \u00016 \u001f-.\u001b Ě&.#'\u001b *\u001b,\u001b ,\u001f\u001d)()\u001d\u001f, &\u001b &ù(\u001f\u001b \u001f,#.,)#\u001e\u001f6 \u001b3/\u001e\u001b(\n\u001b \"\u001b\u001d\u001f, &\u001b \u001e# \u001f,\u001f(\u001d#\u001b\u001d#ĉ( \u001f(.,\u001f /(\u001b \u001f(.#\u001e\u001b\u001e \u001c\u001f(#!(\u001b \u001d)') &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b ) /(\u001b '\u001b&#!(\u001b\n\u001d)') \u001f& -ù(\u001e,)'\u001f '#\u001f&)\u001e#-*&á-#\u001d)\n \n(fig. 4-3)\n8 \u000f.,\u001b '\u001b(\u001f,\u001b \u001e\u001f \u001e# \u001f,\u001f(\u001d#\u001b, \u001f(.,\u001f (\u001f)*&\u001b-#\u001b- '#\u001f&)#\u001e\u001f- ()\n\u001b!/\u001e\u001b- B\u000e\n \n\u000e\u0001C 3 *\u001b\u001e\u001f\u001d#'#\u001f(.)- \u001c\u001f(#!()- ) ,\u001f\u001b\u001d.#0)- &\u001b \u001d)(-.#./3\u001f( &\u001b *)-#.#0#\u001e\u001b\u001e \u001e\u001f \u0003\u0004ij \u001f( &)-\n'\u001f!\u001b\u001d\u001b,#)\u001d#.)-8\n \n\u001b- \u001d# ,\u001b- #!/\u001b&\u001f- ) '\u001b3),\u001f- \u001e\u001f ifz \u001e\u001f '\u001f!\u001b\u001d\u001b,#)\u001d#.)- \u0003\u0004ij\n \n\n \n-\u001f \u001b-)\u001d#\u001b( \u001d)( \u001b(\u001f'#\u001b\n'\u001f!\u001b&)\u001c&á-.#\u001d\u001b 3 () \u001d)( \u000e\n \n\u000e\u00018\n\u0003)( \u001f& á(#') \u001e\u001f \u001f-.\u001b\u001c&\u001f\u001d\u001f, \u001f-.,\u001b.\u001f!#\u001b- \u001e\u001f .,\u001b.\u001b'#\u001f(.)6 \u001f- (\u001f\u001d\u001f-\u001b,#) \u001e\u001f.\u001f,'#(\u001b, &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001f-*\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":85,"lines":{"from":30,"to":54}}}}],["346",{"pageContent":"\u001dùl·\u001d\u001b 3 \u001d/á& \u001f- \u001f& '\u001f\u001d\u001b(#-') +/\u001f &\u001b *,)\u001e/$)8\n \n\u001b '\u001f\u001e#\u001d#ĉ( \u001e\u001f (#0\u001f&\u001f- -ï,#\u001d)- \u001e\u001f 0#.\u001b'#(\u001b \u0002gh 3 á\u001d#\u001e)\nĉ&#\u001d) \u001e\u001f\u001c\u001f -\u001f, ,\u001f\u001b&#4\u001b\u001e\u001b \u001f( \u001d\u001b-)- \u001e\u001f \u001b(\u001f'#\u001b- '\u001b\u001d,)\u001dù.#\u001d\u001b-6 \u001f( '\u001b\u001d,)\u001d#.)-#- \u001d)( 0)&/'\u001f( \u001d),*/-\u001d/&\u001b,\n'\u001f\u001e#) -/*\u001f,#), \u001b ggf̓\n \n3 \u001f( *\u001f,-)(\u001b- \u001d)( \u001b&.\u001f,\u001b\u001d#)(\u001f- (\u001f/,)*-#+/#á.,#\u001d\u001b- \u001f-*\u001f\u001dùl·\u001d\u001b- B#(\u001d&/#\u001e\u001b- &\u001b-\n*\u001b,\u001f-.\u001f-#\u001b-6 \u001b.\u001b2#\u001b6 (\u001f/,)*\u001b.ù\u001b *\u001f,# ï,#\u001d\u001b 3 *ï,\u001e#\u001e\u001b \u001e\u001f &\u001b '\u001f'),#\u001bC8 \u0005( \u001f-.)- Ě&.#')-6 #(0\u001f-.#!\u001b, -)&)\n0#.\u001b'#(\u001b \u0002gh6 \u001b '\u001f()- +/\u001f .\u001f(!\u001b \u001b(\u001f'#\u001b '\u001b\u001d,)\u001dù.#\u001d\u001b6 \u001f( \u001d/3) \u001d\u001b-) -\u001f \u001e\u001f\u001c\u001f '\u001f\u001e#, .\u001b(.) 0#.\u001b'#(\u001b \u0002gh\n\u001d)') á\u001d#\u001e) ĉ&#\u001d)\n \n(cuadro 4-5)\n8\n\u0012\u001f\u001d),\u001e\u001b, +/\u001f /(\u001b .,\u001b(- /-#ĉ( ,\u001f\u001d#\u001f(.\u001f */\u001f\u001e\u001f \u001b&.\u001f,\u001b, .\u001f'*),\u001b&'\u001f(.\u001f \u001f& (#0\u001f& \u001e\u001f á\u001d#\u001e)\n \nĉ&#\u001d)6 \u001b& #!/\u001b&\n+/\u001f &\u001b *,\u001f-\u001f(\u001d#\u001b \u001e\u001f \"\u001f'ĉ&#-#- \u001b& ')'\u001f(.) \u001e\u001f &\u001b .)'\u001b \u001e\u001f -\u001b(!,\u001f6 *), &#\u001c\u001f,\u001b\u001d#ĉ( \u001e\u001f& )&\u001b.) #(.,\u001b\u001f,#.,)\u001d#.\u001b,#)8\n\nFigura 4-3.\n \n\u0001(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8 \u0013\u001f )\u001c-\u001f,0\u001b( *,\u001f\u001d/,-),\u001f- \u001f,#.,)#\u001e\u001f- *)-#.#0)- \u001b !&#\u001d) ),#(\u001b \u00018 \u0013\u001f \u001f2\u001d&/\n-\n\n3ĉ \u001f( \u001f,'\u001f\u001e\u001b\u001e '\u001b&#!(\u001b8\n \n#\u001d,) ).)!,\u001b ù\u001b \u001d),.\u001f-ù\u001b \u001e\u001f &\u001b \u0004,\u001b8 \u0001&\u001f$\u001b(\u001e,\u001b \u001aá,\u001b.\u001f \u000f-),()8 \b)-*#.\u001b& \u0005-*\u001bĄ)&\n\u001e\u001f\n \nï2#\u001d)8\n \nï2#\u001d)6 \u00048\u00068","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":85,"lines":{"from":56,"to":86}}}}],["347",{"pageContent":"3ĉ \u001f( \u001f,'\u001f\u001e\u001b\u001e '\u001b&#!(\u001b8\n \n#\u001d,) ).)!,\u001b ù\u001b \u001d),.\u001f-ù\u001b \u001e\u001f &\u001b \u0004,\u001b8 \u0001&\u001f$\u001b(\u001e,\u001b \u001aá,\u001b.\u001f \u000f-),()8 \b)-*#.\u001b& \u0005-*\u001bĄ)&\n\u001e\u001f\n \nï2#\u001d)8\n \nï2#\u001d)6 \u00048\u00068\n\nRecordar que una transfusión\nreciente puede alterar tempo-\nralmente el nivel de ácido fó-\nlico, al igual que la presencia\nde hemólisis al momento de la\ntoma de sangre, por liberación\ndel folato intraeritrocitario.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":85,"lines":{"from":86,"to":101}}}}],["348",{"pageContent":"CAPÍTULO 4. ANEMIAS MEGALOBLÁSTICAS\n\n59\n\n\u0005- #'*),.\u001b(.\u001f .)'\u001b, \u001f( \u001d/\u001f(.\u001b ).,\u001b- \u001d\u001b/-\u001b- \u001e\u001f '\u001b\u001d,)\u001d#.)-#- \u001d)( 'ï\u001e/&\u001b ĉ-\u001f\u001b (),')\u001c&á-.#\u001d\u001b () ,\u001f&\u001b\u001d#)(\u001b\n-\n\n\u001e\u001b- \u001b& \u001eïl·\u001d#. \u001e\u001f \u0002gh ) á\u001d#\u001e) ĉ&#\u001d)8\n\u0005& \u001b&\u001d)\")&#-') */\u001f\u001e\u001f *,)0)\u001d\u001b, '\u001b\u001d,)\u001d#.)-#- \u001d)( ) -#( \u001b&.\u001f,\u001b\u001d#)(\u001f- \u001f( &\u001b- *,/\u001f\u001c\u001b- \u001e\u001f\n \n/(\u001d#)(\u001b'#\u001f(.)\n\"\u001f*á.#\u001d)8 \u0005-.\u001f \u001e\u001b.) \u001f- #(.\u001f,\u001f-\u001b(.\u001f 3 \u001f- .)'\u001b\u001e) \u001f( \u001d/\u001f(.\u001b *), &\u001b- \u001d)'*\u001bĄù\u001b- \u001b-\u001f!/,\u001b\u001e),\u001b- 3 \u001f( \u001d\u001b-)- \u001e\u001f\n#(0\u001f-.#!\u001b\u001d#ĉ( 'ï\u001e#\u001d)7&\u001f!\u001b&8 \u0005( ).,\u001b- *\u001b&\u001b\u001c,\u001b-6 -# /(\u001b *\u001f,-)(\u001b (#\u001f!\u001b \u001c\u001f\u001c\u001f, \u001b&\u001d)\")& 3 \u001b*\u001b,\u001f\u001d\u001f '\u001b\u001d,)\u001d#.)-#-\n\u001d)') \"\u001b&&\u001b4!) Ě(#\u001d) \u001f( &\u001b \u001d#.)'\u001f.,ù\u001b \"\u001f'á.#\u001d\u001b6 -#( ).,\u001b \u001d\u001b/-\u001b \u001b*\u001b,\u001f(.\u001f6 \u001f- '/3 *,)\u001c\u001b\u001c&\u001f +/\u001f )\u001d/&.\u001f #( ),\n-\n\n'\u001b\u001d#ĉ(8 \u0012\u001f\u001d),\u001e\u001b, +/\u001f \u001d)( j̓'\u001f-\u001f- \u001e\u001f \u001b\u001c-.#(\u001f(\u001d#\u001b \u001b&\u001d)\"ĉ&#\u001d\u001b &\u001b '\u001b\u001d,)\u001d#.)-#- -\u001f ,\u001f0#\u001f,.\u001f8\n\u0005& \"#*).#,)#\u001e#-')6 \u001f& \u001f'\u001c\u001b,\u001b4) 3 \u001f& *\u001f,ù)\u001e) (\u001f)(\u001b.\u001b& */\u001f\u001e\u001f( \u001b/'\u001f(.\u001b, &#!\u001f,\u001b'\u001f(.\u001f \u001f& 0)&/'\u001f( \u001d),\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":86,"lines":{"from":1,"to":19}}}}],["349",{"pageContent":"'\u001b\u001d#ĉ(8 \u0012\u001f\u001d),\u001e\u001b, +/\u001f \u001d)( j̓'\u001f-\u001f- \u001e\u001f \u001b\u001c-.#(\u001f(\u001d#\u001b \u001b&\u001d)\"ĉ&#\u001d\u001b &\u001b '\u001b\u001d,)\u001d#.)-#- -\u001f ,\u001f0#\u001f,.\u001f8\n\u0005& \"#*).#,)#\u001e#-')6 \u001f& \u001f'\u001c\u001b,\u001b4) 3 \u001f& *\u001f,ù)\u001e) (\u001f)(\u001b.\u001b& */\u001f\u001e\u001f( \u001b/'\u001f(.\u001b, &#!\u001f,\u001b'\u001f(.\u001f \u001f& 0)&/'\u001f( \u001d),\n-\n\n*/-\u001d/&\u001b, '\u001f\u001e#)8 \u0003#\u001f,.\u001b- \u001b&.\u001f,\u001b\u001d#)(\u001f- \"\u001f'á.#\u001d\u001b- \u001d)'*&\u001f$\u001b-6 \u001d)') &)- -ù(\u001e,)'\u001f- '#\u001f&)\u001e#-*&á-#\u001d)-6 &\u001b \u001b*&\u001b-#\u001b\n'\u001f\u001e/&\u001b, 3 &\u001b \u001b*&\u001b-#\u001b */,\u001b \u001e\u001f -\u001f,#\u001f ,)$\u001b6 \u001b\u001e\u001f'á- \u001e\u001f \u001d\u001b'\u001c#)- \u001f( &\u001b- *,).\u001fù(\u001b- *&\u001b-'á.#\u001d\u001b-6 \u001d)') \u001f& '#\u001f&)'\u001b\n'Ě&.#*&\u001f6 3 \u001b&!/()- '\u001f\u001e#\u001d\u001b'\u001f(.)- -)( \u001d\u001b/-\u001b \u001e\u001f '\u001b\u001d,)\u001d#.)-#-8\n\u001b '\u001f\u001e#\u001d#ĉ( \u001e\u001f &)- (#0\u001f&\u001f- -ï,#\u001d)- \u001f #(.,\u001b\u001f,#.,)\u001dù.#\u001d)- \u001e\u001f &\u001b \u001d)\u001c\u001b&\u001b'#(\u001b 3 \u001e\u001f& á\u001d#\u001e)\n \nĉ&#\u001d) */\u001f\u001e\u001f(\n\"\u001b\u001d\u001f,-\u001f *), 'ï.)\u001e) '#\u001d,)\u001c#)&ĉ!#\u001d) ) *), .ï\u001d(#\u001d\u001b- ,\u001b\u001e#)#-).ĉ*#\u001d\u001b-8\n \n)- \u001f2*\u001f,.)- \u001e\u001f &\u001b \u000f\n \n\u0013 \"\u001b( \u001f-.\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":86,"lines":{"from":19,"to":34}}}}],["350",{"pageContent":"\u001c&\u001f\u001d#\u001e) +/\u001f \u001f& \u001e#\u001b!(ĉ-.#\u001d) \u001e\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001f( \u001d)\u001c\u001b&\u001b'#(\u001b -\u001f \u001f-.\u001b\u001c&\u001f\u001d\u001f \u001b& \"\u001b&&\u001b, \u001d# ,\u001b- -ï,#\u001d\u001b- '\u001f(),\u001f- \u001e\u001f\nnf 3 glf *!I'\n \n\u001f( &\u001b \u001e\u001f.\u001f,'#(\u001b\u001d#ĉ( #(.,\u001b\u001f,#.,)\u001dù.#\u001d\u001b8\n \n\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f )&\u001b.)- -\u001f \u001d\u001b,\u001b\u001d.\u001f,#4\u001b *), 0\u001b&),\u001f-\n#( \u001f,#),\u001f- \u001b j̓'! \u001f( -/\u001f,) 3 '\u001f()- \u001e\u001f glf̓'!I'\n \n\u001f( &\u001b '\u001f\u001e#\u001d#ĉ( #(.,\u001b\u001f,#.,)\u001dù.#\u001d\u001b8\n\u0005& \u001e#\u001b!(ĉ-.#\u001d) \u001e\u001f \u001eïl·\u001d#. \u001e\u001f 0#.\u001b'#(\u001b \u0002gh '\u001f,\u001f\u001d\u001f &\u001b- -#!/#\u001f(.\u001f- \u001d)(-#\u001e\u001f,\u001b\u001d#)(\u001f-8 \u0015( (#0\u001f& \u001f2.,\u001f\n-\n\n'\u001b\u001e\u001b'\u001f(.\u001f \u001c\u001b$) B̓gff̓*!I'\n \nC\n \n/-/\u001b&'\u001f(.\u001f -\u001f \u001b-)\u001d#\u001b \u001d)( \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001d&ù(#\u001d\u001b: \u001f-.)- (#0\u001f&\u001f- \u001c\u001b$)- ,\u001b,\u001b\n0\u001f4 -)( )\u001c-\u001f,0\u001b\u001e)-8\n \n)- 0\u001b&),\u001f- .\u001b(.)\n \n\u001b&-)- *)-#.#0)- \u001d)')\n \n\u001b&-)- (\u001f!\u001b.#0)- -)( \u001d)'/(\u001f- B\"\u001b-.\u001b \u001f(\n/( kfz \u001e\u001f &\u001b- *,/\u001f\u001c\u001b-C6 /.#&#4\u001b(\u001e) \u001f& &ù'#.\u001f #( \u001f,#), \u001e\u001f& ,\u001b(!) (),'\u001b& ,\u001f*),.\u001b\u001e) *), \u001f& &\u001b\u001c),\u001b.),#)\n\u001d)') */(.) \u001e\u001f \u001d),.\u001f *\u001b,\u001b &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b8\n \n\u001b \u001f&\u001f0\u001b\u001e\u001b .\u001b-\u001b \u001e\u001f ,\u001f-/&.\u001b\u001e)-\n \n\u001b&-)- *)-#.#0)- 3\n \n\u001b&-)- (\u001f!\u001b.#\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":86,"lines":{"from":36,"to":68}}}}],["351",{"pageContent":"0)- */\u001f\u001e\u001f \u001e\u001f\u001c\u001f,-\u001f \u001b& \"\u001f\u001d\") \u001e\u001f +/\u001f -)&) \u001f& hfz \u001e\u001f &\u001b '\u001f\u001e#\u001d#ĉ( .).\u001b& \u001e\u001f 0#.\u001b'#(\u001b \u0002gh -\u001f \u001f(\u001d/\u001f(.,\u001b \u001f(\n&\u001b *,).\u001fù(\u001b \u001e\u001f \u001f(.,\u001f!\u001b \u001d\u001f&/&\u001b,6 &\u001b .,\u001b(-\u001d)\u001c\u001b&\u001b'#(\u001b: \u001f& ,\u001f-.) -\u001f \u001f(\u001d/\u001f(.,\u001b /(#\u001e) \u001b &\u001b \"\u001b*.)\u001d),,#(\u001b6 /(\u001b\n*,).\u001fù(\u001b \u001e\u001f\n \n/(\u001d#ĉ( \u001e\u001f-\u001d)()\u001d#\u001e\u001b8\n\u0001 '\u001f(/\u001e) \"\u001b3 \u001e#-\u001d,\u001f*\u001b(\u001d#\u001b- \u001d/\u001b(\u001e) &\u001b- '/\u001f-.,\u001b- -)( \u001b(\u001b&#4\u001b\u001e\u001b- *), &\u001b\u001c),\u001b.),#)- \u001e# \u001f,\u001f(.\u001f- ) -\u001f\n/.#&#4\u001b( 'ï.)\u001e)- \u001e#-.#(.)-8 \u0004\u001f\u001c#\u001e) \u001b +/\u001f \u001f&\n \n\u001b\u001d.), #(.,ù(-\u001f\u001d) \u001f- /.#&#4\u001b\u001e) \u001d)') *,).\u001fù(\u001b \u001e\u001f /(#ĉ(6\n&)- \u001b(.#\u001d/\u001f,*)- \u001b(.#7 \u001b\u001d.), #(.,ù(-\u001f\u001d) B&)- \u001d/\u001b&\u001f- -)( \u001d)'/(\u001f- \u001f( &\u001b \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001bC \u001e\u001f\u001c\u001f( -\u001f,\n,\u001f')0#\u001e)- +/ù'#\u001d\u001b'\u001f(.\u001f \u001e\u001f &\u001b '/\u001f-.,\u001b6 &) \u001d/\u001b& \"\u001b \u001e\u001f')-.,\u001b\u001e) -\u001f, *,)\u001c&\u001f'á.#\u001d) \u001f( &)- \u001b(á&#-#- \u001b/.)\n-\n\n'\u001b.#4\u001b\u001e)-8 \u0013\u001f \u001e\u001f\u001c\u001f \u001d)(-#\u001e\u001f,\u001b, .\u001b'\u001c#ï( +/\u001f &\u001b '\u001b3),ù\u001b \u001e\u001f &)- &\u001b\u001c),\u001b.),#)- ')\u001e\u001f,()- ,\u001f\u001b&#4\u001b( \u001f(-\u001b3)-\n\u001b/.)'\u001b.#4\u001b\u001e)- \u001e\u001f 0#.\u001b'#(\u001b \u0002gh \u001f( *&\u001b.\u001b ),'\u001b- /.#&#4\u001b\u001e\u001b- *\u001b,\u001b ).,)- \u001b(á&#-#-8\n\u0005-./\u001e#)- ,\u001f\u001d#\u001f(.\u001f- '/\u001f-.,\u001b( 0\u001b&),\u001f- (),'\u001b&\u001f- ) \u001b&-\u001b'\u001f(.\u001f \u001b&.)- \u001e\u001f 0#.\u001b'#(\u001b \u0002gh \u001f( '/\u001d\")- *\u001b\u001d#\u001f(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":86,"lines":{"from":70,"to":86}}}}],["352",{"pageContent":".\u001f- \u001d)( \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b8 \u0004\u001b\u001e\u001b- &\u001b- &#'#.\u001b\u001d#)(\u001f- \u001e\u001f &)- \u001f2á'\u001f(\u001f- \u001e#-*)(#\u001c&\u001f-6 &)- 'ï\u001e#\u001d)- () \u001e\u001f\u001c\u001f,ù\u001b(\n/.#&#4\u001b, \u001f& &ù'#.\u001f #( \u001f,#), \u001e\u001f& ,\u001b(!) (),'\u001b& +/\u001f ,\u001f*),.\u001b \u001f& &\u001b\u001c),\u001b.),#) *\u001b,\u001b \u001e\u001f-\u001d\u001b,.\u001b, \u001f& \u001e#\u001b!(ĉ-.#\u001d) \u001e\u001f\n\u001eïl·\u001d#. \u001e\u001f 0#.\u001b'#(\u001b \u0002gh \u001f( *\u001b\u001d#\u001f(.\u001f- \u001d)( \u001b(),'\u001b&#\u001e\u001b\u001e\u001f- \u001d&ù(#\u001d\u001b- \u001d)'*\u001b.#\u001c&\u001f-8\n \n)- 'ï\u001e#\u001d)- .\u001b'\u001c#ï( \u001e\u001f\n-\n\n\u001c\u001f( ,\u001f\u001d)()\u001d\u001f, +/\u001f &)- 0\u001b&),\u001f- \u001e\u001f 0#.\u001b'#(\u001b \u0002gh () (\u001f\u001d\u001f-\u001b,#\u001b'\u001f(.\u001f -\u001f \u001b-)\u001d#\u001b( \u001b \u001b(\u001f'#\u001b- '\u001f!\u001b&)\u001c&á-.#\u001d\u001b-6\n*/\u001e#\u001f(\u001e) \u001f(\u001d)(.,\u001b,-\u001f \u001c\u001b$)- \u001f( ).,)- *\u001b\u001d#\u001f(.\u001f- -#( \u001f0#\u001e\u001f(\u001d#\u001b '\u001f.\u001b\u001cĉ&#\u001d\u001b ) \u001d&ù(#\u001d\u001b \u001e\u001f 0#.\u001b'#(\u001b \u0002gh6 *),\n\u001f$\u001f'*&)6 &)- \u001b\u001e/&.)- '\u001b3),\u001f-8\n\nMEDICIÓN DE ÁCIDO METILMALÓNICO SÉRICO\nY HOMOCISTEÍNA TOTAL\n\n\u001b '\u001f\u001e#\u001d#ĉ( \u001e\u001f& á\u001d#\u001e) '\u001f.#&'\u001b&ĉ(#\u001d)6 &\u001b \")')\u001d#-.\u001fù(\u001b .).\u001b&6 ) \u001b'\u001c)-6 \u001f- Ě.#& *\u001b,\u001b \"\u001b\u001d\u001f, \u001f& \u001e#\u001b!(ĉ-.#\u001d)\n\u001e\u001f \u001eïl·\u001d#. \u001e\u001f 0#.\u001b'#(\u001b \u0002gh \u001f( *\u001b\u001d#\u001f(.\u001f- +/\u001f \u001bĚ( () \"\u001b( ,\u001f\u001d#\u001c#\u001e) .,\u001b.\u001b'#\u001f(.)8\n \n)- (#0\u001f&\u001f- \u001e\u001f á\u001d#\u001e) '\u001f.#&\n-\n\n'\u001b&ĉ(#\u001d) 3 \")')\u001d#-.\u001fù(\u001b .).\u001b& -)( ().),#\u001b'\u001f(.\u001f \u001f&\u001f0\u001b\u001e)- \u001f( &\u001b !,\u001b( '\u001b3),ù\u001b B̓onzC \u001e\u001f &)- *\u001b\u001d#\u001f(.\u001f- \u001d)(\n\nCuadro 4-5.\n \nCriterios diagnósticos del déficit de vitamina B12","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":86,"lines":{"from":88,"to":112}}}}],["353",{"pageContent":"'\u001b&ĉ(#\u001d) 3 \")')\u001d#-.\u001fù(\u001b .).\u001b& -)( ().),#\u001b'\u001f(.\u001f \u001f&\u001f0\u001b\u001e)- \u001f( &\u001b !,\u001b( '\u001b3),ù\u001b B̓onzC \u001e\u001f &)- *\u001b\u001d#\u001f(.\u001f- \u001d)(\n\nCuadro 4-5.\n \nCriterios diagnósticos del déficit de vitamina B12\n\nNiveles bajos de vitamina B12 en sangre\n(<200 pg/mL)\n \n\u0005( \u001e)- )\u001d\u001b-#)(\u001f- -\u001f*\u001b,\u001b\u001e\u001b-\n\nNiveles séricos elevados de homocisteína\n(> 13 μmol/L) o ácido metilmalónico\n(> 0,4 μmol/L) y una única determinación baja de\nvitamina B12 en plasma (< 200 pg/mL)\n\n\u0004\u001f-\u001d\u001b,.\u001b, \u001eï̑\u001d#.\n \n\u001e\u001f á\u001d#\u001e) ĉ&#\u001d) 3 0#.\u001b\n-\n\n'#(\u001b \u0002l ) #(-/̑\u001d#\u001f(\u001d#\u001b\n \n,\u001f(\u001b&","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":86,"lines":{"from":112,"to":135}}}}],["354",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n60\n\n\u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001d&ù(#\u001d\u001b \u001e\u001f 0#.\u001b'#(\u001b \u0002gh6 #(\u001d&/3\u001f(\u001e) \u001b+/\u001f&&)- +/\u001f -)&\u001b'\u001f(.\u001f .#\u001f(\u001f( '\u001b(# \u001f-.\u001b\u001d#)(\u001f- (\u001f/,)&ĉ\n-\n\n!#\u001d\u001b- -#( \u001b(\u001f'#\u001b8\n \n)- (#0\u001f&\u001f- \u001f&\u001f0\u001b\u001e)- \u001e\u001f á\u001d#\u001e) '\u001f.#&'\u001b&ĉ(#\u001d) 3 \")')\u001d#-.\u001fù(\u001b .).\u001b& \u001e#-'#(/3\u001f( #('\u001f\u001e#\u001b\n-\n\n.\u001b'\u001f(.\u001f \u001e\u001f-*/ï- \u001e\u001f& .,\u001b.\u001b'#\u001f(.) 3 */\u001f\u001e\u001f( '\u001f\u001e#,-\u001f (/\u001f0\u001b'\u001f(.\u001f *\u001b,\u001b \u001e)\u001d/'\u001f(.\u001b, \u001f& ,\u001f\u001f'*&\u001b4) \u001b\u001e\u001f\u001d/\u001b\u001e)\n\u001e\u001f 0#.\u001b'#(\u001b \u0002gh\n \n(cuadro 4-6)\n8\n)- (#0\u001f&\u001f- \u001e\u001f \u001f-.)- '\u001f.\u001b\u001c)&#.)- -)( (),'\u001b&\u001f- \u001f( \u001b& '\u001f()- \u001f& kfz \u001e\u001f &)- *\u001b\u001d#\u001f(.\u001f- \u001d)( (#0\u001f&\u001f- \u001c\u001b$)-\n\u001e\u001f 0#.\u001b'#(\u001b \u0002gh +/\u001f () ,\u001f-*)(\u001e\u001f( \"\u001f'\u001b.)&ĉ!#\u001d\u001b ) (\u001f/,)&ĉ!#\u001d\u001b'\u001f(.\u001f \u001b &\u001b .\u001f,\u001b*#\u001b \u001e\u001f ,\u001f\u001f'*&\u001b4)6 #(\u001e#\n-\n\n\u001d\u001b(\u001e) +/\u001f &)- 0\u001b&),\u001f- #( \u001f,#),\u001f- -)( ,\u001f-/&.\u001b\u001e)-\n \n\u001b&-)- *)-#.#0)-8 \u0004\u001b\u001e\u001b- &\u001b- &#'#.\u001b\u001d#)(\u001f- \u001e\u001f &\u001b- *,/\u001f\u001c\u001b-\n\u001e\u001f 0#.\u001b'#(\u001b \u0002gh *\u001b,\u001b \u001d)(l·,'\u001b, \u001f& \u001e#\u001b!(ĉ-.#\u001d) \u001e\u001f &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f 0#.\u001b'#(\u001b \u0002gh6 -\u001f,ù\u001b *,/\u001e\u001f(.\u001f '\u001f\u001e#,\n\u001f& á\u001d#\u001e) '\u001f.#&'\u001b&ĉ(#\u001d)6 &\u001b \")')\u001d#-.\u001fù(\u001b .).\u001b&6 ) \u001b'\u001c)-6 \u001f( *\u001b\u001d#\u001f(.\u001f- \u001d)( \"\u001b&&\u001b4!)- \u001d&ù(#\u001d)- \u001d)'*\u001b.#\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":87,"lines":{"from":1,"to":27}}}}],["355",{"pageContent":"\u001c&\u001f- ) \u001e\u001b, .,\u001b.\u001b'#\u001f(.) \u001f'*ù,#\u001d) \u001d)( \u001f& /-) \u001e\u001f &ù'#.\u001f- \u001e\u001fl·(#\u001e)- *\u001b,\u001b \u001e)\u001d/'\u001f(.\u001b, /(\u001b ,\u001f-*/\u001f-.\u001b \u001d&ù(#\u001d\u001b8\n\u0015( (#0\u001f& \u001f&\u001f0\u001b\u001e) \u001e\u001f á\u001d#\u001e) '\u001f.#&'\u001b&ĉ(#\u001d) \u001f- ,\u001b4)(\u001b\u001c&\u001f'\u001f(.\u001f \u001f-*\u001f\u001dùl·\u001d) *\u001b,\u001b \u001e#\u001b!()-.#\u001d\u001b, \u001eïl·\u001d#. \u001e\u001f\n0#.\u001b'#(\u001b \u0002gh 3 \u001f& (#0\u001f& -#\u001f'*,\u001f \u001e#-'#(/3\u001f \u001d)( \u001f& .,\u001b.\u001b'#\u001f(.) \u001d)( \u001f-.\u001b 0#.\u001b'#(\u001b8\n \n)- \u001b/'\u001f(.)- ')\u001e\u001f\n-\n\n,\u001b\u001e)- B\u001e\u001f iff \u001b mff̓(')&I\n \nC )\u001d/,,\u001f( \u001f( &\u001b #(-/l·\u001d#\u001f(\u001d#\u001b ,\u001f(\u001b&8 \u0013#( \u001f'\u001c\u001b,!)6 \u001d\u001b-# .)\u001e)- &)- *\u001b\u001d#\u001f(.\u001f-\n\u001d)( \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b ) '#\u001f&)*\u001b.ù\u001b .#\u001f(\u001f( (#0\u001f&\u001f- \u001e\u001f á\u001d#\u001e) '\u001f.#&'\u001b&ĉ(#\u001d) +/\u001f -)( '\u001b3),\u001f- \u001b\nkff̓(')&I\n \n6 3 \u001f( \u001f& nlz -)( '\u001b3),\u001f- \u001e\u001f g̓fff̓(')&I\n \n8\n \n\u0005& (#0\u001f& -ï,#\u001d) .).\u001b& \u001e\u001f \")')\u001d#-.\u001fù(\u001b \u001f- '\u001f()-\n\u001f-*\u001f\u001dùl·\u001d)6 3\u001b +/\u001f .\u001b'\u001c#ï( -\u001f \u001f(\u001d/\u001f(.,\u001b \u001f&\u001f0\u001b\u001e) \u001f( &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f\n \n)&\u001b.)6 &\u001b \")')\u001d#-.\u001f#(/,#\u001b \u001d&á-#\u001d\u001b\n3 &\u001b #(-/l·\u001d#\u001f(\u001d#\u001b ,\u001f(\u001b&8\n\nEXÁMENES PARA DETERMINAR LA CAUSA DEL DÉFICIT\nDE VITAMINA B12\n\n\u0013# \u001f& *\u001b\u001d#\u001f(.\u001f #(!#\u001f,\u001f \u001d\u001b(.#\u001e\u001b\u001e\u001f- -/l·\u001d#\u001f(.\u001f- \u001e\u001f 0#.\u001b'#(\u001b \u0002gh 3 -\u001f &\u001f \"\u001b \u001d)(l·,'\u001b\u001e) \u001d&ù(#\u001d\u001b'\u001f(.\u001f &\u001b \u001e\u001fl·\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":87,"lines":{"from":29,"to":56}}}}],["356",{"pageContent":"EXÁMENES PARA DETERMINAR LA CAUSA DEL DÉFICIT\nDE VITAMINA B12\n\n\u0013# \u001f& *\u001b\u001d#\u001f(.\u001f #(!#\u001f,\u001f \u001d\u001b(.#\u001e\u001b\u001e\u001f- -/l·\u001d#\u001f(.\u001f- \u001e\u001f 0#.\u001b'#(\u001b \u0002gh 3 -\u001f &\u001f \"\u001b \u001d)(l·,'\u001b\u001e) \u001d&ù(#\u001d\u001b'\u001f(.\u001f &\u001b \u001e\u001fl·\n-\n\n\u001d#\u001f(\u001d#\u001b \u001e\u001f \u001f-.\u001f (/.,#'\u001f(.)6 \u001f(.)(\u001d\u001f- \u001e\u001f\u001c\u001f( \u001f2#-.#, *,)\u001c&\u001f'\u001b- \u001f( &\u001b \u001b\u001c-),\u001d#ĉ( #(.\u001f-.#(\u001b&8 \u0015( #( ),'\u001f *)\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":87,"lines":{"from":56,"to":63}}}}],["357",{"pageContent":"-#.#0) *\u001b,\u001b \u001b(.#\u001d/\u001f,*)- \u001b(.#7 \u001b\u001d.), #(.,ù(-\u001f\u001d) ) \u001b(.#7\u001dï&/&\u001b- *\u001b,#\u001f.\u001b&\u001f- \u001f- #(\u001e#\u001d\u001b.#0) \u001e\u001f \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b8\n\u001b 0#!#&\u001b(\u001d#\u001b *\u001b,\u001b \u001f( \u001f,'\u001f\u001e\u001b\u001e .#,)#\u001e\u001f\u001b \u001b/.)#('/(#.\u001b,#\u001b \u001f- ,\u001b4)(\u001b\u001c&\u001f \u001f( *\u001b\u001d#\u001f(.\u001f- +/\u001f .#\u001f(\u001f( \u001b(.#\u001d/\u001f,*)-\n*)-#.#0)-8\n \n\u001b !\u001b-.,#.#- \u001d,ĉ(#\u001d\u001b \u001b.,ĉl·\u001d\u001b */\u001f\u001e\u001f -\u001f, \u001e#\u001b!()-.#\u001d\u001b\u001e\u001b \u001d)( (#0\u001f&\u001f- -ï,#\u001d)- \u001f&\u001f0\u001b\u001e)- \u001e\u001f !\u001b-.,#(\u001b\n\u001f( \u001b3/() 3 (#0\u001f&\u001f- \u001c\u001b$)- \u001e\u001f *\u001f*-#(ĉ!\u001f() -ï,#\u001d)-8 \u0001&!/()- \u001f2*\u001f,.)- ,\u001f\u001d)'#\u001f(\u001e\u001b( ,\u001f\u001b&#4\u001b, /(\u001b \u001f(\u001e)-\u001d)*#\u001b\n*\u001b,\u001b \u001d)(l·,'\u001b, ) \u001e\u001f-\u001d\u001b,.\u001b, \u001d\u001b,\u001d#()'\u001b !á-.,#\u001d) / ).,) .#*) \u001e\u001f \u001dá(\u001d\u001f, \u001e\u001f \u001f-.ĉ'\u001b!)6 \u001e\u001f\u001c#\u001e) \u001b +/\u001f \u001f& ,#\u001f-!)\n\u001e\u001f *,\u001f-\u001f(.\u001b, \u001f-.\u001f .#*) \u001e\u001f (\u001f)*&\u001b-#\u001b- \u001f- '\u001b3), \u001f( *\u001b\u001d#\u001f(.\u001f- \u001d)( \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b8\n\u0004/,\u001b(.\u001f \u001bĄ)-6 \u001b&!/()- \u001d\u001f(.,)- /.#&#4\u001b\u001c\u001b( &\u001b *,/\u001f\u001c\u001b \u001e\u001f \u0013\u001d\"#&&#(!6 +/\u001f \u001d)(-#-.ù\u001b \u001f( &\u001b \u001b\u001e'#(#-.,\u001b\u001d#ĉ( ),\u001b&\n\u001e\u001f \u001d#\u001b()\u001d)\u001c\u001b&\u001b'#(\u001b '\u001b,\u001d\u001b\u001e\u001b \u001d)( \u001d)\u001c\u001b&.) lf6 &\u001b \u001d/\u001b& -\u001f \u001b\u001e'#(#-.,\u001b \u001e\u001f-*/ï- \u001e\u001f -\u001b./,\u001b, \u001b& ),!\u001b(#-') \u001d)(\ng̓ fff̓'! \u001e\u001f 0#.\u001b'#(\u001b \u0002gh () '\u001b,\u001d\u001b\u001e\u001b 3 \u001b*&#\u001d\u001b\u001e\u001b *), 0ù\u001b #(.,\u001b'/-\u001d/&\u001b,8 \u0013\u001f '\u001f\u001eù\u001b &\u001b 0#.\u001b'#(\u001b \u0002gh \u001f&#'#(\u001b\u001e\u001b","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":87,"lines":{"from":65,"to":75}}}}],["358",{"pageContent":"g̓ fff̓'! \u001e\u001f 0#.\u001b'#(\u001b \u0002gh () '\u001b,\u001d\u001b\u001e\u001b 3 \u001b*&#\u001d\u001b\u001e\u001b *), 0ù\u001b #(.,\u001b'/-\u001d/&\u001b,8 \u0013\u001f '\u001f\u001eù\u001b &\u001b 0#.\u001b'#(\u001b \u0002gh \u001f&#'#(\u001b\u001e\u001b\n*), &\u001b ),#(\u001b \u001f( &\u001b- *,#'\u001f,\u001b- hj \"),\u001b- *)-.\u001f,#),\u001f- \u001b &\u001b \u001b\u001e'#(#-.,\u001b\u001d#ĉ( \u001e\u001f \u0002gh '\u001b,\u001d\u001b\u001e\u001b6 3 +/\u001f \u001f( \u001d)(\u001e#\u001d#)(\u001f-\n(),'\u001b&\u001f- \u001e\u001f\u001c\u001f -\u001f, '\u001b3), \u001b nz \u001e\u001f &\u001b \u001e)-#- \u001b\u001e'#(#-.,\u001b\u001e\u001b8 \u0005-.\u001b *,/\u001f\u001c\u001b \u001e\u001f \u001b\u001c-),\u001d#ĉ( ,\u001b\u001e#)\u001b\u001d.#0\u001b \u001e\u001f 0#.\u001b'#(\u001b\n\u0002gh 3\u001b () -\u001f \u001f(\u001d/\u001f(.,\u001b \u001e#-*)(#\u001c&\u001f8 \u0004\u001f &)- hk \u001d\u001b-)- \u001e\u001f.\u001f\u001d.\u001b\u001e)- \u001f( \u0010/\u001f\u001c&\u001b \u001d)') \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b6 \u001b (#(!/()","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":87,"lines":{"from":75,"to":78}}}}],["359",{"pageContent":"Durante años, algunos cen-\ntros utilizaban la prueba de\nSchilling, que consistía en la\nadministración oral de ciano-\ncobalamina marcada con co-\nbalto 60, la cual se administra\ndespués de saturar al organis-\nmo con 1 000 mg de vitamina\nB12 no marcada y aplicada\npor vía intramuscular.\n\nCuadro 4-6.\n \nCausas de elevación sérica de ácido metilmalónico y homocisteína\n\nAlteración\n \nCausas\n\n\u0005&\u001f0\u001b\u001d#ĉ( \u001e\u001f á\u001d#\u001e) '\u001f.#&'\u001b&ĉ(#\u001d)\n\u0004ï̑\u001d#.\n \n\u001e\u001f 0#.\u001b'#(\u001b \u0002g\n(-/l·\u001d#\u001f(\u001d#\u001b ,\u001f(\u001b&\n\b#*)0)&\u001f'#\u001b\n\u0004\u001f \u001f\u001d.) '\u001f.\u001b\u001cĉ&#\u001d) \u001d)(!ï(#.)\n\u0005&\u001f0\u001b\u001d#ĉ( \u001e\u001f \")')\u001d#-.\u001fù(\u001b\n\u0004ïl·\u001d#. \u001e\u001f 0#.\u001b'#(\u001b \u0002gh\n\u0004ïl·\u001d#. \u001e\u001f á\u001d#\u001e) ĉ&#\u001d)\n\u0004ïl·\u001d#. \u001e\u001f 0#.\u001b'#(\u001b \u0002l\n(-/l·\u001d#\u001f(\u001d#\u001b ,\u001f(\u001b&\n\b#*)0)&\u001f'#\u001b\n\b#*).#,)#\u001e#-')\n\u0010-),#\u001b-#-\n\u0004\u001f \u001f\u001d.) '\u001f.\u001b\u001cĉ&#\u001d) \u001d)(!ï(#.)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":87,"lines":{"from":80,"to":114}}}}],["360",{"pageContent":"CAPÍTULO 4. ANEMIAS MEGALOBLÁSTICAS\n\n61\n\n-\u001f &\u001f *,\u001b\u001d.#\u001dĉ *,/\u001f\u001c\u001b \u001e\u001f \u0013\u001d\"#&&#(!8 \u0013\u001f \u001f(\u001d/\u001f(.,\u001b \u001f( \u001e\u001f-\u001b,,)&&) /( *).\u001f(\u001d#\u001b& ,\u001f\u001f'*&\u001b4) \u001e\u001f \u001f-.\u001b *,/\u001f\u001c\u001b6 \u001d)( /(\u001b\n')\u001e\u001f-.\u001b '\u001f$),ù\u001b \u001f( \u001f-*\u001f\u001d#l·\u001d#\u001e\u001b\u001e \u001f( ,\u001f&\u001b\u001d#ĉ( \u001d)( &)- \u001b(á&#-#- \u001e\u001f 0#.\u001b'#(\u001b \u0002gh .).\u001b& -ï,#\u001d\u001b8\n \n\u001b *,/\u001f\u001c\u001b '#\u001e\u001f \u001f&\n\u001b/'\u001f(.) \u001f( &\u001b -\u001b./,\u001b\u001d#ĉ( \u001e\u001f 0#.\u001b'#(\u001b \u0002gh \u001f( &\u001b \")&).,\u001b(-\u001d)\u001c\u001b&\u001b'#(\u001b \u001e\u001f-*/ï- \u001e\u001f 0\u001b,#)- \u001eù\u001b- \u001e\u001f \"\u001b\u001c\u001f, \u001b\u001e'#\n-\n\n(#-.,\u001b\u001e) /(\u001b \u001d\u001b,!\u001b ),\u001b& \u001e\u001f \u0002gh6 *\u001f,) () \"\u001b -#\u001e) 0\u001b&#\u001e\u001b\u001e\u001b \u001d&ù(#\u001d\u001b'\u001f(.\u001f 3 () \u001f-.á \u001e#-*)(#\u001c&\u001f \u001d)'\u001f,\u001d#\u001b&'\u001f(.\u001f6\n\u001b/( \u001f( *\u001bù-\u001f- \u001d)') &)- \u0005-.\u001b\u001e)- \u0015(#\u001e)-8\n\u0014\u001b'\u001c#ï( -\u001f \u001e\u001f\u001c\u001f #(0\u001f-.#!\u001b, &\u001b *,\u001f-\u001f(\u001d#\u001b \u001e\u001f \u001b\u001d#\u001e/,#\u001b '\u001f.#&'\u001b&ĉ(#\u001d\u001b8 \u0015(\u001b \u001f&#'#(\u001b\u001d#ĉ( '\u001b3), \u001e\u001f\niff̓'! \u001b& \u001eù\u001b *\u001f,'#.#,á -)-*\u001f\u001d\"\u001b, +/\u001f \u001f2#-.\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \u001d)\u001c\u001b&\u001b'#(\u001b8 \u0005( *\u001b\u001d#\u001f(.\u001f- \u001d)( \u001e\u001fl·\u001d#\u001f(\u001d#\u001b\n\u001e\u001f )&\u001b.)6 \u001e\u001f\u001c\u001f \u001f \u001f\u001d./\u001b,-\u001f &\u001b '\u001f\u001e#\u001d#ĉ( \u001e\u001f á\u001d#\u001e) ),'#'#()!&/.\u001b'ù(#\u001d) B\u0006 \u0007\n \n\u0015C \u001f( ),#(\u001b6 *,\u001f0#\u001b \u001b\u001e'#\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":88,"lines":{"from":1,"to":19}}}}],["361",{"pageContent":"(#-.,\u001b\u001d#ĉ( \u001e\u001f\n \n7\"#-.#\u001e#(\u001b Bgff \u001b iff̓'!I%!C8 \u0005-.\u001f \u001f-./\u001e#) \u001f-.á *,)-\u001d,#.) \u001f( *\u001b\u001d#\u001f(.\u001f- \u001d)( #(-/l·\u001d#\u001f(\u001d#\u001b\n\"\u001f*á.#\u001d\u001b6 3\u001b +/\u001f */\u001f\u001e\u001f \u001e\u001f-\u001f(\u001d\u001b\u001e\u001f(\u001b, \u001f& \u001d)'\u001b \"\u001f*á.#\u001d)6 *\u001f,) \u001f- ,\u001f\u001d)'\u001f(\u001e\u001b\u001c&\u001f \u001f( \u001f( \u001f,')- \u001d)( \u001e\u001fl·\u001d#\u001f(\n-\n\n\u001d#\u001b (/.,#\u001d#)(\u001b& ) \u001d)( *,)\u001c&\u001f'\u001b- \u001e\u001f \u001b\u001c-),\u001d#ĉ( #(.\u001f-.#(\u001b&8 \u0005- *)\u001d) Ě.#& \u001f( \u001f'\u001c\u001b,\u001b4\u001b\u001e\u001b- 36 \u001f( !\u001f(\u001f,\u001b&6 \u001f(\n.)\u001e)- &)- *\u001b\u001d#\u001f(.\u001f- +/\u001f \u001e\u001f-\u001b,,)&&\u001b( /( \u001f-.\u001b\u001e) \"#*\u001f,\u001d\u001b.\u001b\u001cĉ&#\u001d)8\n\u0005( &\u001b \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b6 \u001f- (\u001f\u001d\u001f-\u001b,#) ,\u001f\u001b&#4\u001b, \u001f-./\u001e#)- \u001e\u001f& $/!) !á-.,#\u001d) \u001c\u001b$) \u001f-.ù'/&) \u001e\u001f \"#-.\u001b'#(\u001b\n\u001f #(0\u001f-.#!\u001b, &\u001b *,\u001f-\u001f(\u001d#\u001b \u001e\u001f \u001b(.#\u001d/\u001f,*)- \u001b(.#'/\u001d)-\u001b 3 \u001f-*\u001f\u001d#\u001b&'\u001f(.\u001f &)- \u001b(.#\u001d/\u001f,*)- \u001b(.#7\u0006\n \n3 \u001b(.#7\u001d)'\n-\n\n*&\u001f$) \u0006 ̓ ̓ \u0002gh8\n \n\u001b \u001f2*&),\u001b\u001d#ĉ( \u001f(\u001e)-\u001dĉ*#\u001d\u001b \u001b&.\u001b \u001f- )\u001c&#!\u001b.),#\u001b \u001d)( \u001f& á(#') \u001e\u001f #(0\u001f-.#!\u001b, *\u001b.)&)!ù\u001b\n\u001e#!\u001f-.#0\u001b8 \u000e) \"\u001b3 +/\u001f )&0#\u001e\u001b, +/\u001f &\u001b \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b *,\u001f\u001e#-*)(\u001f \u001b& \u001e\u001f-\u001b,,)&&) \u001e\u001f \u001dá(\u001d\u001f, !á-.,#\u001d)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":88,"lines":{"from":21,"to":38}}}}],["362",{"pageContent":"(cuadro 4-7)\n8\n\u0004\u001f &)- hk \u001d\u001b-)- \u001e\u001f \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b \u001e\u001f &\u001b \u001d\u001b-/ù-.#\u001d\u001b *)\u001c&\u001b(\u001b6 -\u001f#-\n \n/\u001f,)( -)'\u001f.#\u001e)- \u001b \u001f2*&),\u001b\u001d#ĉ(\n\u001f(\u001e)-\u001dĉ*#\u001d\u001b 3 \u001f( .)\u001e)- \u001f&&)- -\u001f \u001f(\u001d)(.,ĉ \u001b.,)l·\u001b !á-.,#\u001d\u001b8 \u0003/\u001b(\u001e) &)- \u001f( \u001f,')- '\u001b(#l·\u001f-.\u001f( -ù(.)'\u001b-\n+/\u001f -/!#\u001f,\u001b( \u001b\u001c-),\u001d#ĉ( #(.\u001f-.#(\u001b& \u001e\u001fl·\u001d#\u001f(.\u001f6 3\u001b -\u001f\u001b *), \u001f( \u001f,'\u001f\u001e\u001b\u001e *,#'\u001b,#\u001b \u001e\u001f& ./\u001c) \u001e#!\u001f-.#0) ) *),\n,\u001f-\u001f\u001d\u001d#ĉ( !á-.,#\u001d\u001b ) #(.\u001f-.#(\u001b&6 -\u001f \"\u001b,á( &)- \u001f-./\u001e#)- ,\u001b\u001e#)&ĉ!#\u001d)- \u001b\u001e\u001f\u001d/\u001b\u001e)-6 \u001b-ù \u001d)') &\u001b '\u001f\u001e#\u001d#ĉ(\n\u001e\u001f !,\u001b-\u001b- \u001f( \"\u001f\u001d\u001f-6 &\u001b *,/\u001f\u001c\u001b \u001e\u001f \u001b\u001c-),\u001d#ĉ( \u001b &\u001b \u000472#&)-\u001b B\u001f-.)- \u001e)- Ě&.#')- \u001f-./\u001e#)- () -\u001f ,\u001f\u001b&#4\u001b(\n,/.#(\u001b,#\u001b'\u001f(.\u001fC8\n\u001b \u001c#)*-#\u001b *), \u001b-*#,\u001b\u001d#ĉ( \u001e\u001f 'ï\u001e/&\u001b ĉ-\u001f\u001b () \u001f- #(\u001e#-*\u001f(-\u001b\u001c&\u001f *\u001b,\u001b \u001f-.\u001b\u001c&\u001f\u001d\u001f, \u001f& \u001e#\u001b!(ĉ-.#\u001d) \u001e\u001f \u001b(\u001f\n-\n\n'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8 \u00052#-.\u001f( \u001d\u001b-)- \u001e\u001f *\u001b(\u001d#.)*\u001f(#\u001b !,\u001b0\u001f \u001d)( \"#*\u001f,\u001d\u001f&/&\u001b,#\u001e\u001b\u001e6 (),')\u001c&\u001b-.)- \u001b/'\u001f(.\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":88,"lines":{"from":40,"to":54}}}}],["363",{"pageContent":"'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8 \u00052#-.\u001f( \u001d\u001b-)- \u001e\u001f *\u001b(\u001d#.)*\u001f(#\u001b !,\u001b0\u001f \u001d)( \"#*\u001f,\u001d\u001f&/&\u001b,#\u001e\u001b\u001e6 (),')\u001c&\u001b-.)- \u001b/'\u001f(.\u001b\n-\n\n\u001e)- 3 \u001b(),'\u001b&#\u001e\u001b\u001e\u001f- \u001d#.)!\u001f(ï.#\u001d\u001b-6 3 */\u001f\u001e\u001f( -\u001f, \u001f,,ĉ(\u001f\u001b'\u001f(.\u001f \u001e#\u001b!()-.#\u001d\u001b\u001e\u001b- \u001d)') &\u001f/\u001d\u001f'#\u001b- \u001b!/\u001e\u001b-8\n)- \u001f-./\u001e#)- \u001e\u001f #'\u001b!\u001f( \u001e\u001f 'ï\u001e/&\u001b \u001f-*#(\u001b& () \u001f-.á( #(\u001e#\u001d\u001b\u001e)- \u001f( *\u001b\u001d#\u001f(.\u001f- \u001d)( \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f 0#.\u001b'#(\u001b\n\u0002gh6 *\u001f,) \u001f( \u001d\u001b-)- \u001e\u001f '#\u001f&)*\u001b.ù\u001b !,\u001b0\u001f +/\u001f () -)( ,\u001f\u001d)()\u001d#\u001e)- #(#\u001d#\u001b&'\u001f(.\u001f \u001d)') ,\u001f-/&.\u001b\u001e) \u001e\u001f &\u001b \u001e\u001fl·\u001d#\u001f(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":88,"lines":{"from":54,"to":60}}}}],["364",{"pageContent":"\u001d#\u001b \u001e\u001f 0#.\u001b'#(\u001b \u0002gh6 -\u001f \u001f(\u001d/\u001f(.,\u001b \"#*\u001f,#(.\u001f(-#\u001e\u001b\u001e \u001f( &\u001b ,\u001f-)(\u001b(\u001d#\u001b6 \u001e\u001f-\u001d,#.\u001b \u001d)') *\u001b.,ĉ( \u001e\u001f ^\u0016_ #(0\u001f,.#\u001e\u001b\n\u001b (#0\u001f& \u001d\u001f,0#\u001d\u001b& 3 .),á\u001d#\u001d) \u001e\u001f &\u001b 'ï\u001e/&\u001b \u001f-*#(\u001b&8\n\u0005( *\u001b\u001d#\u001f(.\u001f- \u001d)( \u001b(.\u001f\u001d\u001f\u001e\u001f(.\u001f- \u001e\u001f '\u001b&\u001b \u001b&#'\u001f(.\u001b\u001d#ĉ( ) \"\u001f'),,\u001b!#\u001b6 \u001e\u001f\u001c\u001f #(0\u001f-.#!\u001b,-\u001f &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f\n\"#\u001f,,)8\n \n\u001b \u001e)-#l·\u001d\u001b\u001d#ĉ( \u001e\u001f \"#\u001f,,) -ï,#\u001d) \u001f( &)- -/$\u001f.)- \u001d)( \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b \u001f- \u001b&.\u001b B#(\u001d&/3\u001f(\u001e) \u001b +/#\u001f(\u001f-\n\u001f( 0\u001f,\u001e\u001b\u001e -)( (),'\u001b&\u001f- *\u001b,\u001b \u001f& '\u001f.\u001b\u001c)&#-') \u001e\u001f \u001f-\u001f '\u001f.\u001b&C6 *\u001f,) /(\u001b 0\u001f4 #(#\u001d#\u001b\u001e) \u001f& .,\u001b.\u001b'#\u001f(.) 3 +/\u001f -\u001f \"\u001b\n)\u001c-\u001f,0\u001b\u001e) &\u001b \u001e\u001f-\u001b*\u001b,#\u001d#ĉ( \u001e\u001f &)- \u001d\u001b'\u001c#)- '\u001f!\u001b&)\u001c&á-.#\u001d)- 3 &\u001b \u001f&\u001f0\u001b\u001d#ĉ( \u001e\u001f &\u001b \"\u001f')!&)\u001c#(\u001b6 \u001f- \u001d/\u001b(\u001e) -\u001f \"\u001b\u001d\u001f\n\u001f0#\u001e\u001f(.\u001f &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,) B,\u001f\u001e/\u001d\u001d#ĉ( \u001e\u001f& \"#\u001f,,) -ï,#\u001d) 3 \u001b*\u001b,#\u001d#ĉ( \u001e\u001f \"#*)\u001d,)'ù\u001b \u001f( &)- \u001f,#.,)\u001d#.)-C8\n)- -ù(\u001e,)'\u001f- '#\u001f&)\u001e#-*&á-#\u001d)- -)( \u001f( \u001f,'\u001f\u001e\u001b\u001e\u001f- \"\u001f'á.#\u001d\u001b- +/\u001f \u001f0\u001f(./\u001b&'\u001f(.\u001f */\u001f\u001e\u001f( -\u001f, \u001d)( /(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":88,"lines":{"from":62,"to":72}}}}],["365",{"pageContent":"\u001e#\u001e\u001b- \u001d)( \u001b(\u001f'#\u001b- '\u001f!\u001b&)\u001c&á-.#\u001d\u001b-8 \u0005( \u001b'\u001c\u001b- *\u001b.)&)!ù\u001b- \u001f2#-.\u001f \u001b(\u001f'#\u001b6 */\u001e#\u001f(\u001e) &&\u001f!\u001b, \u001b \u001d/\u001b\u001e,)- \u001e\u001f\n*\u001b(\u001d#.)*\u001f(#\u001b8 \u0010), &) !\u001f(\u001f,\u001b& \u001f( \u001f& -ù(\u001e,)'\u001f '#\u001f&)\u001e#-*&á-#\u001d) &\u001b 'ï\u001e/&\u001b ĉ-\u001f\u001b \u001f- \"#*\u001f,\u001d\u001f&/&\u001b,6 \u001d)( \u001d\u001b'\u001c#)-\n\u001e#-*&á-#\u001d)- \u001f( &\u001b- .,\u001f- -\u001f,#\u001f-6 3 !\u001f(\u001f,\u001b&'\u001f(.\u001f *,\u001f-\u001f(.\u001b( \u001e#-'#(/\u001d#ĉ( \u001e\u001f &)- '\u001f!\u001b\u001d\u001b,#)\u001d#.)-8 \u0005( \u001b&!/(\u001b-\n)\u001d\u001b-#)(\u001f- */\u001f\u001e\u001f -\u001f, (\u001f\u001d\u001f-\u001b,#) ,\u001f\u001b&#4\u001b, \u001f-./\u001e#)- \u001d)( #('/()\"#-.)+/ù'#\u001d\u001b *\u001b,\u001b \u001e# \u001f,\u001f(\u001d#\u001b, *&\u001f(\u001b'\u001f(.\u001f \u001f(\n-\n\n.,\u001f /( -ù(\u001e,)'\u001f '#\u001f&)\u001e#-*&á-#\u001d) 3 /(\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8\n\nCuadro 4-7.\n \nProcesos gástricos asociados en 36 pacientes peruanos\n\nHallazgos endoscópicos\n \nNº pacientes\n \nPorcentaje\n\n\u0007\u001b-.,#.#- \u001d,ĉ(#\u001d\u001b \u001b.,ĉ̑\u001d\u001b\n \nhh\n \nlg6g\nÒ&\u001d\u001f,\u001b !\u001b-.,)\u001e/)\u001e\u001f(\u001b&\n \nn\n \nhh6h\n\u0007\u001b-.,#.#- \u001d,ĉ(#\u001d\u001b \u001d)( '\u001f.\u001b*&\u001b-#\u001b #(.\u001f-.#(\u001b&\n \nj\n \ngg6g\n\u0003á(\u001d\u001f, !á-.,#\u001d)\n \nh\n \nk6l","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":88,"lines":{"from":74,"to":111}}}}],["366",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n62\n\nTRATAMIENTO\n\n\u0015( .,\u001b.\u001b'#\u001f(.) \u001f2#.)-) \u001e\u001f*\u001f(\u001e\u001f \u001e\u001f &\u001b #\u001e\u001f(.#l·\u001d\u001b\u001d#ĉ( \u001e\u001f& '\u001f\u001d\u001b(#-') \u001f.#)*\u001b.)!ï(#\u001d)8 \u0005( \u001f& \u001d\u001b-) \u001e\u001f &\u001b-\n\u001b(\u001f'#\u001b- '\u001f!\u001b&)\u001c&á-.#\u001d\u001b- *), \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f 0#.\u001b'#(\u001b \u0002gh6 &)- *\u001b\u001d#\u001f(.\u001f- ,\u001f\u001d#\u001c#,á( *), 0ù\u001b *\u001b,\u001f(.\u001f,\u001b& &\u001b 0#.\u001b\n-\n\n'#(\u001b \u0002gh6 \u001f( 0#,./\u001e \u001e\u001f +/\u001f &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \u001f-.\u001b 0#.\u001b'#(\u001b -\u001f \u001e\u001f\u001c\u001f \u001d\u001b-# -#\u001f'*,\u001f \u001b /( \u001e\u001f \u001f\u001d.) \u001e\u001f \u001b\u001c-),\u001d#ĉ(8\n\u0005& .,\u001b.\u001b'#\u001f(.) \u001b\u001e\u001f\u001d/\u001b\u001e) ,\u001f-)&0\u001f,á &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b 3 '\u001f$),á &\u001b '#\u001f&)*\u001b.ù\u001b8\n\u00052#-.\u001f( 0\u001b,#)- \u001f-+/\u001f'\u001b- ,\u001f\u001d)'\u001f(\u001e\u001b\u001e)- *\u001b,\u001b \u001b*&#\u001d\u001b\u001d#)(\u001f- #(.,\u001b'/-\u001d/&\u001b,\u001f- \u001e\u001f 0#.\u001b'#(\u001b \u0002gh8 \u0003\u001f,\u001d\u001b \u001e\u001f&\ngfz \u001e\u001f &\u001b \u001e)-#- #(3\u001f\u001d.\u001b\u001e\u001b -\u001f ,\u001f.#\u001f(\u001f Bgff \u001e\u001f g̓ fff̓'!C8\n \n)- \u001f( \u001f,')- \u001d)( \u001b(),'\u001b&#\u001e\u001b\u001e\u001f- !,\u001b0\u001f- \u001e\u001f\u001c\u001f(\n,\u001f\u001d#\u001c#, #(3\u001f\u001d\u001d#)(\u001f- \u001e\u001f g̓ fff̓'! *), &) '\u001f()- 0\u001b,#\u001b- 0\u001f\u001d\u001f- \u001b &\u001b -\u001f'\u001b(\u001b6 *), g ) h -\u001f'\u001b(\u001b-8 \u0010)-.\u001f,#),'\u001f(.\u001f\n-\u001f \u001b\u001e'#(#-.,\u001b /(\u001b \u001e)-#- -\u001f'\u001b(\u001b& \"\u001b-.\u001b +/\u001f -\u001f 0\u001f\u001b '\u001f$),ù\u001b\n \n,\u001b(\u001d\u001b6 -\u001f!/#\u001e) \u001e\u001f \u001b*&#\u001d\u001b\u001d#)(\u001f- '\u001f(-/\u001b&\u001f-8\n \n\u001b\n,\u001f-*/\u001f-.\u001b \"\u001f'á.#\u001d\u001b \u001f- ,á*#\u001e\u001b6 \u001d)( #(\u001d,\u001f'\u001f(.) \u001e\u001f ,\u001f.#\u001d/&)\u001d#.)- \u001b &\u001b -\u001f'\u001b(\u001b 3 \u001d),,\u001f\u001d\u001d#ĉ( \u001e\u001f &\u001b \u001b(\u001f'#\u001b '\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":89,"lines":{"from":1,"to":24}}}}],["367",{"pageContent":"!\u001b&)\u001c&á-.#\u001d\u001b \u001f( l \u001b n̓-\u001f'\u001b(\u001b-8\n)- -ù(.)'\u001b- (\u001f/,)&ĉ!#\u001d)- */\u001f\u001e\u001f( \u001f'*\u001f),\u001b, .,\u001b(-#.),#\u001b'\u001f(.\u001f 3 *\u001f,-#-.#, *), -\u001f'\u001b(\u001b- ) '\u001f-\u001f-8\n \n\u001b\n!,\u001b0\u001f\u001e\u001b\u001e 3 &\u001b \u001e/,\u001b\u001d#ĉ( \u001e\u001f &\u001b- \u001b(),'\u001b&#\u001e\u001b\u001e\u001f- (\u001f/,)&ĉ!#\u001d\u001b- *,\u001f0#) \u001b& .,\u001b.\u001b'#\u001f(.) #(ł/3\u001f( \u001f( \u001f& !,\u001b\u001e)\n\u001e\u001f &\u001b ,\u001f\u001d/*\u001f,\u001b\u001d#ĉ(8 \u0005& .,\u001b.\u001b'#\u001f(.) \u001e\u001f &\u001b \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b \u001f- *\u001b,\u001b .)\u001e\u001b &\u001b 0#\u001e\u001b8 \u0003/\u001b(\u001e) -\u001f ,\u001f.#,\u001b &\u001b -/\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":89,"lines":{"from":26,"to":32}}}}],["368",{"pageContent":"*&\u001f'\u001f(.\u001b\u001d#ĉ( \u001e\u001f-*/ï- \u001e\u001f /(\u001b ,\u001f\u001d/*\u001f,\u001b\u001d#ĉ( \u001d&ù(#\u001d\u001b6 &)- -ù(.)'\u001b- (\u001f/,)&ĉ!#\u001d)- ,\u001f\u001b*\u001b,\u001f\u001d\u001f( \u001f( /( *\u001f,ù)\u001e)\n\u001d),.)6 \u001e\u001f l '\u001f-\u001f-6 '#\u001f(.,\u001b- +/\u001f &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b -\u001f *,\u001f-\u001f(.\u001b 0\u001b,#)- \u001bĄ)- \u001e\u001f-*/ï-8\n\u001b- \u001e)-#- \u001b&.\u001b- \u001e\u001f 0#.\u001b'#(\u001b \u0002gh *), 0ù\u001b ),\u001b& -)( #'*,\u001f-#)(\u001b(.\u001f'\u001f(.\u001f *)*/&\u001b,\u001f-8 \b\u001b\u001d\u001f jk \u001bĄ)- /(\n\u001f-./\u001e#) \u001e\u001f')-.,ĉ +/\u001f \u001e\u001f& f6k \u001b& jz \u001e\u001f &\u001b 0#.\u001b'#(\u001b \u0002gh '\u001b,\u001d\u001b\u001e\u001b \u001d)( #-ĉ.)*) ,\u001b\u001e#)\u001b\u001d.#0) *)\u001eù\u001b \u001b\u001c-),\u001c\u001f,-\u001f\n*), \u001e# /-#ĉ( *\u001b-#0\u001b6 .\u001b(.) \u001f( \u001d)(.,)&\u001f- \u001d)') \u001f( *\u001b\u001d#\u001f(.\u001f- \u001d)( \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b8 \u0010), &) .\u001b(.)6 &\u001b- \u001e)-#-\n\u001b&.\u001b- \u001e\u001f g̓fff̓'! *),\n \n0ù\u001b ),\u001b& *,)*),\u001d#)(\u001b( \u001e\u001f k \u001b jf̓'!6 \u001b/(+/\u001f -\u001f .)'\u001f( \u001d)( &)- \u001b&#'\u001f(.)-8\n\u0005( \u001d\u001b'\u001c#)6 \u001f& .,\u001b.\u001b'#\u001f(.) \u001e\u001f &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f )&\u001b.)- */\u001f\u001e\u001f \"\u001b\u001d\u001f,-\u001f *), 0ù\u001b ),\u001b&6 3\u001b +/\u001f \u001d\u001b-# (/(\u001d\u001b \"\u001b3\n\u001e\u001f \u001f\u001d.) \u001e\u001f \u001b\u001c-),\u001d#ĉ( \u001e\u001f \u001f-.\u001b 0#.\u001b'#(\u001b8\n \n\u001b- \u001e)-#- \u001e\u001f \u001d)\u001c\u001b&\u001b'#(\u001b B\u001d#\u001b()\u001d)\u001c\u001b&\u001b'#(\u001b ) \"#\u001e,)2#\u001d)\u001c\u001b&\u001b'#(\u001bC\n\u001e\u001f h \u001b k̓ '! -)( -/l·\u001d#\u001f(.\u001f- *\u001b,\u001b \"\u001b\u001d\u001f, \u001e\u001f-\u001b*\u001b,\u001f\u001d\u001f, &)- \u001d\u001b'\u001c#)- '\u001f!\u001b&)\u001c&á-.#\u001d)-8 \u0013#( \u001f'\u001c\u001b,!)6 \u001f- \u001d)'Ě(\n+/\u001f -\u001f /-\u001f( gff̓ '! \u001b& \u001e ù\u001b *),+/\u001f &)- *,\u001f*\u001b,\u001b\u001e)- \u001d)'\u001f,\u001d#\u001b&\u001f- () *\u001f,'#.\u001f( \u001f'*&\u001f\u001b, \u001e)-#- '\u001f(),\u001f-8\n \n\u001b","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":89,"lines":{"from":34,"to":49}}}}],["369",{"pageContent":"\u001e\u001f h \u001b k̓ '! -)( -/l·\u001d#\u001f(.\u001f- *\u001b,\u001b \"\u001b\u001d\u001f, \u001e\u001f-\u001b*\u001b,\u001f\u001d\u001f, &)- \u001d\u001b'\u001c#)- '\u001f!\u001b&)\u001c&á-.#\u001d)-8 \u0013#( \u001f'\u001c\u001b,!)6 \u001f- \u001d)'Ě(\n+/\u001f -\u001f /-\u001f( gff̓ '! \u001b& \u001e ù\u001b *),+/\u001f &)- *,\u001f*\u001b,\u001b\u001e)- \u001d)'\u001f,\u001d#\u001b&\u001f- () *\u001f,'#.\u001f( \u001f'*&\u001f\u001b, \u001e)-#- '\u001f(),\u001f-8\n \n\u001b\n\u001b\u001e'#(#-.,\u001b\u001d#ĉ( \u001e\u001f g̓ fff̓'! -\u001b./,\u001b &\u001b- .,\u001b(-\u001d)\u001c\u001b&\u001b'#(\u001b- 3 \u001f& \u001f2\u001d\u001f-) \u001e\u001f 0#.\u001b'#(\u001b &#\u001c,\u001f -\u001f \u001f2\u001d,\u001f.\u001b *), &)- ,#\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":89,"lines":{"from":49,"to":54}}}}],["370",{"pageContent":"Ą)(\u001f-8 \u0005& \u001f-+/\u001f'\u001b .ù*#\u001d) \u001d)(-#-.\u001f \u001f( \u001b*&#\u001d\u001b, gff̓'!\n \n\u001e#\u001b,#)- *), h \u001b i -\u001f'\u001b(\u001b-8 \u0005( \u001f-\u001f .#\u001f'*) -\u001f &)!,\u001b\n&\u001b (),'\u001b&#4\u001b\u001d#ĉ( \u001e\u001f &)- 0\u001b&),\u001f- \u001e\u001f -\u001f,#\u001f ,)$\u001b: \u001b *\u001b,.#, \u001e\u001f \u001f(.)(\u001d\u001f- -\u001f \u001b\u001e'#(#-.,\u001b( g̓ fff̓'! \u001d\u001b\u001e\u001b -\u001f'\u001b(\u001b6 3\n\u001e\u001f-*/ï- \u001e\u001f /( '\u001f- &\u001b '#-'\u001b \u001e)-#- \u001d\u001b\u001e\u001b j -\u001f'\u001b(\u001b-8\n\u0005-.\u001b \u001e)-#- \u001e\u001f\u001c\u001f \u001e\u001b,-\u001f *), .)\u001e\u001b &\u001b 0#\u001e\u001b -# () \u001f- *)-#\u001c&\u001f ,\u001f-)&0\u001f, \u001f& *,)\u001c&\u001f'\u001b \u001d\u001b/-\u001b& ) -# () -\u001f #\u001e\u001f(.#l·\u001dĉ \u001d)(\n*,)*#\u001f\u001e\u001b\u001e &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001f-*\u001f\u001dùl·\u001d\u001b B'\u001f\u001e#\u001d#ĉ( \u001c\u001b-\u001b& \u001e\u001f (#0\u001f&\u001f- \u001e\u001f 0#.\u001b'#(\u001b \u0002gh 3 á\u001d#\u001e) ĉ&#\u001d)C8 \u0004\u001f *,\u001f-\u001f(.\u001b,-\u001f\n\u001f-.)- \u001d\u001b-)-6 \u001f- )\u001c&#!\u001b.),#) \u001b\u001e'#(#-.,\u001b, 0#.\u001b'#(\u001b \u0002gh *\u001b,\u001f(.\u001f,\u001b& 3 á\u001d#\u001e) ĉ&#\u001d) ),\u001b& -#'/&.á(\u001f\u001b'\u001f(.\u001f6 3\u001b +/\u001f\n&\u001b -)&\u001b \u001b\u001e'#(#-.,\u001b\u001d#ĉ( \u001e\u001f á\u001d#\u001e)\n \nĉ&#\u001d) */\u001f\u001e\u001f #(\u001e/\u001d#, &\u001b \u001b*\u001b,#\u001d#ĉ( \u001e\u001f '\u001b(# \u001f-.\u001b\u001d#)(\u001f- (\u001f/,)&ĉ!#\u001d\u001b- \u001d/\u001b(\u001e)\n\u001f2#-.\u001f \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \u001d)\u001c\u001b&\u001b'#(\u001b-8 \u0003/\u001b(\u001e) \"\u001b3 -ù(.)'\u001b- (\u001f/,)&ĉ!#\u001d)-6 -\u001f \u001e\u001f\u001c\u001f( \u001b\u001e'#(#-.,\u001b, g̓fff̓'!\n \n\u001d\u001b\u001e\u001b\nh̓ -\u001f'\u001b(\u001b- *), l̓ '\u001f-\u001f-8 \u0005( &\u001b \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001d)(!ï(#.\u001b \u001e\u001f .,\u001b(-\u001d)\u001c\u001b&\u001b'#(\u001b\n \n6 -\u001f \u001b*&#\u001d\u001b \u001f& \u001f-+/\u001f'\u001b \u001b(.\u001f,#),6\n*\u001f,) \u001e/,\u001b(.\u001f .)\u001e\u001b &\u001b 0#\u001e\u001b8\n \n\u001b- \u001e)-#- ),\u001b&\u001f- \u001e\u001f 0#.\u001b'#(\u001b \u0002gh -)&) */\u001f\u001e\u001f( \u001f'*&\u001f\u001b,-\u001f \u001f( &)- \u001d\u001b-)- ,\u001b,)- \u001e\u001f \u001b&.\u001b","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":89,"lines":{"from":56,"to":75}}}}],["371",{"pageContent":"6 -\u001f \u001b*&#\u001d\u001b \u001f& \u001f-+/\u001f'\u001b \u001b(.\u001f,#),6\n*\u001f,) \u001e/,\u001b(.\u001f .)\u001e\u001b &\u001b 0#\u001e\u001b8\n \n\u001b- \u001e)-#- ),\u001b&\u001f- \u001e\u001f 0#.\u001b'#(\u001b \u0002gh -)&) */\u001f\u001e\u001f( \u001f'*&\u001f\u001b,-\u001f \u001f( &)- \u001d\u001b-)- ,\u001b,)- \u001e\u001f \u001b&.\u001b\n\u001e\u001f \u001b*),.\u001f -#( \u001e\u001f \u001f\u001d.) \u001e\u001f \u001b\u001c-),\u001d#ĉ(8 \u000f\u001d\u001b-#)(\u001b&'\u001f(.\u001f6 &\u001b -/*&\u001f'\u001f(.\u001b\u001d#ĉ( \u001d)( 0#.\u001b'#(\u001b \u0002gh */\u001f\u001e\u001f *,)0)\u001d\u001b,\n\u001e\u001f-\u001b,,)&&) \u001e\u001f \u001b\u001d(ï8\n\u001b .\u001f,\u001b*ï/.#\u001d\u001b \u001d)( á\u001d#\u001e) ĉ&#\u001d) -\u001f &&\u001f0\u001b \u001b \u001d\u001b\u001c) \u001d)( \u001e)-#- \u001e\u001f k \u001b gk̓'! \u001b& \u001eù\u001b8\n \n\u001b- \u001e)-#- \u001e\u001f g̓'! ')\u001e#l·\u001d\u001b(\n&\u001b '), )&)!ù\u001b \u001d\u001f&/&\u001b,8\n \n\u001b \u001b\u001e'#(#-.,\u001b\u001d#ĉ( \u001e\u001f \u001d)\u001c\u001b&\u001b'#(\u001b- 3 \u001e\u001f )&\u001b.) \"\u001b\u001d\u001f \u001e\u001f-\u001b*\u001b,\u001f\u001d\u001f, &)- '\u001f!\u001b&)\u001c&\u001b-.)- \u001f( n \u001b\ngh̓\"),\u001b- \u001f #(\u001e/\u001d\u001f &\u001b '\u001b\u001e/,\u001b\u001d#ĉ( (),')\u001c&á-.#\u001d\u001b \u001e\u001f-*/ï- \u001e\u001f jn \u001b mh̓\"),\u001b- \u001e\u001f .,\u001b.\u001b'#\u001f(.)8\n \n\u001b &\u001f/\u001d)*\u001f(#\u001b 3\n&\u001b .,)'\u001c)\u001d#.)*\u001f(#\u001b .\u001b'\u001c#ï( \u001e\u001f-\u001b*\u001b,\u001f\u001d\u001f( \u001f( *)\u001d)- \u001eù\u001b-: -#( \u001f'\u001c\u001b,!)6 &)- '\u001b\u001d,)*)&#\u001d#.)- *\u001f,-#-.\u001f( \u001b&,\u001f\u001e\u001f\u001e),\n\u001e\u001f h̓ -\u001f'\u001b(\u001b-6 \u001b-ù \u001d)') &)- (\u001f/.,ĉl·&)- *)&#-\u001f!'\u001f(.\u001b\u001e)- 3 '\u001b\u001d,)*&\u001b+/\u001f.\u001b-8\n \n\u001b- \u001c#&#,,/\u001c#(\u001b- 3 \u001f& \"#\u001f,,) -ï,#\u001d)\n\u001e#-'#(/3\u001f( ,á*#\u001e\u001b'\u001f(.\u001f6 &) '#-') +/\u001f &\u001b \u001e\u001f-\"#\u001e,)!\u001f(\u001b-\u001b &á\u001d.#\u001d\u001b8\n \n)- ,\u001f.#\u001d/&)\u001d#.)- \u001b/'\u001f(.\u001b( 3 \u001e\u001f& .\u001f,\u001d\u001f,) \u001b&\n+/#(.) \u001eù\u001b &\u001b \u001f&\u001f0\u001b\u001d#ĉ( */\u001f\u001e\u001f -\u001f, -/*\u001f,#), \u001b& hfz8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":89,"lines":{"from":75,"to":97}}}}],["372",{"pageContent":"\u001b- \u001c#&#,,/\u001c#(\u001b- 3 \u001f& \"#\u001f,,) -ï,#\u001d)\n\u001e#-'#(/3\u001f( ,á*#\u001e\u001b'\u001f(.\u001f6 &) '#-') +/\u001f &\u001b \u001e\u001f-\"#\u001e,)!\u001f(\u001b-\u001b &á\u001d.#\u001d\u001b8\n \n)- ,\u001f.#\u001d/&)\u001d#.)- \u001b/'\u001f(.\u001b( 3 \u001e\u001f& .\u001f,\u001d\u001f,) \u001b&\n+/#(.) \u001eù\u001b &\u001b \u001f&\u001f0\u001b\u001d#ĉ( */\u001f\u001e\u001f -\u001f, -/*\u001f,#), \u001b& hfz8\n \n\u001b #(.\u001f(-#\u001e\u001b\u001e \u001e\u001f &\u001b ,\u001f.#\u001d/&)\u001d#.)-#- -\u001f \u001d),,\u001f&\u001b\u001d#)(\u001b \u001d)( \u001f& !,\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":89,"lines":{"from":97,"to":104}}}}],["373",{"pageContent":"\u001e) \u001e\u001f \u001b(\u001f'#\u001b 3 &\u001b (),'\u001b&#4\u001b\u001d#ĉ( \u001e\u001f &)- 0\u001b&),\u001f- \u001e\u001f &\u001b -\u001f,#\u001f ,)$\u001b -\u001f &)!,\u001b \u001e\u001f-*/ï- \u001e\u001f i \u001b j -\u001f'\u001b(\u001b- \u001e\u001f .,\u001b.\u001b'#\u001f(.)8\n\b\u001b\u001c#./\u001b&'\u001f(.\u001f -\u001f \u001f'*&\u001f\u001b &\u001b 0ù\u001b ),\u001b&8\n \n\u001b- \u001e)-#- \u001e\u001f á\u001d#\u001e) ĉ&#\u001d) -\u001f \u001b\u001e'#(#-.,\u001b( \u001e#\u001b,#\u001b'\u001f(.\u001f \"\u001b-.\u001b (),'\u001b&#\n-\n\n4\u001b, &)- 0\u001b&),\u001f- \"\u001f'á.#\u001d)- 3 \u001e\u001f-*/ï- -\u001f ,\u001f\u001e/\u001d\u001f \u001b k̓ '! \u001e#\u001b,#)- *), j̓ -\u001f'\u001b(\u001b-8 \u0003/\u001b(\u001e) -\u001f \"\u001b \u001d),,\u001f!#\u001e) &\u001b \u001d\u001b/-\u001b\n+/\u001f *,)*#\u001d#ĉ &\u001b \u001b(\u001f'#\u001b6 \u001f& .,\u001b.\u001b'#\u001f(.) */\u001f\u001e\u001f -/-*\u001f(\u001e\u001f,-\u001f 3 -\u001f \u001b\u001e'#(#-.,\u001b,á \u001f( ),'\u001b \u001e\u001f \u001d#\u001d&)- '\u001f(-/\u001b&\u001f-\nBk \u001b gf̓\u001eù\u001b- \u001d\u001b\u001e\u001b '\u001f-C *\u001b,\u001b \u001b+/\u001f&&)- \u001d\u001b-)- \u001e\u001f\u001c#\u001e)- \u001b \u001d)(-/') \u001f2\u001b!\u001f,\u001b\u001e)6 \u001d)') &\u001b- \u001b(\u001f'#\u001b- \"\u001f')&ù.#\u001d\u001b-6 \u001f&\n\u001f'\u001c\u001b,\u001b4) 3 &\u001b- \u001e\u001f,'\u001b.#.#- \u001f2 )&#\u001b.#0\u001b-8\n\u001b 0ù\u001b *\u001b,\u001f(.\u001f,\u001b& \u001d)( á\u001d#\u001e) )&ù(#\u001d) B\u000ek7 ),'#&7\u0006\u000ejC6 \u001b \u001e)-#- \u001e\u001f l \u001b hk̓'! \u001d\u001b\u001e\u001b n̓\"),\u001b-6 -\u001f ,\u001f\u001d)'#\u001f(\u001e\u001b\n\u001f( .,\u001f- \u001f-\u001d\u001f(\u001b,#)-9 \u001d/\u001b(\u001e) \u001f2#-.\u001f \u001e\u001fl·\u001d#\u001f(.\u001f \u001b\u001c-),\u001d#ĉ( #(.\u001f-.#(\u001b&6 \u001f( &\u001b .\u001f,\u001b*#\u001b \u001e\u001f ,\u001f-\u001d\u001b.\u001f *)-.\u001f,#), \u001b \u001e)-#-\n#(.\u001f,'\u001f\u001e#\u001b- ) \u001b&.\u001b- \u001e\u001f '\u001f.).,\u001f2\u001b.) *\u001b,\u001b &\u001f/\u001d\u001f'#\u001b ) &#( )'\u001b6 3 \u001b(.\u001f \u001f& \u001e\u001f-\u001b,,)&&) \u001e\u001f \"\u001f')\u001d#.)*\u001f(#\u001b- !,\u001b0\u001f-\n3 -#(.)'á.#\u001d\u001b- \u001f( *\u001b\u001d#\u001f(.\u001f- +/\u001f ,\u001f\u001d#\u001c\u001f( .,\u001b.\u001b'#\u001f(.) \u001d)(.,\u001b &\u001b .)2)*&\u001b-')-#- \u001d)( *#,#'\u001f.\u001b'#(\u001b B\u001f'\u001c\u001b,\u001b4\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":89,"lines":{"from":106,"to":120}}}}],["374",{"pageContent":"\u001e\u001b- ) *\u001f,-)(\u001b- \u001d)( \b \u00167-#\u001e\u001bC8 \u0005( \u001f-.)- \u001d\u001b-)- \u001f- #'*),.\u001b(.\u001f \u001f0#.\u001b, &\u001b- \u001d)'*&#\u001d\u001b\u001d#)(\u001f- -/*&\u001f'\u001f(.\u001b(\u001e) \u001d)(\ná\u001d#\u001e) ĉ&#\u001d) ),\u001b& 3 \u001d)(.,)&\u001b(\u001e) &)- 0\u001b&),\u001f- \"\u001f'\u001b.)&ĉ!#\u001d)-8\n\nEn el caso de las anemias\nmegaloblásticas\n \npor\n \ndefi-\nciencia de vitamina B12, los\npacientes\n \nrecibirán\n \npor\n \nvía\nparenteral la vitamina B12,\nen virtud de que la deficien-\ncia de esta vitamina se debe\ncasi siempre a un defecto de\nabsorción.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":89,"lines":{"from":122,"to":143}}}}],["375",{"pageContent":"CAPÍTULO 4. ANEMIAS MEGALOBLÁSTICAS\n\n63\n\n\b\u001b3 \u001b&!/(\u001b- \u001b(\u001f'#\u001b- '\u001f!\u001b&)\u001c&á-.#\u001d\u001b- +/\u001f \u001d/,-\u001b( \u001d)( \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)8 \u0001 \u001f-.\u001b- \u001b(\u001f'#\u001b- -\u001f &\u001b-\n\u001e\u001f()'#(\u001b ^\u001e#'), \u001b-_6 3\u001b +/\u001f &\u001b- \u001b(),'\u001b&#\u001e\u001b\u001e\u001f- '), )&ĉ!#\u001d\u001b- \u001e\u001f .#*) '\u001f!\u001b&)\u001c&á-.#\u001d\u001b -\u001f \"\u001b\u001d\u001f( '\u001f()-\n\u001f0#\u001e\u001f(.\u001f-8 \u0001-ù6 *), \u001f$\u001f'*&)6 \u001f& 0)&/'\u001f( !&)\u001c/&\u001b, '\u001f\u001e#) -\u001f ,\u001f\u001e/\u001d\u001f \u001b&,\u001f\u001e\u001f\u001e), \u001e\u001f gff̓\n \n6 3 \u001f- \u001d)'Ě(\n)\u001c-\u001f,0\u001b, \u001f0#\u001e\u001f(.\u001f \"#*)\u001d,)'ù\u001b \u001d/\u001b(\u001e) -\u001f \"\u001b #(#\u001d#\u001b\u001e) \u001f& .,\u001b.\u001b'#\u001f(.) \u001d)( &\u001b 0#.\u001b'#(\u001b \u0002gh 3 \u001f&\n \n)&\u001b.)8 \u0005(\n\u001f-.)- *\u001b\u001d#\u001f(.\u001f- \u001d)( \u001b(\u001f'#\u001b- \u001e#'), \u001b- -\u001f \u001e\u001f.#\u001f(\u001f \u001f& #(\u001d,\u001f'\u001f(.) \u001e\u001f \"\u001f')!&)\u001c#(\u001b \u001b *\u001f-\u001b, \u001e\u001f \u001d)(.#(/\u001b,\n\u001f& .,\u001b.\u001b'#\u001f(.) \u001d)( &)-\n \n\u001b\u001d.),\u001f- \u001e\u001f '\u001b\u001e/,\u001b\u001d#ĉ(6 3 \u001f- \"\u001b-.\u001b +/\u001f -\u001f \u001b\u001e'#(#-.,\u001b \u001f& \"#\u001f,,) \u001d/\u001b(\u001e) -\u001f \u001b*,\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":90,"lines":{"from":1,"to":17}}}}],["376",{"pageContent":"\u001d#\u001b &\u001b (),'\u001b&#4\u001b\u001d#ĉ( \u001e\u001f &)- 0\u001b&),\u001f-8 \u0005-.\u001b 0\u001b,#\u001f\u001e\u001b\u001e \u001e\u001f \u001b(\u001f'#\u001b \u001e#'), \u001b \u001b*\u001b,\u001f\u001d\u001f \u001f( &\u001b \u001d\u001b,\u001f(\u001d#\u001b \u001e\u001f \"#\u001f,,)\n3\n \n)&\u001b.)- #(\u001e/\u001d#\u001e\u001b *), \u001e\u001fl·\u001d#\u001f(\u001d#\u001b- (/.,#'\u001f(.\u001b&\u001f- 3 \u001d)(-/') \u001f2\u001d\u001f-#0)6 \u001d)') )\u001d/,,\u001f \u001d)(\n \n,\u001f\u001d/\u001f(\u001d#\u001b \u001f(\n\u001f& \u001f'\u001c\u001b,\u001b4)8\n\u001b \u001d,)(#\u001d#\u001e\u001b\u001e \u001e\u001f &\u001b- \u001b(\u001f'#\u001b- '\u001f!\u001b&)\u001c&á-.#\u001d\u001b- *\u001f,'#.\u001f \u001d#\u001f,.) !,\u001b\u001e) \u001e\u001f \u001b\u001e\u001b*.\u001b\u001d#ĉ( \u001d\u001b,\u001e#)*/&')(\u001b,6\n*), &) +/\u001f ,\u001b,\u001b 0\u001f4 ,\u001f+/#\u001f,\u001f( \u001e\u001f .\u001f,\u001b*#\u001b .,\u001b(- /-#)(\u001b&8 \u0005(\n \n,&\u001b(\u001e\u001b \u001b(\u001b&#4\u001b,)( \u001e\u001f '\u001b(\u001f,\u001b ,\u001f.,)-*\u001f\u001d.#0\u001b &\u001b\n/.#&#\u001e\u001b\u001e \u001e\u001f &\u001b .,\u001b(- /-#ĉ( \u001f( kh *\u001b\u001d#\u001f(.\u001f- \u001d)( \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b8 \u0004\u001f &)- hf *\u001b\u001d#\u001f(.\u001f- .,\u001b(- /(\u001e#\u001e)-6\ngi\n \n/\u001f,)( .,\u001b.\u001b\u001e)- \u001d)( \u001e#/,ï.#\u001d)- 3 -\u001f#- \u001d)( -/*&\u001f'\u001f(.)- \u001e\u001f *).\u001b-#)8 \u0005& ,\u001b(!) \u001e\u001f \"\u001f')!&)\u001c#(\u001b *,\u001f.,\u001b(- /\n-\n\n-#)(\u001b&\n \n/\u001f \u001e\u001f j6n \u001b gf6j̓!I\u001e\n \n8 Ò(#\u001d\u001b'\u001f(.\u001f \u001e)- \u001e\u001f &)- ih *\u001b\u001d#\u001f(.\u001f- () .,\u001b(- /(\u001e#\u001e)- ,\u001f\u001d#\u001c#\u001f,)( -/*&\u001f'\u001f(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":90,"lines":{"from":19,"to":41}}}}],["377",{"pageContent":"-#)(\u001b&\n \n/\u001f \u001e\u001f j6n \u001b gf6j̓!I\u001e\n \n8 Ò(#\u001d\u001b'\u001f(.\u001f \u001e)- \u001e\u001f &)- ih *\u001b\u001d#\u001f(.\u001f- () .,\u001b(- /(\u001e#\u001e)- ,\u001f\u001d#\u001c#\u001f,)( -/*&\u001f'\u001f(\n-\n\n.)- \u001e\u001f *).\u001b-#)8 \u000e) ,\u001f*),.\u001b( \u001d)'*&#\u001d\u001b\u001d#)(\u001f- !,\u001b0\u001f- \u001f( \u001f-.\u001f !,/*): -#( \u001f'\u001c\u001b,!)6 &\u001b .,\u001b(- /-#ĉ( \u001e\u001f *\u001b+/\u001f.\u001f\n!&)\u001c/&\u001b, \u001f( \u001b(\u001f'#\u001b- '\u001f!\u001b&)\u001c&á-.#\u001d\u001b- .#\u001f(\u001f -/ #(\u001e#\u001d\u001b\u001d#ĉ( ,\u001f&\u001b.#0\u001b \u001d/\u001b(\u001e) \u001d)\u001f2#-.\u001b '\u001b,\u001d\u001b\u001e\u001b \"#*)2#\u001b .#-/&\u001b,\n\u001d)(\u001e#\u001d#)(\u001b\u001e\u001b *), /(\u001b \u001d# ,\u001b '/3 \u001c\u001b$\u001b \u001e\u001f \"\u001f')!&)\u001c#(\u001b6 \u001d)( -#!()-\n \n,\u001b(\u001d)- \u001e\u001f #(-/l·\u001d#\u001f(\u001d#\u001b \u001d\u001b,\u001eù\u001b\u001d\u001b6 3 -\u001f\n.,\u001b.\u001f \u001e\u001f \u001b\u001e/&.)- \u001f( *&\u001f(#./\u001e \u001d)( #-+/\u001f'#\u001b \u001d\u001f,\u001f\u001c,\u001b& ) '#)\u001dá,\u001e#\u001d\u001b !,\u001b0\u001f 3 -#(.)'á.#\u001d\u001b6 3 \u001b(.\u001f &\u001b (\u001f\u001d\u001f-#\u001e\u001b\u001e\n\u001e\u001f ,\u001f\u001b&#4\u001b, /(\u001b \u001d#,/!ù\u001b /,!\u001f(.\u001f6 *), \u001f$\u001f'*&)6 \u001f( \u001d\u001b-)- \u001e\u001f .,)'\u001c)-#- '\u001f-\u001f(.ï,#\u001d\u001b8 \u000f.,\u001b -#./\u001b\u001d#ĉ( +/\u001f */\u001f\u001e\u001f\n,\u001f+/\u001f,#, .\u001f,\u001b*#\u001b .,\u001b(- /-#)(\u001b& \u001f- \u001d/\u001b(\u001e) -\u001f (\u001f\u001d\u001f-#.\u001f #(.\u001f,,/'*#, \u001e\u001f '\u001b(\u001f,\u001b /,!\u001f(.\u001f \u001f& \u001f'\u001c\u001b,\u001b4) *), 0ù\u001b\n\u001b\u001c\u001e)'#(\u001b& B\u001d\u001f-á,\u001f\u001bC8 \u0005( &)- \u001d\u001b-)- \u001e\u001f-\u001d,#.)- -\u001f */\u001f\u001e\u001f \u001b\u001e'#(#-.,\u001b, *\u001b+/\u001f.\u001f !&)\u001c/&\u001b, -#\u001f'*,\u001f \u001d)( l·&.,) *\u001b,\u001b\n&\u001f/\u001d)\u001d#.)- \u001f( *\u001f+/\u001fĄ)- 0)&Ě'\u001f(\u001f- Bgf̓'\n \n*), %! \u001e\u001f *\u001f-)C6 ,\u001f\u001d)'\u001f(\u001e\u001b(\u001e) \"\u001b\u001d\u001f, &\u001b .,\u001b(- /-#ĉ( &\u001f(.\u001b'\u001f(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":90,"lines":{"from":41,"to":60}}}}],["378",{"pageContent":".\u001f6 \u001f( *)-#\u001d#ĉ( -\u001f'#7\u0006)1&\u001f, *,\u001f\u001d\u001b&\u001f(.\u001b(\u001e) \u001f& \"\u001f')\u001d)'*)(\u001f(.\u001f *\u001b,\u001b *,)\u001e/\u001d#, 0\u001b-)\u001e#&\u001b.\u001b\u001d#ĉ( 3 /.#&#4\u001b,\n\u001e#/,ï.#\u001d)- \u001b& l·(\u001b&8 \u0014)\u001e) \u001f&&) \u001d)( \u001f& )\u001c$\u001f.) \u001e\u001f \u001e#-'#(/#, \u001f& ,#\u001f-!) \u001e\u001f -)\u001c,\u001f\u001d\u001b,!\u001b \u001d#,\u001d/&\u001b.),#\u001b 3 \u001b*\u001b,#\u001d#ĉ( \u001e\u001f\n\u001f\u001e\u001f'\u001b */&')(\u001b, \u001b!/\u001e)8\n\nCONCLUSIONES\n\n•\n \n\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b \u001f- /( *\u001b\u001e\u001f\u001d#'#\u001f(.) *)\u001d) ,\u001f\u001d/\u001f(.\u001f 3 \u001e\u001f\u001c\u001f -)-*\u001f\u001d\"\u001b,-\u001f \u001f( *\u001b\u001d#\u001f(.\u001f- \u001e\u001f '\u001f\n-\n\n\u001e#\u001b(\u001b \u001f\u001e\u001b\u001e \u001d)( \u001e#\u001b,,\u001f\u001b \u001d,ĉ(#\u001d\u001b6 !&)-#.#-6 \u001b(\u001f'#\u001b '\u001b\u001d,)\u001dù.#\u001d\u001b6 (\u001f/.,ĉl·&)- '/&.#-\u001f!'\u001f(.\u001b\u001e)-6 *&\u001b+/\u001f.\u001b-\n!#!\u001b(.\u001f- 3 \u001f&\u001f0\u001b\u001d#ĉ( \u001e\u001f &\u001b \u001e\u001f-\"#\u001e,)!\u001f(\u001b-\u001b &á\u001d.#\u001d\u001b8 \u0014\u001b'\u001c#ï( -\u001f \u001e\u001f\u001c\u001f \u001d)(-#\u001e\u001f,\u001b, \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b\n\u001f( '/$\u001f,\u001f- \u001f'\u001c\u001b,\u001b4\u001b\u001e\u001b- \u001d)( \u001e#\u001b,,\u001f\u001b \u001d,ĉ(#\u001d\u001b6 \u001b(\u001f'#\u001b '\u001b\u001d,)\u001dù.#\u001d\u001b6 \u001b(.\u001f\u001d\u001f\u001e\u001f(.\u001f- \u001e\u001f '/&.#*\u001b,#\u001e\u001b\u001e6 \u001e\u001f\n-\n\nl·\u001d#\u001f(.\u001f -/*&\u001f'\u001f(.\u001b\u001d#ĉ( \u001d)( á\u001d#\u001e)\n \nĉ&#\u001d) 3 \u001d/\u001b(\u001e) -\u001f \u001d/,-\u001b \u001d)( \u001f'\u001c\u001b,\u001b4) 'Ě&.#*&\u001f8\n \n\u001b \u001b(\u001f'#\u001b '\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":90,"lines":{"from":62,"to":83}}}}],["379",{"pageContent":"!\u001b&)\u001c&á-.#\u001d\u001b \u001f( &\u001b\u001d.\u001b(.\u001f- \u001f- ,\u001b,\u001b 3 !/\u001b,\u001e\u001b ,\u001f&\u001b\u001d#ĉ( \u001d)( &)- \"á\u001c#.)- \u001b&#'\u001f(.\u001b,#)- '\u001b.\u001f,()-8 \u0005& (#0\u001f&\n-ï,#\u001d) \u001e\u001f 0#.\u001b'#(\u001b \u0002gh6 á\u001d#\u001e) '\u001f.#&'\u001b&ĉ(#\u001d) 3 \")')\u001d#-.\u001fù(\u001b \u001e\u001f\u001c\u001f -\u001f, #(0\u001f-.#!\u001b\u001e) \u001f( &)- *\u001b\u001d#\u001f(.\u001f- \u001d)(\n*)&#(\u001f/,)*\u001b.ù\u001b -#'ï.,#\u001d\u001b8\n•\n \n\u001b 0\u001b,#\u001f\u001e\u001b\u001e *\u001f,(#\u001d#)-\u001b6 \u001b/(+/\u001f ,\u001b,\u001b \u001f(\n \nï2#\u001d)6 -ù \u001f2#-.\u001f 3 &)- *\u001b\u001d#\u001f(.\u001f- \u001e\u001f\u001c\u001f( ,\u001f\u001d#\u001c#, 0#.\u001b'#(\u001b \u0002gh *),\n.)\u001e\u001b &\u001b 0#\u001e\u001b8\n \n)- (#0\u001f&\u001f- -ï,#\u001d)- \u001e#-'#(/#\u001e)- \u001e\u001f 0#.\u001b'#(\u001b \u0002gh () -#\u001f'*,\u001f -\u001f \u001f(\u001d/\u001f(.,\u001b( \u001f( &\u001b \u001b(\u001f'#\u001b\n*\u001f,(#\u001d#)-\u001b: \u001f( \u001d\u001b'\u001c#)6 \u001f- \u001d)(-.\u001b(.\u001f \u001f& (#0\u001f& \u001f&\u001f0\u001b\u001e) \u001e\u001f \")')\u001d#-.\u001fù(\u001b 3 á\u001d#\u001e) '\u001f.#&'\u001b&ĉ(#\u001d)8\n•\n \n\u001b -/*&\u001f'\u001f(.\u001b\u001d#ĉ( \u001d)( á\u001d#\u001e) ĉ&#\u001d) 3 0#.\u001b'#(\u001b \u0002gh () *,\u001f0#\u001f(\u001f &\u001b \u001f( \u001f,'\u001f\u001e\u001b\u001e \u001d),)(\u001b,#\u001b (# \u001b/'\u001f(.\u001b\n\u001f& ,#\u001f-!) \u001e\u001f \u001dá(\u001d\u001f,8\n•\n \n)- *\u001b\u001d#\u001f(.\u001f- +/\u001f \u001e\u001f-\u001b,,)&&\u001b( .,)'\u001c)-#- .#\u001f(\u001f( \"#*\u001f,\")')\u001d#-.\u001f#(\u001f'#\u001b6 *\u001f,) \u001f& ,#\u001f-!) \u001e\u001f .,)'\u001c)-#- \u001f(\n&\u001b- \u001b(\u001f'#\u001b- '\u001f!\u001b&)\u001c&á-.#\u001d\u001b- () \"\u001b -#\u001e) \u001e\u001f')-.,\u001b\u001e)8\n•\n \n\u0005& \u001f-./\u001e#) \u001e\u001f 'ï\u001e/&\u001b ĉ-\u001f\u001b \u001f- Ě.#&6 '\u001b- () #(\u001e#-*\u001f(-\u001b\u001c&\u001f *\u001b,\u001b \u001f-.\u001b\u001c&\u001f\u001d\u001f, \u001f& \u001e#\u001b!(ĉ-.#\u001d) \u001e\u001f \u001b(\u001f'#\u001b\n'\u001f!\u001b&)\u001c&á-.#\u001d\u001b8 \u0005& ,\u001f.,\u001b-) \u001f( \u001f& \u001e#\u001b!(ĉ-.#\u001d)6 )'#.#, &\u001b #\u001e\u001f(.#l·\u001d\u001b\u001d#ĉ( \u001e\u001f& '\u001f\u001d\u001b(#-') \u001f.#)*\u001b.)!ï(#\u001d)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":90,"lines":{"from":85,"to":108}}}}],["380",{"pageContent":"•\n \n\u0005& \u001f-./\u001e#) \u001e\u001f 'ï\u001e/&\u001b ĉ-\u001f\u001b \u001f- Ě.#&6 '\u001b- () #(\u001e#-*\u001f(-\u001b\u001c&\u001f *\u001b,\u001b \u001f-.\u001b\u001c&\u001f\u001d\u001f, \u001f& \u001e#\u001b!(ĉ-.#\u001d) \u001e\u001f \u001b(\u001f'#\u001b\n'\u001f!\u001b&)\u001c&á-.#\u001d\u001b8 \u0005& ,\u001f.,\u001b-) \u001f( \u001f& \u001e#\u001b!(ĉ-.#\u001d)6 )'#.#, &\u001b #\u001e\u001f(.#l·\u001d\u001b\u001d#ĉ( \u001e\u001f& '\u001f\u001d\u001b(#-') \u001f.#)*\u001b.)!ï(#\u001d)\n\u001f #(\u001e#\u001d\u001b, /( .,\u001b.\u001b'#\u001f(.) \u001e\u001fl·\u001d#\u001f(.\u001f ) \u001f+/#0)\u001d\u001b\u001e) *,)0)\u001d\u001b( \u001e\u001bĄ)- \u001b &\u001b -\u001b&/\u001e 3 ,\u001f*\u001f,\u001d/.\u001f( \u001f( &\u001b \u001f\u001d)\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":90,"lines":{"from":108,"to":113}}}}],["381",{"pageContent":"()'ù\u001b #(\u001e#0#\u001e/\u001b& 3 \u001d)&\u001f\u001d.#0\u001b8\n\nPREGUNTAS DE AUTOEVALUACIÓN\n\ng8 \u0005- 0\u001f,\u001e\u001b\u001e\u001f,) *\u001b,\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b9\n\u001b8\n \n\u0005& \u001d/\u001b\u001e,) \u001d&ù(#\u001d) \u001f- -#'#&\u001b, \u001f( \u001f& \u001eïl·\u001d#. \u001e\u001f 0#.\u001b'#(\u001b \u0002gh 3 á\u001d#\u001e) ĉ&#\u001d)\n\u001c8\n \n\u001b- ,\u001f-\u001f,0\u001b- \u001e\u001f 0#.\u001b'#(\u001b \u0002gh \u001e/,\u001b( 'á- +/\u001f &\u001b- \u001e\u001f á\u001d#\u001e) ĉ&#\u001d)\n\u001d8\n \n\u001b 3 \u001c -)( \u001d),,\u001f\u001d.\u001b-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":90,"lines":{"from":115,"to":128}}}}],["382",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n64\n\nh8 \u0013\u001f&\u001f\u001d\u001d#)(\u001f &\u001b )*\u001d#ĉ( 0\u001f,\u001e\u001b\u001e\u001f,\u001b *\u001b,\u001b \u001b(\u001f'#\u001b- '\u001f!\u001b&)\u001c&á-.#\u001d\u001b- \u001f( (#Ą)-9\n\u001b8\n \n\u0001&#'\u001f(.\u001b\u001d#ĉ( \u001f2\u001d&/-#0\u001b'\u001f(.\u001f \u001b& -\u001f() '\u001b.\u001f,() *), /(\u001b '\u001b\u001e,\u001f \u001e\u001fl·\u001d#\u001f(.\u001f \u001f( 0#.\u001b'#(\u001b \u0002gh\n\u001c8\n \n\u001b- '\u001b(# \u001f-.\u001b\u001d#)(\u001f- (\u001f/,)&ĉ!#\u001d\u001b- ),#\u001f(.\u001b( \u001b& \u001e#\u001b!(ĉ-.#\u001d)\n\u001d8\n \n\u001b 3 \u001c \u001d)( \u001d),,\u001f\u001d.\u001b-\ni8 \u0013\u001f&\u001f\u001d\u001d#)(\u001f &\u001b )*\u001d#ĉ( \u001d),,\u001f\u001d.\u001b9\n\u001b8\n \n\u001b \"#*\u001f,\")')\u001d#-.\u001f#(\u001f'#\u001b -\u001f \u001b-)\u001d#\u001b \u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b\n\u001c8 \u0005( \u001d\u001b-)- \u001e\u001f .,)'\u001c)-#- &\u001b \")')\u001d#-.\u001fù(\u001b -\u001f \u001f(\u001d/\u001f(.,\u001b \u001f&\u001f0\u001b\u001e\u001b\n\u001d8\n \n\u001b 3 \u001c -)( \u001d),,\u001f\u001d.\u001b-\nj8 \u0005( \u001f& \u001f-./\u001e#) \u001e\u001f 'ï\u001e/&\u001b ĉ-\u001f\u001b \u001f( &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b9\n\u001b8\n \n)- \"\u001b&&\u001b4!)- -)( \u001d\u001b,\u001b\u001d.\u001f,ù-.#\u001d)-\n\u001c8 \u0005( \u001d\u001b-)- \u001b.ù*#\u001d)- */\u001f\u001e\u001f \u001d)( /(\u001e#,-\u001f \u001d)( &\u001f/\u001d\u001f'#\u001b \u001b!/\u001e\u001b\n\u001d8\n \n\u0014)\u001e\u001b- &\u001b- \u001b(.\u001f,#),\u001f-\nk8\n \n\u001b \u001b(\u001f'#\u001b *\u001f,(#\u001d#)-\u001b9\n\u001b8\n \n\u0012\u001f+/#\u001f,\u001f .,\u001b.\u001b'#\u001f(.) \u001e\u001f *), 0#\u001e\u001b\n\u001c8\n \n\u001b 0#.\u001b'#(\u001b \u0002gh *), 0ù\u001b ),\u001b& \u001f- \u001c#\u001f( \u001b\u001c-),\u001c#\u001e\u001b\n\u001d8\n \n\u0015( \u001f-./\u001e#) \u001f(\u001e)-\u001dĉ*#\u001d) \u001b& \u001e#\u001b!(ĉ-.#\u001d) \u001f- #,,\u001f&\u001f0\u001b(.\u001f\n\nBIBLIOGRAFÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":91,"lines":{"from":1,"to":44}}}}],["383",{"pageContent":"\u0001\u0004 6\n \n\u00026 \u0002 \u0003\b6 \u0004 \u0010 \u000f6 \u0012\u0001\u000e\u0004\u0013 \u0007 8 \u00018\n \n\u001f!\u001b&)\u001c&\u001b-.#\u001d \u001b(\u001b\u001f'#\u001b ) *,\u001f!(\u001b(\u001d38 \u0013)/.\" \u0001 ,#\u001d\u001b(\n \n\u001f\u001e 8 gokm9 gf7gk8\n\u0001!Ĝ\u001f,) \u000f6\n \n\u001b3,#--\u001f\n \n8\n \n\u001f!\u001b&)\u001c&\u001b-.#\u001d \u001b(\u001f'#\u001b ) *,\u001f!(\u001b(\u001d3 #( \u0016\u001f(\u001f4/\u001f&\u001b8 \u0001'\n \n\u000f\u001c-.\u001f. \u00073(\u001f\u001d)& gokn: ml9 ofi8\n\u00010\u001b-.\"# \u00126 \u0003\"\u001b/\u001e\"\u001b,3 \u0013\u00038\n \nH. pylori\n9 \u0001--)\u001d#\u001b.#)( 1#.\" '\u001f!\u001b&)\u001c&\u001b-.#\u001d \u001b(\u001b\u001f'#\u001b8\n \n\u0001-)\u001d \u0010\"3-#\u001d#\u001b(- (\u001e#\u001b8 hffm: kl9 gig8\n\u0002#&\u001c\u001b) \u0007\u001b,\u001b3 8 \u0001(\u001f'#\u001b- \u001d\u001b,\u001f(\u001d#\u001b&\u001f-\n \n9 \u0001(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b 3 ).,\u001b- \u001b(\u001f'#\u001b- \u001d\u001b,\u001f(\u001d#\u001b&\u001f-8\n \n( ),'\u001b\u001d#ĉ( \u0014\u001f,\u001b*ï/.#\u001d\u001b\n\u0013#-.\u001f'\u001b \u000e\u001b\u001d#)(\u001b& \u001e\u001f -\u001b&/\u001e B\u0005-*\u001bĄ\u001bC8 hffl: if9 lm7mk8\n\u0003\u001b,'\u001f& \u00126\n \n)\"(-)( \u0003\u00136 \u0017\u001f#(\u001f,\n \n8 \u0010\u001f,(#\u001d#)/- \u001b(\u001f'#\u001b #(\n \n\u001b.#( \u0001'\u001f,#\u001d\u001b #- (). \u001b \u001e#-\u001f\u001b-\u001f ) .\"\u001f \u001f&\u001e\u001f,&38 \u0001,\u001d\"\n \n(.\u001f,(\n\u001f\u001e8 gonm: gjmBggC9 gook7l8\n\u0003))%\n \n\u00046 \u001f. \u001b&8 \u000e/.,#.#)(\u001b& \u001e\u001fl·\u001d#\u001f(\u001d3 \u001b(\u001e \u001b(\u001f'#\u001b #(\n \n\u001b.#( \u0001'\u001f,#\u001d\u001b9 \u0001 \u001d)&&\u001b\u001c),\u001b.#0\u001f -./\u001e38 \u0002&))\u001e8 gomg: in9 kog8\n\u0003\"\u001b(\u001b,#(\n \n8 Ļ\u001f '\u001f!\u001b&)\u001c&\u001b-.#\u001d \u001b(\u001f'#\u001b-8 \u000f2 ),\u001e6 \u0002)-.)(9 \u0002&\u001b\u001d%1\u001f&& \u0013\u001d#\u001f(.#l·\u001d \u0010/\u001c&#\u001d\u001b.#)(-: goof8\n\u0004\u001f &\u001b \u0003,/47\u0007ĉ(!),\u001b \u00166 \u0016#&&\u001b&*\u001b(\u001e) \u00136 \u0012\u001f\u001c)&&\u001b, \u00126 \u001f. \u001b&8 \u000e/.,#.#)(\u001b& \u001d\u001b/-\u001f- ) \u001b(\u001f'#\u001b #(\n \n\u001f2#\u001d\u001b( \u001d\"#&\u001e,\u001f( /(\u001e\u001f, k\n3\u001f\u001b,-8 \u0012\u001f-/&.- ,)' .\"\u001f hffl \u000e\u001b.#)(\u001b& \b\u001f\u001b&.\" \u001b(\u001e (/.,#.#)( \u0013/,0\u001f38 \u0013\u001b& \u0010Ě\u001c","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":91,"lines":{"from":46,"to":95}}}}],["384",{"pageContent":"\u0004\u001f &\u001b \u0003,/47\u0007ĉ(!),\u001b \u00166 \u0016#&&\u001b&*\u001b(\u001e) \u00136 \u0012\u001f\u001c)&&\u001b, \u00126 \u001f. \u001b&8 \u000e/.,#.#)(\u001b& \u001d\u001b/-\u001f- ) \u001b(\u001f'#\u001b #(\n \n\u001f2#\u001d\u001b( \u001d\"#&\u001e,\u001f( /(\u001e\u001f, k\n3\u001f\u001b,-8 \u0012\u001f-/&.- ,)' .\"\u001f hffl \u000e\u001b.#)(\u001b& \b\u001f\u001b&.\" \u001b(\u001e (/.,#.#)( \u0013/,0\u001f38 \u0013\u001b& \u0010Ě\u001c\n \n\u001f28 hfgh: kjBhC9 gfn7gk8\n\u0004ù\u001f47\u00051\u001b&\u001e\n \n6\n \n)&#(\u001b \u0012\u00048\n \n,)( \u001b(\u001e )&#\u001d \u001b\u001d#\u001e \u001e\u001fl·\u001d#\u001f(\u001d3 \u001e/,#(! *,\u001f!(\u001b(\u001d3 #( 1\u001f-.\u001f,( \u0016\u001f(\u001f4/\u001f&\u001b8\n \n\u0014,)*\n \n\u001f\u001e \b3!8\ngomh: hg9 knm8\n\u0005\u001c\u001c#(!\n \n6 \u0002č(\u001b\u001b\n \n\b6 \u000e3!å,\u001e \u000f6 \u0001,(\u001f-\u001f( \u00056 \u0015\u001f&\u001b(\u001e \u0010\n \n6 \u000e),\u001e,\u001f\"\u001b/!\n \n\u00056 \u001f. \u001b&8 \u0003\u001b(\u001d\u001f, #(\u001d#\u001e\u001f(\u001d\u001f \u001b(\u001e '),.\u001b&#.3\n\u001b .\u001f, .,\u001f\u001b.'\u001f(. 1#.\" )&#\u001d \u001b\u001d#\u001e \u001b(\u001e 0#.\u001b'#( \u0002gh8 \u0001\n \n\u00018 hffo: ifhBgoC9 hggo7hl8 \u001e)#9 gf8gffgI$\u001b'\u001b8hffo8glhh8\n\u0007\u001b&&)1\u001b3\n \n6 \b\u001b'#&.)(\n \n8\n \n\u001b\u001d,)\u001d3.)-#-9 \u0010#. \u001b&&- #( .\u001f-.#(! \u001b(\u001e -/''\u001b,3 ) !/#\u001e\u001b(\u001d\u001f8 \u0002,\n \n\u001f\u001e 8 hffm: iik BmlhkC9\nnnj7nnl8\n\u0007ĉ'\u001f47\n \n\u001f\u001b& \u00018 \u0001(\u001f'#\u001b- '\u001f!\u001b&)\u001c&á-.#\u001d\u001b-8 \u0005& \u001f( \u001f,') \u001b(ï'#\u001d)8 h\u001e\u001b \u001f\u001e8\n \n)(.\u001f,,\u001f39 \u0006\u001b\u001d/&.\u001b\u001e \u001e\u001f\n \n\u001f\u001e#\u001d#(\u001b \u0015\u0001\u000e\n \n:\ngono8 *8 glm8\n\u0007)(4á&\u001f47\n \n&\u001b0\u001f(\n \n8 \u0003\u001b,\u001b\u001d.\u001f,ù-.#\u001d\u001b- \u001e\u001f &\u001b \u001b(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b \u001f( &\u001b \u0003#/\u001e\u001b\u001e \u001e\u001f\n \nï2#\u001d)8 \u0012\u001f0#-#ĉ( \u001e\u001f ggf *\u001b\u001d#\u001f(.\u001f-8\n\u0018\u0018\n \n),(\u001b\u001e\u001b \u0001(/\u001b& \u001e\u001f &\u001b \u0001\n \n\u0005\b8 \u0003/&#\u001b\u001dá(6 \u0013#(\u001b&)\u001b9 \u0001\n \n\u0005\b: gong8\n\u0007)(4á&\u001f47\u0016#&&\u001b,,\u001f\u001b&̓\n \n\u00076 \u0010)'*\u001b7\u0007\u001b,4\u001b\n \n\u00146 \u0013\u001f0#&&\u001b \u00126 \u0004\u001f","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":91,"lines":{"from":95,"to":163}}}}],["385",{"pageContent":"ï2#\u001d)8 \u0012\u001f0#-#ĉ( \u001e\u001f ggf *\u001b\u001d#\u001f(.\u001f-8\n\u0018\u0018\n \n),(\u001b\u001e\u001b \u0001(/\u001b& \u001e\u001f &\u001b \u0001\n \n\u0005\b8 \u0003/&#\u001b\u001dá(6 \u0013#(\u001b&)\u001b9 \u0001\n \n\u0005\b: gong8\n\u0007)(4á&\u001f47\u0016#&&\u001b,,\u001f\u001b&̓\n \n\u00076 \u0010)'*\u001b7\u0007\u001b,4\u001b\n \n\u00146 \u0013\u001f0#&&\u001b \u00126 \u0004\u001f\n \n\u001fĉ(7\u0003\u001b(.Ě \u00128 \u0012\u001f*),.\u001f \u001e\u001f \u001e)- \u001d\u001b-)- \u001d)( \u001b(\u001f'#\u001b '\u001f!\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":91,"lines":{"from":163,"to":178}}}}],["386",{"pageContent":"&)\u001c&á-.#\u001d\u001b \u001d)(!ï(#.\u001b *), \u001e\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \u0002gh \u001d)( \u001b&.\u001f,\u001b\u001d#)(\u001f- (\u001f/,)&ĉ!#\u001d\u001b-8 \u0012\u001f0 \u0002#)'\u001f\u001e8 hffg: gh B\u0013/*& gC9 \u0013g7\u0013oi8\n\b\u001b& \u001e\u001b(\u001b,-)( \u0014\u00126 \u0017\u001b&%\u001f,\n \n\u00016\n \n#.4)1\n \n\u00126 \b\u001b(-)( \u0003\u00018 \u0013\u001f0\u001f,\u001f 0#.\u001b'#( \u0002gh \u001e\u001fl·\u001d#\u001f(\u001d3 ,\u001f-/&.#(! #( *\u001b(\u001d3.)*\u001f(#\u001b6\n-*&\u001f()'\u001f!\u001b&3 \u001b(\u001e &\u001f/%)\u001f,3.\",)\u001c&\u001b-.)-#-8 \u0005/,\n \n\b\u001b\u001f'\u001b.)&8 hffn: nfBkC9 jjn7kg8\n\b\u001b&#\u001d#)!&/ \u000f6 \u0001-#% \u0001%'\u001b( \u00136 \u0013/.\u001d/)!&/ \u00136 \u001f. \u001b&8 \u000e/.,#.#)(\u001b& \u0002gh \u001e\u001fl·\u001d#\u001f(\u001d3 #( #( \u001b(.- )\n \n0#.\u001b'#( \u0002gh7\u001e\u001fl·\u001d#\u001f(.\n').\"\u001f,-8\n \n(.\n \n\u0016#.\u001b' \u000e/., \u0012\u001f-8 hfgg: ngBkC9 ihn7ij8\n\b\u001f,\u001c\u001f,. \u00168\n \n\u001f!\u001b&)\u001c&\u001b-.#\u001d \u001b(\u001f'#\u001b8\n \n\u001b\u001c\n \n(0\u001f-.8 gonk: kh9 i8\n(-/\u001b-.#7\u0002\u001f&.,á( \u00076 \u0013.\u001f#\u001e&\u001f, \u000e\n \n6\n \n\u001b(! \b6 \u0012\u001f#\u001d\"\u001b,\u001e\n \n8 \u0003\u0004ij '\u001f!\u001b%\u001b,3)\u001d3.\u001f- BʗifzC \u001b,\u001f \u001b--)\u001d#\u001b.\u001f\u001e 1#.\" '\u001f!\u001b\n-\n\n&)\u001c&\u001b-.#\u001d \u001b(\u001b\u001f'#\u001b \u001b(\u001e ()(7\u001b\u001d/.\u001f '3\u001f&)#\u001e (\u001f)*&\u001b-#\u001b8 \b#-.)*\u001b.\")&)!38 hfgh8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":91,"lines":{"from":180,"to":215}}}}],["387",{"pageContent":"CAPÍTULO 4. ANEMIAS MEGALOBLÁSTICAS\n\n65\n\n#\u001d\".'\u001b(\n \n\u00016 \u0002\u001f/.&\u001f, \u00056\n \n\u001b/-\"\u001b(-%3\n \n6\n \n#**- \u0014 8 Ļ\u001f '\u001f!\u001b&)\u001c\u001b-.#\u001d \u001b(\u001f'#\u001b-9 \u0017#&&#\u001b'- \b\u001f'\u001b.)&)!38 \u0004#!#.\u001b& \u0005\u001e#\n-\n\n.#)(8 \u000e\u001f1 \u0019),%9\n \n\u001d\u0007,\u001b17\b#&&: hffl8\n\u001d\n \n/&&#(\n \n\u00066 \u0003/.\"\u001c\u001f,. \u0012 8 \u0014,\u001b(- /-#)( #( .\"\u001f '\u001b(\u001b!\u001f'\u001f(. )\n \n*\u001b.#\u001f(.- 1#.\" '\u001f!\u001b&)\u001c&\u001b-.#\u001d \u001b(\u001b\u001f'#\u001b8\n \n(.\n \n\u0003&#(\n\u0010,\u001b\u001d.8 gooo: kiBhC9 gfj7l8\nĜ&&\u001f, \u00106 \b),(\u001fL· \u00076 \b\u001f((\u001f,'\u001b((8 \u0001 ,\u001b,\u001f #(\u001c),( \u001f,,), )\n \n#(.,\u001b\u001d\u001f&&/&\u001b, *,)\u001d\u001f--#(! )\n \n\u001d)\u001c\u001b&\u001b'#(\u001f *,\u001f-\u001f(.#(! 1#.\"\n'#\u001d,)\u001d\u001f*\"\u001b&/- \u001b(\u001e '\u001f!\u001b&)\u001c&\u001b-.#\u001d \u001b(\u001f'#\u001b9 \u0001 ,\u001f*),. ) i \u001d\"#&\u001e,\u001f(8\n \n\u0002\n \n&#( \u0010\u001b\u001e#\u001b.,8 hffm: hgo BlC9 ilg7m8\n\u000fŃ\u001d\u001f ) \u0012\u001b,\u001f \u0004#-\u001f\u001b-\u001f-8\n \n\u001f!\u001b&)\u001c&\u001b-.#\u001d \u001b(\u001f'#\u001b8 \u0002\u001f.\"\u001f-\u001e\u001b6\n \n\u00049 \u000e\u001b.#)(\u001b&\n \n(-.#./.\u001f- ) \b\u001f\u001b&.\"8 \u0004#-*)(#\u001c&\u001f \u001f(9 \"..*9II\n,\u001b,\u001f\u001e#-\u001f\u001b-\u001f-8#( )8(#\"8!)0I\n\u000f,!\u001b(#4\u001b\u001d#ĉ(\n \n/(\u001e#\u001b& \u001e\u001f &\u001b \u0013\u001b&/\u001e8 \u0001(\u001f'#\u001b- (/.,#\u001d#)(\u001b&\u001f- B ( ),'\u001f8 gg \u001b& gk \u001e\u001f )\u001d./\u001c,\u001f6 gomgC \u0007#(\u001f\u001c,\u001b9 \u000f\n \n\u0013: gomh8\n*8 kfi8\n\u0010&\u001b3\u001b- \u0010\u00076 \u000f,)4\u001d) \u0010 6\n \nĉ*\u001f4 \u0012\n \n6 \u0012\u001b')- \u0012\u00128 \u0004\u001f!\u001f(\u001f,\u001b\u001d#ĉ( \u001d)'\u001c#(\u001b\u001e\u001b -/\u001c\u001b!/\u001e\u001b \u001e\u001f &\u001b 'ï\u001e/&\u001b \u001f-*#(\u001b& *), \u001e\u001fl·\u001d#\u001f(\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":92,"lines":{"from":1,"to":60}}}}],["388",{"pageContent":"\u001d#\u001b \u001e\u001f 0#.\u001b'#(\u001b \u0002gh8 \u0012\u001f0\n \n\u001f\u001e \b)-* \u0007\u001f(\n \n\u001f28 hffh: lk BhC9 nn7oh8\n\u0012\u001f#\u001d\" \u0010\u00128\n \n\u001f!\u001b&)\u001c&\u001b-.#\u001d \u001b(\u001f'#\u001b8 \u0005(9 \b\u001f'\u001b.)&)!38 \u0010\"3-#)*\u001b.\")&)!3 \u001c\u001b-#- ), \u001d&#(#\u001d\u001b& *,\u001b\u001d.#\u001d\u001f8 \u0002)-.)(9\n \n#..&\u001f \u0002,)1(:\ngomn8 *8 lk7oi8\n\u0012/#47\u0001,!Ĝ\u001f&&\u001f- \u0007 6 \u0012\u001b'ù,\u001f47\u0003#-(\u001f,)- \u00066 \u0012#0\u001b\u001e\u001f(\u001f3,\u001b\n \n6 \u0012/#47\u0004\u001f&!\u001b\u001e)\n \n\u00016\n \n)&#(\u001b7\u0001&\u001b0\u001f4 \u00018\n \n\u001b\n \n,\u001f\u001d/\u001f(\u001d#\u001b \u001e\u001f &\u001b-\n\u001b(\u001f'#\u001b- '\u001f!\u001b&)\u001c&á-.#\u001d\u001b- \u001f( &\u001b *,á\u001d.#\u001d\u001b *,#0\u001b\u001e\u001b \u001f( \u0010/\u001f\u001c&\u001b6\n \nï2#\u001d)9 \u00052*\u001f,#\u001f(\u001d#\u001b \u001e\u001f gm \u001bĄ)-8\n \n\u001f\u001e#\u001d#(\u001b \u0015(#08 gooo:\ngBjC9 glk7m8\n\u0012/#4 \u0007#&6 \u0014)%\u001f-\"#6 \u0003\"\u001b/\u001e8 \u0001(\u001f'#\u001b '\u001f!\u001b&)\u001c&á-.#\u001d\u001b 3 '\u001b(# \u001f-.\u001b\u001d#)(\u001f- !\u001b-.,)#(.\u001f-.#(\u001b&\u001f- \u001f(\n \n#'\u001b8\n \n\u001b */(.\u001b \u001e\u001f& #\u001d\u001f\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":92,"lines":{"from":62,"to":95}}}}],["389",{"pageContent":"\u001c\u001f,!8 \u0012\u001f0 \u0007\u001b-.,)\u001f(. \u0010\u001f,Ě8 gono: o9 ni7of8\n\u0013á(\u001d\"\u001f47\n \n\u001f\u001e\u001b&\n \n6\n \n\u001b\u001c\u001b,\u001e#(#\n \n6 \u001f. \u001b&8 \u0001(\u001f'#\u001b \u001e\u001f& \u001f'\u001c\u001b,\u001b4)8 \u0005-./\u001e#) \u001e\u001f gji \u001f'\u001c\u001b,\u001b4\u001b\u001e\u001b- \u001e\u001f \b/\u001b'\u001b(.&\u001b6 \u0014&\u001b2\u001d\u001b&\u001b8\n\u0007\u001b\u001d\n \n\u001f\u001e\n \n\u001f28 golm: om9 giik8\n\u0013.\u001b\u001c&\u001f, \u0013\u00108 \u0016#.\u001b'#( \u0002gh \u001e\u001fl·\u001d#\u001f(\u001d38 \u000e \u0005(!&\n \n\u001f\u001e8 hfgi: iln9 gjo7lf8\n\u0013.\u001b\u001c&\u001f, \u0013\u00106 \u0001&&\u001f( \u0012\b6 \u0013\u001b0\u001b!\u001f \u0004\u00076\n \n#(\u001e\u001f(\u001c\u001b/'\n \n8 \u0003&#(#\u001d\u001b& -*\u001f\u001d.,/' \u001b(\u001e \u001e#\u001b!()-#- ) \u001d)\u001c\u001b&\u001b'#( \u001e\u001fl·\u001d#\u001f(\u001d38 \u0002&))\u001e8\ngoof: mlBkC9 nmg7nng8\n\u0014),,\u001f- \u0012 6 \u0010/#! \u00078 \b3*)2\u001b(.\"#(\u001f7!/\u001b(#(\u001f*\")-)*\"),#\u001c)-3&.,\u001b(- \u001f,\u001b-\u001f B\b\u0010\u0012\u0014 \u001e\u001fl·\u001d#\u001f(\u001d39\n \n\u001f-\u001d\"7\u000e3\"\u001b( -3(\u001e,)'\u001fC8\n\u000f,*\"\u001b(\u001f.\n \n\u0012\u001b,\u001f \u0004#-8 hffm: nBhC9 jn8\n\u0016\u001b47\u0010#(.) \u00016 \u0006#!/\u001f,)\u001b7\u0013\u001b(\u001e)0\u001b&\n \n\u00066 \u0013á(\u001d\"\u001f47\n \n\u001f\u001e\u001b&\n \n8 \u0001(\u001f'#\u001b- '\u001f!\u001b&)\u001c&á-.#\u001d\u001b- B\u001b&!/()- \u001e\u001b.)- -)\u001c,\u001f &\u001b\n \n,\u001f\u001d/\u001f(\u001d#\u001b\n\u001f(\n \nï2#\u001d)C8 \u0018\u0016 ),(\u001b\u001e\u001b \u0001(/\u001b& \u001e\u001f &\u001b \u0001\n \n\u0005\b8\n \n\u001fĉ(6 \u0007/\u001b(\u001b$/\u001b.)9 \u0001\n \n\u0005\b: gomj8\n\u0016)&&-\u001f. \u0013\u00056 \u0003&\u001b,%\u001f \u00126\n \n\u001f1#(!.)( \u00136 \u001f. \u001b&8 ), .\"\u001f \u00027\u0016#.\u001b'#( \u0014,\u001f\u001b.'\u001f(. \u0014,#\u001b&#-.-] \u0003)&&\u001b\u001c),\u001b.#)(8 \u0005L·\u001f\u001d.- )\n \n)&#\u001d \u001b\u001d#\u001e\n-/**&\u001f'\u001f(.\u001b.#)( )( )0\u001f,\u001b&& \u001b(\u001e -#.\u001f7-*\u001f\u001d#l·\u001d \u001d\u001b(\u001d\u001f, #(\u001d#\u001e\u001f(\u001d\u001f \u001e/,#(! .\"\u001f ,\u001b(\u001e)'#-\u001f\u001e .,#\u001b&-9\n \n\u001f.\u001b7\u001b(\u001b&3-\u001f- ) \u001e\u001b.\u001b\n)( kf̓fff # (\u001e#0#\u001e/\u001b&-8\n \n\u001b(\u001d\u001f.8 hfgi8 \u001e)#9gf8gfglI\u0013fgjf7lmilBghClhffg7m8\n\u0017\b\u000f:","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":92,"lines":{"from":97,"to":156}}}}],["390",{"pageContent":")&#\u001d \u001b\u001d#\u001e\n-/**&\u001f'\u001f(.\u001b.#)( )( )0\u001f,\u001b&& \u001b(\u001e -#.\u001f7-*\u001f\u001d#l·\u001d \u001d\u001b(\u001d\u001f, #(\u001d#\u001e\u001f(\u001d\u001f \u001e/,#(! .\"\u001f ,\u001b(\u001e)'#-\u001f\u001e .,#\u001b&-9\n \n\u001f.\u001b7\u001b(\u001b&3-\u001f- ) \u001e\u001b.\u001b\n)( kf̓fff # (\u001e#0#\u001e/\u001b&-8\n \n\u001b(\u001d\u001f.8 hfgi8 \u001e)#9gf8gfglI\u0013fgjf7lmilBghClhffg7m8\n\u0017\b\u000f:\n \n(.\u001f,(\u001b.#)(\u001b& \u000e/.,#.#)(\u001b& \u0001(\u001f'#\u001b \u0003)(-/&.\u001b.#0\u001f \u0007,)/* B \u000e\u0001\u0003\u0007C8\n \n(.\u001f!,\u001b.#(! *,)!,\u001b'- .) ')0\u001f #,)( \u001e\u001fl·\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":92,"lines":{"from":156,"to":168}}}}],["391",{"pageContent":"\u001d#\u001f(\u001d3 \u001b(\u001e \u001b(\u001b\u001f'#\u001b \u001d)(.,)& ),1\u001b,\u001e8 \u0012\u001f*),. ) .\"\u001f hffi\n \n(.\u001f,(\u001b.#)(\u001b& \u000e/.,#.#)(\u001b&8\n\u0001(\u001f'#\u001b \u0003)(-/&.\u001b.#0\u001f \u0007,)/* \u00133'*)-#/'8 l \u0006\u001f\u001c,/\u001b,3 hffi6\n \n\u001b,,\u001b%\u001f\u001d\"6\n \n),)\u001d\u001d)8 \u0017\u001b-\"#(!.)(6 \u0004\u00039\n \n\u0013\n \n\u0010,\u001f--:\nhffi8 \u0004#-*)(#\u001c&\u001f \u001f(9 \"..*9II#(\u001b\u001d!8#&-#8),!Il·&\u001fI\n \n\u000e\u0001\u0003\u0007l·(\u001b&8*\u001e B\u001b\u001d\u001d\u001f-)9 hffjC8\n\u0017#-- \u00126 \u0006)!\u001f&'\u001b( \u00196 \u0002\u001f((\u001f..\n \n8 \u0013\u001f0\u001f,\u001f 0#.\u001b'#( \u0002gh \u001e\u001fl·\u001d#\u001f(\u001d3 #( \u001b( #( \u001b(. \u001b--)\u001d#\u001b.\u001f\u001e 1#.\" \u001b '\u001b.\u001f,(\u001b& \u001e\u001fl·\u001d#\u001f(\u001d3\n\u001b(\u001e \u001b -.,#\u001d. 0\u001f!\u001f.\u001b,#\u001b( \u001e#\u001f.8 \u0010\u001f\u001e#\u001b., \b\u001f'\u001b.)& \u000f(\u001d)&8 hffj: hlBjC9 hmf7g8\n\u0019\u001f(#\u001d\u001f-/\n \n8 \u0010\u001b(\u001d3.)*\u001f(#\u001b \u001e/\u001f .) 0#.\u001b'#( \u0002gh \u001e\u001fl·\u001d#\u001f(\u001d3 #( \u001b \u001c,\u001f\u001b-.7 \u001f\u001e #( \u001b(.8 \u0010\u001f\u001e#\u001b., \b\u001f'\u001b.)& \u000f(\u001d)&8 hffn: hkBjC9\nilk7m8\n\nRESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\ng8\n \n\u001d\nh8\n \n\u001d\ni8\n \n\u001d\nj8\n \n\u001d\nk8\n \na","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":92,"lines":{"from":170,"to":210}}}}],["392",{"pageContent":"67\n\nINTRODUCCIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":94,"lines":{"from":1,"to":3}}}}],["393",{"pageContent":"Las anemias hemolíticas representan el 5% de todas las anemias y pueden ocurrir en personas de\ncualquier edad, con un índice de mortalidad en general bajo. Se producen por un aumento en la des-\ntrucción de los eritrocitos con una disminución en su supervivencia a menos de 100 días. Aunque la\nhemólisis puede cursar asintomática, lo más común es que se desarrolle anemia cuando la destrucción\ncelular sobrepasa las capacidades de la eritropoyesis. Se conocen dos mecanismos de destrucción eri-\ntrocitaria: extracorpuscular e intracorpuscular, esta última la más común.\nSe tiene conocimiento de la patogenia de las anemias hemolíticas desde 1919, a raíz de que\nAshby pudo medir la supervivencia de lo eritrocitos de una persona normal en la circulación de un\nreceptor también normal. Por el contrario, encontró que cuando se transfundían eritrocitos de una\npersona normal a pacientes con hemólisis, la supervivencia de los eritrocitos se acortaba, lo cual","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":94,"lines":{"from":5,"to":14}}}}],["394",{"pageContent":"receptor también normal. Por el contrario, encontró que cuando se transfundían eritrocitos de una\npersona normal a pacientes con hemólisis, la supervivencia de los eritrocitos se acortaba, lo cual\nseñalaba un defecto en el ambiente del eritrocito en la circulación del enfermo. A esta situación se\nle denominó\n \nanemia hemolítica por defecto extracorpuscular\n \ny se observó que generalmente correspon-\ndía a procesos adquiridos. También se hizo evidente que la mayoría de las anemias hemolíticas por\ndefecto intracorpuscular correspondían a anomalías hereditarias de la membrana del eritrocito, de\nla hemoglobina o de las enzimas eritrocitarias. En estas, la alteración metabólica y la pérdida de la\nflexibilidad del eritrocito o la capacidad de las células del sistema fagocítico mononuclear de unirse\nal fragmento Fc de una inmunoglobulina adherida a un eritrocito, determinan la remoción de los\neritrocitos de la circulación, principalmente en el bazo y en menor proporción en el hígado.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":94,"lines":{"from":14,"to":27}}}}],["395",{"pageContent":"CLASIFICACIÓN ETIOPATOGÉNICA\n\nLas anemias hemolíticas pueden ser intracorpusculares o extracorpusculares. También se clasifican\ncomo\n \nadquiridas\n \n(cuadro 5-1)\n \no\n \nhereditarias\n \n(cuadro 5-2)\n.\n\nCAPÍTULO 5\n\nANEMIAS HEMOLÍTICAS.\nASPECTOS GENERALES\n\nYvette Neme\nÁlvaro Aguayo\n\nObjetivos de aprendizaje\n\n•\n \nConocer la frecuencia de las anemias hemolíticas.\n\n•\n \nComprender la clasificación etiopatogénica de las anemias hemolíticas.\n\n•\n \nDistinguir el cuadro clínico de las anemias hemolíticas.\n\n•\n \nDiferenciar el cuadro clínico de las anemias hemolíticas intravasculares de las extravasculares.\n\n•\n \nSeñalar el método diagnóstico y tratamiento de las anemias hemolíticas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":94,"lines":{"from":29,"to":73}}}}],["396",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n68\n\nCuadro 5-1.\n \nAnemias hemolíticas adquiridas\n\nAutoinmunitarias","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":95,"lines":{"from":1,"to":9}}}}],["397",{"pageContent":"a.\n \nAnticuerpos calientes (80%):\n1. Anemia hemolítica autoinmunitaria idiopática o primaria\n2. Síndrome de Evans\n3. Anemia hemolítica asociada con colitis ulcerativa, lupus eritematoso generalizado y otras\nenfermedades autoinmunitarias\n4. Anemia hemolítica en neoplasias hemáticas (p. ej., leucemia linfocítica crónica, linfomas) o\nno hemáticas (p. ej., tumores de ovario)\n5. Anemia hemolítica en hepatitis viral y en infección por\n \nE. coli\n \n0-111 o por\n \nSalmonella\nparatyphii B\n.\nb. Mediadas por aglutininas frías:\n1. Idiopática (puede presentarse con linfoproliferación clonal B)\n2. Secundaria: asociada a infección (\nMycoplasma pneumoniae\n \no mononucleosis infecciosa) o aso-\nciada a proceso linfoproliferativo clonal clínicamente evidente\nc.\n \nMediada por hemolisinas frías:\n1. Hemoglobinuria paroxística al frío idiopática\n2. Secundaria a sífilis o virosis\nd. Mediadas por anticuerpos fríos y calientes:\n1. Idiopática\n2. Secundaria (asociada a padecimientos reumatológicos, sobre todo lupus eritematoso)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":95,"lines":{"from":11,"to":43}}}}],["398",{"pageContent":"Aloinmunitarias\n\na.\n \nEnfermedad hemolítica del recién nacido\nb. Incompatibilidad ABO en transfusión\n\nInducidas por medicamentos\n\na.\n \nEl anticuerpo actúa sobre el complejo medicamento-(hapteno)-proteína eritrocitaria (p. ej., penicilina)\nb. El complejo anticuerpo-medicamento se fija al eritrocito (p. ej., quinidina)\nc.\n \nEl medicamento induce la formación de anticuerpos (p. ej., metildopa)\n\nNo inmunitarias\n\na. Anemia hemolítica microangiopática:\n1. Coagulación intravascular diseminada:\n\n•\n \npor infecciones\n\n•\n \nen hipoxia grave\n\n•\n \nen leucemia promielocítica\n\n•\n \npor circulación de líquido amniótico o ascítico\n2. Hemangioendotelioma\n3. Síndrome urémico hemolítico\n4. Púrpura trombocitopénica trombótica\nb. Hiperesplenismo\nc.\n \nVálvulas cardíacas protésicas\nd. Infecciones como sepsis, malaria","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":95,"lines":{"from":45,"to":89}}}}],["399",{"pageContent":"CAPÍTULO 5. ANEMIAS HEMOLÍTICAS. ASPECTOS GENERALES\n\n69\n\nLa mayoría de las anemias hemolíticas intracorpusculares son hereditarias, mientras que las extracor-\npusculares casi siempre son adquiridas. Es necesario tener en cuenta las diferentes etiologías tanto para\norientar el estudio del paciente con diagnóstico de anemia hemolítica, como para investigar intencio -\nnadamente algunas de las condiciones patológicas señaladas.\nLas anemias hemolíticas hereditarias representan una entidad distinta con una patogenia y curso di-\nferentes que las anemias hemolíticas adquiridas. Mientras que en las anemias hereditarias se encuentra\nun defecto estructural del eritrocito, en las adquiridas se identifica una “hemolisina” (agente capaz de\nproducir destrucción eritrocitaria) activa en todos los eritrocitos.\n\nCUADRO CLÍNICO","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":96,"lines":{"from":1,"to":14}}}}],["400",{"pageContent":"La mayoría de las veces se determina su presencia mediante pruebas de laboratorio; sin embargo, hay datos\nen la historia clínica y la exploración física que pueden orientar hacia hemólisis y la causa subyacente. La\ndisminución de la supervivencia de los eritrocitos, la lisis de un porcentaje de los glóbulos rojos por día\nsuperior al normal de 0,83%, con incremento en los productos de desdoblamiento de la hemoglobina y\nel estímulo consecutivo de la actividad eritropoyética, constituyen el punto de partida de las manifesta-\nciones clínicas de las anemias hemolíticas. El curso clínico más frecuente es insidioso y crónico, aunque\npuede haber casos de hemólisis aguda, rápida y fulminante. La forma aguda posterior a una transfusión\nde sangre incompatible, por ejemplo, se manifiesta con escalofríos, fiebre, lumbalgia y hemoglobinuria.\nLas formas hereditarias generalmente tienen historia de un padecimiento crónico (a excepción de las","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":96,"lines":{"from":16,"to":24}}}}],["401",{"pageContent":"Las formas hereditarias generalmente tienen historia de un padecimiento crónico (a excepción de las\nanemias hemolíticas por deficiencia de una enzima eritrocitaria, que solo se manifiestan después de la\ningestión de alimentos como habas o de ciertos medicamentos). En general, en las formas adquiridas se\npuede precisar el inicio de la enfermedad, la relación aparente con la condición causal y, en algunos casos,\nlas manifestaciones de procesos patológicos asociados.\nAdemás de la ictericia por incremento de la bilirrubina indirecta, que aparece en las hemorragias\nprofusas de tejidos, debe mencionarse que se observa en la enfermedad de Gilbert por anormalidad de las\ntransferasas que intervienen en la conjugación de la bilirrubina.\nAlgunas anemias hemolíticas cursan con problemas vasooclusivos, con las manifestaciones correspon-\ndientes al área afectada por la isquemia; por ejemplo, en la coagulación intravascular diseminada, en el\nsíndrome urémico hemolítico y en la púrpura trombótica.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":96,"lines":{"from":24,"to":34}}}}],["402",{"pageContent":"dientes al área afectada por la isquemia; por ejemplo, en la coagulación intravascular diseminada, en el\nsíndrome urémico hemolítico y en la púrpura trombótica.\nEn los eritrocitos se pueden percibir tanto cambios por la respuesta eritropoyética como aquellos que\ncorresponden al mecanismo de la hemólisis.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":96,"lines":{"from":34,"to":37}}}}],["403",{"pageContent":"No inmunitarias\n\ne.\n \nPúrpura trombocitopénica trombótica/síndrome urémico hemolítico\nf.\n \nHemoglobinopatías adquiridas:\n\n•\n \nMethemoglobina por exposición tóxica\n\n•\n \nSulfhemoglobina por exposición tóxica\n\n•\n \nCarbonoxihemoglobina\n4. Hemoglobina H en eritroleucemias\n5. Incremento en hemoglobina F en situaciones de estrés y displasia de médula ósea\n\nHemólisis en otras condiciones patológicas\n\na.\n \nHemoglobinuria paroxística nocturna\nb. Hemoglobinuria de la marcha\nc.\n \nHemoglobinuria por\n \nPlasmodium falciparum\n\nd. Veneno de víbora\ne.\n \nPicadura de\n \nPhysalia physalis\n\nf.\n \nHipofosfatemia intensa en el curso de cetoacidosis diabética\ng.\n \nHipolipoproteinemia adquirida\nh. Quemaduras","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":96,"lines":{"from":39,"to":87}}}}],["404",{"pageContent":"d. Veneno de víbora\ne.\n \nPicadura de\n \nPhysalia physalis\n\nf.\n \nHipofosfatemia intensa en el curso de cetoacidosis diabética\ng.\n \nHipolipoproteinemia adquirida\nh. Quemaduras\n\nLa disminución de la super-\nvivencia\n \nde\n \nlos\n \neritrocitos,\nla lisis de un porcentaje de\nlos glóbulos rojos por día su-\nperior al normal de 0,83%,\ncon incremento en los pro-\nductos de desdoblamiento de\nla hemoglobina y el estímulo\nconsecutivo de la actividad\neritropoyética, constituyen el\npunto de partida de las ma-\nnifestaciones\n \nclínicas\n \nde\n \nlas\nanemias hemolíticas.\nLa mayoría de las anemias\nhemolíticas por defecto intra-\ncorpuscular\n \ncorresponden\n \na\nanomalías hereditarias de la\nmembrana del eritrocito, de\nla hemoglobina o de las en-\nzimas\n \neritrocitarias,\n \ny\n \ncasi\ntodas las anemias hemolíticas\npor\n \ndefecto\n \nextracorpuscular\ncorresponden a procesos pato-\nlógicos adquiridos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":96,"lines":{"from":87,"to":151}}}}],["405",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n70\n\nCuadro 5-2.\n \nAnemias hemolíticas her\neditarias\n\nHemoglobinopatías\n\na.\n \nPolimerización anormal de la hemoglobina.\n \nHemoglobinopatía S o anemia de células falcifor-\nmes o drepanocítica\nb.\n \nAfinidad alterada al oxígeno\nc.\n \nHemoglobinopatía\n \nD\nd.\n \nHemoglobinopatía\n \nE\ne.\n \nTalasemias\n \n(\nα\n,\n \nβ\n,\n \nδ\nβ\n,\n \nγ\nβ\n,\n\u0003α\nβ\n)\nf.\n \nPersistencia hereditaria de hemoglobina fetal\ng.\n \nHemoglobinas\n \ninestables\n\nEnzimopatías","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":97,"lines":{"from":1,"to":61}}}}],["406",{"pageContent":"Enzimopatías\n\na.\n \nAnomalía de las enzimas de la vía de la\n \nhexosa-monofosfato:\n \ndeficiencia de\n \nglucosa-6-fosfato-\ndeshidrogenasa\n \ny de la\n \ndeshidrogenasa\n \ndel\n \n6-fosfogluconato\nb. Anomalía de las enzimas glucolíticas:\n \npiruvatocinasa,\n \nglucos\n \na-\nfosfatoisomerasa, hexocinasa,\nfosfoglicerato-cinasa,\n \nfosf\nofruto-\n \ncinasa,\n \ntriosafosfato-isomerasa\n \ny\n \naldolasa\nc.\n \nAnomalías en el\n \nmetabolismo\n \ndel glutatión: defecto de\n \nglutat\n \nión\n \nsintetasa, defecto de gluta-\nmil-cisteína\n \nsintetasa\nd. Otras\n \nenzimopatías:\n \ndeficiencia de la\n \npirimidina-5-nucleotidasa\n \ny de la\n \nedenilcinasa\ne.\n \nIncremento de la\n \nadenosina de aminasa\n\nAlteraciones de la membrana eritrocitaria\n\na.\n \nMicroesferocitosis\n \nher\neditaria\nb. Estomatocitosis\n \nher\neditaria\nc.\n \nEliptocitosis\nd. Incremento en la fosfatidilcolina de la\n \nmembrana\ne.\n \nHEMPAS, por sus siglas en inglés:\n \nhereditary erythroblastic multinuclearity with positive aci-\ndified serum lysis test.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":97,"lines":{"from":61,"to":157}}}}],["407",{"pageContent":"La hemólisis se manifiesta por ictericia, que ocurre por elevación de la bilirrubina indirecta. Se debe\nsospechar anemia hemolítica cuando un paciente se presenta con dos o más cuadros de ictericia, al igual\nque en un paciente con ictericia por un tiempo prolongado.\nLa edad de inicio de la ictericia es un dato que puede orientar al diagnóstico, ya que las anemias hemo-\nlíticas hereditarias suelen manifestarse desde la infancia. En el curso de las anemias crónicas puede haber\ncrisis agudas, en las que la anemia se hace más grave. Esto puede verse en la anemia de células falciformes\ny en otras anemias hemolíticas. También pueden precipitarse crisis agudas por infecciones, aumento en la\ndestrucción eritrocitaria o depleción de la médula ósea (crisis aplásicas), o bien, por deficiencia de ácido\nfólico, vitamina B12 o ambos.\nDentro de los datos clínicos se puede presentar disnea o fatiga a causa de la anemia. En la hemólisis","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":97,"lines":{"from":159,"to":168}}}}],["408",{"pageContent":"fólico, vitamina B12 o ambos.\nDentro de los datos clínicos se puede presentar disnea o fatiga a causa de la anemia. En la hemólisis\nintravascular también puede haber coluria y en ocasiones lumbalgia. Si la anemia es marcada, se puede\npresentar taquicardia y soplo cardíaco.\nLa presencia de linfadenopatías o hepatoesplenomegalia sugiere un proceso linfoproliferativo o neo -\nplásico subyacente, mientras que la esplenomegalia puede reflejar hiperesplenismo. En algunos pro -\ncesos hemolíticos crónicos, como en la anemia de células falciformes y en la esferocitosis, se pueden\npresentar úlceras en miembros pélvicos. En las hemólisis crónicas puede haber litiasis vesicular por\naumento en la excreción de los pigmentos biliares. Debe sospecharse anemia hemolítica en los pacientes\njóvenes con cuadro de colecistitis litiásica.\nEl descenso de la hemoglobina da lugar al estímulo de la eritropoyesis, con aumento progresivo","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":97,"lines":{"from":168,"to":178}}}}],["409",{"pageContent":"jóvenes con cuadro de colecistitis litiásica.\nEl descenso de la hemoglobina da lugar al estímulo de la eritropoyesis, con aumento progresivo\nde las células eritropoyéticas de la médula ósea y formación de focos de hematopoyesis extramedular.\nEl ensanchamiento del tejido hematopoyético en la médula ósea puede alcanzar magnitud suficiente\npara incrementar el espacio medular, con cambios en la imagen radiológica muy acentuados en el","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":97,"lines":{"from":178,"to":182}}}}],["410",{"pageContent":"CAPÍTULO 5. ANEMIAS HEMOLÍTICAS. ASPECTOS GENERALES\n\n71","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":98,"lines":{"from":1,"to":3}}}}],["411",{"pageContent":"71\n\ncráneo y en los arcos costales, pero también evidentes en otras porciones del esqueleto. A su vez, los\nfocos de hematopoyesis extramedular en el bazo y en el hígado y la hiperplasia del sistema fagocítico\nmononuclear contribuyen al crecimiento de estos órganos, que alcanzan dimensiones muy importan -\ntes en anemias hemolíticas hereditarias graves como la talasemia mayor, pero también se encuentran\nen otros órganos; por ejemplo, se han descubierto en el canal raquídeo, causando problemas neuro -\nlógicos por compresión.\nAlgunas anemias hemolíticas cursan con problemas vasooclusivos, con las manifestaciones corres-\npondientes al área afectada por la isquemia, por ejemplo, en la coagulación intravascular diseminada,\nen el síndrome urémico hemolítico y en la púrpura trombótica. También en la hemoglobinopatía S, los\neritrocitos deformados pueden formar cúmulos en la luz vascular lo que puede dar lugar a problemas en\nnumerosas áreas del organismo de estos pacientes.\n\nDIAGNÓSTICO","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":98,"lines":{"from":3,"to":17}}}}],["412",{"pageContent":"Clínicamente puede sospecharse hemólisis en un paciente con ictericia; sin embargo, la ausencia de esta\nno descarta hemólisis, ya que depende también de la reserva hepática, la cual permite la excreción de la\nsobrecarga de bilirrubina.\nLa destrucción eritrocitaria puede confirmarse mediante pruebas de laboratorio, resultando de utilidad\nla biometría hemática con reticulocitos y otros estudios, los cuales se describen a continuación.\nLa biometría hemática y el frotis sanguíneo proporcionan información muy valiosa que permite orien-\ntar el estudio posterior, ya que muestra si se trata de una alteración exclusiva de la serie roja o si coexisten\ncambios patológicos en los leucocitos, en las plaquetas o ambos.\nEn los eritrocitos se puede encontrar reticulocitosis por la respuesta eritropoyética. También se pueden\nencontrar eritrocitos nucleados, en especial en la enfermedad hemolítica del recién nacido y en la talase-\nmia, y en menor cantidad en otras anemias hemolíticas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":98,"lines":{"from":19,"to":29}}}}],["413",{"pageContent":"encontrar eritrocitos nucleados, en especial en la enfermedad hemolítica del recién nacido y en la talase-\nmia, y en menor cantidad en otras anemias hemolíticas.\nEn lo que respecta a cambios en la morfología de los eritrocitos que orientan sobre la patogenia de\nla hemólisis, se pueden mencionar: la presencia de eritrocitos con porciones seccionadas en su periferia\nen las anemias hemolíticas microangiopáticas o macroangiopáticas (esquistocitos); hallazgos de eritro -\ncitos de menor diámetro, con aumento de su densidad (esferocitos), tanto en la esferocitosis hereditaria\ncomo en las anemias hemolíticas por anticuerpos; la presencia de eritrocitos en forma de luna creciente\n(células en hoz o drepanocitos) en la anemia de células falciformes, de eritrocitos de forma ovalada en\nla ovalocitosis, de eritrocitos de formados en la acantocitosis y, finalmente, de eritrocitos grandes de\ncolor normal (megalocitos) y de eritroblastos de mayor tamaño, con núcleo grande de estructura muy","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":98,"lines":{"from":29,"to":38}}}}],["414",{"pageContent":"color normal (megalocitos) y de eritroblastos de mayor tamaño, con núcleo grande de estructura muy\nfina (megaloblastos) en la deficiencia de ácido fólico o de vitamina B12, que también pueden cursar con\nhemólisis.\nEn resumen, con relación al estímulo de la eritropoyesis, deben señalarse la presencia de macro -\ncitosis con basofilia difusa, la elevación de reticulocitos y la presencia de eritroblastos en los frotis\nde sangre. Dentro de los laboratorios podemos encontrar también elevación en los niveles de bili -\nrrubina indirecta y deshidrogenasa láctica, los cuales se liberan a la circulación cuando se destruye\nel eritrocito.\nCuando la hemólisis es intravascular, se encuentra elevación de los niveles de hemoglobina plas -\nmática. La hemoglobina liberada puede convertirse a bilirrubina indirecta o puede unirse a haptoglo -\nbinas plasmáticas. El complejo hemoglobina-haptoglobina es rápidamente depurado por el hígado,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":98,"lines":{"from":38,"to":48}}}}],["415",{"pageContent":"mática. La hemoglobina liberada puede convertirse a bilirrubina indirecta o puede unirse a haptoglo -\nbinas plasmáticas. El complejo hemoglobina-haptoglobina es rápidamente depurado por el hígado,\nlo que lleva a una disminución en los niveles de haptoglobinas. Por otro lado, cuando los niveles de\nhemoglobina rebasan el umbral renal, se presenta hemoglobinuria, la cual clínicamente se manifiesta\ncomo coluria.\nEn casos de hemólisis crónica intravascular, puede encontrarse hemosiderinuria. Ello se debe a que\nel hierro que resulta del desdoblamiento de la hemoglobina en las células de los túbulos renales pasa a la\norina como hemosiderina, la cual puede ser puesta en evidencia tiñendo las células del sedimento urinario\ncon azul de Prusia. Solamente la hemoglobina libre en plasma y la hemosiderinuria/hemoglobinuria pue-\nden diferenciar la hemólisis intravascular de la extravascular.\nExisten otras pruebas que ayudan al diagnóstico y que son específicas para determinadas enfermeda -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":98,"lines":{"from":48,"to":58}}}}],["416",{"pageContent":"den diferenciar la hemólisis intravascular de la extravascular.\nExisten otras pruebas que ayudan al diagnóstico y que son específicas para determinadas enfermeda -\ndes. Como ejemplo podemos citar la prueba de fragilidad osmótica en la esferocitosis o en las talasemias,\nelectroforesis de hemoglobina en las talasemias, prueba de Coombs y niveles de complemento en casos de\nanemias hemolíticas autoinmunitarias, donde se demuestra la presencia de anticuerpos o complemento\nen la superficie de los eritrocitos, y la citometría de flujo o FLAER en la hemoglobinuria paroxística\nnocturna\n \n(fig. 5-1)\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":98,"lines":{"from":58,"to":67}}}}],["417",{"pageContent":"Algunas anemias hemolíticas\ncursan con problemas vasoo-\nclusivos, con las manifestacio-\nnes correspondientes al área\nafectada por la isquemia; por\nejemplo, en la coagulación in-\ntravascular diseminada, en el\nsíndrome urémico hemolítico y\nen la púrpura trombótica.\nEn los eritrocitos se pueden\npercibir tanto cambios por la\nrespuesta eritropoyética como\naquellos que corresponden al\nmecanismo de la hemólisis.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":98,"lines":{"from":69,"to":82}}}}],["418",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n72\n\nABORDAJE DIAGNÓSTICO DE LAS ANEMIAS HEMOLÍTICAS\n\nSi la hemólisis es importante, la eliminación en el hígado del complejo hemoglobina-haptoglobina deter-\nmina la caída de la haptoglobina libre plasmática, que es seguida por el ascenso de la methemalbúmina en\nel plasma durante varios días.\n\nTRATAMIENTO\n\nEn general, el tratamiento de las anemias hemolíticas varía dependiendo de la etiología. En el\n \ncuadro 5-3\n\nse muestran algunos ejemplos.\n\nCONCLUSIONES\n\n•\n \nLas anemias hemolíticas se definen por la disminución en la supervivencia de los eritrocitos. Se dividen\nen anemias hemolíticas intracorpusculares y extracorpusculares.\n\n•\n \nEntre las anemias hemolíticas autoinmunitarias, el 80% son por anticuerpos calientes y el resto por\nanticuerpos fríos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":99,"lines":{"from":1,"to":29}}}}],["419",{"pageContent":"•\n \nEntre las anemias hemolíticas autoinmunitarias, el 80% son por anticuerpos calientes y el resto por\nanticuerpos fríos.\n\n•\n \nEl diagnóstico debe incluir: biometría hemática y frotis de sangre periférica, orientados a la bús -\nqueda de macrocitosis con basofilia difusa, elevación de reticulocitos y presencia de eritroblastos.\nLa prueba de Coombs directa es útil para distinguir entre anemias hemolíticas inmunitarias y no\ninmunitarias.\n\n•\n \nSe deben considerar medicamentos en el diagnóstico diferencial de las anemias hemolíticas inmunitarias.\n\n•\n \nEl tratamiento dependerá del tipo de anemia hemolítica. No debe evitarse la transfusión sanguínea en\npacientes con anemia hemolítica autoinmunitaria sintomática.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":99,"lines":{"from":29,"to":48}}}}],["420",{"pageContent":"•\n \nEl tratamiento dependerá del tipo de anemia hemolítica. No debe evitarse la transfusión sanguínea en\npacientes con anemia hemolítica autoinmunitaria sintomática.\n\nFigura 5-1.\n \nPruebas para el diagnóstico de anemia hemolítica.\nDHL = deshidrogenasa láctica; BI = bilirrubina indirecta; DIC = coagulación intravascular diseminada;\nPTT = púrpura trombocitopénica trombótica; SUH = síndrome urémico hemolítico; HPN = hemoglobi-\nnuria paroxística nocturna; PFO = prueba de fragilidad osmótica; Hb = hemoglobina.\n\nSi la hemólisis es importante,\nla eliminación en el hígado del\ncomplejo\n \nhemoglobina-hapto-\nglobina determina la caída de\nla haptoglobina libre plasmáti-\nca, que es seguida por el ascenso\nde la methemalbúmina en el\nplasma durante varios días.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":99,"lines":{"from":48,"to":69}}}}],["421",{"pageContent":"CAPÍTULO 5. ANEMIAS HEMOLÍTICAS. ASPECTOS GENERALES\n\n73\n\nPREGUNTAS DE AUTOEVALUACIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":100,"lines":{"from":1,"to":5}}}}],["422",{"pageContent":"1. Señale la opción que no es correcta en cuanto a las anemias hemolíticas:\na.\n \nLas anemias hemolíticas representan el 5% de todas las anemias\nb. La forma extracorpuscular es la más común de las anemias hemolíticas\nc.\n \nDe manera general, las anemias intracorpusculares son hereditarias\n2. Señale la opción correcta en cuanto a las anemias hemolíticas autoinmunitarias:\na.\n \nSon más frecuentes las anemias hemolíticas autoinmunitarias por anticuerpos fríos\nb. Las infecciones por\n \nMycoplasma pneumoniae\n \nfrecuentemente producen anemia hemolítica por an-\nticuerpos calientes\nc.\n \nLa prueba de Coombs directa es útil en la valoración inicial para determinar si se trata de anemia\nhemolítica de origen autoinmunitario\n3. Todas las siguientes condiciones pueden causar anemia hemolítica, excepto:\na.\n \nVeneno de víbora\nb. Hemoglobinuria paroxística nocturna\nc.\n \nHiperfosfatemia intensa en el curso de cetoacidosis diabética\n4. Son datos de laboratorio que se pueden encontrar en las anemias hemolíticas, excepto:\na.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":100,"lines":{"from":7,"to":38}}}}],["423",{"pageContent":"b. Hemoglobinuria paroxística nocturna\nc.\n \nHiperfosfatemia intensa en el curso de cetoacidosis diabética\n4. Son datos de laboratorio que se pueden encontrar en las anemias hemolíticas, excepto:\na.\n \nHiperbilirrubinemia indirecta\nb. Haptoglobinas aumentadas\nc.\n \nDeshidrogenasa láctica elevada","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":100,"lines":{"from":38,"to":49}}}}],["424",{"pageContent":"Cuadro 5-3.\n \nTratamiento de las anemias hemolíticas\n\nAnemia hemolítica\ninmunitaria\n\nTratar la enfermedad subyacente\nEsteroides\nEsplenectomía\nAzatioprina\nCiclofosfamida\nCiclosporina\nMicofenolato de mofetilo\nGammaglobulinas\nDanazol\nAnticuerpos monoclonales (rituximab y alemtuzumab)\n\nPúrpura trombocitopénica\n \nPlasmaféresis\n\nTrombótica\n \nTratar la enfermedad subyacente\n\nDeficiencia de G6PD\n \nSuspender y evitar factores desencadenantes\n\nHemoglobinopatías\n\nTransfusiones en caso necesario\nEsplenectomía en algunos casos moderados y graves\nTransfusiones y ácido fólico\n\nHemoglobinuria\nparoxística nocturna\n\nTransfusiones\nEculizumab","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":100,"lines":{"from":51,"to":91}}}}],["425",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n74\n\n5. En cuanto al tratamiento de las anemias hemolíticas, todo es cierto excepto:\na.\n \nEl rituximab es útil en casos de anemias hemolíticas autoinmunitarias\nb. El eculizumab se utiliza en las anemias hemolíticas hereditarias\nc.\n \nSe tienen que evitar factores desencadenantes en el caso de anemias hemolíticas por deficiencia de\nG6PD\n\nBIBLIOGRAFÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":101,"lines":{"from":1,"to":15}}}}],["426",{"pageContent":"Asha S. Hemolytic anemia. Indian J Med Sci. 2004; 58: 400-4.\nAsha S. Hemoglobinopathies and other congenital hemolytic anemia. Indian J Med Sci. 2004: 58; 490-1.\nAsha S. Acquired hemolytic anemia. Indian J Med Sci. 2004: 58; 533-6.\nBrodsky RA. Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria. Blood Rev. 2008;\n22(2): 65-74.\nDhaliwai D, Cornett P, Tierney L. Hemolytic anemia. Am Fam Phys. 2004; 69: 2599-606.\nD’Arena G, et al. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: A retrospective study of 11\npatients. Eur J Haematol. 2007: 79; 53-8.\nDjulbegovic B. Reasoning and decision making in hematology. London: Churchill Livingstone; 1992: 33-59.\nHebbel RP. Beyond hemoglobin polymerization: °e red blood cell membrane and sickle cell disease pathophys\n-\niology. Blood. 1991; 77: 214-37.\nHillman RS, Ault KA. Hemolytic anemias. En: Hematology in Clinical practice. A guide to diagnosis and manage-\nment. New York: McGraw-Hill, Inc.; 1995. p. 172-96.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":101,"lines":{"from":17,"to":30}}}}],["427",{"pageContent":"-\niology. Blood. 1991; 77: 214-37.\nHillman RS, Ault KA. Hemolytic anemias. En: Hematology in Clinical practice. A guide to diagnosis and manage-\nment. New York: McGraw-Hill, Inc.; 1995. p. 172-96.\nHillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, et al. Effect of the complement inhibitor\neculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007; 110(12):\n4123-8.\nHill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal noctur-\nnal haemoglobinuria. Br J Haematol. 2007; 137(3): 181-92.\nHoffman P, Morie G. Hemolytic anemia: Immune. En: Hoffman R. Hematology: Basic principles and practice. 5th\ned. Philadelphia, Pa: Elsevier Churchill Livingstone; 2008.\nPackman Ch. Hemolytic anemia due to warm antibodies. Blood Reviews. 2008; 22: 17-31.\nProvan D, Singer Ch, et al. Oxford handbook of clinical haematology. 2nd ed. Oxford: OUP Oxford; 2005. p. 68-9.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":101,"lines":{"from":30,"to":42}}}}],["428",{"pageContent":"Packman Ch. Hemolytic anemia due to warm antibodies. Blood Reviews. 2008; 22: 17-31.\nProvan D, Singer Ch, et al. Oxford handbook of clinical haematology. 2nd ed. Oxford: OUP Oxford; 2005. p. 68-9.\nRosse WF. °e natural history of paroxysmal nocturnal hemoglobinuria. Rev Invest Clin. 1997; 49, Supl. 1: 8-9.\nRuiz Reyes G. Hemoglobinas anormales y talasemias en la República Mexicana. Rev Invest Clin. 1998; 50:163-70.\nRoss W, Hillman P, et al. Immune-mediated hemolytic anemia. Washington, D.C.: American Society of Hemato-\nlogy. 48-62.\nSavage WJ, Brodsky RA. New insights into paroxysmal nocturnal hemoglobinuria. Hematology. 2007; 20: 1.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":101,"lines":{"from":42,"to":48}}}}],["429",{"pageContent":"RESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\n1.\n \nb\n2.\n \nc\n3.\n \nc\n4.\n \nb\n5.\n \nb","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":101,"lines":{"from":50,"to":66}}}}],["430",{"pageContent":"77\n\nINTRODUCCIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":104,"lines":{"from":1,"to":3}}}}],["431",{"pageContent":"El eritrocito humano se caracteriza por su forma de disco y por su habilidad para deformarse pasiva-\nmente durante sus viajes repetitivos a través de la microcirculación. La deformación pasiva es relevante\npara la liberación tisular de oxígeno ya que para que acontezca adecuadamente y se alcancen los sitios de\nliberación de oxígeno, es necesario que los eritrocitos atraviesen capilares de 2 a 3 micras de diámetro,\ncuando el promedio del diámetro del eritrocito es de 8 micras. Esto es posible gracias a las características\nde la membrana de los eritrocitos. Esta membrana es altamente elástica (100 veces más suave que una\nestructura de caucho de grosor similar) y es capaz de sufrir extensiones de hasta 2,8 veces el diámetro del\neritrocito sin fragmentarse. Así, la membrana eritrocitaria participa de manera importante tanto en la\nforma como en la capacidad de deformación de los eritrocitos. Los defectos en la estructura o función de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":104,"lines":{"from":5,"to":13}}}}],["432",{"pageContent":"forma como en la capacidad de deformación de los eritrocitos. Los defectos en la estructura o función de\nlos componentes de la membrana eritrocitaria ocasionan –en la mayoría de los casos– destrucción pre-\nmatura de los eritrocitos y padecimientos hemáticos con características morfológicas, fisiopatogénicas y\nclínicas que dependen del tipo de defecto que ocurra en la membrana. En este capítulo se describen las\nanemias hemolíticas asociadas con los defectos de la membrana eritrocítica.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":104,"lines":{"from":13,"to":17}}}}],["433",{"pageContent":"CARACTERÍSTICAS Y COMPONENTES\nDE LA MEMBRANA ERITROCÍTICA\n\nLa membrana eritrocítica es una estructura compuesta, en la cual la membrana plasmática –integrada\npor una bicapa de lípidos– está anclada a una red de proteínas que forman el citoesqueleto.\n\nCAPÍTULO 6\n\nANEMIAS HEMOLÍTICAS\nCAUSADAS POR\nTRASTORNOS DE LA\nMEMBRANA ERITROCÍTICA\n\nRenán A. Góngora Biachi\nPedro González Martínez\n\nObjetivos de aprendizaje\n\n•\n \nConocer las características y componentes de la membrana del eritrocito.\n\n•\n \nComprender la estructura del citoesqueleto.\n\n•\n \nEntender los mecanismos de las anemias hemolíticas asociadas con defectos de la membrana eritrocítica.\n\nLa\n \nmembrana\n \neritrocitaria\nparticipa de manera impor-\ntante tanto en la forma como\nen la deformabilidad de los\neritrocitos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":104,"lines":{"from":19,"to":57}}}}],["434",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n78","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":105,"lines":{"from":1,"to":3}}}}],["435",{"pageContent":"La membrana del eritrocito forma una frontera entre el interior de la célula y el plasma. Así, integra\nuna barrera que permite mantener altas concentraciones de hemoglobina y cifras diferentes de iones y\nmetabolitos en plasma. La característica principal de la membrana es su insolubilidad al agua, y esto se\ndebe a que está integrada en más del 50% por lípidos que forman una bicapa.\nEl 95% del total de lípidos de la membrana lo integran los fosfolípidos y el colesterol no esterificado.\nEstos lípidos se hallan en concentraciones equimolares y, en conjunto con otros lípidos (glucolípidos,\nglicéridos y ácidos grasos), constituyen una bicapa en forma de “hojuela” bimolecular, en donde los grupos\npolares de cada capa emergen al ambiente hidrofílico del citoplasma o del plasma, mientras que las termi-\nnaciones de estas moléculas –situadas en la porción central de la bicapa– forman el centro hidrofóbico de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":105,"lines":{"from":5,"to":13}}}}],["436",{"pageContent":"naciones de estas moléculas –situadas en la porción central de la bicapa– forman el centro hidrofóbico de\nla membrana. Este centro hidrofóbico facilita la flexibilidad y deformación de la membrana del eritrocito.\nMuchas de las proteínas de la membrana se insertan en ella a través de esta matriz lipídica, permitiendo\nque parte de la estructura proteica esté en el citoplasma y parte en contacto con el plasma\n \n(fig. 6-1)\n.\nEl esqueleto de la membrana del eritrocito es en sí una red de proteínas en la superficie interna de\nla membrana y es el responsable del mantenimiento de la forma, estabilidad y deformación de estas\ncélulas. Los principales componentes de la membrana son espectrina, actina, proteína 4.1, aducina,\nankirina, tropomiosina, tropomodulina, dematina (banda 4.9), transportador de aniones (banda 3), la\nbanda 4.2 y el anclaje glucolípido (véase fig. 6-1).\nLa espectrina está compuesta por dos subunidades\n \nα\n \ny\n \nβ\n. Son estructuralmente distintas y se encuen-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":105,"lines":{"from":13,"to":32}}}}],["437",{"pageContent":"banda 4.2 y el anclaje glucolípido (véase fig. 6-1).\nLa espectrina está compuesta por dos subunidades\n \nα\n \ny\n \nβ\n. Son estructuralmente distintas y se encuen-\ntran codificadas por genes diferentes. Hay aproximadamente 200 000 copias de espectrina por célula y\nrepresenta el 25 a 30% del total de las proteínas de membrana.\nLos eritrocitos contienen aproximadamente 400 000 a 500 000 monómeros de actina por célula, lo\nque equivale a 15 mg/mL. La actina eritrocitaria se organiza en filamentos cortos de aproximadamente\n30 a 40 nm (12 a 14 monómeros), lo que permite integrar aproximadamente 30 000 complejos de unión\ncon espectrina.\nLa proteína 4.1 es una de las más abundantes en el esqueleto del eritrocito. Está presente aproximada\n-\nmente con 200 000 copias por célula. La proteína 4.1 enlaza los dímeros de espectrina con la glucoforina\ny con la actina. Esta proteína es de aproximadamente 80 kDa.\nLa aducina actúa como un factor de ensamble entre la espectrina y la actina. Está formada por dos\nunidades:\n \nα","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":105,"lines":{"from":32,"to":54}}}}],["438",{"pageContent":"y con la actina. Esta proteína es de aproximadamente 80 kDa.\nLa aducina actúa como un factor de ensamble entre la espectrina y la actina. Está formada por dos\nunidades:\n \nα\n \nde 103 kDa y\n \nβ\n \nde 97 kDa.\nLa ankirina (del griego\n \nankira\n, que significa “ancla”) o banda 2.1 es la principal proteína que participa\nen la fijación del citoesqueleto. Hay 100 000 copias de ankirina por eritrocito y corresponde una ankirina\npor tetrámero de espectrina. La ankirina se fija por un lado a la banda 3 o transportadora de aniones\n(proteína situada a través de la membrana) y, por otro, a la espectrina\n \nβ\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":105,"lines":{"from":54,"to":74}}}}],["439",{"pageContent":"Figura 6-1.\n \nRepresentación esquemática de las estructuras de la membrana eritrocítica y del citoesqueleto\ny su interrelación.\n\nEl esqueleto de la membrana\ndel eritrocito es en sí una red de\nproteínas en la superficie in-\nterna de la membrana y es el\nresponsable del mantenimiento\nde la forma, estabilidad y de-\nformación de estas células.\nLa espectrina está compuesta\npor dos subunidades\n \nα\n \ny\n \nβ\n. Son\nestructuralmente\n \ndistintas\n \ny\nson codificadas por genes dife-\nrentes. Hay aproximadamente\n200 000 copias de espectrina\npor célula, lo que representa el\n25 a 30% del total de las pro-\nteínas de la membrana.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":105,"lines":{"from":76,"to":107}}}}],["440",{"pageContent":"CAPÍTULO 6. ANEMIAS HEMOLÍTICAS\n\n79","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":106,"lines":{"from":1,"to":3}}}}],["441",{"pageContent":"La tropomiosina es una proteína de 60 kDa y representa el 1% del total de las proteínas de la membrana\ndel eritrocito, con 70 000 a 80 000 copias por célula. Esta proteína estabiliza los filamentos de actina.\nLa tropomodulina, polipéptido de 43 kDa, modula la interacción de la tropomiosina con los\nfilamentos de actina y contribuye en el alargamiento de estos.\nLa banda 4.9 (dematina) participa en la estabilización de la membrana a través de la fosforiliza -\nción del AMP cíclico mediante la cinasa de proteínas. El transportador de intercambio de aniones\n(banda 3, AE1) permite el flujo del HCO\n \n3\n–\n \nde la célula en intercambio con el Cl\n \n–\n \nplasmático, para así\nequilibrar el HCO\n \n3\n–\n \nentre los eritrocitos y el plasma. El alto intercambio de Cl -/HCO3- a través de\nla membrana es el resultado de la abundancia de la banda 3 y permite el intercambio de estos iones\nen 0,4 a 0,5 seg en condiciones normales. Por su interacción con la ankirina, forma parte del citoes -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":106,"lines":{"from":5,"to":28}}}}],["442",{"pageContent":"la membrana es el resultado de la abundancia de la banda 3 y permite el intercambio de estos iones\nen 0,4 a 0,5 seg en condiciones normales. Por su interacción con la ankirina, forma parte del citoes -\nqueleto y participa en las propiedades mecánicas del eritrocito.\nLa banda 4.2 es una proteína de 72 kDa que contribuye aproximadamente con el 5% del contenido protei\n-\nco de la membrana y está presente en 200 000 copias por célula. La función de esta proteína aún se desconoce.\nEl anclaje glucolípido de las proteínas de la superficie de la membrana es una estructura que se fija en la\nbicapa lipídica y está formado por un complejo que incluye fosfatidilinositol, glucosamina, manosa y etano-\nlamina. Se ha denominado también “anclaje de glucosilfosfatidilinositol” (GPI). Un conjunto de proteínas\nexternas de la membrana se fijan a esta a través del GPI. En el\n \ncuadro 6-1\n \nse relacionan estas proteínas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":106,"lines":{"from":28,"to":41}}}}],["443",{"pageContent":"ESTRUCTURA DEL CITOESQUELETO","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":106,"lines":{"from":43,"to":43}}}}],["444",{"pageContent":"La espectrina está compuesta por dos subunidades (espectrinas\n \nα\n \ny\n \nβ\n) que se unen lado a lado para formar\nun heterodímero. Los heterodímeros de la espectrina se unen en forma terminoterminal para constituir\ntetrámeros. Las terminaciones de los tetrámeros están unidas con la actina. La longitud del filamento de\nactina puede ser modulada por la tropomiosina. Seis complejos terminales con cada oligómero de actina\ncrean una red de forma hexagonal. Cada unión de espectrina-actina se estabiliza al formar un compuesto\nterciario con la proteína 4.1 mediante una interacción directa con la espectrina. La aducina es otra proteí\n-\nna que estabiliza la interacción de la espectrina con la actina. La unión del esqueleto a la bicapa lipídica\nocurre por medio de la ankirina, que simultáneamente se une con la espectrina en el esqueleto y con la\nbanda 3 en la bicapa.\nEl segundo puente de unión está dado por la glucoforina C con la proteína del esqueleto 4.1. Con estas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":106,"lines":{"from":45,"to":62}}}}],["445",{"pageContent":"banda 3 en la bicapa.\nEl segundo puente de unión está dado por la glucoforina C con la proteína del esqueleto 4.1. Con estas\nuniones, la bicapa lipídica es acoplada mecánicamente al esqueleto\n \n(fig. 6-1)\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":106,"lines":{"from":62,"to":67}}}}],["446",{"pageContent":"Cuadro 6-1.\n \nProteínas ancladas al complejo glucosilfosfatidilinositol de la membrana del eritrocito\n\nClase\n \nProteína\nProteínas de la herencia celular\n \nSulfato de\n \npr\notoheparán\n\nProteínas relacionadas\ncon la función inmunitaria\n\nProteínas reguladoras del complemento: CD55 (DAF)\nCD59 (HRP-CD59)\nProteínas fijadoras de C8 (HRF65/HRFC8bp)\nProteínas inductoras de señales y receptores:\nAntígeno 3 relacionado con la función linfocitaria\nCD14 (proteínas receptora y fijadora de endotoxina)\nCD24 (activador de las células B)\nReceptor IIIa del Fc\n\nEnzimas\n\nFosfatasa\n \nalcalina\nAcetilcolinesterasa\nFosfodiesterasa\n \nalcalina\n5\n \n’-ectonucleotidasa\n \nde los\n \nlinfocitos\n\nReceptores no inmunitarios\n \nProteínas fijadora de\n \nfolatos\nReceptor de\n \nur\nocinasa\nDAF = factor que acelera la degradación de las convertasas; HRF = factor de restricción de la actividad citolítica del comple-\nmento homólogo; Fc = terminación Fc de las inmunoglobulinas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":106,"lines":{"from":69,"to":122}}}}],["447",{"pageContent":"El\n \nanclaje\n \nglucolípido\n \nde\n \nlas\nproteínas de la superficie de la\nmembrana es una estructura que\nse fija en la bicapa lipídica y está\nformado por un complejo que\nincluye fosfatidilinositol, gluco-\nsalina, manosa y etanolamina.\nLa espectrina está compuesta\npor dos subunidades (espectri-\nnas\n \nα\n \ny\n \nβ\n) que se unen lado a\nlado para formar un hetero-\ndímero. Los heterodímeros de\nla espectrina se unen en forma\nterminoterminal para consti-\ntuir tetrámeros. Las termina-\nciones de los tetrámeros están\nunidas con la actina.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":106,"lines":{"from":124,"to":155}}}}],["448",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n80\n\nANEMIAS HEMOLÍTICAS ASOCIADAS CON DEFECTOS\nDE MEMBRANA ERITROCÍTICA\n\nEl\n \ncuadro 6-2\n \ncontiene un grupo de anemias hemolíticas secundarias a la membrana del eritrocito. Como\npuede observarse, la mayoría de ellas es hereditaria.\n\nEsferocitosis hereditaria\n\nLa esferocitosis hereditaria (EH) es un padecimiento hereditario (en la mayoría de los casos) que se carac-\nteriza por defectos en el citoesqueleto de los eritrocitos que condicionan hemólisis de intensidad variable,\nmicroesferocitos en el extendido de sangre periférica, incremento en la fragilidad osmótica de los eritro-\ncitos y una respuesta clínica y favorable a la esplenectomía.\n\nDefinición","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":107,"lines":{"from":1,"to":22}}}}],["449",{"pageContent":"Definición\n\nLas esferocitosis hereditarias (EH) son un grupo de padecimientos hereditarios (en la mayoría de los casos)\nque se caracterizan por defectos en el citoesqueleto de los eritrocitos que condicionan hemólisis de intensidad\nvariable, microesferocitos en el extendido de sangre periférica, incremento en la fragilidad osmótica de los\neritrocitos y una respuesta clínica favorable a la esplenectomía.\n\nEpidemiología","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":107,"lines":{"from":22,"to":29}}}}],["450",{"pageContent":"Es un padecimiento autosómico dominante, de penetrancia variable en el 66 a 75% de los casos. En los\ndemás pacientes la herencia puede ser autosómica recesiva o debido a una mutación de novo. Representa\nla más común de las anemias hemolíticas hereditarias en la población de ascendencia europea, con una\nincidencia de 1 caso en 5 000 personas. Es probable que en esta población la frecuencia del padecimiento\nsea mayor, ya que hay informes que señalan incrementos en la fragilidad osmótica (característica de la\nEH) en alrededor del 1% de los donadores. En otros grupos étnicos (asiáticos y africanos), se desconoce\naún la prevalencia, aunque se informa con menos frecuencia. En las zonas central y noroeste de México\nse reconoce como la anemia hemolítica hereditaria más frecuente, caso diferente a lo encontrado en el\nsureste de este país, en donde su frecuencia es baja. Inclusive la búsqueda intencionada de casos en la etnia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":107,"lines":{"from":31,"to":39}}}}],["451",{"pageContent":"sureste de este país, en donde su frecuencia es baja. Inclusive la búsqueda intencionada de casos en la etnia\nmaya del sureste de México ha demostrado una prevalencia casi nula de esta enfermedad. Asimismo, se\ndesconoce la frecuencia en otras etnias de amerindios.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":107,"lines":{"from":39,"to":41}}}}],["452",{"pageContent":"Cuadro 6-2.\n \nAnemias hemolíticas asociadas con defectos de la membrana eritrocítica\n\nGrupo\n \nPadecimientos\nI. Hereditarias\n\nEsferocitosis\n \nher\neditaria\nEliptocitosis hereditaria\n \ncomún\nEliptocitosis esferocítica u ovalocitosis\n \nher\neditaria\nEliptocitosis\n \nestomatocítica\n \nu ovalocitosis del sureste de Asia\nPiropoiquilocitosis\n \nher\neditaria\nEstomatocitosis\n \nher\neditaria\nAcantocitosis\nAbetalipoproteinemia\n \ncongénita\n \nSíndrome de\n \ncor\nea-acantocitosis\nXerocitosis\n \nher\neditaria\nDeficiencia hereditaria de HRF20/CD59\nDeficiencia de los\n \nantígenos\n \nRh Síndrome de McLeod\n\nII. Adquiridas\n\nAcantocitosis asociada con\n \nhepatopatía\nEstomatocitosis\n \nadquirida\nHemoglobinuria paroxística\n \nnoctur\n \nna","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":107,"lines":{"from":43,"to":108}}}}],["453",{"pageContent":"II. Adquiridas\n\nAcantocitosis asociada con\n \nhepatopatía\nEstomatocitosis\n \nadquirida\nHemoglobinuria paroxística\n \nnoctur\n \nna\n\nLa\n \nesferocitosis\n \nhereditaria\n(EH) es un padecimiento he-\nreditario (en la mayoría de los\ncasos) que se caracteriza por\ndefectos en el citoesqueleto de\nlos eritrocitos que condicio-\nnan hemólisis de intensidad\nvariable, microesferocitos en\nel extendido de sangre perifé-\nrica, incremento en la fragili-\ndad osmótica de los eritrocitos\ny una respuesta clínica y favo-\nrable a la esplenectomía.\nEn las zonas central y noreste\nde México se reconoce como la\nanemia hemolítica heredita-\nria más frecuente, caso di-\nferente a lo encontrado en el\nsureste de este país, en donde\nsu frecuencia es baja.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":107,"lines":{"from":108,"to":145}}}}],["454",{"pageContent":"CAPÍTULO 6. ANEMIAS HEMOLÍTICAS\n\n81\n\nPatogénesis\n\nLas cuatro condiciones que ocasionan este padecimiento son: 1) pérdida del área de la superficie de la membrana,\nque ocasiona disminución de la relación área/volumen y reducción de la capacidad de deformación del eritrocito;\n2) la pérdida del área de superficie es causada por un incremento de la fragilidad de la membrana, debida a su vez\na defectos en las proteínas de la membrana; 3) la fragilidad incrementada de la membrana del eritrocito produce\nvesiculación y pérdida de la misma y 4) una actividad esplénica normal que selectivamente afecta a los esferocitos.\n\nDefectos de la membrana eritrocitaria","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":108,"lines":{"from":1,"to":13}}}}],["455",{"pageContent":"Existe un defecto en algunas de las proteínas de membrana, que incluye a la ankirina, la banda 3, la espec\n-\ntrina\n\u0003β\n, la espectrina\n \nα\n \ny la proteína 4.2. Este defecto debilita la unión del esqueleto a la bicapa lipídica,\nlo que reduce su estabilidad y condiciona la formación de microvesículas en la membrana y pérdida de\nmaterial lipídico. Todo esto ocasiona que disminuya la relación entre el área del volumen del eritrocito y\nque este se torne esférico.\nLa deficiencia concomitante de espectrina (\nα\n \no\n \nβ\n) y ankirina es el hallazgo más común en la membrana\nde los esferocitos. El grado de anormalidad de la espectrina es paralelo al de la ankirina en la EH típica. En\nmuchos casos de EH, la deficiencia de espectrina puede ser secundaria a la deficiencia o disfunción de la an-\nkirina; esta anormalidad, o su acumulación en la membrana del eritrocito, ocasiona disminución del ensam-\nble de la espectrina a la membrana. El grado de la anormalidad de la espectrina correlaciona directamente","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":108,"lines":{"from":15,"to":37}}}}],["456",{"pageContent":"ble de la espectrina a la membrana. El grado de la anormalidad de la espectrina correlaciona directamente\ncon la hemólisis, con el incremento de la fragilidad osmótica y con la respuesta clínica a la esplenectomía.\nOtra causa detectada en el 10% de los casos de EH es un defecto de unión de la espectrina\n β\n \na la proteína\n4.1 y a la actina. Los eritrocitos de estos pacientes también son parcialmente deficientes en espectrina. En\nalgunos enfermos con EH se ha detectado una deficiencia de la proteína 4.2, y en un subgrupo de sujetos con\n“esferocitosis acantocítica” se ha descrito un defecto en la unión de la espectrina con la proteína 4.1. En otros\npacientes se ha informado deficiencia de la banda 3 o alteraciones en la unión de esta con la proteína 4.2.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":108,"lines":{"from":37,"to":46}}}}],["457",{"pageContent":"Actividad esplénica y destrucción de esferocitos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":108,"lines":{"from":48,"to":48}}}}],["458",{"pageContent":"Los efectos del paso de los esferocitos a través del bazo han sido demostrados con eritrocitos obtenidos de\nesplenectomías. Estos son osmóticamente más frágiles, más esféricos y contienen menor concentración\nde Na\n+\n \ny K\n+\n \nque las células obtenidas de la sangre periférica. Asimismo, la esplenectomía reduce la fragi -\nlidad de los esferocitos, aunque no la normaliza. El defecto de unión de la espectrina a la bicapa lipídica\npermite el desprendimiento de pequeños pedazos de esta, en forma de microvesículas de citoesqueleto\nlibre en los vasos sanguíneos. En la medida que un mayor número de vesículas se desprenden, el eritrocito\ndisminuye de tamaño y se hace menos bicóncavo y más redondo, adoptando la forma de microesferocito,\nque resulta más rígido y menos deformable. Estos eritrocitos pueden atravesar las fenestraciones de las\ncélulas endoteliales de la vasculatura sistémica, pero encuentran progresivamente mayor dificultad para","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":108,"lines":{"from":50,"to":64}}}}],["459",{"pageContent":"células endoteliales de la vasculatura sistémica, pero encuentran progresivamente mayor dificultad para\ndeformarse y atravesar las fenestraciones más pequeñas de los senos esplénicos, quedando así atrapados,\ncongestionando la pulpa roja y causando esplenomegalia.\nEl estancamiento esplénico de los microesferocitos permite que los macrófagos remuevan más de la bicapa\nlipídica de la membrana de los eritrocitos. Aunque muchos de estos eventualmente escapan de la pulpa roja,\ndespués de aproximadamente 30 ciclos de paso, son tan rígidos que es imposible salvar estas fenestraciones.\nEstancados en la pulpa roja y depletados de glucosa/ATP, con un pH bajo y altas concentraciones de radicales\nlibres tóxicos, fallan las bombas celulares y sobreviene edema de los microesferocitos y ulterior lisis. Por ello los\neritrocitos defectuosos pueden vivir, en casos graves de EH, solo algunas horas o 25 días en casos moderados. El","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":108,"lines":{"from":64,"to":72}}}}],["460",{"pageContent":"eritrocitos defectuosos pueden vivir, en casos graves de EH, solo algunas horas o 25 días en casos moderados. El\npaso final de la destrucción de estas células es la fagocitosis por macrófagos. Los cambios en los esferocitos que\nfavorecen e inducen esta fagocitosis no han sido totalmente definidos. Se ha propuesto que una alteración en la\norientación de los lípidos de la membrana celular permite el reconocimiento de estas células por los macrófagos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":108,"lines":{"from":72,"to":75}}}}],["461",{"pageContent":"Manifestaciones clínicas\nForma típica\n\nLos datos clínicos incluyen anemia moderada presente desde la edad infantil, ictericia acolúrica, espleno-\nmegalia y hallazgos similares en algunos de los padres o hermanos. Sin embargo, en la misma familia la\nintensidad de la enfermedad es variable y es posible encontrar familiares directos con formas moderadas\n\nLa deficiencia concomitante de\nespectrina (\nα\n \no\n \nβ\n) y ankirina\nes el hallazgo más común en la\nmembrana de los esferocitos.\nLos\n \ndatos\n \nclínicos\n \nincluyen\nanemia\n \nmoderada\n \npresente\ndesde la edad infantil, icteri-\ncia acolúrica, esplenomegalia\ny hallazgos similares en algu-\nnos de los padres o hermanos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":108,"lines":{"from":77,"to":109}}}}],["462",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n82\n\nde EH. Los pacientes con EH típica pueden desarrollar complicaciones que incluyen litiasis vesicular,\nanemia megaloblástica por deficiencia de folatos, aplasia pura de serie roja (habitualmente asociada con\ninfección por parvovirus B19), crisis de aplasia medular y crisis hemolíticas (asociadas con procesos infec-\nciosos). Las crisis hemolíticas se acompañan habitualmente de aumento de la esplenomegalia.\nSe han informado algunos casos de EH “dominante doble” (herencia de ambos padres o herencia de al\nmenos dos defectos para EH), que ocasiona muerte fetal o anemia hemolítica grave en el período neonatal.\n\nForma moderada","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":109,"lines":{"from":1,"to":12}}}}],["463",{"pageContent":"Forma moderada\n\nPor lo regular, la forma moderada de este padecimiento se detecta al evaluar a familiares de un caso ín-\ndice con modalidad típica de EH, durante el embarazo o durante un proceso infeccioso; la anemia está\nausente, ya que la hemólisis está compensada, aunque se detecta de manera frecuente un incremento de\nlos reticulocitos sin hiperbilirrubinemia y sin esplenomegalia. Los defectos morfológicos clásicos (mi-\ncroesferocitos), en la mayoría de los casos, son indetectables y la evidencia de la enfermedad se hace por\nmedio de pruebas de fragilidad osmótica. Ocasionalmente, el diagnóstico se realiza al investigar la causa\nde esplenomegalia o supresión eritropoyética, habitualmente asociada con parvovirus B19.\n\nEstado de portador asintomático","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":109,"lines":{"from":12,"to":22}}}}],["464",{"pageContent":"Estado de portador asintomático\n\nEsta condición se ha detectado en familiares de pacientes con EH. Generalmente la prueba de fragilidad\nosmótica con glóbulos incubados 24 horas es positiva y los valores de hematocrito, reticulocitos, haptoglo-\nbinas plasmáticas y bilirrubinas están en los límites normales.\n\nDiagnóstico","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":109,"lines":{"from":22,"to":28}}}}],["465",{"pageContent":"Diagnóstico\n\nEn los casos típicos de EH, el diagnóstico se lleva a cabo al detectar un patrón de herencia autosómico\ndominante, anemia hemolítica crónica moderada, esplenomegalia, microesferocitos en los extendidos de\nsangre periférica y una prueba positiva de fragilidad osmótica. En quienes no puede determinarse el\npatrón de herencia, el diagnóstico debe diferenciarse de otras causas de esferocitosis, como la anemia\nhemolítica autoinmunitaria, y de las hemoglobinopatías inestables.\nEn los casos moderados de EH o en portadores asintomáticos, el diagnóstico se llevará a cabo deter-\nminando la fragilidad osmótica de eritrocitos incubados 24 horas.\nLa caracterización del defecto de membrana por electroforesis es un método útil, pero que no ha supli-\ndo aún la eficacia de la prueba de fragilidad osmótica. La prueba de autohemólisis también es un examen\nútil para el diagnóstico de la EH, pero no tiene ventaja sobre la prueba de fragilidad osmótica.\n\nComplicaciones","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":109,"lines":{"from":28,"to":41}}}}],["466",{"pageContent":"Complicaciones\n\nLa más común es la colelitiasis y los eventos asociados a ella: obstrucción biliar, colecistitis y colangitis. Lo\ncoexistencia del síndrome de Gilbert (que no es infrecuente en la población mestiza latinoamericana) in-\ncrementa el riesgo de ictericia neonatal y de colelitiasis en estos pacientes. Las crisis hemolíticas (asociadas\nfrecuentemente a infecciones virales en niños), aplásicas (vinculadas a parvovirus B19) y megaloblásticas\n(relacionadas a incremento de demanda de folatos, como el crecimiento, el embarazo y en los ancianos con\ndeficiencias alimenticias) son otras complicaciones.\nEn algunos casos de EH hay retraso en el crecimiento, cambios en el esqueleto, úlceras en piernas y\ntumores hematopoyéticos extramedulares.\n\nTratamiento","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":109,"lines":{"from":41,"to":52}}}}],["467",{"pageContent":"Tratamiento\n\nLas formas moderadas de esferocitosis hereditaria y los portadores asintomáticos no requieren tratamiento. Se\nha sugerido un aporte suplementario de ácido fólico (1 mg/día) en los pacientes con forma moderada de EH.\nPor otro lado, la esplenectomía sigue siendo el tratamiento de elección de la forma típica de EH. En la\nactualidad, la esplenectomía laparoscópica es el método quirúrgico de elección. Es interesante que la inci-\ndencia de infecciones posesplenectomía en la EH ha sido comunicada con menos frecuencia que en otras\ncondiciones hematológicas. La falla de la esplenectomía en algunos pacientes puede deberse a un bazo ac-\ncesorio (informado en alrededor del 39% de los pacientes con EH), autotrasplante esplénico accidental en la\ncavidad peritoneal al momento de la esplenectomía (manifestado 7 a 15 años más tarde) o la presencia de otra","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":109,"lines":{"from":52,"to":61}}}}],["468",{"pageContent":"La esplenectomía sigue siendo\nel tratamiento de elección de\nla forma típica de EH\nEn los casos típicos de EH, el\ndiagnóstico se lleva a cabo al\ndetectar un patrón de heren -\ncia\n \nautosómica\n \ndominante,\nanemia\n \nhemolítica\n \ncrónica\nmoderada,\n \nesplenomegalia,\nmicroesferocitos\n \nen\n \nlos\n \nex -\ntendidos de sangre periféri-\nca y una prueba positiva de\nfragilidad osmótica.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":109,"lines":{"from":63,"to":91}}}}],["469",{"pageContent":"CAPÍTULO 6. ANEMIAS HEMOLÍTICAS\n\n83\n\nenfermedad hemolítica concomitante (p. ej., deficiencia de la piruvatocinasa). También debe considerarse un\ndiagnóstico erróneo de EH. Por el riesgo de infección en los niños, la esplenectomía ha de realizarse hasta\nlos 6 años de edad. Recientemente se han reconocido otras complicaciones asociadas a la esplenectomía,\ncomo la emergencia de neumococos resistentes a penicilina, incremento de riesgo cardiovascular e hiperten-\nsión pulmonar. Aunque queda por definir la incidencia real de estos eventos, deben considerarse antes de la\nindicación de esplenectomía.\n\nEliptocitosis hereditaria y padecimientos relacionados\nDefinición\n\nLa eliptocitosis hereditaria (EL-H) comprende un grupo de padecimientos hereditarios heterogéneos\nclínica, genética y bioquímicamente, que tienen en común la presencia de eritrocitos elípticos.\nLa EL-H se hereda con un patrón autosómico dominante, con raros casos de mutación de novo, y\nmorfológicamente se clasifica en tres grupos:","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":110,"lines":{"from":1,"to":18}}}}],["470",{"pageContent":"•\n \nEL-H común\n\n•\n \nEL-H esferocítica u ovalocitosis hereditaria (un fenotipo híbrido entre la EH y la EL-H)\n\n•\n \nEliptocitosis estomatocítica u ovalocitosis del sureste de Asia (padecimiento altamente prevalente\nen esta región de Asia y que confiere resistencia a la infección por\n \nPlasmodium\n)\nOtro padecimiento relacionado con la EL-H es la piropoiquilocitosis hereditaria (PPH), padecimien-\nto raro, de tipo autosómico recesivo y que se manifiesta por marcada micropoiquilocitosis, microesferoci-\ntosis y ocasionalmente eliptocitosis, con volúmenes corpusculares muy bajos (50 a 60 fL).\n\nPatogénesis","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":110,"lines":{"from":20,"to":39}}}}],["471",{"pageContent":"Patogénesis\n\nLa lesión primaria de eliptocitosis hereditaria se encuentra en las proteínas del esqueleto de la membrana\ny se caracteriza por inestabilidad térmica de la espectrina, desintegración de dicho esqueleto después de\nser sometido a esfuerzos tensionales, defectos en la interunión de la espectrina y alta susceptibilidad a la\ndigestión por tripsina de la espectrina.\nActualmente se reconoce que existe disfunción o deficiencia en algunas proteínas del citoesqueleto de\nlos eritrocitos. Las anormalidades ultraestructurales en la EL-H y la PPH están asociadas con disminu -\nción en la estabilidad de la membrana y con un incremento de la rigidez de estas células, lo que explica su\nfragmentación y destrucción.\n\nDefectos del citoesqueleto","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":110,"lines":{"from":39,"to":50}}}}],["472",{"pageContent":"La mayoría de las mutaciones se localizan en el gen de espectrina (\nα\n \ny\n \nβ\n) (gen\n \nSPTA1\n) de la proteína 4.1\ny con menor frecuencia en el de la glucoforina. En el 50 a 60% de los casos de EL-H se detecta una unión\ndefectuosa entre las porciones terminales de los heterodímeros de la espectrina, más que un defecto es-\ntructural de esta proteína, que impide se formen los tetrámeros de espectrina, lo que en su turno ocasiona\ndesestabilización de citoesqueleto y, en consecuencia, de la membrana del eritrocito. Otros defectos en la\nespectrina que impiden su unión con la ankirina han sido descritos en la EL-H y PPH.\nLa deficiencia de la proteína 4.1 o una mutación en su estructura condicionan defectos en la integridad\nmecánica de la membrana que se traduce en EL-H. Los eritrocitos muestran una acelerada fragmenta-\nción, produciendo una anemia hemolítica de grado moderado a intenso. Se han identificado dos patrones","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":110,"lines":{"from":52,"to":69}}}}],["473",{"pageContent":"mecánica de la membrana que se traduce en EL-H. Los eritrocitos muestran una acelerada fragmenta-\nción, produciendo una anemia hemolítica de grado moderado a intenso. Se han identificado dos patrones\nde EL-H asociados con este defecto: el denominado 4.1(–)HE, que define una deficiencia cuantitativa de\nla proteína, y el patrón 4.1(+)HE, que determina defectos cualitativos y estructurales.\nLa deficiencia de glucoforina C ha sido encontrada en muy pocos casos de EL-H y se considera\ntambién un defecto productor de este padecimiento, aunque característicamente, a pesar de la elip -\ntocitosis, estos pacientes no presentan hemólisis. En algunos casos de EL-H se ha encontrado una\ndeficiencia de ankirina y se ha considerado que este es el defecto primario en estos casos. La deficiencia\ncompleta o parcial de la proteína 4.2 ha sido informada en algunos pacientes con EL-H, la mayoría de\nellos japoneses. Sin embargo, la deficiencia de esta proteína también se ha asociado con EH ovalocito -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":110,"lines":{"from":69,"to":78}}}}],["474",{"pageContent":"ellos japoneses. Sin embargo, la deficiencia de esta proteína también se ha asociado con EH ovalocito -\nsis-estomatocítica. En un informe, la deficiencia de esta proteína no se relacionó con alguna alteración\nmorfológica específica.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":110,"lines":{"from":78,"to":80}}}}],["475",{"pageContent":"En el 50 a 60% de los casos de\nEL-H se detecta una unión\ndefectuosa entre las porciones\nterminales de los heterodíme-\nros de la espectrina, que impi-\nde se formen los tetrámeros de\nespectrina, lo que a su vez oca\n-\nsiona desestabilización del ci-\ntoesqueleto y, en consecuencia,\nde la membrana del eritrocito.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":110,"lines":{"from":82,"to":92}}}}],["476",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n84\n\nEn la ovalocitosis hereditaria se ha identificado una mutación de\n \nLis\n \n56\n \nGlu\n \nque ocasiona una banda 3\ndefectuosa y en otros casos una verdadera deficiencia de esta banda, lo que ocasiona una disminución en\nla relación banda 3/espectrina.\nEn la PPH, dos defectos son los que se han caracterizado más comúnmente: una deficiencia parcial\nde la espectrina y una mutación en la espectrina\n \nα\n, que impide la agrupación de los heterodímeros. La\ndeficiencia de la proteína transportadora de aniones (banda 3) se ha relacionado en casos raros con PPH\ny con ovalocitosis del sureste de Asia.\n\nManifestaciones clínicas\nEL-H común","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":111,"lines":{"from":1,"to":25}}}}],["477",{"pageContent":"Este padecimiento es escaso en la población occidental y comúnmente se detecta en la raza negra. El esta-\ndo de portador asintomático se encuentra de manera habitual al realizar estudio familiar y demostrar las\nalteraciones bioquímicas de la EL-H. Típicamente estos pacientes tienen padres o primos afectados. La\neliptocitosis hereditaria mínima o moderada en la mayoría de los casos es asintomática y su identificación\nacontece al efectuar estudios sanguíneos de rutina. Algunos enfermos tienen datos de hemólisis leve y\ncompensada. En el extendido de sangre periférica, habitualmente se encuentra 16% o más de eliptocitos.\nLa EL-H con hemólisis esporádica define la hemólisis transitoria en los pacientes con este padecimiento y\nse asocia con situaciones condicionantes como infecciones (virales, bacterianas o por protozoarios), esple-\nnomegalia, embarazo, deficiencia de vitamina B12, entre otras. La variante EL-H con hemólisis crónica","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":111,"lines":{"from":27,"to":35}}}}],["478",{"pageContent":"nomegalia, embarazo, deficiencia de vitamina B12, entre otras. La variante EL-H con hemólisis crónica\nse ha descrito en algunos casos que han requerido de esplenectomía para controlar el padecimiento. La\nmayoría de estos casos son homocigotos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":111,"lines":{"from":35,"to":37}}}}],["479",{"pageContent":"Eliptocitosis esferocítica (ovalocitosis hereditaria)\n\nEs una forma relativamente rara de EL-H. Los eritrocitos muestran características de esferocitos y elip -\ntocitos “gordos”. Característicamente, estos pacientes presentan una hemólisis que es independiente del\ngrado de alteración morfológica en la sangre. La esplenomegalia es infrecuente.\n\nEliptocitosis estomatocítica (ovalocitosis del sureste de Asia)\n\nEste padecimiento es altamente prevalente (alrededor de 30%) en Malasia y Melanesia. Se caracteriza\npor su morfología específica: eritrocitos con “arremangamiento” de la hemoglobina que produce una\nimagen similar a la de una boca abierta. Es frecuente encontrar “puentes” que atraviesan al eritrocito","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":111,"lines":{"from":39,"to":49}}}}],["480",{"pageContent":"(fig. 6-2 A y B)\n. Esta condición es asintomática y no se ha asociado con destrucción prematura de eri -\ntrocitos. De hecho, comparada con otros defectos de membrana, en la ovalocitosis del sureste de Asia,\nel patrón de herencia es autosómico dominante y asociado a una deleción de 27 pb del gen de la banda\n3. La elevada prevalencia en esta región de Asia ha sugerido que quizá represente un mecanismo de\ndefensa contra la infección de\n \nPlasmodium\n. En Yucatán, México, se ha identificado este padecimiento\nen descendientes de coreanos que migraron a este país en 1905. Sin embargo, un informe de dos casos\nmexicanos, de familias diferentes, sin antecedentes de familiares asiáticos y con marcadores HLA (de\n\nhistocompatibility locus antigen\n) comunes a amerindios y a poblaciones asiáticas, demuestra que la de -\nleción que produjo este trastorno de membrana en estos pacientes mexicanos es el mismo descrito en\npoblación asiática.\n\nPiropoiquilocitosis hereditaria","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":111,"lines":{"from":51,"to":68}}}}],["481",{"pageContent":"Piropoiquilocitosis hereditaria\n\nEs un padecimiento raro caracterizado por anemia hemolítica intensa, debido a la morfología caracterís-\ntica descrita anteriormente y heredada como autosómica recesiva. Se ha encontrado de manera predomi-\nnante en la raza negra, aunque existen informes en árabes y en caucásicos. Más de la tercera parte de los\nmiembros de una familia de un paciente con PPH padecen de EL-H.\n\nDiagnóstico\n\nLa variabilidad clínica y la ausencia de hemólisis en la mayoría de los pacientes con EL-H hacen que\nel diagnóstico se base fundamentalmente en los datos morfológicos y en el patrón de transmisión","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":111,"lines":{"from":68,"to":78}}}}],["482",{"pageContent":"La variabilidad clínica y la ausencia de hemólisis en la mayoría de los pacientes con EL-H hacen que\nel diagnóstico se base fundamentalmente en los datos morfológicos y en el patrón de transmisión\n\nLa\n \neliptocitosis\n \nesferocítica\nes una forma relativamente\nrara de EL-H. Los eritrocitos\nmuestran características de es-\nferocitos y eliptocitos “gordos”.\nCaracterísticamente,\n \nes-\ntos pacientes presentan una\nhemólisis\n \nque\n \nes\n \nindepen-\ndiente del grado de alteración\nmorfológica en la sangre.\nLa piropoiquilocitosis heredi-\ntaria es un padecimiento raro\ncaracterizado por anemia he-\nmolítica intensa debido a la\nmorfología característica des-\ncrita anteriormente y hereda-\nda como autosómica recesiva.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":111,"lines":{"from":78,"to":109}}}}],["483",{"pageContent":"CAPÍTULO 6. ANEMIAS HEMOLÍTICAS\n\n85","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":112,"lines":{"from":1,"to":3}}}}],["484",{"pageContent":"autosómico dominante. La presencia de eliptocitos en un porcentaje igual o mayor al 15% debe hacer\nsospechar esta entidad (en sujetos normales, el porcentaje de eliptocitos no excede el 5%). Deben\nconsiderarse otras entidades que pueden relacionarse con presencia de eliptocitos: deficiencia de hie -\nrro, síndromes talasémicos, mielofibrosis y deficiencia de piruvatocinasa. En la EL-H con hemólisis\nintensa, el diagnóstico es sugerido por la presencia de eliptocitos, poiquilocitos y fragmentos celula -\nres. La PPH se diagnostica con bases morfológicas y el patrón de herencia autosómico recesivo. La\nprueba de fragilidad osmótica permite distinguir entre la eliptocitosis esferocítica y la EL-H común.\nEn la PPH, esta prueba muestra un incremento en la fragilidad.\nLa prueba de inestabilidad al calor (los eritrocitos normales se fragmentan y la espectrina se desnatu-\nraliza a temperaturas de 49 a 50 ºC) induce fragmentación de eritrocito de 45 a 46 ºC en la PPH y entre","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":112,"lines":{"from":5,"to":14}}}}],["485",{"pageContent":"raliza a temperaturas de 49 a 50 ºC) induce fragmentación de eritrocito de 45 a 46 ºC en la PPH y entre\n47 y 48 ºC en la EL-H, y es útil para el diagnóstico de estos trastornos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":112,"lines":{"from":14,"to":15}}}}],["486",{"pageContent":"Figura 6-2 (A).\n \nPuente intereritrocitario en un paciente con eliptocitosis estomatocítica u ovalocitosis del\nsureste de Asia.\n\nFigura 6-2 (B).\n Extendido de sangre periférica de un paciente con eliptocitosis estomatocítica u ovalocitosis\ndel sureste de Asia. Obsérvense las imágenes de puente intraeritrocitario, un estomatocito y eritrocitos con\nhemoglobina “arremangada”.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":112,"lines":{"from":17,"to":25}}}}],["487",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n86\n\nTratamiento\n\nLas formas intermedias de EL-H no requieren intervención terapéutica. Las formas moderadas de EL-H\ny los casos de PPH necesitan esplenectomía, aunque la respuesta no es tan completa como la que se obtie-\nne en los casos de esferocitosis hereditaria.\n\nAcantocitosis\nDefinición\n\nLos acantocitos o “células en espuela” son eritrocitos con múltiples proyecciones de la membrana celular\ny su presencia se asocia con padecimientos hepáticos, con abetalipoproteinemia congénita, retinitis pig-\nmentosa atípica (con o sin anormalidades de los lípidos), padecimientos neurológicos y fenotipo del grupo\nsanguíneo McLeod.\n\nAcantocitosis asociada con hepatopatía\nPatogénesis","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":113,"lines":{"from":1,"to":20}}}}],["488",{"pageContent":"Acantocitosis asociada con hepatopatía\nPatogénesis\n\nLa formación del acantocito depende de la acumulación de colesterol en la membrana del eritrocito\ny de la “remodelación” de estas células por el bazo. En pacientes con hepatopatía grave, el efecto\nacantocítico se observa aun en eritrocitos transfundidos y el mismo fenómeno acontece in vitro al\nincubar eritrocitos con suero de pacientes con esta condición. Este cambio de forma ocurre por la\ntransferencia de colesterol no esterificado a la membrana del eritrocito. El mecanismo que produce\nel cambio de eritrocito a acantocito se desconoce, pero se sabe que la acumulación del colesterol en\nla bicapa de la membrana es parte importante de él, afectando la función y estructura física de la\nmembrana. El efecto del bazo se puede comprobar en pacientes con esplenectomía, en quienes los\neritrocitos cambian su morfología a la de células en “diana” y hay datos que señalan un incremento\nen la superficie de la membrana celular.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":113,"lines":{"from":20,"to":32}}}}],["489",{"pageContent":"Manifestaciones clínicas\n\nAlgunos pacientes con cirrosis alcohólica desarrollan una anemia hemolítica rápida y progresiva que se\nrelaciona con una gran cantidad de acantocitos. La esplenomegalia y la ictericia se hacen más evidentes,\nse incrementan la ascitis, la tendencia hemorrágica y la encefalopatía hepática.\nMuy pocos enfermos presentan remisión espontánea y la mayoría de ellos fallecen en pocos días o\nsemanas. Un síndrome similar se ha asociado con carcinomatosis hepática metastásica avanzada, en la\nenfermedad de Wilson y en la hepatitis fulminante.\n\nNeuroacantocitosis","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":113,"lines":{"from":34,"to":43}}}}],["490",{"pageContent":"Neuroacantocitosis\n\nLa neuroacantocitosis (NA) define a un grupo heterogéneo de enfermedades genéticas, caracteriza -\ndas por la asociación de anormalidades neurológicas (corea, tics orofaciales, amiotrofía) con eritroci -\ntos de morfología acantocítica. Las NA pueden estar asociadas a niveles sanguíneos bajos o normales\nde apolipoproteína b. También se han descrito síndromes de NA que incluyen parkinsonismo,\nneuropatía periférica, miopatía y psicosis. Las variantes de la NA del adulto han sido asociadas con\nenfermedades cardiopáticas y trastornos del sistema inmunitario. Aunque la acantocitosis es notable\nen sangre periférica, no se asocia esta condición a anemia hemolítica en la gran mayoría de los casos.\nSin embargo, los síndromes de NA son frecuentemente fatales y sin relación con la condición de\nacantocitosis.\n\nAbetalipoproteinemia (síndrome de Bassen-Kornzweig)\nPatogénesis","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":113,"lines":{"from":43,"to":56}}}}],["491",{"pageContent":"Abetalipoproteinemia (síndrome de Bassen-Kornzweig)\nPatogénesis\n\nEl defecto primario es la ausencia congénita de la apolipoproteína\n \nβ\u0003\nen el plasma, secundaria a un\ndefecto de secreción de las células hepáticas de esta apoproteína. Así, todas las lipoproteínas que\n\nLos acantocitos o “células en\nespuela”\n \nson\n \neritrocitos\n \ncon\nmúltiples\n \nproyecciones\n \nde\n \nla\nmembrana celular y su presen-\ncia se asocia con padecimientos\nhepáticos,\n \nabetalipoproteine-\nmia congénita, retinitis pig-\nmentosa atípica, entre otros.\nAlgunos pacientes con cirro-\nsis alcohólica desarrollan una\nanemia hemolítica rápida y\nprogresiva\n \nque\n \nse\n \nrelaciona\ncon\n \nuna\n \ngran\n \ncantidad\n \nde\nacantocitos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":113,"lines":{"from":56,"to":106}}}}],["492",{"pageContent":"CAPÍTULO 6. ANEMIAS HEMOLÍTICAS\n\n87","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":114,"lines":{"from":1,"to":3}}}}],["493",{"pageContent":"contiene esta apoproteína están ausentes en el plasma (quilomicrones, lipoproteínas de muy baja\ndensidad y de baja densidad). En consecuencia, los triglicéridos no son transportados de la mucosa\nintestinal y su concentración plasmática está prácticamente ausente, con niveles marcadamente bajos\nde colesterol y fosfolípidos e incremento de la esfingomielina.\nLos eritrocitos normales adquieren la forma acantocítica cuando son transfundidos a pacientes con\nesta entidad. Sin embargo, la incubación de estas células con el suero de un sujeto con abetalipoprotei -\nnemia no produce este fenómeno.\nSe ha observado que la forma acantocítica se desarrolla en paralelo a la edad de los eritrocitos circulan-\ntes. La participación de los lípidos de la membrana como causa de este defecto se ha sugerido por el hecho\nde que la forma acantocítica es revertida al incubar eritrocitos con detergentes no iónicos. El hallazgo más","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":114,"lines":{"from":5,"to":14}}}}],["494",{"pageContent":"de que la forma acantocítica es revertida al incubar eritrocitos con detergentes no iónicos. El hallazgo más\nprominente en la acantocitosis asociada con abetalipoproteinemia es el incremento en la concentración de\nesfingomielina de la membrana.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":114,"lines":{"from":14,"to":16}}}}],["495",{"pageContent":"Manifestaciones clínicas\n\nEl patrón de herencia es autosómico recesivo y se considera una entidad rara. La manifestación de la\nenfermedad ocurre en los primeros meses de la vida con esteatorrea. Se detecta retinitis pigmentosa\ny manifestaciones neurológicas progresivas –ataxia, neuropatía periférica y temblores– entre los\n5 y 10 años de edad. Habitualmente la muerte ocurre en la segunda o tercera década de la vida. Las\nmanifestaciones hemáticas son anemia moderada, con tasas eritrocíticas normales, presencia de\nacantocitos en 50 a 90% y leve incremento de reticulocitos. En algunos pacientes, la intensidad\nde la anemia es mayor y se relaciona con déficit nutricional (hierro y folatos) por mala absorción\nintestinal.\n\nTratamiento\n\nEl tratamiento incluye restricciones dietéticas y suplementación con hierro, folatos y vitaminas liposolu-\nbles (A, K, D y E). Se ha informado que la vitamina E puede estabilizar, y en algunos casos remitir, las\nanormalidades neuromusculares y de la retina.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":114,"lines":{"from":18,"to":33}}}}],["496",{"pageContent":"Síndrome de HARP\n\nUn padecimiento afín a la abetalipoproteinemia es conocido como el\n \nsíndrome de HARP\n \n(\n \nH\nipoprebe-\nta-lipoproteinemia,\n \nA\ncantocitosis,\n \nR\netinitis pigmentosa y degeneración del núcleo\n \nP\nálido). Esta entidad\nes menos frecuente que la abetalipoproteinemia y al parecer este síndrome guarda relación con la en-\nfermedad de Hallervorden-Spatz, en donde la condición de hipoprebetalipoproteinemia está ausente.\nClínicamente, se caracteriza por disquinecia facio-bucal-lingual que ocasiona disfagia y disartria, retraso\nintelectual, retinitis pigmentosa y ceguera nocturna. Por laboratorio y gabinete se detecta hipoprebetali-\npoproteinemia y acantocitosis, y por resonancia magnética se demuestra disminución de la intensidad del\nnúcleo pálido con hiperintensidad central (signo del “ojo del tigre”). Aún no se ha definido si los compo-\nnentes del síndrome de HARP pueden ser causados por distintas enfermedades genéticas o por un solo\ndefecto genético.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":114,"lines":{"from":35,"to":62}}}}],["497",{"pageContent":"Síndrome de corea-acantocitosis (síndrome de Levine-Critchley)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":114,"lines":{"from":64,"to":64}}}}],["498",{"pageContent":"Se ha comunicado la relación entre la corea amiotrófica y la normolipoproteinemia y acantocitos. Estos\nenfermos no están anémicos, aunque la supervivencia de los eritrocitos se encuentra levemente dismi -\nnuida. El patrón de herencia es autosómico recesivo. En 2001 fue identificado el gen para esta enfer -\nmedad en el cromosoma 9. Desde ese año también se han descrito formas más raras de este síndrome,\ncon penetrancia variable, con y sin anormalidades en el cromosoma 9. La degeneración de los ganglios\nbasales es un hallazgo que concuerda con la presencia de la corea-acantocitosis. El mecanismo de la\nacantocitosis es desconocido y no se ha encontrado alguna alteración en la concentración de los lípidos\nde la membrana.\nHabitualmente, el inicio ocurre en la edad adulta y se caracteriza por disquinesia orofacial progresiva,\nhipotonía muscular neurogénica y atrofia muscular, con hiporreflexia miotática. En todos los casos las","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":114,"lines":{"from":66,"to":75}}}}],["499",{"pageContent":"hipotonía muscular neurogénica y atrofia muscular, con hiporreflexia miotática. En todos los casos las\nmanifestaciones neurológicas son progresivas. Una condición asociada a esta entidad es la secreción in-\nadecuada de las hormonas hipotalámicas-hipofisarias.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":114,"lines":{"from":75,"to":77}}}}],["500",{"pageContent":"Un padecimiento afín a la\nabetalipoproteinemia se cono-\nce como\n \nsíndrome de HARP\n\n(Hipoprebetalipoproteine-\nmia, Acantocitosis, Retinitis\npigmentosa y degeración del\nNúcleo pálido).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":114,"lines":{"from":79,"to":88}}}}],["501",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n88\n\nSíndrome de McLeod\n\nEste síndrome es un trastorno hereditario ligado al cromosoma X y se caracteriza por una miopatía\nbenigna con elevación de la creatina-fosfocinasa, que en ocasiones puede complicarse con cardiomio -\npatías, movimientos involuntarios o demencia. Este síndrome se encuentra en niños y adultos con el\nfenotipo nulo para el antígeno Kell del eritrocito. El antígeno Kell está localizado en una glicoproteína\nde 93 kDa y está asociado a la estructura del esqueleto de la membrana del eritrocito.\n\nEstomatocitosis y padecimientos afines","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":115,"lines":{"from":1,"to":13}}}}],["502",{"pageContent":"Estomatocitosis y padecimientos afines\n\nEs un conjunto de padecimientos que se caracterizan por la presencia de eritrocitos en el extendido\nde sangre periférica, que contienen una hendidura transversal. En imágenes en tercera dimensión,\nlos eritrocitos tienen forma de una taza invertida, por lo que la hendidura resulta ser un artefacto\nal ver estas células en imágenes bidimensionales. La estomatocitosis está asociada a anormalidades\nen la permeabilidad de cationes del eritrocito que permite los cambios en su volumen, ocasionando\ntambién incrementos (hidrocitosis) o decrementos (xerocitosis) en el eritrocito o en algunos casos los\ncambios del volumen son mínimos. Las bases moleculares de las estomatocitosis son desconocidas\naún (2013).\n\nEstomatocitosis adquirida","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":115,"lines":{"from":13,"to":24}}}}],["503",{"pageContent":"Estomatocitosis adquirida\n\nPor lo general del 3 al 5% de los eritrocitos son estomatocitos. Sin embargo, una serie de condiciones se\nasocian con estomatocitosis adquirida, incluyendo neoplasias malignas, enfermedades cardiovasculares\ny hepáticas, alcoholismo y terapéutica con algunos fármacos, especialmente derivados de la vinca. No\nse ha podido establecer alguna relación entre el fenómeno estomatocítico y alguna causa específica en\nestos estados patológicos.\n\nEstomatocitosis hereditaria","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":115,"lines":{"from":24,"to":32}}}}],["504",{"pageContent":"También se ha denominado\n \nhidrocitosis hereditaria\n \ny el nombre define la sobrehidratación de estas\ncélulas. El defecto principal es el incremento del sodio intracelular y del contenido de agua, con\nbajas concentraciones de potasio. La causa de este defecto aún se desconoce. El padecimiento se\nhereda con un patrón autosómico dominante en la mayoría de los pacientes. La anemia hemolítica\nasociada con este padecimiento es de moderada a intensa; los estomatocitos están presentes en cifras\nde 10 a 30%, el volumen corpuscular medio se encuentra elevado (110 a 150 f L) y la concentración\nmedia de hemoglobina corpuscular disminuida (24 a 30%). La fragilidad osmótica y la deforma -\nbilidad celular están reducidas. La anemia hemolítica se corrige parcialmente con esplenectomía.\nAlgunos pacientes con estomatocitosis hereditaria presentan disnea, dolor torácico y abdominal,\nespecialmente después de la esplenectomía. Estos síntomas han sido interpretados como eventos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":115,"lines":{"from":34,"to":47}}}}],["505",{"pageContent":"Algunos pacientes con estomatocitosis hereditaria presentan disnea, dolor torácico y abdominal,\nespecialmente después de la esplenectomía. Estos síntomas han sido interpretados como eventos\nvasooclusivos e inclusive se han documentado fenómenos tromboembólicos como una complicación\nposesplenectomía. Estos eventos han sido atribuidos a la adherencia incrementada de los estoma -\ntocitos al endotelio. El uso de la pentoxifilina como terapia preventiva al parecer es de utilidad.\nLa indicación de esplenectomía en estos pacientes debe evaluarse cuidadosamente al considerar el\nriesgo contra el beneficio.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":115,"lines":{"from":47,"to":53}}}}],["506",{"pageContent":"Xerocitosis hereditaria\n\nLa xerositosis hereditaria es un padecimiento raro, autosómico dominante, que se expresa con anemia\nhemolítica con estomatocitos y eritrocitos con espículas. El gen de la xerocitosis ha sido ubicado en\nla porción cromosómica 16q23-q24. La característica de los eritrocitos es su deshidratación, debida\na la pérdida de potasio intracelular, sin que exista una compensación con el ingreso de sodio. No se\nhan encontrado anormalidades en los lípidos o proteínas de la membrana, excepto un incremento\nen la actividad enzimática de la deshidrogenasa del gliceraldehído-3-fosfato. La concentración media\nde hemoglobina corpuscular y el volumen globular medio (VGM) (95 a 115 fL) están incrementados y\nla fragilidad osmótica disminuida. La anemia hemolítica es moderadamente intensa y la esplenectomía\nreduce los requerimientos transfusionales, pero no elimina la hemólisis. Aproximadamente en un tercio\nde los pacientes hay seudohipercalemia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":115,"lines":{"from":55,"to":66}}}}],["507",{"pageContent":"Normalmente del 3 al 5% de\nlos\n \neritrocitos\n \nson\n \nestomato-\ncitos. Sin embargo, una serie\nde condiciones se asocian con\nestomatocitosis adquirida, in-\ncluyendo neoplasias malignas,\nenfermedades cardiovasculares\ny hepáticas, alcoholismo y tera-\npéutica con algunos fármacos,\nespecialmente derivados de la\nvinca.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":115,"lines":{"from":68,"to":84}}}}],["508",{"pageContent":"CAPÍTULO 6. ANEMIAS HEMOLÍTICAS\n\n89\n\nSíndrome de deficiencia de Rh\n\nEl síndrome de deficiencia de Rh define una rara condición en donde las personas tienen nula expresión\n(Rh\n \nnull\n \n) o en forma reducida (Rh\n \nmod\n \n) del antígeno Rh, anemia hemolítica de moderada intensidad y la\npresencia de estomatocitos y ocasionalmente esferocitos en sangre periférica.\nLos eritrocito de algunos pacientes Rh\n \nnull\n \nmuestran un incremento en la fragilidad osmótica. La ane-\nmia hemolítica se corrige con la esplenectomía.\n\nHemoglobinuria paroxística nocturna\nDefinición","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":116,"lines":{"from":1,"to":26}}}}],["509",{"pageContent":"Hemoglobinuria paroxística nocturna\nDefinición\n\nLa hemoglobinuria paroxística nocturna (HPN) es un padecimiento clonal adquirido del tejido hemato-\npoyético que se caracteriza por la producción de células sanguíneas y precursores medulares que presentan\nmayor sensibilidad al efecto citolítico del complemento. Este defecto es secundario a la pérdida parcial o\ntotal de proteínas ligadas al GPI, la CD55 y la CD59, que regulan la actividad biológica del complemento,\ny su expresión se traduce en hemólisis intravascular. Otra característica de la HPN es la hematopoyesis\nineficaz y, en algunos casos, distonía de músculo liso y fenómenos trombóticos.\n\nEpidemiología\n\nLa frecuencia estimada de la HPN en la población mexicana es de 2 casos por cada 100 000 habitantes y\nes similar a los informes de Tailandia, China y Japón. Aunque la mayoría de los pacientes son adultos, la\nHPN se ha encontrado también en enfermos pediátricos y adolescentes.\n\nPatogénesis","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":116,"lines":{"from":26,"to":42}}}}],["510",{"pageContent":"Patogénesis\n\nLa HPN es un padecimiento clonal adquirido, de causa desconocida y secundario a mutaciones del gen","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":116,"lines":{"from":42,"to":44}}}}],["511",{"pageContent":"PIG-A\n, localizado en el brazo corto del cromosoma X y responsable de la síntesis de las moléculas de\nGPI. Como consecuencia de estas mutaciones, se produce una síntesis anómala del GPI y, en su turno,\ndeficiencia de proteínas que se fijan a esta estructura biológica.\nSe postula que la clona HPN emerge o es resultado de la expansión de una clona ya existente, poste -\nrior a un daño medular y como un mecanismo defensivo de algún factor externo (o interno) que inhiba la\nhematopoyesis normal, pero incapaz de inhibir a las células con el fenotipo HPN. Las evidencias actuales\napoyan el concepto de que en la mayoría de los casos de HPN el daño de la médula ósea es inmunitario,\nya que algunos condicionantes de falla medular, como la radioterapia o quimioterapia, no producen la\nemergencia de clonas HPN.\nEstablecida la clona, gran parte de la expresión clínica dependerá de su capacidad proliferante. El creci\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":116,"lines":{"from":46,"to":57}}}}],["512",{"pageContent":"emergencia de clonas HPN.\nEstablecida la clona, gran parte de la expresión clínica dependerá de su capacidad proliferante. El creci\n-\nmiento lento e ineficaz puede no ser compensatorio y permitir que sea evidente una hipoplasia o aplasia me\n-\ndular. La producción acelerada de células HPN, por su parte, haría evidente el fenómeno hemolítico\n(fig. 6-3)\n.\nEste fenómeno hemolítico se explica por la deficiencia de las proteínas que regulan la actividad del\ncomplemento y que no pueden fijarse al GPI. Estas son el factor que acelera la degradación de las converta\n-\nsas del complemento [CD55 o DAF (de\n \ndecay accelerating factor\n), el factor de restricción de la actividad del\ncomplemento (CD59 o MIRL (de\n \nmembrane inhibitor of reactive lysis\n)\n,\n \ny HRF65/HRF-C8bp (de\n \nhomologous\nrestriction factor\n)]. Esto trae como resultado mayor fijación de complemento al eritrocito y una actividad\nbiológica magnificada en estas células. Se ha sugerido que la “hemoglobinuria nocturna” observada en la","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":116,"lines":{"from":57,"to":83}}}}],["513",{"pageContent":")]. Esto trae como resultado mayor fijación de complemento al eritrocito y una actividad\nbiológica magnificada en estas células. Se ha sugerido que la “hemoglobinuria nocturna” observada en la\nforma clásica de la HPN se debe a la acción del complemento por endotoxinas que son absorbidas del tubo\ndigestivo y cuyo efecto puede ser magnificado por la ausencia en los eritrocito de la proteína CD14 (proteína\nfijadora de endotoxina).\nAunque la hemólisis clínica o la hemoglobinuria –o ambas–, como parte de las manifestaciones iniciales\nde la HPN, solo están presentes en la tercera parte de estos pacientes, las evidencias de hemólisis (hemo-\nglobina libre en plasma o disminución de haptoglobinas) se detectan en el 85% de los casos, independien-\ntemente de la clase clínica a la que pertenezcan los pacientes (véase clasificación clínica más adelante). En\nun grupo de pacientes mexicanos con HPN, los niveles incrementados de hemoglobina libre en suero se","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":116,"lines":{"from":83,"to":92}}}}],["514",{"pageContent":"un grupo de pacientes mexicanos con HPN, los niveles incrementados de hemoglobina libre en suero se\ndetectaron en 75 de 97 (77%) pacientes y no necesariamente asociados a eventos hemolíticos clínicos. Las\ncrisis de hemólisis se asociaron con situaciones de alarma, aunque en la mayoría de los enfermos este evento\nera crónico, persistente, de intensidad variable y dependiente de la proporción de eritrocito-HPN.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":116,"lines":{"from":92,"to":95}}}}],["515",{"pageContent":"La\n \nhemoglobinuria\n \nparoxís-\ntica nocturna (HPN) es un\npadecimiento clonal adquirido\ndel tejido hematopoyético que\nse caracteriza por la producción\nde células sanguíneas y precur-\nsores medulares que presentan\nmayor\n \nsensibilidad\n \nal\n \nefecto\ncitolítico del complemento\nLa HPN es un padecimiento\nclonal adquirido, de causa desco-\nnocida y secundario a mutacio-\nnes del gen\n \nPIG-A\n, localizado\nen el brazo corto del cromosoma\nX y responsable de la síntesis de\nlas moléculas de GPI\nLas crisis de hemólisis se asocia-\nron con situaciones de alarma,\naunque en la mayoría de los\nenfermos este episodio era cró-\nnico, persistente, de intensidad\nvariable y dependiente de la\nproporción de eritrocito HPN.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":116,"lines":{"from":97,"to":132}}}}],["516",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n90","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":117,"lines":{"from":1,"to":3}}}}],["517",{"pageContent":"Recientemente se ha postulado la participación del óxido nítrico en la patogénesis de la HPN. El\nóxido nítrico (ON) es un regulador biológico de gran importancia de homeostasis vascular, incluyendo\nla vasodilatación y la hemostasia. La interacción del ON con la hemoglobina es un campo de reciente\ninterés por sus posibles consecuencias, en especial en condiciones asociadas a hemólisis crónica.\nEl ON tiene una alta capacidad de reacción con la hemoglobina que, además de ser muy rápida\n(10\n \n7\n \nM\n \n–1\ns\n \n–1\n), es irreversible. Hipotéticamente, la hemoglobina intravascular, contenida en su inmensa\nmayoría por los eritrocitos (16 g/dL), si estuviera como hemoglobina libre, inactivaría a todo el ON\nproducido por el endotelio e impediría su difusión paracrina hacia el músculo liso y hacia el torrente\nintravascular. Sin embargo, la habilidad del ON para reaccionar con la hemoglobina es limitada\nporque los eritrocitos actúan como “compartimentos” de hemoglobina e impiden la interacción de\nesta con el ON.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":117,"lines":{"from":5,"to":25}}}}],["518",{"pageContent":"porque los eritrocitos actúan como “compartimentos” de hemoglobina e impiden la interacción de\nesta con el ON.\nEn consecuencia, la hemoglobina libre que se genera con la hemólisis fisiológica es inactivada a\ntravés de varios mecanismos. La hemoglobina libre adopta forma de dímeros y rápidamente se fija a la\nproteína plasmática haptoglobina. El complejo haptoglobina-hemoglobina expone un epítopo que es\nreconocido por el receptor de “remoción” de la hemoglobina, el CD163 de los monocitos/macrófagos,\nque fija el complejo con gran afinidad y posterior a la endocitosis se logra la degradación de la hemo -\nglobina. Debido a que la haptoglobina no es reciclable, la formación de grandes cantidades y complejos\nhaptoglobina-hemoglobina produce una rápida depleción de haptoglobina, lo que explica que sea inde -\ntectable en la mayoría de las anemias hemolíticas con gran componente intravascular, como es el caso\nde la HPN.\nEl hemo ferroso (Fe\n \nII","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":117,"lines":{"from":25,"to":38}}}}],["519",{"pageContent":"tectable en la mayoría de las anemias hemolíticas con gran componente intravascular, como es el caso\nde la HPN.\nEl hemo ferroso (Fe\n \nII\n \n), el componente de la hemoglobina que fija el oxígeno, puede ser oxidado a\nhem férrico (Fe\nIII\n \n), que es luego liberado de la hemoglobina y se fija con gran afinidad a la glicoproteína\nplasmática hemopexina. El hemo fijado a la hemopexina es degradado por el hígado, a través de varios\npasos enzimáticos. La oxigenasa de hemo tipo 1 (HO-1) transforma, en pasos subsecuentes, al prooxi -\ndante y proinflamatorio hemo en monóxido de carbono, biliverdina y hierro. El monóxido de carbono\ntiene propiedades vasodilatadoras, antiproliferativas, antiinflamatorias y antioxidantes. La biliverdina\nes un antioxidante que es convertido a bilirrubina por la enzima reductasa de biliverdina, que en sí\nmisma tiene propiedades catalíticas antioxidantes. El hierro es inactivado por la ferritina. Comple -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":117,"lines":{"from":38,"to":54}}}}],["520",{"pageContent":"misma tiene propiedades catalíticas antioxidantes. El hierro es inactivado por la ferritina. Comple -\nmentariamente a estos procesos, la haptoglobina-hemoglobina fijada al CD163 induce la formación de\ninterleucina 10 (IL-10) (con propiedades antiinflamatorias) y HO-1.\nEn este contexto, los efectos antioxidantes, anticoagulantes, antiproliferativos y vasodilatadores del\nsistema CD163/HO-1/reductasa de biliverdina, parecen representar un sistema biológico compensador a","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":117,"lines":{"from":54,"to":58}}}}],["521",{"pageContent":"Figura 6-3.\n \nModelo hipotético de la patogénesis de la etiología y expresión clínica de la hemoglobinuria\nparoxística nocturna.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":117,"lines":{"from":60,"to":63}}}}],["522",{"pageContent":"CAPÍTULO 6. ANEMIAS HEMOLÍTICAS\n\n91\n\nlos efectos de la hemoglobina, el hemo y el hierro extracelulares (inactivación del ON, vasoconstricción,\nefecto proliferativo y prooxidante).\nCuando la capacidad de estos mecanismos depuradores de la hemoglobina libre y sus compuestos es\nsaturado durante la hemólisis intravascular, los niveles de hemoglobina se incrementan en el plasma y en la\norina. La hemoglobina libre tiene la capacidad de inactivar al ON, mientras que el hemo posee múltiples\npropiedades proinflamatorias y prooxidantes. Así, la hemólisis intravascular crónica, como acontece en la\nHPN, condiciona a un estado de deficiencia de ON\n \n(figs. 6-4 y 6-5)\n.\n\nFigura 6-4.\n \nModelo esquemático del efecto de la hemólisis crónica en la inactivación del óxido nítrico.\n\nFigura 6-5.\n \nMecanismo de depleción del óxido nítrico como consecuencia de la hemólisis crónica (véase\ntexto para mayor descripción).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":118,"lines":{"from":1,"to":23}}}}],["523",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n92","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":119,"lines":{"from":1,"to":3}}}}],["524",{"pageContent":"Una de las consecuencias de la depleción del ON se refleja en la disfunción del músculo liso de\nvarios órganos. Entre estos están el dolor abdominal, los espasmos esofágicos, la disfunción eréctil\ny la trombosis.\nEn nuestro grupo de pacientes (n = 168), el 35% manifestaba dolor abdominal durante las crisis de\nhemólisis clínica, la mayoría de ellos de la clase clínica 3 (grupo hemolítico). Sin embargo, el 54%,\nindependientemente de la clase clínica, refirió dolor abdominal, aun en ausencia de crisis hemolíticas\nclínicamente evidentes. En estos casos se excluyó la posibilidad de trombosis de venas mesentéricas\ncomo causa de dolor; en otras palabras, la hipótesis es que la deficiencia de ON causa distonía intestinal\ny espasmo.\nTambién es común en la HPN el espasmo esofágico y la disfagia, debidos a ondas peristálticas\nintensas. La incidencia en el grupo de pacientes mexicanos es de alrededor del 25%. El grupo de pa -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":119,"lines":{"from":5,"to":15}}}}],["525",{"pageContent":"También es común en la HPN el espasmo esofágico y la disfagia, debidos a ondas peristálticas\nintensas. La incidencia en el grupo de pacientes mexicanos es de alrededor del 25%. El grupo de pa -\ncientes que reportan mayor incidencia y gravedad de estos eventos clínicos es el de los pacientes con\nhemólisis clínica.\nLa disfunción eréctil es un tópico de reciente exploración en la HPN y se ha estimado que ocurre en el\n35% de los varones con esta enfermedad. Aunque la respuesta al inhibidor de fosfodiesterasa 5 (PDE-5)\nes efectiva en estos pacientes, su eficacia es menor cuando existen crisis agudas o crónicas de intensidad\nimportante, lo que apoya el concepto de deficiencia de ON.\nAunque la trombosis no es un evento de presentación frecuente en los pacientes mexicanos y asiáticos\ncon HPN, el 9% de ellos padecen algún fenómeno trombótico durante la evolución de la enfermedad y re-\npresenta el 15% como causa de defunción. Entre las causas fisiopatogénicas de este fenómeno, se considera","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":119,"lines":{"from":15,"to":25}}}}],["526",{"pageContent":"presenta el 15% como causa de defunción. Entre las causas fisiopatogénicas de este fenómeno, se considera\na la disfunción plaquetaria como una de las más importantes. La deficiencia de CD59 en las plaquetas de\nlos pacientes con HPN puede participar en la hipercoagulabilidad y trombosis descritas en este padeci-\nmiento. La fijación de la fracción C9 del complemento ocasiona en la superficie de las plaquetas la forma-\nción de microvesículas en la superficie de las plaquetas con actividad de protrombinasas, las cuales en su\nturno favorecerían la síntesis de mayores cantidades de trombina. Además, las plaquetas HPN muestran\nuna respuesta incrementada a la trombina en presencia de complemento. Así, la deficiencia de ON puede\ncontribuir a estos fenómenos al favorecer la adherencia y agregación plaquetarias, además de estimular la\nactivación del sistema de coagulación.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":119,"lines":{"from":25,"to":33}}}}],["527",{"pageContent":"Defectos de membrana","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":119,"lines":{"from":35,"to":35}}}}],["528",{"pageContent":"En la HPN se han identificado tres poblaciones de eritrocitos con diferente sensibilidad al complemen -\nto. Los eritrocitos HPN I tienen sensibilidad normal al complemento. Los eritrocitos HPN II son de\ntres a cinco veces más sensibles y los eritrocitos HPN III de 15 a 25 veces más. La proporción de estas\ncélulas varía de caso a caso y aun en el mismo sujeto durante el transcurso de la enfermedad. En los\neritrocitos HPN II y III existe una deficiencia de CD55/DAF que ocasiona la formación de cuatro a\ncinco veces más C3b. La sensibilidad mayor al complemento de los eritrocitos HPN se explica por un\nsegundo defecto, que es la deficiencia de los HRF, lo que permite una mayor actividad en la fracción\ncitolítica del complemento (complejo C5b-9). Otras proteínas ancladas al GPI son deficientes en la\nHPN (véase cuadro 6-1). Estas proteínas no participan en el fenómeno hemolítico y son diferentes entre","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":119,"lines":{"from":37,"to":45}}}}],["529",{"pageContent":"citolítica del complemento (complejo C5b-9). Otras proteínas ancladas al GPI son deficientes en la\nHPN (véase cuadro 6-1). Estas proteínas no participan en el fenómeno hemolítico y son diferentes entre\nsí. Junto con el CD55/DAF y los HRF, la única característica similar entre ellas es que están fijadas a\nla superficie externa de la membrana a través del GPI, complejo de fosfatidilinositol defectuoso como\nconsecuencia de las mutaciones del gen\n \nPIG-A\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":119,"lines":{"from":45,"to":52}}}}],["530",{"pageContent":"Manifestaciones clínicas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":119,"lines":{"from":54,"to":54}}}}],["531",{"pageContent":"En una serie de 168 pacientes mexicanos con HPN, 74 (44%) iniciaron su padecimiento con evidencias\nde aplasia medular o hipoplasia medular, con o sin hemólisis o hemoglobinuria (clase 1 de la HPN,\n“grupo aplásico”). El 23% de los casos tenían médulas óseas normo o hipercelulares, sin datos clínicos\nde hemólisis o hemoglobinuria y con una o más citopenias (clase 2 de la HPN, “grupo citopénico”). El\n30% de los pacientes presentaron el cuadro clásico de HPN: hemólisis clínica y hemoglobinuria, con o\nsin citopenias y médulas óseas normo o hipercelulares (clase 3 de la HPN, “grupo hemolítico”) y 2,5%\nde todos los pacientes iniciaron su padecimiento con fenómeno trombótico sin hemólisis clínica ni\nhemoglobinuria, con médulas óseas normo o hipercelulares (clase 4 de la HPN, “grupo trombótico”).\nAunque la hemólisis clínica o la hemoglobinuria –o ambas– solo estuvieron presentes en la tercera\nparte de los sujetos, las evidencias de hemólisis (hemoglobina libre en plasma y disminución de hapto -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":119,"lines":{"from":56,"to":65}}}}],["532",{"pageContent":"Aunque la hemólisis clínica o la hemoglobinuria –o ambas– solo estuvieron presentes en la tercera\nparte de los sujetos, las evidencias de hemólisis (hemoglobina libre en plasma y disminución de hapto -\nglobinas) se detectaron en el 85% de los casos, independientemente de la clase a la que pertenecían los","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":119,"lines":{"from":65,"to":67}}}}],["533",{"pageContent":"En la HPN se han identifica-\ndo tres poblaciones de eritro-\ncitos con diferente sensibilidad\nal complemento. Los eritroci-\ntos HPN I tienen sensibilidad\nnormal al complemento. Los\neritrocitos HPN II son de tres\na cinco veces más sensibles y\nlos eritrocitos HPN III de 15\na 25 veces más.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":119,"lines":{"from":69,"to":78}}}}],["534",{"pageContent":"CAPÍTULO 6. ANEMIAS HEMOLÍTICAS\n\n93","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":120,"lines":{"from":1,"to":3}}}}],["535",{"pageContent":"pacientes. Las crisis de hemólisis se asociaron con situaciones de alarma, aunque en la mayoría de los\nenfermos este evento era crónico, persistente, de intensidad variable y dependiente de la proporción de\neritrocitos HPN. Los casos pertenecientes a las clases 1 y 2 presentan con frecuencia síndrome hemo -\nrrágico por plaquetopenia, que representa la principal causa de defunción en estos pacientes.\nEl curso clínico de la HPN es muy variable. Las muertes tempranas se relacionan con aplasia medular/\nhipoplasia medular y síndrome hemorrágico por trombocitopenia. Los fenómenos tromboembólicos se\nacompañan de alta letalidad en el transcurso de esta enfermedad. En algunos sujetos, la expresión sola de\ncitopenias o hemólisis compensada ocasiona una evolución más favorable y crónica.\nAlgunas complicaciones asociadas con la HPN son: infecciones bacterianas recurrentes, coagulación\nintravascular diseminada, insuficiencia renal aguda o crónica, hemocromatosis, crisis aplásica, desarrollo","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":120,"lines":{"from":5,"to":14}}}}],["536",{"pageContent":"intravascular diseminada, insuficiencia renal aguda o crónica, hemocromatosis, crisis aplásica, desarrollo\nde anemia aplásica, trombosis y, en alrededor del 2% de los casos, anemia refractaria con exceso de blastos\ny leucemia aguda.\nEn general, la HPN puede considerarse como un padecimiento crónico y se ha estimado una super-\nvivencia actuarial a 10 años del 71%, a 20 años del 57% y a 30 años del 54%. La supervivencia más pro-\nlongada se observa en los pacientes con clase III: 95% y 90% a 10 y 20 años, respectivamente\n \n(fig. 6-6)\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":120,"lines":{"from":14,"to":22}}}}],["537",{"pageContent":"Diagnóstico","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":120,"lines":{"from":24,"to":24}}}}],["538",{"pageContent":"El diagnóstico de HPN debe considerarse en todo paciente con citopenia de causa no determinada, en\nlos casos de anemia aplásica/hipoplasia medular, en los enfermos con fenómenos trombóticos y en las\nanemias hemolíticas de causa no bien definida.\nTradicionalmente, el diagnóstico de HPN se ha fundamentado en la identificación de eritrocitos\nsensibles al complemento a través de sistemas de hemólisis específicos in vitro (prueba de hemólisis\nácida o de Ham, prueba de sucrosa y prueba de inulina). Sin embargo, estos sistemas son dependien -\ntes de la concentración de eritrocitos con defecto HPN y de la sensibilidad de estos a la lisis por el\ncomplemento. La prueba de Ham tiene la ventaja de la especificidad: ningún otro eritrocito es lisado\npor este sistema, excepto en la “anemia eritroblástica congénita tipo II”, padecimiento extraordina -\nriamente raro. La prueba de sucrosa tiene acción lítica preferentemente en los eritrocitos-HPN III","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":120,"lines":{"from":26,"to":35}}}}],["539",{"pageContent":"por este sistema, excepto en la “anemia eritroblástica congénita tipo II”, padecimiento extraordina -\nriamente raro. La prueba de sucrosa tiene acción lítica preferentemente en los eritrocitos-HPN III\ny es positiva cuando estos son mayores de 5%. La prueba de inulina, al ser un potente activador del\ncomplemento, puede identificar eritrocito-HPN aunque solamente exista una subpoblación de tipo\nII. El uso simultáneo de estas pruebas, al menos en dos ocasiones, aumenta las probabilidades de\ndiagnóstico de la HPN.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":120,"lines":{"from":35,"to":40}}}}],["540",{"pageContent":"Figura 6-6.\n \nCurvas de supervivencia (modelo de Kaplan-Meier) en 168 pacientes mexicanos con hemoglobinuria paroxística\nnocturna, de acuerdo a la clase clínica correspondiente. (AP = clase aplasia; MDS = clase citopénica (tipo mielodisplasia);\nHemolit = clase hemolítica; Tromb = clase trombosis).\n\nEl diagnóstico de HPN debe\nconsiderarse en todo pacien-\nte con citopenia de causa no\ndeterminada, en los casos de\nanemia\n \naplásica/hipoplasia\nmedular, en los enfermos con\nfenómenos trombóticos y en\nlas\n \nanemias\n \nhemolíticas\n \nde\ncausa no bien definida.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":120,"lines":{"from":42,"to":64}}}}],["541",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n94\n\nLa hemosiderina en sedimento urinario, en asociación con al menos dos pruebas de hemólisis,\nes criterio suficiente para establecer este diagnóstico. Sin embargo, la ausencia de hemosiderinuria\nno excluye el diagnóstico de HPN, ya que su presencia depende de la intensidad y cronicidad de la\nhemólisis.\nLos casos con escasas poblaciones celulares con fenotipo HPN solo pueden ser diagnósticos por\ncitometría de flujo, identificando leucocitos (granulocitos, monocitos y linfocitos) o eritrocitos carentes\nde CD55 y CD59. Esta técnica es ya el patrón de referencia para el diagnóstico de HPN.\nEl diagnóstico diferencial debe hacerse con la “anemia eritroblástica congénita tipo II” (HEMPAS)\ny con la deficiencia hereditaria de HRF20.\n\nTratamiento","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":121,"lines":{"from":1,"to":15}}}}],["542",{"pageContent":"El uso de anabólicos orales del tipo de la mesterolona (25 a 75 mg/día) y el danazol sirve en aquellos\ncasos de HPN con hematopoyesis ineficaz (clases 1 y 2). También se han informado respuestas ade -\ncuadas a la ciclosporina en estos grupos de pacientes con falla medular y HPN. La prednisona limita\ntransitoriamente los síndromes hemorrágicos asociados con plaquetopenia.\nLa deficiencia de hierro debe corregirse con hierro oral para evitar el riesgo de crisis hemolíticas\nrelacionadas con hierro parenteral. Siempre debe considerarse la suplementación con ácido fólico.\nLas crisis hemolíticas de estos pacientes responden adecuadamente a la transfusión de eritrocitos\nempaquetados, ya que por una parte se inhibe transitoriamente la eritropoyesis y, por otro lado, se ad -\nministran eritrocitos capaces de controlar la actividad del complemento.\nRecientemente, en 2007, la\n \nFederal Drug Administration\n \n(FDA) de Estados Unidos aprobó el uso\ndel anticuerpo monoclonal contra C5, denominado\n \neculizumab","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":121,"lines":{"from":17,"to":33}}}}],["543",{"pageContent":"Recientemente, en 2007, la\n \nFederal Drug Administration\n \n(FDA) de Estados Unidos aprobó el uso\ndel anticuerpo monoclonal contra C5, denominado\n \neculizumab\n. En un estudio con asignación al azar de\nopciones terapéuticas, 44 pacientes recibieron placebo y 43 eculizumab IV 600 mg cada semana por\n4 semanas, 900 mg la siguiente semana y luego 900 mg cada segunda semana hasta completar 6 me -\nses. Durante el lapso de los 6 meses del estudio, el grupo con eculizumab no requirió transfusiones,\nmientras que el grupo al que se le administró placebo recibió en promedio 10 transfusiones. También\nfueron significativas la reducción de la deshidrogenasa láctica (DHL), la resolución de la hemólisis\nintravascular y los síntomas asociados a las distonías de los músculos lisos, la disfunción eréctil y la\ncalidad de vida. También se ha comunicado que el eculizumab reduce el riesgo de tromboembolismo.\nEl uso de eculizumab informado en 11 pacientes con HPN tratados con este inhibidor del comple -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":121,"lines":{"from":33,"to":49}}}}],["544",{"pageContent":"calidad de vida. También se ha comunicado que el eculizumab reduce el riesgo de tromboembolismo.\nEl uso de eculizumab informado en 11 pacientes con HPN tratados con este inhibidor del comple -\nmento por 52 semanas y en dos pacientes por 2 años, muestra resultados similares y seguridad en\nsu uso. Los efectos secundarios de este anticuerpo fueron cefalea, nasofaringitis, dolor de espalda e\ninfecciones de vías aéreas superiores. El uso de este anticuerpo monoclonal contra C5 es útil en pa -\ncientes con HPN clase 3 (grupo hemolítico) y en los de clase 2 (tipo mielodisplásico) con hemólisis.\nNo está indicado en pacientes con aplasia y del grupo con trombosis inicial, sin hemólisis (clase 4).\nAdemás, los pacientes candidatos a eculizumab deberán ser vacunados 2 semanas antes de su uso\ncontra infecciones por\n \nNeisseria.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":121,"lines":{"from":49,"to":59}}}}],["545",{"pageContent":"No se ha demostrado un claro beneficio con el uso profiláctico de la heparina, aunque su admi -\nnistración a dosis bajas está indicada en el trasplante exitoso de células troncales hematopoyéticas. El\nempleo de heparinas de bajo peso molecular es en todo caso el indicado. Los supresores de la función\nplaquetaria con efecto inhibitorio en la ciclooxigenasa plaquetaria representan un tratamiento profilác -\ntico útil, aunque la frecuencia de resistencia a la aspirina es mayor en los pacientes con HPN que en la\npoblación general.\nEl trasplante exitoso de células troncales hematopoyéticas es el único recurso capaz de curar esta\nenfermedad en la época actual.\n\nDeficiencia hereditaria de CD59","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":121,"lines":{"from":61,"to":70}}}}],["546",{"pageContent":"Deficiencia hereditaria de CD59\n\nRecientemente se describió una familia japonesa con una deficiencia de HRF20/CD59/MIRL, pro -\nteína que regula la fracción citolítica del complemento. El patrón de herencia de este padecimiento\nes autosómico recesivo y su expresividad es variable, desde formas subclínicas de hemólisis hasta\ncuadros de hemólisis intensa. La identificación de este padecimiento se realizó a partir de un propó -\nsito catalogado como HPN, con pruebas positivas de Ham y de sucrosa. La determinación de CD59\nmostró ausencia en este paciente y disminución variable en los padres y hermanos, quienes se halla -\nban asintomáticos. No se encontró en estos casos mutación del gen\n \nPIG-A\n. La distribución de este\npadecimiento en otros grupos étnicos está por definirse.\n\nEl trasplante exitoso de célu-\nlas troncales hematopoyéticas\nes el único recurso capaz de\ncurar esta enfermedad en la\népoca actual.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":121,"lines":{"from":70,"to":88}}}}],["547",{"pageContent":"CAPÍTULO 6. ANEMIAS HEMOLÍTICAS\n\n95\n\nCONCLUSIONES\n\n•\n \nLas anemias hemolíticas causadas por trastornos de la membrana del eritrocito suponen alteraciones\nen la estructura de su citoesqueleto y su membrana.\n\n•\n \nLos defectos en la función de los componentes de la membrana del eritrocito ocasionan destrucción\nprematura y padecimientos hemáticos con características morfológicas, fisiopatogénicas y clínicas\nque dependen del tipo de defecto que ocurra en la membrana.\n\n•\n \nLa mayoría de las membranopatías hereditarias suponen alteraciones de la molécula de la espectri -\nna. La hemoglobinuria paroxística nocturna es una forma adquirida de alteración de la membrana\neritrocítica.\n\nPREGUNTAS DE AUTOEVALUACIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":122,"lines":{"from":1,"to":24}}}}],["548",{"pageContent":"1. ¿Cuál es la deficiencia proteica más común en la membrana de los esferocitos?\na.\n \nActina y miosina\nb. Tropomiosina y dematina\nc.\n \nEspectrina y ankirina\n2. Se caracteriza por eritrocitos con arremangamiento de la hemoglobina que produce una imagen simi-\nlar a la de una boca abierta:\na.\n \nPiropoiquilocitosis hereditaria\nb. Heliptocitosis esferocítica\nc.\n \nHeliptocitosis estomatocítica\n3. Los datos clínicos de la siguiente patología incluyen anemia moderada presente desde la edad infantil,\nictericia acolúrica, esplenomegalia y hallazgos similares en padres o hermanos:\na.\n \nHeliptocitosis hereditaria\nb. Esferocitosis hereditaria\nc.\n \nAcantocitosis asociada a hepatopatía\n4. Padecimiento clonal adquirido del tejido hematopoyético con producción de células sanguíneas y\nprecursores medulares, secundaria a la pérdida parcial o total de proteínas ligadas al GPI, CD55\ny CD59:\na.\n \nSíndrome de deficiencia de Rh\nb. Hemoglobinuria paroxística nocturna\nc.\n \nDeficiencia hereditaria de CD59\n5. Único tratamiento curativo de la HPN:","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":122,"lines":{"from":26,"to":62}}}}],["549",{"pageContent":"y CD59:\na.\n \nSíndrome de deficiencia de Rh\nb. Hemoglobinuria paroxística nocturna\nc.\n \nDeficiencia hereditaria de CD59\n5. Único tratamiento curativo de la HPN:\na.\n \nDanazol\nb. Eculizumab\nc.\n \nTrasplante de células hematopoyéticas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":122,"lines":{"from":62,"to":77}}}}],["550",{"pageContent":"BIBLIOGRAFÍA\n\nÁlvarez-Moya C, Solís-Zamora R. Deficiencia parcial de la espectrina eritrocítica en pacientes mexicanos con esfe-\nrocitosis hereditaria. Rev Biomed. 1993; 4:81-86.\nAn X, Mohandas N. Disorders of red cell membrane. Br J Haematol. 2008; 141: 367-75.\nBaines AJ. Mechanisms of elliptocytosis: Significant spectrin substitutions. Blood. 2008; 111: 5712.\nBrodsky RA. Narrative review: Paroxysmal nocturnal hemoglobinuria: ¾e physiology of complement-related he-\nmolytic anemia. Ann Intern Med. 2008; 148: 587-95.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":122,"lines":{"from":79,"to":86}}}}],["551",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n96","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":123,"lines":{"from":1,"to":3}}}}],["552",{"pageContent":"Delaunay J. ¾e molecular basis of hereditary red cell membranes disorders. Blood Rev. 2007; 21: 1-20.\nGallagher PG. Red cell membranes disorders. Hematology Am Soc Hematol Educ Program. 2005: 13-8.\nGóngora-Biachi RA, Sosa-Muñoz J, Duarte-Zapata L, Pinto-Escalante D, González-Martínez P, Achach-Asaf J.\nHemoglobinuria paroxística nocturna: Análisis de 36 casos. Sangre. 1987; 32: 27-37.\nGóngora-Biachi RA, González-Martínez P, Aguilar-Ortega M, Achach-Asaf J, Lara-Perera D. Hemoglobinuria\nparoxística nocturna en edad pediátrica: Observaciones en siete casos. Bol Med Hosp Infant Mex. 1987; 44:\n222-9.\nGóngora-Biachi RA, González-Martínez P, Pinto-Escalante D, Ceballos-Quintal JM. Chromosomic findings in\npatients with paroxysmal nocturnal hemoglobinuria. Int J Hematol. 1993; 58: 163-167.\nGóngora-Biachi RA, González-Martínez P, Sosa-Muñoz J, Castro-Sansores C, Delgado-Lamas JL, Vázquez-Vi-\nllegas V, et al. Historia natural de hemoglobinuria paroxística nocturna en adolescentes, adultos y en la edad","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":123,"lines":{"from":5,"to":15}}}}],["553",{"pageContent":"llegas V, et al. Historia natural de hemoglobinuria paroxística nocturna en adolescentes, adultos y en la edad\npediátrica; la experiencia mexicana. Sangre. 1997; 42: 171-7.\nGóngora-Biachi RA. Diagnóstico y clasificación de la hemoglobinuria paroxística nocturna. Gac Med Mex. 2002;\n138 (suppl 1): S19-S21.\nGóngora-Biachi RA. Epidemiología de las enfermedades hematológicas en el ámbito nacional. II. El perfil epidemio\n-\nlógico en la península de Yucatán. Gac Med Mex. 2002; 138 (suppl 1): S13-S14.\nGóngora-Biachi RA. Hemoglobinuria paroxística nocturna: Un síndrome de falla medular. Rev Hematol. 2004;\n5:67- 79.\nGóngora-Biachi RA. Hemoglobinuria paroxística nocturna: Nuevos conceptos de una vieja enfermedad. En:\nGóngora-Biachi RA, editor. Hematología. Actualización 2005. Mérida, México: Agrupación Mexicana para el\nEstudio de la Hematología, A.C; 2005; p. 31-41.\nGóngora-Biachi RA, González-Martínez P, Alonzo-Salomón LG, Lara-Perera D, Pavía-Ruz N. Eliptocitosis esto-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":123,"lines":{"from":15,"to":27}}}}],["554",{"pageContent":"Estudio de la Hematología, A.C; 2005; p. 31-41.\nGóngora-Biachi RA, González-Martínez P, Alonzo-Salomón LG, Lara-Perera D, Pavía-Ruz N. Eliptocitosis esto-\nmatocítica (ovalocitosis del Sureste de Asia). Identificación de los primeros casos en México. Rev Hematol. 2005;\n6 (supl 1):S8.\nHill A, Hillmen P, Richards SJ, Elebute D, Marsh JC, Chan J, et al. Sustained response and long-term safety of\neculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005; 106: 2559-65.\nHillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, et al. ¾e complement inhibitor eculuzimab in\nparoxysmal nocturnal hemoglobinuria. N Engl J Med. 2006; 355: 1233-43.\nIchiba M, Nakamura M, Sano A. Neuroacanthocytosis update. Brain Nerve. 2008; 60: 635-41.\nLi J, Lykotrafitis G, Dao M, Suresh S. Cytoeskeletal dynamics of human erytrocyte. Proc Natl Acad Sci USA. 2007;\n104: 4937-42.\nMalandrini A, Cesaretti S, Mullinaria M, et al. Acanthocytosis, retinitis pigmentosa, pallidal degeneration. Report","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":123,"lines":{"from":27,"to":38}}}}],["555",{"pageContent":"104: 4937-42.\nMalandrini A, Cesaretti S, Mullinaria M, et al. Acanthocytosis, retinitis pigmentosa, pallidal degeneration. Report\nof two cases without serum lipid abnormalities. J Neurol Sci. 1996; 140: 129-131.\nPiedras J, López-Karpovitch X. Flow cytometric analysis of gycosylphosphatidyl-inositol-anchored proteins to assess\nparoxysmal nocturnal hemoglobinuria clone size. Cytometry. 2000; 42: 234-238.\nRamos-Kuri M, Carrillo-Farga J, Zúñiga J, Amador-Guerrero MT, Granados J, Estrada FJ. Molecular demostra-\ntion of SLC4A1 gene deletion in two Mexican patients with Southeast Asian ovalocytosis. Hum Biol. 2005;\n77:399-405.\nRosse WF, Young NS, Góngora-Biachi R. Trastornos hipoproliferativos de la célula tronco. Rev Invest Clin. 1997;\n49 (suppl 1): 83-88.\nRother RP, Bell L, Hillman P, Gladwin MT. ¾e clinical sequelae of intravascular hemolysis and extravascular plas-\nma hemoglobin. A novel mechanism of human disease. JAMA. 2005; 293: 1653-62.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":123,"lines":{"from":38,"to":49}}}}],["556",{"pageContent":"Rother RP, Bell L, Hillman P, Gladwin MT. ¾e clinical sequelae of intravascular hemolysis and extravascular plas-\nma hemoglobin. A novel mechanism of human disease. JAMA. 2005; 293: 1653-62.\nRuiz-Argüelles GJ, Morales-Aceves R, Labardini J, Kraus-Weisman A. Hemoglobinuria paroxística nocturna. Ex-\nperiencia de 30 años en el Instituto Nacional de la Nutrición (México). Sangre. 1981; 26: 463-470.\nRuiz-Argüelles GJ, Ramírez-Cisneros FJ, Ruiz-Argüelles A, Pérez-Romano B, Morales-Aceves R. Deficiencia de\nproteínas de superficie ancladas por glucosilfosfatidilinositol en células de pacientes mestizos mexicanos con hipo-\nplasia medular. Rev Invest Clin. 1999; 51: 5-9.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":123,"lines":{"from":49,"to":55}}}}],["557",{"pageContent":"RESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\n1.\n \nc\n2.\n \nc\n3.\n \nb\n4.\n \nb\n5.\n \nc","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":123,"lines":{"from":57,"to":73}}}}],["558",{"pageContent":"99\n\nINTRODUCCIÓN\n\nLa hemoglobina es una proteína de gran importancia e interés. El estudio de su estructura molecular y\nfisiológica ha llamado la atención de innumerables investigadores y el número de publicaciones que ha\ngenerado es muy elevado. De su estudio se han derivado descubrimientos de gran utilidad. Entre ellos\ncabe señalar que la caracterización de una variante molecular de la proteína, la hemoglobina (Hb) S, dio\nlugar al concepto de “enfermedad molecular” y al desarrollo ulterior de la moderna biología molecular.\nSu estudio condujo a identificar la estructura en doble hélice del ácido desoxirribonucleico (DNA).\n\nCOMPOSICIÓN Y VARIANTES NORMALES DE LA HEMOGLOBINA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":126,"lines":{"from":1,"to":12}}}}],["559",{"pageContent":"La molécula de Hb está compuesta por cuatro porciones diferentes: 1) un componente proteico llama-\ndo\n \nglobina\n, compuesto por cuatro cadenas polipeptídicas que son dos pares (dímeros) y cada par posee\nidéntica estructura primaria; 2) cuatro moléculas de protoporfirina IX; 3) cuatro átomos de hierro en\nestado ferroso que, combinados con la protoporfirina IX, forman las cuatro moléculas de hemo; y 4)\nuna molécula de 2,3-difosfoglicerato (2-3DPG) ubicada en el centro de la unidad de Hb\n \n(fig. 7-1)\n.\nExisten siete tipos de cadenas polipeptídicas que difieren en su estructura primaria (secuencia de aminoáci\n-\ndos) y que han sido denominadas\nα\n \n(alfa),\n β\n \n(beta),\n \nγ\nG\n \n(gammaG),\n \nγ\n \nA\n \n(gammaA),\n \nδ\n \n(delta),\n ¡\n \n(épsilon) y\n\u0003c\n \n(zeta).\nDurante los tres primeros meses de la vida intrauterina, el feto sintetiza cuatro hemoglobinas em-\nbrionarias llamadas Gower 1, Gower 2, Portland 1 y Portland 2, compuestas por los distintos tipos de\ncadenas polipeptídicas indicados en el\n \ncuadro 7-1\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":126,"lines":{"from":14,"to":60}}}}],["560",{"pageContent":"brionarias llamadas Gower 1, Gower 2, Portland 1 y Portland 2, compuestas por los distintos tipos de\ncadenas polipeptídicas indicados en el\n \ncuadro 7-1\n.\nEn el cuarto mes del embarazo se sintetizan las cadenas\n\u0003α\n \ny\n \nγ\n, que al combinarse forman la Hb F\n(fetal), que predomina en esa época de la gestación. Las Hb embrionarias disminuyen hasta desapa-\nrecer en la época del nacimiento.\nAl nacer, la Hb F representa el 80%, aproximadamente, de la totalidad de la Hb, y el 20% restante\nlo forman la Hb A1, o A (adulta), y la Hb A2. Cerca de los 12 meses de edad, prácticamente toda la\nHb se encuentra en su forma adulta (\nα\n2/\nβ\n2), integrando el 97% de la hemoglobina durante el resto de\nla vida. La Hb A2 contribuye con el 2% y el remanente es Hb F.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":126,"lines":{"from":60,"to":81}}}}],["561",{"pageContent":"CAPÍTULO 7\n\nHEMOGLOBINOPATÍAS\nY TALASEMIAS\n\nGuillermo Ruiz Reyes\n\nObjetivos de aprendizaje\n\n•\n \nDistinguir el término\n \nhemoglobinopatía\n \ny el de\n \ntalasemia\n.\n\n•\n \nConocer los trastornos hereditarios que afectan la estructura y la síntesis de la hemoglobina.\n\n•\n \nComprender el concepto de\n \ndrepanocitosis\n \ny sus variantes.\n\nLa molécula de Hb está com-\npuesta por cuatro porciones\ndiferentes: 1) un componente\nproteico\n \nllamado\n \nglobina\n,\ncompuesto por cuatro cadenas\npolipeptídicas que son dos pa-\nres (dímeros) y cada par posee\nidéntica\n \nestructura\n \nprima-\nria; 2) cuatro moléculas de\nprotoporfirina IX; 3) cuatro\nátomos de hierro en estado\nferroso que, combinados con la\nprotoporfirina IX, forman las\ncuatro moléculas de hemo; y 4)\nuna molécula de 2,3-difosfo-\nglicerato (2-3-DPG) ubicada\nen el centro de la unidad de\nHb.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":126,"lines":{"from":83,"to":141}}}}],["562",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n100\n\nTRASTORNOS HEREDITARIOS QUE AFECTAN\nLA ESTRUCTURA Y LA SÍNTESIS DE LA HEMOGLOBINA\n\nLas anormalidades de la hemoglobina pueden ser consecuencia de una variación estructural de la molécula o\nde la producción insuficiente de una o más cadenas de polipéptidos. El término\n \nhemoglobinopatías\n \nse emplea\npara designar a las primeras y el de\n \ntalasemias\n \npara referirse a las segundas. Este capítulo se ocupará de unas\ny otras sucesivamente.\n\nHEMOGLOBINOPATÍAS\n\nLa mayoría de las variantes de la hemoglobina resultan de la sustitución de un aminoácido por otro en algún\nsitio de las cadenas polipeptídicas que la componen. Sin embargo, en menor proporción, también pueden en\n-\ncontrarse otras variaciones estructurales más complejas de la molécula, como la sustitución de dos aminoácidos,\nla deleción de uno o más aminoácidos, el alargamiento de una cadena polipeptídica y las fusiones de cadenas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":127,"lines":{"from":1,"to":27}}}}],["563",{"pageContent":"Figura 7-1.\n \nEstructura de la hemoglobina adulta. Las\ncadenas polipeptídicas están representadas por las áreas\n\nα\n \ny\n\u0003β\n; los círculos indican los cuatro grupos hemo, in-\ntegrados a su vez por sendos átomos de hierro combi-\nnados con protoporfirina IX; el cuadro central (DFG)\nesquematiza al 2,3-difosfoglicerato.\n\nCuadro 7-1.\n \nHemoglobinas\n \nnormalmente presentes\n \nen la vida\n \nadulta,\n \nfetal y\n \nembrionaria\n\nHemoglobina\n \nCadenas\n \nPeríodo en el que\n \nnormalmente\n \nse\n \nencuentran\n\nA\n \na2/\nβ\n2\n \nLa mayor\n \nhemoglobina\n \nen la vida\n \nadulta\nA2\n \na2/\nβ\n2\n \nHemoglobina menor en la vida adulta; menor aún\nen la vida\n \nfetal\n \ny\n \nneonatal\nF\n \na2/\nG\nγ\na2\n \nHemoglobina menor en la vida adulta; mayor en la\nvida fetal; declina a2/\nA\nγ\n2 en el período neonatal\nGower\n \n1\nGower\n \n2\nPortland\n \n1\nPortland\n \n2\n\nc\n2/\n¡\n2\n\nα\n2/\n¡\n2\n\nc\n2/\nγ\n2\n\nc\n2/\nβ\n2\nEmbrionario\nEmbrionario\nEmbrionario\nEmbrionario","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":127,"lines":{"from":29,"to":143}}}}],["564",{"pageContent":"c\n2/\n¡\n2\n\nα\n2/\n¡\n2\n\nc\n2/\nγ\n2\n\nc\n2/\nβ\n2\nEmbrionario\nEmbrionario\nEmbrionario\nEmbrionario\n\nLa mayoría de las variantes\nde la hemoglobina resultan de\nla sustitución de un aminoá-\ncido por otro en algún sitio\nde las cadenas polipeptídicas\nque la componen.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":127,"lines":{"from":143,"to":172}}}}],["565",{"pageContent":"CAPÍTULO 7. HEMOGLOBINOPATÍAS Y TALASEMIAS\n\n101\n\nFrecuencia\n\nLas variantes de la hemoglobina, particularmente las que se acompañan de trastornos clínicos y las tala-\nsemias, son habituales. Tan solo en Estados Unidos se ha calculado que existen por lo menos 8 millones\nde personas con alguna forma de talasemia o de hemoglobinopatía. En el continente africano y en varios\npaíses del Caribe y de Centro y Sudamérica hay regiones con una prevalencia muy alta de hemoglobina S.\nEn ciertas zonas de Asia, los heterocigotos de Hb E oscilan entre 4 y 20%, dependiendo de la región. En\nMéxico, las encuestas practicadas en algunas zonas de su territorio, específicamente en algunos lugares\nubicados en las costas del Golfo y del Pacífico, han descubierto algunos sitios con alta prevalencia de porta-\ndores de hemoglobina S y de talasemia\n \nβ\n. También se han descubierto nuevas variantes de la molécula, las","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":128,"lines":{"from":1,"to":17}}}}],["566",{"pageContent":"hemoglobinas México, Chiapas y Colima\n, e identificado otras hemoglobinas anormales por medio de encues-\ntas o estudiando enfermos con síndromes hemolíticos. Entre ellas pueden citarse las Hb C, D-Los Ángeles\n(Punjab), E, G-San José, I-Filadelfia, J-Baltimore, Fannin-Lubbock, Riyadh, Tarrant Köln y PHHF.\n\nGenética de las anormalidades de la hemoglobina\n\nLa herencia de las variantes de la Hb obedece a las leyes de Mendel. En la\n \nfigura 7-2\n \nse indican ejemplos\nde cinco diferentes patrones hereditarios que pueden encontrarse en los descendientes de los padres, cuyas\ncaracterísticas hipotéticas se señalan.\nUna persona que tiene dos variantes de la hemoglobina (p. ej., Hb SC) se designa\n \ndoble heterocigoto\n \no\n\nheterocigoto compuesto\n, y ha heredado una variante anormal diferente de cada uno de sus padres. Otra ca-\ntegoría doble heterocigota es la combinación de una anormalidad estructural con otra de síntesis; ejemplo\nde ello sería la Hb S-talasemia\n \nβ\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":128,"lines":{"from":19,"to":45}}}}],["567",{"pageContent":"Nomenclatura de las hemoglobinas anormales","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":128,"lines":{"from":47,"to":47}}}}],["568",{"pageContent":"A las variantes de la hemoglobina se las identifica por un nombre propio y una designación científica.\nDurante la época en que se efectuaron las primeras investigaciones en el campo de las hemoglobinas\nanormales, y a medida que se iban identificando las primeras variantes por sus diferencias de motili-\ndad electroforética, se les asignaba el nombre de alguna letra del alfabeto, reservando la letra “A” para\nel componente mayor de la Hb adulta; la letra “F” para la Hb fetal y la “S” para la hemoglobina de la\ndrepanocitosis o anemia de hematíes falciformes, aludiendo a la primera letra del nombre en inglés del\npadecimiento:\n \nsickle cell anemia\n.\nEsta nomenclatura funcionó hasta 1956. Para esa fecha se habían identificado la ya mencionada Hb S\ny también las hemoglobinas C, D, E, F, G, H, I y J. Sin embargo, los investigadores advirtieron que muy\npronto serían insuficientes las letras del alfabeto para designar a las nuevas variantes y acordaron suspen-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":128,"lines":{"from":49,"to":61}}}}],["569",{"pageContent":"pronto serían insuficientes las letras del alfabeto para designar a las nuevas variantes y acordaron suspen-\nder hasta la letra J la nomenclatura basada en este sistema. Desde entonces las nuevas variedades de la\nhemoglobina se designan con los nombres de: a) la familia en donde se descubrió la anomalía; b) el pueblo,\nla ciudad, el estado, el condado o el país de residencia del caso índice; c) el hospital o centro médico en\ndonde se realizó el descubrimiento, y d) el nombre de alguna montaña, río, bahía, estuario u otro sitio, a\nveces relacionados con el lugar de residencia del caso índice.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":128,"lines":{"from":61,"to":66}}}}],["570",{"pageContent":"En\n \nMéxico,\n \nlas\n \nencuestas\npracticadas en algunas zonas\nde\n \nsu\n \nterritorio,\n \nespecífica-\nmente en algunos lugares ubi-\ncados en las costas del Golfo y\ndel Pacífico, han descubierto\nalgunos sitios con alta pre-\nvalencia\n \nde\n \nportadores\n \nde\nhemoglobina S y de talasemia\n\nβ\n. También se han descubier-\nto tres nuevas variantes de la\nmolécula,\n \nlas\n \nhemoglobinas\nMéxico, Chiapas y Colima.\n\nFigura 7-2.\n \nEjemplos de patrones de herencia mendeliana de las hemoglobinopatías.\n1. Homocigoto AA × homocigoto SS. Descendencia 100% AS. 2. Homocigoto AA × heterocigoto AS. Des\n-\ncendencia 50% AA, 50% AS. 3. Heterocigoto AS. Descendencia 25% AA, 50% AS, 25% SS. 4. Heterocigoto\nAS × homocigoto SS. Descendencia 50% AS, 50% SS. 5. Homocigoto SS × homocigoto SS × homocigoto SS.\nDescendencia 100% SS.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":128,"lines":{"from":68,"to":113}}}}],["571",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n102","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":129,"lines":{"from":1,"to":3}}}}],["572",{"pageContent":"La designación científica de las variantes de la hemoglobina se basa en cinco características: 1) la\ncadena de polipéptidos afectada; 2) el o los sitios de las cadenas en donde ocurrieron las sustituciones de\nlos aminoácidos; 3) el número del segmento de la hélice involucrada en la o las sustituciones; y 4) el tipo\nde mutación observada.\nHay que recordar que las cadenas polipeptídicas de la molécula de Hb están compuestas por una secuen-\ncia específica de aminoácidos: 141 en las cadenas\n \nα\n \ny 146 en las\n\u0003β\n. La estructura secundaria se subdivide en\nocho segmentos helicoidales, rígidos, designados con las letras A-H. Existen también siete segmentos no\nhelicoidales que proporcionan flexibilidad a la cadena de globina, permitiendo sus movimientos.\nPor ello, la designación de la Hb S es\n \nβ\n \n6 (A3)Glu Val y puede interpretarse como una variante de\ncadena\n\u0003β\n \nque afecta al aminoácido número 6, ubicado en la tercera porción del segmento helicoidal A.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":129,"lines":{"from":5,"to":27}}}}],["573",{"pageContent":"Por ello, la designación de la Hb S es\n \nβ\n \n6 (A3)Glu Val y puede interpretarse como una variante de\ncadena\n\u0003β\n \nque afecta al aminoácido número 6, ubicado en la tercera porción del segmento helicoidal A.\nLa variante está causada por la sustitución del aminoácido normal (ácido glutámico en ese sitio de la\ncadena\n \nβ\n) por valina.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":129,"lines":{"from":27,"to":40}}}}],["574",{"pageContent":"Clasificación de las anormalidades de la hemoglobina","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":129,"lines":{"from":42,"to":42}}}}],["575",{"pageContent":"Muchas de ellas son clínicamente silenciosas o “inocentes”. Otras, por el contrario, dan lugar a manifestaciones\nclínicas de intensidad variable. Desde el punto de vista funcional, se distinguen cuatro tipos de hemoglobinopatías:\n1.\n \nHemoglobinas agregantes.\n \nPor su capacidad de agregarse tienen reducida su solubilidad y polime-\nrizan, como la Hb S, o cristalizan, como la Hb C, en el interior de los eritrocitos distorsionando su\nforma, disminuyendo su deformabilidad y haciéndolos más susceptibles a la destrucción (hemólisis).\n2.\n \nHemoglobinas inestables.\n \nSe caracterizan por tener reducida su solubilidad y por su tenden-\ncia a precipitar, formando cuerpos de inclusión intraeritrocitarios, conocidos como\n \ncuerpos de\nHeinz-Ehrlich\n, que por su rigidez son incapaces de atravesar la microcirculación esplénica. Los\neritrocitos afectados pierden su membrana y eventualmente son atrapados y destruidos en el bazo.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":129,"lines":{"from":44,"to":63}}}}],["576",{"pageContent":"Heinz-Ehrlich\n, que por su rigidez son incapaces de atravesar la microcirculación esplénica. Los\neritrocitos afectados pierden su membrana y eventualmente son atrapados y destruidos en el bazo.\nEstas hemoglobinas son también sensibles al calor in vitro. Las hemoglobinas Colonia y Gun Hill,\nson ejemplos de esta variedad anormal de la molécula y pueden o no tener alterada su afinidad al\noxígeno. Otras pueden causar metahemoglobinemia.\n3.\n \nMetahemoglobinas.\n \nSe caracterizan por que el hierro se encuentra bajo la forma férrica (Fe\n \n+++\n) e\nimpide la unión reversible con el oxígeno molecular. Al perder su capacidad funcional, se comporta\ncomo metahemoglobina. Se han descrito cinco tipos diferentes de metahemoglobinas: la Saska-\ntoon, la Hyde Park, la Milwaukee-1, la Boston y la Iwate. Los heterocigotos afectados sufren de\ncianosis y las tres primeras variantes indicadas se acompañan de anemia hemolítica crónica.\n4.\n \nHemoglobinas con alteraciones de afinidad al oxígeno.\n \nEl aumento de afinidad al oxígeno se","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":129,"lines":{"from":63,"to":85}}}}],["577",{"pageContent":"cianosis y las tres primeras variantes indicadas se acompañan de anemia hemolítica crónica.\n4.\n \nHemoglobinas con alteraciones de afinidad al oxígeno.\n \nEl aumento de afinidad al oxígeno se\nobserva en algunas variantes de la hemoglobina, como en la Gun Hill. Cuando la liberación de\noxígeno a los tejidos está disminuida, la reducción de la presión parcial de oxígeno origina aumento\nde la producción de eritropoyetina y, como consecuencia, poliglobulia.\nLa disminución de la afinidad al oxígeno puede ocurrir también; tal es el caso de la Hb Kansas. Como\nestas hemoglobinas liberan más oxígeno por gramo de Hb, pueden ocurrir anemias moderadas. Algunas\nvariantes no determinan síntomas ni signos y otras pueden acompañarse de cianosis.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":129,"lines":{"from":85,"to":96}}}}],["578",{"pageContent":"EL LABORATORIO EN LA IDENTIFICACIÓN\nDE LAS ANORMALIDADES DE LA HEMOGLOBINA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":129,"lines":{"from":98,"to":99}}}}],["579",{"pageContent":"La mayoría de las anormalidades de la hemoglobina se pueden identificar en los laboratorios clínicos\nde rutina, empleando las siguientes pruebas: 1) citometría hemática completa, con especial atención a\nla eritrocitometría, búsqueda de alteraciones morfológicas en la serie roja e identificación de cuerpos de\ninclusión intraeritrocitarios; 2) estudio electroforético de la hemoglobina en acetato de celulosa (pH 8,4-\n8,6); 3) estudio electroforético de la hemoglobina en agar citrato (pH 6,0-6,2), cuando está indicada; 4)\nprueba de solubilidad con ditionito de sodio; 5) prueba de inducción de los drepanocitos; 6) cuantificación\nde hemoglobina fetal; 7) cuantificación de hemoglobina A2; 8) investigación de hemoglobinas inestables\ncon las pruebas del calor e isopropanol; 9) electroforesis de las cadenas de globina a pH ácido y alcalino,\ncuando estén indicadas, y 10) cuantificación de P50 y de 2,3-difosfoglicerato, cuando estén indicadas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":129,"lines":{"from":101,"to":109}}}}],["580",{"pageContent":"cuando estén indicadas, y 10) cuantificación de P50 y de 2,3-difosfoglicerato, cuando estén indicadas.\nEl uso de las pruebas anteriores habitualmente conduce a identificar las variantes más frecuentes de la\nhemoglobina. En algunas ocasiones se requiere remitir las muestras problema a centros de referencia para\nsu caracterización final.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":129,"lines":{"from":109,"to":112}}}}],["581",{"pageContent":"La designación científica de las\nvariantes de la hemoglobina se\nbasa en cinco características:\n1) la cadena de polipéptidos\nafectada; 2) el o los sitios de las\ncadenas en donde ocurrieron\nlas sustituciones de los ami-\nnoácidos; 3) el número del seg-\nmento de la hélice involucrada\nen la o las sustituciones; y 4) el\ntipo de mutación observada.\nLas hemoglobinas inestables se\ncaracterizan por tener reduci-\nda su solubilidad y por su ten-\ndencia a precipitar, formando\ncuerpos de inclusión intrae-\nritrocitarios,\n \nconocidos\n \ncomo\n\ncuerpos de Heinz-Ehrlich.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":129,"lines":{"from":114,"to":136}}}}],["582",{"pageContent":"CAPÍTULO 7. HEMOGLOBINOPATÍAS Y TALASEMIAS\n\n103\n\nDREPANOCITOSIS\n\nLa drepanocitosis o anemia de hematíes falciformes es un padecimiento hereditario, ampliamente distribui-\ndo en todo el mundo como gen autosómico codominante. Los sujetos heterocigotos (AS) se designan como\nportadores, o que tienen el rasgo drepanocítico. Los homocigotos (SS) sufren de anemia drepanocítica.\n\nDistribución geográfica","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":130,"lines":{"from":1,"to":11}}}}],["583",{"pageContent":"Es probable que el padecimiento se haya originado en África, en donde en algunas zonas hay una pre-\nvalencia de portadores que oscila entre 20 y 40%. En Estados Unidos, del 0,1 al 0,2% de la población\nde origen africano sufre anemia drepanocítica (SS) y el 8% es portador (AS) de la anormalidad. Entre\nlos descendientes de los esclavos de raza negra traídos al continente americano durante la época de la\ncolonización española, la prevalencia de heterocigotos en algunas regiones es análoga a la del África\ntropical. En el Caribe, Centroamérica, Venezuela y Brasil, la anormalidad es frecuente y, en algunos\nlugares, muy elevada, como ocurre en ciertas localidades de Panamá, en donde los heterocigotos ocupan\nhasta el 30% de la población.\nEn México, Lisker y cols. demostraron que en ciertas zonas de las costas del Golfo y del Pacífico la\nHb S es frecuente, y que existen algunas poblaciones con alta prevalencia de portadores.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":130,"lines":{"from":13,"to":22}}}}],["584",{"pageContent":"En México, Lisker y cols. demostraron que en ciertas zonas de las costas del Golfo y del Pacífico la\nHb S es frecuente, y que existen algunas poblaciones con alta prevalencia de portadores.\nAlgunos investigadores han propuesto que la mutación que origina la Hb S otorga resistencia, pero no\ninmunidad, a uno de los parásitos que causan el paludismo,\n \nPlasmodium falciparum.\n \nCuando los eritrocitos\nparasitados adoptan la forma semilunar o drepanocítica, el parásito muere. Por otro lado, las áreas geográfi-\ncas en donde prevalece\n \nP. falciparum\n \ncoinciden con las zonas donde se han encontrado portadores de Hb S.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":130,"lines":{"from":22,"to":35}}}}],["585",{"pageContent":"Fisiopatología\n\nCuando la Hb S está bien oxigenada es totalmente soluble. Sin embargo, cuando disminuye la presión\nparcial de oxígeno (PO\n \n2\n \n), la molécula de hemoglobina se polimeriza y se forman tactoides, o cristales,\nque vuelven rígidos a los eritrocitos\n \n(fig. 7-3)\n. Estos cambios impiden que la sangre circule normal-\nmente por los tejidos y se produce estancamiento. La PO\n \n2\n \ndesciende más aún, originándose un círculo\nvicioso: los eritrocitos falciformes incrementan el estancamiento, desciende más la PO\n \n2\n \ny la falciforma-\nción se acentúa. Si los eritrocitos adoptan la forma drepanocítica durante un lapso corto, el fenómeno\nes reversible. Contrariamente, si el tiempo se prolonga, se lesiona la membrana celular y el fenómeno se\nvuelve irreversible. En estas condiciones, los hematíes son eliminados de la circulación por las células\ndel sistema mononuclear-fagocítico.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":130,"lines":{"from":37,"to":62}}}}],["586",{"pageContent":"Figura 7-3.\n \nDrepanocitos observados con diversas técnicas. 1. Microscopia electrónica de barrido. 2. Con-\ntraste interferencial diferencial según Nomarski (in vivo). 3. Campo claro. 4. Microscopia electrónica de\nbarrido. 5. Contraste de fases (in vivo). (Microfotografías cortesía del doctor Joaquín Carrillo Farga.)\n\nLa drepanocitosis o anemia\nde hematíes falciformes es un\npadecimiento hereditario am-\npliamente distribuido en todo\nel mundo como gen autonómi-\nco codominante. Los sujetos\nheterocigotos (AS) se designan\ncomo portadores, o que tienen\nel\n \nrasgo\n \ndrepanocítico.\n \nLos\nhomocigotos\n \n(SS)\n \nsufren\n \nde\nanemia drepanocítica.\nCuando la Hb S está bien\noxigenada es totalmente so-\nluble. Sin embargo, cuando\ndisminuye la presión parcial\nde oxígeno (PO\n \n2\n), la molécu-\nla de hemoglobina se polime-\nriza y se forman tactoides, o\ncristales, que vuelven rígidos\na los eritrocitos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":130,"lines":{"from":64,"to":104}}}}],["587",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n104\n\nHEMOGLOBINA S O FORMA HETEROCIGOTA\n(PORTADORES O RASGO DREPANOCÍTICO)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":131,"lines":{"from":1,"to":6}}}}],["588",{"pageContent":"Estos sujetos se hallan habitualmente asintomáticos y la exploración física es negativa. No obstante, es\nconveniente descubrirlos porque algunos pueden llegar a sufrir hematurias secundarias a necrosis papilar\nrenal; otros padecen infartos del bazo y trombosis cerebrales. Estas complicaciones casi siempre ocurren\ncuando los portadores se exponen a situaciones de hipoxia prolongada, como en las anestesias generales\ncon inadecuada aportación de oxígeno, en los procesos neumónicos y durante los viajes en aviones despro-\nvistos de cabina a presión. La exposición al frío intenso puede precipitar también estas complicaciones.\nComo estas últimas son excepcionales, se ha recomendado considerar a los portadores como personas\nsanas, pues se ha comprobado que muchos de ellos pueden tolerar esfuerzos físicos intensos. En apoyo de\nesto, cabe señalar que cerca del 7% de los jugadores de raza negra de la Liga Nacional de Futbol Ameri-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":131,"lines":{"from":8,"to":16}}}}],["589",{"pageContent":"esto, cabe señalar que cerca del 7% de los jugadores de raza negra de la Liga Nacional de Futbol Ameri-\ncano de Estados Unidos son portadores de Hb S. Se conoce también el caso de un excampeón mundial de\nboxeo, portador de la anormalidad.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":131,"lines":{"from":16,"to":18}}}}],["590",{"pageContent":"Datos de laboratorio\n\nCasi nunca existe anemia y la morfología de los eritrocitos es normal. De manera excepcional se encuen-\ntran drepanocitos en los extendidos convencionales de sangre. Para descubrir a los portadores, se requiere\npracticar las pruebas de inducción de los drepanocitos y de solubilidad que son positivas. La electroforesis\nde hemoglobina en acetato de celulosa, pH 8,4-8,6, que nunca debe omitirse, permite demostrar el com-\nponente S de la hemoglobina, de motilidad electroforética más lenta que la Hb A. La combinación de un\npatrón electroforético AS y una prueba de solubilidad positiva establece el diagnóstico de portador (AS)\nde esta variedad de hemoglobina.\n\nHEMOGLOBINA S HOMOCIGOTA (SS)\nO ANEMIA DREPANOCÍTICA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":131,"lines":{"from":20,"to":31}}}}],["591",{"pageContent":"La anemia hemolítica que caracteriza a esta enfermedad se inicia desde los primeros meses de la vida. En\nlos menores de 5 años, la hepatoesplenomegalia es frecuente, pero a medida que se producen los infartos\ndel bazo, se reduce su tamaño y la víscera acaba por desaparecer, característica que se conoce como\n \nautoes-\nplenectomía\n. Esto es tan frecuente que cuando se encuentra esplenomegalia en los enfermos de más edad,\nhay que dudar si verdaderamente sea homocigoto (SS) o doble heterocigoto (heterocigoto compuesto),\ncomo es el caso de los pacientes con las combinaciones genéticas SC, SD y S-talasemia\n \nβ\n, en quienes la\nautoesplenectomía no ocurre.\nLos enfermos, en su mayoría de raza negra o con rasgos negroides, generalmente son altos, delga -\ndos, con cráneo en torre y articulaciones hiperextensibles. Su crecimiento y maduración sexual están\ngeneralmente retardados. Al examinarlos se aprecia ictericia conjuntival y no es raro que este dato des -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":131,"lines":{"from":33,"to":48}}}}],["592",{"pageContent":"generalmente retardados. Al examinarlos se aprecia ictericia conjuntival y no es raro que este dato des -\noriente al médico no familiarizado con esta enfermedad y establezca el diagnóstico clínico de hepatitis.\nLos enfermos sufren úlceras maleolares o cicatrices de úlceras antiguas. En el fondo del ojo, los vasos\nretinianos se encuentran tortuosos o en “tirabuzón”.\nLas crisis vasculares oclusivas son características de la afección, resultado de la oclusión de los vasos,\npor acumulación de drepanocitos que originan estancamiento e infarto; aquellas ocurren en cualquier\nedad y tienen, como denominador común, antecedentes de hipooxigenación excesiva, como la secundaria\na procesos infecciosos, deshidratación, ejercicios violentos, trabajo de parto y grandes altitudes, como a las\nque se exponen las personas cuando viajan en aviones desprovistos de cabina a presión. La fiebre moderada\na menudo se asocia con crisis vasooclusivas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":131,"lines":{"from":48,"to":57}}}}],["593",{"pageContent":"que se exponen las personas cuando viajan en aviones desprovistos de cabina a presión. La fiebre moderada\na menudo se asocia con crisis vasooclusivas.\nEn los niños de 9 meses de edad, las crisis oclusivas que afectan huesos pequeños de manos y pies\ndeterminan dactilitis o síndrome de “mano-pie”, caracterizado por la inflamación dolorosa del dorso de\nestas regiones. A menudo esta es la primera manifestación clínica de la enfermedad.\nLas infecciones por\n \nStreptococcus pneumoniae\n \nson frecuentes en la infancia y se atribuyen a la disfunción\ndel bazo o a la deficiencia inmunitaria, o bien a ambas. En huesos es común que ocurra osteomielitis por","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":131,"lines":{"from":57,"to":67}}}}],["594",{"pageContent":"Salmonella\n \ny otros gérmenes gramnegativos. En los adultos predominan los infartos pulmonares; sin em-\nbargo, cualquier órgano puede afectarse con serias consecuencias para el enfermo, como las secundarias\na infartos cerebrales o del nervio óptico. El depósito de hierro en miocardio, atribuible a las múltiples\ntransfusiones que se aplican a estos enfermos, puede conducir a insuficiencia cardíaca y a producir cardio-\nmegalia desde la infancia. Se puede presentar priapismo.\n\nCerca del 7% de los jugadores\nde raza negra de la Liga Na-\ncional de Futbol Americano\nen Estados Unidos son porta-\ndores de Hb S. Se conoce tam-\nbién el caso de un excampeón\nmundial de boxeo, portador\nde la anormalidad.\nLos enfermos, en su mayoría\nde raza negra o con rasgos\nnegroides, generalmente son\naltos, delgados, con cráneo en\ntorre y articulaciones hiperex-\ntensibles.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":131,"lines":{"from":69,"to":90}}}}],["595",{"pageContent":"CAPÍTULO 7. HEMOGLOBINOPATÍAS Y TALASEMIAS\n\n105","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":132,"lines":{"from":1,"to":3}}}}],["596",{"pageContent":"Las crisis vasculares se inician bruscamente, con fiebre y dolor intenso. El diagnóstico diferencial\ndepende del órgano implicado. Los cuadros abdominales pueden simular apendicitis y dificultar su\ndiagnóstico.\nLas crisis aplásicas son resultado de la interrupción brusca de la eritropoyesis con descenso de la re-\nticulocitosis y de los niveles de hemoglobina. La caída de esta última puede ser muy grave y causar in-\nsuficiencia cardíaca y la muerte en pocas horas. Las crisis aplásicas se han asociado con diversas causas.\nSin embargo, algunos estudios epidemiológicos han demostrado que las infecciones por parvovirus B19\nconstituyen la causa de la mayoría, y posiblemente de todas las crisis aplásicas resultantes de la citotoxi-\ncidad directa del parvovirus en los precursores eritroides, especialmente de las unidades formadoras de\ncolonias eritrocíticas.\nComo en todas las anemias hemolíticas, se demuestra hiperbilirrubinemia indirecta (no conjugada);","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":132,"lines":{"from":5,"to":15}}}}],["597",{"pageContent":"colonias eritrocíticas.\nComo en todas las anemias hemolíticas, se demuestra hiperbilirrubinemia indirecta (no conjugada);\nincremento de la deshidrogenasa láctica; disminución de los niveles de haptoglobina en suero; acorta-\nmiento de la sobrevida de los eritrocitos, e hiperplasia eritroide en médula ósea.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":132,"lines":{"from":15,"to":18}}}}],["598",{"pageContent":"Datos de laboratorio","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":132,"lines":{"from":20,"to":20}}}}],["599",{"pageContent":"La anemia, habitualmente normocítica normocrómica, es grave. Oscila entre 5 y 9 g/dL, comienza entre\nlos 6 y los 9 meses de edad y se mantiene toda la vida. La anisocitosis es frecuente y se observan numero-\nsos dianocitos (eritrocitos en forma de diana) y drepanocitos (véase figura 7-3); también se encuentran los\novalocitos y esquistocitos (eritrocitos fragmentados). Se observan, asimismo, policromatofilia, eritrocitos\nnucleados (normoblastos) y reticulocitosis. Como en todas las anemias hemolíticas, se demuestra hiperbi-\nlirrubinemia indirecta (no conjugada); incremento de la deshidrogenasa láctica; disminución de los niveles\nde haptoglobina en suero; acortamiento de la supervivencia de los eritrocitos e hiperplasia eritroide en\nmédula ósea.\nEl diagnóstico de laboratorio de hemoglobinopatía S se establece con los siguientes estudios: 1)\nprueba de inducción de los drepanocitos positiva o, mejor aún, 2) prueba de solubilidad positiva, re -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":132,"lines":{"from":22,"to":31}}}}],["600",{"pageContent":"El diagnóstico de laboratorio de hemoglobinopatía S se establece con los siguientes estudios: 1)\nprueba de inducción de los drepanocitos positiva o, mejor aún, 2) prueba de solubilidad positiva, re -\ncordando que todos los enfermos con genotipo S (SS, AS, SC, SD y S-talasemia\n \nβ\n) tienen esta prueba\npositiva; 3) estudio electroforético de la hemoglobina en acetato de celulosa, pH 8,4-8,6, compatible\ncon el genotipo SS; 4) estudio electroforético de la hemoglobina en agar citrato, pH 6,0-6,2, compati -\nble con el genotipo SS; 5) determinación de Hb F generalmente aumentada (10-20%), y 6) fracción A2\nde la hemoglobina dentro de límites normales.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":132,"lines":{"from":31,"to":40}}}}],["601",{"pageContent":"Tratamiento","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":132,"lines":{"from":42,"to":42}}}}],["602",{"pageContent":"Por ahora no se dispone de ningún tratamiento específico. Ciertas medidas profilácticas y precauciones\ngenerales contribuyen a reducir las crisis, como son el evitar los cambios bruscos de temperatura, la des-\nhidratación y las infecciones. Entre estas últimas, las ocasionadas por\n \nStreptococcus pneumoniae\n \npueden\nprevenirse con el uso de la vacuna específica y la aplicación profiláctica de penicilina de acción retardada,\nparticularmente en niños de 4 meses a 5 años. Las vacunas en contra de\n \nHaemophilus influenzae,\n \nvirus\nde la influenza y hepatitis B, ofrecen protección adicional a estos pacientes. Como en todos los procesos\nhemolíticos crónicos, debe administrarse ácido fólico permanentemente para impedir su déficit. Dentro\nde estas medidas profilácticas puede incluirse la detección intrauterina de homocigotos, empleando téc-\nnicas de DNA recombinante, cada día más perfeccionadas y con menor riesgo para el producto, pero aún\nlimitadas a los centros que las practican.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":132,"lines":{"from":44,"to":61}}}}],["603",{"pageContent":"nicas de DNA recombinante, cada día más perfeccionadas y con menor riesgo para el producto, pero aún\nlimitadas a los centros que las practican.\nLas crisis vasooclusivas se tratan con reposo, rehidratación, oxigenación y analgésicos. Las infecciones\nse investigan por medio de los cultivos pertinentes y se tratan con los antibióticos y agentes quimioterápi-\ncos requeridos. La administración de eritrocitos empacados se realiza cuando los síntomas y signos físicos\nlo sugieran. Hay que tener en cuenta que muchos pacientes que padecen anemia crónica toleran muy bien\ncifras muy bajas de hemoglobina.\nDe algunos años a la fecha ha sido estudiado el empleo de varios compuestos químicos que impiden\nla polimerización de la hemoglobina S o preservan la integridad de la membrana de los eritrocitos. Desa-\nfortunadamente, no se ha encontrado aún el medicamento idóneo, pero todo hace suponer que a la postre\nhabrá de descubrirse.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":132,"lines":{"from":61,"to":71}}}}],["604",{"pageContent":"fortunadamente, no se ha encontrado aún el medicamento idóneo, pero todo hace suponer que a la postre\nhabrá de descubrirse.\nEntre los fármacos empleados pueden señalarse la urea intravenosa, el cianato de sodio, el nitrógeno de\nmostaza y los compuestos que preservan la integridad de la membrana, como el cinc, el cetiedil y el telu-\nrito. El trasplante de médula ósea constituye una alternativa para algunos pacientes. Debe proporcionarse\nconsejo genético a las parejas en riesgo.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":132,"lines":{"from":71,"to":76}}}}],["605",{"pageContent":"De algunos años a la fecha\nse ha estudiado el empleo de\nvarios\n \ncompuestos\n \nquímicos\nque impiden la polimeriza-\nción de la hemoglobina S o\npreservan la integridad de la\nmembrana de los eritrocitos.\nDesafortunadamente,\n \nno\n \nse\nha encontrado aún el medica-\nmento idóneo, pero todo hace\nsuponer que a la postre habrá\nde descubrirse.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":132,"lines":{"from":78,"to":97}}}}],["606",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n106\n\nCOMBINACIONES DE LA HEMOGLOBINA S CON OTRAS\nANORMALIDADES DE LA HEMOGLOBINA\n\nDentro del grupo de las hemoglobinopatías designadas como “enfermedad drepanocítica”, se incluyen\nlos dobles heterocigotos (heterocigotos compuestos), en los que uno de los padres aporta el gen S y el\notro alguna otra variante anormal de la hemoglobina. Entre ellos se encuentran las hemoglobinopatías\nSC, S-talasemia\n \nβ\n, S-talasemia\n \nα\n, S-persistencia hereditaria de hemoglobina fetal, S-D Los Ángeles\n(Punjab), S-O Árabe, S-G Filadelfia y S-Lepore.\nLa hemoglobinopatía S-C se caracteriza por que la anemia es menos acentuada que en los homo-\ncigotos SS. Sin embargo, las crisis vasculares son más graves y las muertes súbitas por embolia grasa,\nmás frecuentes. Es posible que sea más frecuente también la necrosis aséptica de la cabeza del fémur y la\nosteomielitis por\n \nSalmonella.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":133,"lines":{"from":1,"to":24}}}}],["607",{"pageContent":"En la hemoglobinopatía S-talasemia\n \nβ\n \nse distinguen tres tipos clínicos. El primero incluye a los\npacientes que padecen manifestaciones clínicas leves y cuyo estudio electroforético demuestra una pro -\nporción de Hb A que oscila entre 15 y 30%. Se designan como\n \nhemoglobinopatías S-talasemia\n \nβ\n \n++\n.\nEl segundo tipo sufre manifestaciones clínicas graves, similares a las de los homocigotos SS. Estos\npacientes no sintetizan Hb A y sus alteraciones se conocen como\n \nhemoglobinopatías S-talasemia\n \nβ\n \n0\n. En\nMéxico se han identificado varios enfermos con esta combinación genética, originarios de una región\ncomún ubicada en la parte norte del estado de Veracruz que colinda con el sur del estado de Tamauli -\npas. Finalmente, el tercer grupo incluye a los enfermos con manifestaciones clínicas intermedias y que\nsintetizan una proporción también intermedia de Hb A, alrededor del 15%, y que se designa\n \nhemoglo-\nbinopatía S-talasemia\n \nβ\n \n+\n.\n\nOTRAS HEMOGLOBINOPATÍAS MENOS FRECUENTES","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":133,"lines":{"from":26,"to":62}}}}],["608",{"pageContent":"Con menor prevalencia se identifican alteraciones estructurales de la hemoglobina, que determinan cua-\ndros clínicos diversos. Un grupo de ellas se conocen como\n \nhemoglobinas inestables\n. Se heredan en forma\nautosómica dominante y sobreviven únicamente los heterocigotos. La inestabilidad de la molécula de\nhemoglobina que define a este grupo se puede demostrar en el laboratorio con la prueba de precipitación\ncon isopropanol, la prueba de desnaturalización con calor y observando cuerpos de Heinz en los exten-\ndidos de sangre.\nLa intensidad de los síntomas depende de la variedad y oscila entre ausentes, leves, moderados y graves.\nLas formas graves comienzan en la infancia. Los sujetos con síntomas moderados presentan esplenomega-\nlia, episodios de ictericia y hemólisis. Algunas variantes se identifican después de una crisis hemolítica, a\nmenudo consecutiva a un proceso infeccioso o a la administración de algún medicamento oxidante.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":133,"lines":{"from":64,"to":76}}}}],["609",{"pageContent":"menudo consecutiva a un proceso infeccioso o a la administración de algún medicamento oxidante.\nLas hemoglobinas M o metahemoglobinas son variantes asociadas con la existencia de metahemoglo-\nbina y con cianosis congénita. Su distribución es universal pero tienen mayor prevalencia en Japón.\nEn estas variedades, la sustitución aminoácida dentro de la molécula impide la protección del hierro\nde la oxidación y, como resultado de ello, las Hb M contienen la forma férrica (Fe\n \n+++\n) del hierro, o meta-\nhemoglobina, incapaz de transportar oxígeno.\nLos enfermos tienen un color de piel morado característico y dedos hipocráticos desde la infancia. Al-\ngunas variantes de Hb M causan anemia hemolítica. El análisis espectrofotométrico la necrosis aséptica\nde la cabeza del fémur y la osteomielitis por\n \nSalmonella\n.\nAlgunas hemoglobinas con afinidad aumentada para el oxígeno determinan eritrocitosis de patrón\nhereditario autosómico dominante. La Hb Chesapeake fue la primera variante descrita de este tipo y","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":133,"lines":{"from":76,"to":92}}}}],["610",{"pageContent":".\nAlgunas hemoglobinas con afinidad aumentada para el oxígeno determinan eritrocitosis de patrón\nhereditario autosómico dominante. La Hb Chesapeake fue la primera variante descrita de este tipo y\nhasta la fecha se han descubierto más de 100 hemoglobinas similares. En ocasiones es posible identificarla\npor su motilidad electroforética anormal. Es importante que se mida el contenido de 2,3-difosfoglicerato\npara excluir su deficiencia, capaz por sí sola de aumentar la afinidad al oxígeno de la hemoglobina normal.\nEl P50 en estos pacientes se encuentra generalmente disminuido y por ello la curva de disociación de la\noxihemoglobina se observa desviada hacia la izquierda. Estos pacientes suelen tener una vida normal y no\nrequieren tratamiento; sin embargo, conviene identificarlos para evitar el tratamiento innecesario de sus\neritrocitosis o el establecimiento de diagnósticos erróneos como los de padecimientos mieloproliferativos\no de eritrocitosis secundarias.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":133,"lines":{"from":92,"to":102}}}}],["611",{"pageContent":"eritrocitosis o el establecimiento de diagnósticos erróneos como los de padecimientos mieloproliferativos\no de eritrocitosis secundarias.\nPor otro lado, se han descrito numerosas variantes de la hemoglobina con afinidad disminuida para\nel oxígeno, que en algunos pacientes es tan baja que causa cianosis y a otros les confiere apariencia\nanémica. La curva de disociación de la oxihemoglobina está desviada a la derecha y el P50 se encuentra\nmuy aumentado. Estas variantes pueden ser estables o inestables. Las primeras habitualmente causan","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":133,"lines":{"from":102,"to":107}}}}],["612",{"pageContent":"La hemoglobinopatía S-C se\ncaracteriza por que la anemia\nes menos acentuada que en los\nhomocigotos SS. Sin embargo,\nlas crisis vasculares son más\ngraves y las muertes súbitas\npor embolia grasa, más fre-\ncuentes.\nAlgunas hemoglobinas con afi-\nnidad aumentada para el oxí-\ngeno\n \ndeterminan\n \neritrocitosis\nde patrón hereditario autosó-\nmico dominante.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":133,"lines":{"from":109,"to":125}}}}],["613",{"pageContent":"CAPÍTULO 7. HEMOGLOBINOPATÍAS Y TALASEMIAS\n\n107\n\ncianosis y las segundas con frecuencia anemias hemolíticas moderadas. Muchas de ellas tienen alte -\nraciones electroforéticas.\nDe lo anterior puede inferirse que las anormalidades de la molécula de hemoglobina, además de ane-\nmia, pueden causar eritrocitosis y cianosis y que, en el diagnóstico diferencial de estas alteraciones clíni -\ncas, es importante incluir tales variedades de hemoglobinas.\n\nTALASEMIAS\n\nCon este nombre se designa un amplio grupo de anormalidades hereditarias de la hemoglobina, que se\ncaracteriza por la producción insuficiente de una o más cadenas de globina.\n\nClasificación","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":134,"lines":{"from":1,"to":16}}}}],["614",{"pageContent":"Las talasemias se distinguen con el nombre o nombres de la cadena o cadenas de globina cuya síntesis está\nreducida. De acuerdo con esto, hay talasemia\n \nα\n,\n \nβ\n,\n \nδ\n,\n \nδ\n/\nβ\n \ny talasemia\n \nγ\n/\nδ\n/\nβ\n. Se admite que una variante\nestructural de la hemoglobina, la Hb Lepore, es una forma de talasemia\n\u0003δ\n/\nβ\n \ny que la Hb Constant Spring\nse asocia con talasemia\n \nα\n. Por ello estas variantes se incluyen dentro de los síndromes talasémicos. Existe\ntambién un grupo, no bien definido aún, de alteraciones hereditarias de la hemoglobina, caracterizado por\nla producción extemporánea de Hb fetal en la edad adulta, que se conoce como “persistencia hereditaria\nde hemoglobina fetal”, la cual se considera como una forma atenuada de talasemia.\nLos términos de talasemia “mayor”, “menor”, “intermedia” y “mínima”, utilizados para indicar la gra-\nvedad de las manifestaciones clínicas, no necesariamente indican heterocigotos u homocigotos. Para evi-\ntar confusiones, deben preferirse estos dos últimos términos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":134,"lines":{"from":18,"to":57}}}}],["615",{"pageContent":"Frecuencia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":134,"lines":{"from":59,"to":59}}}}],["616",{"pageContent":"Se considera que las talasemias constituyen el trastorno genético de observación más frecuente y que el 3%\nde la población mundial (180 millones de personas) es portadora de los genes de la talasemia\n\u0003β\n. Estos son\nparticularmente prevalentes en los habitantes de Italia y Grecia. La prevalencia más alta de portadores se\nha encontrado en Cerdeña (34%), la región del río Po cercana a Ferrara (20%) y Sicilia (10%). En África,\nel Medio Oriente, en el subcontinente de la India, en Myanmar y el sudeste de Asia, la frecuencia de por-\ntadores es también elevada. En México la prevalencia de portadores de talasemia\n \nβ\n \nno debe considerarse\ncomo infrecuente. Se han identificado grupos de población cuya prevalencia de talasemia\n \nβ\n \nasciende al\n15%, con datos que sugieren que es autóctona y en otras poblaciones que orientan a considerarlos como\nimportadas del área del Mediterráneo.\nEn el\n \ncuadro 7-2\n \nse indican los resultados de una investigación prospectiva de hemoglobinas anormales","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":134,"lines":{"from":61,"to":84}}}}],["617",{"pageContent":"importadas del área del Mediterráneo.\nEn el\n \ncuadro 7-2\n \nse indican los resultados de una investigación prospectiva de hemoglobinas anormales\nen 4 425 sujetos, efectuada en un lapso de 25 años (1987-2012) en Laboratorios Clínicos de Puebla, en mues-\ntras de sangre referidas de diversas partes de la México para descartar anormalidades de la hemoglobina.\nPuede apreciarse que la prevalencia de talasemia\n \nβ\n \nheterocigota, homocigota y de sus combinaciones\ncon otras variantes de la hemoglobina, ocupa el 74,5% de todas las anormalidades de la hemoglobina de-\ntectadas y que tres de cuatro sujetos con alguna anormalidad de la hemoglobina son heterocigotos, homo-\ncigotos o heterocigotos compuestos de talasemia\n \nβ\n. Se obtuvieron resultados análogos en Guadalajara tras\nestudiar un grupo de enfermos con procesos hemolíticos; dichos resultados se presentan en el\n \ncuadro 7-3\n.\nLos datos anteriores permiten concluir que la talasemia\n \nβ\n \nno es infrecuente en México, como durante","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":134,"lines":{"from":84,"to":111}}}}],["618",{"pageContent":"cuadro 7-3\n.\nLos datos anteriores permiten concluir que la talasemia\n \nβ\n \nno es infrecuente en México, como durante\nmucho tiempo se pensaba, y que en las personas con eritrocitos microcíticos o hipocrómicos, con o sin\nanemia, es aconsejable: 1) investigar primero deficiencia de hierro y 2) en caso de excluir esta deficiencia,\ninvestigar talasemia\n \nβ\n, determinando la fracción A2 de la hemoglobina. Un estudio efectuado en mestizos\nmexicanos demostró que la deficiencia de hierro es 11,5 veces más frecuente que la talasemia\n \nβ\n \ny que esta\núltima es 1,3 veces más frecuente que las anemias macrocíticas megaloblásticas.\nPor las dificultades técnicas que implica el diagnóstico certero de talasemia\n \nα\n \nen México, se desconoce\nsu frecuencia. Debe sospecharse su existencia en los casos de anemias microcíticas hipocrómicas con pa-\nrámetros de hierro y de fracción A2 de la hemoglobina dentro de límites normales.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":134,"lines":{"from":111,"to":136}}}}],["619",{"pageContent":"Talasemia\n\u0003α\n\nEl genotipo normal haploide de los genes de la cadena\n\u0003α\nde la hemoglobina se designa\n α\n/\nα\n. En la talasemia\n \nα\n,\ncuando está involucrada la deleción de genes, son posibles dos haplotipos: una deleción (–/\nα\n) o dos deleciones (–/–).\n\nLas talasemias se distinguen\ncon el nombre o los nombres\nde la cadena o las cadenas de\nglobina cuya síntesis está re-\nducida. De acuerdo con esto,\nhay talasemia\n \nα\n,\n \nβ\n,\n \nδ\n,\n \nδ\n/\nβ\n \ny\ntalasemia\n \nγ\n/\nδ\n/\nβ\n.\nLa talasemia\n \nβ\n \nno es infrecuente\nen México, como durante mucho\ntiempo se pensaba, y en las per\n-\nsonas con eritrocitos microcíticos,\nhipocrómicos, o ambos, con o sin\nanemia, es aconsejable: 1) inves\n-\ntigar primero la deficiencia de\nhierro y 2) en caso de excluir esta\ndeficiencia,\n \ninvestigar\n \ntalase-\nmia\n \nβ\n, determinando la fracción\nA2 de la hemoglobina.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":134,"lines":{"from":138,"to":207}}}}],["620",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n108\n\nLas diversas formas clínicas de\ntalasemia\n \nα\n \nson comunes en los\npaíses del sudeste de Asia, en\nChina y Filipinas. En menor\nproporción se encuentran en\nafroamericanos y en habitantes\nde las costas del Mediterráneo.\n\nCuadro 7-2\n. Hemoglobinas anormales identificadas en 1 392 personas de 4 969 estudiadas\nen los Laboratorios Clínicos de Puebla de septiembre de 1987 a noviembre de 2013\n\nCondición\n \nNúmero\n \n%\nTalasemia\n \nβ\n\nHeterocigotos\nHomocigotos\n922\n4\n66,52\n\nTalasemia\n \nα\n\nDeleción-\nα\n3.7\nHeterocigotos\nHomocigotos\nDeleción-\nα\n2HpH\n8\n2\n1\n \n0,8\n\nTalasemias compuestas\n\nHb S/talasemia\n \nβ\n\nHb S/talasemia\n \nβ\n/PHHF\nTalasemia\n \nδ\n/\nβ\n\n34\n1\n1\n \n2,58\n\nHemoglobina S\n\nHeterocigotos\nHomocigotos\nHb SC\nHb SD-Los Ángeles\n254\n141\n5\n1\n \n28,8\n\nOtras hemoglobinas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":135,"lines":{"from":1,"to":89}}}}],["621",{"pageContent":"Talasemias compuestas\n\nHb S/talasemia\n \nβ\n\nHb S/talasemia\n \nβ\n/PHHF\nTalasemia\n \nδ\n/\nβ\n\n34\n1\n1\n \n2,58\n\nHemoglobina S\n\nHeterocigotos\nHomocigotos\nHb SC\nHb SD-Los Ángeles\n254\n141\n5\n1\n \n28,8\n\nOtras hemoglobinas\n\nHb CC\nHb AC\nHb G-San\n \nJosé\nHb l-Filadelfia\nHb Lepor\ne-W\nashington-Boston\nHb\n \n“rápida”\nHb\n \nD-Los\n \nÁngeles\nHb\n \nHabana\nHb\n \nFannin-Lubbock\n2\n5\n1\n1\n1\n2\n2\n1\n3\n \n1,3\nTotal\n \n1 392\n \n100\nNormalmente se heredan cuatro genes\n \nα\n, dos de cada uno de los padres. Estos cuatro genes producen\ncadenas\n \nα\n \nen cantidad equivalente a la de las cadenas\n \nβ\n, dando lugar a una relación de cadenas\n \nβ\n/cadenas\n \nα","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":135,"lines":{"from":89,"to":181}}}}],["622",{"pageContent":"de 1:1. La mayoría de las talasemias\n \nα\n \nresultan de una disminución en el número de cadenas\n \nα\n \nproducidas,\ndebido a la deleción de uno, dos, tres o de los cuatro genes\n \nα\n. En el\n \ncuadro 7-4\n \nse indican las diversas\nformas de talasemia\n \nα\n, su genotipo y el padecimiento que causan.\nLas diversas formas clínicas de talasemia\n \nα\n \nson comunes en los países del sudeste de Asia, en China y Fili\n-\npinas. En menor proporción se encuentran en afroamericanos y en habitantes de las costas del Mediterráneo.\nLa gravedad clínica de las formas de talasemia\n \nα\n \nindicadas en el cuadro 7-4 depende de su genotipo.\nEn los portadores silenciosos, el cuadro hemático es normal o con algunos cambios leves, con disminución\ndel volumen globular medio (microcitosis) y de la concentración media de hemoglobina (hipocromía).\nSolo en recién nacidos se pueden demostrar vestigios (1 a 2%) de Hb Bart’s (tetrámero de cadenas\n \nγ\n,\n \nγ\n \n4),\nla que desaparece en la edad adulta. El diagnóstico definitivo solo se puede establecer analizando el DNA.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":135,"lines":{"from":183,"to":226}}}}],["623",{"pageContent":"γ\n,\n \nγ\n \n4),\nla que desaparece en la edad adulta. El diagnóstico definitivo solo se puede establecer analizando el DNA.\nEn la talasemia\n \nα\n \nmenor o rasgo talasémico, los hallazgos hematológicos antes descritos se acentúan:\nlos eritrocitos son ligeramente microcíticos e hipocrómicos y la cifra de Hb es normal baja, o ligeramente\ninferior a los valores de referencia. Se observan eritrocitos en diana y poiquilocitosis. En recién nacidos se\nencuentra de 2 a 10% de Hb Bart’s, concentraciones que contribuyen a distinguir esta variedad de talasemia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":135,"lines":{"from":226,"to":240}}}}],["624",{"pageContent":"α\n \nde los portadores silenciosos, cuya concentración de Hb Bart’s es inferior al 2%. Algunos meses después\ndel nacimiento, los métodos electroforéticos no detectan ya Hb Bart’s y solo puede demostrarse induciendo\nla precipitación intraeritrocítica de Hb H con azul brillante de cresil. Igual que en los portadores silencio-\nsos, el padecimiento únicamente puede diagnosticarse con certeza mediante análisis de DNA.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":135,"lines":{"from":242,"to":247}}}}],["625",{"pageContent":"CAPÍTULO 7. HEMOGLOBINOPATÍAS Y TALASEMIAS\n\n109\n\nCuadro 7-3.\n \nHemoglobinas anormales detectadas en 413 personas de 2 015 estudiadas\nen la División de Genética del Centro de Investigación Biomédica de\nOccidente del Instituto Mexicano del Seguro Social de Guadalajara\n\nCondición\n \nNúmero\n \n%\nTalasemia beta\n\nHeterocigotos\nHomocigotos\n194\n14\n\nTalasemia alfa\n\nDeleción-\nα\n3.7\nHeterocigotos\nHomocigotos\nDeleción –\nα\n/–\nα\n \no – –/\nαα\n\nDeleción -SEA\nHeterocigotos\nEnfermedad por HbH\n-\nα\n3.7\n/--SEA\n-\nα\nHph\n \n/--FIL\n-\nα\n3.7\n/--*\n15(2*)\n3\n8(*)\n3\n6\n1\n1\n \n59,3\n\nTalasemias beta compuestas\n\nHb S/Talasemia beta\nHb S/Talasemia delta/beta\nHb D/Talasemia beta\nHb E/Talasemia beta\nTalasemia delta/beta (tipo español)\n21\n1\n1\n1\n13\n\nTalasemias alfa compuestas\n\nHb S/Talasemia alfa\n \n1\n \n9,2\n\nHemoglobina S\n\nHeterocigotos\nHomocigotos\nHb SD-Los Ángeles\nHb SC\nHb SX*\n36\n68\n5\n1\n2\n \n27,1\n\nOtras hemoglobinas\n\nHb AC\nHb AE\nHb AD-Los Ángeles\nHb Chiapas\nHb Tarrant\nHb Colima\nHb Köln\nHb Fannin-Lubbock I\nHb Riyad\n1\n1\n1\n1\n3\n1\n1\n2\n3\n \n3,4","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":136,"lines":{"from":1,"to":121}}}}],["626",{"pageContent":"Otras hemoglobinas\n\nHb AC\nHb AE\nHb AD-Los Ángeles\nHb Chiapas\nHb Tarrant\nHb Colima\nHb Köln\nHb Fannin-Lubbock I\nHb Riyad\n1\n1\n1\n1\n3\n1\n1\n2\n3\n \n3,4\n\nOtras hemoglobinopatías\n\nPHHF**\n \n4\n \n1\nTotal\n \n413\n \n100","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":136,"lines":{"from":121,"to":155}}}}],["627",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n110","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":137,"lines":{"from":1,"to":3}}}}],["628",{"pageContent":"La enfermedad por hemoglobina H es clínicamente más grave. El recién nacido en apariencia es\nnormal, pero al final del primer año de edad presenta esplenomegalia y anemia. Esta última es también\nmicrocítica hipocrómica, con cifras de hemoglobina entre 9 y 12 g/dL. Asimismo, se registra reticulocito-\nsis. En los eritrocitos se observan los precipitados de Hb H característicos. En neonatos, la electroforesis\nde la Hb demuestra Hb Bart’s de 25 a 40% y, a medida que con el crecimiento se dispone de cadenas\n \nβ\n, es\nsustituida por Hb H (tetrámero de cadenas\n \nβ\n,\n \nβ\n \n4). La Hb A2 se halla disminuida casi siempre.\nLa mayoría de los pacientes con enfermedad por Hb H no requieren tratamiento. Sin embargo, las\ninfecciones intercurrentes deben tratarse lo antes posible evitando el uso de medicamentos oxidantes. El\ndesarrollo corporal de estos enfermos habitualmente es normal y el pronóstico bueno.\nLa hidropesía fetal, que de manera casi exclusiva se encuentra en el sureste de Asia y algunas islas del","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":137,"lines":{"from":5,"to":24}}}}],["629",{"pageContent":"desarrollo corporal de estos enfermos habitualmente es normal y el pronóstico bueno.\nLa hidropesía fetal, que de manera casi exclusiva se encuentra en el sureste de Asia y algunas islas del\nMediterráneo, es necesariamente mortal y los recién nacidos que la sufren viven pocas horas. Los neonatos\nson pequeños, edematosos, con ascitis y distensión abdominal. Habitualmente tienen hepatomegalia y esple-\nnomegalia acentuadas. Sus valores eritrocíticos son microcíticos hipocrómicos, con niveles de hemoglobina\nentre 4 y 10 g/dL y cambios morfológicos acentuados. El estudio electroforético de la hemoglobina muestra\ncifras de Hb Bart’s de 80%, con 20% de hemoglobina embrionaria Portland (z2/g2). No se identifica Hb\nadulta. El padecimiento se puede diagnosticar antes del nacimiento, estudiando el DNA de especímenes de\ncorion, obtenidos por biopsia, entre la sexta y la décima semana del embarazo.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":137,"lines":{"from":24,"to":32}}}}],["630",{"pageContent":"Talasemias\n \nβ","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":137,"lines":{"from":34,"to":36}}}}],["631",{"pageContent":"En este padecimiento existe una deficiencia en la producción de las cadenas\n \nβ\n \nde la hemoglobina, debida a\nla ausencia o a la reducción de su síntesis. Por su elevado polimorfismo genético, la expresión clínica de la\nenfermedad puede variar desde un trastorno prácticamente asintomático (rasgo talasémico), hasta formas\nclínicas muy graves, con anemia acentuada, sobrecarga de hierro y muerte antes de la edad adulta, como\nocurre en la talasemia mayor o anemia de Cooley.\nEntre ambos extremos se ubican las formas de talasemia designadas como “talasemia intermedia”, que cur\n-\nsa con anemia moderada, y la “talasemia menor”, casi siempre asintomática y que puede o no cursar con anemia\nleve. Esta última variante, y la designada rasgo talasémico, a menudo se descubren en un estudio hematológico\nrutinario y suelen confundirse con anemias ferroprivas, con las que guardan semejanza y de las que, como se\nindicará más adelante, deben distinguirse para no incurrir en tratamientos innecesarios con hierro.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":137,"lines":{"from":38,"to":52}}}}],["632",{"pageContent":"indicará más adelante, deben distinguirse para no incurrir en tratamientos innecesarios con hierro.\nLas formas heterocigotas de talasemia\n \nβ\n \nse diagnostican determinando la fracción A2 de la hemo-\nglobina, que se encuentra por arriba de lo normal. Ocasionalmente la Hb A2 es normal, en cuyo caso se\nrecurrirá al estudio de la síntesis de cadenas de globina para demostrar el desequilibrio existente, o bien a\ntécnicas de biología molecular.\nLa talasemia\n \nβ\n \nhomocigota, o anemia de Cooley, es un padecimiento grave que comienza en los primeros\nmeses de la vida con anemia grave que requiere transfusiones frecuentes. A los 3 años, la hepatomegalia es","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":137,"lines":{"from":52,"to":66}}}}],["633",{"pageContent":"Cuadro 7-4.\n \nGenotipos de talasemia\n\u0003α\n\nGenes de cadena\n \nα\n*\n \nGenotipo\n \nPadecimiento\n\nαα\n/\nαα\n \nNinguno (normal)\n−\nα\n/\nαα\n \nPortador silencioso (sin enfermedad)\n−\nα\n/−\nα\n \nTalasemia\n\u0003α\n \nmenor\n−−/\nαα\n \nTalasemia\n \nα\n \nmenor\n−−/−\nα\n \nEnfermedad por Hb H\n−−/−−\n \nHidropesía fetal\n\nLa enfermedad por hemoglo-\nbina H es clínicamente más\ngrave. El recién nacido en apa-\nriencia es normal, pero al final\ndel primer año de edad presenta\nesplenomegalia y anemia.\nPor su elevado polimorfismo\ngenético, la expresión clíni-\nca de la enfermedad puede\nvariar\n \ndesde\n \nun\n \ntrastorno\nprácticamente\n \nasintomáti-\nco (rasgo talasémico), hasta\nformas clínicas muy graves,\ncon anemia acentuada, so-\nbrecarga de hierro y muerte\nantes de la edad adulta, como\nocurre en la talasemia mayor\no anemia de Cooley.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":137,"lines":{"from":68,"to":143}}}}],["634",{"pageContent":"CAPÍTULO 7. HEMOGLOBINOPATÍAS Y TALASEMIAS\n\n111","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":138,"lines":{"from":1,"to":3}}}}],["635",{"pageContent":"variable y la esplenomegalia de naturaleza gigante es usual. Esta última cursa con citopenias (anemia, neu-\ntropenia y trombocitopenia) por hiperesplenismo. La exploración física confirma el crecimiento visceral y\ndescubre alteraciones óseas en el cráneo con deformación de la cara. Hay retraso en el crecimiento corporal.\nRadiológicamente, el cráneo presenta un ensanchamiento del díploe y numerosas estrías verticales, imagen\nque se conoce como “cráneo en cepillo”. El exceso de hierro, secundario a las múltiples transfusiones que\nrequieren los enfermos, produce hemocromatosis y sus secuelas: cirrosis hepática, diabetes mellitus y mio-\ncardiopatía, causas habituales de muerte antes de los 25 años.\nEl estudio de la sangre revela alteraciones morfológicas muy acentuadas en la serie roja, con eritrocitos\nde forma y tamaño muy diversos, pero predominando la microcitosis con hipocromía. Se encuentran\neritrocitos en diana (dianocitos), normoblastos y punteado basófilo.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":138,"lines":{"from":5,"to":14}}}}],["636",{"pageContent":"de forma y tamaño muy diversos, pero predominando la microcitosis con hipocromía. Se encuentran\neritrocitos en diana (dianocitos), normoblastos y punteado basófilo.\nLa electroforesis de la hemoglobina demuestra incremento de la Hb F (60 a 98%) con Hb A2 baja,\nnormal o aumentada. Las determinaciones de deshidrogenasa láctica y haptoglobina séricas, así como\nla bilirrubina no conjugada, o indirecta, son compatibles con las alteraciones observadas en los procesos\nhemolíticos.\nLa talasemia\n \nβ\n \nhomocigota puede diagnosticarse in utero con técnicas de análisis del DNA de corion\nobtenido mediante biopsia.\nEl tratamiento a base de transfusiones de paquetes de eritrocitos es la única terapéutica disponible\nque permite mantener la hemoglobina dentro de niveles aceptables. Sin embargo, debe acompañarse de\nmedicación quelante de hierro, como desferroxiamina, para mejorar la sobrecarga tisular de hierro. Se han","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":138,"lines":{"from":14,"to":28}}}}],["637",{"pageContent":"medicación quelante de hierro, como desferroxiamina, para mejorar la sobrecarga tisular de hierro. Se han\npropuesto algunos tratamientos interesantes y promisorios, como la reactivación de la expresión del gen\nde las cadenas\n \nγ\n, la terapéutica génica y el trasplante de médula ósea.\nLa distinción entre anemia por deficiencia de hierro y talasemia\n \nβ\n \nheterocigota es importante. El\nmédico debe considerarlas en el diagnóstico de los sujetos con microcitosis e hipocromía y recordar que\nestos parámetros no son sinónimos de deficiencia de hierro. Es recomendable que en todos los pacientes\ncon microcitosis e hipocromía se estime algún o algunos parámetros de hierro, a saber: el hierro sérico, la\ncapacidad de fijación de hierro, el índice de saturación de la transferrina, la ferritina del suero y la proto-\nporfirina cinc de los eritrocitos, para ratificar o descartar su deficiencia y, en caso de que no se demuestre","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":138,"lines":{"from":28,"to":43}}}}],["638",{"pageContent":"porfirina cinc de los eritrocitos, para ratificar o descartar su deficiencia y, en caso de que no se demuestre\ndeficiencia de hierro, debe cuantificarse la fracción A2 de la hemoglobina y, de encontrarse elevada, esta-\nblecer el diagnóstico de talasemia\n \nβ\n \nheterocigota. En el\n \ncuadro 7-5\n \nse indican las pruebas de laboratorio\nque permiten distinguir las deficiencias de hierro y las talasemias.\nAsimismo, si la Hb A2 se encuentra dentro de límites normales, es probable que el paciente sea por-\ntador de talasemia\n \nβ\n \ncon Hb A2 normal o de talasemia\n \nα\n. En ambos casos está indicado practicar el\nanálisis de la síntesis de cadenas y efectuar los estudios pertinentes de biología molecular para establecer\nel diagnóstico de la variedad de talasemia.\nComo no existe tratamiento alguno para estas anormalidades, el médico debe convencer al paciente\nque cualquier tratamiento es innecesario, insistiendo en que la administración de hierro, particular -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":138,"lines":{"from":43,"to":67}}}}],["639",{"pageContent":"Como no existe tratamiento alguno para estas anormalidades, el médico debe convencer al paciente\nque cualquier tratamiento es innecesario, insistiendo en que la administración de hierro, particular -\nmente sus formas parenterales, además de ineficaz, puede ser dañina. Deben discutirse las implicacio -\nnes genéticas con estas personas y estudiar a otros miembros de la familia para descubrir portadores\nadicionales. El consejo genético entre parejas portadoras se orientará a la profilaxis de descendientes\nhomocigotos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":138,"lines":{"from":67,"to":72}}}}],["640",{"pageContent":"Cuadro 7-5.\n \nPruebas de laboratorio requeridas para distinguir deficiencias\nde hierro y talasemias y heterocigotas\n\nAnchura de\ndistribución\n(RDW)\nFerritina\nsérica\nHierro\nsérico\n \nST\n \nPPZ\n \nHb A2\nTalasemia\n \nα\n \nN\n \nN o E\n \nN\n \nN\n \nN\n \nN\n\nTalasemia\n \nβ\n \nN\n \nN o E\n \nN\n \nN\n \nN\n \nE o N\n\nDeficiencia\nde hierro\n \nE\n \nB\n \nB\n \nB\n \nE\n \nN\nN = Normal\n \nST = Saturación de Transferrina\nE = Elevado\n \nPPZ = Protoporfirina Cinc de los Eritrocitos\nB = Bajo\n \nHb A2 = hemoglobina A2","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":138,"lines":{"from":74,"to":146}}}}],["641",{"pageContent":"Deficiencia\nde hierro\n \nE\n \nB\n \nB\n \nB\n \nE\n \nN\nN = Normal\n \nST = Saturación de Transferrina\nE = Elevado\n \nPPZ = Protoporfirina Cinc de los Eritrocitos\nB = Bajo\n \nHb A2 = hemoglobina A2\n\nLa talasemia\n \nβ\n \nhomocigota,\no anemia de Cooley, es un\npadecimiento grave que co-\nmienza en los primeros meses\nde la vida, con anemia grave\nque\n \nrequiere\n \ntransfusiones\nfrecuentes. A los 3 años, la he-\npatomegalia es variable y la\nesplenomegalia de naturaleza\ngigante es frecuente.\nLa distinción entre anemia\npor\n \ndeficiencia\n \nde\n \nhierro\n \ny\ntalasemia\n \nβ\n \nheterocigoto\n \nes\nimportante. El médico debe\nconsiderarla en el diagnóstico\nde los sujetos con microcitosis\ne hipocromía y recordar que\nestos parámetros no son sinó-\nnimos de deficiencia de hierro.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":138,"lines":{"from":146,"to":210}}}}],["642",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n112\n\nCONCLUSIONES\n\n•\n \nLas hemoglobinopatías y talasemias son defectos hereditarios de la hemoglobina por mutaciones en\nlos genes de la globina.\n\n•\n \nLa alteración estructural de la cadena de la globina provoca las hemoglobinopatías, y la disminución\nparcial o total de la síntesis de las cadenas de la globina genera las talasemias.\n\n•\n \nLas hemoglobinopatías talasémicas son muy raras y se presentan cuando existen alteraciones estructu-\nrales y disminución en la síntesis de la globina.\n\nPREGUNTAS DE AUTOEVALUACIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":139,"lines":{"from":1,"to":22}}}}],["643",{"pageContent":"1. ¿Cuál es la diferencia principal entre las hemoglobinopatías y las talasemias?\na.\n \nLas hemoglobinopatías son trastornos cualitativos de la hemoglobina, en tanto que las talasemias\nson trastornos cuantitativos en la producción de las cadenas de globina\nb. Las hemoglobinopatías son trastornos cuantitativos de la hemoglobina, en tanto que las talasemias\nson trastornos cualitativos en la producción de las cadenas de globina\nc.\n \nLas hemoglobinopatías son trastornos cualitativos de la globina, en tanto que las talasemias son\ntrastornos cuantitativos en la producción de las cadenas de hemoglobina\n2. ¿Cuál es la talasemia más frecuente en México:\na.\n \nLa beta, en su forma homocigota\nb. La beta, en su forma heterocigota\nc.\n \nLa alfa\n3. ¿Cuál es la hemoglobinopatía más frecuente en México?\na.\n \nLa hemoglobinopatía S en su forma heterocigota\nb. La hemoglobinopatía S en su forma homocigota\nc.\n \nLa hemoglobinopatía SC en su forma heterocigota","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":139,"lines":{"from":24,"to":50}}}}],["644",{"pageContent":"a.\n \nLa hemoglobinopatía S en su forma heterocigota\nb. La hemoglobinopatía S en su forma homocigota\nc.\n \nLa hemoglobinopatía SC en su forma heterocigota\n4. Las talasemias beta pueden simular una deficiencia de un nutriente necesario para la síntesis de he-\nmoglobina. ¿Cuál es?\na.\n \nCinc\nb. Vitamina B12\nc.\n \nHierro\n5.\n \n¿Cuál es el tratamiento de la talasemia\n \nβ\n \nhomocigota?\na.\n \nTransfusiones de paquetes de eritrocitos junto con quelante del hierro\nb. Hierro oral\nc.\n \nNo hay tratamiento","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":139,"lines":{"from":50,"to":79}}}}],["645",{"pageContent":"BIBLIOGRAFÍA\n\nBerges García A, Guevara O del A, Ruiz-Reyes G, et al. Hemoglobina E y talasemia beta en una familia mexicana.\nBol Med Hosp Infant (Méx). 1984; 41: 205-210.\nBain BJ. Haemoglobinopathy diagnosis. Londres: Blackwell Science Ltd.; 2001.\nCarver MFH, Huisman THJ. Abstracts describing new hemoglobin variants. Hemoglobin. 1997; 21(5) 473-479.\nEfremov GD, Huisman THJ. Access to a Syllabus of human hemoglobin variants (1996) via the world wide web.\nHemoglobin. 1998; 22: 113-27.\nFairbanks VF. Hemoglobinopathies and thalassemias. Laboratory methods and case studies. New York: Brian C\nDecker; 1980.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":139,"lines":{"from":81,"to":90}}}}],["646",{"pageContent":"CAPÍTULO 7. HEMOGLOBINOPATÍAS Y TALASEMIAS\n\n113","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":140,"lines":{"from":1,"to":3}}}}],["647",{"pageContent":"Hardison, et al. Access to a syllabus of human hemoglobin variants (1996) via the World Wide Web. Hemoglobin.\n1998; 22 (2): 113-127.\nHardison RC, Chui DHK, Riemer CR, Miller W, Carver MFN, Molchanova TP, et al. Hemoglobin Lepore Wash-\nington-Boston in two Mexican mestizo families. Rev Inv Clín (Méx). 1997; 49: 221-3.\nIbarra B. Hemoglobina “Colima” (a2\n \nβ\n49 Ser\nβ\nCist) descubierta en México. Comunicación personal. Abril, 2002.\nIbarra B, Zuñiga P, et al. Detección de alteraciones de la hemoglobina en una muestra de población del Noroccidente\nde México. Informe preliminar. Arch Invest Clin (Méx). 1980; 11: 491-496.\nIbarra B, Perea FJ. Hemoglobinopatías en el occidente de México. Comunicación personal. Octubre, 2012.\nLehmann H, Huntsman RG. Man’s haemoglobins. 2nd ed. Philadelphia: JB Lippincott Co.; 1974.\nLisker R. Estructura genética de la población mexicana. Aspectos médicos y antropológicos. México: Salvat; 1981.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":140,"lines":{"from":5,"to":19}}}}],["648",{"pageContent":"Lisker R. Estructura genética de la población mexicana. Aspectos médicos y antropológicos. México: Salvat; 1981.\nLisker R. Distribution of abnormal hemoglobins in Latin America. En: Bowman JE, ed. Distribution and evolution\nof hemoglobins and globin loci. Elsevier: Science Publishing Co.; 1983. p. 261-278.\nLukens JN. Hemoglobinopathies S, C, D, D, E and associated diseases. En: Lee GR, Bithell TC et al, eds. Wintro-\nbe’s clinical hematology. 9th ed. Philadelphia: Lea & Febiger; 1993.\nPiña FIL, Ruiz-Reyes G. Hemoglobina I-Filadelfia (alfa 16 (A14) Lis-Glu) en una familia identificada durante una\nencuesta realizada en el Estado de Chiapas. Rev Invest Clin (Méx). 1991; 43: 252-253.\nRuiz-Reyes G, Piña-Cámara A, et al. Delta-beta thalassemia in a Mexican family: Clinical differences among ho-\nmozygotes. Hemoglobin. 1978; 2: 517-529.\nRuiz-Reyes G. Hemoglobin variants in Mexico. Hemoglobin. 1983; 7: 603-610.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":140,"lines":{"from":19,"to":28}}}}],["649",{"pageContent":"mozygotes. Hemoglobin. 1978; 2: 517-529.\nRuiz-Reyes G. Hemoglobin variants in Mexico. Hemoglobin. 1983; 7: 603-610.\nRuiz-Reyes G, Ruiz Argüelles GJ. Drepanocitosis. En: Sans SJ, ed. Hematología clínica. 2da ed. Barcelona: Editorial\nDoyma; 1988. p. 284-287.\nReyes-Cruz G, Hernández-Acasiete M, Ruiz-Reyes G. Identificación de un foco de talasemia beta en Tamihua,\nVeracruz. Rev Invest Clin (Méx). 1990; 42: 189-192.\nReyes-Núñez V. Talasemia alfa en 100 pacientes con anemia microcítica y/o hipocrómica por PCR. Tesis de Licencia-\ntura. Depto. de Química y Biología. Universidad de las Américas-Puebla, Diciembre, 1995.\nRuiz-Argüelles GJ, López-Martínez B, Ruiz-Reyes G. Heterozygous beta-thalassemia: Not infrequent in Mexico.\nArch Med Res. 2001; 32: 293-295.\nRuiz-Reyes G. Hemoglobinas anormales y talasemias en la República Mexicana. Rev Invest Clin (Mex). 1998; 50:\n163-70.\nRuiz-Reyes G. Los síndromes talasémicos no son infrecuentes en la población mexicana y se subdiagnostican y con -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":140,"lines":{"from":28,"to":40}}}}],["650",{"pageContent":"163-70.\nRuiz-Reyes G. Los síndromes talasémicos no son infrecuentes en la población mexicana y se subdiagnostican y con -\nfunden con deficiencias de hierro. Medicina Universitaria. 1999; 1: 67.\nRuiz-Argüelles GJ, Ramírez-Cisneros F, Rivadeneyra L, Ruiz-Delgado MA, Molina-Alavez A. La frecuencia de las\nanemias megaloblásticas en la práctica privada en Puebla, México: experiencia de 17 años. Medicina Universitaria.\n1999; 1:165.\nRuiz-Argüelles GJ, López-Martínez B, Ruiz-Reyes G. Heterozygous\n \nβ\n-thalassemia. Not infrequent in Mexico.\nArch Med Res. 2001; 32: 293-295.\nReyes-Núñez V, Garcés-Eisele J, Jorge S, Kimura E, Ferreira-Costa F, Sonati M de F, et al. Molecular characteriza-\ntion of alpha-thalassemia in the Mexican population. Rev Invest Clin (Méx). 2006; 58: 234-236.\nSánchez-Medal L, Ruiz-Reyes G. Blood disease in Central and South America. En: Weatherall DJ, ed. Oxford text\nbook of medicine. 2a ed. Londres: Oxford University Press; 1987. p. 268-319.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":140,"lines":{"from":40,"to":54}}}}],["651",{"pageContent":"RESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\n1.\n \na\n2.\n \nb\n3.\n \na\n4.\n \nc\n5.\n \na","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":140,"lines":{"from":56,"to":72}}}}],["652",{"pageContent":"115\n\nINTRODUCCIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":142,"lines":{"from":1,"to":3}}}}],["653",{"pageContent":"Las enzimopatías del eritrocito comprenden un grupo de deficiencias enzimáticas de la vía glucolítica\nanaeróbica (Embden-Meyerhof), o bien de la vía de las pentosas, y pueden dar lugar a anemia hemolí-\ntica aguda o crónica. Estos defectos deben sospecharse cuando un paciente con hemólisis crónica tiene\nalgunas de las siguientes características: 1) no hay datos morfológicos que sugieran alteración de la\nmembrana del eritrocito; 2) no existe evidencia sugestiva de trastorno en la síntesis de hemoglobina, y\n3) la reacción de Coombs directa es negativa, descartando la presencia de algún fenómeno inmunitario.\nPara comprender la fisiopatología de estas enfermedades, es necesario recordar que los eritrocitos\nmaduros, a diferencia de todas las demás células somáticas, incluyendo los reticulocitos, no tienen\nmitocondrias, que son las principales productoras de energía (trifosfato de adenosina o ATP) del orga-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":142,"lines":{"from":5,"to":13}}}}],["654",{"pageContent":"mitocondrias, que son las principales productoras de energía (trifosfato de adenosina o ATP) del orga-\nnismo. Además, los eritrocitos maduros son incapaces de sintetizar proteínas, por lo cual su dotación\nenzimática al ingresar al torrente sanguíneo es fija y no pueden reponer lo que se va utilizando.\nLa glucosa es el sustrato metabólico más importante de los eritrocitos y se metaboliza por dos\ncaminos: 1) la vía glucolítica anaeróbica (productora de energía en forma de ATP) o ciclo de Emb-\nden-Meyerhof, por la que pasa más del 90% del total, y 2) la vía de las pentosas (protectora), a través\nde la cual se metaboliza el resto de la glucosa. Si bien las anormalidades enzimáticas en estas dos vías\nmetabólicas son la causa más frecuente de anemias hemolíticas (crónicas o agudas), existen además\notras enzimas relacionadas con el metabolismo de los nucleótidos cuyas alteraciones también pueden\nproducir cuadros de anemia hemolítica. Es importante recordar que cerca del 80% de las anemias","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":142,"lines":{"from":13,"to":22}}}}],["655",{"pageContent":"otras enzimas relacionadas con el metabolismo de los nucleótidos cuyas alteraciones también pueden\nproducir cuadros de anemia hemolítica. Es importante recordar que cerca del 80% de las anemias\nhemolíticas por enzimopatías son debidas a deficiencias de las enzimas glucosa-6-fosfato-deshidroge-\nnasa (vía de las pentosas) y de la piruvatocinasa (vía glucolítica).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":142,"lines":{"from":22,"to":25}}}}],["656",{"pageContent":"CAPÍTULO 8\n\nANEMIAS HEMOLÍTICAS\nPOR ALTERACIONES DE\nENZIMAS ERITROCITARIAS\n\nRubén Lisker Y.\nEliakim Arámbula Meraz\nBertha Ibarra\n\nObjetivos de aprendizaje\n\n•\n \nConocer las principales deficiencias de las enzimas eritrocitarias asociadas a anemias hemolíticas\nagudas o crónicas.\n\n•\n \nComprender la fisiopatología de la hemólisis característica de estas enfermedades.\n\n•\n \nDistinguir la hemólisis asociada a anormalidades eritrocitarias del metabolismo de nucleótidos\n\nLa glucosa es el sustrato me-\ntabólico\n \nmás\n \nimportante\n \nde\nlos eritrocitos y se metaboli-\nza por dos caminos: 1) la vía\nglucolítica\n \nanaeróbica\n \n(pro-\nductora de energía) o ciclo de\nEmbden-Meyerhof, por la que\npasa más del 90% del total, y 2)\nla vía de las pentosas (protecto-\nra), a través de la cual se me-\ntaboliza el resto de la glucosa.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":142,"lines":{"from":27,"to":72}}}}],["657",{"pageContent":"116\n \nFUNDAMENTOS DE HEMATOLOGÍA\nHEMÓLISIS ASOCIADA A DEFICIENCIA DE ENZIMAS GLUCOLÍTICAS\n\nCiclo de Embden-Meyerhof (vía glucolítica anaeróbica)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":143,"lines":{"from":1,"to":6}}}}],["658",{"pageContent":"Ciclo de Embden-Meyerhof (vía glucolítica anaeróbica)\n\nLa parte izquierda de la\n \nfigura 8-1\n \nmuestra la vía glucolítica eritrocitaria, por medio de la cual la glucosa\nse convierte en lactato. Es la única fuente de energía del eritrocito (síntesis de ATP) que, si bien es es-\ncasa, comparada con otras vías metabólicas es suficiente para que los eritrocitos circulantes vivan de 100\na 120 días. La disminución de ATP parece ser la responsable de la muerte de los hematíes normales y\nde su destrucción prematura en los casos de anemia hemolítica. Otro aspecto de importancia en esta vía\nmetabólica es la concentración relativamente alta de 2,3-difosfoglicerato (2,3-DPG), que modula la afi -\nnidad de la hemoglobina por el oxígeno. Cuando los niveles de aquel son bajos, la afinidad por el oxígeno\nes elevada, lo que dificulta su liberación en los tejidos periféricos, mientras que ocurre lo contrario si las\nconcentraciones son altas.\n\nFisiopatología de la hemólisis","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":143,"lines":{"from":6,"to":22}}}}],["659",{"pageContent":"Fisiopatología de la hemólisis\n\nLa hemólisis se debe siempre a anormalidades de la membrana eritrocítica que, cuando pierde su de-\nformabilidad (o sea, se vuelve rígida), impiden que el eritrocito se desplace en forma adecuada por la\nmicrocirculación y producen su muerte. Se piensa que este fenómeno ocurre cuando el ATP intracelular\nes insuficiente para mantener las funciones de la membrana celular, lo que no necesariamente se refleja\nen la disminución del contenido de ATP en los eritrocitos circulantes. Para esto hay varias explicaciones:\n1) las células muy deficientes son destruidas y por lo tanto no circulan, y 2) el contenido de ATP de los\nreticulocitos y su porcentaje durante los procesos hemolíticos son altos.\n\nCaracterísticas generales de la hemólisis","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":143,"lines":{"from":22,"to":32}}}}],["660",{"pageContent":"Características generales de la hemólisis\n\nFrecuencia\n. Las anemias hemolíticas debidas a enzimopatías del ciclo de Embden-Meyerhof son muy\npoco comunes. Se han descrito varias deficiencias y se ha comprobado que las que producen anemia\ncon más frecuencia son las de piruvatocinasa (PC), hexocinasa (HC), glucosa-6-fosfato isomerasa (GPI),\nfosfofructocinasa (PFC), aldolasa (A), triosa fosfato isomerasa (TPI) y fosfoglicerato cinasa (PGC). En\nalgunas de estas deficiencias, la alteración enzimática y, por lo tanto, los síntomas no se limitan a los eri-\ntrocitos, sino que afectan también otras células como leucocitos y plaquetas, y aun a tejidos no hemáticos\ncomo el muscular y neural.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":143,"lines":{"from":32,"to":41}}}}],["661",{"pageContent":"Herencia\n. Por lo regular, existe un patrón autosómico recesivo de herencia, por lo que únicamente\nlos individuos homocigotos de ambos sexos están afectados. La excepción la constituye la deficiencia de\nPGC, que también se hereda en forma recesiva pero ligada al cromosoma X, por lo cual los enfermos casi\nsiempre son del sexo masculino.\n\nManifestaciones clínicas\n. Los sujetos afectados tienen anemia hemolítica crónica no esferocítica\n(AHCNE) desde la niñez, generalmente normocítica normocrómica con reticulocitosis y grados va-\nriables de hiperbilirrubinemia no conjugada. La magnitud de la anemia puede aumentar cuando hay\ninfección viral concomitante, lo que ocurre por uno de dos mecanismos: 1) incremento en la hemólisis,\nlo cual eleva el grado de reticulocitosis e ictericia, y 2) disminución en la producción de eritrocitos (crisis\naplásicas), caracterizada por una reducción de la proporción de reticulocitos sin cambio apreciable de\nla ictericia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":143,"lines":{"from":43,"to":56}}}}],["662",{"pageContent":"Diagnóstico\n. Se piensa en esta posibilidad diagnóstica en pacientes con AHCNE no relacionada\ncon ingestión de fármacos o con infecciones, y reacción de Coombs negativa. El diagnóstico se basa en la\nmedición espectrofotométrica de la enzima deficiente, la medición de los metabolitos intermediarios,\nla demostración de anormalidades en las características de la enzima o bien en la identificación de la\nmutación en el gen. En ocasiones es necesario investigar a los padres de los enfermos, quienes son he -\nterocigotos para la deficiencia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":143,"lines":{"from":58,"to":64}}}}],["663",{"pageContent":"Tratamiento\n. El manejo de estos pacientes se realiza mediante transfusiones de sangre, que se re-\nservan para los casos con compromiso cardiovascular significativo. Debe recordarse que los sujetos con\nniveles elevados de 2,3-DPG toleran mucho mejor la anemia que los individuos con concentraciones bajas\nde este metabolito. La administración de hierro está contraindicada y se recomienda la ingestión de 1 mg\ndiario de ácido fólico para compensar los requerimientos excesivos de esta sustancia durante la eritropo-\nyesis activa. La esplenectomía es útil en algunos enfermos, ya que el bazo es el sitio donde se destruyen\nlos eritrocitos deficientes.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":143,"lines":{"from":66,"to":73}}}}],["664",{"pageContent":"Las anemias hemolíticas de-\nbidas a enzimopatías de la\nvía glucolítica anaeróbica son\nmuy poco frecuentes. Se han\ndescrito varias deficiencias y\nse ha comprobado que las que\nproducen anemia son las de\npiruvatocinasa (PC), hexoci-\nnasa (HC), glucosa-6-fosfato\nisomerasa (GPI), fosfofructo-\ncinasa (PFC), aldolasa (A),\ntriosa fosfato isomerasa (TPI)\ny fosfoglicerato cinasa (PGC).\nLa hemólisis se debe siempre\na anormalidades de la mem-\nbrana eritrocítica que, cuando\npierde su deformabilidad (o\nsea, se vuelve rígida), impi-\nden que el eritrocito se despla-\nce en forma adecuada por la\nmicrocirculación\n \ny\n \nproducen\nsu muerte.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":143,"lines":{"from":75,"to":100}}}}],["665",{"pageContent":"117\n\nCAPÍTULO 8. ANEMIAS HEMOLÍTICAS POR ALTERACIONES\n\nFigura 8-1.\n \nUtilización de la glucosa dentro del eritrocito por las vías de Embden-Meyerhof y de las pentosas.\n\nDeficiencia de piruvatocinasa","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":144,"lines":{"from":1,"to":9}}}}],["666",{"pageContent":"La deficiencia de piruvatocinasa es la más común de las deficiencias enzimáticas del ciclo de Embden-Meyerhof,\ny se han publicado algo más de 300 casos desde su descripción original en 1961. Se ha observado en asociación\ncon deficiencia de glucosa-6-fosfato deshidrogenasa, esferocitosis hereditaria y anemia drepanocítica, entre otras\nalteraciones hemáticas. Dicha enzima cataliza el paso de fosfoenolpiruvato a piruvato, generando en el proceso\nuna molécula de ATP (fig. 8-1). Los niveles de 2,3-DPG y otros metabolitos proximales al bloqueo están eleva\n-\ndos. La PC es un tetrámero y se han identificado cuatro isoenzimas con diferentes movilidades electroforéticas\nen distintos tejidos. En la deficiencia clásica de PC, la enzima parece tener una cinética normal, excepto por\nsu baja actividad residual. Se pensó al principio que se trataba simplemente de la disminución en la síntesis de\nuna PC normal, o bien de una alteración estructural que solo afectaba la actividad catalítica. Se sabe en la ac\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":144,"lines":{"from":11,"to":21}}}}],["667",{"pageContent":"una PC normal, o bien de una alteración estructural que solo afectaba la actividad catalítica. Se sabe en la ac\n-\ntualidad que la mayoría de las PC deficientes son proteínas estructuralmente anormales que difieren entre sí en\ncuanto a movilidad electroforética, actividad residual, afinidad por sustratos, inhibición por ATP, estabilidad al\ncalor y otras características bioquímicas. Dado lo poco frecuente del padecimiento, se piensa que, en ausencia\nde consanguinidad, casi todos los enfermos probablemente son heterocigotos compuestos para dos mutantes\ndiferentes, más que homocigotos para una de ellas. Esto podría constituir una explicación parcial de la gran\nvariabilidad clínica de los pacientes, los cuales presentan desde ictericia neonatal acentuada con necesidad de\nexanguinotransfusión, hasta un cuadro hemolítico compensado que se identifica de manera incidental en algún\nadulto. La regla, sin embargo, es que el cuadro clínico se reconoce desde la infancia. No hay datos clínicos carac\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":144,"lines":{"from":21,"to":31}}}}],["668",{"pageContent":"adulto. La regla, sin embargo, es que el cuadro clínico se reconoce desde la infancia. No hay datos clínicos carac\n-\nterísticos; además de anemia e ictericia, la esplenomegalia es frecuente. Debido a los niveles altos de 2,3-DPG,\nla anemia se tolera muy bien. Como en otros cuadros hemolíticos crónicos, la frecuencia de litiasis biliar es alta y\nse pueden encontrar cambios óseos asociados con médula ósea hiperplásica. La presencia de úlceras maleolares\nes infrecuente. La anemia es normocítica normocrómica con concentraciones de Hb entre 6 y 12 g/dL. Las\ncifras de reticulocitos antes de la esplenectomía se hallan entre 2,5 y 15%, y después de ella pueden subir incluso\na 70%. Hay anisocitosis, poiquilocitosis y policromasia, y aparecen algunos eritrocitos nucleados. La prueba de\nla autohemólisis es de tipo II (se corrige con ATP), pero no constituye un hallazgo consistente, por lo que se","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":144,"lines":{"from":31,"to":39}}}}],["669",{"pageContent":"La deficiencia de piruvatoci-\nnasa es la más común de las\ndeficiencias\n \nenzimáticas\n \ndel\nciclo de Embden-Meyerhof, y\nse han publicado algo más de\n300 casos desde su descripción\noriginal en 1961.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":144,"lines":{"from":41,"to":51}}}}],["670",{"pageContent":"118\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":145,"lines":{"from":1,"to":3}}}}],["671",{"pageContent":"requiere medición cuantitativa de la enzima aun cuando existen algunas pruebas de tamizado bastante sensibles.\nEl tratamiento consiste en mantener niveles de Hb entre 8 y 10 g/dL mediante el uso de transfusiones de sangre.\nSe recomienda esplenectomía después de los 5 años de edad, lo que disminuye los requerimientos transfusionales\npero no cura a los enfermos. En perros con anemia hemolítica intensa por deficiencia de PC, se ha utilizado con\néxito trasplante de médula ósea, lo cual podría considerarse para algunos pacientes con esta enfermedad.\nEl gen de la enzima que se expresa en los eritrocitos se denomina\n \nPC-LR\n, se encuentra en 1q21 en un\nsegmento de 9,5 kb con 12 exones y se han identificado alrededor de 130 mutaciones. Algunas de estas\nmutaciones son frecuentes en diferentes poblaciones; por ejemplo, en la europea y americana, los alelos\n1529G>A (Arg510Gln) y 1456C>T (Arg486Trp) se han observado con frecuencias de 39 y 13%, respec -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":145,"lines":{"from":5,"to":16}}}}],["672",{"pageContent":"mutaciones son frecuentes en diferentes poblaciones; por ejemplo, en la europea y americana, los alelos\n1529G>A (Arg510Gln) y 1456C>T (Arg486Trp) se han observado con frecuencias de 39 y 13%, respec -\ntivamente, mientras que en población japonesa los alelos más frecuentes son 1468C>T (Arg490Trp) y\n1261C>A (Gln421Lys), con frecuencias de 18 y 17%, respectivamente.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":145,"lines":{"from":16,"to":19}}}}],["673",{"pageContent":"Deficiencia de hexocinasa","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":145,"lines":{"from":21,"to":21}}}}],["674",{"pageContent":"La hexocinasa es la primera enzima de la vía glucolítica (véase figura 8-1) y tiene importancia estratégica en la\nregulación del consumo de glucosa. Se trata de una enzima cuya actividad depende de la edad de los eritrocitos;\nasí, los niveles son más elevados en los reticulocitos mientras que los de 2,3-DPG son normales o bajos. Como\nen el caso de la deficiencia de PC, la de HC puede ser resultado de la merma en la producción de una enzima\nestructuralmente normal o de una mutación que altere la afinidad por el sustrato o alguna otra función impor\n-\ntante. Se han descrito menos de 20 familias con esta deficiencia, ninguna de ellas en México. En el 25% de los\ncasos se ha observado ictericia neonatal y prácticamente en todos los pacientes la anemia se identifica después de\nlos 10 años. Los enfermos más gravemente afectados presentan esplenomegalia y requieren transfusiones perió\n-\ndicas. La morfología eritrocítica no tiene nada de especial y la prueba de la autohemólisis es de tipo I, o sea, se","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":145,"lines":{"from":23,"to":33}}}}],["675",{"pageContent":"-\ndicas. La morfología eritrocítica no tiene nada de especial y la prueba de la autohemólisis es de tipo I, o sea, se\ncorrige de manera parcial con ATP y glucosa. El diagnóstico se basa en la medición de la actividad enzimática,\ntomando en cuenta que su concentración depende mucho de la edad eritrocítica, por lo que si hay gran cantidad\nde reticulocitos, su actividad puede ser normal. La esplenectomía tiene efectos benéficos pero no es curativa.\nEl gen\n \nHC-1\n \nse localiza en el brazo largo del cromosoma 10 en un segmento de 130 kb y se han des-\ncrito al menos seis mutaciones en pacientes de distintos orígenes étnicos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":145,"lines":{"from":33,"to":43}}}}],["676",{"pageContent":"Deficiencia de isomerasa del fosfato de glucosa (GPI)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":145,"lines":{"from":45,"to":45}}}}],["677",{"pageContent":"Desde el punto de vista cuantitativo, ocupa el tercer lugar de las deficiencias enzimáticas que causan\nanemia hemolítica, solo por debajo de las deficiencias de glucosa-6-fosfato-deshidrogenasa y de la PC. El\ngen se ubica en el brazo largo del cromosoma 19, consta de 18 exones en una extensión de 40 kb, y se han\ndescrito al menos 27 mutaciones con un espectro muy heterogéneo en el que predominan las mutaciones\nsin sentido (> 80%). Es interesante señalar que una de ellas, 1039C>T (Arg347Cys), ha mostrado más\nde un origen, de manera similar a lo observado con otras mutaciones como la Hb S. Los leucocitos y las\nplaquetas también manifiestan la deficiencia, pero sin traducción clínica. La gravedad del cuadro clínico\nes muy variable, y hay pacientes que requieren transfusiones repetidas. El curso clínico puede complicarse\ncon crisis hiperhemolíticas y aplásicas. Los individuos afectados a menudo presentan crisis hemolíticas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":145,"lines":{"from":47,"to":55}}}}],["678",{"pageContent":"con crisis hiperhemolíticas y aplásicas. Los individuos afectados a menudo presentan crisis hemolíticas\ndespués de infecciones virales o bacterianas. Existe anisocitosis, poiquilocitosis, policromasia y células\nrojas nucleadas. La reticulocitosis puede ser muy acentuada, del orden del 50 al 60%. La prueba de la\nautohemólisis es de tipo I. La esplenectomía da resultados favorables en la mayoría de los enfermos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":145,"lines":{"from":55,"to":58}}}}],["679",{"pageContent":"Deficiencia de fosfofructocinasa","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":145,"lines":{"from":60,"to":60}}}}],["680",{"pageContent":"La PFC cataliza la fosforilación de fructosa-6-fosfato a frutosa-1, 6-difosfato y su actividad se conside -\nra clave en la regulación de la glucólisis anaeróbica. Existe como una isoenzima tetramérica compuesta\nde combinaciones variables de subunidades de músculo (M), hígado (L) y plaquetas (P). Los genes que\ncodifican para las diferentes formas se localizan en los cromosomas 12q13.3, 21q22.3 y 110p15.3. Los\neritrocitos contienen cantidades iguales de subunidades M y L hibridizadas al azar para formar cinco\nisoenzimas: M4, M3L, M2L2, ML3 y L4. La estructura de la PFC varía en diferentes tejidos, lo que\nexplica la diversidad de síndromes que se asocian con la deficiencia de esta enzima. Estos síndromes\nincluyen AHCNE sola, relacionada con miopatía y posiblemente miopatía sola.\nLos primeros síntomas musculares que se asocian con anemia hemolítica son fatiga y calambres indu-\ncidos por el ejercicio. Histológicamente, hay aumento del glucógeno de los músculos. La anemia hemo-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":145,"lines":{"from":62,"to":71}}}}],["681",{"pageContent":"Los primeros síntomas musculares que se asocian con anemia hemolítica son fatiga y calambres indu-\ncidos por el ejercicio. Histológicamente, hay aumento del glucógeno de los músculos. La anemia hemo-\nlítica es compensada y tanto la enfermedad hemática como la miopatía resultan de la falta completa de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":145,"lines":{"from":71,"to":73}}}}],["682",{"pageContent":"La hexocinasa es la primera\nenzima de la vía glucolítica y\ntiene importancia estratégica\nen la regulación del consumo\nde glucosa. Su actividad dis-\nminuye con rapidez conforme\nenvejecen los eritrocitos y los\nniveles de 2,3-DPG son nor-\nmales o bajos.\nLa PFC existe como una isoen-\nzima\n \ntetramérica\n \ncompuesta\nde combinaciones variables de\nsubunidades de músculo (M),\nhígado (L) y plaquetas (P). Los\neritrocitos\n \ncontienen\n \ncantida-\ndes iguales de subunidades M\ny L hibridizadas al azar para\nformar cinco isoenzimas: M4,\nM3L, M212, ML3 y L4.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":145,"lines":{"from":75,"to":101}}}}],["683",{"pageContent":"119\n\nCAPÍTULO 8. ANEMIAS HEMOLÍTICAS POR ALTERACIONES\n\nexpresión de la subunidad M. Se ha descrito deficiencia congénita de PFC en perros\n \nSpringer Spaniel\n \ncon\nanemia hemolítica crónica (AHC) y crisis hemolíticas asociadas con hiperventilación. El gen que codifica\npara la forma M se ubica en un segmento de 30 kb distribuido en 24 exones, mientras que el de la forma\nL en 28 kb y 22 exones. Las mutaciones en el gen L parecen ser inocuas al eritrocito, mientras que las que\ncausan la deficiencia enzimática son las mutaciones en el gen que codifica para la forma M, de las que se\nhan reportado al menos 20. Se reconoce que casi un tercio de los pacientes reportados con esta afectación\nson de origen judío, en quienes se han reportado con mayor frecuencia dos mutaciones: IVS5 + 1G>A, que\ncausa deleción del exón 5, y 2003DelC, que produce un codón de terminación en el codón 684.\n\nDeficiencia de aldolasa","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":146,"lines":{"from":1,"to":18}}}}],["684",{"pageContent":"Deficiencia de aldolasa\n\nEn mamíferos se distinguen tres isoenzimas: A, B y C. En los eritrocitos se expresa la forma A y funciona\ncomo un tetrámero; su gen se localiza en 16p11.2 y consta de 12 exones que se extienden en un segmento\nde 7,5 kb. La deficiencia de aldolasa-A se manifiesta como anemia hemolítica crónica moderada, mientras\nque la deficiencia de aldolasa-B hepática causa intolerancia hereditaria a la fructosa. El primer caso se\nencontró en un hijo de primos hermanos, lo que sugiere herencia autosómica recesiva. El enfermo tenía\nanemia hemolítica moderada, hepatomegalia con depósito de glucógeno y retraso psicomotor. Otros ca-\nsos mostraron anemia hemolítica más acentuada sin otras alteraciones. Se desconoce el mecanismo de la\nhemólisis y se requiere mayor experiencia para conocer el verdadero cuadro clínico de esta deficiencia.\n\nDeficiencia de triosa fosfato isomerasa","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":146,"lines":{"from":18,"to":29}}}}],["685",{"pageContent":"La deficiencia de TPI se expresa en muchos tejidos, por lo que la enfermedad hemolítica solo es una de las ma\n-\nnifestaciones de este padecimiento multisistémico. Se han descrito menos de 20 familias con dicho trastorno,\ny una tercera parte estaba formada por negros del estado de Luisiana en Estados Unidos. Es una enferme\n-\ndad progresiva y fatal. La anemia hemolítica se asocia frecuentemente con hiperbilirrubinemia neonatal con\nrequerimientos de exanguinotransfusión, por lo que la ictericia es de aparición temprana, seguidas de daño\nneural que da lugar a paraparesis e hipotonía. Las infecciones intercurrentes son comunes y la muerte suele\nocurrir alrededor de los 5 años de edad, debido a trastornos del ritmo cardíaco. La morfología celular muestra\nproporción baja de acantocitos, y la prueba de autohemólisis es similar a la de la esferocitosis hereditaria. Se\ndesconoce la fisiopatología de la hemólisis. El gen se localiza en 12 p13.3 y consta de 7 exones expandidos en","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":146,"lines":{"from":31,"to":41}}}}],["686",{"pageContent":"desconoce la fisiopatología de la hemólisis. El gen se localiza en 12 p13.3 y consta de 7 exones expandidos en\n5 kb. Se han identificado al menos 9 mutaciones; de ellas, la mutación sin sentido 315G>C (Glu105Asp) se ha\nobservado en el 74% de los pacientes estudiados. Los individuos homocigotos para esta mutación muestran\ndaño neurológico progresivo, lo que demuestra la naturaleza dañina de esta mutación.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":146,"lines":{"from":41,"to":44}}}}],["687",{"pageContent":"Deficiencia de fosfogliceratocinasa","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":146,"lines":{"from":46,"to":46}}}}],["688",{"pageContent":"Esta enzima cataliza la conversión de 1,3-difosfoglicerato a 3-fosfoglicerato, proceso en el que se gana una\nmolécula de ATP (véase figura 8-1). Por ser una enzima que se expresa en todos los tejidos, se considera\ncomo una enfermedad multisistémica con tres características clínicas principales: anemia hemolítica crónica,\ndisfunción del sistema nervioso central y miopatía. La anemia hemolítica crónica se encuentra a menudo\ncompensada. Debido al efecto de inactivación del cromosoma X (lionización), las mujeres pueden tener de-\nficiencia enzimática en grados variables y, por lo tanto, algunas de las manifestaciones clínicas, mientras que\nlos varones afectados tienen AHCNE, que puede requerir tratamiento a base de transfusiones. Se pueden\npresentar crisis de hemólisis intravascular por procesos infecciosos. Existe daño neurológico progresivo que\nsuele empezar a los 4 años e incluye afasia, labilidad emocional, convulsiones y enfermedad extrapiramidal.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":146,"lines":{"from":48,"to":56}}}}],["689",{"pageContent":"suele empezar a los 4 años e incluye afasia, labilidad emocional, convulsiones y enfermedad extrapiramidal.\nAun cuando el daño neurológico y la AHCNE están relacionados con la deficiencia de PGC, se desconoce\nsu base metabólica. El gen estructural está en el brazo largo del cromosoma X (Xq13.3), y lo integran 11\nexones en 23 kb y se han observado al menos 12 mutaciones que presentan un espectro muy heterogéneo.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":146,"lines":{"from":56,"to":59}}}}],["690",{"pageContent":"HEMÓLISIS ASOCIADA A DEFICIENCIA DE ENZIMAS\nDE LA VÍA DE LAS PENTOSAS\n\nVía de las pentosas\n\nEsta vía comienza con la conversión de glucosa-6-fosfato a 6-fosfogluconato (véase figura 8-1, parte superior\nderecha) y es catalizada por la glucosa-6-fosfato deshidrogenasa (G6PD). Aun cuando solo de 5 a 10% de\n\nLa deficiencia de TPI se ex-\npresa en muchos tejidos, por lo\nque la enfermedad hemolítica\nsolo es una de las manifesta-\nciones\n \nde\n \neste\n \npadecimiento\nmultisistémico.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":146,"lines":{"from":61,"to":80}}}}],["691",{"pageContent":"120\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nla glucosa se metaboliza por esta vía, es vital para la integridad de los eritrocitos, ya que constituye la única\nfuente de nicotinamida adenina dinucleótido fosfato reducido (NADPH). Esta sustancia, junto con la gluta\n-\ntión reductasa, convierte el glutatión oxidado (GSSG) a la forma reducida (GSH). El GSH es un tripéptido\n(glutamilcisteinilglicina) que protege a los eritrocitos de agentes oxidantes que se producen durante algunas\ninfecciones o por contacto con ciertas sustancias químicas. Estos oxidantes (O\n2\n–\n \ny H\n \n2\n \nO\n2\n) son inactivados rá-\npidamente por el GSH, pero si este se deja acumular, daña las proteínas eritrocíticas y el hematíe se destruye.\n\nFisiopatología de la hemólisis","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":147,"lines":{"from":1,"to":23}}}}],["692",{"pageContent":"Fisiopatología de la hemólisis\n\nCuando hay un defecto en la vía metabólica de las pentosas o del metabolismo del glutatión, la exposición a un\nagente oxidante lesiona al eritrocito. La hemoglobina se oxida primero a metahemoglobina y después a sulfahe\n-\nmoglobina, la cual se precipita intracelularmente dando lugar a los llamados\ncuerpos de Heinz\n, que se pegan a la\nmembrana celular. El acortamiento en la vida de los eritrocitos es consecuencia de la formación de los cuerpos\nde Heinz, que son rígidos y se destruyen en la microcirculación del bazo. En la gran mayoría de los casos, la\nhemólisis inducida por oxidantes está relacionada con la deficiencia de G6PD eritrocítica.\n\nDeficiencia de G6PD eritrocítica\n\nEs la más común de las deficiencias enzimáticas del eritrocito asociada con cuadros de anemia hemolítica.\nSe calcula que hay más de 400 millones de personas con la enfermedad, la mayoría distribuidas en países\nde la cuenca del Mediterráneo, África y China.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":147,"lines":{"from":23,"to":39}}}}],["693",{"pageContent":"Historia\n. Las primeras descripciones médicas de anemia hemolítica por deficiencia de G6PD apa-\nrecieron en el siglo XIX, aun cuando es muy probable que el padecimiento sea muy antiguo y que, por\nejemplo, Pitágoras haya muerto durante una crisis hemolítica al lado de un sembradío de habas. La iden-\ntificación bioquímica de la deficiencia se hizo en el decenio de 1950, al estudiar pacientes estadounidenses\nde origen africano con cuadros de anemia hemolítica aguda desencadenados por ingestión de primaquina.\nMuy poco tiempo después se informó que quienes padecían la enfermedad, conocida como\n \nfavismo\n \nen\npoblaciones mediterráneas (de la que falleció Pitágoras), sufrían exactamente la misma deficiencia enzi-\nmática pero mucho más acentuada.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":147,"lines":{"from":41,"to":53}}}}],["694",{"pageContent":"Variantes bioquímicas\n. Se han publicado más de 400 variantes con características bioquímicas dis-\ntintas, las cuales, de acuerdo a la clasificación de la Organización Mundial de la Salud, se agrupan en\ncinco clases con base en dos criterios: el primero considera su actividad enzimática residual y la presencia\no ausencia de AHCNE, y el segundo de acuerdo a si son esporádicas o polimórficas\n \n(cuadro 8-1)\n. Las\nvariantes clase I son esporádicas y se caracterizan por presentar AHCNE; sin embargo, las variantes clase\nII y III, asociadas con hemólisis inducida por estrés oxidativo, han adquirido frecuencias polimórficas, es\ndecir, que se observan con una frecuencia de 1% o mayor en algunas poblaciones.\nLos criterios usados hasta hace poco para definir una variante como distinta a las demás eran sus caracte-\nrísticas bioquímicas, como utilización de sustratos, Km para diferentes sustancias, estabilidad al calor, curva","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":147,"lines":{"from":55,"to":67}}}}],["695",{"pageContent":"rísticas bioquímicas, como utilización de sustratos, Km para diferentes sustancias, estabilidad al calor, curva\nde pH y otras más. Desde 1988, sin embargo, se cuenta con la secuencia completa de nucleótidos del gen\nque codifica para la G6PD, y esto ha revolucionado el conocimiento de las variantes enzimáticas. El gen se\nlocaliza en Xq28 en un segmento de 18,5 kb, y la región codificadora tiene 13 exones que codifican para una\ncadena de 515 aminoácidos. La enzima funciona como un homodímero o como un tetrámero, dependiendo\ndel pH de la célula. Al aplicar nuevas técnicas al estudio de las diferentes variantes, se ha averiguado que\nmuchas que se habían descrito como distintas por sus características bioquímicas en diferentes laboratorios\nen realidad son la misma, y que algunas que se creían homogéneas no lo son en verdad. Un ejemplo de la pri\n-\nmera situación lo constituyen ciertas variantes descritas en México, que son G6PD Castilla, G6PD Distrito","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":147,"lines":{"from":67,"to":76}}}}],["696",{"pageContent":"-\nmera situación lo constituyen ciertas variantes descritas en México, que son G6PD Castilla, G6PD Distrito\nFederal, G6PD Tepic y probablemente G6PD Chiapas, las cuales son iguales entre sí e idénticas a la más\ncomún de las variantes africanas A–.\nLa primera variante descrita en México fue la G6PD México, que no produce manifestaciones clíni-\ncas y se pensaba hasta hace poco que era diferente a todas las demás. Sin embargo, en fecha reciente se\nidentificó en el laboratorio del Dr. E. Beutler en California su alteración molecular exacta, que consiste en\nque el nucleótido 844 tiene citosina en lugar de guanina, lo que origina el cambio de histidina por ácido\naspártico en la posición 282, que es la mutación característica de la variante conocida como G6PD Seattle.\nPara los fines de este capítulo se analizarán con mayor cuidado únicamente cuatro variantes:","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":147,"lines":{"from":76,"to":85}}}}],["697",{"pageContent":"•\n \nG6PD B+.\n \nEs la enzima normal que se encuentra en la gran mayoría de los individuos, tiene acti-\nvidad enzimática normal y no se asocia con problemas de hemólisis (clase IV).\n\nLa deficiencia de G6PD eri-\ntrocítica es la más común de\nlas deficiencias enzimáticas del\neritrocito asociada con cuadros\nde anemia hemolítica. Se calcu-\nla que hay más de 400 millones\nde personas con la enfermedad,\nla mayoría distribuidas en paí-\nses de la cuenca del Mediterrá-\nneo, África y China.\nSe ha informado que quienes\npadecían la enfermedad co-\nnocida como\n \nfavismo\n \nen po -\nblaciones\n \nmediterráneas\n \n(de\nla que falleció Pitágoras) su-\nfrían exactamente la misma\ndeficiencia enzimática, pero\nmucho más acentuada.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":147,"lines":{"from":87,"to":119}}}}],["698",{"pageContent":"121\n\nCAPÍTULO 8. ANEMIAS HEMOLÍTICAS POR ALTERACIONES\n\n•\n \nGGPD A+.\n \nSe ha observado en el 20% de los estadounidenses de origen africano, tiene actividad\ncasi normal y no se relaciona con hemólisis. Difiere de la B+ en que posee movilidad electroforética\nmás rápida, debido a que en la posición 126 tiene ácido aspártico en lugar de asparagina, como\nconsecuencia de que el nucleótido 376 es guanina (G) en lugar de adenina (A) (clase IV).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":148,"lines":{"from":1,"to":12}}}}],["699",{"pageContent":"•\n \nG6PD A–.\n \nSe encuentra en el 10% de los negros estadounidenses, tiene solo 15% de actividad enzi\n-\nmática normal y se asocia con cuadros de anemia hemolítica. Posee movilidad electroforética igual a\nla A+, pero además del cambio del nucleótido 376 tiene otro adicional, cerca de 90% de las veces en el\nnucleótido 202 (A en lugar de G, y por consiguiente metionina en lugar de valina en la posición 68) y\naproximadamente el 10% de las veces en el nucleótido 680 [timina (T) en lugar de G, leucina en lugar de\narginina en la posición 227] o en el nucleótido 968 [citosina (C) en lugar T, prolina en lugar de leucina\nen la posición 323] (clase III).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":148,"lines":{"from":14,"to":25}}}}],["700",{"pageContent":"•\n \nG6PD mediterránea.\n \nEs la más común de las variantes encontradas en personas de raza blanca;\ntiene movilidad electroforética normal (B) pero solo 1% de actividad enzimática, por lo que se asocia\ncon problemas hemolíticos más acentuados que la variante A–. Aquella tiene fenilalanina en lugar de\nserina en la posición 188, lo que obedece a un cambio en el nucleótido 563 (T en lugar de C) (clase II).\nEn México se han descrito al menos 18 variantes de G6PD, y tres constituyen aproximadamente el\n80% de las deficiencias (A– 376G/202A, A– 376G/968C y Santamaría 376G/542T). Otras variantes\ndescritas en México en las que se ha identificado la mutación son: Vanua Lava (383C), Tsukui (Del 561-\n563), Ciudad de México (680A), Seattle (844C), Loma Linda (1089A), Guadalajara (1159T), Nashville\n(1178A) y Union (1360T).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":148,"lines":{"from":27,"to":39}}}}],["701",{"pageContent":"Naturaleza del defecto enzimático\n. En los eritrocitos, la vía de las pentosas es la única fuente de NA\n-\nDPH a través de la reacción catalizada por la G6PD y la 6-fosfogluconato deshidrogenasa (6PGD) (véase\nfigura 8-1). El NADPH es esencial en los eritrocitos para protegerlos contra el daño provocado por el\nestrés, lo cual se logra manteniendo los niveles adecuados de glutatión (GSH). El GSH protege los grupos\nsulfidrilo de la hemoglobina y la membrana del eritrocito de la oxidación. En los eritrocitos normales, la\nproporción entre el glutatión oxidado y glutatión reducido (GSSH) es de 1:100. En presencia de agentes\noxidantes en forma de radicales libres o peróxidos, los niveles de GSH disminuyen y pueden ser resta-\nblecidos por la acción de la glutatión reductasa, la cual necesita de un suministro adecuado de NADPH.\nLa G6PD es esencial para la defensa contra el estrés oxidativo. Si las concentraciones de NADPH no","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":148,"lines":{"from":41,"to":51}}}}],["702",{"pageContent":"blecidos por la acción de la glutatión reductasa, la cual necesita de un suministro adecuado de NADPH.\nLa G6PD es esencial para la defensa contra el estrés oxidativo. Si las concentraciones de NADPH no\npueden ser mantenidas como en la deficiencia de G6PD, los niveles de GSH caen y ocurre el daño oxidativo\ny la consecuente hemólisis. En personas con algunas variantes de G6PD, la hemólisis aguda ocurre cuando\nlos agentes oxidantes se generan después de la ingesta de ciertas drogas, habas o durante una infección\naguda. En las variantes esporádicas más graves (clase I), los agentes oxidantes producidos durante el me-\ntabolismo normal de los eritrocitos causan una reducción del GSH y esto, a su vez, una hemólisis crónica.\nPor otra parte, conforme los eritrocitos envejecen, disminuye la actividad de la G6PD. En sujetos con\nla variante A–, hay inestabilidad de la enzima, por lo que las células jóvenes tienen actividad relativamente","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":148,"lines":{"from":51,"to":59}}}}],["703",{"pageContent":"la variante A–, hay inestabilidad de la enzima, por lo que las células jóvenes tienen actividad relativamente\nnormal mientras que las viejas son deficientes. La inestabilidad de la enzima en la variante mediterránea\nes más acentuada aún, y los eritrocitos de todas las edades son deficientes, por lo que la totalidad de la\nmasa eritrocítica es susceptible a los agentes oxidantes y las crisis hemolíticas pueden ser muy intensas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":148,"lines":{"from":59,"to":62}}}}],["704",{"pageContent":"Cuadro 8-1.\n \nClasificación de variantes de G6PD de acuerdo a su actividad enzimática\ny a la presencia o ausencia de AHCNE\n\nVariante\n \nCaracterísticas\n\nClase I\n \nDeficiencia grave (< 1% de actividad residual de la enzima), asociada con anemia\nhemolítica crónica no esferocítica (AHCNE). Variantes esporádicas o raras\nClase II\n \nDeficiencia grave, con una actividad residual del 1 al 10% asociada con anemia he-\nmolítica aguda (AHA). Variantes polimórficas en Asia y en el Mediterráneo\nClase III\n \nDeficiencia moderada a grave, actividad residual del 10-60%. Cursa con AHA.\nG6PD A–\nClase IV\n \nActividad normal (60-100%). Asintomática. G6PD B+, G6PD A+\nClase V\n \nActividad incrementada > 150%. Asintomática\n\nEn México se han descrito al\nmenos 18 variantes de G6PD,\ny tres constituyen aproxima-\ndamente el 80% de las de-\nficiencias\n \n(A–\n \n376G/202A,\nA– 376G/968C y Santama-\nría 376G/542T).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":148,"lines":{"from":64,"to":102}}}}],["705",{"pageContent":"122\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nGenética\n. El gen que codifica para la G6PD está situado en el brazo largo del cromosoma X, por lo cual\nlos varones son hemicigotos y tienen un solo tipo de enzima, mientras que las mujeres con un solo gen muta\n-\ndo son heterocigotas y presentan dos enzimas diferentes. Como se trata de un gen recesivo, la gran mayoría\nde los individuos afectados son de sexo masculino y solo en ocasiones una mujer manifiesta la enfermedad.\nEllo ocurre cuando la mujer es homocigota para un gen anormal, o bien si es heterocigota, por el fenómeno\nde “lionización”, cuando por azar se inactiva de preferencia el cromosoma X con el gen normal. En mujeres\nheterocigotas para variantes clase I se ha observado una expresión preferencial del cromosoma X con el alelo\nnormal, en tanto que en heterocigotas para variantes clase II y III se ha documentado una expresión prefe-\nrencial del cromosoma X con el alelo mutado.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":149,"lines":{"from":1,"to":15}}}}],["706",{"pageContent":"Manifestaciones clínicas.\n \nLa manifestación clínica común es la anemia hemolítica aguda, la cual\nse puede compensar rápidamente y pasar desapercibida; sin embargo, se puede sospechar de anemia por\ndeficiencia de G6PD en las siguientes circunstancias: 1) hemólisis inducida por fármacos; 2) hemólisis\ninducida por infecciones; 3) hemólisis inducida por ingestión de habas; 4) ictericia neonatal; y 5) anemia\nhemolítica crónica no esferocítica. Las crisis de anemia hemolítica se generan por destrucción intravascu-\nlar de eritrocitos, y producen anemia súbita, reticulocitosis, ictericia por elevación de bilirrubina no con-\njugada, hemoglobinuria y esplenomegalia. A continuación se describen las situaciones antes mencionadas\ncon mayor detalle:","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":149,"lines":{"from":17,"to":26}}}}],["707",{"pageContent":"•\n \nHemólisis inducida por fármacos.\n \nLa hemólisis suele comenzar después de 2 a 3 días de estar en\ncontacto con el medicamento (o algunas sustancias químicas)\n \n(cuadro 8-2)\n, empeora alrededor de\nlos siguientes 3 a 4 días e inicia su recuperación a partir del día 8 a 10. Es importante señalar que las\nvariantes genéticas involucradas en el metabolismo de los medicamentos, así como la farmacocinética,\npueden influir en la gravedad de la hemólisis.\n\n•\n \nHemólisis inducida por infecciones.\n \nSe estima que en las zonas geográficas donde no es prevalen\n-\nte el favismo, es la causa más común de hemólisis por deficiencia de G6PD, y puede estar influida\npor el tipo de infección, la administración concomitante de medicamentos, la función hepática y la\nedad. Se estima que muchas de las crisis hemolíticas por infecciones se acompañan de ingestión de\nmedicamentos o sustancias oxidantes.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":149,"lines":{"from":28,"to":50}}}}],["708",{"pageContent":"•\n \nHemólisis inducida por ingestión de habas (favismo).\n \nComo ya se mencionó, la hemólisis por esta\ncausa se ha conocido desde la antigüedad, aun en escala epidémica en algunos países del Medite-\nrráneo; sin embargo, es importante señalar que no todos los individuos deficientes de G6PD son\nsensibles a la ingestión de habas y, además, no todas las especies de habas tienen la misma capacidad\ntóxica. Típicamente, el favismo se ha observado en pacientes con la variante G6PD Mediterráneo,\npero también se ha observado en individuos con otras variantes como G6PD A–.\n\n•\n \nIctericia neonatal.\n \nLa deficiencia de G6PD es la causa más común de hemólisis e ictericia neona-\ntal. La ictericia aparece usualmente entre los 3 y 4 días de edad, de manera similar o más temprano","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":149,"lines":{"from":52,"to":68}}}}],["709",{"pageContent":"El gen que codifica para la\nG6PD está situado en el bra-\nzo largo del cromosoma X, por\nlo cual los varones son hemi-\ncigotos y tienen un solo tipo\nde enzima, mientras que las\nmujeres con un solo gen muta-\ndo son heterocigotas y presen-\ntan dos enzimas diferentes.\n\nCuadro 8-2.\n \nLista parcial de algunas sustancias que pueden desencadenar\ncrisis de anemia hemolítica en pacientes con deficiencia de G6PD eritrocítica\n\nAsociación\ndefinitiva\nPosible\nasociación\nAsociación\ndudosa\n\nAntipalúdicos\n \nPrimaquina\nPamaquina\n \nCloroquina\n \nQuinacrina\nQuinina\nSulfonamidas\nSulfonilamida\nSulfacetamida\nSulfapiridina\nSulfametaxazol\nSulfadimidina\nSulfasalazina\nGlibenclamida\nSulfonas\nSulfadiazina\nSulfafurazol\nAnalgésicos/\nantipiréticos\n \nAcetanilida\n \nAspirina\n \nParacetamol\nFenacetina\nOtros fármacos\nÁcido nalidíxico\nNiridazol\nAzul de metileno\nFenazopiridina\nCotrimoxazol\nCiprofloxacino\nCloranfenicol\nAnálogos de vitamina K\nÁcido ascórbico\nMesalazina\nAc. aminosalicílico\nDoxorrubicina\nProbenecid\nDimercaprol","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":149,"lines":{"from":70,"to":135}}}}],["710",{"pageContent":"Se puede sospechar de anemia\npor deficiencia de G6PD en\nlas siguientes circunstancias:\n1) hemólisis inducida por fár-\nmacos; 2) hemólisis inducida\npor infecciones; 3) hemólisis\ninducida por ingestión de ha-\nbas; 4) ictericia neonatal; y 5)\nanemia hemolítica crónica no\nesferocítica.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":149,"lines":{"from":137,"to":146}}}}],["711",{"pageContent":"123\n\nCAPÍTULO 8. ANEMIAS HEMOLÍTICAS POR ALTERACIONES\n\nque la aparición de la ictericia fisiológica, pero posterior a la ictericia por aloinmunización. Se han\nobservado diferencias étnicas en los niveles de bilirrubina en neonatos de término, lo que puede ser\natribuido, al menos parcialmente, a la presencia de variantes genéticas de la enzima UDP-glucuro-\nniltransferasa, en particular la responsable del síndrome de Gilbert, que cursa con niveles elevados\nde bilirrubinas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":150,"lines":{"from":1,"to":9}}}}],["712",{"pageContent":"•\n \nAnemia hemolítica crónica no esferocítica.\n \nEste estado lo presentan particularmente los pacien-\ntes con variantes de clase I, si bien pueden presentar crisis hemolíticas agudas por estrés oxidativo\npor medicamentos o infecciones. Cerca del 1% de los sujetos con G6PD mediterránea cursan con\nAHCNE, similar a la que se observa en pacientes con enzimopatías de la vía glucolítica.\nLa citometría hemática muestra, además de los datos de anemia hemolítica, presencia de cuerpos de\nHeinz en los eritrocitos. En los sujetos con la variante A–, que es la más común en México, dada la mag-\nnitud de la inmigración negra durante la Colonia, las crisis suelen ser autolimitadas, ya que solo del 20 al\n30% de los eritrocitos están deficientes. En cambio, en enfermos con la variante mediterránea, los cuadros\npueden ser mucho más graves, puesto que todos los hematíes están afectados. Una complicación peligrosa\nes la insuficiencia renal aguda por necrosis tubular y el tratamiento debe buscar evitarla; además, ha de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":150,"lines":{"from":11,"to":24}}}}],["713",{"pageContent":"es la insuficiencia renal aguda por necrosis tubular y el tratamiento debe buscar evitarla; además, ha de\nadministrarse sangre según se requiera. Una vez pasada la fase aguda, las anormalidades clínicas ceden\ncon rapidez y los pacientes se recuperan solos. Quizá se necesite administrar hierro, ya que este se pierde\ndebido a la hemoglobinuria. Es importante que los enfermos eviten el contacto con sustancias que se co-\nnoce pueden ser peligrosas para ellos. En todo caso, esta posibilidad diagnóstica debe tomarse en cuenta\nen los sujetos de extracción mediterránea o negra que presenten cuadros agudos de ictericia, anemia y\norina de color oscuro. Según la experiencia del autor (RL), se establece un diagnóstico inicial equivocado\nde hepatitis aguda en la mayoría de los individuos afectados.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":150,"lines":{"from":24,"to":31}}}}],["714",{"pageContent":"Diagnóstico\n. El diagnóstico de laboratorio de la deficiencia de G6PD es relativamente sencillo, ex-\ncepto justo después de una crisis hemolítica, porque: 1) los pacientes pueden haber recibido transfusiones\nde sangre, y 2) es posible que se hayan destruido los eritrocitos deficientes y persistan de preferencia los\nque tienen concentraciones normales de la enzima. Por estas razones, es necesario dejar pasar un tiempo\nrazonable para llevar a cabo las pruebas de laboratorio. Existen técnicas de tamizado fáciles de realizar y\ncon suficiente sensibilidad para emplearse en estudios de población, pero a nivel de enfermos individuales\nes indispensable utilizar una técnica cuantitativa basada en la medición de la velocidad de reducción de\nnicotina adenin dinucleótido fosforilado (NADP) en presencia de glucosa-6-fosfato.\n\nDeficiencia de glutamil-cisteín-sintetasa y de glutatión sintetasa","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":150,"lines":{"from":33,"to":43}}}}],["715",{"pageContent":"Deficiencia de glutamil-cisteín-sintetasa y de glutatión sintetasa\n\nEl GSH se sintetiza en dos pasos. En el primero se forma el dipéptido glutamil-cisteína de ácido glutá-\nmico y cisteína, reacción catalizada por la glutamil-cisteín-sintetasa. En el segundo paso se añade glicina\npara completar el tripéptido, lo que es catalizado por la glutatión sintetasa GHS. La deficiencia de esta\nenzima es muy poco frecuente y se hereda en forma autosómica recesiva, y puede presentarse como una\nanemia hemolítica aislada o en forma multisistémica caracterizada por acidosis metabólica severa. Los\neritrocitos tienen niveles muy bajos de GSH y el cuadro clínico es similar al de la deficiencia de G6PD.\n\nDeficiencia de glutatión reductasa","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":150,"lines":{"from":43,"to":52}}}}],["716",{"pageContent":"Deficiencia de glutatión reductasa\n\nEsta deficiencia es también muy poco frecuente y se hereda en forma autosómica recesiva. Las\nconcentraciones de GSH son normales, pero la estabilidad de este último durante la incubación con\nagentes oxidantes (acetilfenil hidracina) es muy baja. Clínicamente, el cuadro es muy similar al de\nla deficiencia de G6PD, con destrucción intravascular de eritrocitos causada por algunas sustancias\nquímicas.\n\nHEMÓLISIS ASOCIADA A ANORMALIDADES ERITROCÍTICAS\nDEL METABOLISMO DE NUCLEÓTIDOS\n\nEl interés por el estudio del metabolismo intraeritrocítico de los nucleótidos surgió por el conocimiento\nde que algunos de ellos, incluyendo la inosina y la adenosina, eran capaces de mejorar la viabilidad de la\nsangre almacenada en los bancos para propósitos de transfusión sanguínea. Posteriormente se describie-\nron tres cuadros de anemia hemolítica debidos a deficiencia de alguna enzima en el metabolismo de las\npurinas y pirimidinas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":150,"lines":{"from":52,"to":67}}}}],["717",{"pageContent":"La citometría hemática mues-\ntra, además de los datos de\nanemia hemolítica, presencia\nde cuerpos de Heinz en los\neritrocitos. En los sujetos con\nla variante A–, que es la más\ncomún\n \nen\n \nMéxico,\n \ndada\n \nla\nmagnitud de la inmigración\nnegra durante la Colonia, las\ncrisis suelen ser autolimitadas,\nya que solo del 20 al 30% de los\neritrocitos están deficientes.\nLa\n \ndeficiencia\n \nde\n \nglutatión\nreductasa\n \nes\n \ntambién\n \nmuy\npoco frecuente y se hereda en\nforma\n \nautosómica\n \nrecesiva.\nLas concentraciones de GSH\nson normales, pero la estabi-\nlidad de este último durante\nla incubación con agentes oxi-\ndantes es muy baja.\nEl interés por el estudio del me\n-\ntabolismo intraeritrocítico de los\nnucleótidos surgió por el conoci-\nmiento de que algunos de ellos,\nincluyendo la inosina y la ade-\nnosina, eran capaces de mejorar\nla viabilidad de la sangre alma-\ncenada en los bancos para propó-\nsitos de transfusión sanguínea","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":150,"lines":{"from":69,"to":123}}}}],["718",{"pageContent":"124\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nDeficiencia de pirimidina 5’-nucleotidasa","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":151,"lines":{"from":1,"to":5}}}}],["719",{"pageContent":"El RNA ribosómico es degradado en los reticulocitos normales a nucleótidos-5’. Estos catabolitos no son\ndifusibles y se desfosforilan por medio de la pirimidina 5’-nucleotidasa (Pir 5’-N) para que puedan atravesar\nla membrana celular. Los reticulocitos con deficiencia de esta enzima acumulan cantidades importantes de\nRNA ribosómico parcialmente degradado, que se observa como punteado basófilo grueso en extendidos\nde sangre teñidos con colorante de Wright. La deficiencia de Pir 5’-N es la más frecuente de las enzimo-\npatías en esta vía metabólica; se han descrito cuando menos 30 familias afectadas y en todas el patrón de\nherencia ha sido autosómico recesivo. Los sujetos afectados tienen AHCNE asociada con esplenomegalia\ne ictericia intermitente. Las concentraciones de Hb están entre 8 y 10 g/dL, con reticulocitos de 10%. Los\nrequerimientos transfusionales suelen ser bajos y la esplenectomía es de poca utilidad. El punteado basófilo","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":151,"lines":{"from":7,"to":15}}}}],["720",{"pageContent":"requerimientos transfusionales suelen ser bajos y la esplenectomía es de poca utilidad. El punteado basófilo\nde los eritrocitos constituye un hallazgo muy consistente que, en ausencia de datos de intoxicación por\nplomo, en que ocurre deficiencia adquirida de Pir 5’-N, debe hacer pensar en esta enfermedad.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":151,"lines":{"from":15,"to":17}}}}],["721",{"pageContent":"Exceso de adenosina desaminasa\n\nLa adenosina desaminasa (ADA) es la enzima que convierte la adenosina a inosina. La deficiencia de\nADA en los linfocitos produce una forma autosómica recesiva de inmunodeficiencia combinada grave,\nque no se acompaña de anemia hemolítica y es de las primeras enfermedades hereditarias que se han tra-\ntado con éxito mediante terapéutica génica. Existe una forma de anemia hemolítica muy infrecuente y la\nanemia está ligada a un aumento en la cantidad de ADA en los eritrocitos. Se han descrito cuando menos\ndos familias con este trastorno, en las cuales se ha encontrado incremento de 45 a 70 unidades de ADA,\ny se hereda en forma autosómica dominante. La magnitud de la anemia es discreta y hay esplenomegalia\nligera e ictericia intermitente. El mecanismo por el que la enzima está incrementada no se conoce, ni\ntampoco por qué produce anemia.\n\nDeficiencia de adenilatocinasa","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":151,"lines":{"from":19,"to":31}}}}],["722",{"pageContent":"Deficiencia de adenilatocinasa\n\nLa adenilatocinasa (AC) cataliza la interconversión de monofosfato de adenosina (AMP), difosfato de adeno\n-\nsina (ADP) y ATP. Se han descrito varias familias con deficiencia de esta enzima, que se hereda en forma auto\n-\nsómica recesiva. En todos los casos menos uno, se ha asociado con anemia hemolítica de intensidad moderada,\npero la excepción basta para poner en duda la relación causa-efecto entre la deficiencia y la anemia, y deberán\nconocerse más pacientes antes de estar ciertos de cuál es la consecuencia clínica de la deficiencia de AC.\n\nCONCLUSIONES\n\n•\n \nLas alteraciones en las enzimas del eritrocito causan destrucción eritrocítica que debe sospecharse en\npacientes con cuadros de hemólisis crónica.\n\n•\n \nLa glucosa es el sustrato metabólico más importante de los eritrocitos, metabolizada por la vía anae-\nróbica y la vía de las pentosas.\n\n•\n \nLas alteraciones en las enzimas del metabolismo de los nucleótidos también producen hemólisis.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":151,"lines":{"from":31,"to":55}}}}],["723",{"pageContent":"•\n \nLas alteraciones en las enzimas del metabolismo de los nucleótidos también producen hemólisis.\n\nPREGUNTAS DE AUTOEVALUACIÓN\n\n1. El sustrato metabólico más importante de los eritrocitos es:\na.\n \nGalactosa\nb. Fructosa\nc.\n \nGlucosa\n2. La vida media de un eritrocito es de:\na.\n \n30 días\nb. 120 días\nc.\n \n160 días","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":151,"lines":{"from":55,"to":76}}}}],["724",{"pageContent":"125\n\nCAPÍTULO 8. ANEMIAS HEMOLÍTICAS POR ALTERACIONES\n\n3. La deficiencia enzimática más común del ciclo de Embden-Meyerhof es:\na.\n \nHexocinasa\nb. Glucosa-6-fosfato\nc.\n \nPiruvatocinasa\n4. La deficiencia enzimática más común del ciclo de las pentosas es:\na.\n \nHexocinasa\nb. Glucosa 6 fosfato\nc.\n \nAldolasa\n5. En la crisis de anemia hemolítica, podemos encontrar:\na.\n \nBilirrubina directa elevada\nb. Bilirrubina indirecta elevada\nc.\n \nBilirrubina directa disminuida\n\nBIBLIOGRAFÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":152,"lines":{"from":1,"to":30}}}}],["725",{"pageContent":"Beutler E. Glucose-6-phosphate dehydrogenase. New perspectives. Blood. 1989; 74: 1397-401.\nBeutler E, Kuhl W, et al. Some Mexican glucose-6-phosphate dehydrogenase variants revisited. Hum Genet. 1991;\n86: 371-374.\nBeutler E, Kuhl W. Linkage between a PvuII restriction fragment length polymorphism and G-6-PD A- 202A/376G:\nEvidence for a single origin of the common G-6-PD A- mutation. Hum Genet. 1990; 85: 9-11.\nBeutler E, Kuhl W. »e NT 1311 polymorphism of G-6-PD: G-6-PD Mediterranean mutation may have originated\nindependently in Europe and Asia. Am J Hum Genet. 1990; 1008-1012.\nHirono A, Kanno H, Miwa S, Beutler E. Pyruvate kinase deficiency and other enzymopathies of the erythrocyte. »e\nOnline Metabolic and Molecular Bases of Inherited Diseases (OMMBID). PART 19: BLOOD. 2006. Chapter 182.\nLisker R. Panorama de la deficiencia de la glucosa-6-fosfato dehidrogenasa eritrocítica. Rev Invest Clin. 1992; 44: 277-282.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":152,"lines":{"from":32,"to":41}}}}],["726",{"pageContent":"Lisker R. Panorama de la deficiencia de la glucosa-6-fosfato dehidrogenasa eritrocítica. Rev Invest Clin. 1992; 44: 277-282.\nLisker R, Ramírez E, et al. Gene frequencies and admixture estimates in four Mexican urban centers. Hum Biol.\n1990; 62: 791-801.\nLisker R, Linares C, et al. Glucose 6-phosphate dehydrogenase México. A new variant with enzyme deficiency, ab -\nnormal mobility and abscence of hemolysis. J Lab Clin Med. 1972; 79: 788-793.\nLukens JN. Hereditary hemolytic anemias associated with abnormalities of erythrocyte anaerobic glycolisis and\nnucleotide metabolism. En: Lee RG, Bithell TC, et al (eds). Wintrobe’s Clinical hematology. Philadelphia:\nLea-Febiger; 1993. p. 990-1005.\nLuzzatto L, Mehta A, Vulliamy T. Glucose 6-phosphate dehydrogenase deficiency. »e Online Metabolic and Mo -\nlecular Bases of Inherited Diseases (OMMBID). PART 19: BLOOD. 2006; 179: 1-87.\nPersico MG, Viglietto G, et al. Isolation of human glucose-6-phosphate dehydrogenase (G-6-PD) cDNA clones:","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":152,"lines":{"from":41,"to":51}}}}],["727",{"pageContent":"lecular Bases of Inherited Diseases (OMMBID). PART 19: BLOOD. 2006; 179: 1-87.\nPersico MG, Viglietto G, et al. Isolation of human glucose-6-phosphate dehydrogenase (G-6-PD) cDNA clones:\nPrimary structure of the protein and unusual 5’non coding region. Nucleic Acid Res. 1986; 14: 2511-2523.\nSullivan DW, Glader BE. Erythrocyte enzyme disorders in children. Ped Clin N A. 1980; 27: 449-462.\nVaca G, Arámbula-Meraz E. DNA sequencing analysis of several G6PD variants previously defined by PCR-restric\n-\ntion enzyme analysis. Genet Mol Biol. 2006; 29: 31-35.\nVives-Corrons JL. Red blood cell enzyme defects. En: European School of Hematology. Handbook on disorders of\nerythropoiesis, erythrocytes and iron metabolism. 2009. p. 436-453.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":152,"lines":{"from":51,"to":59}}}}],["728",{"pageContent":"RESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\n1.\n \nc\n2.\n \nb\n3.\n \nc\n4.\n \nb\n5.\n \nb","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":152,"lines":{"from":61,"to":77}}}}],["729",{"pageContent":"127\n\nINTRODUCCIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":154,"lines":{"from":1,"to":3}}}}],["730",{"pageContent":"Se denomina\n \nanemia hemolítica\n \na todo proceso en el que se produce anemia, es decir, reducción de las cifras de\nhemoglobina por debajo de los valores de referencia para la población sana, como resultado de la destrucción\nexcesiva de eritrocitos. Cuando en los mecanismos de destrucción excesiva de hematíes participan anticuerpos,\nse puede hablar de anemia hemolítica inmunitaria. Los anticuerpos responsables de aumentar la destrucción\nde los eritrocitos pueden ser autoinmunes, es decir, producidos por el paciente contra sus propios eritrocitos, o\naloinmunes, que son los que un individuo genera contra eritrocitos alogénicos, esto es, de otro sujeto diferente.\nLa presencia de eritrocitos de un individuo en otro habitualmente se debe a transfusiones, o bien al paso de\neritrocitos fetales a la circulación materna durante el embarazo o más comúnmente durante el parto.\nFinalmente, en las anemias hemolíticas inmunitarias pueden participar anticuerpos dirigidos contra","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":154,"lines":{"from":5,"to":17}}}}],["731",{"pageContent":"eritrocitos fetales a la circulación materna durante el embarazo o más comúnmente durante el parto.\nFinalmente, en las anemias hemolíticas inmunitarias pueden participar anticuerpos dirigidos contra\nmedicamentos o metabolitos de estos, que al depositarse en forma pasiva en la superficie eritrocitaria pue\n-\nden causar su destrucción temprana. En este capítulo se revisarán los mecanismos de las anemias he\n-\nmolíticas inmunitarias, su diagnóstico y tratamiento. Se describirá la utilidad del empleo de pruebas de\nlaboratorio muy sensibles para la demostración de anticuerpos antieritrocitarios, pues este hallazgo cons\n-\ntituye uno de los pilares más sólidos para el diagnóstico y seguimiento de este grupo de padecimientos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":154,"lines":{"from":17,"to":26}}}}],["732",{"pageContent":"ANEMIA HEMOLÍTICA AUTOINMUNITARIA\n\nLa categoría de\n \nanemia hemolítica autoinmunitaria\n \n(AHAU) comprende todas las anemias hemo-\nlíticas en las que existen anticuerpos autoinmunes, es decir, anticuerpos específicamente dirigidos\ncontra antígenos naturales de los eritrocitos del mismo individuo. Se dice que el trastorno es prima-\nrio cuando no existe otra enfermedad subyacente a la que se asocie, o bien es secundario cuando se\nrelaciona con otras entidades, entre las que destacan alteraciones del tejido conjuntivo y síndromes\nlinfoproliferativos. Como en todos los procesos hemolíticos, los pacientes con AHAU presentan\nanemia sin evidencia de sangrado, aumento en el recuento de reticulocitos y en los niveles de deshi-\ndrogenasa láctica, disminución de haptoglobina sérica e hiperbilirrubinemia de grado variable. Para\n\nSe denomina\n \nanemia hemo-\nlítica\n \na todo aquel proceso en\nque se produce anemia como\nresultado\n \nde\n \nla\n \ndestrucción\nexcesiva de eritrocitos.\n\nCAPÍTULO 9","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":154,"lines":{"from":28,"to":59}}}}],["733",{"pageContent":"Se denomina\n \nanemia hemo-\nlítica\n \na todo aquel proceso en\nque se produce anemia como\nresultado\n \nde\n \nla\n \ndestrucción\nexcesiva de eritrocitos.\n\nCAPÍTULO 9\n\nANEMIAS HEMOLITÍCAS\nINMUNITARIAS\n\nAlejandro Ruiz Argüelles\n\nObjetivos de aprendizaje\n\n•\n \nComprender el término\n \nanemia hemolítica autoinmunitaria\n \ny\n \naloinmunitaria.\n\n•\n \nConocer los mecanismos de la anemia hemolítica del recién nacido.\n\n•\n \nEntender las causas y mecanismos de las anemias hemolíticas autoinmunitarias.\n\n•\n \nDistinguir la anemia hemolítica inducida por fármacos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":154,"lines":{"from":59,"to":104}}}}],["734",{"pageContent":"128\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":155,"lines":{"from":1,"to":3}}}}],["735",{"pageContent":"confirmar el origen autoinmunitario de la hemólisis en un enfermo con las características anteriores,\ndeben demostrarse anticuerpos sobre la membrana de los eritrocitos; esto se efectúa con la prueba directa\nde antiglobulina, conocida muy ampliamente como\n \nprueba de Coombs directa\n. Este procedimiento con-\nsiste en incubar los eritrocitos del paciente con suero heterólogo que está dirigido contra las principales\ninmunoglobulinas (Ig) humanas y la fracción 3 del sistema de complemento. Si los eritrocitos están\nsensibilizados con estas proteínas, el antisuero causa su aglutinación, la cual puede detectarse visual-\nmente. En el 90 a 95% de los sujetos en quienes la prueba directa de Coombs es positiva, los anticuerpos\nresponsables de la hemólisis son de la clase IgG, y la aglutinación con dicho suero se pone en evidencia a\ntemperaturas de 37 °C, por lo que en el pasado fueron llamados anticuerpos “calientes”.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":155,"lines":{"from":5,"to":16}}}}],["736",{"pageContent":"responsables de la hemólisis son de la clase IgG, y la aglutinación con dicho suero se pone en evidencia a\ntemperaturas de 37 °C, por lo que en el pasado fueron llamados anticuerpos “calientes”.\nEn el 5 a 10% restante de pacientes con AHAU en quienes se pueden demostrar anticuerpos unidos a\nla membrana eritrocítica, la reacción de aglutinación ocurre a temperaturas bajas, y es más fácil de eviden-\nciar si se emplean sueros de Coombs que reaccionen primordialmente con IgM y con las fracciones C3 y\nC4 del complemento. Este grupo de individuos, de quienes se dice que presentan enfermedad por “crioa-\nglutininas” o anticuerpos “fríos”, suele manifestar síntomas, por ejemplo, acrocianosis o hemoglobinuria,\npor exposición a temperaturas bajas. Finalmente, existe un grupo de individuos en los que los anticuerpos\nde la clase IgM pueden ponerse de manifiesto en una reacción que ocurre a 4 °C en su primera fase y a\n37 °C en la segunda. Estos anticuerpos se denominan\n \nbifásicos D-L","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":155,"lines":{"from":16,"to":27}}}}],["737",{"pageContent":"de la clase IgM pueden ponerse de manifiesto en una reacción que ocurre a 4 °C en su primera fase y a\n37 °C en la segunda. Estos anticuerpos se denominan\n \nbifásicos D-L\n \n(por las iniciales de sus descubridores\nde 1904, Donath y Landsteiner) y se presentan en una fracción pequeña de casos con AHAU.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":155,"lines":{"from":27,"to":33}}}}],["738",{"pageContent":"Manifestaciones clínicas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":155,"lines":{"from":35,"to":35}}}}],["739",{"pageContent":"Desde el punto de vista clínico, los pacientes con anticuerpos de la clase IgG suelen tener la forma primaria\no idiopática de AHAU, y cuando está asociada con otro padecimiento, este suele ser alguna enfermedad del\ntejido conjuntivo, leucemia linfocítica crónica o linfoma. Algunas series indican que aproximadamente\nel 45% de los casos de AHAU por anticuerpos IgG son idiopáticos, en tanto que otro 45% se relaciona con\nlos padecimientos mencionados. Sin embargo, en opinión de muchos expertos, los enfermos idiopáticos o\nprimarios de AHAU no representan sino casos en los que inicia la aparición de una entidad autoinmunitaria\nmultiorgánica como lupus eritematoso generalizado o síndrome primario de anticuerpos antifosfolípido.\nDe acuerdo con esta teoría, la gran mayoría de los individuos con AHAU primaria desarrollarán, tarde o\ntemprano, otras manifestaciones clínicas de enfermedad generalizada, lo que por definición cambiará su clasifi\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":155,"lines":{"from":37,"to":46}}}}],["740",{"pageContent":"temprano, otras manifestaciones clínicas de enfermedad generalizada, lo que por definición cambiará su clasifi\n-\ncación a AHAU secundaria. En apoyo de esta posibilidad, si bien es cierto que solo el 5% de los pacientes con\nlupus eritematoso generalizado tienen como manifestación inicial la AHAU, esta se presenta en algún momento\ndel padecimiento en más del 40% de todos los enfermos afectados de lupus generalizado. En el caso del síndro\n-\nme de anticuerpos antifosfolípido, aunque la AHAU no es un hallazgo frecuente, la positividad de la prueba de\nCoombs sí lo es. Finalmente, en el 10 a 15% de los casos de AHAU por anticuerpos IgG, es posible documentar\nque el enfermo ha recibido algún medicamento que podría ser responsable del fenómeno autoinmune. Entre\nestos fármacos destacan\n \nα\n-metildopa, L-dopa, procainamida e ibuprofeno (véase más adelante,\nAnemia hemolítica\ninducida por fármacos\n). Con respecto a la AHAU causada por anticuerpos de tipo IgM, llamada\nenfermedad por\ncrioaglutininas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":155,"lines":{"from":46,"to":63}}}}],["741",{"pageContent":"Anemia hemolítica\ninducida por fármacos\n). Con respecto a la AHAU causada por anticuerpos de tipo IgM, llamada\nenfermedad por\ncrioaglutininas\n, se sabe que se presenta en su forma primaria en menos de la tercera parte de los casos, y con mucha\nfrecuencia se asocia con gammapatías policlonales (como las secundarias a infecciones por virus Epstein-Barr o","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":155,"lines":{"from":63,"to":69}}}}],["742",{"pageContent":"Mycoplasma pneumoniae\n) o monoclonales, debidas a padecimientos linfoproliferativos malignos. Los pacientes en\nquienes se demuestran anticuerpos bifásicos tienen un síndrome poco frecuente llamado\nhemoglobinuria paroxís-\ntica del frío\n; esta entidad se caracteriza por hemólisis masiva y hemoglobinuria, ocasionalmente acompañadas de\nurticaria, después de exposición a bajas temperaturas. El cuadro puede ser transitorio y es posible que se asocie con\ninfecciones virales agudas, pero también existen formas crónicas, en su mayoría idiopáticas o secundarias a sífilis\ntardía. En el pasado, la sífilis congénita era la causa más común de esta forma de AHAU.\n\nFisiopatología","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":155,"lines":{"from":71,"to":81}}}}],["743",{"pageContent":"Fisiopatología\n\nDesde el punto de vista de su fisiopatología, la hemólisis en aquellos enfermos que tienen anticuerpos IgG\nocurre fuera del torrente sanguíneo, es decir, se presenta hemólisis extravascular en el sistema fagocítico\nmononuclear predominantemente esplénico. Por su parte, la hemólisis de los sujetos con anticuerpos del\ntipo IgM sucede dentro del sistema circulatorio como resultado de la activación del sistema del comple-\nmento y, como consecuencia, suele acompañarse de hemoglobinuria.\nLas causas por las que se producen autoanticuerpos eritrocitarios son aún muy obscuras. Como en casi\ntodos los procesos autoinmunitarios, se han evocado diversos fenómenos que actúan en sinergia o coope-\nración en un momento dado. Así, se sabe que hay una clara predisposición genética, evidenciada por la","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":155,"lines":{"from":81,"to":90}}}}],["744",{"pageContent":"Para confirmar el origen au-\ntoinmunitario de la hemólisis\nen un enfermo con las carac-\nterísticas mencionadas, deben\ndemostrarse anticuerpos sobre\nla membrana de los eritrocitos;\nesto se efectúa con la prueba\ndirecta de antiglobulina, cono-\ncida muy ampliamente como\n\nprueba de Coombs directa.\n\nAlgunas\n \nseries\n \nindican\n \nque\naproximadamente el 45% de\nlos casos de AHAU por anti-\ncuerpos IgG son idiopáticos,\nen tanto que el 45% se rela-\nciona con padecimientos del\ntejido\n \nconjuntivo,\n \nleucemia\nlinfocítica crónica o linfoma.\nLas causas por las que se pro-\nducen autoanticuerpos eritro-\ncitarios son aún muy oscuras.\nComo en casi todos los procesos\nautoinmunes, se han evocado\ndiversos\n \nfenómenos\n \nque\n \nac-\ntúan en sinergia o cooperación\nen un momento dado.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":155,"lines":{"from":92,"to":135}}}}],["745",{"pageContent":"129\n\nCAPÍTULO 9. ANEMIAS HEMOLITÍCAS INMUNITARIAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":156,"lines":{"from":1,"to":3}}}}],["746",{"pageContent":"agregación familiar de los procesos autoinmunitarios, así como por la asociación de ciertas enfermedades\npor autoinmunidad con ciertos genes del complejo principal de histocompatibilidad. En el ratón NZB, que\nes el modelo animal por excelencia de la AHAU, el rasgo de anemia autoinmunitaria se hereda en forma\nautosómica dominante a toda la progenie. Asimismo, se han encontrado alteraciones en la inmunorregula-\nción, en las proporciones de células cooperadoras y citotóxicas, y en la producción de ciertas citocinas. En\naños recientes, ha cobrado interés particular el análisis del balance entre las células T cooperadoras tipo 1\n(¢1) y las del tipo 2 (¢2), que a la fecha solo pueden distinguirse unas de otras por el tipo de interleucinas\n(IL) que secretan. Las primeras son células que, a través de producir interferón-\nγ\n, factor de necrosis tumoral\ne IL-2, promueven respuestas inmunitarias primordialmente inflamatorias y citotóxicas, mientras que las","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":156,"lines":{"from":5,"to":15}}}}],["747",{"pageContent":"γ\n, factor de necrosis tumoral\ne IL-2, promueven respuestas inmunitarias primordialmente inflamatorias y citotóxicas, mientras que las\nsegundas, al producir IL-4, IL-5 e IL-10, cooperan con el desarrollo de respuestas fundamentalmente a\nbase de la producción de anticuerpos, con poco o nulo componente inflamatorio\n \n(fig. 9-1)\n.\nEl balance de la actividad de estas dos poblaciones celulares, que a la sazón se estimulan en forma au-\ntocrina y se inhiben recíprocamente, ha sido implicado en la progresión clínica de diversas anfermedades\ninfecciosas, parasitarias y anafilácticas; recientemente, se ha sugerido que los fenómenos autoinmunitarios\nocurren en los individuos con un predominio de la función de las células ¢2, mientras que en individuos\ncon carga genética igual, pero en quienes predomina la actividad de las células ¢1, la ocurrencia de efec-\ntores autoinmunitarios, principalmente de autoanticuerpos, es mucho menos frecuente.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":156,"lines":{"from":15,"to":28}}}}],["748",{"pageContent":"Demostración de anticuerpos antieritrocíticos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":156,"lines":{"from":30,"to":30}}}}],["749",{"pageContent":"Como se ha mencionado, la prueba directa de Coombs ocupa un papel muy importante en el diagnóstico\ny la clasificación de pacientes con AHAU; sin embargo, en su forma tradicional, su sensibilidad no es\nóptima. Esto obedece al hecho de que los eritrocitos normalmente tienden a repelerse unos a otros, debido\nal llamado “potencial Z”, como un mecanismo fisiológico para evitar su autoagregación en la microcircu-\nlación. Así, para vencer tales fuerzas de repulsión es necesaria la existencia de muchos “puentes”, formados\npor la antiglobulina entre distintos eritrocitos, para que estos puedan ser aglutinados. Cuando la densidad\nde moléculas de inmunoglobulina es menor de 300 por eritrocito, la prueba directa de aglutinación de\nCoombs proporciona resultados falsos negativos. Para superar esta limitación técnica, en fechas recientes\nse han aplicado dos métodos que permiten la detección de 10 o 15 moléculas de IgG por célula, al no estar","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":156,"lines":{"from":32,"to":40}}}}],["750",{"pageContent":"se han aplicado dos métodos que permiten la detección de 10 o 15 moléculas de IgG por célula, al no estar\nafectados por las fuerzas repulsivas de los eritrocitos. Estos métodos son: 1) el inmunoanálisis enzimático\nde fase sólida (ELISA) y 2) la citometría de flujo. La prueba de Coombs por medio de ELISA consiste en","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":156,"lines":{"from":40,"to":42}}}}],["751",{"pageContent":"Figura 9-1.\n \nLa célula presentadora del antígeno (CPA) puede activar preferentemente a las células ¢1 o\n¢2. Las primeras producen citocinas sobre todo proinflamatorias, mientras que las segundas promueven\nlas síntesis de anticuerpos con poca o nula actividad inflamatoria. Ambas células se estimulan en forma\nautocrina y se inhiben recíprocamente. De su equilibrio funcional parece depender la progresión clínica de\ndiversas enfermedades infecciosas, por hipersensibilidad y por autoinmunidad.\n\nLa prueba directa de Coombs\ndesempeña un papel muy im-\nportante en el diagnóstico y la\nclasificación de pacientes con\nAHAU; sin embargo, en su\nforma tradicional, su sensibi-\nlidad no es óptima.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":156,"lines":{"from":44,"to":58}}}}],["752",{"pageContent":"130\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":157,"lines":{"from":1,"to":3}}}}],["753",{"pageContent":"construir una curva de referencia con eritrocitos Rh (D)+ sensibilizados en el laboratorio con cantidades\nvariables y conocidas de anticuerpos IgG anti-D de origen humano. Utilizando los propios eritrocitos\ncomo la fase sólida sobre la cual ocurre la reacción, los anticuerpos se ponen en evidencia mediante una\nreacción inmunoenzimática. La actividad de la enzima es proporcional al número de moléculas que se\nencuentra en cada eritrocito\n \n(fig. 9-2)\n.\nEn forma similar, puede prepararse una curva de referencia con eritrocitos Rh+ y anticuerpos IgG an-\nti-Rh, pero el conjugado enzimático debe sustituirse por un conjugado fluorescente. Las células así prepara-\ndas se analizan en un citómetro de flujo, instrumento que permite cuantificar la intensidad de la fluorescencia\npresente en los eritrocitos, que es directamente proporcional al número promedio de moléculas de IgG que\nse hallan en cada uno de los eritrocitos. Si los hematíes de un individuo en quien se presume la presencia de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":157,"lines":{"from":5,"to":17}}}}],["754",{"pageContent":"se hallan en cada uno de los eritrocitos. Si los hematíes de un individuo en quien se presume la presencia de\nIgG se incuban directamente con el conjugado fluorescente y se analizan en el citómetro de flujo, también\nes posible saber, de acuerdo con la intensidad de fluorescencia que emitan, el número promedio de molécu-\nlas de IgG que tienen dichos eritrocitos\n \n(fig. 9-3)\n. Asimismo, tanto en el método de ELISA como en el de\ncitometría de flujo, pueden demostrarse y cuantificarse otros tipos de anticuerpos (IgM o IgA) o proteínas\ndel sistema de complemento en la membrana eritrocítica; ello se logra utilizando conjugados enzimáticos o\nfluorescentes, respectivamente, dirigidos en forma específica contra estas proteínas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":157,"lines":{"from":17,"to":26}}}}],["755",{"pageContent":"Papel de los inhibidores del complemento,\nCD55 y CD59, en el proceso hemolítico","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":157,"lines":{"from":28,"to":29}}}}],["756",{"pageContent":"Existen dos proteínas con capacidad de inhibir la activación del sistema de complemento, que tienen la\npeculiaridad de anclarse en la membrana celular a través del grupo glucosil-fosfatidilinositol; estas se conocen\ncomo\n \nfactor acelerador del decaimiento\n \n(DAF, por sus siglas en inglés), o CD55, y el\n \ninhibidor de membrana de\nlisis reactiva\n \n(MIRL) o CD59. En la hemoglobinuria paroxística nocturna existe un trastorno genético que\nimpide el anclaje adecuado de estos inhibidores, lo que hace a los eritrocitos más susceptibles a la hemólisis\nmediada por complemento. En la anemia hemolítica autoinmunitaria primaria o secundaria a lupus eritema\n-\ntoso generalizado, existe una deficiencia adquirida de estas proteínas, aparentemente por inhibición alostérica\nde su anclaje, secundaria a la presencia de autoanticuerpos. Más que la causa inicial de la hemólisis, este me\n-\ncanismo parecería ser un facilitador de esta, y podría participar tanto en la hemólisis mediada por anticuerpos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":157,"lines":{"from":31,"to":49}}}}],["757",{"pageContent":"Figura 9-2.\n \nRepresentación esquemática del método inmunoenzimático para detectar anticuerpos unidos\na la membrana eritrocitaria. Los eritrocitos Rh+ se sensibilizan con cantidades conocidas de IgG anti-Rh\n(D) para construir una curva de referencia. La cantidad de IgG se revela mediante un conjugado enzimáti\n-\nco que, al digerir a un sustrato cromogénico, produce color de intensidad proporcional al número promedio\nde moléculas de IgG por eritrocito. Las muestras de pacientes se incuban directamente con el conjugado\nenzimático y el cromógeno, y de acuerdo con la intensidad del color que se desarrolle, se calcula el número\nde moléculas de IgG por eritrocito. De su equilibrio funcional parece depender la progresión clínica de\ndiversas enfermedades infecciosas, por hipersensibilidad y por autoinmunidad.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":157,"lines":{"from":51,"to":61}}}}],["758",{"pageContent":"Tanto en el método de ELI-\nSA como en el de citometría\nde flujo pueden demostrarse\ny cuantificarse otros tipos de\nanticuerpos\n \n(IgM\n \no\n \nIgA)\n \no\nproteínas del sistema de com-\nplemento\n \nen\n \nla\n \nmembrana\neritrocítica; ello se logra utili-\nzando conjugados enzimáticos\no fluorescentes, respectivamen-\nte, dirigidos en forma específi-\nca contra estas proteínas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":157,"lines":{"from":63,"to":88}}}}],["759",{"pageContent":"131\n\nCAPÍTULO 9. ANEMIAS HEMOLITÍCAS INMUNITARIAS\n\nIgM como aquella mediada por anticuerpos de isotipo IgG, ya que si bien el CD59 inhibe la formación del\ncomplejo de ataque a la membrana y, por ende, las formas intravasculares de hemólisis, la molécula CD55 es\ncapaz de inhibir eficazmente la opsonización mediada por C3b que participa en la hemólisis extravascular.\n\nTratamiento y pronóstico","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":158,"lines":{"from":1,"to":9}}}}],["760",{"pageContent":"Para la anemia hemolítica causada por anticuerpos IgG, la terapéutica de elección son los corticoides. Su\nempleo ha reducido la mortalidad de los pacientes afectados por la forma idiopática de más de 40% a menos\nde 10%. Su mecanismo de acción parece ser múltiple. Por una parte, en enfermos que responden favora-\nblemente a este tratamiento (aproximadamente el 66%) se puede demostrar una reducción en la producción\nde anticuerpos antieritrocíticos; por otro lado, hay una disminución en la unión de dichos anticuerpos a la\nmembrana de los hematíes. Finalmente, también existe menor captación de eritrocitos sensibilizados en\nel sistema fagocítico mononuclear. La suma de los tres efectos resulta en una notable disminución de la\ndestrucción acelerada de eritrocitos y la consecuente elevación de las cifras de hemoglobina. Las dosis reco-\nmendadas para inducir remisión del proceso hemolítico son relativamente altas (60 a 100 mg de prednisona","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":158,"lines":{"from":11,"to":19}}}}],["761",{"pageContent":"mendadas para inducir remisión del proceso hemolítico son relativamente altas (60 a 100 mg de prednisona\nal día), pero estas no suelen mantenerse por más de 2 a 3 semanas, período en el que han de reducirse de\nmanera gradual a la mitad o a la cuarta parte de la dosis inicial, la que se mantiene por varios meses.\nCuando el enfermo se ha estabilizado hematológicamente y los anticuerpos unidos a los eritrocitos han\ndisminuido en grado considerable o han desaparecido del todo (de allí la necesidad de disponer de métodos\nmuy sensibles para su detección), los esteroides pueden retirarse con lentitud. En el 25 a 30% de los sujetos\nasí tratados, la respuesta solo es parcial y el tratamiento debe prolongarse por más tiempo o ha de decidirse\nel uso de otras alternativas. En el 5 a 10% de los casos, no hay respuesta alguna con el empleo de corticoides.\nLa esplenectomía está indicada en pacientes que no pueden estabilizarse con corticoides o en aquellos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":158,"lines":{"from":19,"to":27}}}}],["762",{"pageContent":"La esplenectomía está indicada en pacientes que no pueden estabilizarse con corticoides o en aquellos\nen quienes es necesario usar dosis muy altas para mantener cifras estables de hemoglobina. En muchos\nenfermos, el procedimiento resulta de gran beneficio, pudiéndose reducir o incluso eliminar el empleo de\ncorticoides; sin embargo, en una fracción no despreciable de casos no se obtiene tal respuesta. Finalmen-\nte, en algunos individuos se observa favorable respuesta inmediata seguida de una recaída que parecería\nexplicarse por el incremento en la cantidad de anticuerpos antieritrocíticos, o bien por un cambio en su\nisotipo que les conferiría la capacidad de activar al sistema de complemento. Algunos fármacos citotóxicos,\ncomo azatioprina, tioguanina y ciclofosfamida, se han utilizado con resultados variables. Dado que estos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":158,"lines":{"from":27,"to":34}}}}],["763",{"pageContent":"Figura 9-3.\n \nRepresentación esquemática del método citoflurométrico para detectar anticuerpos unidos a la\nmembrana eritrocitaria. Los eritrocitos Rh+ se sensibilizan con cantidades conocidas de IgG anti-Rh (D)\npara construir una curva de referencia. La cantidad de IgG se revela mediante un conjugado fluorescente,\ny la intensidad de la fluorescencia de las células, que es proporcional al número promedio de moléculas de\nIgG por eritrocito, se determina en un citómetro de flujo. Las muestras de pacientes se incuban directa-\nmente con el conjugado fluorescente, y de acuerdo con la intensidad de fluorescencia que emitan, se calcula\nel número de moléculas de IgG por eritrocito. De su equilibrio funcional parece depender la progresión\nclínica de diversas enfermedades infecciosas, por hipersensibilidad y por autoinmunidad.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":158,"lines":{"from":36,"to":45}}}}],["764",{"pageContent":"Para\n \nla\n \nanemia\n \nhemolítica\ncausada por anticuerpos IgG,\nla terapéutica de elección son\nlos corticoides. Su empleo ha\nreducido la mortalidad de los\npacientes afectados por la for-\nma idiopática de más de 40%\na menos de 10% .","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":158,"lines":{"from":47,"to":60}}}}],["765",{"pageContent":"132\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":159,"lines":{"from":1,"to":3}}}}],["766",{"pageContent":"medicamentos son depresores de la eritropoyesis, su efecto neto puede resultar contraproducente. En ge-\nneral se recomienda evitar las transfusiones de paquete globular en estos pacientes, ya que, además de los\nanticuerpos demostrables en los eritrocitos autólogos, es común que en el plasma se encuentren anticuerpos\nlibres que pueden unirse y destruir a los eritrocitos alogénicos contenidos en la transfusión. Solo en casos\nen los que es posible seleccionar un donador cuyos eritrocitos no expresen el antígeno o los antígenos al\ncual o a los cuales están dirigidos los anticuerpos del paciente, puede realizarse la transfusión sin este ries-\ngo en particular. Sin embargo, los autoanticuerpos de estos sujetos suelen estar dirigidos contra diversos\ncomponentes antigénicos de la membrana eritrocítica, que son de muy amplia distribución en la especie.\nLa enfermedad por aglutininas frías solo ocasionalmente pone en peligro la vida de los enfermos, y en","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":159,"lines":{"from":5,"to":13}}}}],["767",{"pageContent":"La enfermedad por aglutininas frías solo ocasionalmente pone en peligro la vida de los enfermos, y en\ngeneral como la mejor medida terapéutica se recomienda la prevención de episodios hemolíticos, evitando\nexposición al frío. Si no es posible que un determinado paciente habite en alguna zona cálida, es recomenda-\nble que se le asegure casa y ropa calientes. Los esteroides no tienen en estos casos los mismos efectos que en\nlos enfermos con AHAU por anticuerpos IgG, salvo cuando se emplean en dosis mucho más elevadas, que\ndeben limitarse a individuos graves. La esplenectomía, por razones obvias, no es de mayor beneficio para es-\ntos pacientes. Algunos agentes alquilantes, como clorambucil y ciclofosfamida, pueden ofrecer algún benefi-\ncio como inmunosupresores; sin embargo, su administración ha de ser responsabilidad de un especialista.\nEn sujetos con hemoglobinuria paroxística por frío secundaria a infecciones virales, la primera remite","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":159,"lines":{"from":13,"to":21}}}}],["768",{"pageContent":"En sujetos con hemoglobinuria paroxística por frío secundaria a infecciones virales, la primera remite\nespontáneamente cuando las segundas se autolimitan. En aquellos casos secundarios a sífilis, el trata-\nmiento adecuado de la infección con frecuencia termina en la curación del proceso hemolítico. Finalmen-\nte, en los casos idiopáticos ninguna terapéutica es mejor que una casa tibia y ropa abrigadora. Cuando la\nurticaria es muy molesta, los medicamentos antihistamínicos (tipo I) y adrenérgicos pueden estar indica-\ndos. El tratamiento con esteroides y la esplenectomía no aportan beneficio a estos enfermos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":159,"lines":{"from":21,"to":26}}}}],["769",{"pageContent":"ANEMIA HEMOLÍTICA ALOINMUNITARIA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":159,"lines":{"from":28,"to":28}}}}],["770",{"pageContent":"Se denomina\n \nanemia hemolítica aloinmunitaria\n \n(AHAL), de manera general, a cualquier proceso hemolíti-\nco en el que los eritrocitos de un individuo son destruidos por anticuerpos que produce otro sujeto diferen-\nte. En la forma más común, tal situación ocurre cuando un individuo recibe una transfusión de eritrocitos\nincompatibles en alguno de los sistemas antigénicos eritrocíticos. Si por transfusión previa el receptor de\nla transfusión ya posee anticuerpos séricos contra los eritrocitos del donador, el resultado es la destrucción\nacelerada y masiva de los hematíes contenidos en la transfusión. Esto se acompaña de síntomas agudos\ncaracterizados por sensación de angustia y aprensión, malestar general, dolores en extremidades, disnea\nde grado variable, taquicardia e hipotensión arterial, que puede llegar al choque en casos graves. En etapas\niniciales ocurre hipotermia, seguida de hipertermia y oliguria que, en los enfermos más graves, puede","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":159,"lines":{"from":30,"to":42}}}}],["771",{"pageContent":"iniciales ocurre hipotermia, seguida de hipertermia y oliguria que, en los enfermos más graves, puede\nllegar a la anuria. En pacientes sensibilizados mucho tiempo antes de la transfusión, la destrucción de\neritrocitos y los síntomas pueden aparecer 5 a 7 días después del procedimiento; ello, como resultado\nde una respuesta secundaria de producción de anticuerpos que es reactivada por reinfusión de hematíes.\nEn aquellos enfermos que no se encuentren sensibilizados con anterioridad, la destrucción de eritrocitos\npuede ocurrir incluso 2 semanas después de la transfusión, período en el que se producen anticuerpos en\nforma de respuesta primaria contra los aloantígenos de los hematíes transfundidos.\nLa intensidad de las manifestaciones clínicas parece depender de la masa de eritrocitos destruidos, así\ncomo de la velocidad con la que esto ocurre. En las formas más agudas, debidas a presencia de anticuerpos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":159,"lines":{"from":42,"to":50}}}}],["772",{"pageContent":"como de la velocidad con la que esto ocurre. En las formas más agudas, debidas a presencia de anticuerpos\nséricos preformados en gran abundancia, se observan las manifestaciones clínicas más graves y notables.\nPara establecer el origen inmunitario de estos cuadros, es necesaria la demostración de anticuerpos séricos,\nya sean libres en el suero o unidos a los hematíes transfundidos. Para esto se emplean las pruebas indirecta\ny directa de antiglobulina, respectivamente. La primera consiste en mezclar una muestra de eritrocitos\ntransfundidos con suero del paciente, en diversas condiciones que favorecen o no la aglutinación, para\ndemostrar la presencia de dichos anticuerpos. Se han utilizado con éxito como indicadores de la unión\nantígeno-anticuerpo variantes metodológicas como la activación de complemento, ELISA y citometría de\nflujo. Cuando los anticuerpos antieritrocíticos son muy abundantes, no es necesario usar suero antiglobuli-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":159,"lines":{"from":50,"to":58}}}}],["773",{"pageContent":"flujo. Cuando los anticuerpos antieritrocíticos son muy abundantes, no es necesario usar suero antiglobuli-\nna para demostrar su presencia, ya que ocurre aglutinación espontánea de eritrocitos en solución salina, en\nausencia de coloides, lectinas o enzimas. En muchas ocasiones, se emplean colecciones de eritrocitos con\nun perfil antigénico ya conocido para reconocer el antígeno involucrado en la reacción hemolítica y evitar,\nen lo sucesivo, transfundir a ese mismo paciente eritrocitos de donadores que tengan dicho antígeno. Este\ntipo de tarea debe ser responsabilidad de los laboratorios especializados en medicina transfusional.\nUna segunda forma a través de la cual los eritrocitos pueden entrar en contacto con anticuerpos alogénicos\nes aquella en la que la sangre (o plasma) transfundida contiene anticuerpos contra los hematíes del receptor.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":159,"lines":{"from":58,"to":65}}}}],["774",{"pageContent":"Cuando los anticuerpos an-\ntieritrocíticos son muy abun-\ndantes, no es necesario usar\nsuero antiglobulina para de-\nmostrar su presencia, ya que\nocurre aglutinación espontá-\nnea de eritrocitos en solución\nsalina, en ausencia de coloi-\ndes, lectinas o enzimas.\nAnemia hemolítica aloinmu-\nnitaria (AHAL) es cualquier\nproceso hemolítico en el que los\neritrocitos de un individuo son\ndestruidos por anticuerpos que\nproduce un sujeto diferente.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":159,"lines":{"from":67,"to":81}}}}],["775",{"pageContent":"133\n\nCAPÍTULO 9. ANEMIAS HEMOLITÍCAS INMUNITARIAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":160,"lines":{"from":1,"to":3}}}}],["776",{"pageContent":"Normalmente, toda persona con determinado tipo sanguíneo del grupo ABO tiene anticuerpos naturales\ncontra los antígenos que no posee. En otras palabras: un sujeto con el tipo O presenta anticuerpos contra\nlos antígenos A y B, aquellos con el grupo B tienen anticuerpos contra el antígeno A, mientras que los\nindividuos con el grupo A los poseen contra el del grupo B. Estos anticuerpos, llamados\n isohemaglutininas\n,\nno requieren inducirse por medio de transfusiones previas y su concentración plasmática suele ser muy baja.\nPor lo general, cuando se transfunde plasma a un receptor, las isohemaglutininas del donador se diluyen\nen forma tan importante en la circulación del receptor que no ocasionan ningún proceso hemolítico; sin em-\nbargo, si por alguna razón su título es anormalmente elevado o la cantidad de plasma transfundida es muy\ngrande, sí pueden sensibilizar los eritrocitos del receptor y causar crisis hemolíticas de magnitud variable.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":160,"lines":{"from":5,"to":15}}}}],["777",{"pageContent":"grande, sí pueden sensibilizar los eritrocitos del receptor y causar crisis hemolíticas de magnitud variable.\nEl tratamiento de las anemias hemolíticas por aloanticuerpos consiste en la aplicación de medidas\ngenerales tendientes a prevenir o resolver complicaciones como choque e insuficiencia renal. No existen\nmedidas terapéuticas específicas y, en la inmensa mayoría de los casos, las buenas prácticas clínicas y de\nlaboratorio para la selección de donadores de sangre o sus derivados pueden prevenir las complicaciones.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":160,"lines":{"from":15,"to":19}}}}],["778",{"pageContent":"ANEMIA HEMOLÍTICA DEL RECIÉN NACIDO","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":160,"lines":{"from":21,"to":21}}}}],["779",{"pageContent":"Otra entidad en la que puede presentarse hemólisis por aloanticuerpos es la eritroblastosis fetal o anemia hemo\n-\nlítica del recién nacido. En esta circunstancia, lo que ocurre con mayor frecuencia es que una madre con el tipo\nRh– procrea un producto con fenotipo Rh+ por herencia paterna. Bien sea en el embarazo o en el momento del\nparto, los eritrocitos Rh+ pasan a la circulación materna e inducen al sistema inmunitario a la producción\nde anticuerpos anti-Rh. Vale la pena aclarar aquí que un aborto anterior, amniocentesis u otro traumatismo, o\nbien transfusiones previas, pueden también ser causa de sensibilización al Rh. En un embarazo ulterior en el que\nel producto también tenga el fenotipo Rh+, los anticuerpos maternos de la clase IgG serán capaces de atravesar\nla barrera placentaria y producir destrucción de eritrocitos fetales en el útero. La hemólisis intrauterina por an\n-\nticuerpos contra antígenos del sistema ABO es mucho menos frecuente; así, se calcula que a pesar de que casi","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":160,"lines":{"from":23,"to":33}}}}],["780",{"pageContent":"-\nticuerpos contra antígenos del sistema ABO es mucho menos frecuente; así, se calcula que a pesar de que casi\nel 20% de las parejas que tienen hijos es incompatible en el sistema ABO, solo en el 10% de ellas (es decir, 2%\ndel total) se presentan manifestaciones hemolíticas menores. Las manifestaciones clínicas pueden ir desde una\nforma muy moderada de anemia al momento del nacimiento, a formas graves de anemia e hiperbilirrubinemia\nque pueden condicionar kernícterus, y aun muerte intrauterina por hidropesía fetal. El tratamiento de los niños\nafectados varía de acuerdo con la gravedad del caso y consiste primordialmente en recambios sanguíneos y foto\n-\nterapia. Por lo que toca a las madres Rh–, desde su primer embarazo y en lo sucesivo, se les debe realizar investi\n-\ngación repetida de anticuerpos anti-Rh (D). Cuando estos no se detectan o su título es muy bajo (< 1 U/mL), no\nes necesario efectuar ninguna medida diagnóstica adicional ni mucho menos terapéutica. Si las concentraciones","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":160,"lines":{"from":33,"to":44}}}}],["781",{"pageContent":"es necesario efectuar ninguna medida diagnóstica adicional ni mucho menos terapéutica. Si las concentraciones\naumentan, ha de investigarse la magnitud de la hemólisis fetal por medio de estudio del líquido amniótico. Si\nesta es muy grave, puede hacerse recambio sanguíneo in uteroy, cuando sea posible, se debe interrumpir el em\n-\nbarazo a las 35 semanas de gestación para realizar los recambios en el recién nacido. Si la hemólisis no es grave,\nel embarazo debe dejarse llegar a término y hay que estar preparado para llevar a cabo los recambios sanguíneos.\nAl momento del nacimiento de todo producto de una madre Rh–, ha de investigarse su grupo sanguí-\nneo en una muestra del cordón umbilical. Si el recién nacido es también del fenotipo Rh–, no es necesario\ntomar medida alguna; sin embargo, si es Rh+, la madre debe tratarse con suero anti-Rh (D) para evitar su\nsensibilización. El fundamento teórico de esta conducta se basa en que los anticuerpos anti-Rh se unirán","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":160,"lines":{"from":44,"to":53}}}}],["782",{"pageContent":"sensibilización. El fundamento teórico de esta conducta se basa en que los anticuerpos anti-Rh se unirán\na los antígenos Rh (D) de los eritrocitos fetales que pudiesen haber pasado a la circulación materna, ocul-\ntándolos del reconocimiento del sistema inmunitario y produciendo su remoción acelerada. La adminis-\ntración de este suero debe hacerse dentro de las 72 horas siguientes al nacimiento. Desde la introducción y\npráctica rutinaria de esta medida preventiva, la prevalencia de las formas graves de enfermedad hemolítica\ndel recién nacido se ha abatido considerablemente. En la actualidad, son más frecuentes los casos por\nincompatibilidad ABO que, como se mencionó, producen formas leves de hemólisis.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":160,"lines":{"from":53,"to":59}}}}],["783",{"pageContent":"ANEMIA HEMOLÍTICA INDUCIDA POR FÁRMACOS\n\nEn esta clasificación se agrupan en realidad tres formas de anemia hemolítica con mecanismos\nfisiopatológicos distintos, cuyo único denominador común es que los cuadros hemolíticos ocurren después\nde la administración de ciertos fármacos\n \n(fig. 9-4)\n.\nEn el primer caso, se desarrollan anticuerpos contra fármacos o metabolitos que directamente se de-\npositan de manera pasiva sobre la membrana eritrocítica. Los anticuerpos interactúan con estas sustancias\ny el eritrocito es destruido de manera incidental. La penicilina y la cefalotina son ejemplos de esta forma\nde anemia hemolítica adquirida.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":160,"lines":{"from":61,"to":72}}}}],["784",{"pageContent":"El tratamiento de las anemias\nhemolíticas por aloanticuer-\npos consiste en la aplicación de\nmedidas generales tendientes\na prevenir o resolver compli-\ncaciones como choque e insufi-\nciencia renal.\nLo que ocurre con mayor fre-\ncuencia es que una madre con\nel tipo Rh– procrea un pro-\nducto con fenotipo Rh+ por\nherencia paterna. Bien sea en\nel embarazo o en el momento\ndel parto, los eritrocitos Rh+\npasan a la circulación mater-\nna e inducen al sistema in-\nmunitario a la producción de\nanticuerpos anti-Rh.\nAl momento del nacimiento\nde todo producto de una ma-\ndre Rh–, ha de investigarse\nsu grupo sanguíneo en una\nmuestra del cordón umbilical.\nSi el recién nacido es también\ndel fenotipo Rh–, no es nece-\nsario tomar medida alguna;\nsin embargo, si es Rh+, la\nmadre debe tratarse con suero\nanti-Rh (D) para evitar su\nsensibilización.\nEn la clasificación de anemia\nhemolítica inducida por fár-\nmacos se agrupan en realidad\ntres formas de anemia hemo-\nlítica con mecanismos fisiopa-\ntológicos distintos, cuyo único","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":160,"lines":{"from":74,"to":109}}}}],["785",{"pageContent":"sensibilización.\nEn la clasificación de anemia\nhemolítica inducida por fár-\nmacos se agrupan en realidad\ntres formas de anemia hemo-\nlítica con mecanismos fisiopa-\ntológicos distintos, cuyo único\ndenominador común es que los\ncuadros\n \nhemolíticos\n \nocurren\ndespués de la administración\nde ciertos fármacos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":160,"lines":{"from":109,"to":123}}}}],["786",{"pageContent":"134\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":161,"lines":{"from":1,"to":3}}}}],["787",{"pageContent":"En el segundo caso, el blanco de los anticuerpos es un complejo formado por una proteína plasmática\nautóloga y un fármaco. Ya sea que este complejo se deposite inicialmente en la membrana eritrocítica y\ndespués se le una el anticuerpo, o bien que el complejo proteína-fármaco-anticuerpo se forme en el plasma\npara luego depositarse sobre la membrana eritrocítica, el resultado final es la destrucción acelerada de\neritrocitos, una vez más, de manera incidental. La quinidina, la cloropropamida y la fenacetina inducen\nanemia hemolítica por medio de este mecanismo.\nEn el tercer caso, el fármaco tiene un papel misterioso porque no reacciona con la membrana de los\neritrocitos ni con los anticuerpos responsables de la hemólisis. En estos casos, existen verdaderos anticuer-\npos autoinmunitarios que reaccionan con antígenos nativos de la membrana eritrocítica para mediar su\ndestrucción. La\n\u0003α\n-metildopa es el mejor ejemplo de agente inductor de este tipo de anemias hemolíticas,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":161,"lines":{"from":5,"to":16}}}}],["788",{"pageContent":"destrucción. La\n\u0003α\n-metildopa es el mejor ejemplo de agente inductor de este tipo de anemias hemolíticas,\nen las que es muy probable que el medicamento altere mecanismos centrales de la regulación del sistema\ninmunitario, condicionando un verdadero estado de autoinmunidad.\nEn los dos primeros casos, al dejar de administrar el fármaco el proceso hemolítico se controla,\npues, aunque no desaparezcan los anticuerpos, estos no pueden causar hemólisis en ausencia del me -\ndicamento. Sin embargo, en el tercero, la suspensión de la sustancia no resulta en remisión del proceso\nhemolítico, lo que apoya el concepto de que el trastorno causado por este tipo de fármacos ocurre a\nnivel central.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":161,"lines":{"from":16,"to":25}}}}],["789",{"pageContent":"CONCLUSIONES\n\n•\n \nEn las anemias hemolíticas inmunitarias provocadas por la destrucción excesiva de eritrocitos, se de-\nben demostrar anticuerpos sobre la membrana de los hematíes mediante la prueba directa de antiglo-\nbulina, conocida como\n \nprueba de la antiglobulina o de Coombs\n.\n\n•\n \nEl conocimiento de las causas primarias o secundarias de las anemias hemolíticas inmunitarias es\nesencial para un diagnóstico y tratamiento adecuado.\n\nPREGUNTAS DE AUTOEVALUACIÓN\n\n1. ¿Con qué padecimientos se asocian las formas secundarias de anemia hemolítica autoinmunitaria?\na.\n \nLupus eritematoso\nb. Anemia megaloblástica\nc.\n \nLeucemia aguda","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":161,"lines":{"from":27,"to":52}}}}],["790",{"pageContent":"PREGUNTAS DE AUTOEVALUACIÓN\n\n1. ¿Con qué padecimientos se asocian las formas secundarias de anemia hemolítica autoinmunitaria?\na.\n \nLupus eritematoso\nb. Anemia megaloblástica\nc.\n \nLeucemia aguda\n\nFigura 9-4.\n \nExisten tres tipos de mecanismos para explicar la anemia hemolítica inducida por fármacos. En\nel primero (tipo penicilina), los anticuerpos reaccionan con el medicamento unido a la membrana celular;\nen el segundo (tipo fenacetina), los anticuerpos reconocen un complejo proteína-fármaco que se deposita en\nla membrana celular; y en el tercero (tipo\n \nα\n-metildopa), los anticuerpos están dirigidos contra antígenos\nconstituitivos de la membrana eritrocitaria.\n\nAl dejar de administrar los\nfármacos de los dos primeros\ngrupos, el proceso hemolítico\nse controla, pues, aunque no\ndesaparezcan\n \nlos\n \nanticuer-\npos, estos no pueden causar\nhemólisis en ausencia del me-\ndicamento.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":161,"lines":{"from":52,"to":85}}}}],["791",{"pageContent":"135\n\nCAPÍTULO 9. ANEMIAS HEMOLITÍCAS INMUNITARIAS\n\n2. ¿Qué tipo de citocinas producen las células ¢1 y ¢2?\na.\n \nInterferón gamma\nb. Factor de necrosis tumoral\nc.\n \nAmbas son correctas\n3. ¿Cuál es el fundamento de la prueba directa de antiglobulina o prueba de Coombs?\na.\n \nLa demostración de anticuerpos antieritrocitos\nb. La búsqueda de cadenas ligeras en suero\nc.\n \nLa enumeración de reticulocitos\n4. ¿Cuál es el tratamiento inicial de la anemia hemolítica autoinmunitaria?\na.\n \nRituximab\nb. Azatioprina\nc.\n \nEsteroides\n5. ¿En qué se distinguen los tres tipos de anemia hemolítica inducida por fármacos?\na.\n \nEn el mecanismo por el que se producen\nb. En el tipo de anticuerpo involucrado\nc.\n \nEn los niveles de haptoglobinas\n\nBIBLIOGRAFÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":162,"lines":{"from":1,"to":38}}}}],["792",{"pageContent":"Givan AL. Flow cytometry. First Principles. New York: Wiley Liss; 1992.\nHoff brand AV, Pettit JE. Essential haematology. 3rd ed. London: Blackwell Scientific Publications; 1993.\nLaurence J, Wong JE, Nachman R. ¢e cellular hematology of systemic lupus erythematosus. En: Lahita RG. Sys-\ntemic lupus erythematosus. New York: Churchill Livingstone; 1992. p. 771-807.\nMollison PL, Engelfreit CP, et al. Blood transfusion in clinical medicine. 9th ed. Oxford: Blackwell Scientific Pub-\nlications; 1993.\nPetz LD. Autoimmune and drug induced immune hemolytic anemia. En: Rose NR, Conway de Macario E, et al.\nManual of clinical laboratory immunology. Washington: American Society for Microbiology; 1992. p. 325-344.\nRuiz-Argüelles A. Clinical value of intracellular detection of cytokines and cell activation. Proc 12th. IFCC Euro -\npean Congress of Clinical Chemistry 1997. Abstract L12.\nRuiz-Argüelles A. Flow cytometry in the clinical laboratory. Principles, applications and problems. Clin Chim Acta.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":162,"lines":{"from":40,"to":50}}}}],["793",{"pageContent":"pean Congress of Clinical Chemistry 1997. Abstract L12.\nRuiz-Argüelles A. Flow cytometry in the clinical laboratory. Principles, applications and problems. Clin Chim Acta.\n1992; 211: S13-S27.\nRuiz-Argüelles A, Langholz-Scholz P. Detección inmunoenzimática de anticuerpos en la membrana eritrocítica de\npacientes politransfundidos. Rev Invest Clín Méx. 1987; 39: 35-40.\nRuiz-Argüelles GJ. Anemia hemolítica autoinmune. En: Uribe M, editor. Tratado de medicina interna. 2a ed. Méxi-\nco: Editorial Médica Panamericana; 1995. p. 1178-1180.\nRuiz-Argüelles GJ. Laboratory measurement of human cytokines. J Int Fed Clin Chem. 1995; 7: 12-15.\nRichaud-Patin Y, Pérez-Romano B, Carrillo-Maravilla E, Rodríguez AB, Simón AJ, Cabiedes J, et al. Deficiency of red\ncell bound CD55 and CD59 in patients with systemic lupus erythematosus. Immunology Letters. 2003; 88: 95-99.\nRuiz-Argüelles A, Llorente L. ¢e role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":162,"lines":{"from":50,"to":60}}}}],["794",{"pageContent":"Ruiz-Argüelles A, Llorente L. ¢e role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of\nautoimmune hemocytopenias. Autoimm Rev. 2007; 6: 1551-161.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":162,"lines":{"from":60,"to":61}}}}],["795",{"pageContent":"RESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\n1.\n \na\n2.\n \nc\n3.\n \na\n4.\n \nc\n5.\n \na","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":162,"lines":{"from":63,"to":79}}}}],["796",{"pageContent":"137\n\nINTRODUCCIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":164,"lines":{"from":1,"to":3}}}}],["797",{"pageContent":"El término de “anemia aplásica”, de amplia difusión, es incorrecto, ya que se refiere a la ausencia total\nde la médula ósea, situación incompatible con la vida. El término de “anemia hipoplásica” estricta-\nmente también es incorrecto, pues en este padecimiento suele haber, además de anemia, otras cito-\npenias en sangre periférica; lo correcto debería ser\n \nhipoplasia medular\n. En general, en las hipoplasias\nmedulares hay disminución absoluta del tejido hematopoyético en la médula ósea, en tanto que en\nlas displasias medulares el problema principal es el mal funcionamiento de la médula ósea y no su\ndisminución. En algunas circunstancias, las hipoplasias medulares pueden acompañarse de displasia\ny viceversa.\nEn las hipoplasias medulares clásicas, el número de células hematopoyéticas pluripotenciales dis -\nminuye por debajo del nivel crítico para mantener la autorreplicación propia de las células pluripo-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":164,"lines":{"from":5,"to":17}}}}],["798",{"pageContent":"En las hipoplasias medulares clásicas, el número de células hematopoyéticas pluripotenciales dis -\nminuye por debajo del nivel crítico para mantener la autorreplicación propia de las células pluripo-\ntenciales, se agotan las células bien diferenciadas en el tejido de la médula y la cavidad medular es\nocupada por tejido adiposo. En las displasias medulares ocurre algo similar, pero la cantidad absoluta\nde tejido hematopoyético no se reduce tanto; la cantidad absoluta de células hematopoyéticas es nor-\nmal, pero su progenie es defectuosa estructural y funcionalmente. En otras situaciones, la hipoplasia\nde la médula ocurre como resultado de infiltración de la médula ósea por células malignas, entidad\nconocida como\n \nmieloptisis medular\n \no\n \nmielopatía infiltrativa\n. En esta enfermedad, es notable la leucoe-\nritroblastosis, caracterizada por la presencia en sangre periférica de formas inmaduras de elementos\nde serie granulocítica y eritroide.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":164,"lines":{"from":17,"to":33}}}}],["799",{"pageContent":"ALGUNOS CONCEPTOS DE LA HEMATOPOYESIS\n\nLa célula precursora de la médula ósea es una célula progenitora totipotencial hematopoyética (CTH)\ncon capacidad de proliferación, diferenciación y autorrenovación. Estas CTH germinales no pueden\nidentificarse con precisión empleando criterios puramente morfológicos. Sin embargo, mediante téc-\nnicas de concentración celular y estudios de ultraestructura e inmunología, se han identificado como\n\nEn general, en las hipopla-\nsias\n \nmedulares\n \nhay\n \ndismi-\nnución\n \nabsoluta\n \ndel\n \ntejido\nhematopoyético en la médu-\nla ósea, en tanto que en las\ndisplasias medulares el pro-\nblema\n \nprincipal\n \nes\n \nel\n \nmal\nfuncionamiento de la médula\nósea y no su disminución.\n\nCAPÍTULO 10\n\nHIPOPLASIAS Y DISPLASIAS\nMEDULARES\n\nGuillermo J. Ruiz Argüelles\nGuillermo J. Ruiz Delgado\n\nObjetivos de aprendizaje\n\n•\n \nDiferenciar los conceptos de\n \nhipoplasia\n \ny de\n \ndisplasia medular\n.\n\n•\n \nConocer la etiología de la hipoplasia medular, sus mecanismos y tratamiento.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":164,"lines":{"from":35,"to":95}}}}],["800",{"pageContent":"Objetivos de aprendizaje\n\n•\n \nDiferenciar los conceptos de\n \nhipoplasia\n \ny de\n \ndisplasia medular\n.\n\n•\n \nConocer la etiología de la hipoplasia medular, sus mecanismos y tratamiento.\n\n•\n \nComprender la clasificación de las displasias medulares y entender los fundamentos de sus tratamientos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":164,"lines":{"from":95,"to":114}}}}],["801",{"pageContent":"138\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":165,"lines":{"from":1,"to":3}}}}],["802",{"pageContent":"linfocitos de tamaño pequeño. Estos pueden expresar antígenos HLA-DR, CD33 y CD34; el último\nse acepta actualmente como el mejor marcador antigénico de las CTH. A partir de la CTH se generan\nlas células germinales linfoide, granulomonocítica (unidad formadora de colonias granulomonocítica o\nUFC-GM), eritroide (unidad formadora de brotes eritroide o UFB-E) y megacariocítica (UFC-Meg).\nEstas constituyen las células germinales “comprometidas” que se diferencian en una estirpe celular defi -\nnida. Existen tres tipos de células “comprometidas” para la eritropoyesis que son sensibles a la eritro-\npoyetina: UFC-E, UFB-E madura y UFB-E primitiva; la más inmadura es la UFB-E. Dichas células\neritroides pueden expresar antígenos HLA-DR, CD33, glucoforina, receptores de transferrina (CD71) o\nantígenos de grupos eritrocíticos característicos como los del sistema Gerbich. La UFC-GM y sus deri-\nvados, así como la UFC-G y la UFC-M, son sensibles a la acción de factores estimuladores de colonias de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":165,"lines":{"from":5,"to":14}}}}],["803",{"pageContent":"vados, así como la UFC-G y la UFC-M, son sensibles a la acción de factores estimuladores de colonias de\ngranulocitos y monocitos (GM-CSF o G-CSF, por sus siglas en inglés); la célula comprometida para\nla granulomonopoyesis (UFC-GM) prolifera y madura bajo la acción del GM-CSF, originando poste-\nriormente el mieloblasto y monoblasto. La UFC-GM expresa, además de los antígenos HLA-DR, CD33\ny CD34, el antígeno CD13. El antígeno CD34 desaparece cuando las células “comprometidas” evolucio-\nnan a formas más maduras, lo cual sugiere que esta glucoproteína se relaciona con alguna forma de pro-\nceso de diferenciación de células pluripotenciales. El antígeno CD33 se expresa en células de línea tanto\ngranulocítica como monocítica, y aparentemente está restringido a células no linfoides normales; puede\ntambién detectarse en precursores megacariocíticos (UFC-Meg). Es posible detectar el antígeno CD11b\nen formas más maduras de células tanto mieloides como monocíticas; está ausente en la UFC-GM. Los","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":165,"lines":{"from":14,"to":23}}}}],["804",{"pageContent":"también detectarse en precursores megacariocíticos (UFC-Meg). Es posible detectar el antígeno CD11b\nen formas más maduras de células tanto mieloides como monocíticas; está ausente en la UFC-GM. Los\nantígenos CD14 y CD15 se expresan en formas maduras de células monocíticas y granulocíticas, respec-\ntivamente. La célula comprometida para la megacariopoyesis se conoce como UFC-Meg; en esta línea\nse expresan los antígenos de membrana CD41 (glucoproteína IIb/IIIa), CD42 (glucoproteína Ib/IX),\nCD42a (glucoproteína IX), CD42b (glucoproteína Ib), CD61 (glucoproteína IIIa) y otros antígenos cito\n-\nplasmáticos como factor de von Willebrand, trombospondina, factor plaquetario IV, fibrinógeno y factor\nde crecimiento derivado de plaquetas. El precursor pluripotencial de la serie linfoide no ha sido identifi-\ncado con precisión. Es posible que algunos de dichos antígenos expresen actividad de transferasa terminal","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":165,"lines":{"from":23,"to":32}}}}],["805",{"pageContent":"cado con precisión. Es posible que algunos de dichos antígenos expresen actividad de transferasa terminal\nde desoxinucleótidos (TdT) y antígenos de clase II del sistema mayor de histocompatibilidad (HLA-DR).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":165,"lines":{"from":32,"to":33}}}}],["806",{"pageContent":"HIPOPLASIAS MEDULARES\n\nFisiopatología\n\nCuando el número de células totipotenciales hematopoyéticas disminuye por debajo de sus niveles\ncríticos, estimados en 10% de lo normal, predomina la capacidad de autorreplicación a expensas del\nsacrificio de la capacidad de diferenciación. Si el compartimiento de CTH no puede ser renovado, se\nabate la generación de células “comprometidas” y, en consecuencia, descienden los recuentos en sangre\nperiférica. La médula ósea restante se localiza en focos activos, y hay infiltración de tejido adiposo en\nla cavidad medular. La mejor manera de valorar la celularidad de la médula en estas condiciones es me -\ndiante una biopsia de hueso\n \n(fig. 10-1)\n, dado que la información producida por un simple aspirado pue -\nde ser errónea si, por ejemplo, se aspira un foco de hematopoyesis activa, que en inglés se conoce como","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":165,"lines":{"from":35,"to":49}}}}],["807",{"pageContent":"hot pocket\n. La mayoría de las células hematopoyéticas residuales funciona en condiciones de extrema\npresión por la eritropoyetina; esto causa diseritropoyesis que produce eritrocitos macrocíticos con nive -\nles incrementados de hemoglobina fetal e incluso anormalmente sensibles a la acción del complemento\nhemolítico, como ocurre en la hemoglobinuria paroxística nocturna. El hecho de que el trasplante de\nmédula ósea resuelva aproximadamente el 70% de los casos de hipoplasia medular es una evidencia in -\ndirecta de que el problema principal en las hipoplasias medulares es la disminución absoluta del tejido\nhematopoyético, y no trastornos en las células estromales del “microambiente” de la médula ósea, dado\nque estas últimas no son trasplantables.\n\nIncidencia y pronóstico","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":165,"lines":{"from":51,"to":61}}}}],["808",{"pageContent":"Incidencia y pronóstico\n\nEn los países anglosajones, la enfermedad tiene una incidencia que oscila entre 2 y 13 casos por millón\nde habitantes por año. La frecuencia encontrada en México es comparable a las más altas comunicadas\nen la literatura médica: 18,7 por millón de habitantes en China y 13 por millón por año en Suecia. En\nEspaña se señalan 2,2 casos por millón de habitantes. Es probable que algunos factores ambientales, la\nautomedicación y la falta de protección industrial, desempeñen algún papel en la elevada prevalencia de\nla hipoplasia medular. Es interesante que la proporción de casos de hipoplasia medular en nuestro país","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":165,"lines":{"from":61,"to":68}}}}],["809",{"pageContent":"Los linfocitos de tamaño pe-\nqueño pueden expresar an-\ntígenos HLA-DR, CD33 y\nCD34; el último se acepta ac-\ntualmente como el mejor mar-\ncador antigénico de las CTH.\nCuando el número de células\ntotipotenciales\n \nhematopoyé-\nticas\n \ndisminuye\n \npor\n \ndebajo\nde sus niveles críticos, esti-\nmados en 10% de lo normal,\npredomina\n \nla\n \ncapacidad\n \nde\nautorreplicación\n \na\n \nexpensas\ndel sacrifico de la capacidad de\ndiferenciación.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":165,"lines":{"from":70,"to":102}}}}],["810",{"pageContent":"139\n\nCAPÍTULO 10. HIPOPLASIAS Y DISPLASIAS MEDULARES\n\nha disminuido en los últimos años. Por otra parte, es bien sabido que la mayoría de los pobladores de\nAmérica Latina recibieron carga genética de la raza asiática, y en ellos la incidencia del padecimiento es\nmuy elevada.\nAproximadamente el 25% de los pacientes tiene un curso rápido y fatal, con una supervivencia media\nde 4 meses. El 50% muere dentro del primer año después del diagnóstico, y en el 10% de los casos la en -\nfermedad presenta un curso más o menos benigno. Cuando la hipoplasia medular se considera grave, el\npronóstico es mucho más sombrío: solo el 20% de los enfermos sobrevive a un año.\n\nEtiología","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":166,"lines":{"from":1,"to":13}}}}],["811",{"pageContent":"Más del 50% de los casos de hipoplasia medular son idiopáticos, expresión que debe considerarse como\nadmisión de ignorancia; en muchos de estos pacientes es posible que se encuentre involucrado primaria\no secundariamente un mecanismo autoinmunitario. Existen varios agentes que causan daño a la médula\nósea en relación con la dosis; entre ellos han de señalarse las radiaciones ionizantes, los antineoplásicos y\nlos derivados del benceno y el etanol. La lesión causada a la médula ósea por estas sustancias depende de\nla dosis, y en la mayoría de los casos es reversible. Otros agentes causales son aquellos que producen daño\nmedular independientemente de la dosis; en estos casos, la eliminación del agente no siempre resuelve la\nhipoplasia. El\n \ncuadro 10-1\n \nmuestra algunas de las causas de hipoplasia medular.\nNo es sencillo adjudicar a un agente específico la hipoplasia medular. El trabajo\n \nInternational Agra-\nnulocytosis and Aplastic Anemia Study","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":166,"lines":{"from":15,"to":30}}}}],["812",{"pageContent":"muestra algunas de las causas de hipoplasia medular.\nNo es sencillo adjudicar a un agente específico la hipoplasia medular. El trabajo\n \nInternational Agra-\nnulocytosis and Aplastic Anemia Study\n \nadmite como causa probable de la entidad el contacto con sustancias\nquímicas que ocurre como mínimo durante 29 días en un período de 180 días previos a la admisión del\nenfermo. Los insecticidas con gran frecuencia se identifican como causantes de hipoplasia medular en\nMéxico, Brasil y Cuba. En México se ha informado algún contacto con DDT en el 24% de los pacientes\ncon hipoplasia medular y con cloranfenicol en el 7%, pero no ha sido posible establecer con certeza la\nrelación causa-efecto. Estas experiencias contrastan con lo que se comunica en los países de Oriente y\nEuropa, así como en Estados Unidos, donde se considera que el cloranfenicol tiene relación causal en 1 de\ncada 2,5 a 5 enfermos. En China, 1 de cada 60 000 personas que recibe cloranfenicol desarrolla anemia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":166,"lines":{"from":30,"to":43}}}}],["813",{"pageContent":"cada 2,5 a 5 enfermos. En China, 1 de cada 60 000 personas que recibe cloranfenicol desarrolla anemia\naplásica. Los analgésicos constituyen agentes que con frecuencia se relacionan con hipoplasia medular. La\nindometacina es el fármaco más comúnmente involucrado (12,7%); el diclofenaco se asocia con el 8,8% y\nla butazona con el 8,7%. Se considera que el riesgo de adquirir anemia aplásica con butazona es 400 veces\nmás alto que en la población no expuesta. El mismo riesgo se corre con los anticonvulsivos. Las sales de\noro inducen citopenias en el 5% de los pacientes e hipoplasia medular en el 1%. La relación de hipoplasia\nmedular con padecimientos infecciosos es cada vez más evidente.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":166,"lines":{"from":43,"to":49}}}}],["814",{"pageContent":"Figura 10-1.\n \nHipoplasia medular. La tinción (Masson) resalta las trabéculas óseas y hace más aparente la\nausencia completa de tejido hematopoyético; los espacios intertrabeculares están ocupados exclusivamente\npor tejido adiposo. (Fotografía cortesía del Dr. Ruy Pérez Tamayo.)\n\nMás\n \ndel\n \n50%\n \nde\n \nlos\n \ncasos\nde\n \nhipoplasia\n \nmedular\n \nson\nidiopáticos, expresión que debe\nconsiderarse como admisión de\nignorancia; en muchos de estos\npacientes es posible que un me-\ncanismo\n \nautoinmunitario\n \nse\nencuentre involucrado prima-\nria o secundariamente.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":166,"lines":{"from":51,"to":85}}}}],["815",{"pageContent":"140\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nHipoplasia medular autoinmunitaria","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":167,"lines":{"from":1,"to":5}}}}],["816",{"pageContent":"La sospecha de que algunas formas de hipoplasia medular obedecen a mecanismos autoinmunitarios deriva\nde varios hechos. La hipoplasia medular puede acompañar al timoma y es posible que se desarrolle en pa-\ncientes inmunodeficientes congénitos, quienes reciben transfusiones que incluyen linfocitos competentes. In\nvitro se ha logrado encontrar que la eliminación de las células T supresoras puede aumentar la proliferación\nde las UFB-E; se han descrito alteraciones en las células T inmunorreguladoras en sujetos con hipoplasia\nmedular. El empleo de inmunosupresores como la globulina antitimocito (GAT) o la ciclosporina A (CyA)\npuede causar remisiones del padecimiento. Algunos autores han encontrado que las células T supresoras,\nactivadas y productoras de interferón-\nγ\u0003\nson las responsables de la supresión inmunitaria de la hematopoyesis\nen algunos pacientes con hipoplasia medular. El avance en el conocimiento de los mecanismos inmunitarios","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":167,"lines":{"from":7,"to":17}}}}],["817",{"pageContent":"γ\u0003\nson las responsables de la supresión inmunitaria de la hematopoyesis\nen algunos pacientes con hipoplasia medular. El avance en el conocimiento de los mecanismos inmunitarios\ninvolucrados en el padecimiento permitirá un tratamiento más racional de esta enfermedad. Es probable,\nademás, la participación del complemento en la lisis de algunas células hematopoyéticas, ya que algunos\npacientes con hipoplasia medular presentan deficiencias en la expresión de los antígenos CD55, CD59 y\nFLAER en diversos linajes celulares, tal y como sucede en otras hemocitopenias de origen autoinmunitario.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":167,"lines":{"from":17,"to":23}}}}],["818",{"pageContent":"Hipoplasia medular asociada a infección\n\nMuchas infecciones son mielosupresoras; habitualmente la supresión es transitoria y autolimitada cuando se\ntrata de infecciones agudas. En infecciones crónicas, hay mielosupresión y acortamiento de la supervivencia\neritrocítica. Las hepatitis virales por virus B o no-A, no-B, no-C pueden generar hipoplasia medular, lo que se\nconoce como\n \nsíndrome de hepatitis/aplasia\n. Actualmente se considera que 1 de cada 1 000 enfermos de hepatitis\ndesarrolla hipoplasia medular y que el virus responsable es el no-A, no-B, no-C, aunque algunos casos están\nrelacionados con el virus B. Los parvovirus, específicamente el B19, son causa frecuente de hipoplasia medular.\n\nHipoplasia medular causada por parvovirus B19\n\nEste es un virus con DNA, sin envoltura, que infecta células que se replican rápidamente; tiene particu-\nlar predilección por los precursores eritroides de la médula ósea y es responsable de muchas hipoplasias","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":167,"lines":{"from":25,"to":40}}}}],["819",{"pageContent":"Cuadro 10-1.\n \nEtiología de las hipoplasias\n \nmedulares\n\n1. Primaria o\n \nidiopática\n2. Secundaria a\n \nagentes\n \nfísicos o\n \nquímicos\na.\n \nAgentes que causan daño medular\n \ndependiente\n \nde\n \ndosis\nRadiaciones\n \nionizantes\nMedicamentos quimioterapéuticos\nBenceno\nArsénico\nAlcohol\nb. Agentes que causan daño medular por\n \nidiosincracia\nCloranfenicol\nFenilbutazona y similares\nInhibidores de anhidrasa\n \ncarbónica\nSales de\n \nor\no\nMisceláneos\n3.\n \nInfecciones\n4.\n \nTra\n \nstor\n \nnos\n \nmetabólicos\n5. Her\neditaria\n6. Anemia de la insuficiencia renal\n \ncrónica\n7.\n \nAplasia pura de serie r\noja\na.\n \nCongénita\nb.\n \nAdquirida\n\nEl empleo de inmunosupreso-\nres como la globulina antiti-\nmocito (GAT) o la ciclosporina\nA (CyA) puede causar remisio-\nnes del padecimiento.\nLas hepatitis virales por virus\nB o no-A, no-B, no-C pueden\ngenerar hipoplasia medular, lo\nque se conoce como\n \nsíndrome\nde hepatitis/aplasia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":167,"lines":{"from":42,"to":126}}}}],["820",{"pageContent":"141\n\nCAPÍTULO 10. HIPOPLASIAS Y DISPLASIAS MEDULARES","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":168,"lines":{"from":1,"to":3}}}}],["821",{"pageContent":"adquiridas agudas en sujetos con eritropoyesis acelerada. Dada su capacidad genética limitada, para su\nreplicación, los parvovirus dependen por completo de células en síntesis activa de ácido desoxirribonu-\ncleico: aparentemente requieren algún producto de la fase “S” (síntesis de DNA) del ciclo celular para su\ncrecimiento. La palabra\n \nparvo\n \nen latín significa “pequeño”. Los parvovirus son los virus de menor tamaño\nque contienen DNA y pueden infectar a los mamíferos. El parvovirus B19 es un virus autónomo, antigé-\nnicamente distinto de otros parvovirus; una vez que infecta al ser humano, causa depresión de la médula\nósea aproximadamente en siete días. En individuos con supervivencia eritrocítica normal (120 días), es\nposible que la infección pase inadvertida; sin embargo, en sujetos con acortamiento de la supervivencia\neritrocítica por cualquier padecimiento hemolítico (10 a 15 días), la infección puede condicionar una","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":168,"lines":{"from":5,"to":17}}}}],["822",{"pageContent":"eritrocítica por cualquier padecimiento hemolítico (10 a 15 días), la infección puede condicionar una\n“crisis hipoplásica”, caracterizada por un descenso brusco en las cifras de hemoglobina y en el recuento\nde reticulocitos. Dicho tipo de “crisis eritroblastopénicas” se puede presentar en individuos con diver-\nsas condiciones hemolíticas o de acortamiento de la supervivencia eritrocítica. Aproximadamente uno\nde cada tres pacientes con “crisis hipoplásicas” o de eritroblastopenia por parvovirus B19 desarrolla granu-\nlocitopenia o trombocitopenia, o ambas. En los seres humanos, el parvovirus B19 puede causar adicional-\nmente la “quinta enfermedad” exantemática, fetopatía en mujeres embarazadas, hidropesía fetal y cuadros\npoliarticulares clínicamente indistinguibles de la artritis reumatoide.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":168,"lines":{"from":17,"to":24}}}}],["823",{"pageContent":"Anemias hipoplásicas hereditarias o constitucionales","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":168,"lines":{"from":26,"to":26}}}}],["824",{"pageContent":"Las alteraciones congénitas asociadas con insuficiencia de la médula ósea incluyen: a) anemia aplásica\nde Fanconi, b) síndrome de Estren-Dameshek, c) disqueratosis congénita, d) síndrome de Shwach -\nman-Diamond, e) síndrome de Bloom, f) trombocitopenia amegacariocítica, g) síndrome de tromboci -\ntopenia con ausencia de radio y h) anemia aplásica relacionada con síndrome linfoproliferativo asociado\nal cromosoma X.\nEntre el 20 y 30% de las hipoplasias medulares observadas en la infancia son de origen hereditario o ge\n-\nnético. La anemia de Fanconi se transmite con carácter hereditario autosómico recesivo, tiene una frecuencia\ngenética de 1 en 600 a 1 000 casos y se presenta con heterogeneidad en su expresión. Los análisis cromosó-\nmicos presentan un cariotipo normal, con inestabilidad cromosómica que condiciona anormalidades mixtas\ncomo supresiones, roturas cromosómicas, traslocaciones, cromosomas dicéntricos y en anillo, y endorredu-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":168,"lines":{"from":28,"to":38}}}}],["825",{"pageContent":"como supresiones, roturas cromosómicas, traslocaciones, cromosomas dicéntricos y en anillo, y endorredu-\nplicaciones de material genético. En las células de individuos con anemia de Fanconi existe dificultad para\nla síntesis del DNA y alteraciones en reparaciones o arreglos de este ácido, específicamente defectos en la\nreunión de las roturas del DNA. Todo paciente menor de edad con hipoplasia medular debe ser investigado\npara anemia de Fanconi, lo que se hace por medio del cariotipo en presencia de diepoxibutano, que induce\nfractura de los cromosomas en estos pacientes. Existen subgrupos clínicos de anemia constitucional de\nFanconi, como la anemia de Fanconi relacionada con disfunción de médula ósea familiar o el síndrome\nde Estren-Dameshek, en los que los estudios citogenéticos sugieren que las alteraciones cromosómicas son\nsimilares, pero el daño del DNA puede ser solamente parcial. Estas anormalidades no se asocian con altera-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":168,"lines":{"from":38,"to":46}}}}],["826",{"pageContent":"similares, pero el daño del DNA puede ser solamente parcial. Estas anormalidades no se asocian con altera-\nciones físicas importantes, lo que establece la diferencia clínica con anemia aplásica constitucional de Fanco-\nni. La disqueratosis congénita se transmite por medio del cromosoma X; entre el 35 y 50% de los pacientes\ndesarrolla hipoplasia medular. En esta entidad, es posible que el defecto básico se localice en la capacidad de\nreplicación de las células. Algunas observaciones han sugerido que en sujetos con disqueratosis congénita,\nla presencia de material genético viral condiciona la expresión de la anormalidad cromosómica que altera la\nreplicación celular, incluyendo hematopoyesis y, en consecuencia, la aplasia medular. El síndrome de Bloom\nse hereda con carácter autosómico recesivo; es propio de ciertos grupos étnicos como los judíos askenazi,\ny su característica particular es la inestabilidad cromosómica con intercambios de cromátides simétricos y","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":168,"lines":{"from":46,"to":54}}}}],["827",{"pageContent":"y su característica particular es la inestabilidad cromosómica con intercambios de cromátides simétricos y\ncuadrirradiales. En el síndrome linfoproliferativo asociado al cromosoma X se observa una anormalidad\nconstitucional que afecta exclusivamente a las células B y se caracteriza por alteración en la producción de\ngammaglobulinas y proliferación maligna de células B. En apariencia, la expresión genética requiere la par-\nticipación de un genoma viral, de manera específica del virus de Epstein-Barr, el cual altera o sobreexpresa\nla anormalidad cromosómica ya existente.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":168,"lines":{"from":54,"to":59}}}}],["828",{"pageContent":"Cuadro clínico\n\nLa mayoría de los pacientes con hipoplasia medular presentan síndrome anémico, infecciones por neutro-\npenia y síndrome hemorrágico mucocutáneo secundario a trombocitopenia. La presencia de adenopatía\ny esplenomegalia es infrecuente, y casi siempre hace dudar sobre el diagnóstico de hipoplasia de médula\nósea. Cuando se observa adenopatía cervical en estos enfermos, deben investigarse procesos infecciosos\n\nEntre 20 y 30% de las hipo-\nplasias medulares observadas\nen la infancia son de origen\nhereditario o genético.\nLa mayoría de los pacientes con\nhipoplasia medular presentan\nsíndrome anémico, infecciones\npor\n \nneutropenia\n \ny\n \nsíndrome\nhemorrágico mucocutáneo se-\ncundario a trombocitopenia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":168,"lines":{"from":61,"to":83}}}}],["829",{"pageContent":"142\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nlocalizados en la boca (abscesos peridentales, gingivitis, amigdalitis, otitis, etc.). La esplenomegalia puede\nser parte de un estado de septicemia y, en formas muy crónicas de la enfermedad, de cirrosis secundaria a\nsobrecarga de hierro postransfusión. En el caso de las hipoplasias hereditarias o constitucionales, el 80%\nde los pacientes tienen estatura baja y entre el 15 y 50% cursan con alguna de estas alteraciones: manchas\n“café con leche”, sindactilia, disminución del número de huesos del carpo, microsomía, microcefalia, mal-\nformaciones renales, estrabismo, hipogenitalismo, criptorquidia, retraso mental o sordera.\n\nDiagnóstico","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":169,"lines":{"from":1,"to":12}}}}],["830",{"pageContent":"En sangre periférica habitualmente hay pancitopenia. La anemia es normocítica normocrómica o macro-\ncítica y existe reticulocitopenia. La granulocitopenia puede ser grave y puede haber linfocitosis relativa;\nla trombocitopenia casi siempre es intensa. En el aspirado de médula ósea, hay sustitución de esta por\ntejido adiposo y pueden encontrarse células remanentes como basófilos tisulares, linfocitos, plasmocitos\ne histiocitos. Nunca debe establecerse el diagnóstico de hipoplasia medular solo mediante la imagen del\naspirado de médula ósea y el cuadro en sangre periférica. Es imprescindible efectuar una biopsia de hueso\npara valorar de manera precisa la celularidad de la médula y cuantificar la proporción remanente, expre-\nsada en porcentaje.\nLa gravedad de la hipoplasia debe juzgarse con base en varios criterios: se habla de hipoplasia grave\ncuando el recuento corregido de reticulocitos es menor de 1%, el recuento absoluto de neutrófilos es infe-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":169,"lines":{"from":14,"to":23}}}}],["831",{"pageContent":"cuando el recuento corregido de reticulocitos es menor de 1%, el recuento absoluto de neutrófilos es infe-\nrior a 500, el recuento de plaquetas es menor de 20 000 y la celularidad, juzgada por medio de biopsia de\nhueso, inferior a 25%.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":169,"lines":{"from":23,"to":25}}}}],["832",{"pageContent":"Índices pronósticos\n\nPara establecer el pronóstico de forma individualizada se han diseñado distintos índices que han\ndemostrado su eficacia en series independientes. El\n \nInternational Prognostic Scoring System\n \n(IPSS), que\nse muestra en el\n \ncuadro 10-2\n, incluye el porcentaje medular de blastos, cariotipo y número de citopenias.\n\nCuadro 10-2.\n \nÍndice Pronóstico Internacional (IPSS)\n\nPuntos\n \n0\n \n0,5\n \n1\n \n1,5\n \n2\n\nBlastos en médula ósea\n \n< 5%\n \n5-10%\n \n11-20%\n \n21-30%\n\nCariotipo\n \nBueno\n \nIntermedio\n \nMalo\n\nCitopenias\n \n0 o 1\n \n2 o 3\n\nCariotipo\n \nIntermedio\n \nMalo\n\nDependencia transfusional\n \nNo\n \nSí\n\nGrupo de riesgo\n \nBajo\n \nIntermedio-1\n \nIntermedio-2\n \nAlto\n\nPuntuación\n \n0\n \n0,5-1\n \n0,5-1\n \n1,5-2\n \n2,5-3,5\n\nTratamiento","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":169,"lines":{"from":27,"to":114}}}}],["833",{"pageContent":"Grupo de riesgo\n \nBajo\n \nIntermedio-1\n \nIntermedio-2\n \nAlto\n\nPuntuación\n \n0\n \n0,5-1\n \n0,5-1\n \n1,5-2\n \n2,5-3,5\n\nTratamiento\n\nLos objetivos principales del tratamiento de la hipoplasia medular son: 1) apoyar al paciente durante las\ncomplicaciones agudas de la insuficiencia medular, como anemia, trombocitopenia o granulocitopenia;\n2) evitar la exposición del enfermo a otros agentes potencialmente mielotóxicos que pudieran agravar o\nperpetuar la hipoplasia, y 3) intentar estimular la médula ósea residual o abatir la supresión de su funcio-\nnamiento, o ambas cosas.\nEn las transfusiones deben usarse paquetes de eritrocitos o concentrados plaquetarios; las transfusiones\nde granulocitos cada vez se indican menos cuando hay fiebre y granulocitopenia grave, han de usarse antibió\n-\nticos de amplio espectro y antimicóticos, y los factores estimulantes de colonias como el G-CSF pueden ser\nde utilidad para incrementar la cantidad de granulocitos. Deben evitarse las inyecciones intramusculares, las","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":169,"lines":{"from":114,"to":147}}}}],["834",{"pageContent":"Los\n \nobjetivos\n \nprincipales\n \ndel\ntratamiento\n \nde\n \nla\n \nhipoplasia\nmedular son: 1) apoyar al pa-\nciente durante las complicacio-\nnes agudas de la insuficiencia\nmedular, como anemia, trombo-\ncitopenia o granulocitopenia; 2)\nevitar la exposición del enfermo\na otros agentes potencialmente\nmielotóxicos que pudieran agra-\nvar o perpetuar la hipoplasia, y\n3) intentar estimular la médula\nósea residual o abatir la supre-\nsión de su funcionamiento.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":169,"lines":{"from":149,"to":174}}}}],["835",{"pageContent":"143\n\nCAPÍTULO 10. HIPOPLASIAS Y DISPLASIAS MEDULARES","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":170,"lines":{"from":1,"to":3}}}}],["836",{"pageContent":"sustancias mielotóxicas o los medicamentos que interfieran con la función plaquetaria, que podrían agravar\nla diátesis hemorrágica condicionada por la trombocitopenia. El ácido\n \nY\n-aminocaproico, un inhibidor de la\nfibrinólisis, puede ser de utilidad para abatir la tendencia al sangrado cuando hay trombocitopenia grave;\npuede administrarse por vía tanto oral como parenteral. En las formas leves o moderadas de hipoplasia me-\ndular, el empleo de andrógenos puede ser de utilidad para estimular la médula ósea residual. En las formas\ngraves de la enfermedad, el mejor método terapéutico es el trasplante alogénico de células hematopoyéticas\ntotipotenciales, ya sea de médula ósea o de sangre periférica. La inmunosupresión intensa es también de\ngran utilidad y se calcula que alrededor del 50 al 60% de los casos de hipoplasias medulares graves pueden\nresponder a inmunosupresores como la globulina antitimocito (GAT), la ciclosporina A (CyA) y el alem-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":170,"lines":{"from":5,"to":16}}}}],["837",{"pageContent":"responder a inmunosupresores como la globulina antitimocito (GAT), la ciclosporina A (CyA) y el alem-\ntuzumab. Cada vez se emplea más la combinación de estos dos inmunosupresores, que produce remisiones\nen el 80% de los pacientes con formas graves de hipoplasia medular. El empleo inicial de inmunosupresión\nintensa no evita la posibilidad de llevar a cabo, en un segundo tiempo, un trasplante de células hematopo-\nyéticas. Algunos pacientes con hipoplasia medular tratados con esquemas inmunosupresores desarrollan\nfinalmente una enfermedad hemática clonal, como hemoglobinuria paroxística nocturna o incluso leucemia\naguda. El empleo de factores de estimulación de granulocitos puede ser útil en momentos en los que se pre-\ncise incrementar el recuento de granulocitos, pero su efecto es transitorio. Algunos pacientes con hipoplasia\nmedular pueden mejorar sus cuentas plaquetarias con medicamentos análogos de la trombopoyetina, como","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":170,"lines":{"from":16,"to":24}}}}],["838",{"pageContent":"medular pueden mejorar sus cuentas plaquetarias con medicamentos análogos de la trombopoyetina, como\nel romiplostim o el eltrombopag, los cuales también tienen efectos adversos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":170,"lines":{"from":24,"to":25}}}}],["839",{"pageContent":"DISPLASIAS MEDULARES O SÍNDROMES MIELODISPLÁSICOS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":170,"lines":{"from":27,"to":27}}}}],["840",{"pageContent":"Se han utilizado diversos términos para designar un grupo de padecimientos de la médula ósea que se conocen\ncomo\n \ndisplasias medulares\n \no\n \nsíndromes mielodisplásicos\n. Los sinónimos empleados son varios: anemias refrac-\ntarias, anemias arregenerativas, mielodisplasias, síndromes dismielopoyéticos, anemias dishemopoyéticas,\nanemias sideroacrésticas, anemias sideroblásticas, etcétera. Las displasias medulares que se abordan en esta\nsección no se refieren, desde luego, a las displasias de otra médula, la espinal, como podrían ser el mielocele,\nel meningocele o el mielomeningocele. Excluidas las displasias del raquis, las displasias medulares forman un\ngrupo heterogéneo de padecimientos de la médula ósea, adquiridos o heredados, los cuales se caracterizan\npor una eritropoyesis ineficaz que conduce casi siempre a anemia y citopenias variables en la sangre periférica.\nLas formas adquiridas de estos padecimientos\n \n(cuadro 10-3)\n \nson más frecuentes que las heredadas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":170,"lines":{"from":29,"to":48}}}}],["841",{"pageContent":"Las formas adquiridas de estos padecimientos\n \n(cuadro 10-3)\n \nson más frecuentes que las heredadas.\nLas displasias medulares suponen tejido hematopoyético cuantitativamente normal pero cualitativamente\n“defectuoso”, diferencia muy importante para distinguir estos trastornos de las hipoplasias medulares que\nya se mencionaron\n \n(fig. 10-2)\n. A continuación se presenta un breve glosario de términos importantes para\ncomprender las displasias medulares:","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":170,"lines":{"from":48,"to":59}}}}],["842",{"pageContent":"•\n \nDishemopoyesis.\n \nEl concepto de\n \ndishemopoyesis\n \ndebe entenderse como común a todas las formas de\ndisplasias medulares; su presencia, de diversas maneras, es una de sus características.\n\n•\n \nDiseritropoyesis.\n \nSideroblastos en anillo, multicelularidad de eritroblastos, fragmentos nucleares\nde diversos tamaños, cambios megaloblastoides, asincronía en la maduración núcleo-citoplasma de\nlos precursores rojos, anillos de Cabot, cuerpos de Howell-Jolly, etcétera.\n\n•\n \nDisgranulopoyesis.\n \nNeutrófilos hipogranulares o agranulares, hiposegmentación (anomalía de\nPelger-Huet) o hipersegmentación de granulocitos, tinción anormal de gránulos primarios (azu-\nrófilos) de los granulocitos jóvenes en médula ósea, principalmente promielocitos y mielocitos, y\nausencia de gránulos secundarios en granulocitos maduros.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":170,"lines":{"from":61,"to":87}}}}],["843",{"pageContent":"•\n \nDismegacariocitopoyesis.\n \nDisminución del número de megacariocitos, megacariocitos mononu-\ncleares grandes, micromegacariocitos y megacariocitos con múltiples núcleos pequeños separados\n(“núcleos deshilachados”).\nLos síndromes mielodisplásicos son un grupo de padecimientos clonales indolentes que suponen\ncélulas hematopoyéticas totipotenciales anormales, ya que la monoclonalidad de las células de estirpe\nmieloide es característica. Se ha postulado una teoría para explicar los síndromes mielodisplásicos en la\nque coexisten una médula ósea hipercelular con apoptosis incrementada de las células hematopoyéticas,\nesta última derivada del exceso de producción de citocinas: factor de necrosis tumoral\n\u0003 α\n \n(TNF-\nα\n),\nfactor de transformación de crecimiento\n \nβ\n \n(TGF-\nβ\n), interleucina 1\nα\n \n(IL1\nα\n) y enzima convertidora de\ninterleucina 1\nα\n \n(ICE). La proliferación exagerada característica del carácter clonal de la hematopoyesis","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":170,"lines":{"from":89,"to":121}}}}],["844",{"pageContent":"β\n \n(TGF-\nβ\n), interleucina 1\nα\n \n(IL1\nα\n) y enzima convertidora de\ninterleucina 1\nα\n \n(ICE). La proliferación exagerada característica del carácter clonal de la hematopoyesis\nestá asociada con exceso de apoptosis, lo que explicaría la coexistencia de médulas óseas hipercelulares\ncon citopenias en sangre periférica, característica de estas enfermedades.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":170,"lines":{"from":121,"to":136}}}}],["845",{"pageContent":"El concepto de “dishemopoyesis”\ndebe entenderse como común a\ntodas las formas de displasias\nmedulares; su presencia, en di-\nversas maneras, es una caracte-\nrística de las mismas.\nLos síndromes mielodisplásicos\nson un grupo de padecimientos\nclonales indolentes que supo-\nnen\n \ncélulas\n \nhematopoyéticas\ntotipotenciales anormales, ya\nque la monoclonalidad de las\ncélulas de estirpe mieloide es\ncaracterística.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":170,"lines":{"from":138,"to":155}}}}],["846",{"pageContent":"144\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nClasificación\n\nLa clasificación propuesta en 1982 por Bennet, Catovsky, Daniel, Flandrin, Galton, Gralnick y Sultan,\nque forman el grupo FAB (\n¢e French-American-British Cooperative Group\n), se presenta en el cuadro 10-3.\n\n1. Displasia medular tipo I (anemia refractaria indiferenciada)\n\nEsta displasia medular se presenta preferentemente en sujetos mayores de 50 años. Las manifestaciones\nde anemia dominan casi invariablemente el cuadro clínico. En sangre periférica hay reticulocitopenia,\ndiseritropoyesis variable y pocas veces disgranulopoyesis. En los extendidos de médula ósea, la celularidad\nes normal o aumentada, con hiperplasia eritroide, diseritropoyesis o ambas. Las series granulocítica y me-\ngacariocítica casi siempre son normales y en la médula hay menos del 5% de blastos. Solo ocasionalmente\npueden incluirse en esta categoría pacientes con granulocitopenia, trombocitopenia o ambas, sin anemia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":171,"lines":{"from":1,"to":19}}}}],["847",{"pageContent":"2. Displasia medular tipo II (anemia sideroblástica idiopática adquirida)\n\nLa diferencia fundamental con la displasia medular tipo I es que, en médula ósea, más del 15% de los\nprecursores eritroides son sideroblastos en anillo, es decir, células eritroides que exhiben gránulos de\nhemosiderina en torno al núcleo, dispuestos a manera de un anillo perinuclear. En ocasiones, la hemoglo-\nbinización defectuosa de los precursores eritroides da lugar a una población eritrocítica dimórfica. Dado\nque esta condición de dishemopoyesis solo puede distinguirse de la anemia refractaria indiferenciada por\nmedio de tinciones de hemosiderina, es indispensable practicar este estudio en toda médula ósea dishe-\nmopoyética con hiperplasia eritroide con o sin incremento del número de blastos.\n\n3. Displasia medular tipo III (anemia refractaria con exceso de blastos)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":171,"lines":{"from":21,"to":31}}}}],["848",{"pageContent":"3. Displasia medular tipo III (anemia refractaria con exceso de blastos)\n\nEste trastorno aparece en grupos de edad parecidos a los de las displasias medulares tipo I. Siempre hay\nalgún grado de citopenia que afecta dos o más de las series hematopoyéticas.\nLa sangre periférica casi invariablemente muestra anormalidades de dishemopoyesis en las tres series.\nLa disgranulopoyesis es muy frecuente, a diferencia de las displasias medulares tipo I. En sangre peri-\nférica, casi siempre existen blastos que numéricamente deben ser menos de 5% de las células nucleadas.\n\nCuadro 10-3.\n \nClasificación de las displasias medulares adquiridas\n\nCondición\n \nSangre periférica\n \nMédula ósea","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":171,"lines":{"from":31,"to":47}}}}],["849",{"pageContent":"Cuadro 10-3.\n \nClasificación de las displasias medulares adquiridas\n\nCondición\n \nSangre periférica\n \nMédula ósea\n\nDisplasia medular tipo I\n(refractaria indiferenciada)\n \nMenos de 1% blastos\n \nMenos de 5% blastos\nDisplasia medular tipo II\n(sideroblástica adquirida)\n \nMenos de 1% blastos\nMenos de 5% de blastos\nMás de 15% de eritro-\nblastos son “sideroblas-\ntos en anillo”\nDisplasia medular tipo III\n(refractaria con exceso de blastos)\n \nMenos de 5% blastos\n \nBlastos entre 5 y 20%\nDisplasia medular tipo IV\n(leucemia mielomonocítica crónica)\nMonocitosis mayor de 1 × 10\n \n9\n \nL\ny menos de 5% blastos\nMonocitosis y hasta\n20% monoblastos\nDisplasia medular tipo V\n(refractaria con exceso de blastos,\nen transformación)\nMás de 5% blastos\n \nBlastos entre 20 y 30%","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":171,"lines":{"from":47,"to":92}}}}],["850",{"pageContent":"La displasia medular tipo III\n(anemia refractaria con exceso\nde blastos) aparece en grupos de\nedad\n \nparecidos\n \na\n \nlos\n \nde\n \nlas\ndisplasias\n \nmedulares\n \ntipo\n \nI.\nSiempre hay algún grado de\ncitopenia que afecta a dos o más\nde las series hematopoyéticas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":171,"lines":{"from":94,"to":117}}}}],["851",{"pageContent":"145\n\nCAPÍTULO 10. HIPOPLASIAS Y DISPLASIAS MEDULARES","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":172,"lines":{"from":1,"to":3}}}}],["852",{"pageContent":"La médula ósea es hipercelular y muestra grados variables de hiperplasia eritroide o granulocítica. Siem-\npre hay datos de diseritropoyesis, disgranulopoyesis o dismegacariocitopoyesis, o estas dos últimas. Pue\n-\nde haber sideroblastos en anillo. El porcentaje de blastos en médula ósea es, por definición, mayor de\n5% y menor de 20%. Casi siempre hay datos de maduración de blastos a promielocitos y formas más\nevolucionadas de elementos de la serie granulocítica. A pesar de que clásicamente se ha aceptado que\nestos padecimientos constituyen alteraciones de la eritropoyesis y mielopoyesis, y por ende se esperaría\nque los blastos en estos trastornos fueran mieloblastos, monoblastos o megacarioblastos, esto no siempre\nes así. Se han encontrado megacarioblastos, mieloblastos, blastos indiferenciados e incluso linfoblastos.\nEl hallazgo de casos de anemia refractaria con exceso de linfoblastos, afirmación derivada de la presencia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":172,"lines":{"from":5,"to":14}}}}],["853",{"pageContent":"El hallazgo de casos de anemia refractaria con exceso de linfoblastos, afirmación derivada de la presencia\nde marcadores linfoides en los blastos, sugiere que la alteración celular que conduce a estas condiciones de\ndishemopoyesis no ocurre en la célula comprometida a diferenciarse en la serie mieloide, sino en una\ncélula más inmadura, probablemente pluripotencial. El cuadro clínico de los pacientes con displasia\nmedular tipo III es variable. Además de los datos propios de las citopenias involucradas, los enfermos\nsufren fiebre de grado diverso, dolor óseo y, en ocasiones, manifestaciones de hiperhistaminemia, como\nprurito cutáneo, enfermedad péptica, sangrado de tubo digestivo, etcétera.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":172,"lines":{"from":14,"to":20}}}}],["854",{"pageContent":"4. Displasia medular tipo IV (leucemia mielomonocítica crónica)\n\nLa característica que define esta entidad es la monocitosis en sangre periférica mayor de 1 × 10\n \n9\n \n/L, gene-\nralmente asociada con el incremento en granulocitos maduros, con o sin evidencia de disgranulopoyesis.\nEl porcentaje de blastos en sangre periférica es inferior al 5%. La médula semeja la de la displasia medular\ntipo III, pero muestra aumento en monocitos y promonocitos. El número de blastos en médula ósea pue-\nde ser incluso del 20%. Estrictamente, esta condición debería estar clasificada dentro de los síndromes\nmieloproliferativos crónicos y no entre las displasias medulares. Se espera que en el futuro se cambie de\nasignación esta entidad verdaderamente neoplásica.\n\n5. Displasia medular tipo V (anemia refractaria con exceso de blastos, en transformación)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":172,"lines":{"from":22,"to":36}}}}],["855",{"pageContent":"5. Displasia medular tipo V (anemia refractaria con exceso de blastos, en transformación)\n\nEste trastorno incluye casos de citopenias en pacientes de cualquier edad (generalmente con un período\ncorto de síntomas), que no pueden clasificarse en ninguno de los tipos de leucemia aguda mieloide (M0 a\n\nFigura 10-2.\n \nMielodisplasia. Médula ósea hiperplásica (obsérvese la escasez de células adiposas) con ele-\nmentos de las tres series, pero con predominio de precursores de la serie roja, algunos atípicos. No hay\nmegaloblastos y se observan escasas células maduras. (Fotografía cortesía del Dr. Ruy Pérez Tamayo.)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":172,"lines":{"from":36,"to":45}}}}],["856",{"pageContent":"146\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nM7 de la clasificación FAB). Los enfermos tienen más de 5% de blastos en la sangre periférica, así como\nblastos tipos I y II en la médula ósea, entre 20 y 30%, en ocasiones con cuerpos de Auer en los precur-\nsores granulocíticos. En la actualidad, esta forma de mielodisplasia se considera estrictamente como una\nleucemia aguda.\nEl\n \ncuadro 10-4\n \nmuestra la clasificación de los síndromes mielodisplásicos de acuerdo a la Organiza-\nción Mundial de la Salud (OMS), que es más moderna y que algunos hematólogos prefieren usar.\n\nDisplasias medulares secundarias","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":173,"lines":{"from":1,"to":16}}}}],["857",{"pageContent":"Displasias medulares secundarias\n\nLas leucemias agudas mieloides secundarias al empleo de radioterapia o quimioterapia, o ambas, casi\nsiempre evolucionan a través de una fase de dishemopoyesis, que puede ser indistinguible de cualquiera\nde las condiciones antes descritas (displasias medulares tipos I a V). Además se asocian con ciertas ca-\nracterísticas de la médula ósea, como hipocelularidad, mielofibrosis con hipercelularidad y numerosos\nsideroblastos en anillo. Las leucemias agudas secundarias a estas condiciones son de muy difícil control\ncon tratamiento específico y tienen pronóstico malo.\n\nAlteraciones cromosómicas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":173,"lines":{"from":16,"to":25}}}}],["858",{"pageContent":"Alteraciones cromosómicas\n\nEl 30% de los pacientes con displasias medulares presentan alteraciones cromosómicas, cifra que se in-\ncrementa incluso más de 50% si se incluyen las mielodisplasias que evolucionan a leucemia aguda. Las\nanomalías más frecuentes afectan los cromosomas 5, 7, 8 y 17, en especial las monosomías en 5 y 7,\nisocromosomas en el brazo largo del 17 o trisomía del 8. Es de particular interés el síndrome de 5q (–),\nque cursa con anemia macrocítica, recuentos plaquetarios normales o aumentados, hipoplasia eritroide y\nmegacariocitos hipolobulados.\n\nPronóstico","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":173,"lines":{"from":25,"to":34}}}}],["859",{"pageContent":"Pronóstico\n\nEstos padecimientos pueden considerarse como premalignos en tanto que algunos de ellos evolucionan\na formas francas de leucemia aguda; esta es la razón por la que también se han llamado “preleucemias”,\ntérmino estrictamente incorrecto dado que no todas las displasias medulares evolucionan a leucemia agu-\nda, ni todas las leucemias agudas son precedidas por una fase de displasia medular. Algunos autores han\nencontrado que incluso el 22% de las displasias medulares culminan en leucemia aguda; otros señalan\n\nCuadro 10-4.\n \nClasificación de la OMS\n\nSubtipo\nmorfológico\n \nBlastos SP\n \nBlastos MO\n \nSideroblastos\nen anillo MO\nSider\noblastos\nen anillo MO","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":173,"lines":{"from":34,"to":57}}}}],["860",{"pageContent":"Cuadro 10-4.\n \nClasificación de la OMS\n\nSubtipo\nmorfológico\n \nBlastos SP\n \nBlastos MO\n \nSideroblastos\nen anillo MO\nSider\noblastos\nen anillo MO\n\nAR\n \nsimple\n \n< 1%\n \n< 5%\n \n≤ 15%\n \nSolo\n \neritr\noide\nAR\n \nsideroblástica\n \n< 1%\n \n< 5%\n \n< 15%\n \nSolo\n \neritr\noide\nCitopenia\n \nrefrac-\ntaria con displasia\nmultilineal\n< 1%\n \n< 5%\n \nIndiferente\nAl menos\nde\n \n2\n \nlíneas\nhematopoyéticas\nAREB\nTipo 1\nTipo 2\n< 1%\n1-5%\n6-19%\n5-19%\n5-19%\n10-19%\nIndiferente\n \nIndifer\nente\nSíndrome 5q–\n \n< 5%\n \n< 5%\n \nIndiferente\n \nIndifer\nente\nSMD\n \ninclasificable\n \n< 1%\n \n< 5%\n \nIndiferente\n \nDe línea\n \nmieloide\no\n \nmegacariocítica\n\nLas leucemias agudas mieloi-\ndes secundarias al empleo de\nradioterapia o quimioterapia,\no ambas, casi siempre evolu-\ncionan a través de una fase de\ndishemopoyesis que puede ser\nindistinguible de las displa-\nsias medulares tipos I a V.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":173,"lines":{"from":57,"to":166}}}}],["861",{"pageContent":"147\n\nCAPÍTULO 10. HIPOPLASIAS Y DISPLASIAS MEDULARES\n\nque la proporción de casos que evoluciona a este tipo de leucemia es del 10%. Mientras más alteraciones\ncromosómicas y más blastos existan en la médula ósea, el riesgo de evolucionar a leucemia aguda es mayor;\nasimismo, si existen conglomerados de blastos (agregados de precursores granulocíticos inmaduros) en la\nbiopsia de hueso, el pronóstico es más grave. Las displasias medulares secundarias a radioterapia o qui-\nmioterapia tienen mayor riesgo de progresión a leucemia aguda; mientras más grave sea la pancitopenia\nen sangre periférica, el pronóstico será peor.\n\nTratamiento","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":174,"lines":{"from":1,"to":12}}}}],["862",{"pageContent":"No hay actualmente una terapéutica de elección para los pacientes que sufren displasias medulares.\nLas transfusiones de paquetes de eritrocitos o plaquetas, o ambos, así como el apoyo con antibióticos\nde amplio espectro o antimicóticos deben emplearse en casos necesarios. El uso de andrógenos ana -\nbólicos (oximetolona, mesterolona, danazol) tiene utilidad en algunos enfermos con mielodisplasias,\nprincipalmente en la tipo I, donde se ha informado que incluso el 60% de los enfermos puede tener\nrespuestas favorables. En las mielodisplasias tipo II, hay comunicaciones anecdóticas de respuesta\na la piridoxina, que se sigue empleando a razón de 100 mg/día por lo menos durante 3 meses. La\nposibilidad de respuesta con este tratamiento es del orden del 5%. Existen también informes anecdó -\nticos de mielodisplasias tipo II, que han respondido a azatioprina y ácido nicotínico. Los derivados\ndel ácido retinoico, que son poco tóxicos, pueden ser útiles en algunos casos. En casos de displasias","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":174,"lines":{"from":14,"to":23}}}}],["863",{"pageContent":"del ácido retinoico, que son poco tóxicos, pueden ser útiles en algunos casos. En casos de displasias\nmedulares con mayor probabilidad de progresar a leucemia aguda (de riesgo alto), se han empleado\ndosis bajas de algunos antineoplásicos como arabinósido de citosina (10 mg/m\n \n2\n \n/día, por vía subcu-\ntánea, en cursos de 14 a 21 días consecutivos), con lo que se han logrado respuestas satisfactorias en\nel 25 a 50% de los pacientes. El mecanismo de acción de estos tratamientos supone probablemente\nvarios efectos, entre los que es posible citar citorreducción de la clona maligna e inducción de di -\nferenciación celular. Otros agentes inductores de diferenciación no parecen ser de mucha utilidad.\nLas hormonas hematopoyéticas, así como los factores de estimulación de granulocitos y monocitos,\nla eritropoyetina (EPO) o la darbepoyetina, pueden mejorar las citopenias en sangre periférica. La\nEPO humana recombinante asociada con factores de crecimiento hemolinfopoyético ha sido útil en","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":174,"lines":{"from":23,"to":36}}}}],["864",{"pageContent":"la eritropoyetina (EPO) o la darbepoyetina, pueden mejorar las citopenias en sangre periférica. La\nEPO humana recombinante asociada con factores de crecimiento hemolinfopoyético ha sido útil en\nel tratamiento de mielodisplasias de riesgo alto. Se ha propuesto una terapia “anticitocinas” emplean -\ndo pentoxifilina o su metabolito lisofilina, que inhiben el TNF-\nα\n, combinada con ciprofloxacino, que\ndisminuye el metabolismo hepático de la pentoxiflina, y con corticoides del tipo de la dexametasona.\nEste tratamiento, llamado PCD (\n \nP\nentoxifilina,\n \nC\niprofloxacino y\n \nD\nexametasona), podría ser útil en\nel tratamiento de las citopenias en algunos pacientes con síndromes mielodisplásicos. Recientemente\nse ha empleado la azacitidina con resultados aparentemente halagüeños, así como la decitabina, la\nclofarabina, la talidomida y el vorinostat. En los pacientes con deleción del brazo largo del cromo -\nsoma 5 (5q–), el empleo de lenalidomida ha tenido buenos resultados. El trasplante de médula ósea","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":174,"lines":{"from":36,"to":56}}}}],["865",{"pageContent":"clofarabina, la talidomida y el vorinostat. En los pacientes con deleción del brazo largo del cromo -\nsoma 5 (5q–), el empleo de lenalidomida ha tenido buenos resultados. El trasplante de médula ósea\nes la única opción verdaderamente curativa en las mielodisplasias, pero no puede ofrecerse a todos\nlos pacientes que las sufren. Los agentes análogos de la trombopoyetina, como el romiplostim o el\neltrombopag, han mostrado ser útiles en la mejoría de la trombocitopenia asociada a los síndromes\nmielodisplásicos.\nEn la actualidad, se acepta que una vez que se hace el diagnóstico de síndrome mielodisplásico, debe\nhacerse observación del caso: si la enfermedad permanece estable, es razonable llevar a cabo solo trata-\nmiento de soporte con antibióticos, transfusiones y factores de crecimiento. Si la enfermedad tiene un\ncurso progresivo, pueden intentarse tratamientos citotóxicos, trasplante de médula ósea o modificadores","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":174,"lines":{"from":56,"to":65}}}}],["866",{"pageContent":"curso progresivo, pueden intentarse tratamientos citotóxicos, trasplante de médula ósea o modificadores\nde la respuesta biológica. La quimioterapia agresiva, seguida o no de trasplante de médula ósea, de manera\nsimilar al tratamiento de las leucemias agudas, puede ser de utilidad en las formas de displasia con exceso\nde blastos o en transformación.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":174,"lines":{"from":65,"to":68}}}}],["867",{"pageContent":"CONCLUSIONES\n\n•\n \nLas hipoplasias medulares involucran la disminución absoluta del tejido hematopoyético en la médula\nósea, en tanto que en las displasias medulares la alteración principal estriba en el funcionamiento\ninadecuado de la médula ósea.\n\n•\n \nLa principal etiología de las hipoplasias medulares es autoinmunitaria.\n\n•\n \nEs fundamental una adecuada y correcta clasificación de los pacientes con mielodisplasia para realizar\nun pronóstico y tratamiento certeros.\n\nLas displasias medulares se-\ncundarias\n \na\n \nradioterapia\n \no\nquimioterapia\n \ntienen\n \nmayor\nriesgo de progresión a leucemia\naguda; mientras más grave\nsea la pancitopenia en sangre\nperiférica, el pronóstico será\npeor.\nLa EPO humana recombi-\nnante asociada con factores de\ncrecimiento hemolinfopoyético\nha sido útil en mielodisplasias\nde riesgo alto.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":174,"lines":{"from":70,"to":109}}}}],["868",{"pageContent":"148\n \nFUNDAMENTOS DE HEMATOLOGÍA\nPREGUNTAS DE AUTOEVALUACIÓN\n\n1. ¿Cuál es la etiología más frecuente de hipoplasia medular?\na.\n \nInfecciosa\nb. Hereditaria\nc.\n \nAutoinmunitaria\n2. ¿Cuáles son las células linfoides que suprimen la hematopoyesis en la hipoplasia medular?:\na.\n \nLinfocitos T cooperadores\nb. Linfocitos T productores de interferón\nc.\n \nLinfocitos B\n3. ¿Cuál es el tratamiento de elección inicial de la hipoplasia medular?\na.\n \nInmunosupresión intensa\nb. Trasplante de médula ósea\nc.\n \nNo hay tratamiento\n4. ¿Cuál es el tratamiento de elección de la mielodisplasia con deleción del brazo largo del cromo-\nsoma 5 (5q–) ?\na.\n \nRomiplostim\nb. Lenalidomida\nc.\n \nEltrombopag\n5. ¿En qué tipo de mielodisplasia tienen utilidad algunos andrógenos anabólicos?\na.\n \nTipo I\nb. Tipo III\nc.\n \nTipo V\n\nBIBLIOGRAFÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":175,"lines":{"from":1,"to":48}}}}],["869",{"pageContent":"Bennet JM, Catovsky D, et al. ·e French American British (FAB) Cooperative Group. Proposals for the classifica-\ntion of the myelodisplastic syndromes. Brit J Haematol. 1982; 51: 189.\nDelgado-Lamas JL, López-Karpovitch X, et al. Low doses of high-potency antithymocyte globulin (ATG) in severe\naplastic anemia: Experience with the Mexican ATG. Acta Haematol. 1989; 81: 70-74.\nDorantes-Mesa S. Nuevas perspectivas en la anemia aplásica. Gac Med Méx. 1989; 125: 341-343.\nFanconi G. Familiäre infantile pernizosaartige anämie (perniziöses blutbild und konstitution). Jahrb Kinderheilk\n1927; 117: 257-280.\nGómez-Almaguer D, Jaime-Pérez JC, Garza-Rodríguez V, Chapa-Rodríguez A, Tarín-Arzaga LC, Herrera-Garza JL, et\nal. Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia. Ann Hematol. 2010; 89: 299-303.\nHoff brand AV, Pettit JE. Essential hematology. London: Blackwell Scientific Publications; 1993. p. 121-140.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":175,"lines":{"from":50,"to":59}}}}],["870",{"pageContent":"Hoff brand AV, Pettit JE. Essential hematology. London: Blackwell Scientific Publications; 1993. p. 121-140.\nJaime-Pérez JC, Ruiz-Argüelles GJ, Gómez-Almaguer D. Haematopoietic stem cell transplantation to treat aplastic\nanemia. Expert Opin Biol ·er. 2005: 5: 617-626.\nRaza A, Mundle S, Shetty V, et al. A paradigm shift in myelodysplatic syndromes. Leukemia. 1996; 10: 1648-1652.\nRuiz-Argüelles A, León-Lloret M, Richard-Patin Y, Llorente L, Ruiz-Argüelles GJ. Acquired deficiency of CD55\nand CD59 in autoimmune hemocytopenias. En: Veskler BA, ed. Leading edge immunology research. New York:\nNova Science Publishing; 2006. p. 79-94.\nRuiz-Argüelles A, Ruiz-González JD, et al. Preparación y características de una globulina gamma equina antitimo -\ncitos humanos producida en México. Rev Invest Clin Mex. 1986; 38: 273-278.\nRuiz-Argüelles GJ. Aplasia pura de serie roja. En: López-Borrasca A, ed. Enciclopedia de hematología iberoameri -\ncana. Salamanca: Ediciones Universidad de Salamanca; 1992. p. 535-539.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":175,"lines":{"from":59,"to":69}}}}],["871",{"pageContent":"149\n\nCAPÍTULO 10. HIPOPLASIAS Y DISPLASIAS MEDULARES","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":176,"lines":{"from":1,"to":3}}}}],["872",{"pageContent":"Ruiz-Argüelles GJ. Clasificación de las anemias dishemopoyéticas. Rev Invest Clin (Mex). 1983; 35: 1-2.\nRuiz-Argüelles GJ, Díaz-Jouanen E. ¿Existen formas autoinmnunes de aplasia medular? Rev Invest Clin Mex. 1979;\n31: 195-198.\nRuiz-Argüelles GJ, Katzmann JA, et al. Lymphocyte subsets in patients with aplastic anemia. Am J Hematol. 1984;\n16:267-275.\nRuiz-Argüelles GJ. Síndromes mielodisplásicos. Medicine. 1985; 9: 556-560.\nSánchez-Medal L, Ruiz-Argüelles GJ. Introducción y anemia. En: Jinich H, ed. Tratado de medicina interna. Méxi-\nco: El Manual Moderno; 1988. p. 403-418.\nVadhan-Raj, Keating M, et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in\npatients with myelodysplastic syndromes. N Engl J Med. 1987; 317: 1545.\nYoung NS, Barret AJ. ·e treatment of severe aplastic anemia. Blood. 1995; 85: 3367.\nZoumbos NC, Gascón P, et al. Circulating activated suppresor T lymphocytes in aplastic anemia. N Engl J Med.\n1985; 312: 257.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":176,"lines":{"from":5,"to":17}}}}],["873",{"pageContent":"RESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\n1.\n \nc\n2.\n \nb\n3.\n \na\n4.\n \nb\n5.\n \na","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":176,"lines":{"from":19,"to":35}}}}],["874",{"pageContent":"151\n\nINTRODUCCIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":178,"lines":{"from":1,"to":3}}}}],["875",{"pageContent":"Las anemias debidas a padecimientos no hemáticos constituyen una gran mayoría en comparación con\naquellas que se originan por enfermedades primariamente hemáticas. Las primeras forman el grupo\nmás numeroso de pacientes hospitalizados con anemia, tanto en adultos como en niños, al igual que\nsucede en los enfermos atendidos en consulta externa.\nLos trastornos no hemáticos capaces de producir anemia son muy numerosos. Debido a que gene -\nralmente implica padecimientos de evolución crónica, se ha creado el apartado de “anemia de trastornos\ncrónicos” (ATC), en el cual se suscriben mecanismos patogénicos comunes para anemias de origen tan\ndisímbolo como infecciones, neoplasias, inflamaciones, traumatismos y “misceláneas”. Ciertamente los\nmecanismos de la ATC constituyen una parte importante en la producción de la anemia de las infec-\nciones, inflamaciones y neoplasias malignas, pero existen también causas particulares para cada una de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":178,"lines":{"from":5,"to":14}}}}],["876",{"pageContent":"mecanismos de la ATC constituyen una parte importante en la producción de la anemia de las infec-\nciones, inflamaciones y neoplasias malignas, pero existen también causas particulares para cada una de\nellas que frecuentemente condicionan su producción. Por otro lado, se considerarán también algunos\npadecimientos en los cuales la anemia es independiente de los mecanismos productores de la ATC.\nInicialmente analizaremos de manera breve en qué consiste la ATC y luego se estudiarán por se-\nparado, de acuerdo a la frecuencia con la que suelen observarse en la práctica médica, los principales\npadecimientos no hemáticos que comúnmente producen anemia. Se enfocarán los mecanismos bási-\ncos de su producción y se apuntarán los recursos racionales de tratamiento.\nLas principales anemias secundarias a padecimientos no hemáticos son:","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":178,"lines":{"from":14,"to":22}}}}],["877",{"pageContent":"•\n \nAnemia de los trastornos crónicos\n\n•\n \nAnemias secundarias a infecciones\n\n•\n \nAnemia de la insuficiencia renal crónica\n\nCAPÍTULO 11\n\nANEMIAS SECUNDARIAS\nA PADECIMIENTOS\nNO HEMÁTICOS\n\nEnrique Torre López\nJosé Salazar Pachicano\nLas anemias debidas a pade-\ncimientos no hemáticos cons-\ntituyen\n \nuna\n \ngran\n \nmayoría\nen comparación con las que\nse originan por enfermedades\nprimariamente hemáticas.\n\nObjetivos de aprendizaje\n\n•\n \nConocer las principales causas de las anemias secundarias a padecimientos no hemáticos.\n\n•\n \nSeñalar las anemias de los trastornos crónicos y sus mecanismos de producción.\n\n•\n \nComprender la fisiopatología y el tratamiento de la anemia de la insuficiencia renal crónica.\n\n•\n \nReconocer los mecanismos y las causas de la anemia en el etilismo crónico.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":178,"lines":{"from":24,"to":73}}}}],["878",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n152\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\n•\n \nAnemias secundarias a trastornos endocrinos\n\n•\n \nAnemias secundarias a neoplasias malignas no hemáticas\n\n•\n \nAnemias secundarias a alcoholismo y a cirrosis\n\n•\n \nAnemias secundarias a inflamaciones crónicas\n\n•\n \nAnemias por desnutrición\n\nANEMIA DE LOS TRASTORNOS CRÓNICOS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":179,"lines":{"from":1,"to":27}}}}],["879",{"pageContent":"De manera simplificada puede decirse que esta anemia es la que acompaña a los padecimientos infeccio-\nsos, inflamatorios y neoplásicos de evolución crónica. Generalmente se trata de anemias de moderada in-\ntensidad, normocíticas normocrómicas, de entre 8 y 11 g/dL de hemoglobina. Las causas de la anemia de\nlos trastornos crónicos (ATC) siguen en discusión. Mencionaremos cuatro mecanismos que básicamente\ncondicionan su producción:\n1.\n \nAlteración en el metabolismo del hierro:\n \nconstituye la característica más distintiva y, a la vez, la más\nfácil de identificar. Esencialmente existe hipoferremia en presencia de hierro de depósito elevado. Las\nrazones de esta profunda alteración en el metabolismo del hierro no están claras, pero sí se sabe que la\ninterleucina 1 (IL-1) va a estimular la síntesis de la apoferritina, la cual inmoviliza el hierro intracelu\n-\nlar. Por otro lado, hay liberación de lactoferrina (presente en gránulos de neutrófilos), la cual no tiene","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":179,"lines":{"from":29,"to":43}}}}],["880",{"pageContent":"-\nlar. Por otro lado, hay liberación de lactoferrina (presente en gránulos de neutrófilos), la cual no tiene\ncapacidad de donar hierro a los eritroblastos, sino que lo cede a los macrófagos. Estos hechos, la inmo\n-\nvilización del hierro intracelular y la transferencia de este metal a los macrófagos, explican la aparente\nparadoja de la hipoferremia con aumento de depósitos de hierro. Por laboratorio clínico se encuentra:","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":179,"lines":{"from":43,"to":48}}}}],["881",{"pageContent":"•\n \nHierro sérico bajo con capacidad de fijación normal o disminuida (en contraposición a la anemia\nferropriva, en la que la última está aumentada)\n \n(fig. 11-1)\n. El índice de saturación de la transfe-\nrrina es normal (arriba de 15%).\n\n•\n \nNivel bajo de transferrina.\n\n•\n \nConcentraciones altas de ferritina.\n\n•\n \nHemosiderina aumentada en médula ósea.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":179,"lines":{"from":50,"to":69}}}}],["882",{"pageContent":"•\n \nSideroblastos disminuidos.\n2.\n \nDestrucción eritrocítica exagerada:\n \nla vida de los eritrocitos se encuentra disminuida alrededor\nde 20 a 30% en la ATC. El defecto responsable es extracorpuscular, ya que los eritrocitos de los\npacientes que se transfunden a receptores normales tienen supervivencia normal. La naturaleza de\nesta alteración radica –como veremos más adelante– en la activación inmunitaria de los macrófa-\ngos, inducida por infección, inflamación o cáncer.\n3.\n \nEritropoyetina e insuficiencia de la médula ósea:\n \nla producción de la eritropoyetina endógena\n(EPO) está regulada, esencialmente, por la hipoxia tisular y por el grado de anemia. El nivel\nde EPO en suero es inversamente proporcional a los niveles de hemoglobina, como sucede, por\nejemplo, en la anemia ferropriva. En la ATC, en cambio, el nivel de EPO, aunque generalmente\nestá aumentado, es menor de lo que se esperaría para la magnitud de la anemia. Por otro lado, su","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":179,"lines":{"from":71,"to":91}}}}],["883",{"pageContent":"ejemplo, en la anemia ferropriva. En la ATC, en cambio, el nivel de EPO, aunque generalmente\nestá aumentado, es menor de lo que se esperaría para la magnitud de la anemia. Por otro lado, su\nacción sobre la médula ósea está inhibida. Estos dos factores, disminución relativa de EPO y\nsu inhibición, condicionan la insuficiente producción eritropoyética de la médula ósea.\n4.\n \nMacrófagos y citocinas:\n \npor último, la fisiopatogenia de la ATC está condicionada, esencialmente, a\nla activación del sistema inmunitario y a la elaboración de citocinas por los macrófagos. Mencionamos\nya la acción de la IL-1 en el metabolismo alterado del hierro. Aparte de esta citocina, que participa\ntambién en la destrucción eritrocítica exagerada y en la inhibición de la producción y de la acción de la\nEPO, existen otras que actúan en estos mecanismos; mencionaremos únicamente el factor de necrosis\ntumoral (TNF), el interferón g y el factor transformador de crecimiento\n \nβ\n \n(TGF-\nβ\n).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":179,"lines":{"from":91,"to":110}}}}],["884",{"pageContent":"Diagnóstico\n\nDeberá hacerse dentro del contexto clínico del paciente y del tipo de enfermedad crónica que sufra.\nHabitualmente se trata de una anemia de grado moderado (9 a 11 g/dL de hemoglobina) normocítica\nnormocrómica; sin embargo, en ocasiones se aprecian hipocromía y microcitosis, lo cual plantea el diag-\nnóstico diferencial con la anemia por deficiencia de hierro. Esto último es importante, ya que la conducta\nterapéutica es radicalmente diferente.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":179,"lines":{"from":112,"to":118}}}}],["885",{"pageContent":"De manera simplificada puede\ndecirse que la anemia de los\ntrastornos crónicos es la que\nacompaña a padecimientos in-\nfecciosos, inflamatorios y neo-\nplásicos, de evolución crónica.\nEl nivel de EPO en suero es\ninversamente proporcional a\nlos niveles de hemoglobina,\ncomo sucede, por ejemplo, en\nla anemia ferropriva.\nHabitualmente se trata de una\nanemia\n \nde\n \ngrado\n \nmoderado\n(9 a 11 g/dL de hemoglobina)\nnormocítica normocrómica; sin\nembargo, en ocasiones se apre-\ncian hipocromía y microcitosis,\nlo cual plantea el diagnóstico\ndiferencial con la anemia por\ndeficiencia de hierro.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":179,"lines":{"from":120,"to":145}}}}],["886",{"pageContent":"153\n\nCAPÍTULO 11. ANEMIAS SECUNDARIAS A PADECIMIENTOS NO HEMÁTICOS\n\nOtros estudios útiles para precisar el diagnóstico son, especialmente, la determinación de ferritina, que\nindica los niveles de hierro total, esto es, el existente tanto en sangre como en los sitios de depósito. En el\n\ncuadro 11-1\n \nse sintetizan las alteraciones metabólicas del hierro en las dos situaciones comentadas.\n\nTratamiento\n\nComo lineamientos generales para el tratamiento de este tipo de anemias, es importante mencionar los\nsiguientes puntos:\n\n•\n \nComo en todo paciente con anemia, la investigación adecuada del origen de esta permitirá realizar\nun tratamiento eficaz.\n\n•\n \nAunque con frecuencia se encuentra ferropenia en sangre, no debe administrarse hierro; no solo porque\nresulta innecesario, sino porque puede agravar la acumulación de este metal en los sitios de depósito.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":180,"lines":{"from":1,"to":25}}}}],["887",{"pageContent":"•\n \nLa administración de eritropoyetina recombinante humana (EPOrHu) debe considerarse después\nde haber valorado los beneficios que sobre la anemia tengan el tratamiento de la enfermedad de base\ny la corrección de posibles deficiencias de factores antianémicos.\n\n•\n \nLa transfusión de sangre, en paquete globular, debe hacerse únicamente cuando hayan sido valo-\nrados de manera adecuada los incisos anteriores y cuando el grado de anemia origine descompen -\nsación cardiorrespiratoria. La sola cifra del nivel de hemoglobina nunca debe ser el dato único para\ntransfundir al paciente.\n\nANEMIAS SECUNDARIAS A INFECCIONES","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":180,"lines":{"from":27,"to":40}}}}],["888",{"pageContent":"ANEMIAS SECUNDARIAS A INFECCIONES\n\nLa anemia es una complicación muy común de los padecimientos infecciosos. Los enfermos con infección\ncrónica invariablemente presentan cierto grado de anemia. Es posible generalizar y decir que cualquier mi\n-\ncroorganismo patógeno que persista más de 2 a 3 semanas en los tejidos humanos es capaz de producir anemia.\nSi se toma en cuenta el gran número de padecimientos infecciosos y los diversos mecanismos que pueden\ncausar anemia, su estudio y clasificación resultan complicados. Existen, sin embargo, grupos que comparten\ncaracterísticas básicamente comunes: 1) anemias secundarias a infecciones crónicas; 2) anemias secundarias\na padecimientos infecciosos en las que la hemólisis es el mecanismo principal, y 3) anemia asociada al sida.\n\nAnemias secundarias a infecciones crónicas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":180,"lines":{"from":40,"to":51}}}}],["889",{"pageContent":"Anemias secundarias a infecciones crónicas\n\nEstas anemias se desarrollan de modo gradual y frecuentemente los niveles de hemoglobina varían entre\n9 y 12 g/dL. Este tipo de infecciones ocasionan manifestaciones generalizadas como fiebre y pérdida de\npeso. La gravedad de la anemia tiene cierta correlación con la intensidad de estos síntomas y con los signos\nde inflamación y supuración.\nLos mecanismos de esta forma de anemia son característicamente los que corresponden a la llamada\n“anemia de los trastornos crónicos”, los cuales se han mencionado previamente. La disminución de hierro\n\nCuadro 11-1.\n \nAlteraciones en el metabolismo del hierro\n\nDeficiencia de hierro\n \nTrastornos crónicos\nSangre\n\nHierro sérico\nCapacidad de fijación\nÍndice de saturación\nTransferrina\n(capacidad total de fijación)\nFerritina\nDisminuido\nAlta\nBajo\nAlta\nBaja\nDisminuido\nNormal o baja\nNormal o alto\nBaja\nNormal o alta\n\nMédula ósea","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":180,"lines":{"from":51,"to":86}}}}],["890",{"pageContent":"Médula ósea\n\nHierro de depósito\n(hemosiderina)\nSideroblastos\nBajo o ausente\nNormales o bajos\nAumentado\nBajos o ausentes\n\nLos\n \nenfermos\n \ncon\n \ninfección\ncrónica invariablemente pre-\nsentan cierto grado de ane-\nmia. Es posible generalizar y\ndecir que cualquier microor-\nganismo patógeno que persista\nmás de 2 a 3 semanas en los\ntejidos humanos es capaz de\nproducir anemia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":180,"lines":{"from":86,"to":110}}}}],["891",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n154\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nplasmático, según han señalado diversos autores, desempeña un mecanismo de adaptación en contra de\nlas bacterias que utilizan este elemento para aumentar su virulencia.\nLos ejemplos de entidades crónicas, tanto bacterianas como micóticas, capaces de producir esta forma\nde anemia son muy numerosos. En el\n \ncuadro 11-2\n \nse anotan los principales padecimientos y sus agentes\netiológicos más comunes.\n\nAnemias por hemólisis exagerada","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":181,"lines":{"from":1,"to":17}}}}],["892",{"pageContent":"Anemias por hemólisis exagerada\n\nLas anemias hemolíticas pueden dividirse en dos grupos: las mediadas por anticuerpos (ya analizadas en el\ncap. 9) y las que son producidas por efecto directo del agente patógeno. En estas últimas, no existe clara evi\n-\ndencia de algún defecto intrínseco en los eritrocitos ni de la presencia de anticuerpos dirigidos contra estas\ncélulas. Se trata, pues, de anemias hemolíticas no inmunitarias que son consecuencia de la acción directa del\nagente infeccioso en contra del eritrocito o de sus productos. Se comentan brevemente los padecimientos más\ncomunes de este grupo, producidos tanto por protozoarios como por bacterias, en el\n \ncuadro 11-3\n.\n\nPaludismo\n\nMéxico, Centroamérica y Haití son zonas endémicas de paludismo. En la República Mexicana, a pesar\nde las extensas campañas para su erradicación, continúa habiendo casos transmitidos tanto por\n \nAnopheles","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":181,"lines":{"from":17,"to":35}}}}],["893",{"pageContent":"como por transfusión sanguínea.\nLa anemia es una manifestación común del paludismo. Su prevalencia y grado dependen del estado\nnutricional e inmunitario de los pacientes. La anemia tiende a ser más común y más profunda en razón\ninversa de la edad.\n\nPatogenia\n\nLa mayoría de las manifestaciones hematológicas del paludismo están en relación con la invasión del\neritrocito por el parásito. De las especies que infectan al ser humano,\n \nel P. vivax\n \ny el\n \nP. ovale\n \ninvaden solo\nlos reticulocitos; el\n \nP. malarie\n \nataca únicamente células maduras, y el\n \nP. falciparum\n \ninfecta eritrocitos en\ntodos los estadios de maduración. Esto explica la mayor intensidad de la infección producida por la última\nespecie. Tales patrones de invasión sugieren que las diferentes especies plasmodiales utilizan diversos\nreceptores. Los factores más importantes en la producción de esta anemia hemolítica son la digestión de\nla hemoglobina y la rotura celular originadas por invasión eritrocítica.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":181,"lines":{"from":37,"to":66}}}}],["894",{"pageContent":"Figura 11-1.\n \nHierro sérico y capacidad total de fijación a la transferrina en condiciones normales, en tras-\ntornos crónicos y en otros padecimientos.\n\nEn la República Mexicana, a\npesar de las extensas campañas\npara su erradicación, continúa\nhabiendo casos trasmitidos tanto\npor\n \nAnopheles\n \ncomo por trans-\nfusión sanguínea.\nLas anemias hemolíticas pue-\nden dividirse en dos grupos: las\nmediadas por anticuerpos y las\nque son producidas por efecto\ndirecto del agente patógeno.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":181,"lines":{"from":68,"to":87}}}}],["895",{"pageContent":"155\n\nCAPÍTULO 11. ANEMIAS SECUNDARIAS A PADECIMIENTOS NO HEMÁTICOS\n\nOtras infecciones por protozoarios\n\nEn casos de toxoplasmosis, tanto congénita como adquirida, se ha comunicado anemia hemolítica, así\ncomo en los de\n \nkala-azar\n \n(leishmaniosis visceral). La anemia por “enfermedad del sueño”, en África, es un\nhallazgo muy común. Esta entidad, a menudo fatal, es causada por\n \nTrypanosoma gambiense\n \ny\n \nT. rhodesiense\n;\nla infección por este último produce un curso más crónico. Estos parásitos son transmitidos al ser humano\ny a los animales domésticos por la mosca tse-tsé.\n\nBartonelosis\n\nUna anemia hemolítica grave y aguda es producida por un organismo calificado como bacilo flagelado,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":182,"lines":{"from":1,"to":26}}}}],["896",{"pageContent":"Bartonelosis\n\nUna anemia hemolítica grave y aguda es producida por un organismo calificado como bacilo flagelado,\n\nBartonella bacilliformis.\n \nLa bartonelosis existe especialmente en Perú, Ecuador y Colombia. Es transmi-\ntida por el mosquito\n \nPhlebotomus.\n \nLa fase aguda de la enfermedad se conoce como “fiebre de Oroya”, y la\netapa crónica, con manifestaciones eruptivas de piel, corresponde a la “verruga peruana”. Tanto esta como\nla fiebre de Oroya constituyen las dos fases de la\n \nenfermedad de Carrión\n, llamada así en honor del estudian-\nte de Medicina que en 1885 perdió la vida mientras investigaba este padecimiento.\n\nOtros agentes","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":182,"lines":{"from":26,"to":45}}}}],["897",{"pageContent":"Clostridium perfringens\n \nproduce cuadros septicémicos después de abortos sépticos o por heridas traumáticas\ninfectadas, los cuales pueden producir anemias hemolíticas graves. Los signos de hemólisis intravascular son\nprominentes y se encuentran numerosos microesferocitos.\nEn pacientes con septicemia por gérmenes patógenos tanto gramnegativos como grampositivos, se\nhalla anemia hemolítica en aproximadamente el 40% de los casos. En enfermos con cólera y con salmone-\nlosis se ha observado hemólisis intravascular con hemoglobinuria.\nLa tuberculosis merece un párrafo especial. Aparte de los padecimientos en los que se ha mencio-\nnado como agente causal al\n \nM. tuberculosis\n, este puede producir desde cuadros graves de pancitopenia o\nde “reacciones leucemoides”, hasta anemias hemolíticas de gran actividad, en ocasiones con pruebas de\nCoombs positivas. Estas anemias son más comunes en la tuberculosis de tipo miliar, pero es posible que\nse presenten también en formas localizadas en el pulmón.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":182,"lines":{"from":47,"to":62}}}}],["898",{"pageContent":"Cuadro 11-3\n. Agentes infecciosos que producen anemia hemolítica no inmunitaria\n\nProtozoarios\n \nBacterias\n\nPlasmodium\nToxoplasma\nLeishmania\nTripanosoma\nBartonella\nChlostridiae\nVibrio cholerae\nM. tuberculosis\n\nCuadro 11-2\n.\n \nPadecimientos y\n \nagentes\n \netiológicos que\n \npueden\nproducir anemia\n \nde\n \ninfecciones\n \ncrónicas\n\nPadecimiento\n \nAgente etiológico\n \ncomún\n\nInfección\n \npulmonar\nEmpiema\nMeningitis\nInfecciones\n \nurinarias\nEndocar\n \nditis\nPeritonitis\nAbscesos\nintraabdominales\nOsteomielitis\nInfecciones virales\n\nM. tuberculosis, Histoplasma capsulatum, Staphylococcus aureus\n,\n \nbacterias\ngramnegativas\n\nM. tuberculosis\n, criptococo,\n \nCoccidioides immitis\n\nGérmenes\n \ngramnegativos\nEstafilococos y\n \nestreptococos,\n \nCandida albicans\nM. tuberculosis\n\nBacterias\n \nanaeróbicas\n \ny bacilos\n \ngramnegativos\n\nStaphylococcus aureus\n, bacterias\n \nanaeróbicas\nHIV\n \ny otros virus","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":182,"lines":{"from":64,"to":156}}}}],["899",{"pageContent":"Bacterias\n \nanaeróbicas\n \ny bacilos\n \ngramnegativos\n\nStaphylococcus aureus\n, bacterias\n \nanaeróbicas\nHIV\n \ny otros virus\n\nAparte de los padecimientos en\nlos que se ha mencionado como\nagente causal a\n \nM. tubercu-\nlosis\n, este puede producir desde\ncuadros graves de pancitopenia\no de “reacciones leucemoides”,\nhasta anemias hemolíticas de\ngran actividad, en ocasiones con\npruebas de Coombs positivas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":182,"lines":{"from":156,"to":183}}}}],["900",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n156\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nAnemia asociada al sida","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":183,"lines":{"from":1,"to":7}}}}],["901",{"pageContent":"Aproximadamente el 15% de los individuos asintomáticos infectados por el virus del sida tienen anemia.\nEsta incidencia aumenta a 35% en pacientes que tienen complejo relacionado con el sida y a 80% en quie-\nnes presentan el síndrome establecido.\nLas causas potenciales de esta anemia son múltiples. Aparte del común denominador de los mecanis-\nmos de infección e inflamación crónicas, los principales factores propios de la anemia que complica el sida\nson: 1) invasión de la médula ósea por\n \nMycobacterium avium intracellulare,\n \nque afecta la eritropoyesis; 2)\nfalta de maduración de precursores de normoblastos a causa del parvovirus humano B19; 3) inhibición de\neritropoyesis por parte de células T supresoras; 4) mielosupresión inducida por fármacos, principalmente\nla zidovudina (AZT) y algunos antibacterianos y antivirales; 5) producción disminuida de eritropoyeti-\nna; y 6) invasión directa del HIV-1 a las células troncales. En el manejo de esta anemia, el control de las","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":183,"lines":{"from":9,"to":22}}}}],["902",{"pageContent":"na; y 6) invasión directa del HIV-1 a las células troncales. En el manejo de esta anemia, el control de las\ninfecciones secundarias resulta fundamental. El único tratamiento específico para la anemia inducida por\nAZT es la EPOrHu. En un estudio reciente, se trataron 255 pacientes con anemia asociada con sida y\ncon AZT, y se encontró que aquellos con concentraciones de eritropoyetina sérica menores de 500 U/I se\nbeneficiaron de manera importante con el uso de EPOrHu.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":183,"lines":{"from":22,"to":26}}}}],["903",{"pageContent":"ANEMIA DE LA INSUFICIENCIA RENAL CRÓNICA\n\nLa anemia es una manifestación constante de la insuficiencia renal crónica (IRC) y a la vez constituye una\ncomplicación importante de este estado patológico. Es el resultado directo de las fallas de las funciones\nendocrinas y excretoras del riñón. La naturaleza de la entidad renal primaria no tiene relación con la\ngravedad de la anemia, aunque esta es generalmente de menor grado en las enfermedades hipertensivas\ny quística renal. En esta última, incluso puede haber poliglobulia secundaria, debida a la eritropoyetina\nproducida en las células próximas a los quistes.\n\nPatogenia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":183,"lines":{"from":28,"to":37}}}}],["904",{"pageContent":"La patogenia de esta anemia es múltiple y compleja\n \n(cuadro 11-4)\n. Existen tres mecanismos mayores para\nsu producción. El primero y más importante es la secreción disminuida de eritropoyetina. El segundo es\nla depresión de la eritropoyesis y, finalmente, la supervivencia acortada de los eritrocitos.\nRespecto de la disminución de eritropoyetina, se sabe que el riñón es fuente del 85 al 90% de esta hormo-\nna en el ser humano y que se produce en las células intersticiales o endoteliales de la corteza. La capacidad\ndel riñón para secretar eritropoyetina se compromete cuando disminuye su función excretora.\nEsta cantidad insuficiente de eritropoyetina es incapaz de compensar la necesidad de una mayor eri-\ntropoyesis en el enfermo renal, lo que está condicionado a la supervivencia acortada de eritrocitos y a otros\nfactores que se analizan posteriormente. La mejoría o corrección de la anemia del sujeto urémico, median-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":183,"lines":{"from":39,"to":50}}}}],["905",{"pageContent":"factores que se analizan posteriormente. La mejoría o corrección de la anemia del sujeto urémico, median-\nte administración de eritropoyetina humana recombinante, ha sido la prueba definitiva para establecer la\nrelación directa entre la carencia de eritropoyetina endógena y la anemia del paciente.\nEl segundo factor es la depresión de la médula ósea debida al efecto tóxico de las sustancias retenidas en\nla IRC. Se ha demostrado que el plasma de pacientes urémicos puede deprimir la síntesis del hemo e inhibir\nel crecimiento de colonias eritroides in vitro. El tercer factor patogénico mayor es la hemólisis exagerada. La\nsupervivencia de los eritrocitos en la IRC disminuye a 50 e incluso 66% de lo normal. Aunque no se ha diluci\n-\ndado el mecanismo específico que produce esta hemólisis, sí se ha probado que es de origen extracorpuscular.\nEn esto intervienen tanto factores metabólicos generados por la uremia misma como factores traumáticos,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":183,"lines":{"from":50,"to":59}}}}],["906",{"pageContent":"En esto intervienen tanto factores metabólicos generados por la uremia misma como factores traumáticos,\nlos cuales son determinantes de la destrucción de los eritrocitos en el “síndrome hemolítico urémico”, en el\nque como dato obligado se encuentran hematíes fragmentados o esquistocitos, producidos por el paso de las\ncélulas sanguíneas a través de capilares glomerulares y de pequeños vasos dañados en su endotelio.\nAparte de estos mecanismos mayores y constantes en la anemia de la IRC, existen otros que contribuyen,\nde manera muy variable, a una mayor demanda de eritropoyetina. Un ejemplo es la deficiencia de hierro: debi\n-\ndo al trastorno hemostático que existe en el sujeto urémico, el sangrado crónico, especialmente gastrointesti\n-\nnal, es más frecuente. Además, en enfermos sometidos a diálisis peritoneal ambulatoria crónica (CAPD) hay\nuna pérdida de hierro aproximada de 5 a 6 mg/día. Debe tomarse en cuenta también la frecuente extracción","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":183,"lines":{"from":59,"to":69}}}}],["907",{"pageContent":"una pérdida de hierro aproximada de 5 a 6 mg/día. Debe tomarse en cuenta también la frecuente extracción\nde sangre para estudios de rutina y de investigación en estos enfermos, particularmente en niños.\nOtro de los mecanismos de la anemia por IRC es la deficiencia de folatos. El ácido fólico es un elemento\ndializable, por lo que de manera especial en individuos pobremente nutridos puede contribuir en mayor o\nmenor grado a acentuar la anemia. Otro mecanismo inducido por el tratamiento es el exceso de aluminio,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":183,"lines":{"from":69,"to":73}}}}],["908",{"pageContent":"La anemia es una manifes-\ntación constante de la insu-\nficiencia renal crónica (IRC)\ny\n \na\n \nla\n \nvez\n \nconstituye\n \nuna\ncomplicación\n \nimportante\n \nde\neste estado patológico. Es el\nresultado directo de las fallas\nde las funciones endocrinas y\nexcretoras del riñón.\nLa mejoría o corrección de la\nanemia\n \ndel\n \nsujeto\n \nurémico,\nmediante\n \nadministración\n \nde\neritropoyetina\n \nhumana\n \nre-\ncombinante, ha sido la prueba\ndefinitiva para establecer la\nrelación directa entre la ca-\nrencia de eritropoyetina endó-\ngena y la anemia del paciente.\nEl ácido fólico es un elemen-\nto dializable, por lo que, en\nespecial en individuos pobre-\nmente nutridos, puede contri-\nbuir en mayor o menor grado\na acentuar la anemia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":183,"lines":{"from":75,"to":126}}}}],["909",{"pageContent":"157\n\nCAPÍTULO 11. ANEMIAS SECUNDARIAS A PADECIMIENTOS NO HEMÁTICOS\n\nlo cual ocurre cuando se administra en antiácidos como ligador de fosfatos a largo plazo o bien cuando\nse utiliza agua no desionizada para diálisis peritoneal ambulatoria continua (CAPD). El aluminio puede\ninterferir con la síntesis del hemo y con el transporte del hierro unido a transferrina, por lo que produce\nanemia de tipo microcítico. El hiperparatiroidismo secundario es un mecanismo más de anemia. En indi-\nviduos con IRC, después de paratiroidectomía, el hematocrito aumenta de 40 a 50%. En algunos pacientes,\nel hiperparatiroidismo, capaz de suprimir la eritropoyesis y de causar fibrosis en médula ósea, puede llegar a\nproducir mielofibrosis con esplenomegalia y metaplasia mieloide, lo cual complica la anemia.\n\nDatos clínicos y de laboratorio","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":184,"lines":{"from":1,"to":13}}}}],["910",{"pageContent":"Según se sabe en la actualidad, muchos de los síntomas de los individuos con IRC, como letargo, astenia\no mareo, se deben más a la anemia que a la uremia. En varias ocasiones, la palidez acentuada es el primer\nsigno que lleva al paciente con el médico.\nLa anemia “no complicada” de la IRC es habitualmente de tipo normocítico normocrómico. En casos\nmás graves se pueden encontrar acantocitos o células espiculadas. El recuento de reticulocitos casi siem-\npre es normal o ligeramente elevado; al hacer la corrección, no excede de 2%. El grado de anemia es muy\nvariable, pero en uremias bien instaladas, la hemoglobina está entre 5 y 10 g/dL, y el hematocrito entre 17\ny 33%. Existe cierto paralelismo entre el grado de anemia y el nivel de depuración de creatinina; general-\nmente no hay anemia mientras la depuración de creatinina no descienda de 40 mL/min.\nLos valores del hierro sérico varían en gran medida en la IRC y dependen en buena parte de las com-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":184,"lines":{"from":15,"to":24}}}}],["911",{"pageContent":"mente no hay anemia mientras la depuración de creatinina no descienda de 40 mL/min.\nLos valores del hierro sérico varían en gran medida en la IRC y dependen en buena parte de las com-\nplicaciones o del tratamiento de la enfermedad, como sangrado crónico o deficiencias previas de hierro,\ntransfusiones repetidas, intoxicación con aluminio, etcétera. Sin embargo, puede decirse que en la IRC el\nhierro sérico casi siempre está dentro de límites normales y que la capacidad de fijación es normal o baja.\nLa ferritina, que refleja de manera adecuada el hierro de reserva, por lo regular está aumentada, así como\nlos depósitos de hemosiderina en médula ósea.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":184,"lines":{"from":24,"to":30}}}}],["912",{"pageContent":"Tratamiento","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":184,"lines":{"from":32,"to":32}}}}],["913",{"pageContent":"Hasta 1987, año en el que se publicaron los primeros estudios sobre la EPOrHu en enfermos anémicos por\nIRC, los resultados del tratamiento eran bastante pobres. Los pacientes dependían esencialmente de trans-\nfusiones repetidas de eritrocitos, con los consiguientes riesgos y complicaciones. Los andrógenos producían\ncorrección parcial de la anemia en algunos sujetos, pero su administración se acompañó de daño hepático y\nefectos virilizantes en mujeres, así como de acné en ambos sexos, por lo cual su uso se limitó mucho.\nLa terapéutica ideal para el enfermo con IRC progresiva es el trasplante renal, el cual restablece las fun\n-\nciones endocrinas y excretoras del riñón; sin embargo, por diversas razones, este procedimiento se lleva a\ncabo en muy pocos pacientes. La hemodiálisis corrige solo ligeramente la anemia. La CAPD, en cambio, ha\nproporcionado mejoría sustancial de la anemia, con aumento real de la masa eritrocítica e incluso de la eritro\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":184,"lines":{"from":34,"to":44}}}}],["914",{"pageContent":"proporcionado mejoría sustancial de la anemia, con aumento real de la masa eritrocítica e incluso de la eritro\n-\npoyetina. En la actualidad, el tratamiento de elección para la anemia del paciente con IRC, en sujetos someti\n-\ndos a hemodiálisis, en fase de prediálisis y en CAPD, es el uso de la EPOrHu. Su administración aumenta el\nhematocrito, según la dosis, elimina los requerimientos transfusionales y produce mejoría física y psicológica.\nLa EPOrHu puede utilizarse por vía IV o subcutánea. Los esquemas detallados de tratamiento con\nesta hormona recombinante exceden los propósitos de este capítulo. Solo se mencionará que la dosis\ninicial habitual está en los límites de 50 a 150 U/kg, tres veces por semana, con ajustes subsecuentes en\nincrementos de 12,5 a 25 U/kg para individualizar la dosis en relación con la respuesta.\nComo objetivo se recomienda lograr un nivel de hematocrito de 33 a 36%, lo cual suele corregir total-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":184,"lines":{"from":44,"to":54}}}}],["915",{"pageContent":"incrementos de 12,5 a 25 U/kg para individualizar la dosis en relación con la respuesta.\nComo objetivo se recomienda lograr un nivel de hematocrito de 33 a 36%, lo cual suele corregir total-\nmente los síntomas de la anemia, aunque no se dispone de datos suficientes para rechazar cifras un poco","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":184,"lines":{"from":54,"to":56}}}}],["916",{"pageContent":"Cuadro 11-4.\n \nMecanismos de la anemia en la insuficiencia renal\n \ncrónica\n\nFactores mayores\n \nFactores\n \nmenor\n \nes\n\nDeficiencia en secreción\nde eritropoyetina\nDepresión de médula ósea\nDisminución de supervivencia\neritrocítica\nDeficiencia de hierro\nDeficiencia de folatos\nHiperparatiroidismo y mielofibrosis\nToxicidad por aluminio","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":184,"lines":{"from":58,"to":80}}}}],["917",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n158\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nmayores o menores que las señaladas. No debe olvidarse, sin embargo, que la anemia del enfermo urémico\nes una forma de adaptación para exponer el mayor volumen de plasma a una filtración glomerular que está\ncomprometida. Si se incrementa en demasía la masa eritrocítica, la consecuente disminución del volumen\nplasmático puede comprometer más la filtración.\nPor último, es importante llevar a cabo suplementación racional de folatos y hierro. Respecto de este\núltimo, debe disponerse de buenas reservas, ya que la administración de EPOrHu demanda gran cantidad\nde hierro para transferirlo a precursores eritroides.\n\nANEMIAS EN PACIENTES CON TRASTORNOS\nENDOCRINOS Y METABÓLICOS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":185,"lines":{"from":1,"to":16}}}}],["918",{"pageContent":"ANEMIAS EN PACIENTES CON TRASTORNOS\nENDOCRINOS Y METABÓLICOS\n\nLa anemia acompaña a menudo diversas insuficiencias endocrinas (especialmente hipotiroidismo), así como\ntrastornos metabólicos (en particular, diabetes mellitus). Por lo general, cuando no hay otras complicacio-\nnes propias de estos trastornos, la anemia casi siempre es moderada y, en ocasiones, no produce síntomas.\n\nHipotiroidismo","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":185,"lines":{"from":16,"to":23}}}}],["919",{"pageContent":"Las causas de anemia en la insuficiencia tiroidea generalmente son mixtas, es decir, tanto por la disminu-\nción de las hormonas tiroideas como por la deficiencia de sustancias específicas de la eritropoyesis. Se sigue\naceptando que existe un mecanismo de adaptación en el paciente hipotiroideo, debido a las demandas dis-\nminuidas de O\n2\n \n, lo cual hace que la secreción de la eritropoyetina sea restringida y los niveles de hemoglobi-\nna y hematocrito sean menores. Por ello se concluye que la anemia del mixedema se explica razonablemente\npor una producción eritrocítica reducida. La supervivencia de hematíes es normal e incluso un tanto au-\nmentada, pero el transporte plasmático del hierro y el grado de recambio de este metal están disminuidos.\nEn el 20 a 60% de los sujetos con hipotiroidismo se ha encontrado anemia, con cifras de hemoglobina\nque van de 7 a 12 g/dL. En mujeres, posiblemente por la elevada frecuencia de anemia ferropriva que","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":185,"lines":{"from":25,"to":36}}}}],["920",{"pageContent":"En el 20 a 60% de los sujetos con hipotiroidismo se ha encontrado anemia, con cifras de hemoglobina\nque van de 7 a 12 g/dL. En mujeres, posiblemente por la elevada frecuencia de anemia ferropriva que\npadecen, no es raro encontrar casos, casi siempre de edad media, que han sido tratados durante períodos\nlargos con preparaciones de hierro (por lo general parenterales) sin obtener respuesta y, desde luego, sin\nhaber detectado la insuficiencia tiroidea, en ocasiones en franco mixedema. El tipo morfológico de la\nanemia no complicada del hipotiroidismo es tanto normocítico como moderadamente macrocítico (entre\n90 y 110 fL), aun en enfermos con vitamina B12 y folatos normales. Esto es, se acepta que ambos tipos de\nanemia son compatibles con hipotiroidismo “puro”. En cambio, cuando se encuentra anemia microcítica\ndebe interpretarse como secundaria a ferropenia. Aparte de las causas que comúnmente originan anemia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":185,"lines":{"from":36,"to":44}}}}],["921",{"pageContent":"anemia son compatibles con hipotiroidismo “puro”. En cambio, cuando se encuentra anemia microcítica\ndebe interpretarse como secundaria a ferropenia. Aparte de las causas que comúnmente originan anemia\nferropriva, en los pacientes con mixedema existen mecanismos particulares más frecuentes que acentúan\nesta deficiencia, como hipermenorrea y como aclorhidria, que limitan la absorción de hierro. En algunos\ncasos hay disminución de vitamina B12 por limitación en la producción de factor intrínseco.\nRespecto del manejo de esta anemia, cuando se encuentran deficiencias de factores hematopoyéticos,\ndebe investigarse su causa y corregir el déficit correspondiente. La respuesta a la administración de hormona\ntiroidea suele ocurrir en el lapso de varias semanas; ha de utilizarse diariamente y mantenerse hasta que se\ncorrijan por completo tanto los niveles de hemoglobina como las manifestaciones de hipofunción tiroidea.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":185,"lines":{"from":44,"to":52}}}}],["922",{"pageContent":"Diabetes mellitus","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":185,"lines":{"from":54,"to":54}}}}],["923",{"pageContent":"La diabetes es la enfermedad más común de todos los padecimientos endocrinos. Las complicaciones a largo\nplazo de esta entidad a menudo originan anemia. Muy posiblemente por ello es que la anemia del paciente\ndiabético sea la más frecuente que se encuentra dentro de la gama de padecimientos endocrinos y metabólicos.\nEn la diabetes existen diversos cambios intraeritrocíticos derivados de las altas concentraciones de\nglucosa; por ejemplo, el aumento de incluso dos o tres veces de la hemoglobina A1c, que es la formada\npor la glucosilación no enzimática de la hemoglobina A. Aunque se ha comunicado una disminución\nde la supervivencia de eritrocitos en pacientes diabéticos (la cual se normaliza cuando se controla la\nglucosa), las alteraciones eritrocíticas propias de la diabetes no ocasionan anemia por sí solas.\nLa anemia del diabético es, esencialmente, consecuencia de varias de las complicaciones y alteraciones","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":185,"lines":{"from":56,"to":64}}}}],["924",{"pageContent":"glucosa), las alteraciones eritrocíticas propias de la diabetes no ocasionan anemia por sí solas.\nLa anemia del diabético es, esencialmente, consecuencia de varias de las complicaciones y alteraciones\nque originan la enfermedad de larga evolución. Las dos complicaciones que más la producen son la insufi-\nciencia renal crónica y las infecciones. Entre estas últimas, se hallan principalmente las sepsis urorrenales\nagudas y crónicas, el pie diabético infectado y ulcerado, etcétera. Cuando se asocian ambas complicacio-\nnes, uremia e infección de repetición, el grado de anemia puede ser muy acentuado, a veces con niveles por\nabajo de 5 g/dL de hemoglobina (en otras secciones de este capítulo se revisa la patogenia de las anemias","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":185,"lines":{"from":64,"to":70}}}}],["925",{"pageContent":"Las causas de anemia en las\ninsuficiencias tiroideas gene-\nralmente son mixtas, es decir,\ntanto por la disminución de\nlas hormonas tiroideas como\npor la deficiencia de sustancias\nespecíficas de la eritropoyesis.\nLa anemia del diabético es,\nesencialmente, consecuencia\nde varias de las complicacio-\nnes y alteraciones que origi-\nnan la enfermedad de larga\nevolución.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":185,"lines":{"from":72,"to":84}}}}],["926",{"pageContent":"159\n\nCAPÍTULO 11. ANEMIAS SECUNDARIAS A PADECIMIENTOS NO HEMÁTICOS\n\npor uremia y por infección crónica, y se apuntan los recursos terapéuticos). Otros mecanismos propios\ndel diabético que favorecen la anemia son la aclorhidria y la enteropatía diabética, que originan absorción\ndeficiente con disminución consecuente de hierro, folatos y vitamina B12. Por último, se menciona que\nen individuos con diabetes deficientes en glucosa-6-fosfato deshidrogenasa (G6PD) eritrocítica se pueden\ndesencadenar crisis de anemia hemolítica grave inducidas por cetoacidosis diabética. La corrección de la\nacidosis y del descontrol de la homeostasis de la glucosa revierte el problema hemolítico.\n\nHipogonadismo","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":186,"lines":{"from":1,"to":12}}}}],["927",{"pageContent":"Hipogonadismo\n\nEs bien sabido que, después de la pubertad, los valores de serie roja aumentan a favor del varón aproxima-\ndamente en 10 a 13%. La testosterona y los anabólicos androgénicos estimulan la eritropoyesis, de manera\nprincipal por aumento de secreción de eritropoyetina, tanto de sitios renales como extrarrenales. Por otro\nlado, los estrógenos pueden ejercer un efecto inhibitorio. En pacientes sometidos a orquiectomía se ha\nobservado una caída del 6% en el hematocrito, para alcanzar luego un nivel estable aproximadamente a\nlos 40 días. Estas alteraciones son reversibles con tratamientos de reemplazo, no solo hasta llegar a cifras\nnormales sino, a veces, incluso a niveles de poliglobulia.\nEl hipogonadismo en la mujer, sea por castración o por menopausia, no va a originar cambios signifi-\ncativos en la eritropoyesis.\n\nANEMIAS SECUNDARIAS A NEOPLASIAS MALIGNAS NO HEMÁTICAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":186,"lines":{"from":12,"to":24}}}}],["928",{"pageContent":"ANEMIAS SECUNDARIAS A NEOPLASIAS MALIGNAS NO HEMÁTICAS\n\nLa anemia es una de las complicaciones más frecuentes de las enfermedades malignas y es uno de los factores\ndeterminantes en la calidad de vida de los pacientes. Los cánceres de origen no hemático participan, desde lue\n-\ngo, de los mecanismos que producen anemia en las hemopatías malignas, los cuales son comentados a lo largo\nde los capítulos correspondientes del libro. En este capítulo se enfoca el tema hacia las anemias originadas por\npadecimientos malignos no hemáticos. Las causas particulares que dan lugar a la anemia en este tipo de cáncer\nson múltiples y complejas; sin embargo, hay dos que son las más comunes y también las más obvias:\n\n•\n \nPérdidas sanguíneas por hemorragias agudas o crónicas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":186,"lines":{"from":24,"to":36}}}}],["929",{"pageContent":"•\n \nPérdidas sanguíneas por hemorragias agudas o crónicas\n\n•\n \nEfectos del tratamiento con quimioterapia o cobaltoterapia\nExisten además otros factores que frecuentemente coexisten con los antes mencionados, como son la\nllamada “anemia de los trastornos crónicos”, las metástasis tumorales a médula ósea y las anemias mi-\ncroangiopáticas secundarias a algunos carcinomas productores de mucina. En el\n \ncuadro 11-5\n \nse anotan\nestas causas, las cuales se comentarán brevemente.\n\nHemorragias","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":186,"lines":{"from":36,"to":52}}}}],["930",{"pageContent":"Hemorragias\n\nEn no pocas ocasiones la hemorragia, sea aguda o crónica, es el primer signo de la enfermedad maligna, par\n-\nticularmente en neoplasias tan frecuentes como las de los aparatos gastrointestinal, ginecológico, pulmonar y\nurinario. A lo largo del padecimiento correspondiente, estas hemorragias constituyen complicaciones frecuentes\nque incluso pueden poner en peligro la vida. Menos aparentes y comunes son las hemorragias intratumorales que\nse originan en grandes masas neoplásicas, particularmente en sarcomas o en carcinomas de hígado o de ovario.\n\nEfectos secundarios al tratamiento","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":186,"lines":{"from":52,"to":61}}}}],["931",{"pageContent":"Efectos secundarios al tratamiento\n\nEn primer lugar se deben contar la mielosupresión y la mielodisplasia originadas por la quimioterapia\ny por la radiación, que producen citopenias cuya magnitud es generalmente paralela a la intensidad del\ntratamiento. Debe mencionarse, como efecto particular, el síndrome hemolítico-urémico que pueden\nproducir algunos quimioterápicos como la mitomicina-C, utilizada en carcinomas diseminados, y el\ncisplatino, ampliamente usado en oncología.\n\nAnemia de los trastornos crónicos\n\nAparte del común denominador en la patogenia de este tipo de anemia, comentado previamente, se añade,\nparticularmente, la sobreproducción de algunas citocinas que van a deprimir la eritropoyesis, particular -\nmente dos, cuya acción ha sido bien probada: el factor de necrosis tumoral y la interleucina 1.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":186,"lines":{"from":61,"to":73}}}}],["932",{"pageContent":"La anemia es una de las com-\nplicaciones más frecuentes de\nlas enfermedades malignas y\nuno de los factores determi-\nnantes en la calidad de vida de\nlos\n \npacientes.\n \nLos\n \ncánceres\nde origen no hemático partici-\npan, desde luego, de los meca-\nnismos que producen anemia\nen las hemopatías malignas.\nEn no pocas ocasiones la hemo-\nrragia, sea aguda o crónica, es el\nprimer signo de la enfermedad\nmaligna,\n \nparticularmente\n \nen\nneoplasias tan frecuentes como\nlas de los aparatos gastrointes-\ntinal, ginecológico, pulmonar y\nurinario.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":186,"lines":{"from":75,"to":102}}}}],["933",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n160\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nMetástasis a médula ósea\n\nCasi todos los cánceres pueden metastatizar a hueso. Sin embargo, los que más comúnmente lo hacen son los de\npróstata, pulmón y mama. Generalmente no hay paralelismo entre la magnitud de la invasión metastásica y el\ngrado de anemia. En ocasiones es sorprendente observar cómo extensas infiltraciones carcinomatosas son nota\n-\nblemente bien toleradas; esto puede ser debido, en parte, a la hematopoyesis extramedular. En sangre periférica\nse aprecian alteraciones que pueden dar la pista de enfermedad metastásica, como son la presencia de eritrocitos\ny leucocitos inmaduros, así como de leucocitosis y plaquetosis para dar la llamada “imagen leucoeritroblástica”.\n\nAnemia hemolítica microangiopática","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":187,"lines":{"from":1,"to":17}}}}],["934",{"pageContent":"Anemia hemolítica microangiopática\n\nEste tipo de anemia hemolítica intravascular, cuyo mecanismo esencial es la fragmentación de eritrocitos\ndebido a su paso a través de capilares y arteriolas anormales, está asociado a numerosas situaciones patológi-\ncas, entre las que se cuentan las neoplasias malignas; de estas, particularmente los carcinomas diseminados\nproductores de mucina, como los de estómago y mama.\n\nFactores nutricionales\n\nEn etapas avanzadas del paciente con cáncer, la inanición y la caquexia requieren vigilar la suplementación\nadecuada de “factores antianémicos”, en particular en casos de neoplasias malignas gastrointestinales con\nproblemas de mala absorción.\n\nTratamiento","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":187,"lines":{"from":17,"to":30}}}}],["935",{"pageContent":"El tratamiento efectivo de la anemia del cáncer dependerá primariamente de la evolución del problema neo-\nplásico y de la adecuada identificación de sus causas. Aparte de la corrección de los mecanismos particulares\nmencionados, existe el valioso recurso del uso de la EPOrHu, que después de casi 10 años de experiencia\nha mostrado que, en general, se obtienen buenas respuestas en aproximadamente el 50% de todos los cán-\nceres con anemia. La respuesta a la EPOrHu parece ser independiente de si son pacientes que reciben o no\nquimioterapia o radioterapia, y lo más importante es que se observa una disminución en la necesidad de\ntransfusiones así como mejoría en la calidad de vida. Las dosis utilizadas son mayores que en la insuficiencia\nrenal; generalmente se emplean 150 a 300 U/kg, por vía subcutánea, tres veces por semana. Las respuestas\nson mayores si el nivel de EPO endógena es bajo; sin embargo, pueden obtenerse buenos resultados en indi-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":187,"lines":{"from":32,"to":40}}}}],["936",{"pageContent":"son mayores si el nivel de EPO endógena es bajo; sin embargo, pueden obtenerse buenos resultados en indi-\nviduos con cifras normales o algo elevadas de esta hormona. Generalmente se tolera muy bien la administra-\nción de EPOrHu y no hay evidencias de que en cánceres no hemáticos pueda estimular la actividad tumoral.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":187,"lines":{"from":40,"to":42}}}}],["937",{"pageContent":"ANEMIAS SECUNDARIAS A ALCOHOLISMO CRÓNICO Y CIRROSIS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":187,"lines":{"from":44,"to":44}}}}],["938",{"pageContent":"La ingestión de bebidas alcohólicas en forma moderada y ocasional no produce problemas hemáticos\napreciables; en cambio, la ingestión de cantidades excesivas de alcohol genera alteraciones importantes, a\nla cabeza de ellas, la anemia megaloblástica. La complicación más frecuente y más seria del alcoholismo\nexagerado es la cirrosis alcohólica, en la cual se encuentra anemia aproximadamente en el 75% de los ca-\nsos. Se examinan primero los efectos del alcoholismo crónico sobre la eritropoyesis.\nLa alteración más constante de los eritrocitos en el alcoholismo crónico, aun sin anemia, es la macroci-\ntosis originada posiblemente por acción directa del alcohol. Habitualmente, esta macrocitosis oscila entre\n100 y 110 fL. En pacientes con anemia, la causa más común de esta es la deficiencia de ácido fólico; en\nalcohólicos crónicos se encuentran niveles bajos de folatos hasta en el 93% de los casos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":187,"lines":{"from":46,"to":54}}}}],["939",{"pageContent":"100 y 110 fL. En pacientes con anemia, la causa más común de esta es la deficiencia de ácido fólico; en\nalcohólicos crónicos se encuentran niveles bajos de folatos hasta en el 93% de los casos.\nLas razones de este déficit obedecen, en primer lugar, a la pobre alimentación del alcohólico. En segundo\ntérmino, existen alteraciones en el metabolismo del ácido fólico, como una capacidad reducida de almace-\nnamiento de folatos en el hígado y una excreción exagerada por orina. Por último, hay una interferencia\ndel alcohol en el ciclo enterohepático de los folatos que origina aumento de retención de estos en la célula\nhepática. La anemia megaloblástica se encuentra en el 40% de los sujetos hospitalizados por alcoholismo\ncrónico; es de grado variable y puede llegar a niveles muy bajos de hemoglobina. Las características clínicas\ny de laboratorio de este tipo de anemia son similares a las de otras variedades causadas por deficiencia de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":187,"lines":{"from":54,"to":62}}}}],["940",{"pageContent":"y de laboratorio de este tipo de anemia son similares a las de otras variedades causadas por deficiencia de\nfolatos. En el alcohólico crónico, los niveles de vitamina B12 habitualmente son normales o incluso elevados.\nLa anemia megaloblástica por deficiencia de ácido fólico responde de manera notable cuando se admi-\nnistra esta vitamina. Las preparaciones que casi siempre se encuentran son de 5 mg por tableta, dosis que","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":187,"lines":{"from":62,"to":65}}}}],["941",{"pageContent":"El tratamiento efectivo de la\nanemia del cáncer dependerá\nprimariamente de la evolu-\nción del problema neoplásico\ny de la adecuada identifica-\nción de sus causas.\nLa alteración más constante de\nlos eritrocitos en el alcoholismo\ncrónico, aun sin anemia, es la\nmacrocitosis\n \noriginada\n \nposi-\nblemente por acción directa del\nalcohol.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":187,"lines":{"from":67,"to":82}}}}],["942",{"pageContent":"161\n\nCAPÍTULO 11. ANEMIAS SECUNDARIAS A PADECIMIENTOS NO HEMÁTICOS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":188,"lines":{"from":1,"to":3}}}}],["943",{"pageContent":"es excesiva. Sin embargo, es posible administrar una tableta diariamente durante 2 a 3 semanas y luego\nproporcionar 2,5 mg a lo largo de varios meses. Una vez que el paciente disminuya o elimine el alcoho-\nlismo y se nutra más adecuadamente, la suplementación de folatos se reduce y puede llegar a suspenderse.\nOtro mecanismo que contribuye a la anemia del alcoholismo es la sideroblastosis de la médula ósea. En esta\nalteración se encuentran numerosos sideroblastos en anillo y se acompaña de anemia con eritrocitos hipocrómi\n-\ncos y normocrómicos. Los sideroblastos están cargados de ferritina en mitocondrias. Estas alteraciones aparecen\nposteriormente a la deficiencia de folatos y pueden ser reversibles después de la suspensión de bebidas alcohólicas.\nEn relación con la anemia de pacientes con cirrosis alcohólica, son muchos los factores que contribuyen a\ndesarrollarla. Desde luego encontramos las alteraciones mencionadas de deficiencia de ácido fólico y de anemia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":188,"lines":{"from":5,"to":14}}}}],["944",{"pageContent":"desarrollarla. Desde luego encontramos las alteraciones mencionadas de deficiencia de ácido fólico y de anemia\nsideroblástica, las cuales se acentúan en la enfermedad hepática por alcoholismo. Deben tomarse en cuenta\nmecanismos más obvios y de frecuente presentación, como hemorragias por gastritis alcohólica o por hiper\n-\ntensión portal, así como por trastornos hemorragíparos. Estos últimos pueden ocurrir por alteraciones de la\ncoagulación debidas a hipoprotrombinemia, o bien de la función capilar, causadas por plaquetopenia. El hipe\n-\nresplenismo del cirrótico contribuye tanto a la disminución de las plaquetas como a la acentuación de la anemia.\nLa corrección de la anemia del enfermo con cirrosis alcohólica nutricional está limitada a la adminis-\ntración de sustancias cuya carencia se haya demostrado específicamente, y al uso juicioso de transfusión\nde paquetes de eritrocitos en episodios de anemia aguda.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":188,"lines":{"from":14,"to":24}}}}],["945",{"pageContent":"ANEMIAS SECUNDARIAS A INFLAMACIONES CRÓNICAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":188,"lines":{"from":26,"to":26}}}}],["946",{"pageContent":"El grupo de las inflamaciones crónicas, de origen no infeccioso, comprende fundamentalmente enfermedades\nreumáticas generalizadas: artritis reumatoide, lupus eritematoso generalizado, dermatomiositis, escleroderma\ny otros padecimientos menos frecuentes. Todos estos trastornos de evolución crónica son capaces de originar\nanemia secundaria. Generalmente, en casos “no complicados” se encuentra anemia de grado medio, de entre\n9 y 12 g/dL de hemoglobina, de tipo normocítico normocrómico y con reticulocitos normales o bajos.\nEn esta anemia participan, de manera característica, los mecanismos de la ATC analizados anterior-\nmente. Aparte de estas alteraciones, existen otros factores más obvios que pueden producir anemia en las\ninflamaciones no infecciosas, especialmente deficiencia de hierro por sangrado gastrointestinal crónico\nsecundario a administración de antiinflamatorios esteroideos y no esteroideos. Es importante hacer notar","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":188,"lines":{"from":28,"to":36}}}}],["947",{"pageContent":"secundario a administración de antiinflamatorios esteroideos y no esteroideos. Es importante hacer notar\nque este sangrado quizá no se detecte clínicamente ni por medio de investigación de sangre oculta. En la\nartritis reumatoide se han encontrado también deficiencias de vitamina B12 (29%) y ácido fólico (21%).\nLa mejoría de la anemia habitualmente corre paralela con la mejoría del padecimiento inflamatorio. La utili\n-\nzación de hierro y de otros “hematínicos” se justifica solo cuando se prueba la deficiencia correspondiente. En ar\n-\ntritis reumatoide se han demostrado niveles de eritropoyetina comparativamente menores en relación con otros\ntipos de anemia con cifras similares de hemoglobina. La administración de eritropoyetina recombinante en estos\npacientes con artritis reumatoide ha demostrado ser efectiva en la mayoría de los casos. En estudios independien\n-\ntes, la aplicación de eritropoyetina, en dosis de 150 a 300 U/kg por semana, originó respuestas favorables en el","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":188,"lines":{"from":36,"to":47}}}}],["948",{"pageContent":"-\ntes, la aplicación de eritropoyetina, en dosis de 150 a 300 U/kg por semana, originó respuestas favorables en el\n81% de los enfermos después de 6 semanas, y en el 90% después de 24 semanas no hubo toxicidad significativa.\nEn un trabajo efectuado en México sobre lupus eritematoso generalizado, se encontró anemia en 6\nde 34 casos; esta osciló entre 5 y 12 g/dL y fue de tipo normocítico normocrómico, con reticulocitosis y\npositividad de la prueba directa de la antiglobulina humana. La respuesta de esta anemia a los corticoides\nes satisfactoria en aproximadamente dos terceras partes de los pacientes.\nPor último, un comentario sobre una anemia de origen claramente iatrogénico. En reumatología y medicina in\n-\nterna se utiliza, cada vez con más frecuencia, el metotrexato como inmunosupresor, el cual, aun a dosis bajas, es capaz\nde diezmar las reservas de folatos. Si no se administra adecuadamente ácido folínico para rescatar la acción antifólica","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":188,"lines":{"from":47,"to":57}}}}],["949",{"pageContent":"de diezmar las reservas de folatos. Si no se administra adecuadamente ácido folínico para rescatar la acción antifólica\ndel metotrexato, se desarrolla mayor o menor grado de anemia megaloblástica. Los autores de este capítulo han\ntratado a varios pacientes con anemias acentuadas debidas a la falta de previsión del efecto secundario mencionado.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":188,"lines":{"from":57,"to":59}}}}],["950",{"pageContent":"Cuadro 11-5.\n \nCausas de anemia en cáncer no hemático\n\nHemorragias agudas y\n \ncrónicas\nEfectos secundarios de la quimioterapia y\n \ncobaltoterapia\nAnemia de los\n \ntrastornos crónicos\nMetástasis tumorales a médula\n \nósea\nAnemias\n \nmicroangiopáticas\n \nsecundarias a liberación de mucina por\n \nalgunos\n \ncarcinomas\n \ndiseminados\nFactores nutricionales e\n \ninanición","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":188,"lines":{"from":61,"to":90}}}}],["951",{"pageContent":"Otro mecanismo de anemia en\nel alcohólico es la insuficiencia\nen\n \nla\n \nproducción\n \neritropoyé-\ntica, debida a dos factores: 1)\nsupresión por acción directa del\nalcohol y 2) sideroblastosis de la\nmédula ósea. En esta alteración\nse encuentran numerosos side-\nroblastos en anillo y se acom-\npaña de anemia con eritrocitos\nhipocrómicos y normocrómicos.\nLa corrección de la anemia del\nenfermo con cirrosis alcohólica\nnutricional\n \ngeneralmente\n \nes\nbastante limitada, ya que su\ncurso es paralelo a la evolu-\nción de la hepatopatía, la cual\nes irreversible en la gran ma -\nyoría de los casos.\nEn reumatología y medicina\ninterna se utiliza, cada vez\ncon más frecuencia, el meto-\ntrexato, como inmunosupre-\nsor, el cual aun a dosis bajas es\ncapaz de depletar las reservas\nde folatos. Si no se administra\nadecuadamente ácido folínico\npara rescatar la acción anti-\nfólica del metotrexato se desa-\nrrolla mayor o menor grado de\nanemia megaloblástica.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":188,"lines":{"from":92,"to":132}}}}],["952",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n162\n \nFUNDAMENTOS DE HEMATOLOGÍA\nANEMIA POR DESNUTRICIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":189,"lines":{"from":1,"to":6}}}}],["953",{"pageContent":"En pediatría, los factores nutricionales tienen especial importancia en el desarrollo de anemia. En el\nadulto, la desnutrición por sí sola va a originar anemia solo en etapas muy avanzadas de deprivación ali-\nmenticia. Incluso en individuos estrictamente vegetarianos, que se abstienen totalmente de proteínas de\norigen animal, el problema de la anemia es bastante raro. En la anemia “carencial” más frecuente, como es\nla anemia ferropriva, los factores nutricionales representan un papel totalmente secundario; personas con\ndesnutrición extrema, como en casos de kwashiorkor, no presentan deficiencia de hierro.\nLas deficiencias de factores antianémicos específicos, como ácido fólico, vitamina B12 y hierro, son\ndebidas primordialmente a factores ajenos a la desnutrición, como son el aumento de demandas, el alcoho-\nlismo, los defectos de absorción y el sangrado crónico. Las anemias por carencia de estos elementos están\nbien definidas y su caracterización se ha precisado en capítulos anteriores.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":189,"lines":{"from":8,"to":17}}}}],["954",{"pageContent":"lismo, los defectos de absorción y el sangrado crónico. Las anemias por carencia de estos elementos están\nbien definidas y su caracterización se ha precisado en capítulos anteriores.\nOtras anemias “nutricionales” que se han descrito, especialmente en la infancia, como secundarias\na “micronutrientes”, tales como algunas vitaminas (A, B2, B6, C y E) o bien deficiencias de cobre o\ncinc, son entidades pobremente definidas, aparte de que se presentan muy rara vez como causa pri -\nmaria de anemia.\nDebe insistirse en que la anemia que presenta un individuo adulto “desnutrido” nunca debe atribuirse\nprimariamente a falta de alimentación y sí, en cambio, se debe investigar cuidadosamente su origen. Es\nsorprendente cómo las consejas populares de que la persona está anémica “porque no come” o incluso,\nen anemias agudas, “porque ha estado comiendo mal”, son aceptadas por una gran proporción de traba-\njadores de la salud, incluyendo a médicos generales y otros profesionistas no hematólogos. Estos juicios","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":189,"lines":{"from":17,"to":27}}}}],["955",{"pageContent":"jadores de la salud, incluyendo a médicos generales y otros profesionistas no hematólogos. Estos juicios\ncontinúan originando lamentables errores en el diagnóstico y, por supuesto, inútiles y hasta perjudiciales\nmedidas dietéticas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":189,"lines":{"from":27,"to":29}}}}],["956",{"pageContent":"CONCLUSIONES\n\n•\n \nLas anemias secundarias a padecimientos no hemáticos constituyen el grupo más numeroso de pacien-\ntes hospitalizados con anemia, tanto en niños como en adultos.\n\n•\n \nLa etiología de este grupo de anemias puede deberse a padecimientos infecciosos, metabólicos, infla-\nmatorios y neoplásicos. Habitualmente son anemias moderadas normocíticas normocrómicas.\n\n•\n \nEl tratamiento de una gran parte de ellas consiste en la eritropoyetina parenteral y el hierro, pero\nresulta fundamental tratar la causa subyacente.\n\nPREGUNTAS DE AUTOEVALUACIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":189,"lines":{"from":31,"to":48}}}}],["957",{"pageContent":"1. ¿Qué tan frecuentes son las anemias producidas por padecimientos no hemáticos en comparación con\nlas originadas por alteraciones primariamente hemáticas?\na.\n \nLas primeras constituyen la gran mayoría de las anemias atendidas tanto en consulta externa como\nen pacientes hospitalizados\nb. Las segundas constituyen la gran mayoría de las anemias atendidas\nc.\n \nSon igualmente frecuentes\n2. ¿Cuál es la característica habitual en la determinación de hierro en los trastornos crónicos en contra-\nposición con anemia ferropriva?\na.\n \nHierro bajo, aunque más alto que en la ferropriva, y fijación a la transferrina normal o disminuida\nb. Hierro muy bajo y capacidad de fijación aumentada\nc.\n \nNinguna de las anteriores\n3. ¿Es conveniente administrar hierro en la anemia de trastornos crónicos?\na.\n \nSí, porque el hierro total o de depósito está aumentado y puede agravar la acumulación del mismo\nb. No, porque el hierro total o de depósito está aumentado y puede agravar la acumulación del mismo\nc.\n \nNinguna de las anteriores","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":189,"lines":{"from":50,"to":76}}}}],["958",{"pageContent":"Debe insistirse en que la ane-\nmia que presenta un indivi-\nduo adulto “ desnutrido” nunca\ndebe atribuirse primariamen-\nte a falta de alimentación y sí,\nen cambio, se debe investigar\ncuidadosamente su origen.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":189,"lines":{"from":78,"to":84}}}}],["959",{"pageContent":"163\n\nCAPÍTULO 11. ANEMIAS SECUNDARIAS A PADECIMIENTOS NO HEMÁTICOS\n\n4. ¿Qué niveles de hematocrito se recomienda mantener en los pacientes con insuficiencia renal crónica?\na.\n \nEntre 15 y 23%\nb. Entre 24 y 32%\nc.\n \nEntre 33 y 36%\n5. ¿Cuál es la alteración eritrocítica más común en individuos con alcoholismo crónico?\na.\n \nReticulocitosis\nb. Macrocitosis\nc.\n \nMicrocitosis\n\nBIBLIOGRAFÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":190,"lines":{"from":1,"to":22}}}}],["960",{"pageContent":"Beutler E. μe common anemias. JAMA. 1988; 259: 2433-37.\nBeutler E, et al. (eds.) Williams Hematology. 6th ed. New York: McGraw-Hill; 2001.\nErsler AJ. Anemia of chronic disorders. En: Williams Hematology, 6th ed. New York: McGraw-Hill; 2001.\nFrenkel EP, Bick RL, et al. Anemia of malignancy. Hematol Oncol Clin North Am. 1996; 10(4): 861-73.\nHenry DH, Beall GN, et al. Recombinant human erythropoietin in the treatment of anemia associated with human\nimmunodeficiency virus (HIV) infection and zidovudine therapy. Ann Intern Med. 1992; 117: 739-48.\nHocking WD. Hematological abnormalities in patients with renal disease. Hematol Oncol Clin North Am. 1987;\n1(2): 229-59.\nHumphries JE. Anemia of the renal failure, use of erythropoietin. Med Clin North Am. 1992; 76: 711-25.\nKrantz SB. Pathogenesis and treatment of the anemia of chronic disorders. Am J Med Sci. 1994; 307 (5): 353-59.\nLee GR. Acquired hemolytic anemias resulting from direct effects of infections, chemical, or physical agents. En:","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":190,"lines":{"from":24,"to":34}}}}],["961",{"pageContent":"Lee GR. Acquired hemolytic anemias resulting from direct effects of infections, chemical, or physical agents. En:\nWintrobe’s Clinical Hematology.\n \n9th\n \ned. Philadelphia: Lea & Febiger; 1993. p. 1179-1210.\nLee GR. μe normocytic, normochromic anemias. En: Wintrobe’s Clinical Hematology.\n \n9th\n \ned. Philadelphia: Lea &\nFebiger, 1993. p. 1179-1210.\nLudwig H, Sundal E, et al. Recombinant human erythropoietin for the correction of cancer associated anemia with\nand without concomitant cytotoxic chemotherapy. Cancer. 1995; 76(11): 2319-29.\nMoliterno AR, Spivak JL. Anemia of cancer. Hematol Oncol Clin North Am. 1996; 10 (2): 345-363.\nOrwoll ES, Orwoll RL. Hematological abnormalities in patients with endocrine and metabolic disorders. Hematol\nOncol Clin North Am. 1987; 1(2): 261-79.\nPincus T, Olsen NJ, et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheu-\nmatoid arthritis. Am J Med. 1990; 89: 161-68.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":190,"lines":{"from":34,"to":52}}}}],["962",{"pageContent":"Oncol Clin North Am. 1987; 1(2): 261-79.\nPincus T, Olsen NJ, et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheu-\nmatoid arthritis. Am J Med. 1990; 89: 161-68.\nRomero-García F, Aguilar JA, et al. Anormalidades hematológicas en el lupus eritematoso generalizado. Rev Invest\nClin. 1988; 40: 119-24.\nSánchez-Medal L. Efectos del alcohol en el sistema hemático. En: El alcoholismo en México. 1. Patología. 2a. ed.\nMéxico: Fundación de Investigaciones Sociales, A.C.; 1985. p. 133-145.\nSchilling RF. Anemia of chronic disease: A misnomer. Ann Intern Med. 1991; 115: 572-3.\nStrausbaugh LJ. Hematological manifestations of bacterial and fungal infections. Hematol Oncol Clin North Am.\n1987; 1(2): 185-205.\nVreugdenhil G, Wognum AW, et al. Anemia in rheumatoid arthritis: μe role of iron, vitamin B12, and folic acid\ndeficiency, and erythropoietin responsiveness. Ann Rheum Dis. 1990; 49: 93-8.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":190,"lines":{"from":52,"to":63}}}}],["963",{"pageContent":"RESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\n1.\n \na\n2.\n \na\n3.\n \nb\n4.\n \nc\n5.\n \nb","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":190,"lines":{"from":65,"to":81}}}}],["964",{"pageContent":"PARTE 3\nOncología hemática\n\n12\n\nLeucemias agudas\n\n13\n\nLeucemias crónicas\n\n14\n\nn\neop\nL\nasias\n \nmie\nL\nopro\nL\ni\nF\nera\nT\ni\nV\nas\n \ncrónicas\n\n15\n\nLin\nF\nomas\n\n16\n\nLin\nF\noma de Hodgkin\n\n17\n\nT\nras\nT\nornos\n \ninmunopro\nL\ni\nF\nera\nT\ni\nV\nos\n \nma\nL\nignos\n\n167\n195\n183\n205\n223\n239","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":192,"lines":{"from":1,"to":71}}}}],["965",{"pageContent":"167\n\nINTRODUCCIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":194,"lines":{"from":1,"to":3}}}}],["966",{"pageContent":"Las leucemias agudas (LA) son un grupo heterogéneo de padecimientos que suponen la proliferación desorde\n-\nnada de una clona de células hematopoyéticas. La falla de los mecanismos de control negativo del crecimiento\nclonal mutante casi siempre se debe a cambios en los genes reguladores, lo que conduce a una sobreproducción\nsin sentido de células incapaces de madurar y funcionar normalmente. Las células malignas individuales ma\n-\nduran con lentitud y de manera incompleta; el tiempo de su ciclo celular a menudo es prolongado y la mayoría\nde dichas células incompetentes sobreviven más que las normales, sin cumplir con su misión ordinaria.\nLa palabra\n \nleucemia\n \nsignifica “sangre blanca” y el término\n \naguda\n \nse conserva en la actualidad por\nrazones históricas. Antaño, los pacientes con leucemias “agudas” vivían menos que aquellos con leuce-\nmias “crónicas”, situación que ha cambiado por completo gracias al empleo de tratamientos cada vez más","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":194,"lines":{"from":5,"to":23}}}}],["967",{"pageContent":"mias “crónicas”, situación que ha cambiado por completo gracias al empleo de tratamientos cada vez más\neficaces. Un término más adecuado que el de “leucemia aguda” sería el de “leucemia de blastos”, dado\nque en estos trastornos el tipo predominante de célula maligna proliferante es una célula inmadura poco\ndiferenciada conocida como\n \nblasto\n. La proliferación descontrolada de estas células en la médula ósea, el\ndesplazamiento de los precursores medulares normales y la invasión del resto de los órganos son los me\n-\ncanismos principalmente responsables de los efectos devastadores de la enfermedad.\nLa letalidad media anual de las LA es de 3 a 5 casos por cada 100 000 habitantes y hay una tendencia no\n-\ntable al aumento del padecimiento. En los niños, las LA son la causa más frecuente de muerte por neoplasia.\nEn la segunda mitad del siglo XX ocurrieron avances importantes en el tratamiento de las leucemias agudas,\nque cambiaron de modo notable la creencia de que la palabra\nleucemia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":194,"lines":{"from":23,"to":38}}}}],["968",{"pageContent":"En la segunda mitad del siglo XX ocurrieron avances importantes en el tratamiento de las leucemias agudas,\nque cambiaron de modo notable la creencia de que la palabra\nleucemia\n \nera sinónimo de muerte a muy corto\nplazo. Estos avances han permitido que en la actualidad se curen casi todos los niños y aproximadamente un\ntercio de los adultos con LA linfoblástica. En el caso de las LA mieloblásticas, los avances terapéuticos han\nsido menos notables y las cifras de curación para niños y adultos oscilan en torno a 25 y 15%, respectivamente.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":194,"lines":{"from":38,"to":45}}}}],["969",{"pageContent":"ETIOLOGÍA\n\nLa causa precisa de las LA se desconoce. La proliferación clonal por medio de divisiones sucesivas a partir de\nuna célula progenitora constituye el origen de las leucemias agudas, tanto linfoblásticas como mieloblásticas.\n\nCAPÍTULO 12\n\nGuillermo J. Ruiz Argüelles\nGuillermo J. Ruiz Delgado\n\nObjetivos de aprendizaje\n\n•\n \nConocer la clasificación morfológica de las leucemias agudas y sus limitaciones.\n\n•\n \nEntender la clasificación inmunológica y citogenética de las leucemias agudas.\n\n•\n \nComprender la trascendencia de la clasificación citogenética de las leucemias agudas mieloides\ny sus marcadores moleculares.\n\n•\n \nDistinguir el cuadro clínico de una leucemia aguda.\n\n•\n \nComprender el diagnóstico y el tratamiento de las leucemias agudas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":194,"lines":{"from":47,"to":78}}}}],["970",{"pageContent":"•\n \nDistinguir el cuadro clínico de una leucemia aguda.\n\n•\n \nComprender el diagnóstico y el tratamiento de las leucemias agudas.\n\nLas leucemias agudas (LA)\nson un grupo heterogéneo de\npadecimientos que suponen la\nproliferación desordenada de\nuna clona de células hemato-\npoyéticas. La falla de los me-\ncanismos de control negativo\ndel crecimiento clonal mutante\ncasi siempre se debe a cambios\nen los genes reguladores, lo que\nconduce a una sobreproducción\nsin sentido de células incapa-\nces de madurar y funcionar\nnormalmente.\n\nLEUCEMIAS AGUDAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":194,"lines":{"from":78,"to":101}}}}],["971",{"pageContent":"168\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":195,"lines":{"from":1,"to":3}}}}],["972",{"pageContent":"La activación de oncogenes como\n \nMLL\n,\n \nMYC\n,\n \nABL\n,\n \nBCL-2\n \ny\n \nRAS\n, al igual que la formación de genes qui\n-\nméricos como\n \nBCR/ABL\n \n(leucemia linfoblástica aguda o mielocítica crónica),\n \nPML/RAR-\nα\n \n(leucemia aguda\npromielocítica), o AML1/ETO (leucemia aguda mieloblástica), probablemente sea multifactorial. Es posible\nque la exposición a derivados del benceno desempeñe algún papel en la leucemogénesis, así como la exposición\na radiaciones ionizantes. Los agentes que dañan el ácido desoxirribonucleico (DNA), como los alquilantes,\npueden causar leucemia; asimismo, las leucemias agudas secundarias al uso de sustancias quimioterapéuticas\npara otras enfermedades son muy agresivas. Algunos virus pueden generar leucemias; entre ellos es posible\nmencionar retrovirus como los virus linfotrópicos T humanos (HTLV) I y II, que tienen semejanzas con el virus\nHIV-1, agente causal del sida. Los padecimientos en los que hay inestabilidad cromosómica, como el síndrome","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":195,"lines":{"from":5,"to":39}}}}],["973",{"pageContent":"HIV-1, agente causal del sida. Los padecimientos en los que hay inestabilidad cromosómica, como el síndrome\nde Fanconi, pueden culminar en leucemia aguda, y la prevalencia de este tipo de leucemia es mayor en individuos\ncon trisomía del cromosoma 21 (síndrome de Down) que en la población general.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":195,"lines":{"from":39,"to":41}}}}],["974",{"pageContent":"CLASIFICACIÓN\n\nLa mejor clasificación que puede efectuarse de una LA es la clasificación MIC (morfológica, inmunoló-\ngica y citogenética).\n\nClasificación morfológica","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":195,"lines":{"from":43,"to":48}}}}],["975",{"pageContent":"En l976, fueron propuestos por un grupo internacional de investigadores (franceses, estadounidenses y\nbritánicos) los criterios para realizar la clasificación morfológica de las LA, que las dividía en nueve tipos,\ntres de estirpe linfoide y seis de estirpe mieloide. El desarrollo de esta clasificación franco-americano-bri-\ntánica (FAB) fue estimulado por la necesidad de un esquema que unificara los criterios morfológicos\ny sirviera para correlacionarlos con el pronóstico de la enfermedad. Algunos años más tarde, y ante el\ncúmulo de información generada por el uso de inmunorreactivos para estudiar y clasificar a las células\nleucémicas, los mismos miembros del grupo FAB agregaron a esta clasificación inicial dos variedades más\nde leucemia mieloblástica (MO y M7), las cuales estrictamente no pueden ser diagnosticadas solo con\nbases puramente morfológicas, ya que requieren estudios adicionales para ser definidas.\nEl\n \ncuadro 12-1","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":195,"lines":{"from":50,"to":61}}}}],["976",{"pageContent":"bases puramente morfológicas, ya que requieren estudios adicionales para ser definidas.\nEl\n \ncuadro 12-1\n \ndescribe los 11 tipos de LA que en la actualidad reconoce el grupo FAB. Esta clasificación\nmorfológica de las LA es la única que debe considerarse actualmente. Las\nfiguras 12-1\n \na\n \n12-9\n \nilustran algunas\nvariantes morfológicas de las LA, en tanto que las\n \nfiguras 12-10\n \ny\n \n12-11\n \nesquematizan las diferenciaciones\nlinfoide y mieloide, respectivamente, con la expresión de algunos de los antígenos de diferenciación que se\nemplean para definir los estadios celulares y para hacer la clasificación inmunológica de las leucemias.\nCuando se emplea la morfología panóptica convencional como medio único para efectuar la clasificación de\nlas leucemias agudas, se pueden cometer errores diagnósticos y, en consecuencia, terapéuticos en aproximada\n-\nmente el 20% de los casos de LA. Las equivocaciones más frecuentes son: no diferenciar entre variedades L1 y","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":195,"lines":{"from":61,"to":89}}}}],["977",{"pageContent":"-\nmente el 20% de los casos de LA. Las equivocaciones más frecuentes son: no diferenciar entre variedades L1 y\nM0, L2 y M0, L1 y M1, y L2 y M1; no reconocer las variantes M0 y M7; no distinguir una LAM-M3 micro\n-\ngranular de una LAM-M4, y no diferenciar una LAM-M5a de un linfoma centroblástico/inmunoblástico en\nfase leucémica. El empleo de tinciones citoquímicas de la clasificación inmunológica de las leucemias, de la cito\n-\ngenética, de la biología molecular y, en algunos casos, de la microscopia electrónica, permite establecer con cer\n-\nteza la naturaleza de las células malignas y, por lo tanto, efectuar un diagnóstico preciso y tratamiento adecuado.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":195,"lines":{"from":89,"to":98}}}}],["978",{"pageContent":"Clasificación inmunológica","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":195,"lines":{"from":100,"to":100}}}}],["979",{"pageContent":"Los marcadores inmunológicos, al identificar las células a través de sus características antigénicas, han per-\nmitido en el estudio de las células hematopoyéticas: a) reconocer estirpes o tipos celulares que difícilmente\npodrían clasificarse mediante métodos morfológicos y citoquímicos convencionales; b) establecer subgrupos\ninmunológicos en poblaciones celulares normales y en su contraparte leucémica; y c) definir poblaciones ce\n-\nlulares con propiedades biológicas específicas. Por lo tanto, mediante los métodos inmunológicos es posible\nreconocer antígenos (Ag) en la membrana o en el citoplasma de las células, algunos de los cuales son espe -\ncíficos para diferentes poblaciones celulares específicas. Para identificar dichos Ag se dispone de heteroan-\ntisueros contra inmunoglobulinas de superficie o citoplasmáticas y de múltiples anticuerpos monoclonales\n(AcMo) que identifican Ag citoplasmáticos o membranales. Algunos AcMo pueden ser específicos para una","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":195,"lines":{"from":102,"to":111}}}}],["980",{"pageContent":"(AcMo) que identifican Ag citoplasmáticos o membranales. Algunos AcMo pueden ser específicos para una\ndeterminada línea celular e incluso para un estadio concreto de maduración; otros, sin embargo, detectan\nAg más ampliamente distribuidos. La selección apropiada de un grupo de AcMo y de otros marcadores\nconvencionales permite establecer el origen de la mayoría de las leucemias, resultando de gran ayuda en\naquellos casos en los que los datos morfológicos y citoquímicos no son concluyentes. El\n cuadro 12-2\n \nmuestra","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":195,"lines":{"from":111,"to":118}}}}],["981",{"pageContent":"La\n \nactivación\n \nde\n \noncogenes\ncomo\n \nMLL,\n \nMYC,\n \nABL,\nBCL-2 y RAS, al igual que\nla formación de genes qui-\nméricos\n \ncomo\n \nTEL/AMLI,\nBCR/ ABL, PML/RAR-\nα\n,\nAML1/ETO, probablemente\nsea multifactorial.\nCuando se emplea la morfología\npanóptica\n \nconvencional\n \ncomo\nmedio único para efectuar la cla\n-\nsificación de las leucemias agu-\ndas, se pueden cometer errores\ndiagnósticos y, en consecuencia,\nterapéuticos\n \nen\n \naproximada-\nmente el 20% de los casos de LA.\nLa selección apropiada de un\ngrupo de AcMo y de otros mar-\ncadores convencionales permite\nestablecer el origen de la mayo-\nría de las leucemias, y resulta\nde gran ayuda en aquellos casos\nen los que los datos morfológicos\ny citoquímicos no son conclu-\nyentes.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":195,"lines":{"from":120,"to":171}}}}],["982",{"pageContent":"169\n\nCAPÍTULO 12. LEUCEMIAS AGUDAS\n\nCuadro 12-1.\n \nClasificación morfológica de las leucemias agudas\n\nLeucemias agudas linfoblásticas (LAL)\n\nLA-L1: linfoblástica “típica” LA-L2: linfoblástica “atípica”\nLA-L3: parecida al linfoma de Burkitt\n\nLeucemias agudas mieloblásticas (LAM)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":196,"lines":{"from":1,"to":14}}}}],["983",{"pageContent":"LA-M0: mieloblástica diferenciada mínimamente\nLA-M1: mieloblástica inmadura\nLA-M2: mieloblástica madura\nLA-M3: promielocítica hipergranular\nLA-M4: mielomonoblástica\nLA-M5: monoblástica pura\nLA-M6: eritroleucemia\nLA-M7: megacarioblástica\nla manera simplificada de realizar la asignación del fenotipo de las LA agudas de acuerdo con la expresión\nde los Ag u otros marcadores en células leucémicas. Se trata de una clasificación inmunológica simplificada,\nelaborada por un grupo de hematólogos latinoamericanos y adaptada a las limitaciones económicas de los\npaíses en desarrollo. Empleando pocos AcMo, este sistema realiza la clasificación de las LA en solo tres\nvariedades de repercusión pronóstica y terapéutica bien definida: leucemia aguda linfoblástica B, leucemia\naguda linfoblástica T y leucemia aguda mieloblástica, con dos estadios de maduración para cada variedad.\nEs importante resaltar que los anticuerpos monoclonales necesarios para llevar a cabo esta clasificación","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":196,"lines":{"from":16,"to":30}}}}],["984",{"pageContent":"Es importante resaltar que los anticuerpos monoclonales necesarios para llevar a cabo esta clasificación\nidentifican antígenos tanto de la superficie como del citoplasma celulares.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":196,"lines":{"from":30,"to":31}}}}],["985",{"pageContent":"Clasificación citogenética\n\nEn muchos casos de LA se encuentran alteraciones cromosómicas. En las LAM ocurren en más del 50%\nde los enfermos. Se han encontrado algunas correlaciones entre las anomalías cromosómicas y el tipo de\n\nFigura 12-1.\n \nLeucemia aguda linfoblástica L1.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":196,"lines":{"from":33,"to":40}}}}],["986",{"pageContent":"170\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":197,"lines":{"from":1,"to":3}}}}],["987",{"pageContent":"leucemia aguda. De las alteraciones únicas en la LAM, pueden señalarse la t(4:11) (q21;q23) de LAM-M4\n(mielomonoblástica), la t(8;21) (q22.1;q22.3) de LAM-M2 (mieloblástica con maduración), la t(15;17)\n(q22;q11.2) en LAM-M3 (promielocítica) y la inv(16) (p13.2q22) en LAM-M4Eo (mielomonoblástica\ncon eosinofilia). La respuesta al tratamiento en la LAM es mejor en sujetos que no presentan alteraciones\ncromosómicas; entre estas, las de mayor significado pronóstico en la LAM son tres: la translocación (15;17)\n(q22;q11.2) de la LAM-M3 (promielocítica), que produce el gen quimérico PML/RAR-\nα\n \n(de\n \npromyelocytic\nleukemia/retinoid acid receptor alpha\n); la translocación (8;21) de la LAM-M2, que da lugar al gen quimérico\nAML1/ETO (de\n \nacute myelogenous leukemia/eight twenty one\n); y la inversión del cromosoma 16 (inv16) de la\nleucemia mielomonoblástica con eosinofilia (LAM-M4Eo). La presencia de cualquiera de estas tres altera-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":197,"lines":{"from":5,"to":22}}}}],["988",{"pageContent":"acute myelogenous leukemia/eight twenty one\n); y la inversión del cromosoma 16 (inv16) de la\nleucemia mielomonoblástica con eosinofilia (LAM-M4Eo). La presencia de cualquiera de estas tres altera-\nciones genéticas en la LAM se asocia con un pronóstico menos sombrío, con mayor probabilidad de lograr\nla remisión y con supervivencias más prolongadas. Actualmente, es probable que las derivaciones terapéu-\nticas prácticas más importantes en la clasificación de las LAM dependan de su clasificación citogenética.\nEn las LAM, otros marcadores moleculares de valor pronóstico favorable y de respuesta al tratamien-\nto son los biomarcadores CBF-AML, NPM-1 y CEBPA, entre otros. Por otro lado, los biomarcadores\nFLT3-ITD (identificado en el 20% de los pacientes con LAM), WT1, RUNX1 y TET2 se asocian con\nun valor pronóstico pobre y de poca respuesta al tratamiento.\nEn las LAL, una alteración cromosómica frecuente es el cromosoma Philadelphia: t (9q+:22q-) (q34.1;q11.2),","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":197,"lines":{"from":22,"to":32}}}}],["989",{"pageContent":"un valor pronóstico pobre y de poca respuesta al tratamiento.\nEn las LAL, una alteración cromosómica frecuente es el cromosoma Philadelphia: t (9q+:22q-) (q34.1;q11.2),\nque produce también un gen quimérico llamado\n BCR/ABL\n \n(de\n \nbreakpoint cluster region\n/Abelson), el cual codi-\nfica la síntesis de las proteínas p190, característica de la leucemia linfoblástica, y p210, de la leucemia mieloide\ncrónica, ambas con función de tirosina-cinasa . El cromosoma Philadelphia aparece en el 2% de los enfermos\nde LAL infantil y hasta en el 25% de los casos adultos; su presencia se ha asociado con pronóstico sombrío. El\ngen\n \nMLL\n \n(de\n \nmixed lineage leukemia\n) (11q23) se localiza en el cromosoma 11 y se encuentra frecuentemente al\n-\nterado en la LAL y la LAM, especialmente cuando esa última es secundaria al empleo de fármacos inhibidores\nde la topoisomerasa II, y en algunas LAL de estirpe B; se asocia a un pronóstico sombrío.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":197,"lines":{"from":32,"to":54}}}}],["990",{"pageContent":"CUADRO CLÍNICO\n\nLos pacientes que sufren LA se presentan con síndromes hemorrágico, anémico o infiltrativo, ais -\nladamente o en combinación. La hemorragia puede deberse a trombocitopenia por invasión leu -\ncémica de médula ósea o a coagulopatía por consumo, como en casos de leucemia promielocítica\n(LAM-M3). La anemia se debe también a invasión tumoral de médula ósea y habitualmente es más\ngrave en la leucemia linfoblástica. De manera interesante, la anemia grave es un dato de buen pro -\nnóstico en la leucemia linfoblástica infantil. El síndrome infiltrativo supone crecimiento de ganglios,\nbazo o hígado; las leucemias con componente monoblástico infiltran las encías con mayor frecuencia\nque las leucemias linfoblásticas. La expansión de la cavidad medular por la proliferación celular mo -\nnoclonal puede causar dolores óseos. Las LAL de linfocitos T con frecuencia generan crecimiento\ndel timo, visible en telerradiografías del tórax. Solo la mitad de los enfermos con leucemia aguda","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":197,"lines":{"from":56,"to":67}}}}],["991",{"pageContent":"Cuadro 12-2.\n \nClasificación inmunológica de las leucemias agudas\n\nLeucemia\n \nVariantes\n \nAc. obligados\n \nAc. opcionales\n\nLAL T\n \nNinguna\n \nCD7, CD3c, CD2\nCD34, CD45 y TdT\nLAL B\nPro-B\nB común\nPre-B\nB\nCD79a, CD19,\nCD10, Ig, cadenas\nμ, HLA-DR, TdT,\nCD34 y CD45\nCD20 y CD38\nMieloblástica\n \nLAM 15:17++\nLAM 15:17–\nMPOc, CD13, CD33\nCD117, CD34,\nCD15,HLA-DR y CD45\nCD36 y CD64\nAc. = anticuerpo; LAL T = leucemia aguda linfoblástica T; LAL B = leucemia aguda linfoblástica B; LAM = leucemia\naguda mieloblástica; CD = designación de grupo (\ncluster designation\n); Ig = inmunoglobulina de superficie; TdT = trans-\nferasa de desoxinucleótidos terminales identificada por anticuerpo monoclonal; MPOc = mieloperoxidasa citoplasmática\nidentificada por anticuerpo monoclonal.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":197,"lines":{"from":69,"to":110}}}}],["992",{"pageContent":"Las\n \nde\n \nmayor\n \nsignificado\npronóstico\n \nen\n \nla\n \nLAM\n \nson\ntres: la translocación (15;17)\n(q22;q11,2) de la LAM-M3\n(promielocítica), que produce el\ngen quimérico PML/ RAR-\nα\n;\nla translocación (8;21) de la\nLAM-M2, que da lugar al\ngen quimérico AMLI/ETO; y\nla inversión del cromosoma 16\n(inv 16) de la leucemia mielo-\nmonoblástica\n \ncon\n \neosinofilia\n(LAM-M4Eo).\nEn las LAM, otros marcado-\nres moleculares de valor pro-\nnóstico favorable y de respuesta\nal tratamiento son los biomar-\ncadores CBF-AML, NPM-1\ny CEBPA, entre otros. Por\notro lado, los biomarcadores\nFLT3-ITD (identificado en\nel 20% de los pacientes con\nLAM),\n \nWT1,\n \nRUNX1\n \ny\nTET2 se asocian con un valor\npronóstico pobre y de poca res-\npuesta al tratamiento.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":197,"lines":{"from":112,"to":163}}}}],["993",{"pageContent":"171\n\nCAPÍTULO 12. LEUCEMIAS AGUDAS\n\nmuestra incremento en leucocitos; una cuarta parte tiene cifras de leucocitos en rangos normales y\notra cuarta parte presenta disminución leucocitaria. Por ende, nunca debe descartarse el diagnóstico\nde LA solo porque la cuenta de glóbulos blancos sea normal.\n\nDIAGNÓSTICO\n\nEl diagnóstico de LA se efectúa con el estudio de extendidos de sangre periférica o aspirados de médula ósea, em\n-\npleando tinciones pancromáticas del tipo May-Grunwald-Giemsa, Wright o Romanowsky. Cuando la invasión\nblástica de la sangre periférica es muy grave, no hay dificultad para establecer el diagnóstico de LA; esto ocurre\nsobre todo en casos de LAL, por lo que en algunas ocasiones no es estrictamente necesario llevar a cabo el estudio\nde la médula ósea. Sin embargo, cuando existen dudas o cuando la invasión por blastos de la sangre periférica no\n\nFigura 12-3.\n \nLeucemia aguda linfoblástica L3.\n\nFigura 12-2.\n \nLeucemia aguda linfoblástica L2.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":198,"lines":{"from":1,"to":24}}}}],["994",{"pageContent":"172\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":199,"lines":{"from":1,"to":3}}}}],["995",{"pageContent":"es tan grave, sí es necesario hacer este estudio. Idealmente debe realizarse siempre la biopsia de hueso, junto con\nel aspirado de la médula, para lo cual se emplean agujas especiales que permiten ejecutar ambos procedimientos\nen una sola punción; el prototipo de estas agujas es la de Jamshidi\n®\n, con la que debe puncionarse de preferencia\nla cresta ilíaca. El aspirado de la médula ósea del esternón cada vez se usa menos porque en ese sitio no se puede\nhacer la biopsia de hueso. Se acepta que se requiere que más del 20% de las células nucleadas de la médula ósea\nsean blastos para establecer el diagnóstico certero de LA. Cuando la invasión por blastos de la sangre periférica es\nmasiva, se infiere que hay más de 20% de blastos en la médula ósea. La presencia de cuerpos o bastones de Auer en\nlas células leucémicas de sangre periférica o de médula ósea es suficiente para establecer el diagnóstico inequívoco\nde LAM. La identificación de las proteínas de fusión PML/RAR-\nα","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":199,"lines":{"from":5,"to":16}}}}],["996",{"pageContent":"las células leucémicas de sangre periférica o de médula ósea es suficiente para establecer el diagnóstico inequívoco\nde LAM. La identificación de las proteínas de fusión PML/RAR-\nα\n, AML1/ETO, BCR/ABL u otras por\nmedio de biología molecular empleando reacción en cadena de la polimerasa (PCR) permite establecer tanto el\ndiagnóstico como la variedad de la leucemia, y es también útil en el seguimiento de los pacientes, para identificar\nla enfermedad residual mínima una vez lograda la remisión completa del padecimiento.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":199,"lines":{"from":16,"to":22}}}}],["997",{"pageContent":"TRATAMIENTO","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":199,"lines":{"from":24,"to":24}}}}],["998",{"pageContent":"El tratamiento de un individuo con leucemia aguda siempre debe ser conducido por un hematólogo u oncólogo\ncapacitado. Los medicamentos que pueden utilizarse tienen diversos efectos: agentes alquilantes como ciclofos\n-\nfamida, clorambucilo, busulfano y nitrosureas (BCNU, CCNU); antimetabolitos como metotrexato, 6-mercap\n-\ntopurina, arabinósido de citosina, 6-tioguanina, hidroxiurea y azatioprina; sustancias que se fijan al DNA como\nlas antraciclinas (daunorrubicina, adriamicina, mitoxantrona o idarrubicina); inhibidores de la mitosis como al\n-\ncaloides de la vinca (vincristina, vinblastina, vindesina); inhibidores de la topoisomerasa II (etopósido, tenipósi\n-\ndo, topotecán), y medicamentos misceláneos como corticoides, L-asparaginasa, interferones, desoxicoformicina\n(pentostatina), 2 cloro-desoxiadenosina (cladribina), fludarabina, ácido holotransrretinoico, etcétera.\nLa manera de administrar y combinar estos fármacos y las fases del tratamiento depende del tipo de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":199,"lines":{"from":26,"to":38}}}}],["999",{"pageContent":"La manera de administrar y combinar estos fármacos y las fases del tratamiento depende del tipo de\nLA que sufra el paciente. Muchos hematólogos usan antibióticos (cotrimoxazol, quinolonas), antimicóticos\n(itraconazol, fluconazol) e inhibidores de la fibrinólisis (ácido\n \n¡\n-aminocaproico) de manera profiláctica en\nlos pacientes leucémicos, cuando se prevé que van a generarse granulocitopenias o trombocitopenias iatro-\ngénicas, o ambas. En enfermos con trombocitopenia grave (menos de 10 a 15 × 10\n9\n/L), se emplean trans-\nfusiones de concentrados plaquetarios (4 unidades/m\n \n2\n) cada 24 a 48 horas para evitar sangrados profusos.\nLa instalación de catéteres centrales de duración prolongada, como el catéter de Hickman o los tipo\nPort, facilita la venoclisis de medicamentos, las transfusiones y la extracción de muestras, además de que\nproporciona al paciente comodidad y disminuye el riesgo de infección en los sitios de venipuntura; en","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":199,"lines":{"from":38,"to":54}}}}],["1000",{"pageContent":"proporciona al paciente comodidad y disminuye el riesgo de infección en los sitios de venipuntura; en\nalgunos centros de tratamiento de pacientes con leucemia se emplean rutinariamente.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":199,"lines":{"from":54,"to":55}}}}],["1001",{"pageContent":"Figura 12-4.\n \nLeucemia aguda mieloblástica M1. Imagen cortesía del Dr. Joaquín Carrillo.\n\nSe acepta que se requiere que\nmás del 20% de las células\nnucleadas de la médula ósea\nsean blastos para establecer el\ndiagnóstico certero de LA.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":199,"lines":{"from":57,"to":65}}}}],["1002",{"pageContent":"173\n\nCAPÍTULO 12. LEUCEMIAS AGUDAS\n\nDesde el punto de vista pronóstico, en términos generales, puede decirse que, con los tratamientos anti-\nleucémicos modernos, alrededor del 90% de los pacientes con LAL, sobre todo los niños, logran la remisión\ncompleta de la enfermedad y que más del 60% de ellos lograrán sobrevivir más de 5 años después del diag\n-\nnóstico, libres de enfermedad. En cambio, en el caso de los pacientes con LAM, la probabilidad de lograr la\nremisión completa es de 60 a 70% y la de supervivencia a 5 años aproximadamente 20%. En consecuencia,\nes claro que los pacientes con LAM tienen un pronóstico mucho más sombrío que el de aquellos con LAL.\n\nLeucemias agudas linfoblásticas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":200,"lines":{"from":1,"to":13}}}}],["1003",{"pageContent":"Las características iniciales del enfermo con LAL permiten predecir con cierta seguridad la respuesta a la\nterapéutica y las probabilidades de supervivencia prolongada o curación. Esto indica que la enfermedad es\nheterogénea y variable en presentación, morfología, inmunología, citogenética, bioquímica, etcétera. Por\notra parte, las características del paciente también influyen en el pronóstico: edad, sexo, estado nutricional\ny raza. La división en grupos de riesgo de los sujetos con LAL es un tanto arbitraria; en general se acepta\nque la edad, el sexo, el estado nutricional y el recuento leucocitario son datos muy importantes, seguidos\nde la estirpe T o B de la leucemia y los cambios cromosómicos en un cariotipo de médula ósea. Conocer el\ninmunofenotipo del blasto permite separar las leucemias tipos T y B. La leucemia tipo T tiene tratamiento\ndiferente y peor pronóstico cuando se presenta con hiperleucocitosis; las LAL de estirpe B tienen un curso","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":200,"lines":{"from":15,"to":23}}}}],["1004",{"pageContent":"diferente y peor pronóstico cuando se presenta con hiperleucocitosis; las LAL de estirpe B tienen un curso\nmenos agresivo y las LAL con antígenos mieloides son de mal pronóstico. La presencia del BCR/ABL en\nlas LAL supone un peor pronóstico y un tratamiento diferente.\nSe clasifican como pacientes de riesgo “habitual” o “normal” aquellos con edades entre 18 meses y\n10 años, estado nutricional normal, menos de 30 000 leucocitos al diagnóstico, leucemias de estirpe B,\nausencia de translocaciones o de marcadores mieloides, carencia de infiltración al sistema nervioso central\nal diagnóstico y contenido euploide o hiperdiploide de ácido desoxirribonucleico. En los niños, el estado\nnutricional tiene valor pronóstico, ya que los niños desnutridos responden menos favorablemente al tra-\ntamiento antileucémico. Las LAL de los adultos tienen un pronóstico más sombrío que las pedíatricas, si\nbien las características terapéuticas generales son parecidas.\nEl tratamiento se realiza en varias fases:\n1.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":200,"lines":{"from":23,"to":34}}}}],["1005",{"pageContent":"bien las características terapéuticas generales son parecidas.\nEl tratamiento se realiza en varias fases:\n1.\n \nInducción a la remisión.\n \nEn esta fase se pretende destruir la mayoría de las células leucémicas y\nrecuperar la hematopoyesis normal y el bienestar del paciente. Para ello se utilizan fármacos que no\nafectan mayormente la síntesis del DNA (vincristina, prednisona, asparaginasa), no producen daño\na la médula ósea normal y actúan rápidamente, pero no son útiles para tratamiento a largo plazo.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":200,"lines":{"from":34,"to":43}}}}],["1006",{"pageContent":"Figura 12-5.\n \nLeucemia aguda mieloblástica M3. Imagen cortesía del Dr. Joaquín Carrillo\n\nEn los niños, el estado nu-\ntricional tiene un gran valor\npronóstico, ya que los desnu-\ntridos\n \nresponden\n \nmenos\n \nfa-\nvorablemente al tratamiento\nantileucémico.\nDesde el punto de vista pro-\nnóstico, en términos genera-\nles, puede decirse que, con los\ntratamientos\n \nantileucémicos\nmodernos, alrededor del 90%\nde los pacientes con LAL, sobre\ntodo los niños, logran la remi-\nsión completa de la enferme-\ndad y que más del 60% de ellos\nlograrán\n \nsobrevivir\n \nmás\n \nde\n5 años después del diagnóstico,\nlibres de enfermedad. En cam-\nbio, en el caso de los pacientes\ncon LAM, la probabilidad de\nlograr la remisión completa es\nde 60 a 70% y la de supervi-\nvencia a 5 años es de aproxi-\nmadamente 20% .","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":200,"lines":{"from":45,"to":86}}}}],["1007",{"pageContent":"174\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":201,"lines":{"from":1,"to":3}}}}],["1008",{"pageContent":"En las LAL con BCR/ABL, deben incluirse medicamentos inhibidores de la tirosina-cinasa, como\nimatinib, dasatinib, nilotinib y otros.\nLos pacientes con LAL BCR/ABL positivo requieren un tratamiento más intensivo con quimiote-\nrapia, trasplante alogénico/autólogo de células hematopoyéticas e inhibidor de tirosina cinasa oral\n(imatinib, nilotinib o dasatinib).\n2.\n \nTratamiento posremisión.\n \nEl objetivo es destruir las células residuales que han sobrevivido en la\netapa previa; se pueden utilizar medicamentos que afecten la síntesis de DNA e, idealmente, que\npuedan destruir células en reposo o fuera de ciclo, en la fase G0 del ciclo celular.\n3.\n \nTratamiento preventivo de la leucemia meníngea.\n \nA esta etapa también se le llama “profilaxis\ndel sistema nervioso central”, ya que la quimioterapia intravenosa no alcanza niveles óptimos en\ndicho sistema. Se administran fármacos por vía intratecal (metotrexato, arabinósido de citosina y","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":201,"lines":{"from":5,"to":23}}}}],["1009",{"pageContent":"del sistema nervioso central”, ya que la quimioterapia intravenosa no alcanza niveles óptimos en\ndicho sistema. Se administran fármacos por vía intratecal (metotrexato, arabinósido de citosina y\ncorticoides) para destruir células que se han alojado en este sitio. También se ha recurrido a radio-\nterapia craneal, práctica que tiende a abandonarse y que se reserva para los pacientes de alto riesgo\ncomo aquellos con hiperleucocitosis en el momento del diagnóstico. De no llevarse el tratamiento\npreventivo de la leucemia meníngea, más del 50% de los enfermos recaerán en el sistema nervioso\ncentral.\n4.\n \nTratamiento de continuación.\n \nEn esta fase, también llamada “de mantenimiento de la remisión”,\nel objetivo es destruir los últimos vestigios de leucemia residual, utilizando medicamentos que\ninterfieran en la síntesis de DNA (mercaptopurina y metotrexato), produciendo en consecuen-\ncia mielosupresión. Estos fármacos son tolerados adecuadamente y se administran durante 2 a 3","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":201,"lines":{"from":23,"to":37}}}}],["1010",{"pageContent":"interfieran en la síntesis de DNA (mercaptopurina y metotrexato), produciendo en consecuen-\ncia mielosupresión. Estos fármacos son tolerados adecuadamente y se administran durante 2 a 3\naños consecutivos; además pueden utilizarse otros tipos de quimioterapias intermitentes, como la\nadministración de vincristina, prednisona, antraciclinas, citarabina, etopósido, tenipósido, me-\ntotrexato a dosis altas, etcétera. En las LAL con BCR/ABL, en esta fase del tratamiento deben\nincluirse también medicamentos inhibidores de la tirosina-cinasa, como imatinib, dasatinib, nilo-\ntinib y otros.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":201,"lines":{"from":37,"to":43}}}}],["1011",{"pageContent":"Leucemias mieloblásticas\n\nLos avances más notables se han realizado en el tratamiento de la LAL pediátrica, en donde ha sido\nposible la curación de la enfermedad; esto se entiende como la remisión completa sostenida por más de 5\naños, lo cual ocurre en aproximadamente el 90% de los casos. Sin embargo, en las leucemias agudas mie-\nloblásticas (LAM), aunque existe notable mejoría en los resultados terapéuticos a largo plazo, las posibili-\ndades de remisión completa y sostenida son menores, del orden del 15 al 40% a 5 años; ello, a pesar de los\n\nFigura 12-6.\n \nLeucemia aguda mieloblástica M4. Imagen cortesía del Dr. Joaquín Carrillo.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":201,"lines":{"from":45,"to":55}}}}],["1012",{"pageContent":"Figura 12-6.\n \nLeucemia aguda mieloblástica M4. Imagen cortesía del Dr. Joaquín Carrillo.\n\nEn las LAM, aunque existe\nnotable mejoría en los resulta-\ndos terapéuticos a largo plazo,\nlas posibilidades de remisión\ncompleta y sostenida son me-\nnores, del orden de 15 a 40%\na 5 años.\nLos pacientes con LAL BCR/\nABL positivo requieren un\ntratamiento\n \nmás\n \nintensivo\ncon quimioterapia, trasplante\nalogénico/autólogo de células\nhematopoyéticas e inhibidor\nde tirosina cinasa oral (ima-\ntinib, nilotinib o dasatinib).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":201,"lines":{"from":55,"to":77}}}}],["1013",{"pageContent":"175\n\nCAPÍTULO 12. LEUCEMIAS AGUDAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":202,"lines":{"from":1,"to":3}}}}],["1014",{"pageContent":"avances en el desarrollo de nuevos medicamentos antileucémicos, apoyo transfusional y antimicrobiano\ny advenimiento del trasplante de médula ósea. Excluyendo a las leucemias agudas promielocíticas, que\nrequieren de un tratamiento muy diferente y que tienen muy buen pronóstico, las probabilidades de lograr\nla remisión completa en la LAM con quimioterapia varían entre 50 y 70%. El enfermo con LAM requiere\nayuda suficiente para evitar las complicaciones propias de la entidad o de la quimioterapia. Se necesita\napoyo transfusional suficiente, en particular en lo relativo a la transfusión de concentrados plaquetarios\nque eviten hemorragias letales; también se requiere uso de antimicrobianos y antimicóticos profilácticos\npara prevenir la infección por gérmenes patógenos oportunistas durante los períodos de neutropenia.\nExcluyendo a las LAM-M3, que deben tratarse de manera totalmente diferente, el tratamiento quimio-\nterapéutico en las LAM se hace habitualmente en tres etapas:","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":202,"lines":{"from":5,"to":14}}}}],["1015",{"pageContent":"Figura 12-7.\n \nLeucemia aguda mieloblástica M5 y M5b. Imagen cortesía del Dr. Joaquín Carrillo.\n\nSe necesita apoyo transfusio-\nnal suficiente, en particular\nen lo relativo a la transfusión\nde concentrados plaquetarios\nque eviten hemorragias leta-\nles; también se requiere uso de\nantimicrobianos y antimicóti-\ncos profilácticos para evitar la\ninfección por gérmenes pató-\ngenos oportunistas durante los\nperíodos de neutropenia.\n\nFigura 12-8.\n \nLeucemia aguda mieloblástica M6. Imagen cortesía del Dr. Joaquín Carrillo.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":202,"lines":{"from":16,"to":34}}}}],["1016",{"pageContent":"176\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":203,"lines":{"from":1,"to":3}}}}],["1017",{"pageContent":"1.\n \nInducción a la remisión.\n \nSe debe lograr que desaparezca clínica y hematológicamente el cuadro\nleucémico (menos de 5% de blastos en médula ósea, sin blastos en sangre periférica; más de 1 000\nneutrófilos absolutos, sin otras citopenias). La mayoría de los esquemas de inducción a remisión\ncombinan arabinósido de citosina con un antracíclico. En esta fase se induce hipoplasia medular\ngrave para que posteriormente se recupere solo la médula ósea normal; es en esta etapa cuando se\nprecisa apoyo transfusional y medicamentoso enérgico.\n2.\n \nTratamiento posremisión.\n \nLa terapéutica posterior a que la entidad ha remitido por completo,\ny su efecto sobre la prolongación de la remisión y de la supervivencia, aún resultan polémicos.\nVarios autores han demostrado que el tratamiento quimioterapéutico posremisión con uno o más\ncursos de arabinósido de citosina a dosis altas, en ocasiones combinado con asparaginasa, pro -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":203,"lines":{"from":5,"to":22}}}}],["1018",{"pageContent":"Varios autores han demostrado que el tratamiento quimioterapéutico posremisión con uno o más\ncursos de arabinósido de citosina a dosis altas, en ocasiones combinado con asparaginasa, pro -\nlonga la duración de la remisión. Cuando es posible, cabe utilizar trasplante de células hemato -\npoyéticas de médula ósea o de sangre periférica; este puede ser alogénico o autotrasplante. En las\nLAM con marcadores citogenéticos de “buen” pronóstico es probable que la sola quimioterapia\nposremisión sea suficiente, en tanto que el trasplante de células hematopoyéticas podría ser útil\nen los casos con factores pronósticos desfavorables.\n3.\n \nTratamiento de continuación.\n \nSe apoya en el uso de fármacos citorreductores que se administran\ndurante 24 a 36 meses. A diferencia de lo que se ha observado en la LAL, en la LAM el trata-\nmiento de continuación o mantenimiento de la remisión no parece ofrecer mayores ventajas en la\nsupervivencia a largo plazo, si se ha empleado tratamiento posremisión suficiente.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":203,"lines":{"from":22,"to":36}}}}],["1019",{"pageContent":"Tratamiento de algunas formas específicas de LAM","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":203,"lines":{"from":38,"to":38}}}}],["1020",{"pageContent":"La leucemia aguda promielocítica (LAM-M3) se caracteriza por rearreglos en los receptores\n \nα\n \ndel\nácido retinoico secundarios a la formación del gen quimérico\n \nPML/R AR-\nα\n \nresultante de la transloca-\nción cromosómica (15;17), que codifica la producción de un receptor\n \nα\n \nmutado para el ácido retinoico,\nmismo que no responde a niveles normales de tretinoína o ácido holotransrretinoico (ATRA), pero sí\na concentraciones muy altas de este. En este grupo de pacientes, el empleo de ATRA produce remi -\nsiones completas en más del 90% de los casos. El empleo de ATRA como agente único se asocia con\nrecaídas en casi todos los pacientes después de haber logrado la remisión, por lo que se requiere un\nesquema combinado de tratamiento con ácido holotransrretinoico y quimioterapia mielosupresora, pre -\nferentemente con antracíclicos; en la actualidad todo paciente con LAM-M3 debe recibir tratamiento\ninicial con ATRA/antraciclina; solo debe ofrecerse ATRA a los pacientes en quienes se demuestre la","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":203,"lines":{"from":40,"to":62}}}}],["1021",{"pageContent":"ferentemente con antracíclicos; en la actualidad todo paciente con LAM-M3 debe recibir tratamiento\ninicial con ATRA/antraciclina; solo debe ofrecerse ATRA a los pacientes en quienes se demuestre la\ntranslocación t(15:17) o la proteína de fusión PML/RAR-\n \nα\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":203,"lines":{"from":62,"to":67}}}}],["1022",{"pageContent":"Figura 12-9.\n \nLeucemia aguda mieloblástica M7. Imagen cortesía del Dr. Joaquín Carrillo.\n\nTodo paciente con LAM-M3\ndebe recibir ATRA como trata-\nmiento inicial. Estrictamente,\nsolo debe ofrecerse ATRA a los\npacientes en quienes se demues-\ntre la translocación t(15:17) o\nla proteína de fusión PML/\nRAR-\nα\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":203,"lines":{"from":69,"to":82}}}}],["1023",{"pageContent":"177\nCAPÍTULO 12.\n \nL\n \nE\n \nU\n \nC\n \nE\n \nM\n \nI\n \nA\n \nS\n \nA\n \nG\n \nU\n \nD\n \nA\n \nS\n\nFigura 12-10.\n \nDiferenciación linfoide. Abreviaturas: TdT = trasferencia terminal de desoxinucleótidos; IgH R = inmunoglo-\nbulina de cadena pesada, rearreglada; IgL R = inmunoglobulina de cadena ligera rearreglada; cIgM = cadena citoplasmática M;\ncCD3 = CD3 citoplasmático; TCR R = receptor T, rearreglado.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":204,"lines":{"from":1,"to":38}}}}],["1024",{"pageContent":"178\nFUNDAMENTOS DE HEMATOLOGÍA\n\nFigura 12-11.\n \nDiferenciación mieloide. Abreviaturas: D = designación de grupo (\ncluster designation\n); UFB = unidad forma-\ndora de brotes; UFC = unidad formadora de colonias; HLA-DR = antígeno leucocitario humano relacionado con el locus D\ndel cromosoma clase II.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":205,"lines":{"from":1,"to":10}}}}],["1025",{"pageContent":"179\n\nCAPÍTULO 12. LEUCEMIAS AGUDAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":206,"lines":{"from":1,"to":3}}}}],["1026",{"pageContent":"En las leucemias agudas con componentes monocíticos (LAM-M4 y LAM-M5), la infiltración al\nsistema nervioso central es probablemente más frecuente que en otras variedades de leucemias mieloides,\npor lo que algunos autores sugieren un tratamiento profiláctico con quimioterapia intratecal; en general,\neste no debe efectuarse de manera rutinaria, como en los casos de leucemias linfoblásticas. Los niños\ncon estas variedades de leucemia y con recuentos muy altos de leucocitos en el momento del diagnóstico\nprobablemente se beneficien con dicha terapéutica profiláctica. Las combinaciones de quimioterapia que\nincluyen inhibidores de la topoisomerasa II, como topotecán, etopósido y tenipósido, parecen ser más\nútiles en las leucemias con componente monoblástico.\nEn las leucemias agudas megacarioblásticas (M7), el pronóstico no es peor que el de otros pacientes\ncon otras formas de LAM, como inicialmente se había supuesto. Es frecuente que los enfermos obtengan","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":206,"lines":{"from":5,"to":14}}}}],["1027",{"pageContent":"En las leucemias agudas megacarioblásticas (M7), el pronóstico no es peor que el de otros pacientes\ncon otras formas de LAM, como inicialmente se había supuesto. Es frecuente que los enfermos obtengan\nremisiones con dosis baja de citarabina, pero estas son de corta duración si no se utiliza quimioterapia\nagresiva u otros tratamientos posremisión.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":206,"lines":{"from":14,"to":17}}}}],["1028",{"pageContent":"Leucemias agudas bifenotípicas y de linaje mixto\n\nSon un grupo de leucemias poco frecuentes, que representan entre el 3 y el 5% de todas las leucemias\nagudas. Poseen características inmunofenotípicas de células precursoras linfoides y mieloides.\nEl tratamiento óptimo de este tipo de leucemia no está bien definido, aunque los protocolos de trata-\nmiento de LAL han mostrado resultados alentadores. En general, su pronóstico es desfavorable y la gran\nmayoría de ellas requieren trasplante de células hematopoyéticas.\n\nOtras alternativas terapéuticas en leucemia aguda","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":206,"lines":{"from":19,"to":27}}}}],["1029",{"pageContent":"Se han estudiado otras alternativas terapéuticas en las LA, como otros agentes de diferenciación celular\nademás del ATRA. La inyección intravenosa de anticuerpos monoclonales tiene efecto transitorio y no logra\nremisiones duraderas; el más usado es el gemtuzumab-ozogamicina. El factor de necrosis tumoral y la inter-\nleucina-2 tienen capacidad lítica sobre las células leucémicas. El empleo de factores de crecimiento o hemolin\n-\nfopoyetinas humanas recombinantes, como el factor estimulante de colonias de granulocitos (G-CSF), o de\ngranulocitos y monocitos (GM-CSF), podría ser útil en el tratamiento de los pacientes con LAM, acortando\nla duración de la neutropenia iatrogénica, pero no parece tener repercusión favorable en la respuesta al trata-\nmiento antileucémico. Es muy probable que el empleo de la trombopoyetina o agentes similares (eltrombopag,\nromiplostim) acorte la duración de la trombocitopenia iatrogénica que debe ocurrir en el tratamiento de los","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":206,"lines":{"from":29,"to":38}}}}],["1030",{"pageContent":"romiplostim) acorte la duración de la trombocitopenia iatrogénica que debe ocurrir en el tratamiento de los\npacientes con LAM. En casos de LAL, el uso de estas hemolinfopoyetinas no ha mostrado mayores ventajas.\nEl uso de anticuerpos monoclonales anti-CD20, CD22 y CD19 ha mostrado utilidad en el trata -\nmiento de algunas LAL.\nEl trasplante de células hematopoyéticas, antaño llamado “trasplante de médula ósea”, es un recurso\nterapéutico imprescindible en el tratamiento actual de los pacientes con LAM; los resultados son mejores\ncuando se lleva a cabo en primera remisión, comparado con después de que el paciente ha sufrido una re-\ncaída leucémica. En el capítulo 23 se analizan las indicaciones y resultados de esta modalidad terapéutica.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":206,"lines":{"from":38,"to":45}}}}],["1031",{"pageContent":"CONCLUSIONES\n\n•\n \nLas leucemias agudas son un grupo de enfermedades malignas hemáticas que se caracterizan por\nla proliferación incontrolada de una clona de células inmaduras de la hematopoyesis que infiltran\na la médula ósea e invaden la sangre periférica y otros órganos.\n\n•\n \nEl pronóstico y el tratamiento dependen del tipo de leucemia aguda.\n\n•\n \nLa gran mayoría de las leucemias agudas requieren de trasplante de células hematopoyéticas para su curación.\n\nPREGUNTAS DE AUTOEVALUACIÓN\n\n1. ¿Cuál es el marcador molecular de mayor agresividad en LAL?\na.\n \nNPM-1\nb. BCR-ABL\nc.\n \nCEBPA\n\nEl\n \ntratamiento\n \nóptimo\n \nde\neste tipo de leucemia no está\nbien\n \ndefinido,\n \naunque\n \nlos\nprotocolos de tratamiento de\nLAL han mostrado resulta-\ndos alentadores. En general,\nsu pronóstico es desfavorable\ny la gran mayoría de ellas\nrequieren trasplante de célu-\nlas hematopoyéticas.\nEl uso de anticuerpos mono-\nclonales anti-CD20, CD22 y\nCD19 ha mostrado utilidad en\nel tratamiento de algunas LAL.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":206,"lines":{"from":47,"to":99}}}}],["1032",{"pageContent":"180\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\n2. ¿Qué porcentaje de blastos en sangre periférica y en médula ósea se requiere para realizar el diagnóstico\nde leucemia aguda?\na.\n \nMás del 20%\nb. Más del 40%\nc.\n \nMás del 60%\n3. De acuerdo a la clasificación morfológica de las LAL, ¿cuál es la que se asemeja al linfoma de Burkitt?\na.\n \nLA-L1\nb. LA-L2\nc.\n \nLA-L3\n4. ¿Cuál es la LAM más común en México y que se asocia a coagulación intravascular diseminada?\nd. M3\ne.\n \nM4\nf.\n \nM5\n5. ¿Cuál es el único tratamiento curativo de las leucemias agudas mieloides?\na.\n \nTrasplante de células hematopoyéticas\nb. Quimioterapia\nc.\n \nRadioterapia\n\nBIBLIOGRAFÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":207,"lines":{"from":1,"to":39}}}}],["1033",{"pageContent":"Deffis-Court M, Alvarado-Ibarra M, Ruiz-Argüelles GJ, Rosas-López A, Barrare-Lumbreras G, Aguayo-González\nA, et al. Diagnosing and treating mixed phenotype acute leukemia: A multicenter 10-year experience in Mexico.\n[Epub ahead of print). Ann Hematol; 2013.\nGutiérrez-Aguirre CH, Gómez-Almaguer D, et al. Non-myeloablative stem cell transplantation in patients with\nrelapsed acute lymphoblastic leukemia: Results of a multicenter study. Bone Marrow Transplant. 2007: 40:\n535-539.\nLobato-Mendizábal E, Ruiz-Argüelles GJ, et al. Dosis altas de arabinósido de citosina en el tratamiento de pacientes\ncon leucemia aguda refractaria o en recaída. Rev Invest Clin (Mex). 1989; 41: 139-145.\nLobato-Mendizábal E, Marín-López A, et al. Congenital acute megakaryoblastic leukemia in Down’s syndrome.\nLeuk Lymph. 1990; 2: 137-139.\nLobato-Mendizábal E, Ruíz-Argüelles GJ, et al. Tratamiento a largo plazo y factores pronósticos en la leucemia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":207,"lines":{"from":41,"to":51}}}}],["1034",{"pageContent":"Leuk Lymph. 1990; 2: 137-139.\nLobato-Mendizábal E, Ruíz-Argüelles GJ, et al. Tratamiento a largo plazo y factores pronósticos en la leucemia\naguda mieloblástica del adulto. Experiencia del grupo INNSZ (Puebla-Monterrey-México). Rev Invest Clin.\n1991;43:215-222.\nRego EM, Kim HT, Ruiz-Argüelles GJ, Uriarte M del R, Jacomo RH, Gutiérrez-Aguirre H, et al. ¾e impact\nof medical education and networking on the outcome of leukemia treatment in developing countries. ¾e\nexperience of International Consortium on Acute Promyelocytic Leukemia (IC-APL). Hematology. 2012; 17\n(Suppl 1): 36-8.\nRego EM, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte MD, Jacomo RH, et al. Improving acute promyelo-\ncytic leukemia (APL) outcome in developing countries through networking, results of the International Consor-\ntium on APL. Blood. 2013; 121: 1935-43.\nRuiz-Argüelles A, Rivadeneyra-Espinoza L, et al. Report on the second Latin American consensus conference for","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":207,"lines":{"from":51,"to":62}}}}],["1035",{"pageContent":"tium on APL. Blood. 2013; 121: 1935-43.\nRuiz-Argüelles A, Rivadeneyra-Espinoza L, et al. Report on the second Latin American consensus conference for\nflow cytometric immunophenotyping of hematological malignancies. Cytometry. 1005; 70B: 39-44.\nRuiz-Argüelles GJ, Apreza-Molina MG, et al. Outpatient supportive therapy after induction to remission therapy\nin adult acute myelogenous leukaemia (AML) is feasible: A multicentre study. Eur J Haematol. 1995; 54: 18-20.\nRuiz-Argüelles GJ, Gómez-Almaguer D, et al. Allogeneic hematopoietic stem cell transplantation with non-mye-\nloablative conditioning in patients with acute myelogenous leukemia eligible for conventional allografting: A\nprospective study. Leukemia Lymphoma. 2004; 45: 1191-1195.\nRuiz-Argüelles GJ, Lobato-Mendizábal E, et al. Long-term results of the treatment of patients with acute megacaryo-\nblastic leukaemia: A multicenter study. Brit J Haematol. 1992; 82: 671-675.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":207,"lines":{"from":62,"to":71}}}}],["1036",{"pageContent":"181\n\nCAPÍTULO 12. LEUCEMIAS AGUDAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":208,"lines":{"from":1,"to":3}}}}],["1037",{"pageContent":"Ruiz-Argüelles GJ, Lobato-Mendizábal E, et al. ¾e incidence of hybrid acute leukemias. Leuk Res. 1988; 12:\n707-709.\nRuiz-Argüelles GJ, Marín-López A, et al. Acute megakaryoblastic leukemia: A prospective study of its identification\nand treatment. Brit J Haematol. 1986; 2: 55-63.\nRuiz-Delgado GJ, Macías-Gallardo J, Lutz-Presno J, Montes-Montiel M, Ruiz-Argüelles GJ. Outcome of adults\nwith acute lymphoblastic leukemia treated with a pediatric-inspired therapy: A single institution experience.\nLeukemia Lymphoma. 2011; 52: 314-6.\nRuiz-Argüelles GJ, Marín-López A, et al. A prospective trial of the treatment of acute megakaryoblastic leukemia.\nClin Lab Haematol. l988; 10: 15-23.\nRuiz-Argüelles GJ, Marín-López A, et al. Estudio prospectivo de la clasificación inmunológica de 128 casos de leu-\ncemia aguda linfoblástica en la Ciudad de Puebla, México. Rev Invest Clin (Mex). l987; 39: 137.\nRuiz-Argüelles GJ, Morales-Toquero A, et al. Treatment of acute promyelocytic leukemia: A single institution expe-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":208,"lines":{"from":5,"to":16}}}}],["1038",{"pageContent":"Ruiz-Argüelles GJ, Morales-Toquero A, et al. Treatment of acute promyelocytic leukemia: A single institution expe-\nrience. Rev Invest Clín (Méx). 2005; 57: 415-419.\nRuiz-Argüelles GJ, Ruiz-Argüelles A, et al. Citometría de flujo en la inmunotipificación de las leucemias agudas. Rev\nInvest Clín. 1993; 45: 93.\nRuiz-Argüelles GJ, Ruiz-Argüelles A, et al. Clasificación inmunológica de leucemia aguda. Rev Invest Clin (Mex).\n1989; 41: 391.\nRuiz-Argüelles GJ, Ruiz-Argüelles A, et al. Infusion of anti-CD 10 monoclonal antibody (J5) following ablative\nchemotherapy in a patient with refractory leukemia. Rev Invest Clin. 1991; 43: 259-253.\nRuiz-Argüelles GJ, Ruiz-Reyes G. El tratamiento de las leucemias en países en desarrollo. En: Ruiz-Argüelles GJ,\nSan- Miguel JF (eds.). Actualización en leucemias. México: Editorial Médica Panamericana; 1996. p. 147-151.\nRuiz-Delgado GJ, Macías-Gallardo J, Lutz-Presno J, Garcés-Eisele J, Hernández-Arizpe A, Montes-Montiel M,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":208,"lines":{"from":16,"to":26}}}}],["1039",{"pageContent":"Ruiz-Delgado GJ, Macías-Gallardo J, Lutz-Presno J, Garcés-Eisele J, Hernández-Arizpe A, Montes-Montiel M,\net al. Core binding factor acute myeloid leukemia (CBF-AML) in México: A single institution experience. Rev\nInvest Clin Méx. 2011; 63: 25-30.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":208,"lines":{"from":26,"to":28}}}}],["1040",{"pageContent":"RESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\n1.\n \nb\n2.\n \na\n3.\n \nc\n4.\n \na\n5.\n \na","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":208,"lines":{"from":30,"to":46}}}}],["1041",{"pageContent":"183\n\nINTRODUCCIÓN\n\nLas leucemias crónicas de importancia en México son tres: linfocítica, granulocítica y de células pelu-\ndas o tricoleucemia. Su curso indolente, larga evolución y ausencia de células muy indiferenciadas las\ndistinguen de las leucemias agudas. Se hace referencia a cada una de ellas en forma separada.\n\nLEUCEMIA GRANULOCÍTICA CRÓNICA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":210,"lines":{"from":1,"to":9}}}}],["1042",{"pageContent":"La leucemia granulocítica crónica consiste en una proliferación neoplásica predominantemente\nde la serie granulocítica; sin embargo, se observan alteraciones en la serie roja y en las plaquetas,\nlo cual indica que el origen de la entidad parte de la célula troncal o pluripotencial (\n \nstem cell\n). Esta\nenfermedad se ha relacionado con una anormalidad cromosómica (translocación del cromosoma 22\nal 9; t:9q+; 22q–) que se denomina\n \ncromosoma Philadelphia\n \n(CrPh1), la cual se observa en más del\n90% de los pacientes.\nLa enfermedad en México es menos común que la leucemia aguda, pero más frecuente que la\nleucemia linfocítica crónica; esto es muy diferente de lo que ocurre en los países anglosajones, donde\nla leucemia linfocítica crónica es mucho más frecuente. A nivel internacional se considera que la\nincidencia es de 1-1,5 por cada 100 000 habitantes. La entidad se puede observar a cualquier edad,\npero en los niños constituye el 3% de las leucemias en general; su frecuencia aumenta gradualmente","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":210,"lines":{"from":11,"to":28}}}}],["1043",{"pageContent":"incidencia es de 1-1,5 por cada 100 000 habitantes. La entidad se puede observar a cualquier edad,\npero en los niños constituye el 3% de las leucemias en general; su frecuencia aumenta gradualmente\ny predomina en adultos entre los 40 y 60 años. Es más frecuente en varones que en mujeres con una\nrelación de 3:2.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":210,"lines":{"from":28,"to":31}}}}],["1044",{"pageContent":"Anatomía patológica\n\nComo se señaló, la célula proliferante no es una en especial, como en el caso de las leucemias agu-\ndas, sino prácticamente todas las células hematopoyéticas, si bien predomina la serie granulocítica.\nLa médula ósea de hecho es de poca utilidad para el diagnóstico, ya que solo se observa hiperplasia\ngranulocítica, la cual es inespecífica en ausencia de un cuadro clínico y de laboratorio característico.\nEn ocasiones existe cierto grado de fibrosis, los elementos maduros de la serie granulocítica demues-\ntran disminución de la fosfatasa alcalina leucocitaria y el hallazgo más consistente y específico es la\n\nCAPÍTULO 13\n\nDavid Gómez Almaguer\n\nObjetivos de aprendizaje\n\n•\n \nSeñalar las principales leucemias\n \ncrónicas.\n\n•\n \nDistinguir el cuadro clínico de la leucemia granulocítica\n \ncrónica.\n\n•\n \nEntender las bases moleculares de la\n \nleucemogénesis\n \ny sus implicaciones\n \ntera\npéuticas.\n\n•\n \nComprender\n \nel diagnóstico y el\n \ntratamiento\n \nde las leucemias\n \ncrónicas\n \n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":210,"lines":{"from":33,"to":83}}}}],["1045",{"pageContent":"•\n \nEntender las bases moleculares de la\n \nleucemogénesis\n \ny sus implicaciones\n \ntera\npéuticas.\n\n•\n \nComprender\n \nel diagnóstico y el\n \ntratamiento\n \nde las leucemias\n \ncrónicas\n \n.\n\n•\n \nConocer las principales clasificaciones de las leucemias linfáticas\n \ncrónicas.\n\nLEUCEMIAS CRÓNICAS\n\nLa\n \nleucemia\n \ngranulocítica\ncrónica consiste en una pro-\nliferación\n \nneoplásica\n \npre-\ndominantemente de la serie\ngranulocítica;\n \nsin\n \nembargo,\nse observan alteraciones en la\nserie roja y en las plaquetas,\nlo cual indica que el origen de la\nentidad\n \nparte\n \nde\n \nla\n \ncélula\ntroncal o pluripotencial.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":210,"lines":{"from":83,"to":145}}}}],["1046",{"pageContent":"184\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\npresencia de CrPh1. La translocación condiciona la aparición de un gen quimérico\n \nBCR-ABL\n, el cual se\nasocia a una tirosina-cinasa que otorga ventajas proliferativas a la célula leucémica. Esta proteína de fusión\no gen quimérico puede ser detectada mediante técnicas de biología molecular como la de PCR. Encontrar\neste gen equivale a encontrar al CrPh1. En el 90% de los pacientes se halla el cromosoma Philadelphia,\nmientras que en otro 5% solo se encuentra el gen quimérico sin detectar la translocación cromosómica,\ny en el 5% restante simplemente la enfermedad no es leucemia granulocítica crónica, aunque lo parezca.\nLa proliferación de células se correlaciona con crecimiento esplénico y, en menor grado, hepático;\ntambién se puede encontrar hematopoyesis extramedular en estos sitios. Pocas veces se halla invasión a\notros tejidos, pero si esto ocurre, se denomina a este tumor extrahemático\n \nsarcoma granulocítico\n \no\n \ncloroma\n.\n\nEtiopatogenia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":211,"lines":{"from":1,"to":25}}}}],["1047",{"pageContent":"Etiopatogenia\n\nLa causa y el origen de la leucemia granulocítica crónica no se conoce. Se sabe que la frecuencia aumentó en la\npoblación japonesa expuesta a la radiación atómica en 1945. Existe menos evidencia que en la leucemia aguda\nen relación con fármacos, agentes químicos o factores hereditarios como causas directas de la enfermedad.\nSe ha demostrado, como se señaló, que existen genes alterados que directamente se vinculan con la pre-\nsencia y permanencia de la entidad, los cuales se conocen como\n \noncogenes\n; sin embargo, el porqué aparecen\ndichos genes o las alteraciones cromosómicas de la enfermedad no se ha aclarado con certeza.\n\nFisiopatología y cuadro clínico","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":211,"lines":{"from":25,"to":37}}}}],["1048",{"pageContent":"En muchas ocasiones (10 a 20%), el diagnóstico se efectúa cuando el paciente se encuentra asintomático, en un\nestudio rutinario, ya que en la citometría hemática por regla general se hallan más de 30 000 leucocitos/mm\n3\n \ny\nusualmente es frecuente encontrar cifras superiores a 100 000. En el Hospital Universitario de la Universidad\nAutónoma de Nuevo León se han observado más de 10\n6\n \n/mm\n \n3\n \nde leucocitos. La anemia puede no existir y\ncuando se presenta suele ser moderada (menos del 10% de los pacientes requieren transfusiones al inicio del\ndiagnóstico); las plaquetas suelen estar aumentadas en la mitad de los casos y la trombocitopenia al momento\ndel diagnóstico es excepcional. Los síntomas más frecuentes al momento del diagnóstico son: debilidad (75-\n80%), pérdida de peso (55-60%), hiporexia (35-40%) y molestias abdominales (30-35%).\nLa aparición de síntomas vagos, y que en ocasiones pueden desorientar, es lo que lleva al paciente a su","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":211,"lines":{"from":39,"to":57}}}}],["1049",{"pageContent":"80%), pérdida de peso (55-60%), hiporexia (35-40%) y molestias abdominales (30-35%).\nLa aparición de síntomas vagos, y que en ocasiones pueden desorientar, es lo que lleva al paciente a su\nprimera entrevista médica. Los más comunes son fatiga, pérdida de peso, plenitud abdominal y en oca-\nsiones sangrados o dolor de abdomen. En la exploración física se encuentra esplenomegalia en el 95% de\nlos enfermos y hepatomegalia aproximadamente en la mitad; es común hallar adenomegalia moderada. Se\nreconocen púrpura o fiebre en menos de una cuarta parte de los pacientes.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":211,"lines":{"from":57,"to":62}}}}],["1050",{"pageContent":"Diagnóstico","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":211,"lines":{"from":64,"to":64}}}}],["1051",{"pageContent":"Como se ha señalado, el diagnóstico se basa principalmente en los hallazgos de la citometría hemática.\nCuando la leucocitosis de causa no explicada, la proliferación de formas jóvenes de la serie mieloide, el au-\nmento de plaquetas, etcétera, se asocian con esplenomegalia, las posibilidades diagnósticas diferenciales son\nescasas\n \n(fig. 13-1)\n. En ocasiones, ciertas infecciones crónicas como la tuberculosis (en especial en ancianos),\nlos tumores que invaden médula ósea o las infecciones agudas pueden simular la enfermedad. La vigilancia\nadecuada y el estudio integral del individuo suelen ser suficientes para aclarar el diagnóstico. En casos de\nduda se puede recurrir a la determinación del CrPh1, o bien de los niveles de fosfatasa alcalina leucocitaria.\nLa investigación del gen quimérico\n \nBCR/ABL\n \nempleando la técnica de laboratorio conocida como\n \nhibrida-\nción fluorescente in situ\n \n(FISH, por sus siglas en inglés), o bien, la reacción en cadena de la polimerasa, tiene","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":211,"lines":{"from":66,"to":85}}}}],["1052",{"pageContent":"BCR/ABL\n \nempleando la técnica de laboratorio conocida como\n \nhibrida-\nción fluorescente in situ\n \n(FISH, por sus siglas en inglés), o bien, la reacción en cadena de la polimerasa, tiene\nmayor sensibilidad que la investigación del CrPh1 por medio de la citogenética.\nLa mielofibrosis primaria, también llamada\n \nmetaplasia mieloide agnogénica\n, suele ser el diagnóstico\ndiferencial más difícil de precisar, ya que a menudo cursa con gran esplenomegalia y leucocitosis. Sin em\n-\nbargo, la biopsia de médula ósea, que demuestra fibrosis, y una gran esplenomegalia que no es proporcio-\nnal a la leucocitosis moderada en pacientes usualmente mayores de 50 años, son datos que con frecuencia\naclaran el diagnóstico. En estos pacientes es negativo el CrPh1.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":211,"lines":{"from":85,"to":102}}}}],["1053",{"pageContent":"Evolución, tratamiento y pronóstico\n\nLa evolución natural del padecimiento, una vez que se detecta en forma clínica, tiene una duración de\naproximadamente 3 a 4 años. La enfermedad al inicio se mantiene estable y responde en forma adecuada\n\nLa translocación condiciona la\naparición de un gen quimérico\nBCR-ABL, el cual se asocia a\nuna tirosina-cinasa que otor-\nga ventajas proliferativas a la\ncélula leucémica. Esta proteí-\nna de fusión o gen quimérico\npuede ser detectada mediante\ntécnicas de biología molecular\ncomo la de PCR. Encontrar\neste gen equivale a encontrar\nal CrPhl.\nEl diagnóstico se basa prin-\ncipalmente en los hallazgos\nde\n \nla\n \ncitometría\n \nhemática.\nCuando la leucocitosis de cau-\nsa no explicada, la prolifera-\nción de formas jóvenes de la\nserie mieloide, el aumento de\nplaquetas, etcétera, se asocian\ncon esplenomegalia, las posi-\nbilidades\n \ndiagnósticas\n \ndife-\nrenciales son escasas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":211,"lines":{"from":104,"to":141}}}}],["1054",{"pageContent":"185\n\nCAPÍTULO 13. LEUCEMIAS CRÓNICAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":212,"lines":{"from":1,"to":3}}}}],["1055",{"pageContent":"y rápida al tratamiento (fase crónica). Después de algunos años, la respuesta es errática y la enfermedad\nse torna más agresiva y resistente (fase acelerada), para posteriormente, en un lapso menor a un año,\ntransformarse en una enfermedad aguda con la presencia de numerosos blastos (más del 20%), que\nfinalmente termina con la vida del enfermo (fase o crisis blástica). A veces existen otros cambios dife-\nrentes a los señalados; sin embargo, la mayoría de los sujetos mueren en esta fase por “crisis blástica”.\nLos pacientes con gran esplenomegalia, con aumento notable de blastos y basófilos, trombocitopenia y\nanemia importante, tienen generalmente peor pronóstico, en especial si no reciben rápidamente el mejor\ntratamiento, como los inhibidores de la tirosina-cinasa (imatinib, nilotinib, dasatinib) o trasplante de\ncélulas hematopoyéticas.\nEl tratamiento, antes de la era del interferón y el imatinib, difícilmente cambiaba el destino del pacien-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":212,"lines":{"from":5,"to":14}}}}],["1056",{"pageContent":"células hematopoyéticas.\nEl tratamiento, antes de la era del interferón y el imatinib, difícilmente cambiaba el destino del pacien-\nte; sin embargo, en la actualidad prolonga la vida en muchos casos y en definitiva mejora la calidad de esta,\npor lo que siempre es recomendable. Un medicamento utilizado es el agente alquilante conocido como","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":212,"lines":{"from":14,"to":17}}}}],["1057",{"pageContent":"busulfán\n, el cual se administra por vía oral continua a una dosis inicial de 4 a 10 mg/día con vigilancia se-\nmanal; la dosis se ajusta de acuerdo a la respuesta clínica y de laboratorio del enfermo. En un lapso variable\nentre 2 y 6 semanas se observa respuesta favorable en la mayoría de los casos, lo que permite reducir o en\nmuchas ocasiones suspender el tratamiento por períodos variables. Tiene el defecto de que se asocia a ca-\ntaratas, hiperpigmentación y fibrosis pulmonar, entre otros problemas, por lo que solo se usa en ocasiones\nespeciales y hasta que se obtiene remisión. Su uso tiende a abandonarse. Solo se utiliza ocasionalmente en\npacientes que no tienen acceso a los nuevos tratamientos.\nLos criterios utilizados para considerar a un enfermo en remisión clínica son los siguientes:\n\n•\n \nDesaparición de síntomas\n\n•\n \nAusencia de visceromegalia\n\n•\n \nHemoglobina superior a 10 g/dL","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":212,"lines":{"from":19,"to":39}}}}],["1058",{"pageContent":"•\n \nDesaparición de síntomas\n\n•\n \nAusencia de visceromegalia\n\n•\n \nHemoglobina superior a 10 g/dL\n\n•\n \nRecuento leucocitario menor de 15 000/mm\n \n3\nOtro medicamento que puede utilizarse es la hidroxiurea, además de otro agente alquilante como\nel melfalán, con resultados muy similares. En la actualidad, muchos hematólogos prefieren utilizar hi-\ndroxiurea, ya que la respuesta es más rápida y la toxicidad, menor y predecible.\n\nFigura 13-1.\n \nLeucemia granulocítica crónica.\n\nLa enfermedad al inicio se\nmantiene estable y responde\nen forma adecuada y rápida\nal tratamiento (fase crónica);\ndespués de algunos años, la\nrespuesta es errática y el pade-\ncimiento se torna más agresivo\ny resistente (fase acelerada),\npara\n \nposteriormente,\n \nen\n \nun\nlapso menor a un año, trans-\nformarse en una enfermedad\naguda con la presencia de nu-\nmerosos blastos (más del 20%)\nque finalmente termina con la\nvida del paciente (fase o crisis\nblástica).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":212,"lines":{"from":39,"to":85}}}}],["1059",{"pageContent":"186\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":213,"lines":{"from":1,"to":3}}}}],["1060",{"pageContent":"Otra opción terapéutica es el uso de una proteína humana denominada\n \ninterferón\n \nα\n. Este producto,\nobtenido por medio de ingeniería genética, es capaz de mantener la remisión de la enfermedad y reducir\nla cantidad de células CrPh1 positivas. Se utiliza a razón de 5 millones de unidades/m\n \n2\n \n/día; algunos\nenfermos requieren dosis mayores o menores. Tiene como inconveniente su alto costo, que se aplica en\ninyección subcutánea por tiempo prolongado y que puede causar efectos colaterales como fiebre, aste-\nnia, cefalea y dolor óseo. El interferón fue considerado como uno de los mejores tratamientos y puede\ncombinarse con quimioterapéuticos como la hidroxiurea o, mejor aún, el arabinósido de citosina para\npotenciar su efecto. Esta es una terapia que prolonga la fase crónica y la supervivencia, lo cual resulta\nespecialmente cierto en aquellos pacientes en los cuales se obtiene la remisión citogenética de la enferme-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":213,"lines":{"from":5,"to":22}}}}],["1061",{"pageContent":"especialmente cierto en aquellos pacientes en los cuales se obtiene la remisión citogenética de la enferme-\ndad; sin embargo, en la actualidad su uso tiende a abandonarse por los efectos colaterales y la aparición\nde medicamentos más específicos.\nEl mesilato de imatinib es un medicamento que inhibe la tirosina-cinasa creada por el gen\n \nBCR-ABL\n,\npor lo que se trata de un tratamiento extraordinariamente novedoso y dirigido de manera predominante\ncontra la célula anormal. La inhibición de esta cinasa causa la muerte de la célula leucémica . El imatinib\nse administra por vía oral a razón de 400 a 800 mg/día, tiene muy buena tolerancia y se obtienen respues-\ntas hematológicas completas hasta en el 99% de los casos y citogenéticas hasta en el 40 a 50% de los casos.\nEn la actualidad constituye un tratamiento ideal y de primera elección que puede prolongar la superviven-\ncia y quizá en algunos casos pudiera llegar a curar la enfermedad, aunque se necesita más tiempo de ob-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":213,"lines":{"from":22,"to":34}}}}],["1062",{"pageContent":"cia y quizá en algunos casos pudiera llegar a curar la enfermedad, aunque se necesita más tiempo de ob-\nservación para afirmar lo anterior. El único defecto grave es su alto costo, que es prohibitivo para la mayor\nparte de los habitantes de los países en desarrollo. De hecho, el trasplante de médula ósea tiene un costo\nmenor si consideramos el largo plazo. Existen otros medicamentos que tienen un mecanismo de acción\nsimilar al imatinib, pero son mucho más potentes: nilotinib, dasatinib y bosutinib. Su uso actualmente se\nrestringe a pacientes resistentes al imatinib; no obstante, su utilización en primera línea permite obtener\nuna respuesta más rápida y mejor que la del imatinib, especialmente en pacientes de alto riesgo o bien en\nfase acelerada o blástica de la enfermedad. Para elegir el cambio en el tratamiento ideal en un paciente\ndeterminado, es necesario valorar la respuesta al tratamiento mediante citogenética o estudio cuantitativo\ndel gen\n \nBCR-ABL\n \nmediante técnica de PCR\n \n(cuadro 13-1)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":213,"lines":{"from":34,"to":49}}}}],["1063",{"pageContent":"determinado, es necesario valorar la respuesta al tratamiento mediante citogenética o estudio cuantitativo\ndel gen\n \nBCR-ABL\n \nmediante técnica de PCR\n \n(cuadro 13-1)\n. Las respuestas mayores suelen asociarse con\nsupervivencia prolongada e incluso curación.\nEl trasplante de médula ósea es realmente la única opción curativa en esta enfermedad; sin embargo,\nel alto costo del procedimiento, la necesidad ideal de contar con un donador relacionado de locus de\nantígeno de histocompatibilidad (HLA) idéntico, la enfermedad del injerto contra el huésped y la edad\navanzada de muchos pacientes, limitan la aplicación frecuente de esta modalidad de tratamiento. Si se re-\núnen las condiciones ideales, es la mejor opción terapéutica para los menores de 65 años que no obtienen o\nmantienen la remisión citogenética con el imatinib. Recientemente se han obtenido excelentes resultados\nen México (Monterrey y Puebla) con una modalidad de trasplante que utiliza dosis reducidas de quimio-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":213,"lines":{"from":49,"to":65}}}}],["1064",{"pageContent":"en México (Monterrey y Puebla) con una modalidad de trasplante que utiliza dosis reducidas de quimio-\nterapia en la etapa de preparación del trasplante. Este trasplante es conocido como\n \ntrasplante no mieloa-\nblativo\n \no\n \nminitrasplante\n, y permite con menos toxicidad lograr la curación del enfermo mediante el efecto\ndel injerto contra el tumor, es decir, los linfocitos del donador terminan por destruir las células leucémicas\nremanentes del enfermo. Esta modalidad tiene un costo mucho menor que el trasplante convencional, así\ncomo menos morbimortalidad, y permite que individuos mayores de 60 años toleren el procedimiento.\nEl pronóstico depende las variantes atípicas de esta suelen tener un pronóstico peor. Existen dos esca-\nlas o clasificaciones de riesgo: una conocida como\n \nSokal\n \ny otra denominada\n \nHasford\n. El tamaño del bazo,\nel porcentaje de blastos circulantes, la cuenta plaquetaria y la edad son los factores más importes a ser\ntomados en cuenta para determinar el pronóstico.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":213,"lines":{"from":65,"to":88}}}}],["1065",{"pageContent":"Cuadro 13-1.\n \nClasificación citogenética y molecular de la respuesta al tratamiento\n\nRespuesta citogenética mínima: 66-95% metafases Ph positivas\nRespuesta citogenética menor: 36-65% metafases Ph positivas\nRespuesta citogenética mayor : 1-35% metafases Ph positivas\nRespuesta citogenética completa: 0% metafases Ph positivas\nRespuesta molecular mayor: reducción de 3 logaritmos en la cantidad de\n \nBCR-ABL","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":213,"lines":{"from":90,"to":100}}}}],["1066",{"pageContent":"Respuesta molecular completa: ausencia de\n \nBCR-ABL\nEl mesilato de imatinib es un\nmedicamento que inhibe la ti-\nrosina-cinasa creada por el gen\nBCR-ABL, por lo que se trata\nde un tratamiento extraordi-\nnariamente novedoso y diri-\ngido de manera predominante\ncontra la célula anormal. Se\nadministra\n \npor\n \nvía\n \noral\n \na\nrazón de 400 a 800 mg/día,\ntiene muy buena tolerancia y\nse obtienen respuestas hema-\ntológicas completas hasta en el\n99% de los casos, y citogenéti-\ncas hasta en el 40 a 50%\nEl trasplante de médula ósea\nes realmente la única opción\ncurativa en esta enfermedad;\nsin embargo, el alto costo del\nprocedimiento,\n \nla\n \nnecesidad\nideal de contar con un do-\nnador relacionado de HLA\nidéntico, la enfermedad del\ninjerto contra el huésped y la\nedad\n \navanzada\n \nde\n \nmuchos\npacientes, limitan la aplica-\nción frecuente de esta modali-\ndad de tratamiento.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":213,"lines":{"from":102,"to":150}}}}],["1067",{"pageContent":"187\n\nCAPÍTULO 13. LEUCEMIAS CRÓNICAS\n\nEn algunas ocasiones, se ha observado individuos con supervivencias mayores de 10 años y quizá esto\nse deba a la desaparición por reducción máxima de la clona celular CrPh1 positiva; sin embargo, la super\n-\nvivencia habitual oscila entre los 3 y 4 años a partir del momento del diagnóstico si el paciente recibe solo\nquimioterapia, y mejora sensiblemente en aquellos pacientes que responden al interferón o al mesilato de\nimatinib. El tratamiento farmacológico moderno tiene el defecto que, aunque posibilita prolongar la fase\ncrónica muchos años, muy rara vez es curativo, y la aparición de mutaciones puede afectar la respuesta a los\nmedicamentos más potentes, como el caso de la mutación T315. No obstante, en la actualidad se encuentra\nen estudio un nuevo medicamento inhibidor de tirosina-cinasa, el ponatinib, el cual es útil aun en pacientes\ncon esta mutación. El trasplante sí puede curar definitivamente la enfermedad.\n\nLEUCEMIA LINFOCÍTICA CRÓNICA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":214,"lines":{"from":1,"to":16}}}}],["1068",{"pageContent":"La leucemia linfocítica crónica es una neoplasia hemática que se caracteriza por la proliferación y\nacumulación de linfocitos de aspecto relativamente maduro o normal\n \n(fig. 13-2)\n. Esta leucemia se\norigina, en el 90% de los casos, en linfocitos de tipo B. La leucemia linfocítica crónica es la leucemia\nmás común en Estados Unidos; en el año 2004 se diagnosticaron 12 000 nuevos casos y en Europa la\nfrecuencia es muy similar y comprende el 30% de todos los casos de leucemia. En el Lejano Oriente\nes muy escasa y en México, aunque se observa con alguna frecuencia, probablemente ocupa el último\nlugar, solo antes que la leucemia de células peludas.\nLa enfermedad aparece de manera típica en individuos mayores de 50 años, es infrecuente en extremo\nen adultos menores de 35 años e inexistente en niños. En México, el diagnóstico casi siempre se efectúa\ntardíamente y en muchos casos es posible que el sujeto fallezca sin que se haya hecho el diagnóstico en","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":214,"lines":{"from":18,"to":30}}}}],["1069",{"pageContent":"tardíamente y en muchos casos es posible que el sujeto fallezca sin que se haya hecho el diagnóstico en\nvida, ya que la enfermedad es de curso indolente y menos notoria que, por ejemplo, el mieloma múltiple.\nEsto explica en parte por qué en México la entidad se diagnostica con menos frecuencia que en Estados\nUnidos, a lo cual también contribuyen las diferentes situaciones socioculturales, económicas y el hecho de\nque en México los jóvenes todavía predominan.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":214,"lines":{"from":30,"to":34}}}}],["1070",{"pageContent":"Anatomía patológica\n\nEn esta enfermedad proliferan linfocitos morfológicamente indistinguibles de los normales en la mayoría\nde los pacientes; se han descrito algunas variantes del padecimiento y en estos casos se observan linfocitos\nanormales con grandes nucléolos, como en la llamada\n \nleucemia prolinfocítica\n.\n\nFigura 13-2.\n \nLeucemia granulocítica crónica.\n\nLa leucemia linfocítica crónica\nes la más común en Estados\nUnidos y Europa y comprende\nel 30% de todos los casos de leu\n-\ncemia. En el Lejano Oriente es\nmuy escasa y en México, aun-\nque se observa con alguna fre-\ncuencia, probablemente ocupa\nel último lugar, solo antes que\nla leucemia de células peludas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":214,"lines":{"from":36,"to":59}}}}],["1071",{"pageContent":"188\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nLos órganos afectados casi en forma exclusiva son aquellos en los que normalmente se encuentra tejido\nlinfoide, como sangre, médula ósea, ganglios linfáticos y bazo. Muy pocas veces se hallan infiltraciones a\notros órganos, y más que proliferación acelerada de estas células, en apariencia existe supervivencia pro-\nlongada de estas y, en consecuencia, acumulación de linfocitos en los órganos señalados. El diagnóstico\ncasi siempre requiere estudio por medio de aspiración de médula ósea, en la que se observa infiltración\nvariable de linfocitos. Por lo menos al inicio de la enfermedad, dicha infiltración ocurre en forma nodular\ne irregular, lo cual se asocia con mejor pronóstico que cuando la médula ósea se encuentra infiltrada de\nmanera difusa.\n\nEtiopatogenia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":215,"lines":{"from":1,"to":14}}}}],["1072",{"pageContent":"Etiopatogenia\n\nEn este padecimiento, a diferencia de otras variantes de leucemias, la radiación no desempeña un papel\nrelevante al igual que los agentes químicos. Algunos estudios han implicado en gran medida a los virus\n(retrovirus) como causa etiológica más probable en esta enfermedad, y de hecho se han demostrado\npartículas virales en células cultivadas de pacientes con leucemia linfocítica crónica. Sin embargo, estos\nhechos requieren confirmación. Existe predisposición genética familiar y la mayoría de los enfermos\npresentan alteraciones cromosómicas, especialmente en los cromosomas 13, 11, 12, 14 y 17.\n\nFisiopatología y cuadro clínico","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":215,"lines":{"from":14,"to":23}}}}],["1073",{"pageContent":"Como se señaló en un principio, la enfermedad es poco agresiva e indolente, por lo que los síntomas que\npresentan los pacientes casi siempre son inespecíficos: fatiga, hiporexia y ocasionalmente fiebre moderada,\no bien los sujetos acuden al médico porque notan la presencia de adenomegalia. En muchas ocasiones,\nel diagnóstico se efectúa por hallazgos de laboratorio y sin haberse sospechado la entidad, por lo que la\nlinfocitosis en una citometría hemática de un enfermo asintomático con frecuencia constituye el dato ini-\ncial que lleva al diagnóstico. En la exploración física puede encontrarse adenomegalia y esplenomegalia;\nsin embargo, cuando el diagnóstico se efectúa tempranamente, es posible que estos datos clínicos estén\nausentes y aparezcan a medida que pasa el tiempo.\nSe ha propuesto una clasificación clínica\n \n(cuadro 13-2)\n \nen la cual se señala como\n \nestadio temprano\n \na\naquel en el que se registra linfocitosis y mínimo crecimiento ganglionar sin anemia o trombocitopenia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":215,"lines":{"from":25,"to":42}}}}],["1074",{"pageContent":"(cuadro 13-2)\n \nen la cual se señala como\n \nestadio temprano\n \na\naquel en el que se registra linfocitosis y mínimo crecimiento ganglionar sin anemia o trombocitopenia.\nEn los casos donde existe anemia, trombocitopenia o esplenomegalia importante, el pronóstico es peor.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":215,"lines":{"from":42,"to":50}}}}],["1075",{"pageContent":"Diagnóstico\n\nEl diagnóstico generalmente requiere confirmación absoluta de linfocitosis (como mínimo 5 000 o\nmás por mm\n \n3\n) en la citometría hemática, así como demostrar que la médula ósea se encuentra infil -\ntrada por linfocitos de aspecto maduro (más del 30%) de origen clonal. En esta enfermedad es con -\nveniente estudiar la médula ósea. La mayoría de las leucemias linfocíticas crónicas son de tipo B, y\npresentan positividad a los antígenos CD5 y CD23, además de los habituales de la línea B, lo cual casi\nsiempre implica buen pronóstico y supervivencia promedio igual o mayor a los 5 años, por lo que es\nconveniente complementar el estudio del paciente con técnicas inmunológicas especiales que indiquen\nsi las células leucémicas son de tipo B o T. Este último fenotipo celular por lo general implica pronós -\n\nCuadro 13-2.\n \nEstadios de Binet (clasificación internacional de la leucemia linfocítica crónica)\n\nEstadio\n \nCriterios\n \nSupervivencia mediana (años)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":215,"lines":{"from":52,"to":74}}}}],["1076",{"pageContent":"Cuadro 13-2.\n \nEstadios de Binet (clasificación internacional de la leucemia linfocítica crónica)\n\nEstadio\n \nCriterios\n \nSupervivencia mediana (años)\n\nA\n \nAusencia de anemia y\n \ntr\n \nombocitopenia\nMenos de tres áreas “linfoides”\n \ninvadidas\n \n> 10\nB\n \nAusencia de anemia y\n \ntrombocitopenia\nTres\n \no más áreas “linfoides”\n \ninvadidas\n \n5\nC\nAnemia (hemoglobina < 100 g/dL)\ny/o trombocitopenia\n(plaquetas < 100 × 10\n \n9\n \n/L)\n2","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":215,"lines":{"from":74,"to":116}}}}],["1077",{"pageContent":"En la exploración física pue-\nden\n \nencontrarse\n \nadenome-\ngalia\n \ny\n \nesplenomegalia;\n \nsin\nembargo, cuando el diagnós-\ntico se efectúa tempranamen-\nte, es posible que estos datos\nclínicos estén ausentes y apa-\nrezcan a medida que pasa el\ntiempo.\nLa mayoría de las leucemias\nlinfocíticas crónicas son de tipo\nB, y presentan prositividad a\nlos antígenos CD5 y CD23,\nademás de los habituales de\nla línea B, lo cual casi siempre\nimplica buen pronóstico y su-\npervivencia promedio igual o\nmayor a los 5 años, por lo que\nes conveniente complementar\nel estudio del paciente con téc-\nnicas inmunológicas especiales\nque indiquen si las células leu-\ncémicas son de tipo B o T.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":215,"lines":{"from":118,"to":150}}}}],["1078",{"pageContent":"189\n\nCAPÍTULO 13. LEUCEMIAS CRÓNICAS\n\ntico menos favorable y, por consiguiente, pobre respuesta al tratamiento. Es importante señalar que\nlos linfomas en fase leucémica indolentes pueden simular una leucemia linfoblástica crónica (LLC),\npor lo que es necesario efectuar un inmunofenotipo para demostrar el CD5 y el CD23, combinación\nque casi asegura el diagnóstico.\nFinalmente, cabe mencionar que muchos de estos enfermos presentan alteraciones inmunológicas de\ndos tipos:\n\n•\n \nDisminución de las inmunoglobulinas y tendencia a desarrollar complicaciones infecciosas.\n\n•\n \nEnfermedades autoinmunitarias, en especial anemia hemolítica autoinmunitaria.\n\nEvolución, tratamiento y pronóstico","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":216,"lines":{"from":1,"to":20}}}}],["1079",{"pageContent":"En muchos de los pacientes, la enfermedad es tan leve y sutil que no requiere terapéutica alguna, en\nparticular en individuos con recuento linfocitario bajo, sin anemia o trombocitopenia y con ausencia de\ncrecimiento ganglionar y esplénico. Se considera que estos enfermos se hallan en un estadio temprano, lo\ncual no se modifica prácticamente con el tratamiento convencional. Existen en la actualidad estudios que\npermiten un mejor pronóstico que la simple clasificación clínica. Un caso es la presencia de la deleción\ncromosómica 13q, que resulta de buen pronóstico, mientras que la de 17p y la de 11q no tienen pronóstico\nalentador. El estado de mutación de genes de las inmunoglobulinas (IgV) también tiene importancia. Por\nejemplo, un paciente con genes mutados en etapa A de Binet tiene una esperanza de vida cercana a los 25\naños, en tanto que uno igual con genes no mutados tiene tan solo 8 años. La presencia de los marcadores","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":216,"lines":{"from":22,"to":30}}}}],["1080",{"pageContent":"años, en tanto que uno igual con genes no mutados tiene tan solo 8 años. La presencia de los marcadores\nCD38 y ZAP70 que se detectan en la superficie de la célula por citometría de flujo implica generalmente\nun mal pronóstico. Estos estudios pueden ayudar a tomar decisiones anticipadas en el tratamiento de los\npacientes sin esperar la evolución negativa.\nLa terapéutica que se utiliza es la quimioterapia sola o en combinación con inmunoterapia. Tradi-\ncionalmente se utilizaba un medicamento conocido como\n \nclorambucilo\n, un agente alquilante que altera\nel DNA de los linfocitos malignos y los destruye. En la actualidad se utiliza solo en casos selectos o en\ncircunstancias en las cuales no es posible o conveniente aplicar otra terapia más eficaz. El tratamiento, ya\nsea con monofármaco o en combinación, se reserva, como se señaló, para aquellos pacientes en etapas más\navanzadas de la enfermedad. Actualmente se prefiere otro medicamento conocido como\n \nfludarabina\n; esta","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":216,"lines":{"from":30,"to":45}}}}],["1081",{"pageContent":"avanzadas de la enfermedad. Actualmente se prefiere otro medicamento conocido como\n \nfludarabina\n; esta\nes la mejor opción farmacológica para el tratamiento de la LLC, mejorando más las expectativas favora-\nbles de esta leucemia. La fludarabina en combinación con la ciclofosfamida es particularmente eficaz, aun\nen pacientes previamente tratados y con resistencia al clorambucilo. Sin embargo, causa mielodepresión\ne inmunodeficiencia prolongada. A pesar de ello, es la que más rápidamente reduce la cifra leucocitaria y\nla carga tumoral, y si además se agrega un anticuerpo monoclonal anti-CD20 (rituximab) a esta combi-\nnación, los resultados son excelentes desde el punto de vista antitumoral, y la supervivencia libre de en-\nfermedad se prolonga en pacientes refractarios a otros tratamientos o en pacientes en estadios avanzados.\nA esta combinación se le conoce como\n \nFCR\n, y actualmente es un esquema muy popular en los Estados","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":216,"lines":{"from":45,"to":59}}}}],["1082",{"pageContent":"A esta combinación se le conoce como\n \nFCR\n, y actualmente es un esquema muy popular en los Estados\nUnidos. Un nuevo anticuerpo ha mostrado gran utilidad, el alemtuzumab, que está dirigido contra el\nantígeno CD52. Es muy potente y resulta eficaz en primera línea o como rescate después de recaída; se\npuede usar por vía intravenosa o subcutánea. La dosis habitual ha sido 30 mg tres veces por semana por 12\nsemanas. En la actualidad se estudian dosis menores y combinaciones con quimioterapia para encontrar la\nforma ideal de utilizar este anticuerpo; como defecto se puede mencionar que, al ser un potente inmuno-\nsupresor, se ha asociado a infecciones frecuentes que pueden deberse a gérmenes oportunistas agresivos e\ninesperados. Algunas nuevas moléculas que intervienen en la regulación de los linfocitos B o del receptor\nde céulas B son el ibrutinib y el fostamatinib; ambas inhiben cinasas esenciales para el receptor mencio -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":216,"lines":{"from":59,"to":70}}}}],["1083",{"pageContent":"de céulas B son el ibrutinib y el fostamatinib; ambas inhiben cinasas esenciales para el receptor mencio -\nnado y la citodinámica de la enfermedad y por lo tanto son efectivas en la LLC. Aun se encuentran en\ndesarrollo, pero tendrán seguramente un lugar en el tratamiento de esta leucemia crónica.\nEl objetivo del tratamiento es controlar y, en su caso, hacer retroceder los efectos negativos del padeci-\nmiento, ya que no se pretende lograr la curación en vista de que es prácticamente imposible erradicar por\ncompleto la clona de células leucémicas responsables de la enfermedad, a menos que se recurra a un tras-\nplante alogénico de células hematopoyéticas. Los tratamientos más agresivos que los señalados con qui-\nmioterapia e inmunoterapia suelen ser poco útiles y se asocian con mayor frecuencia con complicaciones,\nen especial de tipo infeccioso. El trasplante alogénico de médula ósea, tradicional o convencional, está","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":216,"lines":{"from":70,"to":78}}}}],["1084",{"pageContent":"en especial de tipo infeccioso. El trasplante alogénico de médula ósea, tradicional o convencional, está\nindicado en pacientes menores de 50 años con estadios avanzados de la enfermedad; sin embargo, la nueva\nmodalidad de trasplante utiliza quimioterapia de preparación menos agresiva: trasplante no mieloablativo\no minitrasplante, que permiten aspirar a la curación en pacientes mayores de 60 años.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":216,"lines":{"from":78,"to":81}}}}],["1085",{"pageContent":"La fludarabina en combina-\nción con la ciclofosfamida es\nparticularmente eficaz, aun en\npacientes previamente tratados\ny con resistencia al clorambu-\ncilo. Sin embargo, esta combi-\nnación causa mielodepresión e\ninmunodeficiencia prolongada.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":216,"lines":{"from":83,"to":90}}}}],["1086",{"pageContent":"190\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nLa supervivencia promedio que se señaló antes es aproximadamente de 5 años; algunos pacientes\npueden sobrevivir por períodos mayores (aunque se ha observado individuos que han sobrevivido más de\n15 años desde el momento del diagnóstico). En algunos enfermos con estadios clínicos más avanzados\nal momento del diagnóstico, o bien con fenotipo leucémico tipo T, la supervivencia promedio suele ser\nmenor de 3 años, si bien las nuevas modalidades de terapia seguramente habrán de mejorar estos números.\n\nLEUCEMIA DE CÉLULAS PELUDAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":217,"lines":{"from":1,"to":11}}}}],["1087",{"pageContent":"LEUCEMIA DE CÉLULAS PELUDAS\n\nEsta leucemia es una enfermedad linfoproliferativa que se origina en los linfocitos B. Las células leucémicas\nse caracterizan por tener prolongaciones en el citoplasma (“pelos”); además, poseen fosfatasa ácida positiva\ny resistente al tartrato\n \n(fig. 13-3)\n. La enfermedad es poco frecuente, tan solo comprende el 2% de todas las\nleucemias, y en México predomina en el norte. Es la menos usual de las leucemias crónicas, si bien es posible\nque el diagnóstico en nuestro medio no se efectúe con la frecuencia correcta o esperada. Se ha calculado que\nla incidencia es tan solo de 0,3 casos por cada 100 000 habitantes por año y predomina enlos varones 4-5:1.\n\nAnatomía patológica","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":217,"lines":{"from":11,"to":23}}}}],["1088",{"pageContent":"Anatomía patológica\n\nLa médula ósea suele mostrar infiltración por parte de las células ya descritas y fibrosis en grado variable,\npor lo que el aspirado de médula suele ser difícil; así, con frecuencia se requiere de biopsia de hueso y\nmédula ósea para obtener suficiente tejido demostrativo. Casi invariablemente el bazo está infiltrado di-\nfusamente por las células peludas; en ocasiones se encuentra crecimiento ganglionar e infiltración de los\nganglios por las mismas células.\n\nEtiopatogenia, fisiopatología y cuadro clínico","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":217,"lines":{"from":23,"to":31}}}}],["1089",{"pageContent":"Etiopatogenia, fisiopatología y cuadro clínico\n\nAl igual que en la leucemia linfocítica crónica, la causa exacta no se conoce; sin embargo, es posible que\nlos virus, y en particular los retrovirus, desempeñen un papel importante en la génesis de esta enfermedad.\nUna mutación BRAFV600E se encuentra presente en más del 85% de los pacientes y se estan desarrollan-\ndo tratamientos dirigidos contra esta mutación.\nLa infiltración de la médula ósea produce pancitopenia moderada en la mayoría de los pacientes. Casi\ntodos los casos muestran esplenomegalia moderada al momento del diagnóstico. La adenomegalia es\n\nFigura 13-3.\n \nLeucemia de células peludas. Cortesía del Dr. Joaquín Carrillo.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":217,"lines":{"from":31,"to":42}}}}],["1090",{"pageContent":"Figura 13-3.\n \nLeucemia de células peludas. Cortesía del Dr. Joaquín Carrillo.\n\nLa leucemia de células peludas\nes una enfermedad linfoproli-\nferativa que se origina en los\nlinfocitos B.\nLas células leucémicas se\ncaracterizan por tener prolon-\ngaciones en el citoplasma (“pe-\nlos”); además, poseen fosfatasa\nácida positiva y resistente al\ntartrato.\n \nLa\n \nenfermedad\n \nes\npoco frecuente, y en México\npredomina en el norte.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":217,"lines":{"from":42,"to":63}}}}],["1091",{"pageContent":"191\n\nCAPÍTULO 13. LEUCEMIAS CRÓNICAS\n\nmenos frecuente y rara vez es importante. Los enfermos se presentan con debilidad por anemia y pueden\nsufrir sangrado por trombocitopenia, o bien infecciones repetidas. La enfermedad se puede confundir con\nmielodisplasia, anemia aplásica y linfomas indolentes, en especial una variante conocida como\n \nlinfoma\nesplénico con linfocitos vellosos circulantes\n. Es necesario sospechar la enfermedad para pedir los estudios que\nla confirman y revisar cuidadosamente la sangre periférica para encontrar las células peludas.\n\nDiagnóstico","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":218,"lines":{"from":1,"to":14}}}}],["1092",{"pageContent":"Diagnóstico\n\nEl diagnóstico se basa en la demostración de linfocitos característicos de la enfermedad en sangre periféri-\nca, médula ósea o bazo. Generalmente se sospecha el padecimiento en un varón adulto (entre 35 y 55 años)\ncon pancitopenia y esplenomegalia, si bien el 20% de los pacientes presentan leucocitosis con numerosas\ncélulas peludas. Es necesario destacar que las células deben ser positivas a la fosfatasa ácida resistente\nal tartrato. El diagnóstico también se debe confirmar mediante citometría de flujo. Suelen ser positivos\nmarcadores como CD20, CD22, FMC7, CD11c, CD 103, CD25 y CD123.\n\nEvolución, tratamiento y pronóstico","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":218,"lines":{"from":14,"to":23}}}}],["1093",{"pageContent":"La enfermedad, como se señaló, tiene un curso lento aunque progresivo; aun sin terapéutica, la supervi-\nvencia puede ser incluso superior a los 5 años a partir del diagnóstico. En la actualidad se prefiere tratar a\nlos enfermos, especialmente a aquellos con pancitopenia y síntomas. La esplenectomía mejora de manera\nsignificativa las alteraciones de la sangre en estos enfermos, incluso en el 90% de los casos. Sin embargo,\nno cambia en grado importante el curso de la enfermedad ni mejora la tendencia a infectarse de los pa-\ncientes. Por ello, se recomienda solo en aquellos casos en los que no se pueda recurrir al uso de interferón\no clorodeoxiadenosina. El interferón\n \nα\n \nmejora significativamente a más del 80% de los pacientes, por lo\nque en la actualidad es todavía una opción viable. Es posible usar dosis variables que van de 1 millón de\nunidades tres veces por semana a 5 millones de unidades, y resulta factible combinarlo con rituximab","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":218,"lines":{"from":25,"to":37}}}}],["1094",{"pageContent":"unidades tres veces por semana a 5 millones de unidades, y resulta factible combinarlo con rituximab\npara aumentar la eficacia. La mayoría de los enfermos pueden mantenerse con dosis bajas de interferón o\ndosis intermitentes durante muchos años. Algunos sujetos son resistentes al interferón, o bien desarrollan\nresistencia al paso de los años. En la mayoría de los países desarrollados el interferón ha sido abandonado\ny la leucemia se trata con dos medicamentos: pentostatina y clorodeoxiadenosina, mismos que tienen\ngran actividad antileucémica en esta entidad, en especial este último, cuyo defecto es el alto costo. Ade -\nmás, no se consigue fácilmente en todos los países. El uso de anticuerpos monoclonales contra antígenos\nlinfoides, en especial el rituximab (anti-CD20), es útil y puede producir respuesta duradera o mejorar la\nrespuesta inicial a la quimioterapia o interferón. Otro anticuerpo, el alemtuzumab (anti-CD52), también","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":218,"lines":{"from":37,"to":45}}}}],["1095",{"pageContent":"respuesta inicial a la quimioterapia o interferón. Otro anticuerpo, el alemtuzumab (anti-CD52), también\nha demostrado ser útil. Existen estudios que muestran actividad antileucémica de nuevos anticuerpos e\ninmunoconjugados que pronto podrán ser utilizados. El pronóstico de esta enfermedad ha mejorado mu-\ncho debido a la aparición de nuevos tratamientos, y la supervivencia prolongada es la regla. Asimismo, es\nposible que se pueda llegar a obtener la curación completa en un futuro no muy lejano.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":218,"lines":{"from":45,"to":49}}}}],["1096",{"pageContent":"CONCLUSIONES\n\n•\n \nLas leucemias crónicas en México con mayor relevancia son la granulocítica, la linfocítica, principal-\nmente de tipo B, y la tricoleucemia (de células peludas).\n\n•\n \nEl diagnóstico de estas patologías se basa principalmente en los hallazgos y demostración de las células\ncaracterísticas en sangre periférica, médula ósea o bazo.\n\n•\n \nEl trasplante alogénico de células hematopoyéticas es estrictamente la única opción curativa en estas\nenfermedades.\n\nPREGUNTAS DE AUTOEVALUACIÓN\n\n1. ¿Cuál es la leucemia crónica más común en México?\na.\n \nLinfocítica crónica\nb. Células peludas\nc.\n \nGranulocítica crónica","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":218,"lines":{"from":51,"to":77}}}}],["1097",{"pageContent":"PREGUNTAS DE AUTOEVALUACIÓN\n\n1. ¿Cuál es la leucemia crónica más común en México?\na.\n \nLinfocítica crónica\nb. Células peludas\nc.\n \nGranulocítica crónica\n\nLa leucemia de células peludas\nse trata con dos medicamentos\nrelativamente nuevos: pentos-\ntatina y clorodeoxiadenosina,\nmismos que tienen gran acti-\nvidad antileucémica en esta\nentidad, en especial este últi-\nmo, cuyo defecto es el alto costo.\nEl diagnóstico se basa en la de-\nmostración de linfocitos carac-\nterísticos de la enfermedad en\nsangre periférica, médula ósea o\nbazo. Generalmente se sospecha\nel padecimiento en un varón\nadulto (entre 35 y 55 años) con\npancitopenia y esplenomegalia,\nsi bien el 20% de los pacientes\npresentan leucocitosis con nu-\nmerosas células peludas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":218,"lines":{"from":77,"to":106}}}}],["1098",{"pageContent":"192\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\n2. ¿En qué porcentaje se presenta el CrPh1(+) en la leucemia granulocítica crónica?\na.\n \n100%\nb. 50%\nc.\n \n10%\n3. ¿Cuáles son las fases de la leucemia granulocítica crónica?\na.\n \nBlástica y aguda\nb. Crónica, acelerada y blástica\nc.\n \nCrónica, crisis aguda y remisión\n4. Inhibe la tirosina cinasa creada por el gen\n \nBCR-ABL\n:\na.\n \nRituximab\nb. Romiplostim\nc.\n \nImatinib\n5. ¿Cuál es un método diagnóstico para la leucemia de células peludas?\na.\n \nTinción para fosfatasa ácida resistente al tartrato\nb. Cuadro clínico\nc.\n \nAspirado de médula ósea\n\nBIBLIOGRAFÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":219,"lines":{"from":1,"to":41}}}}],["1099",{"pageContent":"Abboud C, Berman E, Cohen A, Cortes J, DeAngelo D, Deininger M, et al. μe price of drugs for chronic myeloid\nleukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group\nof CML experts. Blood. 2013; 121: 4439-4442.\nAlemán-Hoey DD, Ruiz-Argüelles GJ, et al. Leucemia linfocítica crónica 1. Experiencia de 35 años en el Instituto\nNacional de la Nutrición Salvador Zubirán. Rev Invest Clin (Méx). 1982; 34: 151-156.\nCortés J. CML: μe good, the better and the difficult choices. Blood. 2012; 120: 3866-3867.\nCortés J, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Eng\nJ Med. 2012; 367: 2075-2088.\nFrench Cooperative Group on Chronic Lymphocytic Leukemia. Effects of chlorambucil and therapeutic decision in\ninitial forms of chronic lymphocytic leukemia (Stage A): Results of a randomized clinical trial on 612 patients.\nBlood. 1990; 75: 1414-1421.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":219,"lines":{"from":43,"to":53}}}}],["1100",{"pageContent":"initial forms of chronic lymphocytic leukemia (Stage A): Results of a randomized clinical trial on 612 patients.\nBlood. 1990; 75: 1414-1421.\nCheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lym-\nphocytic leukemia. J Clin Oncol. 2012; 30: 2820-2822.\nChiorazzi N. Implications of new prognostic markers in chronic lymphocytic leukemia. Hematology Am Soc Hema\n-\ntol Educ Program. 2012; 2012: 76-87.\nGómez-Almaguer D, Tarín-Arzaga L. Tratamiento de la leucemia granulocítica crónica en fase crónica. Una pers-\npectiva mexicana. Rev Hematol Mex. 2011; 12: 267-275.\nGómez-Almaguer D. Tratamiento de las leucemias linfoblásticas. En: Ruiz-Argüelles GJ, ed. Leucemias agudas.\nTemas de medicina interna. México: Interamericana/McGraw-Hill; 1993.\nGómez-Almaguer D, Jaime-Pérez JC, et al. Interferón alfa intermitente en el tratamiento de la leucemia de células\npeludas. Rev Invest Clin (Mex). 1998; 20: 221-224.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":219,"lines":{"from":53,"to":65}}}}],["1101",{"pageContent":"Gómez-Almaguer D, Jaime-Pérez JC, et al. Interferón alfa intermitente en el tratamiento de la leucemia de células\npeludas. Rev Invest Clin (Mex). 1998; 20: 221-224.\nGómez-Almaguer D, Ruiz-Argüelles GJ, et al. Hematopoietic stem cell allografts using a non-myeloabltive condi -\ntioning regimen can be safely performed on an outpatient basis. Bone Marrow Transplant. 2000; 25: 131-133.\nGuilhot F, Chastang C, Michalllet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in\nchronic myelogenous leukemia. N Engl J Med. 1997; 337: 223-229.\nKeating MJ, Kantarjian , et al. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia.\nBlood. 1989; 74: 19-25.\nOzer H. Biotherapy of chronic myelogenous leukemia with interferon. Semin Oncol. 1988; 15: 14-20.\nRatain MJ, Vardiman JW, et al. Prognostic variables in hairy cell leukemia after splenectomy as initial therapy. Can-\ncer. 1988; 62: 2420-2424.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":219,"lines":{"from":65,"to":75}}}}],["1102",{"pageContent":"193\n\nCAPÍTULO 13. LEUCEMIAS CRÓNICAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":220,"lines":{"from":1,"to":3}}}}],["1103",{"pageContent":"Ruiz-Argüelles GJ, Cantú-Rodríguez OC, Gómez-Almaguer D, et al. Hairy cell leukemia is infrequent in Mexico\nand has a geographic distribution. Am J Hematol. 1996; 52: 316-318.\nRuiz-Argüelles GJ, Velázquez BM, Apreza-Molina MG, Pérez-Romano B, Ruiz-Reyes G, Ruiz-Argüelles A.\nChronic lymphocytic leukemia is infrequent in Mexican Mestizos. Int J Hematol. 1999; 69: 253-255.\nRuiz-Argüelles\n \nGJ,\n \nGómez-Almaguer\n \nD,\n \nMorales-Toquero\n \nA,\n \nGutiérrez-Aguirre\n \nCH,\n \nVela-Ojeda\n \nJ,\n \nGar-\ncía-Ruiz-Esparza MA, et al; Latin American Cooperative Oncohematology Group. μe early referral for redu-\nced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in\nthe imatinib era: Results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective,\nmulticenter study. Bone Marrow Transplant. 2005; 36: 1043-7.\nRuiz-Argüelles GJ, Tarín-Arzaga LC, González-Carrillo ML, Gutiérrez-Riveroll KI, Rangel-Malo R, Guitié-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":220,"lines":{"from":5,"to":34}}}}],["1104",{"pageContent":"multicenter study. Bone Marrow Transplant. 2005; 36: 1043-7.\nRuiz-Argüelles GJ, Tarín-Arzaga LC, González-Carrillo ML, Gutiérrez-Riveroll KI, Rangel-Malo R, Guitié-\nrrez-Aguirre CH, et al. μerapeutic choices in patients with Ph1 (+) chronic myelogenous leukemia living in\nMexico in the tyrosine kinase inhibitors (TKI) era: Stem cell transplantation or TKI’s ? Bone Marrow Transplant.\n2008: 42: 23-28\nRuiz-Delgado GJ, Tarin-Arzaga LC, Alarcón-Urdaneta C, et al. Treatment of hairy cell leukemia: Long term results\nin a developing country. Hematology. 2012; 17: 140-143.\nSpiers ASD, Moore D, et al. Remissions in hairy-cell leukemia with pentostatin (2-deoxycoformycin). N Engl J Med.\n1987; 316: 825-830.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":220,"lines":{"from":34,"to":42}}}}],["1105",{"pageContent":"RESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\n1.\n \nc\n2.\n \na\n3.\n \nb\n4.\n \nc\n5.\n \na","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":220,"lines":{"from":44,"to":60}}}}],["1106",{"pageContent":"195\n\nINTRODUCCIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":222,"lines":{"from":1,"to":3}}}}],["1107",{"pageContent":"Las neoplasias mieloproliferativas crónicas (NMP) son enfermedades clonales, es decir, que provie-\nnen de una sola célula anormal que corresponde a la célula progenitora hematopoyética pluripotencial.\nEsta célula es la responsable de la proliferación, autorrenovación y diferenciación de tres líneas celula-\nres que provienen de la médula ósea en un individuo normal: eritroide, mieloide (neutrófilos, eosinó-\nfilos, basófilos y monocitos) y megacariocítica. Estas enfermedades se caracterizan por la proliferación\ncelular excesiva y desordenada, que da lugar a un número aumentado de eritrocitos, granulocitos y\nplaquetas, respectivamente.\nLa clasificación de las NMP se realiza de acuerdo a la presencia o ausencia del cromosoma\nPhiladelphia (Ph+), el resultado de la translocación 9:22 y el origen genético de la leucemia granu -\nlocítica crónica (LGC), una neoplasia mieloproliferativa que será abordada en otro capítulo. Las","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":222,"lines":{"from":5,"to":14}}}}],["1108",{"pageContent":"Philadelphia (Ph+), el resultado de la translocación 9:22 y el origen genético de la leucemia granu -\nlocítica crónica (LGC), una neoplasia mieloproliferativa que será abordada en otro capítulo. Las\nNMP “clásicas” que no presentan esta alteración cromosómica (Ph–) son tres: policitemia vera,\ntrombocitosis esencial y mielofibrosis primaria, y se revisarán en este capítulo\n \n(fig. 14-1)\n. Otras\nNMP menos comunes son: leucemia neutrofílica crónica, leucemia eosinofílica crónica/síndrome\nhipereosinofílico y mastocitosis sistémica. Aunque difieren en la estirpe celular predominante, estas\nneoplasias comparten algunas características, como la proliferación aumentada de células maduras,\nun curso clínico frecuentemente indolente y un potencial variable de progresión y transformación\nmaligna. La clasificación de la Organización Mundial de la Salud (OMS) sobre neoplasias mielo -\nproliferativas se encuentra en el\n \ncuadro 14-1\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":222,"lines":{"from":14,"to":29}}}}],["1109",{"pageContent":"CAPÍTULO 14\n\nLuz Tarín Arzaga\nAndrés Gómez de León\n\nObjetivos de aprendizaje\n\n•\n \nComprender los conceptos fisiopatológicos de las neoplasias mieloproliferativas crónicas.\n\n•\n \nConocer los marcadores moleculares de estas neoplasias y su importancia clínica.\n\n•\n \nIdentificar los signos y síntomas asociados a la policitemia vera, trombocitosis esencial y mielofibrosis.\n\n•\n \nSeñalar los métodos diagnósticos de elección para las neoplasias mieloproliferativas crónicas.\n\n•\n \nMencionar el tratamiento de estas enfermedades y las implicaciones de los marcadores moleculares\nespecíficos.\n\nNEOPLASIAS\nMIELOPROLIFERATIVAS\nCRÓNICAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":222,"lines":{"from":31,"to":61}}}}],["1110",{"pageContent":"196\n \nFUNDAMENTOS DE HEMATOLOGÍA\nMUTACIÓN JAK2\nV617F","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":223,"lines":{"from":1,"to":5}}}}],["1111",{"pageContent":"Para el diagnóstico y la clasificación correcta de estas enfermedades neoplásicas se requiere de la inte-\ngración de los hallazgos clínicos, hematológicos, morfológicos y de genética molecular. Esta última ha\nadquirido gran relevancia en los últimos años con el descubrimiento de algunas mutaciones con impli-\ncaciones pronósticas y terapéuticas, particularmente en el caso de la LGC. Recientemente se ha descrito\nuna mutación en el gen denominado\n \nJAK2\n, que codifica para una tirosina-cinasa citoplasmática, la cual\ncataliza la fosforilación de proteínas activando la vía de señalización JAK/STAT (de\n \nJanus kinase/signal\ntransducers and transcription activator\n). Esta vía es activada normalmente por la presencia de factores de\ncrecimiento (eritropoyetina, trombopoyetina y factor estimulante de colonias de granulocitos y macró-\nfagos), estimulando la transcripción de genes que promueven la proliferación y diferenciación celular, e\ninhiben por otra parte la apoptosis o muerte celular programada.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":223,"lines":{"from":7,"to":22}}}}],["1112",{"pageContent":"fagos), estimulando la transcripción de genes que promueven la proliferación y diferenciación celular, e\ninhiben por otra parte la apoptosis o muerte celular programada.\nLa mutación JAK2\nV617F\n \nse origina por la sustitución del aminoácido valina por fenilalanina en la posi-\nción 617, de donde toma su nombre. El cambio de aminoácidos produce una pérdida de la función inhi-\nbitoria, activando de manera aberrante la vía JAK/STAT. Consecuentemente, esta mutación estimula la\nproducción de células en la médula ósea tornándola excesiva y anormal, aun en la ausencia de factores de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":223,"lines":{"from":22,"to":30}}}}],["1113",{"pageContent":"Cuadro 14-1.\n \nNeoplasias mieloproliferativas crónicas\n\nLeucemia granulocítica crónica\n \nLeucemia neutrofílica crónica\nPolicitemia vera\n \nLeucemia eosinofílica crónica\nTrombocitosis esencial\n \nMastocitosis\nMielofibrosis primaria\n \nNeoplasia mieloproliferativa no clasificable\n\nFigura 14-1.\n \nInterrelación de las neoplasias proliferativas (NMP) agudas como la leucemia aguda mie-\nloblástica (LAM) y los síndromes mieloproliferativos crónicos: leucemia granulocítica crónica (LGC),\npolicitemia vera (PV), trombocitosis primaria (TP) y mielofibrosis con metaplasia mieloide agnogénica\n(MF/MMA).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":223,"lines":{"from":32,"to":54}}}}],["1114",{"pageContent":"197\n\nCAPÍTULO 14. NEOPLASIAS MIELOPROLIFERATIVAS CRÓNICAS\n\ncrecimiento. El desarrollo de esta mutación en la célula progenitora pluripotencial es la base fisiopatológi-\nca de las neoplasias mieloproliferativas crónicas y su presencia es altamente específica para el diagnóstico.\nEs importante señalar que su ausencia no descarta el diagnóstico, ya que se han descrito otras mutaciones\ncon consecuencias similares.\n\nPOLICITEMIA VERA\n\nLa policitemia vera (PV), también llamada\n \npolicitemia rubra vera\n, es una neoplasia mieloproliferativa\ncaracterizada por un aumento en la cantidad de eritrocitos circulantes, acompañada usualmente por leu-\ncocitosis y trombocitosis moderadas, y en ocasiones esplenomegalia. Es una enfermedad de comienzo\ninsidioso y curso crónico e indolente.\n\nEpidemiología","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":224,"lines":{"from":1,"to":20}}}}],["1115",{"pageContent":"Epidemiología\n\nLa incidencia de esta neoplasia es de 2 por cada 100 000 personas por año aproximadamente y ocurre de\nmanera más frecuente en hombres, con una relación de 1,2-2,2:1. Es una enfermedad de adultos mayores\ny su pico de incidencia se registra en personas entre 60 y 80 años, aunque puede presentarse a edades más\ntempranas. Es más común en personas de raza caucásica y en México se ha demostrado que la frecuencia\nde esta enfermedad es menor que en otros países. Aunque se han informado casos familiares de PV, el\ncomponente hereditario no parece ser importante en la mayoría de los casos.\n\nFisiopatología","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":224,"lines":{"from":20,"to":29}}}}],["1116",{"pageContent":"El descubrimiento de la mutación JAK2\nV617F\n \nha mejorado el entendimiento de esta enfermedad, la cual se\npresenta hasta en el 95% de los casos, y en el resto de los pacientes se puede encontrar otra mutación si-\nmilar en el mismo gen. La presencia de esta mutación en la célula progenitora hematopoyética origina un\nestado de proliferación y diferenciación continua, independiente e hipersensible a factores de crecimiento\ncomo la eritropoyetina. En consecuencia, observamos la aparición progresiva de eritrocitosis, acompañada\nfrecuentemente de leucocitosis y trombocitosis. El aumento en la celularidad en la sangre periférica pro-\nduce un incremento en el volumen y viscosidad sanguínea que da lugar a algunas de las manifestaciones\nclínicas. En contraste con las leucemias agudas, donde la célula neoplásica (blasto) es una forma inmadura\ny no funcional, las células neoplásicas en la PV son predominantemente eritrocitos maduros y funcionales.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":224,"lines":{"from":31,"to":42}}}}],["1117",{"pageContent":"y no funcional, las células neoplásicas en la PV son predominantemente eritrocitos maduros y funcionales.\nEl aumento en la cantidad de eritrocitos en la sangre periférica es la característica que separa\nesta NMP de otras, pues en ocasiones la cantidad total de estas células se encuentra duplicada e in -\nclusive triplicada. Este aumento puede producir deficiencia de hierro así como una disminución en\nla producción de eritropoyetina en el riñón por retroalimentación negativa, una característica útil\nen el diagnóstico diferencial y que la distingue de otras policitemias. La proliferación de las otras\nlíneas celulares es variable. Durante el curso de esta enfermedad, el 20% de los pacientes desarro -\nllan una mielofibrosis secundaria o pospolicitémica conocida como la “fase gastada” de la PV. Una\nproporción mucho menor de pacientes (1,3%) sufrirán transformación de la enfermedad a leucemia\naguda mieloblástica (LMA).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":224,"lines":{"from":42,"to":51}}}}],["1118",{"pageContent":"Presentación clínica","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":224,"lines":{"from":53,"to":53}}}}],["1119",{"pageContent":"Casi la mitad de los pacientes al momento del diagnóstico muestran síntomas poco específicos como\ncefalea, debilidad, mareo, alteraciones visuales, molestias epigástricas y parestesias. Un tercio de los\npacientes presentan prurito, y en algunos es el síntoma principal, exacerbado con el baño de agua\ncaliente. Aproximadamente el 15% de los pacientes sufren trombosis venosa o arterial. Menos fre -\ncuente es la eritromelalgia, dolor quemante en manos y pies, ocasionado por la oclusión microvascular\nacompañado de eritema o cianosis. Un ataque agudo de gota es la presentación inicial en una minoría\nde los pacientes.\nEn el examen físico es posible encontrar esplenomegalia, plétora facial y hepatomegalia en el 70,\n67 y 40% de los casos, respectivamente. De forma variable es posible encontrar excoriaciones en la\npiel, inyección conjuntival y examen del fondo de ojo anormal por aumento del diámetro de las venas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":224,"lines":{"from":55,"to":64}}}}],["1120",{"pageContent":"67 y 40% de los casos, respectivamente. De forma variable es posible encontrar excoriaciones en la\npiel, inyección conjuntival y examen del fondo de ojo anormal por aumento del diámetro de las venas\nretinianas. La hemoglobina y el hematocrito están aumentados en todos los pacientes, a menos que\ncursen con deficiencia de hierro; existe trombocitosis y leucocitosis en el 50 y 40% de los pacientes,\nrespectivamente.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":224,"lines":{"from":64,"to":68}}}}],["1121",{"pageContent":"198\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nDiagnóstico\n\nEn el\n \ncuadro 14-2\n \nse enumeran los criterios diagnósticos de la OMS para la PV.\n\nTratamiento\n\nEl tratamiento de la PV incluye cuatro aspectos: modificar los factores de riesgo cardiovascular, antiagre-\ngantes plaquetarios, flebotomía y citorreducción. La administración de dosis bajas de ácido acetilsalicílico,\n100 mg diarios, disminuye el número de eventos trombóticos y los síntomas por oclusión microvascular.\nSe deben realizar flebotomías de 250 a 400 mL en cada sesión hasta alcanzar un hematocrito de 45%. En\npacientes de alto riesgo es necesario aplicar quimioterapia con hidroxiurea 15-20 mg/kg por día. El ruxo-\nlitinib es un inhibidor de JAK1-2 aprobado para el tratamiento de mielofibrosis; actualmente se encuentra\nen estudio para pacientes con PV, con buenos resultados preliminares. Este fármaco podría ser una buena\nopción para pacientes resistentes a la hidroxiurea.\n\nTROMBOCITOSIS ESENCIAL","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":225,"lines":{"from":1,"to":24}}}}],["1122",{"pageContent":"TROMBOCITOSIS ESENCIAL\n\nLa trombocitosis esencial (TE), también conocida como\n \ntrombocitosis primaria\n,\n \nhemorrágica\n \no\n \nidiopática\n,\nes una NMP Ph(–) que compromete primordialmente la línea megacariocítica. Se caracteriza por una\ntrombocitosis sostenida en la sangre periférica y un aumento en el número y tamaño de megacariocitos\nen la médula ósea. Es una enfermedad crónica y de curso benigno con bajo riesgo de transformación\nleucémica. Es el síndrome mieloproliferativo menos agresivo y el diagnóstico requiere de la exclusión de\notras causas de trombocitosis, así como del resto de las neoplasias mieloides que producen un aumento en\nla cuenta plaquetaria.\n\nEpidemiología","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":225,"lines":{"from":24,"to":44}}}}],["1123",{"pageContent":"Epidemiología\n\nLa TE es un padecimiento de la edad adulta que se observa entre los 50 y 70 años, sin predominio en el\nsexo y que puede ocurrir en personas más jóvenes. Es la NMP Ph(–) más común en el mundo, con una\nincidencia de 2,5 por cada 100 000 habitantes por año y una prevalencia de 30 por cada 100 000 personas,\naunque se cree que estas cifras son mayores, ya que es una enfermedad frecuentemente asintomática y por\nlo tanto difícil de reconocer en la población general.\n\nFisiopatología\n\nAl igual que otras NMP Ph(–), la etiología de esta enfermedad es desconocida. A diferencia de la PV,\nla mutación JAK2\n \nV617F\n \nse asocia solamente en el 60% de los casos de TE. Se han descrito otras muta -\nciones con consecuencias similares, particularmente en el gen\n \nMPL\n, el cual codifica para el receptor\n\nCuadro 14-2.\n \nCriterios de la OMS para el diagnóstico de PV\n\nCriterios mayores","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":225,"lines":{"from":44,"to":69}}}}],["1124",{"pageContent":"Cuadro 14-2.\n \nCriterios de la OMS para el diagnóstico de PV\n\nCriterios mayores\n\nHemoglobina > 18,5 g/dL en hombres, > 16,5 g/dL en mujeres, o evidencia de aumento del volumen\nde eritrocitos\nPresencia de la mutación JAK2\n\nCriterios menores\n\nBiopsia de médula ósea hipercelular con hiperplasia de las tres líneas\nEritropoyetina sérica por debajo de los niveles normales\nFormación endógena de colonias eritroides in vitro*\n*Para el diagnóstico de PV se requieren los dos criterios mayores y uno menor o el primer criterio mayor y dos menores.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":225,"lines":{"from":69,"to":84}}}}],["1125",{"pageContent":"199\n\nCAPÍTULO 14. NEOPLASIAS MIELOPROLIFERATIVAS CRÓNICAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":226,"lines":{"from":1,"to":3}}}}],["1126",{"pageContent":"de la trombopoyetina ocasionando su activación constitutiva. La presencia de esta mutación se ha\nencontrado hasta en el 4% de los pacientes. Estas alteraciones genéticas –y seguramente otras aún no\ndescritas– originan la proliferación exagerada de una clona comprometida a la línea megacariocítica. La\ncuenta plaquetaria elevada, en ocasiones hasta 15 veces el valor normal, aumenta el riesgo de trombosis.\nAdicionalmente se cree que existe una alteración cualitativa en las plaquetas que provoca interacciones\nanormales con el endotelio, secreción de citocinas, agregación anormal y degradación del factor de von\nWillebrand circulante, por lo que paradójicamente, y a pesar del gran número de plaquetas circulantes,\nel paciente puede desarrollar hemorragias y, por otra parte, síntomas microvasculares característicos.\nAl igual que la PV, puede haber progresión a mielofibrosis o transformación leucémica, aunque en una","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":226,"lines":{"from":5,"to":13}}}}],["1127",{"pageContent":"Al igual que la PV, puede haber progresión a mielofibrosis o transformación leucémica, aunque en una\nminoría de pacientes. La mayoría de estos pacientes pueden aspirar a una esperanza de vida casi similar\na la de personas normales.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":226,"lines":{"from":13,"to":15}}}}],["1128",{"pageContent":"Presentación clínica","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":226,"lines":{"from":17,"to":17}}}}],["1129",{"pageContent":"Hasta la mitad de los pacientes pueden cursar asintomáticos y permanecer así por años. El resto de\nlos pacientes presentan síntomas tromboembólicos, hemorrágicos o relacionados a oclusiones micro -\nvasculares. Las manifestaciones tromboembólicas aparecen en alrededor del 20% de los pacientes al\nmomento del diagnóstico y en la misma proporción como complicaciones durante el curso de la en -\nfermedad. Los eventos trombóticos tienen diversas formas de presentación: isquemia digital, isquemia\nmiocárdica, isquemia cerebral, trombosis venosa profunda, trombosis de la circulación portal o hepáti -\nca, embolismo pulmonar y oclusión de la vena o arteria central de la retina. Los eventos arteriales son\nmás comunes que los venosos. La edad avanzada, mayor de 60 años, y el antecedente de trombosis\nson los factores más importantes que determinan el riesgo de trombosis. Otros factores que aumen -\ntan las probabilidades son las comorbilidades de riesgo cardiovascular: diabetes mellitus, hipertensión","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":226,"lines":{"from":19,"to":28}}}}],["1130",{"pageContent":"tan las probabilidades son las comorbilidades de riesgo cardiovascular: diabetes mellitus, hipertensión\narterial, dislipidemia, tabaquismo y trombofilias. No se ha encontrado correlación entre el número de\nplaquetas y el riesgo de trombosis. La hemorragia es más común, principalmente cuando las plaquetas\nsobrepasan la cifra de 1 000 × 10\n \n9\n \n/L, debido a que se acompaña de una alteración en la función plaque -\ntaria llamada\n \nenfermedad de von Willebrand adquirida\n \n. Los síntomas ocasionados por la oclusión micro-\nvascular se presentan en el 30 a 40% de los pacientes, entre los cuales predominan cefalea, parestesias\nde extremidades, eritromelalgia, amaurosis fugaz, síncope, dolor torácico atípico y livedo reticularis.\nEn la exploración física, el dato más relevante y la mayoría de las veces único es la esplenomegalia leve\no moderada, presente en casi la mitad de los pacientes.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":226,"lines":{"from":28,"to":44}}}}],["1131",{"pageContent":"Diagnóstico\n\nEl diagnóstico de TE requiere de la exclusión de otras probables causas de trombocitosis: procesos in-\nfecciosos o inflamatorios, deficiencia de hierro, esplenectomía y otras enfermedades mieloproliferativas.\nLa persistencia de una cuenta plaquetaria mayor de 450 × 10\n \n9\n \n/L, aislada y sin causa aparente, aunado a\nesplenomegalia, sugiere el diagnóstico de TE. La OMS dicta cuatro criterios diagnósticos\n \n(cuadro 14-3)\n;\ndos de los criterios están orientados a la trombocitosis e hiperplasia de megacariocitos en la médula ósea\ny dos para descartar otras enfermedades.\n\nCuadro 14-3.\n \nCriterios diagnósticos de TE","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":226,"lines":{"from":46,"to":64}}}}],["1132",{"pageContent":"Cuadro 14-3.\n \nCriterios diagnósticos de TE\n\nCuenta de plaquetas sostenida > 450 × 10\n \n9\n \n/L\nBiopsia de médula ósea con un aumento en el número y tamaño de los megacariocitos maduros, sin\nun aumento significativo de granulopoyesis o eritropoyesis\nNo reunir criterios diagnósticos según la OMS para PV, mielofibrosis primaria, leucemia mieloide\ncrónica, síndromes mielodisplásicos u otras neoplasias mieloides\nDemostrar la presencia de un marcador de clonalidad: JAK\n \n2V617F\n \no MPLW515L/K; en su ausencia,\ndescartar deficiencia de hierro y trombocitosis reactiva","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":226,"lines":{"from":64,"to":82}}}}],["1133",{"pageContent":"200\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nTratamiento\n\nLos pacientes menores de 60 años, sin antecedente de trombosis y con menos de 1 000 × 10\n9\n/L, se consideran\nde bajo riesgo y son candidatos a recibir dosis bajas de ácido acetilsalicílico. Los pacientes de alto riesgo, es\ndecir, mayores de 60 años o con historia de trombosis, además requieren de un medicamento citorreductor.\nLa mejor opción es la hidroxiurea, iniciando con dosis de 500 mg dos veces al día. En casos de resistencia\no intolerancia a la hidroxiurea, la anagrelida es considerada la segunda línea de tratamiento. Otros medica-\nmentos disponibles son el interferón\n \nα\n \ny el busulfano. La aféresis plaquetaria es una opción que se reserva\npara casos de trombocitosis extrema con complicaciones agudas y serias, hemorrágicas o trombóticas. De-\nbido a que el efecto de la aféresis es transitorio, esta opción debe venir seguida de un agente mielosupresor.\n\nMIELOFIBROSIS PRIMARIA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":227,"lines":{"from":1,"to":22}}}}],["1134",{"pageContent":"MIELOFIBROSIS PRIMARIA\n\nLa mielofibrosis (MF) primaria es una NMP caracterizada por el desarrollo de fibrosis medular, hema-\ntopoyesis extramedular y esplenomegalia. Puede ocurrir de novo (primaria) o durante la historia natural\nde cualquier otra neoplasia mieloproliferativa (secundaria). Otros nombres de esta enfermedad incluyen\n\nmielofibrosis crónica idiopática\n \ny\n \nmielofibrosis con metaplasia mieloide agnogénica\n.\n\nEpidemiología\n\nDe manera similar a otras NMP Ph(–), la mielofibrosis primaria ocurre en adultos. Es una enfermedad\ninfrecuente con una incidencia de 0,5 a 1 por cada 100 000 habitantes. La edad mediana al diagnóstico es\nentre los 65 y 70 años, aunque se sabe que puede ocurrir en niños. La MF tiene una frecuencia similar en\nambos sexos, y a pesar de que a nivel mundial representa la forma más infrecuente de las NMP Ph(–), se\nha reportado una frecuencia mayor en el centro de México.\n\nFisiopatología","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":227,"lines":{"from":22,"to":43}}}}],["1135",{"pageContent":"La etiología de esta enfermedad es desconocida, aunque se ha asociado a la exposición de solventes (ben-\nceno) y radiación. Como en cualquier otra NMP, la transformación neoplásica de una célula hematopo-\nyética anormal provoca el desarrollo de la enfermedad. La causa principal de esta transformación no se ha\nidentificado, y se ha asociado a la mutación JAK2\nV617F\n \nsolamente en el 50% de los casos. Adicionalmente,\nse han descrito otras mutaciones y alteraciones cromosómicas, como la mutación en el gen\n \nMPL\n \npresente\nen una minoría de pacientes.\nLos mecanismos fisiopatológicos responsables del cuadro clínico de estos pacientes incluyen: prolife-\nración de megacariocitos anormales, cambios fibróticos en la médula ósea y aparición de hematopoyesis\nextramedular o\n \nmetaplasia mieloide\n. Los megacariocitos y monocitos neoplásicos secretan una cantidad\nelevada de citocinas, como el factor de crecimiento transformante\n \nβ\u0003\n(TGF-\nβ\n) y el factor de crecimiento","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":227,"lines":{"from":45,"to":69}}}}],["1136",{"pageContent":"metaplasia mieloide\n. Los megacariocitos y monocitos neoplásicos secretan una cantidad\nelevada de citocinas, como el factor de crecimiento transformante\n \nβ\u0003\n(TGF-\nβ\n) y el factor de crecimiento\nderivado de plaquetas (PDGF), estimulando la producción de colágena tipo 1 y reticulina (colágena tipo\n3) por parte de fibroblastos normales. Además del depósito progresivo de estas proteínas, existe formación\nanormal de hueso u osteoesclerosis en la médula ósea\n.\n \nEstos procesos se conocen en conjunto como\n \nfibrosis\nmedular\n \ny le confieren el nombre a la enfermedad\n.\n \nEl desarrollo de fibrosis interfiere poco a poco con la\nhematopoyesis normal y produce citopenias en los pacientes, en especial anemia, con un grado de progre-\nsión variable. Es importante mencionar que este hallazgo histopatológico no es específico de la MF y suele\npresentarse en otras enfermedades. Otra de las características de la MF es la movilización anormal de\ncélulas inmaduras de la médula ósea hacia la sangre periférica, conocida como","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":227,"lines":{"from":69,"to":94}}}}],["1137",{"pageContent":"presentarse en otras enfermedades. Otra de las características de la MF es la movilización anormal de\ncélulas inmaduras de la médula ósea hacia la sangre periférica, conocida como\n \nleucoeritroblastosis\n. Dentro\nde esta movilización podemos encontrar células hematoprogenitoras CD34+, y se cree que el flujo anor-\nmal de estas es el responsable de la capacidad de estos pacientes para establecer sitios de hematopoyesis\nextramedular en el hígado, bazo y otros órganos\n \n(cuadro 14-4)\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":227,"lines":{"from":94,"to":104}}}}],["1138",{"pageContent":"Presentación clínica\n\nLos pacientes con MF usualmente se presentan con síndrome anémico y hepatoesplenomegalia, y en\ncasos avanzados pérdida de peso, fiebre y diaforesis nocturna. Otros síntomas que pueden presentar son\ndolor abdominal, principalmente en hipocondrio izquierdo, saciedad temprana, edema periférico, ascitis,\nlinfadenopatía y sangrado mucocutáneo. El 80% de los casos muestran esplenomegalia y el 50% hepato -\nmegalia; en un tercio de los pacientes la esplenomegalia es grado III o IV. La característica principal de la","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":227,"lines":{"from":106,"to":112}}}}],["1139",{"pageContent":"201\n\nCAPÍTULO 14. NEOPLASIAS MIELOPROLIFERATIVAS CRÓNICAS\n\nMF al analizar la sangre periférica es la presencia de dacriocitos y células inmaduras: eritrocitos nuclea -\ndos, mieloblastos, promielocitos, mielocitos y metamielocitos. En el 60% de los pacientes la hemoglobina\nes menor de 10 g/dL, y en el 40 a 49% de los casos presentan leucocitosis, 7 a 21% leucopenia, 13 a 31%\ntrombocitosis, 21 a 37% trombocitopenia, 33 a 53% blastos circulantes y, en más de la mitad de los casos,\ndeshidrogenasa láctica (DHL) elevada.\n\nDiagnóstico","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":228,"lines":{"from":1,"to":11}}}}],["1140",{"pageContent":"Diagnóstico\n\nLa presencia de esplenomegalia y mieloptisis sugiere MF. El examen de médula ósea es esencial para el\ndiagnóstico, y no es raro que al intento de aspiración de médula ósea se obtenga una punción seca. En la\nbiopsia de médula ósea se observa hiperplasia mieloide y megacariocítica, con grados variables de fibrosis\ny osteoesclerosis. Sin embargo, la fibrosis de la médula ósea no es específica de MF, por lo que es necesario\ndescartar otros procesos que producen fibrosis reactiva, como infecciones, inflamaciones u otras enferme-\ndades mieloproliferativas.\n\nTratamiento","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":228,"lines":{"from":11,"to":20}}}}],["1141",{"pageContent":"Tratamiento\n\nEl trasplante de médula ósea es la única opción con potencial curativo. Los pacientes que no son\ncandidatos a trasplante reciben tratamientos dirigidos a aliviar los síntomas y a mejorar la calidad de\nvida. La combinación de andrógenos y corticoides mejora la anemia en algunos pacientes. En casos\nseleccionados se aplica talidomida, lenalidomida, quimioterapia con hidroxiurea, radiación al bazo o\nesplenectomía. El ruxolitinib, inhibidor selectivo de JAK1/JAK2, disminuye los síntomas y el tamaño\ndel bazo en MF.\n\nCONCLUSIONES\n\n•\n \nLas neoplasias mieloproliferativas son padecimientos tumorales del sistema hematopoyético mieloide,\ncaracterizados por la proliferación exagerada de las líneas eritrocítica, granulocítica, trombocítica o\nfibroblástica, de forma aislada o combinada.\n\n•\n \nLas entidades principales son: leucemia granulocítica crónica (100% con\n \nBCR/ABL\n), policitemia vera\n(95% con\n \nJAK2\n), trombocitemia esencial y mielofibrosis primaria con metaplasia mieloide agnogénica.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":228,"lines":{"from":20,"to":46}}}}],["1142",{"pageContent":"•\n \nLa terapia utilizada depende del padecimiento y puede incluir hidroxiurea, esplenectomía, interferón\n\u0003α\u0003\n\ny trasplante de médula ósea. Los fármacos inhibidores de JAK2 tienen efectos paliativos.\n\nCuadro 14-4.\n \nCriterios de la OMS para MF\n\nCriterios mayores\n\nAumento y atipia de megacariocitos con fibrosis; en caso de ausencia de fibrosis, las anorma -\nlidades de los megacariocitos deberán acompañarse de hiperplasia granulocítica con eritropo -\nyesis disminuida\nNo reunir criterios para PV, TE, síndrome mielodisplásico u otra neoplasia mieloide\nDemostrar la presencia de un marcador de clonalidad JAK\n \nV617F\n \n; en ausencia de marcador clonal,\ndescartar procesos infamatorios o neoplásicos como causa de fibrosis\n\nCriterios menores\n\nLeucoeritroblastosis\nDHL elevada\nAnemia\nEsplenomegalia*\n*Para el diagnóstico de MF se requieren los tres criterios mayores y dos menores.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":228,"lines":{"from":48,"to":78}}}}],["1143",{"pageContent":"202\n \nFUNDAMENTOS DE HEMATOLOGÍA\nPREGUNTAS DE AUTOEVALUACIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":229,"lines":{"from":1,"to":4}}}}],["1144",{"pageContent":"1. ¿Cuál es la edad de presentación de las neoplasias mieloproliferativas crónicas?\na.\n \nNiñez\nb. Adolescencia\nc.\n \nAdultez\n2. ¿Cuál es la mutación recientemente descrita que se ha asociado a las neoplasias mieloproliferativas crónicas?\na.\n \nJAK2\nV617F\nb. JAK/STAT\nc.\n \nBMP\n3. ¿Cuál es el tratamiento de la policitemia vera?\na.\n \nModificar los factores de riesgo cardiovascular, antiagregantes plaquetarios, flebotomía y citorreducción\nb. Quimioterapia y radioterapia\nc.\n \nTrasplante de médula ósea, flebotomía y citorreducción\n4. ¿Cómo se realiza el diagnóstico de trombocitosis esencial?\na.\n \nCitometría hemática y biopsia de médula ósea\nb. Marcadores clonales\nc.\n \nCuenta plaquetaria, biopsia de médula ósea y presencia de un marcador de clonalidad\n5. ¿Cuáles son los hallazgos característicos en la médula ósea de pacientes con mielofibrosis?\na.\n \nHipoplasia mieloide, fibrosis y osteoporosis\nb. Hiperplasia mieloide y megacariocítica, fibrosis y osteoesclerosis\nc.\n \nHiperplasia megaloblástica y fibrosis","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":229,"lines":{"from":6,"to":46}}}}],["1145",{"pageContent":"BIBLIOGRAFÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":229,"lines":{"from":48,"to":48}}}}],["1146",{"pageContent":"Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: Critical con-\ncepts and management recommendations from European Leukemia Net. J Clin Oncol. 2011; 29: 761-70.\nBaxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloprolifera-\ntive disorders. Lancet. 2005; 365: 1054-61.\nCampbell PJ, Green AR. ¶e myeloproliferative disorders. N Eng J Med. 2006; 355: 2452-66.\nFinazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera. An analysis of 1,638 patients enrolled\nin a prospective observational study. Blood. 2005; 105: 2664-2670.\nJames C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes poly-\ncythaemia vera. Nature. 2005; 434: 1144-8.\nJohansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia.\nSemin ¶romb Hemost. 2006; 32: 171-3.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":229,"lines":{"from":50,"to":60}}}}],["1147",{"pageContent":"cythaemia vera. Nature. 2005; 434: 1144-8.\nJohansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia.\nSemin ¶romb Hemost. 2006; 32: 171-3.\nLawrence JH, Winchel HS, Donald WG. Leukemia in polycythemia vera relationship to splenic myeloid metaplasia\nand therapeutic radiation dose. Ann Intern Med. 1969; 70: 763-771.\nLevine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essen-\ntial thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7: 387-97.\nPardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: A\nstudy of 1182 patients. Blood. 2006; 108: 3472-3476.\nRuiz-Argüelles GJ, Garcés-Eisele J, Ortiz-López R, et al. Molecular characterization of chronic myeloproliferative\nneoplasias in Mexico. Hematology. 2009; 14: 261-265.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":229,"lines":{"from":60,"to":70}}}}],["1148",{"pageContent":"Ruiz-Argüelles GJ, Garcés-Eisele J, Ortiz-López R, et al. Molecular characterization of chronic myeloproliferative\nneoplasias in Mexico. Hematology. 2009; 14: 261-265.\nRuiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, et al. Clearance of the Janus kinase 2 (JAK2) V617F mutation\nafter allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia. Am J Hematol.\n2006; 82: 400-2.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":229,"lines":{"from":70,"to":74}}}}],["1149",{"pageContent":"203\n\nCAPÍTULO 14. NEOPLASIAS MIELOPROLIFERATIVAS CRÓNICAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":230,"lines":{"from":1,"to":3}}}}],["1150",{"pageContent":"Ruiz-Argüelles GJ, López-Martínez B, Lobato-Mendizábal E, Ruiz-Delgado GJ. An addition to geographic\nhematology: Chronic myeloproliferative diseases are infrequent in Mexican Mestizos. Int J Hematol. 2002;\n75: 499-502.\nRuiz-Argüelles GJ, Ruiz-Delgado GJ, Galo-Hooker E, Sánchez-Sosa S. Ruxolitinib in chronic myelomonocytic\nleukemia associated myelofibrosis: A case report. J Bone Marrow Res. 2013; 1: 109-110.\nRuiz-Delgado GJ, Lutz-Presno J, Macías-Gallardo J, Ruiz-Argüelles GJ. Concurrent MPL515 and JAK\n \n2V617F\n \nmu-\ntations in a patient with chronic idiopathic myelofibrosis. Case report and review of the literature. Rev Hematol\nMex. 2011; 12: 138-139.\nTefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and man-\nagement. Am J Hematol. 2012; 87: 284-93.\nTefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL,\nTET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010; 24: 1128-38.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":230,"lines":{"from":5,"to":20}}}}],["1151",{"pageContent":"Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL,\nTET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010; 24: 1128-38.\nTefferi A, ¶iele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic\ncriteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an\nad hoc international expert panel. Blood. 2007; 110: 1092-7.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":230,"lines":{"from":20,"to":24}}}}],["1152",{"pageContent":"RESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\n1.\n \nc\n2.\n \na\n3.\n \na\n4.\n \nc\n5.\n \nb","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":230,"lines":{"from":26,"to":42}}}}],["1153",{"pageContent":"205\n\nINTRODUCCIÓN\n\nEl término\n \nlinfoma no Hodgkin\n \n(LNH) es una definición negativa poco afortunada, que se refiere a\nlas neoplasias del sistema reticuloendotelial diferentes del linfoma de Hodgkin. El concepto de LNH\ncomprende entidades con un amplio espectro en cuanto a agresividad clínica, desde aquellas neoplasias\ncon un curso largo e indolente (linfomas foliculares), hasta aquellas con una extraordinaria velocidad de\ncrecimiento e invasividad (linfoma linfoblástico y linfoma de células pequeñas no hendidas).\n\nEPIDEMIOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":232,"lines":{"from":1,"to":15}}}}],["1154",{"pageContent":"En los Estados Unidos se informan anualmente 45 000 casos nuevos de LNH, lo que representa alrededor del\n4% de todos los cánceres diagnosticados en ese país. En México, de acuerdo al último informe del Registro His\n-\ntopatológico de Neoplasias en México (RHNM) del 2003, se diagnosticaron 5 818 casos nuevos de LNH, lo\nque representa el 5,43% de todas las neoplasias malignas; por otro lado, de acuerdo a este mismo registro,\nlos LHN ocupan el décimo primer lugar en hombres y el décimo tercero en mujeres como causa de muerte.\nLa incidencia de estas neoplasias ha venido incrementándose continuamente en los países occiden-\ntales desde 1960. La explicación de este fenómeno no es clara, aunque ha contribuido el hecho de que\nalgunas variedades de LNH se asocian a la infección del virus de inmunodeficiencia humana (HIV).\nEn Estados Unidos se informa que, en 1992, un 8 a 27% de los LNH se encontraron asociados a esta","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":232,"lines":{"from":17,"to":26}}}}],["1155",{"pageContent":"algunas variedades de LNH se asocian a la infección del virus de inmunodeficiencia humana (HIV).\nEn Estados Unidos se informa que, en 1992, un 8 a 27% de los LNH se encontraron asociados a esta\ninfección. Por otro lado, en los pacientes sin infección por HIV este incremento en la frecuencia se ha\nobservado en los grupos de mayor edad.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":232,"lines":{"from":26,"to":29}}}}],["1156",{"pageContent":"ETIOLOGÍA\n\nLas translocaciones y rearreglos moleculares participan en la patogénesis de muchos linfomas y\nse correlacionan con tipos histológicos específicos. La alteración cromosómica más comúnmente\nasociada al LNH es la t(14;18) (q32;21), que se encuentra en el 85% de los linfomas foliculares\ny en el 28% de los LNH de grado intermedio o alto. La translocación t(11;14) (q13;32) produce\nuna sobreexpresión de\n \nBCL1\n, gen localizado en el cromosoma 11q13 que participa en el control\n\nObjetivos de aprendizaje\n\n•\n \nConocer la epidemiología y la etiología de los linfomas no Hodgkin.\n\n•\n \nMencionar los métodos para definir la extensión de los linfomas.\n\n•\n \nConocer las clasificaciones histológicas y moleculares de los linfomas.\n\n•\n \nEntender las bases del tratamiento de los linfomas no Hodgkin.\n\n•\n \nSeñalar los principales anticuerpos monoclonales utilizados en su tratamiento.\n\nCAPÍTULO 15\n\nEucario León Rodríguez\nKarla Adriana Espinosa Bautista\n\nLINFOMAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":232,"lines":{"from":31,"to":69}}}}],["1157",{"pageContent":"•\n \nSeñalar los principales anticuerpos monoclonales utilizados en su tratamiento.\n\nCAPÍTULO 15\n\nEucario León Rodríguez\nKarla Adriana Espinosa Bautista\n\nLINFOMAS\n\nEl concepto de LNH compren-\nde entidades con un amplio es-\npectro en cuanto a agresividad\nclínica, desde neoplasias con\nun curso largo e indolente (lin-\nfomas\n \nfoliculares),\n \nhasta\n \nlas\nque presentan una extraordi-\nnaria velocidad de crecimiento\ne invasividad (linfoma lin-\nfoblástico y linfoma de células\npequeñas no hendidas).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":232,"lines":{"from":69,"to":96}}}}],["1158",{"pageContent":"206\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":233,"lines":{"from":1,"to":3}}}}],["1159",{"pageContent":"del ciclo celular y se encuentra asociado con linfomas del manto. La translocación que involucra 8q24\ncondiciona una desregulación de\n \nC-MYC\n \ny se asocia frecuentemente con linfomas de Burkitt o simi -\nlares a Burkitt (\nBurkitt\n-\nlike)\n, incluyendo los asociados con infección por HIV.\nExiste evidencia de que ciertos agentes infecciosos participan en la patogénesis de algunos LNH; así,\nel virus del herpes ha sido aislado en linfomas de aves, se han identificado retrovirus del tipo C en linfo-\nmas de roedores, y ambos tipos se han encontrado en primates con linfomas linfocíticos. En humanos, el\nvirus de Epstein-Barr (EBV) guarda estrecha relación con el desarrollo del linfoma de Burkitt, y el virus\nlinfotrópico T humano 1 (HTLV-1) parece ser el agente causal de la leucemia/linfoma de células T del\nadulto, que es endémico del Caribe y el sur de Japón. Algunas lesiones inmunoproliferativas angiocéntri-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":233,"lines":{"from":5,"to":21}}}}],["1160",{"pageContent":"adulto, que es endémico del Caribe y el sur de Japón. Algunas lesiones inmunoproliferativas angiocéntri-\ncas, incluyendo el granuloma de la línea media y la granulomatosis linfomatoide, son neoplasias de células\nT en cuya patogénesis interviene el EBV. Recientemente, los linfomas gástricos, sobre todo los del tipo\nMALT (tejido linfoide asociado a mucosa), se han asociado a la infección por\n \nHelicobacter pylori\n.\nTambién los LNH se han asociado a diferentes estados patológicos o a exposición a diferentes sustancias\nque se muestran en el\n \ncuadro 15-1\n. La difenilhidantoína puede producir una hiperplasia linfoide que en\nocasiones es difícil de distinguir patológicamente de un LNH, y aunque la hiperplasia regresa en la mayoría\nde los casos al suspenderse el fármaco, en un número significativo de casos el paciente puede desarrollar\nun linfoma. Más polémico es el papel etiopatogénico de otros químicos (herbicidas, pesticidas, tinturas de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":233,"lines":{"from":21,"to":35}}}}],["1161",{"pageContent":"un linfoma. Más polémico es el papel etiopatogénico de otros químicos (herbicidas, pesticidas, tinturas de\npelo) en el desarrollo de estas neoplasias. Los factores industriales que posiblemente pueden asociarse con\nel desarrollo de LNH son: arsénico, clorofenoles, solventes orgánicos, plomo, cloruro de vinilo y asbesto.\nPor otro lado, se ha registrado un incremento en la frecuencia del LNH en los sobrevivientes de explo-\nsiones nucleares o de accidentes de reactores nucleares. También estos linfomas se han observado como\ncomplicaciones tardías de quimioterapia o radioterapia, especialmente en pacientes con enfermedad de\nHodgkin que han sido tratados con esquemas combinados de radioquimioterapia.\nLas enfermedades autoinmunitarias, así como las inmunodeficiencias hereditarias y adquiridas, cursan\ncon un incremento en la frecuencia de LNH. Vale la pena señalar que la incidencia de estos linfomas se","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":233,"lines":{"from":35,"to":43}}}}],["1162",{"pageContent":"con un incremento en la frecuencia de LNH. Vale la pena señalar que la incidencia de estos linfomas se\nencuentra incrementada 100 veces en pacientes sometidos a trasplante de órganos y que requieren inmu-\nnosupresión crónica. En estos casos las variedades histológicas más frecuentes son el linfoma difuso de\ncélulas grandes y el linfoma inmunoblástico de estirpe B.\nEn contraste, las inmunodefiencias hereditarias, así como la inmunodeficiencia asociada al HIV, se\nasocian con linfomas de alto grado (linfoma de células pequeñas no hendidas y linfoma inmunoblástico).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":233,"lines":{"from":43,"to":48}}}}],["1163",{"pageContent":"Cuadro 15-1.\n \nEntidades asociadas con riesgo incrementado para el desarrollo de LNH\n\nFármacos o exposiciones a químicos\n\nDifenilhidantoína\nRadiación\nQuimioterapia\nRadioterapia\n\nInmunodeficiencia hereditaria\n\nSíndrome de Klinefelter\nSíndrome de Chédiak-Higashi\nSíndrome de ataxia-telangiectasia\nSíndrome de Wiskott-Aldrich\nSíndrome de inmunodeficiencia común variable\n\nInmunodeficiencia adquirida\n\nInmunosupresión crónica\nSida\n\nEnfermedades autoinmunitarias\n\nSíndrome de Sjögren\nArtritis reumatoide\nLupus eritematoso generalizado","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":233,"lines":{"from":50,"to":78}}}}],["1164",{"pageContent":"Inmunodeficiencia adquirida\n\nInmunosupresión crónica\nSida\n\nEnfermedades autoinmunitarias\n\nSíndrome de Sjögren\nArtritis reumatoide\nLupus eritematoso generalizado\n\nEn humanos, el virus de Ep-\nstein-Barr guarda estrecha rela-\nción con el desarrollo del linfoma\nde Burkitt y el virus HTLV-1\nparece ser el agente causal de la\nleucemia/linfoma de células T\ndel adulto, que es endémico del\nCaribe y el sur de Japón.\nLas enfermedades autoinmu-\nnitarias, así como las inmu-\nnodeficiencias\n \nhereditarias\n \ny\nadquiridas, cursan con un in-\ncremento de la frecuencia de\nLNH. Vale la pena señalar\nque la incidencia de estos lin-\nfomas se encuentra incremen-\ntada 100 veces en pacientes\nsometidos a trasplante de ór-\nganos y que requieren inmu-\nnosupresión crónica.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":233,"lines":{"from":78,"to":112}}}}],["1165",{"pageContent":"207\n\nCAPÍTULO 15. LINFOMAS\n\nEl 30% de los pacientes con infección por HIV desarrollan LNH y en el 40 a 50% de ellos se encuentra\nasociada una infección por EBV. La incidencia de linfomas en inmunosupresión iatrogénica, en sida y\nen enfermedades autoinmunitarias, apoya fuertemente que una desregulación del sistema inmunitario\ninterviene en la patogénesis de los LNH.\n\nDIAGNÓSTICO Y EVALUACIÓN INICIAL","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":234,"lines":{"from":1,"to":10}}}}],["1166",{"pageContent":"La prueba diagnóstica básica en estos casos indudablemente es una biopsia, ya sea de ganglio linfático o\ndel tejido afectado. También es recomendable llevar a cabo la determinación del inmunofenotipo en este\nmomento, pudiendo realizarse con tejido fresco o tejido ya fijado en parafina. Una vez establecido el diag-\nnóstico, el siguiente paso es determinar la extensión de la enfermedad, para lo cual se recomienda efectuar\ndiferentes estudios de laboratorio e imagen que se muestran en el\n \ncuadro 15-2\n. Estos incluyen exáme-\nnes generales (citometría hemática, química sanguínea, pruebas de función hepática, etc.), electroforesis\nde proteínas (para investigar la presencia de un pico monoclonal), deshidrogenasa láctica (DHL) y\nB2 microglobulina (importantes para establecer un pronóstico). Dentro de los estudios de imagen, debe\nobtenerse una telerradiografía de tórax para investigar masa mediastinal, adenopatía hiliar, derrame o","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":234,"lines":{"from":12,"to":23}}}}],["1167",{"pageContent":"obtenerse una telerradiografía de tórax para investigar masa mediastinal, adenopatía hiliar, derrame o\ninfiltrados pulmonares, mientras que la tomografía computarizada (TC) de tórax solo es recomendable\nadquirirla en pacientes con una placa de tórax anormal. La TC de abdomen y pelvis es indispensable\npara determinar la existencia de adenopatía en retroperitoneo, mesenterio o áreas retrocrurales. Mientras\ntanto, la linfangiografía no es útil en el LNH, ya que los ganglios en el mesenterio y los hilios hepático,\nrenal o esplénico, así como los de la pelvis profunda, no se detectan por este procedimiento. Otro estudio\nque debe realizarse inicialmente es una biopsia de hueso percutánea, ya que la infiltración a la médula ósea\n(MO) es muy frecuente, especialmente en linfomas de bajo grado. En pacientes con linfomas agresivos\nque tienen infiltración a MO y a senos paranasales, debe llevarse a cabo una punción lumbar con examen","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":234,"lines":{"from":23,"to":31}}}}],["1168",{"pageContent":"que tienen infiltración a MO y a senos paranasales, debe llevarse a cabo una punción lumbar con examen\ndel líquido cefalorraquídeo (LCR). La laparotomía exploradora no debe considerarse como un procedi-\nmiento de rutina en pacientes con LNH. La razón de lo anterior es que, por un lado, la mayoría de los\npacientes cursan con enfermedad diseminada al momento del diagnóstico (determinada con los estudios\nde rutina iniciales) y, por el otro, que en los escasos casos de pacientes con estudios tempranos, frecuente-\nmente se utilizan esquemas combinados de radioquimioterapia que hacen innecesario tener un estudio pa\n-\ntológico preciso. El valor de la resonancia magnética (RM) en la detección de actividad de estos linfomas\naún se encuentra en investigación, aunque estudios preliminares indican que puede ser de mayor utilidad\nque la TC para detectar actividad residual en MO, cerebro y médula espinal. El gammagrama con radio-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":234,"lines":{"from":31,"to":40}}}}],["1169",{"pageContent":"que la TC para detectar actividad residual en MO, cerebro y médula espinal. El gammagrama con radio-\nnúclidos, especialmente con galio-67 (positivo en la mayoría de los linfomas de grado alto e intermedio\ny en el 50% de los de bajo grado), tiene utilidad clínica, sobre todo para valorar respuesta al tratamiento.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":234,"lines":{"from":40,"to":42}}}}],["1170",{"pageContent":"CLASIFICACIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":234,"lines":{"from":44,"to":44}}}}],["1171",{"pageContent":"Se han desarrollado numerosas clasificaciones histológicas en las últimas décadas; todas ellas tenían en\ncomún intentar predecir el pronóstico de los pacientes. Sin embargo, la comparación entre ellas fue difícil\ny condujo a una confusión en la interpretación de lo publicado en la bibliografía médica. En un intento\npara resolver esto, un grupo de expertos desarrolló en 1982 una clasificación que se proponía condensar\ny unificar todas las clasificaciones en uso en ese momento. La denominada\n \nWorking Formulation\n \nha sido,\ndesde entonces, el sistema de clasificación para el LNH más utilizado. Esta clasificación los divide en\nlinfomas de grado bajo, intermedio y alto\n \n(cuadro 15-3)\n, y es de gran utilidad para predecir su evolución\nclínica y respuesta al tratamiento.\nLa principal crítica que se ha hecho contra esta clasificación es el hecho de que no separa a los linfomas\nen los subtipos B y T, de acuerdo al fenotipo de la célula que los origina, ya que aunque la mayoría de los","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":234,"lines":{"from":46,"to":62}}}}],["1172",{"pageContent":"en los subtipos B y T, de acuerdo al fenotipo de la célula que los origina, ya que aunque la mayoría de los\nLNH son de estirpe B, un porcentaje no despreciable son de estirpe T. Así, los linfomas linfoblásticos\ngeneralmente son tumores de linfocitos T, como lo son la mitad de los linfomas difusos mixtos.\nHay una gran diferencia en la incidencia de los diferentes subtipos de LNH de acuerdo a la edad; así,\nen los niños, los linfomas tipo Burkitt, el linfoblástico y el difuso de células grandes son los más comu-\nnes, en tanto que los linfomas foliculares y los de linfocitos pequeños son extremadamente raros; en los\nadultos jóvenes, los linfomas difusos de células grandes son los más frecuentes. Conforme aumenta la\nedad, la incidencia de los linfomas foliculares y los de grado intermedio incrementa, y así, los de linfocitos\npequeños difusos y los foliculares son los que se diagnostican con mayor frecuencia en pacientes mayores","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":234,"lines":{"from":62,"to":70}}}}],["1173",{"pageContent":"pequeños difusos y los foliculares son los que se diagnostican con mayor frecuencia en pacientes mayores\nde 60 años. El linfoma de linfocitos pequeños (LDLP) es una neoplasia de linfocitos “bien diferenciados”\nque morfológica e inmunológicamente es similar a la leucemia linfocítica crónica (LLC), considerándose","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":234,"lines":{"from":70,"to":72}}}}],["1174",{"pageContent":"Dentro de los estudios de ima-\ngen,\n \ndebe\n \nobtenerse\n \nuna\n \nte-\nlerradiografía\n \nde\n \ntórax\n \npara\ninvestigar masa mediastinal,\nadenopatía hiliar, derrame o\ninfiltrados pulmonares, mien-\ntras que la tomografía compu-\ntarizada (TC) de tórax solo es\nrecomendable aquirirla en pa-\ncientes con una placa de tórax\nanormal.\nLa denominada\n \nWorking For-\nmulation\n \nha sido, desde 1982,\nel sistema de clasificación para\nel LNH más utilizado. Esta\nclasificación los divide en linfo-\nmas de grado bajo, intermedio y\nalto, y es de gran utilidad para\npredecir su evolución clínica y\nrespuesta al tratamiento.\nConforme aumenta la edad,\nla incidencia de los linfomas\nfoliculares y los de grado inter-\nmedio incrementa, y así, los de\nlinfocitos pequeños difusos y los\nfoliculares son los que con mayor\nfrecuencia se diagnostican en\npacientes mayores de 60 años.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":234,"lines":{"from":74,"to":119}}}}],["1175",{"pageContent":"208\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nCuadro 15-2.\n \nEstudios para establecer la extensión del linfoma no\n \nHodgkin\n\nNecesarios\n\n1. Biopsia\n \nadecuada,\n \nrevisada por un\n \npatólogo experimentado\n2. Historia detallada, precisando velocidad de crecimiento\n \nde\n \nlesiones y presencia de síntomas B\n3. Exploración física completa, examinando\n \nintencionadamente\n \nár\n \neas\n \nganglionares\n \ny anillo\nde W\naldeyer\n4. Estudios de\n \nlaboratorio:\na.\n \nCitometría hemática con\n \nsedimentación\n \nglobular\nb. Pruebas de función hepática y\n \nrenal\nc.\n \nDeshidrogenasa láctica\nd. Ácido\n \núrico\ne.\n \nElectroforesis de\n \npr\n \noteínas\nf.\n \nB2\n \nmicr\n \noglobulina\n5. Estudios de\n \nimagen:\na.\n \nRadiografía de tórax PA y lateral\nb.\n \nTC\n \nabdominopélvica\n6. Aspirado y biopsia de médula ósea con\n \naguja\n7.\n \nInmunofenotipo\n\nNecesarios bajo ciertas circunstancias","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":235,"lines":{"from":1,"to":89}}}}],["1176",{"pageContent":"Necesarios bajo ciertas circunstancias\n\n1.\n \nTC\n \nde\n \ntórax\n2.\n \nTC\n \no\n \nRM\n \nde\n \ncráneo\n3. Punción lumbar con estudio citológico de líquido cefalorraquídeo\n4. Estudios baritados o\n \nendoscópicos\n \nde tubo\n \ndigestivo\n5. Estudio citológico de\n \nderrame\n6.\n \nGammagrama\n \ncon galio-\n \n67\n\nCuadro 15-3.\n \nClasificación de linfomas no Hodgkin\n\nGrado bajo\n\na. Linfoma difuso de linfocitos pequeños\nb. Linfoma folicular de células pequeñas hendidas\nc. Linfoma folicular mixto\n\nGrado intermedio\n\nd. Linfoma folicular de células grandes\ne. Linfoma difuso de células pequeñas hendidas\nf. Linfoma difuso mixto\ng. Linfoma difuso de células grandes, hendidas o no hendidas\n\nGrado alto\n\nh. Linfoma difuso inmunoblástico\ni. Linfoma de células pequeñas no hendidas\nj. Linfoma linfoblástico","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":235,"lines":{"from":89,"to":149}}}}],["1177",{"pageContent":"209\n\nCAPÍTULO 15. LINFOMAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":236,"lines":{"from":1,"to":3}}}}],["1178",{"pageContent":"que representa su contraparte en tejidos sólidos. Estas neoplasias representan el 4% de los linfomas no\nHodgkin, generalmente son de estirpe B y se encuentran diseminados en el 80% de los casos al momento\ndel diagnóstico. En la mayoría de los pacientes tienen un curso crónico con supervivencia mayor de 5 años,\naunque no son curables con quimioterapia a pesar de mostrar una respuesta inicial a diferentes agentes\ncitotóxicos.\nLos linfomas foliculares representan aproximadamente un tercio de los casos e incluyen los subtipos\nfolicular de células pequeñas hendidas (LFCPH), folicular mixto (LFM) y folicular de células grandes\n(LFCG). Estos son tumores de estirpe B, frecuentemente asociados con la translocación t(14:18) (q32, q21)\ny tienden a estar diseminados al diagnóstico. Aunque son altamente sensibles a la quimioterapia y a la radio-\nterapia, rara vez son curados con estos tratamientos; sin embargo, su supervivencia media es de 8 a 10 años.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":236,"lines":{"from":5,"to":14}}}}],["1179",{"pageContent":"terapia, rara vez son curados con estos tratamientos; sin embargo, su supervivencia media es de 8 a 10 años.\nEl linfoma folicular de células grandes (LFCG) se incluye en la categoría de linfomas de grado in-\ntermedio, lo que sugeriría que tiene un curso más agresivo y que podría ser curable con quimioterapia\nconvencional. Existen evidencias que apoyan lo anterior, sobre todo para pacientes con enfermedad me-\nnos avanzada. Los linfomas difusos de células pequeñas hendidas (LDCPH) son muy poco frecuentes,\nconstituyendo alrededor del 7% de los LNH. Algunos de estos casos sin lugar a dudas representan la\ncontraparte difusa del LFCPH, ya que comparten características biológicas similares, tales como la trans-\nlocación t(14:18) y su curso indolente, además de que a menudo tienen un estadio IV al diagnóstico. Sin\nembargo, otros tumores que caen en esta categoría presentan un curso más agresivo, lo cual puede estar\nasociado a un inmunofenotipo T más que B, o a una elevada expresión del antígeno Ki-67.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":236,"lines":{"from":14,"to":23}}}}],["1180",{"pageContent":"embargo, otros tumores que caen en esta categoría presentan un curso más agresivo, lo cual puede estar\nasociado a un inmunofenotipo T más que B, o a una elevada expresión del antígeno Ki-67.\nEl linfoma difuso mixto (LDM), el difuso de células grandes (LDCG) y el inmunoblástico (LI) pue-\nden ser considerados como una sola entidad clínica. La inclusión del LI en los linfomas de alto grado no\nes apropiada desde este punto de vista. Estos linfomas comprenden aproximadamente un tercio de todos\nlos linfomas y son los más comunes en la edad adulta. Estos tumores son quimiosensibles y curables en\nuna proporción significativa de casos.\nTanto el linfoma linfoblástico (LL) como el de células pequeñas no hendidas (LCPNH) son tumores\ncon una velocidad de crecimiento extraordinariamente alta, comprenden alrededor del 9% de los casos de\nlinfoma y tienden a diseminarse tempranamente en el sistema nervioso central (SNC) y en la sangre. El","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":236,"lines":{"from":23,"to":32}}}}],["1181",{"pageContent":"linfoma y tienden a diseminarse tempranamente en el sistema nervioso central (SNC) y en la sangre. El\nLL está estrechamente relacionado con la leucemia linfoblástica aguda (LLA) de células T, mientras que\nel LCPNH es la contraparte sólida de la LLA L3 o tipo Burkitt. Ambos linfomas son potencialmente\ncurables con quimioterapia en niños, mientras que tienen un pronóstico muy pobre en adultos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":236,"lines":{"from":32,"to":35}}}}],["1182",{"pageContent":"Nuevas clasificaciones\n\nEn 1998, el Grupo Internacional de Estudio de Linfomas (ILSG) propuso una nueva clasificación deno-\nminada\n \nREAL\n \n(por sus siglas en inglés), que se basa en la caracterización de las diferentes enfermedades\nlinfoproliferativas en base a criterios morfológicos, inmunológicos y genéticos. Esta clasificación elimina\nlas categorías de bajo, intermedio o alto grado, e incorpora nuevas entidades que no se consideran en la","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":236,"lines":{"from":37,"to":46}}}}],["1183",{"pageContent":"Working Formulation\n \n(WF), comprendiendo 12 tipos diferentes de neoplasias de células B y 11 tipos de\ncélulas T; los subtipos de enfermedad de Hodgkin también se incluyen.\nEl grado 3 corresponde al linfoma folicular de células grandes, que es considerado un linfoma de\ngrado intermedio por la WF y es generalmente tratado como un linfoma de células grandes. También en\nestas clasificaciones se considera al linfoma linfocítico de células pequeñas como sinónimo de la leucemia\nlinfocítica crónica. Otros linfomas indolentes reconocidos por estas clasificaciones pero no por la WF\nincluyen: el linfoma linfoplasmacítico, el linfoma esplénico de células B de la zona marginal, el linfoma\nextranodal de células B de la zona marginal, el linfoma tipo MALT y el linfoma ganglionar de células B\nde la zona marginal.\nQue estas clasificaciones sean superiores a la de la WF, aún está por definirse; sin embargo, diversos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":236,"lines":{"from":48,"to":59}}}}],["1184",{"pageContent":"de la zona marginal.\nQue estas clasificaciones sean superiores a la de la WF, aún está por definirse; sin embargo, diversos\nestudios han mostrado que la clasificación REAL/WHO tiene importancia clínica, así como el hecho de\nque identifica entidades linfoproliferativas que tienen características clínicas y pronósticas muy particu-\nlares\n \n(cuadro 15-4)\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":236,"lines":{"from":59,"to":66}}}}],["1185",{"pageContent":"MODO DE PRESENTACIÓN Y DIAGNÓSTICO DIFERENCIAL\n\nAlrededor de dos terceras partes de los LNH se presentan como linfadenopatías persistentes, periféricas e\nindoloras. En estos casos el diagnóstico diferencial incluye etiologías infecciosas y parasitarias, así como en-\nfermedades autoinmunitarias y neoplásicas. En términos generales se acepta que un ganglio duro, mayor de\n1 cm, que no se asocia a una infección aparente y que persiste por 4 a 6 semanas, debe ser sometido a biopsia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":236,"lines":{"from":68,"to":73}}}}],["1186",{"pageContent":"El linfoma folicular de células\ngrandes (LFCG) se incluye\nen la categoría de linfomas de\ngrado intermedio, lo que suge-\nriría que tiene un curso más\nagresivo y que podría ser cu-\nrable con quimioterapia con-\nvencional. Existen evidencias\nque apoyan esto, sobre todo\npara pacientes con enfermedad\nmenos avanzada.\nQue estas clasificaciones sean su-\nperiores a la de la WF, aún está\npor definirse; sin embargo, di-\nversos estudios han mostrado que\nla clasificación REAL/WHO\ntiene\n \nimportancia\n \nclínica,\n \nasí\ncomo el hecho de que identifica\nentidades linfoproliferativas que\ntienen características clínicas y\npronósticas muy particulares","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":236,"lines":{"from":75,"to":101}}}}],["1187",{"pageContent":"210\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nCuadro 15-4.\n \nClasificación\n \nREAL/WHO\n \nde neoplasias\n \nlinfoides\n\na.\n \nNeoplasias de células\n \nB\n\n1. Neoplasia de precursores de células B\nLeucemia/linfoma linfoblástico de precursores\n \nB\n \n(leucemia aguda linfobástica pre-B)\n2. Neoplasias de células\n \nB\n \nmaduras\nLeucemia linfocítica crónica/linfoma de linfocitos pequeños de células B\nLeucemia prolinfocítica de células B\nLinfoma linfoplasmocítico de células B\nLinfoma esplénico de células B de la zona marginal (con o sin linfocitos vellosos)\nLeucemia de células peludas\nMieloma de células plasmáticas/plasmocitoma\nLinfoma extranodal de células B de la zona marginal de tipo MALT\nLinfoma ganglionar de células B de la zona marginal (con o sin células B monocitoides)\nLinfoma folicular\nLinfoma de células del manto\nLinfoma difuso de células grandes B\nLinfoma mediastínico de células grandes B\nLinfoma de cavidades\n\nb.\n \nNeoplasia de células\n \nT\n \ny NK","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":237,"lines":{"from":1,"to":52}}}}],["1188",{"pageContent":"b.\n \nNeoplasia de células\n \nT\n \ny NK\n\n1. Neoplasia de precursores de células\n \nT\nLeucemia/linfoma linfoblástico de precursores\n \nT\n \n(leucemia aguda linfoblástica de precursores\n \nT\n \n)\n2. Neoplasias de células\n \nT\n \nmaduras\nLeucemia prolinfocítica de células\n \nT\nLeucemia\n \nlinfocítica\n \ngranular de células\n \nT\nLeucemia de células\n \nNK\n \nagr\n \nesiva\nLeucemia/linfoma de células\n \nT\n \ndel adulto\n \n(HTL\nV\n-1+)\nLinfoma de células\n \nT\n/\n \nNK\n \nextranodal de tipo\n \nnasal\nLinfoma de células\n \nT\n \ntipo\n \nenter\n \nopatía\nLinfoma de células\n \nT\n \ngd\n \nhepatoesplénico\nLinfoma de células\n \nT\n \ntipo paniculitis\n \nsubcutánea\nLinfoma anaplásico de células\n \ngrandes, cutáneo,\n \nprimario de células T/nulas\nSíndrome de Sézary/micosis\n \nfungoide\nLinfoma de células\n \nT\n \nperiférico, no clasificable\nLinfoma de células\n \nT\n \nangioinmunoblástico\nLinfoma de células grandes anaplásico de células T/nulas, sistémico\n \nprimario\n\nc.\n \nLinfoma de Hodgkin (enfermedad de\n \nHodgkin)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":237,"lines":{"from":52,"to":162}}}}],["1189",{"pageContent":"c.\n \nLinfoma de Hodgkin (enfermedad de\n \nHodgkin)\n\n1. Linfoma de Hodgkin de predominio linfocítico\n \nnodular\n2. Linfoma de Hodgkin clásico\nLinfoma de Hodgkin esclerosis nodular (grado 1 y\n \n2)\nLinfoma de Hodgkin rico en\n \nlinfocitos\nLinfoma de Hodgkin celularidad\n \nmixta\nLinfoma de Hodgkin disminución\n \nlinfocitaria","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":237,"lines":{"from":162,"to":183}}}}],["1190",{"pageContent":"211\n\nCAPÍTULO 15. LINFOMAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":238,"lines":{"from":1,"to":3}}}}],["1191",{"pageContent":"También hay que recordar que las adenopatías en varios subtipos de LNH frecuentemente fluctúan\nen tamaño, por lo que una regresión incompleta no excluye el diagnóstico de LNH. En adolescentes\ny adultos jóvenes, el diagnóstico diferencial obligado ante una linfadenopatía generalizada es el de\nmononucleosis infecciosa y enfermedad de Hodgkin. A este respecto, hay que señalar que la infiltración\ndel anillo de Waldeyer y de ganglios epitrocleares y mesentéricos es más frecuente en el LNH que en\nla enfermedad de Hodgkin (EH), mientras que los síntomas generales (fiebre, diaforesis nocturna y\npérdida de peso) frecuentes en esta última se presentan en menos del 20% de los pacientes con LNH,\nasociándose primordialmente con histologías difusas y con infiltración hepática o extranodal. Aunque\nmenos común que en la EH, el 20% de los pacientes con LNH se presentan con adenopatía mediastí -\nnica, asociándose con tos persistente, dolor torácico o sin sintomatología pero con una radiografía de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":238,"lines":{"from":5,"to":14}}}}],["1192",{"pageContent":"menos común que en la EH, el 20% de los pacientes con LNH se presentan con adenopatía mediastí -\nnica, asociándose con tos persistente, dolor torácico o sin sintomatología pero con una radiografía de\ntórax anormal. El diagnóstico diferencial en esta presentación incluye: infecciones (tuberculosis, toxo -\nplasmosis, mononucleosis infecciosa), enfermedad de Hodgkin, sarcoidosis y otras neoplasias. La infil-\ntración de ganglios retroperitoneales, mesentéricos o pélvicos es común en la mayoría de los subtipos\nde LNH, pero a menos que sea masiva o produzca obstrucción, generalmente es asintomática; por otro\nlado, los LNH que cursan con grandes masas, esplenomegalia masiva o con localización gastrointes -\ntinal, se presentan con manifestaciones clínicas similares a otras lesiones ocupativas intraabdominales\n(dolor crónico, distensión abdominal, plenitud posprandial, síntomas de obstrucción visceral, perfo -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":238,"lines":{"from":14,"to":22}}}}],["1193",{"pageContent":"(dolor crónico, distensión abdominal, plenitud posprandial, síntomas de obstrucción visceral, perfo -\nración o hemorragia gastrointestinal). La presentación extranodal es rara en los linfomas foliculares,\nmientras que los linfomas difusos de células grandes y los linfomas de alto grado pueden presentarse\ncon infiltración primaria a diferentes órganos.\nCuando los LNH se presentan en un sitio extranodal (lesiones cutáneas; masas testiculares, ováricas,\nmamarias, tiroideas, adrenales; lesiones óseas solitarias, etc.), el diagnóstico diferencial es más difícil, ya\nque los LNH son, por lo general, muy poco frecuentes en comparación con otras patologías locales. Así,\nlos LNH del SNC constituyen solo el 1% de todos los linfomas, aunque con el incremento en la incidencia\nde la infección por el virus de la inmunodeficiencia humana y el aumento en el uso de inmunosupresores,\nestos linfomas son en la actualidad uno de los tumores primarios más frecuentes del SNC. Otro sitio","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":238,"lines":{"from":22,"to":31}}}}],["1194",{"pageContent":"estos linfomas son en la actualidad uno de los tumores primarios más frecuentes del SNC. Otro sitio\nextranodal poco común es el linfoma primario de hueso, que representa menos del 5% de todos los LNH;\nla mayoría de los casos son linfomas difusos de células grandes que afectan primordialmente fémur, pelvis\ny vértebras, presentándose generalmente como una lesión lítica aislada y dolorosa. En contraste, la infil-\ntración hepática es común, pero generalmente no produce manifestaciones clínicas. Así, del 25 al 50%\nde los pacientes con LNH se presentan con infiltración hepática, aunque muy pocos cursan con grandes\nmasas. Por otro lado, los linfomas primarios de hígado son extremadamente raros y casi siempre son del\ntipo difuso y con una variedad histológica agresiva.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":238,"lines":{"from":31,"to":38}}}}],["1195",{"pageContent":"DETERMINACIÓN DE LA EXTENSIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":238,"lines":{"from":40,"to":40}}}}],["1196",{"pageContent":"El\n \nsistema de Ann Arbor\n \npara establecer la extensión de la enfermedad (estadio) fue desarrollado en 1971\npara la enfermedad de Hodgkin y ha sido adoptado para utilizarse en los LNH. Este sistema se basa en\nel número de sitios afectados, su localización y la presencia o ausencia de síntomas sistémicos (véase el\ncapítulo de\n \nEnfermedad de Hodgkin\n). Ya que los LNH generalmente se diseminan por vía hematógena\n(a diferencia de la EH, que lo hace por vía linfática, en regiones contiguas), se ha hecho evidente que\neste sistema es de menor utilidad que en la EH; sin embargo, continúa siendo el más utilizado para\nreportar la extensión de la enfermedad. El concepto de\n \nestadio\n \ntiene menos impacto en los LNH que\nen la EH, ya que solo el 10% de los pacientes con linfomas foliculares tienen enfermedad localizada al\ndiagnóstico y la mayoría de los individuos con linfoma difuso tienen un estadio avanzado al momento\nde ser diagnosticados.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":238,"lines":{"from":42,"to":62}}}}],["1197",{"pageContent":"diagnóstico y la mayoría de los individuos con linfoma difuso tienen un estadio avanzado al momento\nde ser diagnosticados.\nPor otro lado, generalmente se acepta que la distinción entre estadio III y IV tiene muy poca im -\nportancia desde el punto de vista del tratamiento, ya que las opciones terapéuticas son casi idénticas.\nTambién diferentes estudios han demostrado que el pronóstico en estos casos depende primordial -\nmente del subtipo histológico, secundariamente influido por parámetros clínicos diferentes al estadio\n(edad, masa tumoral, enfermedad extranodal y estado general). De acuerdo a lo anterior, la utilidad\ndel estadio en el LNH sería para identificar el pequeño número de pacientes con enfermedad limita -\nda que pueden ser tratados con terapias locales, para estratificarlos dentro de los diferentes subtipos\nhistológicos con fines pronósticos y para valorar el impacto del tratamiento. En virtud de lo anterior,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":238,"lines":{"from":62,"to":71}}}}],["1198",{"pageContent":"histológicos con fines pronósticos y para valorar el impacto del tratamiento. En virtud de lo anterior,\nse han desarrollado otros sistemas que toman en cuenta otros factores pronósticos, tales como los\nniveles de DHL y de B2 microglobulina, el diámetro de la masa más voluminosa y el número de\nsitios extranodales. Aunque estos sistemas son muy diferentes al de Ann Arbor, pueden predecir con","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":238,"lines":{"from":71,"to":74}}}}],["1199",{"pageContent":"Cuando los LNH se presentan\nen un sitio extranodal (lesiones\ncutáneas;\n \nmasas\n \ntesticulares,\nováricas, mamarias, tiroideas,\nadrenales; lesiones óseas solita-\nrias, etc.), el diagnóstico dife-\nrencial es más difícil, ya que los\nLNH son, por lo general, muy\npoco frecuentes en comparación\ncon otras patologías locales.\nLa utilidad del estadio en el\nLNH sería para identificar\nel pequeño número de pacien-\ntes con enfermedad limitada\nque pueden ser tratados con\nterapias\n \nlocales,\n \ncomo\n \npara\nestratificarlos\n \ndentro\n \nde\n \nlos\ndiferentes subtipos histológicos\ncon fines pronósticos y valorar\nel impacto del tratamiento.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":238,"lines":{"from":76,"to":111}}}}],["1200",{"pageContent":"212\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":239,"lines":{"from":1,"to":3}}}}],["1201",{"pageContent":"bastante certeza el curso clínico y la respuesta al tratamiento. En un intento por estandarizar estos\nparámetros, se ha creado el llamado\n \nÍndice Pronóstico Internacional\n \n(IPI)\n \n(cuadro 15-5)\n, desarrollado\npor 16 instituciones y grupos cooperativos en Estados Unidos, Europa y Canadá. Los pacientes cla -\nsificados como de bajo riesgo en este sistema tienen una supervivencia a 5 años del 73%, en compara -\nción con los pacientes de alto riesgo, cuya supervivencia es del 26%. Este sistema es el más utilizado\nactualmente en pacientes con LNH.\nDado que en el IPI la mayoría de los casos de linfoma folicular están dentro del grupo de bajo riesgo,\nse ha desarrollado un nuevo modelo predictivo de pronóstico para este tipo de linfomas denominado\n \nIPI\nde Linfoma Folicular\n \n(FLIPI)\n \n(cuadro 15-6)\n, el cual toma en cuenta la edad (> 60 contra < 60), el estadio\n(III-IV contra I-II), el número de sitios extranodales (> 4 contra < 4), nivel de DHL (> normal contra","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":239,"lines":{"from":5,"to":28}}}}],["1202",{"pageContent":"(FLIPI)\n \n(cuadro 15-6)\n, el cual toma en cuenta la edad (> 60 contra < 60), el estadio\n(III-IV contra I-II), el número de sitios extranodales (> 4 contra < 4), nivel de DHL (> normal contra\nnormal) y el nivel de hemoglobina (< 12 g/L contra > 12 g/L).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":239,"lines":{"from":28,"to":33}}}}],["1203",{"pageContent":"TRATAMIENTO\n\nLinfomas de bajo grado\nEnfermedad localizada (estadios I-II)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":239,"lines":{"from":35,"to":38}}}}],["1204",{"pageContent":"Generalmente los casos localizados son linfomas foliculares de células pequeñas hendidas o foliculares\nmixtos, ya que otras variantes histológicas rara vez se encuentran limitadas al diagnóstico.\nEl tratamiento de elección es la radioterapia (RT) de toda la región linfoide afectada (de acuerdo a la\nclasificación de Ann Arbor) o solo de la región involucrada, más una región linfoide no afectada a cada\nlado de los ganglios infiltrados (RT de campo involucrado). La dosis recomendada es de 30 Gy para en-\nfermedad no voluminosa o con respuesta rápida, y de 36 Gy para enfermedad voluminosa o que responde\nlentamente. El uso de RT nodal total o de campo extendido solo mejora el período libre de recaída, pero\nno la supervivencia. Si la administración de quimioterapia (QT) además de la RT mejora el pronóstico\nen este grupo de pacientes, es una pregunta aún no resuelta; sin embargo, algunos autores la recomien-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":239,"lines":{"from":40,"to":48}}}}],["1205",{"pageContent":"en este grupo de pacientes, es una pregunta aún no resuelta; sin embargo, algunos autores la recomien-\ndan en casos selectos en estadio II con factores desfavorables (síntomas B o más de dos sitios nodales\nno contiguos), o bien con histología folicular mixta. El uso de la tomografía por emisión de positrones\n(PET) puede mejorar los resultados de la RT con campo involucrado al identificar con mayor certeza los\npacientes con enfermedad localizada.\nLos linfomas MALT suelen ser indolentes y se diagnostican como una enfermedad localizada (estadio\nI-II). El estómago es el sitio más frecuente, pero la mayoría de linfomas de bajo grado de pulmón, tiroides,\nglándula salival y órbita también son de este tipo. Los linfomas gástricos tipo MALT, en cuya patogénesis\ninterviene la infección por\n \nH. pylori\n, pueden ser tratados inicialmente con esquemas de erradicación para\nesta bacteria (omeprazol, metronidazol y amoxicilina), dado que con esta terapéutica existe una regresión","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":239,"lines":{"from":48,"to":60}}}}],["1206",{"pageContent":"H. pylori\n, pueden ser tratados inicialmente con esquemas de erradicación para\nesta bacteria (omeprazol, metronidazol y amoxicilina), dado que con esta terapéutica existe una regresión\nde la mayoría de las lesiones tempranas. Aquellos pacientes que no respondan a este manejo pueden ser\ntratados con radioterapia (30 Gy) que incluya estómago y ganglios perigástricos. Si la RT falla, puede\nutilizarse quimioterapia, cirugía o ambas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":239,"lines":{"from":60,"to":65}}}}],["1207",{"pageContent":"Cuadro 15-5.\n \nÍndice internacional de factores pronósticos para linfomas no Hodgkin\n\nFactores\n \npr\n \nonósticos\n\nEdad > 60\n \naños\nEstadio III o IV (Ann Arbor)\nMás de un sitio\n \nextranodal\nDesempeño\n \nfísico 2, 3 o 4 (ECOG)\nElevación de DHL\n\nCategoría de riesgo\n \nNo. factor pronóstico\n \nSupervivencia a 5 años\n\nBajo\nIntermedio bajo\nIntermedio alto\nAlto\n0-1\n2\n3\n4-5\n73%\n50%\n43%\n26%\n\nGeneralmente los casos locali-\nzados son linfomas foliculares\nde células pequeñas hendidas\no foliculares mixtos, ya que\notras variantes histiológicas\nrara vez se encuentran limi-\ntadas al diagnóstico.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":239,"lines":{"from":67,"to":114}}}}],["1208",{"pageContent":"213\n\nCAPÍTULO 15. LINFOMAS\n\nEnfermedad avanzada","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":240,"lines":{"from":1,"to":5}}}}],["1209",{"pageContent":"El tratamiento inicial de los linfomas de bajo grado es materia de controversia. La larga historia natural\nde estos linfomas y la ausencia de síntomas al diagnóstico en la mayoría de los casos han apoyado una\nvigilancia estrecha como el manejo inicial de estos pacientes. Las ventajas de este abordaje incluyen un\nprolongado período sin tratamiento, durante el cual las células tumorales no se seleccionan desde el punto\nde vista de resistencia a fármacos. Por otro lado, se han reportado remisiones espontáneas mayores a 1 año\nen el 23% de los pacientes (fundamentalmente LFCPH), haciendo innecesario un tratamiento en estos\ncasos. Múltiples estudios de fase III que han comparado quimioterapia de inicio contra observación en\npacientes con linfoma folicular (LF) avanzado, asintomáticos, no han mostrado diferencias con respecto\na la supervivencia. Más aún, en un estudio reciente se observó que en pacientes mayores de 70 años las\nprobabilidades de no requerir quimioterapia a 10 años fueron del 40%.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":240,"lines":{"from":7,"to":16}}}}],["1210",{"pageContent":"a la supervivencia. Más aún, en un estudio reciente se observó que en pacientes mayores de 70 años las\nprobabilidades de no requerir quimioterapia a 10 años fueron del 40%.\nEn pacientes con enfermedad sintomática, con grandes masas o aquellos que no están de acuerdo\nsin un manejo inicial, las opciones terapéuticas incluyen: monoquimioterapia, quimioterapia combinada,\nquimiorradioterapia o dosis bajas de radioterapia corporal total (RCT). La RCT fraccionada se ha em-\npleado para tratar pacientes en estadios III/IV. Con ella se obtiene una elevada tasa de respuesta completa\n(70-85%), pero la supervivencia libre de enfermedad (SLE) es de solo un 25% a 5 años. Las complicacio-\nnes más frecuentes son la mielodisplasia y citopenias prolongadas, aunque las complicaciones infecciosas\nagudas son raras. Se obtienen respuestas completas (RC) entre el 30 y 60% de los casos en pacientes sin\ntratamiento previo con agentes alquilantes únicos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":240,"lines":{"from":16,"to":25}}}}],["1211",{"pageContent":"agudas son raras. Se obtienen respuestas completas (RC) entre el 30 y 60% de los casos en pacientes sin\ntratamiento previo con agentes alquilantes únicos.\nPor otro lado, con el esquema CVP (ciclofosfamida, vincristina y prednisona) se obtiene un 65%\nde RC, similar a lo obtenido con la RCT, aunque su duración es de solo 18 a 24 meses. Un estudio de\nla Universidad de Stanford que comparó el tratamiento con un solo agente alquilante, quimioterapia\ncombinada tipo CVP o RCT, no encontró diferencias significativas en términos de supervivencia global\no SLE entre los tres grupos, aunque se observó que el tiempo para adquirir la RC varió de acuerdo al\ntipo de tratamiento (12 meses, 5 meses y 3 meses, para agente único, CVP y RCT, respectivamente).\nEn términos generales, se puede concluir que con un agente único o con el esquema CVP solo\nun 20 a 25% de los pacientes se encuentran sin evidencia de enfermedad a 5 años. Para mejorar","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":240,"lines":{"from":25,"to":34}}}}],["1212",{"pageContent":"En términos generales, se puede concluir que con un agente único o con el esquema CVP solo\nun 20 a 25% de los pacientes se encuentran sin evidencia de enfermedad a 5 años. Para mejorar\nestos resultados se han intentado esquemas más agresivos. Con estos esquemas (CHOP, BACOP,\nM-BACOD, BCVP, etc.) se han obtenido RC de 50 a 70%; sin embargo, la SLE es similar a la ob -\ntenida con CVP (1,5 a 3 años). El razonamiento para utilizar tratamientos combinados (RT + QT)\nse basa en la observación de que los sitios de recaída extranodales son comunes al utilizar RT y que\nla radiación proporciona excelente control local para este tipo de linfomas. A este respecto, los estu -\ndios iniciales de los Institutos Nacionales de Salud de los Estados Unidos y los de la Universidad de\nStanford no demostraron una mejoría en la SLE o en la SG al utilizar quimioterapia (CVP + RT).\nEstudios más recientes han mostrado tasas mayores del 50% de sobrevivientes sin enfermedad utili -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":240,"lines":{"from":34,"to":43}}}}],["1213",{"pageContent":"Stanford no demostraron una mejoría en la SLE o en la SG al utilizar quimioterapia (CVP + RT).\nEstudios más recientes han mostrado tasas mayores del 50% de sobrevivientes sin enfermedad utili -\nzando RT combinada con esquemas de QT más agresivos; no obstante, se requiere un seguimiento\nmás prolongado y estudios adicionales para considerar este abordaje como un tratamiento estándar\nen linfomas de bajo grado.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":240,"lines":{"from":43,"to":47}}}}],["1214",{"pageContent":"Cuadro 15-6.\n \nÍndice pronóstico internacional para linfomas foliculares (FLIPI)\n\nParámetro\n \nFactor adverso\n\nEdad\nEstadio\nNivel de hemoglobina\nNivel de DHL\nNúmero de áreas ganglionares afectadas\n> 60 años 5 años 10 años\nIII o IV\n< 12 g/dL\n> al límite superior normal\n> 4\n\nCategoría de riesgo\n \nNo. factores pronósticos\n \nSupervivencia\n5 años 10 años\n\nBajo\nIntermedio\nAlto\n0-1\n2-3\n4-5\n91%\n \n71%\n78%\n \n51%\n52%\n \n36%\n\nEl\n \ntratamiento\n \ninicial\n \nde\nlos linfomas de bajo grado es\nmateria de controversia. La\nlarga historia natural de es-\ntos linfomas y la ausencia de\nsíntomas al diagnóstico en la\nmayoría de los casos han apo-\nyado una vigilancia estrecha\ncomo el manejo inicial de estos\npacientes.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":240,"lines":{"from":49,"to":106}}}}],["1215",{"pageContent":"214\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":241,"lines":{"from":1,"to":3}}}}],["1216",{"pageContent":"Nuevas terapias para linfomas foliculares incluyen: interferón, rituximab como monofármaco o asocia-\ndo a quimioterapia y radioinmunoconjugados.\nEl interferón-\nα\n \n(IFN-\nα\n) se ha utilizado en combinación con quimioterapia y como terapia de man-\ntenimiento. En la mayoría de los estudios su utilización junto con quimioterapia se ha asociado con pro-\nlongación de la remisión, pero no con incremento en la supervivencia. El Grupo Oncológico del Suroeste\n(SWOG, por sus siglas en inglés) recientemente comunicó los resultados de un estudio de fase III en\npacientes con linfomas indolentes que comparó el uso de IFN-\nα\n \ncontra la observación después de qui -\nmioterapia de inducción con un esquema intensivo a base de antraciclinas. El interferón no prolongó la\nsupervivencia libre de progresión (SLP) o la supervivencia global, por lo que actualmente esta terapia no\npuede ser recomendada salvo en estudios clínicos.\nEl anticuerpo anti-CD20 (rituximab) como monoterapia en linfomas indolentes en recaída o refracta-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":241,"lines":{"from":5,"to":23}}}}],["1217",{"pageContent":"puede ser recomendada salvo en estudios clínicos.\nEl anticuerpo anti-CD20 (rituximab) como monoterapia en linfomas indolentes en recaída o refracta-\nrios se asocia a una respuesta del 50%, con una mediana de duración de la repuesta de 1 año. En pacientes\nno tratados, la respuesta global es del 80%, con una mediana de SLP de 18 meses. Hay que señalar que el\n34% de los pacientes que responden mantienen su respuesta por 5 o más años.\nEstudios de fase II iniciales que utilizaron rituximab en combinación con quimioterapia tipo CHOP\nmostraron un mayor porcentaje de respuesta con remisiones prolongadas en pacientes con LF. A partir\nde estos resultados se han llevado a cabo cuatro estudios fase III que compararon QT combinada con\nrituximab contra QT sola. En todos los estudios, la respuesta global, la mediana del tiempo a la recaída y\nla supervivencia libre de eventos fue superior en el brazo de quimioinmunoterapia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":241,"lines":{"from":23,"to":32}}}}],["1218",{"pageContent":"rituximab contra QT sola. En todos los estudios, la respuesta global, la mediana del tiempo a la recaída y\nla supervivencia libre de eventos fue superior en el brazo de quimioinmunoterapia.\nLos radioinmunoconjugados con anticuerpos anti-CD20 con uso clínico en la actualidad son el ibri-\ntumomab tiuxetán Y-90 (Zevalin\n®\n) y el tositumomab I-131 (Bexxar\n \n®\n). Ambos suministran radiación ioni-\nzante a células diana y también retienen su capacidad de inducir citotoxicidad dependiente de anticuerpos.\nEl ibritumomab tiuxetán Y-90, un emisor\n \nβ\n \nde alta energía, en pacientes previamente tratados se asocia\na una tasa de respuesta del 80% en linfomas en recaída o refractarios o linfomas trasformados, con una\nduración de respuesta de 14 meses. En pacientes refractarios al rituximab, la respuesta con este fármaco es\nalta (~70%) pero con duraciones de respuesta cortas (6,4 meses). La dosis limitante de este tratamiento es la\nmielosupresión, que se presenta durante 7 a 9 semanas postratamiento.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":241,"lines":{"from":32,"to":50}}}}],["1219",{"pageContent":"alta (~70%) pero con duraciones de respuesta cortas (6,4 meses). La dosis limitante de este tratamiento es la\nmielosupresión, que se presenta durante 7 a 9 semanas postratamiento.\nEl tositumomab I-131, un emisor\n \nβ\n \ny\n \nγ\n, resulta eficaz en pacientes previamente tratados con linfomas\nen recaída o refractarios. Su tasa de respuesta es del 65% (20% de respuestas completas), con una duración\nde respuesta de 6,5 meses. En pacientes sin tratamiento previo, la tasa de respuesta completa es del 75%,\ncon una SLP a 5 años del 62%. Este radioconjugado se ha utilizado para consolidar la respuesta con qui-\nmioterapia tipo CHOP. En un estudio fase II, el porcentaje de respuestas completas incrementó de 39%\ndespués de CHOP a 60% después de la consolidación con tositumomab I-131. A 2 años, el 80% de los\npacientes permanecían libres de enfermedad. Con base en estos resultados, actualmente se está llevando a\ncabo un estudio aleatorio que compara el uso de CHOP seguido de tositumomab I-131 contra R-CHOP","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":241,"lines":{"from":50,"to":66}}}}],["1220",{"pageContent":"pacientes permanecían libres de enfermedad. Con base en estos resultados, actualmente se está llevando a\ncabo un estudio aleatorio que compara el uso de CHOP seguido de tositumomab I-131 contra R-CHOP\nen pacientes vírgenes a tratamiento.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":241,"lines":{"from":66,"to":68}}}}],["1221",{"pageContent":"Linfomas de grado intermedio\n\nLa discusión sobre el tratamiento en este tipo de linfomas se concentra en el LDCG, ya que su manejo es\nel prototipo para el resto de linfomas dentro de esta categoría.\n\nEnfermedad localizada","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":241,"lines":{"from":70,"to":75}}}}],["1222",{"pageContent":"Menos del 20% de los pacientes con LDCG tienen enfermedad limitada. Algunos pacientes con\nestadio I sin grandes masas o estadio II limitado han sido tratados exclusivamente con radioterapia.\nSe necesitan dosis entre 4 500 y 5 000 cGy para lograr un adecuado control local, obteniéndose\nun 50% de pacientes vivos y sin enfermedad a 5 años. Cuando la determinación del estadio es pa -\ntológica (mediante laparotomía exploradora), la SLE es de 70 a 85% con este abordaje\n \n.\n \nDiferentes\nestudios han mostrado que el uso combinado de quimioterapia (tipo CHOP, BACOP, M-BACOD,\netc.) y radioterapia en las regiones afectadas mejora los resultados en comparación con la RT sola.\nCon base en estos estudios, actualmente se acepta que estos pacientes deben ser tratados con la\ncombinación de RT y QT. Una controversia que existe hoy en día es si la dosis total de quimiote -\nrapia puede ser reducida en relación con la que se usa en enfermedad avanzada. A este respecto,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":241,"lines":{"from":77,"to":90}}}}],["1223",{"pageContent":"combinación de RT y QT. Una controversia que existe hoy en día es si la dosis total de quimiote -\nrapia puede ser reducida en relación con la que se usa en enfermedad avanzada. A este respecto,\nvarios estudios han demostrado que un número menor de ciclos (3 a 4) seguidos de RT en el rango\nde 30 a 36 Gy representa un tratamiento adecuado, con una SLE de 80 a 100% en estadio I y de 60\na 80% en estadio II.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":241,"lines":{"from":90,"to":94}}}}],["1224",{"pageContent":"Diferentes estudios han mos-\ntrado que el uso combinado de\nquimioterapia\n \n(tipo\n \nCHOP,\nBACOP,\n \nM-BACOD,\n \netc.)\ny radioterapia en las regiones\nafectadas obtiene mejores re-\nsultados que con la RT sola.\nCon base en estos estudios, ac-\ntualmente se acepta que estos\npacientes deben ser tratados con\nla combinación de RT y QT.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":241,"lines":{"from":96,"to":114}}}}],["1225",{"pageContent":"215\n\nCAPÍTULO 15. LINFOMAS\n\nExiste evidencia de que la adición de rituximab (anticuerpo anti-CD20) a la QT + RT de campo\ninvolucrado mejora la SLP y la supervivencia global. De acuerdo a lo anterior, actualmente se consi -\ndera que el tratamiento de elección para los linfomas localizados es la administración de 3 a 4 ciclos\nde CHOP con rituximab y RT con campo involucrado. Para pacientes con enfermedad voluminosa,\nse recomienda un mínimo de seis ciclos de quimioterapia. Linfomas de cabeza y cuello pueden ser\nmanejados con quimioterapia únicamente para evitar la toxicidad aguda de mucositis y la xerostomía\na largo plazo cuando se requieran campos extensos que incluyan ambas parótidas.\n\nEnfermedad avanzada","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":242,"lines":{"from":1,"to":13}}}}],["1226",{"pageContent":"La elevada tasa de remisión completa y la supervivencia a largo plazo observada en estos pacientes es uno\nde los mayores éxitos en la historia de la quimioterapia. Con base en los resultados exitosos del MOPP en el\ntratamiento de la enfermedad de Hodgkin, los esquemas de quimioterapia inicialmente desarrollados para\nLDCG fueron el C-MOPP y el CHOP\n \n(cuadro 15-7).\n \nEstos esquemas produjeron un 50% de remisiones\ncompletas con un 35% de sobrevivientes sin enfermedad a largo plazo. Otros esquemas de los llamados de\n“primera generación” fueron desarrollados para tratar de mejorar estos resultados, los cuales incluyeron el\nBACOP y el COMLA. En el primero se añadió la bleomicina y en el segundo el metotrexato (MTX) y\nel arabinósido de citosina, con el objeto de vencer la quimiorresistencia. Aunque las investigaciones iniciales\nsugirieron que se obtenía una mayor tasa de remisiones completas, la mayoría de los estudios subsecuentes no","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":242,"lines":{"from":15,"to":27}}}}],["1227",{"pageContent":"sugirieron que se obtenía una mayor tasa de remisiones completas, la mayoría de los estudios subsecuentes no\ndemostraron mejoría significativa sobre el CHOP o el C-MOPP, pero sí una mayor toxicidad.\nLa “segunda generación” de esquemas intentó agregar al C-MOPP y al BACOP algunos agentes que\nno tuvieran resistencia cruzada, creándose el M-BACOD, el m-BACOD y el ProMACE-MOPP. En\nel primero de ellos, se añadió metotrexato a dosis altas con el objeto de proporcionar profilaxis al SNC,\ndada la frecuencia tan elevada de recaída a este nivel observada con el BACOP. Con este nuevo esquema\nse reportaron tasas de RC del 75%, con una SLE de alrededor del 55% y una disminución significativa de\nlas recaídas en el SNC. Este régimen se asoció con efectos secundarios adicionales que incluyen mucositis\ne infiltrados pulmonares.\nEn el m-BACOD, la dosis de metotrexato se redujo, obteniéndose idénticos resultados. El Instituto","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":242,"lines":{"from":27,"to":36}}}}],["1228",{"pageContent":"e infiltrados pulmonares.\nEn el m-BACOD, la dosis de metotrexato se redujo, obteniéndose idénticos resultados. El Instituto\nNacional del Cáncer (INC) desarrolló el ProMACE-MOPP, en el cual el ProMACE se administra hasta\nque deja de haber respuesta tumoral, administrando en este momento el MOPP; si la respuesta al MOPP\ndisminuye, entonces el ProMACE se administra nuevamente. Este esquema fue diseñado en base a la\nteoría de Norton-Simon, que plantea que siguiendo un tratamiento inicial, las células residuales serán\nmás resistentes a un nuevo tratamiento, lo cual se evitaría al administrar fármacos sin resistencia cruzada\nsecuencialmente. Este esquema produjo un 80% de RC con 50% de sobrevivientes libres de enfermedad\na largo plazo; sin embargo, no pudo confirmar la hipótesis antes señalada, ya que los pacientes que no\nobtenían remisión con el ProMACE, pero sí con el C-MOPP, aún recaían. Por otro lado, este esquema\nfue significativamente más tóxico que el C-MOPP o el M-BACOD.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":242,"lines":{"from":36,"to":46}}}}],["1229",{"pageContent":"obtenían remisión con el ProMACE, pero sí con el C-MOPP, aún recaían. Por otro lado, este esquema\nfue significativamente más tóxico que el C-MOPP o el M-BACOD.\nDado que no se lograron mayores avances con estos esquemas de segunda generación, se diseñaron\nesquemas más agresivos, llamados de “tercera generación”. En estos se añade un número mayor de agentes\nactivos en un período más corto de tiempo\n \n(cuadro 15-7)\n. En el ProMACE-CytaBOM, los nuevos agentes\nque lo componen se administran en ciclos de 28 días. En el COPBLAM-III, el ciclo se acorta a 21 días,\nreduciendo la dosis de ciclofosfamida. Con estos esquemas se informó inicialmente un 80% de RC con 60%\nde sobrevivientes sin enfermedad a largo plazo. El MACOP-B exploró un concepto diferente, que consiste\nen administrar un régimen agresivo en solo 12 semanas, utilizando seis agentes a intervalos cortos entre sí,\ncon lo que inicialmente se comunicaron respuestas completas en el orden del 80% con 65% de SLE.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":242,"lines":{"from":46,"to":58}}}}],["1230",{"pageContent":"con lo que inicialmente se comunicaron respuestas completas en el orden del 80% con 65% de SLE.\nAun cuando estos resultados eran superiores a los publicados previamente, el seguimiento de estos\nestudios al momento de ser presentados era muy corto, además de que sus resultados no pudieron ser\nreproducidos en estudios multicéntricos. En virtud de lo anterior, el Grupo Oncológico de Suroeste de\nlos Estados Unidos llevó a cabo un estudio que comparó el esquema CHOP contra esquemas de segun-\nda y tercera generación, que incluía los esquemas m-BACOD, MACOP-B y ProMACE-CytaBOM. El\nestudio aleatorizado que contempló 897 pacientes no mostró diferencias en cuanto a remisión completa o\nsupervivencia. Así, a 4 años, los pacientes vivos sin enfermedad ascendieron al 36,4% para CHOP, 34,4%\npara m-BACOD, 45,1% para ProMACE-CytaBOM y 38,8% para MACOP-B (\np\n \n= 0,14). Posteriormente\nhubo otros estudios aleatorios que contrastaron el uso de MACOP-B contra el de ProMACE-CytaBOM,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":242,"lines":{"from":58,"to":70}}}}],["1231",{"pageContent":"para m-BACOD, 45,1% para ProMACE-CytaBOM y 38,8% para MACOP-B (\np\n \n= 0,14). Posteriormente\nhubo otros estudios aleatorios que contrastaron el uso de MACOP-B contra el de ProMACE-CytaBOM,\ndosis progresivamente altas contra dosis estándares de doxorrubicina en el esquema BACOP-B, y CHOP\ncontra m-BACOD, los que en su conjunto han puesto en claro que los esquemas más intensivos no mejoran\nel porcentaje de respuesta o de supervivencia libre de enfermedad, pero sí incrementan la toxicidad.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":242,"lines":{"from":70,"to":77}}}}],["1232",{"pageContent":"Aunque las investigaciones ini-\nciales sugirieron que se obtenía\nuna mayor tasa de remisiones\ncompletas, la mayoría de los\nestudios subsecuentes no demos-\ntraron mejoría significativa so-\nbre el CHOP o C-MOPP, pero\nsí una mayor toxicidad.\nEl Grupo Oncológico del Su-\nroeste de Estados Unidos llevo\na cabo un estudio que compa-\nró el esquema CHOP contra\nesquemas de segunda y terce-\nra\n \ngeneración,\n \nque\n \nincluían\nm-BACOD,\n \nMACOP-B\n \ny\nProMACE-CytaBOM. El es-\ntudio aleatorio que contempló\n897 pacientes no mostró dife-\nrencias en cuanto a remisión\ncompleta o supervivencia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":242,"lines":{"from":79,"to":108}}}}],["1233",{"pageContent":"216\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":243,"lines":{"from":1,"to":3}}}}],["1234",{"pageContent":"Datos recientes sugieren una ventaja en el uso de tratamientos con dosis densas, que acortan el inter-\nvalo entre los ciclos de 3 a 2 semanas con apoyo del factor estimulante de colonias.\nCoiffier y cols. demostraron que la adición de rituximab mejora la respuesta y la supervivencia en\npacientes ancianos con LDCG. Estudios más recientes han confirmado la utilidad del rituximab también\nen pacientes jóvenes, con tasas de respuesta del 80% y remisiones completas del 50 a 60%.\nAlgunos investigadores consideran que se debe administrar RT después de la quimioterapia de induc-\nción, en los casos en los que exista enfermedad residual localizada o en áreas con enfermedad inicialmente\nvoluminosa. Estas recomendaciones se basan en la observación de que las recaídas en los LDCG suelen\nser en estas áreas. De acuerdo a lo anterior, y basándose en el recién desarrollado Índice Pronóstico\nInternacional (IPI), se puede plantear que para los pacientes con datos de buen pronóstico, el tratamiento","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":243,"lines":{"from":5,"to":14}}}}],["1235",{"pageContent":"Internacional (IPI), se puede plantear que para los pacientes con datos de buen pronóstico, el tratamiento\nde elección es el esquema CHOP, mientras que para los pacientes de los subgrupos de peor pronóstico, los\nesquemas actuales no parecen ser suficientes, por lo que se requiere desarrollar nuevos programas de tra-\ntamiento. A este respecto, el uso de quimioterapia a dosis altas con autotrasplante de células progenitoras\nhematopoyéticas (CPH) en los estudios aleatorios no ha demostrado incremento en la supervivencia en\npacientes con alto riesgo de recaída.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":243,"lines":{"from":14,"to":19}}}}],["1236",{"pageContent":"Linfomas de alto grado\n\nEn este tipo de linfomas los resultados del tratamiento dependen de la edad. En los niños se obtienen\ntasas elevadas de curación con esquemas diseñados para el manejo de la leucemia linfoblástica aguda y\nel linfoma de Burkitt. En los adultos, los resultados son inferiores; así, en los pacientes con LL tratados\ncon CHOP más dosis altas de metotrexato, L-asparaginasa y MTX intratecal, se obtiene un 56% de\nSLE a 3 años, mientras que con esquemas pediátricos para manejo de LLA, un 40% a 5 años. Resulta\ncrítico en el tratamiento la profilaxis al SNC, dada la elevada frecuencia de recaída en este sitio. En\ncuanto al LCPNH, los adultos también han sido tratados con esquemas diseñados para población\npediátrica a base de ciclofosfamida, Ara-C y profilaxis al SNC con MTX intratecal, con lo que se ob -\ntienen SLE de 50 a 65%; sin embargo, cuando existe infiltración a MO o SNC, la supervivencia a largo\nplazo solo es de 0 a 30%.\n\nLINFOMAS CUTÁNEOS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":243,"lines":{"from":21,"to":34}}}}],["1237",{"pageContent":"LINFOMAS CUTÁNEOS\n\nExiste controversia en relación con la clasificación de este tipo de linfomas. La de la Organización Euro-\npea para la Investigación y Tratamiento del Cáncer (EORTC, por sus siglas en inglés) es la clasificación\n\nCuadro 15-7.\n \nTratamiento de LNH de grado intermedio\n\nEsquema\n \nRemisión completa (%)\n \nSLE%\nPrimera generación\n\nC-MOPP\nCHOP\nBACOP\nCOMLA\n40\n50\n50\n50\n30\n30\n35\n30\n\nSegunda generación\n\nProMACE-MOPP\nm-BACOD\n75\n70\n50\n50\n\nTercera generación\n\nProMACE-CytaBOM\nCOP-BLAM III\nMACOP-B\n80\n85\n85\n60\n65\n65\nSLE: supervivencia libre de enfermedad.\n\nEn los linfomas de alto grado\nlos resultados del tratamiento\ndependen de la edad. En los\nniños se obtienen tasas eleva-\ndas de curación con esquemas\ndiseñados para el manejo de la\nleucemia linfoblástica aguda y\nel linfoma de Burkitt.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":243,"lines":{"from":34,"to":92}}}}],["1238",{"pageContent":"217\n\nCAPÍTULO 15. LINFOMAS\n\nmás práctica y concisa de los linfomas cutáneos, aunque no está comprendida en la clasificación REAL/\nWHO\n \n(cuadro 15-8).\n\nLinfomas cutáneos primarios de células T (LCPCT)\n\nConstituyen un grupo de LNH cutáneos con expansión clonal de linfocitos T en la piel. Sus formas más\ncomunes son: micosis fungoide (MF) y el síndrome de Sézary (SS). De acuerdo a la clasificación de la\nEORTC, la MF se considera indolente mientras que el SS es agresivo.\nLa MF se presenta como manchas o placas eritematosas circunscritas que progresan hasta involucrar\ntoda la piel y posteriormente forma tumores e invade ganglios. El síndrome de Sézary es la variante agre-\nsiva leucémica y eritrodérmica. Se caracteriza por la presencia de linfocitos T malignos circulantes con\nnúcleo cerebriforme y linfadenopatía.\n\nCuadro 15-8.\n \nClasificación de linfomas cutáneos primarios (EORTC)\n\nLinfomas T y NK\nMicosis fungoides","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":244,"lines":{"from":1,"to":25}}}}],["1239",{"pageContent":"Cuadro 15-8.\n \nClasificación de linfomas cutáneos primarios (EORTC)\n\nLinfomas T y NK\nMicosis fungoides\n\nVariantes de micosis fungoides:\nMicosis fungoide foliculotrópica\nReticulosis pagetoide\nPiel laxa granulomatosa\n\nSíndrome de Sézary\n\nLeucemia/linfoma de células T del adulto\nEnfermedades linfoproliferativas primariamente cutáneas CD30+\n\n•\n \n#( )'\u001b *,#'\u001b,#\u001b'\u001f(.\u001f \u001d/.á(\u001f) \u001e\u001f \u001dï&/&\u001b- !,\u001b(\u001e\u001f- \u001b(\u001b*&á-#\u001d)\n•\n \n\u0010\u001b*/&)-#- &#( )'\u001b.)#\u001e\u001f\n\nPaniculitis subcutánea semejante a linfoma de células T\nLinfoma extranodal de células NK/T de tipo nasal\n\nLinfoma primariamente cutáneo de células T periférico, no especificado\n\nLinfoma primariamente cutáneo de células T epidermotrópico agresivo CD8+ (provisional)\nLinfoma de células T cutáneo (provisional)\nLinfoma primariamente cutáneo de células T de tamaño pequeño/mediano pleomórfico CD4+\n(provisional)\n\nLinfoma cutáneo de células B","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":244,"lines":{"from":25,"to":59}}}}],["1240",{"pageContent":"Linfoma cutáneo de células B\n\nLinfoma primariamente cutáneo de células B de la zona marginal\nLinfoma primariamente cutáneo centrofolicular\nLinfoma primariamente cutáneo de células grandes difuso, variedad de la pierna\nOtros linfomas primariamente cutáneos de células grandes difuso\nLinfoma primariamente cutáneo de células grandes B intravascular\n\nNeoplasias de precursores hemáticos\n\nNeoplasia hematodérmica CD4+/CD56+ (antes linfoma blástico de células NK)\n\nLas\n \nformas\n \nmás\n \ncomunes\ndel linfoma cutáneo prima-\nrio de células T (LCPCT)\nson: micosis fungoide (MF)\ny síndrome de Sézary (SS).\nDe acuerdo con la clasifica-\nción de la EORTC, la MF\nse considera indolente, mien-\ntras que el SS agresivo.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":244,"lines":{"from":59,"to":85}}}}],["1241",{"pageContent":"218\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nTratamiento","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":245,"lines":{"from":1,"to":5}}}}],["1242",{"pageContent":"La RT es muy eficaz para controlar a la MF. La RT externa con haz de fotones solo es usada para MF\nresistentes o para paliación de lesiones voluminosas. La RT con haz de electrones es mejor tolerada y\nmás efectiva. Con este tipo de radiación solo es tratada la piel, ya que tiene una penetración máxima\nde 5 mm. La dosis estándar es de 36 Gy a toda la piel, con lo que se obtiene una respuesta completa\nen el 56 a 96% de los casos. Dado que existe una frecuencia muy elevada de recaída después de la RT\ncon electrones (35 a 52% a 10 años en estadios IA), se recomienda administrar en forma adyuvante\nquimioterapia tópica o con psoralogenos más radiación ultravioleta de longitud de onda A (PUVA).\nEsto último consiste en administrar por vía oral 8-metoxipsoraleno, un compuesto que es fotoactivado\ny que inhibe la síntesis de DNA y RNA. Este fármaco se activa al exponerse a la luz ultravioleta de una\nlongitud de onda entre 330 y 340 nm.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":245,"lines":{"from":7,"to":16}}}}],["1243",{"pageContent":"y que inhibe la síntesis de DNA y RNA. Este fármaco se activa al exponerse a la luz ultravioleta de una\nlongitud de onda entre 330 y 340 nm.\nLa quimioterapia generalmente se utiliza para el manejo paliativo de enfermedad refractaria o\nen recaída, o bien ante cualquier variedad en etapa avanzada. Tanto con monoterapia como con qui -\nmioterapia combinada (COP o CHOP), se obtiene una tasa de respuesta completa del 30 al 50%; sin\nembargo, estas respuestas generalmente son de corta duración. El denileukin diftitox es una proteína\nrecombinante formada de la fusión del receptor para IL-2 y la toxina diftérica, y ha sido aprobada para\nel tratamiento de la micosis fungoide de CD25 +. Este compuesto produce una respuesta completa o\nparcial en el 30% de los pacientes. Su toxicidad incluye fiebre, escalofríos, náuseas y síndrome similar\na influenza (\n \nflu-like)\n \ny de fuga capilar. Su utilidad en linfomas de bajo grado CD25+ se encuentra en\ninvestigación.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":245,"lines":{"from":16,"to":30}}}}],["1244",{"pageContent":"Linfomas cutáneos de células B\n\nLos linfomas cutáneos de células B (LCCB) son entidades poco frecuentes, al representar el 25% de los lin-\nfomas cutáneos, y la mayoría de ellos se asocian a un excelente pronóstico. Se han descrito varios tipos, en-\ntre los cuales los más comunes son el linfoma centrofolicular (LCF) y el linfoma de zona marginal (LZM).\n\nLinfoma centrofolicular","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":245,"lines":{"from":32,"to":38}}}}],["1245",{"pageContent":"Es el subtipo más común, al representar el 40% de los LCCB. Se clasifica como linfoma de células grandes\ndifuso en la clasificación de la OMS (WHO por sus siglas en inglés). Se caracteriza por una proliferación de\ncentrocitos y centroblastos y por mostrar un infiltrado nodular o difuso, y rara vez se asocian a un verdadero\npatrón folicular. Tiene predilección por la cabeza, cuello y tronco, con una media de edad de 60 años y un\npredominio en el sexo masculino (1,5:1). Su cuadro clínico generalmente es indolente, con una supervi-\nvencia de hasta el 97%, aunque las recaídas son frecuentes. Es altamente radiosensible, por lo que la RT\nes el tratamiento de elección a dosis de 30 Gy. Aun cuando se realice cirugía como tratamiento local, debe\nadministrarse RT complementaria debido al alto riesgo de recaída. Las reincidencias locales después de RT\npueden ser reirradiadas, con buenos resultados. La quimioterapia combinada tipo CHOP generalmente se","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":245,"lines":{"from":40,"to":48}}}}],["1246",{"pageContent":"pueden ser reirradiadas, con buenos resultados. La quimioterapia combinada tipo CHOP generalmente se\nreserva para casos con diseminación extracutánea o presencia de infiltración en múltiples sitios no contiguos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":245,"lines":{"from":48,"to":49}}}}],["1247",{"pageContent":"Linfoma de la zona marginal/inmunocitoma\n\nRepresenta el segundo subtipo más común de los LCCB. Se presenta predominantemente en las\nextremidades. La media de edad es de 55 años y las mujeres son afectadas más frecuentemente que\nlos hombres. Su supervivencia es de 97 a 100%, aunque comúnmente presentan recaídas. Histo -\nlógicamente, este linfoma tiene datos de linfomas MALT y en contraste con el LCF es negativo\npara BCL-6 y CD10. En el 50% de los casos el CD43 es expresado intensamente. El tratamiento\nes similar al del LCF.\n\nTRASPLANTE AUTÓLOGO DE CÉLULAS\nPROGENITORAS HEMATOPOYÉTICAS\n\nLinfomas en recaída\n\nAun cuando ha habido importantes avances en el manejo de los LNH, la mayoría de los pacientes no son\ncurados con los esquemas previamente mencionados. Así, cuando menos el 50% de los enfermos con linfomas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":245,"lines":{"from":51,"to":66}}}}],["1248",{"pageContent":"Aun cuando ha habido im-\nportantes avances en el ma-\nnejo de los LNH, la mayoría\nde los pacientes no son curados\ncon los esquemas previamen-\nte mencionados. Así, cuando\nmenos el 50% de los enfermos\ncon linfomas de grados inter-\nmedio y alto recaen, y vir-\ntualmente todos los pacientes\ncon\n \nlinfoma\n \nde\n \ngrado\n \nbajo\ntarde o temprano lo harán.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":245,"lines":{"from":68,"to":87}}}}],["1249",{"pageContent":"219\n\nCAPÍTULO 15. LINFOMAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":246,"lines":{"from":1,"to":3}}}}],["1250",{"pageContent":"de grado intermedio y alto recaen, y virtualmente todos los pacientes con linfoma de bajo grado tarde o tem\n-\nprano lo harán. Para tratar a estos pacientes en recaída, se han desarrollado diferentes esquemas usando fár\n-\nmacos sin resistencia, cruzadas con las utilizadas en los esquemas de primera línea. Estos esquemas emplean\ncombinaciones de cisplatino, etopósido e ifosfamida, y aun cuando con ellos se logran RC de alrededor de 35\na 40%, menos del 5% de los casos tendrán una supervivencia libre de enfermedad a largo plazo.\nEn virtud de estos pobres resultados, en la última década se han venido utilizando, con una frecuencia\ncada vez mayor, dosis supraletales de QT o RT con trasplante de CPH para el manejo de estos casos.\nEste abordaje se basa en el hecho de que, así como las leucemias, los linfomas tienen una curva progresiva\nde dosis-respuesta, tanto con QT como con RT, por lo que los linfomas que son resistentes a las dosis de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":246,"lines":{"from":5,"to":15}}}}],["1251",{"pageContent":"de dosis-respuesta, tanto con QT como con RT, por lo que los linfomas que son resistentes a las dosis de\nQT convencionales pueden ser sensibles si las dosis de los citotóxicos o de la RT se incrementan signifi-\ncativamente.\nA pesar de que la fuente de las células troncales hematopoyéticas puede ser una médula ósea singé -\nnica o alogénica, la mayoría de los estudios han utilizado médula ósea autóloga o CPH autólogas de\nsangre periférica. En virtud del riesgo de reinfundir células linfomatosas con la médula trasplantada,\nla mayoría de las series han excluido pacientes con evidencia histológica de MO y algunos grupos han\nrecurrido a la eliminación (purga) in vitro de células linfomatosas de la MO antes de trasplantarla (con\nanticuerpos monoclonales o con derivados de ciclofosfamida).\nSe ha demostrado que la quimiosensibilidad de la enfermedad al momento de realizar el trasplante\nautólogo de células progenitoras hematopoyéticas (TACPH) es el principal factor pronóstico para el éxito","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":246,"lines":{"from":15,"to":25}}}}],["1252",{"pageContent":"Se ha demostrado que la quimiosensibilidad de la enfermedad al momento de realizar el trasplante\nautólogo de células progenitoras hematopoyéticas (TACPH) es el principal factor pronóstico para el éxito\nde este procedimiento. Así, los pacientes en recaída que aún demuestran sensibilidad a QT convencional\n(recaída sensible) tienen un 30 a 60% de probabilidades de tener una supervivencia libre de enfermedad\na largo plazo, mientras que los que presentan recaídas resistentes solo tendrán un 15% de probabilidades\nde ser sobrevivientes a largo plazo. Por otro lado, los pacientes que cursan con una enfermedad resistente\na un tratamiento inicial (enfermedad refractaria primaria), tienen menos del 10% de probabilidades de\ncuración.\nResultados recientes de estudios aleatorios en linfomas de grado intermedio o alto en recaída han\nmostrado una SLE y una SG significativamente mayor en el grupo tratado con QT a dosis altas (QTDA)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":246,"lines":{"from":25,"to":34}}}}],["1253",{"pageContent":"Resultados recientes de estudios aleatorios en linfomas de grado intermedio o alto en recaída han\nmostrado una SLE y una SG significativamente mayor en el grupo tratado con QT a dosis altas (QTDA)\ny autotrasplante de células progenitoras hematopoyéticas (ACPH), que en el grupo tratado con un esque-\nma convencional de rescate. Así, en el estudio del grupo europeo (estudio PARMA), la SLE y la SG del\ngrupo tratado con QTDA + ACPH fue de 46 y 53%, respectivamente, significativamente mayor que las\ndel grupo tratado con DHAP (dexametasona, Ara-C y cisplatino) (12 y 32%, respectivamente).\nEn contraste con los LNH de grado intermedio o alto, muy pocos pacientes con linfoma de bajo grado\nhan sido tratados con TACPH. Esto se ha debido, por un lado, a que por la larga historia natural de estos\nlinfomas, la toxicidad potencialmente fatal de este procedimiento se ha considerado muy discutible y,\npor el otro, a que la elevada recurrencia de infiltración de la MO ha sido un obstáculo para realizarlo. En","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":246,"lines":{"from":34,"to":43}}}}],["1254",{"pageContent":"por el otro, a que la elevada recurrencia de infiltración de la MO ha sido un obstáculo para realizarlo. En\nvirtud de esto último, la mayoría de los pacientes tratados con este procedimiento han sido trasplantados\ncon MO purgada.\nLos resultados de estudios fase II en este tipo de linfomas (en pacientes con recaída sensible o con una\nremisión incompleta inicial) muestran un 50 a 60% de SLE, con menos de 5% de mortalidad.\nEl único estudio fase III que intentó investigar el papel del TACPH en pacientes con linfoma folicular\nen recaída cerró prematuramente por un pobre reclutamiento.\nVarios grupos han investigado el papel del TACPH en pacientes en primera remisión completa o\nparcial. Los diferentes estudios muestran un incremento en la supervivencia libre de progresión, pero sin\nmejoría en la supervivencia global. Un incremento en la incidencia de mielodisplasia secundaria posterior\na un TACPH en pacientes en primera remisión completa ha limitado la investigación del trasplante au-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":246,"lines":{"from":43,"to":53}}}}],["1255",{"pageContent":"a un TACPH en pacientes en primera remisión completa ha limitado la investigación del trasplante au-\ntólogo en linfomas foliculares.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":246,"lines":{"from":53,"to":54}}}}],["1256",{"pageContent":"Linfomas en primera remisión\n\nVarios grupos han utilizado el TACPH en pacientes con LNH de grado intermedio y alto en primera\nremisión completa. Sus resultados mostraron un 70 a 80% de sobrevivientes libres de enfermedad a 3 años,\nlo que sugería que las dosis elevadas de quimioterapia pueden ser eficaces en pacientes con alto riesgo de\nrecaída, después de haber obtenido una RC con QT convencional.\nCon base en estas investigaciones iniciales, se llevaron a cabo diversos estudios aleatorios para investigar\nel papel del trasplante autólogo de células progenitoras hematopoyéticas (ATCPH), como consolidación\ndespués de QT de inducción. Sus resultados han sido muy discrepantes: la minoría favorecen la consolida-\nción con ATCPH, y la mayoría muestran equivalencia o superioridad con el uso de la QT exclusivamente.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":246,"lines":{"from":56,"to":65}}}}],["1257",{"pageContent":"Aun cuando la fuente de las cé-\nlulas troncales hematopoyéticas\npuede ser una médula ósea sin-\ngénica o alogénica, la mayoría\nde los estudios han utilizado\nmédula ósea autóloga o células\ntroncales autólogas de sangre\nperiférica.\nEn contraste con los LNH de\ngrado intermedio o alto, muy\npocos pacientes con linfoma de\ngrado bajo han sido tratados\ncon TACPH. Esto se ha debi-\ndo, por un lado, a que por la\nlarga historia natural de estos\nlinfomas, la toxicidad poten-\ncialmente mortal de este pro-\ncedimiento se ha considerado\nmuy discutible.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":246,"lines":{"from":67,"to":85}}}}],["1258",{"pageContent":"220\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nAdemás del dudoso beneficio que confiere el ATCPH, se ha planteado que las infusiones de las CPH pue-\ndan estar contaminadas con células tumorales que pudieran condicionar una recaída subsecuente.\nDe acuerdo a lo anterior, se puede concluir que, en la actualidad, la administración de QTDA + AT-\nCPH, no se recomienda como parte del tratamiento inicial de pacientes con LNH, aun si pertenecen a\ngrupos de alto riesgo para recaída, y que la única indicación del TACPH es en pacientes con LNH que\ncursen con una recaída quimiosensible.\nAún quedan varias preguntas por responder: a) ¿cuál es el esquema óptimo de acondicionamiento?, b)\n¿cuál es el papel de la purga de la MO?\n\nComplicaciones del tratamiento","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":247,"lines":{"from":1,"to":14}}}}],["1259",{"pageContent":"Complicaciones del tratamiento\n\nDiversos estudios han mostrado un riesgo incrementado de desarrollar segundas neoplasias en pacientes\ncon LNH que han sobrevivido a largo plazo después del tratamiento. Los factores de riesgo que se han\ndescrito son la utilización de radioterapia y una edad menor de 25 años. El riesgo de segundas neoplasias\nen una cohorte de 2 456 pacientes menores de 60 años tratados entre 1973 y 2000 fue de 11,2% a 15\naños. Las segundas neoplasias más frecuentes fueron cáncer de pulmón, leucemia, cáncer de mama y\ncáncer de colon.\nEl riesgo de padecer enfermedades cardiovasculares también ha sido motivo de estudio, y se encontró\nuna incidencia de 12 y 22% a 5 y 10 años, respectivamente, en pacientes con LNH tratados con un míni-\nmo de seis ciclos de quimioterapia.\n\nCONCLUSIONES\n\n•\n \nLos linfomas no Hodgkin son neoplasias del sistema reticuloendotelial. De acuerdo a su comporta-\nmiento clínico, se clasifican en grado bajo, intermedio y alto.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":247,"lines":{"from":14,"to":31}}}}],["1260",{"pageContent":"CONCLUSIONES\n\n•\n \nLos linfomas no Hodgkin son neoplasias del sistema reticuloendotelial. De acuerdo a su comporta-\nmiento clínico, se clasifican en grado bajo, intermedio y alto.\n\n•\n \nLa estirpe histológica más común es el linfoma difuso de células grandes de células B.\n\n•\n \nLa quimioterapia combinada es el tratamiento de elección en estos padecimientos, y el rituximab\nincrementa la eficacia de la quimioterapia en los linfomas cuyas células malignas expresan el antí -\ngeno CD20.\n\nPREGUNTAS DE AUTOEVALUACIÓN\n\n1. ¿Cuál es el virus asociado al linfoma de Burkitt?\na.\n \nCitomegalovirus\nb. Virus de la hepatitis B\nc.\n \nVirus de Epstein-Barr\n2. Todas son clasificaciones del linfoma no Hodgkin, excepto:\na.\n \nMaltoma\nb. Linfoma difuso mixto\nc.\n \nEsclerosis nodular\n3. ¿Qué agente infeccioso está relacionado con el linfoma tipo MALT?\na.\n \nVirus de Epstein-Barr\nb. Retrovirus del tipo C\n\nc.\n \nHelicobacter pylori","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":247,"lines":{"from":31,"to":74}}}}],["1261",{"pageContent":"c.\n \nHelicobacter pylori\n\n4. Pertenecen a los linfomas cutáneos primarios, excepto:\na.\n \nMucosis fungoides\nb. Linfoma cutáneo de células B\nc.\n \nLinfoma folicular mixto\n\nEn conclusión, puede decirse\nque en la actualidad las indi-\ncaciones del TACTH son los\npacientes con LHN que cursen\ncon una recaída quimiosensible.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":247,"lines":{"from":74,"to":91}}}}],["1262",{"pageContent":"221\n\nCAPÍTULO 15. LINFOMAS\n\n5. ¿Cuál de los siguientes parámetros no se toma en cuenta en el índice pronóstico internacional para\nlinfomas foliculares?\na.\n \nEdad, estadio y sexo\nb. Edad, estadio, número de ganglios afectados\nc.\n \nHemoglobina y DHL\n\nBIBLIOGRAFÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":248,"lines":{"from":1,"to":15}}}}],["1263",{"pageContent":"Avilés A, Zepeda G, Díaz-Maqueo JC, et al. Beta 2 microglobulin level as an indicator of prognosis in difuse large\ncell lymphoma. Leuk Lymph. 1992; 7: 135.\nCoiffer B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly\npatients with difuse large B-cell lymphoma. N Engl J Med. 2002; 346: 235-42.\nCzucman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade\nor follicular non Hodg-kin lymphoma treated with rituximab plus CHOP chemotherapy: 9 years follow-up. J Clin\nOncol. 2004; 22: 4711-16.\nFisher RI, Gaynor EI, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemo-\ntherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993; 328: 1002-1010.\nFreedman A, Neugerg D, Gribben J, Mauch P, Anderson K, Soiffer R, et al. Autologous bone marrow transplantation\nin relapsed low grade non Hodg-kin lymphoma. Blood. 1994; 84: 203a.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":248,"lines":{"from":17,"to":27}}}}],["1264",{"pageContent":"Freedman A, Neugerg D, Gribben J, Mauch P, Anderson K, Soiffer R, et al. Autologous bone marrow transplantation\nin relapsed low grade non Hodg-kin lymphoma. Blood. 1994; 84: 203a.\nGutiérrez-Aguirre CH, Ruiz-Argüelles G, Cantú-Rodríguez OG, González-Llano O, Jaime-Pérez JC, García-Ro-\ndríguez F, et al. Outpatient reduced-compared with autologous stem cell transplantation using a simplified meth-\nod. Ann Hematol. 2010; 10: 1045-1052.\nInternational Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodg-\nkin lymphoma. N Engl J Med. 1993; 329: 987.\nKraus-Weisman A, Ruiz-Argüelles GJ, De-León-Vega O, Pérez-Tamayo R. Estudio sobre linfomas. I. Frecuencia\nrelativa de los linfomas en México. Rev Invest Clin (Méx). 1980; 32: 179.\nMiller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for\nlocalized intermediate and high-grade-non-Hodgkin ́s lymphoma. N Engl J Med. 1998; 336: 21-26.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":248,"lines":{"from":27,"to":37}}}}],["1265",{"pageContent":"localized intermediate and high-grade-non-Hodgkin ́s lymphoma. N Engl J Med. 1998; 336: 21-26.\nRuiz-Delgado GJ, Gómez-Almaguer D, Tarín-Arzaga LC, Cantú-Rodríguez OG, Alarcón-Urdaneta C, Rodrí-\nguez-Morales U, et al. Is there a benefit to adding rituximab to CHOP in the overall survival of patients with\nB-cell non-Hodgkin’s lymphoma in a developing country?. Hematology. 2012; 17: 193-7.\nPandolfino T, Siegel RS, Kuzel TM. Primary cutaneous B-cell lymphoma: Review and current concepts. J Clin\nOncol. 2000; 18(10): 2152-2168.\nSolai-Celigny P, Roy P, Colombat P, et al. Follicular Lymphoma International Prognostic Index. Blood. 2004; 104:\n1258-65.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":248,"lines":{"from":37,"to":44}}}}],["1266",{"pageContent":"RESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\n1. c\n2. c\n3. c\n4. c\n5. a","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":248,"lines":{"from":46,"to":52}}}}],["1267",{"pageContent":"223\n\nINTRODUCCIÓN\n\nDescrito en 1832 por Sir Thomas Hodgkin, el linfoma que lleva su nombre es una entidad neo -\nplásica de las células que normalmente existen en el tejido linfoide y que afecta los órganos del\nsistema inmunitario. Aún no se precisa su origen celular, pero existen informes cada vez más\nnumerosos de que se genera en los linfocitos B activados de los folículos linfoides ganglionares.\nSternberg, en 1898, y Reed, en 1902, describieron las células gigantes características de la enti -\ndad que llevan sus nombres y las distinguieron claramente de las que aparecen en la tuberculosis","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":250,"lines":{"from":1,"to":10}}}}],["1268",{"pageContent":"(fig. 16-1)\n. Con el uso de anticuerpos monoclonales específicos, las células características de la\nenfermedad tienen el fenotipo CD15+, CD30+, CD79a+ y CD45+, son células B de expresión\nfrustrada, y las formas nodulares tienen CD20+ débil. El tejido linfoide que rodea estas células\nes del tipo T CD4+ y no se conoce su agente causal. Algunos estudios epidemiológicos de brotes\nen comunidades, áreas escolares y familias, sugieren una respuesta excesiva a un agente infec -\ncioso, que puede ser viral. El agente viral más estudiado ha sido el de Epstein-Barr (EBV), un\nherpesvirus que suele causar linfopenia, depresión de linfocitos cooperadores CD4 y reducción\nde la inmunidad celular. Sin embargo, hasta la fecha se ha demostrado el genoma viral solo en un\npoco más de la mitad de los tejidos afectados por el linfoma de Hodgkin, con mayor frecuencia\nen los pacientes mestizos latinos que en los caucásicos. Otros hallazgos anormales informados","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":250,"lines":{"from":12,"to":22}}}}],["1269",{"pageContent":"poco más de la mitad de los tejidos afectados por el linfoma de Hodgkin, con mayor frecuencia\nen los pacientes mestizos latinos que en los caucásicos. Otros hallazgos anormales informados\nincluyen el antecedente de amigdalectomía, mayor frecuencia en primogénitos, historia fami -\nliar de linfoma, escaso número de compañeros en la escuela y ciertos antígenos del sistema de\nantígenos leucocitarios humanos (HLA), lo cual sugiere que factores genéticos y ambientales\nparticipan en la génesis de la enfermedad.\nOcurren 2 a 4 casos por cada 100 000 habitantes por año. En Estados Unidos hubo cerca de\n9 060 enfermos en 2012 y habrá 9 290 en 2013. En México hubo cerca de 1 290 casos de linfoma\nde Hodgkin en 2002.\nEl padecimiento tiene dos formas de presentación: aparece en gente joven de entre 15 y 25 años,\ny luego en sujetos de más de 50 años. En las naciones menos industrializadas, la aparición en el\ngrupo juvenil se diluye por una mayor presentación en niños desde la edad escolar, donde también","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":250,"lines":{"from":22,"to":33}}}}],["1270",{"pageContent":"y luego en sujetos de más de 50 años. En las naciones menos industrializadas, la aparición en el\ngrupo juvenil se diluye por una mayor presentación en niños desde la edad escolar, donde también\nse ven formas abdominales con datos histológicos desfavorables, más del 90% con EBV positivo,\ngeneralmente en varones (80%).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":250,"lines":{"from":33,"to":36}}}}],["1271",{"pageContent":"Objetivos de aprendizaje\n\n•\n \nConocer la prevalencia e incidencia de la enfermedad de Hodgkin.\n\n•\n \nSeñalar el cuadro clínico y el diagnóstico de la enfermedad de Hodgkin.\n\n•\n \nIdentificar las variantes histológicas de la enfermedad de Hodgkin.\n\n•\n \nMencionar el esquema de quimioterapia de primera línea en la enfermedad de Hodgkin.\n\nCAPÍTULO 16\n\nJosé Luis Delgado Lamas\nÓscar Miguel Garcés Ruiz\n\nLINFOMA DE HODGKIN\n\nDescrito en 1832 por Sir \u0001o-\nmas Hodgkin, el linfoma que\nlleva su nombre es una enti-\ndad neoplásica de las células\nque normalmente existen en\nel tejido linfoide y que afecta\na los órganos del sistema in-\nmunitario.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":250,"lines":{"from":38,"to":70}}}}],["1272",{"pageContent":"224\n \nFUNDAMENTOS DE HEMATOLOGÍA\nANATOMÍA PATOLÓGICA\n\nEl diagnóstico de la enfermedad depende del estudio histológico de un ganglio linfático. Las biopsias\npor medio de aguja o los aspirados ganglionares no son útiles para el diagnóstico. Desde l945, Lukes y\nParker elaboraron las primeras clasificaciones diagnósticas. Dicha clasificación fue modificada después\npor Lukes y Butler en 1960 y desde 1966 se definió en la convención de Rye en Nueva York, donde se\nincluyeron cinco variedades que aún persisten en las nuevas clasificaciones de la\n \nRevised European-Ameri-\ncan Lymphoma Classification\n \n(REAL) de 1994 y de la Organización Mundial de la Salud (OMS) de 2001","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":251,"lines":{"from":1,"to":15}}}}],["1273",{"pageContent":"(cuadro 16-1)\n.\nLa evolución histológica descrita muestra clara progresión de la abundancia de linfocitos a la escasez,\ny de la pobreza de células de Reed-Sternberg a gran cantidad de las mismas. En ese mismo orden, sucede\nla respuesta al tratamiento quimioterapéutico solo o combinado con radioterapia o inmunoterapia. En un\nanálisis de 220 pacientes adultos con linfoma de Hodgkin en México, en 12 años, las frecuencias histo-\nlógicas fueron PL 6,6%, EN 31,7% (27% en el H. Gral. de la Cd. de México), CM 47,8 % y DL 13,2%.\nEstas frecuencias varían según el área geográfica: en 682 pacientes atendidos en Chile el PL fue de 8%,\nEN: 41%, CM: 41% y DL: 9,0%, en cambio en Canadá, en 302 casos la distribución fue de PL: 6%, EN:\n65%, CM: 12 %, RL: 3%, DL: 2%, parecido a EUA.\nEl antígeno Ki-1 específico de la célula de Reed-Sternberg se designa con el CD30 y también se ob-\nserva en linfomas unicelulares de carácter anaplásico y en linfomas de células grandes.\n\nCUADRO CLÍNICO","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":251,"lines":{"from":17,"to":30}}}}],["1274",{"pageContent":"Los enfermos generalmente cursan con crecimientos ganglionares de consistencia aumentada, móviles, in-\ndoloros, que tienen más de 6 semanas de evolución y miden más de 3 cm debido a que uno o varios ganglios\nhan confluido\n \n(fig. 16-2)\n. El sitio de presentación más frecuente (70% de los casos) es el cuello, y en el 90%\nde los pacientes son superficiales. Inicialmente no hay otras manifestaciones clínicas concomitantes, pero\nconforme avanza la enfermedad, hasta el 50% de los sujetos empieza a tener síntomas constitucionales, fiebre\nde escasa magnitud, casi siempre vespertina o nocturna, seguida de sudoración nocturna, ambas intermiten-\ntes y producidas por la liberación de interleucina 1 y 2. Estos síntomas persisten por semanas y desaparecen\npor períodos semejantes; en ocasiones esta periodicidad se logra identificar en el interrogatorio (15% de los\npacientes), misma que se conoce en la bibliografía médica como\n \nfiebre de Pel-Ebstein\n. Con el paso del tiempo","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":251,"lines":{"from":32,"to":46}}}}],["1275",{"pageContent":"pacientes), misma que se conoce en la bibliografía médica como\n \nfiebre de Pel-Ebstein\n. Con el paso del tiempo\ncrecen ganglios nuevos y en algunas ocasiones se logra demostrar también un cambio histológico de una\nvariedad benigna a otra más agresiva. Además, suelen doler con la ingesta de alcohol. Algunos ganglios se\nmantienen del mismo tamaño y a veces desaparecen, y otros nuevos crecen más que los iniciales. En el 50%\nde los casos, al momento del diagnóstico en la variedad esclerosis nodular ya hay enfermedad mediastínica;\nla cual se debe a la liberación del factor de transformación del crecimiento por las células enfermas, casi","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":251,"lines":{"from":46,"to":54}}}}],["1276",{"pageContent":"Figura 16-1.\n \nGanglio linfático de un linfoma de Hodgkin, celularidad mixta, 1+CD30+P53, anormal en el\nnúcleo de una célula de Reed-Sternberg. Modificado de: Hoff brand AV, Petit JE. Atlas of clinical haema-\ntology illustrated. London: Gower Medical Publishing; 1988.\n\nEl diagnóstico de la enferme-\ndad de Hodgkin depende del\nestudio histológico de un gan-\nglio linfático. Las biopsias por\nmedio de aguja o los aspirados\nganglionares\n \nno\n \nson\n \nútiles\npara el diagnóstico.\nLos\n \nenfermos\n \ngeneralmente\ncursan con crecimientos gan-\nglionares de consistencia au-\nmentada, móviles, indoloros,\nque tienen más de 6 semanas\nde evolución y miden más de 3\ncm, debido a que un ganglio o\nvarios han confluido.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":251,"lines":{"from":56,"to":86}}}}],["1277",{"pageContent":"225\n\nCAPÍTULO 16. LINFOMA DE HODGKIN\n\nCuadro 16-1.\n \nClasificación histológica del linfoma de Hodgkin\n\na) Predominio linfocítico (PL)\n\nTiene una incidencia de 2 a 6,5%, según la población estudiada y la oportunidad del diagnóstico. En\nesta variedad se observan escasas células de Reed-Sternberg y algunas variantes de ella, conocidas\ncomo\n \ncélulas de Hodgkin\n, así como linfocitos maduros reactivos, y se conserva la disposición nodular\nnormal de los folículos linfoides. Constituye el grupo de mejor pronóstico. Se reconoce como una\nentidad distinta. Son CD 20+, CD45+, CD15– y CD30–. La OMS considera las formas nodulares\ny difusas.\n\nb) Esclerosis nodular (EN)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":252,"lines":{"from":1,"to":21}}}}],["1278",{"pageContent":"b) Esclerosis nodular (EN)\n\nSe observan bandas gruesas de tejido fibroso y células de Reed-Sternberg en un espacio claro y re-\ntraído que se conoce como\n \ncélula lacunar\n. Tiene una incidencia de entre 40 y 80% y buen pronóstico\nen general. Es frecuente en mujeres jóvenes con masa mediastínica, y algunos casos muestran resis-\ntencia al tratamiento; son EMA+ CD15+ y CD 30+.\n\nc) Celularidad mixta (CM)\n\nSe aprecia una mezcla de células de Reed-Sternberg con células no neoplásicas, histiocitos, neutrófi\n-\nlos, células plasmáticas, eosinófilos y linfocitos. Existen focos de necrosis y se observa en el 15 a 30%\nde los casos en pacientes de mayor edad, en comparación con las variedades anteriores y en estadios\nmás avanzados. Son CD20+/–, CD45–, EMA+, CD15+ y CD 30+, además de EBV positivo en el\n40 a 70% de los casos.\n\nd) Rico en linfocitos (RL)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":252,"lines":{"from":21,"to":40}}}}],["1279",{"pageContent":"d) Rico en linfocitos (RL)\n\nSemejan un cuadro intermedio entre celularidad mixta y predominio linfocitario, las células de\nHodgkin y Reed-Sternberg son escasas, los neutrófilos, las células plasmáticas y los eosinófilos son\nperivasculares, a veces conservan la imagen nodular de un pequeño centro germinal reactivo. Los\nlinfocitos son de tipo “B” y ocupan la parte externa del folículo linfoide en manto. Son CD30-,\nCD15-, CD 20+ y CD 45+.\n\ne) Disminución linfocítica (DL)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":252,"lines":{"from":40,"to":48}}}}],["1280",{"pageContent":"Se observan abundantes células de Reed- Sternberg, grandes, deformes y pleomórficas, mezcladas\ncon áreas hipocelulares de material fibrilar, así como una sustancia amorfa eosinofílica no refrin-\ngente. Esta variedad ocurre en pacientes de mayor edad, con localización abdominal, gran extensión\ntumoral y pobre respuesta a la quimioterapia a largo plazo. Se conocen las variedades de esclerosis\ndifusa y la celular.\nLos diagnósticos histológicos b, c, d y e se conocen como\n \nlinfoma de Hodgkin clásico\n.\nsiempre en el mediastino anterior, en ganglios paratraqueales o traqueobronquiales\n \n(fig. 16-3).\n \nLos ganglios\nsupraclaviculares derechos revelan participación mediastínica y los izquierdos retroperitoneal. Con la dise-\nminación de la enfermedad, cualquier área ganglionar u órgano puede resultar afectado, sobre todo bazo,\npulmón, ganglios paraaórticos, hígado, hueso y médula ósea, convirtiéndose la entidad de proliferativa a","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":252,"lines":{"from":50,"to":66}}}}],["1281",{"pageContent":"pulmón, ganglios paraaórticos, hígado, hueso y médula ósea, convirtiéndose la entidad de proliferativa a\ninvasiva y ocupativa. Los ganglios retroperitoneales y mediastínicos se acompañan de pocos síntomas. El en-\nfermo empieza a perder peso, lo cual se vuelve significativo cuando ocurre una reducción ponderal mayor de\n10% del total del peso en menos de 6 meses; esto se debe a la liberación de factor de necrosis tumoral por los\nlinfocitos reactivos. Se sabe que la mayoría de los bazos palpables (65%) están afectados por el padecimien-\nto, aunque solo el 30% de estos órganos clínicamente anormales muestran linfoma histológicamente. La\nevolución del trastorno por lo general es indolente. La supervivencia natural depende del comportamiento\nespecífico de la variedad y de la respuesta del huésped al tumor. Las supervivencias largas se asocian con falta\nde síntomas, estadios tempranos, no invasión de órganos vitales y ausencia de enfermedad extraganglionar","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":252,"lines":{"from":66,"to":74}}}}],["1282",{"pageContent":"de síntomas, estadios tempranos, no invasión de órganos vitales y ausencia de enfermedad extraganglionar\n(4 años o más). Una enfermedad más agresiva (histológicamente) con síntomas constitucionales (fiebre,\nsudor, pérdida de peso, prurito, etc.) en sujetos de más de 60 años y con enfermedad extraganglionar, casi\nsiempre tiene una supervivencia promedio de 2 años o menos sin tratamiento.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":252,"lines":{"from":74,"to":77}}}}],["1283",{"pageContent":"226\nFUNDAMENTOS DE HEMATOLOGÍA\n\nFigura 16-2.\n \nCrecimientos ganglionares exuberantes por enfermedad de Hodgkin en ambos lados de las\nestructuras vasculares intraabdominales. Modificado de: Hoff brand AV, Petit JE. Atlas of clinical haema-\ntology illustrated. London: Gower Medical Publishing; 1988.\n\nFigura 16-3.\n \nEn los pacientes con la variedad de esclerosis nodular de la\nenfermedad de Hodgkin es frecuente que haya crecimientos ganglionares\nmediastínicos, como el que se muestra en la figura. Modificado de: Hoff-\nbrand AV, Petit JE. Atlas of clinical haematology illustrated. London:\nGower Medical Publishing; 1988.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":253,"lines":{"from":1,"to":16}}}}],["1284",{"pageContent":"227\n\nCAPÍTULO 16. LINFOMA DE HODGKIN\n\nEn conclusión, una adenopatía indolora creciente de más de 3 semanas de evolución, sin causa aparen-\nte, asociada o no a fiebre, pérdida de peso o tos, deberá estudiarse como probable linfoma.\n\nDIAGNÓSTICO DIFERENCIAL","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":254,"lines":{"from":1,"to":8}}}}],["1285",{"pageContent":"Debe diferenciarse de los linfomas unicelulares (no Hodgkin) y de las variedades inmunoblástica, pleo-\nmórfica, anaplásica, linfoma mediastínico de células grandes y linfoma de zona gris, ya que el tratamiento\ny la evolución son distintos. En el linfoma no Hodgkin, suele ocurrir afección de médula ósea, sistema\nnervioso central y órganos sólidos, situaciones muy poco frecuentes en el linfoma de Hodgkin. Por otra\nparte, este último pocas veces afecta las amígdalas y el anillo de Waldeyer, y en muy pocas ocasiones\nexisten ganglios epitrocleares palpables. Ambas características ayudan al diagnóstico diferencial. Debe\ndiferenciarse de los tumores germinales y se debe distinguir de toxoplasmosis, mononucleosis infecciosa,\nbrucelosis, tuberculosis y entidades infecciosas asociadas o no al virus de la inmunodeficiencia humana.\nLa vacunación reciente, el lupus eritematoso generalizado, la ingestión de difenilhidantoinato y otros","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":254,"lines":{"from":10,"to":18}}}}],["1286",{"pageContent":"La vacunación reciente, el lupus eritematoso generalizado, la ingestión de difenilhidantoinato y otros\nanticonvulsivantes, y la sarcoidosis, pueden causar una adenopatía inflamatoria muy parecida clínica e his-\ntológicamente a la enfermedad de Hodgkin. Los antecedentes y otras manifestaciones clínicas asociadas\nson la guía más útil para la diferenciación.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":254,"lines":{"from":18,"to":21}}}}],["1287",{"pageContent":"ESTUDIOS DE LABORATORIO","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":254,"lines":{"from":23,"to":23}}}}],["1288",{"pageContent":"La velocidad de eritrosedimentación, la proteína C reactiva de alta sensibilidad y el nivel de fibrinógeno son\npruebas útiles para medir la actividad de la enfermedad; se han utilizado para separar grupos de pronóstico\nfavorable y desfavorable en 15 estudios secuenciales en Europa (EORTC)\n \n(cuadro 16-4)\n. La biometría ge-\nneralmente es normal, pero puede mostrar anemia moderada, normocítica e hipocrómica, con monocitosis,\neosinofilia, linfopenia y trombocitosis, que acompañan a la enfermedad desde los estadios tempranos. Suele\nhaber leucocitosis en estadios avanzados. Si existe leucopenia, es probable que haya infiltración medular.\nLa biopsia de médula ósea se recomienda para estadios avanzados después del IIB, en vista de que solo el\n10% o menos de los estadios tempranos muestran ocupación medular. En estos casos ocurre eosinofilia produc\n-\nto de la liberación de interleucina 6, monocitosis y linfopenia (20% de los casos). La anemia de los padecimien\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":254,"lines":{"from":25,"to":38}}}}],["1289",{"pageContent":"-\nto de la liberación de interleucina 6, monocitosis y linfopenia (20% de los casos). La anemia de los padecimien\n-\ntos crónicos y la trombocitopenia son condiciones poco frecuentes pero bien reconocidas en etapas avanzadas.\nDebe estudiarse su origen autoinmunitario con prueba de Coombs o mediante la búsqueda de anti -\ncuerpos antiplaquetarios. La elevación de los niveles de cobre y cinc del suero ha sido propuesta como\nun marcador de actividad de la enfermedad, pero también es inespecífica. Las pruebas de función\nhepática más alteradas son las de fosfatasa alcalina, la deshidrogenasa láctica, las bilirrubinas, la 5’-nu -\ncleotidasa y la\n \nγ\n-glutamil transpeptidasa, sin indicar específicamente alteración por la enfermedad. Se\nmodifican en diferente grado si la infiltración es a hígado o solo ocurre compresión extrínseca a través\ndel crecimiento de los ganglios del hilio hepático que obstruya la vía biliar. A veces se presenta síndro -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":254,"lines":{"from":38,"to":51}}}}],["1290",{"pageContent":"del crecimiento de los ganglios del hilio hepático que obstruya la vía biliar. A veces se presenta síndro -\nme nefrótico sin afección linfomatosa al riñón, por amiloidosis o por los productos metabólicos de las\nprostaglandinas liberadas por las células tumorales.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":254,"lines":{"from":51,"to":53}}}}],["1291",{"pageContent":"ESTUDIOS DE GABINETE","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":254,"lines":{"from":55,"to":55}}}}],["1292",{"pageContent":"La radiografía simple de tórax, en vista posteroanterior y en forma lateral, ofrecen un primer abordaje útil\npara la clasificación de la extensión del linfoma de Hodgkin. La tomografía simple de tórax se usa poco\ny se indica con más frecuencia la tomografía computarizada torácica de alta resolución, de sustracción\ndigital o helicoidal, cuando se tratan de definir lesiones residuales o pequeñas antes y después del trata -\nmiento. La gammagrafía con galio es de poca utilidad, ya que tiene falsas positivas y negativas numerosas;\ndebe hacerse antes y después del tratamiento para seguir los ganglios positivos, pero resulta muy costosa.\nRecientemente, la tomografía por emisión de positrones (PET, por sus siglas en inglés) con 18-fluoro-\ndesoxiglucosa se usa con mayor frecuencia para detectar lesiones residuales activas insospechadas y como\nvalor pronóstico después de 2 a 3 ciclos del tratamiento.\nAparentemente semeja en costo a las tomografías semestrales, las cuales no muestran la actividad","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":254,"lines":{"from":57,"to":66}}}}],["1293",{"pageContent":"valor pronóstico después de 2 a 3 ciclos del tratamiento.\nAparentemente semeja en costo a las tomografías semestrales, las cuales no muestran la actividad\nmetabólica de los ganglios pequeños. Dado que la linfangiografía ya no se realiza en la actualidad y\nque la laparotomía se ha ido abandonando, se ha apoyado el diagnóstico en los estudios tomográficos\ncontrastados abdominopélvicos con material oral e intravenoso simultáneo, con el objeto de precisar\nlas adenopatías retroperitoneales y de los hilios hepáticos y esplenorrenales. La resonancia magnética\nda otra dimensión a las estructuras ganglionares cuando se estudian en relación con las óseas, pero no","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":254,"lines":{"from":66,"to":72}}}}],["1294",{"pageContent":"Una adenopatía indolora cre-\nciente de más de 3 semanas de\nevolución, sin causa aparente,\nasociada o no a fiebre, pérdida\nde peso o tos, deberá estudiarse\ncomo probable linfoma.\nLa\n \nbiopsia\n \nde\n \nmédula\n \nósea\nse recomienda para estadios\navanzados después del IIB, en\nvista de que solo el 10% de los\nestadios tempranos muestran\nocupación medular.\nEn casos extremos se ha suge-\nrido la tomografía por emisión\nde positrones (PET, por sus\nsiglas en inglés) para detectar\nlesiones residuales activas in-\nsospechadas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":254,"lines":{"from":74,"to":99}}}}],["1295",{"pageContent":"228\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\ndefine claramente cuando se trata de diferenciar tejidos blandos entre sí (grasa contra adenopatía). Solo\nusando óxido de hierro en partículas ultrapequeñas cubiertas con dextrán se ha ido mejorando la calidad\nde la imagen ganglionar.\n\nESTADIOS DE EXTENSIÓN DEL LINFOMA DE HODGKIN\n\nDesde 1971 se ha utilizado un sistema numérico ordinal para designar las etapas de extensión de la enti-\ndad; ello, con el fin de definir poblaciones uniformes de pacientes que tengan pronóstico semejante y que\nademás reciban recomendación terapéutica común. Este sistema clasificatorio es conocido como\n \nclasifica-\nción de Ann Arbor\n, sitio donde se llegó a este acuerdo, que luego fuera modificado en Cotswold, Inglaterra,\nen 1989\n \n(cuadro 16-2 y fig. 16-4)\n.\n\nEVALUACIÓN CLÍNICA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":255,"lines":{"from":1,"to":23}}}}],["1296",{"pageContent":"EVALUACIÓN CLÍNICA\n\nDebe disponerse de una historia clínica cuidadosa y de un examen físico completo, con atención\na la presencia de signos y síntomas “B” del linfoma. Los antecedentes son útiles para los estudios\nepidemiológicos, pues la historia de un familiar con Hodgkin u otro linfoma aumenta cinco veces la\nprobabilidad de padecer la enfermedad. Ha de insistirse en la búsqueda de afecciones de los sistemas\nnervioso central y musculoesquelético o del aparato digestivo. En el examen físico deben describirse\ntodos los ganglios periféricos aumentados de tamaño, así como su sitio, dimensiones y número\n \n(fig.\n16-5)\n. Lo anterior se realiza con el objeto de conocer primero la extensión de la enfermedad y después\nla respuesta al tratamiento. Ha de ponerse especial cuidado en el anillo de Waldeyer y en los gan -\nglios epitrocleares, poplíteos, crurales e inguinales. Los ganglios axilares siguen en frecuencia a los","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":255,"lines":{"from":23,"to":36}}}}],["1297",{"pageContent":"Cuadro 16-2.\n \nClasificación de Ann Arbor por estadios del linfoma\nde Hodgkin, modificada en Costwold\n\nEstadio I\n\nAfección de una región ganglionar única o de un sitio u órgano extralinfático.\n\nEstadio II\n\nAfección de dos o más regiones ganglionares sobre el mismo lado del diafragma (IIo). Afección localizada\nde un órgano extralinfático (tiroides, timo, bazo), o de un sitio y de una o más regiones ganglionares sobre\nel mismo lado del diafragma (IIE). Deberá señalarse en subíndice el número de regiones afectadas (II).\n\nEstadio III\n\nAfección de ganglios en ambos lados del diafragma (III), acompañada o no de alteración localizada\nen un órgano o sitio extralinfático (IIIE) o del bazo (IIIS).\nIII1: Con o sin afectación esplénica, hiliar, mesentérica o portal.\nIII2: Con afectación de ganglios paraaórticos, ilíacos y mesentéricos.\n\nEstadio IV","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":255,"lines":{"from":38,"to":60}}}}],["1298",{"pageContent":"Afección diseminada o difusa de uno o más órganos o tejidos extralinfáticos (pulmón, intestino, hueso,\ntejidos blandos, etc.) con o sin crecimiento ganglionar asociado. Cada estadio se divide en “A” si no hay\nsíntomas generales o “B” si existe pérdida ponderal mayor de 10% del peso los meses previos o fiebre\ninexplicable mayor de 38 °C, o ambas cosas, o bien sudores nocturnos. La enfermedad extraganglionar\nconfirmada histológicamente se define con letras después del estadio seleccionado: h (hígado), s (bazo),\nl (pulmón), m (médula ósea), o (hueso) y d (piel). El estadio clínico (EC) se determina por los hallazgos\nde la historia clínica, el examen físico y la evaluación radiológica o de imagen al menos por dos mé-\ntodos, simple y tomográfica. El estadio patológico (EP) se establece con los resultados de las biopsias\nganglionares o los tejidos sometidos a biopsia. Cada paciente debe tener, por lo tanto, un estadio clínico","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":255,"lines":{"from":62,"to":70}}}}],["1299",{"pageContent":"ganglionares o los tejidos sometidos a biopsia. Cada paciente debe tener, por lo tanto, un estadio clínico\ny uno patológico. Por su valor pronóstico, se ha introducido al estudio clínico la evaluación del volu-\nmen del tumor; así, cuando tiene más de 6 cm en lesión abdominal y cuando existe un tumor mayor\nde 10 cm ocupando un tercio del diámetro torácico, se marca con una “X”. Cuando existe afección\nextraganglionar se añade al estadio la letra “E”. Hay dos formas de afección: la que se presenta como\ncontinuidad de ganglios linfáticos enfermos y la que ocurre como diseminación de la enfermedad.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":255,"lines":{"from":70,"to":75}}}}],["1300",{"pageContent":"Cada estadio se divide en “A”\nsi no hay síntomas generales o\n“B” si existe pérdida ponderal\nmayor de 10% del peso los me-\nses previos o fiebre inexplica-\nble mayor de 38 °C, o ambas\ncosas, o bien sudores nocturnos\nLos ganglios axilares siguen\nen frecuencia a los cervicales;\nidentificar\n \nhepatomegalia\n \no\nesplenomegalia, o ambas, re-\npresenta encontrar un estadio\nmás avanzado, y sus dimen-\nsiones se correlacionan con la\nduración de la enfermedad y\nsu extensión.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":255,"lines":{"from":77,"to":96}}}}],["1301",{"pageContent":"229\n\nCAPÍTULO 16. LINFOMA DE HODGKIN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":256,"lines":{"from":1,"to":3}}}}],["1302",{"pageContent":"Figura 16-4.\n \nClasificación por estadios de la enfermedad de Hodgkin. Modificado de: Hoff brand AV, Petit\nJE. Atlas of clinical haematology illustrated. London: Gower Medical Publishing; 1988.\ncervicales; identificar hepatomegalia o esplenomegalia, o ambas, representa encontrar un estadio más\navanzado, y sus dimensiones se correlacionan con la duración de la enfermedad y su extensión. En -\nseguida debe evaluarse la afección del mediastino con estudios clínicos y radiológicos simples (pos -\nteroanterior y lateral) que describan forma y tamaño; tiene valor pronóstico si es mayor de 10 cm. En\ndichos estudios han de identificarse ganglios paratraqueales, caridales o de los bronquios principales,\ny sobre todo se debe reconocer si hay afección pulmonar por extensión o por diseminación.\nLa tomografía computarizada de tórax resulta recomendable: a) si hay resultados dudosos en los es-\ntudios simples; b) cuando una gran masa mediastínica no permite visualizar afección parenquimatosa","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":256,"lines":{"from":5,"to":16}}}}],["1303",{"pageContent":"La tomografía computarizada de tórax resulta recomendable: a) si hay resultados dudosos en los es-\ntudios simples; b) cuando una gran masa mediastínica no permite visualizar afección parenquimatosa\npulmonar o pericárdica; y c) para la evaluación de la respuesta.\nEl estudio de la extensión de la enfermedad a nivel del abdomen se hace con el estudio clínico de la ex-\nploración abdominal; la identificación de visceromegalias o masas palpables indicará el estudio a realizar.\nEl estudio linfangiográfico, que tiene alto valor predictivo positivo (60 a 80%) y especificidad de 90 a 95%\npara ganglios ilíacos y paraaórticos, ya prácticamente no se realiza. Su mayor limitante es que no permite\nvisualizar ganglios mesentéricos, celíacos o esplénicos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":256,"lines":{"from":16,"to":23}}}}],["1304",{"pageContent":"Figura 16-5.\n \nGanglio linfático de un linfoma de Hodgkin: celularidad mixta, antígeno latente de mem-\nbrana, positivo para el virus de Epstein-Barr. Modificado de: Hoff brand AV, Petit JE. Atlas of clinical\nhaematology illustrated. London: Gower Medical Publishing; 1988.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":256,"lines":{"from":25,"to":29}}}}],["1305",{"pageContent":"230\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nActualmente se efectúa tomografía computarizada de abdomen y pelvis, que permite reconocer gan-\nglios profundos del retroperitoneo, subhepáticos, del hilio esplénico y de la cavidad pélvica; se utiliza con\nmedio de contraste intravenoso y oral y permite separar los ganglios preaórticos de la cabeza del páncreas\ny de la rodilla duodenal de la tercera porción del duodeno, que a esa altura se hace retroperitoneal; sin\nembargo, tiene un bajo valor predictivo de 65% por los falsos negativos. Es el método diagnóstico más uti-\nlizado en la actualidad por su rapidez y sencillez, para repetirlo en el curso de la evolución. La laparotomía\nexploradora está en desuso. Los casos de histología agresiva presentan más probabilidades de detectarse\nen estadio avanzado si se asocian con síntomas generales o si los pacientes tienen menos de 40 años de\nedad\n \n(cuadro 16-3)\n. La presencia de cada factor reduce en promedio un 8% la supervivencia a 5 años.\n\nTRATAMIENTO","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":257,"lines":{"from":1,"to":18}}}}],["1306",{"pageContent":"TRATAMIENTO\n\nEn los últimos 20 años, la enfermedad que era casi siempre fatal ahora es en su mayor parte curable. Para\nalcanzar óptimos resultados en el tratamiento es indispensable contar con:\n1. Una clasificación histológica precisa.\n2. Un conocimiento lo más exacto posible sobre la extensión de la enfermedad.\n3. Un programa terapéutico que brinde las máximas posibilidades de curación.\nLos medios actualmente disponibles para su tratamiento son diversos: radioterapia (RT), quimiotera-\npia (QT), inmunoterapia, modificadores de la respuesta inmunitaria, factores de crecimiento hematopo-\nyético, trasplante de médula ósea (TMO) y una combinación de los anteriores.\n\nRadioterapia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":257,"lines":{"from":18,"to":29}}}}],["1307",{"pageContent":"En la actualidad se acepta que la radioterapia es el tratamiento de elección en la enfermedad localizada IA\nsin tumor voluminoso, con 0 o 1 factores pronósticos adversos, lo que ocurre en el 10 % de los pacientes.\nSe logran curaciones definitivas en el 80 a 95% de los casos, siempre y cuando se empleen aceleradores\nlineales modernos de 4 a 10 Mev. En estos mismos estadios con masa voluminosa tratados solo con radio-\nterapia, recaen el 60% de los pacientes, por lo que debe recurrirse a la variedad de tratamiento combinado\n(QT + RT). La radioterapia de 20 a 30 Gy debe asociarse a cuatro ciclos de quimioterapia en estadios\ntempranos IA, IIA y IIIA; para estadios avanzados IB, IIB y II o IV sin tumor voluminoso, seis a ocho\nciclos de ABVD (adriamicina, bleomicina, vinblastina y dacarbacina) más radioterapia a campo afectado\nresidual, áreas voluminosas o de lenta respuesta, sin perjuicio de mayor toxicidad y con mejor respuesta a\nlargo plazo\n \n(cuadros 16-4 y 16-5)\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":257,"lines":{"from":31,"to":43}}}}],["1308",{"pageContent":"residual, áreas voluminosas o de lenta respuesta, sin perjuicio de mayor toxicidad y con mejor respuesta a\nlargo plazo\n \n(cuadros 16-4 y 16-5)\n.\nEn las etapas IA y IIA bien definidas poslaparotomía, no se han observado diferencias en las respuestas\ncon irradiación a campo local (solo regiones invadidas), en comparación con las de campo extenso (regiones\ninvadidas más radiación a áreas contiguas). En cambio, en estos mismos estadios pero con síntomas B u otros\nfactores de mal pronóstico, la respuesta y supervivencia son superiores con radioterapia a campo extenso.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":257,"lines":{"from":43,"to":51}}}}],["1309",{"pageContent":"Cuadro 16-3.\n \nFactores pronósticos para linfoma de Hodgkin avanzado y supervivencia\n\nNúmero\nde factores\n \n% casos\n \n% libre de progresión a 5 años\n \nSupervivencia\nglobal%\n\n0\n \n7\n \n84 ± 4\n \n89 ± 2\n1\n \n22\n \n77 ± 3\n \n90 ± 2\n2\n \n29\n \n67 ± 2\n \n81 ± 2\n3\n \n23\n \n60 ± 3\n \n78 ± 3\n4\n \n12\n \n51 ± 4\n \n61 ± 4\n> 5\n \n7\n \n42 ± 5\n \n56 ± 5\nFactores pronósticos: 1) sexo masculino. 2) Albúmina en suero < 4 g/dL. 3) Hemoglobina < 10 g/dL. 4) Estadio IV. 5) Más de 45\naños. 6) Más de 15 000 leucocitos /mL. 7) Menos de 600 linfocitos absolutos. 8) Linfocitos < 8% de la cuenta leucocitaria total.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":257,"lines":{"from":53,"to":110}}}}],["1310",{"pageContent":"Los casos de histología agresiva\npresentan más probabilidades\nde detectarse en estadio avan-\nzado si se asocian con síntomas\ngenerales o si los pacientes tie-\nnen menos de 40 años de edad.\nLos medios actualmente dis-\nponibles para su tratamiento\nson diversos, lo que indica\nque ninguno de ellos es 100%\nefectivo: radioterapia (RT),\nquimioterapia (QT), inmu-\nnoterapia, modificadores de la\nrespuesta inmunitaria, facto-\nres de crecimiento hematopo-\nyético, trasplante de médula\nósea (TMO) y una combina-\nción de los anteriores.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":257,"lines":{"from":112,"to":129}}}}],["1311",{"pageContent":"231\n\nCAPÍTULO 16. LINFOMA DE HODGKIN\n\nLos pacientes en estadio I y II con tumor voluminoso recaen cerca del 80% de las veces cuando reciben\nsolo radioterapia. Este porcentaje se reduce en forma importante si se usan 3 600 cGy al campo invadido y\nterapia combinada (RT + QT). Asimismo, algunos estudios clínicos aleatorizados han puesto de manifiesto\nque tanto la radio como la quimioterapia tienen una eficacia similar para el tratamiento de los pacientes en\nestadios I y II cuando se valora supervivencia total (80% a 5 años), pero no son iguales si se considera la\nsupervivencia libre de enfermedad (65% contra 80%), por lo que es importante tener en cuenta los riesgos\nrelativos asociados a cada una de estas modalidades terapéuticas para seleccionar la de máxima utilidad con\nmenores efectos tóxicos inmediatos y tardíos. Existe renovado interés en radiar solo en ganglios afectados, y\nse han establecido guías más precisas que estandarizan tratamientos y resultados.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":258,"lines":{"from":1,"to":13}}}}],["1312",{"pageContent":"Cuadro 16-4.\n \nRecomendaciones terapéuticas según estadio evolutivo\n(Connor’s, EORTC H7, 8 y 9, Grupo Coop. Alemán HD 8,11,14,15)\n\nEstadio\n \nTratamiento recomendado\n \nTratamiento alternativo\n\nI y IIA\n2-4 ciclos ABVD o VAMP + RT\n15-25 Gy a campo afectado (ries-\ngo favorable)\nRT en manto + 30-40 Gy solo\nadultos (riesgo muy favorable)\nIIE (A o B) con gran\nmasa mediastínica\n4-6 ciclos ABVD + RT 30 Gy\na campo afectado (riesgo desfa-\nvorable)\n4-6 ciclos ABVD + RT en campo\nextendido. 6 ABVD a fumadores\ny mujeres > 27 años\nIIIA (enfermedad\nesplénica mínima)\n6-8 ciclos ABVD + RT\n20-30 Gy con RP\n+ Stanford V + RT a campos in-\nvadidos\nIIIA2 (enfermedad\nextensa esplénica)\n6-8 ciclos ABVD + 20-30 Gy\nEnfermedad residual\nCirugía, RT + BEACOPP o\nStanford V\nIIIB y IVB\n \n6-8 ciclos ABVD + RT enf. res.\nAutotrasplantes en < 60 años\nICE, BEACOPP, BEAM contra\n2 con más de 4 factores adversos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":258,"lines":{"from":15,"to":57}}}}],["1313",{"pageContent":"Muy favorable:\n \nI y II. Femenino: escleroso nodular, < 3 sitios, cuello alto y < 26 años. Masculino: predominio linfocítico, solo\ncuello, velocidad de sedimentación globular (VSG) < 30 mm/h.\n\nFavorable\n: Femenino, o hasta 3 sitios, < 50 años, VSG < 30 mm/h.\n\nDesfavorabl\ne IIB: > 50 años, > 4 sitios, mediastino > 10 cm, VSG > 30 mm/h, fiebre o pérdida de peso. Enfermedad extra-\nganglionar.\n\nCuadro 16-5.\n \nTécnicas de radioterapia más usadas\n\nMinimanto\n \nCervical, supraclavicular y axilares bilateral, estadio I\n\nEn manto\n \nPara enfermedad supradiafragmática (bilateral a ganglios submaxilares, cer-\nvicales, supra e infraclaviculares, axilares, mediastínicos e hiliares)\n\nCampo afectado\n \nRegiones linfáticas afectadas\n\nCampo regional\n \nÁreas linfáticas afectadas y regiones linfáticas adyacentes\n\n“Y” invertida\n \nPara enfermedad infradiafragmática y pelvis (inguinales, crurales, ilíacos,\nparaórticos, paracavales, campo esplénico)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":258,"lines":{"from":59,"to":95}}}}],["1314",{"pageContent":"“Y” invertida\n \nPara enfermedad infradiafragmática y pelvis (inguinales, crurales, ilíacos,\nparaórticos, paracavales, campo esplénico)\n\nEn barra\n \nFragmento de “Y” invertida (ganglios paraaórticos, paracavales y puede\nextenderse a bazo)\nRadioterapia volumétrica de 3 dimensiones\nRadioterapia de intensidad modulada\n* Las dosis tumoricidas para la enfermedad van de 3 500 a 4 400 cGy. Con quimioterapia asociada se recomiendan 30 a 36\nGy a regiones afectadas y 20 a 30 Gy a regiones no afectadas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":258,"lines":{"from":95,"to":107}}}}],["1315",{"pageContent":"232\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nQuimioterapia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":259,"lines":{"from":1,"to":5}}}}],["1316",{"pageContent":"El tratamiento de elección para pacientes con enfermedad avanzada es la poliquimioterapia. El pronós-\ntico de los pacientes con EH en estadios avanzados se modificó favorablemente a partir de 1967, con la\nintroducción del esquema MOPP (mostaza nitrogenada, vincristina, prednisona y procarbazina). Cada\nuno de sus medicamentos fue seleccionado en base a su eficacia antitumoral como agente único, meca-\nnismo de acción diferente, sin incremento de su toxicidad. Su dosis de acuerdo a un plan o programa\ndefinido y los días de reposo o intervalo entre ciclos fueron calculados según la cinética celular. Este\nrégimen se administra cada 3 semanas en número de seis, obteniéndose remisión completa (RC: ausencia\nabsoluta de las manifestaciones objetivas y subjetivas de la enfermedad) de 80% aproximadamente, así\ncomo supervivencia de 60% a 10 años. Con el objetivo de mejorar las respuestas e incrementar la su-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":259,"lines":{"from":7,"to":15}}}}],["1317",{"pageContent":"absoluta de las manifestaciones objetivas y subjetivas de la enfermedad) de 80% aproximadamente, así\ncomo supervivencia de 60% a 10 años. Con el objetivo de mejorar las respuestas e incrementar la su-\npervivencia con menos efectos colaterales indeseables, se han ensayado diversos esquemas semejantes al\nMOPP, compuestos por un alquilante, un derivado de la vinca, procarbazina y un corticoide; sin embar-\ngo, sus respuestas son inferiores al MOPP, por lo que su aceptación ha sido menor. En 1975, Bonadona\ncomunicó los resultados obtenidos con el esquema ABVD, compuesto por adriamicina, bleomicina, vin-\nblastina y dacarbazina, fármacos diferentes en estructura, actividad antitumoral y toxicidad que carecen\nde resistencia cruzada con el MOPP.\nLa frecuencia de respuestas fue 10 a 15% mayor que con el MOPP o los esquemas combinados co-\nnocidos como “híbridos”, donde se mezclan los dos esquemas el mismo mes o secuencial un mes MOPP","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":259,"lines":{"from":15,"to":24}}}}],["1318",{"pageContent":"La frecuencia de respuestas fue 10 a 15% mayor que con el MOPP o los esquemas combinados co-\nnocidos como “híbridos”, donde se mezclan los dos esquemas el mismo mes o secuencial un mes MOPP\ny otro mes ABVD; además, produce menor daño gonadal y la frecuencia de segundas neoplasias es\nmenor aunque con mayor efecto tóxico inmediato y costo. El MOPP y el ABVD son los esquemas de\npoliquimioterapia más usados. Diversos estudios controlados indican la superioridad de los programas\ntipo ABVD sobre el esquema MOPP y sus análogos, por lo que el esquema óptimo en la actualidad es el\nABVD. Otros esquemas que han mostrado alta efectividad en estadios avanzados son el esquema BEA-\nCOPP de los alemanes, quienes han propuesto dos formas, una convencional y un tratamiento con dosis\nmayores que llaman “escalado”, y actualmente las respuestas son del 80% a 5 años con supervivencias\ndel 87%.\nOtro esquema en uso es el llamado\n Stanford V\n, que incluye tratamientos cortos de 12 semanas a dosis máxi\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":259,"lines":{"from":24,"to":37}}}}],["1319",{"pageContent":"del 87%.\nOtro esquema en uso es el llamado\n Stanford V\n, que incluye tratamientos cortos de 12 semanas a dosis máxi\n-\nma, haciendo énfasis en la intensidad de la dosis como estrategia básica del manejo. Dos estudios italianos que\ncomparan ABVD contra Stanford V no muestran diferencias, pero el ABVD es más manejable en cuanto a\nefectos supresivos de la médula ósea. Existen controversias sobre cuál es la terapia ideal para pacientes en estadio\nIIIA, pues tanto la RT como la QT muestran respuestas semejantes (80 al 85%); sin embargo las recaídas son\nmayores con la RT, por lo que se prefiere la forma combinada.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":259,"lines":{"from":37,"to":46}}}}],["1320",{"pageContent":"Modalidad de la terapia combinada\n\nEntre el 25 y 35% de los pacientes en estadios avanzados que obtuvieron RC con quimioterapia recaen,\ndisminuyendo las posibilidades de curación definitiva y obligando a una apropiada terapia de rescate\na fin de obtener una nueva remisión. Diversos autores, con el objeto de erradicar la enfermedad resi -\ndual, consolidar las respuestas y disminuir recurrencias con intento de curación definitiva, administran\nposterior a la QT pequeñas dosis de radioterapia (2 000 a 2 500 cGy) sobre las regiones gangliona -\nres inicialmente afectadas, que constituyen el sitio principal de recaídas. Con ello lograron que estas\ndisminuyeran a menos del 10%, y además que se incrementaran 20% las RC en comparación con las\nalcanzadas solo con quimioterapia. Entre las indicaciones de la modalidad de terapia combinada se\nencuentran los estadios avanzados con más de tres factores de mal pronóstico y todos los casos con\ntumor voluminoso.\n\nConcepto de intensidad de dosis","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":259,"lines":{"from":48,"to":61}}}}],["1321",{"pageContent":"Concepto de intensidad de dosis\n\nUn factor adicional e importante que ha emergido de varios análisis, y que definitivamente influye en las\nrespuestas y curaciones, es la dosis de los medicamentos recibidos y el momento oportuno de su aplicación\n(concepto de\n \nintensidad de dosis\n), en comparación con la dosis que tentativamente debería administrarse\nsegún el régimen y su día programado. Una reducción significativa en la intensidad de las dosis es direc-\ntamente proporcional a una disminución importante en la tasa de respuestas.\nSe señala la necesidad de recibir al menos un 80% o más de la cantidad calculada de medicamentos\npara obtener mayores probabilidades de éxito. En los pacientes mayores de 55 años generalmente la res-\npuesta es deficiente, por tolerar cantidades menores de los antitumorales.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":259,"lines":{"from":61,"to":73}}}}],["1322",{"pageContent":"El\n \ntratamiento\n \nde\n \nelección\npara pacientes con enfermedad\navanzada es la poliquimio-\nterapia. El pronóstico de los\npacientes con EH en estadios\navanzados se modificó favora-\nblemente a partir de 1967, con\nla introducción del esquema\nMOPP (mostaza nitrogena-\nda, vincristina, prednisona y\nprocarbazina).\nEl\n \nesquema\n \nABVD\n \nestá\ncompuesto\n \npor\n \nadriamicina,\nbleomicina, vinblastina y da-\ncarbazina, fármacos diferen-\ntes en estructura, actividad\nantitumoral y toxicidad que\ncarecen de resistencia cruzada\ncon el MOPP; la frecuencia\nde respuestas es de 10 a 15%\nmayor que con este último o\ncon los esquemas combinados,\nconocidos como “ híbridos”.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":259,"lines":{"from":75,"to":113}}}}],["1323",{"pageContent":"233\n\nCAPÍTULO 16. LINFOMA DE HODGKIN\nTERAPIA PARA RECAÍDA O ENFERMEDAD REFRACTARIA\n\nLos enfermos que recaen posterior a la radioterapia tienen respuestas de 70 a 85% con el esquema ABVD\nu otros similares y curaciones de 50 a 60%. En cambio, en los que recaen después de obtener buena\nrespuesta con QT, se requiere el empleo de regímenes sin resistencia cruzada con el usado inicialmente.\nPueden preverse estas recaídas si se consideran los factores pronósticos iniciales.\nCuando la recaída es dentro del primer año de haber suspendido el tratamiento, el pronóstico es más des\n-\nfavorable que cuando recaen después del año de la suspensión. A los casos que recaen después del año de RC,\nse les puede administrar para reinducción de remisión el mismo régimen empleado inicialmente, o bien, otro\nde los usados para recaídas o de rescate (VEPP, EVA, MIME, ESHAP, etc.). Se definen como\ncasos refractarios","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":260,"lines":{"from":1,"to":15}}}}],["1324",{"pageContent":"los que no remiten dentro del primer año de iniciada la terapia con dos esquemas de primera línea, o en su\ndefecto, se dice que están\n \nen progresión\n \ncuando la respuesta no es completa posterior a la administración de al\nmenos tres dosis del esquema de terapia elegido.\nOtros esquemas de rescate novedosos incluyen fludarabina, Ara-C, ifosfamida, clorodeoxiadenosina,\nidarrubicina o gemcitabina, bendamustina, anti-CD30, doxorrubicina pegilada y vinorelbina en combi-\nnaciones. Algunas alternativas son el uso de inmunotoxinas o radiomiméticos.\n\nTrasplante de médula ósea","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":260,"lines":{"from":17,"to":28}}}}],["1325",{"pageContent":"Deben trasplantarse en forma autóloga los pacientes que:\n1. Tengan progresión de la enfermedad durante el tratamiento de primera línea.\n2. Recaigan antes del primer año de haber terminado el tratamiento de elección de primera línea.\n3. Sean jóvenes con cuatro o más factores pronósticos adversos iniciales.\nPara la selección del candidato idóneo al trasplante, también se han descrito factores pronósticos que\ndeben de estudiarse antes de ser aceptado, y son los siguientes:\n1. Capacidad física funcional en el momento de la recaída.\n2. Estadio al momento de las dosis altas de quimioterapia, con o sin síntomas “B”, pérdida de peso y\nsudores nocturnos.\n3. Quimiosensibilidad del tumor en la recaída.\n4. Tamaño del tumor en la recaída: más de 6 cm en abdomen o más de 10 cm en mediastino, más que\nenfermedad mínima.\n5. Recaída extraganglionar: pulmón, médula ósea, hígado o bazo.\n6. Tiempo previo de la remisión y menos de 20 meses de la enfermedad.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":260,"lines":{"from":30,"to":43}}}}],["1326",{"pageContent":"enfermedad mínima.\n5. Recaída extraganglionar: pulmón, médula ósea, hígado o bazo.\n6. Tiempo previo de la remisión y menos de 20 meses de la enfermedad.\nWheeler describió supervivencias actuariales del 82, 56 y 19% para cero, uno o más de dos factores\npronósticos, respectivamente, en 102 pacientes sometidos a autotrasplante. La misma observación reali-\nzaron Horning y cols. al mostrar 85, 57, 41% y menos de 20% de supervivencia global, cuando hubo cero,\nuno, dos y tres factores pronósticos, respectivamente, al momento del trasplante. Para reducir las recaídas\no la refractariedad con un solo trasplante, ahora se han estado utilizando dobles autotrasplantes, con una\ndiferencia entre ellos menor a 3 meses; se esperan los resultados a largo plazo.\nLos porcentajes de RC varían de 40 a 70%, con supervivencias globales de alrededor de 40 a 50% a 5\naños. Los trasplantes alogénicos de donador familiar compatible empiezan a ser otra opción cuando, ade-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":260,"lines":{"from":43,"to":53}}}}],["1327",{"pageContent":"años. Los trasplantes alogénicos de donador familiar compatible empiezan a ser otra opción cuando, ade-\nmás de recaída, hay refractariedad y las condiciones del paciente lo permiten. Este método tiene más mor-\nbilidad y los resultados a corto plazo son semejantes al autotrasplante en primera recaída o en progresión.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":260,"lines":{"from":53,"to":55}}}}],["1328",{"pageContent":"Inmunoterapia\n\nUn 20% de las células de Hodgkin clásico tienen el marcador CD20+ y pueden ser susceptibles a los an-\nticuerpos monoclonales anti-CD20 o rituximab, que ha sido ensayado con buenos resultados solo o con\ninterleucina 2 en los linfomas de Hodgkin con predominio linfocitario y rico en linfocitos refractarios o\nen recaída. Existen otros anti-CD16/anti-CD30 asociados a itrio-90, yodo-131 o antiferritina que pueden\ntambién ser útiles al actuar en forma selectiva y dirigida contra las células neoplásicas; también mejoran la\nsensibilidad al rituximab y a otros inmunomoduladores, como el inhibidor del proteosoma conocido como\n\nbortezomib\n, y a las desacetilasas de histonas o vorinostat.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":260,"lines":{"from":57,"to":67}}}}],["1329",{"pageContent":"bortezomib\n, y a las desacetilasas de histonas o vorinostat.\n\nLos enfermos que recaen pos -\nterior a de la radioterapia\ntienen respuestas de 70 a 85%\ncon el esquema ABVD u otros\nsimilares, y curaciones de 50\na 60%. En cambio, en los\nque recaen después de obtener\nbuena respuesta con QT, se\nrequiere el empleo de regíme -\nnes sin resistencia cruzada\ncon el utilizado inicialmente.\nUn 20% de las células de Hodg-\nkin clásico tienen el marcador\nCD20+ y pueden ser susceptibles\nde ser tratadas con anticuerpos\nmonoclonales, como el rituximab.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":260,"lines":{"from":67,"to":85}}}}],["1330",{"pageContent":"234\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nComplicaciones del tratamiento","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":261,"lines":{"from":1,"to":5}}}}],["1331",{"pageContent":"Son diversas y de magnitud variable, por ejemplo, náuseas, vómitos, caída de pelo, mielosupresión,\nhepatotoxicidad, cardiotoxicidad, entre otras. Hay dos complicaciones de aparición mediata y tardía im-\nportantes por su morbimortalidad:\n1. Daño gonadal, que en ocasiones llega hasta la esterilidad irreversible.\n2. Segundas neoplasias.\nEn publicaciones recientes que revisan la incidencia de segundas neoplasias posteriores a la sus -\npensión de la terapia en 1 093 y 794 pacientes, se ha encontrado esta complicación en el 13,4 y 11,2%,\nrespectivamente. En estas y otras series, la leucemia aguda mieloide y los linfomas no Hodgkin son\nlos tumores más frecuentes. El tiempo de su aparición posterior al tratamiento es de 72 meses como\npromedio (9 a 330 meses). Otros cánceres que también pueden aparecer son los de tubo digesti -\nvo, mama, pulmón, tiroides, piel, tejidos blandos, entre otros. Los regímenes que incluyen algún","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":261,"lines":{"from":7,"to":17}}}}],["1332",{"pageContent":"promedio (9 a 330 meses). Otros cánceres que también pueden aparecer son los de tubo digesti -\nvo, mama, pulmón, tiroides, piel, tejidos blandos, entre otros. Los regímenes que incluyen algún\nalquilante o nitrosureas, sobre todo cuando se combinan con radioterapia (modalidad de terapia\ncombinada), constituyen los factores más importantes de riesgo para estas complicaciones. La neu -\ntropenia con la quimioterapia se da más en mujeres, pero su efecto a largo plazo para el control de la\nenfermedad es mejor en los que no recibieron factores de crecimiento de granulocitos que en aquellos\nque sí lo hicieron.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":261,"lines":{"from":17,"to":23}}}}],["1333",{"pageContent":"CONCLUSIONES\n\n•\n \nEl linfoma de Hodgkin es una entidad neoplásica de células linfoides. La célula maligna pro -\nliferante es la célula de Reed-Sternberg, una célula linfoide de estirpe B modif icada.\n\n•\n \nEl tratamiento se elige con base en la extensión de la neoplasia, y habitualmente se lleva a cabo con\nquimioterapia combinada con ABVD (adriamicina, bleomicina, vinblastina y dacarbazina).\n\n•\n \nLos tratamientos actuales logran curación definitiva de la enfermedad en más del 90% de los pacientes\ncon linfoma de Hodgkin.\n\nPREGUNTAS DE AUTOEVALUACIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":261,"lines":{"from":25,"to":42}}}}],["1334",{"pageContent":"•\n \nLos tratamientos actuales logran curación definitiva de la enfermedad en más del 90% de los pacientes\ncon linfoma de Hodgkin.\n\nPREGUNTAS DE AUTOEVALUACIÓN\n\n1. Variedad histológica más común del linfoma de Hodgkin:\na.\n \nPredominio linfocítico\nb. Celularidad mixta\nc.\n \nEsclerosis nodular\n2. En una adenopatía se debe descartar linfoma cuando:\na.\n \nEs dolorosa\nb. Se acompaña de fiebre\nc.\n \nTiene más de 3 semanas de evolución, sin causa aparente\n3. Es dato patognomónico de linfoma de Hodgkin:\na.\n \nCélulas clave\nb. Células de Reed-Sternberg\nc.\n \nCuerpos de Howell-Jolly\n4. Tratamiento de elección para linfoma de Hodgkin:\na.\n \nMOPP\nb. ABVD\nc.\n \nATRA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":261,"lines":{"from":42,"to":80}}}}],["1335",{"pageContent":"235\n\nCAPÍTULO 16. LINFOMA DE HODGKIN\n\n5. Mujer de 30 años que presenta fiebre, diaforesis nocturna y pérdida importante de peso en 3 meses.\nA la exploración física se encuentra adenopatía cervical indolora y ganglio axilar homolateral. Ligera\nesplenomegalia. Se realiza una tomografía computarizada en la que se observa una masa mediastínica.\nDe acuerdo a la clasificación de Ann Arbor, ¿en qué estadio se encuentra la paciente?\na.\n \nI\nb. II\nc.\n \nIII\n\nBIBLIOGRAFÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":262,"lines":{"from":1,"to":17}}}}],["1336",{"pageContent":"Aisenberg A. Problems in Hodgkin’s disease management. Blood. 1999; 93: 761-779.\nArmitage JO. Current concepts early stage Hodgkin’s lymphoma. N Engl J Med. 2010; 363: 653-662.\nAltamirano J, Reyes Esparza J, de la Garza-Salazar J, Sobrevilla-Calvo P, Rivas Vera S, Chalapud-Revelo JR,\net al. Staging, response to therapy and restaging of lymphomas with 18F-FDG PET. Arch Med Res. 2008;\n39: 69-77.\nAnagnostopoulos I, Hansman ML, Franssila K, Harris M, Harris NL. Jaffe ES, et al. European Task Force on\nLymphoma project on lymphocyte predominance Hodgkin’s disease: Histologic and immunohistologic analysis\nof submitted cases reveals 2 types of Hodgkin’s disease with a nodular growth pattern and abundant lymphocytes.\nBlood. 2000; 96: 1889-1899.\nAnsell SM, Armitage JO. Management of Hodgkin lymphoma. Mayo Clin Proceed. 2006; 81: 419-426.\nAvilés A, Díaz MJC, et al. Hodgkin’s disease. A historical perspective. Arch Invest Med. 1991; 22: 27-31.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":262,"lines":{"from":19,"to":29}}}}],["1337",{"pageContent":"Ansell SM, Armitage JO. Management of Hodgkin lymphoma. Mayo Clin Proceed. 2006; 81: 419-426.\nAvilés A, Díaz MJC, et al. Hodgkin’s disease. A historical perspective. Arch Invest Med. 1991; 22: 27-31.\nAvilés A, Talavera A, Guzmán R, Fernández R. An intensive chemotherapy regimen for Hodgkin’s disease with\nGM-CSF as support. J ¿er Control Cancer. 1999.\nAvilés A, Neri N. Hematological malignancies and pregnancy. A final report of 84 children who received chemother\n-\napy in utero. Clin Lymphoma. 2001; 2: 173-177.\nAvilés A, Cleto S, Neri N, Huerta-Guzmán J, Talavera A, Castañeda C, et al. Treatment of advanced Hodgkin’s\ndisease: EBVD versus intensive brief chemotherapy. Leukemia and Lymphoma. 2003; 44: 1361-5.\nAvilés A, Talavera A, García EL. La fosfatasa alcalina como factor pronóstico en enfermedad de Hodgkin. Rev Gas-\ntroenterol Méx. 1990; 55: 211-214.\nBiti G, Cimino G, et al. Extended field radiotherapy is superior to MOPP for the treatment of pathologic stage I-II","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":262,"lines":{"from":29,"to":40}}}}],["1338",{"pageContent":"troenterol Méx. 1990; 55: 211-214.\nBiti G, Cimino G, et al. Extended field radiotherapy is superior to MOPP for the treatment of pathologic stage I-II\nA Hodgkin’s disease. J Clin Oncol. 1992; 16: 378-82.\nBoll B, Hansen H, Heuck F. ¿e fully human anti CD30 antibody 5 F 11 activates NF-kB and sensitizes lymphoma\ncells to bortezomib-induced apoptosis. Blood. 2005; 106: 1839-1842.\nBoleti E, Mead GM. ABVD for Hodgkin’s lymphoma: Full dose chemotherapy without dose reductions or growth\nfactors. Ann Oncol. 2007; 18: 376-380.\nBothe A, Sass S, Goergen H, Eichenhauer DA. Bretuximab vedotin for relapsed refractory CD30 in hematological\nmalignancies. GHSG. Blood. 2012; 120: 1470-1472.\nBonnadona G, Valagussa P, et al. Alternating non-cross resistant combination chemoterapy MOPP in stage IV\nHodgkin’s disease. Ann Inter Med. 1986; 104: 739-746.\nCabrera CME, García LH, Lois VV, León RA, Peña NK, Rossle SA, et al. Linfoma de Hodgkin en Chile. Experiencia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":262,"lines":{"from":40,"to":51}}}}],["1339",{"pageContent":"Hodgkin’s disease. Ann Inter Med. 1986; 104: 739-746.\nCabrera CME, García LH, Lois VV, León RA, Peña NK, Rossle SA, et al. Linfoma de Hodgkin en Chile. Experiencia\nde 15 años de Programa Nacional de Cáncer del adulto. Rev Méd Chile. 2007; 135: 341-350.\nCheson BD, Pfistner B, Juweid ME, Gayscone RD, Speecht L, Horning SJ, et al. Revised response criteria for ma-\nlignant lymphoma. J Clin Oncol. 2007; 25: 579-586.\nCanellos J, Anderson J, et al. Chemoterapy in advanced Hodgkin’s disease with MOPP, ABVD or MOPP alternating\nwith ABVD. N Engl J Med. 1992; 327: 1487-1492.\nConnors JM, Noordijk EM, Horning SJ. Hodgkin’s lymphoma: Basing the treatment on the evidence. Education\nBook. Orlando, Florida: American Society of Hematology; 2001.\nConnors JM. State of Art. ¿erapeutics Hodgkin’s Lymphoma. J Clin.Oncol 2005; 23: 6400-6408.\nConnors JM. Hodgkin’s lymphoma . Cecil’s Medicine. 23rd ed. USA: Saunders-Elsevier; 2012. p. 1228-1233.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":262,"lines":{"from":51,"to":61}}}}],["1340",{"pageContent":"Connors JM. State of Art. ¿erapeutics Hodgkin’s Lymphoma. J Clin.Oncol 2005; 23: 6400-6408.\nConnors JM. Hodgkin’s lymphoma . Cecil’s Medicine. 23rd ed. USA: Saunders-Elsevier; 2012. p. 1228-1233.\nConnors JM. Hodgkin’s lymphoma. ¿e great teacher. N Eng J Med. 2011; 365: 264-265.\nDiehl V, Franklin J, Hasenclever D. BEACOPP new dose escalated and accelerated regimen, is at least as effective as\nCOPP/ ABVD in patients with advanced stage Hodgkin’s lymphoma. J Clin Oncol. 1998; 16: 3810-3821.\nDe Vita V. Hodgkin’s disease. New Eng J Med. 1993; 328: 560-566.\nDelgado-Lamas JL. Tratamiento del linfoma de Hodgkin y el autotrasplante de células hematopoyéticas. Rev Invest\nClín. 2001; 53: 552-560.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":262,"lines":{"from":61,"to":68}}}}],["1341",{"pageContent":"236\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":263,"lines":{"from":1,"to":3}}}}],["1342",{"pageContent":"Diepstra A, Niens M, Vellenga E. Assocation with HLA class I in EB virus positive and class III in EB virus negative\nHodgkin’s lymphoma. Lancet. 2005; 365: 2216-2224.\nDonaldson SS, Link MP, Weinstein HJ, Rai SN, Brain S, Billet AL, et al. Final results of a prospective clinical trial\nwith VAMP and low dose involved field radiation for children with low risk Hodgkin’s disease. J Clin Oncol.\n2007; 25: 332-337.\nFarrel K, Jarret RF. ¿e molecular pathogenesis of Hodgkin’s lymphoma. Review Histopathology. 2011; 58: 15-25.\nFermé C, Mounier , Divine M, Brice P, Stomatoullas A, Reman O, et al. Intensive salvage therapy with high-dose\nchemotherapy for patients with advanced Hodgkin’s disease in relapse or failure after initial chemotherapy. J Clin\nOncol. 2002; 20: 467-475.\nFriedmann AM, Weinstein HJ. ¿e evolving standard of care for Hodgkin lymphoma. J Pediatr Hematol Oncol.\n2008; 30: 121-123.\nFoltz LM, Song KW, Connors JM. Hodgkin’s lymphoma in adolescents. J Clin Oncol. 2006; 24: 2520-2526.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":263,"lines":{"from":5,"to":16}}}}],["1343",{"pageContent":"2008; 30: 121-123.\nFoltz LM, Song KW, Connors JM. Hodgkin’s lymphoma in adolescents. J Clin Oncol. 2006; 24: 2520-2526.\nGirinsky T, Ghalibafian M. Radiotherapy of Hodgkin lymphoma indications, new fields and techniques. Semin Rad\nOncol. 2007; 17: 206-222.\nGómez-Almaguer D, Ruiz-Argüelles GJ, López-Martínez B, Estrada E, Lobato-Mendizábal E, Jaime-Pérez JC.\nRole of bone marrow examination in staging Hodgkin’s disease: Experience in Mexico. Clin Lab Haematol.\n2002; 24: 221-223.\nGoldin LR, Pfeiffer RM, Gridley G. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer. 2004;\n100: 1902-1908.\nGulley ML, Eagan PA, Quintanilla-Martínez L, Picado AL, Smir BN, Childs G, et al. Epstein-Barr virus DNA is\nabundant and monoclonal in the Reed-Sternberg cells of Hodgkin’s disease: Association with mixed cellularity\nsubtype and Hispanic American ethnicity. Blood. 1994; 83: 1595-1602.\nHansenclever D, Diëhl V. A prognostic score for advanced Hodgkin’s disease. New Engl J Med. 1998; 339: 1506-1516.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":263,"lines":{"from":16,"to":28}}}}],["1344",{"pageContent":"subtype and Hispanic American ethnicity. Blood. 1994; 83: 1595-1602.\nHansenclever D, Diëhl V. A prognostic score for advanced Hodgkin’s disease. New Engl J Med. 1998; 339: 1506-1516.\nHarris NL, Jaffe ES, Diebold J, Flandrin G, Müller-Hermelink HK, Vardiman J, et al. ¿e World Health Organi-\nzation classification of lymphoid neoplastic disease of the hematopoietic and lymphoid tissues. Ann Oncol. 1999;\n10: 1419-1432.\nHoppe R. ¿e management of bulky mediastinal Hodgkin disease. Hematology/Oncology Clinics of North America.\n1989: 265-276.\nHoppe RT, Mauch PT, Armitage JO, Diehl V, Weiss LM. Hodgkin’s lymphoma. 2nd ed. USA: Lippincot Williams\nand Wilkins; 2007.\nHorning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown W, Rosenberg AS. Stanford V and radiotherapy for locally extensive\nand advanced Hodgkin’s disease: Mature results of a prospective clinical trial. J Clin Oncol. 2002; 20: 630-637.\nHorning SJ, Chao NJ, Negrin RS. High-Dose therapy and autologous hematopoietic progenitor cell transplantation","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":263,"lines":{"from":28,"to":39}}}}],["1345",{"pageContent":"Horning SJ, Chao NJ, Negrin RS. High-Dose therapy and autologous hematopoietic progenitor cell transplantation\nfor recurrent or refractory Hodgkin’s disease. Analysis of the Stanford University results and prognostic indices.\nBlood. 1997; 89: 801-813.\nJones GL, Taylor PRA, Windebank KP, Hoye NA, Lucraft H, Wood K, et al. Outcome of a risk related therapeutic\nstrategy used prospectively in a population-based study of Hodgkin’s lymphoma in adolescents. Brit J Canc. 2007;\n97: 29-36.\nJosting A. Müller H, Borchmann, Baars JW. Dose intensity of chemotherapy in patients with relapse Hodgkin’s\nlymphoma. J Clin Oncol. 2012; 28: 5074-5080.\nKlimo P, Connors J. An update on the Vancouver experience in the management of advanced Hodgkin’s disease\ntreated with the MOPP/ABVD. Sem Hematol. 1988; 25(2): 34-40.\nKlimm B, Reineke T, Haverkamp H, Behringer K, Eich HT, Josting A, et al. Role of the hematotoxicity and sex in","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":263,"lines":{"from":39,"to":49}}}}],["1346",{"pageContent":"treated with the MOPP/ABVD. Sem Hematol. 1988; 25(2): 34-40.\nKlimm B, Reineke T, Haverkamp H, Behringer K, Eich HT, Josting A, et al. Role of the hematotoxicity and sex in\npatients with Hodgkin’ lymphoma: An analysis from the German Hodgkin Study Group. J Clin Oncol. 2005;\n23: 8003-8011.\nKüppers R. ¿e biology of Hodgkin’s lymphoma. Nat Rev Cancer. 2009; 9: 15-27.\nKraus-Weisman A, Ruiz-Argüelles GJ, et al. Estudios sobre linfomas. I. Frecuencia relativa de los linfomas en Mé-\nxico. Rev Invest Clin. 1980; 32: 179-186.\nLongo D, Young R, Uesley M, et al. Twenty years of MOPP therapy for Hodgkin disease. J Clin Oncol. 1986; 4:\n1295-1306.\nNational Comprehensive Cancer Network Guidelines. Practice Guidelines in Oncology. Hodgkin’s disease. NCCN. 2012.\nPavlovsky S. Progress in the treatment of Hodgkin’s disease in the last two decades: Implications for Latin America.\nSelected topics in the practice of hematology in Latin America. 28th World Congress. ISH. Aug. 30, 2000.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":263,"lines":{"from":49,"to":60}}}}],["1347",{"pageContent":"Selected topics in the practice of hematology in Latin America. 28th World Congress. ISH. Aug. 30, 2000.\nProsnitz L, Farber L, Kapp D, et al. Combined modality therapy for advanced Hodgkin disease: 15 years follow-up\ndata. J Clin Oncol. 1988; 6(4): 603-612.\nQuintanilla-Martínez L, Gamboa-Domínguez A, Godoy-Ledesma I. Association of Epstein-Barr virus latent mem\n-\nbrane protein and Hodgkin’s disease in Mexico. Modern Pathology. 1995; 8: 675-679.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":263,"lines":{"from":60,"to":65}}}}],["1348",{"pageContent":"237\n\nCAPÍTULO 16. LINFOMA DE HODGKIN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":264,"lines":{"from":1,"to":3}}}}],["1349",{"pageContent":"Ruiz-Argüelles GJ, Ruiz-Argüelles A, Pérez-Romano B, Marín-López A, Larregina-Díez A, Apreza-Molina MG.\nFilgrastim-mobilized peripheral-blood stem cells can be stored at 4 degrees and used in autografts to rescue high-\ndose chemotherapy. Am J Hematol. 1995; 48: 100-103.\nRuiz-Argüelles GJ, Gómez-Almaguer D, Apreza-Molina MG. Chemotherapy alone may be an efficient alternative\nin the treatment of early stage Hodgkin’s disease if optimal radiotherapy is not available. Leuk & Lymphoma.\n1997; 27: 179-183.\nRuiz-Argüelles GJ, López-Martínez B, López-Ariza B. Succesful allogeneic stem cell transplantation with non -\nmyeloablative conditioning in patients with relapsed Hodgkin’s disease following autologous stem cell trans -\nplantation. Arch Med Res. 2003; 34: 242-245.\nSaber M, Plutschow A, Jachimowitz RD. Baseline serum TARC levels predicts therapy outcome in patients with\nHodgkin’s lymphoma. Am J Hematol. 2013; 88: 113-115.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":264,"lines":{"from":5,"to":15}}}}],["1350",{"pageContent":"Saber M, Plutschow A, Jachimowitz RD. Baseline serum TARC levels predicts therapy outcome in patients with\nHodgkin’s lymphoma. Am J Hematol. 2013; 88: 113-115.\nSantoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine and vinorelbine for refractory and relapse Hodg-\nkin’s lymphoma. Haematologica. 2007; 92: 35-41.\nSoriano J, Lazos M, Rojo J, Manrique JJ, Herrera D. Enfermedad de Hodgkin en el Hospital General de México.\nEstudio de 309 casos. Sangre (Barc.). 1990; 35: 447-450.\nStraus D. Treatment of advanced Hodgkin disease. Hematology/Oncology Clinics of North America. 1989; 287-302.\nSutcliffe, Wrigley P, Peto J, et al. MOPP chemotherapy regimen for advanced Hodgkin disease. Br Med J. 1978; 1:\n679-83.\nSweetenham JW, Carella AM, Taghipour G, et al. High dose therapy and autologous stem cell transplantation for\nadult patients with Hodgkin’s disease who do not enter remission after induction chemotherapy. J Clin Oncol.\n1999; 17: 3101-3109.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":264,"lines":{"from":15,"to":26}}}}],["1351",{"pageContent":"adult patients with Hodgkin’s disease who do not enter remission after induction chemotherapy. J Clin Oncol.\n1999; 17: 3101-3109.\nTownsed W, Lynch D. Hodgkin’s lymphoma in adults. Lancet. 2012: 836-847.\n¿omas RK, Re D, Jürgen W, Diehl V. Hodgkin’s lymphoma molecular biology of Hodgkin and Reed-Sternberg\ncells. Part I. Hodgkin’s lymphoma: Diagnosis and treatment. Part II. Lancet Onc. 2004; 50: 11-26.\nWheeler C, Eickhoff C, Elias A. High dose cyclophosphamide, carmustine and etoposide with autologous transplan-\ntation in advanced Hodgkin’s disease. Biol Blood Marrow Transplant. 1998; 3: 98-10.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":264,"lines":{"from":26,"to":32}}}}],["1352",{"pageContent":"RESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\n1.\n \nc\n2.\n \nc\n3.\n \nb\n4.\n \nb\n5.\n \nb","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":264,"lines":{"from":34,"to":50}}}}],["1353",{"pageContent":"239\n\nINTRODUCCIÓN\n\nLa transformación maligna puede ocurrir en cualquier etapa de la maduración de los linfocitos. En\neste capítulo se describirán los padecimientos malignos que involucran a las células que se encuentran\nen la etapa final de diferenciación de los linfocitos B: las células plasmáticas y los linfocitos plasmo-\ncitoides. Las gammapatías monoclonales incluyen todas las enfermedades que se originan a partir\ndel linfocito B, caracterizadas por la producción de moléculas o fragmentos de inmunoglobulinas\nabsolutamente idénticas entre sí, y que se identifican en suero u orina en forma de una banda proteica\nllamada\n \ncomponente monoclonal\n.\n\nSinonimia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":266,"lines":{"from":1,"to":16}}}}],["1354",{"pageContent":"Sinonimia\n\nA las gammapatías monoclonales se les conoce también como\n \nenfermedades\n \no\n \n“ discrasias” de células plas-\nmáticas\n,\n \ninmunoglobulinopatías\n,\n \nparaproteinemias\n,\n \ndisproteinemias\n \ny\n \ndisglobulinemias\n. Las gammapatías\nmonoclonales incluyen: mieloma múltiple, la macroglobulinemia de Waldenström, las enfermedades\nde cadenas pesadas, las gammapatías monoclonales de significado indeterminado, la amiloidosis pri-\nmaria y la crioglobulinemia\n \n(cuadro 17-1)\n.\n\nESTRUCTURA DE LAS INMUNOGLOBULINAS\n\nComo\n \ninmunoglobulinas\n \n(Ig) se conocen las glucoproteínas que migran en la región\n \nγ\n \ndel corrimiento\nelectroforético y que poseen actividad de anticuerpo. Como se indica en la\nfigura 17-1\n, cada molécula de\ninmunoglobulina está formada por cuatro cadenas de polipéptidos: dos cadenas pesadas o cadenas H (del\ninglés\n \nheavy\n \n= pesada) y dos cadenas ligeras o cadenas L (del inglés\nlight\n \n= ligera) unidas entre sí por puentes\n\nCAPÍTULO 17\n\nGuillermo Ruiz Reyes\nAlejandro Ruiz Argüelles","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":266,"lines":{"from":16,"to":74}}}}],["1355",{"pageContent":"CAPÍTULO 17\n\nGuillermo Ruiz Reyes\nAlejandro Ruiz Argüelles\n\nObjetivos de aprendizaje\n\n•\n \nConocer la estructura de las inmunoglobulinas y los conceptos de\n \npoliclonalidad\n \ny\n \nmonoclonalidad\n.\n\n•\n \nDefinir los términos\n \nmieloma múltiple, macroglobulinemia de Waldenström\n \ny\n \namiloidosis\n.\n\n•\n \nComprender el método diagnóstico y los conceptos actuales del tratamiento del mieloma múltiple.\n\nTRASTORNOS\nINMUNOPROLIFERATIVOS\nMALIGNOS\n\nLas gammapatías monoclo-\nnales incluyen todas las en-\nfermedades que se originan a\npartir del linfocito B, carac-\nterizadas por la producción\nde moléculas o fragmentos de\ninmunoglobulinas\n \nabsoluta-\nmente idénticas entre sí, y que\nse identifican en suero u orina\nen forma de una banda pro-\nteica\n \nllamada\n \ncomponente\nmonoclonal.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":266,"lines":{"from":74,"to":128}}}}],["1356",{"pageContent":"240\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nCuadro 17-1.\n \nClasificación de las\n \ngammapatías monoclonales*\n\nMalignas\n\nMieloma múltiple: IgG, IgA, IgM, IgD, IgE y de cadenas ligeras (mieloma de Bence-Jones)\nLeucemias de células plasmáticas\nMieloma no secretor\nPlasmocitoma:\n\n•\n \nÁ-\u001f) -)&#.\u001b,#)\n•\n \n\u00052.,\u001b'\u001f\u001e/&\u001b,6 -)&#.\u001b,#) 3 'Ě&.#*&\u001f\n\nEnfermedades linfoproliferativas malignas\nMacroglobulinemia de Waldenström\nLinfoma maligno\nEnfermedades de cadenas pesadas:\n\nγ\nα\nμ\nδ\n\nAmiloidosis:\n\n•\n \n\u0010,#'\u001b,#\u001b\n•\n \n\u0003)( '#\u001f&)'\u001b\n\nDe significado indeterminado\n\nBenignas IgG, IgA, IgM, IgD e, infrecuentemente, de cadenas\nligeras o cadenas pesadas\n \nγ\n\nAsociadas a neoplasias de células no productoras de proteínas\nmonoclonales\nGammapatías biclonales\n* De Kyle y Greipp, ligeramente modificada.\n\nFigura 17-1.\n \nLa molécula de inmunoglobulina que se representa está formada por cuatro cadenas de poli-\npéptidos: dos cadenas pesadas (H) y dos ligeras (L), unidas entre sí por puentes disulfuro.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":267,"lines":{"from":1,"to":59}}}}],["1357",{"pageContent":"241\n\nCAPÍTULO 17. TRASTORNOS INMUNOPROLIFERATIVOS MALIGNOS\n\n\u001e#-/& /,)8 \u00052#-.\u001f( \u001d#(\u001d) \u001d&\u001b-\u001f- \u001e\u001f #('/()!&)\u001c/&#(\u001b- +/\u001f \u001e#̑\u001f,\u001f(\n \n\u001f( &\u001b -\u001f\u001d/\u001f(\u001d#\u001b \u001e\u001f \u001b'#()á\u001d#\u001e)- \u001e\u001f -/- \u001d\u001b\u001e\u001f\n-\nnas pesadas (H) y en su disposición estructural, lo que les otorga funciones propias. Las diversas cadenas H se\ndesignan como\n \nγ\n,\n \nα\n,\n \nμ\n,\n \nδ\n \ny\n \n¡\n, y corresponden a las cinco clases de inmunoglobulinas: IgG, IgA, IgM, IgD e\n\n!\u00058\n \n\u001b\n \n!\u0007 .#\u001f(\u001f \u001d/\u001b.,) -/\u001c\u001d&\u001b-\u001f-9\n \n!\u0007g6\n \n!\u0007h6\n \n!\u0007i \u001f\n \n!\u0007j6 3 &\u001b\n \n!\u00016 \u001e)-9\n \n!\u0001g \u001f\n \n!\u0001h8 \u0013)&) \u001f2#-.\u001f( \u001e)-\n\ntipos de cadenas ligeras:\n \ng\n \ny\n\u0003h\n.\n\n\u001b-\n \n!\u0007 \u001f2#-.\u001f( \u001d)') ')(ĉ'\u001f,)- \u001d)( *\u001f-) ')&\u001f\u001d/&\u001b, \u001e\u001f gkf̓fff \u0004\u001b8 \u0013)( ,\u001f-*)(-\u001b\u001c&\u001f- \u001e\u001f &\u001b ,\u001f-*/\u001f-.\u001b\n\ninmunitaria secundaria y de la formación de anticuerpos precipitantes, anticuerpos que neutralizan virus,\nhemaglutininas, hemolisinas y activadores de la vía clásica del complemento.\n\n\u001b\n \n!\u0001 \u001b '\u001f(/\u001e) \u001f2#-.\u001f \u001d)') \u001eù'\u001f,) 3 \u001f- /(\u001b ')&ï\u001d/&\u001b &#!\u001f,\u001b'\u001f(.\u001f 'á- !,\u001b(\u001e\u001f Bgnf̓fff\n \n\u0004\u001bC +/\u001f &\u001b","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":268,"lines":{"from":1,"to":67}}}}],["1358",{"pageContent":"\u001b\n \n!\u0001 \u001b '\u001f(/\u001e) \u001f2#-.\u001f \u001d)') \u001eù'\u001f,) 3 \u001f- /(\u001b ')&ï\u001d/&\u001b &#!\u001f,\u001b'\u001f(.\u001f 'á- !,\u001b(\u001e\u001f Bgnf̓fff\n \n\u0004\u001bC +/\u001f &\u001b\n\nIgG. Se sintetiza en las células plasmáticas del epitelio de los aparatos respiratorio y digestivo, propor-\ncionando la primera línea de defensa en las mucosas.\n\n\u001b\n \n!\n \n\u001f- &\u001b #('/()!&)\u001c/&#(\u001b \u001d)( '\u001b3), *\u001f-) ')&\u001f\u001d/&\u001b, Boff̓fff̓ \u0004\u001bC\n \n3 \u001d\u001b\u001e\u001b ')&ï\u001d/&\u001b \u001f-.á ),'\u001b\u001e\u001b\n*), \u001d#(\u001d) -/\u001c/(#\u001e\u001b\u001e\u001f- #\u001eï(.#\u001d\u001b- \u001e\u001f gnf̓ fff̓ \u0004\u001b\n \n\u001d\u001b\u001e\u001b /(\u001b8\n \n\u001b- #('/()!&)\u001c/&#(\u001b-\n \n-)( &\u001b- *,#'\u001f,\u001b-\n\nen producirse en la respuesta inmunitaria primaria.\n\n\u001b !\u0004 \u001f- /( ')(ĉ'\u001f,) \u001d)( *\u001f-) ')&\u001f\u001d/&\u001b, \u001e\u001f gjf̓fff̓\u0004\u001b8\n \n\u0005( \u001f& -/\u001f,) -)&) -\u001f #\u001e\u001f(.#̑\u001d\u001b(\n \n0\u001f-.#!#)- \u001e\u001f \u001f&&\u001b8\n\nSe encuentra en la superficie de los linfocitos, donde parece desempeñar funciones de activación y supresión.\n\n\u001b\n \n!\u0005 \u001f- .\u001b'\u001c#ï( /( ')(ĉ'\u001f,) \u001d)( *\u001f-) ')&\u001f\u001d/&\u001b, \u001e\u001f hff̓fff̓\u0004\u001b6\n \n*,\u001f-\u001f(.\u001f \u001f( \u001d\u001b(.#\u001e\u001b\u001e\u001f- ù(̑'\u001b-\n \n\u001f(","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":268,"lines":{"from":67,"to":107}}}}],["1359",{"pageContent":"\u001b\n \n!\u0005 \u001f- .\u001b'\u001c#ï( /( ')(ĉ'\u001f,) \u001d)( *\u001f-) ')&\u001f\u001d/&\u001b, \u001e\u001f hff̓fff̓\u0004\u001b6\n \n*,\u001f-\u001f(.\u001f \u001f( \u001d\u001b(.#\u001e\u001b\u001e\u001f- ù(̑'\u001b-\n \n\u001f(\n\nel suero. Es responsable de la reacción de tipo reagínico. Se fija a los receptores de las células cebadas (masto-\ncitos) y de los basófilos, y es mediadora de las reacciones alérgicas y de la respuesta a infecciones parasitarias.\n\nCONCEPTOS DE POLICLONALIDAD Y MONOCLONALIDAD\n\nLas inmunoglobulinas del suero y otros líquidos orgánicos pueden separarse de otras proteínas por sus di-\nferencias en peso y carga cuando se las somete a la acción de un campo eléctrico; este proceso se denomina","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":268,"lines":{"from":107,"to":121}}}}],["1360",{"pageContent":"electroforesis\n. En este procedimiento se deposita la muestra por analizar en un medio de soporte sobre el\ncual se aplica corriente eléctrica; al cabo de cierto tiempo, las proteínas y diferentes componentes proteicos\nse habrán separado. Se tiñe el medio de soporte, se transparenta y se integra por medio de densitometría,\nobteniéndose la silueta que se ilustra en la\n \nfigura 17-2\n. Dicha silueta se denomina\n \nelectroforograma de pro-\nteínas\n \no\n \nproteinograma\n, y representa las distintas fracciones proteicas del suero, que en condiciones norma-\nles son: albúmina y globulina\n \nα\n1,\n \nα\n2,\n \nβ\n \ny\n \nγ\n. Conviene recordar que los estímulos antigénicos condicionan\nla diferenciación de diversas clonas de células plasmáticas productoras de inmunoglobulinas, que en el\nproteinograma se traducen por la formación, en la región\n \nγ\n, de un componente de base ancha, densidad\ndifusa y altura mediana. Dicho componente refleja un aumento de diversas clonas, cada una de las cuales","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":268,"lines":{"from":123,"to":158}}}}],["1361",{"pageContent":"γ\n, de un componente de base ancha, densidad\ndifusa y altura mediana. Dicho componente refleja un aumento de diversas clonas, cada una de las cuales\nproduce un tipo específico de inmunoglobulina que configura, por su heterogeneidad, lo que se conoce","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":268,"lines":{"from":158,"to":161}}}}],["1362",{"pageContent":"Figura 17-2.\n \nInmunofijación de las inmunoglobulinas séricas. En el primer carril (ELP) aparece el elec -\ntroforograma del suero y en los siguientes la precipitación con sueros específicos contra cadenas pesadas (\nγ\nα\n \ny\n \nμ\n) y ligeras (\ng\n \ny\n \nh\n). Las flechas señalan la precipitación de cadenas H y L, lo que indica que la proteína\ninvolucrada es del isotipo IgGl.\n\nCada molécula de inmunoglo-\nbulina está formada por cuatro\ncadenas de polipéptidos: dos ca-\ndenas pesadas o cadenas H (del\ninglés\n \nheavy\n \n= pesadas) y dos\ncadenas ligeras o cadenas L (del\ninglés\n \nlight\n \n= ligera) unidas en\n-\ntre sí por puentes disulfuro.\nLas\n \ninmunoglobulinas\n \ndel\nsuero y otros líquidos orgáni-\ncos pueden separarse de otras\nproteínas por sus diferencias\nen peso y carga cuando se las\nsomete a la acción de un campo\neléctrico; este proceso se deno-\nmina\n \nelectroforesis.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":268,"lines":{"from":163,"to":212}}}}],["1363",{"pageContent":"242\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\ncomo\n \nbanda policlonal\n; esta se encuentra principalmente en hepatopatías, lupus eritematoso generalizado\n\n\u001f #( \u001f\u001d\u001d#)(\u001f- \u001d,ĉ(#\u001d\u001b-8 \u0003/\u001b(\u001e) )\u001d/,,\u001f &\u001b \u001f2*\u001b(-#ĉ( (\u001f)*&á-#\u001d\u001b \u001e\u001f /(\u001b \u001d&)(\u001b \u00026 -\u001f !\u001f(\u001f,\u001b( #('/()!&)\n-\nbulinas idénticas entre sí que se identifican en el proteinograma porque tienen carga eléctrica igual y,\npor lo tanto, motilidad electroforética homogénea y simétrica; estas últimas forman un pico alto, de base\nestrecha y gran densidad, que se designa como\n \nbanda\n \no\n \ncomponente monoclonal\n; también se conoce como\n\ncomponente “M”\n \no\n \nparaproteína\n. La\n \nfigura 17-3\n \nmuestra ejemplos de los patrones electroforéticos aludidos.\nPara identificar la variedad inmunológica de las gammapatías monoclonales, es preciso recurrir al estudio\ninmunoelectroforético de las cadenas pesadas y ligeras de las inmunoglobulinas.\n\nMIELOMA MÚLTIPLE\n\nSe desconoce la etiología del mieloma múltiple, pero algunos factores han sido asociados con el pade -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":269,"lines":{"from":1,"to":38}}}}],["1364",{"pageContent":"MIELOMA MÚLTIPLE\n\nSe desconoce la etiología del mieloma múltiple, pero algunos factores han sido asociados con el pade -\n\n\u001d#'#\u001f(.)6 *), \u001f$\u001f'*&)9 ,\u001b\u001e#\u001b\u001d#)(\u001f- #)(#4\u001b(.\u001f-6 #( \u001f\u001d\u001d#)(\u001f- 0#,\u001b&\u001f- 3 \u001b!\u001f(.\u001f- .ĉ2#\u001d)-8 \u0014\u001b'\u001c#ï( -\u001f \"\u001b(\n\nimplicado factores genéticos. El número de casos de mieloma se ha incrementado en los últimos años,\nposiblemente porque los estudios de médula ósea y la electroforesis de las proteínas del suero se prac -\n\n.#\u001d\u001b( \u001d)( '\u001b3),\n \n,\u001f\u001d/\u001f(\u001d#\u001b8 \u0005( \u0005-.\u001b\u001e)- \u0015(#\u001e)-6 \u001f& '#\u001f&)'\u001b 'Ě&.#*&\u001f \u001d)(-.#./3\u001f \u001f& gfz \u001e\u001f .)\u001e\u001b- &\u001b-\n\u001f( \u001f,'\u001f\u001e\u001b\u001e\u001f- \"\u001f'á.#\u001d\u001b- '\u001b&#!(\u001b- 3 \u001f(\n \nï2#\u001d) \u001f-.\u001b \u001d# ,\u001b -\u001f ,\u001f\u001e/\u001d\u001f \u001b i6mz8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":269,"lines":{"from":38,"to":52}}}}],["1365",{"pageContent":".#\u001d\u001b( \u001d)( '\u001b3),\n \n,\u001f\u001d/\u001f(\u001d#\u001b8 \u0005( \u0005-.\u001b\u001e)- \u0015(#\u001e)-6 \u001f& '#\u001f&)'\u001b 'Ě&.#*&\u001f \u001d)(-.#./3\u001f \u001f& gfz \u001e\u001f .)\u001e\u001b- &\u001b-\n\u001f( \u001f,'\u001f\u001e\u001b\u001e\u001f- \"\u001f'á.#\u001d\u001b- '\u001b&#!(\u001b- 3 \u001f(\n \nï2#\u001d) \u001f-.\u001b \u001d# ,\u001b -\u001f ,\u001f\u001e/\u001d\u001f \u001b i6mz8\n\nFigura 17-3.\n \nEl proteinograma superior esquematiza un incremento policlonal en la región\n \nγ\n, de base\nancha, densidad difusa y altura mediana, que refleja el aumento de diversas clonas de células plasmáticas,\ncada una de las cuales sintetiza un tipo distinto de inmunoglobulina. El proteinograma inferior corres-\nponde al estudio electroforético de una gammapatía monoclonal que se traduce por la formación de una\n\n\u001c\u001b(\u001e\u001b \")')!ï(\u001f\u001b6 !\u001f(\u001f,\u001b&'\u001f(.\u001f \u001b&.\u001b6 \u001e\u001f \u001c\u001b-\u001f \u001b(!)-.\u001b6 *,)\u001e/\u001d#\u001e\u001b *), &\u001b \u001f2*\u001b(-#ĉ( '\u001b&#!(\u001b \u001e\u001f /(\u001b \u001d&)(\u001b \u00026\n\nproductora de inmunoglobulinas idénticas que se identifican en el proteinograma por tener carga eléctrica\nigual. Este componente se designa como c\nomponente monoclonal\n \no “M”.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":269,"lines":{"from":52,"to":75}}}}],["1366",{"pageContent":"productora de inmunoglobulinas idénticas que se identifican en el proteinograma por tener carga eléctrica\nigual. Este componente se designa como c\nomponente monoclonal\n \no “M”.\n\nEl número de casos de mielo-\nma se ha incrementado en los\núltimos años, tal vez porque\nlos estudios de médula ósea y\nla electroforesis de las proteí-\nnas del suero se practican con\nmayor frecuencia. En Estados\nUnidos, el mieloma múltiple\nconstituye el 10% de todas las\nenfermedades hemáticas ma-\nlignas y en México esta cifra\nse reduce a 3,7% .","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":269,"lines":{"from":75,"to":92}}}}],["1367",{"pageContent":"243\n\nCAPÍTULO 17. TRASTORNOS INMUNOPROLIFERATIVOS MALIGNOS\n\nPatogenia\n\nLas manifestaciones clínicas en el mieloma múltiple derivan de la proliferación incontrolable de las cé-\nlulas plasmáticas que causan: 1) desplazamiento del tejido hematopoyético normal de la médula ósea y,\nen consecuencia, anemia, leucopenia, granulocitopenia y plaquetopenia; 2) destrucción de los huesos;\n3) deficiencias inmunitarias y, por lo tanto, mayor susceptibilidad a infecciones; 4) sobreproducción de\ninmunoglobulinas, que a su vez ocasiona hiperviscosidad de la sangre, crioglobulinemia, amiloidosis e\n\n#(.\u001f, \u001f,\u001f(\u001d#\u001b \u001d)( &)- *,)\u001d\u001f-)- (),'\u001b&\u001f- \u001e\u001f &\u001b \u001d)\u001b!/&\u001b\u001d#ĉ(: 3 kC \u001f2\u001d,\u001f\u001d#ĉ( \u001e\u001f \u001d\u001b\u001e\u001f(\u001b- &#!\u001f,\u001b- *), \u001f& ,#Ąĉ(6\n\nque contribuye a la producción de insuficiencia renal.\n\nCuadro clínico\n\n\u0005- /( *\u001b\u001e\u001f\u001d#'#\u001f(.) \u001e\u001f &\u001b \u001f\u001e\u001b\u001e \u001b\u001e/&.\u001b6 *)\u001d\u001b- 0\u001f\u001d\u001f- )\u001c-\u001f,0\u001b\u001e) \u001f( '\u001f(),\u001f- \u001e\u001f jf \u001bĄ)-: \"\u001b\u001c#./\u001b&'\u001f(.\u001f 0#\u001f(\u001f","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":270,"lines":{"from":1,"to":19}}}}],["1368",{"pageContent":"Cuadro clínico\n\n\u0005- /( *\u001b\u001e\u001f\u001d#'#\u001f(.) \u001e\u001f &\u001b \u001f\u001e\u001b\u001e \u001b\u001e/&.\u001b6 *)\u001d\u001b- 0\u001f\u001d\u001f- )\u001c-\u001f,0\u001b\u001e) \u001f( '\u001f(),\u001f- \u001e\u001f jf \u001bĄ)-: \"\u001b\u001c#./\u001b&'\u001f(.\u001f 0#\u001f(\u001f\n\nprecedido por un período asintomático de duración variable. La mayoría de los enfermos sufren manifes-\ntaciones óseas caracterizadas por dolor en los huesos de intensidad variable (lo que a menudo se confunde\ncon “reumatismo”), deformidades óseas y fracturas patológicas. Estas últimas con frecuencia son la ma-\nnifestación inicial de la entidad. Los aplastamientos vertebrales pueden causar disminución de la estatura\ndebido a que la enfermedad afecta la columna dorsolumbar. Radiológicamente se encuentran múltiples\nlesiones osteolíticas, sin esclerosis peritumoral, sobre todo en los huesos del cráneo. En la columna verte-\nbral se hallan aplastamientos vertebrales y los huesos largos afectados suelen ser el sitio donde ocurren las\nfracturas patológicas. La osteoporosis generalizada con frecuencia es una manifestación de mieloma. Del","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":270,"lines":{"from":19,"to":30}}}}],["1369",{"pageContent":"h \u001b& gfz\n \nde los enfermos presentan tumores óseos solitarios de aspecto quístico\n \n(figs. 17-4 y 17-5)\n, como\npompas de jabón, más grandes e irregulares que las lesiones del mieloma múltiple; estos tumores antes se\nconsideraban benignos, pero su evolución debe vigilarse. Un número importante de pacientes sufre mani-\nfestaciones neurológicas de tipo radicular e intercostal, así como paraplejías y dolores de tipo ciático, casi\nsiempre secundarios a la compresión de la médula por algún aplastamiento vertebral.\nAlrededor de la mitad de los sujetos con mieloma padecen insuficiencia renal y es común que acudan\nal médico por esta razón. Su causa más frecuente es la eliminación de las cadenas ligeras de las inmu-\nnoglobulinas (proteína de Bence-Jones). Sin embargo, otros factores que contribuyen a la disfunción\nrenal son hipercalcemia, deshidratación, hiperuricemia y amiloidosis. En estos enfermos la urografía","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":270,"lines":{"from":32,"to":45}}}}],["1370",{"pageContent":"\u001f2\u001d,\u001f.),\u001b \u001f- \u001e\u001f-\u001b\u001d)(-\u001f$\u001b\u001c&\u001f6 */\u001f- */\u001f\u001e\u001f \u001e\u001f-\u001f(\u001d\u001b\u001e\u001f(\u001b, #(-/̑\u001d#\u001f(\u001d#\u001b\n \n,\u001f(\u001b& \u001b!/\u001e\u001b8 \u0010), &\u001b '#-'\u001b ,\u001b4ĉ(6 ()\n\u001e\u001f\u001c\u001f( /.#&#4\u001b,-\u001f \u001b(.#\u001c#ĉ.#\u001d)- (\u001f ,).ĉ2#\u001d)-8 \u0012\u001f-/&.\u001b \"\u001b\u001c#./\u001b& /(\u001b '\u001b3), -/-\u001d\u001f*.#\u001c#&#\u001e\u001b\u001e \u001b &\u001b- #( \u001f\u001d\u001d#)(\u001f-6\n\nFigura 17-4.\n \nRadiografía de cráneo que muestra las lesiones osteolíticas características del mieloma múltiple.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":270,"lines":{"from":47,"to":54}}}}],["1371",{"pageContent":"244\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nparticularmente por neumococo y gérmenes gramnegativos, y se debe a una disminución de las inmuno-\nglobulinas no involucradas en el padecimiento y a otros factores asociados.\nEl síndrome de hiperviscosidad ocurre en particular en los mielomas IgA, debido a la polimerización\nde las moléculas de esta inmunoglobulina, y determina: 1) hemorragias, principalmente de las mucosas;\n2) trastornos visuales con dilatación y segmentación de los vasos de la retina (vasos “en salchicha”), hemo-\nrragia y a veces edema de la papila; 3) manifestaciones neurológicas como cefalea, vértigo, somnolencia,\n\n\u001f-./*), 3 \u001d)'\u001b: jC \u001e#-.\u001f(-#ĉ( \u001e\u001f 0\u001f(\u001b- 3 &\u001f\u001d\")- \u001d\u001b*#&\u001b,\u001f-6 \u001d)( \u001f\u001e\u001f'\u001b *\u001f,# ï,#\u001d): 3 kC \u001e#-(\u001f\u001b \u001f #(-/̑\u001d#\u001f(\u001d#\u001b\n\u001d\u001b,\u001eù\u001b\u001d\u001b \u001d)(!\u001f-.#0\u001b8 \u0001&!/()- *\u001b\u001d#\u001f(.\u001f- -/ ,\u001f( -\u001f(-#\u001c#&#\u001e\u001b\u001e \u001f2\u001b!\u001f,\u001b\u001e\u001b \u001b&\n \n,ù)8\n \n\u001b *,\u001f\u001d#*#.\u001b\u001d#ĉ( #,,\u001f0\u001f,-#\u001c&\u001f","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":271,"lines":{"from":1,"to":17}}}}],["1372",{"pageContent":"de las inmunoglobulinas anormales a baja temperatura ocasiona urticaria al frío, acrocianosis, prurito,\nadormecimiento y fenómeno de Raynaud, y puede conducir a trombosis y gangrena de los dedos.\nLas manifestaciones hemorrágicas se deben ya sea a plaquetopenia o a interacción de la proteína mo-\nnoclonal hiperproducida con las proteínas de la coagulación y las propias plaquetas, o bien a ambas cosas.\n\nHallazgos de laboratorio\n\nLa mayoría de los enfermos de mieloma sufren anemia de grado variable, normocítica normocrómica. El\n\n\u001f2\u001b'\u001f( \u001e\u001f &)- \u001f2.\u001f(\u001e#\u001e)- \u001e\u001f -\u001b(!,\u001f \u001e\u001f-\u001d/\u001c,\u001f &\u001b .\u001f(\u001e\u001f(\u001d#\u001b \u001e\u001f &)- \u001f,#.,)\u001d#.)- \u001b \u001b!,/*\u001b,-\u001f \u001f( ^*#&\u001b- \u001e\u001f ')(\u001f\u001e\u001b-_\n\no\n \nrouleaux\n. Este fenómeno y la eritrosedimentación acelerada se deben a la hiperproteinemia y se observan\nen tres de cada cuatro pacientes con mieloma. En ocasiones se aprecian en la sangre linfocitos inmaduros y","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":271,"lines":{"from":19,"to":34}}}}],["1373",{"pageContent":"\u001dï&/&\u001b- *&\u001b-'á.#\u001d\u001b- \u001b(),'\u001b&\u001f-8 \u0003/\u001b(\u001e) \u001f-.\u001b- Ě&.#'\u001b- *,\u001f\u001e)'#(\u001b( *), \u001b,,#\u001c\u001b \u001e\u001f h̓f ffI''\n3\n \n, el padecimiento\nse conoce como\n \nleucemia de células plasmáticas\n. La médula ósea muestra infiltración de células plasmáticas\n\n*), \u001b,,#\u001c\u001b \u001e\u001f& gkz6 &\u001b- \u001d/\u001b&\u001f- '/\u001d\"\u001b- 0\u001f\u001d\u001f- .#\u001f(\u001f( \u001b*\u001b,#\u001f(\u001d#\u001b '\u001b&#!(\u001b: \u001b&!/(\u001b- -)( '/&.#(/\u001d&\u001f\u001b\u001e\u001b- 3 *)-\u001f\u001f(\n\ngrandes nucléolos\n \n(fig. 17-6)\n8 \u0015( \u001f-./\u001e#) \u001e\u001f 'ï\u001e/&\u001b ĉ-\u001f\u001b (\u001f!\u001b.#0) () \u001f2\u001d&/3\u001f \u001f& \u001e#\u001b!(ĉ-.#\u001d)6 */\u001f- &\u001b 'ï\u001e/&\u001b\n\nresulta afectada en forma focal. En tales casos está indicado puncionar otro sitio u otros más.\n\n\u0005& \u001f-./\u001e#) \u001f&\u001f\u001d.,) ),ï.#\u001d) \u001e\u001f &\u001b- *,).\u001fù(\u001b- (/(\u001d\u001b \u001e\u001f\u001c\u001f )'#.#,-\u001f8 \u0014#\u001f(\u001f '/\u001d\"\u001b #'*),.\u001b(\u001d#\u001b \u001f( \u001f& \u001e#\u001b!(ĉ-\n-\ntico para identificar el componente monoclonal de sangre u orina, o ambas, característico de la enfermedad.\n\nFigura 17-5.\n \nRadiografía de pelvis que permite ver las lesiones osteolíticas\ncaracterísticas del mieloma múltiple.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":271,"lines":{"from":36,"to":61}}}}],["1374",{"pageContent":"Figura 17-5.\n \nRadiografía de pelvis que permite ver las lesiones osteolíticas\ncaracterísticas del mieloma múltiple.\n\nLa mayoría de los enfermos\nde mieloma sufren anemia de\ngrado variable, normocítica\nnormocrómica. El examen de\nlos extendidos de sangre des-\ncubre la tendencia de los eri-\ntrocitos a agruparse en “pilas\nde monedas” o\n \n,)/&\u001f\u001b/28","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":271,"lines":{"from":61,"to":75}}}}],["1375",{"pageContent":"245\n\nCAPÍTULO 17. TRASTORNOS INMUNOPROLIFERATIVOS MALIGNOS\n\n\u0005& \u001f-./\u001e#) #('/()\u001f&\u001f\u001d.,) ),ï.#\u001d) \u001e\u001f -/\u001f,) 3 ),#(\u001b \u001d)'*&\u001f'\u001f(.\u001b \u001f& \u001f2\u001b'\u001f( \u001f&\u001f\u001d.,) ),ï.#\u001d)6 *\u001f,'#.\u001f ,\u001b.#̑\u001d\u001b,\n\ny, no pocas veces, establecer el diagnóstico, así como clasificar la variedad inmunológica del mieloma.\n\n\u0005& \u001f2\u001b'\u001f( \u001e\u001f ),#(\u001b\n \n,\u001f\u001d/\u001f(.\u001f'\u001f(.\u001f \u001e\u001f'/\u001f-.,\u001b *,).\u001f#(/,#\u001b6 +/\u001f */\u001f\u001e\u001f \u001e\u001f\u001c\u001f,-\u001f \u001b &\u001b \u001f2\u001d,\u001f\u001d#ĉ( \u001e\u001f \u001d\u001b\u001e\u001f\n-\nnas ligeras de inmunoglobulinas (proteína de Bence-Jones) o de otras proteínas del suero, particularmente\nalbúmina, secundaria a la lesión renal. En el sedimento urinario es posible encontrar cilindros hialinos y\nevidencia de degeneración tubular renal caracterizada por presencia de células del epitelio tubular incluidas\nen cilindros hialinos. La hiperuricemia e hipercalcemia señalan destrucción de los huesos. Las elevaciones\ndel nitrógeno ureico y de la creatinina son indicativas de la insuficiencia renal que complica al padecimiento.\n\nDiagnóstico","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":272,"lines":{"from":1,"to":19}}}}],["1376",{"pageContent":"Diagnóstico\n\nLa combinación de la información clínica y los datos de laboratorio establece el diagnóstico. Idealmente, cuan\n-\ndo la enfermedad se sospecha debe solicitarse al laboratorio: 1) citometría hemática completa; 2) mielograma\n\n3 \u001c#)*-#\u001b \u001e\u001f 'ï\u001e/&\u001b ĉ-\u001f\u001b: iC \u001f-./\u001e#) \u001f&\u001f\u001d.,) ),ï.#\u001d) \u001e\u001f &\u001b- *,).\u001fù(\u001b- \u001e\u001f& -/\u001f,): jC #('/()̑$\u001b\u001d#ĉ(\n \n\u001f( \u001f& -/\u001f,): kC\n\u001d/\u001b(.#̑\u001d\u001b\u001d#ĉ(\n \n\u001e\u001f #('/()!&)\u001c/&#(\u001b- \u001f( \u001f& -/\u001f,): lC \u001d/\u001b(.#̑\u001d\u001b\u001d#ĉ(\n \n\u001e\u001f &\u001b- *,).\u001fù(\u001b- /,#(\u001b,#\u001b-: mC \u001f&\u001f\u001d.,) ),\u001f-#- \u001e\u001f\n&\u001b- *,).\u001fù(\u001b- \u001e\u001f &\u001b ),#(\u001b: nC #('/()̑$\u001b\u001d#ĉ(\n \n\u001f( ),#(\u001b \u001e\u001f hj \"),\u001b- \u001d)(\u001d\u001f(.,\u001b\u001e\u001b: 3 oC ,\u001b\u001e#)!,\u001b ù\u001b- \u001e\u001f& \u001f-+/\u001f&\u001f.)8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":272,"lines":{"from":19,"to":35}}}}],["1377",{"pageContent":"Otros estudios de laboratorio útiles en el curso del padecimiento incluyen: la determinación de microglo\n-\nbulina\n \nβ\n2 en el suero, cuyos niveles se incrementan en proporción a la masa tumoral y contribuyen a establecer\nel pronóstico; y las pruebas de funcionamiento renal y la viscosidad del suero. Esta última deberá llevarse a\ncabo cuando los niveles del componente monoclonal, en el caso de los mielomas IgG e IgA, sean mayores","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":272,"lines":{"from":37,"to":44}}}}],["1378",{"pageContent":"\u001e\u001f j6f̓!I\u001e\n \n6 ) -/*\u001f,#),\u001f- \u001b i6f !I\u001e\n \n\u001f( \u001b+/\u001f&&)- \u001e\u001f !\n \n8 \u0005& -ù(\u001e,)'\u001f \u001e\u001f \"#*\u001f,0#-\u001d)-#\u001e\u001b\u001e ,\u001b,\u001b 0\u001f4 )\u001d/,,\u001f *),\n\u001b\u001c\u001b$) \u001e\u001f j̓\u001d\u001f(.#*)#-\u001f-6 /(#\u001e\u001b\u001e \u001e\u001f '\u001f\u001e#\u001e\u001b \u001e\u001f &\u001b 0#-\u001d)-#\u001e\u001b\u001e8\n\u0005( \u001e#0\u001f,-)- \u001f-./\u001e#)- -\u001f \"\u001b \u001e\u001f')-.,\u001b\u001e) +/\u001f \u001f& gffz \u001e\u001f &)- *\u001b\u001d#\u001f(.\u001f- \u001d)( '#\u001f&)'\u001b 'Ě&.#*&\u001f \u001e\u001f \u001d\u001b\u001e\u001f(\u001b-\n&#!\u001f,\u001b- B\u0002\u001f(\u001d\u001f7 )(\u001f-C6 \u001f& nhz \u001e\u001f \u001b+/\u001f&&)- \u001d)( '#\u001f&)'\u001b 'Ě&.#*&\u001f () -\u001f\u001d,\u001f.),6 'á- \u001e\u001f& onz \u001e\u001f &)- *\u001b\u001d#\u001f(.\u001f- \u001d)(\n\u001b'#&)#\u001e)-#- 3 \u001f& olz \u001e\u001f &)- \u001d\u001b-)- \u001e\u001f '#\u001f&)'\u001b 'Ě&.#*&\u001f \u001d)( #('/()!&)\u001c/&#(\u001b- #(.\u001b\u001d.\u001b-6 .#\u001f(\u001f( \u001d)(\u001d\u001f(.,\u001b\u001d#)\n-\nnes anormales de cadenas ligeras libres en el suero. La elevada sensibilidad nosográfica y la utilidad clínica\nde esta determinación permiten obviar en forma definitiva la detección de cadenas ligeras en orina en la gran\nmayoría de los pacientes con gammapatías monoclonales. Adicionalmente, el cociente de la concentración\nde cadenas ligeras en suero ha sido identificado como un factor independiente de riesgo para la progresión","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":272,"lines":{"from":46,"to":61}}}}],["1379",{"pageContent":"de cadenas ligeras en suero ha sido identificado como un factor independiente de riesgo para la progresión\nhacia mieloma múltiple en pacientes con gammapatía monoclonal de significado indeterminado. Esta deter-\nminación se realiza por métodos inmunonefelométricos. La identificación de cadenas ligeras libres en orina\npor métodos fisicoquímicos debe abandonarse.\nEl estudio inmunofenotípico por citometría de flujo es de particular utilidad en pacientes con masa\ntumoral baja, principalmente después de recibir tratamiento. Las células plasmáticas malignas son","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":272,"lines":{"from":61,"to":66}}}}],["1380",{"pageContent":"Figura 17-6.\n \n\u00052.\u001f(\u001e#\u001e) \u001e\u001f 'ï\u001e/&\u001b ĉ-\u001f\u001b \u001e\u001f /( *\u001b\u001d#\u001f(.\u001f \u001d)( '#\u001f&)'\u001b 'Ě&.#*&\u001f +/\u001f '/\u001f-.,\u001b \u001dï&/&\u001b- *&\u001b-'á\n-\nticas anormales, algunas de ellas binucleadas.\n\nEl examen de orina frecuen-\ntemente\n \ndemuestra\n \nprotei-\nnuria, que puede deberse a la\nexcreción de cadenas ligeras de\ninmunoglobulinas\n \n(proteína\nde Bence-Jones) o de otras pro-\nteínas del suero, en particular\nalbúmina, secundaria a la le-\nsión renal.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":272,"lines":{"from":68,"to":88}}}}],["1381",{"pageContent":"246\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\n#\u001e\u001f(.#l·\u001d\u001b\u001c&\u001f- *), &\u001b \u001f2*,\u001f-#ĉ( #(.\u001f(-\u001b \u001e\u001f& \u001b(.ù!\u001f() \u0003\u0004in 3 .\u001f(/\u001f \u001e\u001f &)- \u001b(.ù!\u001f()- \u0003\u0004go 3 \u0003\u0004jk8 \u0005(\n)\u001d\u001b-#)(\u001f-6 .\u001b'\u001c#ï( \u001d)\u001f2*,\u001f-\u001b( \u001f(\n \n),'\u001b \u001b\u001c\u001f,,\u001b(.\u001f \u001b(.ù!\u001f()- \u001e\u001f& &#(\u001b$\u001f \u000e\n \n8\n \n\u001b\n \nfigura 17-7\n \nmuestra\nun ejemplo de células plasmáticas malignas en una médula ósea en recuperación. En el\n \ncuadro 17-2\n \nse\npresentan los criterios diagnósticos del mieloma múltiple.\n\nClasificación de la inmunoglobulina monoclonal","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":273,"lines":{"from":1,"to":24}}}}],["1382",{"pageContent":"Para conocer el tipo de cadena pesada y ligera de la inmunoglobulina monoclonal, se utiliza la inmunofija-\nción. En esta técnica se emplea una matriz de agarosa para separar las proteínas del suero por electroforesis\nconvencional de alta resolución y, en un segundo paso, las cadenas pesadas y ligeras se precipitan mediante\nel empleo de sueros policlonales monoespecíficos. La banda de precipitación correspondiente a la cadena pe-\nsada y ligera, además de que es muy abundante, coincide en su morfología y posición con el del componente\nM. La\n \nfigura 17-8\n \nilustra esta técnica que, además, ha sustituido a la inmunoelectroforesis convencional.\nEn los enfermos con hiperproteinemia y en aquellos con mieloma IgA, es pertinente determinar la vis-\ncosidad relativa del suero, pues estos casos a menudo sufren síndrome de hiperviscosidad. Si el diagnóstico\nno se comprueba de esta manera, se requiere investigar otras enfermedades malignas que ocasionalmente","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":273,"lines":{"from":26,"to":38}}}}],["1383",{"pageContent":"no se comprueba de esta manera, se requiere investigar otras enfermedades malignas que ocasionalmente\npresentan bandas monoclonales, como leucemia, linfoma y algunos carcinomas. Otra entidad que habrá\nde considerarse en el diagnóstico diferencial es la gammapatía monoclonal de significado indeterminado,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":273,"lines":{"from":38,"to":40}}}}],["1384",{"pageContent":"+/\u001f -\u001f \u001e\u001f̑(\u001f\n \n*), +/\u001f .#\u001f(\u001f9 \u001bC \u001d)'*)(\u001f(.\u001f ')()\u001d&)(\u001b& #( \u001f,#), \u001b i̓ !I\u001e\n \n: \u001cC '\u001f()- \u001e\u001f mz \u001e\u001f *&\u001b-')\u001d#\n-\ntos en médula ósea; y c) ausencia de anemia, lesiones osteolíticas, proteína monoclonal en orina y cifras\n\n(),'\u001b&\u001f- \u001e\u001f \u001b&\u001cĚ'#(\u001b \u001f( -\u001b(!,\u001f8 \u0005-.)- *\u001b\u001d#\u001f(.\u001f- \u001e\u001f\u001c\u001f( 0#!#&\u001b,-\u001f *\u001f,#ĉ\u001e#\u001d\u001b'\u001f(.\u001f6 */\u001f- \u001f& ggz \u001e\u001f \u001f&&)-\n\u001e\u001f-\u001b,,)&&\u001b6 \u001f(.,\u001f k 3 n \u001bĄ)- \u001e\u001f-*/ï-6 '#\u001f&)'\u001b6 '\u001b\u001d,)!&)\u001c/&#(\u001f'#\u001b ) \u001b'#&)#\u001e)-#- *,#'\u001b,#\u001b8\n\nFigura 17-7.\n \nFenotipo inmunológico de las células plasmáticas neoplásicas. El primer histograma muestra\n\n&\u001b \u001d)\u001f2*,\u001f-#ĉ( \u001e\u001f &)- \u001b(.ù!\u001f()- \u0003\u0004go 3 \u0003\u0004in8 \u0005( \u001f& -\u001f!/(\u001e) -\u001f \u001b(\u001b&#4\u001b \u001f& *\u001b.,ĉ( \u001e\u001f \u001d)\u001f2*,\u001f-#ĉ( \u001e\u001f& \u001b(.ù\n-\n\n!\u001f() \u0003\u0004jk \u001d)( \u001f& \u0003\u0004in 3 \u001f( \u001f& .\u001f,\u001d\u001f,) \u001d)( \u001f& \u0003\u0004go8\n \n\u001b- \u001dï&/&\u001b- *&\u001b-'á.#\u001d\u001b- (\u001f)*&á-#\u001d\u001b- B\u001f( ,)$)C \u001f2*,\u001f-\u001b(\n#(.\u001f(-\u001b'\u001f(.\u001f \u001f& \u001b(.ù!\u001f() \u0003\u0004in6 *\u001f,) \u001f& \u0003\u0004go \u001d)( #(.\u001f(-#\u001e\u001b\u001e '\u001f(), \u001b &) (),'\u001b&8 \u0005& \u001b(.ù!\u001f() \u0003\u0004jk \u001f-\n\nmás tenue que en las células mononucleares normales (azul).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":273,"lines":{"from":42,"to":65}}}}],["1385",{"pageContent":"247\n\nCAPÍTULO 17. TRASTORNOS INMUNOPROLIFERATIVOS MALIGNOS\n\nPronóstico\n\n)- '#\u001f&)'\u001b- () .,\u001b.\u001b\u001e)- .#\u001f(\u001f( /(\u001b -/*\u001f,0#0\u001f(\u001d#\u001b \u001d),.\u001b6 \u001e\u001f m̓' \u001f-\u001f- \u001f( *,)'\u001f\u001e#)8\n \n\u001b +/#'#).\u001f,\u001b*#\u001b \"\u001b\n\u001c\u001f(\u001f̑\u001d#\u001b\u001e)\n \n\u001b &\u001b '\u001b3),ù\u001b \u001e\u001f &)- \u001f( \u001f,')-6 +/#\u001f(\u001f- &)!,\u001b( -)\u001c,\u001f0#0#, \u001f(.,\u001f h 3 j̓\u001b Ą)- \u001d)( *)\u001d\u001b- ) 'ù(#'\u001b-\n')&\u001f-.#\u001b-8\n \n\u001b #(-/̑\u001d#\u001f(\u001d#\u001b\n \n,\u001f(\u001b& \u001f(-)'\u001c,\u001f\u001d\u001f \u001f& *,)(ĉ-.#\u001d)8 \u0014\u001b'\u001c#ï( #(̒/3\u001f(\n \n&\u001b ,\u001f-*/\u001f-.\u001b #(\u001e#0#\u001e/\u001b&\n\nal tratamiento, la velocidad de replicación de las células plasmáticas malignas, la magnitud de la masa\ntumoral, la respuesta inmunitaria del paciente, la presencia de complicaciones de la enfermedad, entre\notros factores.\n\nTratamiento\n\nEl mieloma múltiple es seguramente la enfermedad en la que más avances terapéuticos ha habido en\nlos últimos años. El tratamiento inicial ideal en países en desarrollo es la combinación de talidomida","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":274,"lines":{"from":1,"to":28}}}}],["1386",{"pageContent":"El mieloma múltiple es seguramente la enfermedad en la que más avances terapéuticos ha habido en\nlos últimos años. El tratamiento inicial ideal en países en desarrollo es la combinación de talidomida\n\n),\u001b& \u001e#\u001b,#\u001b Bgff '!I\u001eù\u001bC 3 &\u001b \u001e\u001f2\u001b'\u001f.\u001b-)(\u001b ),\u001b& ) #(.,\u001b0\u001f()-\u001b -\u001f'\u001b(\u001b& Bjf '!I-\u001f'C8\n \n\u001b \u001b\u001e#\u001d#ĉ( \u001e\u001f\n\u001c),.\u001f4)'#\u001c #(.,\u001b0\u001f()-) ) -/\u001c\u001d/.á(\u001f) /(\u001b 0\u001f4 \u001b &\u001b -\u001f'\u001b(\u001b Bg6k '!I'\n2\n \n) mejora el índice de respuestas.\nUna vez lograda la remisión del mieloma, el tratamiento de consolidación ideal consiste en el trasplante\nde células hematopoyéticas autólogas. En pacientes que no vayan a ser trasplantados por alguna razón,\n\n\u001f- ,\u001b4)(\u001b\u001c&\u001f #(#\u001d#\u001b, \u001f& .,\u001b.\u001b'#\u001f(.) \u001d)( .\u001b&#\u001e)'#\u001e\u001b6 \u001e\u001f2\u001b'\u001f.\u001b-)(\u001b 3 '\u001f& \u001b&á(8 \u0005( \u001b+/\u001f&&)- +/\u001f 0\u001b( \u001b","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":274,"lines":{"from":28,"to":41}}}}],["1387",{"pageContent":"\u001f- ,\u001b4)(\u001b\u001c&\u001f #(#\u001d#\u001b, \u001f& .,\u001b.\u001b'#\u001f(.) \u001d)( .\u001b&#\u001e)'#\u001e\u001b6 \u001e\u001f2\u001b'\u001f.\u001b-)(\u001b 3 '\u001f& \u001b&á(8 \u0005( \u001b+/\u001f&&)- +/\u001f 0\u001b( \u001b\n\nsometerse a quimioterapia a dosis altas con trasplante hematopoyético autólogo, en el tratamiento ini-\ncial deben evitarse los agentes alquilantes, ya que lesionan las células hematopoyéticas y complican la\nrealización del trasplante. Al obtenerse una remisión completa o parcial, debe hacerse un trasplante de\n\n\u001dï&/&\u001b- \"\u001f'\u001b.)*)3ï.#\u001d\u001b- \u001b/.ĉ&)!\u001b-6 \u001f'*&\u001f\u001b(\u001e) \u001d)') \u001b\u001d)(\u001e#\u001d#)(\u001b'#\u001f(.) \u001e)-#- \u001b&.\u001b- Bhff '!I'\n2\n \n) de mel-\nfalán intravenoso. Después del autotrasplante, el uso de talidomida prolonga la duración de la remisión.\nDebe administrarse aspirina para evitar los fenómenos trombóticos que causa la talidomida. Cuando el\npaciente desarrolla complicaciones del uso crónico de la talidomida, como neuropatía periférica o der-\n\n'\u001b.)-#-6 */\u001f\u001e\u001f \u001f'*&\u001f\u001b,-\u001f \u001d)( ï2#.) &\u001b &\u001f(\u001b&#\u001e)'#\u001e\u001b ) \u001f& \u001c),.\u001f4)'#\u001c8 \u0005( \u001d\u001b-)- ,\u001f ,\u001b\u001d.\u001b,#)- ) \u001f( ,\u001f\u001d\u001bù\u001e\u001b","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":274,"lines":{"from":41,"to":55}}}}],["1388",{"pageContent":"'\u001b.)-#-6 */\u001f\u001e\u001f \u001f'*&\u001f\u001b,-\u001f \u001d)( ï2#.) &\u001b &\u001f(\u001b&#\u001e)'#\u001e\u001b ) \u001f& \u001c),.\u001f4)'#\u001c8 \u0005( \u001d\u001b-)- ,\u001f ,\u001b\u001d.\u001b,#)- ) \u001f( ,\u001f\u001d\u001bù\u001e\u001b\n\nde la enfermedad, se pueden emplear combinaciones con bortezomib, ciclofosfamida, claritromicina,\n\n'\u001f& \u001b&á(6 \u001e)2),,/\u001c#\u001d#(\u001b6 \u001f.\u001dï.\u001f,\u001b8\n\nLa destrucción de los huesos, propia de la enfermedad, ocasiona intensos dolores e incapacidad; el ali-\nvio del dolor es un aspecto importante de la atención de estos pacientes. Los bisfosfonatos son útiles para\ntratar la enfermedad ósea; el clodronato empleado de manera mensual parece ser de utilidad y tener menos\nefectos adversos que otros bisfosfonatos. La insuficiencia renal en ocasiones requiere diálisis. Las infec-\nciones se vigilan y previenen. Para la hiperviscosidad se necesita plasmaféresis si los síntomas lo ameritan.\n\nCuadro 17-2.\n \nCriterios de diagnóstico del mieloma\n \nmúltiple\n\nCriterios mayores\n\n•\n \n\u0010&\u001b-')\u001d#.)-#- \u001f( 'ï\u001e/&\u001b ĉ-\u001f\u001b B̓ gkzC \u001d)( \u001f2*,\u001f-#ĉ( \u001e\u001f /(\u001b \u001d&\u001b-\u001f\n \nde\n \ncadena pesada y ligera\nde\n \ninmunoglobulina","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":274,"lines":{"from":55,"to":84}}}}],["1389",{"pageContent":"Cuadro 17-2.\n \nCriterios de diagnóstico del mieloma\n \nmúltiple\n\nCriterios mayores\n\n•\n \n\u0010&\u001b-')\u001d#.)-#- \u001f( 'ï\u001e/&\u001b ĉ-\u001f\u001b B̓ gkzC \u001d)( \u001f2*,\u001f-#ĉ( \u001e\u001f /(\u001b \u001d&\u001b-\u001f\n \nde\n \ncadena pesada y ligera\nde\n \ninmunoglobulina\n\n•\n \nComponente\n \n\u001f( \u001f& -/\u001f,)6 ̓i6 k̓!I\u001e\n \n\u001e\u001f\n \n!\u0007 ) ̓h 6f̓!I\u001e\n \n\u001e\u001f\n \n!\u0001\n•\n \n\u00052\u001d,\u001f\u001d#ĉ( /,#(\u001b,#\u001b \u001e\u001f \u001d\u001b\u001e\u001f(\u001b- &#!\u001f,\u001b- ̓g !Ihj \" \u001e\u001f /(\u001b -)&\u001b \u001d&\u001b-\u001f\n \n(\ng\n \no\n \nh\n)\n\n•\n \n\u0002#)*-#\u001b \u001e#\u001b!(ĉ-.#\u001d\u001b \u001e\u001f\n \nplasmocitoma\n\nCriterios menores\n\nA. Menos de\n \ngkz\n \nde células plasmáticas en la médula, pero con predominio\n \nde\n \nuna clase de\ncadena ligera de\n \ninmunoglobulina\nB.\n\n•\n \n\u0015(\n \ncomponente\n \nM\n \ncuantitativamente\n \ninferior al indicado\n \nantes\n\n•\n \n\u001f-#)(\u001f- &ù.#\u001d\u001b- \u001f( \"/\u001f-)- /\n \nosteopenia\n \nradiológica\n \n#(\u001f2*&#\ncable\n\n•\n \n\u0004#-'#(/\u001d#ĉ( \u001e\u001f\n \ninmunoglobulinas\n \n(no del\n \ncomponente\n \nM)\n\n•\n \n\u0001(\u001f'#\u001b (),')\u001dù.#\u001d\u001b (),')\u001d,ĉ'#\u001d\u001b\n \n#(\u001f2*&#\u001d\u001b\u001c&\u001f\n•\n \nConcentraciones\n \nde microglobulina\n \nβ\nh \u001f( \u001f& -/\u001f,) ̓j '!I\n•\n \n\u0004#- /(\u001d#ĉ( ,\u001f(\u001b&\n \n#(\u001f2*&#\u001d\u001b\u001c&\u001f\n•\n \n\b#*\u001f,\u001d\u001b&\u001d\u001f'#\u001b\n \n#(\u001f2*&#\u001d\u001b\u001c&\u001f","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":274,"lines":{"from":84,"to":209}}}}],["1390",{"pageContent":"•\n \n\u0001(\u001f'#\u001b (),')\u001dù.#\u001d\u001b (),')\u001d,ĉ'#\u001d\u001b\n \n#(\u001f2*&#\u001d\u001b\u001c&\u001f\n•\n \nConcentraciones\n \nde microglobulina\n \nβ\nh \u001f( \u001f& -/\u001f,) ̓j '!I\n•\n \n\u0004#- /(\u001d#ĉ( ,\u001f(\u001b&\n \n#(\u001f2*&#\u001d\u001b\u001c&\u001f\n•\n \n\b#*\u001f,\u001d\u001b&\u001d\u001f'#\u001b\n \n#(\u001f2*&#\u001d\u001b\u001c&\u001f\n\nEl diagnóstico de mieloma requiere, por lo menos, de un criterio mayor y otro menor, o de tres criterios menores incluyendo los A y B.\n\nLos agentes alquilantes no de-\nben usarse cuando se planea\nun\n \ntrasplante\n \nhematopoyético\nautólogo y quimioterapia a do-\nsis altas, pues lesiona las células\nhematopoyéticas. Recientemen-\nte, la combinación de melfalán,\ntalidomida\n \ny\n \ndexametasona,\nque es de mucha utilidad en\ncasos refractarios de mieloma,\nha mostrado ser muy útil como\ntratamiento de primera línea en\nmieloma múltiple.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":274,"lines":{"from":209,"to":255}}}}],["1391",{"pageContent":"248\n \nFUNDAMENTOS DE HEMATOLOGÍA\nMACROGLOBULINEMIA DE WALDENSTRÖM\n\n\u001b '\u001b\u001d,)!&)\u001c/&#(\u001f'#\u001b \u001e\u001f \u0017\u001b&\u001e\u001f(-.,Č' \u001f- /(\u001b \u001f( \u001f,'\u001f\u001e\u001b\u001e \u001e\u001f \u001f\u001e\u001b\u001e\u001f- \u001b0\u001b(4\u001b\u001e\u001b- Blf \u001b mf \u001bĄ)-C6 /( *)\u001d)\n'á- *,\u001f0\u001b&\u001f(.\u001f \u001f( 0\u001b,)(\u001f-8 \u0005(\n \nï2#\u001d) .#\u001f(\u001f /(\u001b ,\u001f\u001d/\u001f(\u001d#\u001b #( \u001f,#), Bj6nz \u001e\u001f &\u001b- !\u001b''\u001b*\u001b.ù\u001b- ')()\u001d&)\n-\n\n(\u001b&\u001f-C \u001b &\u001b +/\u001f -\u001f )\u001c-\u001f,0\u001b \u001f( ).,)- *\u001bù-\u001f-6 \u001d)') \u0005-.\u001b\u001e)- \u0015(#\u001e)- Bgn6mzC 3 \u0006,\u001b(\u001d#\u001b Bhm6izC8 \u0003&ù(#\u001d\u001b'\u001f(.\u001f\n\nse caracteriza por linfadenopatía, visceromegalia, síndrome de hiperviscosidad y proliferación de células\nlinfoplasmocitoides productoras de una banda monoclonal. Pocas veces se acompaña de insuficiencia\n\n,\u001f(\u001b& 36 \u001e\u001f '\u001b(\u001f,\u001b \u001f2\u001d\u001f*\u001d#)(\u001b&6 \u001e\u001f &\u001f-#)(\u001f- )-.\u001f)&ù.#\u001d\u001b- \u001d)( #(̑&.,\u001b\u001d#ĉ(\n \n\u001e\u001f \u001dï&/&\u001b- \u001d&\u001b,\u001b'\u001f(.\u001f *&\u001b-'á.#\u001d\u001b-\n*,)\u001e/\u001d.),\u001b- \u001e\u001f\n \n!\n \n8 \u0001&!/()- \u001b/.),\u001f- \u001e\u001f-#!(\u001b( \u001f-.)- \u001d\u001b-)- #( ,\u001f\u001d/\u001f(.\u001f- Bf6kz \u001f( &\u001b -\u001f,#\u001f \u001e\u001f& \u001b/.),C \u001d)')","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":275,"lines":{"from":1,"to":24}}}}],["1392",{"pageContent":"mielomas IgM y los tratan como tales. El paciente se queja de debilidad física, hemorragias anormales\ny visión borrosa. Esta última es consecutiva al síndrome de hiperviscosidad que sufren dichos enfermos\ncon mucha frecuencia, el cual en el fondo del ojo determina dilatación de los vasos de la retina, y en el\nsistema nervioso, manifestaciones centrales y periféricas, así como ocasionalmente trastornos psiquiátri-\ncos. Los estudios de laboratorio muestran anemia normocítica normocrómica y en algunos casos trom-\nbocitopenia. En la médula ósea se observa infiltración de células linfoplasmocitoides que alternan con\npequeños linfocitos. En el estudio electroforético del suero se identifica una banda monoclonal IgM. En\nel tratamiento se han empleado clorambucilo o ciclofosfamida, y hay datos que sugieren que los análogos\nde nucleósidos, como la fludarabina o la cladribina, son también de utilidad. El anticuerpo monoclonal","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":275,"lines":{"from":26,"to":34}}}}],["1393",{"pageContent":"\u001b(.#7\u0003\u0004hf B,#./2#'\u001b\u001cC */\u001f\u001e\u001f *,)\u001e/\u001d#, ,\u001f-*/\u001f-.\u001b- \u001f2\u001d\u001f&\u001f(.\u001f-8\n \n\u001b- '\u001b(# \u001f-.\u001b\u001d#)(\u001f- \u001d&ù(#\u001d\u001b- \u001b.,#\u001c/#\u001c&\u001f- \u001b&\n\nsíndrome de hiperviscosidad mejoran, en ocasiones, con plasmaféresis. La respuesta al tratamiento se\nevalúa con determinaciones periódicas de la viscosidad del suero.\n\nENFERMEDADES DE CADENAS PESADAS\n\nLas enfermedades de cadenas pesadas son trastornos muy raros. En la serie de gammapatías monoclonales\nreunidas por los autores de este capítulo\n \n(cuadro 17-3)\n6 \u001f& g6lz \u001d),,\u001f-*)(\u001e#ĉ \u001b \u001f-.\u001f .#*) \u001e\u001f *\u001b\u001e\u001f\u001d#'#\u001f(.)-8\n\nFigura 17-8.\n \n\u0005&\u001f\u001d.,) ),\u001f-#- 3 \u001f&\u001f\u001d.,) ),)!,\u001b'\u001b- \u001e\u001f *,).\u001fù(\u001b- -ï,#\u001d\u001b- \u001f( \u001b!\u001b,)-\u001b \u001e\u001f *\b n6l9 gC -/\u001f,) (),'\u001b&:\nhC !\u001b''\u001b*\u001b.ù\u001b *)&#\u001d&)(\u001b&: iC !\u001b''\u001b*\u001b.ù\u001b ')()\u001d&)(\u001b&\n \n!\u0007: jC !\u001b''\u001b*\u001b.ù\u001b ')()\u001d&)(\u001b&\n \n!\n \n: kC !\u001b'\n-\nmapatía monoclonal IgA.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":275,"lines":{"from":36,"to":62}}}}],["1394",{"pageContent":"Es una enfermedad de edades\navanzadas (60 a 70 años), un\npoco más prevalente en varo-\nnes. En México tiene una fre-\ncuencia inferior (4,8% de las\ngammapatías monoclonales) a\nla que se observa en otros países,\ncomo Estados Unidos (18,5%) y\nFrancia (27,3%).\nEn\n \nel\n \ntratamiento\n \nse\n \nhan\nempleado clorambucilo o ci-\nclofosfamida, y hay datos que\nsugieren que los análogos de\nnucleósidos, como la fludara-\nbina o la cladribina, son tam-\nbién de utilidad.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":275,"lines":{"from":64,"to":87}}}}],["1395",{"pageContent":"249\n\nCAPÍTULO 17. TRASTORNOS INMUNOPROLIFERATIVOS MALIGNOS\n\nCuadro 17-3.\n \nClasificación inmunológica de 1 778 gammapatías\nestudiadas en Laboratorios Clínicos de Puebla\n\nPadecimiento\n \nClase\n \nTipo\n \nNúmero\n \nPor\ncentaje\nMieloma\nmúltiple\n\nIgG\n\ng\nh\ng\n+Bence-Jones\n \nh\nh\n+Bence-Jones\n \ng\n\nBiclonal\nG3\nh\n+G1\ng\n\nkfo\nhof\nm\n\n3\n3\n1\n \nngi\n \njk6m\n\nIgA\n\ng\nh\ng\n+Bence-Jones\n \nh\nh\n+Bence-Jones\n \ng\n\nBiclonal\n\nhkn\ngim\n\n3\n2\n2\n \njfh\n \n22,6\nIgM\n \ng\n \nin\n \nin\n \n2,1\nIgD\n \nh\nh\n+Bence-Jones\n \ng\n\nk\n\n1\n \n6\n \nf6i\n\nBence-\nJones\n \ng\nh\n\nhkl\ngkg\n \njfm\n \n22,9\n\n\u000e)\n\nsecretor\n \n3\n \n3\n \nf6h\n\nMacroglobulinemia\n(Waldenström)\n\ng\nh\n\n34\n29\n \n63\n \n3,6\n\nEnfermedades de\ncadena pesada\n\nγ\nα\nμ\n\n6\n\ngf\nk\n \n21\n \n1,2\n\nAmiloidosis\nprimaria\n\nIgG-\ng\n\nIgG-\nh\n\nIgD-\nh\n\n2\n\ngf\n\n1\n \n13\n \nf6m\n\nGMSI\n\nIgG\nIgA\nIgM\n\nk\n\n3\n4\n \n12\n \nf6m\n\nTOTAL\n \ng mmn\n \ng mmn\n\ng\n: kappa;\n \nh\n: lambda;\n \nγ\n: gamma;\n \nα\n; alfa; μ: mu; GMSI: Gamopatía monoclonal de significado indeterminado.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":276,"lines":{"from":1,"to":209}}}}],["1396",{"pageContent":"250\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\n\u0003)') &)- -/$\u001f.)- \u001d)( '#\u001f&)'\u001b 3 '\u001b\u001d,)!&)\u001c/&#(\u001f'#\u001b6 \u001f-.)- *\u001b\u001d#\u001f(.\u001f- */\u001f\u001e\u001f( -#(.\u001f.#4\u001b, /(\u001b \u001d\u001b(.#\u001e\u001b\u001e \u001f2\u001d\u001f\n-\n\n-#0\u001b \u001e\u001f \u001d\u001b\u001e\u001f(\u001b- &#!\u001f,\u001b-6 +/\u001f -)( \u001f2\u001d,\u001f.\u001b\u001e\u001b- *), &\u001b ),#(\u001b \u001d)') *,).\u001fù(\u001b \u001e\u001f \u0002\u001f(\u001d\u001f7 )(\u001f-8\n\u00052#-.\u001f( \u001f( \u001f,')- +/\u001f \u001f2\u001d,\u001f.\u001b( ).,\u001b *),\u001d#ĉ( \u001e\u001f #('/()!&)\u001c/&#(\u001b6 \u001f&\n \n,\u001b!'\u001f(.) \u0006\u001d8 \u0005-.\u001b *),\u001d#ĉ( \u001f-.á\n\nformada por dos mitades de cadenas pesadas (de aquí deriva el término “enfermedad de cadenas pesadas”),\n\n\u001e\u001f &\u001b- +/\u001f .\u001fĉ,#\u001d\u001b'\u001f(.\u001f */\u001f\u001e\u001f( \u001f2#-.#, \u001d#(\u001d) .#*)-6 &) +/\u001f \u001e\u001f*\u001f(\u001e\u001f \u001e\u001f \u001d/á& \u001e\u001f &\u001b- \u001d#(\u001d) #('/()!&)\u001c/&#(\u001b-\n\nse encuentra involucrada. Sin embargo, hasta la fecha solo se han descrito cuatro variantes de la enferme-\ndad, que corresponden a las inmunoglobulinas\n \nγ\n,\n \nα\n,\n \nμ\n \ny\n \nδ\n.\n\nEnfermedad de cadenas pesadas\n \nγ","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":277,"lines":{"from":1,"to":35}}}}],["1397",{"pageContent":"Enfermedad de cadenas pesadas\n \nγ\n\nEs un padecimiento infrecuente. En la serie reunida por el autor se identificaron dos casos. El cuadro clí-\nnico semeja el del linfoma y cursa con adenomegalia, visceromegalia, debilidad, fatiga y fiebre. Se acom-\npaña de anemia y, en la mitad de los casos, de trombocitopenia. El estudio electroforético del suero no\nsiempre demuestra banda monoclonal y se requiere inmunoelectroforesis para establecer el diagnóstico.\n\nEnfermedad de cadenas pesadas\n \nα","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":277,"lines":{"from":35,"to":46}}}}],["1398",{"pageContent":"Enfermedad de cadenas pesadas\n \nα\n\nDentro del grupo de enfermedades de cadena pesada, la variedad\n \nα\n \nes la más frecuente. Se ha observado\nen jóvenes, sobre todo en originarios del área del Mediterráneo, de donde deriva el sinónimo de “linfoma\nmediterráneo” con el que también se conoce. Los síntomas habituales se localizan en el aparato digestivo:\nsíndrome de malabsorción intestinal grave, pérdida de peso, diarrea y esteatorrea. En ocasiones se ve\nafectado el aparato respiratorio. El diagnóstico se establece por medio de inmunoelectroforesis del suero,\nque comprueba la anormalidad de las cadenas pesadas\n \nα\n \ny la normalidad de las cadenas ligeras. Se han\nobtenido remisiones con melfalán o ciclofosfamida y prednisona. Algunos pacientes se han curado con\nantibióticos, lo que ha sugerido que en la etiología del padecimiento está involucrado algún agente infec-\ncioso. Algunos enfermos desarrollan sarcomas inmunoblásticos u otros linfomas agresivos.\n\nEnfermedad de cadenas pesadas\n \nμ","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":277,"lines":{"from":46,"to":70}}}}],["1399",{"pageContent":"Enfermedad de cadenas pesadas\n \nμ\n\nEn varios enfermos se asocia con leucemia linfática crónica, de cuya forma clásica puede distinguirse por\n\n&\u001b \u001b/-\u001f(\u001d#\u001b \u001e\u001f &#( \u001b\u001e\u001f()*\u001b.ù\u001b *\u001f,# ï,#\u001d\u001b6 *,\u001f-\u001f(\u001d#\u001b \u001e\u001f *&\u001b-')\u001d#.)- 0\u001b\u001d/)&\u001b\u001e)- \u001f( 'ï\u001e/&\u001b ĉ-\u001f\u001b 3 \u001f2\u001d,\u001f\u001d#ĉ(\n\u001f2\u001d\u001f-#0\u001b \u001e\u001f *,).\u001fù(\u001b \u001e\u001f \u0002\u001f(\u001d\u001f7 )(\u001f-8\n \n\u001b 0#-\u001d\u001f,)'\u001f!\u001b&#\u001b \u001f- \u001d)'Ě( 3 \u001f- '/3 ,\u001b,) \u001f& \"\u001b&&\u001b4!) \u001e\u001f \u001c\u001b(\u001e\u001b ')\n-\nnoclonal en el suero. El diagnóstico se establece por medio de inmunoelectroforesis.\n\nFigura 17-9.\n \n\u0004#-.,#\u001c/\u001d#ĉ( \u001e\u001f !\u001b''\u001b*\u001b.ù\u001b- ')()\u001d&)(\u001b&\u001f- \u001f( g hon \u001d\u001b-)- \u001f-./\u001e#\u001b\u001e)- \u001f( &\u001b \u0003&ù(#\u001d\u001b\n \n\u001b3)\n\u001f( \u0012)\u001d\"\u001f-.\u001f,6\n \n\u000e6 \u0005-.\u001b\u001e)- \u0015(#\u001e)- B!,ál·\u001d\u001b \u0001C 3 \u001f( gmf \u001d\u001b-)- \u001f-./\u001e#\u001b\u001e)- \u001f( &\u001b \u0003&ù(#\u001d\u001b \u0012/#4 \u001f( \u0010/\u001f\u001c&\u001b6\nï2#\u001d) B!,ál·\u001d\u001b \u0002C8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":277,"lines":{"from":70,"to":91}}}}],["1400",{"pageContent":"251\n\nCAPÍTULO 17. TRASTORNOS INMUNOPROLIFERATIVOS MALIGNOS\n\nEnfermedad de cadenas pesadas\n \nδ\n\nEl único caso informado en la bibliografía médica cursó con insuficiencia renal, lesiones osteolíticas y\ncuadro clínico de mieloma. El estudio electroforético del suero mostró una banda monoclonal identificada\ncomo un tetrámero de cadenas pesadas\n \nδ\n.\n\nAMILOIDOSIS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":278,"lines":{"from":1,"to":16}}}}],["1401",{"pageContent":"AMILOIDOSIS\n\nEl término\n \namiloidosis\n \nincluye un grupo de padecimientos que tienen en común el depósito, en diversos órga\n-\nnos y tejidos del organismo, de un material homogéneo y amorfo llamado\namiloide\n \npor su afinidad con el yodo,\nlo que le confiere alguna semejanza con el almidón. En la actualidad se sabe que este material es de naturaleza\nproteica y no hidrocarbonada, como supuso Virchow, su descubridor y quien le confirió tal nombre.\nSe conocen dos grandes grupos de amiloidosis: las formas generalizadas y las localizadas. Las formas gene\n-\nralizadas de amiloidosis incluyen algunas variedades como: 1) amiloidosis primaria; 2) la asociada con enfer\n-\n\n'\u001f\u001e\u001b\u001e\u001f- \u001e\u001f &\u001b- \u001dï&/&\u001b- *&\u001b-'á.#\u001d\u001b- B'#\u001f&)'\u001b6 '\u001b\u001d,)!&)\u001c/&#(\u001f'#\u001bC: iC &\u001b- -\u001f\u001d/(\u001e\u001b,#\u001b-6 +/\u001f \u001d)\u001f2#-.\u001f( \u001d)( ).,)-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":278,"lines":{"from":16,"to":35}}}}],["1402",{"pageContent":"'\u001f\u001e\u001b\u001e\u001f- \u001e\u001f &\u001b- \u001dï&/&\u001b- *&\u001b-'á.#\u001d\u001b- B'#\u001f&)'\u001b6 '\u001b\u001d,)!&)\u001c/&#(\u001f'#\u001bC: iC &\u001b- -\u001f\u001d/(\u001e\u001b,#\u001b-6 +/\u001f \u001d)\u001f2#-.\u001f( \u001d)( ).,)-\n\npadecimientos, como artritis reumatoide, infecciones crónicas y linfoma de Hodgkin; y 4) las formas heredofa\n-\nmiliares. Las amiloidosis no generalizadas pueden confinarse a un órgano o sistema o estar localizadas.\nEl cuadro clínico depende del órgano o tejido afectado. La participación del riñón es común y constituye una\n\n\u001d\u001b/-\u001b #'*),.\u001b(.\u001f \u001e\u001f '/\u001f,.\u001f8 \u0005& \u001d),\u001b4ĉ( -\u001f 0\u001f \u001b \u001f\u001d.\u001b\u001e) 3 \u001f( \u001b&!/(\u001b- -\u001f,#\u001f- #(\u001d&/-) \u001f& ifz \u001e\u001f &)- *\u001b\u001d#\u001f(.\u001f- -/ ,\u001f(\n#(-/̑\u001d#\u001f(\u001d#\u001b\n \n\u001d\u001b,\u001eù\u001b\u001d\u001b8\n \n\u001b \u001b'#&)#\u001e)-#- \u001e\u001f& \u001b*\u001b,\u001b.) ,\u001f-*#,\u001b.),#) -\u001f *,\u001f-\u001f(.\u001b \u001f( \u001f& hfz \u001e\u001f &)- \u001d\u001b-)-6 3 &)- -ù(.)'\u001b-\n0\u001b,ù\u001b( \u001e\u001f \u001b\u001d/\u001f,\u001e) \u001d)( &)- .\u001f$#\u001e)- #(̑&.,\u001b\u001e)-9\n \n&\u001b,#(!\u001f6 .,á+/\u001f\u001b6 \u001c,)(+/#)-6 \u001f.\u001dï.\u001f,\u001b8 \u0014\u001b'\u001c#ï( ,\u001f-/&.\u001b \u001b \u001f\u001d.\u001b\u001e) \u001f&","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":278,"lines":{"from":35,"to":50}}}}],["1403",{"pageContent":"sistema nervioso y es habitual la neuropatía periférica. El síndrome del túnel del carpo se origina por infiltración\nde sus ligamentos. Los depósitos cerebrales de amiloide producen deterioro mental (síndrome de Alzheimer).\nEn el aparato digestivo se encuentra macroglosia en uno de cada cinco enfermos y hepatomegalia en la mitad de\nlos casos. Cuando se ven alteradas las articulaciones, los síntomas semejan artritis reumatoide.\nCon frecuencia se observan manifestaciones hemorrágicas por deficiencia adquirida de factores de la\ncoagulación e infiltración de los vasos por el amiloide. La púrpura periorbitaria consecutiva a rectoscopia\nes característica del trastorno. Los estudios de laboratorio demuestran proteinuria frecuente y en muchos\n\n\u001d\u001b-)- \u001f2\u001d,\u001f\u001d#ĉ( /,#(\u001b,#\u001b \u001e\u001f \u001d\u001b\u001e\u001f(\u001b- &#!\u001f,\u001b- ')()\u001d&)(\u001b&\u001f- \u001e\u001f')-.,\u001b\u001e\u001b- *), '\u001f\u001e#) \u001e\u001f #('/()\u001f&\u001f\u001d.,) ),\u001f\n-\n\n-#-8 \u0013)&) \u001f( \u001f& hnz \u001e\u001f &)- \u001f( \u001f,')- &\u001b \u001f&\u001f\u001d.,) ),\u001f-#- \u001e\u001f& -/\u001f,) \u001e\u001f-\u001d/\u001c,\u001f \u001b&!Ě( \u001d)'*)(\u001f(.\u001f ')()\u001d&)(\u001b&8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":278,"lines":{"from":52,"to":63}}}}],["1404",{"pageContent":"-#-8 \u0013)&) \u001f( \u001f& hnz \u001e\u001f &)- \u001f( \u001f,')- &\u001b \u001f&\u001f\u001d.,) ),\u001f-#- \u001e\u001f& -/\u001f,) \u001e\u001f-\u001d/\u001c,\u001f \u001b&!Ě( \u001d)'*)(\u001f(.\u001f ')()\u001d&)(\u001b&8\n\nEl diagnóstico se establece demostrando la típica birrefringencia verde esmeralda en el tejido infiltra-\n\n\u001e)6 .\u001fĄ#\u001e) \u001d)( \u0003)(!) ,)$)6 \u001b& \u001f2\u001b'#(\u001b,-\u001f \u001d)( '#\u001d,)-\u001d)*#) \u001e\u001f &/4 *)&\u001b,#4\u001b\u001e\u001b8\n \n\u001b \u001c#)*-#\u001b \u001e\u001f\u001c\u001f .)'\u001b,-\u001f\n\npreferentemente de los órganos afectados, lo que no siempre es posible. Las biopsias rectales y de grasa\nsubcutánea periumbilical también son útiles.\nLos trasplantes hematopoyéticos autólogos usando dosis altas de melfalán pueden producir remisiones\n\n*,)&)(!\u001b\u001e\u001b- \u001e\u001f &\u001b \u001f( \u001f,'\u001f\u001e\u001b\u001e6 '#\u001f(.,\u001b- +/\u001f \u001f& \u001c),.\u001f4)'#\u001c */\u001f\u001e\u001f ,\u001f0\u001f,.#, \u001f& \u001e\u001bĄ) ,\u001f(\u001b&8 \u0014\u001b'\u001c#ï( -\u001f \"\u001b(\n/-\u001b\u001e) \u001d)( ï2#.) &\u001b .\u001b&#\u001e)'#\u001e\u001b 3 &\u001b &\u001f(\u001b&#\u001e)'#\u001e\u001b8\n\nCRIOGLOBULINEMIA\n\nLas crioglobulinas son proteínas que se precipitan al enfriarse y se redisuelven al recalentarse. Se clasifican\n\n\u001f( .,\u001f- .#*)-9\n \nB')()\u001d&)(\u001b&C6\n \nB'#2.)C 3\n \nB*)&#\u001d&)(\u001b&C8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":278,"lines":{"from":63,"to":88}}}}],["1405",{"pageContent":"CRIOGLOBULINEMIA\n\nLas crioglobulinas son proteínas que se precipitan al enfriarse y se redisuelven al recalentarse. Se clasifican\n\n\u001f( .,\u001f- .#*)-9\n \nB')()\u001d&)(\u001b&C6\n \nB'#2.)C 3\n \nB*)&#\u001d&)(\u001b&C8\n\nEl tipo I está compuesto de proteínas IgM, IgG, IgA, o de Bence-Jones (cadenas ligeras monoclo-\nnales). Este tipo de crioglobulinemia se observa en el mieloma múltiple, la macroglobulinemia de Wal-\ndenström, la gammapatía monoclonal de significado indeterminado, la enfermedad por aglutininas frías\ncrónica y otras afecciones linfoproliferativas.\nLas crioglobulinas tipo IIson inmunoglobulinas monoclonales (habitualmente IgM) y policlonales IgG.\nEste tipo se encuentra en las enfermedades infecciosas crónicas, incluyendo la hepatitis C. En estos enfermos\nla incidencia de trastornos linfoproliferativos de células B es mayor. Los niveles de proteínas generalmente\n\n-)( \u001b&.)- Bg \u001b if̓'!I\u001e\n \nC \u001f( &)- .#*)-\n \n3\n \n\u001e\u001f \u001d,#)!&)\u001c/&#(\u001f'#\u001b6 3 &\u001b \u001d,#)*,\u001f\u001d#*#.\u001b\u001d#ĉ( )\u001d/,,\u001f \u001d)( \u001b\u001d#&#\u001e\u001b\u001e8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":278,"lines":{"from":88,"to":114}}}}],["1406",{"pageContent":"-)( \u001b&.)- Bg \u001b if̓'!I\u001e\n \nC \u001f( &)- .#*)-\n \n3\n \n\u001e\u001f \u001d,#)!&)\u001c/&#(\u001f'#\u001b6 3 &\u001b \u001d,#)*,\u001f\u001d#*#.\u001b\u001d#ĉ( )\u001d/,,\u001f \u001d)( \u001b\u001d#&#\u001e\u001b\u001e8\n\nAlgunos enfermos no tienen síntomas relacionados con la crioglobulinemia y otros sufren manifestaciones\ncutáneas como dolor, púrpura, fenómeno de Raynaud y ulceraciones. Los pacientes con crioglobulinemia\npueden sufrir dolores articulares, nefritis y síntomas neurales. El padecimiento habitualmente responde al\n\n/-) \u001e\u001f \u001d),.#\u001d)#\u001e\u001f- 3 \u001b(.#\"#-.\u001b'ù(#\u001d)-: \u001f& \u001b(.#\u001d/\u001f,*) ')()\u001d&)(\u001b& \u001b(.#7\u0003\u0004hf \u001d\u001b/-\u001b ,\u001f'#-#)(\u001f- \u001e/,\u001b\u001e\u001f,\u001b-8\n \n)-\n\nagentes alquilantes, la plasmaféresis y el interferón a se han usado con buenos resultados.\nEn la crioglobulinemia de tipo III se encuentran una o más clases de inmunoglobulinas policlonales.\n\n\u001b \u001d)(\u001d\u001f(.,\u001b\u001d#ĉ( \u001e\u001f *,).\u001fù(\u001b \u001f- \u001c\u001b$\u001b6 \u001e\u001f f6g \u001b g6f '!I\u001e\n \n6 3 &\u001b *,\u001f\u001d#*#.\u001b\u001d#ĉ( () )\u001d/,,\u001f\n \ná\u001d#&'\u001f(.\u001f8 \u0005-.\u001f","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":278,"lines":{"from":114,"to":137}}}}],["1407",{"pageContent":"\u001b \u001d)(\u001d\u001f(.,\u001b\u001d#ĉ( \u001e\u001f *,).\u001fù(\u001b \u001f- \u001c\u001b$\u001b6 \u001e\u001f f6g \u001b g6f '!I\u001e\n \n6 3 &\u001b *,\u001f\u001d#*#.\u001b\u001d#ĉ( () )\u001d/,,\u001f\n \ná\u001d#&'\u001f(.\u001f8 \u0005-.\u001f\n\nEl término\n \namiloidosis\n \ninclu-\nye un grupo de padecimientos\nque tienen en común el depósi-\nto, en diversos órganos y tejidos\ndel organismo, de un material\nhomogéneo y amorfo llamado\n\namiloide\n \npor su afinidad con\nel yodo, lo que le confiere algu-\nna semejanza con el almidón.\nEn la actualidad se sabe que\neste material es de naturaleza\nproteica y no hidrocarbonada.\nLa participación del riñón es\ncomún y constituye una causa\nimportante de muerte. El co-\nrazón se ve afectado y, en al-\ngunas series incluso el 30% de\nlos pacientes sufre insuficiencia\ncardíaca.\nLa crioglobulinemia tipo II se\nencuentra en las enfermedades\ninfecciosas crónicas, incluyendo\nla hepatitis C. En estos enfer-\nmos la incidencia de trastornos\nlinfoproliferativos de células B\nes mayor.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":278,"lines":{"from":137,"to":175}}}}],["1408",{"pageContent":"252\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\ntipo de crioglobulinemia se encuentra en muchos enfermos afectados por trastornos inflamatorios o in-\nfecciosos. La crioglobulinemia tipo III se ha encontrado asociada a hepatitis, por lo cual ha provocado\nresultados falsos positivos para anticuerpos anti-HIV.\n\nCONCLUSIONES\n\n•\n \nLa transformación maligna de las células linfoides de estirpe B puede ocurrir durante cual -\nquier etapa de la maduración linfocítica; de esta transformación neoplásica se originan las gam -\nmapatías monoclonales: mieloma múltiple, macroglobulinemia de Waldenström, amiloidosis\nprimaria generalizada de cadenas ligeras, enfermedades de cadenas pesadas y crioglobulinemia\nmonoclonal.\n\n•\n \nCon la combinación de electroforesis de las proteínas, inmunofijación de las proteínas del suero y de la\norina e investigación de cadenas ligeras en suero y orina, se puede establecer el diagnóstico y clasificar\na las neoplasias inmunoproliferativas o gammapatías monoclonales.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":279,"lines":{"from":1,"to":23}}}}],["1409",{"pageContent":"•\n \nEn el tratamiento del mieloma múltiple se han obtenido grandes avances en la última década, y la\n\n\u001f2*\u001f\u001d.\u001b.#0\u001b \u001e\u001f 0#\u001e\u001b \u001e\u001f &)- *\u001b\u001d#\u001f(.\u001f- \u001d)( \u001f-.\u001b- (\u001f)*&\u001b-#\u001b- \"\u001b '\u001f$),\u001b\u001e) ().\u001b\u001c&\u001f'\u001f(.\u001f8\n\nPREGUNTAS DE AUTOEVALUACIÓN\n\n1. ¿A qué se refiere el término\n \nmonoclonalidad\n?\na.\n \nQue se origina en una sola clona de células\nb. Que es maligno\nc.\n \nQue es benigno\n2.\n \n?\u0003/á& \u001f- \u001f& \u001f2\u001b'\u001f( \u001e\u001f &\u001b\u001c),\u001b.),#) #\u001eĉ(\u001f) *\u001b,\u001b \u001e\u001f')-.,\u001b, &\u001b *,\u001f-\u001f(\u001d#\u001b \u001e\u001f /(\u001b *,).\u001fù(\u001b ')()\u001d&)(\u001b&>\n\na.\n \nElectroforesis de proteínas\nb. Inmunofijación del suero\nc.\n \nProteinuria de Bence-Jones\n3. ¿Cuál es el papel del estudio inmunofenotípico en las gammapatías monoclonales?\na.\n \nLa clasificación del tipo de gammapatía\nb. El establecimiento del pronóstico\nc.\n \nAmbas son correctas\n4. ¿Cuál es el papel del trasplante hematopoyético en el tratamiento del mieloma múltiple?\na.\n \nImprescindible en el tratamiento actual\nb. Debe hacerse con células hematopoyéticas periféricas\nc.\n \nAmbas son correctas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":279,"lines":{"from":25,"to":70}}}}],["1410",{"pageContent":"k8\n \n¿Qué fármaco debe evitarse en pacientes con mieloma múltiple que van a ser sometidos a trasplante\nhematopoyético?\na.\n \nCiclofosfamida\nb. Melfalán\nc.\n \n\u0004\u001f2\u001b'\u001f.\u001b-)(\u001b\n\nBIBLIOGRAFÍA\n\n\u0002,\u001b\u001e1\u001f&& \u0001\u00126 \u0003\u001b,,7\u0013'#.\" \b\u00046\n \n\u001f\u001b\u001e \u0007\u0010\n6 \b\u001b,0\u001f3 \u0014\u00036 \u0004,\u001b3-)(\n \n\u00148 \u0013\u001f,/' .\u001f-.\n \n), \u001b--\u001f--'\u001f(. )\n \n*\u001b.#\u001f(.- 1#.\"\n\u0002\u001f(\u001d\u001f7 )(\u001f- '3\u001f&)'\u001b8\n \n\u001b(\u001d\u001f.8 hffi: ilg9 jno7jog8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":279,"lines":{"from":72,"to":98}}}}],["1411",{"pageContent":"253\n\nCAPÍTULO 17. TRASTORNOS INMUNOPROLIFERATIVOS MALIGNOS\n\n\u0004,\u001b3-)(\n \n\u00146 \u0014\u001b(!\n \n\u00186 \u0004,\u001f1 \u00126\n \n\u001f\u001b\u001e \u0007\u00106 \u0003\u001b,,7\u0013'#.\" \b\u00046 \u0002,\u001b\u001e1\u001f&& \u0001\u00128 \u0013\u001f,/'\n \n,\u001f\u001f &#!\".7\u001d\"\u001b#( '\u001f\u001b-/,\u001f'\u001f(.-\n), #\u001e\u001f(.# 3#(! \u001b(\u001e ')(#.),#(! *\u001b.#\u001f(.- 1#.\" ()(-\u001f\u001d,\u001f.),3 '/&.#*&\u001f '3\u001f&)'\u001b8 \u0002&))\u001e8 hffg: om9 o9 hoff7hofh8\n\nHernández-Reyes J, Galo-Hooker E, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. Systemic immunoglobulin light chain\n\n\u001b'3&)#\u001e)-#-9 \u0001 -#(!&\u001f7#(-.#./.#)(6 if 3\u001f\u001b, \u001f2*\u001f,#\u001f(\u001d\u001f8 \u0012\u001f0\n \n(0\u001f-. \u0003&#( B\n \nï2C8 hfgi6 \u001f( *,\u001f(-\u001b8\n3&\u001f \u0012\u00018\n \n)()\u001d&)(\u001b& !\u001b'')*\u001b.\"3 )\n \n/(\u001e\u001f.\u001f,'#(\u001f\u001e -#!(#̑\u001d\u001b(\u001d\u001f8\n \n\u000e\u001b./,\u001b& \"#-.),3 #( hjg \u001d\u001b-\u001f-8 \u0001'\n \n\u001f\u001e8 gomn:\nlj9 ngj7nhl8\n3&\u001f \u0012\u00016 \u0012\u001b$%/'\u001b, \u0016\u00018\n \n/&.#*&\u001f '3\u001f&)'\u001b8 \u0002&))\u001e8 hffn: gg9 holh7mh8\n\u001f,\u001f( \u0004\u00068 \b#!\" ,\u001f-)&/.#)( \u001f&\u001f\u001d.,)*\"),\u001f-#- \u001b(\u001e #''/()̑2\u001b.#)(\n \n.\u001f\u001d\"(#+/\u001f- \u001b(\u001e #(.\u001f,*,\u001f.\u001b.#)(8 h(\u001e \u001f\u001e86\n \n\u00016 \u0015\u0013\u00019\n\u0002/..\u001f,1),.\"7\b\u001f#(\u001f'\u001b((6 \u0017)\u001c/,(: gooj8 *8 iom8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":280,"lines":{"from":1,"to":41}}}}],["1412",{"pageContent":"Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, et al. Outcome in systemic\nAL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following\n\n\u001d\"\u001f').\"\u001f,\u001b*38 \u0002,#.\n \n\b\u001f'\u001b.8 hffi: ghh9 mn7nj8\n\nLópez-Otero A, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. A simplified method for stem cell autografting in multiple\n\n'3\u001f&)'\u001b9 \u0001 -#(!&\u001f #(-.#./.#)( \u001f2*\u001f,#\u001f(\u001d\u001f8 \u0002)(\u001f\n \n\u001b,,)1 \u0014,\u001b(-*&\u001b(.8 hffo: jj9 mgk7o8\n\u001b,ù(7\n \nĉ*\u001f4 \u00016\n \n\u001b(\u001e\u001f,) \u001e\u001f \u0012/#4 \u000e6 \u001f. \u001b&8\n \n#\u001f&)'\u001b 'Ě&.#*&\u001f\n \n!\n \n8 \u0012\u001f*),.\u001f \u001e\u001f /( \u001d\u001b-) 3 \u001c,\u001f0\u001f ,\u001f0#-#ĉ( \u001e\u001f &\u001b &#.\u001f,\u001b\n-\n\n./,\u001b8 \u0012\u001f0\n \n(0\u001f-. \u0003&#( B\n \nï2C8 gonh: ij9 gmk7gmn8\n\u001f\u001b\u001e \u0007\u00106 \u0003\u001b,,7\u0013'#.\" \b\u00046 \u0004,\u001b3-)(\n \n\u00146\n \n),!\u001b( \u0007 6 \u0003\"#&\u001e \u00016 \u0002,\u001b\u001e1\u001f&& \u0001\u00128 \u0013\u001f,/'\n \n,\u001f\u001f &#!\". \u001d\"\u001b#(- ), ')(#.)\n-\n\n,#(! '/&.#*&\u001f '3\u001f&)'\u001b8 \u0002,#.\n \n\b\u001f'\u001b.8 hffj: ghl9 ijn7ikj8\n\u0012\u001b$%/'\u001b, \u0013\u00166\n \n3&\u001f \u0012\u00016 Ļ\u001f,(\u001f\u001b/ \u0014\n \n6\n \n\u001f&.)(\n \n6 \u0002,\u001b\u001e1\u001f&& \u0001\u00126 \u0003&\u001b,% \u0012 6 \u001f. \u001b&8 \u0013\u001f,/'\n \n,\u001f\u001f &#!\". \u001d\"\u001b#( ,\u001b.#) #-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":280,"lines":{"from":43,"to":95}}}}],["1413",{"pageContent":",#(! '/&.#*&\u001f '3\u001f&)'\u001b8 \u0002,#.\n \n\b\u001f'\u001b.8 hffj: ghl9 ijn7ikj8\n\u0012\u001b$%/'\u001b, \u0013\u00166\n \n3&\u001f \u0012\u00016 Ļ\u001f,(\u001f\u001b/ \u0014\n \n6\n \n\u001f&.)(\n \n6 \u0002,\u001b\u001e1\u001f&& \u0001\u00126 \u0003&\u001b,% \u0012 6 \u001f. \u001b&8 \u0013\u001f,/'\n \n,\u001f\u001f &#!\". \u001d\"\u001b#( ,\u001b.#) #-\n\nan independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS).\n\n\u0002&))\u001e8 hffk: gfl: i9 ngh7ngm8\n\nRuiz-Argüelles GJ, Gómez-Almaguer D. Crioglobulinemias. En: López Borrasca A, ed. Enciclopedia Iberoamerica-\n\n(\u001b \u001e\u001f \b\u001f'\u001b.)&)!ù\u001b8 \u0013\u001b&\u001b'\u001b(\u001d\u001b9 \u0005\u001e#.),#\u001b& \u001e\u001f &\u001b \u0015(#0\u001f,-#\u001e\u001b\u001e \u001e\u001f \u0013\u001b&\u001b'\u001b(\u001d\u001b: gooh8 *8 kmm7kni8\n\u0012/#47\u0001,!Ĝ\u001f&&\u001f- \u0007 6 \u0012/#47\u000f,.\u001f!\u001b\n \n6 \u0012/#47\u0001,!Ĝ\u001f&&\u001f- \u00018 \u0003,#)!&)\u001c/&#(\u001f'#\u001b '#2.\u001b *)&#\u001d&)(\u001b& B.#*)\n \nC9 j \u001bĄ)- \u001e\u001f \u001f2\n-\n\n*\u001f,#\u001f(\u001d#\u001b \u001f( &\u001b \u0003#/\u001e\u001b\u001e \u001e\u001f \u0010/\u001f\u001c&\u001b8 \u0013\u001b(!,\u001f8 gonn: ii9 mj8\n\nRuiz-Argüelles A, Valls de Ruiz M, et al. “Incomplete” pyroglobulin gamma chain disease in a patient with osteos -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":280,"lines":{"from":95,"to":126}}}}],["1414",{"pageContent":"*\u001f,#\u001f(\u001d#\u001b \u001f( &\u001b \u0003#/\u001e\u001b\u001e \u001e\u001f \u0010/\u001f\u001c&\u001b8 \u0013\u001b(!,\u001f8 gonn: ii9 mj8\n\nRuiz-Argüelles A, Valls de Ruiz M, et al. “Incomplete” pyroglobulin gamma chain disease in a patient with osteos -\n\n\u001d&\u001f,).#\u001d '3\u001f&)'\u001b8 \u0013\u001d\u001b(\u001e\n \n\b\u001b\u001f'\u001b.)&8 gonj: ii9 ikg7ikk8\n\u0012/#47\u0001,!Ĝ\u001f&&\u001f- \u0007 6\n \n\u001b.4'\u001b(( \u00016 \u0007,\u001f#** \u0010\u00126 \u0007)(\u001d\"),)L· \u000e 6 \u0007\u001b,.)( \u00106\n \n3&\u001f \u0012\u00018\n \n/&.#*&\u001f '3\u001f&)'\u001b9 \u0003#,\u001d/&\u001b.#(!\n&3'*\")\u001d3.\u001f- .\"\u001b. \u001f2*,\u001f-- *&\u001b-'\u001b \u001d\u001f&& \u001b(.#!\u001f(-8 \u0002&))\u001e8 gonj: lj9 ikh7ikl8\n\u0012/#47\u0001,!Ĝ\u001f&&\u001f- \u0007 6 \u0013\u001b(7\n \n#!/\u001f&\n \n\u00068 \u0003\u001f&& -/, \u001b\u001d\u001f '\u001b,%\u001f,- #( '/&.#*&\u001f '3\u001f&)'\u001b8\n \n\u001b3) \u0003&#( \u0010,)\u001d8 gooj: lo9 lnj7lof8\n\u0012/#47\u0001,!Ĝ\u001f&&\u001f- \u0007 6 \u0007ĉ'\u001f47\u0012\u001b(!\u001f& \u00046 \u0012/#47\u0004\u001f&!\u001b\u001e) \u0007 6 \u0001!/#&\u001b,7\u0012)'\u001f,)\n \n8\n \n/&.#*&\u001f '3\u001f&)'\u001b #(\n \n\u001f2#\u001d)9 \u0001 -#(!&\u001f\n#(-.#./.#)(6 .1\u001f(.373\u001f\u001b, \u001f2*\u001f,#\u001f(\u001d\u001f8 \u0001,\u001d\"\n \n\u001f\u001e \u0012\u001f-8 hffj: ik9 gli7glm8\n\nRuiz-Argüelles GJ, Gómez-Rangel D, Ruiz-Delgado GJ. Pegylated-interferon induced severe bone marrow hypo-\n\n*&\u001b-#\u001b #( \u001b *\u001b.#\u001f(. 1#.\" '/&.#*&\u001f '3\u001f&)'\u001b ,\u001f\u001d\u001f#0#(! .\"\u001b&#\u001e)'#\u001e\u001f8 \u0001'\n \n\b\u001f'\u001b.)&8 hffi: mj9 hof7hog8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":280,"lines":{"from":126,"to":163}}}}],["1415",{"pageContent":"*&\u001b-#\u001b #( \u001b *\u001b.#\u001f(. 1#.\" '/&.#*&\u001f '3\u001f&)'\u001b ,\u001f\u001d\u001f#0#(! .\"\u001b&#\u001e)'#\u001e\u001f8 \u0001'\n \n\b\u001f'\u001b.)&8 hffi: mj9 hof7hog8\n\nRuiz-Argüelles GJ, Ruiz-Delgado GJ. More in the genetic origin of the monoclonal gammopathy of undetermined\n\n-#!(#̑\u001d\u001b(\u001d\u001f8\n \n\u001b3) \u0003&#( \u0010,)\u001d8 hffn: ni9 lfg7lfi8\n\u0012/#47\u0012\u001f3\u001f- \u00078 \u0005( \u001f,'\u001f\u001e\u001b\u001e\u001f- \u001e\u001f &\u001b- \u001dï&/&\u001b- *&\u001b-'á.#\u001d\u001b-8 \u0005(9 \u0001\u001d\u001b\u001e\u001f'#\u001b \u000e\u001b\u001d#)(\u001b& \u001e\u001f\n \n\u001f\u001e#\u001d#(\u001b \u001e\u001f\n \nï2#\u001d)8 \u0014,\u001b.\u001b\u001e) \u001e\u001f\n'\u001f\u001e#\u001d#(\u001b #(.\u001f,(\u001b8\n \nï2#\u001d)9 \u0005&\n \n\u001b(/\u001b&\n \n)\u001e\u001f,(): gonn8\n\u0012/#47\u0012\u001f3\u001f- \u00076\n \n\u001b(\u001e\u001f,) \u001e\u001f \u0012/#4 \u000e6 \u0001,'\u001f(.\u001b7\u000f&0\u001f,\u001b \u00146 \u001f. \u001b&8 \u0007\u001b''\u001b*\u001b.ù\u001b- ')()\u001d&)(\u001b&\u001f-8 8 \u0004#-.,#\u001c/\u001d#ĉ( \u001e\u001f \u001d&\u001b-\u001f- 3\n.#*)- \u001e\u001f \u001d\u001b\u001e\u001f(\u001b- *\u001f-\u001b\u001e\u001b- 3 &#!\u001f,\u001b- \u001f( gnh \u001d\u001b-)-8 \u0012\u001f0\n \n(0\u001f-. \u0003&#( B\n \nï2C8 gomn: if9 iko7ilk8\n\nRuiz-Reyes G, López-Borrasca A. Fisiopatología y semiología de las proteínas plasmáticas. En: López-Borrasca A, ed. En\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":280,"lines":{"from":163,"to":194}}}}],["1416",{"pageContent":"Ruiz-Reyes G, López-Borrasca A. Fisiopatología y semiología de las proteínas plasmáticas. En: López-Borrasca A, ed. En\n-\n\n\u001d#\u001d&)*\u001f\u001e#\u001b \u001c\u001f,)\u001b'\u001f,#\u001d\u001b(\u001b \u001e\u001f \b\u001f'\u001b.)&)!ù\u001b8 \u0013\u001b&\u001b'\u001b(\u001d\u001b9 \u0005\u001e#.),#\u001b& \u001e\u001f &\u001b \u0015(#0\u001f,-#\u001e\u001b\u001e \u001e\u001f \u0013\u001b&\u001b'\u001b(\u001d\u001b: gooh8 *8 jni7jon8\n\u0013#&0\u001b7\n \n),\u001f()\n \n6 \u0012/#47\u0001,!Ĝ\u001f&&\u001f- \u0007 6 \u001f. \u001b&8 \u0005( \u001f,'\u001f\u001e\u001b\u001e \u001e\u001f \u001d\u001b\u001e\u001f(\u001b- *\u001f-\u001b\u001e\u001b-8 ( ),'\u001f \u001e\u001f \u001d/\u001b.,) \u001d\u001b-)-8 \u0013\u001b(!,\u001f8 gooi: hn9 no7on8\n\u0013/\n \n6\n \n\u001f,\u001f( \u0004\u00066 \u0017\u001b,,\u001f( \u0013 8 \u0006\u001b#&/,\u001f ) \u001b(.#7&\u001b'\u001c\u001e\u001b #''/()̑2\u001b.#)(\n \n,\u001f\u001b!\u001f(.- '#'#\u001d- \u001b&*\"\u001b \"\u001f\u001b037\u001d\"\u001b#( \u001e#-\u001f\u001b-\u001f8 \u0003&#(\n\u0003\"\u001f'8 gook: jg9 ghg7ghh8\n\nVela-Ojeda J, García-Ruiz-Esparza MA, Padilla-Gonzalez Y, Gómez-Almaguer D, Gutiérrez-Aguirre CH, Gó-\nmez-Rangel D, et al. Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus\n\n8\u00168 '\u001f&*\"\u001b&\u001b(8 \u0001(( \b\u001f'\u001b.)&8 hffm: nl9 hmm7hnh8\n\nRESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\n1.\n \na\n2.\n \nb\n3.\n \nc\n4.\n \nc\n\nk8\n \nb","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":280,"lines":{"from":194,"to":234}}}}],["1417",{"pageContent":"PARTE 4\nSistema\nde la coagulación\ny hemostasia\n\n18\n\nFISIOLOGÍA DE LA HEMOSTASIA\n\n19\n\nTROMBOCITOPENIAS\n\n20\n\nC\nOAG\nu\nLOPATÍAS\n \nHEREDITARIAS\n\n21\n\nT\nROMBOFILIA\n\n257\n303\n277\n327","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":282,"lines":{"from":1,"to":31}}}}],["1418",{"pageContent":"257\n\nINTRODUCCIÓN\n\nEn condiciones normales, el sistema de coagulación mantiene la sangre líquida, condición impe -\nrativa para la vida. Sin embargo, si un vaso se daña, el mismo sistema de coagulación mantiene\nla integridad vascular y preserva la vida al limitar inmediatamente la hemorragia mediante la\nformación del coágulo, fenómeno al cual llamamos\n \nhemostasia\n. Además, cuando termina la repa-\nración tisular, el sistema también se encarga de eliminar el coágulo, un mecanismo denominado","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":284,"lines":{"from":1,"to":12}}}}],["1419",{"pageContent":"fibrinólisis\n. Estos dos subsistemas, hemostasia y fibrinólisis, requieren de un tercero llamado\n \nregu-\nlación natural\n, el cual hace que funcionen todos armónica y precisamente. No solo eso, el sistema\nde coagulación también interviene en la inflamación, metástasis, regulación de la tensión arterial\ny aterogénesis. Para que el sistema funcione bien, también se requiere una función apropiada del\nvaso sanguíneo (incluyendo la pared vascular, el endotelio y el flujo sanguíneo) y las células hemá-\nticas circulantes.\n\nDEFINICIONES\n\n•\n \n\u0013#-.\u001f'\u001b \u001e\u001f \u001d)\u001b!/&\u001b\u001d#ĉ(8\n \nSistema homeostático que mantiene la sangre en estado líquido, reac-\nciona ante cualquier daño vascular para sellar inmediatamente el defecto vascular y promueve la\nposterior recanalización del vaso reparado.\n\n•\n \n\b\u001f')-.\u001b-#\u001b8\n \nParte del sistema de coagulación encargada de formar un coágulo para sellar los\ndefectos vasculares y la pérdida hemática subsecuente.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":284,"lines":{"from":14,"to":40}}}}],["1420",{"pageContent":"•\n \n\b\u001f')-.\u001b-#\u001b8\n \nParte del sistema de coagulación encargada de formar un coágulo para sellar los\ndefectos vasculares y la pérdida hemática subsecuente.\n\n•\n \n\u0006\u001b-\u001f ł/#\u001e\u001b \u001e\u001f &\u001b \"\u001f')-.\u001b-#\u001b B\u001b(.\u001f-\n \ncascadas de coagulación\nC8\n \nSerie de reacciones entre los factores\nhemostáticos que termina en la generación de fibrina a partir del fibrinógeno por la acción de una\nenzima denominada\n \ntrombina\n.\n\n•\n \n\u0006#\u001c,#(ĉ&#-#-8\n \nParte del sistema de coagulación que destruye el coágulo una vez que cesaron los\nmecanismos de reparación tisular, permitiendo así la recanalización vascular.\n\nAbraham Majluf Cruz\n\nObjetivos de aprendizaje\n\n•\n \nEntender la fisiología normal del sistema de coagulación.\n\n•\n \nEstablecer las diferencias entre los términos\n \nhemostasia\n \ny\n \nfibrinólisis\n.\n\n•\n \nComprender los mecanismos de control del sistema de coagulación.\n\n•\n \nConocer e interpretar las pruebas de escrutinio hemostático empleadas en la práctica médica\ndiaria.\n\nCAPÍTULO 18\n\nFISIOLOGÍA\nDE LA HEMOSTASIA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":284,"lines":{"from":40,"to":99}}}}],["1421",{"pageContent":"•\n \nConocer e interpretar las pruebas de escrutinio hemostático empleadas en la práctica médica\ndiaria.\n\nCAPÍTULO 18\n\nFISIOLOGÍA\nDE LA HEMOSTASIA\n\nEn condiciones normales, el\nsistema de coagulación man-\ntiene la sangre líquida, con-\ndición\n \nimperativa\n \npara\n \nla\nvida. Sin embargo, si un vaso\nse daña, el mismo sistema de\ncoagulación mantiene la in-\ntegridad vascular y preserva\nla vida al limitar inmediata-\nmente la hemorragia median-\nte la formación del coágulo,\nfenómeno\n \nal\n \ncual\n \nllamamos\n\nhemostasia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":284,"lines":{"from":99,"to":134}}}}],["1422",{"pageContent":"258\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\n•\n \n\b\u001f'),,\u001b!#\u001b8\n \nPérdida hemática debida a una lesión vascular.\n\n•\n \n\u0003)á!/&)\n. Tapón vascular fisiológico formado en el sitio de daño vascular y que tiene como función\nimpedir la pérdida hemática.\n\n•\n \n\u0014,)'\u001c)-#-8\n \nObstrucción patológica de la luz vascular, arterial o venosa.\n\n•\n \n\u0014,)'\u001c)8\n \nCoágulo patológico formado en un momento y sitio inadecuados y que produce una obstruc-\nción vascular arterial o venosa. También puede localizarse en las cavidades cardíacas.\n\n•\n \n\u0003#'ĉ!\u001f()8\n \nProteína inactiva precursora de una enzima que requiere ser activada para transformarse\nen su forma catalítica.\n\n•\n \n\u0010,).\u001f\u001b-\u001b \u001e\u001f -\u001f,#(\u001b8\n \nEnzima que en su sitio activo tiene el aminoácido serina necesario para su activi-\ndad proteolítica.\n\n•\n \n\u0006\u001b\u001d.), \"\u001f')-.á.#\u001d)8\n \nProteína plasmática inactiva capaz de transformarse en una enzima activa por la\nacción de otro factor activado.\n\n•\n \n\u0006\u001b\u001d.), \"\u001f')-.á.#\u001d) \u001b\u001d.#0\u001b\u001e) B\u0006\u001bC8\n \nEnzima activa capaz de activar a otros factores hemostáticos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":285,"lines":{"from":1,"to":55}}}}],["1423",{"pageContent":"•\n \n\u0006\u001b\u001d.), \"\u001f')-.á.#\u001d) \u001b\u001d.#0\u001b\u001e) B\u0006\u001bC8\n \nEnzima activa capaz de activar a otros factores hemostáticos.\n\nEL SISTEMA DE COAGULACIÓN EN CONDICIONES NORMALES","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":285,"lines":{"from":55,"to":61}}}}],["1424",{"pageContent":"El endotelio tiene múltiples funciones necesarias para la vida y una de ellas es la de ser el centro del\nsistema de coagulación. La primera función de este sistema es mantener la sangre líquida dentro\nde los vasos sanguíneos y el corazón. Para que esta función ocurra, es necesario que el endotelio\nsano no activado mantenga un fenotipo fundamentalmente anticoagulante, el cual depende de la\nproducción y expresión de: a) sustancias antiplaquetarias que evitan que las plaquetas se adhieran a\nél, como la prostaciclina (PGI\n \n2\n \n) y el factor de relajación endotelial (óxido nítrico, NO); b) factores\nantihemostáticos como la antitrombina (AT) y el cofactor II de la heparina (CoII-Hep) (inhibido -\nres de factores hemostáticos activados), la trombomodulina (Tm), la cual inhibe a la trombina, y el\ninhibidor de la vía del factor tisular (IVFT), proteína reguladora de la hemostasia; y c) proteínas\nfibrinolíticas, como el activador tisular del plasminógeno (aTP), y su contraparte, el inhibidor del","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":285,"lines":{"from":63,"to":76}}}}],["1425",{"pageContent":"inhibidor de la vía del factor tisular (IVFT), proteína reguladora de la hemostasia; y c) proteínas\nfibrinolíticas, como el activador tisular del plasminógeno (aTP), y su contraparte, el inhibidor del\naTP tipo 1 (IaTP-1), ambos clave en la fibrinólisis\n \nB #!8 gn7gC\n. Como se aprecia, el endotelio es la\nbase del sistema de coagulación.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":285,"lines":{"from":76,"to":82}}}}],["1426",{"pageContent":"HEMOSTASIA\n\nAnte una lesión vascular, la hemostasia se activa para detener la hemorragia\n \nBl·!8 gn7hC\n. La primera\nrespuesta es la vasoconstricción e inmediatamente se produce el coágulo plaquetario, que requiere una\nmalla de fibrina que le confiera firmeza. Cualquier alteración de estos tres mecanismos impide la forma-\nción de un coágulo de calidad y predispone a la hemorragia. La hemostasia se divide en: a) hemostasia\n\nprimaria\n, que se ocupa del cierre inmediato de la lesión por vasoconstricción y activación plaquetaria\nsin que se forme fibrina (fase marginal, ya que la hemorragia se reactiva si el coágulo plaquetario no\nse refuerza con una red de fibrina); y b)\n \nhemostasia secundaria,\n \nencargada de la formación de la malla de\nfibrina al final de la fase fluida y cuya función es hacer más estable el coágulo. Si la fibrina se destruye\nprematuramente por la fibrinólisis, la hemorragia reaparece.\n\nLa pared vascular en la hemostasia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":285,"lines":{"from":84,"to":105}}}}],["1427",{"pageContent":"La pared vascular en la hemostasia\n\nLa vasoconstricción ayuda a controlar la hemorragia porque las arterias y venas tienen una capa de\nmúsculo liso que se contrae al dañarse el vaso. Como esta capa es mayor en las arterias, la contrac -\nción arterial es más intensa que la venosa. La vasoconstricción reduce el f lujo sanguíneo que debía\nllegar a la lesión, lo cual disminuye la hemorragia parcialmente. Aunque transitoria, es importante\npara controlar la hemorragia de pequeños vasos y en la menstruación. Algunas sustancias gene -\nradas en la lesión son vasoconstrictoras, por ejemplo, el tromboxano A\n \n2\n \n(TxA\n \n2\n \n) secretado por las\nplaquetas.\n\nEndotelio y hemostasia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":285,"lines":{"from":105,"to":123}}}}],["1428",{"pageContent":"Endotelio y hemostasia\n\nEl endotelio también es clave en toda la hemostasia, ya que controla el tono vascular y activa las pla -\nquetas, la fase fluida y la fibrinólisis. Las características funcionales del endotelio cambian según su\nlocalización; por ejemplo, en los capilares secreta cien veces más aTP que en las venas, aunque ambos\nsecretan igualmente Tm. Ante una lesión, el fenotipo normal anticoagulante cambia a procoagulante,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":285,"lines":{"from":123,"to":128}}}}],["1429",{"pageContent":"El endotelio tiene múltiples\nfunciones necesarias para la\nvida y una de ellas es la de ser\nel centro del sistema de coagu-\nlación. La primera función\nde este sistema es mantener la\nsangre líquida dentro de los\nvasos sanguíneos y el corazón.\nPara que esta función ocurra,\nes necesario que el endotelio\nsano no activado mantenga\nun\n \nfenotipo\n \nfundamental-\nmente anticoagulante.\nLa vasoconstricción ayuda a\ncontrolar la hemorragia por-\nque las arterias y venas tienen\nuna capa de músculo liso que\nse contrae al dañarse el vaso.\nComo esta capa es mayor en las\narterias, la contracción arterial\nes más intensa que la venosa.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":285,"lines":{"from":130,"to":154}}}}],["1430",{"pageContent":"259\n\nCAPÍTULO 18. FISIOLOGÍA DE LA HEMOSTASIA\n\n\u0006#!/,\u001b gn7g8\n \nEfectos anticoagulantes del endotelio. De las funciones endoteliales, quizá la más importante\nsea la anticoagulante. El endotelio mantiene inactivas a las plaquetas y a la fase fluida, y promueve en todo\nmomento la fibrinólisis. El resultado es un estado anticoagulante leve y suficiente para mantener la sangre\nlíquida, condición imperativa para la vida (aPU = activador del plasminógeno tipo urocinasa).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":286,"lines":{"from":1,"to":10}}}}],["1431",{"pageContent":"\u0006#!/,\u001b gn7h8\n \nHemostasia. Las fases principales en la hemostasia desde la lesión vascular hasta la formación\ndel coágulo hemostático. FP = factor plaquetario 3.\nya que secreta factor de von Willebrand (FvW), IaTP-1 y FV, y permite que se le unan plaquetas y los\nfactores IX, IXa y X. Además, estimula la activación plaquetaria y produce factor tisular (FT), que\ninicia la formación de trombina. Este fenotipo procoagulante es estimulado por citocinas inflamatorias\ncomo la interleucina 1 o el factor de necrosis tumoral, los cuales aumentan el FT y el IaTP-1 y dismi -\nnuyen la Tm. En presencia de trombina, el endotelio produce activadores de plaquetas y leucocitos que\natraen más de estas células a la lesión.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":286,"lines":{"from":12,"to":21}}}}],["1432",{"pageContent":"260\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nFlujo sanguíneo y hemostasia\n\nEl flujo sanguíneo modula el sistema de coagulación y, por lo tanto, la fluidez y la hemostasia. Normalmente,\ntodo el tiempo se están activando plaquetas y factores en la circulación. El flujo dispersa estos componentes\nactivados impidiendo que se acumulen y que favorezcan una trombosis.\nEn caso de lesión, el flujo facilita el transporte de plaquetas y factores hemostáticos a este sitio. Al\ncontactar el endotelio, el flujo genera una fuerza de rozamiento, con la cual la sangre frota al endotelio","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":287,"lines":{"from":1,"to":11}}}}],["1433",{"pageContent":"Bl·!8 gn7iC\n. La sangre tiene diversos constituyentes con diferentes densidades que se mueven a distintas\nvelocidades en el torrente sanguíneo. En el centro del flujo van eritrocitos y leucocitos (más pesados y\nmás rápidos), mientras que las plaquetas y el plasma (más ligeros y más lentos) son empujados a la peri-\nferia, cerca del endotelio. Si aumenta la fuerza de rozamiento, las plaquetas tienen una mayor activación\nespontánea y algunas reacciones hemostáticas se aceleran.\n\nCélulas hemáticas circulantes y hemostasia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":287,"lines":{"from":13,"to":20}}}}],["1434",{"pageContent":"Células hemáticas circulantes y hemostasia\n\nLos eritrocitos y los leucocitos intervienen en la hemostasia. El tiempo de hemorragia se alarga en el\npaciente anémico y se normaliza con la transfusión. Los eritrocitos influyen en la hemostasia primaria\nliberando difosfato de adenosina (ADP) y mejoran la adhesión plaquetaria al empujar a las los trombocitos\nhacia las paredes del vaso. Los eritrocitos y los leucocitos forman parte del coágulo porque las plaquetas\nlos atraen y los fijan. Los eritrocitos aumentan la reactividad plaquetaria y los neutrófilos la inhiben, un\nefecto que modula el tamaño del coágulo. La membrana monocítica puede iniciar y amplificar la hemos-\ntasia al expresar FT y ensamblar algunas reacciones hemostáticas.\n\nPlaquetas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":287,"lines":{"from":20,"to":30}}}}],["1435",{"pageContent":"Plaquetas\n\nSon fragmentos citoplasmáticos formados de los megacariocitos de la médula ósea. Miden de 2 a 3 micras\nde diámetro, tienen forma discoide, circulan en la sangre durante 10 días y sus valores normales oscilan\nentre 150 y 450 × 10\n \n9\n \n/L.\nEn reposo, no se adhieren al endotelio o a otras plaquetas. Su membrana externa tiene glucoproteí-\nnas (GP), que se unen a otras proteínas adhesivas que permiten la adherencia y agregación plaquetarias.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":287,"lines":{"from":30,"to":40}}}}],["1436",{"pageContent":"\u0006#!/,\u001b gn7i8\n \nCaracterísticas del flujo sanguíneo. La velocidad de la sangre es mayor en el centro del vaso\ndebido a que los hematíes circulan a ese nivel, empujando a las plaquetas y el plasma hacia la periferia.\nLa fuerza de rozamiento se genera por la diferencia de velocidades entre las diversas capas de flujo, lo que\nhace que las de mayor velocidad “rueden” sobre las de menor velocidad. El rozamiento es más intenso a\nmedida que la capa se acerca al endotelio. Por lo tanto, las plaquetas están expuestas a fuerzas de roza -\nmiento más altas y a una mayor activación espontánea, independiente de los agonistas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":287,"lines":{"from":42,"to":49}}}}],["1437",{"pageContent":"Normalmente, todo el tiempo\nse están activando plaquetas y\nfactores en la circulación. El\nflujo dispersa estos componen-\ntes activados impidiendo que\nse acumulen y que favorezcan\nuna trombosis.\nSon fragmentos citoplasmá-\nticos formados de los mega-\ncariocitos de la médula ósea.\nMiden de 2 a 3 micras de\ndiámetro, tienen forma dis-\ncoide, circulan en la sangre\ndurante 10 días y sus valores\nnormales oscilan entre 150 y\n450 × 10\n \n9\n \n/L.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":287,"lines":{"from":51,"to":70}}}}],["1438",{"pageContent":"261\n\nCAPÍTULO 18. FISIOLOGÍA DE LA HEMOSTASIA\n\nEl citoplasma tiene gránulos\n \nα\n \ny densos. Los últimos contienen ADP, trifosfato de adenosina, calcio y sero-\ntonina, y los primeros\n \nβ\n-tromboglobulina, factor plaquetario 4 (FP4), factor de crecimiento derivado de pla-\nquetas (FCDP), FvW, FV, fibrinógeno, IaTP-1 y trombospondina\n8\n \nLa deficiencia de gránulos\n \nα\u0003\n(síndrome de\nla plaqueta gris) genera hemorragia. El citoplasma plaquetario tiene actina, que participa en la retracción del\ncoágulo y en el cambio de forma de la plaqueta cuando se activa. El sistema canalicular abierto del citoplasma\nplaquetario expulsa sustancias de la plaqueta durante la secreción. Después del daño vascular, las plaquetas\nforman un tapón que sella la lesión vascular y su superficie es ideal para acelerar las reacciones de la fase fluida.\n\nEl coágulo plaquetario","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":288,"lines":{"from":1,"to":26}}}}],["1439",{"pageContent":"Cuando las plaquetas se activan y sellan la lesión, simultáneamente su membrana cambia bioquímica-\nmente para convertirse en la superficie ideal para favorecer y acelerar las reacciones de la fase fluida de la\nhemostasia.\nEl coágulo plaquetario se forma en diversas etapas solo para fines didácticos\n \nBl·!-8 gn7j 3 gn7kC\n. Ante\nuna lesión, la plaqueta se une al subendotelio expuesto a la sangre (adhesión plaquetaria) (véase fig. 18-4b).\nEl subendotelio tiene proteínas adhesivas que se unen a receptores específicos de la membrana plaqueta-\nria; por ejemplo, el colágeno se une a la GPIb/IX (proteína deficiente en el síndrome de Bernard-Soulier)\nmediante el FvW (véase fig. 18-5).\nEste último es el factor deficiente en la enfermedad hemorrágica del mismo nombre, una proteína\nmultimérica formada por subunidades de 250 kDa ensambladas en multímeros que se almacenan en los\ncuerpos de Weibel-Palade endoteliales antes de su secreción. El endotelio secreta el FvW al plasma y al","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":288,"lines":{"from":28,"to":41}}}}],["1440",{"pageContent":"multimérica formada por subunidades de 250 kDa ensambladas en multímeros que se almacenan en los\ncuerpos de Weibel-Palade endoteliales antes de su secreción. El endotelio secreta el FvW al plasma y al\nsubendotelio para ayudar a una buena adherencia plaquetaria. La otra función importante de este factor\nes la de proteger al FVIII en la circulación.\nAl activarse, las plaquetas cambian de forma y ocurre la secreción plaquetaria de las sustancias alma-\ncenadas en sus gránulos (véanse figs. 18-4c y 18-5). Algunas de estas sustancias aceleran la formación del\ntapón plaquetario (agonistas) y la reparación tisular. Cada agonista [epinefrina, trombina, ADP, TxA\n \n2\n \n,\ncolágeno y factor activador plaquetario (FAP)] tiene un receptor específico en otras plaquetas y estimula la\nunión de unas plaquetas con otras (agregación plaquetaria) (véanse figs. 18-4d y 18-5). En este momento,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":288,"lines":{"from":41,"to":53}}}}],["1441",{"pageContent":"Cuando las plaquetas se acti-\nvan y sellan la lesión, simul-\ntáneamente\n \nsu\n \nmembrana\ncambia bioquímicamente para\nconvertirse\n \nen\n \nla\n \nsuperficie\nideal para favorecer y acelerar\nlas reacciones de la fase fluida\nde la hemostasia.\nEl FvW es el factor deficiente\nen la enfermedad hemorrágica\ndel mismo nombre, una proteí-\nna multimérica formada por\nsubunidades de 250 kDa en-\nsambladas en multímeros que\nse almacenan en los cuerpos de\nWeibel-Palade endoteliales an-\ntes de su secreción. El endotelio\nsecreta el FvW al plasma y al\nsubendotelio para ayudar a una\nbuena adherencia plaquetaria.\nLa otra función importante de\neste factor es la de proteger al\nFVIII en la circulación.\n\n\u0006#!/,\u001b gn7j8\n \nDisposición del flujo sanguíneo normal y de las fases de la respuesta plaquetaria después de la\nlesión del vaso. FCDP = factor de crecimiento derivado de plaquetas; FAP = factor activador plaquetario.\nLas demás abreviaturas son similares a las del texto.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":288,"lines":{"from":55,"to":93}}}}],["1442",{"pageContent":"262\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nel coágulo es una masa de plaquetas desgranuladas y rodeadas de poca fibrina. Todos los agonistas termi-\nnan en una vía común que aumenta el calcio citoplasmático (véase fig. 18-5).\nLas\n \nprostaglandinas\n \nson sustancias clave en la plaqueta. El colágeno y la epinefrina activan fosfolipasas\nque convierten algunos lípidos de la membrana en araquidonato.\nLa ciclooxigenasa convierte araquidonato en prostaglandinas inestables que se convierten en TxA\n \n2\n \n.\nFinalmente, la agregación plaquetaria requiere fibrinógeno y su receptor, la GPIIb/IIIa. Las alteraciones\ndel fibrinógeno o la deficiencia de GPIIb/IIIa (trombastenia de Glanzmann) se caracterizan por cursar\ncon hemorragia.\n\nLas plaquetas en la formación de fibrina","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":289,"lines":{"from":1,"to":22}}}}],["1443",{"pageContent":"Las plaquetas en la formación de fibrina\n\nLa membrana plaquetaria activada es el ambiente ideal para acelerar las reacciones de la fase fluida y\nlocalizar la activación del FII y FX en el sitio de la lesión. Además, varios factores hemostáticos se alma-\ncenan en las plaquetas, por lo que, al ser secretados en el sitio de la lesión, su concentración en el coágulo\naumenta. Los pacientes deficientes de FXI o FV plasmáticos no tienen hemorragia, ya que ambos factores\nplaquetarios sostienen la hemostasia.\n\nLa fase fluida de la hemostasia\nConsideraciones básicas\n\nLa vasoconstricción y el coágulo plaquetario son importantes pero requieren una red de fibrina que se\nforma en la fase fluida para consolidar la hemostasia. La importancia de la fase fluida se aprecia en los\nsujetos deficientes de alguno de los factores y que sufren hemorragia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":289,"lines":{"from":22,"to":35}}}}],["1444",{"pageContent":"\u0006#!/,\u001b gn7k8\n \nFisiología plaquetaria y principales vías metabólicas. La adherencia plaquetaria al subendotelio\nnecesita de la interacción entre colágeno, FvW y GPIb/IXa. La agregación plaquetaria depende de la interacción\nentre la GPIIb/IIIa de plaquetas activadas, teniendo como puente al fibrinógeno. Los agonistas plaquetarios\ninteractúan con sus receptores e inducen la activación de la fosfolipasa C (FLC), la cual hidroliza al fosfatidilino\n-\nsitol para generar inositol trifosfato. Este moviliza calcio desde el sistema tubular. A partir del fosfatidilinositol\ntambién se forma diacilglicerol, el cual activa a la proteína cinasa C (PCC), que fosforila proteínas citoplasmáticas\nimportantes en la secreción plaquetaria. El aumento del calcio citoplasmático fosforila la cadena ligera de la mio\n-\nsina mediante una cinasa de miosina (CM) y activa la fosfolipasa A\n2\n \n(FLA\n \n2\n), que interviene en la generación de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":289,"lines":{"from":37,"to":54}}}}],["1445",{"pageContent":"-\nsina mediante una cinasa de miosina (CM) y activa la fosfolipasa A\n2\n \n(FLA\n \n2\n), que interviene en la generación de\naraquidonato. Este último es oxigenado por la ciclooxigenasa (CO) y modificado por la sintetasa de tromboxanos\n(ST) para producir TxA\n2\n \n. Se muestran las principales reacciones hemostáticas ensambladas en la membrana\nplaquetaria, los complejos “diezasa” y “protrombinasa”.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":289,"lines":{"from":54,"to":67}}}}],["1446",{"pageContent":"La vasoconstricción y el coágulo\nplaquetario\n \nson\n \nimportantes\npero requieren una red de fibri-\nna que se forma en la fase fluida\npara consolidar la hemostasia.\nLa importancia de la fase flui-\nda se aprecia en los sujetos defi-\ncientes de alguno de los factores\ny que sufren hemorragia.\nLas\n \nprostaglandinas\n \nson sus-\ntancias clave en la plaqueta.\nEl colágeno y la epinefrina\nactivan fosfolipasas que con-\nvierten algunos lípidos de la\nmembrana en araquidonato.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":289,"lines":{"from":69,"to":91}}}}],["1447",{"pageContent":"263\n\nCAPÍTULO 18. FISIOLOGÍA DE LA HEMOSTASIA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":290,"lines":{"from":1,"to":3}}}}],["1448",{"pageContent":"La fase fluida consiste en una serie de reacciones bioquímicas de los factores hemostáticos\n \nBl·!-8 gn7l\n3 gn7mC\n \ncuyas características se muestran en el\n \n\u001d/\u001b\u001e,) gn7g\n. Los factores III, IV y VI no existen. Los\nfactores son glucoproteínas que se agrupan por su función. Los factores XII, XI, X, IX, VII, II y la pre-\ncalicreína (PK) son cimógenos de proteasas de serina. Los factores V y VIII, el FT y el cininógeno de alto\npeso molecular (CAPM) son cofactores. Los factores V, VIII y el CAPM deben activarse para funcionar,\nmientras que el FT se activa al hacer contacto con la sangre. La síntesis de los factores II, VII, IX y X de-\npende de la vitamina K. Estos tienen una región de 10 a 12 ácidos glutámicos (Gla) que se junta al calcio,\nel cual, a su vez, une a los factores con los fosfolípidos de la membrana celular activada. Si los factores no\ntienen carboxilados sus Gla, son hemostáticamente inútiles. La síntesis de los factores dependientes de\nvitamina K ocurre en dos fases\n \nBl·!8 gn7oC","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":290,"lines":{"from":5,"to":23}}}}],["1449",{"pageContent":"tienen carboxilados sus Gla, son hemostáticamente inútiles. La síntesis de los factores dependientes de\nvitamina K ocurre en dos fases\n \nBl·!8 gn7oC\n. Primero, sin necesidad de vitamina K, se sintetiza un polipép-\ntido. Después, una carboxilasa añade un segundo grupo carboxilo a los Gla del polipéptido, y la vitamina\nK es el cofactor de la reacción. En el proceso, la vitamina K pasa a epoxivitamina K, la cual se reutiliza por\nefecto de las epoxivitamina K reductasas.\nLos anticoagulantes coumadínicos inhiben estas reductasas y bloquean el reciclaje hepático de la vi-\ntamina K, lo que resulta en la ausencia de Gla carboxilados en los factores dependientes de vitamina K.\nEn la fase fluida, el fibrinógeno plasmático soluble se convierte en fibrina insoluble mediante la\ntrombina (véase fig. 18-7). La formación de trombina depende de dos vías o cascadas hemostáticas. La\nvía extrínseca se activa si la sangre se pone en contacto con los tejidos, ya que el único factor localizado","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":290,"lines":{"from":23,"to":35}}}}],["1450",{"pageContent":"vía extrínseca se activa si la sangre se pone en contacto con los tejidos, ya que el único factor localizado\nfuera de la sangre (extrínseco) es el FT. En la vía intrínseca, los factores están en la sangre y se activa\nal contacto del FXII con superficies extrañas al vaso, aun sin tocar tejido extrasanguíneo. La diferencia\nentre ambas vías es la manera en la que activan al FX, ya que, luego de hacerlo, siguen una vía común\nque activa la protrombina. En las cascadas, un cimógeno se convierte en una enzima, que a su vez activa\nal cimógeno siguiente amplificando cualquier estímulo hemostático pequeño hasta generar trombina\nexplosivamente (véase fig. 18-7). Las reacciones ocurren solo en las membranas activadas de plaquetas,\nleucocitos o de células musculares lisas expuestas después de la lesión, lo que limita la hemostasia al\nsitio lesionado.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":290,"lines":{"from":35,"to":43}}}}],["1451",{"pageContent":"\u0006#!/,\u001b gn7l8\n \nFormación de la malla de fibrina y estabilización del tapón hemostático plaquetario. El ob-\njetivo final de las vías de la fase fluida de la hemostasia es formar una malla de fibrina. El resultado es la\nenvoltura del coágulo plaquetario, el cual termina siendo más resistente a la degradación. Nótese cómo\nen el coágulo quedan embebidos algunos eritrocitos y leucocitos, que también son importantes en la for-\nmación del tapón hemostático. Por supuesto, mientras mayor sea la calidad del coágulo plaquetario mejor\ncumplirá su función hemostática.\n\nLos anticoagulantes coumadí-\nnicos inhiben estas reductasas\ny bloquean el reciclaje hepá-\ntico de la vitamina K, lo que\nresulta en la ausencia de Gla\ncarboxilados en los factores de-\npendientes de vitamina K.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":290,"lines":{"from":45,"to":60}}}}],["1452",{"pageContent":"264\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nCuadro 18-1.\n \nPrincipales características de los componentes del sistema de coagulación\n\n\u0010,).\u001fù(\u001b\n \n\u0013#(ĉ(#')\n \n\u0010\nB%\u0004\u001bC\n\u0003)(\u001d\u001f(.,\u001b\u001d#ĉ( *&\u001b-7\n'á.#\u001d\u001b B'!I\u001e\n \nC\n\u0016#\u001e\u001b '\u001f\u001e#\u001b\nB\"C\n\u0003,)')-)'\u001b\n\u001d)\u001e#l·\u001d\u001b\u001e),\n \n\u0013ù(.\u001f-#-\n \n\u0003\u001b,\u001b\u001d.\u001f,ù-.#\u001d\u001b-\n\u0006\u001b\u001d.),\u001f- \"\u001f')-.á.#\u001d)-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":291,"lines":{"from":1,"to":27}}}}],["1453",{"pageContent":"FI\n \nFibrinógeno\n \n340\n \n200-400\n \n72-120\n \n4\n \nHígado\n \nDimérica\nFII\n \nProtrombina\n \n71\n \n1-2\n \n50-80\n \n11\n \nHígado\n \nDepende de VK\nFIII\n \nTromboplastina tisular\n \n44\n \nndp\n \nndp\n \n1\n \nHígado\nFIV\n \nCalcio\n \n40\n \n9-10\n \nNo se considera un factor\nFV\n \nProacelerina\n \n330\n \n0,4-1,4\n \n12-15\n \n1\n \nMegacarioci-\ntos, ¿Hígado?\n \nCofactor de FXa\nFVII\n \nProtrombina sérica\n \n48\n \n0,05\n \n6\n \n13\n \nHígado\n \nDepende de VK\nFVIII\n \nFactor antihemofílico\n \n330\n \n0,02\n \n12\n \nX\n \nHígado, TE\n \n*\n \nCofactor de FIXa\nFIX\n \nFactor de Christmas\n \n56\n \n0,5\n \n24\n \nX\n \nHígado\n \nDepende de VK\nFX\n \nFactor de Stuart-Prower\n \n58\n \n1\n \n25-60\n \n13\n \nHígado\n \nDepende de VK\nFXI\n \nAntecedente de la trom-\nboplastina plasmática\n \n160\n \n5\n \n40-80\n \n4\n \nHígado\n \nHomodímero\nFXII\n \nFactor de Hageman\n \n76\n \n3\n \n50-70\n \n5\n \nHígado\n \nMonómero\nFXIII\n \nEstabilizador de la\nfibrina\n \n75/80\n \n†\n \n1,5/2,1\n†\n \n150\n \n†\n \n6/1\n†\n \n¿?/Hígado\n†\n \nTetrámero a2 b2\nFvW\n \nFactor de von\nWillebrand\n \n250\n \n**\n \n1\n \n24\n \n12\n \nMegacarioci-\ntos, endotelio\nPK\n \nFactor de Fletcher\n \n85\n \n5\n \n35\n \n4\n \nHígado\n \nMonómero\nCAPM\n \nFactor de Williams\n \n120\n \n7-9\n \n150\n \n3\n \nHígado\n \nMonómero\nFT\n \nFactor tisular\n \n44\n \nndp\n \nndp\n \n1\n \nEndotelio","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":291,"lines":{"from":29,"to":272}}}}],["1454",{"pageContent":"265\n\nCAPÍTULO 18. FISIOLOGÍA DE LA HEMOSTASIA\n\nTE*: tejido extravascular; †: concentraciones de las subunidades a y b (a/b), respectivamente; **: peso molecular del monómero de FvW; ¿?: se desconoce; ndp: no demostrable en plasma.\n\n\u0010,).\u001fù(\u001b\n \n\u0013#(ĉ(#')\n \n\u0010\nB%\u0004\u001bC\n\u0003)(\u001d\u001f(.,\u001b\u001d#ĉ( *&\u001b-7\n'á.#\u001d\u001b B'!I\u001e\n \nC\n\u0016#\u001e\u001b '\u001f\u001e#\u001b\nB\"C\n\u0003,)')-)'\u001b\n\u001d)\u001e#l·\u001d\u001b\u001e),\n \n\u0013ù(.\u001f-#-\n \n\u0003\u001b,\u001b\u001d.\u001f,ù-.#\u001d\u001b-\n\u0006\u001b\u001d.),\u001f- l·\u001c,#()&ù.#\u001d)-\n\nPlasminógeno\n \n88\n \n2,1\n \n50\n \n6\n \nHígado\naTP\n \n72\n \n0,002\n \n5 min\n \n8\n \n¿Endotelio?\n\n(\"#\u001c#\u001e),\u001f- (\u001b./,\u001b&\u001f-\n\nAT-III\n \n58\n \n14\n \n1\n \nHígado\n \nRequiere heparanes endo-\nteliales\nPC\n \n62\n \n0,04\n \n10\n \n2\n \nHígado\nPS\n \n77\n \n0,2\n \n3\n \nHígado, endo-\ntelio\n \nCofactor de la PC\nTm\n \n105\n \nndp\n \nndp\n \n20\n \nEndotelio\nCo-IIHep\n \n65\n \n9\n \n22\n \n¿?\n\nα\n2-AP\n \n68\n \n6,9\n \n58\n \n18\n \nHígado\nIaTP-1\n \n50\n \n0,025\n \n7\nHígado,\nendotelio,\nfibroblastos\nPrincipal inhibidor fibri-\nnolítico\nInhibidor de la\nPCa\n \nIaTP tipo 3\n \n57\n \n0,5\n \n14\n \n¿?\nIVFT\n \n38\n \n0,01\n \n2\n \nHígado, endo-\ntelio","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":292,"lines":{"from":1,"to":153}}}}],["1455",{"pageContent":"α\n2-macroglo-\nbulina\n \n725\n \n25\n \n12\n \nHígado\nC1-Inh\n \n105\n \n40\n \n11\n \nHígado\n\nα\n1-antitripsina\n \n53\n \n0,8\n \n11\n \nHígado","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":292,"lines":{"from":155,"to":185}}}}],["1456",{"pageContent":"266\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nLa vía extrínseca\n\nEmpieza realmente la fase fluida mientras que la intrínseca mantiene y amplifica la formación de fibrina.\nLa hemostasia comienza cuando el FT del subendotelio o de las células no vasculares (normalmente no\nestá en la sangre o en el endotelio) hace contacto con la sangre (véase fig. 18-7). El FT se une inmedia-\ntamente al FVII convirtiéndolo en FVIIa. El complejo FT-FVIIa activa al FX, el cual genera trombina\na partir de FII. El FVII es el primero en desaparecer del plasma ante una deficiencia de vitamina K. Las\nvías intrínseca y extrínseca convergen en el FX, que es activado por el complejo FT-FVIIa (directamente)\no el FIXa (indirectamente, véase más adelante).\n\nLa vía intrínseca","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":293,"lines":{"from":1,"to":15}}}}],["1457",{"pageContent":"La vía intrínseca\n\nEmpieza in vitro al contacto de la sangre con superficies extrañas al vaso. En la fase de contacto comienza\nuna serie de reacciones entre cuatro proteínas plasmáticas (FXI, FXII, PK y CAPM), que convierten al\nFXI en FXIa (véase fig. 18-7). Este genera FIXa, el cual, en presencia de calcio, fosfolípidos y FVIIIa,\nconvierte el FX en FXa. Los enfermos deficientes de FXI tienen hemorragia de gravedad variable. Las\nproteínas reguladoras de esta fase son la\n \nα\n1-antitripsina, el inhibidor del componente C1 del complemento\ny la\n \nα\n2-macroglobulina. El FIX es el factor deficiente en la hemofilia B. Cuando el FIXa (la enzima) hace\nun complejo con el FVIIIa (el cofactor), el calcio y fosfolípidos (complejo diezasa o tenasa), convierten al\nFX en FXa. La plaqueta activada provee los fosfolípidos necesarios para ensamblar este complejo. El FVIII\nse encuentra deficiente en la hemofilia A y circula en el plasma junto al FvW en concentraciones muy bajas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":293,"lines":{"from":15,"to":31}}}}],["1458",{"pageContent":"Trombina y la formación de fibrina\n\nEl FII se convierte en trombina al final de la fase fluida por efecto del FXa (véase fig. 18-7). La acción\ndel FXa se acelera 300 000 veces en presencia de FVa, fosfolípidos y calcio (complejo protrombinasa), un\nefecto que depende de los fosfolípidos aniónicos de las membranas celulares activadas que permiten que,\nen presencia de calcio, se les unan los Gla de los factores II, IXa y Xa. El objetivo es alinear y localizar en un","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":293,"lines":{"from":33,"to":38}}}}],["1459",{"pageContent":"\u0006#!/,\u001b gn7m8\n \nLa fase fluida de la hemostasia. Después de una lesión vascular, se exponen a la sangre múltiples proteínas de la\nmatriz extracelular (la más importante el FT) y fosfolípidos provenientes tanto de membranas celulares que normalmente no\nestán en contacto con la sangre como de membranas celulares que se activan ante la lesión (membranas plaquetarias o endo\n \n-\nteliales activadas). El resultado y punto de convergencia de ambas vías es la formación del FXa. A partir de este existe una vía\ncomún de activación que culmina en la formación de trombina.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":293,"lines":{"from":40,"to":48}}}}],["1460",{"pageContent":"267\n\nCAPÍTULO 18. FISIOLOGÍA DE LA HEMOSTASIA\n\npunto los factores que circulan por separado en el plasma para que las reacciones ocurran exactamente don-\nde se necesitan. La trombina transforma al fibrinógeno en fibrina y luego la estabiliza al activar el FXIII.\nEl fibrinógeno está formado por dos pares de tres cadenas polipeptídicas –A\nα\n, B\nβ\n \ny\n \nγ\n– unidas por puentes\ndisulfuro. Para convertirse en fibrina, primero se liberan dos fibrinopéptidos A (FPA) y dos fibrinopépti-\ndos B (FPB)\n \nBl·!8 gn7nC\n \nquedando solo los monómeros de fibrina, los cuales polimerizan y forman fibrillas\ninmaduras que se disuelven fácilmente. La formación de polímeros resistentes requiere FXIIIa y calcio. El\nFXIIIa entrecruza los polímeros estabilizando la malla de fibrina y haciéndola resistente a la fibrinólisis.\n\nFIBRINÓLISIS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":294,"lines":{"from":1,"to":25}}}}],["1461",{"pageContent":"La fibrinólisis y la hemostasia están relacionadas, ya que una forma y la otra degrada fibrina. La fibrinólisis\nes una serie de eventos en cascada de cimógenos, enzimas activas e inhibidores, la cual evita el depósito de\nfibrina en el vaso e impide la obstrucción del flujo\n \nBl·!8 gn7gfC\n.\nDepende de la enzima plasmina, cuyo precursor es el plasminógeno. Este se encuentra en el plasma\ny se convierte en plasmina por medio de activadores intrínsecos y extrínsecos. Los primeros actúan si la\nsangre contacta superficies extrañas, por lo que son fisiológicamente cuestionables, ya que son activa-\ndores débiles. Los extrínsecos están fuera de la sangre en casi todos los tejidos y en el endotelio. El aTP\ntiene gran afinidad por la fibrina (punto clave en la fibrinólisis) y se libera del endotelio en caso de de -\nmanda fisiológica, local o sistémica, como ocurre con el ejercicio, con el uso de adrenalina o en presencia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":294,"lines":{"from":27,"to":38}}}}],["1462",{"pageContent":"manda fisiológica, local o sistémica, como ocurre con el ejercicio, con el uso de adrenalina o en presencia\nde trombina. La plasmina hidroliza patológicamente al fibrinógeno (fibrinogenólisis) o fisiológicamente\na la fibrina (fibrinólisis), generando productos de degradación del fibrinógeno (PDF) o de la fibrina\n(PDf) (véase fig. 18-10).\nLa fibrinólisis está regulada por inhibidores específicos que limitan la generación y acción de la plas-\nmina. Los más importantes son el IaTP-1 y la\n \nα\n2-antiplasmina. El primero se produce en el endotelio, se\nsecreta al plasma e inactiva rápidamente al aTP y, por lo tanto, regula la activación del plasminógeno. La","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":294,"lines":{"from":38,"to":47}}}}],["1463",{"pageContent":"α\n2-antiplasmina inhibe instantáneamente a la plasmina, que escapa del coágulo a la circulación y bloquea\nla unión del plasminógeno a la fibrina, limitando así la cantidad de plasminógeno disponible en el coágulo\nde fibrina. Si la concentración de plasmina excede la del inhibidor, se produce fibrinogenólisis, fibrinólisis\no lisis de otras proteínas (véase fig. 18-10). Las plaquetas intervienen en la fibrinólisis, ya que el IaTP-1\nque almacenan se libera en el sitio de formación del coágulo. El FXIII entrecruza la\n \nα\n2-antiplasmina con\nla fibrina en el coágulo, haciendo a esta última más resistente a la plasmina.\n\n\u0006#!/,\u001b gn7n8\n \nVías bioquímicas en la formación de la malla de fibrina. A partir del fibrinógeno se forman\nmonómeros de fibrina y fibrinopéptidos. Estos monómeros se aglutinan para dar lugar a mallas de fibrina\ninestables que requieren de la acción del FXIIIa y calcio para quedar estabilizadas. El resultado final es una\nred resistente a la plasmina.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":294,"lines":{"from":49,"to":65}}}}],["1464",{"pageContent":"La fibrinólisis es una serie de\neventos en cascada de cimóge-\nnos, enzimas activas e inhibi-\ndores, la cual evita el depósito\nde fibrina en el vaso e impide\nla obstrucción del flujo","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":294,"lines":{"from":67,"to":72}}}}],["1465",{"pageContent":"268\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nNormalmente el sistema fi-\nbrinolítico está en reposo. La\nmanera en la que se activa y\nregula para disolver la fibrina\ninnecesaria sin lisar prema-\nturamente al coágulo verda-\ndero depende de la producción\nendotelial de aTP e IaTP-1,\nde\n \nla\n \ndepuración\n \nhepática\ndel aTP, de la activación del\nplasminógeno y de la inacti-\nvación de la plasmina.\nAl lesionarse un vaso, inme-\ndiatamente se forma el coá-\ngulo. Normalmente este no se\nextiende a lo largo del lumen\ndel vaso ni tampoco lo ocluye.\nLa formación del coágulo ocu-\nrre y se mantiene solo donde\ny cuando es necesario. Así, su\ninicio, crecimiento y mante-\nnimiento están estrechamente\nregulados, temporal y espa-\ncialmente.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":295,"lines":{"from":1,"to":34}}}}],["1466",{"pageContent":"\u0006#!/,\u001b gn7o8\n \nPapel de la vitamina K en la síntesis de factores hemostáticos. La vitamina K reducida se convier\n-\nte en un epóxido durante la carboxilación de los Gla de los factores dependientes de vitamina K para producir\nácidos\n \nγ\n-carboxiglutámicos. La forma oxidada de la vitamina K es reciclada por una serie de enzimas denomi\n-\nnadas\n \nreductasas\n. Una vez reducida, la vitamina K vuelve a entrar al ciclo. Los anticoagulantes orales bloquean\nla acción de estas reductasas, lo que lleva a la producción de factores hemostáticos funcionalmente inactivos.\nNormalmente el sistema fibrinolítico está en reposo. La manera en la que se activa y regula para\ndisolver la fibrina innecesaria sin lisar prematuramente al coágulo verdadero depende de la producción\nendotelial de aTP e IaTP-1, de la depuración hepática del aTP, de la activación del plasminógeno y de la\ninactivación de la plasmina.\nPor lo tanto, la actividad fibrinolítica depende del balance aTP/IaTP-1. La unión del plasminógeno y","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":295,"lines":{"from":36,"to":55}}}}],["1467",{"pageContent":"inactivación de la plasmina.\nPor lo tanto, la actividad fibrinolítica depende del balance aTP/IaTP-1. La unión del plasminógeno y\ndel aTP a la fibrina localiza la fibrinólisis, aumenta la activación del plasminógeno y permite que ambos\nqueden protegidos de sus inhibidores.\nEl paciente con deficiencia de los factores fibrinolíticos está expuesto a sufrir trombosis, mientras que los\nque tienen exceso de su efecto tienen una tendencia hemorrágica, como en el caso de los sujetos deficientes\nde\n \nα\n2-antiplasmina o IaTP-1, ya que la pérdida de la regulación fibrinolítica disuelve prematuramente el\ncoágulo. Este efecto hemorrágico también aparece en pacientes con tratamiento trombolítico con aTP, uro-\ncinasa o estreptocinasa, puesto que en ellos la plasmina induce fibrinogenólisis y lisis de los factores V y VIII.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":295,"lines":{"from":55,"to":66}}}}],["1468",{"pageContent":"MECANISMOS DE REGULACIÓN DEL SISTEMA DE COAGULACIÓN\n\nAl lesionarse un vaso, inmediatamente se forma el coágulo. Normalmente este no se extiende a lo largo\ndel lumen del vaso ni tampoco lo ocluye. La formación del coágulo ocurre y se mantiene solo donde y\ncuando es necesario. Así, su inicio, crecimiento y mantenimiento están estrechamente regulados, tempo-\nral y espacialmente.\nYa se mencionaron tres fenómenos que limitan la propagación del coágulo: el patrón anticoagulante\nendotelial, la dependencia de la hemostasia y de la fibrinólisis de una superficie celular, y la misma fibri-\nnólisis. Sin embargo, la regulación es mucho más amplia.\n\nFlujo sanguíneo","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":295,"lines":{"from":68,"to":78}}}}],["1469",{"pageContent":"Flujo sanguíneo\n\nEl movimiento de la sangre evita que se acumulen factores y plaquetas activados en el sitio del daño vascular.\nLa importancia del flujo sanguíneo en la prevención de la trombosis se demostró inyectando factores activados\nen animales; los trombos no aparecieron a menos de que el flujo fuera interrumpido. Por lo tanto, para que el\ntrombo se forme, se requiere ineludiblemente estasis venosa, lesión vascular y un estado protrombótico.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":295,"lines":{"from":78,"to":83}}}}],["1470",{"pageContent":"269\n\nCAPÍTULO 18. FISIOLOGÍA DE LA HEMOSTASIA\n\nRegulación de la fase fluida de la hemostasia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":296,"lines":{"from":1,"to":5}}}}],["1471",{"pageContent":"El plasma tiene inhibidores de los factores hemostáticos activados que limitan y localizan la hemostasia:\nla AT, el CoII-Hep, el sistema de la proteína C (PC) y el IVFT.\nLa AT es el inhibidor más importante de la trombina, aunque también inhibe los factores XIIa, XIa,\nXa, IXa, FT-VIIIa, calicreína y plasmina\n \nBl·!8 gn7ggC\n. Su efecto se acelera por la heparina, la cual cambia\nsu conformación y permite que se una más rápidamente a la trombina. Otros glucosaminoglicanos simila-\nres a la heparina están en el endotelio humano y también aceleran el efecto de la AT. La deficiencia congé-\nnita o adquirida de esta proteína se asocia con trombosis. El CoII-Hep inhibe la trombina y, al igual que\nla AT, su actividad aumenta con la heparina; sin embargo, no inhibe otros factores activados. El IVFT se\nencuentra en concentraciones altas en el endotelio y es clave en la regulación de la fase fluida, puesto que\ninactiva al complejo FT-FVIIa. El exceso de FXa generado en ambas vías hemostáticas se une al IVFT,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":296,"lines":{"from":7,"to":19}}}}],["1472",{"pageContent":"inactiva al complejo FT-FVIIa. El exceso de FXa generado en ambas vías hemostáticas se une al IVFT,\ny este complejo luego inhibe al complejo FT-FVIIa, un mecanismo de regulación negativa que limita la\ngeneración de trombina extrínseca sin interferir con la generación de trombina intrínseca.\nComo ya vimos, cualquier estímulo hemostático mínimo activa la fase fluida, que genera trombina\npor amplificación de las vías hemostáticas. La generación de trombina es regulada por varios inhibidores;\nentre ellos el más importante es el sistema de la PC, el cual está formado por la PC, la proteína S (PS) y\nla Tm, el receptor endotelial para la trombina (véase fig. 18-11).\nLa activación de la PC ocurre si la Tm se une a la trombina. La PS es el cofactor del sistema, mientras\nque la Tm inhibe la activación del fibrinógeno, el FV y las plaquetas por trombina, permite la activación\nde la PC por trombina y aumenta la inhibición de la trombina por AT. Este paso resulta crítico, ya que","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":296,"lines":{"from":19,"to":28}}}}],["1473",{"pageContent":"de la PC por trombina y aumenta la inhibición de la trombina por AT. Este paso resulta crítico, ya que\nconvierte a la trombina procoagulante en anticoagulante. Si hay exceso de trombina circulante, la Tm\nla captura inmediatamente y el complejo trombina-Tm resultante activa la PC. Esta se une a la PS en la","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":296,"lines":{"from":28,"to":30}}}}],["1474",{"pageContent":"El plasma tiene inhibidores\nde\n \nlos\n \nfactores\n \nhemostáticos\nactivados que limitan y loca-\nlizan la hemostasia: la AT,\nel CoII-Hep, el sistema de la\nproteína C (PC) y el IVFT.\nCualquier\n \nestímulo\n \nhemos-\ntático mínimo activa la fase\nfluida, que genera trombina\npor amplificación de las vías\nhemostáticas. La generación\nde trombina es regulada por\nvarios inhibidores; entre ellos\nel más importante es el siste-\nma de la PC, el cual está for-\nmado por la PC, la proteína\nS (PS) y la Tm, el receptor\nendotelial para la trombina.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":296,"lines":{"from":32,"to":59}}}}],["1475",{"pageContent":"\u0006#!/,\u001b gn7gf8\n \nMecanismos de regulación de la fase fluida de la hemostasia. En el panel superior izquier\n-\ndo se muestran las reacciones de regulación del sistema de la PC. Obsérvese cómo la trombina unida a la\nTM activa a la PC, es decir, pasa de ser una enzima procoagulante a una anticoagulante. A su vez, la PC\ninhibe a los factores V y VIII, con lo cual detiene eficientemente la vía intrínseca. En el panel superior\nderecho se muestra el efecto del IVFT. Nótese que las primeras moléculas de FXa que se generan en la\nvía extrínseca se unen inmediatamente al IVFT, y que juntos inhiben a su vez al complejo FT-FVIIa. De\nesa manera la vía extrínseca es rápidamente silenciada. En el panel interior se muestra el efecto regulador\nde la AT, la cual puede ser activada por los heparanes normalmente presentes en el organismo o por la\naplicación de heparina. Aunque tiene un efecto más pronunciado sobre la trombina, obsérvese cómo en","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":296,"lines":{"from":61,"to":72}}}}],["1476",{"pageContent":"de la AT, la cual puede ser activada por los heparanes normalmente presentes en el organismo o por la\naplicación de heparina. Aunque tiene un efecto más pronunciado sobre la trombina, obsérvese cómo en\nrealidad la AT es capaz de inhibir a casi todos los factores de la vía intrínseca. En todos los paneles se\nmarcan en rojo las vías inhibitorias.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":296,"lines":{"from":72,"to":75}}}}],["1477",{"pageContent":"270\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\n\u0006#!/,\u001b gn7gg8\n \nEsquema simplificado de la fibrinólisis. Se muestran las vías principales del sistema. En\nlíneas continuas se muestran las reacciones activadoras y en líneas punteadas, las inhibidoras.\nsuperficie plaquetaria o endotelial e inhibe los factores Va y VIIIa. Las deficiencias del sistema de la PC\ngeneran trombosis, pero además existen defectos funcionales como la resistencia a la PCa (RPCa), alte-\nración secundaria a diversas mutaciones del gen del FV. Además de la RPCa secundaria a mutaciones del\nFV, existe la RPCa adquirida que acompaña a una gran cantidad de patologías.\n\nInhibidores fibrinolíticos\n\nLa\n \nα\n2-antiplasmina fue descrita en la sección de fibrinólisis. La deficiencia de este inhibidor se asocia\ncon la trombosis. El IaTP-1 se produce en el endotelio, hepatocitos y fibroblastos, y se almacena en los\ngránulos plaquetarios\n \nα\n. Regula la fibrinólisis al inhibir al aTP y su deficiencia se asocia con hemorragia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":297,"lines":{"from":1,"to":24}}}}],["1478",{"pageContent":"Depuración de fibrina, factores y complejos enzima-inhibidor activados\n\nEl hígado y el sistema reticuloendotelial remueven fibrina, factores y complejos activados generados en la\nhemostasia. La perfusión hepática de FXa o FX lleva a la depuración casi inmediata del FXa, pero deja\ncircular al FX. Los complejos activador-inhibidor, por ejemplo FXa-AT y aTP-IaTP-1, son depurados\nrápidamente por el hígado. El bloqueo del sistema reticuloendotelial induce una coagulación intravascular\ndiseminada al permitir la circulación de factores o complejos activados. Las células de Kupffer depuran la\nfibrina formada después de infundir trombina.\n\nPRUEBAS DE ESCRUTINIO HEMOSTÁTICO","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":297,"lines":{"from":26,"to":35}}}}],["1479",{"pageContent":"PRUEBAS DE ESCRUTINIO HEMOSTÁTICO\n\nDespués de realizar la historia clínica y la exploración del paciente con hemorragia o trombosis, es nece-\nsario evaluar qué tipo de prueba se requiere para complementar su diagnóstico. Los pacientes con hemo-\nrragia se clasifican en cuatro categorías: con tendencia hemorrágica grave, leve, dudosa y sin tendencia\nhemorrágica.\nLa hemorragia aparece por alteraciones del vaso, las plaquetas, la fase fluida o la fibrinólisis. Excepto la\nenfermedad de von Willebrand, las alteraciones hereditarias se localizan en solo una de estas categorías,\nmientras que las adquiridas se pueden localizar en todas.\n\nDespués de realizar la historia\nclínica y la exploración del pa-\nciente con hemorragia o trom-\nbosis, es necesario evaluar qué\ntipo de prueba se requiere para\ncomplementar su diagnóstico.\nLos pacientes con hemorragia\nse clasifican en cuatro catego-\nrías: con tendencia hemorrá-\ngica grave, leve, dudosa y sin\ntendencia hemorrágica.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":297,"lines":{"from":35,"to":55}}}}],["1480",{"pageContent":"271\n\nCAPÍTULO 18. FISIOLOGÍA DE LA HEMOSTASIA\n\nCuenta plaquetaria\n\nLa trombocitopenia puede ser multifactorial. Con excepción de los traumatismos, la trombocitopenia es la\ncausa más frecuente de hemorragia. Toda trombocitopenia debe corroborarse en el frotis de sangre periférica.\nEn general, la hemorragia es rara si las plaquetas son mayores de 50 × 10\n9\n/L, aunque no solo su número es im-\nportante sino también su calidad. Aunque algunas condiciones congénitas y adquiridas se asocian a tromboci\n-\ntopenia y a alteraciones cualitativas, en la mayoría de los trastornos cualitativos la cuenta plaquetaria es normal.\n\nTiempo de hemorragia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":298,"lines":{"from":1,"to":16}}}}],["1481",{"pageContent":"Tiempo que transcurre entre la producción de una pequeña herida en la piel hasta el momento en el que\ncesa la hemorragia. Es difícil de estandarizar pero ofrece información muy importante. Evalúa las etapas\nhemostáticas iniciales: la interacción entre plaquetas y vaso, y la formación del coágulo.\nSe prolonga en la trombocitopenia, con plaquetas disfuncionales o cuando estas no interactúan con el\nvaso. También se extiende por ausencia o anormalidad del FvW, fibrinógeno o FV, o si existen alteracio-\nnes vasculares como en el escorbuto.\nSi no existe explicación para el alargamiento, el paciente tiene seudohemofilia. Hoy en día la prueba\naceptada es la de Ivy, en la cual, mediante un dispositivo comercial, se hace una incisión de 5 mm de lon-\ngitud por 1 mm de profundidad en la fosa antecubital, mientras se ejerce una presión continúa en el brazo\ninsuflando un manguito de baumanómetro arriba del corte cutáneo. Una causa frecuente de alargamiento","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":298,"lines":{"from":18,"to":27}}}}],["1482",{"pageContent":"insuflando un manguito de baumanómetro arriba del corte cutáneo. Una causa frecuente de alargamiento\nes la ingesta de medicamentos, principalmente analgésicos no esteroideos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":298,"lines":{"from":27,"to":28}}}}],["1483",{"pageContent":"Tiempo de tromboplastina parcial activada","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":298,"lines":{"from":30,"to":30}}}}],["1484",{"pageContent":"El tiempo de tromboplastina parcial activada (TTPa) analiza la vía intrínseca de la fase fluida\n \nBl·!-8 gn7n\n3 gn7ghC\n. La prueba original (el tiempo de tromboplastina parcial, TTP) consistía en agregar una trom-\nboplastina parcial al plasma. Hoy se utiliza una variación que activa la prueba al máximo adicionando una\nsustancia negativa al plasma antes de agregar la tromboplastina parcial, es decir, un TTPa. La recolección\nde la muestra debe ser cuidadosa para no activar la fase de contacto, y la prueba comienza cuando a la\nmuestra descalcificada se le agrega calcio.\nEl TTPa se prolonga si disminuye la actividad de los factores hemostáticos o si existe algún anticoagulante.\nLos factores (excepto calcio y fibrinógeno) se encuentran normalmente a una concentración de\n100 U/dL. Al mezclar plasma de un paciente con TTPa prolongado con el de un individuo normal,\npodemos distinguir una deficiencia de factores o de un anticoagulante. Si al mezclar un volumen","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":298,"lines":{"from":32,"to":44}}}}],["1485",{"pageContent":"Se prolonga en la tromboci-\ntopenia,\n \ncon\n \nplaquetas\n \ndis-\nfuncionales o cuando estas no\ninteractúan con el vaso. Tam-\nbién se extiende por ausencia\no anormalidad del FvW, fi-\nbrinógeno o FV, o si existen\nalteraciones vasculares como\nen el escorbuto.\nEl TTPa se prolonga si dis-\nminuye la actividad de los\nfactores hemostáticos o si exis-\nte algún anticoagulante.\n\n\u0006#!/,\u001b gn7gh8\n \nPrincipales pruebas de escrutinio de la fase fluida de la hemostasia. El TTPa analiza la vía intrínseca desde la activación\nde la fase de contacto hasta la formación de la fibrina. El TP explora la vía extrínseca hasta la formación de fibrina también. El tiempo\nde trombina es una prueba que analiza la formación del fibrinógeno, por lo que es útil en el diagnóstico de las alteraciones de esta pro\n-\nteína. Finalmente, la prueba de solubilidad del coágulo explora la parte final de la formación y el reforzamiento de la malla de fibrina.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":298,"lines":{"from":46,"to":72}}}}],["1486",{"pageContent":"272\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nigual de plasma normal y de control el TTPa no muestra corrección, existe un anticoagulante. Si\nexiste corrección parcial o absoluta, es factible la deficiencia de uno o varios factores. Si el alarga -\nmiento se debe a deficiencia, es posible saber cuál es el factor deficiente usando plasma depletado\nartificialmente de un factor específico. La identificación del factor deficiente se hace mezclando\nel plasma problema con plasma normal, lo que permite que el plasma con deficiencia se corrija\ncon el plasma normal. Por ejemplo, si el paciente tiene 5% de FV, solo corrige discretamente al\nplasma deficiente de FV utilizado en la prueba. Si no existe corrección, ambos plasmas tienen la\nmisma deficiencia.\n\nTiempo de protrombina","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":299,"lines":{"from":1,"to":14}}}}],["1487",{"pageContent":"Tiempo de protrombina\n\nEl tiempo de protrombina (TP) mide la formación del coágulo dependiente de la vía extrínseca (véanse\nfigs. 18-8 y 18-12). Utiliza una tromboplastina “completa” (equivalente a la tromboplastina tisular). La\nprueba también inicia al recalcificar la muestra.\nEl TP se alarga en la deficiencia de los factores V, X, II, VII y fibrinógeno. Al igual que el TTPa, el\nTP se prolonga por deficiencia de un factor o por un anticoagulante.\nLas pruebas de mezcla con plasma normal también discriminan entre anticoagulantes y la defi -\nciencia de factores se corrobora con plasma depletado artificialmente de un factor específico, igual\nque en el TTPa. La importancia de la sensibilidad de la tromboplastina es muy importante, por\nlo que se calibra internacionalmente con el ISI (Índice de Sensibilidad Internacional). Si sabemos\nel ISI, el TP puede expresarse como un cociente estandarizado internacional, mejor conocido como","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":299,"lines":{"from":14,"to":25}}}}],["1488",{"pageContent":"INR\n, el cual traduce la intensidad de la anticoagulación cuando se usan anticoagulantes antagonistas\nde la vitamina K.\nEl INR se obtiene mediante la siguiente fórmula:\n \n[TP del paciente/TP del control]\n \nISI\n. El ISI viene\nsiempre indicado en el equipo comercial. El resultado es un número mayor a 1,0, y dependiendo de la\nindicación, el coumadínico se ajusta para tener al INR en el nivel deseado.\n\nTiempo de trombina","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":299,"lines":{"from":27,"to":39}}}}],["1489",{"pageContent":"Tiempo de trombina\n\nEl tiempo de trombina (TT) consiste en adicionar directamente trombina al plasma (véanse figs.\n18-8 y 18-12).\nEl TT se prolonga solo en cuatro situaciones: si el fibrinógeno está bajo, en las disfibrinogenemias,\nen presencia de PDF y si hay anticoagulante o inhibidor de la trombina en el plasma.\nEn ocasiones, un paciente con fibrinógeno anormal puede tener un TT alargado con TP o TTPa\nnormales o levemente alargados, y a menos de que se realice el TT, algunas disfibrinogenemias no se\ndiagnostican. Otro uso del TT consiste en detectar heparina en pacientes con hemorragia y terapia con\neste anticoagulante, ya que identifica dosis del fármaco que no modifican el TP o el TTPa. Si hay un\nalargamiento discreto del TT con TTPa y TP normales, la heparina circulante es mínima, y es poco\nprobable que cause la hemorragia.\n\nDiagnóstico diferencial","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":299,"lines":{"from":39,"to":52}}}}],["1490",{"pageContent":"El uso adecuado de las pruebas antes descritas permite discriminar alteraciones hemostáticas adquiridas y\nhereditarias\n \nB\u001d/\u001b\u001e,)- gn7h 3 gn7iC\n. Las alteraciones del patrón I tienen actividad anormal de los factores\niniciales de la fase fluida y se subdividen en dos grupos. La deficiencia de CAPM, PK y FXII no se asocia\na hemorragia; no así la deficiencia de los otros tres.\nEl perfil II corresponde a un TP prolongado con TTPa y TT normales. La única condición asociada a\neste patrón es la deficiencia de FVII tanto hereditaria (muy rara) como adquirida (deficiencia de vitamina\nK, coumadínicos, antibióticos, malabsorción o ictericia obstructiva).\nEl patrón III consiste en TTPa y TP prolongados con TT normal o anormal. Estos pacientes tienen\ndeficiencia funcional hereditaria (fibrinógeno, FII, FV o FX) o deficiencia funcional adquirida (déficit de\nvitamina K, coagulación intravascular diseminada, anticoagulantes circulantes o insuficiencia hepática).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":299,"lines":{"from":54,"to":66}}}}],["1491",{"pageContent":"vitamina K, coagulación intravascular diseminada, anticoagulantes circulantes o insuficiencia hepática).\nSi el fibrinógeno está deficiente o anormal, el TT también se prolonga. La falta de proteínas de la vía\ncomún (fibrinógeno, FII, FV y FX) puede tener este patrón. Ocasionalmente, ocurren deficiencias mixtas\nde FV y FVII. En las deficiencias de los factores dependientes de vitamina K, los factores II, IX, VII y\nX están reducidos y el FV está normal. En pacientes con hepatopatía, el fibrinógeno es anormal, lo que\nalarga el TT.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":299,"lines":{"from":66,"to":71}}}}],["1492",{"pageContent":"El\n \ntiempo\n \nde\n \nprotrombina\n(TP) mide la formación del\ncoágulo dependiente de la vía\nextrínseca (véanse figs. 18-8 y\n18-12). Utiliza una trombo-\nplastina “completa”.\nEl TP se alarga en la defi-\nciencia de los factores V, X,\nII, VII y fibrinógeno. Al igual\nque el TTPa, el TP se prolon-\nga por deficiencia de un factor\no por un anticoagulante.\nEl TP puede expresarse como\nun\n \ncociente\n \nestandarizado\ninternacional, mejor conoci-\ndo como\n \nINR\n, el cual traduce\nla intensidad de la anticoa-\ngulación cuando se usan an -\nticoagulantes antagonistas de\nla vitamina K.\nEl TT se prolonga solo en\ncuatro situaciones: si el fibri-\nnógeno está bajo, en las disfi-\nbrinogenemias, en presencia\nde PDF y si hay anticoagu-\nlante o inhibidor de la trom-\nbina en el plasma.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":299,"lines":{"from":73,"to":112}}}}],["1493",{"pageContent":"273\n\nCAPÍTULO 18. FISIOLOGÍA DE LA HEMOSTASIA\n\nEl grupo IV tiene TT prolongado y TT y TTPa normal o alargado. Estos pacientes pueden tener\nhipofibrinogenemia, disfibrinogenemia, presencia de PDF o heparina. Si existe deficiencia total de fi-\nbrinógeno, las pruebas pueden prolongarse indefinidamente. En la hipofibrinogenemia moderada, el TT\ntiende a ser más alargado que el TP y el TTPa. La hipofibrinogenemia puede ser hereditaria pero más\nfrecuentemente se debe a coagulación intravascular diseminada (CID) descompensada o insuficiencia\nhepática. La causa más frecuente de disfibrinogenemia es la insuficiencia hepática.\n\nCONCLUSIONES","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":300,"lines":{"from":1,"to":12}}}}],["1494",{"pageContent":"CONCLUSIONES\n\n•\n \nEn condiciones normales, el sistema de coagulación permite que la sangre se mantenga en esta -\ndo líquido, una función elemental para la vida. Sin embargo, cuando hay una lesión vascular, el\nsistema torna su fenotipo anticoagulante en procoagulante mediante la activación de uno de sus\nsubsistemas denominado\n \nhemostasia\n. Esta tiene como función evitar la pérdida sanguínea. Cuando\ncesan los mecanismos de reparación tisular, la fibrinólisis se encarga de recanalizar el vaso lesiona -\ndo. Al final, el sistema regresa a su estado inicial, en el cual su función fundamental es mantener\nla sangre en estado líquido.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":300,"lines":{"from":12,"to":25}}}}],["1495",{"pageContent":"•\n \nEn la práctica clínica cotidiana, estudiar el estado funcional de la hemostasia es posible median -\nte un escrutinio hemostático que incluye el tiempo de hemorragia, la cuenta de plaquetas y los\ntiempos de coagulación (TP, TTPa y TT). Con estas pruebas es factible tener una idea clara de\nla actividad hemostática del paciente y de la posibilidad de que presente en algún momento una\nhemorragia inesperada.\n\nCuadro 18-2.\n \nClasificación de las anormalidades hemostáticas\n\n\u0004\u001fl·\u001d#\u001f(\u001d#\u001b\n \n\u0014\u0014\u0010\u001b *,)&)(!\u001b\u001e)\n \n\u0014\u0010 *,)&)(!\u001b\u001e)\n \n\u0010\u001b.,ĉ( .#*)\n\nCAPM\n \n+\n \n–\n \nI\nPK\n \n+\n \n–\n \nI\nFXII\n \n+\n \n–\n \nI\nFXI\n \n+\n \n–\n \nI\nFIX\n \n+\n \n–\n \nI\nFVIII\n \n+\n \n–\n \nI\nFVII\n \n–\n \n+\n \nII\nFV\n \n+\n \n+\n \nIII\nFX\n \n+\n \n+\n \nIII\nFII\n \n+\n \n+\n \nIII\nFibrinógeno\n \n+\n \n+\n \nIII, IV\nFXIII\n \n–\n \n–\n \nIII, IV\n\nCuadro 18-3.\n \nEvaluación hemostática global\n\n\u0007,/*)\n \nTP\n \nTTPa\n \nTT","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":300,"lines":{"from":27,"to":142}}}}],["1496",{"pageContent":"Cuadro 18-3.\n \nEvaluación hemostática global\n\n\u0007,/*)\n \nTP\n \nTTPa\n \nTT\n\nVía intrínseca alterada\n \nNormal\n \nAnormal\n \nNormal\nVía extrínseca alterada\n \nAnormal\n \nNormal\n \nNormal\nVía común alterada o defectos múltiples\n \nAnormal\n \nAnormal\n \nUsualmente normal\nFibrinógeno alterado\n \nNormal\n \nNormal*\n \nAnormal\n* A menos de que la deficiencia de fibrinógeno o su inhibición sean graves.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":300,"lines":{"from":142,"to":182}}}}],["1497",{"pageContent":"274\n \nFUNDAMENTOS DE HEMATOLOGÍA\nPREGUNTAS DE AUTOEVALUACIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":301,"lines":{"from":1,"to":4}}}}],["1498",{"pageContent":"1. ¿Cuál es la función principal del sistema de coagulación?\na.\n \nMantener la sangre en estado líquido\nb. Reaccionar ante cualquier daño vascular y sellar cualquier defecto vascular\nc.\n \nPromover la recanalización del vaso reparado\n2. ¿Cuáles son los subsistemas del sistema de coagulación?\na.\n \nLíquido y sólido\nb. Hemostasia y la fibrinólisis\nc.\n \nPlaquetas y fibrina\n3. ¿Cuáles son las fases de la hemostasia?\na.\n \nFase sólida y fase fluida\nb. Daño vascular, vasoconstricción, activación plaquetaria, fase fluida y formación del coágulo\nc.\n \nPlaquetaria, anticoagulante, fibrinolítica y coagulante\n4. ¿Cuáles son los principales sistemas reguladores del sistema de coagulación?\na.\n \nFlujo sanguíneo, regulación de fase fluida de hemostasia, inhibidores fibrinolíticos y depuración\nde fibrina\nb. Fibrinólisis y coagulación\nc.\n \nNinguna de las anteriores\n5. ¿Cuáles son las pruebas de escrutinio hemostático más importantes en la práctica clínica cotidiana?\na.\n \nElectroforesis y radioinmunoanálisis\nb. PCR y TTPa\nc.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":301,"lines":{"from":6,"to":44}}}}],["1499",{"pageContent":"c.\n \nNinguna de las anteriores\n5. ¿Cuáles son las pruebas de escrutinio hemostático más importantes en la práctica clínica cotidiana?\na.\n \nElectroforesis y radioinmunoanálisis\nb. PCR y TTPa\nc.\n \nCuenta plaquetaria, TTPa, TP y TT","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":301,"lines":{"from":44,"to":54}}}}],["1500",{"pageContent":"BIBLIOGRAFÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":301,"lines":{"from":56,"to":56}}}}],["1501",{"pageContent":"Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to\nactivated protein C. Nature. 1994; 369: 64-7.\nDavie EW, Fujikawa K, Kisiel W. ¼e coagulation cascade: Initiation, maintenance, and regulation. Biochemistry.\n1991; 30: 10363-70.\nDe La Cadena RA, Majluf-Cruz A, Stadnicki A, Agosti JM, Colman RW, Sufffredini AF. Activation of the contact\nand fibrinolytic systems after intravenous administrations of endotoxin to normal human volunteers: Correlation\nwith the cytokine profile. Immunopharmacology. 1996; 33: 231-7.\nFurie B, Furie C. Molecular and cellular biology of blood coagulation. N Engl J Med. 1992; 326: 800-6.\nFurie B, Furie C. Molecular basis of vitamin K-dependent\n \nγ\n-carboxilation. Blood. 1990; 75: 1753-62.\nMajluf-Cruz A, Hurtado-Monroy R, Sansores-García L, Labardini-Méndez J. ¼e incidence of protein C deficiency\nin thrombosis-related portal hypertension. Am J Gastroenterol. 1996; 91: 976-80.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":301,"lines":{"from":58,"to":71}}}}],["1502",{"pageContent":"Majluf-Cruz A, Hurtado-Monroy R, Sansores-García L, Labardini-Méndez J. ¼e incidence of protein C deficiency\nin thrombosis-related portal hypertension. Am J Gastroenterol. 1996; 91: 976-80.\nMajluf-Cruz A, De La Cadena R. El sistema de contacto: Su papel en la hemostasia y su relación con otros sistemas\nbiológicos. En: Martínez-Murillo C, Quintana-González S. Manual de hemostasia y trombosis. México: Edito-\nrial Prado; 1996.\nRapaport SI, Rao LV. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler ¼romb.\n1992; 12: 1111-21.\nRuggeri ZM, Ware J. Von Willebrand factor. FASEB J. 1993; 7: 308-16.\nRuiz-Argüelles G. Resistencia a la proteína C activada como causa de trombofilia. Rev Invest Clin. 1996; 48:\n223-9.\nSansores-García L, Majluf-Cruz AS, Vargas-Vorackova F, Labardini-Méndez J. El cociente de normalización inter-\nnacional en la vigilancia de la terapia anticoagulante oral. Rev Invest Clin. 1993; 45: 463-7.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":301,"lines":{"from":71,"to":82}}}}],["1503",{"pageContent":"275\n\nCAPÍTULO 18. FISIOLOGÍA DE LA HEMOSTASIA\n\nSansores-García L, Majluf-Cruz A. Arterial and venous thrombosis associated to combined deficiency of protein\nC and antithrombin III. Am J Hematol. 1998; 57: 182-183.\nSlack SM, Cui Y, Turitto VT. ¼e effects of flow on blood coagulation and thrombosis. ¼romb Haemost. 1993; 70:\n129-34.\nStern D, Nawroth P, Handley D, et al. An endothelial cell-dependent pathway of coagulation. Proc Natl Acad Sci\nUSA. 1985; 82: 2523-7.\n\nRESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\n1.\n \na\n2.\n \nb\n3.\n \nb\n4.\n \na\n5.\n \nc","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":302,"lines":{"from":1,"to":28}}}}],["1504",{"pageContent":"277\n\nINTRODUCCIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":304,"lines":{"from":1,"to":3}}}}],["1505",{"pageContent":"La producción de plaquetas depende de la proliferación y diferenciación de células progenitoras hacia las\ncélulas comisionadas llamadas\n \nmegacariocitos\n, los cuales, al fragmentarse, forman las plaquetas; se les dis\n-\ntingue en la circulación sanguínea por su forma discoide y tamaño aproximado de 1 a 3 micras de diámetro.\nDentro del microambiente de la médula ósea (MO), también son importantes las células del estroma, que\nle brindan soporte a las células progenitoras hematopoyéticas, y las citocinas, incluyendo la trombopoyetina\n(TPO), las interleucinas 6 y 11, así como el SCF (de\n stem cell factor\n), con lo cual se lleva a cabo el proceso\nde producción plaquetaria. Las plaquetas normalmente sobreviven entre 7 y 10 días, y cuando aumenta su\nutilización o destrucción, generalmente también lo hace su producción, es decir, se incrementa el recambio\nplaquetario, caracterizado por hiperplasia de megacariocitos en la MO. La función normal de las plaquetas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":304,"lines":{"from":5,"to":19}}}}],["1506",{"pageContent":"plaquetario, caracterizado por hiperplasia de megacariocitos en la MO. La función normal de las plaquetas\nconsiste en contribuir a mantener la integridad del sistema de hemostasia, al evitar la aparición de hemo\n-\nrragia o trombosis. Se estima que por día se producen entre 160 y 280 × 10\n9\n/L, lo que puede incrementarse\ndurante el tiempo de mayor demanda.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":304,"lines":{"from":19,"to":25}}}}],["1507",{"pageContent":"Trombocitopenia\n \nse refiere a la disminución de las plaquetas por debajo de las cifras normales, que\ngeneralmente oscilan entre 150 y 450 × 10\n9\n/L, y sus causas se pueden dividir desde un punto de vista\nfisiopatológico en: 1) producción insuficiente, 2) aumento en su destrucción y 3) distribución y almace-\nnamiento inadecuados. También se puede presentar una combinación de ellas.\nPara fines de este capítulo, y por cuestiones de espacio, mencionaremos solo algunas de las en-\nfermedades más representativas dentro de la amplia gama de trombocitopenias existentes. Conviene\nmencionar que el término\n \npúrpura\n \nse refiere a la presencia de sangrados o hemorragias en la piel, las\nmucosas, o ambas, y con frecuencia esto puede ser secundario a la trombocitopenia. Sin embargo,\ndebe aclararse también que muchos pacientes con trombocitopenia no presentan púrpura y que, por\notra parte, hay enfermedades que presentan púrpura sin trombocitopenia, como las púrpuras vascula-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":304,"lines":{"from":27,"to":44}}}}],["1508",{"pageContent":"debe aclararse también que muchos pacientes con trombocitopenia no presentan púrpura y que, por\notra parte, hay enfermedades que presentan púrpura sin trombocitopenia, como las púrpuras vascula-\nres. Con base en lo anterior, las púrpuras también se han clasificado en\n \ntrombocitopénicas\n \ny\n \nno trombo-\ncitopénicas\n, dependiendo si existen o no plaquetas disminuidas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":304,"lines":{"from":44,"to":54}}}}],["1509",{"pageContent":"TROMBOCITOPENIAS POR PRODUCCIÓN\nINSUFICIENTE DE PLAQUETAS\n\nEstas trombocitopenias pueden tener un origen congénito o adquirido\n \n(cuadro 19-1)\n.\n\nGuillermo R. Gutiérrez Espíndola\nJavier Pizzuto Chávez\n\nObjetivos de aprendizaje\n\n•\n \nConocer la clasificación de las trombocitopenias.\n\n•\n \nDescribir las trombocitopenias más frecuentes.\n\n•\n \nDestacar los principales cambios fisiopatológicos y clínicos.\n\n•\n \nSeñalar los tratamientos actuales de las trombocitopenias más importantes.\n\nCAPÍTULO 19\n\nTROMBOCITOPENIAS\n\nLas plaquetas provienen de\nlos megacariocitos de la mé-\ndula ósea, y se les distingue en\nla circulación sanguínea por\nsu forma discoide y tamaño\naproximado de 1 a 3 micras\nde diámetro;\n \nnormalmente so-\nbreviven de 7 a 10 días.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":304,"lines":{"from":56,"to":98}}}}],["1510",{"pageContent":"278\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nOrigen congénito\nTrombocitopenia congénita amegacariocítica","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":305,"lines":{"from":1,"to":6}}}}],["1511",{"pageContent":"Es una enfermedad autosómica recesiva en la cual se observa trombocitopenia grave al primer día de\nnacimiento. Se confunde con la trombocitopenia inmunitaria primaria (TIP) o trombocitopenia aloin-\nmunitaria neonatal, y la MO muestra ausencia o disminución de los megacariocitos. En estos pacientes\nse han descrito alteraciones en la estructura o señalización de los receptores de la TPO por mutaciones\nen el gen\n \nc-MPL\n. Los niveles de TPO se encuentran elevados debido a la disminución de plaquetas y me-\ngacariocitos. Los pacientes tienen riesgo de desarrollar mielodisplasias o leucemia, pero principalmente\nevolucionan a anemia aplásica. Los pacientes pueden presentar hemorragia intracraneal, lo cual puede\nafectar el desarrollo de los niños afectados. La transfusión de plaquetas ofrece ayuda temporal y el trata-\nmiento curativo es el trasplante de células progenitoras hematopoyéticas (TCPH). Otros tratamientos son","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":305,"lines":{"from":8,"to":19}}}}],["1512",{"pageContent":"miento curativo es el trasplante de células progenitoras hematopoyéticas (TCPH). Otros tratamientos son\nla transfusión de eritrocitos, el uso de antifibrinolíticos y antibióticos si fuera necesario.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":305,"lines":{"from":19,"to":20}}}}],["1513",{"pageContent":"Trombocitopenia con ausencia de radio","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":305,"lines":{"from":22,"to":22}}}}],["1514",{"pageContent":"La trombocitopenia con ausencia de radio (TAR) es una enfermedad que también tiene un patrón here-\nditario y muestra trombocitopenia con plaquetas de 10 a 100 × 10\n \n9\n \n/L. La trombocitopenia mejora durante\nla infancia y puede aún ser normal en pacientes adultos con este síndrome. En la médula ósea se observa\ndisminución en el tamaño y número de megacariocitos con bloqueo en la señalización de la TPO, los ni-\nveles de TPO se encuentran incrementados y también se han identificado anormalidades en el cromosoma\n1q21.1. Además de la ausencia de ambos radios puede haber otras malformaciones acompañantes en los\nhuesos de las extremidades, estatura corta, anormalidades faciales, renales y cardíacas. Los niños afecta -\ndos con esta enfermedad pueden tener alergia a la leche de vaca, lo cual empeora la trombocitopenia. La\ntransfusión de plaquetas es parte del tratamiento y se reserva para trombocitopenias graves, en especial en","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":305,"lines":{"from":24,"to":36}}}}],["1515",{"pageContent":"transfusión de plaquetas es parte del tratamiento y se reserva para trombocitopenias graves, en especial en\nedades tempranas o cuando se requiera de procedimientos invasivos, por ejemplo, la cirugía ortopédica.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":305,"lines":{"from":36,"to":37}}}}],["1516",{"pageContent":"Cuadro 19-1.\n \nTrombocitopenias por producción insuficiente de plaquetas\n\nOrigen congénito\n\nTrombocitopenia congénita amegacariocítica\nTrombocitopenia con ausencia de radio\nAsociada al síndrome de Bernard-Soulier\nAsociada a la mutación del gen\n \nMYH9\n\nAsociada al síndrome de Wiskott-Aldrich\n\nOrigen adquirido\n\nAplasia pura de serie megacariocítica\nAsociada a quimioterapia, radioterapia y otros fármacos\nAsociada a infecciones virales\nAsociada a consumo de alcohol\nAsociada a deficiencia de ácido fólico y vitamina B12\nAsociada a deficiencia de hierro\nAsociada a infiltración de la médula ósea\nAsociada a síndromes mielodisplásicos\nAsociada a sida\nAsociada a anemia aplásica adquirida y hemoglobinuria paroxística nocturna (HPN)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":305,"lines":{"from":39,"to":65}}}}],["1517",{"pageContent":"279\n\nCAPÍTULO 19. TROMBOCITOPENIAS\n\nOtros tratamientos realizados han sido el TCPH, en casos refractarios; el uso de agonistas de TPO es\nuna posibilidad que causa entusiasmo, pero se limita si los niveles de TPO son elevados o si hay defectos\nen la señalización de los megacariocitos. Existen informes de pacientes cuya trombocitopenia mejoró\ncon el uso de eritropoyetina e interleucina 6. Se recomienda la vigilancia después de que se ha resuelto\nla trombocitopenia, por la posibilidad de trombocitopenia recurrente o el riesgo de desarrollar leucemia.\n\nAsociada al síndrome de Bernard-Soulier","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":306,"lines":{"from":1,"to":11}}}}],["1518",{"pageContent":"Los pacientes con esta enfermedad autosómica recesiva muestran trombocitopenia por una trombopoyesis\ndisminuida e ineficaz. Presentan plaquetas gigantes y disfuncionales por diversas mutaciones genéticas\nocasionando una falta de expresión del complejo glucoproteico GP Ib-IX-V la membrana plaquetaria, lo\ncual ocasiona una falta de interacción con el factor de von Willebrand, la trombina y los factores XI y XII\nde la coagulación entre otras moléculas, alterándose la adhesión plaquetaria; la supervivencia plaquetaria\ntambién se encuentra acortada. Las hemorragias se ven favorecidas principalmente por las anormalida-\ndes funcionales de las plaquetas, ya que las cifras son variables desde 20 × 10\n \n9\n \n/L hasta casi normales.\nEstos pacientes con macrotrombocitopenia en las pruebas de agregación plaquetaria presentan falta de\nagregación inducida con ristocetina, mientras que con otros agonistas como ADP, adrenalina, colágeno","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":306,"lines":{"from":13,"to":25}}}}],["1519",{"pageContent":"Estos pacientes con macrotrombocitopenia en las pruebas de agregación plaquetaria presentan falta de\nagregación inducida con ristocetina, mientras que con otros agonistas como ADP, adrenalina, colágeno\ny ácido araquidónico, la agregación es normal. Otras pruebas como el tiempo de sangrado y PFA 100\ntambién se encuentran prolongadas. Los estudios de las plaquetas con citometría de flujo son también muy\nimportantes en la caracterización y diagnóstico de la enfermedad. Se observa con frecuencia epistaxis,\ngingivorragia, equimosis, menorragia, sangrado gastrointestinal o sangrado después de una cirugía; sin\nembargo, las hemorragias son variables entre los mismos pacientes. Algunas medidas de tratamiento son\nlos anticonceptivos orales, la desmopresina, la transfusión de plaquetas, el factor VII, agentes antifibrino-\nlíticos, gelfoam y la octreotida (usada durante las hemorragias por angiodisplasias gástricas); también se\nhan empleado el TCPH y la terapia génica.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":306,"lines":{"from":25,"to":34}}}}],["1520",{"pageContent":"Asociada a la mutación del gen\nMYH9","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":306,"lines":{"from":36,"to":37}}}}],["1521",{"pageContent":"La mutación de este gen localizado en el cromosoma 22q12-13v incluye a la anomalía de May-Hegglin,\nel síndrome de Fechtner, el síndrome de Sebastian y el síndrome de Epstein. Se ve afectada la distri-\nbución de la miosina no muscular presente en las plaquetas. La trombocitopenia se produce por una\nfalta de maduración de las plaquetas y los cambios de laboratorio observados incluyen trombocitopenia,\nplaquetas gigantes e inclusiones en los leucocitos (cuerpos de Döhle). El número y la morfología de los\nmegacariocitos son normales; las pruebas de agregación en las plaquetas muestran anormalidades meno-\nres y respuesta alterada al colágeno. Los pacientes pueden cursar con lesiones glomerulares, problemas de\naudición, cataratas y tendencia a los sangrados. Se recomienda la evaluación periódica de la función renal\ny pruebas de audición en estos pacientes. Algunos individuos pueden ser confundidos como pacientes de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":306,"lines":{"from":39,"to":47}}}}],["1522",{"pageContent":"y pruebas de audición en estos pacientes. Algunos individuos pueden ser confundidos como pacientes de\ntrombocitopenia inmunitaria y recibir tratamientos indebidos. Solo se recomienda soporte transfusional\nprevio a cirugías, por hemorragia incontrolable o durante el trabajo de parto complicado. También se ha\nutilizado la desmopresina combinada con el ácido tranexámico.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":306,"lines":{"from":47,"to":50}}}}],["1523",{"pageContent":"Asociada al síndrome de Wiskott-Aldrich","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":306,"lines":{"from":52,"to":52}}}}],["1524",{"pageContent":"Es un tipo de inmunodeficiencia ligada al cromosoma X caracterizada por microtrombocitopenia, defi-\nciencia de linfocitos T, infecciones recurrentes, eccema y riesgo de desarrollar enfermedades autoinmuni-\ntarias o linfoproliferativas. Los estudios apoyan que la trombocitopenia se debe en parte a una destrucción\naumentada de plaquetas, pero además se postula que puede haber una trombopoyesis ineficaz. La des-\ntrucción de plaquetas puede ser debida a un aumento de la fosfatidilserina expuesta en su superficie o por\nla presencia de anticuerpos antiplaquetarios reportados en estos pacientes, aunque esta última hipótesis\naún es polémica.\nLas plaquetas pueden ser menores de 50 × 10\n \n9\n \n/L y tener déficits funcionales. Pocas veces la trombo-\ncitopenia se debe a fenómenos autoinmunitarios que pueden desarrollar estos pacientes. Desde el na-\ncimiento puede haber hemorragias (incidencia mayor de 80%) de leves (epistaxis, petequias, púrpura","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":306,"lines":{"from":54,"to":67}}}}],["1525",{"pageContent":"citopenia se debe a fenómenos autoinmunitarios que pueden desarrollar estos pacientes. Desde el na-\ncimiento puede haber hemorragias (incidencia mayor de 80%) de leves (epistaxis, petequias, púrpura\ny gingivorragia) a graves [hemorragia intestinal o en sistema nervioso central (SNC)], posteriormente\neccema e infecciones. La muerte por hemorragias en estos pacientes asciende a 21%.\nEn cuanto al tratamiento, el TCPH es de elección en pacientes con enfermedad grave; otros trata-\nmientos son el apoyo transfusional con plaquetas, el uso de antibióticos, los esteroides, la esplenectomía","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":306,"lines":{"from":67,"to":72}}}}],["1526",{"pageContent":"280\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\ny la terapia génica. Se piensa que el bazo desempeña un importante papel en la destrucción periférica de\nplaquetas en estos pacientes, debido a la importante mejoría en la cifra y el tamaño de las plaquetas que se\nha reportado después de la esplenectomía.\nAlgunas razones para sospechar trombocitopenias hereditarias son: la historia familiar de tromboci-\ntopenia, la falta de respuesta al tratamiento para trombocitopenia autoinmunitaria, el tamaño anormal de\nlas plaquetas, la presentación o ataque al nacimiento, anormalidades estructurales asociadas, sangrados\nfuera de proporción con las cifras de plaquetas y la trombocitopenia estable por años.\n\nOrigen adquirido\nAplasia pura de serie megacariocítica","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":307,"lines":{"from":1,"to":14}}}}],["1527",{"pageContent":"Origen adquirido\nAplasia pura de serie megacariocítica\n\nEsta aplasia cursa con trombocitopenia por supresión autoinmunitaria sobre los megacariocitos; también\nse han descrito anticuerpos contra la TPO y su receptor, y se puede asociar a enfermedades autoinmu-\nnitarias como el lupus o infecciones como la hepatitis C. Esta aplasia pura de megacariocitos puede pre-\nceder el desarrollo de otras enfermedades, como la anemia aplásica o las mielodisplasias. Como medidas\nterapéuticas para bloquear la respuesta inmunitaria se ha utilizado ciclosporina y globulina antitimocito.\n\nAsociada a quimioterapia, radioterapia y otros fármacos\nque afectan la producción plaquetaria","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":307,"lines":{"from":14,"to":24}}}}],["1528",{"pageContent":"Los fármacos de quimioterapia y la radioterapia causan trombocitopenia, pero además anemia y neu-\ntropenia; la gravedad puede ser proporcional a la intensidad de la dosis. En la mayoría de los casos estas\ncitopenias son reversibles, aunque algunos pacientes presentan citopenias prolongadas por daño tóxico a\nla médula ósea. Para el tratamiento mientras se recupera la médula ósea de la acción mielotóxica, puede\nser necesario el apoyo transfusional con plaquetas y eritrocitos, e incluso el uso de citocinas como el factor\nestimulante de colonias de granulocitos (en caso de neutropenia) y agonistas de los receptores de la TPO\n(en caso de trombocitopenia).\nAlgunos fármacos no antineoplásicos pueden causar de forma selectiva aplasia de megacariocitos,\nlo cual ocasiona trombocitopenia; entre estos fármacos encontramos a las tiazidas, que han sido las\nmás frecuentemente implicadas. Informes aislados han informado un descenso en la producción de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":307,"lines":{"from":26,"to":35}}}}],["1529",{"pageContent":"lo cual ocasiona trombocitopenia; entre estos fármacos encontramos a las tiazidas, que han sido las\nmás frecuentemente implicadas. Informes aislados han informado un descenso en la producción de\nplaquetas por el dietilestilbestrol y por el factor estimulante de colonias granulocito-macrófago. La\ngravedad del cuadro es variable y el tratamiento consistiría en el retiro del fármaco sospechoso, entre\notras medidas. Más adelante se mencionan algunos fármacos que potencialmente también disminuyen\nla producción de plaquetas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":307,"lines":{"from":35,"to":40}}}}],["1530",{"pageContent":"Asociada a infecciones virales que afectan la producción plaquetaria","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":307,"lines":{"from":42,"to":42}}}}],["1531",{"pageContent":"La trombocitopenia puede deberse a supresión directa de los megacariocitos por invasión viral o una reacción\ncruzada de anticuerpos. Se ha descrito en casos de sarampión, rubéola, varicela, dengue, virus de Epstein-\nBarr, citomegalovirus y parvovirus. También es un mecanismo descrito en pacientes con infección por HIV,\nque se mencionará más delante de forma detallada. En algunos casos el hiperesplenismo o la esplenomegalia\nacompañantes contribuyen también a la trombocitopenia. Las manifestaciones hemorrágicas por la trombo-\ncitopenia son variables y dependen de la gravedad de la trombocitopenia; dichas manifestaciones se acompa\n-\nñan también de los cambios clínicos propios de la enfermedad viral desencadenante. El tratamiento estaría\ndirigido contra la enfermedad de base, pero puede llegar a requerirse de apoyo transfusional con plaquetas, la\ngammaglobulina IV (IgG IV) e incluso el uso de esteroides. En algunos casos también se ha informado del","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":307,"lines":{"from":44,"to":53}}}}],["1532",{"pageContent":"gammaglobulina IV (IgG IV) e incluso el uso de esteroides. En algunos casos también se ha informado del\nuso de agonistas de los receptores de TPO para mejorar el grado de trombocitopenia, aunado a otras medidas\nterapéuticas para la infección viral. Los pacientes con hepatitis viral aguda o crónica pueden presentar tam\n-\nbién trombocitopenia debido a hiperesplenismo, anticuerpos antiplaquetas, citotoxicidad directa del virus en\nmegacariocitos y la falta de producción de TPO a nivel hepático. Con más frecuencia se ha observado en pa\n-\ncientes con hepatitis por virus C y menos frecuentemente con el virus B. En algunos estudios se ha observado\nque el tratamiento antiviral para el virus de la hepatitis C ha mejorado la trombocitopenia; sin embargo, la\ntrombocitopenia misma contraindica el uso de antivirales como el interferón, ya que este fármaco puede su\n-\nprimir la producción plaquetaria y, en consecuencia, agravar la trombocitopenia. Existen informes de pacien\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":307,"lines":{"from":53,"to":65}}}}],["1533",{"pageContent":"-\nprimir la producción plaquetaria y, en consecuencia, agravar la trombocitopenia. Existen informes de pacien\n-\ntes con hepatitis C que mejoraron su trombocitopenia con agonistas de TPO (eltrombopag y romiplostim),\ny posteriormente han podido recibir y completar el tratamiento antiviral para la hepatitis C con interferón.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":307,"lines":{"from":65,"to":69}}}}],["1534",{"pageContent":"281\n\nCAPÍTULO 19. TROMBOCITOPENIAS\n\nAsociada a consumo de alcohol\n\nEl consumo de alcohol durante varios días y en grandes cantidades puede producir trombocitopenia por\nla supresión directa de la producción plaquetaria en la MO. Otras causas de trombocitopenia en pacientes\nalcohólicos son la esplenomegalia congestiva, la cirrosis con deficiencia en la producción de TPO y la\ndeficiencia de ácido fólico. Las cuentas plaquetarias pueden retornar a lo normal después de suspender\nla ingesta de alcohol, ocurriendo en ocasiones trombocitosis reactiva y transitoria. Dentro de las medidas\nterapéuticas el retiro del alcohol es fundamental.\n\nAsociada a deficiencia de ácido fólico y vitamina B12","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":308,"lines":{"from":1,"to":14}}}}],["1535",{"pageContent":"Asociada a deficiencia de ácido fólico y vitamina B12\n\nEl déficit de ácido fólico y vitamina B12 es capaz de producir anemia megaloblástica y trombocitopenia\npor un defecto en la producción plaquetaria en la MO. La trombocitopenia también puede ser debida a\nfenómenos autoinmunitarios asociados con la anemia megaloblástica. En Estados Unidos, un 20% de los\npacientes con anemia debida a deficiencia de vitamina B12 pueden mostrar trombocitopenia moderada.\nLas plaquetas pueden mostrar también alteraciones en su funcionamiento. El tratamiento debe ser\nsustitutivo, con vitamina B12 y ácido fólico, una vez que se ha corregido o identificado la causa del\ndéficit de los hematínicos mencionados.\n\nAsociada a deficiencia de hierro","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":308,"lines":{"from":14,"to":24}}}}],["1536",{"pageContent":"Asociada a deficiencia de hierro\n\nTambién se han descrito casos con trombocitopenia asociada a la deficiencia grave de hierro (Fe),\npero el defecto más frecuentemente observado es la trombocitosis. La trombocitopenia de los casos\nmencionados se resolvió con la sustitución de hierro. No es raro que puedan coexistir la anemia por\ndeficiencia de hierro y la anemia megaloblástica por deficiencia de vitamina B12 o ácido fólico, y esta\núltima anemia ser la causante de la trombocitopenia, como ya lo hemos mencionado anteriormente. El\ntratamiento se debe hacer con la corrección de la causa de la deficiencia de hierro y con la sustitución\nde este por vía oral o intravenosa.\n\nAsociada a infiltración de la médula ósea","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":308,"lines":{"from":24,"to":34}}}}],["1537",{"pageContent":"Asociada a infiltración de la médula ósea\n\nLa médula ósea suele ser un sitio de infiltración por malignidades hemáticas como las leucemias o\nlinfomas; también por cánceres de pulmón, mama o próstata. Algunas infecciones como las micosis\ny tuberculosis pueden también infiltrarla, así como los trastornos metabólicos como la enfermedad de\nGaucher. A causa de dichas infiltraciones se puede entorpecer la hematopoyesis normal, observándose\ndisminución de plaquetas por una producción ineficaz. No es raro observar además pancitopenia por la\nmisma hematopoyesis inefectiva. El tratamiento será enfocado a la enfermedad de base.\n\nAsociada a síndromes mielodisplásicos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":308,"lines":{"from":34,"to":43}}}}],["1538",{"pageContent":"Los síndromes mielodisplásicos (SMD) son trastornos clonales de las células mieloides que causan cito-\npenias como la trombocitopenia, que de forma aislada se observa en el 5% de mielodisplasias y en el 50%\nde los casos combinada con otras citopenias. Las plaquetas de pacientes con SMD también pueden ser\ndisfuncionales lo que favorece aún más los sangrados. Con frecuencia se observan micromegacariocitos\nen la MO de estos pacientes con arresto en su maduración, lo que sugiere una trombopoyesis ineficaz. El\ntratamiento en estos casos incluye las medidas de soporte transfusional con eritrocitos y plaquetas, qui-\nmioterapia, agentes hipometilantes, citocinas como la eritropoyetina o el factor estimulante de colonias\nde granulocitos, globulina antitimocito, el TCPH, etcétera. En estudios recientes se ha informado que,\nen pacientes con SMD y trombocitopenia, durante el tratamiento con agentes hipometilantes, disminuyó","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":308,"lines":{"from":45,"to":53}}}}],["1539",{"pageContent":"en pacientes con SMD y trombocitopenia, durante el tratamiento con agentes hipometilantes, disminuyó\nla trombocitopenia clínicamente importante así como su frecuencia transfusional con plaquetas cuando\nrecibieron agonistas de la TPO (romiplostim), probando ser de beneficio clínico este agente.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":308,"lines":{"from":53,"to":55}}}}],["1540",{"pageContent":"Asociada al HIV\n\nLa trombocitopenia asociada con la infección por el virus de la inmunodeficiencia humana (HIV)\ntiene diversas explicaciones: destrucción acelerada de plaquetas por complejos inmunitarios, produc -\nción de plaquetas disminuida, secuestro esplénico, consumo de plaquetas cuando se presenta púrpura","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":308,"lines":{"from":57,"to":61}}}}],["1541",{"pageContent":"282\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\ntrombocitopénica trombótica (PTT) o por el uso de medicamentos antivirales, por infección asociada\nde hepatitis C, y también por neoplasias hemáticas asociadas. Estos pacientes pocas veces presentan\nsangrados importantes y sus cuentas plaquetarias son mayores de 50 × 10\n \n9\n \n/L. El tratamiento antiviral\nes muy eficaz y en otros casos más graves el tratamiento es similar al de la trombocitopenia inmunitaria\nprimaria, por medio de esteroides, gammaglobulina intravenosa e incluso con esplenectomía, con la\ncual puede haber respuestas hasta del 80%. No se ha observado progresión del sida posterior a la esple -\nnectomía. Más recientemente se han empleado los agonistas de los receptores de TPO, con lo cual la\ntrombocitopenia mejora y puede evitar que estos pacientes sean sometidos a esplenectomía.\n\nAsociada a anemia aplásica adquirida y hemoglobinuria paroxística nocturna","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":309,"lines":{"from":1,"to":18}}}}],["1542",{"pageContent":"Otras enfermedades que producen trombocitopenia por una producción inadecuada de las plaquetas son\nla anemia aplásica adquirida (AAA), en la cual se pueden suprimir las células progenitoras pluripoten-\nciales por la acción de células T activadas ocasionando no solo trombocitopenia sino pancitopenia. Con\nfrecuencia es necesario mantener plaquetas mayores de 10 × 10\n \n9\n \n/L para evitar hemorragias en los pacientes\na base de soporte transfusional; no se recomienda la transfusión profiláctica de plaquetas en pacientes con\ncuentas mayores de 10 × 10\n \n9\n \n/L y en quienes no presentan sangrados. Otros tratamientos son la ciclospo-\nrina, la globulina antitimocito y el TCPH.\nEn algunos pacientes con anemia aplásica grave refractarios a tratamiento inmunosupresor, se observó\nque al utilizar el agonista de la TPO, eltrombopag, presentaron aumento en su hematopoyesis con me-\njoría no solo de las plaquetas sino también de la anemia y neutropenia. Por otra parte, la hemoglobinuria","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":309,"lines":{"from":20,"to":37}}}}],["1543",{"pageContent":"joría no solo de las plaquetas sino también de la anemia y neutropenia. Por otra parte, la hemoglobinuria\nparoxística nocturna (HPN) es una anormalidad de las células hematopoyéticas con hemólisis y riesgo de\ntrombosis o supresión de la MO dada por la mayor sensibilidad a la lisis mediada por el sistema de com-\nplemento. En esta enfermedad se puede observar una proliferación y diferenciación disminuidas de los\nmegacariocitos, lo que conduce a la trombocitopenia. Otra causa de trombocitopenia se debe al consumo\nde plaquetas durante fenómenos trombóticos. Los tratamientos de la HPN incluyen el soporte transfusio-\nnal, el TCPH y el eculizumab (anticuerpo monoclonal anti-C5), entre otros.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":309,"lines":{"from":37,"to":43}}}}],["1544",{"pageContent":"TROMBOCITOPENIAS POR AUMENTO\nEN LA DESTRUCCIÓN DE PLAQUETAS\n\nEstas trombicitopenias pueden tener un origen inmunitario o no inmunitario\n \n(cuadro 19-2)\n.\n\nOrigen inmunitario\nTrombocitopenia inmunitaria primaria","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":309,"lines":{"from":45,"to":54}}}}],["1545",{"pageContent":"Esta enfermedad autoinmunitaria anteriormente era conocida como “púrpura trombocitopénica idiopáti-\nca” o “púrpura trombocitopénica inmune” (PTI), y se caracteriza por trombocitopenia aislada con cuentas\nplaquetarias menores de 100 × 10\n \n9\n \n/L y la ausencia de otras causas o enfermedades que puedan estar aso-\nciadas con trombocitopenia. Se considera\n \nprimaria\n \ncuando ya han sido excluidas otras entidades capaces\nde producir trombocitopenia inmunitaria, y la forma\n \nsecundaria\n \nincluye a todas aquellas enfermedades que\npuedan producir trombocitopenia inmunitaria, como el lupus eritematoso, el síndrome antifosfolípido, la\ninfección por\n \nH. pylori\n \ny el virus C de la hepatitis, entre otras.\nEn la TIP actualmente se reconocen las siguientes fases: a) de reciente diagnóstico, con menos de\n3 meses desde el diagnóstico; b) persistente, con 3 a 12 meses de diagnóstico; c) crónica, con más\nde 12 meses de diagnóstico; d) grave, cuando los pacientes presentan síntomas de sangrado al inicio o","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":309,"lines":{"from":56,"to":81}}}}],["1546",{"pageContent":"3 meses desde el diagnóstico; b) persistente, con 3 a 12 meses de diagnóstico; c) crónica, con más\nde 12 meses de diagnóstico; d) grave, cuando los pacientes presentan síntomas de sangrado al inicio o\ndurante su evolución y que ameriten tratamiento, aumento de dosis o la adición de otro medicamento;\ne) refractaria, cuando se cumplen dos criterios: primero, si existe falla a la esplenectomía o tener recaída\ndespués de haber existido respuesta con esta; segundo, tener una TIP grave o tener riesgo de hemorra -\ngia que requiera tratamiento. La distición entre la forma primaria y la secundaria es importante, ya que\nla historia natural y el tratamiento pueden ser diferentes.\nLa patogénesis de esta enfermedad se debe a la pérdida de tolerancia del sistema inmunitario a antí-\ngenos propios localizados en la superficie de las plaquetas y los megacariocitos. Los linfocitos B producen\nanticuerpos contra glucoproteínas en la superficie de las plaquetas (IIb/IIIa) y megacariocitos, lo que","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":309,"lines":{"from":81,"to":90}}}}],["1547",{"pageContent":"anticuerpos contra glucoproteínas en la superficie de las plaquetas (IIb/IIIa) y megacariocitos, lo que\nocasiona aumento en la eliminación de plaquetas por el sistema reticuloendotelial como el bazo y apop-\ntosis de los megacariocitos, causando una disminución en la producción de plaquetas. Por otra parte,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":309,"lines":{"from":90,"to":92}}}}],["1548",{"pageContent":"283\n\nCAPÍTULO 19. TROMBOCITOPENIAS\n\nlas células presentadoras de antígenos interactúan con las células T, las cuales son activadas; también se\nincrementa la relación entre ²1/²2 y emergen células ²17 que producen IL-17, todo esto favoreciendo\nla autoinmunidad. Últimamente también se menciona una disminución de las células T reguladoras en\npacientes con TIP; dichas células son importantes para mantener la tolerancia propia y reducir la respuesta\ninmunitaria mediada por anticuerpos y células. Los pacientes cursan con sangrados variables relacionados\ncon la cifra plaquetaria: con cuentas mayores de 30 a 40 × 10\n \n9\n \n/L, generalmente están asintomáticos, y con\nplaquetas menores de 10 × 10\n \n9\n \n/L, pueden tener púrpura en piel y mucosas, e incluso sangrados graves en\ntubo digestivo, vías urinarias o sistema nervioso central. Dentro de los estudios que se deben tener\nen cuenta para el diagnóstico se recomiendan:","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":310,"lines":{"from":1,"to":21}}}}],["1549",{"pageContent":"•\n \nBásicos:\n \nhistoria clínica y examen físico, biometría hemática, examen del frotis de sangre periféri-\nca, inmunoglobulinas, reticulocitos, grupo y Rh, perfil viral de hepatitis, HIV, Coombs directo y\nbúsqueda de\n \nH.pylori\n.\n\n•\n \nOtros de potencial utilidad:\n \naspirado de médula ósea, biopsia de hueso, anticardiolipinas, tiempos\nde coagulación, anticuerpos anti-DNA y antinucleares, hormonas tiroideas y biometría hemática\ncon EDTA, citrato y heparina.\nEl tratamiento de la TIP se recomienda si los pacientes tienen cuentas plaquetarias menores de 30 a\n50 × 10\n \n9\n \n/L, y puede ser dividido en:\n\nCuadro 19-2.\n \nTrombocitopenias por aumento de la destrucción de plaquetas\n\nOrigen inmunitario\n\nTrombocitopenia inmunitaria primaria (TIP)\nTIP durante el embarazo\nAsociada a lupus eritematoso generalizado\nAsociada a síndrome antifosfolípido\nAsociada a infección por\n \nHelicobacter pylori","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":310,"lines":{"from":23,"to":60}}}}],["1550",{"pageContent":"Trombocitopenia inmunitaria primaria (TIP)\nTIP durante el embarazo\nAsociada a lupus eritematoso generalizado\nAsociada a síndrome antifosfolípido\nAsociada a infección por\n \nHelicobacter pylori\n\nAsociada a malignidad\nTrombocitopenia inmunitaria por medicamentos\nAsociada a inmunodeficiencia común variable\nTrombocitopenia inducida por heparina\nTrombocitopenia postransfusional\nTrombocitopenia aloinmunitaria neonatal\n\nOrigen no inmunitario\n\nPúrpura trombocitopénica trombótica y síndrome urémico hemolítico\nAsociada a preeclampsia y síndrome de HELLP\nTrombocitopenia asociada a infecciones\nAsociada a trasplante de células progenitoras hematopoyéticas\nAsociada al síndrome de Kasabach-Merritt\nTrombocitopenia gestacional\nAsociada a la cirugía cardíaca\nAsociada a la enfermedad de von Willebrand","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":310,"lines":{"from":60,"to":84}}}}],["1551",{"pageContent":"284\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\n1. Tratamiento de primera línea:\n\n•\n \nCorticoides.\n \nPrednisona, 0,5-2 mg/kg/día (respuesta del 70%) o dexametasona 40 mg/día\npor 4 días en 1 a 4 ciclos (respuestas de 50 a 86%, respectivamente); también se ha empleado\nla metilprednisolona en dosis altas con 80% de respuesta. Los efectos secundarios de los corti -\ncoides incluyen hiperglucemia, hipocalemia, miopatía, debilidad, osteoporosis, hipertensión\narterial, entre otros, por lo que se recomienda no usar estos fármacos de forma prolongada.\n\n•\n \nInmunoglobulina anti-D.\n \nSe aplica por vía IV en dosis de 75 μg/kg, y se recomienda a pa-\ncientes con grupo Rh positivo, sin esplenectomía. Sus efectos secundarios incluyen la anemia\nhemolítica autoinmunitaria, insuficiencia renal y coagulación intravascular diseminada (CID).\nSu respuesta inicial es semejante a la de la IgG IV.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":311,"lines":{"from":1,"to":24}}}}],["1552",{"pageContent":"•\n \nInmunoglobulina G (IgG IV).\n \nSe aplica por vía intravenosa, con respuestas de hasta el 80%\npero de duración corta; el incremento de plaquetas es rápido, las dosis pueden ser de 1 a 2 g/kg\npor día durante 1 o 2 días, y otra dosis recomendada es 400 mg/kg/día por 5 días; sus efectos\nsecundarios incluyen cefalea, cambios en la tensión arterial, taquicardia, insuficiencia renal\ny trombosis.\n2. Tratamiento de emergencia:\nSe puede aplicar a pacientes con trombocitopenia grave que requieren un tratamiento quirúrgico, o en\naquellos que presentan un sangrado inminente o activo en SNC, tracto gastrointestinal o vías urinarias.\nPuede ser apropiada la transfusión de plaquetas y combinar los tratamientos de primera línea (por ejem-\nplo, corticoides + IgG IV).\n\n•\n \nTransfusión de plaquetas.\n \nPuede incrementar las plaquetas y reducir los sangrados con míni-\nmos efectos secundarios; se puede asociar a la administración de IgG IV.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":311,"lines":{"from":26,"to":46}}}}],["1553",{"pageContent":"•\n \nTransfusión de plaquetas.\n \nPuede incrementar las plaquetas y reducir los sangrados con míni-\nmos efectos secundarios; se puede asociar a la administración de IgG IV.\n\n•\n \nMetilprednisolona.\n \nSe ha utilizado en dosis altas de 1 g/día por 1 o 2 días, sola o en combina-\nción con IgG IV o transfusión de plaquetas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":311,"lines":{"from":46,"to":58}}}}],["1554",{"pageContent":"•\n \nOtros tratamientos.\n \nIncluyen los alcaloides de la vinca, como la vincristina, los antifibrinolíti-\ncos y la esplenectomía de emergencia.\n3. Tratamiento de segunda línea:\nLa esplenectomía y varios medicamentos han sido usados como tratamiento de segunda línea con\nrespuestas variables; el objetivo de estos tratamientos es mantener la cuenta de plaquetas en cifras\nseguras o hemostáticas. La esplenectomía se recomienda después de 6 meses del diagnóstico, si las con -\ndiciones del paciente lo permiten, ante la posibilidad de remisión espontánea que puede ocurrir de 6 a\n12 meses después del diagnóstico. En el\n \ncuadro 19-3\n \naparecen las opciones de tratamiento de segunda\nlínea actualmente recomendadas.\nLa esplenectomía es recomendada principalmente en adultos y se trata de evitar en los niños; se extir-\npa el mayor sitio de destrucción de plaquetas así como la fuente de producción de anticuerpos contra las","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":311,"lines":{"from":60,"to":78}}}}],["1555",{"pageContent":"pa el mayor sitio de destrucción de plaquetas así como la fuente de producción de anticuerpos contra las\nplaquetas, y responde el 80% de los pacientes. Está indicada en los que no responden a glucocorticoides\no que dependen de estos para mantener plaquetas en cifras seguras. En pacientes que serán sometidos a\nesplenectomía, se recomienda aplicar antes del procedimiento vacuna contra neumococo, que protege a los\npacientes por 5 años y luego deben ser revacunados. Otras vacunas que se recomiendan previas a la esple-\nnectomía son contra\n \nH. influenzae\n \ny meningococo. En manos expertas, la esplenectomía por laparoscopia\nes una buena alternativa al procedimiento abierto. La respuesta sostenida a la esplenectomía es del 66%\nsin tratamientos adicionales por al menos 5 años; aproximadamente el 20% tendrán recaída meses o años\ndespués. Sus principales complicaciones son los sangrados, infecciones, trombosis y además se requiere\nhospitalización prolongada.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":311,"lines":{"from":78,"to":91}}}}],["1556",{"pageContent":"después. Sus principales complicaciones son los sangrados, infecciones, trombosis y además se requiere\nhospitalización prolongada.\nOtro tratamiento que vale la pena mencionar es el rituximab, un anticuerpo monoclonal an -\nti-CD20 que se empezó a utilizar en pacientes con linfoma pero que actualmente también es empleado\nen aquellos con TIP. Su aplicación ha sido en pacientes con y sin esplenectomía así como en adultos\ny niños; de acuerdo a los resultados del total de respuestas (completas y parciales) que se informan,\nestas alcanzan el 57% y son semejantes en niños y adultos. La tolerancia del medicamento es bastante\nbuena, con poca toxicidad, y las respuestas a 5 años son de 21 a 26% de adultos y niños con TIP crónica\ntratados con dosis estándar. La respuesta a rituximab está asociada con cambios en las células T, tales","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":311,"lines":{"from":91,"to":99}}}}],["1557",{"pageContent":"285\n\nCAPÍTULO 19. TROMBOCITOPENIAS\n\nCuadro 19-3.\n \nTratamientos de segunda línea en trombocitopenia inmunitaria primaria\n\nTratamiento\n \nRespuesta\n \nPrincipales efectos secundarios","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":312,"lines":{"from":1,"to":13}}}}],["1558",{"pageContent":"Azatioprina\n \n1-2\n \nmg/kg/día\n(máximo 150 mg/día)\n \n66%\n \nNeutropenia, pancreatitis y elevación\nde transaminasas\nCiclosporina\n \n2,5-3\n \nmg/kg/día\n(nivel en plasma: 100-200 ng/mL).\n \n50-80%\n \nAumento\n \nde\n \ncreatinina,\n \nhiperten-\nsión, hiperplasia gingival\nCiclofosfamida\n \n1-2\n \nmg/kg/día\nVO por 16 sem o 0,3-1 g/m\n \n2\n \nIV\npor 1-3 dosis cada 2-4 sem\n24-85%\nNeutropenia,\n \nnáuseas,\n \nvómitos,\ntrombosis venosa aguda, cistitis he-\nmorrágica\nDanazol 200 mg, 2-4 veces/día\n \n67%\n \nAcné, amenorrea, elevación de tran-\nsaminasas, vello facial\nDapsona 75-100 mg/día\n \n50%\nAnorexia, náuseas, distensión abdo-\nminal, anemia hemolítica en defi-\ncientes de G6PD, hemoglobinuria\nMicofenolato 1 000 mg/día\npor 3-4 sem\n \n75%\n \nAnorexia, náuseas, distensión abdo-\nminal, cefalea, dolor de espalda\nRituximab 375 mg/m\n \n2\n \n, 1 vez por\nsemana por 4 semanas\n \n60%\nFiebre, exantema, dolor de garganta,\nenfermedad del suero, anafilaxia, in-\nfecciones, trombosis de arteria de la\nretina, embolismo pulmonar, reactiva-\nción de hepatitis B, leucoencefalopatía\nEsplenectomía\n \n80%","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":312,"lines":{"from":15,"to":96}}}}],["1559",{"pageContent":"enfermedad del suero, anafilaxia, in-\nfecciones, trombosis de arteria de la\nretina, embolismo pulmonar, reactiva-\nción de hepatitis B, leucoencefalopatía\nEsplenectomía\n \n80%\nHemorragia, hematoma peripancreá-\ntico, absceso subfrénico, infección de\nla herida, infección por neumococo,\nsepsis, trombosis\nEltrombopag 25-75 μg/día\n \n70% con 50 μg\ny 81% con 75 μg\nCefalea, incremento de reticulina en\nmédula ósea, trombosis, trombocito-\npenia al suspenderse, anormalidades\nde la función hepática\nRomiplostim 1-10 μg/kg\nsubcutáneos semanalmente\n88% sin\nesplenectomía\ny 79% con\nesplenectomía\nCefalea, fatiga, epistaxis, artralgias,\nincremento de reticulina en médula\nósea, trombosis, trombocitopenia al\nsuspenderse\nAlcaloides de la vinca: vincris-\ntina\n \n1-2\n \nmg\n \npor\n \ninfusión\n \nse-\nmanalmente (dosis total 6 mg);\nvinblastina 10 mg por infusión\nsemanalmente (dosis total 30 mg)\n10-75%\nNeuropatía con dosis repetidas, es-\npecialmente\n \nen\n \npacientes\n \nañosos,\nneutropenia, fiebre, tromboflebitis en\nsitio de infusión","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":312,"lines":{"from":96,"to":150}}}}],["1560",{"pageContent":"286\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":313,"lines":{"from":1,"to":3}}}}],["1561",{"pageContent":"como la restauración de la relación ²1/²2 y el incremento en el número y función de las células T\nreguladoras (Tregs) en respondedores, lo cual indica que el efecto del rituximab no simplemente es la\ndepleción de linfocitos B.\nEl 20% de los pacientes con TIP no responden a la esplenectomía, o a tratamientos de primera o se -\ngunda línea; los tratamientos que se mencionan para estos casos son la quimioterapia combinada (ciclo -\nfosfamida, prednisona y vincristina), Campath 1-H, trasplante de células progenitoras y los agonistas\nde los receptores de TPO (eltrombopag y romiplostim). Estos nuevos fármacos estimulan la producción\nplaquetaria y están aprobados por la\n \nFood and Drug Administration\n \n(FDA) de Estados Unidos para el\ntratamiento de la TIP.\nEl romiplostim se aplica por vía subcutánea de forma semanal con dosis de 1 a 10 μg/kg y el el -\ntrombopag se administra por vía oral en dosis de 25, 50 o 75 μg diariamente. El romiplostim aplicado","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":313,"lines":{"from":5,"to":19}}}}],["1562",{"pageContent":"El romiplostim se aplica por vía subcutánea de forma semanal con dosis de 1 a 10 μg/kg y el el -\ntrombopag se administra por vía oral en dosis de 25, 50 o 75 μg diariamente. El romiplostim aplicado\na pacientes con y sin esplenectomía ha mostrado respuestas del 79 y 88%, respectivamente, y se ha\nobservado algo similar con el uso de eltrombopag. Además, en el 87% de los pacientes tratados con\nromiplostim se ha reducido o descontinuado el tratamiento concurrente para la TIP, incluyendo corti -\ncoides y gammaglobulina IV. Los principales efectos adversos que se han reportado con estos fármacos\nson el aumento de reticulina en la biopsia de hueso, hepatotoxicidad, cataratas, malignidades hemáticas\ny trombosis. En estudios a 3 años usando estos agonistas de TPO informan que el 62 a 90% de los\npacientes fueron capaces de mantener plaquetas mayores de 50 × 109/L, asociado con una reducción de\nlos sangrados, disminuyendo la necesidad de tratamientos adicionales y mejorando la calidad de vida.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":313,"lines":{"from":19,"to":28}}}}],["1563",{"pageContent":"pacientes fueron capaces de mantener plaquetas mayores de 50 × 109/L, asociado con una reducción de\nlos sangrados, disminuyendo la necesidad de tratamientos adicionales y mejorando la calidad de vida.\nEl uso de romiplostim en niños ha producido un 88% de respuestas, mejorando también la calidad de\nvida. Por último, algunos pacientes han presentado respuesta sostenida a agonistas de TPO después\nde su administración, por lo que se postula que estos fármacos pueden restaurar la tolerancia inmuni -\ntaria mejorando la función de las células Tregs.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":313,"lines":{"from":28,"to":33}}}}],["1564",{"pageContent":"Trombocitopenia inmunitaria primaria durante el embarazo","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":313,"lines":{"from":35,"to":35}}}}],["1565",{"pageContent":"La TIP durante el embarazo con una frecuencia de 2 en 1 000 mujeres embarazadas puede causar trom -\nbocitopenia moderada o grave en los dos primeros trimestres; también puede exacerbarse durante esta\netapa y mejorar después del parto. Debe ser distinguida de trombocitopenias más comunes incidentales\ndurante el embarazo, como preeclampsia, síndrome de HELLP o PTT. En una revisión de 92 pacien -\ntes se observó que aquellas con TIP previamente diagnosticadas fueron menos probables de requerir\ntratamiento para TIP que aquellas con TIP de reciente diagnóstico, pero el curso varía ampliamente.\nPor otra parte, los tratamientos pueden complicar el embarazo o el desarrollo fetal. Si no hay sangrados\ny la paciente tiene una cifra plaquetaria mayor de 30 × 10\n \n9\n \n/L, solo se recomienda la observación. En un\nestudio retrospectivo de 119 pacientes con TIP durante el embarazo, solo el 30% ameritaron de alguna\nintervención terapéutica para incrementar la cuenta de plaquetas. En caso de requerirse tratamiento,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":313,"lines":{"from":37,"to":50}}}}],["1566",{"pageContent":"estudio retrospectivo de 119 pacientes con TIP durante el embarazo, solo el 30% ameritaron de alguna\nintervención terapéutica para incrementar la cuenta de plaquetas. En caso de requerirse tratamiento,\nse recomienda:\n1. Primera línea de tratamiento:","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":313,"lines":{"from":50,"to":53}}}}],["1567",{"pageContent":"•\n \nPrednisona.\n \nSe puede emplear de forma inicial en dosis de 10 a 20 mg/día para mantener las\nplaquetas en una cifra hemostáticamente eficaz, por ejemplo, más de 50 × 10\n \n9\n \n/L, y con esta\ncifra se puede llegar a tener un parto por vía vaginal normal, pero si se requiere cesárea o\nanestesia epidural, es recomendable tener plaquetas por arriba de 80 × 10\n \n9\n \n/L. Las dosis bajas\nde prednisona administradas en períodos cortos generalmente son consideradas efectivas y\nseguras para la madre, pero los corticoides pueden exacerbar la hipertensión, producir hi -\nperglucemia u osteoporosis y pueden causar ganancia de peso y psicosis. Después del parto,\nse debe vigilar la cuenta de plaquetas y disminuir los corticoides lentamente para evitar\nuna exacerbación de la trombocitopenia en la paciente y asegurar que no se afecte su estado\nmental.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":313,"lines":{"from":55,"to":76}}}}],["1568",{"pageContent":"•\n \nInmunoglobulina G intravenosa.\n \nSi las pacientes tienen plaquetas por debajo de 10 × 10\n \n9\n \n/L\ny no hay respuesta con esteroides, se puede emplear IgG IV 400 mg/kg/día por 5 días\n \no\n1 g/kg/día por 2 días; las respuestas son similares a las de pacientes no embarazadas. Des -\npués de una respuesta inicial, las infusiones de IgG IV simples son bien toleradas y pueden\nrepetirse como sea necesario para prevenir hemorragias y tener una cuenta de plaquetas\nadecuada para el parto. Una combinación de corticosteroides e IgG IV puede ser eficaz\ncuando no se observa respuesta a dichos agentes solos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":313,"lines":{"from":78,"to":94}}}}],["1569",{"pageContent":"287\n\nCAPÍTULO 19. TROMBOCITOPENIAS\n\n•\n \nGlobulina anti-D intravenosa.\n \nOtro tratamiento recomendado en pacientes no esplenectomiza-\ndas y con grupo Rh positivo es la administración de esta globulina en dosis de 50 a 75 μg/kg, resul\n-\ntando seguros para la madre y el feto en el segundo y tercer trimestres. Aunque las complicaciones\nson raras, se recomienda vigilar ictericia neonatal, anemia y prueba de Coombs positiva después\ndel parto, debido a que el anticuerpo puede atravesar la barrera placentaria.\n2. Opciones de tratamiento para pacientes con falla a la primera línea de tratamiento:\n\n•\n \nMetilprednisolona.\n \nSe puede administrar en dosis de 1 g, posiblemente combinada con IgG\nIV o azatioprina para pacientes que son refractarias a corticoides por vía oral o IgG IV sola, o\ntengan una mala respuesta a estas últimas.\n\n•\n \nAzatioprina\n. Se considera segura durante el embarazo y se puede recomendar en pacientes\nrefractarias a corticoides o IgG IV.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":314,"lines":{"from":1,"to":29}}}}],["1570",{"pageContent":"•\n \nAzatioprina\n. Se considera segura durante el embarazo y se puede recomendar en pacientes\nrefractarias a corticoides o IgG IV.\n\n•\n \nCiclosporina A\n. No se ha asociado con toxicidad significativa en la madre o el feto durante el\nembarazo en pacientes con enfermedad inflamatoria intestinal, pero no hay experiencia publi-\ncada en embarazo y TIP.\n\n•\n \nRituximab\n. Su uso es limitado en pacientes con embarazo y enfermedades linfoproliferativas;\nla experiencia es limitada y no se recomienda en TIP y embarazo.\n\n•\n \nEsplenectomía\n. Si es necesaria, debe ser practicada en el segundo trimestre por vía laparos-\ncópica. Esta técnica puede ser difícil después de la semana 20 de gestación. Se recomienda la\nvacunación profiláctica durante o después del embarazo.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":314,"lines":{"from":29,"to":53}}}}],["1571",{"pageContent":"•\n \nOtros agentes.\n \nEl danazol no se recomienda por sus posibles efectos teratogénicos y no hay\ndatos sobre el uso de agonistas de trombopoyetina en el embarazo y sus efectos en el feto son\ndesconocidos.\nLa modalidad del parto en pacientes con TIP debe ser determinada por indicaciones puramente obs-\ntétricas. No se recomienda la medición de las plaquetas fetales para predecir la trombocitopenia neonatal\npor el riesgo del procedimiento; el mejor predictor de trombocitopenia al nacimiento es su presencia en\nun hermano previo.\nLa trombocitopenia neonatal se origina en un producto de madre con TIP primaria o secundaria debido\nal paso transplacentario de los anticuerpos maternos causando inmunización y descenso en las plaquetas del\nrecién nacido. La frecuencia de púrpura neonatal con cuentas plaquetarias menores de 50 × 10\n9\n/L es de 8,9\na 14,7% y la hemorragia intracerebral en los neonatos es de 0 a 1,5% aproximadamente.\n\nAsociada a lupus eritematoso generalizado","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":314,"lines":{"from":55,"to":73}}}}],["1572",{"pageContent":"La trombocitopenia en el lupus eritematoso generalizado (LEG) se reporta en el 20 a 40% de los casos\ny su origen es multifactorial, debido a hiperesplenismo, supresión de MO, origen inmunitario, púrpura\ntrombocitopénica trombótica, síndrome urémico hemolítico (SUH), CID, estados dilucionales, sepsis y\nrelacionada a tratamiento para el LEG. Los autoanticuerpos contra las plaquetas son la causa más fre-\ncuente; su especificidad puede ser contra glucoproteínas IIb/IIIa, pero también puede haber complejos\ninmunitarios y anticuerpos antifosfolípidos que favorecen la trombocitopenia. El título de anticuerpos se\ncorrelaciona con la trombocitopenia y la actividad del LEG. En estos pacientes también se han descrito\naltos niveles séricos de TPO y anticuerpos contra TPO y su receptor, lo que estaría asociado a una baja\nproducción plaquetaria. La trombocitopenia grave en el LEG es rara, pero puede ser fatal en caso de he-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":314,"lines":{"from":75,"to":83}}}}],["1573",{"pageContent":"producción plaquetaria. La trombocitopenia grave en el LEG es rara, pero puede ser fatal en caso de he-\nmorragia de tubo digestivo, SNC o pulmonar, y por otra parte puede ser un indicador de mal pronóstico\npor asociarse a enfermedad neuropsiquiátrica, renal y síndrome antifosfolípido.\nEl tratamiento debe dirigirse para controlar la actividad del LEG y es un tanto similar al de la TIP;\npuede incluir corticoides solos o combinados con inmunosupresores, y estos medicamentos también pue-\nden controlar la trombocitopenia. Estos pacientes tienen mayor riesgo de necrosis avascular de la cabeza\nfemoral. Otro tratamiento es el rituximab, que ha demostrado ser eficaz en el tratamiento de pacientes con\nLEG refractario, especialmente aquellos con nefritis y trombocitopenia grave. En caso de trombocitope-\nnia grave, puede requerirse IgG IV e incluso la esplenectomía, con remisiones sostenidas en el 60% de los","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":314,"lines":{"from":83,"to":91}}}}],["1574",{"pageContent":"nia grave, puede requerirse IgG IV e incluso la esplenectomía, con remisiones sostenidas en el 60% de los\nenfermos; sin embargo, se han descrito casos que con el procedimiento quirúrgico pueden incrementarse\nlas complicaciones del LEG. Otros medicamentos útiles pueden ser el danazol, el cual debe ser probado\nantes de realizar la esplenectomía (para tratar de evitar el procedimiento quirúrgico), y la cloroquina, la\nazatioprina, la ciclofosfamida y la ciclosporina A.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":314,"lines":{"from":91,"to":95}}}}],["1575",{"pageContent":"288\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nAsociada al síndrome antifosfolípido","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":315,"lines":{"from":1,"to":5}}}}],["1576",{"pageContent":"En los pacientes con síndrome antifosfolípido (SAF) se puede observar trombocitopenia en el 20 a 40%\nde los casos, la cual generalmente es leve y puede ser debida a la destrucción directa de plaquetas por\nanticuerpos antifosfolípido, desintegración inmunitaria por anticuerpos contra plaquetas (observados en\nel 40% de los enfermos), consumo y agregación plaquetaria. La trombocitopenia grave con plaquetas por\ndebajo de 50 × 10\n \n9\n \n/L se presenta en el 5 a 10% de los casos.\nCon el tratamiento inmunosupresor, las plaquetas pueden aumentar y disminuir los títulos de anti-\ncuerpos antiplaquetarios, pero no así los anticuerpos antifosfolípido, sugiriendo que la trombocitopenia\nes un fenómeno inmunitario secundario concomitante con el SAF. Se ha encontrado que la trombocito-\npenia en pacientes con SAF no previene los fenómenos trombóticos, por lo cual en ciertos pacientes debe\nvalorarse una terapia profiláctica antitrombótica, aunque cursen con trombocitopenia. Las hemorragias","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":315,"lines":{"from":7,"to":20}}}}],["1577",{"pageContent":"valorarse una terapia profiláctica antitrombótica, aunque cursen con trombocitopenia. Las hemorragias\nen pacientes con SAF y trombocitopenia son poco frecuentes, y su presencia debe llevar a descartar otra\nalteración de la hemostasia, como la CID o los anticuerpos antiprotrombina. En cuanto al tratamiento de\nla trombocitopenia, puede darse de forma semejante que en pacientes con TIP, a base de corticoides, IgG\nIV, ciclofosfamida e incluso esplenectomía, con profilaxis antitrombótica en el período posoperatorio.\nOtros tratamientos descritos y que pueden ayudar a incrementar las plaquetas en estos pacientes son el\nrituximab, en casos con trombocitopenia refractaria, la aspirina, la warfarina y la cloroquina.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":315,"lines":{"from":20,"to":26}}}}],["1578",{"pageContent":"Asociada a infección por\nHelicobacter pylori","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":315,"lines":{"from":28,"to":29}}}}],["1579",{"pageContent":"La infección por\n \nH. pylori\n \nse ha relacionado con trombocitopenia inmunitaria (TI), por una reacción\ninmunológica cruzada (los anticuerpos contra\n \nH. pylori\n \npueden reaccionar contra las plaquetas) entre\notros mecanismos. La prevalencia de la infección en pacientes con TI de algunos países es variable: Italia\n50%, Japón 70% y Estados Unidos 22%, lo cual es comparable con la población general. La erradicación\nde la bacteria ha sido asociada con una respuesta en la cifra de plaquetas en aproximadamente el 50% de\nlos pacientes con TI. El tratamiento contra\n \nH. pylori\n \nparece ser menos eficaz en pacientes con TI grave\n(plaquetas por debajo de 30 × 10\n \n9\n \n/L) o con una enfermedad de larga evolución. El tratamiento de erradi-\ncación para\n \nH. pylori\n \nes fácil y barato, y si se logra la erradicación y hay respuesta plaquetaria, los pacientes\npueden evitarse otros tratamientos para la TI, como los esteroides, los inmunosupresores e incluso la\nesplenectomía.\n\nAsociada a malignidad","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":315,"lines":{"from":31,"to":62}}}}],["1580",{"pageContent":"Otras trombocitopenias que se han asociado con malignidad incluyen la trombocitopenia inmunitaria, la\nCID y la PTT. La trombocitopenia inmunitaria puede acompañar a procesos linfoproliferativos como los\nlinfomas, la leucemia linfocítica crónica y el mieloma múltiple.\nLa CID puede estar asociada a los adenocarcinomas de mama, colon, pulmón, páncreas, etcétera, y los\npacientes pueden presentar trombocitopenia, además de trombosis (con más frecuencia venosa). Los pacientes\ncon trombosis se benefician con la administración de heparina, observándose mejoría en la trombocitopenia.\nLos pacientes portadores de leucemia promielocítica pueden también cursar con CID y trombocitopenia\ncon tendencia a las hemorragias; dentro del tratamiento recomendado para ellos está la administración de\nla tretinoína (ácido holotransretinoico), la cual puede ayudar a corregir las alteraciones en la coagulación, la\nquimioterapia y el apoyo transfusional.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":315,"lines":{"from":64,"to":73}}}}],["1581",{"pageContent":"la tretinoína (ácido holotransretinoico), la cual puede ayudar a corregir las alteraciones en la coagulación, la\nquimioterapia y el apoyo transfusional.\nLa importancia de la trombocitopenia en pacientes con posibles malignidades radica en que puede ser\nuna manifestación o clave que sugiera la posible coexistencia de CID.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":315,"lines":{"from":73,"to":76}}}}],["1582",{"pageContent":"Trombocitopenia inmunitaria por medicamentos\n\nLa trombocitopenia por medicamentos fue descrita hace más de 100 años por la ingesta de quinina, que es\nun agente antipalúdico. Hoy en día la quinina también es utilizada como un componente del agua tónica\npara algunas bebidas. Posteriormente se ha informado con un gran número de fármacos\n \n(cuadro 19-4)\n.\nOtro de los medicamentos que pueden causar este tipo de trombocitopenia es la heparina, la cual será\ndescrita más adelante en este capítulo. Los principales mecanismos explicativos incluyen la formación de\nanticuerpos IgG dependientes del fármaco, que se unen a las glucoproteínas de la membrana plaquetaria\ny posteriormente las plaquetas opsonizadas con IgG son retiradas por los macrófagos del sistema reticu -\nloendotelial (SRE); otro mecanismo es la formación de inmunocomplejos entre el fármaco o su metabolito","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":315,"lines":{"from":78,"to":90}}}}],["1583",{"pageContent":"La trombocitopenia por me-\ndicamentos fue descrita hace\nmás de 100 años por la inges-\nta de quinina; posteriormente\nse informó con otros fármacos.\nLa quinidina y las sulfona-\nmidas\n \nson\n \nde\n \nlos\n \nfármacos\nmás citados como causantes de\ntrombocitopenia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":315,"lines":{"from":92,"to":108}}}}],["1584",{"pageContent":"289\n\nCAPÍTULO 19. TROMBOCITOPENIAS\n\nCuadro 19-4.\n \nFármacos que pueden causar trombocitopenia\n\nMediante alteración en la producción de plaquetas\n \nMediante aumento en la destrucción de plaquetas por me-\ncanismos inmunitarios\nRiesgo alto\n \nQuinina\n\nAlquilantes: ciclofosfamida, busulfano, melfalán\nFármacos cardiovasculares:\n \nquinidina\n, amiodarona, procai-\nnamida, captopril,\n \nmetildopa\n, digoxina, alprenolol, amlodi-\npino, diltiazem, losartán, nitroglicerina, pentoxifilina\nAntimetabolitos: metotrexato, mercaptopurina, fluoracilo\n \nSedantes: clordiazepóxido, diazepam, haloperidol\nAntracíclicos: daunorrubicina, mitoxantrona, doxorrubicina\n \nSulfas\n: trimetoprim-sulfametoxazol\n, sulfisoxasol, sulfasalazina\n\nRiesgo intermedio\n \nAntiácidos:\n \ncimetidina\n,\n \nranitidina","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":316,"lines":{"from":1,"to":43}}}}],["1585",{"pageContent":"Riesgo intermedio\n \nAntiácidos:\n \ncimetidina\n,\n \nranitidina\n\nSales de oro\n \nHipoglucemiantes: clorpropamida, glibenclamida, rosiglitazona\nCarbamazepina\n \nAnticonvulsivantes:\n \ncarbamazepina\n, fenitoína\nHidantoína\n \nAnalgésicos:\n \nparacetamol\n,\n \ndiclofenaco\n, naproxeno, sulin-\ndaco, ibuprofeno, indometacina, rofecoxib, piroxicam\nFenilbutazona\n \nSales de oro\n\nCloranfenicol\n \nDiuréticos: acetazolamida,\n \nhidroclorotiazida\n\nSulfonamidas\n \nAntimicóticos: anfotericina, fluconazol, terbinafina, itraconazol\nAcetazolamida\nAntibióticos: ampicilina, piperacilina, ciprofloxacino, cefa-\nlosporinas, claritromicina, meloxicam, oxitetraciclina, peni-\ncilina,\n \nvancomicina\n, gentamicina\n\nRiesgo bajo\n \nAntituberculosos:\n \nrifampicina\n, etambutol, isoniazida\nAspirina y salicilatos\n \nAntiagregantes plaquetarios: ticlopidina, clopidogrel,\n \nab-\nciximab\n,\n \neptifibatida, tirofibán\n\nQuinidina\n \nAntivirales: indinavir, adefovir\nColchicina\n \nAntipsoriásicos:\n \nefalizumab","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":316,"lines":{"from":43,"to":115}}}}],["1586",{"pageContent":"Quinidina\n \nAntivirales: indinavir, adefovir\nColchicina\n \nAntipsoriásicos:\n \nefalizumab\n\nAnticonvulsivantes: etosuximida, primidona, valproato\n \nIsotretinoína\nDiuréticos: clorotiazida, furosemida\n \nNimesulida\nAntidiabéticos: clorpropamida, tolbutamida\n \nAntiparasitarios: albendazol, piperacina\nClorfeniramina\n \nÁcido nalidíxico\n\nCaptopril\n \nHipolipemiantes: simvastatina, atorvastatina\nAntiinflamatorios no esteroideos\n \nTamoxifeno\nPenicilina\n \nHierro dextrán\nEstreptomicina\n \nInfliximab\n\nβ\n-lactámicos\n \nClorfeniramina\nDapsona\n \nDrogas: cocaína, heroína\nAntimicóticos: anfotericina, flucitosina\n \nAntidepresivos: amitriptilina, mianserina\nAntipalúdicos: cloroquina, pirimetamina\n \nDanazol\n\nTiclopidina\n \nLevodopa\nAntitiroideos: metimazol, propiltiouracilo, carbimazol\n \nMorfina\nSedantes: clordiacepóxido, clorpromazina\n \nInterferón\n\u0003α","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":316,"lines":{"from":115,"to":173}}}}],["1587",{"pageContent":"Ticlopidina\n \nLevodopa\nAntitiroideos: metimazol, propiltiouracilo, carbimazol\n \nMorfina\nSedantes: clordiacepóxido, clorpromazina\n \nInterferón\n\u0003α\n\nOtros: interferón, alopurinol, pentoxifilina\n \nVacunas: antiinfluenza, anti-hepatitis B\nLos fármacos en letras\n negritas\n \nson los que han sido reportados como causantes de trombocitopenia inmunitaria con mayor frecuencia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":316,"lines":{"from":173,"to":190}}}}],["1588",{"pageContent":"290\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":317,"lines":{"from":1,"to":3}}}}],["1589",{"pageContent":"más el anticuerpo más las plaquetas, con una extracción subsecuente de estos complejos por parte el SRE.\nDe forma más rara, los anticuerpos inducidos por los medicamentos pueden estar dirigidos contra eritro-\ncitos o leucocitos, además de las plaquetas.\nEl tiempo aproximado entre la exposición a los fármacos y el desarrollo de la trombocitopenia es varia-\nble, pero en promedio son 14 días o menos y se pueden observar desde hemorragias (petequias o púrpura)\nhasta pacientes asintomáticos y solo con trombocitopenia; por lo mismo, la vigilancia intrahospitalaria\ndependerá de las manifestaciones de cada paciente\nEl diagnóstico puede confirmarse si la recuperación de las plaquetas sucede después del retiro del fár-\nmaco sospechoso. Las plaquetas pueden llegar a descender hasta 20 × 10\n \n9\n \n/L. En cuanto al uso de vacunas,\nse ha informado recientemente que la exposición a vacunas de uso común en pacientes adultos no se asoció","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":317,"lines":{"from":5,"to":18}}}}],["1590",{"pageContent":"9\n \n/L. En cuanto al uso de vacunas,\nse ha informado recientemente que la exposición a vacunas de uso común en pacientes adultos no se asoció\ncon un riesgo observable de desarrollar trombocitopenia inmunitaria; no obstante, en informes previos se\nsostiene que algunas vacunas pueden causar trombocitopenia.\nEl tratamiento incluye, según el caso, no solo la suspensión obligada del fármaco sospechoso y la\nsustitución por otro que no cause trombocitopenia, sino también el uso de glucocorticoides, que aunque\nno acortan la duración de la trombocitopenia, favorecen la integridad vascular disminuyendo los sangra-\ndos; por otra parte, la transfusión de plaquetas puede ser útil por el riesgo o la presencia de sangrados\nque pongan en peligro la vida de los pacientes. La administración de IgG IV y esteroides en dosis altas\ntambién puede ser muy útil, sobre todo en los pacientes de alto riesgo de hemorragias. Otros autores","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":317,"lines":{"from":18,"to":29}}}}],["1591",{"pageContent":"también puede ser muy útil, sobre todo en los pacientes de alto riesgo de hemorragias. Otros autores\nhan mencionado la utilidad del recambio plasmático en casos refractarios. Generalmente, con retirar el\nagente agresor la recuperación suele iniciar 1 o 2 días después de descontinuar el fármaco; sin embargo,\nalgunas sustancias como las sales de oro pueden causar trombocitopenia incluso durante meses. Además,\ndebe aclararse que la sensibilidad al medicamento productor de la trombocitopenia también puede durar\nindefinidamente, por lo que la readministración del fármaco causante puede ser capaz de producir nue-\nvamente trombocitopenia.\nEn el cuadro 19-4 se mencionan los fármacos que provocan más frecuentemente trombocitopenia de\norigen inmunitario y por supresión de la producción en la médula ósea.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":317,"lines":{"from":29,"to":37}}}}],["1592",{"pageContent":"Asociada a inmunodeficiencia común variable\n\nLa inmunodeficiencia común variable (IDCV) es una enfermedad caracterizada por trombocitopenia,\ninfecciones bacterianas recurrentes (pueden incluir neumonía o gastrointestinales), hipogammaglobu-\nlinemia y respuesta defectuosa de anticuerpos. También hay hiperplasia linfoide en el intestino delga-\ndo y fenómenos autoinmunitarios como artritis reumatoide, anemia hemolítica, trombocitopenia y\nneutropenia. En estos pacientes se puede encontrar disminución de linfocitos B y T. La trombo-\ncitopenia inmunitaria se asocia con una frecuencia del 10%. Los estudios de laboratorio muestran\ntrombocitopenia y disminución de inmunoglobulinas (p. ej., G, A y M), lo cual debe hacer sospechar su\ndiagnóstico. Se deben evitar la esplenectomía y los agentes inmunosupresores, resultando preferible la\naplicación periódica de IgG IV.\n\nTrombocitopenia inducida por heparina","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":317,"lines":{"from":39,"to":51}}}}],["1593",{"pageContent":"La trombocitopenia inducida por heparina (TIH) es una complicación del tratamiento con heparina en la\ncual las plaquetas disminuyen un 50% respecto de la cifra basal o se reducen por debajo de 150 × 10\n9\n/L, con\nel riesgo también de presentar fenómenos trombóticos. La frecuencia es mayor en pacientes tratados con he-\nparina no fraccionada (HNF: 1-5%) en comparación con la heparina fraccionada (HF: 0,2-1%). Se relaciona\ncon la duración de la exposición y se observa con más frecuencia en pacientes quirúrgicos (traumatismos o\nprocedimientos ortopédicos), con una frecuencia del 2 al 5%; comparado con pacientes no quirúrgicos cuya\nfrecuencia es del 0,8 al 3%.\nPara el diagnóstico se toma en cuenta la aparición de trombocitopenia sin otra causa que la explique\ny la presencia de un nuevo evento trombótico en pacientes con trombosis que se encontraran recibiendo\nheparina.\nLa aparición de la TIH se debe a la interacción entre la heparina, el factor plaquetario 4 (secretado","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":317,"lines":{"from":53,"to":65}}}}],["1594",{"pageContent":"heparina.\nLa aparición de la TIH se debe a la interacción entre la heparina, el factor plaquetario 4 (secretado\npor las plaquetas y células endoteliales) y un anticuerpo IgG, formándose un complejo capaz de activar\na las plaquetas y causar agregación plaquetaria con trombocitopenia secundaria a la misma agregación,\ny por aclaramiento de plaquetas cubiertas de anticuerpos en el SRE. La trombosis también se ve fa -\nvorecida por la interacción de los complejos inmunitarios (heparina-FP4-IgG) con las células endote -\nliales y los macrófagos, causando un proceso de expresión del factor tisular que acelera la coagulación","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":317,"lines":{"from":65,"to":71}}}}],["1595",{"pageContent":"La aparición de esta trom-\nbocitopenia se debe a la inte-\nracción entre la heparina, el\nfactor plaquetario 4 (secreta-\ndo por las plaquetas y células\nendoteliales) y un anticuerpo\nIgG, formándose un complejo\ncapaz de activar a las plaque-\ntas y causar agregación pla-\nquetaria con trombocitopenia\nsecundaria a la misma agre-\ngación, y por aclaramiento de\nplaquetas cubiertas de anti-\ncuerpos en el SRE.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":317,"lines":{"from":73,"to":86}}}}],["1596",{"pageContent":"291\n\nCAPÍTULO 19. TROMBOCITOPENIAS\n\ny refuerza la activación plaquetaria. La trombocitopenia aparece entre 5 y 10 días después de haberse\niniciado la heparina. Se han descrito dos tipos de TIH: la de tipo I, con plaquetas arriba de 100 ×\n10\n \n9\n \n/L, sin manifestaciones clínicas de ningún tipo, y la de tipo II, que es menos frecuente y cursa con\nplaquetas por debajo de 50 × 10\n \n9\n \n/L y alto riesgo de trombosis.\nPara mejorar y estandarizar el diagnóstico fue creado una puntuación que incluye cuatro “T”:\na.\n \nMagnitud de la\n \nTrombocitopenia\n\nb.\n \nTiempo\n \nde la trombocitopenia con respecto a la exposición de la heparina\nc.\n \nTrombosis\n \nu otras secuelas de la TIH\nd. Probabilidad de\n \notras causas de Trombocitopenia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":318,"lines":{"from":1,"to":36}}}}],["1597",{"pageContent":"Esta puntuación permite clasificar a los pacientes en baja, intermedia y alta probabilidad de presentar\nTIH. La trombosis se observa en aproximadamente el 17 a 53% de los pacientes con TIH aislada. Son más\nfrecuentes las trombosis venosas, entre las que figuran la trombosis venosa de las extremidades, la trom-\nboembolia pulmonar, el infarto suprarrenal o la trombosis venosa cerebral, y dentro de las arteriales la\ntrombosis arterial miocárdica o cerebral, la trombosis de la arteria mesentérica y la trombosis de la arteria\nrenal. Algunos cambios clínicos que son relativamente específicos de TIH son las lesiones gangrenosas de\nla piel en los sitios de la inyección de heparina (necrosis o placas eritematosas).\nEn algunos casos se ha reportado que la trombocitopenia apareció junto con eventos trombóticos o\ndías después de haberse suspendido una terapia con heparina, por lo que se debe tener en cuenta. La\nprueba diagnóstica de elección es la demostración de anticuerpos contra heparina-FP4 por método","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":318,"lines":{"from":38,"to":47}}}}],["1598",{"pageContent":"días después de haberse suspendido una terapia con heparina, por lo que se debe tener en cuenta. La\nprueba diagnóstica de elección es la demostración de anticuerpos contra heparina-FP4 por método\ninmunoenzimático, con certeza de 80 a 90%. Si el diagnóstico es confirmado por el laboratorio, se reco -\nmienda realizar un estudio ecográfico en las extremidades superiores e inferiores para descartar trom -\nbosis subclínicas, ya que dichas complicaciones pueden alterar la duración de la terapia anticoagulante.\nEn la prevención de esta enfermedad se recomienda usar heparina fraccionada, ya que ofrece un menor\nriesgo que la heparina no fraccionada, y limitar los períodos de uso de heparina para tromboprofilaxis;\nla utilización de pentasacáridos sintéticos también puede reducir el riesgo de TIH. El reemplazo de\nheparina no fraccionada por heparina fraccionada impone un riesgo por reactividad cruzada, por lo que\ntampoco se recomienda.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":318,"lines":{"from":47,"to":56}}}}],["1599",{"pageContent":"heparina no fraccionada por heparina fraccionada impone un riesgo por reactividad cruzada, por lo que\ntampoco se recomienda.\nLos inhibidores directos de la trombina sustituyen a la heparina y con estos fines son utilizados el arga-\ntroban, lepirudina, bivalirudina y desirudina. También se puede sustituir la heparina con los inhibidores del\nfactor Xa: danaparoide y fondaparinux. Todos ellos son los agentes recomendados para el tratamiento de la\ntrombosis asociada a TIH. Todos estos fármacos deben usarse con precaución por el riesgo de hemorragias.\nOtros tratamientos concomitantes pueden ser la tromboembolectomía, la IgG IV, la aspirina y la plasmafé\n-\nresis con plasma fresco congelado en casos refractarios al tratamiento con inhibidores directos de la trombina o\ncon trombosis progresiva. La transfusión de plaquetas rara vez está indicada y solo se deja en caso de hemorra\n-\ngia clínicamente significativa, alto riesgo de hemorragia o un diagnóstico incierto. Posteriormente los pacientes","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":318,"lines":{"from":56,"to":67}}}}],["1600",{"pageContent":"-\ngia clínicamente significativa, alto riesgo de hemorragia o un diagnóstico incierto. Posteriormente los pacientes\nrecibirán anticoagulantes orales como la warfarina cuando sus plaquetas se hayan normalizado. La duración\nde la terapia anticoagulante se recomienda por 4 semanas en casos de TIH aislada y un mínimo de 3 meses en\ncasos de TIH complicada.\nLos anticuerpos producidos en la TIH son transitorios y después de algunas semanas o meses desaparecen.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":318,"lines":{"from":67,"to":72}}}}],["1601",{"pageContent":"Trombocitopenia postransfusional","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":318,"lines":{"from":74,"to":74}}}}],["1602",{"pageContent":"Es una complicación de la transfusión sanguínea con trombocitopenia aguda y grave que se registra en\naproximadamente 1/7 000 transfusiones. Suele ocurrir de 7 a 10 días después de una transfusión de cual\n-\nquier componente sanguíneo, debido a la presencia de aloanticuerpos específicos para algunos antígenos\nplaquetarios, el más frecuentemente reportado es contra el antígeno (PI)A1 (HPA-1a). Generalmente\nafecta a multíparas sensibilizadas por embarazos previos, mujeres de edad media o edad avanzada o mul-\ntitransfundidas. También se ha descrito en pacientes posterior al trasplante de MO o de órganos sólidos.\nLos pacientes frecuentemente están hospitalizados con estados agudos, los cuales tienen antecedente\nde transfusión, generalmente con paquete eritrocitario, y cursan con trombocitopenia grave (menor de\n10 × 10\n9\n \n/L), fiebre, púrpura mucocutánea con petequias y equimosis, e incluso hemorragia en el SNC,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":318,"lines":{"from":76,"to":88}}}}],["1603",{"pageContent":"de transfusión, generalmente con paquete eritrocitario, y cursan con trombocitopenia grave (menor de\n10 × 10\n9\n \n/L), fiebre, púrpura mucocutánea con petequias y equimosis, e incluso hemorragia en el SNC,\nespecialmente en las primeras 24 a 48 horas. En la patogenia se ha propuesto la formación de complejos\ninmunitarios que favorecen el aclaramiento de las plaquetas a nivel esplénico o por acción del comple-\nmento y también se planteó el paso de un antígeno soluble HPA-1a y/o la formación de un aloanticuerpo\nde especificidad anti-HPA-1a, que se fija a las plaquetas del paciente posterior a la transfusión.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":318,"lines":{"from":88,"to":96}}}}],["1604",{"pageContent":"Es poco frecuente y suele ocu-\nrrir de 7 a 10 días después de\nuna\n \ntransfusión\n \nde\n \nsangre,\ndebido\n \na la presencia de aloan-\nticuerpos específicos para antí-\ngenos plaquetarios PIA\n \n1\n; el más\nfrecuentemente observado es el\nanti-PI\n \nA1\n \n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":318,"lines":{"from":98,"to":120}}}}],["1605",{"pageContent":"292\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nPara su tratamiento se han usado el intercambio plasmático, los corticoides y la administración de\nIgG IV, que suelen ser eficaces y acortan el período de trombocitopenia. La plasmaféresis es eficaz en el\n80% de los casos pero se prefiere a la IgG IV por ser un tratamiento menos invasivo. La transfusión de\nplaquetas se reserva para pacientes con hemorragias graves. Después de algunos días de tratamiento, la\ntrombocitopenia se resuelve.\n\nTrombocitopenia aloinmunitaria neonatal","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":319,"lines":{"from":1,"to":11}}}}],["1606",{"pageContent":"La destrucción de plaquetas en estos casos se debe al paso transplacentario de los anticuerpos maternos\ncontra las plaquetas del producto; las plaquetas fetales son portadoras de antígenos heredados del pa-\ndre, mostrando algunas semejanzas a la anemia hemolítica del recién nacido por la incompatibilidad al\nRh(D)+, excepto que la trombocitopenia se puede presentar desde el primer embarazo. Se ha descrito una\nasociación de la trombocitopenia y la presencia de HLA-DRB3* 0101 en las mujeres PI\n \nA1\n \nnegativas, lo\ncual aumenta el riesgo de trombocitopenia aloinmunitaria neonatal (TAN).\nSu frecuencia se estima en 1:500 a 1:2 000 nacidos vivos. Esta trombocitopenia es más grave y la\nhemorragia intracraneal es más frecuente que en los casos de recién nacidos de madres con TIP; se ve\nfavorecida por la prematurez. La cuenta materna de plaquetas es normal en la TAN a diferencia de la TIP,\nen la que la madre suele tener trombocitopenia. Se manifiesta por lesiones purpúricas generalizadas en la","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":319,"lines":{"from":13,"to":26}}}}],["1607",{"pageContent":"en la que la madre suele tener trombocitopenia. Se manifiesta por lesiones purpúricas generalizadas en la\npiel y mucosas del recién nacido, ya sea desde el nacimiento o a las pocas horas de vida; además, aparece\nanemia secundaria a los sangrados que pueden ocurrir incluso in utero. Los aloanticuerpos pueden cruzar\nla placenta desde la semana 14 y el paso aumenta con la edad gestacional. El diagnóstico se sospecha en\nneonatos con trombocitopenia grave sin una causa explicable, como sepsis o TIP. Los recién nacidos afec-\ntados pueden estar asintomáticos (13-59%), tener síntomas hemorrágicos (18-65%) o mostrar hemorragia\nen el SNC (22-23%), y la mortalidad asciende al 25%. Las medidas terapéuticas en la etapa prenatal que\nse recomiendan actualmente incluyen a la IgG IV semanal a la madre, con o sin glucocorticoides. La\ntransfusión de plaquetas in utero puede acarrear morbilidad maternofetal.\nEn la etapa posnatal se puede emplear la IgG IV con o sin glucocorticoides en el recién nacido, la","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":319,"lines":{"from":26,"to":35}}}}],["1608",{"pageContent":"transfusión de plaquetas in utero puede acarrear morbilidad maternofetal.\nEn la etapa posnatal se puede emplear la IgG IV con o sin glucocorticoides en el recién nacido, la\ntransfusión de plaquetas PI\nA1\n \nnegativas y eritrocitos compatibles ABO-Rh. La lactancia debe restringirse,\nya que los anticuerpos reactivos pueden excretarse por la leche materna.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":319,"lines":{"from":35,"to":41}}}}],["1609",{"pageContent":"Origen no inmunitario\nLa púrpura trombótica-trombocitopénica-síndrome urémico hemolítico (PTT-SUH)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":319,"lines":{"from":43,"to":44}}}}],["1610",{"pageContent":"Es un síndrome caracterizado por episodios de trombocitopenia, fiebre, signos neurólogicos fluctuantes,\nfalla renal y anemia hemolítica microangiopática debido a trombosis microvascular diseminada. Con ma-\nyor frecuencia se llega a observar solo trombocitopenia, anemia hemolítica, esquistocitos y DHL elevada.\nEste síndrome se debe a la deficiencia grave de una proteasa llamada\n \nADAMTS-13\n \nque puede ser debi-\nda a mutaciones en el gen de la ADAMTS-13 (PTT congénita) o a autoanticuerpos anti-ADAMTS-13\n(PTT autoinmunitaria). La deficiencia grave de ADAMTS-13 mediada por anticuerpos, más común-\nmente de tipo IgG, puede ser detectada en la mayoría de los pacientes con PTT idiopática, mientras su\nprevalencia es mucho menor en los pacientes con PTT secundaria (asociada a embarazo, infecciones,\nenfermedades autoinmunitarias y el uso de fármacos, tales como la ticlopidina, clopidogrel, trimetoprim,\ninterferón pegilado, simvastatina y quinina). También se debe mencionar que hay formas idiopáticas de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":319,"lines":{"from":46,"to":59}}}}],["1611",{"pageContent":"interferón pegilado, simvastatina y quinina). También se debe mencionar que hay formas idiopáticas de\nPTT con solo deficiencia leve o aun con niveles normales de ADAMTS-13 en la presentación.\nLa forma idiopática tiende a ser menos grave, pero el riesgo de enfermedad recurrente es mayor que\nen las formas secundarias. Su mortalidad era mayor a 90%, pero ha disminuido después del tratamiento\nde intercambio plasmático. La mortalidad es mayor en los casos de PTT secundaria (39%) en compa-\nración con la primaria (21%), a lo cual posiblemente contribuya la enfermedad subyacente. El riesgo de\nrecurrencias es alto (40%) en pacientes con deficiencia grave de ADAMTS-13 y autoanticuerpos an-\nti-ADAMTS-13. La persistencia de autoanticuerpos anti-ADAMTS-13 y la deficiencia marcada en la\nactividad de la enzima (menos del 10%) durante la remisión de la enfermedad se asocian también al riesgo\nincrementado de recurrencia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":319,"lines":{"from":59,"to":68}}}}],["1612",{"pageContent":"actividad de la enzima (menos del 10%) durante la remisión de la enfermedad se asocian también al riesgo\nincrementado de recurrencia.\nLa proteasa ADAMTS-13 fragmenta los grandes multímeros del factor de von Willebrand (FvW); la\nfalta de fragmentación del FvW facilita la agregación plaquetaria en la microcirculación.\nLa inhibición de la proteasa ADAMTS-13 facilita la formación de trombos compuestos por plaque-\ntas, FvW, fibrina y células inflamatorias en arteriolas y capilares de cualquier órgano, pero en especial","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":319,"lines":{"from":68,"to":73}}}}],["1613",{"pageContent":"La destrucción de plaquetas en\nla trombocitopenia aloinmu-\nnitaria neonatal se debe al paso\ntransplacentario de los anti-\ncuerpos\n \nmaternos\n \ncontra\n \nlas\nplaquetas del producto, las pla-\nquetas fetales son portadoras de\nantígenos heredados del padre,\nmostrando algunas semejanzas\ncon la anemia hemolítica del\nrecién nacido.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":319,"lines":{"from":75,"to":91}}}}],["1614",{"pageContent":"293\n\nCAPÍTULO 19. TROMBOCITOPENIAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":320,"lines":{"from":1,"to":3}}}}],["1615",{"pageContent":"en corazón, riñón, páncreas, cerebro y glándula suprarrenal. La forma idiopática con más frecuencia se\npresenta en mujeres de 20 a 50 años, observándose anemia hemolítica microangiopática, púrpura, cam-\nbios neurológicos e insuficiencia renal. La hemoglobina se encuentra baja y se registra trombocitopenia,\naumento de deshidrogenasa láctica (DHL), esquistocitos, disminución en la actividad de ADAMTS-13\ny aumento del FvW.\nDespués del diagnóstico, el recambio plasmático es el tratamiento de elección para episodios agu -\ndos de PTT, ya que reduce importantemente la mortalidad y es superior a la infusión de plasma; debe\niniciarse inmediatamente y continuarse diariamente hasta que el paciente tenga plaquetas por arriba de\n150 × 10\n \n9\n \n/L y DHL normal. Puede usarse una infusión de plasma de 15 a 30 mL/kg/día para reponer\nla ADAMTS-13 mientras comienza el recambio plasmático El recambio plasmático retira anticuerpos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":320,"lines":{"from":5,"to":18}}}}],["1616",{"pageContent":"150 × 10\n \n9\n \n/L y DHL normal. Puede usarse una infusión de plasma de 15 a 30 mL/kg/día para reponer\nla ADAMTS-13 mientras comienza el recambio plasmático El recambio plasmático retira anticuerpos\ncontra ADAMTS-13 y reemplaza la enzima. El número de recambios para lograr la remisión es varia-\nble y generalmente mayor en la enfermedad adquirida mediada por anticuerpos. Se recomienda iniciar\nel intercambio de 1,5 volúmenes de plasma, los cuales se pueden reducir a 1 cuando los síntomas y las\npruebas de laboratorio se estabilicen. En la forma hereditaria o congénita de la PTT solo se recomienda\nla infusión de plasma y la frecuencia dependerá de los síntomas y pruebas de laboratorio, pero típica -\nmente se requiere cada 3 a 4 semanas. También se han administrado glucocorticoides, ciclosporina y\nazatioprina, los cuales se han adicionado al tratamiento de plasmaféresis, aunque su eficacia nunca se\nha confirmado con estudios bien controlados.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":320,"lines":{"from":18,"to":31}}}}],["1617",{"pageContent":"azatioprina, los cuales se han adicionado al tratamiento de plasmaféresis, aunque su eficacia nunca se\nha confirmado con estudios bien controlados.\nLa transfusión de plaquetas está contraindicada y queda reservada ante hemorragias graves; los agentes\nantiplaquetarios son materia de polémica y no han mostrado la modificación de la enfermedad.\nTambién se ha utilizado el rituximab, un anticuerpo monoclonal que actúa contra linfocitos CD20;\naplicando una vez por semana de 2 a 8 dosis, la mayoría de los pacientes que han sido tratados con este\nagente han respondido favorablemente. La respuesta llega a ser del 95% de 1 a 3 semanas después de haber\niniciado el tratamiento, normalizándose los niveles de ADAMTS-13 y desapareciendo los anticuerpos.\nEn los pacientes con PTT, debido al riesgo de recaídas, es aconsejable el seguimiento con ADAMTS-13\ny se puede considerar el tratamiento electivo.\nOtros tratamientos que se encuentran en investigación son la administración de ADAMTS-13","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":320,"lines":{"from":31,"to":41}}}}],["1618",{"pageContent":"y se puede considerar el tratamiento electivo.\nOtros tratamientos que se encuentran en investigación son la administración de ADAMTS-13\nrecombinante, que restaura la fragmentación del FvW, y fármacos que pueden bloquear la activación\nplaquetaria mediada por el FvW. Puede ser necesaria la transfusión de eritrocitos, hemodiálisis, anti -\nhipertensivos y anticonvulsivantes\nLas pruebas de coagulación por lo general no muestran anormalidades. El diagnóstico diferencial\ndebe hacerse con la anemia hemolítica autoinmunitaria, preeclampsia, síndrome de HELLP, síndrome de\nEvans, TIP, endocarditis bacteriana, CID, sepsis, lupus eritematoso, síndrome antifosfolípido, hemoglo-\nbinuria paroxística nocturna con complicación trombótica y con la anemia hemolítica asociada a cáncer","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":320,"lines":{"from":41,"to":49}}}}],["1619",{"pageContent":"(cuadro 19-5)\n.\nEl síndrome urémico hemolítico puede aparecer a los pocos días de comenzada una enfermedad\ndiarreica; se presenta a cualquier edad, pero afecta principalmente a niños menores de 10 años y es a\nconsecuencia de la ingesta de la toxina\n \nShiga\n \nderivada de las bacterias, en especial de la\n \nE. coli\n \n0157:H7\n(80% de los casos), aunque puede desencadenarse por otras toxinas y bacterias. Se manifiesta con ane -\nmia hemolítica microangiopática, trombocitopenia e insuficiencia renal, que puede incluir proteinuria,\nhematuria, hipertensión arterial, oliguria o anuria; el nivel de la enzima ADAMTS-13 es normal, a\ndiferencia de la PTT, donde se encuentra baja o ausente. Puede haber compromiso del sistema nervioso\ncentral, como convulsiones o coma, lo cual sucede en el 20 a 40% de los casos e indica un mal pronós -\ntico. La terapéutica con plasma (infusión de plasma o plasmaféresis) es de poca utilidad en estos casos;","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":320,"lines":{"from":51,"to":69}}}}],["1620",{"pageContent":"tico. La terapéutica con plasma (infusión de plasma o plasmaféresis) es de poca utilidad en estos casos;\nademás, requiere diálisis en algunas circunstancias, corrección de la anemia con transfusiones, control\nantihipertensivo y control metabólico. La expansión temprana de volumen intravenoso parece dismi -\nnuir los riesgos de desarrollar SUH; no se recomiendan los antibióticos y sí se requiere principalmente\nde una terapia de soporte.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":320,"lines":{"from":69,"to":73}}}}],["1621",{"pageContent":"Asociada a la preeclampsia y síndrome de HELLP\n\nLa preeclampsia y el síndrome de HELLP (de\n \nHemolysis, Elevated Liver enzymes\n \ny\n \nLow Platelet count\n) son\ncausas importantes de morbimortalidad maternofetal. La trombocitopenia en pacientes con preeclampsia\nse puede observar en el 10% de los casos, y en el 12% son síndrome de HELLP. Las plaquetas por debajo\nde 100 × 10\n \n9\n \n/L son relativamente raras en la preeclampsia, pero son frecuentes en pacientes con TIP y\nsíndrome de HELLP. El descenso de plaquetas en el síndrome de HELLP se debe a su consumo incre-\nmentado; las plaquetas están activadas y se adhieren a las células endoteliales dañadas, produciendo un","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":320,"lines":{"from":75,"to":93}}}}],["1622",{"pageContent":"294\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":321,"lines":{"from":1,"to":3}}}}],["1623",{"pageContent":"recambio incrementado con supervivencia acortada. El síndrome de HELLP se presenta en el 10 a 20%\nde las pacientes con preeclampsia grave, el 70% ocurre antes del parto (semana 27 a 37 de la gestación)\ny el resto sucede en el posparto dentro de las primeras 48 horas. Además de trombocitopenia, se observa\nanemia hemolítica microangiopática y elevación de enzimas hepáticas.\nAlgunas de las complicaciones del síndrome de HELLP incluyen eclampsia,\n \nabruptio placentae\n, CID,\ninsuficiencia renal aguda, hemorragia cerebral, muerte perinatal o materna y la trombocitopenia neonatal,\nentre otras.\nLas principales medidas terapéuticas en pacientes con preeclampsia, eclampsia y síndrome de HELLP\nestarán dirigidas por el equipo obstétrico, con el apoyo del hematólogo si fuera necesario. Algunas reco-\nmendaciones del tratamiento hematológico en estos procesos son las siguientes:\n1. Con la adecuada preparación, la terminación del embarazo es lo más eficaz para la preeclamp-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":321,"lines":{"from":5,"to":18}}}}],["1624",{"pageContent":"mendaciones del tratamiento hematológico en estos procesos son las siguientes:\n1. Con la adecuada preparación, la terminación del embarazo es lo más eficaz para la preeclamp-\nsia-eclampsia y el síndrome de HELLP. Las plaquetas aumentarán en pocos días.\n2. El apoyo transfusional con plaquetas puede ser necesario antes del parto por vía vaginal con pla-\nquetas menores de 50 × 10\n \n9\n \n/L, o antes de la cesárea con plaquetas menores de 80 × 10\n \n9\n \n/L. En caso\nde anemia grave, también se recomienda el apoyo con transfusión de eritrocitos.\n3. La anestesia epidural se recomienda con plaquetas por arriba de 75 × 10\n \n9\n \n/L.\n4. El tratamiento agresivo con antihipertensivos y el reposo en cama han mejorado la trombocitopenia\nen algunas pacientes.\n5. Será indispensable también corregir los tiempos de coagulación antes del parto o de los procedi-\nmientos invasivos con transfusión de plasma. El plasma y los crioprecipitados también serán nece-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":321,"lines":{"from":18,"to":40}}}}],["1625",{"pageContent":"5. Será indispensable también corregir los tiempos de coagulación antes del parto o de los procedi-\nmientos invasivos con transfusión de plasma. El plasma y los crioprecipitados también serán nece-\nsarios, así como las plaquetas en caso de hemorragias o de documentarse CID.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":321,"lines":{"from":40,"to":42}}}}],["1626",{"pageContent":"Cuadro 19-5.\n \nDiagnóstico diferencial entre púrpura trombocitopénica trombótica\ny otras microangiopatías trombóticas\n\nEnfermedades\n \nSíntomas comunes\n \nSíntomas diferenciales\n\nSíndrome urémico\nhemolítico\nTrombocitopenia, anemia\nhemolítica con esquistocitos\nInfección gastrointestinal:\n \nE. coli","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":321,"lines":{"from":44,"to":61}}}}],["1627",{"pageContent":"0157:H7,\n \nShigella dysenteriae\n. Co-\nlitis hemorrágica, creatinina séri-\nca elevada\nSíndrome de HELLP\n \nAnemia hemolítica, trombo-\ncitopenia\n \nEnzimas hepáticas elevadas\nPreeclampsia -eclampsia\n \nTrombocitopenia, proteinuria\nHipertensión, edema\nperiférico, proteinuria, dímero D\nelevado\nCoagulación\nintravascular diseminada\n \nTrombocitopenia\nIncremento marcado del dímero D,\ntiempos de coagulación prolonga-\ndos o acortados\nSíndrome antifosfolípido\ncatastrófico\nTrombocitopenia, anticoa-\ngulante lúpico positivo\nAnticuerpos antinucleares, síndro-\nme antifosfolípido\nSíndrome de Evans\n \nAnemia hemolítica, trombo-\ncitopenia\nPrueba\n \nde\n \nCoombs\n \npositiva,\nusualmente ausencia de isquemia\nen órganos\nTrombocitopenia\ninducida por heparina\n \nTrombocitopenia\nTrombosis\n \nprincipalmente\n \nen\ngrandes\n \narterias\n \ny\n \nvenas,\n \nanti-\ncuerpos antiplaquetas\nFuente: ASH Education Program Book. 2007:121.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":321,"lines":{"from":63,"to":126}}}}],["1628",{"pageContent":"295\n\nCAPÍTULO 19. TROMBOCITOPENIAS\n\n6. En algunas pacientes se debe valorar la terapia profiláctica antitrombótica; si no existen contrain -\ndicaciones, esta terapia se recomienda principalmente en el posparto, por ejemplo, con heparina\nfraccionada.\n7.\n \nOtorgar medidas generales como reposo, control de la tensión arterial y evitar procedimientos\ninvasivos innecesarios por el riesgo de sangrados favorecidos por la trombocitopenia.\n8. Recambio plasmático en caso de trombocitopenia grave y hemólisis microangiopática, cuando el\nfeto aún no pudiera ser extraído o por falta de mejoría incluso después de terminado el embarazo,\no ante la posibilidad diagnóstica de PTT-SUH o elevación de bilirrubina o creatinina por más\nde 72 horas después del parto. El uso de plasma fresco congelado está indicado para el recambio\nplasmático.\n\nTrombocitopenia asociada a infecciones","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":322,"lines":{"from":1,"to":18}}}}],["1629",{"pageContent":"Las infecciones pueden causar trombocitopenia por un aumento en la destrucción de las plaquetas, con\nuna frecuencia de 50 a 75% en pacientes con bacteriemia o fungemia y en casi todos con choque séptico\no CID; generalmente es leve y casi no se acompaña de anormalidades de la coagulación o sangrados.\nOtras causas responsables de trombocitopenia pueden ser la hemofagocitosis, la CID, autoanticuerpos,\nSUH, hiperesplenismo, reemplazo de la médula ósea por granulomas, infección de megacariocitos,\naplasia inducida por virus (parvovirus B19) y anticuerpos contra antígenos de bacterias adheridos a las\nplaquetas.\nLa trombocitopenia puede ser un signo de infección grave que indica la necesidad de un tratamiento\noportuno con antibióticos. Las infecciones por grampositivos por medio de exotoxinas pueden da -\nñar directamente a las plaquetas causando trombocitopenia y trombosis; el estafilococo y estreptococo\npueden producir agregación plaquetaria. En infecciones por gramnegativos, la trombocitopenia puede","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":322,"lines":{"from":20,"to":30}}}}],["1630",{"pageContent":"ñar directamente a las plaquetas causando trombocitopenia y trombosis; el estafilococo y estreptococo\npueden producir agregación plaquetaria. En infecciones por gramnegativos, la trombocitopenia puede\nocurrir por agregación plaquetaria con liberación de endotoxinas o activación de monocitos que expre -\nsan factor tisular y favorecen la generación de trombina y CID. La activación de neutrófilos también\npuede favorecer la trombocitopenia en pacientes con endotoxemia. Otras infecciones pueden inducir\nhiperplasia histiocítica en la MO con hemofagocitosis. Las infecciones por rickettsias son capaces de\ninfectar a las células endoteliales y producir vasculitis, lo que ocasiona la trombocitopenia por incre -\nmento de la adhesión plaquetaria; puede además activarse el sistema de coagulación y la fibrinólisis.\nLa trombocitopenia secundaria a infecciones virales puede ser debida a una falla en la producción de\nMO, como se ha mencionado anteriormente. Las infecciones por micoplasma y micobacterias pueden","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":322,"lines":{"from":30,"to":39}}}}],["1631",{"pageContent":"La trombocitopenia secundaria a infecciones virales puede ser debida a una falla en la producción de\nMO, como se ha mencionado anteriormente. Las infecciones por micoplasma y micobacterias pueden\ntambién causar trombocitopenia, así como diferentes agentes tales como histoplasma, plasmodium y\ntoxoplasma, que pueden ocasionar interacciones directas con las plaquetas, con el consecuente desarro-\nllo de la trombocitopenia.\nEl tratamiento principal deberá dirigirse hacia la infección responsable en un tiempo oportuno.\nOtras medidas pueden consistir en el apoyo transfusional con plaquetas en pacientes con CID, disfun-\nción plaquetaria por uremia, o en aquellos que requieran un procedimiento invasivo. Otros pacientes con\nevidencia de trombosis microvascular y CID requerirán de heparina. En otros pacientes con meningococ-\ncemia y CID con deficiencia adquirida de proteína C acompañante, podrán requerir en su tratamiento la","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":322,"lines":{"from":39,"to":48}}}}],["1632",{"pageContent":"cemia y CID con deficiencia adquirida de proteína C acompañante, podrán requerir en su tratamiento la\ntransfusión de plasma, vitamina K y proteína C activada recombinante. Para pacientes con HIV y trom -\nbocitopenia ya se mencionó su tratamiento previamente. De forma más reciente se han reportado casos de\ntrombocitopenia asociada a procesos infecciosos con respuesta a la aplicación de nuevos agentes, como los\nagonistas de los receptores de TPO.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":322,"lines":{"from":48,"to":52}}}}],["1633",{"pageContent":"Asociada al trasplante de células progenitoras hematopoyéticas y otros órganos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":322,"lines":{"from":54,"to":54}}}}],["1634",{"pageContent":"En pacientes sometidos a trasplante de células progenitoras hematopoyéticas (TCPH) es posible\nobservar trombocitopenia como parte del tratamiento mieloablativo de preparación y después del\nTCPH. Esta puede ser grave y el tiempo de recuperación puede ser más prolongado que el de eritro -\ncitos y leucocitos. En estos pacientes también se atribuye la trombocitopenia a una causa autoinmuni -\ntaria que puede responder a corticoides, IgG IV y esplenectomía. Otra causa en pacientes que reciben\nTCPH está asociada a microangiopatía trombótica (PTT) con trombocitopenia, insuficiencia renal y\nesquistocitos; su causa no se conoce exactamente y la respuesta al recambio plasmático es mala. En pa -\ncientes que presentan rechazo después del trasplante de un órgano, se ha observado trombocitopenia\npor activación y depósito en la vasculatura del órgano trasplantado; además, los fármacos utilizados\npara modular el rechazo pueden también causarla.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":322,"lines":{"from":56,"to":65}}}}],["1635",{"pageContent":"296\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nAsociada al síndrome de Kasabach-Merritt\n\nEste síndrome presenta una trombocitopenia grave por el atrapamiento plaquetario en un tumor vascular\nde localización superficial o que invade órganos internos. La adherencia de plaquetas al endotelio anormal\nviene seguida de la agregación plaquetaria finalizando en la activación de la CID; los tratamientos que\nse han intentado incluyen esteroides, inmunosupresores, quimioterapia, interferón, radiación, resección\nquirúrgica, embolización arterial y la compresión neumática, pero nada ha sido consistente. Los pacientes\npueden fallecer por complicaciones relacionadas a trombocitopenia, CID o infecciones.\n\nTrombocitopenia gestacional","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":323,"lines":{"from":1,"to":14}}}}],["1636",{"pageContent":"Trombocitopenia gestacional\n\nEs la causa más común de trombocitopenia durante el embarazo; ocurre en el 65 a 80% de los casos. El\nincremento en el volumen de sangre, en la activación plaquetaria y en el aclaramiento de plaquetas contri-\nbuye a un descenso fisiológico de plaquetas.\nSe caracteriza por ser en general muy leve y asintomática, ocurrir en el tercer trimestre del embarazo,\nno tener antecedentes previos de trombocitopenia, no asociarse a trombocitopenia fetal y no presentar\ncomplicaciones durante el embarazo ni el parto. Se puede detectar de forma incidental al realizar un\nestudio de rutina, no está asociada con incremento en el riesgo de sangrado.\nLa cuenta de plaquetas en estas pacientes es mayor de 70 × 10\n \n9\n \n/L y retorna a lo normal después del\nparto, por lo que si hubiera plaquetas inferiores a esta cifra en el primer o segundo trimestre del embarazo,\nse deberá descartar una etiología diferente\n \n(cuadro 19-6)\n.\n\nAsociada a cirugía cardíaca","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":323,"lines":{"from":14,"to":34}}}}],["1637",{"pageContent":"Asociada a cirugía cardíaca\n\nEn muchos pacientes sometidos a este tipo de cirugía, con el apoyo de bomba extracorpórea se pueden\nobservar hemorragias en el período posoperatorio, lo cual amerita apoyo transfusional e incluso la rein -\ntervención quirúrgica. Dentro de las causas de esta complicación se encuentran la trombocitopenia y la\ndisfunción plaquetaria; la disminución de plaquetas se puede explicar por un estado de hemodilución,\nla pérdida de plaquetas, por el sangrado y el secuestro, por la bomba extracorpórea; la trombocitopenia\nsuele mejorar en pocos días.\n\nCuadro 19-6.\n \nCausas de trombocitopenia en el embarazo","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":323,"lines":{"from":34,"to":45}}}}],["1638",{"pageContent":"Cuadro 19-6.\n \nCausas de trombocitopenia en el embarazo\n\nTrombocitopenia gestacional (incidental)\nPreeclampsia\nSíndrome de HELLP\nHígado graso agudo del embarazo\nPúrpura trombocitopénica trombótica\nSíndrome urémico hemolítico\nLupus eritematoso generalizado\nSíndrome antifosfolípido\nCoagulación intravascular diseminada\nInfección viral\nDeficiencia nutricional\nUso de fármacos\nEnfermedades de la médula ósea\nTrombocitopenia inmune primaria\n\nLa trombocitopenia gestacio-\nnal es la causa más frecuente\nde trombocitopenia durante el\nembarazo; ocurre en el 65 a\n80% de los casos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":323,"lines":{"from":45,"to":68}}}}],["1639",{"pageContent":"297\n\nCAPÍTULO 19. TROMBOCITOPENIAS\n\nLa disfunción plaquetaria que también suele presentarse en estos pacientes se debe a defectos intrínse-\ncos de las plaquetas, los cuales pueden ser reversibles, así como al uso de heparina durante el procedimien-\nto quirúrgico, el uso de la bomba extracorpórea y en algunos pacientes el antecedente de administración\nde heparina.\n\nAsociada a la enfermedad de von Willebrand","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":324,"lines":{"from":1,"to":10}}}}],["1640",{"pageContent":"Los pacientes con esta enfermedad congénita que cursa con un déficit cuantitativo o cualitativo del factor\nde von Willebrand (FvW) pueden presentar también trombocitopenia, lo cual se observa especialmente\nen los pacientes con el subtipo 2B. En estos pacientes, el FvW del plasma se fija al receptor GP Ib de las\nplaquetas circulantes (lo cual no ocurre normalmente), y este receptor plaquetario no está disponible para\nunirse al FvW depositado en el subendotelio vascular. Esta alteración favorece una rápida eliminación de\nlas plaquetas de la circulación, produciendo trombocitopenia. Con frecuencia los pacientes pueden tener\nhemorragia en mucosas. La trombocitopenia puede exacerbarse con el embarazo, la cirugía y el estrés\nfisiológico, cursando con cuentas plaquetarias de hasta 20 × 10\n \n9\n \n/L. Estos hallazgos con frecuencia hacen\nconfundir la enfermedad de von Willebrand con la TIP, llevando a la administración de tratamientos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":324,"lines":{"from":12,"to":24}}}}],["1641",{"pageContent":"9\n \n/L. Estos hallazgos con frecuencia hacen\nconfundir la enfermedad de von Willebrand con la TIP, llevando a la administración de tratamientos\ninnecesarios con esteroides, IgG IV y esplenectomía. Algunas medidas terapéuticas en pacientes con\nenfermedad de von Willebrand incluyen la aplicación de concentrados de factor VIII-FvW, la transfusión\nde crioprecipitados y la desmopresina.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":324,"lines":{"from":24,"to":30}}}}],["1642",{"pageContent":"TROMBOCITOPENIA POR DISTRIBUCIÓN\nY ALMACENAMIENTO INADECUADOS DE PLAQUETAS\n\nEsplenomegalia e hiperesplenismo","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":324,"lines":{"from":32,"to":35}}}}],["1643",{"pageContent":"El almacenamiento o la distribución anormal de la masa plaquetaria también pueden ser causa de trom-\nbocitopenia; esto ocurre principalmente en los padecimientos que evolucionan con esplenomegalia\no hiperesplenismo, en los que la mayoría de las plaquetas son secuestradas en el compartimento esplénico.\nEl bazo puede almacenar en condiciones normales hasta una tercera parte del total de plaquetas\ncirculantes, de tal forma que la esplenomegalia puede aumentar el secuestro de plaquetas y causar\ntrombocitopenia.\nEl hiperesplenismo está caracterizado por esplenomegalia y cualquiera o todas de las siguientes\ncitopenias: anemia, leucopenia o trombocitopenia. La MO puede mostrar una hiperplasia compensadora\nde la línea celular disminuida, la cual puede ser corregida después de la esplenectomía\n \n(cuadro 19-7)\n.\nLa trombocitopenia debida a hiperesplenismo no tiene importancia clínica, ya que los pacientes suelen\ntener cuentas plaquetarias de 50 a 150 × 10\n \n9","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":324,"lines":{"from":37,"to":52}}}}],["1644",{"pageContent":"(cuadro 19-7)\n.\nLa trombocitopenia debida a hiperesplenismo no tiene importancia clínica, ya que los pacientes suelen\ntener cuentas plaquetarias de 50 a 150 × 10\n \n9\n \n/L y no presentan sangrados; más bien los síntomas están\nrelacionados con la enfermedad de base. La trombocitopenia también puede estar relacionada con el ta-\nmaño del bazo y una deficiencia en la producción de TPO si los pacientes cursan con alguna hepatopatía\ncomo la cirrosis. Los estudios que ayudan al diagnóstico son la ecografía, la tomografía computarizada\ny estudios de medicina nuclear. El tratamiento estará dirigido a la enfermedad subyacente, y en algunos\npacientes seleccionados será necesario realizar la esplenectomía como maniobra diagnóstica o terapéutica.\nEn otros pacientes que ameriten una intervención quirúrgica se deberá valorar el apoyo transfusional con\nplaquetas, plasma o crioprecipitados si existieran alteraciones de la coagulación. El uso de agonistas de la","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":324,"lines":{"from":52,"to":66}}}}],["1645",{"pageContent":"plaquetas, plasma o crioprecipitados si existieran alteraciones de la coagulación. El uso de agonistas de la\nTPO también se ha utilizado en algunos pacientes con cirrosis y trombocitopenia que requerían de algún\nprocedimiento invasivo electivo, con lo cual mejoraron su trombocitopenia y no fue necesario el apoyo\ntransfusional con plaquetas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":324,"lines":{"from":66,"to":69}}}}],["1646",{"pageContent":"CONCLUSIONES\n\n•\n \nTomando como punto de partida la historia clínica del paciente, el cuadro clínico y la cifra de\nplaquetas, es posible predecir cuál es el diagnóstico fisiopatológico de la trombocitopenia, ya sea\npor falta de producción, aumento en la destrucción, secuestro, distribución anormal, o bien una\ncausa combinada.\n\n•\n \nDe acuerdo a la integración de los datos clínicos y de laboratorio y los conocimientos del médico, se\ndeberán solicitar estudios que confirmen el diagnóstico para iniciar el tratamiento dirigido a corre -\ngir la causa de la trombocitopenia, sobre todo si existe el riesgo de hemorragias.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":324,"lines":{"from":71,"to":84}}}}],["1647",{"pageContent":"298\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\n•\n \nEs importante reconocer y corregir la causa de la trombocitopenia apoyándose en medidas farmaco -\nlógicas, apoyo transfusional, retiro de algunos fármacos causantes de trombocitopenia, el control de\nalgunas infecciones o incluso por medio de la realización de algunas medidas terapéuticas invasivas\ncomo la esplenectomía o el recambio plasmático. Los agonistas de los receptores de la TPO actual -\nmente son un tratamiento de gran utilidad en las trombocitopenias, pero su uso debe estar bien\njustificado tomando en cuenta sus efectos secundarios y sus altos costos. El estudio y la comprensión\nde las trombocitopenias permitirá al médico un diagnóstico y tratamiento oportunos.\n\nPREGUNTAS DE AUTOEVALUACIÓN\n\n1. Tiempo de vida de las plaquetas:\na.\n \n100-120 días\nb. 15-30 días\nc.\n \n7-10 días\n\nCuadro 19-7.\n \nAlgunas causas de esplenomegalia e hiperesplenismo\n\nInfecciones","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":325,"lines":{"from":1,"to":30}}}}],["1648",{"pageContent":"PREGUNTAS DE AUTOEVALUACIÓN\n\n1. Tiempo de vida de las plaquetas:\na.\n \n100-120 días\nb. 15-30 días\nc.\n \n7-10 días\n\nCuadro 19-7.\n \nAlgunas causas de esplenomegalia e hiperesplenismo\n\nInfecciones\n\nTuberculosis\nBacterianas (salmonelosis, brucelosis, etc.)\nVirales (hepatitis, mononucleosis, etc.)\nPaludismo\n\nCongestivas\n\nCirrosis\nObstrucción venosa portal o esplénica\nTrombosis de venas suprahepáticas (síndrome de Budd-Chiari)\n\nNeoplasias\n\nSíndromes mieloproliferativos crónicos (metaplasia mieloide, policitemia vera, trombocitemia esencial)\nLeucemias agudas o crónicas\nLinfomas\n\nInflamación\n\nFiebre reumática\nLupus eritematoso\nSíndrome de Felty\n\nAnemias\n\nHemolítica autoinmunitaria\nTalasemia\nDrepanocitosis","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":325,"lines":{"from":30,"to":74}}}}],["1649",{"pageContent":"299\n\nCAPÍTULO 19. TROMBOCITOPENIAS\n\n2. Se habla de trombocitopenia cuando la cifra plaquetaria es menor de:\na.\n \n50 000/mL\nb. 100 000/mL\nc.\n \n200 000/mL\n3. Causa de trombocitopenia de origen no inmunitario:\na.\n \nMedicamentosa\nb. Postransfusional\nc.\n \nPúrpura trombocitopénica trombótica-síndrome urémico hemolítico\n4. Anormalidad en el complejo glucoproteico Ib/IX:\na.\n \nTrombastenia de Glanzmann\nb. Síndrome de Bernard-Soulier\nc.\n \nEnfermedad de von Willebrand\n5. Se caracteriza por anemia hemolítica microangiopática, trombocitopenia e insuficiencia renal:\na.\n \nSíndrome urémico hemolítico (SUH)\nb. Síndrome de DiGeorge\nc.\n \nSíndrome de Fanconi\n\nBIBLIOGRAFÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":326,"lines":{"from":1,"to":38}}}}],["1650",{"pageContent":"Afdhal NH, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med.\n2012; 367 (8): 716-724.\nAndemariam B, Psaila B, Bussel J. Novel thrombopoietic agents. ASH Education Program Book. 2007. p. 106-113.\nAndersen JC. ²rombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med. 1994; 330: 1560-64.\nArkfeld D, et al. Immune thrombocytopenia in patients with connective tissue disorders and the antiphospholipid\nantibody syndrome. Hematol Oncol Clin N Am. 2009; 23: 1239-1249.\nBosticardo M, et al. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood.\n2009; 113: 6288-6295.\nBussel J, Cines D, McMillan R, et al. Congenital and acquired thrombocytopenia. ASH Education Program Book.\nHematology. 2004: 390-406.\nBussel J, Kuter D, Phil D, George J, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Eng\nJ Med. 2006; 355: 1672-81.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":326,"lines":{"from":40,"to":51}}}}],["1651",{"pageContent":"Hematology. 2004: 390-406.\nBussel J, Kuter D, Phil D, George J, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Eng\nJ Med. 2006; 355: 1672-81.\nCines D. ²e ITP syndrome: Pathogenic and clinical diversity. Blood. 2009; 113: 6511-6521.\nCines D, et al. Pathobiology of secondary immune thrombocytopenia. Semin Hematol. 2009; 46 (Suppl 2): S2-14.\nCooper N, Stasi R, Cunningham-Rundles S, et al. ²e efficacy and safety of B-cell depletion with anti-CD20 mono-\nclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004; 125: 232-239.\nCooper N, Bussel J. ²e pathogenesis of immune thrombocytopaenic purpura. Br J Haematol. 2006; 133: 364-374.\nCuker A, et al. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: A systematic re-\nview and meta-analysis. Blood. 2012; 120 (20): 4160-4167.\nCuker A. Toxicities of the thrombopoietic growth factors. Semin Hematol. 2010; 47 (3): 289-298.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":326,"lines":{"from":51,"to":61}}}}],["1652",{"pageContent":"view and meta-analysis. Blood. 2012; 120 (20): 4160-4167.\nCuker A. Toxicities of the thrombopoietic growth factors. Semin Hematol. 2010; 47 (3): 289-298.\nDiz-Kücükkaya R. Inherited platelet disorders including Glanzmann thombasthenia and Bernard-Soulier syndrome.\nASH Program Book. Hematology. 2013; 1: 268-275.\nEstrada-Gómez RA, Parra-Ortega I, Martínez-Barreda C, Ruiz-Argüelles GJ.\n \nHelicobacter pylori\n \ninfection and\nthrombocytopenia: A single-institution experience in Mexico. Rev Invest Clín (Méx). 2007; 59: 112-115.\nEstrada-Gómez R, Vargas O, Oropeza M. A single-institution, 20-year prospective experience with an affordable Fc\nreceptor blockade method to treat patients with chronic, refractory autoimmune thrombocytopenic purpura. Rev\nInvest Clin (Méx). 2007; 59(6): 424-427.\nFlores A, et al. Púrpura trombocitopénica inmune. Haematologica. 2009; 94 (Suppl 7): 25-30.\nFurlan M, Robles R, Lämmle BL. Partial purification and characterization of a protease from human plasma cleaving","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":326,"lines":{"from":61,"to":75}}}}],["1653",{"pageContent":"Furlan M, Robles R, Lämmle BL. Partial purification and characterization of a protease from human plasma cleaving\nvon Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996; 87: 4223-4234.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":326,"lines":{"from":75,"to":76}}}}],["1654",{"pageContent":"300\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nGasbarrini A, Francechi F, Tartaglione R, et al. Regression of autoimmune thrombocytopenia after eradication of","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":327,"lines":{"from":1,"to":5}}}}],["1655",{"pageContent":"Helicobacter pylori\n. Lancet. 1998; 352: 878.\nGeddis A. Congenital amegacaryocytic thrombocytopenia and thrombocytopenia with absent radii. Hematol Oncol\nClin North Am. 2009; 23 (2): 321-331.\nGeorge JN, El-Harake MA. Chronic idiopathic thrombocytopenic purpura. N Eng J Med. 1994; 331: 1207-1210.\nGeorge JN, Rizvi MA. ²rombocytopenia. En: Beutler E, Lichtman MA. Williams Hematology. New York:\nMcGraw-Hill; 2001. p. 1495-1539.\nGeorge JN. Diagnosis and management of ITP in children and adults: Recomendations of the ASH Practice Guide-\nline. Hematology. Educ Prog ASH. 1996: 88-92.\nGeorge J, et al. Drug-induced thrombocytopenia: Pathogenesis, evaluation and management. Hematology. ASH\nProgram Book. 2009: 153-158.\nGernsheimer T. ²rombocytopenia in pregnancy: Is this immune thrombocytopenia or ...? Hematology. ASH Pro -\ngram Book. 2012: 198-202.\nGrimaldi L, et al. A case-control study to assess the risk of immune thrombocytopenia associated with vaccines.\nBlood. 2012; 120 (25): 4938-4944.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":327,"lines":{"from":7,"to":21}}}}],["1656",{"pageContent":"gram Book. 2012: 198-202.\nGrimaldi L, et al. A case-control study to assess the risk of immune thrombocytopenia associated with vaccines.\nBlood. 2012; 120 (25): 4938-4944.\nIMSS. Guía de práctica clínica, diagnóstico y tratamiento de púrpura trombocitopénica inmunológica. México: Ins-\ntituto Mexicano del Seguro Social; 2009.\nGutiérrez-Espíndola G, Morales-Polanco R, Guerrero-Rivera S, et al. High doses of dexamethasone in adult patients\nwith idiopathic thrombocytopenic purpura. Arch Med Res. 2003; 34: 31-34.\nGutiérrez G. ¿Cuál es la evidencia científica para el tratamiento de erradicación de\n \nHelicobacter pylori\n \nen la púrpura\ntrombocitopénica idiopática crónica? Revista de Hematología. 2010; 11 (Supl 1): 93-95.\nHaram K, et al. ²e HELLP syndrome: Clinical issues and management. A review. Bio Med Central Pregnancy and\nChildbirth. 2009; 9:8: 1-15.\nHoffman R. Hematology. Basic principles and practice. 5th ed. USA: Churchill Livingstone Elsevier; 2009.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":327,"lines":{"from":21,"to":36}}}}],["1657",{"pageContent":"Childbirth. 2009; 9:8: 1-15.\nHoffman R. Hematology. Basic principles and practice. 5th ed. USA: Churchill Livingstone Elsevier; 2009.\nKantarjian HM, et al. Phase 2 study of romiplostim in patients with low-or intermediate-risk myelodisplastic syn-\ndrome receiving azacitidine therapy. Blood. 2010; 116 (17): 3163-3170.\nKaushansky K. Williams Hematology. 8th ed. New York: McGraw-Hill; 2010.\nKumar V, Aster J, Fausto N, Abbas A. Robbins y Cotran. Patología estructural y funcional. 8a ed. España:\nElsevier; 2010.\nKuter D, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind\nrandomized controlled trial. Lancet. 2008; 371: 395-403.\nJinich H. Síntomas y signos cardinales de las enfermedades. 5a ed. México: Manual Moderno; 2009.\nLlamas P, Busto MJ. Eficacia de distintos tratamientos en el manejo de la púrpura trombocitopénica idiopática (PTI)\ndel adulto. Sangre. 1995; 40: 181-186.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":327,"lines":{"from":36,"to":47}}}}],["1658",{"pageContent":"Llamas P, Busto MJ. Eficacia de distintos tratamientos en el manejo de la púrpura trombocitopénica idiopática (PTI)\ndel adulto. Sangre. 1995; 40: 181-186.\nMannucci P, Peyvandi F. TTP and ADAMTS 13: When is testing appropriate? ASH Education Program Book.\n2007. p. 121-126.\nMagnani HN. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org\n10172). ²romb Haemost. 1993; 70: 554-561.\nMazzucconi MG, Fazi P, Bernasconi S, et al. ²erapy with high-dose dexamethasone (HD-DXM) in previously\nuntreated patients affected by idiopathic thrombocytopenic purpura: A GIMEMA experience. Blood 2007; 109:\n1401-1407.\nMcCrae KR, Samuels P, Schreiber AD, et al. Pregnancy-associated thrombocytopenia: Pathogenesis and manage-\nment. Blood. 1992; 80: 2697.\nMcCrae KR, Cines BD. ²rombotic microangiopathy during pregnancy. Semin Hematol, 1997; 34: 148-158.\nMcCrae KR, Herman JH. Posttransfusion purpura: Two unusual cases and a literature review. Am J Hematol.\n1996; 52: 205.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":327,"lines":{"from":47,"to":60}}}}],["1659",{"pageContent":"McCrae KR, Herman JH. Posttransfusion purpura: Two unusual cases and a literature review. Am J Hematol.\n1996; 52: 205.\nMcHutchison J, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated wit hepatitis C. N\nEngl J Med. 2007; 357: 2227-2236.\nMcMillan R. Classical management of refractory adult immune (idiopathic) thrombocytopenic purpura (ITP). Blood\nReviews. 2002; 16: 51-55.\nNewman GC, Novoa MV, Fodero EM, et al. A dose of 75 mg/kg/d of IV anti-D increases the platelet count more\nrapidly and for a longer period of time than does 50 mg/kg/d in adults with immune thrombocytopenic purpura.\nBr J Hem. 2001; 112: 1076-1078.\nOksenhendler E, Bierling P. Splenectomy is safe and effective in human immunodeficiency virus-related inmune\nthrombocytopenia. Blood. 1993; 82: 29-32.\nOlnes MJ, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;\n367 (3): 284.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":327,"lines":{"from":60,"to":72}}}}],["1660",{"pageContent":"301\n\nCAPÍTULO 19. TROMBOCITOPENIAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":328,"lines":{"from":1,"to":3}}}}],["1661",{"pageContent":"Patel V, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombo-\ncytopenia. Blood. 2012; 119 (25): 5989-5995.\nPeyvandi F, et al. Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura. Haema\n-\ntologica. 2010; 95 (9): 1444-1447.\nPizzuto J, Ambriz R, Restrepo A, et al. ²erapeutic experience on 934 adults with idiopathic thrombocytopenic\npurpura (ITP). Multicentric trial of the Cooperative Latinamerican Group on ²rombosis (CLATH Group).\nBlood. 1984; 64: 1179- 1183.\nPizzuto J. Púrpura trombocitopénica idiopática del adulto. Rev Invest Clin. 1995; 47(Suppl 1): 39-43.\nProvan D, et al. International consensus report on the investigation and management of primary immune thrombo -\ncytopenia. Blood. 2010; 115: 168-186.\nRemold-O’Donell E, Rosen F. Defects in Wiskott-Aldrich syndrome blood cells. Blood. 1996; 87: 2621-2631.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":328,"lines":{"from":5,"to":16}}}}],["1662",{"pageContent":"cytopenia. Blood. 2010; 115: 168-186.\nRemold-O’Donell E, Rosen F. Defects in Wiskott-Aldrich syndrome blood cells. Blood. 1996; 87: 2621-2631.\nRice L, Attisha W, Drexler A, et al. Delayed-onset heparin-induced thrombocytopenia. Ann Inter Med. 2002; 136:\n210-215.\nRodhegiero F, et al. Standardization of terminology definitions and outcome criteria in immune thrombocytopenic\npurpura of adults and children: Report from an international working group. Blood. 2009; 113: 2386-2393.\nRuiz-Argüelles GJ, Apreza-Molina MG, et al. ²e infusion of anti-RhO-(D) opsonized erythrocytes may be useful\nin the treatment of patients, splenectomized or not, with chronic, refractory autoimmune thrombocytopenic pur-\npura: A prospective study. Am J Hematol. 1993; 43: 72-73.\nRuiz-Argüelles GJ, Ruiz-Delgado GJ, Velázquez-Sánchez-de-Cima S, Zamora-Ortiz G. Simultaneous romiplostin,\neltrombopag and prednisone were successful in severe thrombocytopenia of Evans syndrome refractory to hydro-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":328,"lines":{"from":16,"to":26}}}}],["1663",{"pageContent":"eltrombopag and prednisone were successful in severe thrombocytopenia of Evans syndrome refractory to hydro-\ncortisone, splenectomy, intravenous IgG and rituximab. Hematology. 2012, in press.\nSans-Sabrafen J. Hematología clínica. 5a ed. España: Elsevier; 2006.\nStasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with\nchronic idiopathic thrombocytopenic purpura. Blood. 2001; 98: 952-957.\nStasi R, et al. Trombopoietic agents. Blood Reviews. 2010; 24: 179-190.\nStasi R, et al. Infectious causes of chronic immune thrombocytopenia. Hematol Oncol Clin N Am. 2009; 23:\n1275-1297.\nStasi R. Rituximab in autoimmune hematologic diseases: Not just a matter of B cells. Sem in Hematol. 2010; 47 (2):\n170-179.\nStasi R, et al.\n \nHelicobacter pylori\n \nand chronic ITP. Hematology. ASH Program Book, 2008: 206-211.\nVinograd Ch, Bussel J. Antenatal treatment of fetal alloimmune thrombocytopenia: A current perspective. Haema-\ntologica. 2010; 95 (11): 1807-1811.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":328,"lines":{"from":26,"to":42}}}}],["1664",{"pageContent":"Vinograd Ch, Bussel J. Antenatal treatment of fetal alloimmune thrombocytopenia: A current perspective. Haema-\ntologica. 2010; 95 (11): 1807-1811.\nVesely S, Perdue J, Rizvi M. Management of adults patients with persistent idiopathic thrombocytopenic purpura\nfollowing splenectomy. Ann Intern Med. 2004; 140: 112-120.\nWarkentin T. ²ink of HIT. Hematology. ASH Education Program Book. 2006: 408-414.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":328,"lines":{"from":42,"to":46}}}}],["1665",{"pageContent":"RESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\n1.\n \nc\n2.\n \nb\n3.\n \nc\n4.\n \nb\n5.\n \na","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":328,"lines":{"from":48,"to":64}}}}],["1666",{"pageContent":"303\n\nINTRODUCCIÓN\n\nEl término\n \ncoagulopatía\n \nse emplea para definir un grupo heterogéneo de enfermedades hemorrágicas\nque afectan los diferentes mecanismos de la coagulación. Estos defectos se agrupan dentro de las en-\nfermedades de tendencia hemorrágica, que pueden ser de origen primario (hereditario) o secundario\n(adquirido).\n\nCLASIFICACIÓN\n\nLas enfermedades hemorrágicas se dividen en defectos que involucran los mecanismos de la\n \nhemos-\ntasia primaria\n \no de la\n \nhemostasia secundaria.\n \nLa división de los defectos hemorrágicos en estos dos\ngrandes grupos resulta útil para orientar diagnósticos y distinguir patrones clínicos que diferencian\ncada uno de estos defectos. Las coagulopatías constituyen trastornos de la hemostasia secundaria.\n\nA. Púrpuras o defectos en la hemostasia primaria","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":330,"lines":{"from":1,"to":29}}}}],["1667",{"pageContent":"A. Púrpuras o defectos en la hemostasia primaria\n\nClínicamente, las púrpuras se pueden manifestar por hemorragias mucocutáneas de intensidad varia-\nble. Cuando estas lesiones involucran principalmente la piel (petequias, equimosis o telangiectasias),\nse conocen como\n \npúrpura seca\n \ny, por otro lado, cuando las hemorragias comprometen las mucosas\n(epistaxis, gingivorragias, hemorragia transvaginal, etc.), se denominan\n \npúrpura húmeda\n. Los enfer-\nmos con defectos en la hemostasia primaria comúnmente presentan ambos componentes, y la gra-\nvedad de las manifestaciones dependerá del defecto intrínseco que afecte a la hemostasia primaria.\nLas púrpuras se dividen en vasculares (p. ej., púrpura de Henoch-Schönlein, púrpura senil, púrpura\nsimple, etc.), trombocitopénicas (p. ej., púrpura trombocitopénica autoinmunitaria, púrpura trombo-\ncitopénica por secuestro esplénico, púrpura trombocitopénica secundaria a coagulación intravascular\n\nCarlos Martínez Murillo\nSandra Quintana González","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":330,"lines":{"from":29,"to":49}}}}],["1668",{"pageContent":"Carlos Martínez Murillo\nSandra Quintana González\n\nObjetivos de aprendizaje\n\n•\n \nComprender la clasificación de las coagulopatías hereditarias.\n\n•\n \nReconocer las diferencias entre hemofilia A, hemofilia B y enfermedad de von Willebrand.\n\n•\n \nSeñalar las pruebas de laboratorio necesarias para realizar el diagnóstico.\n\n•\n \nMencionar los puntos sobresalientes del diagnóstico y tratamiento de las hemofilias.\n\n•\n \nConocer otros defectos hereditarios menos frecuentes de la coagulación.\n\nCAPÍTULO 20\n\nCOAGULOPATÍAS\nHEREDITARIAS\n\nEl término\n \ncoagulopatía\n \nse\nemplea para definir a un gru-\npo heterogéneo de enfermeda-\ndes hemorrágicas que afectan\nlos diferentes mecanismos de\nla coagulación. Estos defectos\nse agrupan dentro de las en-\nfermedades de tendencia he-\nmorrágica, que pueden ser de\norigen primario (hereditario)\no secundario (adquirido).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":330,"lines":{"from":49,"to":93}}}}],["1669",{"pageContent":"304\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\ndiseminada, etc.) y trombocitopáticas, es decir, por disfunción plaquetaria (p. ej., enfermedad de Ber-\nnard-Soulier, trombastenia de Glanzmann, púrpura trombocitopénica secundaria a ingesta de aspirina,\netc.) y, finalmente, la enfermedad de von Willebrand, que clínicamente se manifiesta como púrpura; sin\nembargo, algunas variedades pueden presentar otro patrón de hemorragias más intenso.\n\nB. Coagulopatías o defectos de la hemostasia secundaria","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":331,"lines":{"from":1,"to":10}}}}],["1670",{"pageContent":"B. Coagulopatías o defectos de la hemostasia secundaria\n\nClínicamente se manifiestan por seguir un patrón hemorrágico caracterizado por la presencia de hemar-\ntrosis recurrentes, hematomas diseminados, hemorragias gastrointestinales, retroperitoneales, intraab -\ndominales y en sistema nervioso central, hemotórax, etcétera. Estos defectos se deben principalmente a\ntrastornos en la síntesis de los factores de la coagulación, que pueden producir moléculas disfuncionales\no una disminución en la concentración. Estos trastornos pueden ser de origen primario o secundario. Las\ncoagulopatías a su vez se clasifican en:\n\nB.1. Coagulopatías hereditarias.\n \nDe los defectos hereditarios, las deficiencias de factor VIII y factor\nIX de la coagulación (hemofilia A y B, respectivamente) son las más comunes, y con menor fre-\ncuencia están la deficiencia de factor VII:C, factor XI:C, factor X:C, factor II:C, afibrinogenemias,\nentre otras.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":331,"lines":{"from":10,"to":24}}}}],["1671",{"pageContent":"B.2. Coagulopatías adquiridas.\n \nLos defectos de origen adquirido pueden ser ocasionados por múl-\ntiples factores; sin embargo, entre los más comunes encontramos hepatopatías, uremias, enfer-\nmedades autoinmunitarias con generación de anticuerpos neutralizantes contra factores de la\ncoagulación, ingesta de medicamentos, etcétera.\n\nB.3. Coagulopatías combinadas.\n \nAlgunos enfermos pueden presentar datos clínicos de defectos de\nhemostasia primaria y secundaria, por ejemplo, petequias, equimosis, epistaxis, hemorragia in-\ntraabdominal y hematomas, es decir, tener ambas presentaciones clínicas, probablemente por un\ndefecto que afecta de manera global a la hemostasia, como afibrinogenemias, disfibrinogenemias,\ncirrosis hepática y coagulación intravascular diseminada\n \n(cuadro 20-1)\n.\n\nHEMOFILIA A Y B","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":331,"lines":{"from":26,"to":44}}}}],["1672",{"pageContent":"HEMOFILIA A Y B\n\nLas hemofilias A y B son coagulopatías hereditarias caracterizadas por la deficiencia funcional o cuantita-\ntiva del factor VIII (hemofilia A) o del factor IX (hemofilia B) de la coagulación. Ello se debe a un defecto\nen los genes que se encuentran localizados en el brazo largo del cromosoma X, por lo que constituyen\nuna enfermedad que se transmite ligada al cromosoma X. Clínicamente se manifiestan por la presencia\nde hemorragias, principalmente en músculos y articulaciones, de intensidad variable, de acuerdo al nivel\ncirculante del factor deficiente. En la hemofilia A o B, los hombres son los principales afectados y las\nmujeres son quienes portan y transmiten la enfermedad; sin embargo, en casos raros se pueden presentar\nestas coagulopatías en el sexo femenino.\n\nHistoria","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":331,"lines":{"from":44,"to":55}}}}],["1673",{"pageContent":"Historia\n\nLa hemofilia probablemente existe desde que aparecieron las primeras generaciones del hombre, y segu-\nramente fue ocasionada por una mutación de novo que progresivamente se fue difundiendo. Esta teoría\ntiene sustento en los primeros relatos escritos de los hebreos (rabi Simon ben Gamaliel), referidos en el","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":331,"lines":{"from":55,"to":59}}}}],["1674",{"pageContent":"Talmud\n, donde se hace referencia a un defecto hemorrágico de índole hereditaria que particularmente\nafectaba a hombres y que impedía que se llevara a cabo la circuncisión ritual, producto del pacto de Abra-\nham, esto hace aproximadamente 4 000 años.\nEn el siglo pasado, después de algunos siglos donde no existe relato alguno sobre la enfermedad, re-\nsurge el interés en este padecimiento, producto de la afectación de uno de los miembros de la Familia Real\ninglesa, la reina Victoria de Inglaterra, quien sufre una mutación de novo y posteriormente transmite la\nenfermedad a algunos de los miembros de la familia, lo que posibilita la transmisión del trastorno a gran\nparte de la realeza europea. Pero quizás el caso más connotado de hemofilia lo representa el príncipe o\nzarovich Alexis, hijo del zar Nicolás II de Rusia y de la zarina Alexandra (nieta de la reina Victoria), quien\nfrecuentemente pasaba largas temporadas en cama, producto de los múltiples eventos hemorrágicos que","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":331,"lines":{"from":61,"to":71}}}}],["1675",{"pageContent":"frecuentemente pasaba largas temporadas en cama, producto de los múltiples eventos hemorrágicos que\npresentaba en articulaciones y músculos. Esto sirvió para que el monje Rasputín se acercara a la corte de\nRusia con el pretexto de efectuar curaciones sobre los sitios de hemorragia del príncipe Alexis; sin embar-\ngo, paradójicamente la muerte trágica del príncipe no dependió de su enfermedad\n \n(fig. 20-1)\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":331,"lines":{"from":71,"to":77}}}}],["1676",{"pageContent":"De los defectos hereditarios,\nla deficiencia de factor VIII\ny factor IX de la coagulación\n(hemofilia A y B, respectiva-\nmente) es la más frecuente, y\nen menor grado están la de-\nficiencia de FVII:C, FXI:C,\nFX:C, FII:C, afibrinogene-\nmias, etcétera.\nLas hemofilias A y B son coa-\ngulopatías hereditarias carac-\nterizadas por la deficiencia\nfuncional o cuantitativa del\nfactor VIII (hemofilia A) o\ndel factor IX (hemofilia B) de\nla coagulación.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":331,"lines":{"from":79,"to":94}}}}],["1677",{"pageContent":"305\n\nCAPÍTULO 20. COAGULOPATÍAS HEREDITARIAS\n\nCuadro 20-1.\n \nClasificación de las enfermedades hemorrágicas\n\nPúrpuras o defectos\nde\n \nhemostasia\n \npri-\nmaria\nVasculares\n\n•\n \n\u0014\u001f&\u001b(!#\u001f\u001d.\u001b-#\u001b \"\u001f'),,á!#\u001d\u001b \"\u001f,\u001f\u001e#.\u001b,#\u001b\n•\n \n\u0010Ě,*/,\u001b -#'*&\u001f\n•\n \n\u0010Ě,*/,\u001b \u001e\u001f \b\u001f()\u001d\"7\u0013\u001d\"Č(&\u001f#(\n•\n \n\u0010Ě,*/,\u001b -\u001f(#&\n\u0014,)'\u001c)\u001d#.)*ï(#\u001d\u001b-\n•\n \n\u0010\u0014 \u001b'\u001f!\u001b\u001d\u001b,#)\u001dù.#\u001d\u001b\n•\n \n\u0010\u0014 \u001b/.)#('/(#.\u001b,#\u001b\n•\n \n\u0010\u0014 *)-.,\u001b(- /-#)(\u001b&\n•\n \n\u0010\u0014 *), \"#*\u001f,\u001f-*&\u001f(#-')\n•\n \n\u0010\u0014 *)-'#\u001f&)-/*,\u001f-#ĉ(\n\u0014,)'\u001c)\u001d#.)*á.#\u001d\u001b-\n•\n \n\u0005( \u001f,'\u001f\u001e\u001b\u001e \u001e\u001f \u0002\u001f,(\u001b,\u001e7\u0013)/&#\u001f,\n•\n \n\u0014,)'\u001c\u001b-.\u001f(#\u001b \u001e\u001f \u0007&\u001b(4'\u001b((\n•\n \n\u0013ù(\u001e,)'\u001f \u001e\u001f &\u001b *&\u001b+/\u001f.\u001b !,#-\n•\n \n\u0004\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \u001d/\u001f,*)- \u001e\u001f(-)-\n\nCoagulopatías\n \no de-\nfectos\n \nde\n \nhemostasia\nsecundaria\nHer\neditarias\n\n•\n \nHemofilias A y B\n\n•\n \nDeficiencia de\n \nfibrinógeno\n\n•\n \nDeficiencia de\n \npr\notr\nombina\n\n•\n \nDeficiencia de los factores\n \nXI, VII\n \ny V\n\n•\n \nDeficiencia de CAPM y\n \ncalicr\neína\nAdquiridas\n\n•\n \n\u0003#,,)-#-\n \nhepática\n\n•\n \nFibrinogenólisis anormal\n \nprimaria","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":332,"lines":{"from":1,"to":116}}}}],["1678",{"pageContent":"•\n \nDeficiencia de\n \npr\notr\nombina\n\n•\n \nDeficiencia de los factores\n \nXI, VII\n \ny V\n\n•\n \nDeficiencia de CAPM y\n \ncalicr\neína\nAdquiridas\n\n•\n \n\u0003#,,)-#-\n \nhepática\n\n•\n \nFibrinogenólisis anormal\n \nprimaria\n\n•\n \nHemofilias y\n \nenfermedad\n \nde\n \nvon\nWillebrand\n \nadquiridas\nCoagulopatías o de-\nfectos de hemostasia\nsecundaria\nHereditarias\n\n•\n \n\b\u001f')l·&#\u001b- \u0001 3 \u0002\n•\n \n\u0004\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f l·\u001c,#(ĉ!\u001f()\n•\n \n\u0004\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f *,).,)'\u001c#(\u001b\n•\n \n\u0004\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f &)- \u001b\u001d.),\u001f- \u0018 6 \u0016\n \n3 \u0016\n•\n \n\u0004\u001fl·\u001d#\u001f(\u001d#\u001b \u001e\u001f \u0003\u0001\u0010\n \n3 \u001d\u001b&#\u001d,\u001fù(\u001b\n\nAdquiridas\n\n•\n \n\u0003#,,)-#- \"\u001f*á.#\u001d\u001b\n•\n \n\u0006#\u001c,#()!\u001f(ĉ&#-#- \u001b(),'\u001b& *,#'\u001b,#\u001b\n•\n \n\b\u001f')l·&#\u001b- 3 \u001f( \u001f,'\u001f\u001e\u001b\u001e \u001e\u001f 0)(\n\nWillebrand adquiridas\n\nB\u0010\u0014  *Ě,*/,\u001b .,)'\u001c)\u001d#.)*ï(#\u001d\u001b6 \u0003\u0001\u0010\n \n \u001d#(#(ĉ!\u001f() \u001e\u001f \u001b&.) *\u001f-) ')&\u001f\u001d/&\u001b,C","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":332,"lines":{"from":116,"to":205}}}}],["1679",{"pageContent":"Adquiridas\n\n•\n \n\u0003#,,)-#- \"\u001f*á.#\u001d\u001b\n•\n \n\u0006#\u001c,#()!\u001f(ĉ&#-#- \u001b(),'\u001b& *,#'\u001b,#\u001b\n•\n \n\b\u001f')l·&#\u001b- 3 \u001f( \u001f,'\u001f\u001e\u001b\u001e \u001e\u001f 0)(\n\nWillebrand adquiridas\n\nB\u0010\u0014  *Ě,*/,\u001b .,)'\u001c)\u001d#.)*ï(#\u001d\u001b6 \u0003\u0001\u0010\n \n \u001d#(#(ĉ!\u001f() \u001e\u001f \u001b&.) *\u001f-) ')&\u001f\u001d/&\u001b,C\n\nPor otra parte, los primeros relatos científicos de la enfermedad surgen en 1839 con Otto, quien describe\nclaramente la enfermedad, y en 1893 Wright llama la atención sobre el alargamiento del tiempo de coagula\n-\nción en estos pacientes. Más tarde, en 1910, Addis refiere que la anormalidad fundamental en la hemofilia A se\ndebe a un defecto en una proteína de la coagulación. Posteriormente, después de arduos estudios, el factor VIII\nlogró identificarse y purificarse. Por su parte, la hemofilia B fue identificada en 1947 por Pavlovsky y su grupo.\n\nIncidencia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":332,"lines":{"from":205,"to":230}}}}],["1680",{"pageContent":"Incidencia\n\nLa incidencia mundial de la hemofilia se ha estimado en 1:10 000 habitantes hombres y en el caso de la\nhemofilia B en 1:40 000 varones. De acuerdo a la Federación Mundial de Hemofilia, actualmente existen\nregistrados más de 116 000 pacientes hemofílicos en 77 países; sin embargo, se estima que hay 400 000\nhemofílicos en todo el mundo.\nEn Estados Unidos existen aproximadamente 15 000 hemofílicos registrados, y en el caso de México se\ninforma en el registro actual la existencia de 3 805 hemofílicos. No obstante, debemos considerar que, de\nacuerdo a la incidencia mundial, en México deben existir aproximadamente entre 4 000 y 5 000 pacientes\ncon hemofilia A y entre 1 000 y 1 250 pacientes con hemofilia B, es decir, en total debe existir una población\nde entre 5 000 y 6 250 enfermos, de los cuales el 45% tienen hemofilia grave (2 250 y 2 812, respectivamen\n-\nte). La hemofilia A se presenta en el 80% de los casos, contra el 20 a 25% de los casos de hemofilia B.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":332,"lines":{"from":230,"to":242}}}}],["1681",{"pageContent":"En Estados Unidos existen\ncasi 15 000 hemofílicos regis -\ntrados; en el caso de México se\ninforman en el registro actual\n3 805 hemofílicos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":332,"lines":{"from":244,"to":248}}}}],["1682",{"pageContent":"306\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nNaturaleza de la alteración genética","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":333,"lines":{"from":1,"to":5}}}}],["1683",{"pageContent":"Las alteraciones que afectan al factor VIII de la coagulación (FVIII:C) producen hemofilia A o clásica,\nmientras que la deficiencia del factor IX de la coagulación (FIX:C) determina la hemofilia B o enferme-\ndad de Christmas. El gen que codifica para ambos defectos se encuentra localizado en el brazo largo del\ncromosoma X, en regiones cercanas pero totalmente diferentes.\nEl gen que codifica al factor VIII se localiza en el extremo del brazo largo del cromosoma X (q28) y tiene\nuna longitud de 186 kb (186 000 bases), representa el 0,1% de la longitud total dicho cromosoma X y la\ninformación para el FVIII se localiza en 26 exones; su mRNA es de 9 kb. Se ha descrito gran homología en\nsu secuencia de aminoácidos y en su organización a nivel genético con el factor V de la coagulación, ambos\nconsiderados cofactores de la coagulación al intervenir complejos enzimáticos (X-asa y protrombinasa) de\nla coagulación.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":333,"lines":{"from":7,"to":16}}}}],["1684",{"pageContent":"considerados cofactores de la coagulación al intervenir complejos enzimáticos (X-asa y protrombinasa) de\nla coagulación.\nEl sitio de síntesis celular ha sido bien estudiado. El mRNA para el FVIII se ha detectado en hepatocitos,\nbazo, nodos linfáticos y riñón; la observación de que la hemofilia A puede ser curada en perros deficientes de\nFVIII y en humanos mediante el trasplante de hígado sugiere que el hígado es el sitio principal de síntesis\ndel FVIII. El estudio de ambas cadenas de DNA, así como de la secuencia de aminoácidos de esta proteína,\nindica que el FVIII es expresado en células de mamífero como un precursor de 2 351 aminoácidos, de los\ncuales los primeros 19 aminoácidos de la secuencia constituyen un péptido de señal para la secuencia del\nFVIII que sufren una rotura durante su translación. De manera específica, los primeros 12 aminoácidos\nguían la secuencia del FVIII. Debido al gran tamaño y complejidad del gen que determina la gran hetero-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":333,"lines":{"from":16,"to":25}}}}],["1685",{"pageContent":"guían la secuencia del FVIII. Debido al gran tamaño y complejidad del gen que determina la gran hetero-\ngeneidad de la molécula del FVIII:C, se explica la elevada frecuencia de nuevas mutaciones, y esto ocasiona\nque la identificación de la alteración genética se convierta en un análisis individual de gran dificultad. Origi-\nnalmente el análisis mutacional se efectuaba por Southern blot, y en la actualidad se realiza mediante la téc-\nnica de amplificación del genoma del DNA, por el método de la reacción en cadena de la polimerasa (PCR)\ncombinado con técnicas de secuenciación directa. Actualmente se han identificado más de 600 mutaciones\nque se incluyen en deleciones, inserciones y un elevado número de mutaciones puntuales; se han descrito más\nde 40 genes anormales, con deleciones que afectan desde todo el gen hasta segmentos tan pequeños como\nuna sola base. Casi todos los pacientes con deleciones presentan hemofilia grave. La frecuencia elevada de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":333,"lines":{"from":25,"to":33}}}}],["1686",{"pageContent":"una sola base. Casi todos los pacientes con deleciones presentan hemofilia grave. La frecuencia elevada de\nmutación esporádica (2 a 30% de todas las mutaciones) del gen codificador del FVIII:C puede ser debida en\nparte a la presencia de polimorfismos en la línea germinal materna, lo cual hace que sea difícil el diagnóstico\nprenatal y el análisis de portadores en la hemofilia A\n(cuadro 20-2)\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":333,"lines":{"from":33,"to":38}}}}],["1687",{"pageContent":"Figura 20-1.\n \nFotografía de la familia del zar Nicolás II y de su hijo hemofílico, el zarovich Alexis.\n\nDebido al gran tamaño y com-\nplejidad del gen que determina\nla gran heterogeneidad de la\nmolécula del FVIII:C, se expli\n-\nca la alta frecuencia de nuevas\nmutaciones, y esto ocasiona que\nla identificación de la altera-\nción genética se convierta en\nun análisis individual de gran\ndificultad.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":333,"lines":{"from":40,"to":54}}}}],["1688",{"pageContent":"307\n\nCAPÍTULO 20. COAGULOPATÍAS HEREDITARIAS\n\nPor otra parte, el gen del factor IX está localizado en la región distal del brazo largo del cromosoma X y\ntiene una longitud de 34 kb y mRNA de 2,8 kb. En plasma, el FIX humano circula como glucoproteína de\n\n/(\u001b -)&\u001b \u001d\u001b\u001e\u001f(\u001b \u001f(\n \n),'\u001b \u001e\u001f \u001d#'ĉ!\u001f() B\n \n kk̓ fffC \u001b /(\u001b \u001d)(\u001d\u001f(.,\u001b\u001d#ĉ( \u001e\u001f of̓ (\n \n8 \u0014#\u001f(\u001f 0#\u001e\u001b '\u001f\u001e#\u001b\n\nde un día. Presenta un dominio gla en su molécula que contiene 12 residuos de ácido\n \nγ\n-carboxiglutámico\ny un residuo de ácido\n \nβ\n-hidroxiaspártico en la región aminoterminal de la proteína. Los residuos de ácido","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":334,"lines":{"from":1,"to":23}}}}],["1689",{"pageContent":"γ\n-carboxiglutámico están relacionados con la unión al calcio, mientras que la función del ácido\n β\n-hidroxias-\npártico se desconoce. La región aminoterminal de la cadena contiene la región del sitio activo. Se han iden-\ntificado en el gen del FIX diez polimorfismos, siete intragénicos y tres extragénicos. Aproximadamente el\n4% de las mutaciones del gen son debidas a defectos gruesos como deleciones, inserciones o reagrupamiento.\nLas deleciones pequeñas pueden producir desplazamientos en las lecturas, dando lugar a proteínas acabadas\nprematuramente y que son inactivas. En México se han investigado nuevas mutaciones de líneas germinales\nen la población de hemofílicos B. El estudio para evaluar el patrón de mutación en población mexicana del\ngen del FIX:C mostró 30 mutaciones de 31 familias estudiadas. En el análisis de estas 30 mutaciones, se\nencontró un patrón de mutación independiente similar al patrón observado en 127 familias caucásicas.\n\nHerencia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":334,"lines":{"from":25,"to":38}}}}],["1690",{"pageContent":"Debido a la codificación genética de las moléculas de FVIII:C y FIX:C, la enfermedad tiene una heren-\ncia ligada al cromosoma X, es decir, que las mujeres portan la enfermedad y los hombres la manifiestan.\nEsto significa que los hijos de una mujer portadora tienen 50% de probabilidades de tener el gen anormal.\nAproximadamente entre el 70 y 75% de los hemofílicos tienen antecedentes familiares de la enfermedad,\nlo cual significa que entre el 25 y 30% de los casos presentan una mutación de novo.\nDe acuerdo a su forma\nde herencia, se puede concluir que: 1) todas las hijas de un hemofílico son portadoras obligadas; 2) todos\nlos hijos de un hemofílico son normales; 3) aproximadamente la mitad de las hermanas de un hemofílico\nson portadoras; 4) alrededor de la mitad de los hijos de una portadora serán hemofílicos y 5) cerca de la\nmitad de las hijas de una portadora serán portadoras\n \n(fig. 20-2)\n.\nPor otro lado, la presencia de hemofilia en las mujeres solo se presenta en los siguientes casos: a) lio-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":334,"lines":{"from":40,"to":53}}}}],["1691",{"pageContent":"mitad de las hijas de una portadora serán portadoras\n \n(fig. 20-2)\n.\nPor otro lado, la presencia de hemofilia en las mujeres solo se presenta en los siguientes casos: a) lio-\nnización extrema al azar, b) hija de padre hemofílico y madre portadora y c) asociación de la enfermedad","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":334,"lines":{"from":53,"to":58}}}}],["1692",{"pageContent":"\u001d)( -ù(\u001e,)'\u001f \u001e\u001f \u0014/,(\u001f,8 \u0005- \u001d)'Ě( )\u001c-\u001f,0\u001b, \u001f( *),.\u001b\u001e),\u001b- \u001e\u001f \"\u001f')̑&#\u001b\n \n\u001d)(\u001d\u001f(.,\u001b\u001d#)(\u001f- *&\u001b-'á.#\u001d\u001b- \u001e\u001f&\n\nFVIII:C o del FIX:C menores de 50 UI/dL\n \n(fig. 20-3)\n.\n\nGravedad de la enfermedad\n\nLos defectos en las moléculas de FVIII:C o FIX:C se pueden deber principalmente a un defecto de sín -\ntesis que ocasiona una disminución en la concentración plasmática de la molécula; sin embargo, también\nexisten defectos cualitativos en la molécula que se traducen en factores disfuncionales, aunque desde el\npunto de vista coagulométrico estos dos trastornos son indistinguibles. Los defectos cualitativos de la\nmolécula se denominan\n \nmaterial de reacción cruzada.\n \nLa deficiencia de estos dos factores de la coagulación\n\nCuadro 20-2.\n \nCaracterísticas del factor VIII\n\nFactor VIII","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":334,"lines":{"from":60,"to":85}}}}],["1693",{"pageContent":"Cuadro 20-2.\n \nCaracterísticas del factor VIII\n\nFactor VIII\n\n• \u0003)\u001e#l·\u001d\u001b\u001d#ĉ( \u0003,8 \u0018 B+hnC\n• gnl %\u001c\n• \u0014\u001b'\u001bĄ) \u001e\u001f& !\u001f( f6gz \u001e\u001f &\u001b &)(!#./\u001e \u001e\u001f& \u001d,)')-)'\u001b\n• hl \u001f2)(\u001f- 3 hk #(.,)(\u001f-\n• '\u0012\u000e\u0001 \u001e\u001f o %\u001c\n• \u0003)(.#\u001f(\u001f h ikg \u001b'#()á\u001d#\u001e)-\n• \u0010\u001f-) hjf %\u001c\n• \u0004#'\u001f(-#ĉ( ')&\u001f\u001d/&\u001b, \"\u001f.\u001f,)\u001eù'\u001f,)\n• \u0010,)\u001e/\u001d\u001d#ĉ( \"\u001f*á.#\u001d\u001b6 \u001f-*&ï(#\u001d\u001b6 (ĉ\u001e/&)- &#( á.#\u001d)- 3 ,#Ąĉ(\n• \u0003)(\u001d\u001f(.,\u001b\u001d#ĉ( *&\u001b-'á.#\u001d\u001b g (')&I\n\nDebido a la codificación ge-\nnética\n \nde\n \nlas\n \nmoléculas\n \nde\nFVIII:C y FIX:C, la en-\nfermedad tiene una heren-\ncia ligada al cromosoma X,\nes decir, que las mujeres la\nportan y los hombres la ma-\nnifiestan. De acuerdo a su\nforma de herencia, se puede\nconcluir que: 1) todas las hi-\njas de un hemofílico son por-\ntadoras obligadas; 2) todos\nlos hijos de un hemofílico son\nnormales;\n \n3)\n \naproximada-\nmente la mitad de las her-\nmanas de un hemofílico son\nportadoras; 4) alrededor de\nla mitad de los hijos de una\nportada serán hemofílicos; y\n5) cerca la mitad de las hi-\njas de una portadora serán\nportadoras.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":334,"lines":{"from":85,"to":135}}}}],["1694",{"pageContent":"308\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nse divide con base en la intensidad del factor deficiente, esto determinado por método funcional (coagulo-\nmétrico y más recientemente cromogénico), en leve, moderado y grave\n \n(cuadro 20-3)\n.\n\nFisiopatología de la enfermedad\n\nLa deficiencia cuantitativa o cualitativa del factor VIII:C o IX:C se traduce como un defecto en los\nmecanismos de activación de la coagulación. Normalmente el FIX:C y el FVIII:C participan de\nmanera conjunta integrando un poderoso complejo de activación del FX:C denominado\n \ncomplejo X-asa\n.\nEstos dos factores participan en una fase de sostén o mantenimiento de la coagulación, después de que\nel complejo FVII:C/factor tisular ha iniciado la activación del FX:C y el FIX:C. La deficiencia de\nestos dos factores se traduce en un retraso en la formación del coágulo; considerando que la fase inicial\nde activación de la coagulación dependiente del complejo FVII:C/factor tisular se encuentra bloquea -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":335,"lines":{"from":1,"to":22}}}}],["1695",{"pageContent":"\u001e\u001b *), \u001f& #(\"#\u001c#\u001e), \u001e\u001f &\u001b 0ù\u001b \u001e\u001f&\n \n\u001b\u001d.), .#-/&\u001b, B \u0016\u0006\u0014C6 \u001f-.) *,)0)\u001d\u001b +/\u001f &\u001b\n \n),'\u001b\u001d#ĉ( \u001e\u001f& *)&ù'\u001f,) \u001e\u001f\n\nfibrina se efectúe de manera tardía y clínicamente predisponga al enfermo a hemorragias\n \n(fig. 20-4)\n \n.\nSe observa la participación de los factores de la coagulación en la generación de cantidades suficientes\nde trombina para generar el coágulo de fibrina. En el paciente con hemofilia A o B existe una incapacidad\npara integrar el complejo X-asa sobre la superficie de las plaquetas activadas que ocasiona que no se gene-\nren cantidades suficientes de trombina para formar un coágulo de fibrina. En otras palabras, en el paciente\ncon hemofilia existe una incapacidad para generar dosis suficientes de trombina.\n\nPresentación clínica","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":335,"lines":{"from":24,"to":41}}}}],["1696",{"pageContent":"Presentación clínica\n\nLos datos clínicos de los dos tipos de hemofilia son sustancialmente idénticos y varían solo en relación al\ngrado de la deficiencia. El síntoma por excelencia de la hemofilia es la hemorragia y la intensidad de esta de-\npenderá de diversos factores, a saber: nivel circulante del factor deficiente, presencia de inhibidores, trauma-\ntismos, tipo de actividad física cotidiana y deportiva, entre otros. Esto significa que un hemofílico con una\ndeficiencia grave puede presentar hemorragias al mínimo traumatismo, e incluso con el desarrollo diario de\nuna actividad física intensa como la deambulación continua y persistente, así como subir escaleras, etcétera.\nLa mayor parte de la sintomatología del paciente hemofílico se debe a secuelas y complicaciones del síndro-\nme hemorrágico. No siempre se puede encontrar el factor desencadenante de la aparición de la hemorragia\n(hemorragias espontáneas), pero en general suele obedecer a causas mínimas que en un sujeto normal pueden","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":335,"lines":{"from":41,"to":51}}}}],["1697",{"pageContent":"Figura 20-2.\n \nÁrbol genealógico de una familia con hemofilia. Cada mujer portadora tiene 50% de proba-\nbilidades de tener hijos o hijas afectados.\n\nLa deficiencia cuantitativa o\ncualitativa del factor VIII:C\no IX:C se traduce como defecto\nen los mecanismos de activa-\nción de la coagulación.\nEl síntoma por excelencia de\nla hemofilia es la hemorragia,\ny la intensidad de esta depen-\nderá de diversos factores, a sa-\nber: nivel circulante del factor\ndeficiente, presencia de inhi-\nbidores,\n \ntraumatismos,\n \ntipo\nde actividad física cotidiana\ny deportiva, etc.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":335,"lines":{"from":53,"to":75}}}}],["1698",{"pageContent":"309\n\nCAPÍTULO 20. COAGULOPATÍAS HEREDITARIAS\n\nFigura 20-3.\n \nEsquema de la herencia en mujer hemofílica.\n\nCuadro 20-3.\n \nClasificación de la gravedad de las hemofilias\n\nTipo\n \nActividad del factor deficiente\n\nGrave\n \n< 1 UI/dL\nModerado\n \n1 a 4 UI/dL\nLeve\n \n5-25 UI/dL\nSubhemofílicos/portadoras\n \n5-50 UI/dL\nValores normales\n \n50-150 UI/dL\n\n\u0015 I\u001e\n \n \u0015(#\u001e\u001b\u001e\u001f-\n \n(.\u001f,(\u001b\u001d#)(\u001b&\u001f- *), \u001e\u001f\u001d#&#.,)8\n\nFigura 20-4.\n \nEsquema del modelo celular de la coagulación.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":336,"lines":{"from":1,"to":41}}}}],["1699",{"pageContent":"310\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\npasar inadvertidas. Las hemofilias A y B, por ser defectos primarios que involucran a la hemostasia secun-\ndaria, clínicamente se manifiestan por hemorragias profundas, como pueden ser la hemartrosis, hematomas\nmusculares, hemorragias quirúrgicas, gastrointestinales, urinarias, entre otras\n \n(cuadro 20-4)\n.\n\nHemartrosis\n\nLa hemorragia intraarticular es la manifestación clínica más frecuente y característica de la enferme -\ndad, y en las formas graves representa el principal problema de tratamiento. Durante la hemartrosis,\nla articulación afectada se encuentra aumentada de tamaño, caliente, dolorosa y el paciente asume la\nposición antiálgica que permite la máxima capacidad y la menor distensión de la cápsula intraarticular.\nLas articulaciones más afectadas son rodillas, tobillos y codos\n \n(fig. 20-5)\n.\n\nHematomas musculares","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":337,"lines":{"from":1,"to":23}}}}],["1700",{"pageContent":"Hematomas musculares\n\nLos músculos más frecuentemente afectados son: psoas, ilíaco, glúteos, gemelos, cuádriceps, bíceps y\ngrandes dorsales; estos hematomas con frecuencia se presentan después de traumatismos. Generalmente\nlas hemorragias se manifiestan por tumefacción dolorosa, que puede ocasionar serias consecuencias según\nel sitio de localización, como isquemias distales por compromiso circulatorio (síndrome compartamental),\ncontracturas y trastornos neurotróficos debidos a la compresión que ejerce el hematoma\n \n(fig. 20-6)\n.\n\nHematuria\n\nEs frecuente en los pacientes hemofílicos graves y se puede acompañar de dolor lumbar irradiado hacia la\npelvis, que se explica por la formación de pequeños coágulos que, al ser eliminados, estimulan la contrac-\nción dolorosa de los uréteres.\n\nHemorragias gastrointestinales","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":337,"lines":{"from":23,"to":40}}}}],["1701",{"pageContent":"Hemorragias gastrointestinales\n\nLas hemorragias gastrointestinales son poco frecuentes y casi siempre ligadas a alteraciones orgánicas del\ntubo digestivo (úlceras pépticas, gastritis, angiodisplasia intestinal, hemorroides, etc.).\n\nHemorragia del sistema nervioso central\n\nEsta hemorragia constituye una de las más graves manifestaciones de la enfermedad, y algunas veces es\nmortal. Según su intensidad, puede provocar datos focales o de mayor extensión\n \n(fig. 20-7)\n.\n\nCuadro 20-4.\n \nLos datos clínicos en el paciente con hemofilia dependen del sitio de localización\nde las hemorragias; sin embargo, están descritas en el cuadro por el orden de frecuencia\n\nSintomatología\n\n•\n \nHemartr\nosis\n\n•\n \nHematomas\n\n•\n \nHematuria\n\n•\n \n\b\u001f'),,\u001b!#\u001b-\n \ngastr\nointestinales\n\n•\n \n\b\u001f'),,\u001b!#\u001b \u001f( -#-.\u001f'\u001b (\u001f,0#)-)\n \ncentral\n\n•\n \n\b\u001f'),,\u001b!#\u001b\n \nbucal","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":337,"lines":{"from":40,"to":90}}}}],["1702",{"pageContent":"Sintomatología\n\n•\n \nHemartr\nosis\n\n•\n \nHematomas\n\n•\n \nHematuria\n\n•\n \n\b\u001f'),,\u001b!#\u001b-\n \ngastr\nointestinales\n\n•\n \n\b\u001f'),,\u001b!#\u001b \u001f( -#-.\u001f'\u001b (\u001f,0#)-)\n \ncentral\n\n•\n \n\b\u001f'),,\u001b!#\u001b\n \nbucal\n\n•\n \n\b\u001f'),,\u001b!#\u001b- \u001f( -#.#)- *)\u001d)\n \nusuales:\n-\n \nHemorragia\n \nintraabdominal\n-\n \nHemorragia r\netr\noperitoneal\n-\n \nHemorragia\n \npulmonar\n-\n \nHemorragia\n \npericár\ndica\n-\n \nHemorragia traqueal,\n \netc.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":337,"lines":{"from":90,"to":154}}}}],["1703",{"pageContent":"311\n\nCAPÍTULO 20. COAGULOPATÍAS HEREDITARIAS\n\nHemorragia posoperatoria\n\nSe presenta cuando el paciente ha sido intervenido quirúrgicamente sin la adecuada preparación con te-\nrapia sustitutiva, esto debido a: 1) desconocimiento médico de la enfermedad, 2) paciente hemofílico leve\nsin diagnóstico previo; o 3) presencia de inhibidores.\n\nHemorragias bucales\n\nLa buena higiene bucal es particularmente importante para los pacientes con hemofilia, sobre todo para\nprevenir la necesidad de extracciones dentales. En caso de extracciones dentales u otro tipo de procedi-\nmientos, tradicionalmente se emplea terapia sustitutiva y la aplicación local de antifibrinolíticos (ácido\naminocaproico o tranexámico)\n \n(fig. 20-8)\n.\n\nDIAGNÓSTICO\n\nHistoria familiar","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":338,"lines":{"from":1,"to":23}}}}],["1704",{"pageContent":"El diagnóstico se sospechará en hijos de mujeres portadoras conocidas (historia familiar de hemofilia). El\nestudio a los recién nacidos debe efectuarse tempranamente. En situaciones de urgencia se aconseja tomar\nla muestra de sangre del cordón umbilical, de lo contrario lo prudente es tomar muestra de una vena pe -\nriférica después de los 6 meses de edad, para mayor exactitud del resultado, una vez que se haya superado\nla inmadurez hepática del recién nacido.\nDe no existir historia familiar de hemofilia, el diagnóstico del afectado se realiza para los casos graves\naproximadamente al año de vida, cuando existe mayor movilidad y se evidencia por hemorragias en sitios\nde presión y apoyo. Para los casos moderados y leves, el diagnóstico a veces se retrasa incluso hasta la vida\nadulta, al presentarse hemorragia posterior a una agresión externa (trauma, cirugía, extracción dental, etc.).\nSi el antecedente familiar o el cuadro clínico hacen sospechar que se trata de hemofilia, el diagnóstico","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":338,"lines":{"from":25,"to":34}}}}],["1705",{"pageContent":"Si el antecedente familiar o el cuadro clínico hacen sospechar que se trata de hemofilia, el diagnóstico\nse establece por los estudios de laboratorio. Las pruebas de escrutinio ofrecen una visión general del estado\ndel paciente y orientan a un diagnóstico definitivo.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":338,"lines":{"from":34,"to":36}}}}],["1706",{"pageContent":"Estudios de laboratorio\n\nLos exámenes hematológicos básicos, como la citometría hemática, no muestran hallazgos característi-\ncos. La presencia o ausencia de anemia depende de la magnitud y frecuencia de las hemorragias y es más\ncomún observarla en los niños.\n\nFigura 20-5.\n \nHemartrosis en rodilla izquierda.\n\nSi el antecedente familiar o el\ncuadro clínico hacen sospechar\nque se trata de hemofilia, el\ndiagnóstico se establece por los\nestudios de laboratorio. Las\npruebas de escrutinio ofrecen\nuna visión general del estado\ndel paciente y orientan a un\ndiagnóstico definitivo.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":338,"lines":{"from":38,"to":56}}}}],["1707",{"pageContent":"312\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nFigura 20-6.\n \nHematoma muscular.\n\nFigura 20-7.\n \nHemorragia cerebral en hemofilia.\n\nPruebas de escrutinio\n\nLas hemofilias A y B van a diferenciarse una de otra solo con la cuantificación de los factores involucrados;\nsin embargo, en las pruebas de pantalla puede orientarse el diagnóstico de manera inicial. Los estudios que\n\n\u001f0\u001b&Ě\u001b( &\u001b \"\u001f')-.\u001b-#\u001b *,#'\u001b,#\u001b6 \u001d)') -)( &\u001b \u001d/\u001f(.\u001b \u001e\u001f *&\u001b+/\u001f.\u001b- B\u0003\u0010C 3 \u001f& .#\u001f'*) \u001e\u001f \"\u001f'),,\u001b!#\u001b B\u0014\bC6\n-)( (),'\u001b&\u001f-8\n \n)- \u001f-./\u001e#)- +/\u001f \u001f0\u001b&Ě\u001b( &\u001b \u001d)\u001b!/&\u001b\u001d#ĉ(6 \u001d)') \u001f& .#\u001f'*) \u001e\u001f *,).,)'\u001c#(\u001b B\u0014\u0010C 3 \u001f& .#\u001f'*)\n\u001e\u001f .,)'\u001c#(\u001b B\u0014\u0014C6 \u001f-.á( (),'\u001b&\u001f-: () )\u001c-.\u001b(.\u001f6 \u001f& .#\u001f'*) \u001e\u001f .,)'\u001c)*&\u001b-.#(\u001b *\u001b,\u001d#\u001b& \u001b\u001d.#0\u001b\u001e\u001b B\u0014\u0014\u0010\u001bC -\u001f\n\nencuentra alargado. Si el alargamiento es significativo, se puede inferir que existe un nivel de FVIII:C o\nFIX:C menor del 50%, con sospecha de hemofilia. En casos de hemofilia moderada o leve, el alargamiento\n\n\u001e\u001f& \u0014\u0014\u0010\u001b */\u001f\u001e\u001f -\u001f, &#!\u001f,)6 -)\u001c,\u001f .)\u001e) -# &\u001b \u001b\u001d.#0#\u001e\u001b\u001e \u001e\u001f& \u0006\u0016\n \n9\u0003 ) \u0006 \u00189\u0003 \u001f- \u001d\u001f,\u001d\u001b(\u001b \u001b& hfz8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":339,"lines":{"from":1,"to":29}}}}],["1708",{"pageContent":"\u001e\u001f& \u0014\u0014\u0010\u001b */\u001f\u001e\u001f -\u001f, &#!\u001f,)6 -)\u001c,\u001f .)\u001e) -# &\u001b \u001b\u001d.#0#\u001e\u001b\u001e \u001e\u001f& \u0006\u0016\n \n9\u0003 ) \u0006 \u00189\u0003 \u001f- \u001d\u001f,\u001d\u001b(\u001b \u001b& hfz8\n\nPara determinar que se trata de la deficiencia de factores de la coagulación, se procede a realizar co-\n\n,,\u001f\u001d\u001d#)(\u001f- \u001b \u001f-.\u001f \u0014\u0014\u0010\u001b *,)&)(!\u001b\u001e)6 '\u001f\u001e#\u001b(.\u001f &\u001b '\u001f4\u001d&\u001b \u001e\u001f *&\u001b-'\u001b (),'\u001b& )\u001c.\u001f(#\u001e) \u001e\u001f #(\u001e#0#\u001e/)- -\u001b()-\n\nLos estudios que evalúan\n \nla\ncoagulación, como el tiempo\nde protrombina (TP) y el\ntiempo\n \nde\n \ntrombina\n \n(TI),\nestán normales; no obstante,\nel tiempo de tromboplastina\nparcial activada (T TPa) se\nencuentra alargado.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":339,"lines":{"from":29,"to":52}}}}],["1709",{"pageContent":"313\n\nCAPÍTULO 20. COAGULOPATÍAS HEREDITARIAS\n\n\u001f( /(\u001b *,)*),\u001d#ĉ( \u001e\u001f g9g8 \u0013# \u001f& \u0014\u0014\u0010\u001b -\u001f \u001d),,#!\u001f \u001b -/ 0\u001b&), (),'\u001b&6 #(\u001e#\u001d\u001b +/\u001f \u001f& *&\u001b-'\u001b (),'\u001b& \u001b\u001e#\u001d#)(\u001b\u001e)\n\naportó el factor deficiente, y este efecto corrector constituye la base de muchos estudios presuntivos sim-\nples utilizados en la hemofilia.\nDe no corregir, se sospecha la presencia de un inhibidor dirigido contra algún factor que interviene en\nla vía intrínseca. Para descartar tal situación, antes de orientar el estudio hacia la búsqueda del inhibidor\n\nB\u001e#&/\u001d#)(\u001f- \u001e\u001f& \u0014\u0014\u0010\u001bC6 -\u001f ,\u001f\u001d)'#\u001f(\u001e\u001b +/\u001f &\u001b '\u001f4\u001d&\u001b \u001e\u001f& *&\u001b-'\u001b \u001e\u001f& *\u001b\u001d#\u001f(.\u001f \u001d)( \u001f& *&\u001b-'\u001b (),'\u001b& *\u001b,\u001b\n\u001e\u001f.\u001f,'#(\u001b, \u001f& \u0014\u0014\u0010\u001b -\u001f\u001b #(\u001d/\u001c\u001b\u001e) *), g \u001b h \"),\u001b- \u001b im\n \nºC. En muchas ocasiones el alargamiento de tal\nestudio se corrige en ese momento\n \n(cuadro 20-5)\n.\n\nCuantificación de factores","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":340,"lines":{"from":1,"to":21}}}}],["1710",{"pageContent":"Orientado el diagnóstico a hemofilia, se procede a la cuantificación del FVIII:C, el FIX:C, o ambos.\nLos factores de coagulación son proteínas difíciles de evaluar por métodos químicos. La cuantificación\ntradicional de laboratorio consiste en estudios que no distinguen las alteraciones cuantitativas de las cua-\nlitativas. Por mucho tiempo se supuso que las coagulopatías hereditarias se debían a la deficiencia de la\nproteína específica; ahora, con las técnicas inmunológicas, se ha demostrado que la pérdida de la actividad\ncoagulante puede derivar de la biosíntesis deficiente o defectuosa de la proteína afectada. Actualmente\nlos estudios relacionados a estos factores se expresan como\n \nmaterial de reacción cruzada\n \n(MRC) positivo\no negativo. Lo que indica un estudio MRC positivo es que a nivel plasmático existe una sustancia con\nsimilitud antigénica al factor de coagulación anormal (MRC positiva o cualitativa), en tanto que los ha-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":340,"lines":{"from":23,"to":35}}}}],["1711",{"pageContent":"similitud antigénica al factor de coagulación anormal (MRC positiva o cualitativa), en tanto que los ha-\nllazgos MRC negativos indican ausencia de la proteína antigénica y sugieren que la biosíntesis del factor\ninvolucrado es escasa (MRC negativo o cuantitativo).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":340,"lines":{"from":35,"to":37}}}}],["1712",{"pageContent":"Los métodos de cuantificación de factores\n\nLos métodos que miden la actividad funcional del factor deficiente se clasifican en coagulométricos y\ncromogénicos. Los primeros consisten en medir el tiempo que tarda en formarse un coágulo a través de\nun sensor que capta cambios en la luz del plasma y los cromogénicos miden la reacción producida por la\nliberación de un compuesto colorido mediante fotometría.\nLas proteínas de FVIII:C y FIX:C se determinan mediante ensayos inmunológicos del antígeno (Ag)\n\n\u001e\u001f& \u0006\u0016\n \n3 \u0006 \u0018 B\u0005\n \n\u0013\u0001C8 \u0014#\u001f(\u001f( &\u001b \u001d\u001b*\u001b\u001d#\u001e\u001b\u001e \u001e\u001f \u001e\u001f.\u001f\u001d.\u001b, ')&ï\u001d/&\u001b- (),'\u001b&\u001f- ) \u001b(),'\u001b&\u001f- \u001e\u001f&\n \n\u001b\u001d.),\n\nafectado. Si el nivel del Ag del factor es normal y la actividad coagulante está disminuida, el paciente\ntiene una molécula de factor disfuncional (hemofilia Ag-positiva), o lo que también se ha denominado\n\nmaterial de reacción cruzada positiva\n \n(MRC positiva). Para otros pacientes, tanto el Ag como la actividad\nson indetectables, y se denominan\n \nhemofilia Ag negativo\n \no bien\n \nMRC negativo\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":340,"lines":{"from":39,"to":68}}}}],["1713",{"pageContent":"material de reacción cruzada positiva\n \n(MRC positiva). Para otros pacientes, tanto el Ag como la actividad\nson indetectables, y se denominan\n \nhemofilia Ag negativo\n \no bien\n \nMRC negativo\n.\n\nFigura 20-8.\n \nHemorragia bucal.\n\nOrientado\n \nel\n \ndiagnóstico\n \na\nhemofilia,\n \nse\n \nprocede\n \na\n \nla\ncuantificación del FVIII:C, el\nFIX:C, o ambos. Los factores\nde coagulación son proteínas\ndifíciles de evaluar por méto-\ndos químicos. La cuantifica-\nción tradicional de laboratorio\nconsiste en estudios que no dis-\ntinguen las alteraciones cuan-\ntitativas de las cualitativas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":340,"lines":{"from":68,"to":108}}}}],["1714",{"pageContent":"314\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nInhibidores en hemofilia\n\nEs indispensable realizar también la búsqueda de inhibidores contra el factor afectado, que se lleva a cabo\npor el método de las unidades Bethesda, descrito por Kasper.\nLa investigación de inhibidores en el laboratorio generalmente se sospecha con la prolongación del\n\n\u0014\u0014\u0010\u001b 3 \u001f( \u001d#\u001f,.\u001b- \u001d)(\u001e#\u001d#)(\u001f- \u001d&ù(#\u001d\u001b-9","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":341,"lines":{"from":1,"to":11}}}}],["1715",{"pageContent":"1. Pacientes con diagnóstico de hemofilia que no responden al tratamiento sustitutivo con una dosis\nadecuada.\n2. Pacientes sin historia clínica previa de hemorragia y que presentan de manera súbita hemorragias graves.\n3. Pacientes con hemofilia B que presentan anafilaxia al concentrado de factor transfundido.\nEl diagnóstico en los pacientes con sospecha de inhibidores debe realizarse de manera rápida y precisa.\nEn pacientes sin historia de hemorragia siempre se debe descartar la presencia de anticoagulante lúpico.\nLa prueba confirmatoria para la detección del inhibidor se realiza en el laboratorio. Entre los métodos\npara la detección del inhibidor se encuentran: la determinación por unidades Oxford, la prueba clásica de\nBethesda, la modificación a la prueba de unidades Bethesda (determinación de Nijmegen) y la técnica\nde ELISA. La detección se realiza en unidades Bethesda (UB). Una UB se define como la cantidad de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":341,"lines":{"from":13,"to":22}}}}],["1716",{"pageContent":"Bethesda, la modificación a la prueba de unidades Bethesda (determinación de Nijmegen) y la técnica\nde ELISA. La detección se realiza en unidades Bethesda (UB). Una UB se define como la cantidad de\nanticuerpo que neutraliza el 50% de la actividad del factor VIII o IX encontrado en el plasma normal (sin","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":341,"lines":{"from":22,"to":24}}}}],["1717",{"pageContent":"\u001f'\u001c\u001b,!)6 */\u001f\u001e\u001f ,\u001f\u001b&#4\u001b,-\u001f *\u001b,\u001b \u001e\u001f.\u001f,'#(\u001b, \u001f& ,\u001f-.) \u001e\u001f &)- \u001b\u001d.),\u001f- +/\u001f '#\u001e\u001f \u001f& \u0014\u0014\u0010\u001b9 \u0018\n \n6 \u0018 6 \u0018 3 \u0016\n \nC8\n\nLa presencia del inhibidor debe ser cuantificada, para lo cual la Sociedad Internacional de Hemostasia y\n\n\u0014,)'\u001c)-#- B \u0013\b\u0014C \u001e\u001f̑(\u001f\n \n\u001e)- .#*)- \u001e\u001f #(\"#\u001c#\u001e), \u001e\u001f \u001b\u001d/\u001f,\u001e) \u001b &\u001b ,\u001f-*/\u001f-.\u001b #('/(#.\u001b,#\u001b B*)-\u001f-.ù'/&) \u001e\u001f\n\nfactor): inhibidor de alta respuesta > 5 UB y de baja respuesta < 5 UB.\nLa prueba clásica de UB es el método más empleado para la detección de estos inhibidores, pero carece","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":341,"lines":{"from":26,"to":39}}}}],["1718",{"pageContent":"factor): inhibidor de alta respuesta > 5 UB y de baja respuesta < 5 UB.\nLa prueba clásica de UB es el método más empleado para la detección de estos inhibidores, pero carece\n\n\u001e\u001f \u001f-*\u001f\u001d#̑\u001d#\u001e\u001b\u001e6\n \n\u001f( \u001f-*\u001f\u001d#\u001b& \u001f( &)- *\u001b\u001d#\u001f(.\u001f- \u001d)( (#0\u001f&\u001f- \u001c\u001b$)- \u001e\u001f #(\"#\u001c#\u001e),8 \u0010), .\u001b& ').#0)6 &\u001b \u0013\b\u0014 ,\u001f\u001d)\n-\nmienda en la actualidad la prueba modificada a la clásica de Bethesda, la prueba modificada de Nijmegen.\nLa diferencia entre ambos métodos consiste en dos modificaciones a la prueba clásica\n \n(figs. 20-9 y 20-10)\n:\n1) el búfer de plasma normal usado en la mezcla del plasma problema y el plasma control es con imidazol,\n0,1 moles a un pH de 7,4; y 2) el reemplazo del imidazol en la mezcla control por plasma deficiente de\nfactor VIII. Los objetivos de esta modificación son evitar falsas positivas con la prueba clásica de UB y\ndeterminar niveles bajos de inhibidor.\n\nEl estudio de portadoras","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":341,"lines":{"from":39,"to":56}}}}],["1719",{"pageContent":"El estudio de portadoras\n\nEn familias con historia de hemofilia, el diagnóstico de las portadoras también es muy importante, sobre\ntodo para brindar un adecuado consejo genético en las mujeres afectadas. Para casos de hemofilia de novo,\nse debe estudiar el gen afectado (VIII o IX) y detectar la posible mutación.\n\nCuadro 20-5.\n \nPruebas de hemostasia. Hemofilia A, B y enfermedad de von Willebrand*\n\nPruebas de hemostasia\n \nHemofilia A\n \nHemofilia B\n \nEvW*\n\nCuenta de plaquetas\n \nNormal\n \nNormal\n \nNormal\n\n\u0014#\u001f'*) \u001e\u001f \"\u001f'),,\u001b!#\u001b\n \nNormal\n \nNormal\n \nProlongado\n\n\u0014\u0010\n \nNormal\n \nNormal\n \nNormal\n\n\u0014\u0014\u0010\u001b\n \nProlongado\n \nProlongado\n \nNormal/Prolongado\n\n\u0014\u0014\n \nNormal\n \nNormal\n \nNormal\nFibrinógeno\n \nNormal\n \nNormal\n \nNormal\nFVIII:C\n \nBajo\n \nNormal\n \nBajo\nFIX:C\n \nNormal\n \nBajo\n \nNormal\nFvW:Ag\n \nNormal\n \nNormal\n \nBajo\nFvW:RiCof\n \nNormal\n \nNormal\n \nBajo","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":341,"lines":{"from":56,"to":147}}}}],["1720",{"pageContent":"315\n\nCAPÍTULO 20. COAGULOPATÍAS HEREDITARIAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":342,"lines":{"from":1,"to":3}}}}],["1721",{"pageContent":"En las portadoras, el factor deficiente se encuentra en una concentración plasmática cercana al 50%.\nAntiguamente se determinaba la actividad funcional del FVIII:C o FIX:C, pero los resultados positivos\ny fidedignos para el estado de portadora solo alcanzaban el 35% de todas las mujeres estudiadas, por lo\nque esta técnica está en desuso.\nEl inmunoensayo es una técnica que en la actualidad se utiliza en conjunto con la actividad funcio-\nnal del factor afectado. En el caso de la hemofilia A, se aplica al FvW y posteriormente se determina la\nproporción entre el FVIII:C y el FvW, con lo cual es posible diferenciar a la población portadora de las\nmujeres sanas. La tasa de detección global va de 72 a 94%, lo que la hace una técnica eficaz.\nEl análisis de polimorfismo de fragmentos de restricción (RFLP) puede ser exitoso para determinar de\nmanera indirecta el gen afectado (árbol genealógico), y se realiza a la madre de un hemofílico. Cerca del\n70% de las portadoras se detectan por este método.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":342,"lines":{"from":5,"to":15}}}}],["1722",{"pageContent":"manera indirecta el gen afectado (árbol genealógico), y se realiza a la madre de un hemofílico. Cerca del\n70% de las portadoras se detectan por este método.\nExisten técnicas con DNA recombinante que también son útiles para detectar a las portadoras o\npara el diagnóstico prenatal (productos de madres portadoras conocidas), y la prueba más específica es\npor análisis de DNA mediante la reacción en cadena de la polimerasa (PCR), que detecta hasta el 95%\nde las mujeres afectadas. Otro estudio útil es la identificación directa de la mutación patogénica en el\ngen del FVIII:C o FIX:C.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":342,"lines":{"from":15,"to":21}}}}],["1723",{"pageContent":"Diagnóstico diferencial\n\nEl diagnóstico diferencial debe realizarse con el resto de las deficiencias hereditarias de los factores\nde coagulación, y que además se evidencian por hemorragias, por ejemplo, las deficiencias de FVI -\nI:C, FX:C, FII:C, etcétera, o bien con deficiencias hereditarias combinadas, como lo es la deficiencia\nde FV:C/FVIII:C, y que se debe a la deficiencia del inhibidor de la proteína C activada (PAI-3)\n\n(cuadro 20-6)\n.\n\nFigura 20-9.\n \nMétodo original de la Dra. Kasper para la detección de inhibidores.\n\nExisten\n \ntécnicas\n \ncon\n \nDNA\nrecombinante que también son\nútiles para detectar a las por-\ntadoras, o para el diagnóstico\nprenatal (productos de madres\nportadoras\n \nconocidas),\n \ny\n \nla\nprueba más específica es por\nanálisis de DNA mediante la\nreacción en cadena de la poli-\nmerasa (PCR).\n\nCuadro 20-6.\n \nDiagnóstico diferencial\n\n•\n \n\u000f.,\u001b- \u001e\u001fl·\u001d#\u001f(\u001d#\u001b- \"\u001f,\u001f\u001e#.\u001b,#\u001b- \u001e\u001f &\u001b\n \ncoagulación\n\n•\n \nDeficiencias\n \ncombinadas\n \nde\n \nFV\n:C/FVIII:C\n\n•\n \nEnfermedad de von W\n \nillebrand","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":342,"lines":{"from":23,"to":85}}}}],["1724",{"pageContent":"Cuadro 20-6.\n \nDiagnóstico diferencial\n\n•\n \n\u000f.,\u001b- \u001e\u001fl·\u001d#\u001f(\u001d#\u001b- \"\u001f,\u001f\u001e#.\u001b,#\u001b- \u001e\u001f &\u001b\n \ncoagulación\n\n•\n \nDeficiencias\n \ncombinadas\n \nde\n \nFV\n:C/FVIII:C\n\n•\n \nEnfermedad de von W\n \nillebrand\n\n•\n \nHemofilia\n \nadquirida","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":342,"lines":{"from":85,"to":116}}}}],["1725",{"pageContent":"316\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nEspecíficamente, la hemofilia A debe diferenciarse de la enfermedad de von Willebrand (EvW), tras-\ntorno hemorrágico hereditario caracterizado por la síntesis, liberación o función anormal del factor de von\nWillebrand (FvW) plasmático y plaquetario.\n\nTRATAMIENTO\n\nEl objetivo del tratamiento en pacientes con hemofilia es incrementar el nivel plasmático del factor defi-\nciente mediante la administración de concentrados crudos o purificados que contengan el factor que se\n\n\u001f(\u001d/\u001f(.,\u001f \u001e#-'#(/#\u001e)8 \u0014)\u001e\u001b \"\u001f'),,\u001b!#\u001b \u001f( \u001f& *\u001b\u001d#\u001f(.\u001f \u001d)( \"\u001f')̑&#\u001b \u001f- \u001d )(-#\u001e\u001f,\u001b\u001e\u001b \u001d)') /(\u001b /,!\u001f(\u001d#\u001b 3","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":343,"lines":{"from":1,"to":14}}}}],["1726",{"pageContent":"el tratamiento debe iniciarse de inmediato, de ser posible domiciliario con la aplicación de medidas loca-\nles (taponamiento, inmovilización, aplicación de compresas frías, etc.) y medidas generales (analgésicos,\nantiinflamatorios, antifibrinolíticos y concentrados purificados del factor deficiente). Además, se pueden\nemplear medidas farmacológicas con la finalidad de cohibir la hemorragia (desmopresina, fibrinas adhe-\nsivas, trombina tópica, etc). El tipo de tratamiento que debe recibir el paciente está en relación con el tipo\nde hemofilia, el sitio de la hemorragia y la presencia de inhibidores.\nEl tratamiento del paciente con coagulopatías hereditarias requiere de la integración multidiscipli-\nnaria del personal médico y paramédico involucrado, como el hematólogo, el pediatra, el ortopedista, el\nreumatólogo, el odontólogo, el médico en rehabilitación, terapistas físicos y ocupacionales, el psicólogo,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":343,"lines":{"from":16,"to":24}}}}],["1727",{"pageContent":"reumatólogo, el odontólogo, el médico en rehabilitación, terapistas físicos y ocupacionales, el psicólogo,\nla trabajadora social, enfermería, el infectólogo, etcétera. El objetivo del tratamiento conjunto es propor-\ncionar al paciente y a sus familiares educación y ayuda para tomar medidas preventivas y terapéuticas,\ndisminuyendo o evitando las complicaciones de la enfermedad. Este grupo de especialistas necesita de la\natención coordinada por un grupo interdisciplinario\n \n(fig. 20-11)\n.\nPara un adecuado tratamiento sustitutivo, es necesario el diagnóstico biológico correcto del paciente,\nel tipo de hemofilia, el nivel de actividad y la presencia de inhibidores. Por otro lado, se requiere detectar\nclínicamente el sitio de la hemorragia para indicar la dosis necesaria y la frecuencia del tratamiento. Como\nregla general, la infusión de 1 UI de FVIII/kg de peso corporal incrementa la concentración de FVIII","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":343,"lines":{"from":24,"to":35}}}}],["1728",{"pageContent":"regla general, la infusión de 1 UI de FVIII/kg de peso corporal incrementa la concentración de FVIII\nen plasma a 2 UI/dL, con una vida media de 8 a 12 horas, mientras que la infusión de 1 UI de FIX/kg\nde peso corporal incrementa la concentración de FIX a 1 UI/dL, con una vida media de 18 a 24 horas.\nEl éxito del tratamiento dependerá del nivel de factor que sea necesario para corregir la hemorragia en el\npaciente; por ejemplo, en un individuo con hemorragia intracraneal la concentración de FVIII y de FIX\nque se requiere es de 100 UI/ dL, por lo que la dosis recomendada en pacientes con deficiencia de FVIII\nes de 50 UI/kg/dosis cada 8 a 12 horas, mientras que en la deficiencia de FIX deberá ser de 100 UI/kg/\ndosis cada 24 horas\n \n(cuadro 20-7)\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":343,"lines":{"from":35,"to":45}}}}],["1729",{"pageContent":"Figura 20-10.\n \nPrueba modificada de Nijmegen (Verbrugen, 1995).\n\nEl\n \ntratamiento\n \ndel\n \npaciente\ncon\n \ncoagulopatías\n \nheredita-\nrias requiere de la integración\nmultidisciplinaria del perso-\nnal médico y paramédico invo-\nlucrado, como el hematólogo,\npediatra, ortopedista, reuma-\ntólogo, odontólogo, médico de\nrehabilitación, terapistas físi-\ncos y ocupacionales, psicólogo,\ntrabajadora social, enferme-\nría, infectólogo, etc.\nPara un adecuado tratamien-\nto sustitutivo, es necesario el\ndiagnóstico biológico correcto\ndel paciente, el tipo de hemo-\nfilia, el nivel de actividad y la\npresencia de inhibidores. Por\notro lado, se requiere detectar\nclínicamente el sitio de la he-\nmorragia para indicar la dosis\nnecesaria y la frecuencia del\ntratamiento.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":343,"lines":{"from":47,"to":83}}}}],["1730",{"pageContent":"317\n\nCAPÍTULO 20. COAGULOPATÍAS HEREDITARIAS\n\nHemofilia A\n\nEl tratamiento de la hemofilia A ha tenido notables avances y en la actualidad disponemos de un gran\nnúmero de concentrados liofilizados de FVIII, caracterizados de acuerdo a la cantidad de proteínas en\nconcentrados de pureza baja, intermedia, alta y muy alta.\nLos concentrados purificados de factores se obtienen a partir de la mezcla de plasma proveniente de\nmiles de donadores (máximo 60 000 donadores), los cuales son sometidos a un estricto escrutinio clínico\ny de laboratorio con el objeto de disminuir al mínimo el riesgo de contaminación; algunos fabricantes\n\n\u001f \u001f\u001d.Ě\u001b( '\u001f\u001e#\u001e\u001b- +/\u001f \u001b3/\u001e\u001b( \u001b !\u001b,\u001b(.#4\u001b, &\u001b -\u001f!/,#\u001e\u001b\u001e \u001e\u001f& *&\u001b-'\u001b8\n \n\u001b- *,/\u001f\u001c\u001b- \u001e\u001f \u000e\u0001\u0014 B\u001e\u001f\n \nnucleic acid\ntechnology\n) son pruebas que determinan los ácidos nucleicos de algunos virus a la fabricación del produc-\n\n.)6 *\u001f,) () \u001b& *,)\u001e/\u001d.)̑\n \n(\u001b&: \u001b&!/(\u001b- \u001d)'*\u001bĄù\u001b- ,\u001f\u001b&#4\u001b( &\u001b \u001e\u001f.\u001f,'#(\u001b\u001d#ĉ( \u001e\u001f \u000e\u0001\u0014 *\u001b,\u001b &)- 0#,/- \b\u0001\u00166","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":344,"lines":{"from":1,"to":24}}}}],["1731",{"pageContent":".)6 *\u001f,) () \u001b& *,)\u001e/\u001d.)̑\n \n(\u001b&: \u001b&!/(\u001b- \u001d)'*\u001bĄù\u001b- ,\u001f\u001b&#4\u001b( &\u001b \u001e\u001f.\u001f,'#(\u001b\u001d#ĉ( \u001e\u001f \u000e\u0001\u0014 *\u001b,\u001b &)- 0#,/- \b\u0001\u00166\n\nHBV, HCV, HIV y parvovirus B19, y posteriormente durante su procesamiento el plasma puede ser\nsometido a nanofiltración, cromatografía por afinidad, etcétera, y a diferentes métodos de inactivación\nviral con solvente detergente, calor (seco o húmedo) o pasteurización. Los mejores concentrados son los\nque durante su proceso reciben doble inactivación viral.\n\nFigura 20-11.\n \nEquipo multidisciplinario en las clínicas de hemofilia.\n\nCuadro 20-7.\n \nDosis terapéuticas en hemofilia\n\nSitio de la\nhemorragia\nNivel del factor\ndeficiente (U/dL)\nDosis del FVIII:C\n(U/kg/dosis)\nDosis del FIX:C\n(U/kg/dosis)\nDuración del\ntratamiento","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":344,"lines":{"from":24,"to":50}}}}],["1732",{"pageContent":"Cuadro 20-7.\n \nDosis terapéuticas en hemofilia\n\nSitio de la\nhemorragia\nNivel del factor\ndeficiente (U/dL)\nDosis del FVIII:C\n(U/kg/dosis)\nDosis del FIX:C\n(U/kg/dosis)\nDuración del\ntratamiento\n\nHemartrosis\n \n20-30\n \n10-15\n \n20-30\n \n1 dosis*\nHematomas\nmusculares\n \n40\n \n20\n \n40\n \n1 a 3 dosis*\nHematoma\nde psoas\n \n40-50\n \n20-25\n \n40-50\n \nHasta\nresolución\nHematuria\n \n40-50\n \n20-25\n \n40-50\n \n5 días\nHemorragia\nen SNC*\n \n100\n \n50\n \n100\n7-14 días\no hasta\nresolución\nPreparación\nquirúrgica:\n\n•\n \n\u0003#,/!ù\u001b\n\nmenor\n\n•\n \n\u0003#,/!ù\u001b\n\nmayor\n40-50\n80-100\n20-25\n40-50\n40-50\n80-100\nVariable\n7-14 días\n\nEl tratamiento de la hemofilia\nA ha tenido notables avances y\nen la actualidad disponemos de\nun gran número de concentrados\nliofilizados de FVIII, caracteri-\nzados de acuerdo con la cantidad\nde proteínas en concentrados de\npureza baja, intermedia, alta y\nmuy alta.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":344,"lines":{"from":50,"to":146}}}}],["1733",{"pageContent":"318\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":345,"lines":{"from":1,"to":3}}}}],["1734",{"pageContent":"Los concentrados de FVIII se clasifican de acuerdo a su pureza. El término\n \npureza\n \nse refiere a la ac-\ntividad específica, o sea, al contenido de FVIII:C en UI/mg de proteína; sin embargo, la actividad espe -\ncífica no es una buena medida de pureza porque la albúmina es agregada como una proteína acarreadora\ny algunos factores contienen FvW. Los concentrados de pureza intermedia contienen de 1 a 50 UI de\nFVIII:C, los de alta pureza una actividad específica de 50 a 200 UI y los ultrapuros o de muy alta pureza,\nlos cuales pueden contener de 1 000 a 3 000 UI de factor, son obtenidos con anticuerpos monoclonales.\nEn años recientes, los concentrados de factor VIII y factor IX se han obtenido por tecnología recombi-\nnante; el factor es producido por células de hámster en cultivo y el factor posteriormente es purificado por\ncromatografía por inmunoafinidad con anticuerpos monoclonales y estabilizado en albúmina humana,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":345,"lines":{"from":5,"to":17}}}}],["1735",{"pageContent":"cromatografía por inmunoafinidad con anticuerpos monoclonales y estabilizado en albúmina humana,\npero los concentrados de nueva generación ya no son estabilizados en albúmina e incluso son sometidos a\nprocesos de inactivación. De hecho el tratamiento mundialmente aceptado de la hemofilia es el empleo de\nconcentrados purificados de factores a las dosis adecuadas\n \n(cuadro 20-8)\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":345,"lines":{"from":17,"to":23}}}}],["1736",{"pageContent":"Hemofilia B\n\nEl tratamiento para pacientes con hemofilia B comenzó con la administración de plasma fresco congela-\ndo, y posteriormente con concentrados liofilizados derivados del plasma llamados\n \nconcentrados de complejo\nprotrombínico\n \n(CCP); estos productos posteriormente se han purificado en concentrados de factor IX.\n\nConcentrados de factor IX","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":345,"lines":{"from":25,"to":35}}}}],["1737",{"pageContent":"Los concentrados de factor IX se clasifican en concentrados de pureza intermedia, también conocidos\ncomo\n \ncomplejos protrombínicos\n, porque contienen otros factores dependientes de la vitamina K (II, VII, IX\ny X), y los complejos de factor IX purificado (alta pureza y recombinante), que tienen la ventaja de mejorar\nla hemostasia y evitar el riesgo de trombosis asociado con los complejos protrombínicos.\nLos concentrados pueden ser usados para controlar hemorragias agudas o prevenir o controlar las he-\nmorragias en cirugía en pacientes con hemofilia B. Los complejos protrombínicos, como más adelante lo\ndetallaremos, pueden ser usados por su efecto de\n \nbypass\n \nen pacientes con hemofilia e inhibidor. Otra de las\nindicaciones es en pacientes con deficiencia de factores dependientes de vitamina K hereditario o adqui -\nrido, como sucede en aquellos con hemorragia asociada al empleo de anticoagulantes orales, hepatopatías","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":345,"lines":{"from":37,"to":52}}}}],["1738",{"pageContent":"rido, como sucede en aquellos con hemorragia asociada al empleo de anticoagulantes orales, hepatopatías\ncrónicas como la cirrosis hepática, o deficiencia de factor VII; la recomendación principal es con Proplex,\npor su alto contenido de factor VII en su composición.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":345,"lines":{"from":52,"to":54}}}}],["1739",{"pageContent":"Terapia transfusional o no farmacológica","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":345,"lines":{"from":56,"to":56}}}}],["1740",{"pageContent":"Para un adecuado tratamiento sustitutivo, es necesario conocer el diagnóstico biológico correcto del paciente, el\ntipo de hemofilia, el nivel de actividad y la presencia de inhibidores. Por otro lado, se debe detectar clínicamen\n-\nte el sitio de la hemorragia para indicar la dosis necesaria y la frecuencia del tratamiento. Como regla general,\nla infusión de 1 UI de FVIII/kg de peso corporal incrementa la concentración de FVIII en plasma a 2 UI/dL,\ncon una vida media de 8 a 12 horas, mientras que la infusión de 1 UI de FIX/kg de peso corporal aumenta la\nconcentración de FIX a 1 UI/dL con una vida media de 18 a 24 horas. El éxito del tratamiento dependerá del\nnivel de factor que sea necesario para corregir la hemorragia en el paciente; por ejemplo, en un paciente con he\n-\nmorragia intracraneal, la concentración de FVIII y de FIX que se requiere es de 100 UI/dL, por lo que la dosis\nrecomendada en deficientes de FVIII es de 50 UI/kg/dosis cada 8 a 12 horas, mientras que en la deficiencia de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":345,"lines":{"from":58,"to":68}}}}],["1741",{"pageContent":"recomendada en deficientes de FVIII es de 50 UI/kg/dosis cada 8 a 12 horas, mientras que en la deficiencia de\nFIX deberá ser de 100 UI/kg/ dosis cada 24 horas\n (cuadro 20-9)\n. En México y en otros países en desarrollo,\nel aporte de los concentrados de FVIII o de FIX no se encuentra disponible en grandes cantidades por su alto\ncosto, y la mayor disponibilidad de productos con los que se cuenta son los crioprecipitados.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":345,"lines":{"from":68,"to":73}}}}],["1742",{"pageContent":"Tratamiento farmacológico\nDesmopresina (1 desamino-8-d-arginina vasopresina/DDAVP)\n\nEs el medicamento de elección para pacientes con hemofilia leve y EvW tipo 1. La desmopresina es un\nanálogo sintético de la hormona antidiurética, cuya acción consiste en liberar FVIII:C y FvW de los sitios\ndonde se almacenan, permitiendo su paso a la circulación sanguínea. La dosis es de 0,3 mg/kg/dosis por\nvía IV (máximo 20 mg) diluido en 50 cc de solución fisiológica; la vida media es de 8 a 12 horas. Se puede\nadministrar en forma intranasal (\nspray\n) a una dosis de 300 mg; el efecto se observa a los 60 minutos, en","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":345,"lines":{"from":75,"to":84}}}}],["1743",{"pageContent":"En México y en otros países\nen desarrollo, el aporte de los\nconcentrados de FVIII o de\nFIX no se encuentra dispo-\nnible en grandes cantidades\npor su alto costo, y la mayor\ndisponibilidad\n \nde\n \nproductos\ncon los que se cuenta son los\ncrioprecipitados.\nLa desmopresina es un análo-\ngo sintético de la hormona an-\ntidiurética; su acción consiste\nen liberar FVIII:C y FvW de\nlos sitios donde se almacenan,\npermitiendo su paso a la circu-\nlación sanguínea.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":345,"lines":{"from":86,"to":105}}}}],["1744",{"pageContent":"319\n\nCAPÍTULO 20. COAGULOPATÍAS HEREDITARIAS\n\nCuadro 20-8.\n \nConcentrados de factor VIII\n\nMarca\n \nCompañía\n \nProcedencia del plasma\n \nInactivación viral\nPureza intermedia: contiene 1-50 UI de FVIII:C\n\nDried Factor VIII\nFraction, type 8Y\n \nBioProducts Lab\n \nEUA; aféresis remunerada\n \nCalor seco, 80 ºC, 72 h\nHaemate P®\n \nCSL Behring\n \nEUA, Alemania, Austria; re-\nmunerado y no remunerado\nPasteurización, 60 ºC,\n10 h\nKoāte-DVI®\n \n\u0014\u001b&\u001f\u001d,#-\n \nEUA; aféresis remunerada\n \n\u0014\u000e\u0002\u0010I *)&#-),\u001c\u001b.) nf 3\n\ncalor seco, 80 ºC, 72 h\n\nAlta pureza: contiene 50-200 UI de FVIII:C\n\nImmunate®\n \nBaxter\nEUA, Austria, Rep. Checa,\nAlemania,\n \nSuecia;\n \naféresis\nremunerada\nS/D, vapor-calor, 60 ºC,\n10 h a 190 mbar\nEmoclot D.I.®\n \nKedrion\n \nEuropa y EUA; remunerado\ny no remunerado\n\n\u0014\u000e\u0002\u0010I*)&#-),\u001c\u001b.) nf 3 \u001d\u001b&),\n\nseco, 100 ºC, 30 min\nOctanate®\n \nOctapharma\n \nSuecia,\n \nAustria,\n \nAlemania,\nEUA\n\n\u0014\u000e\u0002\u0010I*)&#-),\u001c\u001b.) nf 3 \u001d\u001b\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":346,"lines":{"from":1,"to":80}}}}],["1745",{"pageContent":"\u0014\u000e\u0002\u0010I*)&#-),\u001c\u001b.) nf 3 \u001d\u001b&),\n\nseco, 100 ºC, 30 min\nOctanate®\n \nOctapharma\n \nSuecia,\n \nAustria,\n \nAlemania,\nEUA\n\n\u0014\u000e\u0002\u0010I*)&#-),\u001c\u001b.) nf 3 \u001d\u001b\n-\n\n&), -\u001f\u001d) \u0014\u001f,'#(\u001b&6 gff\n \nºC,\n30 min con humedad resi-\ndual controlada\nBeriate-P\n \nCSL Behring\n \nEUA; aféresis remunerada\n \n\u0014\u000e\u0002\u0010I*)&#-),\u001c\u001b.) nf 3 \u001d\u001b\n-\nlor seco, 80 ºC, 72 h\nAplanate®\n \nGrifols\n \nEUA; aféresis remunerada\n \n\u0014\u000e\u0002\u0010I*)&#-),\u001c\u001b.) nf 3 \u001d\u001b\n-\nlor seco, 80 ºC, 72 h\n\nMuy alta pureza: contiene de 1 000-3 000 UI de FVIII:C\n\nMonoclate-P\n \nCSL Behring\n \nEUA; aféresis remunerada\n \nPasteurización a 60 ºC, 10 h\nHemofil M AHF\n \nBaxter\n \nEUA; aféresis remunerada\n \n\u0014\u000e\u0002\u0010I\u000f\u001d.)23()& o\n\nOctanativ-M\n \nOctapharma\n \nSuecia; recuperado\nno remunerado y aféresis\n \n\u0014\u000e\u0002\u0010I\u000f\u001d.)23()& o\n\nRecombinante contiene: > 3 000 UI de FVIII:C\n1ª generación, contiene albúmina humana como estabilizador\n\nRecombinate\n \nBaxter\nBioscience\nNo aplica, producto\nrecombinante\n \nNinguno\n\n2ª generación, libre de albúmina humana en el producto final","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":346,"lines":{"from":80,"to":159}}}}],["1746",{"pageContent":"Recombinate\n \nBaxter\nBioscience\nNo aplica, producto\nrecombinante\n \nNinguno\n\n2ª generación, libre de albúmina humana en el producto final\n\nKogenate FS\n \nBayer\n \nNo aplica, producto\nrecombinante\n \n\u0014\u000e\u0002\u0010I*)&#-),\u001c\u001b.) nf\n\nHelixate FS\n \nCSL Behring\n \nNo aplica, producto\nrecombinante\n \n\u0014\u000e\u0002\u0010I*)&#-),\u001c\u001b.) nf\n\nReFacto (deleción\ndel dominio B)\n \nWyeth\n \nNo aplica, producto\nrecombinante\n \n\u0014\u000e\u0002\u0010I\u0014,#.)( \u0018 gff\n\n3ª generación, no contiene proteína humana ni animal\n\nAdvate\n \nBaxter Bioscien-\nce\nNo aplica, producto\nrecombinante\n\n\u0014\u000e\u0002\u0010I*)&#-),\u001c\u001b.) nf6\n\u0014,#.)( \u0018 gff","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":346,"lines":{"from":159,"to":208}}}}],["1747",{"pageContent":"320\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\ncomparación con la administración IV que es a los 30 minutos. Previo a la administración de este me-\ndicamento, al paciente se le debe realizar la prueba terapéutica, ya que desafortunadamente no todos los\npacientes responden. La respuesta del FvW y el FVIII a la DDAVP disminuye gradualmente con dosis\nrepetidas del fármaco cada 12 a 24 horas (taquifilaxia), por lo que es recomendable que la DDAVP se\nadministre solo en los casos en los que la hemorragia se controle con una sola dosis de tratamiento.\n\nAntifibrinolíticos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":347,"lines":{"from":1,"to":11}}}}],["1748",{"pageContent":"Antifibrinolíticos\n\nEstos productos inhiben la activación del plasminógeno y la actividad de la plasmina; por lo tanto, pre -\nvienen la lisis del coágulo. Se usan con frecuencia en hemorragias de mucosas, orales y dentales, sitios\nen donde existen grandes cantidades de activador del plasminógeno tisular (t-PA). Los antifibrinolíti -\ncos se pueden administrar en forma sistémica o local; entre ellos se encuentran el ácido aminocaproico\n(Amicar\n \n®\n), el cual se indica a dosis de 75 mg/kg cada 6 horas, el ácido tranexámico (25 mg/kg/8 horas)\ny la aprotinina.\n\nCuadro 20-9.\n \nConcentrados de factor IX disponibles\n\nMarca\n \nCompañía\n \nProcedencia del plasma\n \nInactivación viral\nPureza intermedia\n\n\u0010,)*&\u001f2 \u0014\n®\n \nBaxter Bioscience\n \nEUA; aféresis remunerada\n \nExposición\n \na\n \n20%\n \netanol;\ncalor seco, 60 ºC, 144 hrs\nProfilnine SD\n \n®\n \nGrifols\n \nEUA; aféresis remunerada\n \nSolvente/Detergente\n\nAlta Pureza","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":347,"lines":{"from":11,"to":61}}}}],["1749",{"pageContent":"Alta Pureza\n\nBerinine\n®\n \nCSL Behring\n \nEUA, Austria, Alemania; remu-\nnerado y no remunerado\nPasteurización a 60 ºC,\n10 h\nImmunine\n®\n \nBaxter Bioscience\nEUA, Austria, Rep. Checa, Ale-\nmania,\n \nSuecia;\n \nprincipalmente\nde aféresis remunerada\nPolisorbato 80 y calor\npor vapor 60 ºC, 10 h,\n190 mbar, luego 80 ºC,\n1 h, 375 mbar\nOctanyne\n®\n \nOctapharma\n \nSuecia, Austria, Alemania y EUA\n \n\u0014\u000e\u0002\u0010I*)&#-),\u001c\u001b.) nf\n\nOctanine-F\n \n®\n \nOctapharma\n \nSuecia, Austria, Alemania y EUA\n \n\u0014\u000e\u0002\u0010I*)&#-),\u001c\u001b.) nf\n\ny nanofiltración\nAimafix\n \n®\n \nKedrion\n \nEuropa y EUA; remunerado y no\nremunerado\n\n\u0014\u000e\u0002\u0010I*)&#-),\u001c\u001b.) nf:\n\ncalor seco 100 ºC,\n30 min; nanofiltración\n35 + 15 nm (registro pen-\ndiente para nanofiltración)\nFactor IX Gri-\nfols\n \nGrifols\n \nEUA; remunerado\n \nSolvente/detergente,\n15 nm nanofiltración\nAlphaNine\n®\n \nGrifols\n \nEUA; aféresis remunerada\n \nSolvente/detergente;\nnanofiltración\nMononine\n®\n \nCSL Behring\n \nEUA; aféresis remunerada\n \n\u0014#)\u001d#\u001b(\u001b.) \u001e\u001f -)\u001e#) 3","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":347,"lines":{"from":61,"to":147}}}}],["1750",{"pageContent":"ultrafiltración\nReplenine-VF\n \n®\n \nBioProducts Lab\n \nEUA; aféresis remunerada\n \nSolvente/detergente;\n15 nm nanofiltración\n\nRecombinantes\n\nBeneFix\n \n®\n \nWyeth\n \nNo aplica, producto recombinante\n \nNanofiltración\n\nLos antifibrinolíticos se pue-\nden\n \nadministrar\n \nen\n \nforma\nsistémica o local; entre ellos\nse encuentran el ácido ami-\nnocaproico (Amicar\n \n®\n), el cual\nse indica a dosis de 75 mg/kg\ncada 6 horas, el ácido trane-\nxámico (25 mg/kg 8 horas) y\nla aprotinina.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":347,"lines":{"from":149,"to":190}}}}],["1751",{"pageContent":"321\n\nCAPÍTULO 20. COAGULOPATÍAS HEREDITARIAS\n\nHemostáticos locales","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":348,"lines":{"from":1,"to":5}}}}],["1752",{"pageContent":"Hoy en día se administran hemostáticos locales o sistémicos en pacientes con defectos de la hemostasia\n(hereditaria o adquirida), para evitar o disminuir los requerimientos transfusionales y prevenir los riesgos\ninherentes a la transfusión de componentes sanguíneos. Entre los hemostáticos locales se encuentran:\nfibrinas adhesivas (producidas en bancos de sangre o salas de cirugía, también denominadas\n \ncaseras\n, y\ntambién las de origen comercial), alginato, lápiz estíptico, bismuto, cementos, colágena, antifibrinolíticos,\nesponjas, celulosa oxidada, veneno de la víbora de Russell y trombina tópica, entre otros.\nEl objetivo de las fibrinas adhesivas es imitar la última fase de la coagulación sanguínea; estas fibrinas\npueden ser producidas de manera casera, utilizando crioprecipitados en forma autóloga o alogénica. Sin em-\nbargo, en países europeos generalmente son fibrinas producidas comercialmente. En términos generales, las","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":348,"lines":{"from":7,"to":18}}}}],["1753",{"pageContent":"bargo, en países europeos generalmente son fibrinas producidas comercialmente. En términos generales, las\nfibrinas adhesivas están formadas por fibrinógeno, trombina, cloruro de calcio, algunas con FXIII y antifi-\nbrinolíticos de administración local. Las fibrinas adhesivas comerciales son inactivadas viralmente; en 1998,\nlas fibrinas adhesivas fueron aprobadas por la\n \nFood and Drug Administration\n \n(FDA) de Estados Unidos.\nLas fibrinas adhesivas han sido ampliamente utilizadas, sobre todo en cirugía, para disminuir las hemorra\n-\ngias en estos pacientes y por otro lado reducir los requerimientos transfusionales. Entre las especialidades qui\n-\nrúrgicas donde más se emplean están: neurocirugía, ortopedia, cirugía cardiovascular, otorrinolaringología,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":348,"lines":{"from":18,"to":30}}}}],["1754",{"pageContent":"\u001d#,/!ù\u001b *&á-.#\u001d\u001b6 \u001f(.,\u001f ).,)-8 \u0014\u001b'\u001c#ï( -\u001f /.#&#4\u001b( '/\u001d\") \u001f( *\u001b\u001d#\u001f(.\u001f- \"\u001f*\u001b,#(#4\u001b\u001e)- ) +/\u001f ,\u001f\u001d#\u001c\u001f( \u001b(.#\u001d)\u001b!/\n-\nlantes orales, aquellos con enfermedades hemorrágicas hereditarias (hemofilia, disminución de otros factores\nde coagulación, enfermedad de von Willebrand, etc.), enfermedades hemorrágicas adquiridas, etcétera.\nRecientemente, otras indicaciones del uso de las fibrinas adhesivas incluyen combinarlas con antibió-\nticos en dehiscencias de heridas o heridas infectadas. Esta combinación produce mayor concentración del\nmedicamento en la herida, además de promover la cicatrización de estas. Las fibrinas adhesivas actúan\ncomo un sistema de liberación lenta para los antibióticos, incrementan la concentración local y extienden\nsu período de tiempo activo; esto también permite la erradicación de infecciones que son resistentes a\nterapia sistémica, por los mismos antibióticos que se incorporan a las fibrinas adhesivas. Estas también","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":348,"lines":{"from":32,"to":41}}}}],["1755",{"pageContent":"terapia sistémica, por los mismos antibióticos que se incorporan a las fibrinas adhesivas. Estas también\npueden utilizarse para liberar localmente agentes quimioterapéuticos como el taxol; otro uso es la combi-\nnación de fibrinas adhesivas con citocinas como el factor de crecimiento de fibroblastos para promover la\nendotelización del injerto vascular in vivo.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":348,"lines":{"from":41,"to":44}}}}],["1756",{"pageContent":"COMPLICACIONES\n\nInhibidores","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":348,"lines":{"from":46,"to":48}}}}],["1757",{"pageContent":"Una de las secuelas más graves del tratamiento de la hemofilia es el desarrollo de anticuerpos (inhibidores)\nque evitan que el tratamiento de reemplazo con el factor deficiente actúe de manera adecuada. Los inhi-\nbidores son de tipo IgG, principalmente IgG4 de tipo\n\u0003g\n. Los inhibidores pueden ocurrir en el 30% de los\npacientes con hemofilia A grave y en general en el 15% de los pacientes con hemofilia A; es menos frecuente\nen los pacientes con hemofilia B (1-3%). En los pacientes con inhibidores de baja respuesta (< 5 UB), la he -\nmostasia se puede alcanzar saturando de manera adecuada al inhibidor con dosis altas del factor deficiente,\npero en los pacientes con inhibidor de alta respuesta (> 5 UB) se deben adoptar otras estrategias\n (fig. 20-12)\n.\nPor lo tanto, la presencia de anticuerpos contra el factor de coagulación complica el tratamiento\nde la hemorragia en los pacientes con hemofilia. Para los pacientes con inhibidor de alta respuesta,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":348,"lines":{"from":50,"to":62}}}}],["1758",{"pageContent":".\nPor lo tanto, la presencia de anticuerpos contra el factor de coagulación complica el tratamiento\nde la hemorragia en los pacientes con hemofilia. Para los pacientes con inhibidor de alta respuesta,\nel tratamiento de primera línea para el control de la hemorragia es con agentes de\n \nbypass\n. El control\nde la hemorragia en los pacientes con inhibidor de baja respuesta puede ser con dosis altas del factor.\nSin embargo, la piedra angular del tratamiento en estos pacientes es la erradicación del inhibidor en los","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":348,"lines":{"from":62,"to":70}}}}],["1759",{"pageContent":"*,)!,\u001b'\u001b- \u001e\u001f #(\u001e/\u001d\u001d#ĉ( \u001b &\u001b .)&\u001f,\u001b(\u001d#\u001b #('/(#.\u001b,#\u001b B \u0014 C6 +/\u001f \u001d)(-#-.\u001f \u001f( &\u001b \u001b\u001e'#(#-.,\u001b\u001d#ĉ(\n \n,\u001f\u001d/\u001f(.\u001f","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":348,"lines":{"from":72,"to":74}}}}],["1760",{"pageContent":"del factor deficiente a dosis relativamente altas con o sin inmunosupresor.\nLos productos de primera línea utilizados en el tratamiento de los pacientes con hemofilia e inhibido-\nres para tratar los eventos hemorrágicos, o para prevenir la hemorragia, son conocidos como\n \nproductos de\nbypass\n, por su capacidad de promover hemostasia a través de mecanismos que son distintos del complejo\nX-asa fisiológico, el cual promueve la explosión de trombina y es un complejo dependiente de fosfolípidos,\niones calcio, factor IXa (enzima) y factor VIIIa (cofactor), que actúan sobre su sustrato, el factor X.\nLas dos preparaciones empleadas para el tratamiento de\n \nbypass\n \nen estos pacientes y aprobadas inter-\nnacional y nacionalmente son: el factor VII activado recombinante (rFVIIa; NovoSeven\n®\n, fabricado por\nNovo Nordisk, Dinamarca) y el concentrado de complejo protrombínico activado (CCPa; FEIBA, fabri-\ncado por Baxter AG, Austria)\n \n(fig. 20-13)\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":348,"lines":{"from":76,"to":97}}}}],["1761",{"pageContent":"322\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nArtropatía hemofílica\n\nLa artropatía constituye la complicación más frecuente en estos pacientes y produce la discapacidad física\ndel enfermo. Cuando las hemartrosis son recurrentes y existe sinovitis proliferativa, se puede realizar con\néxito una sinovectomía quirúrgica o radioactiva; esta última consiste en la aplicación intraarticular de un\nradioisótopo radioactivo (itrio, oro coloidal, fósforo radioactivo, etc.). Estos radioisótopos emiten radia-\nción\n \nβ\n, la cual penetra en la articulación produciendo cauterización de la lesión y reducción de la infla-\nmación y de las hemorragias. En caso de presentar daño articular grave, se han empleado otras técnicas\nquirúrgicas con el objeto de corregir el daño articular provocado por las hemartrosis frecuentes, a saber:\nartrodesis, sinovectomías quirúrgicas, colocación de prótesis articular, entre otras.\n\nSeudotumor hemofílico","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":349,"lines":{"from":1,"to":19}}}}],["1762",{"pageContent":"Seudotumor hemofílico\n\nEsta complicación es rara y su nombre proviene de\n \nseudo\n \n(falso) y\n \ntumor\n \n(crecimiento). Los seudotumores\nno son cánceres y generalmente se deben a un mal tratamiento de los hematomas musculares; esto trae\ncomo consecuencia pérdida de la estructura ósea por el crecimiento lento del hematoma muscular. El\ndiagnóstico se establece por radiografías y el tratamiento se basa en radioterapia local.\n\nContaminación viral\n\nLa transmisión del virus HIV en las décadas de 1980 y 1990 con la transfusión de factor VIII o IX en\n \n-\nsombreció el tratamiento de los pacientes; sin embargo, la experiencia positiva permitió mejorar la calidad","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":349,"lines":{"from":19,"to":39}}}}],["1763",{"pageContent":"Figura 20-12.\n \nExisten dos tipos de inhibidores en los pacientes de hemofilia. Inhibidor de alta respuesta\n(> 5 UB) e inhibidor de baja respuesta (< 5 UB). El tipo de inhibidor se define también por la respuesta amnésica\nde este. Los pacientes con inhibidor de baja respuesta, a pesar de un estímulo con factor VIII, no incrementan\nsu nivel (línea roja), a diferencia de los pacientes que pueden tener, por ejemplo, 2 UB, pero cuando el inhibidor\nse estimula con factor VIII, días más tarde presentarán incremento del inhibidor (línea amarilla).\n\nFigura 20-13.\n \n\u0001(á&#-#- \u001e\u001f \u001e\u001f\u001d#-#ĉ( \u001f( /( *\u001b\u001d#\u001f(.\u001f \u001d)( #(\"#\u001c#\u001e),8\n \n\u0014 9\n \n(\u001e/\u001d\u001d#ĉ( \u001b &\u001b .)&\u001f,\u001b(\u001d#\u001b #('/(#.\u001b\n-\nria. rFVIIa: factor VII activado recombinante. CCPa: concentrado de complejo protrombínico activado.\nFVIIIp: factor VIII porcino.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":349,"lines":{"from":41,"to":58}}}}],["1764",{"pageContent":"323\n\nCAPÍTULO 20. COAGULOPATÍAS HEREDITARIAS\n\nde los concentrados tratados con solvente detergente y calentamiento. La frecuencia de la hepatitis B y C\nse estima en la actualidad del 0 al 8%; también se ha comunicado la presencia del parvovirus B19. Recien-\ntemente se publicó la presencia de hepatitis A en Italia y algunos países de Europa con la transfusión de\nconcentrados de pureza intermedia. Esto significa que aunque el riesgo sea mínimo, todavía sigue exis-\ntiendo un bajo riesgo de contaminación viral. El empleo de crioprecipitados y de plasma fresco congelado\ncomo terapia sustitutiva incrementa los porcentajes de contaminación viral.\n\nOTROS DEFECTOS HEREDITARIOS RAROS DE LA COAGULACIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":350,"lines":{"from":1,"to":12}}}}],["1765",{"pageContent":"OTROS DEFECTOS HEREDITARIOS RAROS DE LA COAGULACIÓN\n\nLas coagulopatías hereditarias constituyen un grupo de defectos hereditarios raros de la coagulación que\nse transmiten con una herencia autosómica y que clínicamente se manifiestan con hemorragias (hemato-\nmas, hemartrosis, hemorragia gastrointestinal, retroperitoneal, transvaginal, hemotórax, etc.) de intensi-\ndad variable de acuerdo al nivel plasmático del factor que se encuentre afectado.\n\nDefectos del fibrinógeno\n\nDentro de estas coagulopatías se encuentran los defectos del fibrinógeno, que pueden presentarse como\nafibrinogenemias, hipofibrinogenemias o disfibrinogenemias. Clínicamente, estos pacientes presentan\nhematomas, hemartrosis y otros tipos de hemorragias sistémicas desde la infancia. El diagnóstico de la-\n\n\u001c),\u001b.),#) -\u001f \u001c\u001b-\u001b \u001f( \u001f& \u001b&\u001b,!\u001b'#\u001f(.) \u001e\u001f \u0014\u00106 \u0014\u0014\u0010\u001b 3 \u0014\u00146 \u001d)( (#0\u001f&\u001f- 0\u001b,#\u001b\u001c&\u001f- \u001e\u001f&̑\n \n\u001c,#(ĉ!\u001f() \u001e\u001f \u001b\u001d/\u001f,\u001e)\n\u001b& \u001e\u001f \u001f\u001d.) #(0)&/\u001d,\u001b\u001e)8 \u0001\u001e\u001f'á-6 \u001b&!/()- \u001f( \u001f,')- */\u001f\u001e\u001f( *,\u001f-\u001f(.\u001b, \u0014\b *,)&)(!\u001b\u001e) \u001e\u001f\u001c#\u001e) \u001b /( \u001e\u001f \u001f\u001d.)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":350,"lines":{"from":12,"to":28}}}}],["1766",{"pageContent":"en la agregación plaquetaria primaria. El tratamiento de estos pacientes consiste en la administración de\ncrioprecipitados para un adecuado aporte de fibrinógeno.\n\nDeficiencia de protrombina\n\nDesde los primeros informes de la literatura médica de la década de 1950 a la actualidad, se han descrito poco\nmás de 55 casos de defectos congénitos de protrombina. Al igual que en otros defectos de la coagulación, po-\ndemos encontrar hipoprotrombinemia o disprotrombinemia; de estos dos defectos, las disprotrombinemias\n\n-)( &\u001b- 'á- \u001d)'/(\u001f-8 \u0005-.)- *\u001b\u001d#\u001f(.\u001f- *,\u001f-\u001f(.\u001b( \u0014\u0010 3 \u0014\u0014\u0010\u001b *,)&)(!\u001b\u001e)-6 \u001d)( /( (#0\u001f& \u001e\u001f \u0006\n \n9\u0003 \u001e#-'#(/#\u001e)8\n\nEl tratamiento de estos pacientes consiste en la administración de plasma fresco congelado o CCP.\n\nDeficiencia del factor XI","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":350,"lines":{"from":30,"to":45}}}}],["1767",{"pageContent":"El tratamiento de estos pacientes consiste en la administración de plasma fresco congelado o CCP.\n\nDeficiencia del factor XI\n\nEsta enfermedad ocurre principalmente en judíos asquenazí descendientes de Europa del Este. En Israel, entre\nel 6 y el 13% de estos judíos son heterocigotos para la deficiencia del FXI:C, y del 0,1 al 0,3% son homocigotos.\nEn la población en general se ha estimado una incidencia de deficiencia del FXI:C en 1 de cada 100 000 habi\n-\ntantes. El déficit del factor XI se transmite de modo autosómico recesivo y los pacientes manifiestan gran varia\n-\nbilidad clínica, con hemorragias leves seguidas de largos períodos sin sangrados; sin embargo, son comunes las\nhemorragias posteriores a eventos quirúrgicos, particularmente de cavidad bucal. El tratamiento de estos pacien\n-\ntes consiste en la administración de plasma fresco congelado o el empleo de concentrados purificados de FXI:C.\n\nDeficiencia congénita de factor X","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":350,"lines":{"from":45,"to":60}}}}],["1768",{"pageContent":"Deficiencia congénita de factor X\n\nLa deficiencia del factor X tiene una incidencia de 1: 500 000 habitantes, razón por la cual los informes de las\nfamilias afectadas son escasos. Clínicamente presentan manifestaciones hemorrágicas que pueden ocurrir\na cualquier edad; estas manifestaciones pueden variar de acuerdo al grado de deficiencia. Estos pacientes\n\n*,\u001f-\u001f(.\u001b( \u0014\u0010 3 \u0014\u0014\u0010\u001b *,)&)(!\u001b\u001e)-6 \u001d)( /(\u001b \u001d/\u001b(.#̑\u001d\u001b\u001d#ĉ(\n \n\u001e\u001f \u0006\u00189\u0003 \u001e#-'#(/#\u001e\u001b8 \u0005& .,\u001b.\u001b'#\u001f(.) \u001d)(-#-.\u001f \u001f(\n\nla administración de plasma fresco congelado o el uso de CCP.\n\nCONCLUSIONES\n\n•\n \nLas coagulopatías son un grupo de enfermedades hemorrágicas que afectan diferentes mecanismos de\nla coagulación, pudiendo ser hereditarias o adquiridas.\n\n•\n \nLa hemofilia A resulta de la deficiencia funcional o cuantitativa del factor VIII de la coagulación, a\ndiferencia de la hemofilia B, donde el factor de la coagulación afectado es el IX.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":350,"lines":{"from":60,"to":82}}}}],["1769",{"pageContent":"•\n \nLa hemofilia A resulta de la deficiencia funcional o cuantitativa del factor VIII de la coagulación, a\ndiferencia de la hemofilia B, donde el factor de la coagulación afectado es el IX.\n\nEl déficit del factor XI se\ntransmite de modo autosómi-\nco recesivo y los pacientes ma-\nnifiestan gran variabilidad\nclínica, con hemorragias leves\nseguidas de largos períodos\nsin sangrados; sin embargo,\nson comunes las hemorragias\nposteriores a eventos quirúr-\ngicos, particularmente de ca-\nvidad bucal.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":350,"lines":{"from":82,"to":97}}}}],["1770",{"pageContent":"324\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\n•\n \nLa enfermedad de von Willebrand es más frecuente que cualquiera de las otras hemofilias, y como se\nhereda con un patrón autosómico, puede afectar a hombres y mujeres, a diferencia de las hemofilias A\no B, que afectan solo a hombres.\n\n•\n \nEl tratamiento de los pacientes con hemofilia requiere de la participación de diversos especialistas.\n\nPREGUNTAS DE AUTOEVALUACIÓN\n\n1. Hemofilia más frecuente a nivel mundial:\na.\n \nHemofilia A\nb. Hemofilia B\nc.\n \nSíndrome de plaqueta gris\n2. En la hemofilia, la manifestación clínica más frecuente es:\na.\n \nHematuria\nb. Hematomas musculares\nc.\n \nHemartrosis\n3. En la hemofilia, el tiempo de sangrado se encuentra:\na.\n \nNormal\nb. Prolongado\nc.\n \nDisminuido\n4. La deficiencia de factor XI se transmite de modo:\na.\n \nAutosómico dominante\nb. Autosómico recesivo\nc.\n \nLigado a X\n5. En la hemofilia, la vía de la coagulación que se resulta afectada es la:\na.\n \nVía común\nb. Vía intrínseca\nc.\n \nVía extrínseca\n\nBIBLIOGRAFÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":351,"lines":{"from":1,"to":58}}}}],["1771",{"pageContent":"BIBLIOGRAFÍA\n\nAlving BM, Weinstein MJ, Finlayson JS, Menitove JE, Frantantoni JC. Fibrin sealant: Summary of a conference on\n\n\u001d\"\u001b,\u001b\u001d.\u001f,#-.#\u001d- \u001b(\u001e \u001d&#(#\u001d\u001b& /-\u001f-8 \u0014,\u001b(- /-#)(8 gook: ik9 mni7mof8\n\nDe Brasi D, Larripa I, Pérez-Bianco R. Genética de la hemofilia A y B. Hemofilia. México: Prado; 2001. p. 55-66.\n\n\u0007,\u001f\u001f( \u00046 \u0017)(! \u0003\u00016 \u00141\u001b,\u001e)1-%# \u00108 \u0005 ̑ \u001d\u001b\u001d3\n \n) \"\u001f')-.\u001b.#\u001d \u001b!\u001f(.- #( #'*,)0#(! -/,!#\u001d\u001b& \"\u001f')-.\u001b-#-8 \u0014,\u001b(-\n \n\u001f\u001e \u0012\u001f08\n\n1996; X: 171-182.\nKasper C, Aledort L, Counts R, Edson J, Fratantoni J, Green D, et al. A more uniform measurement of factor VIII\ninhibitors. ·rom Diathes Haemorrh. 1975; 34: 869-72.\n\n\u001f..\u001f,#(! \u0012\u00106\n \n#/$46\n \n#\u001b) \u00046\n \n\u001b-*\u001f, \u0003\n \n6 \u0001'\u001c,#4 \u00126 \u0010\u001b,\u001f\u001e\u001f- \u00126 \u001f. \u001b&8 \u00141) ()0\u001f& \u001b\u001d.), \u0018 *,)').\u001f, '/.\u001b.#)(- #(\u001d,\u001f'\u001f(.\u001b&\n*,)!,\u001f-- .)1\u001b,\u001e- -\u001b./,\u001b.#)( #( 0#0) '/.\u001b!\u001f(\u001f-#- ) \u001b \"/'\u001b( *,)').\u001f, ,\u001f!#)(8 \b/'\n \n)& \u0007\u001f(\u001f.8 gook: j9 mlo7mf8\n\nLusher JM. Advances in the treatment of hemophilia. American Society of Hematology; 2000. p. 246-248.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":351,"lines":{"from":58,"to":89}}}}],["1772",{"pageContent":"Lusher JM. Advances in the treatment of hemophilia. American Society of Hematology; 2000. p. 246-248.\n\n\u001b((/\u001d\u001d# \u0010\n \n8 \b\u001f')*\"#&#\u001b9 \u0014,\u001f\u001b.'\u001f(. )*.#)(- #( .\"\u001f .1\u001f(.37̑,-.\n \n\u001d\u001f(./,38\n \nĻ,)'\u001c \b\u001b\u001f')-.8 hffi:g9 gijo7gikk8\n\u001b((/\u001d\u001d# \u0010\n \n6 \u0014/\u001e\u001e\u001f(\"\u001b' \u0005\u0007\u00048\n \n\u001f\u001e#\u001d\u001b& *,)!,\u001f--9 Ļ\u001f \"\u001f')*\"#&#\u001b-7 ,)' ,)3\u001b& !\u001f(\u001f- .) !\u001f(\u001f .\"\u001f,\u001b*38 \u000e \u0005(!&\n\nMed. 2001; 344 (23); 1773-1779.\nMartínez-Murillo C, Quintana-González S, Ambriz FR. Empleo terapéutico de la desmopresina y hemostáticos loca-\nles. En: Martínez-Murillo C, Quintana-González S, eds. Manual de hemostasia y trombosis. Bases fisiopatológicas\ny clínicas de las enfermedades hemorrágicas y trombóticas. México: Prado; 1996. p. 393-404.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":351,"lines":{"from":89,"to":107}}}}],["1773",{"pageContent":"325\n\nCAPÍTULO 20. COAGULOPATÍAS HEREDITARIAS\n\nMartínez-Murillo C, Quintana-González S, Ambriz FR, Esparza JC. Hemofilia y enfermedad de von Willebrand.\n\n\u0014,\u001b.\u001b\u001e) \u001e\u001f\n \n\u001f\u001e#\u001d#(\u001b *,á\u001d.#\u001d\u001b8 j.\u001b \u001f\u001e8\n \nï2#\u001d)9\n \n\u001f\u001e#\u001d#(\u001f: gooi8 *8 jlf7n8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":352,"lines":{"from":1,"to":13}}}}],["1774",{"pageContent":"Martínez-Murillo C, Quintana-González S, Ambriz FR, Domínguez V, Rodríguez H. Enfermedad de von Wille-\nbrand y hemofilia adquiridas. Rev Invest Clin. 1995; 47: 211-6.\nMartínez-Murillo C, Quintana-González S, Ambriz FR. Empleo terapéutico de la desmopresina y hemostáticos\nlocales. Manual de hemostasia y trombosis. México: Prado; 1996. p. 393-404.\nMartínez-Murillo C, Quintana-González S, Ambriz FR. Hemofilia. Manual de hemostasia y trombosis. México: Prado; 1996. p. 169-188.\nMartínez-Murillo C, Quintana-González S, Ambriz R, Domínguez V, Rodríguez-Moyado H, Arias A, et al. Informe de\ndos casos con enfermedad de von Willebrand adquirida y uno con hemofilia A adquirida. Rev Invest Clin. 1995; 47: 211-6.\nMartínez-Murillo C, Viveros-Sandoval M. Enfermedad de von Willebrand. En: Martínez-Murillo C, Quintana-Gon-\nzález S, eds. Manual de hemostasia y trombosis. Bases fisiopatológicas y clínicas de las enfermedades hemorrágicas y\ntrombóticas. México: Prado; 1996. p. 189-206.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":352,"lines":{"from":15,"to":24}}}}],["1775",{"pageContent":"zález S, eds. Manual de hemostasia y trombosis. Bases fisiopatológicas y clínicas de las enfermedades hemorrágicas y\ntrombóticas. México: Prado; 1996. p. 189-206.\nMartínez-Murillo C, Quintana-González S. Hemofilias. Fundamentos de hematología. 2da ed. México: Panameri-\ncana; 1998. p. 312-330.\nMartínez-Murillo C, Quintana-González S, Ambriz R, Benitez H, Bravo A, Collazo J, et al. Comité Mexicano de Hemostasia y","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":352,"lines":{"from":24,"to":28}}}}],["1776",{"pageContent":"\u0014,)'\u001c)-#-8 \u0003)(-\u001f(-) \u001e\u001f \u001f2*\u001f,.)- \u001e\u001f \"\u001f')̑&#\u001b\n \n\u001f(\n \nï2#\u001d)8 \u0012\u001f\u001d)'\u001f(\u001e\u001b\u001d#)(\u001f- \u001e\u001f \u00010á(\u001e\u001b,)8 \u0007\u001b\u001d\n \n\u001f\u001e \u001e\u001f\n \nï2#\u001d): hfff9 gil8\n\nMartínez-Murillo C, Quintana-González S. Fisiología del factor VIII y factor IX de la coagulación. Hemofilia.\nMéxico: Prado; 2001. p. 43-54.\nMartínez-Murillo C, Quintana-González S. Enfermedad de von Willebrand. Hemofilia. México: Prado; 2001. p. 93-108.\nMartínez-Murillo C, Quintana-González S. Diagnóstico de la hemofilia A y B. Hemofilia. México: Prado; 2001. p. 117-128.\nMartínez-Murillo C, Quintana-González S. Las clínicas de hemofilia. Hemofilia. México: Prado; 2001. p. 141-150.\n\n\u001b,.ù(\u001f47\n \n/,#&&) \u00036 \u0011/#(.\u001b(\u001b7\u0007)(4á&\u001f4 \u00136 \u0014\u001f$\u001b\u001e\u001b7\u0012)'\u001f,)\n \n8 \u0005'*&\u001f) \u001e\u001f &\u001b \u001e\u001f-')*,\u001f-#(\u001b8 \b\u001f')̑&#\u001b8\n \nï2#\u001d)9\n\nPrado; 2001. p. 227-236.\nMartínez-Murillo C, Quintana-González S. Fibrinas adhesivas en hemofilia. Hemofilia. México: Prado; 2001. p. 237-248.\n\n\u001b,.ù(\u001f47\n \n/,#&&)\u00036 \u0011/#(.\u001b(\u001b7\u0007)(4á&\u001f4 \u00138 \u0014,\u001b.\u001b'#\u001f(.) #(.,\u001b7\u001b,.#\u001d/&\u001b, \u001f( \"\u001f')̑&#\u001b8\n \n\b\u001f')̑&#\u001b8\n \nï2#\u001d)9 \u0010,\u001b\u001e): hffg8 *8 hno7ifl8","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":352,"lines":{"from":30,"to":63}}}}],["1777",{"pageContent":"\u001b,.ù(\u001f47\n \n/,#&&)\u00036 \u0011/#(.\u001b(\u001b7\u0007)(4á&\u001f4 \u00138 \u0014,\u001b.\u001b'#\u001f(.) #(.,\u001b7\u001b,.#\u001d/&\u001b, \u001f( \"\u001f')̑&#\u001b8\n \n\b\u001f')̑&#\u001b8\n \nï2#\u001d)9 \u0010,\u001b\u001e): hffg8 *8 hno7ifl8\n\nMartínez-Murillo C, Quintana-González S. Infección por el virus de inmunodeficiencia humana (VIH). Hemofilia.\nMéxico: Prado; 2001. p. 325-334.\nMartínez-Murillo C, Quintana-González S. Hemofilia adquirida. Hemofilia. México: Prado; 2001. p. 367-380.\nOldenburg J, Ananyeva NM, Saenko EI. Molecular basis of haemophilia A. Haemophilia. 2004; 10, suppl. 4: 133-139.\nPizzuto J, Ambriz R, De la Paz RM, Monroy LM, Morales M, Avilés A, et al. Acquired von Willebrand’s syndrome\nduring autoimmune disorder. ·romb Haemost. 1980; 5, 42: 1523-8.\nQuintana-González S, Martínez-Murillo C, Collazo J. Hemofilia. Medicine; 1998.\nQuintana-González S, Martínez-Murillo C, Ambriz R. Fisiología de la coagulación. Hemofilia. México: Prado; 2001. p.19-42.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":352,"lines":{"from":63,"to":78}}}}],["1778",{"pageContent":"\u0011/#(.\u001b(\u001b7\u0007)(4á&\u001f4 \u00136\n \n\u001b,.ù(\u001f47\n \n/,#&&) \u00036 \u0001'\u001c,#4 \u0006\u00126 \u0003)&&\u001b4)\n \n8 \u0014,\u001b.\u001b'#\u001f(.) \u001e\u001f &\u001b \b\u001f')̑&#\u001b8\n \n\b\u001f')̑&#\u001b8\n \nï\n-\nxico: Prado; 2001. p. 175-192.\nRadillo GA, Collazo JJ. Deficiencias raras de la coagulación. En: Martínez-Murillo C, Quintana-González S, eds.\nManual de hemostasia y trombosis. Bases fisiopatológicas y clínicas de las enfermedades hemorrágicas y trombó -\nticas. México: Prado; 1996. p. 207-24.\nReport on the World Federation of Hemophilia Global survey. WFH 2001.\n\n\u0012)\u001e,ù!/\u001f47\n \n)3\u001b\u001e) \b6 \u0001'\u001c,#4 \u0006\u00126 \u0010#44/.) \u0003 6 \u001f. \u001b&8 \u0014,\u001b.\u001b'#\u001f(.) )*),./() \u001e\u001f &\u001b \"\u001f'),,\u001b!#\u001b \u001f( \"\u001f')̑&#\u001b\n \n\u001d&á-#\u001d\u001b8\n\nEstudio del Grupo Cooperativo Mexicano de Hemofilia. Bol Med Hosp Infant Mex. 1986; 43: 742-9.\nRosendaal FR, Smit C, Varekamp I, et al. Modern hemophilia treatment: Medical improvements and quality-of-life.\nJ Intern Med. 1990; 228: 633-640.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":352,"lines":{"from":80,"to":106}}}}],["1779",{"pageContent":"\u0012)-\u001f(\u001e\u001b\u001b& \u0006\u00126 \u0002,#\u001f \u0014\u00058 Ļ\u001f #(\u001d,\u001f\u001b-#(! *,\u001f0\u001b&\u001f(\u001d\u001f ) \"\u001f')*\"#&#\u001b8 Ļ,)'\u001c \b\u001b\u001f')-.8 goof: li9 gjk8\n\u0013%#((\u001f,\n \n\u00178 \u0014,\u001f\u001b.'\u001f(. ), \u001b&&9 \u0001 0#-#)( ), .\"\u001f\n \n/./,\u001f8 \b\u001b\u001f')*\"#&#\u001b8 hffl: gh6 -/**&8 i9 glo7gmi8\n\u0014\u001f#.\u001f&\n \n8 \u0013\u001b \u001f.3 ) \u001d)\u001b!/&\u001b.#)( \u001b\u001d.), \u001d)(\u001d\u001f(.,\u001b.\u001f-8 \b\u001b\u001f')*\"#&#\u001b8 goon: j9 ioi7jfg8\n\nVerbruggen B, Novakova I, Wessels H, Boezeman J, Van den Berg M, Mauser-Bunschoten E. ·e Nijmegen modification\nof the Bethesda assay for factor VIII:C inhibitors: Improved specificity and reliability. ·romb Haemost. 1995; 247-51.\n\nRESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\n1.\n \na\n2.\n \nc\n3.\n \na\n4.\n \nb\n5.\n \nb","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":352,"lines":{"from":108,"to":137}}}}],["1780",{"pageContent":"327\n\nINTRODUCCIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":354,"lines":{"from":1,"to":3}}}}],["1781",{"pageContent":"El término\n \ntrombofilia\n \nfue usado por primera vez en 1965 por Egeberg para designar una enfermedad\nasociada con trombosis venosa; se refería entonces específicamente a la deficiencia familiar de antitrom-\nbina III. Desde entonces, el concepto de\n \ntrombofilia\n \nse ha usado, no muy ampliamente, para referirse\na diversos trastornos, adquiridos o heredados, en los que hay riesgo de trombosis arterial o venosa. El\nantónimo de trombofilia es\n \nhemofilia\n, palabra de uso común que agrupa diversos padecimientos en los\nque hay riesgo de sangrado.\n \nTrombofilia\n \nes un término correcto que incluye varias entidades que se han\ndescrito como situaciones de hipercoagulabilidad o estados pretrombóticos. Los padecimientos trom-\nbóticos son responsables de más de la mitad de los fallecimientos de los miembros de sociedades bien\ndesarrolladas. La enfermedad por trombosis incapacitante o fatal deriva de la formación de trombos en","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":354,"lines":{"from":5,"to":28}}}}],["1782",{"pageContent":"desarrolladas. La enfermedad por trombosis incapacitante o fatal deriva de la formación de trombos en\nlas arterias en sitios donde ha habido daño endotelial, o bien en las venas como consecuencia de estasis\nvenosa e hipercoagulabilidad. Los trombos arteriales tienen un componente plaquetario importante,\nademás de fibrina, en tanto que los trombos venosos habitualmente poseen menos plaquetas; en estos\núltimos, el daño endotelial no es tan marcado como en los trombos que se originan en las arterias.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":354,"lines":{"from":28,"to":32}}}}],["1783",{"pageContent":"TROMBOSIS ARTERIAL\n\nLa aterosclerosis de la pared arterial, la rotura de una placa de ateroma y el daño endotelial exponen la\nsangre a la colágena subendotelial y a factores tisulares; esto inicia la formación de un nido de plaque-\ntas que, por producción de tromboxano A2, comienza la agregación plaquetaria. El agregado de pla-\nquetas se adhiere al endotelio por medio de fibrina, y la disminución del flujo sanguíneo y el aumento\nde la turbulencia colaboran al crecimiento del trombo, que puede más tarde fragmentarse y dar lugar\na émbolos. Los factores de riesgo trombótico arterial son: sexo masculino, historia familiar, hiperli-\npidemia, hipertensión arterial, diabetes mellitus, hiperuricemia, eritrocitosis, tabaquismo, trastornos\nelectrocardiográficos, incremento en las concentraciones de factor VIII y de fibrinógeno, entre otros.\n\nTROMBOSIS VENOSA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":354,"lines":{"from":34,"to":45}}}}],["1784",{"pageContent":"TROMBOSIS VENOSA\n\nEl principal factor de riesgo para esta entidad es la hipercoagulabilidad sanguínea. Dado que los\ntrombos venosos son menos firmes, es más fácil que se fragmenten y originen émbolos que pueden\n\nGuillermo J. Ruiz Argüelles\nGuillermo J. Ruiz Delgado\n\nObjetivos de aprendizaje\n\n•\n \nDiferenciar los conceptos de\n \ntrombofilia primaria\n \ny\n \nsecundaria.\n\n•\n \nMencionar los principales estados de trombofilia identificados.\n\n•\n \nSeñalar la distribución de los estados de trombofilia en México.\n\nCAPÍTULO 21\n\nTROMBOFILIA\n\nEl término\n \ntrombofilia\n \nse ha\nempleado, no muy amplia-\nmente, para referirse a di-\nversos trastornos, adquiridos\no heredados, en los que hay\nriesgo de trombosis arterial\no\n \nvenosa.\n \nEl\n \nantónimo\n \nde\ntrombofilia es\n \nhemofilia\n, pa-\nlabra de uso común que agru-\npa diversos padecimientos en\nlos que hay riesgo de sangrado.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":354,"lines":{"from":45,"to":102}}}}],["1785",{"pageContent":"328\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\ncausar daño a distancia, condición conocida como\n \ntromboembolia venosa\n. El\n \ncuadro 21-1\n \nmuestra algunos\nde los padecimientos asociados a la trombosis.\n\nCARACTERÍSTICAS GENERALES DE LA TROMBOFILIA\n\nLos estados de trombofilia suponen un desequilibrio entre las actividades de los mecanismos procoagu-\nlantes y anticoagulantes naturales. La\n \nfigura 21-1\n \nrepresenta el equilibrio que normalmente existe entre\nellos; desde un punto de vista teórico, se encuentran varias anormalidades que pueden condicionar un\nestado de trombofilia:\n1. Hipercoagulabilidad debida a:\n\n•\n \nAumento del número o función, o ambos, de las plaquetas.\n\n•\n \nIncremento en los niveles de los factores procoagulantes.\n\n•\n \nDisminución en la actividad de los inhibidores fisiológicos de la coagulación, ya sea por falta del\ninhibidor o por disminución de su activación.\n2. Hipofibrinólisis debida a:\n\n•\n \nDisminución de la activación del plasminógeno.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":355,"lines":{"from":1,"to":43}}}}],["1786",{"pageContent":"•\n \nDisminución de la activación del plasminógeno.\n\n•\n \nIncremento en los iniciadores de la fibrinólisis.\n\n•\n \nCapacidad disminuida de lisis del coágulo de fibrina.\n\nDiagnóstico de la trombosis\n\nLos métodos para diagnosticar y cuantificar la trombosis son varios. El método de referencia sigue siendo la\nangiografía (flebografía, venografía o arteriografía) con medios de contraste. Otros métodos son la pletismo\n-\ngrafía de impedancia, la gammagrafía con varios radioisótopos (fibrina, plasmina o plaquetas marcadas), la\ntomografía computarizada, la resonancia nuclear, la termografía, la ecografía, entre otros. Una vez confirmado\n\nCuadro 21-1.\n \nEstados de trombofilia\n\nAnormalidades\n \nMecanismos\n1. Hereditarias:","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":355,"lines":{"from":43,"to":70}}}}],["1787",{"pageContent":"Cuadro 21-1.\n \nEstados de trombofilia\n\nAnormalidades\n \nMecanismos\n1. Hereditarias:\n\na) Síndrome de las plaquetas “pegajosas”\nb) Resistencia a la PC activada\nc)\n \nDeficiencia de PC o PS\nd) Deficiencia de AT III\ne)\n \nHomocistinuria, mutación MTHFR\nf)\n \nMutación protrombina\ng) Disfibrinogenemias\nh) Displasminogenemia\nHiperagregabilidad plaquetaria\nFalla de inhibición proteolítica de Va\nFalla de inhibición proteolítica de VIIIa y Va\nNeutralización inadecuada de proteasas (trom-\nbina, IXa, Xa)\nDaño endotelial\nHiperprotrombinemia (¿?)\nNeutralización inadecuada de trombina (¿?)\nInsuficiente producción de plasmina\n\n2. Adquiridas:\n\na) Cirugía, traumatismo, puerperio\n \nVarios factores de riesgo, puerperio\nb) Cáncer\n \nExposición de la sangre a células tumorales o\nsus productos tromboplásicos\nc) Padecimientos hemáticos malignos:\n\n•\n \n\u001f/\u001d\u001f'#\u001b *,)'#\u001f&)\u001dù.#\u001d\u001b\n•\n \n\u0010)&#\u001d#.\u001f'#\u001b 0\u001f,\u001b\n•\n \n\u0014,)'\u001c)\u001d#.)-#- '\u001b&#!(\u001b\n•\n \n\b\u001f')!&)\u001c#(/,#\u001b *\u001b,)2ù-.#\u001d\u001b ()\u001d./,(\u001b","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":355,"lines":{"from":70,"to":125}}}}],["1788",{"pageContent":"•\n \n\u001f/\u001d\u001f'#\u001b *,)'#\u001f&)\u001dù.#\u001d\u001b\n•\n \n\u0010)&#\u001d#.\u001f'#\u001b 0\u001f,\u001b\n•\n \n\u0014,)'\u001c)\u001d#.)-#- '\u001b&#!(\u001b\n•\n \n\b\u001f')!&)\u001c#(/,#\u001b *\u001b,)2ù-.#\u001d\u001b ()\u001d./,(\u001b\n\nLiberación de tromboplastina de los gránulos\nHiperviscosidad, trombocitosis\nTrombocitosis, trombocitopatía\nTrombocitopatía (¿?)\n\nLos estados de trombofilia su-\nponen un desequilibrio entre\nlas actividades de los meca-\nnismos procoagulantes y anti-\ncoagulantes naturales.\nLos métodos para diagnosticar\ny cuantificar la trombosis son\nvarios. El método de referencia\nsigue siendo la angiografía (fle-\nbografía, venografía o arterio-\ngrafía) con medios de contraste.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":355,"lines":{"from":125,"to":153}}}}],["1789",{"pageContent":"329\n\nCAPÍTULO 21. TROMBOFILIA\n\nel diagnóstico del fenómeno vasooclusivo, debe decidirse el tratamiento, que puede incluir anticoagulantes,\nantiplaquetarios y agentes fibrinolíticos. Hacer caso omiso del estudio de las causas de la trombosis lleva im\n-\nplícita una pena que puede ser catastrófica: la repetición del episodio vasooclusivo, posiblemente más grave, o\nbien que ocurra en otro miembro de la familia en situaciones de trombofilia familiar.\nCada vez queda más claro que los estados de trombofilia se producen con frecuencia como resultado de\nla coexistencia de varias condiciones trombofílicas, tanto heredadas como adquiridas; este es el concepto\nde\n \ntrombofilia multifactorial\n. A continuación se señalan las condiciones de trombofilia más frecuentes,\ntanto hereditarias (primarias) como adquiridas (secundarias).\n\nESTADOS DE TROMBOFILIA PRIMARIA O HEREDITARIA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":356,"lines":{"from":1,"to":18}}}}],["1790",{"pageContent":"ESTADOS DE TROMBOFILIA PRIMARIA O HEREDITARIA\n\nLos estados de trombofilia primaria más frecuentes son: el síndrome de las plaquetas “pegajosas”, la resis-\ntencia a la proteína C activada, las deficiencias de proteína C, proteína S, antitrombina III y las mutaciones\nde los genes del factor V, de la protrombina y de la reductasa del metilentetrahidrofolato (MTHFR). Los\nindicadores clínicos que sugieren un estado de trombofilia primaria son: trombosis en sujetos jóvenes, me-\nnores de 40 años; historia familiar de trombosis; trombosis recurrente sin factores precipitantes aparentes;\ntrombosis en sitios anatómicos poco usuales y resistencia a tratamientos antitrombóticos convencionales.\n\nSíndrome de las plaquetas “pegajosas”","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":356,"lines":{"from":18,"to":27}}}}],["1791",{"pageContent":"Síndrome de las plaquetas “pegajosas”\n\nDescrito en 1983, este síndrome no fue reconocido como causa de trombofilia sino hasta 1995. El sín-\ndrome de las plaquetas “pegajosas” (SPP) es una causa común de trombosis arterial y venosa; en Estados\nUnidos, el SPP es la causa del 20% de las trombosis arteriales y del 13% de las trombosis venosas. Esta\nenfermedad hereditaria supone hiperagregabilidad de las plaquetas cuando se estudia la función de estas\nin vitro, empleando como agentes agregantes adrenalina o difosfato de adenosina (ADP). En México, el\nSPP parece ser más frecuente que en otros países\n \n(cuadro 21-2)\n, y ocurre en el 50 a 60% de los mestizos\nmexicanos que tienen un marcador clínico de trombofilia. La administración de agentes antiplaquetarios\na los pacientes que sufren esta condición heredada revierte la hiperagregabilidad plaquetaria en la mayoría\nde los casos y disminuye el riesgo de trombosis.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":356,"lines":{"from":27,"to":40}}}}],["1792",{"pageContent":"Figura 21-1.\n \nEsquema del equilibrio entre los mecanismos procoagulantes y anticoagulantes. La trombofilia re\n-\nsulta del exceso de actividades procoagulantes o de la deficiencia de actividades anticoagulantes. u-PA = activador\ndel plasminógeno tipo urocinasa; t-PA = activador del plasminógeno tipo tisular; AT III = antitrombina III; PAI\n= inhibidor del activador del plasminógeno; PC / PS = sistema proteína C / proteína S;\nα\n2-AP =\n \nα\n2-antiplasmina;\nHCII = cofactor II de la heparina; HRGP = glucoproteína rica en histidina; EPI = inhibidor de la vía extrínseca.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":356,"lines":{"from":42,"to":54}}}}],["1793",{"pageContent":"Los más frecuentes son: la resis-\ntencia a la proteína C activa-\nda, las deficiencias de proteína\nC, proteína S, antitrombina\nIII, el síndrome de las plaque-\ntas “pegajosas” y las mutaciones\nde los genes del factor V, de la\nprotrombina y de la reducta-\nsa del metilentetrahidrofolato\n(MTHFR).\nEl síndrome de las plaquetas\n“pegajosas” (SPP) es una causa\ncomún de trombosis arterial y\nvenosa. Esta enfermedad here-\nditaria supone hiperagregabi-\nlidad de las plaquetas cuando\nse estudia la función de estas in\nvitro, empleando como agentes\nagregantes adrenalina o difos-\nfato de adenosina (ADP).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":356,"lines":{"from":56,"to":75}}}}],["1794",{"pageContent":"330\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nResistencia a la proteína C activada","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":357,"lines":{"from":1,"to":5}}}}],["1795",{"pageContent":"La forma heredada de la resistencia a la proteína C activada (RPCa) supone alteraciones en la estructura del gen\nque codifica la síntesis de la molécula del factor V de coagulación, el cual, conservando su función procoagulan\n-\nte, es resistente a su inhibición por la proteína C activada.\n(fig. 21-2)\n. Una mutación puntual en el residuo 506\ndel gen del factor V causa la forma heredada más frecuente de la enfermedad, que ocurre en hasta el 15% de los\nhabitantes de Suecia y en el 4 a 5% de los habitantes de México. Esta mutación se conoce como\nmutación tipo\nLeiden del factor V de la coagulación.\n \nLas formas adquiridas de esta enfermedad ocurren por incremento en las\nconcentraciones del factor VIII, anticuerpos antifosfolípido, anticoagulantes lúpicos, hepatopatías, embarazo,\nempleo de anovulatorios, etcétera. En México parecen ser más frecuentes las formas adquiridas de la enferme\n-\ndad que las formas heredadas, aun cuando es posible que existan otras mutaciones de los genes de los factores","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":357,"lines":{"from":7,"to":22}}}}],["1796",{"pageContent":"-\ndad que las formas heredadas, aun cuando es posible que existan otras mutaciones de los genes de los factores\nV y VIII que conduzcan en México al fenotipo de RPCa. En indígenas puros mexicanos no se ha encontrado\nla mutación Leiden del factor V de la coagulación, que es más frecuente en poblaciones caucásicas. El 13% de\nlos mestizos mexicanos con trombofilia, tienen la citada mutación (véase cuadro 21-2).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":357,"lines":{"from":22,"to":26}}}}],["1797",{"pageContent":"Mutación C677T del gen\nMTHFR\n\nEsta mutación se ha encontrado en el 67 y 11% de los pacientes mestizos mexicanos con algún marcador\nclínico de trombofilia (véase cuadro 21-2). Dado que la mutación ocurre también en el 80% de los mes-\ntizos mexicanos sin trombofilia, su papel en la génesis de esta condición es dudosa. Cuando se identifica\nesta alteración en un paciente trombofílico, es razonable administrarle suplementos de ácido fólico para\nevitar la hiperhomocisteinemia que puede ocurrir en la deficiencia de folatos, y que podría agravar la hi-\nperhomocisteinemia que ocurre en algunos sujetos con esta mutación, sobre todo cuando es homocigota.\nLos heterocigotos para la mutación habitualmente no desarrollan hiperhomocisteinemia.\n\nDeficiencia heredada de proteína C","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":357,"lines":{"from":28,"to":39}}}}],["1798",{"pageContent":"Deficiencia heredada de proteína C\n\nLa proteína C inactiva los factores Va y VIIIa y depende para sus síntesis hepática de la vitamina K. La\ndeficiencia heredada se transmite con carácter autosómico dominante; el gen que codifica su síntesis se\nlocaliza en el cromosoma 2. Algunos autores han descrito que la proporción de sujetos heterocigotos para\nla deficiencia es tan alta como 1 en 200 a 300 individuos de la población general; las cifras de proteína C\nen ellos son menores del 60% del valor normal. No todos los heterocigotos para la deficiencia sufren\n\nCuadro 21-2.\n \nHallazgos en un grupo de 100 mestizos mexicanos con trombosis\ny un marcador clínico de trombofilia primaria. Las cifras encontradas en mestizos\nmexicanos normales se incluyen para propósitos de comparación\n\nCondición\n \n%\n \n% en sanos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":357,"lines":{"from":39,"to":57}}}}],["1799",{"pageContent":"Condición\n \n%\n \n% en sanos\n\nMutación C677T del gen\n \nMTHFR\n \n67\n \n78\nSíndrome de las plaquetas pegajosas\n \n57\n \n15\nHaplotipo HR2 del gen\n \nFV\n \n21\n \n8\nFenotipo RPCa\n \n20\n \n2\nAntifosfolípidos\n \n15\n \n3\nMutación Leiden del gen\n \nFV\n \n13\n \n0,7\nMutación G20210A del gen protrombina\n \n11\n \n0\nDeficiencia de proteína C\n \n7\n \n0\nDeficiencia de proteína S\n \n6\n \n0\nDeficiencia de AT III\n \n1\n \n0\nMutación Hong Kong del gen\n \nFV\n \n1\n \n0\n\nEn\n \nindígenas\n \npuros\n \nmexi-\ncanos no se ha encontrado la\nmutación Leiden del factor V\nde la coagulación, que es más\nfrecuente en poblaciones cau-\ncásicas. el 13% de mestizos\nmexicanos\n \ncon\n \ntrombofilia,\ntienen la citada mutación.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":357,"lines":{"from":57,"to":144}}}}],["1800",{"pageContent":"331\n\nCAPÍTULO 21. TROMBOFILIA\n\nfenómenos vasooclusivos, y se han identificado algunos factores que propician que ocurra trombosis en\ndichos sujetos: anovulatorios, embarazo, infecciones graves, lupus eritematoso y el uso de algunos agentes\nquimioterapéuticos como L-asparaginasa, entre otros. Los homocigotos para la deficiencia sufren púrpura\n\nfulminans\n, condición de extrema gravedad que termina con la vida de los recién nacidos en pocos días; en\nellos, la concentración de la proteína C es menor de 1% del valor normal.\n\nDeficiencia heredada de proteína S","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":358,"lines":{"from":1,"to":13}}}}],["1801",{"pageContent":"Deficiencia heredada de proteína S\n\nLa deficiencia se transmite con carácter autosómico codominante y la proporción de sujetos heterocigotos\nu homocigotos para la deficiencia no se conoce a detalle. Aparentemente esta deficiencia es menos fre-\ncuente que la de la proteína C. Entre el 2 y el 5% de los pacientes con marcadores clínicos de un estado\ntrombofílico primario sufren deficiencia hereditaria de proteína S; en México es rara esta enfermedad. El\n60% de la proteína S se encuentra unida con C4 y el 40% restante se encuentra libre; solo la fracción libre\ntiene actividad anticoagulante como cofactor de la proteína C. La proteína S es también dependiente de\nla vitamina K.\n\nDeficiencia heredada de antitrombina III","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":358,"lines":{"from":13,"to":23}}}}],["1802",{"pageContent":"Deficiencia heredada de antitrombina III\n\nLa AT III es responsable del 75% de la actividad inhibidora de la trombina. La deficiencia se transmite\ncon carácter autosómico dominante; la proporción de heterocigotos es de 1 en 2 000 y sus concentraciones\nson menores del 50%. Aproximadamente la mitad de los sujetos heterocigotos para la deficiencia sufren\nun episodio vasooclusivo en la adolescencia. El estado homocigoto para la deficiencia de AT III es incom-\npatible con la vida. En México esta enfermedad es una causa muy infrecuente de trombofilia.\n\nESTADOS DE TROMBOFILIA SECUNDARIA\n\nLos estados trombofílicos secundarios más frecuentes son: posoperatorio, traumatismo, posparto, neo-\nplasias malignas, tratamiento con estrógenos y enfermedades autoinmunitarias, como el síndrome de\nanticuerpos antifosfolípido y el lupus eritematoso generalizado.\n\nPeríodo posparto","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":358,"lines":{"from":23,"to":37}}}}],["1803",{"pageContent":"Período posparto\n\nEste período, y no el embarazo, es trombogénico y las causas son múltiples: disminución en la actividad\nfibrinolítica, estasis en venas profundas, dilatación de venas intraabdominales por presión uterina, hi-\nperfibrinogenemia, deficiencia adquirida de AT III, etcétera.\n\nFigura 21-2.\n \nModelo molecular especulativo de la degradación de los factores V (FV) y VIII (FVIII) de\nla coagulación por la proteína C activada (PCa). En la superficie de las membranas de fosfolípidos, el com\n-\nplejo proteína S (PS) / FV constituye un sitio de unión para la PCa. La resistencia a esta es causada por el\ncambio de Arg 506 por Gln en el sitio de fractura del FV por la PCa, lo que produce un FV resistente a la\nacción de la PCa. El FVa y el FVIIIIa son las formas activas, en tanto que el FVi y el FVIIIi son las formas\ninactivas de los FV y FVIII, respectivamente.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":358,"lines":{"from":37,"to":51}}}}],["1804",{"pageContent":"Entre el 2 y el 5% de los pacien-\ntes con marcadores clínicos de\nun estado trombofílico prima-\nrio sufren deficiencia heredita-\nria de proteína S; en México es\nrara esta enfermedad.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":358,"lines":{"from":53,"to":58}}}}],["1805",{"pageContent":"332\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nNeoplasias malignas\n\nEn los tumores malignos del tubo digestivo puede haber trombofilia. La tromboflebitis migratoria, el\nllamado\n \nsíndrome de Trousseau\n, es una forma de trombofilia venosa que fue descrita en él mismo por\nel médico que le dio nombre.\n\nSíndrome de anticuerpos antifosfolípido","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":359,"lines":{"from":1,"to":14}}}}],["1806",{"pageContent":"El término de\n \nsíndrome de anticuerpos antifosfolípido\n \no\n \nsíndrome antifosfolípido\n \n(SAF) se ha empleado en los\núltimos 10 años para describir a la entidad de un grupo de pacientes con anticuerpos antifosfolípido o anti-\ncoagulantes lúpicos que tienen algunas características clínicas asociadas: trombosis arterial o venosa, pérdida\nfetal repetida o trombocitopenia. La asociación de uno de los datos serológicos con una de las características\nclínicas antes señaladas permite establecer el diagnóstico de SAF. Se han identificado dos tipos de SAF: el\nprimario, que se presenta en pacientes que no tienen suficientes criterios para establecer el diagnóstico de una\nenfermedad autoinmunitaria definida, y el secundario, que ocurre en pacientes con otro trastorno autoinmu-\nnitario definido, frecuentemente lupus eritematoso generalizado (LEG). El SAF primario es una entidad\nnosológica bien definida e independiente en la que se han descrito algunos datos clínicos como migraña,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":359,"lines":{"from":16,"to":32}}}}],["1807",{"pageContent":"livedo reticularis\n, síndrome de Evans (anemia hemolítica y púrpura trombocitopénica autoinmunitarias si-\nmultáneas), corea, hipertensión pulmonar, anormalidades en las válvulas cardíacas, entre otros.\n\nLupus eritematoso generalizado","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":359,"lines":{"from":34,"to":38}}}}],["1808",{"pageContent":"Los pacientes con LEG sufren un estado de trombofilia adquirida; se han identificado diversos meca-\nnismos como responsables de ella, entre los que destacan anormalidades funcionales del complejo factor\nVIII/factor von Willebrand, anticoagulantes lúpicos, anticuerpos antifosfolípido, deficiencia de pros-\ntaciclina y otros que el autor ha estudiado con más detalle. En individuos con LEG se ha estudiado el\nfuncionamiento de algunos de los mecanismos antitrombóticos naturales, como los sistemas proteína\nC/proteína S/trombomodulina, trombina/antitrombina III, lipoproteína (a) y fibrinólisis/antifibrinólisis.\nEn todos estos sistemas se han encontrado alteraciones relacionadas con trombofilia y, en algunos casos,\ncon autoanticuerpos. Al parecer, la alteración de los mecanismos antitrombóticos más frecuentemente\nasociada con la trombofilia observada en estos pacientes es el fenotipo de la resistencia a la proteína C ac-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":359,"lines":{"from":40,"to":48}}}}],["1809",{"pageContent":"asociada con la trombofilia observada en estos pacientes es el fenotipo de la resistencia a la proteína C ac-\ntivada, alteración que además es reversible. Todos estos datos apoyan la idea de que la trombofilia lúpica es\nmultifactorial y que el mal funcionamiento de algunos de los mecanismos antitrombóticos naturales des-\nempeña un papel en esta. Se han descrito también anticuerpos anti-proteína C, anti-proteína S, anti-PAI\ny anti-TPA, en algunos casos asociados a diátesis trombofílica. La presencia de anticuerpos antifosfolípi-\ndo se asocia con trombosis venosa recurrente, trombosis arterial, pérdida fetal repetida y trombocitopenia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":359,"lines":{"from":48,"to":53}}}}],["1810",{"pageContent":"EVALUACIÓN DE PACIENTES CON RIESGO TROMBÓTICO ALTO","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":359,"lines":{"from":55,"to":55}}}}],["1811",{"pageContent":"El que ocurra un fenómeno vasooclusivo en la vena iliofemoral de un anciano que ha sufrido fractura inter\n-\ntrocantérea de fémur y ha permanecido inmóvil durante algún tiempo no sorprende en forma notable. Sin\nembargo, hay situaciones en las que deben realizarse estudios orientados a aclarar la causa de la trombofilia;\nentre ellas se pueden considerar las mencionadas con anterioridad: trombosis en sujetos jóvenes, menores\nde 45 años, con factores predisponentes evidentes o sin estos; trombosis en sitios anatómicos poco habitua-\nles; historia familiar de trombosis; resistencia o reacciones infrecuentes a tratamientos anticoagulantes o\nantitrombóticos (necrosis cutánea por cumarínicos, incapacidad para lograr anticoagulación con heparina,\netc.). En estos pacientes deben hacerse las investigaciones de las condiciones de trombofilia heredada que\nse señalan en el cuadro 21-2. Si se encuentra el fenotipo de la resistencia a la proteína C activada mediante","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":359,"lines":{"from":57,"to":66}}}}],["1812",{"pageContent":"se señalan en el cuadro 21-2. Si se encuentra el fenotipo de la resistencia a la proteína C activada mediante\nun tiempo de tromboplastina parcial activada en presencia de cantidades conocidas de proteína C, debe\ninvestigarse si se trata de una forma heredada o adquirida del padecimiento, buscando la mutación Leiden\ndel gen del factor V por medio de biología molecular u otras causas de las formas adquiridas de la entidad.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":359,"lines":{"from":66,"to":69}}}}],["1813",{"pageContent":"PROFILAXIS Y TRATAMIENTO\nDE LOS TRASTORNOS TROMBÓTICOS\n\nPueden utilizarse medicamentos antiplaquetarios como la aspirina y el clopidogrel; el dipiridamol debe\nolvidarse como antiplaquetario. También es posible usar anticoagulantes orales, cumarínicos y heparinas\n\nEl\n \ntérmino\n \nde\n \nsíndrome\nde\n \nanticuerpos\n \nantifos-\nfolípido\n \no\n \nsíndrome\n \nan-\ntifosfolípido (SAF)\n \nse ha\nempleado\n \nen\n \nlos\n \núltimos\n10 años para describir a la\nentidad de un grupo de pa -\ncientes con anticuerpos anti -\nfosfolípido o anticoagulantes\nlúpicos que algunas carac-\nterísticas clínicas asociadas:\ntrombosis arterial o veno -\nsa, pérdida fetal repetida o\ntrombocitopenia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":359,"lines":{"from":71,"to":114}}}}],["1814",{"pageContent":"333\n\nCAPÍTULO 21. TROMBOFILIA\n\n(convencionales o de bajo peso molecular) o heparinoides. Algunos procedimientos quirúrgicos, como la\ninterrupción de la vena cava inferior o la instalación dentro de esta de dispositivos como la “sombrilla” de\nMobin-Uddin o el filtro de Greenfield, pueden ser de utilidad para prevenir la embolia a partir de venas\nprofundas de la pelvis o de miembros inferiores. Es posible utilizar tratamientos trombolíticos en casos\nde trombosis coronaria (infarto del miocardio), trombosis venosa profunda o tromboembolia pulmonar;\nse ha usado estreptocinasa, urocinasa, activador tisular del plasminógeno recombinante, activador del\ncomplejo plasminógeno/estreptocinasa (APSAC), entre otros.\n\nHeparinas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":360,"lines":{"from":1,"to":13}}}}],["1815",{"pageContent":"Son mucopolisacáridos ácidos que inhiben la coagulación merced a su interacción con la antitrombina\nIII; no se absorben en el aparato digestivo, de allí que haya que administrarlos por vía parenteral (intra -\nvenosa o subcutánea). Su vida media biológica es aproximadamente de 1 hora. Las heparinas potencian\nla formación de complejos entre la antitrombina III y las proteasas de serina: IXa, Xa y XIa. Las hepa -\nrinas de bajo peso molecular (HBPM) (4 000 a 8 000 Da), a diferencia de las heparinas convencionales\n(15 000 a 18 000 Da), tienen mayor capacidad para inhibir el factor Xa. El uso de heparinas puede\nvigilarse mediante el tiempo de tromboplastina parcial activada, que conviene mantener entre 1,5 y dos\nveces el valor basal que tenía antes de la administración de la heparina. En el caso de las HBPM, no\nes necesario hacer estudios de laboratorio para vigilar su efecto. Las HBPM son fármacos antitrombó -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":360,"lines":{"from":15,"to":23}}}}],["1816",{"pageContent":"es necesario hacer estudios de laboratorio para vigilar su efecto. Las HBPM son fármacos antitrombó -\nticos derivados de la heparina que tienen poco efecto anticoagulante y gran actividad antitrombótica,\npor lo que resultan ideales para la profilaxis y el tratamiento de la trombosis. Las HBPM son útiles\nen la prevención de trombosis en cirugía ortopédica y para tratar tromboflebitis e incluso tromboem -\nbolia pulmonar. A pesar de que son caras, el hecho de que se administren una sola vez al día, de que\nno necesiten vigilancia con pruebas de laboratorio y de que pueden emplearse en la casa del paciente,\nhace que la relación costo-beneficio sea mejor para estos fármacos que para la heparina no fraccionada\ny otros anticoagulantes. Los anticoagulantes orales deben iniciarse 2 a 7 días después de comenzar el\nuso terapéutico de las heparinas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":360,"lines":{"from":23,"to":31}}}}],["1817",{"pageContent":"Anticoagulantes orales","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":360,"lines":{"from":33,"to":33}}}}],["1818",{"pageContent":"Son derivados de la cumarina o de la indandiona, y actúan antagonizando la vitamina K. Dado que\nla absorción del aparato digestivo es adecuada, se administran por vía oral. El uso de los cumarínicos\nproduce una disminución de la actividad biológica de los factores de coagulación dependientes de\nvitamina K: II, VII, IX y X, al bloquearse la\n\u0003γ\n \n-carboxilación posribosomal de los residuos de ácido\nglutámico de estas proteínas. El efecto de los cumarínicos debe vigilarse cuantificando el tiempo de\nprotrombina; idealmente ha de mantenerse una tasa normalizada de protrombina (INR) de acuerdo\ncon los límites que muestra el\n \ncuadro 21-3\n. Recientemente se ha introducido el uso de inhibido -\nres directos del factor Xa (activado) administrados por vía oral, como el rivaroxabán, que luce muy\npromisorio como antitrombótico tanto profiláctico como terapéutico. El rivaroxabán, el apixaban, el\nfondaparinux (subcutáneo) y el dabigatrán (inhibidor directo de la trombina) se están usando en la","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":360,"lines":{"from":35,"to":50}}}}],["1819",{"pageContent":"promisorio como antitrombótico tanto profiláctico como terapéutico. El rivaroxabán, el apixaban, el\nfondaparinux (subcutáneo) y el dabigatrán (inhibidor directo de la trombina) se están usando en la\nactualidad como antitrombóticos orales, y en varias condiciones han mostrado ser mejores que los\ncumarínicos. Es probable que en el futuro los pacientes que necesiten de anticoagulación continua\npuedan tratarse con estos fármacos. Además de ser más seguros, estos agentes no requieren de control\npor medio de pruebas de laboratorio, lo que facilita su empleo. Todos ellos son considerablemente más\ncostosos que los cumarínicos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":360,"lines":{"from":50,"to":56}}}}],["1820",{"pageContent":"Fibrinolíticos\n\nSe han usado fibrinolíticos de primera generación: estreptocinasa (SK) y urocinasa (UK); de segunda ge-\nneración: activador tisular del plasminógeno (TPA); y de tercera generación: activador del plasminógeno\ntipo urocinasa de una sola cadena (SCU-PA) y complejo activador acilado de plasminógeno/estreptoci-\nnasa (APSAC). Los medicamentos trombolíticos se han utilizado con éxito en el tratamiento de infarto\nagudo de miocardio, tromboembolia pulmonar y trombosis venosa profunda. Idealmente deben aplicarse\nen las primeras 6 horas del proceso vasooclusivo. En el primer caso, la SK parece ser tan efectiva como el\nTPA recombinante humano, y es más barata; de manera habitual se utiliza una dosis inicial de 250 000 U\nde SK seguida de una dosis de mantenimiento de 100 000 U/h durante 12 a 48 horas. En el infarto del\nmiocardio se pueden usar 1,5 millones de unidades en un período de 60 minutos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":360,"lines":{"from":58,"to":68}}}}],["1821",{"pageContent":"334\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nAntiplaquetarios\nAspirina\n\nSigue siendo el mejor fármaco antiplaquetario; inhibe de manera irreversible la ciclooxigenasa plaquetaria,\nreduciendo la producción de tromboxano A\n \n2\n \n. Se utiliza en pacientes que han sufrido infarto del miocardio\no ataques isquémicos transitorios, y también en aquellos con trombocitosis o que han sido sometidos a\nesplenectomía. Es el tratamiento de elección para los pacientes con síndrome de las plaquetas “pegajosas”.\nLa dosis de 100 mg cada 24 o 48 horas es suficiente para producir un efecto antiplaquetario adecuado.\n\nOtros antiplaquetarios","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":361,"lines":{"from":1,"to":18}}}}],["1822",{"pageContent":"Otros antiplaquetarios\n\nEl clopidogrel se utiliza frecuentemente como agente antiagregante plaquetario; el ticagrelor tiene tam-\nbién propiedades antiplaquetarias adecuadas. Los anticuerpos monoclonales que identifican y bloquean a\nla glucoproteína IIb/IIIa en la superficie de las plaquetas se emplean también como agentes antiplaqueta-\nrios. El propranolol, el nifedipino y el diltiazem también tienen efecto antiagregante.\n\nCONCLUSIONES\n\n•\n \nEl término\n \ntrombofilia\n \nse refiere a la tendencia anormal a hacer trombos en arterias o venas; se denomi-\nna también\n \nestado de hipercoagulabilidad\n \no\n \nestado protrombótico\n, y casi siempre se debe a un desequilibrio\nentre las actividades de los mecanismos procoagulantes y anticoagulantes naturales.\n\n•\n \nLas trombofilias pueden ser heredadas o adquiridas. El síndrome de plaquetas pegajosas es el estado\ntrombofílico más común en México. La mayoría de los pacientes que sufren un fenómeno vasooclusivo\ntienen dos o más condiciones trombofílicas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":361,"lines":{"from":18,"to":48}}}}],["1823",{"pageContent":"•\n \nLa identificación adecuada de las condiciones de trombofilia permite dar el tratamiento adecuado y\nevitar nuevos fenómenos trombóticos.\n\nPREGUNTAS DE AUTOEVALUACIÓN\n\n1. ¿Cuál es la causa más frecuente de trombofilia heredada en México?\na.\n \nResistencia a la proteína C activada\nb. Deficiencia heredada de proteína S\nc.\n \nSíndrome de las plaquetas pegajosas\n2. ¿Cuál es el tratamiento de elección en el síndrome de las plaquetas pegajosas?\na.\n \nHeparinas\nb. Fibrinolíticos\nc.\n \nAntiplaquetarios, principalmente aspirina\n\nCuadro 21-3.\n \nLímites ideales de la tasa internacional normalizada\nde protrombina (INR, de\n \ninternational normalized ratio\n)\n\nINR\n \nCondición","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":361,"lines":{"from":50,"to":84}}}}],["1824",{"pageContent":"Cuadro 21-3.\n \nLímites ideales de la tasa internacional normalizada\nde protrombina (INR, de\n \ninternational normalized ratio\n)\n\nINR\n \nCondición\n\n2,0 a 2,5\n \nProfilaxis de trombosis venosa profunda\n2,0 a 3,0\nTratamiento de trombosis venosa profunda, tromboembolia pulmonar, in-\nfarto del miocardio, estenosis mitral, fibrilación auricular e isquemia cere-\nbral transitoria\n3,0 a 4,5\n \nTratamiento de recurrencias de trombosis venosa profunda, tromboembolia\npulmonar, injertos vasculares y válvulas cardíacas artificiales","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":361,"lines":{"from":84,"to":106}}}}],["1825",{"pageContent":"335\n\nCAPÍTULO 21. TROMBOFILIA\n\n3. ¿Cuál es la mutación del gen del factor V más frecuente en México como causa de fenotipo de resis-\ntencia a la proteína C activada?\na.\n \nLa mutación del gen\n \nMTHFR\n\nb. La mutación tipo Leiden\nc.\n \nLa mutación del gen de protrombina\n4. ¿Cuál es la condición fisiológica más trombogénica en la mujer?\na.\n \nEl puerperio\nb. La menstruación\nc.\n \nEl embarazo\n5. ¿Cuál es la dosis de estreptocinasa recomendable en el tratamiento del infarto del miocardio?\na.\n \n100 000 U/hora\nb. 250 000 U/hora\nc.\n \n1 500 000 U en 1 hora\n\nBIBLIOGRAFÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":362,"lines":{"from":1,"to":34}}}}],["1826",{"pageContent":"Alarcón-Segovia D, Ruiz-Argüelles GJ, Garcés-Eisele J, et al. Inherited activated protein C resistance in a patient\nwith familial antiphospholipid syndrome. J Rheumatol. 1996; 23: 2162-5.\nCésarman G, Villazón S, Zúñiga J, et al. Absence of factor V Leiden mutation in Mazateco Indians: A polymorphism\nof recent acquisition in the Americas. Int J Haematol. 1996; 64 (Suppl. 1): s111.\nGarcés-Eisele J, González-Carrillo ML, Reyes-Núñez V, Ruiz-Argüelles GJ. Primary thrombophilia in Mé -\nxico VII: The V617F mutation of JAK2 is not a frequent cause of thrombosis. Hematology. 2008; 13:\n244-6.\nLobato-Mendizábal E, Ruiz-Argüelles GJ. Proteína C, proteína S y trombomodulina: Uno de los mecanismos anti -\ntrombóticos naturales. Rev Invest Clin (Mex). 1990; 42: 54-62.\nRuiz-Argüelles GJ. El laboratorio en el estudio de pacientes con trombosis y estados pre-trombóticos. Gac Med Mex.\n1989; 125.\nRuiz-Argüelles GJ, Lanzetti-de-Peschard C, et al. Alteraciones hemostáticas en diabetes mellitus idiopática. Rev","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":362,"lines":{"from":36,"to":47}}}}],["1827",{"pageContent":"1989; 125.\nRuiz-Argüelles GJ, Lanzetti-de-Peschard C, et al. Alteraciones hemostáticas en diabetes mellitus idiopática. Rev\nInvest Clin (Mex). 1981; 33: 355-259.\nRuiz-Argüelles GJ, Ruiz-Argüelles A, Alarcón-Segovia D, et al. Natural anticoagulants in systemic lupus erythe-\nmatosus. Deficiency of protein S bound to C4bp associates with recent history of venous thrombosis and the\nantiphospholipid syndrome. J Rheumatol. 1991; 18: 552-558.\nRuiz-Argüelles GJ, Ruiz-Argüelles A, et al. Acquired protein C deficiency in a patient with primary antiphospho-\nlipid syndrome. Relationship to reactivity of the anticardiolipin antibody with thrombomodulin. J Rheumatol.\n1989; 16: 381-383.\nRuiz-Argüelles GJ, Ruiz-Argüelles A, Lobato-Mendizábal E, et al. Disturbances in the tissue plasminogen ac-\ntivator/plasminogen activator inhibitor (TPA/PAI) system in systemic lupus erythematous. Am J Hematol.\n1991; 37: 9-13.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":362,"lines":{"from":47,"to":58}}}}],["1828",{"pageContent":"tivator/plasminogen activator inhibitor (TPA/PAI) system in systemic lupus erythematous. Am J Hematol.\n1991; 37: 9-13.\nRuiz-Argüelles GJ, González-Estrada S, Garcés-Eisele J, Ruiz-Argüelles A. Primary thrombophilia in Mexico: A\nprospective study. Am J Hematol. 1999; 60: 1-5.\nRuiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, Ramírez-Cisneros F. Primary thrombophilia in Mexico II: Fac-\ntor V G1691A (Leiden), prothrombin G20210A and methylenetetrahydrofolate reductase C677T polymorphism\nin thrombophilic Mexican Mestizos. Am J Hematol. 2001; 66: 28-31.\nRuiz-Argüelles GJ, López-Martínez B, Cruz-Cruz D, Reyes-Aulis MB. Primary thrombophilia in México III: A\nprospective study of the sticky platelet syndrome. Clin Appl ¶romb Hemost. 2002; 8: 273-7.\nRuiz-Argüelles GJ, González-Carrillo ML, Reyes-Núñez V, Garcés-Eisele J, Estrada-Gómez R, Valdés-Tapia P, et\nal. Trombofilia primaria en México, parte VI: Falta de asociación estadística entre las condiciones trombofílicas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":362,"lines":{"from":58,"to":68}}}}],["1829",{"pageContent":"al. Trombofilia primaria en México, parte VI: Falta de asociación estadística entre las condiciones trombofílicas\nheredadas. Gac Méd Méx. 2007; 143: 317-22.\nRuiz-Argüelles GJ, Alarcón-Urdaneta C, Calderón-García J, Ruiz-Delgado GJ. Primary thrombophilia in México\nVIII: Description of five kindreds of familial sticky platelet syndrome phenotype. Rev Hematol Méx. 2011;\n12: 73-8.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":362,"lines":{"from":68,"to":72}}}}],["1830",{"pageContent":"336\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":363,"lines":{"from":1,"to":3}}}}],["1831",{"pageContent":"Ruiz-Argüelles GJ, Garcés-Eisele J, Camacho-Alarcón C, Reyes-Núñez V, Moncada-González B, Valdés-Tapia P,\net al. Primary thrombophilia in Mexico IX: ¶e glycoprotein IIIa PLA1/A2 polymorphism is not associated with\nthe sticky platelet syndrome phenotype. Clin Appl ¶romb Hemost. 2012. [Epub ahead of print].\nRuiz-Argüelles GJ, Ruiz-Argüelles A. Síndrome anti-fosfolípido. En: López-Borrasca A, ed. Enciclopedia de He-\nmatología Iberoamericana. Salamanca: Ediciones Universidad de Salamanca; 1992. p. 191-195.\nRuiz-Argüelles GJ. Resistencia a la proteína C activada como causa de trombofilia. Rev Invest Clin (Méx). 1996; 48:\n223-229.\nRuiz-Argüelles GJ, Ruiz-Delgado GJ, López-Martínez B. El “síndrome de las plaquetas pegajosas”: Una causa fre-\ncuente pero ignorada de trombofilia. Rev Invest Clín (Méx). 2002; 54: 394-396.\nRuiz-Argüelles GJ, Poblete-Naredo I, Reyes-Núñez V, Garcés-Eisele J, López-Martínez B, Gómez-Rangel D. Pri -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":363,"lines":{"from":5,"to":14}}}}],["1832",{"pageContent":"cuente pero ignorada de trombofilia. Rev Invest Clín (Méx). 2002; 54: 394-396.\nRuiz-Argüelles GJ, Poblete-Naredo I, Reyes-Núñez V, Garcés-Eisele J, López-Martínez B, Gómez-Rangel D. Pri -\nmary thrombophilia in México IV: Leiden, Cambridge, Hong Kong, Liverpool and HR2 haplotype polymor-\nphisms in the factor V gene of a group of thrombophilic Mexican Mestizos. Rev Invest Clín (Méx). 2004; 56:\n600-604.\nRuiz-Argüelles GJ, López-Martínez B, Valdés-Tapia P, Gómez-Rangel JD, Reyes-Núñez V, Garcés-Eisele J. Pri-\nmary thrombophilia in México V: A comprehensive prospective study indicates that most cases are multifactorial.\nAm J Hematol. 2005; 78: 21-26.S.\nVelázquez-Sánchez-de-Cima S, Zamora-Ortiz G, Hernández-Reyes J, Vargas-Espinosa J, García-Chávez J, Rosa-\nles-Padrón J, et al. Primary thrombophilia in Mexico X: A prospective study of the treatment of the sticky platelet\nsyndrome. Clin Appl ¶romb Hemost. 2013; 19: 107-121.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":363,"lines":{"from":14,"to":24}}}}],["1833",{"pageContent":"RESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\n1.\n \nc\n2.\n \nc\n3.\n \nb\n4.\n \na\n5.\n \nc","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":363,"lines":{"from":26,"to":42}}}}],["1834",{"pageContent":"PARTE 5\nAspectos\nterapéuticos\n\n22\n\nTerapéu\nT\nica\n \nT\nransfusional\n\n23\n\nTrasplan\nT\ne de células hema\nT\nopoyé\nT\nicas\n\n341\n361","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":366,"lines":{"from":1,"to":25}}}}],["1835",{"pageContent":"341\n\nINTRODUCCIÓN\n\nLa terapéutica transfusional moderna debe orientarse a proporcionar los elementos sanguíneos ce-\nlulares o plasmáticos, o ambos, que el enfermo requiere. Se trata de un tratamiento transitorio o no\ndefinitivo y debe considerarse como un trasplante de tejido de vida corta y autolimitada. Puede ser\nde gran valor para mantener o salvar una vida y para permitir un tratamiento definitivo eficaz, pero\nsu uso puede condicionar también efectos adversos, por lo que su indicación debe considerarse muy\ncuidadosamente en función de la relación riesgo-beneficio. El contar con equipos de plástico estériles\ndesechables y con anticoagulantes y conservadores adecuados para la obtención, fraccionamiento y\nconservación de la sangre ha hecho posible separar sus diferentes componentes, cuyo uso ha permitido\nel desarrollo de modalidades terapéuticas tanto médicas como quirúrgicas en prácticamente todas las\náreas de la medicina, que de otra manera no serían posibles\n \n(fig. 22-1)\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":368,"lines":{"from":1,"to":17}}}}],["1836",{"pageContent":"SANGRE TOTAL","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":368,"lines":{"from":19,"to":19}}}}],["1837",{"pageContent":"La sangre total es aquella que se colecta de un solo donador, en una bolsa de 500 mL, diluida en pro-\nporción de 1 a 8 con anticoagulantes o conservadores (citrato de sodio, fosfato, dextrosa y adenina), que\ndebe contener 450 mL ± 10% excluyendo el anticoagulante. Hace aproximadamente 30 años, la sangre\ntotal era prácticamente el único producto transfundido, pero en la actualidad su uso está limitado a los\nprocedimientos de exanguinotransfusión, sobre todo en neonatos y algunos casos de sangrado agudo\nprofuso, aunque en estos últimos la transfusión de eritrocitos empaquetados es igualmente eficaz y\nmenos riesgosa. En estas condiciones, la volemia puede mantenerse más oportuna y rápidamente con\nsoluciones cristaloides o coloides. En la actualidad, la transfusión de sangre total como único recurso\nterapéutico constituye una conducta errónea y debe evitarse. Definitivamente está contraindicada\nen los casos de anemia crónica, en los cuales el volumen de eritrocitos se halla disminuido pero el","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":368,"lines":{"from":21,"to":30}}}}],["1838",{"pageContent":"terapéutico constituye una conducta errónea y debe evitarse. Definitivamente está contraindicada\nen los casos de anemia crónica, en los cuales el volumen de eritrocitos se halla disminuido pero el\nvolumen plasmático se encuentra aumentado en forma compensatoria. El enfermo en este caso no","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":368,"lines":{"from":30,"to":32}}}}],["1839",{"pageContent":"CAPÍTULO 22\n\nTERAPÉUTICA\nTRANSFUSIONAL\n\nAbel Lomelí Guerrero\nMiguel Velázquez Ferrari\n\nObjetivos de aprendizaje\n\n•\n \nComprender los conceptos de\n \nsangre total\n,\n \nconcentrado eritrocitario\n,\n \nplasma\n \ny\n \nplasma fresco congelado\n.\n\n•\n \nConocer las indicaciones de la transfusión de eritrocitos y de plaquetas.\n\n•\n \nSeñalar los principales efectos adversos de las transfusiones.\n\n•\n \nConocer el estado actual de las enfermedades transmisibles por transfusión.\n\nLa terapéutica transfusional\nmoderna\n \ndebe\n \norientarse\n \na\nproporcionar\n \nlos\n \nelementos\nsanguíneos celulares o plas-\nmáticos, o ambos, que el en-\nfermo requiere. Se trata de un\ntratamiento transitorio o no\ndefinitivo y debe considerarse\ncomo un trasplante de tejido\nde vida corta y autolimitada.\nEn la actualidad, la transfu-\nsión de sangre total como único\nrecurso terapéutico constituye\nuna conducta errónea y debe\nevitarse.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":368,"lines":{"from":34,"to":97}}}}],["1840",{"pageContent":"342\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nnecesita plasma y puede desarrollar fácilmente insuficiencia cardíaca. Esto es aún más frecuente en niños,\nancianos y cuando existe daño renal o cardíaco previo. En un adulto de 70 kg de peso, la transfusión de 1 U\nde sangre total produce un incremento de aproximadamente 1 a 1,5 g/dL en la hemoglobina (Hb) y de 3\na 5% de hematocrito (Htc); este se hace evidente 48 a 72 horas después de la transfusión, una vez que el\nvolumen sanguíneo se reajusta a lo normal. Este aumento es ligeramente mayor o menor cuanto menor o\nmayor sean el peso y el volumen circulante del receptor.\n\nCONCENTRADO ERITROCITARIO","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":369,"lines":{"from":1,"to":12}}}}],["1841",{"pageContent":"El paquete globular tiene un volumen aproximado de 250 a 300 mL y contiene todos los eritrocitos de 1 U\nde sangre pero solo una pequeña fracción de plasma (Htc de 65 a 75%), así como plaquetas y leucocitos en\npequeña cantidad y no funcionales. Debe tener hemólisis mínima menor de 0,8% de la masa eritrocítica,\nmantenerse en refrigeración a 4 °C y no permanecer fuera del refrigerador más de 6 horas; casi nunca requie-\nre calentamiento para ser transfundido y esto no debe hacerse si no es en un incubador específico a 37 °C.\nLa transfusión de paquete globular está indicada para incrementar la masa eritrocítica en un paciente\nen quien se requiera aumentar su capacidad de transporte de oxígeno por síndrome anémico y que no se\nespera que responda pronto a otra terapéutica específica. Este tipo de transfusión está contraindicada si el\npaciente no tiene manifestaciones clínicas o síndrome anémico (anemia compensada), como en algunos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":369,"lines":{"from":14,"to":22}}}}],["1842",{"pageContent":"paciente no tiene manifestaciones clínicas o síndrome anémico (anemia compensada), como en algunos\ncasos de anemia por insuficiencia renal crónica, así como en anemia carencial por deficiencia de hierro,\nácido fólico o vitamina B12, a menos de que haya datos de descompensación o exista urgencia para au-\nmentar la capacidad de transporte de O\n2\n \n, como ocurre en urgencias quirúrgicas y el parto inminente.\nNo hay una cifra o nivel “crítico” de Hb o Htc que indique la necesidad de transfundir eritrocitos;\nesta dependerá siempre de la condición clínica de cada enfermo en particular. Por muchos años se esta -\nbleció en cirugía la cifra de 10 g/dL de Hb como mínimo para llevar a cabo una intervención electiva,\nconcepto que ha cambiado gracias a la información y difusión entre los cirujanos y anestesiólogos,\ndonde se sabe que un sujeto con 8,5 g/dL de Hb y 27% de Htc bien manejado durante la cirugía puede\nmantener un transporte óptimo de O\n \n2","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":369,"lines":{"from":22,"to":36}}}}],["1843",{"pageContent":"donde se sabe que un sujeto con 8,5 g/dL de Hb y 27% de Htc bien manejado durante la cirugía puede\nmantener un transporte óptimo de O\n \n2\n \na los tejidos y presentar menos complicaciones posoperatorias.\nLos pacientes con insuficiencia renal crónica pueden tolerar perfectamente cifras de 7 g/dL de Hb.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":369,"lines":{"from":36,"to":42}}}}],["1844",{"pageContent":"PLASMA\n\nUna unidad de plasma tiene un volumen aproximado de 200 a 250 mL. Si es separado y congelado a –30 °C\ndentro de las 6 horas siguientes a la obtención de la sangre, el plasma conserva la actividad de todos los\nfactores de la coagulación, y si se mantiene a esta temperatura, posee una vigencia de hasta un año. Al des\n-\ncongelarse el plasma, debe transfundirse de inmediato [plasma fresco congelado (PFC)]; si el plasma no se\n\nFigura 22-1.\n \nPosibilidades de fraccionamiento de la sangre total.\n\nPor muchos años se ha estable-\ncido en cirugía la cifra de 10 g/\ndL de Hb como mínimo para\nllevar a cabo una intervención\nelectiva; sin embargo, ahora se\nsabe que un sujeto con 8,5 g/dL\nde Hb y 27% de Htc bien ma-\nnejado durante la cirugía puede\nmantener un transporte óptimo\nde O2 a los tejidos y presentar\nmenos\n \ncomplicaciones\n \nposope-\nratorias.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":369,"lines":{"from":44,"to":71}}}}],["1845",{"pageContent":"343\n\nCAPÍTULO 22. TERAPÉUTICA TRANSFUSIONAL\n\ncongela y se conserva en refrigeración, los factores lábiles de la coagulación (V y VIII) pierden su actividad\nprocoagulante y, por lo tanto, no es útil para el tratamiento de enfermos con deficiencia de estos factores\n(plasma de banco o refrigerado). Puede usarse en algunas otras deficiencias, especialmente de factor IX\n(FIX) o hemofilia B; sin embargo, en casos de sangrado mayor o en procedimientos quirúrgicos en sujetos\ndeficientes de FIX, los requerimientos pueden no ser alcanzados sin sobrecargar de volumen al paciente. El\nplasma refrigerado (plasma de banco, plasma envejecido) no se debe usar como fuente de proteína (albúmina)\npara aumentar el poder coloidosmótico del plasma o como expansor del volumen plasmático si se dispone de\nalbúmina liofilizada o en solución. Estas unidades de plasma puedan usarse para procesamiento industrial y\nla obtención de concentrado de factores, al igual que el plasma fresco congelado.\n\nPLASMA FRESCO CONGELADO","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":370,"lines":{"from":1,"to":15}}}}],["1846",{"pageContent":"Como se mencionó antes, si el plasma se separa inmediatamente después de la recolección de sangre por\ncentrifugación en frío y se congela enseguida, conserva la actividad prácticamente íntegra de todos los fac-\ntores de coagulación. Su uso está indicado en el tratamiento de sangrado secundario a deficiencias de cual-\nquiera de los factores de coagulación, si no se dispone de concentrados específicos del factor deficiente.\nUna\n \nunidad de actividad\n \nde cualquier factor de la coagulación se define como la actividad procoagulan-\nte de este factor contenida en 1 mL de plasma normal o de una mezcla de plasmas normales. Habitual-\nmente se requiere menos del 50% de actividad de cualquier factor para lograr una hemostasia adecuada; en\nel plasma fresco o fresco congelado, la actividad de cada uno de los factores varía entre 0,7 y 1 U/mL, por\nlo que se requiere de poco menos de la mitad del volumen plasmático del enfermo para corregir el defecto","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":370,"lines":{"from":17,"to":29}}}}],["1847",{"pageContent":"lo que se requiere de poco menos de la mitad del volumen plasmático del enfermo para corregir el defecto\nhemostático, una práctica no desprovista de riesgos de hipervolemia, por lo que es mejor la utilización del\nfactor concentrado específico deficiente. En sangrados mayores, heridas o intervenciones quirúrgicas, se\nnecesitan transfusiones repetidas hasta lograr la cicatrización; por ejemplo, el FIX tiene una vida media\nde 18 a 24 horas, por lo que se requieren transfusiones diarias.\nEl PFC está indicado también en la deficiencia de múltiples factores, como en insuficiencia hepática,\nsíndrome de desfibrinación o CID, sangrados por deficiencia de vitamina K no detectada, toxicidad por\ncumarínicos o durante la reposición masiva de sangre (transfusión masiva). El PFC tiene las mismas contra\n-\nindicaciones y riesgos que el plasma de banco. Actualmente existe plasma fresco congelado con grupo san\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":370,"lines":{"from":29,"to":39}}}}],["1848",{"pageContent":"-\nindicaciones y riesgos que el plasma de banco. Actualmente existe plasma fresco congelado con grupo san\n-\nguíneo específico obtenido de mezclas de grandes volúmenes de plasma de donadores con inactivación viral\npor el método solvente detergente con tritón 100 y posterior nanofiltración, lo que disminuye la posibilidad\nde transmisión de enfermedades infecciosas virales, aunque no está del todo exento de reacciones adversas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":370,"lines":{"from":39,"to":44}}}}],["1849",{"pageContent":"CONCENTRADO DE FACTOR IX\n\nEn realidad el concentrado de FIX contiene todo el “complejo protrombínico”, factores II, VII, IX y X, y\nse obtiene de mezclas de plasmas, fraccionado y liofilizado. Aun cuando estos factores son relativamente\nestables y su reposición se puede lograr habitualmente con el plasma de banco, hace necesario el uso del\nconcentrado liofilizado en casos especiales.\nActualmente existen concentrados de complejo protrombínico que tienen concentraciones terapéuticas\nde proteína C y proteína S de la coagulación. Ello disminuye el riesgo de trombosis y es útil para revertir el\nsangrado por sobredosis de anticoagulantes orales antagonistas de la vitamina K. La dosis es de 25 a 50 uni\n-\ndades por kg de peso corporal y su efecto se manifiesta a los 10 minutos posteriores a su aplicación. También\nes tratado con técnica solvente detergente para disminuir la posibilidad de transmisión de infecciones virales.\n\nCRIOPRECIPITADO Y CONCENTRADO DE FACTOR VIII","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":370,"lines":{"from":46,"to":59}}}}],["1850",{"pageContent":"Los crioprecipitados se obtienen por congelación del plasma fresco, con menos de 6 horas de extraído y\ndescongelación lenta entre 1 y 6 °C, o bien usando un horno de microondas especial para este propósito.\nEl crioprecipitado contiene de 80 a 100 U de factor VIII, aproximadamente 250 mg de fibrinógeno, 30%\nde actividad plasmática del factor XIII, 40 a 70% de factor de von Willebrand y fibronectina. La principal\nutilidad del crioprecipitado es en el tratamiento de pacientes con hemofilia A y en deficiencias de los otros\nfactores contenidos en él. Puede ser preparado en cualquier banco de sangre que cuente con centrífuga\nrefrigerada, y su costo de producción es bajo. No es fácil de transportar ni de reconstituir, por lo que\nno es recomendable para el tratamiento domiciliario de los hemofílicos. Mediante un sistema adecuado\n(flujo laminar), puede prepararse en una sola bolsa el contenido de varios crioprecipitados individuales,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":370,"lines":{"from":61,"to":69}}}}],["1851",{"pageContent":"(flujo laminar), puede prepararse en una sola bolsa el contenido de varios crioprecipitados individuales,\nfacilitando así su administración posterior. Debe conservarse en congelación a -30 °C hasta 36 meses. Los","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":370,"lines":{"from":69,"to":70}}}}],["1852",{"pageContent":"Si\n \nel\n \nplasma\n \nse\n \nsepara\n \nin-\nmediatamente\n \ndespués\n \nde\n \nla\nrecolección de sangre por centri-\nfugación en frío y se congela en-\nseguida, conserva la actividad\nprácticamente íntegra de todos\nlos factores de coagulación.\nEl crioprecipitado contiene de\n80 a 100 U de factor VIII,\naproximadamente 250 mg de\nfibrinógeno, 30% de actividad\nplasmática del factor XIII, 40\na 70% de factor de von Wille-\nbrand y fibronectina.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":370,"lines":{"from":72,"to":101}}}}],["1853",{"pageContent":"344\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":371,"lines":{"from":1,"to":3}}}}],["1854",{"pageContent":"crioprecipitados deben descongelarse a 37 °C antes de su aplicación y transfundirse en cuanto sea posible,\ndentro de las siguientes 4 a 6 horas. La vida media del factor VIII transfundido es de 8 a 12 horas, por lo\nque deben repetirse las aplicaciones para mantener un nivel hemostático adecuado.\nOtras presentaciones disponibles de factor VIII son los concentrados comerciales obtenidos por fracciona\n-\nmiento del plasma, utilizando precipitación con polietilenglicol, filtrados para remover proteínas contaminantes\npurificados mediante cromatografía y anticuerpos monoclonales y sometidos a un proceso de inactivación viral,\nya sea por pasteurización o tratamiento con solvente detergente, o ambos. Posteriormente se liofilizan y su\nactividad coagulante se expresa en unidades de factor VIII en la etiqueta de cada frasco. Existen concentrados\nde pureza intermedia y de alta pureza que dependen del porcentaje de proteína que corresponda al factor VIII.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":371,"lines":{"from":5,"to":14}}}}],["1855",{"pageContent":"de pureza intermedia y de alta pureza que dependen del porcentaje de proteína que corresponda al factor VIII.\nExiste factor VIII obtenido por medio de tecnología recombinante, que codifica la secuencia de 2 351\naminoácidos semejante al factor VIII humano. Este producto ha sido empleado en ensayos clínicos con bue-\nnos resultados y no transmite enfermedades virales. Sin embargo, se ha informado la existencia de pacientes\nque han desarrollado inhibidores de factor VIII, como sucede con los concentrados derivados de plasma.\nUna fórmula para calcular la dosis de factor VIII necesario se obtiene multiplicando el volumen plas-\nmático por el porcentaje de factor VIII a elevar:","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":371,"lines":{"from":14,"to":20}}}}],["1856",{"pageContent":"UR =\n \nVP (mL) × (% nivel deseado – % nivel actual)\n100\n\nEn donde:\n\nUR\n \n= unidades de factor VIII requeridas\n\nVP\n \n= volumen plasmático estimado (peso en kilogramos × 40)\nPor ejemplo, para elevar a 50% el nivel de factor VIII en un varón de 70 kg, con un hematocrito de\n40% y un nivel de factor VIII de 0%, aplicando la fórmula se tiene: VP: 70 × 40 = 2 800 mL × (50 – 0%)\n= 140 000/100 = 1 400 U. Si se divide esta cantidad entre las 100 U que contiene cada bolsa de criopreci-\npitado, será igual a 14 bolsas que han de administrarse a ese paciente. Esa dosis elevará a 50% el nivel de\nfactor VIII inmediatamente después de la transfusión. Esta fórmula puede ser aplicada para calcular la\ndosis de cualquier otro factor que sea necesario administrar.\n\nTRANSFUSIÓN DE PLAQUETAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":371,"lines":{"from":22,"to":43}}}}],["1857",{"pageContent":"TRANSFUSIÓN DE PLAQUETAS\n\nEl empleo de plaquetas es una práctica que se ha incrementado en el curso de los últimos años y que ha\ncontribuido notablemente al tratamiento de los pacientes oncohematológicos; esto se debe a la mayor dispo-\nnibilidad de concentrados plaquetarios de varios donadores o de plaquetas obtenidas de un solo donador por\nmedio de un procedimiento de separación con una máquina de flujo continuo o intermitente (aféresis). No\nhay discusión sobre la indicación de transfundir plaquetas en un paciente con sangrado activo por tromboci-\ntopenia o trombocitopatía (hereditaria o secundaria al uso terapéutico de antiagregantes plaquetarios); el uso\nprofiláctico de plaquetas en pacientes hospitalizados se menciona en el siguiente apartado.\n\nIndicaciones para la transfusión de plaquetas\nTrombocitopenia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":371,"lines":{"from":43,"to":54}}}}],["1858",{"pageContent":"Se aplica en pacientes con insuficiente producción de plaquetas, ya sea por padecimientos que afecten la\nmédula ósea, terapéutica citotóxica o irradiación. Las manifestaciones de sangrado espontáneo rara vez\nocurren en individuos con cuentas mayores de 20 × 10\n9\n/L (20 000 por mL), a no ser que existan factores\nque incrementen la utilización de las plaquetas, como fiebre, sepsis, coagulación intravascular, o causas que\nalteren el funcionamiento plaquetario, como ingestión de\n \nmedicamentos, insuficiencia renal, etcétera. Se\nrecomienda que el paciente sea valorado considerando aspectos clínicos más que cifras de laboratorio. Los\nsujetos sin fiebre ni sangrado pueden tolerar cifras de 10 × 10\n \n9\n/L, como los enfermos con anemia aplásica o\nmielodisplasias; sin embargo, en individuos con epistaxis u otra manifestación de sangrado mucocutáneo,\npor otra vía, o fiebre, la transfusión de plaquetas deberá realizarse aun con cifras mayores de 20 o 30 × 10\n9\n/L,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":371,"lines":{"from":56,"to":73}}}}],["1859",{"pageContent":"por otra vía, o fiebre, la transfusión de plaquetas deberá realizarse aun con cifras mayores de 20 o 30 × 10\n9\n/L,\ny si se presenta un fenómeno quirúrgico, se recomienda que la cifra sea mayor (70 a 80 × 10\n9\n \n/L).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":371,"lines":{"from":73,"to":79}}}}],["1860",{"pageContent":"Los crioprecipitados deben des-\ncongelarse a 37 °C antes de su\naplicación y transfundirse en\ncuanto sea posible, dentro de\nlas siguientes 4 a 6 horas. La\nvida\n \nmedia\n \ndel\n \nfactor\n \nVIII\ntransfundido es de 8 a 12 ho-\nras, por lo que deben repetirse\nlas aplicaciones para mantener\nun nivel hemostático adecuado.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":371,"lines":{"from":81,"to":98}}}}],["1861",{"pageContent":"345\n\nCAPÍTULO 22. TERAPÉUTICA TRANSFUSIONAL\n\nDefectos funcionales plaquetarios\n\nLos pacientes con tromboastenia de Glanzmann o síndrome de Bernard-Soulier, y trombocitopatía por\nanalgésicos o antiagregantes plaquetarios, como aspirina, clopidogrel y análogos, requerirán de transfu-\nsión de plaquetas si son sometidos a intervención quirúrgica o en caso de sangrado espontáneo. En casos\nde cirugía cardíaca, las plaquetas se dañan funcionalmente en los filtros de la máquina de circulación\nextracorpórea; si el paciente sangra por una causa que no pueda ser corregida quirúrgicamente, quizá\nrequiera plaquetas. El uso profiláctico rutinario no está indicado ni justificado.\n\nTrombocitopenia inmunitaria","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":372,"lines":{"from":1,"to":14}}}}],["1862",{"pageContent":"Trombocitopenia inmunitaria\n\nComo la causa es la presencia de anticuerpos dirigidos contra las plaquetas, la supervivencia plaquetaria\nse ve acortada y la transfusión debe limitarse a pacientes con hemorragias graves; el número de concen -\ntrados plaquetarios necesarios puede ser alto. Otros padecimientos que pueden requerir transfusiones\nde plaquetas son: coagulación intravascular diseminada, donde además puede ser necesario plasma\ncon factores de coagulación; y trombocitopenia dilucional en transfusiones masivas, donde la cuenta\nplaquetaria debe mantenerse por arriba de 50 × 10\n \n9\n \n/L. Esta cifra se recomienda también en enfermos\nen quienes se realice biopsia hepática, punción lumbar, instalación de catéteres intravenosos, etcétera.\nSi la intervención quirúrgica se efectúa en sistema nervioso o globo ocular, la cifra debe ser mayor de\n100 000 U/L.\n\nOtros aspectos importantes en la transfusión de plaquetas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":372,"lines":{"from":14,"to":30}}}}],["1863",{"pageContent":"Cada unidad de plaquetas obtenida de sangre fresca por centrifugación contiene aproximadamente\n6 × 10\n10\n \nplaquetas en un volumen de 40 a 60 mL de plasma. Deben almacenarse a 22 ± 2 °C en agitación\ncontinua suave y así conservan su viabilidad hasta por 72 horas en sistemas plásticos con anticoagu -\nlantes habituales ACD, CPD, CPD-A. Si se utilizan sistemas de plástico especiales que permitan\nun mejor intercambio gaseoso, pueden almacenarse hasta por 5 días y hasta por 7 días si se emplean\nsistemas de reducción bacteriana y detección de contaminación bacteriana. Las plaquetas obtenidas por\nprocedimientos de aféresis de un solo donador deben contener por lo menos 2 × 10\n \n11\n \nplaquetas en un\nvolumen de 200 mL de plasma.\nLas transfusiones se deben realizar con plaquetas del mismo grupo ABO, pero en caso de urgencia\npueden emplearse de cualquier grupo cuidando la hemólisis por anticuerpos anti-A o anti-B con título","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":372,"lines":{"from":32,"to":48}}}}],["1864",{"pageContent":"Las transfusiones se deben realizar con plaquetas del mismo grupo ABO, pero en caso de urgencia\npueden emplearse de cualquier grupo cuidando la hemólisis por anticuerpos anti-A o anti-B con título\nalto, sobre todo si se usan plaquetas de donadores de tipo O obtenidas por aféresis. Si el receptor es una\nmujer Rh negativo (D negativo) y recibe plaquetas D positivas (Rh positivas), es conveniente administrar\n300 mg de inmunoglobulina anti-D por cada seis concentrados plaquetarios transfundidos.\nLas plaquetas contienen antígenos del sistema de antígenos antileucocitarios humanos (HLA) y\nantígenos propios (antígenos plaquetarios humanos HPA 1 a 5 y otros más), por lo que los pacientes\nsometidos a transfusión repetida pueden desarrollar anticuerpos contra estos antígenos (HLA, HPA);\nde aparecer falta de respuesta a la transfusión de plaquetas (refractariedad), deben aplicarse aquellas de\ndonadores compatibles en los antígenos de clase 1 HLA-A y B, o bien realizarse pruebas de compa -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":372,"lines":{"from":48,"to":57}}}}],["1865",{"pageContent":"donadores compatibles en los antígenos de clase 1 HLA-A y B, o bien realizarse pruebas de compa -\ntibilidad para plaquetas entre receptor y donador o varios donadores. Lo anterior en ocasiones resulta\ndifícil de llevar a cabo, por lo que en pacientes aloinmunizados o sensibilizados el manejo se vuelve\nproblemático. En caso de sangrado, administrar plaquetas de donadores incluso incompatibles, aunque\npueden requerirse grandes cantidades de concentrados para controlar el sangrado.\nHay varias formas de calcular el número de plaquetas necesarias. Una práctica útil es calcular 1 U de\nplaquetas por cada 10 kg de peso. Las plaquetas deben transfundirse con un filtro para remover leucocitos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":372,"lines":{"from":57,"to":63}}}}],["1866",{"pageContent":"TRANSFUSIÓN DE GRANULOCITOS\n\nLa utilidad principal está en pacientes con neutropenia intensa y un proceso infeccioso, en los que, a\npesar del uso de antimicrobianos, la morbilidad o mortalidad por neutropenia es alta. La indicación\nes neutropenia menor de 500 neutrófilos/mL con sospecha de infección confirmada y en la que no ha\nhabido respuesta satisfactoria a antimicrobianos en pacientes con probabilidad de recuperación de la\nmedula ósea. Estudios en adultos han mostrado aumento de la supervivencia en pacientes neutropéni -\ncos tratados con antibióticos más leucocitos en relación con un grupo control; la utilidad ha sido más\nevidente en recién nacidos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":372,"lines":{"from":65,"to":73}}}}],["1867",{"pageContent":"346\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nProcedimientos de obtención","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":373,"lines":{"from":1,"to":5}}}}],["1868",{"pageContent":"Los granulocitos de 1 U de sangre son insuficientes y poco útiles; deben usarse procedimientos de aféresis con\nun separador celular de flujo continuo o intermitente que en el lapso de 2 o 3 horas permitan obtener suficien\n-\ntes granulocitos, del orden de 10\n10\n \ncélulas. Los granulocitos deben utilizarse lo más pronto posible después de\nsu extracción, pero pueden ser viables si se conservan sin agitar a 22 °C hasta por 8 a 24 horas. Los mejores\nparámetros para valorar la eficacia de la transfusión de granulocitos son los datos clínicos y la negativización\nde los cultivos, más que un incremento en la cifra. Resulta deseable la tipificación de histocompatibilidad\nentre donador y receptor, pero no es necesario cuando el paciente no ha sido previamente transfundido.\nCon la aparición de los factores estimulantes de colonias de granulocitos (G-CSF) o de granulocitos y\nmonocitos (GM-CSF) que estimulan la granulopoyesis, la transfusión de granulocitos se usará cada vez","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":373,"lines":{"from":7,"to":19}}}}],["1869",{"pageContent":"monocitos (GM-CSF) que estimulan la granulopoyesis, la transfusión de granulocitos se usará cada vez\nmenos. Las complicaciones frecuentes comprenden escalofríos y fiebre, que se presentan en el 20 y 40% de\nlos casos, sobre todo si se han obtenido por filtración, e insuficiencia respiratoria por atrapamiento de estas\ncélulas en el parénquima pulmonar (daño pulmonar agudo asociado con transfusión). Recientemente, en\npacientes con leucemia mieloide crónica y otras formas de leucemia aguda que han sido trasplantados\ncon células progenitoras hematopoyéticas, se ha empleado la linfocitoféresis para recolección de células\nmononucleares del donador e infusión de estas en el enfermo para reducir la posibilidad de recurrencia\nde la enfermedad, tratando de lograr un efecto de injerto de las células mononucleares contra leucemia; el\nprocedimiento de recolección se hace con una máquina de aféresis.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":373,"lines":{"from":19,"to":27}}}}],["1870",{"pageContent":"TRANSFUSIÓN DE ALBÚMINA\n\nLa albúmina es la proteína más abundante en el plasma; tiene un peso molecular de 67 000 Da. Se sabe que\nsolo el 40% de la albúmina corporal es intravascular. Se obtiene de sangre, plasma, suero o placentas huma-\nnas; en los concentrados comerciales la cantidad de proteína es de 96% y se presenta en solución al 25% y al\n50%; cada volumen utilizado incrementa 3,5 veces la volemia dentro de los siguientes 15 min a su aplicación;\nsus principales indicaciones están dadas en pacientes hipovolémicos sin pérdida de sangre, traumatismos,\ninfecciones, intervenciones quirúrgicas o quemaduras, en las cuales es particularmente útil porque ayuda\na mantener el volumen plasmático y el contenido proteico. La albúmina es usada frecuentemente en la en-\nfermedad hemolítica del recién nacido y como fuente de reemplazo de proteínas en casos de plasmaféresis.\n\nGENERALIDADES DE LA AFÉRESIS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":373,"lines":{"from":29,"to":40}}}}],["1871",{"pageContent":"Aféresis\n \nse refiere al proceso de retirar selectivamente uno de los componentes de la sangre total y retornar\nel resto al donador o paciente; la sangre se recolecta por un acceso venoso, se mezcla con un anticoagulante\ny se procesa por medio de una máquina, en la cual por centrifugación, de acuerdo a su diferencia de peso\n(gravedad específica), se separa en eritrocitos, plasma y un componente de leucocitos y plaquetas.\nExisten dos modalidades de aféresis: la primera es la obtención de componentes de la sangre de dona-\ndores normales sanos para su empleo en pacientes, y la segunda es terapéutica, para tratar padecimientos\nen los que se desea extraer uno de los componentes, ya sea celular (citoféresis) o plasmático (recambio\nplasmático), que sea responsable de los síntomas del enfermo y permita mejorar su condición clínica.\nLas máquinas utilizadas emplean el método de centrifugación para separación y pueden ser de flujo in\n-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":373,"lines":{"from":42,"to":53}}}}],["1872",{"pageContent":"Las máquinas utilizadas emplean el método de centrifugación para separación y pueden ser de flujo in\n-\ntermitente o de flujo continuo; en las máquinas de flujo intermitente la sangre del donador sale a través de\nuna punción venosa, se mezcla con un anticoagulante [ácido cítrico-citrato-dextrosa (ACD)] y, a través de un\nsistema propulsor, es bombeada hacia una cámara de concentración, separando la sangre en sus componentes,\npudiendo ser específicamente seleccionados hacia bolsas plásticas. Las máquinas actuales son automáticas y\nestán provistas de sensores ópticos que detectan las células en interfase y evitan la contaminación de leucocitos\ny eritrocitos. Los sensores además señalan el tiempo de duración del\n \nprocedimiento, el volumen sanguíneo\nprocesado y la cuenta cuando se trata de cosecha plaquetaria.\nPuede manejarse con un solo acceso venoso (procedimiento de un brazo), en el que la sangre sale y","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":373,"lines":{"from":53,"to":64}}}}],["1873",{"pageContent":"procedimiento, el volumen sanguíneo\nprocesado y la cuenta cuando se trata de cosecha plaquetaria.\nPuede manejarse con un solo acceso venoso (procedimiento de un brazo), en el que la sangre sale y\nregresa por la misma vena, o pueden emplearse los dos brazos, uno de salida y el otro de retorno, lo que\nreduce el tiempo del procedimiento.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":373,"lines":{"from":64,"to":68}}}}],["1874",{"pageContent":"Plaquetoféresis para obtención de concentrado plaquetario de donador único\n\nEs el procedimiento de aféresis más realizado. Para la recolección de componentes debe contener por lo\nmenos 2 × 10\n11\n \nplaquetas/L; se obtiene por procesamiento de 4 000 a 5 000 mL de sangre del donador en\n\nCon la aparición de los factores\nestimulantes de colonias de gra-\nnulocitos (G-CSF) o de granu-\nlocitos y monocitos (GM-CSF)\nque estimulan la granulopoye-\nsis, la transfusión de granulo-\ncitos se usará cada vez menos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":373,"lines":{"from":70,"to":84}}}}],["1875",{"pageContent":"347\n\nCAPÍTULO 22. TERAPÉUTICA TRANSFUSIONAL\n\nun período aproximado de 90 min. El donador debe ser estudiado de manera semejante que los donadores\nde sangre total. La unidad obtenida contiene aproximadamente 200 mL de plasma con alto contenido de\nplaquetas, y es rotulada con grupo sanguíneo Rh y los exámenes realizados para evitar la transmisión\nde enfermedades. Se puede almacenar hasta por 5 días a 22 ± 2 °C en agitación continua. En el control de ca\n-\nlidad se señala el contenido de leucocitos y eritrocitos y se recomienda transfundir con filtro leucorreductor.\n\nAféresis terapéutica\n\nEl objetivo consiste en retirar células o algún componente plasmático.\n\nCitoféresis","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":374,"lines":{"from":1,"to":16}}}}],["1876",{"pageContent":"Aféresis terapéutica\n\nEl objetivo consiste en retirar células o algún componente plasmático.\n\nCitoféresis\n\nPlaquetoféresis utilizada en pacientes con síntomas relacionados o con riesgo de desarrollar alguna com-\nplicación hemorrágica o trombótica, en enfermedades mieloproliferativas del tipo de la policitemia vera y\ntrombocitosis primaria; puede disminuir hasta la mitad de la cifra inicial de plaquetas y el procedimiento\nse puede repetir hasta lograr el efecto deseado en tanto actúa un tratamiento más específico.\n\nLeucoféresis","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":374,"lines":{"from":16,"to":27}}}}],["1877",{"pageContent":"Leucoféresis\n\nLos padecimientos proliferativos mieloides agudos o crónicos con cifras de leucocitos superiores a\n100 000 mL pueden producir leucostasis en el sistema nervioso central con hemorragia intracraneal o\ntrombosis, insuficiencia pulmonar u oclusión coronaria, por lo que conjuntamente con el tratamiento\nde quimioterapia se debe realizar leucoféresis temprana. La disminución de células puede ser del\norden del 10\n \n11\n \no 10\n \n12\n \n. La cuenta leucocitaria se puede reducir entre un 20 y 80%, dependiendo de la\ncifra inicial. Clínicamente, se puede observar una reducción del tamaño del hígado y del bazo; se\nsuelen requerir uno o dos procedimientos de extracción de leucocitos.\n\nEritrocitoféresis o recambio eritrocitario\n\nSe utiliza mucho menos frecuentemente que los procedimientos anteriores. Las indicaciones incluyen\nprevenir o tratar una crisis de anemia de células falciformes o casos graves de paludismo.\n\nRecambio plasmático","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":374,"lines":{"from":27,"to":50}}}}],["1878",{"pageContent":"Es la forma más común de aféresis terapéutica y puede ser utilizada para extraer anticuerpos (IgG o IgM),\ncomplejos inmunitarios, sustancias tóxicas o mediadores de la inflamación\n \n(cuadro 22-1)\n.\nExisten indicaciones bien definidas y generalmente aceptadas. Es utilizada en las enfermedades neurológi\n-\ncas del tipo de la miastenia gravis y el síndrome de Guillain-Barré, y en parte ha sido desplazada por el uso de\ngammaglobulina intravenosa. Se requiere un acceso venoso central con un catéter del tipo Mahurkar. Se reco\n-\nmienda retirar por lo menos el equivalente a un volumen plasmático (\n¾\n \n40 mL × peso en kg = mL de plasma).\nLa reposición de líquidos se realiza con solución salina con albúmina al 5% y electrolitos, y en algunos\ncasos puede ser necesario plasma fresco congelado para aportar factores de coagulación.\nEs indispensable que el personal médico o técnico cuente con entrenamiento y experiencia, manuales","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":374,"lines":{"from":52,"to":68}}}}],["1879",{"pageContent":"casos puede ser necesario plasma fresco congelado para aportar factores de coagulación.\nEs indispensable que el personal médico o técnico cuente con entrenamiento y experiencia, manuales\nde procedimientos de control de calidad y consentimiento informado con autorización por escrito del\npaciente, ya que los efectos indeseables ocurren hasta en un 12% de los casos y las complicaciones graves\nentre un 0,5 y 2%.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":374,"lines":{"from":68,"to":72}}}}],["1880",{"pageContent":"EFECTOS ADVERSOS DE LAS TRANSFUSIONES\n\nLa sangre es un tejido complejo; el receptor de una transfusión también es un organismo complejo. Desde\neste punto de vista, no sorprende en absoluto que la transfusión de sangre o de cualquier hemocomponente\nconlleve una serie de riesgos y pueda tener complicaciones y efectos adversos en el receptor. Algunas de\nlas complicaciones más conocidas y temidas son las crisis hemolíticas mediadas por anticuerpos por una\ntransfusión incompatible y la transmisión de infecciones, sobre todo virales; en realidad, ambas son hoy\nen día bastante infrecuentes, aunque graves y potencialmente fatales. Existen otras complicaciones que\npueden ser de presentación inmediata o tardía y de gravedad variable. El orden en el que se presentan a\ncontinuación no obedece en forma alguna a su importancia o gravedad\n \n(cuadro 22-2)\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":374,"lines":{"from":74,"to":86}}}}],["1881",{"pageContent":"Algunas de las complicaciones\nmás conocidas y temidas son las\ncrisis hemolíticas mediadas por\nanticuerpos por una transfusión\nincompatible y la trasmisión de\ninfecciones, sobre todo virales; en\nrealidad, ambas son en la actua\n-\nlidad muy infrecuentes, aunque\ngraves y potencialmente fatales.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":374,"lines":{"from":88,"to":97}}}}],["1882",{"pageContent":"348\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nComplicaciones inmunitarias\nNo hemolíticas\nFebriles","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":375,"lines":{"from":1,"to":7}}}}],["1883",{"pageContent":"En un hospital general, estas se presentan en menos del 1% de todas las transfusiones. Esta disminución\nse debe a la leucorreducción, ya que el mecanismo de producción actúa en la presencia de anticuerpos y\nantileucocitos en el receptor dirigido contra la membrana de linfocitos o granulocitos, en algunos pacientes\npolitransfundidos o en mujeres multíparas que han tenido sensibilización y formación de anticuerpos con-\ntra antígenos leucocitarios y plaquetarios. Habitualmente se deben a la presencia de anticuerpos antileuco\n-\ncitos en el receptor, dirigidos contra antígenos de la membrana de linfocitos o granulocitos o contra ambos.\nLa reacción se define como el aumento de por lo menos 1 °C en la temperatura corporal durante o en las si\n-\nguientes 24 horas después de la transfusión, sin otra causa aparente. Con frecuencia va precedida o acompaña\n-\nda de escalofríos, lo cual puede liberar pirógenos de los granulocitos o interleucina 1 de los linfocitos, o ambos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":375,"lines":{"from":9,"to":20}}}}],["1884",{"pageContent":"-\nda de escalofríos, lo cual puede liberar pirógenos de los granulocitos o interleucina 1 de los linfocitos, o ambos\nfenómenos. El cuadro febril no complicado no amerita suspender la transfusión y cede con la administración\nde antipiréticos, antihistamínicos o hidrocortisona. El servicio de medicina transfusional debe ser informado\ny realizar el protocolo de estudio correspondiente. Como esta reacción puede ser producida también por una\nhemólisis intravascular, se debe tener una vigilancia estrecha para eliminar esta posibilidad. Otras causas\nde fiebre por transfusión mucho menos frecuentes son la contaminación por bacterias por el uso de sistemas\nestériles cerrados para la extracción, fraccionamiento y conservación de la sangre y hemocomponentes.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":375,"lines":{"from":20,"to":27}}}}],["1885",{"pageContent":"Alérgicas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":375,"lines":{"from":29,"to":29}}}}],["1886",{"pageContent":"Las complicaciones alérgicas son relativamente frecuentes, se presentan en menos del 1% de los casos\ncomo un cuadro de urticaria y están relacionadas con la liberación de histamina y otras aminas vasoacti -\nvas por una reacción antígeno-anticuerpo. Aunque la evidencia experimental al respecto es limitada, en\nalgunas ocasiones se han demostrado anticuerpos de tipo IgG con especificidad contra alotipos de IgA, y\nson más frecuentes en sujetos que han recibido múltiples transfusiones.\nLos pacientes con antecedentes alérgicos casi siempre presentan reacciones alérgicas a la transfusión de\nsangre o hemocomponentes. Sin embargo, la transfusión de sangre de un donador atópico puede producir\nurticaria y reacciones de tipo asmático en un receptor sin estos antecedentes. Los donadores con cualquier\ntipo de antecedente alérgico no deben ser aceptados. Una reacción de tipo urticaria no es indicación para","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":375,"lines":{"from":31,"to":39}}}}],["1887",{"pageContent":"tipo de antecedente alérgico no deben ser aceptados. Una reacción de tipo urticaria no es indicación para\nsuspender la transfusión, ya que cede rápidamente con la administración de antihistamínicos IV, y solo debe\nanotarse el fenómeno en el expediente y notificarlo a medicina transfusional. El uso profiláctico de antihis-\ntamínicos en pacientes con este tipo de reacciones previas es una práctica justificada. Cuando un paciente","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":375,"lines":{"from":39,"to":42}}}}],["1888",{"pageContent":"Cuadro 22-1.\n \nIndicaciones de recambio plasmático\n\nExtracción de IgG\nSíndrome de Guillain-Barré\nMiastenia grave\nSíndrome de\n \nGoodpastur\ne\nHemofilia A con inhibidor de factor VIII\nO\n \nt\n \nr\no\n \ns\nExtracción de IgM\nSíndrome de\n \nhiperviscosidad\nMacroglobulinemia de W\naldenst\n \nröm\nO\n \nt\n \nr\no\n \ns\nComplejos inmunitarios\n \nGlomerulonefritis\n \nrápidamente\n \npr\nogr\nesiva\nLupus\n \neritematoso generalizado\nMetabólicos\n \nColestasis\n \ngrave\nHiperlipopr\noteinemia\nOtros\nTormenta tiroidea\nIntoxicaciones\nPúrpura trombocitopénica trombótica","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":375,"lines":{"from":44,"to":102}}}}],["1889",{"pageContent":"349\n\nCAPÍTULO 22. TERAPÉUTICA TRANSFUSIONAL","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":376,"lines":{"from":1,"to":3}}}}],["1890",{"pageContent":"tiene antecedentes alérgicos o ha presentado este tipo de reacciones en transfusiones previas, está indicado el\nuso profiláctico de antihistamínicos inmediatamente antes de iniciar una transfusión. El uso de eritrocitos\nlavados con solución salina está indicado en estos casos para evitar transfundir elementos del plasma.\nEn ocasiones se presentan reacciones alérgicas graves con datos de choque anafiláctico, las cuales son\natribuidas a la liberación masiva de histamina y otras aminas vasoactivas, y pueden llegar a incluir edema\ngeneralizado, hipertensión súbita seguida de hipotensión, edema laríngeo, náuseas, vómitos, diarrea,\ninsuficiencia respiratoria, entre otras. La transfusión debe suspenderse de inmediato y han de instalarse\nlas medidas necesarias para combatir el choque anafiláctico; está indicada la aplicación de hidrocortisona\nIV y adrenalina. Asimismo, una vez yugulado o estabilizado el cuadro, debe regresarse el producto al","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":376,"lines":{"from":5,"to":13}}}}],["1891",{"pageContent":"IV y adrenalina. Asimismo, una vez yugulado o estabilizado el cuadro, debe regresarse el producto al\nbanco de sangre con la notificación de la reacción para una investigación exhaustiva que habrá de incluir\nlo necesario para descartar una incompatibilidad y buscar deficiencia de IgA, tanto en el donador como\nen el receptor. Si el paciente requiere la transfusión de eritrocitos, estos deben lavarse con solución salina.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":376,"lines":{"from":13,"to":16}}}}],["1892",{"pageContent":"Hemolíticas\n\nLas reacciones hemolíticas de tipo inmunitario, en las que los eritrocitos transfundidos se destruyen al re-\naccionar con anticuerpos específicos presentes en el receptor, casi nunca ocurren, pero constituyen el cua-\ndro más grave y temido entre las complicaciones de las transfusiones. Las reacciones hemolíticas pueden\nser de presentación inmediata o tardía y de gravedad variable; la frecuencia con la cual se presentan es baja:\nde 1 en 6 000 a 7 000 transfusiones, y en países como Estados Unidos es de 1 en 40 000. La frecuencia en\nnuestro medio ha disminuido debido a la adecuada identificación del receptor, la revisión del brazalete\nen la cama del enfermo con el nombre, fecha de nacimiento y el código de barras, y la confirmación de los\nmismos datos en la unidad a transfundir para el receptor para el cual fue seleccionada.\n\nCuadro 22-2.\n \nComplicaciones de las transfusiones\n\nI. Inmunitarias\n\n• \u000e) \"\u001f')&ù.#\u001d\u001b-\n \nFiebre\nAlérgicas (donador o receptor\n \natópico;\n \ndeficiencia de IgA)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":376,"lines":{"from":18,"to":42}}}}],["1893",{"pageContent":"Cuadro 22-2.\n \nComplicaciones de las transfusiones\n\nI. Inmunitarias\n\n• \u000e) \"\u001f')&ù.#\u001d\u001b-\n \nFiebre\nAlérgicas (donador o receptor\n \natópico;\n \ndeficiencia de IgA)\n\n•\n \nHemolíticas\n \nInmediatas: sistema ABO\nTardías: sistemas Kidd, Duffy, Rh: C, c y\n \ne\n\n•\n \nInmunomodulación\n\n•\n \nEnfermedad de injerto contra\n \nhuésped\n \nasociada a\n \ntransfusión\n\n•\n \nLesión pulmonar aguda asociada a transfusión (TRALI)\n\nII. Metabólicas\n\n•\n \nToxicidad por citrato\n \nAcidosis metabólica\nHipocalcemia\n\n•\n \nHipercalemia\n\n•\n \nHipotermia\n\n•\n \nHemorragia por efecto dilucional\n\n•\n \nSobrecarga circulatoria\n\nIII. Infecciosas\n\n• \b\u001f*\u001b.#.#- B\u00016 \u00026 \u00036 \u00046 \u0003\n \n\u0016\n6\u0016\u0005\u0002C\n•\n \nSida (HIV-I, HIV-II)\n\n•\n \nOtras enfermedades virales (HTLV-I, CMV, VEB, dengue)\n\n•\n \nSífilis\n\n•\n \nPaludismo\n\n•\n \nEnfermedad de Chagas (tripanosomiasis americana)\n\n•\n \nBacterianas (\nYersinia enterocolitica\n, sepsis por contaminación por gramnegativos)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":376,"lines":{"from":42,"to":139}}}}],["1894",{"pageContent":"•\n \nSífilis\n\n•\n \nPaludismo\n\n•\n \nEnfermedad de Chagas (tripanosomiasis americana)\n\n•\n \nBacterianas (\nYersinia enterocolitica\n, sepsis por contaminación por gramnegativos)\n\nEn ocasiones se presentan re-\nacciones alérgicas graves con\ndatos de choque anafiláctico,\nlas cuales son atribuidas a la\nliberación masiva de histami-\nna y otras aminas vasoactivas,\ny pueden llegar a incluir ede-\nma generalizado, hipertensión\nsúbita seguida de hipotensión,\nedema laríngeo, náuseas, vó-\nmitos,\n \ndiarrea,\n \ninsuficiencia\nrespiratoria, entre otras.\nLas reacciones hemolíticas pue-\nden ser de presentación inme-\ndiata o tardía y de gravedad\nvariable; la frecuencia con la\ncual se presentan es muy baja:\nde 1 en 6 000 a 7 000 trans -\nfusiones.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":376,"lines":{"from":139,"to":179}}}}],["1895",{"pageContent":"350\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":377,"lines":{"from":1,"to":3}}}}],["1896",{"pageContent":"Las crisis hemolíticas pueden ser de tipo intravascular o extravascular, y habitualmente ocurren ambas\ncon predominio de una de ellas. La mayoría de las reacciones hemolíticas graves o fatales es mediada por\nanticuerpos de tipo IgM con especificidad anti-A o anti-B, que activan complemento y se encuentran en\ngrandes concentraciones y reaccionan con sitios antigénicos también presentes de manera abundante en la\nmembrana de los eritrocitos. La destrucción de hematíes no es la única ni tal vez la más seria consecuencia de\nla incompatibilidad; en realidad suceden fenómenos complejos y encadenados que incluyen: activación\ndel sistema de complemento, total o parcial, con liberación de sustancias con actividad lítica, anafilotóxica,\netcétera; activación del sistema de la coagulación, que puede conducir incluso a un cuadro de coagulación\nintravascular diseminada con todas sus consecuencias; activación del sistema de fibrinólisis, que puede co-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":377,"lines":{"from":5,"to":13}}}}],["1897",{"pageContent":"intravascular diseminada con todas sus consecuencias; activación del sistema de fibrinólisis, que puede co-\nadyuvar a la presentación de diátesis hemorrágica; activación del sistema de la bradicinina y liberación de\notros mediadores vasoactivos que afectan los sistemas cardiovascular, reticuloendotelial y nervioso autóno-\nmo. Todo esto conforma un cuadro clínico aparatoso que puede comenzar cuando se han transfundido ape-\nnas 25 a 30 mL de sangre o eritrocitos incompatibles, y que se caracteriza por fiebre y escalofríos intensos,\nhipotensión, dolor precordial y lumbar, datos de choque, hemoglobinuria y tardíamente insuficiencia renal;\npueden aparecer datos de coagulación intravascular diseminada y sangrados anormales.\nLa hemólisis extravascular es mediada por anticuerpos de tipo IgG, que casi nunca activan comple-\nmento o lo hacen en forma parcial. Los eritrocitos cubiertos en su membrana por estos anticuerpos o por","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":377,"lines":{"from":13,"to":21}}}}],["1898",{"pageContent":"La hemólisis extravascular es mediada por anticuerpos de tipo IgG, que casi nunca activan comple-\nmento o lo hacen en forma parcial. Los eritrocitos cubiertos en su membrana por estos anticuerpos o por\nC3d (forma inactiva de C3b) son fijados por los macrófagos del sistema reticuloendotelial del bazo y del\nhígado a través de sus receptores para Fc y C3, y son destruidos completa o parcialmente. El cuadro clínico\nse caracteriza por fiebre sin causa infecciosa evidente e ictericia por hiperbilirrubinemia indirecta; puede\nhaber hemoglobinemia leve y el cuadro se presenta 2 a 14 días después de la transfusión.\nLa causa más frecuente es la incompatibilidad en los sistemas Kidd, Duffy y Rh (C, c y e). Estas com-\nplicaciones, sobre todo la incompatibilidad en el sistema ABO, son siempre resultado de un error humano.\nPor lo tanto, son prevenibles o evitables con un estricto cuidado y apego a las normas de procedimientos,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":377,"lines":{"from":21,"to":29}}}}],["1899",{"pageContent":"Por lo tanto, son prevenibles o evitables con un estricto cuidado y apego a las normas de procedimientos,\ndesde la selección del donador, recolección, identificación y etiquetado de muestras, llenado de la solicitud,\nidentificación del enfermo, de las unidades de sangre y hemocomponentes, de los tubos pilotos, tipificación\ny realización de pruebas pretransfusionales de compatibilidad, hasta la entrega y transfusión del produc-\nto. En el cuidado están involucrados tanto el personal del banco de sangre como el médico que indica la\ntransfusión y es responsable de esta, así como la enfermera que la aplica y vigila, quienes deben siempre\nverificar tanto los datos e identidad del enfermo como los del producto que el banco entregó para él antes\nde proceder a su aplicación.\nCuando se sospecha una crisis hemolítica intravascular, debe detenerse de inmediato la transfusión,\ncerrando el paso de la sangre sin desechar el remanente que, junto con el equipo, han de regresarse al","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":377,"lines":{"from":29,"to":38}}}}],["1900",{"pageContent":"cerrando el paso de la sangre sin desechar el remanente que, junto con el equipo, han de regresarse al\nbanco con una muestra de sangre del enfermo, de preferencia de otra vena, y la tarjeta de identificación de\nla bolsa. Es necesario verificar los datos del paciente. El banco de sangre ha de llevar a cabo una investiga-\nción exhaustiva tanto en el donador como en el receptor para descubrir cualquier error o incompatibilidad\ny precisar si efectivamente hubo hemólisis.\nEl tratamiento del enfermo debe enfocarse a prevenir el daño renal, manteniendo una buena hidra-\ntación y diuresis; si se desarrolla CID o choque, se establecerá la terapéutica adecuada. Si se comprueba\nque la hemólisis no fue de tipo inmunitario, es necesario investigar causas de daño a los eritrocitos antes\no durante la transfusión, como exposición a calor o frío inadecuados, presión excesiva para infundir a\ntravés de aguja delgada, infusión junto con soluciones incompatibles, contaminación bacteriana, etcétera.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":377,"lines":{"from":38,"to":47}}}}],["1901",{"pageContent":"Inmunomodulación","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":377,"lines":{"from":49,"to":49}}}}],["1902",{"pageContent":"En las últimas dos décadas han aparecido múltiples estudios e informes que sugieren que la transfusión sanguí\n-\nnea tiene un efecto inmunosupresor o inmunomodulador importante. Los mecanismos íntimos y la importancia\nreal de estos efectos no están aún totalmente definidos. Muchos estudios en animales y humanos han demos\n-\ntrado que la secreción de prostaglandina E2 (PGE2) por los macrófagos puede conducir a una reducción en la\nliberación de interleucina 2 (IL-2) por las células T. Las células efectoras, como las asesinas naturales (NK) y las\ncélulas asesinas activadas por linfocina (LAK) dependen de IL-2; estas células efectoras participan importante\n-\nmente en el rechazo de trasplantes, la destrucción de células tumorales y en la protección contra virus y bacterias.\nSe ha demostrado que la transfusión alogénica, sobre todo de componentes celulares que contienen\nlinfocitos, disminuye la capacidad de las células mononucleares para secretar IL-2 en respuesta a estímu-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":377,"lines":{"from":51,"to":62}}}}],["1903",{"pageContent":"linfocitos, disminuye la capacidad de las células mononucleares para secretar IL-2 en respuesta a estímu-\nlos; pero se ha propuesto también como mediadores, además de la exposición a leucocitos, la exposición\na moléculas HLA alogénicas solubles e incluso a factores plasmáticos como el factor de crecimiento B.\nEsta\n \ninmunomodulación\n \nsugiere\n \nun\n \nincremento\n \nen\n \nla\n \nfrecuencia\n \nde\n \ninfecciones\n \nposquirúrgicas\n \nen","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":377,"lines":{"from":62,"to":87}}}}],["1904",{"pageContent":"Cuando se sospecha una cri-\nsis\n \nhemolítica\n \nintravascular,\ndebe detenerse de inmediato la\ntransfusión, cerrando el paso de\nla sangre sin desechar el rema-\nnente que, junto con el equipo,\nhan de regresarse al banco con\nuna muestra de sangre del en-\nfermo, de preferencia de otra\nvena, y la tarjeta de identifica-\nción de la bolsa.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":377,"lines":{"from":89,"to":103}}}}],["1905",{"pageContent":"351\n\nCAPÍTULO 22. TERAPÉUTICA TRANSFUSIONAL\n\npacientes transfundidos y en recaídas tumorales, aunque en un metanálisis posterior no fue estadísticamente\nsignificativo, ya que se sabe que la leucorreducción de los productos a transfundir disminuye el riesgo de\ninmunosupresión y sus efectos.\n\nEnfermedad de injerto contra huésped asociada a transfusión","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":378,"lines":{"from":1,"to":9}}}}],["1906",{"pageContent":"La enfermedad de injerto contra huésped asociada a transfusión (EICH-AT) constituye una complicación\naguda y grave debida a la transfusión de linfocitos citotóxicos alogénicos inmunocompetentes, que establecen\nuna reacción dirigida contra un receptor inmunocomprometido. En contraste con la EICH secundaria a tras\n-\nplante de médula ósea (TMO), la EICH-AT es de instalación rápida, con un cuadro aparatoso caracterizado\npor fiebre continua, ictericia, diarrea profusa, exantema eritematoso maculopapular y hepatomegalia, con\naplasia medular y pancitopenia y muy pobre respuesta al tratamiento. La mortalidad es muy alta, llegando\nhasta 90%. Se presenta sobre todo en pacientes inmunocomprometidos que reciben transfusiones de sangre,\npaquete globular o concentrados de plaquetas, como los pacientes que recientemente recibieron un TMO y\npacientes con inmunodeficiencias tanto congénitas como adquiridas. Otros grupos que parecen estar en un","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":378,"lines":{"from":11,"to":20}}}}],["1907",{"pageContent":"pacientes con inmunodeficiencias tanto congénitas como adquiridas. Otros grupos que parecen estar en un\nriesgo intermedio son los recién nacidos prematuros que se someten a exanguinotransfusión y pacientes con\nleucemias y linfomas durante la inducción o en los períodos de mielodepresión por la quimioterapia.\nLa EICH-AT puede no ser tan infrecuente como se cree. Un estudio informó una frecuencia de 0,1 a\n1,0% de todas las transfusiones realizadas en un hospital pediátrico; otros han informado una frecuencia\nsemejante en un hospital oncológico.\nInicialmente se consideró que esta complicación no se presentaba en sujetos inmunocompetentes; sin\nembargo, cuando un receptor es heterocigoto para un haplotipo HLA y recibe sangre de un sujeto ho-\nmocigoto para ese haplotipo, los linfocitos T citotóxicos transfundidos pueden no ser reconocidos como\nextraños y estos sí reconocer a las células del receptor como extrañas por el haplotipo diferente, e iniciar el","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":378,"lines":{"from":20,"to":29}}}}],["1908",{"pageContent":"extraños y estos sí reconocer a las células del receptor como extrañas por el haplotipo diferente, e iniciar el\nataque contra ellas. En Japón se ha considerado la posibilidad de que esto suceda en la población general\nen aproximadamente 1 de cada 3 000 transfusiones; mientras que en poblaciones blancas en los Estados\nUnidos se ha estimado en 1 en cada 500 transfusiones. Sin embargo, cuando el paciente recibe múltiples\ntransfusiones, las probabilidades aumentan hasta 1 en 300 a 600, por ejemplo, en cirugía de corazón abier-\nto. Por otra parte, a mayor número de unidades transfundidas, el efecto inmunosupresor es mayor, lo que\naumenta la susceptibilidad o probabilidades de padecer EICH-AT.\nEn todas las situaciones mencionadas está indicada la transfusión de hemocomponentes previamente\nirradiados (habitualmente se utilizan entre 1 500 y 5 000 rads) para evitar la viabilidad y funcionalidad de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":378,"lines":{"from":29,"to":37}}}}],["1909",{"pageContent":"irradiados (habitualmente se utilizan entre 1 500 y 5 000 rads) para evitar la viabilidad y funcionalidad de\nlos linfocitos contaminantes. La leucorreducción no parece ser suficiente para evitar el riesgo de EICH-AT.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":378,"lines":{"from":37,"to":38}}}}],["1910",{"pageContent":"Complicaciones metabólicas\n\nEn general son complicaciones poco frecuentes que se presentan casi exclusivamente cuando un enfermo\nrecibe diez o más unidades de sangre por hora en situaciones de sangrado agudo o en cirugía de corazón\nabierto, pero pueden ocurrir también en un recién nacido sometido a exanguinotransfusión con sangre\ntotal, sobre todo en prematuros.\n\nToxicidad por citrato","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":378,"lines":{"from":40,"to":47}}}}],["1911",{"pageContent":"El citrato usado como anticoagulante confiere a la sangre un pH ácido. En condiciones habituales, con\nla transfusión de 2 a 3 U en un sujeto adulto, esto no representa ningún problema, pero en enfermos en\nestado de choque con insuficiencia hepática o renal, o ambas, que deben recibir múltiples transfusiones\nen un período corto debido a sangrado agudo, el citrato se metaboliza con dificultad y puede conducir\na acidosis metabólica grave.\nEl citrato es un agente quelante del calcio; cuando se transfunden más de 10 U de sangre por hora en\nun adulto o más de 500 mL por hora en un niño, o bien en presencia de daño hepático, el citrato puede\nalcanzar niveles tóxicos (> 100 mg/dL) y ocasionar hipocalcemia.\nDurante una exanguinotransfusión con sangre total, el recién nacido recibe 600 mg de citrato por ki-\nlogramo de peso o más, lo que lo pone en riesgo de alcanzar niveles tóxicos del compuesto. Una unidad de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":378,"lines":{"from":49,"to":58}}}}],["1912",{"pageContent":"logramo de peso o más, lo que lo pone en riesgo de alcanzar niveles tóxicos del compuesto. Una unidad de\nsangre con hematocrito de 40% contiene aproximadamente 5 mmol de citrato, mientras que eliminando\nun poco de plasma de la bolsa para permitir que la sangre tenga un hematocrito del 70%, el contenido\nde citrato es de 0,5 mmol o menor, por lo que a menos que haya daño hepático, el riesgo de intoxicación por\ncitrato este agente es mínimo. Se recomienda, por lo tanto, llevar esto a cabo en las exanguinotransfusiones.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":378,"lines":{"from":58,"to":62}}}}],["1913",{"pageContent":"El\n \ncitrato\n \nutilizado\n \ncomo\nanticoagulante confiere a la\nsangre un pH ácido. En con-\ndiciones\n \nhabituales,\n \ncon\n \nla\ntransfusión de 2 a 3 U en un\nsujeto adulto, esto no repre-\nsenta ningún problema, pero\nen enfermos en estado de cho-\nque con insuficiencia hepática\no renal, o ambas, que deben\nrecibir múltiples transfusio-\nnes en un período corto debido\na sangrado agudo, el citrato\nse metaboliza con dificultad y\npuede conducir a acidosis me-\ntabólica grave.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":378,"lines":{"from":64,"to":91}}}}],["1914",{"pageContent":"352\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nHipercalemia\n\nLa sobrecarga de potasio es otro riesgo para el recién nacido sometido a exanguinotransfusión. En un adul-\nto, la carga de 7 a 8 mEq de potasio por unidad de sangre almacenada no representa ningún problema; sin\nembargo, en sujetos con daño renal o con grandes zonas de tejido dañado por traumatismo, trituración o\nquemadura, la carga de potasio puede ser riesgosa; en estos casos, la sangre transfundida debe tener menos\nde una semana de almacenamiento y, por supuesto, es indicación precisa para el uso de paquete globular,\ncon lo que se minimiza la carga de este ión.\n\nHipotermia","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":379,"lines":{"from":1,"to":14}}}}],["1915",{"pageContent":"Hipotermia\n\nSolo constituye un riesgo cuando son transfundidas más de 6 a 8 U de sangre por hora; la hipotermia puede favore\n-\ncer la aparición de arritmias cardíacas y contribuye a disminuir los niveles de 2,3-DPG intraeritrocítico y aumentar\nla acidosis por inducción del metabolismo del lactato y del citrato en el hígado. El calentamiento de la sangre solo\ndebe hacerse en incubadores específicos a 37 °C o sumergiendo el tubo del equipo de transfusión en un recipiente\ncon agua a 37 °C; de otra manera, existe riesgo de hemólisis con peores consecuencias. La transfusión habitual de\n2 a 3 U en varias horas no requiere calentamiento del producto; en cambio, en pacientes con anemia hemolítica por\nanticuerpos fríos (crioglobulimenia o crioaglutininas), está contraindicada la transfusión de sangre fría.\n\nComplicaciones hemorrágicas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":379,"lines":{"from":14,"to":25}}}}],["1916",{"pageContent":"Complicaciones hemorrágicas\n\nSe trata de complicaciones bastante raras. Solo cuando se transfunden grandes volúmenes de sangre alma\n-\ncenada (que no tiene plaquetas ni factores lábiles de la coagulación V y VIII) o paquete globular en pocas\nhoras, puede producirse un efecto dilucional para estos factores, que además se pierden o se consumen du-\nrante el sangrado y la hemostasia. En estos casos, es recomendable la transfusión de 1 U de plasma fresco o\nfresco congelado por cada 10 U de sangre almacenada o paquete globular transfundidos. Los concentrados\nde plaquetas solo están indicados si la cifra de plaquetas es menor de 50 000 U/L y hay sangrado activo.\n\nSobrecarga circulatoria","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":379,"lines":{"from":25,"to":35}}}}],["1917",{"pageContent":"Es un riesgo potencial en todo paciente que se somete a una transfusión, pero es mayor en niños pequeños,\nancianos, en pacientes con daño cardíaco o renal, o en enfermos graves cuyas condiciones hemodinámicas son\nlábiles; asimismo, en sujetos con anemia crónica de tipo carencial y cuando se transfunden múltiples unidades\nde sangre por sangrado activo. El riesgo consiste en ocasionar insuficiencia cardíaca y edema pulmonar agudo\nque puede conducir a la muerte. El volumen transfundido no debe exceder de 1,5 a 2 mL/kg/h, y siempre debe\nusarse concentrado eritrocitario en lugar de sangre total. El paciente debe ser transfundido semisentado y vigilar\nfrecuentemente sus constantes vitales como tensión arterial, frecuencia cardíaca, diuresis y, si es posible, presión\nvenosa central cuando el caso lo amerite. Conviene recordar que nunca se debe intentar llevar al paciente a cifras\nde Hb y Htc normales; la terapéutica transfusional está encaminada a mejorar o mantener las condiciones o","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":379,"lines":{"from":37,"to":45}}}}],["1918",{"pageContent":"de Hb y Htc normales; la terapéutica transfusional está encaminada a mejorar o mantener las condiciones o\nconstantes vitales del enfermo, en tanto que el tratamiento específico y definitivo resuelve el problema de base.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":379,"lines":{"from":45,"to":46}}}}],["1919",{"pageContent":"Complicaciones infecciosas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":379,"lines":{"from":48,"to":48}}}}],["1920",{"pageContent":"La posibilidad de transmitir uno o más agentes infecciosos, principalmente virus, a un enfermo continúa\nsiendo uno de los mayores temores en la medicina transfusional. Desde 1940 y hasta 1981, la hepatitis\nfue la única enfermedad transmitida por transfusión que preocupaba y ocupaba al médico. La aparición\ndel síndrome de inmunodeficiencia adquirida (SIDA) en 1981, y la demostración subsecuente de que este\npodía transmitirse por transfusión, condujo a cambios profundos tanto en actitudes como en la práctica de\nla medicina transfusional. Cuatro factores han contribuido fundamentalmente en la prevención de la trans-\nmisión de enfermedades infecciosas por transfusión: 1) reducción del número de transfusiones homólogas o\ninnecesarias; 2) la selección cuidadosa de los donadores; 3) la realización de pruebas específicas de labora-\ntorio en la sangre colectada y 4) un manejo y conservación adecuados de la sangre y los hemocomponentes.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":379,"lines":{"from":50,"to":58}}}}],["1921",{"pageContent":"torio en la sangre colectada y 4) un manejo y conservación adecuados de la sangre y los hemocomponentes.\nActualmente, la legislación mexicana establece como obligatorio el estudio clínico del donador, así como\nlas pruebas para la detección del antígeno de superficie del virus de la hepatitis B (AgsHB), detección de\nanticuerpos contra el virus C de la hepatitis (HCV), la determinación de anticuerpos contra el HIV-I y el\nHIV-II, así como el VDRL (sífilis), y en sitios endémicos\n \nTrypanosoma cruzi\n, además de detección de otros\nagentes como\n \nBrucella\n \ny\n \nPlasmodium\n \nen sitios endémicos de la enfermedad en todos los donadores.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":379,"lines":{"from":58,"to":74}}}}],["1922",{"pageContent":"La sobrecarga de potasio es\notro riesgo para el recién na-\ncido sometido a exanguino-\ntransfusión. En un adulto, la\ncarga de 7 a 8 mEq de potasio\npor unidad de sangre alma-\ncenada no representa ningún\nproblema;\n \nsin\n \nembargo,\n \nen\nsujetos con daño renal o con\ngrandes zonas de tejido daña-\ndo por traumatismo, tritura-\nción o quemadura, la carga de\npotasio puede ser riesgosa.\nLa aparición del síndrome de\ninmunodeficiencia adquirida\n(SIDA) en 1981 y la demos-\ntración subsecuente de que este\npodía transmitirse por trans-\nfusión,\n \ncondujo\n \na\n \ncambios\nprofundos, tanto en actitudes\ncomo en la práctica de la me-\ndicina transfusional.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":379,"lines":{"from":76,"to":109}}}}],["1923",{"pageContent":"353\n\nCAPÍTULO 22. TERAPÉUTICA TRANSFUSIONAL\n\nMuchos, aunque no todos los agentes infecciosos transmisibles por transfusión, son también transmitidos\npor vía sexual; esto en ocasiones hace difícil poder precisar la forma en la que un paciente determinado ad-\nquirió la infección y dificulta también la interpretación de las estadísticas de frecuencia y vía de transmisión.\n\nHepatitis\nHepatitis A\n\nEs extremadamente rara como hepatitis postransfusión (HPT), aunque ha habido informes aislados de\nhepatitis A por transfusión de sangre de un donador infectado, obtenida justo antes del desarrollo de los\nsíntomas o con un cuadro subclínico, durante el breve período de viremia.\n\nHepatitis B","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":380,"lines":{"from":1,"to":16}}}}],["1924",{"pageContent":"Hepatitis B\n\nEl virus B de la hepatitis (HBV) se transmite por la transferencia de fluidos corporales de un individuo\na otro. En los sujetos infectados el virus circula libremente en el plasma y todos los hemocomponentes\npueden transmitir la infección, aun administrados en cantidades muy pequeñas. En el pasado, los pa-\ncientes que requerían transfusiones múltiples o frecuentes tenían el mayor riesgo de adquirir la infección.\nEn la actualidad las estrategias de selección cuidadosa y estricta del donador y las pruebas serológicas\nprácticamente han logrado evitar por completo la transmisión por transfusión. En México la frecuencia\nde positividad para el AgsHB en donadores es de 0,19%, y la probabilidad de transmisión de hepatitis B\npor transfusión es del orden de 1 entre 100 000 a 150 000 unidades.\n\nHepatitis por virus Delta","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":380,"lines":{"from":16,"to":27}}}}],["1925",{"pageContent":"Hepatitis por virus Delta\n\nSe ha descrito una forma más virulenta y a veces fulminante de hepatitis B relacionada con una sobreinfec-\nción o coinfección con el virus Delta; este es un virus de RNA “defectuoso” o incompleto que solo puede\ninfectar y causar enfermedad a personas que tienen HBV, ya que para ser infeccioso necesita tener una\ncubierta exterior de AgsHB. La infección es particularmente probable en sujetos crónicamente transfun-\ndidos. La inmunidad contra el HBV confiere también inmunidad para el virus D.\n\nHepatitis C","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":380,"lines":{"from":27,"to":35}}}}],["1926",{"pageContent":"A principios de los noventas se pudo caracterizar el virus C de la hepatitis (HCV) y se desarrolló un ensayo\ninmunoenzimático (ELISA) que permitió demostrar los anticuerpos contra el virus en el suero de los pa-\ncientes. Ello vino a revolucionar la investigación de la HPT y se pudo demostrar que el HCV era el causante\nde la mayoría de los casos hasta entonces denominados “hepatitis no A, no B”. El HCV se trasmite por varias\nvías parenterales; los usuarios de drogas intravenosas tienen una seroprevalencia de hasta un 80%; la trans-\nmisión sexual es poco frecuente, aunque algunas poblaciones de varones homosexuales con múltiples parejas\ntienen una frecuencia discretamente mayor que la población general, al igual que los sujetos con múltiples\nparejas heterosexuales. La seroprevalencia en la población general va de 0 a 1%, y alcanza hasta 2% en al-\ngunas poblaciones como en Japón. En México, la frecuencia de seropositividad en donadores voluntarios de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":380,"lines":{"from":37,"to":45}}}}],["1927",{"pageContent":"gunas poblaciones como en Japón. En México, la frecuencia de seropositividad en donadores voluntarios de\nsangre es de aproximadamente 0,5%, por lo que la frecuencia esperada de HPT por el HCV es menor de 1\nen 1 000 000; de cualquier forma, la gran frecuencia con la que la infección evoluciona a la cronicidad como\nhepatitis crónica activa o persistente y cirrosis, y a carcinoma hepático, le confiere gran importancia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":380,"lines":{"from":45,"to":48}}}}],["1928",{"pageContent":"Virus de la inmunodeficiencia humana\n\nEs un virus de la familia Retroviridae (virus de RNA) y constituye el agente causal del sida. En América,\nal igual que en Europa, Asia y Oceanía, predomina el HIV-I, mientras que el HIV-II parece predomi-\nnar en la región subsahariana de África occidental pero se ha observado en algunas partes de Europa y\nSudamérica. La transmisión a través de la transfusión sanguínea fue reconocida tempranamente en los\nochentas; muchos enfermos desarrollaron la infección y posteriormente la enfermedad después de la\ntransfusión de una unidad de sangre. De hecho, en nuestro medio, más de la mitad de los adultos que\ndesarrollaron sida por transfusión recibió una sola unidad de sangre. En Estados Unidos, los casos de\nsida asociados a transfusión llegaron a representar el 2% del total y en la República Mexicana alcanzaron\nhasta el 11,6%.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":380,"lines":{"from":50,"to":60}}}}],["1929",{"pageContent":"En México la frecuencia de\npositividad para el AgsHB\nen donadores es de 0,19%,\ny la probabilidad de trans-\nmisión\n \nde\n \nhepatitis\n \nB\n \npor\ntransfusión es del orden de\n1 entre 100 000 a 150 000\nunidades.\nEn nuestro medio, más de la mi\n-\ntad de los adultos que desarrolla\n-\nron sida por transfusión recibió\nuna sola unidad de sangre. En\nEstados Unidos, los casos de sida\nasociados a transfusión llegaron\na representar el 2% del total y en\nla República Mexicana alcan-\nzaron hasta el 11,6% .","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":380,"lines":{"from":62,"to":88}}}}],["1930",{"pageContent":"354\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":381,"lines":{"from":1,"to":3}}}}],["1931",{"pageContent":"En México, la frecuencia de transmisión por transfusión se detuvo y luego disminuyó rápidamente después\nde prohibirse la comercialización de la sangre en 1987 y al hacerse obligatoria la prueba de detección de anti\n-\ncuerpos contra el HIV en todos los donadores, pero sobre todo con la selección cuidadosa de los donadores vo-\nluntarios y las campañas permanentes de educación e información para la donación de sangre y el uso cuidadoso\ny racional de esta, llevadas a cabo por los centros estatales y nacional de la transfusión sanguínea. De cualquier\nmanera, siempre existe la posibilidad de que un donador haya adquirido la infección recientemente, niegue o\nno manifieste sus antecedentes o prácticas sexuales de riesgo y aún no sean detectables los anticuerpos contra el\nHIV en su suero (período de “ventana”). Al transfundir esa sangre, se transmitirá la infección al receptor. La fre\n-\ncuencia real con la que se transmite en la actualidad la infección por transfusión es muy baja y difícil de establecer","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":381,"lines":{"from":5,"to":15}}}}],["1932",{"pageContent":"-\ncuencia real con la que se transmite en la actualidad la infección por transfusión es muy baja y difícil de establecer\ncon precisión, debido al largo período de incubación de la enfermedad, que se ha estimado de 4 a 5 años, y a la\nalta mortalidad de los pacientes que reciben transfusiones en general dentro de los siguientes 6 meses al evento y\npor causas ajenas y diversas. El riesgo de contraer el HIV asociado a transfusión se estima en 1 por 1 000 000 de\nunidades transfundidas. En el\n cuadro 22-3\n \nse señalan los períodos de “ventana” de acuerdo a la técnica utilizada:","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":381,"lines":{"from":15,"to":23}}}}],["1933",{"pageContent":"Otras enfermedades virales\nVirus linfotrópico T humano I (HTLV-I)\n\nVirus que causa leucemia de células T en adultos y síndromes de desgaste neuromuscular. Se han descrito\ncasos de seroconversión atribuibles a transfusión.\n\nCitomegalovirus (CMV) y virus de Epstein-Barr (EBV)\n\nAmbos de la familia Herpesviridae, pueden trasmitirse por transfusión. En la población general se encuentran\nanticuerpos contra CMV en el 40 a 90% de los habitantes, y contra VEB hasta en 90%, por lo que la trans-\nmisión por transfusión no debe ser importante. La transmisión de CMV constituye un problema en recién\nnacidos, sobre todo de bajo peso, y en sujetos inmunodeprimidos y postrasplantados. La importancia de\nusar sangre o paquete globular desleucocitado o de donadores seronegativos para CMV en estos pacientes\ndependerá de si el receptor o la madre del recién nacido son seropositivos o seronegativos para CMV.\n\nVirus del dengue","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":381,"lines":{"from":25,"to":40}}}}],["1934",{"pageContent":"Virus del dengue\n\nAunque el número de casos de la enfermedad viral transmitida por el mosco\n \nAedes aegypti\n \nes muy frecuen-\nte en algunas zonas de México, los donadores en etapa de viremia capaces de transmitir la enfermedad\ntienen una sintomatología evidente, por lo que la probabilidad de rechazo en la selección del donador es\nmuy alta y no serían aceptados. No hay información en México sobre dengue asociado a transfusión ni\ntampoco casos asociados a transmisión del virus del Nilo occidental.\n\nSífilis\n\nLa trasmisión por transfusión es en la actualidad extremadamente rara, tanto por la selección y estudio\ndel donador y las pruebas serológicas obligatorias como por el almacenamiento de la sangre a bajas tem-\nperaturas, lo que inactiva al treponema.\n\nCuadro 22-3.\n \nPeríodos de ventana reportados para positividad de infecciones virales\npor HBV, HCV y HIV de acuerdo a la técnica utilizada\n\nCon técnica\nVirus\n \n*ELISA-quimioluminiscencia\n \n**NAT\nHBV\n \n32 días\n \n28 días\n\nHCV\n \n38 días\n \n7 días","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":381,"lines":{"from":40,"to":79}}}}],["1935",{"pageContent":"Con técnica\nVirus\n \n*ELISA-quimioluminiscencia\n \n**NAT\nHBV\n \n32 días\n \n28 días\n\nHCV\n \n38 días\n \n7 días\n\nVIH\n \n60 días\n \n7 días\n*Ensayo inmunoenzimático\n**Ácidos nucleicos virales (\nnuclear acid testing\n)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":381,"lines":{"from":79,"to":105}}}}],["1936",{"pageContent":"355\n\nCAPÍTULO 22. TERAPÉUTICA TRANSFUSIONAL\n\nPaludismo\n\nEn áreas endémicas para paludismo sigue existiendo la posibilidad de transmisión por transfusión, igual\nque cuando el donador procede de zonas palúdicas. La Norma Oficial Mexicana para la disposición de\nsangre humana y hemocomponentes señala los antecedentes que deben excluir a un donador en relación\ncon el cuadro clínico de paludismo, tiempo desde el diagnóstico, tratamiento recibido, etcétera.\n\nEnfermedad de Chagas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":382,"lines":{"from":1,"to":12}}}}],["1937",{"pageContent":"La infección por\n \nTrypanosoma cruzi\n \no tripanosomiasis americana puede constituir también un problema,\nsobre todo en áreas donde la infección es endémica o cuando no se establece adecuadamente el sitio de\norigen y residencia de los donadores o no se investigan específicamente los datos clínicos de la enfermedad.\nEn México se han hecho múltiples estudios epidemiológicos y “encuestas centinelas” buscando establecer la\nprevalencia real, la distribución geográfica y la importancia de la infección en relación con la transmisión por\ntransfusión, ofreciendo resultados muy variables dependiendo de la metodología y los reactivos utilizados.\nRecientemente se realizó un estudio epidemiológico y de rastreo en donadores de sangre sanos seleccio-\nnados, procedentes de áreas tanto urbanas como suburbanas y rurales que acudieron a donar sangre a dos\ninstituciones de la ciudad de Guadalajara y otras dos de la ciudad de Tepic, ambas en el occidente del país.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":382,"lines":{"from":14,"to":26}}}}],["1938",{"pageContent":"instituciones de la ciudad de Guadalajara y otras dos de la ciudad de Tepic, ambas en el occidente del país.\nSe estudiaron 6 250 sujetos, de los cuales 57 resultaron positivos en una prueba de rastreo (ELISA o EIA) y\nconfirmados con una prueba de radioinmunoprecipitación (RIPA), lo que resultó en una frecuencia global de\n0,9%. Se pudo localizar solo a nueve de los enfermos que fueron transfundidos con sangre de estos donado-\nres; de ellos, cuatro resultaron positivos por RIPA. Estos datos establecen la necesidad de realizar de manera\nsistemática y obligatoria una prueba de rastreo para\n \nTripanosoma cruzi\n \nen todos los donadores de sangre.\nYersinia enterocolitica","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":382,"lines":{"from":26,"to":36}}}}],["1939",{"pageContent":"Las infecciones bacterianas transmitidas por transfusión son en la actualidad un fenómeno extrema -\ndamente raro. Las bacterias pueden contaminar la sangre durante el procedimiento de extracción o\nseparación de hemocomponentes; otra posibilidad es que las bacterias se encuentren presentes en la\nsangre del donador y luego proliferen durante el almacenamiento. Se han informado ya varios casos de\nsepsis y choque por\n \nYersinia enterocolitica\n \ny la evidencia actual sugiere que la bacteria sobrevive dentro\nde los neutrófilos polimorfonucleares durante un tiempo indeterminado después de la infección en una\npersona; si esta dona sangre, sus neutrófilos pueden contener el germen patógeno y después de más de\nuna semana de almacenamiento, cuando empiezan a desintegrarse los leucocitos, liberan las bacterias\nque crecen fácilmente a 4 °C y causan la sepsis al transfundir la sangre o el paquete globular a un en -","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":382,"lines":{"from":38,"to":50}}}}],["1940",{"pageContent":"que crecen fácilmente a 4 °C y causan la sepsis al transfundir la sangre o el paquete globular a un en -\nfermo. Se necesitan más evidencias para establecer los cuidados necesarios que eviten el fenómeno si se\ncorrobora su importancia, por ejemplo desleucocitar los paquetes globulares.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":382,"lines":{"from":50,"to":52}}}}],["1941",{"pageContent":"LEUCORREDUCCIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":382,"lines":{"from":54,"to":54}}}}],["1942",{"pageContent":"Los leucocitos están presentes en diferentes concentraciones en todos los componentes celulares sanguí-\nneos, como la sangre total, los concentrados de eritrocitos o paquete globular, el concentrado de plaquetas\nobtenido de una unidad de sangre total o colectado por aféresis. La cantidad de leucocitos varía de 2 × 10\n \n9\nen un paquete globular a 0,5 a 2,5 × 10\n \n8\n \nen concentrados plaquetarios obtenidos de una unidad de sangre\ntotal y hasta 5 × 10\n \n9\n \nen concentrados de plaquetas obtenidos por aféresis tradicional.\nEn los últimos años se ha podido demostrar que los leucocitos contaminantes transfundidos en un\nhemocomponente son los mediadores de complicaciones y efectos adversos, por ejemplo, las reacciones\nfebriles no hemolíticas, la aloinmunización a HLA y la refractariedad a la transfusión de plaquetas, la\ntransmisión de virus leucotrópicos como el citomegalovirus y la reactivación o transmisión de otros virus","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":382,"lines":{"from":56,"to":74}}}}],["1943",{"pageContent":"transmisión de virus leucotrópicos como el citomegalovirus y la reactivación o transmisión de otros virus\ncomo el de Epstein-Barr, herpes, HTLV-I y -II y posiblemente la enfermedad de injerto contra huésped\nasociada a transfusión y la inmunomodulación o inmunosupresión, y su relación con un aumento de reci-\ndivas tumorales, infecciones posquirúrgicas y reactivación viral.\nRecientemente se ha mencionado que los linfocitos B pueden ser responsables de la transmisión de prio-\nnes, que se supone son la causa de la nueva variante de la enfermedad de Creutzfeldt-Jacob (nvECJ) o\nencefalitis espongiforme recientemente descrita.\nLa leucorreducción o disminución en el número de leucocitos en los hemocomponentes ha demostrado ser una\nmedida que reduce importantemente algunas de las complicaciones de las transfusiones asociadas a leucocitos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":382,"lines":{"from":74,"to":82}}}}],["1944",{"pageContent":"En áreas endémicas para pa-\nludismo\n \nsigue\n \nexistiendo\n \nla\nposibilidad de transmisión por\ntransfusión, igual que cuando\nel donador procede de zonas\npalúdicas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":382,"lines":{"from":84,"to":95}}}}],["1945",{"pageContent":"356\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nLa Asociación Americana de Bancos de Sangre (AABB) ha establecido que un producto leucorreducido\ndebe contener menos de 5 × 10\n6\n \nleucocitos por unidad (5 millones de leucocitos totales). El Comité de expertos\nen transfusión sanguínea e inmunohematología del Consejo Europeo considera un componente leucorreduci-\ndo cuando contiene menos de 1 × 10\n6\n \nleucocitos por unidad (menos de un millón de leucocitos totales).\nEn la actualidad se puede contar con filtros de muy alta eficacia leucorreductora y alto rendimiento que\npermiten leucorreducir la cifra de leucocitos en un concentrado eritrocitario o concentrado plaquetario\nal momento de su preparación (prealmacenamiento) o en el momento de su aplicación en la cama del\nenfermo (posalmacenamiento).\nEn el\n \ncuadro 22-4\n \nse describen las indicaciones de la leucorreducción aceptadas.\n\nALTERNATIVAS DE LA TRANSFUSIÓN DE SANGRE HOMÓLOGA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":383,"lines":{"from":1,"to":25}}}}],["1946",{"pageContent":"En los últimos años se han introducido en la terapéutica transfusional procedimientos tendientes a evitar los\nriesgos potenciales de la transfusión homóloga; de estos, algunos se encuentran todavía a nivel experimental,\npor ejemplo, la utilización de sustancias transportadoras de oxígeno como los carbonofluorados, soluciones de\nhemoglobina y hemoglobina de doble enlace o recombinante, cuya eficacia no es aún satisfactoria y su toxicidad\ny costo no permiten su uso clínico extendido. Otros procedimientos son ya de uso común, como la autodona-\nción, que puede ser de tres modalidades:\n1.\n \nAutodonación preoperatoria.\n \nAplicable en pacientes que serán intervenidos quirúrgicamente en\nforma programada; 2 semanas antes de la intervención quirúrgica se obtienen de 2 a 3 U de sangre\nque se conservan adecuadamente y que, de ser necesario, se utilizan durante la cirugía o en el poso-\nperatorio inmediato.\n2.\n \nHemodilución normovolémica preoperatoria.\n \nSe lleva a cabo en pacientes con buen funciona-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":383,"lines":{"from":27,"to":45}}}}],["1947",{"pageContent":"peratorio inmediato.\n2.\n \nHemodilución normovolémica preoperatoria.\n \nSe lleva a cabo en pacientes con buen funciona-\nmiento cardiopulmonar y hematocrito normal o alto; se realiza sangría para lograr un Htc de al-\nrededor de 30% inmediatamente antes de la intervención quirúrgica, en el quirófano, restituyendo\nsimultáneamente el volumen con una solución macromolecular (dextrán); la sangre se reinfunde, si\nes necesario, durante la operación o en el posoperatorio inmediato.\n3.\n \nRecuperación intraoperatoria o posoperatoria de eritrocitos.\n \nCon equipos especiales se recupera\nla sangre acumulada en el lecho quirúrgico, y los eritrocitos son infundidos después de filtrarse y\nlavarse. Este procedimiento está contraindicado en operaciones contaminadas y oncológicas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":383,"lines":{"from":45,"to":61}}}}],["1948",{"pageContent":"HEMOVIGILANCIA\n\nLa transfusión sanguínea debe considerarse como una terapia de muy alta frecuencia y de alto riesgo que\ndebe ser manejada cuidadosamente.\n\nCuadro 22-4.\n \nIndicaciones de la leucorreducción\n\nIndicaciones aceptadas\n\n•\n \n\u0012\u001f\u001e/\u001d#, ) \u001f0#.\u001b, &\u001b- ,\u001f\u001b\u001d\u001d#)(\u001f- \u001f\u001c,#&\u001f- () \"\u001f')&ù.#\u001d\u001b- ,\u001f\u001d/,,\u001f(.\u001f-\n•\n \n\u0012\u001f\u001e/\u001d#, ) \u001f0#.\u001b, &\u001b \u001b&)#('/(#4\u001b\u001d#ĉ( \b\n \n\u0001 \u001b *&\u001b+/\u001f.\u001b- B*\u001b\u001d#\u001f(.\u001f- +/\u001f ,\u001f\u001d#\u001c\u001f( +/#'#).\u001f,\u001b*#\u001b \u001e\u001f\n\ninducción, candidatos a transfusiones repetidas de plaquetas)\n\n•\n \n\u0012\u001f\u001e/\u001d#, ) \u001f0#.\u001b, &\u001b .,\u001b(-'#-#ĉ( \u001e\u001f \u0003\n \n\u0016 B,\u001f\u001d#ï( (\u001b\u001d#\u001e)- *,\u001f'\u001b./,)- ) \u001e\u001f \u001c\u001b$) *\u001f-)6 *\u001b\u001d#\u001f(.\u001f- #(\n-\nmunosuprimidos, pacientes postrasplantados)","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":383,"lines":{"from":63,"to":91}}}}],["1949",{"pageContent":"•\n \n\u0012\u001f\u001e/\u001d#, ) \u001f0#.\u001b, &\u001b .,\u001b(-'#-#ĉ( \u001e\u001f \u0003\n \n\u0016 B,\u001f\u001d#ï( (\u001b\u001d#\u001e)- *,\u001f'\u001b./,)- ) \u001e\u001f \u001c\u001b$) *\u001f-)6 *\u001b\u001d#\u001f(.\u001f- #(\n-\nmunosuprimidos, pacientes postrasplantados)\n\n•\n \n\u0010,\u001f0\u001f(#, &\u001b ,\u001f ,\u001b\u001d.\u001b,#\u001f\u001e\u001b\u001e \u001b *&\u001b+/\u001f.\u001b-\n•\n \n\u0012\u001f\u001e/\u001d#, &\u001b ,\u001f\u001d/\u001f(\u001d#\u001b \u001e\u001f #( \u001f\u001d\u001d#ĉ( *)-)*\u001f,\u001b.),#\u001b *), #('/()-/*,\u001f-#ĉ(\n•\n \n\u00050#.\u001b, &\u001b ,\u001f\u001b\u001d.#0\u001b\u001d#ĉ( \u001e\u001f *\u001b\u001e\u001f\u001d#'#\u001f(.)- 0#,\u001b&\u001f- \u001f2#-.\u001f(.\u001f- \u001f( \u001f& ,\u001f\u001d\u001f*.),\n•\n \n\u0010,\u001f0\u001f(#, &\u001b \u001b&)#('/(#4\u001b\u001d#ĉ( \b\n \n\u0001 \u001f( \u001d\u001b(\u001e#\u001e\u001b.)- \u001b .,\u001b-*&\u001b(.\u001f\n•\n \n\u0010,\u001f0\u001f(#, \u001f& \u001e\u001bĄ) */&')(\u001b, \u001b!/\u001e) *), \u001b\u001e'#(#-.,\u001b\u001d#ĉ( *\u001b-#0\u001b \u001e\u001f \u001b(.#\u001d/\u001f,*)- \u001b(.#&\u001f/\u001d)\u001d#.)-\n•\n \n\u0012\u001f\u001e/\u001d#, &\u001b ,\u001f\u001d/\u001f(\u001d#\u001b \u001e\u001f ,\u001f\u001d/,,\u001f(\u001d#\u001b ./'),\u001b& *)-,\u001f-\u001f\u001d\u001d#ĉ(\n•\n \n\u0012\u001f\u001e/\u001d#, &\u001b ,\u001f\u001d/\u001f(\u001d#\u001b \u001e\u001f #( \u001f\u001d\u001d#ĉ( *)-)*\u001f,\u001b.),#\u001b\n•\n \n\u00050#.\u001b, &\u001b ,\u001f\u001b\u001d.#0\u001b\u001d#ĉ( \u001e\u001f \u0003\n \n\u0016 &\u001b.\u001f(.\u001f\n•\n \n\u00050#.\u001b, &\u001b ,\u001f\u001b\u001d.#0\u001b\u001d#ĉ( \u001e\u001f \b \u0016\n•\n \nPrevenir la aloinmunización HLA en candidatos a trasplante","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":383,"lines":{"from":91,"to":132}}}}],["1950",{"pageContent":"Autodonación preoperatoria.\nAplicable en pacientes que se-\nrán intervenidos quirúrgica-\nmente en forma programada;\n2 semanas antes de la inter-\nvención quirúrgica se obtie-\nnen de 2 a 3 U de sangre que\nse conservan adecuadamente\ny que, de ser necesario, se uti-\nlizan durante la cirugía o en\nel posoperatorio inmediato.\nCon equipos especiales se recu-\npera la sangre acumulada en el\nlecho quirúrgico, y los eritroci-\ntos son infundidos después de\nfiltrarse y lavarse. Este proce-\ndimiento está contraindicado\nen operaciones contaminadas y\noncológicas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":383,"lines":{"from":134,"to":152}}}}],["1951",{"pageContent":"357\n\nCAPÍTULO 22. TERAPÉUTICA TRANSFUSIONAL","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":384,"lines":{"from":1,"to":3}}}}],["1952",{"pageContent":"Garantizar la seguridad transfusional debe ser un elemento esencial y prioritario en los programas de\nsalud nacionales; las estrategias para lograrlo incluyen la selección de donadores de bajo riesgo, buenas prác-\nticas de manufactura en la preparación de los hemocomponentes y un buen uso clínico de ellos. La hemovi\n-\ngilancia se enfoca en garantizar la identificación de eventos adversos conocidos e informar efectos adversos\nno esperados, pero además favorece la seguridad transfusional constituyendo un punto de referencia que\npromueve las buenas prácticas y facilita una rápida respuesta ante nuevas amenazas. La prevención de en-\nfermedades infecciosas ha sido la principal preocupación; la selección del donador y las pruebas de seguri-\ndad para marcadores infecciosos, aunque altamente eficaces para disminuir el riesgo, no pueden eliminarlo\ncompletamente y deben irse introduciendo nuevas tecnologías dirigidas hacia infecciones emergentes. La","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":384,"lines":{"from":5,"to":14}}}}],["1953",{"pageContent":"completamente y deben irse introduciendo nuevas tecnologías dirigidas hacia infecciones emergentes. La\ntecnología para la reducción de patógenos ofrece la posibilidad de inactivar un amplio espectro de agentes\ntransmisibles y proteger contra nuevas amenazas infecciosas emergentes.\nLa “seguridad” de la transfusión sanguínea, como la concebimos actualmente, es muy diferente en países\n“desarrollados”, países “en desarrollo” y países “menos desarrollados”, debido a las grandes diferencias de or\n-\nganización, que dependen de educación y recursos financieros. En 1995, la Organización Mundial de la Salud\n(OMS) informaba que el 100% de los países desarrollados encuestados, el 66% de los países en desarrollo y el\n46% de los países menos desarrollados realizaban una prueba de rastreo para HIV en todos los donadores de\nsangre. La prueba de antígeno de superficie de hepatitis B era aplicada en el 100, 62 y 23%, respectivamente.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":384,"lines":{"from":14,"to":23}}}}],["1954",{"pageContent":"sangre. La prueba de antígeno de superficie de hepatitis B era aplicada en el 100, 62 y 23%, respectivamente.\nLa justificación habitual eran los costos y la irregularidad en la disponibilidad de reactivos. La informa\n-\nción y la educación desempeñan un papel muy importante en toda la cadena de actividades que constituye la\ntransfusión sanguínea, y esto también va en relación directa con el grado de desarrollo y capacidad económica\ny organizacional de cada país. Aún en la década del noventa, los esfuerzos se encaminaban hacia las buenas\nprácticas de manufactura; sin embargo, la responsabilidad no termina al entregar un hemocomponente “se\n-\nguro”: resulta indispensable promover el buen uso de la sangre y sus componentes. En ese tiempo en los países\ndesarrollados se decía que era “una triste realidad” que muchos médicos tenían aún conceptos erróneos en el\nuso apropiado de los hemocomponentes. En un estudio realizado en Inglaterra en 1997 se encontró que los","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":384,"lines":{"from":23,"to":33}}}}],["1955",{"pageContent":"uso apropiado de los hemocomponentes. En un estudio realizado en Inglaterra en 1997 se encontró que los\nmédicos residentes eran los que mayores conocimientos tenían en medicina transfusional (aproximadamente el\n80%), que los médicos especialistas y cirujanos conocían menos que los residentes, y que, a mayor edad, menor\ngrado de conocimientos. Después de 2 años de introducir y aplicar las guías de prácticas transfusionales, el\n44% de los encuestados desconocían su existencia, el 46% de los que sí las conocían manifestaron que estas no\ntenían ninguna influencia en su práctica clínica y solo el 25% de los hematólogos usaban las guías.\nAl contrario de los esfuerzos crecientes para lograr “sangre segura”, se ha puesto menos atención a mejorar\nla seguridad en toda la cadena transfusional en los hospitales. De acuerdo a los informes del programa SHOT\n(\nSerious Hazards of Transfusion\n), en Inglaterra, entre 1968 y 2003, el riesgo de cometer un error durante un","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":384,"lines":{"from":33,"to":43}}}}],["1956",{"pageContent":"(\nSerious Hazards of Transfusion\n), en Inglaterra, entre 1968 y 2003, el riesgo de cometer un error durante un\nacto transfusional era de 1 en 16 500; una transfusión incompatible en el sistema ABO aparecía en 1 de cada\n100 000 casos. Existen puntos críticos en la cadena transfusional en donde se pueden cometer errores, empe\n-\nzando por la decisión de transfundir un hemocomponente, la prescripción y la solicitud, la identificación y la\ntoma de la muestra de sangre al paciente, el etiquetado de esta, la tipificación (sistema ABO y Rh) y la reali\n-\nzación de las pruebas de compatibilidad o pruebas cruzadas, y finalmente la toma de la sangre del refrigerador\ny su aplicación al paciente; estos últimos fueron los puntos de error más comunes en los informes al SHOT.\nEl enfoque de la hemovigilancia debe dirigirse a identificar las causas del problema; los errores deben acep\n-\ntarse como una ventana que permite ver los defectos del proceso y ayuda a identificar caminos para mejorarlo;","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":384,"lines":{"from":43,"to":56}}}}],["1957",{"pageContent":"-\ntarse como una ventana que permite ver los defectos del proceso y ayuda a identificar caminos para mejorarlo;\nlos actores son participantes activos en los procesos de aseguramiento y mejoramiento de la calidad. El enfo\n-\nque es hacia la corrección y la educación. La nueva Norma Oficial Mexicana (NOM 253-SSA1-2012) para\nla disposición de sangre humana y sus componentes con fines terapéuticos establece la obligatoriedad de que\ntodo banco de sangre y servicio de transfusión desarrolle y lleve a cabo un proceso o sistema de hemovigilancia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":384,"lines":{"from":56,"to":62}}}}],["1958",{"pageContent":"CONCLUSIONES\n\n•\n \nLa medicina transfusional es una rama de la medicina que ha tenido cambios en la información dispo-\nnible en todo lo relacionado con la transfusión sanguínea.\n\n•\n \nEl médico responsable de la transfusión es aquel que la indica como se ha señalado en la Norma\nOficial Mexicana para la disposición de sangre humana y sus componentes con fines terapéuticos;\nel resto de los procesos deben ser llevados a cabo por el servicio de medicina transfusional, desde la\nselección de los donadores hasta la obtención de la sangre, el fraccionamiento y el almacenamiento.\nSe deben realizar todas las prácticas de buena medicina transfusional, desde la selección del hemocompo\n-\nnente solicitado, que debe ser transfundido cumpliendo con todos los criterios de seguridad y calidad, hasta","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":384,"lines":{"from":64,"to":79}}}}],["1959",{"pageContent":"358\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\nla aplicación por el personal de enfermería, quien corroborará toda la información conjuntamente con el\npersonal de medicina transfusional, para asegurar que corresponda al paciente a quien le será aplicado.\n\nPREGUNTAS DE AUTOEVALUACIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":385,"lines":{"from":1,"to":8}}}}],["1960",{"pageContent":"1. ¿Cuál es el efecto adverso más catastrófico en la transfusión de concentrados eritrocitarios?\na.\n \nSobrecarga circulatoria\nb. Intoxicación por citrato\nc.\n \nReacción hemolítica intravascular por transfusión incompatible\n2. ¿En qué casos se indica la transfusión de plaquetas?\na.\n \nCirugía abdominal\nb. Sangrado por trombocitopenia\nc.\n \nCorregir la cifra plaquetaria\n3. ¿Cuál constituye el mejor tratamiento para los hemofílicos?\na.\n \nPlasma fresco congelado\nb. Crioprecipitado\nc.\n \nConcentrado de factor deficiente específico\n4. ¿Cuál de las siguientes es una práctica que reduce en forma importante las reacciones asociadas a la transfusión?\na.\n \nLavado del concentrado eritrocitario con solución salina\nb. Aplicar antihistamínicos\nc.\n \nUtilizar sangre de familiares\n5. ¿Qué se debe realizar para disminuir las probabilidades de contraer hepatitis C asociada a transfusión?\na.\n \nCitometría hemática del donador\nb. Pruebas de funcionamiento hepático al receptor\nc.\n \nTodas las anteriores son falsas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":385,"lines":{"from":10,"to":49}}}}],["1961",{"pageContent":"BIBLIOGRAFÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":385,"lines":{"from":51,"to":51}}}}],["1962",{"pageContent":"Arsura EL, Bortelle A, Minkowitz S. Transfusion-associated graft-versus-host disease in a presumed immunocompe\n-\ntent patient. Arch Intern Med. 1988; 148: 1941-48.\nArroyo-Pérez JA, et al. Prevalencia de virus B en donadores de sangre mexicanos. Revista Hospital General de Mé -\nxico. 2010; 73: 283-87.\nAyob Y. Hemovigilance in developing countries. Biologicals. 2010.\nBaron JF. Âe hemovigilance network: Âe French experience. En: Building a blood system for the 21st century.\nProceedings and recommendations. Nov. 3-4, 1997. Health Canada-Canadian Blood Agency. p. 37-39.\nBrecher ME. Hemapheresis. American Association of Blood Banks Technical Manual. 17th ed. Bethesda, MD,\nUSA: AABB Press; 2010.\nByrnes JJ, Moake JL, Klug P. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory\nthrombotic thrombocytopenia purpura. Amer J Hemat. 1990; 34: 169-174.\nBrubacker DB. Transfusion-associated graft-versus-host disease. Hum Pathol. 1986; 17: 1085-88.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":385,"lines":{"from":53,"to":65}}}}],["1963",{"pageContent":"thrombotic thrombocytopenia purpura. Amer J Hemat. 1990; 34: 169-174.\nBrubacker DB. Transfusion-associated graft-versus-host disease. Hum Pathol. 1986; 17: 1085-88.\nCairo MS. Neutrophil transfusions in the treatment of neonatal sepsis. Amer J Pediat Hematol Oncol. 1989; II: 227-234.\nChernoff A, Snyder EL. Âe cellular and molecular basis of the platelet storage lesion: A symposium summary. 1992;\n32: 386-390.\nDomínguez JL, Rodríguez MH, Quintanar E, et al. Manual de las indicaciones y manejo de transfusión sanguínea.\nMéxico: SSA.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":385,"lines":{"from":65,"to":71}}}}],["1964",{"pageContent":"359\n\nCAPÍTULO 22. TERAPÉUTICA TRANSFUSIONAL","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":386,"lines":{"from":1,"to":3}}}}],["1965",{"pageContent":"Dood RY. Transfusion transmitted diseases. En: Anderson KC. Scientific basis of transfusion medicine, implications\nfor clinical practices. Philadephia: W.B. Saunders Company; 1994. p. 599-619.\nDodd RY, Sullivan MT. Creutzfeldt-Jacob disease and transfusion safety: Tilting at icebergs? Transfusion. 1998; 38: 221-3.\nDwire DM, Fernando CP. Hepatitis B, hepatitis C and HIV transfusion transmitted diseases in 21 century. Vox\nSang. 2011; 100: 92-98.\nEpstein JS. Alternative strategies in assure blood safety. An overview. Biologicals. 2010.\nGibas WN, Corcoran P. Blood safety in developing countries. Vox Sang. 1994; 67(4): 377-381.\nHarris AM, Atterbury CLJ, Chaffe B, C Elliott, et al. Guideline on the Administration of Blood Components.\nBritish Committee for Standards in Haematology; 2009 (review 2012).\nHogman CF, Gong J, Hambraeus A, et al. Âe role of white cells in the transmission of\n \nYersinia enterocolitica\n \nin blood\ncomponents. Tranfusion. 1992; 32: 654-657.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":386,"lines":{"from":5,"to":19}}}}],["1966",{"pageContent":"Hogman CF, Gong J, Hambraeus A, et al. Âe role of white cells in the transmission of\n \nYersinia enterocolitica\n \nin blood\ncomponents. Tranfusion. 1992; 32: 654-657.\nHywood AM. Transmissible spongiform encephalopathies. N Engl J Med. 1997; 337: 1821-3.\nKirchhoff LV, Paredes P, Becerra-Leyva G, Lomelí-Guerrero A, Ron-Guerrero C. American trypanosomiasis (Cha -\ngas disease) in Mexico: Implications for transfusion medicine in the United States. Transfusion. 2006; 46: 298-304.\nKlumpp T, Siegel D. Transfusion medicine. 3rd. ed. USA: ASH; 2007. p. 408, 443.\nKruskall MS, Alper CA, Yunis EJ. HLA-homozygous donors and transfusion-associated graft-versus-host disease.\nN Engl J Med. 1990; 322: 1005-6.\nLinares J. Inmunohematología y transfusión. Caracas: Cromotip; 1986.\nMcCullough J. Transfusion medicine. New York: McGraw-Hill; 1998.\nMenitove JE, ed. Standards of blood banks and transfusion services. 19th ed. Bethesda, MD: American Association\nof Blood Banks; 1999.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":386,"lines":{"from":19,"to":34}}}}],["1967",{"pageContent":"McCullough J. Transfusion medicine. New York: McGraw-Hill; 1998.\nMenitove JE, ed. Standards of blood banks and transfusion services. 19th ed. Bethesda, MD: American Association\nof Blood Banks; 1999.\nMollison PL, Engelfried CP, Contreras M. Blood transfusion in clinical medicine. Oxford: UK Blackwell Scientific\nPublications; 1993.\nMurphy MF, Brozovic B, Murphy W, et al. Guidelines for platelet transfusions. Transfusion Medicine. 1992; 2: 311-318.\nNorma Oficial Mexicana para la disposición de sangre humana y sus componentes con fines terapéuticos. México:\n253-SS A1-2012.\nPatten E. Prophylactic platelet transfusion revisited after 25 years. Transfusion. 1992; 32: 381-386.\nRetter A, Wyncoll D, Pearse R, Carson D, et al. Guidelines on the management of anaemia and red cell transfusion\nin adult critically ill patients. British Committee for Standards in Haematology; 2012.\nRodríguez-Moyado H. Enfermedades infecciosas por transfusión en México. Revista Asociación Mexicana de Me-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":386,"lines":{"from":34,"to":45}}}}],["1968",{"pageContent":"in adult critically ill patients. British Committee for Standards in Haematology; 2012.\nRodríguez-Moyado H. Enfermedades infecciosas por transfusión en México. Revista Asociación Mexicana de Me-\ndicina Transfusional. 2011; 4(2): 78-90.\nStephan RN, Kisala JM, Dean RA. Effect of blood transfusion on antigen presentation function and on IL-2 gene -\nration. Arch Surg. 1988; 123: 235-240.\nStainsby D, Russell J, Cohen H, Lilleyman J. Reducing adverse events in blood transfusion. Br J Haematol. 2005; 131(1): 8-12.\nSullivan P. Developing an administrative plan for transfusion medicine: A global perspective. Transfusion. 2005; 45 (4 suppl): 2245.\nVon Fliedner V, Higby DJ, Kim V. Graft-versus-host reaction following blood products transfusion. Amer J Med.\n1982; 72: 951-61.\nWinslow RM. Red cell substitutes, current status 1992. En: Blood safety current challenges. Bethesda: AABB; 1992.p. 151-167.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":386,"lines":{"from":45,"to":54}}}}],["1969",{"pageContent":"1982; 72: 951-61.\nWinslow RM. Red cell substitutes, current status 1992. En: Blood safety current challenges. Bethesda: AABB; 1992.p. 151-167.\nWidman FK. Adverse effects of blood transfusion. En: Blood safety current challenges Bethesda: AABB; 1992. p. 291-306.\nWilliamson LM, Bruce D, Lubenko A, et al. Molecular biology for platelet alloantigen typing. Transfusion Medi-\ncine. 1992; 32: 250-264.\nWilkinson SL, Lipton KS. Leukocyte reduction. Association Bulletin #99-7. Bethesda, MD: American Association\nof Blood Banks; 1999.\nWood ML, Gottschalk R, Mónaco AP. Effect of blood transfusion on IL-2 production. Transplantation. 1988; 45: 930-935.\nYazdanbakhs K, Bao W, Zhong H. Immunoregulatory effects of stored red blood cells, adverse complications of\nstored blood. Transfusion Medicine Educational Program. 2011.\nYang OH. Leukocyte-reduced, cytomegalovirus-screened and irradiated blood components: Indications and contro-\nversies. Curr Issues Transf Med. 1993.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":386,"lines":{"from":54,"to":65}}}}],["1970",{"pageContent":"RESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\n1.\n \nc\n2.\n \nb\n3.\n \nc\n4.\n \nb\n5.\n \nc","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":386,"lines":{"from":67,"to":83}}}}],["1971",{"pageContent":"361\n\nINTRODUCCIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":388,"lines":{"from":1,"to":3}}}}],["1972",{"pageContent":"El trasplante de células hematopoyéticas totipotenciales (TCH) se ha convertido en un recurso tera-\npéutico imprescindible en la práctica moderna de la medicina; dado que es un procedimiento de in-\ntroducción relativamente reciente en la práctica clínica diaria, continúa en plena evolución. El primer\nTCH se llevó a cabo en 1957, hace más de 50 años, y desde entonces el número de TCH realizados en\ntodo el mundo ha tenido un crecimiento exponencial. Los TCH son fundamentalmente de dos\ntipos: autólogos y alogénicos. Los trasplantes de células hematopoyéticas\n \nautólogas\n \n(auto-TCH) se\nefectúan con el objeto de poder administrar al paciente quimioterapia o radioterapia a dosis altas, sin\ndañar de manera irreversible la función hematopoyética de la médula ósea; por ello, los auto-TCH\nse llevan a cabo en pacientes con tumores sensibles a la quimioterapia o radioterapia. Por otro lado,\nlos trasplantes de células hematopoyéticas\n \nalogénicas\n \n(alo-TCH) se realizan con tres objetivos fun-","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":388,"lines":{"from":5,"to":22}}}}],["1973",{"pageContent":"se llevan a cabo en pacientes con tumores sensibles a la quimioterapia o radioterapia. Por otro lado,\nlos trasplantes de células hematopoyéticas\n \nalogénicas\n \n(alo-TCH) se realizan con tres objetivos fun-\ndamentales: reemplazar el tejido hematopoyético defectuoso insuficiente o neoplásico, poder ad-\nministrar al paciente quimioterapia o radioterapia a dosis altas e inducir el efecto de injerto contra\ntumor en los pacientes con tumores malignos hematopoyéticos o de otra estirpe, al introducir en el\nreceptor un nuevo sistema inmunocompetente. Con el fin de tener una información adecuada de los\nTCH llevados a cabo en todo el mundo, desde hace varios años funciona el Centro Internacional de\nInvestigación de Trasplantes de Células Hematopoyéticas de Sangre y de Médula Ósea (CIBMTR,\nde\n \nCenter for International Blood and Marrow Transplantation Research\n)\n,\n \nal que idealmente todas las\ninstituciones que hacen trasplantes hematopoyéticos debieran informar sus resultados.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":388,"lines":{"from":22,"to":41}}}}],["1974",{"pageContent":"FUENTES DE CÉLULAS HEMATOPOYÉTICAS TOTIPOTENCIALES\n\nEn el capítulo 1 del libro se ha señalado que las células hematopoyéticas (CH) totipotenciales tienen\ndos características funcionales sobresalientes: son autoperpetuables, es decir, son capaces de generar\n\nCAPÍTULO 23\n\nTRASPLANTE DE CÉLULAS\nHEMATOPOYÉTICAS\n\nGuillermo J. Ruiz Argüelles\nGuillermo J. Ruiz Delgado\nDavid Gómez Almaguer\n\nObjetivos de aprendizaje\n\n•\n \nDistinguir las diferencias entre los trasplantes autólogos y los alogénicos.\n\n•\n \nReconocer los mecanismos del reemplazo de la hematopoyesis como opción terapéutica.\n\n•\n \nComprender los esquemas de acondicionamiento pretrasplante.\n\n•\n \nConocer las indicaciones de los trasplantes de células hematopoyéticas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":388,"lines":{"from":43,"to":73}}}}],["1975",{"pageContent":"362\n \nFUNDAMENTOS DE HEMATOLOGÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":389,"lines":{"from":1,"to":3}}}}],["1976",{"pageContent":"una célula idéntica a sí misma, y son capaces de diferenciarse para generar las tres líneas celulares de la\nsangre: eritrocitos, leucocitos y plaquetas.\nDesde el punto de vista de la expresión de antígenos, estas CH se caracterizan por expresar el antí-\ngeno CD34, sin expresar otros antígenos de diferenciación de línea (lin –). Cuando se llevan a cabo los\nTCH, el objetivo principal es trasplantar estas CH CD34 (+), lin (–). Las células con estas características\nse encuentran tanto en la médula ósea (MO) como en la sangre periférica (SP) y en la sangre del cordón\numbilical (CU), también llamada\n \nsangre placentaria\n. En virtud de que en la actualidad las CH se pueden\nobtener de la MO, de la SP y de los CU, hoy día se prefiere hablar de\n \ntrasplante de células hematopoyéticas\ntotipotenciales\n \ny no de\n \ntrasplante de médula ósea\n, como antes se hacía. Las CH CD34 (+) lin (–) corresponden\naproximadamente al 1% de las células nucleadas de la MO, al 0,1% de las células nucleadas de la SP y al 1%","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":389,"lines":{"from":5,"to":24}}}}],["1977",{"pageContent":"y no de\n \ntrasplante de médula ósea\n, como antes se hacía. Las CH CD34 (+) lin (–) corresponden\naproximadamente al 1% de las células nucleadas de la MO, al 0,1% de las células nucleadas de la SP y al 1%\nde las células nucleadas de la sangre de CU. Por medio de maniobras que emplean medicamentos como\nalgunos factores de crecimiento hemolinfopoyético, principalmente el filgrastim (G-CSF), asociado o no\nal empleo de quimioterapia, es posible hacer que las CD34 (+) lin (–) se transporten de la médula ósea\nhacia la sangre periférica, incrementando hasta en un logaritmo su cantidad en la SP. Estas maniobras se\nconocen genéricamente como “movilización” de las CH de la MO a la SP\n \n(fig. 23-1)\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":389,"lines":{"from":24,"to":36}}}}],["1978",{"pageContent":"AUTO-TCH","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":389,"lines":{"from":38,"to":38}}}}],["1979",{"pageContent":"Los auto-TCH se llevan a cabo como una maniobra para que el paciente pueda recibir dosis altas de\nquimioterapia o radioterapia sin dañar de manera irreversible su capacidad hematopoyética, de la que\ndepende la producción de todas las células de la sangre.\nEn consecuencia, los auto-TCH se realizan en sujetos que tienen tumores o enfermedades sensibles\nal efecto de la quimioterapia o de la radioterapia a dosis altas. Las indicaciones más frecuentes de los au-\nto-TCH son el mieloma múltiple, los linfomas no Hodgkin, los linfomas de Hodgkin, algunos tumores\nsólidos como el cáncer de mama, algunos padecimientos autoinmunitarios como la esclerosis múltiple, la\nartritis reumatoide, el lupus eritematoso generalizado y algunas leucemias agudas y crónicas. Los esque-\nmas de acondicionamiento para hacer los auto-TCH son variables y entre ellos se encuentran el melfalán\na dosis altas, el BEAM (BCNU, etopósido, citarabina y melfalán), el ICE (ifosfamida, ciclofosfamida","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":389,"lines":{"from":40,"to":49}}}}],["1980",{"pageContent":"a dosis altas, el BEAM (BCNU, etopósido, citarabina y melfalán), el ICE (ifosfamida, ciclofosfamida\ny etopósido) y otros. Es preferible usar CH obtenidas de la sangre periférica en los auto-TCH: la recu-\nperación de la hematopoyesis es más rápida y las complicaciones menos frecuentes y menos graves. La\nmovilización de las CH en los auto-TCH habitualmente se hace empleando filgrastim durante 5 días","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":389,"lines":{"from":49,"to":52}}}}],["1981",{"pageContent":"Figura 23-1.\n \nHierro sérico y capacidad total de fijación a la transferrina en condiciones normales, en tras -\ntornos crónicos y en otros padecimientos.\n\nEn el capítulo 1 del libro se ha\nseñalado que las células he-\nmatopoyéticas totipotenciales\n(CH) tienen dos característi-\ncas funcionales sobresalientes:\nson autoperpetuables, es decir,\nson capaces de generar una cé-\nlula idéntica a sí misma, y son\ncapaces de diferenciarse para\ngenerar las tres líneas celula-\nres de la sangre: eritrocitos,\nleucocitos y plaquetas.\nLos auto-TCH se llevan a\ncabo como una maniobra para\nque el paciente pueda recibir\ndosis altas de quimioterapia\no radioterapia sin dañar de\nmanera irreversible su capa-\ncidad hematopoyética, de la\nque depende la producción de\ntodas las células de la sangre.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":389,"lines":{"from":54,"to":79}}}}],["1982",{"pageContent":"363\n\nCAPÍTULO 22. TRASPLANTE DE CÉLULAS HEMATOPOYÉTICAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":390,"lines":{"from":1,"to":3}}}}],["1983",{"pageContent":"consecutivos antes de iniciar la obtención de las CH de la sangre periférica por medio de sistemas cerrados\nde aféresis. Cuando se usan esquemas de acondicionamiento pretrasplante “cortos”, como el melfalán a\ndosis altas en una sola inyección, no hay necesidad de hacer la criopreservación (congelamiento) de las\nCH, ya que estas pueden mantenerse en refrigerados convencionales hasta por 96 horas sin deterioro de\nsu viabilidad y de su capacidad de regenerar la hematopoyesis; sin embargo, cuando se emplean otros es-\nquemas de acondicionamiento pretrasplante hay necesidad de criopreservar las CH antes de reinfundirlas\nal paciente. La necesidad de hacer el congelamiento de las CH incrementa los costos del procedimiento.\nEl auto-TCH es el tratamiento de elección en los pacientes con mieloma múltiple menores de 70\naños que no tengan una contraindicación formal para llevarlo a cabo. En los enfermos con linfomas de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":390,"lines":{"from":5,"to":13}}}}],["1984",{"pageContent":"El auto-TCH es el tratamiento de elección en los pacientes con mieloma múltiple menores de 70\naños que no tengan una contraindicación formal para llevarlo a cabo. En los enfermos con linfomas de\nHodgkin y no Hodgkin que han tenido una recaída, la realización del auto-TCH se asocia con una mejor\nsupervivencia a largo plazo. Durante muchos años, la indicación más frecuente de los auto-TCH fue el\ncáncer de mama metastático; en la actualidad parece razonable seguir realizándolos con esta indicación\nen casos selectos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":390,"lines":{"from":13,"to":18}}}}],["1985",{"pageContent":"ALO-TCH","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":390,"lines":{"from":20,"to":20}}}}],["1986",{"pageContent":"Para llevar a cabo los alo-TCH, las CH alogénicas pueden obtenerse de un hermano compatible por\nel sistema de antígenos leucocitarios humanos (HLA), de un gemelo idéntico (alo-TCH singénico) o\nde un donador compatible no emparentado (no relacionado). El donador ideal es un hermano de HLA\nidéntico (los diez antígenos HLA A, B, C, DR, DQ del donador son idénticos a los diez antígenos del\nreceptor). Como ya se mencionó, los alo-TCH se llevan a cabo con tres objetivos fundamentales: re -\nemplazar el tejido hematopoyético defectuoso, insuficiente o neoplásico, poder administrar al paciente\nquimioterapia o radioterapia a dosis altas e inducir el efecto de injerto contra tumor en los pacientes\ncon tumores malignos hematopoyéticos o de otra estirpe celular, al introducir en el receptor un nuevo\nsistema inmunocompetente.\nEn la actualidad, parece que este último efecto es el de mayor utilidad en el control a largo plazo de los","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":390,"lines":{"from":22,"to":31}}}}],["1987",{"pageContent":"sistema inmunocompetente.\nEn la actualidad, parece que este último efecto es el de mayor utilidad en el control a largo plazo de los\ntumores malignos, hemáticos o de otra estirpe celular. Las indicaciones más frecuentes de los alo-TCH son:\nleucemias agudas o crónicas, hipoplasia medular grave, síndromes mielodisplásicos, inmunodeficiencias\ngraves, hemoglobinopatías y talasemias, linfomas, mielomas y algunos tumores sólidos. Se han empleado\ndiversos esquemas de acondicionamiento pretrasplante, que de una manera simplista pueden dividirse en\ndos grandes grupos: los esquemas clásicos de acondicionamiento mieloablativo y los esquemas de intensidad\nreducida.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":390,"lines":{"from":31,"to":38}}}}],["1988",{"pageContent":"INDICACIONES DE LOS TRASPLANTES\nDE CÉLULAS HEMATOPOYÉTICAS\n\nLas siguientes son situaciones en las que se debe considerar la posibilidad de llevar a cabo un trasplante de\ncélulas hematopoyéticas:\n1. Trasplantes autólogos:\n\n•\n \nMieloma múltiple en primera o segunda remisión\n\n•\n \nLinfomas de Hodgkin refractarios o en segunda remisión\n\n•\n \nLinfomas no Hodgkin refractarios o en segunda remisión\n\n•\n \nLinfomas de células del manto\n2. Trasplantes alogénicos:\n\n•\n \nLeucemia aguda mieloblástica en primera remisión, de riesgo alto\n\n•\n \nLeucemia aguda mieloblástica en segunda remisión\n\n•\n \nLeucemia aguda linfoblástica en segunda remisión\n\n•\n \nLeucemia aguda linfoblástica con cromosoma Philadelphia\n\n•\n \nLeucemia aguda linfoblástica en primera remisión, de riesgo alto\n\n•\n \nSíndromes mielodisplásicos de riesgo alto\n\n•\n \nLeucemia granulocítica crónica refractaria a inhibidores de tirosina-cinasa\n\n•\n \nLeucemia granulocítica crónica en fase acelerada o blástica\n\n•\n \nHipoplasia medular refractaria a inmunosupresión intensa","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":390,"lines":{"from":40,"to":98}}}}],["1989",{"pageContent":"•\n \nLeucemia granulocítica crónica en fase acelerada o blástica\n\n•\n \nHipoplasia medular refractaria a inmunosupresión intensa\n\nLos alo-TCH se llevan a cabo\ncon tres objetivos fundamenta-\nles: reemplazar el tejido hemato-\npoyético defectuoso, insuficiente\no neoplásico, poder administrar\nal paciente quimioterapia o ra-\ndioterapia a dosis altas e inducir\nel efecto de injerto contra tumor\nen\n \nlos\n \npacientes\n \ncon\n \ntumores\nmalignos hematopoyéticos o de\notra estirpe celular, al introducir\nen el receptor un nuevo sistema\ninmunocompetente.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":390,"lines":{"from":98,"to":126}}}}],["1990",{"pageContent":"364\n \nFUNDAMENTOS DE HEMATOLOGÍA\nETAPAS DEL TRASPLANTE\n\nEvaluación del paciente y donador\n\nEn esta etapa se valora cuidadosamente al donador y al receptor. Al primero se le verifica su salud ge -\nneral, estudios serológicos, HLA, etcétera. Al enfermo se le revisa su estado general y si es necesario\nse realizan estudios especiales, como ecocardiograma, pruebas respiratorias, riesgo de trasplante de\nacuerdo a su edad, tipo de enfermedad, estadio de esta, entre otros.\n\nTrasplante\n\nDespués de que se administra la quimioterapia al enfermo, se obtienen las células del donador de la sangre\nperiférica o de la médula ósea y se infunden por una vena al receptor.\n\nEtapa postrasplante","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":391,"lines":{"from":1,"to":18}}}}],["1991",{"pageContent":"Después de que se administra la quimioterapia al enfermo, se obtienen las células del donador de la sangre\nperiférica o de la médula ósea y se infunden por una vena al receptor.\n\nEtapa postrasplante\n\nSe vigila el riesgo de infecciones y la necesidad de transfusiones sanguíneas. En el caso del trasplante\nalogénico, además de lo anterior, se administran inmunosupresores como la ciclosporina para evitar el\nrechazo y la enfermedad del injerto contra huésped. Posteriormente, mediante estudios de quimerismo,\nse verifica si las células sanguíneas del paciente son del donador.\n\nESQUEMAS DE ACONDICIONAMIENTO\n\nEsquemas de acondicionamiento ablativo","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":391,"lines":{"from":18,"to":30}}}}],["1992",{"pageContent":"ESQUEMAS DE ACONDICIONAMIENTO\n\nEsquemas de acondicionamiento ablativo\n\nEstos esquemas dañan de manera irreversible la médula ósea del receptor, la cual debe ser reemplazada\npor el tejido hematopoyético del donador, obtenido de la MO, la SP o la sangre de uno o más CU. El\nprototipo de este esquema es el BuCY (busulfán y ciclofosfamida), empleado desde hace muchos años en\nel acondicionamiento pretrasplante. Estos esquemas convencionales mieloablativos se asocian a diversas\ncomplicaciones en el receptor y producen morbilidad y mortalidad causada por el acondicionamiento en\nel orden del 30 al 50% de los pacientes trasplantados. Los períodos de recuperación de la hematopoyesis\nen el receptor suelen ser prolongados, y durante estos se pueden presentar infecciones graves o sangrados.\n\nEsquemas de acondicionamiento de intensidad reducida","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":391,"lines":{"from":30,"to":42}}}}],["1993",{"pageContent":"Estos esquemas inducen fundamentalmente inmunosupresión más que mielosupresión; el objetivo\nes que el receptor no dañe ni el tejido hematopoyético ni el sistema inmunocompetente del donador,\nel cual es introducido por medio de células del donante obtenidas de la MO, la SP o el CU. Estos\nesquemas usan medicamentos inmunosupresores poderosos como la fludarabina u otros análogos de\nlos nucleósidos. Las células inmunitarias del donador, principalmente los linfocitos T, además de que\ncrean espacio para alojar a las células hematopoyéticas trasplantadas, identifican como ajenas a las\ncélulas malignas del receptor y montan una respuesta inmunitaria contra ellas, denominada\n \nefecto de\ninjerto contra tumor\n. Dado que el daño al tejido hematopoyético del receptor es menor con estos esque -\nmas de intensidad reducida, la recuperación de la hematopoyesis es más rápida y los períodos de riesgo\nderivados de la leucopenia o trombocitopenia son más cortos, por lo que la morbimortalidad de estos","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":391,"lines":{"from":44,"to":56}}}}],["1994",{"pageContent":"derivados de la leucopenia o trombocitopenia son más cortos, por lo que la morbimortalidad de estos\npacientes es menor. Se han empleado diversos esquemas de acondicionamiento de intensidad reducida\npara llevar a cabo los alo-TCH; desde hace varios años en México se usa el “esquema mexicano” de\nacondicionamiento, que emplea fludarabina, busulfán y ciclofosfamida y produce resultados a largo\nplazo muy similares a los de los esquemas tradicionales de acondicionamiento ablativo, con costos\nnotablemente menores, lo que lo ha convertido en un recurso terapéutico más accesible a pacientes de\neste país. Los trasplantes hematopoyéticos que emplean esquemas de acondicionamiento de intensidad\nreducida producen menos enfermedad de injerto contra huésped.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":391,"lines":{"from":56,"to":63}}}}],["1995",{"pageContent":"RESULTADOS\n\nEn términos generales, alrededor del 50% de los pacientes que son sometidos a un TCH son supervivien-\ntes a largo plazo. Es importante tener en cuenta este dato, ya que los TCH se indican en enfermedades","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":391,"lines":{"from":65,"to":68}}}}],["1996",{"pageContent":"365\n\nCAPÍTULO 22. TRASPLANTE DE CÉLULAS HEMATOPOYÉTICAS\n\ncuya mortalidad es mayor al 50% en caso de no llevar a cabo el trasplante. En algunas enfermedades los\nresultados son mejores que en otras; por ejemplo, en leucemia granulocítica crónica y en la hipoplasia me-\ndular se obtienen los mejores resultados con el alo-TCH, en tanto que en la recaída de leucemia linfoblás-\ntica los resultados son menos halagüeños. Más del 50% de los pacientes con mieloma múltiple sometidos\na auto-TCH viven en buenas condiciones por más de 5 años. La\n \nfigura 23-2\n \nresume los resultados de los\nalo-TCH en México, empleando un esquema de acondicionamiento no ablativo.\n\nCOMPLICACIONES","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":392,"lines":{"from":1,"to":16}}}}],["1997",{"pageContent":"COMPLICACIONES\n\nLos TCH no están exentos de complicaciones. En el caso de los auto-TCH, las infecciones que se presen-\ntan durante el período de mielosupresión pueden ser graves y hasta fatales. La trombocitopenia que ocurre\nen el período de máxima mielosupresión puede causar sangrados graves. Algunos pacientes sometidos a\nalo-TCH pueden desarrollar segundas neoplasias. En el caso de los alo-TCH, además de las complicacio-\nnes antes mencionadas, se puede presentar la enfermedad de injerto contra huésped (EICH), que es una\nrespuesta inmunitaria de las células T inmunocompetentes del donador en contra de las células del recep-\ntor; esta complicación, que ocurre hasta en el 50% de los pacientes sometidos a alo-TCH, puede variar\nentre una erupción de la piel hasta una enfermedad que puede acabar con la vida del paciente trasplantado.\nLos trasplantes hematopoyéticos que utilizan esquemas de acondicionamiento de intensidad reducida\nproducen menos enfermedad de injerto contra huésped.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":392,"lines":{"from":16,"to":27}}}}],["1998",{"pageContent":"CONCLUSIONES\n\n•\n \nEl trasplante de células hematopoyéticas totipotenciales tiene dos modalidades: autólogo y alogénico.\n\n•\n \nEl objetivo de llevar a cabo trasplantes autólogos es poder administrar al paciente dosis altas de qui-\nmioterapia; en la actualidad la indicación más frecuente de esta modalidad de trasplante es el mieloma\nmúltiple.\n\nFigura 23-2.\nSupervivencia global de los pacientes en quienes se llevó a cabo un trasplante de células he-\nmatopoyéticas alogénicas empleando el “método mexicano” de acondicionamiento de intensidad reducida.\nLGC, FC = leucemia granulocítica crónica en primera fase crónica; AA = anemia aplásica; LAM = leu-\ncemia aguda mieloblástica en segunda o tercera remisión; LGC = leucemia granulocítica crónica en fases\ncrónica, blástica o acelerada; LLA = leucemia linfoblástica aguda.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":392,"lines":{"from":29,"to":46}}}}],["1999",{"pageContent":"366\n \nFUNDAMENTOS DE HEMATOLOGÍA\n\n•\n \nEl trasplante alogénico busca reemplazar completamente el tejido hematopoyético anormal e inducir el\nefecto de injerto contra tumor: la indicación más frecuente consiste en las leucemias agudas y crónicas.\n\n•\n \nEn México se han llevado a cabo modificaciones sustanciales a los métodos para realizar los trasplantes\nhematopoyéticos, los cuales han hecho más accesibles y eficaces estos procedimientos terapéuticos,\nimprescindibles en la práctica moderna de la medicina.\n\nPREGUNTAS DE AUTOEVALUACIÓN","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":393,"lines":{"from":1,"to":16}}}}],["2000",{"pageContent":"1. ¿Cuál es el mecanismo principal por el que un trasplante alogénico puede curar una leucemia?\na.\n \nEl efecto de injerto contra leucemia\nb. El efecto de injerto contra huésped\nc.\n \nMielosupresión\n2. ¿Cuál es el fármaco más frecuentemente usado para “movilizar” las células hematopoyéticas de la\nmédula ósea a la sangre periférica?\na.\n \nBusulfán\nb. Ciclofosfamida\nc.\n \nFilgrastim (G-CSF)\n3. ¿Cuál es el objetivo principal de hacerle a un paciente un trasplante de médula ósea autóloga?\na.\n \nReemplazar el tejido hematopoyético defectuoso insuficiente o neoplásico\nb. Poder administrarle dosis altas de quimioterapia\nc.\n \nInducir el efecto de injerto contra tumor\n4. ¿Qué porcentaje de pacientes alotrasplantados desarrollan enfermedad de injerto contra huésped?\na.\n \nAlrededor del 30%\nb. Alrededor del 50%\nc.\n \nAlrededor del 80%\n5. ¿Qué esquemas de acondicionamiento causan menor morbimortalidad?\na.\n \nLos de acondicionamiento ablativo\nb. Los de intensidad reducida\nc.\n \nAmbos causan la misma morbimortalidad","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":393,"lines":{"from":18,"to":58}}}}],["2001",{"pageContent":"BIBLIOGRAFÍA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":393,"lines":{"from":60,"to":60}}}}],["2002",{"pageContent":"Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, Jaime-Pérez JC, Treviño-Montemayor OR, Martínez-Cabriales SA,\nGómez-Peña A, et al. Low incidence and severity of graft-versus-host disease after outpatient allogeneic peripheral\nblood stem cell transplantation employing a reduced-intensity conditioning. Eur J Haematol. 2011: 87: 521-30.\nGómez-Almaguer D, Vela-Ojeda, et al. Allografting in patients with severe aplastic anemia using peripheral blood\nstem cells and a fludarabine-based conditoning regimen: μe Mexican Experience. Am J Hematol. 2006, 81:\n157-161.\nGutiérrez-Aguirre CH, Gómez-Almaguer D, et al. Non-myeloablative stem cell transplantation in patients with re-\nlapsed acute lymphoblastic leukemia: Results of a multicenter study. Bone Marrow Transplant. 2007: 40: 535-539.\nRuiz-Argüelles GJ, Gómez-Rangel D, et al. Results of an autologous non-cryopreserved, unmanipulated peripheral\nblood hematopoietic stem cell transplant program: A single institution, 10-years experience. Acta Haematologica.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":393,"lines":{"from":62,"to":71}}}}],["2003",{"pageContent":"blood hematopoietic stem cell transplant program: A single institution, 10-years experience. Acta Haematologica.\n2003; 110: 179-183.\nRuiz-Argüelles GJ, Gómez-Almaguer D, et al. Allogeneic hematopoietic stem cell transplantation with non-mye-\nloablative conditioning in patients with acute myelogenous leukemia eligible for conventional allografting: A\nprospective study. Leukemia Lymphoma. 2004; 45: 1191-1195.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":393,"lines":{"from":71,"to":75}}}}],["2004",{"pageContent":"367\n\nCAPÍTULO 22. TRASPLANTE DE CÉLULAS HEMATOPOYÉTICAS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":394,"lines":{"from":1,"to":3}}}}],["2005",{"pageContent":"Ruiz-Argüelles GJ, Gómez-Almaguer D. Breaking dogmata to help patients: Non-myeloablative hematopoietic stem\ncell transplantation. Expert Opin Biol Ther. 2004; 4: 1693-99.\nRuiz-Argüelles GJ, Gómez-Almaguer D, et al. Ocho años de experiencia con el “método mexicano” en la realización de\ntrasplantes de células hematopoyéticas alogénicas. Gac Med Mex. 2007; 143: 231-235.\nRuiz-Delgado GJ, Mancías-Guerra C, et al. Trasplante alogénico de células hematopoyéticas de dos cordones umbi -\nlicales. Medicina Universitaria. 2007; 9: 112-116.\nRuiz-Delgado GJ, Ruiz-Argüelles GJ. A Mexican way to cope with stem cell transplantation. Hematology. 2012; 17\n(Suppl. 1): 195-7.\nVela-Ojeda J, García-Ruíz-Ezparza MA, et al. Autologous peripheral blood stem cell transplantation in multiple mye-\nloma using oral versus I.V\n. melphalan. Ann Hematol. 2007; 86: 277-282.\nZamora-Ortiz G, Velázquez-Sánchez-de-Cima S, Hernández-Reyes J, Vargas-Espinosa J, Ruiz-Delgado GJ,","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":394,"lines":{"from":5,"to":16}}}}],["2006",{"pageContent":"loma using oral versus I.V\n. melphalan. Ann Hematol. 2007; 86: 277-282.\nZamora-Ortiz G, Velázquez-Sánchez-de-Cima S, Hernández-Reyes J, Vargas-Espinosa J, Ruiz-Delgado GJ,\nRuiz-Argüelles GJ. Veinte años de experiencia con transplantes de células hematopoyéticas en la Clínica Ruiz de\nPuebla, México. Rev Hematol Mex. 2013; 14: 63-70.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":394,"lines":{"from":16,"to":20}}}}],["2007",{"pageContent":"RESPUESTAS A LAS PREGUNTAS DE AUTOEVALUACIÓN\n\n1.\n \na\n2.\n \nc\n3.\n \nb\n4.\n \nb\n5.\n \nb","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":394,"lines":{"from":22,"to":38}}}}],["2008",{"pageContent":"369\n\naceleradores lineales.\n \nMáquinas que emiten electro-\nnes de alta energía por medio de un campo magnético,\nusadas ampliamente en el tratamiento de los tumores\nmalignos.\n\nagnogénica.\n \nDe origen o etiología desconocidos.\n\naloanticuerpos.\n \nAnticuerpos que reaccionan específi-\ncamente con aloantígenos.\n\naloantígenos.\n \nAntígenos de un tejido o célula pre -\nsentes en algunos miembros de una especie pero no\nen otros y que son reconocidos como extraños en un\nalotrasplante. Los aloantígenos suelen ser productos de\ngenes polimórficos.\n\nalogénico.\n \nConcerniente a la existencia de células in-\nmunogénicamente diferentes.\n\nalquilantes.\n \nCompuestos químicos que interfieren en\nla división celular al inhibir la replicación del DNA, ge-\nnerando sólidos puentes de unión entre ambas hebras de\nDNA.\n\namiloidosis.\n \nTrastorno metabólico que consiste en el\ndepósito tisular difuso de sustancia amiloide; complejo\nproteico polisacárido amorfo de localización extracelular\nen distintos órganos y tejidos del cuerpo.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":396,"lines":{"from":1,"to":44}}}}],["2009",{"pageContent":"anagrelida.\n \nDerivado de la quinazolina; posee gran efi-\ncacia en el manejo de la trombocitosis primaria, reducien\n-\ndo la cuenta plaquetaria.\n\naneuploidia.\n \nEstado de desequilibrio en los pares de\ncromosomas.\n\nangiodisplasia.\n \nAnormalidades\n \nvasculares,\n \nespecial-\nmente las del tracto digestivo; segunda causa de sangrado\nde tubo digestivo bajo en pacientes mayores de 60 años\nde edad.\n\nanillos de Cabot.\n \nInclusiones filiformes dispuestas en\nforma de anillo o de ocho invertido, cuyo origen parece\nresidir en restos de filamentos del huso acromático de la\nmitosis. Su presencia produce un trastorno profundo de\nla eritropoyesis.\n\nanisocitosis.\n \nCoexistencia de eritrocitos de diferentes\ntamaños.\n\nanisocromía.\n \nExistencia de eritrocitos de coloración\ndistinta (eritrocitos hipocrómicos y normocrómicos).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":396,"lines":{"from":46,"to":85}}}}],["2010",{"pageContent":"anisocitosis.\n \nCoexistencia de eritrocitos de diferentes\ntamaños.\n\nanisocromía.\n \nExistencia de eritrocitos de coloración\ndistinta (eritrocitos hipocrómicos y normocrómicos).\n\nanomalía de May-Hegglin.\n \nPuede cursar en forma\nasintomática o con alguna manifestación hemorrágica; se\nasocia a trombocitopenia y presencia de plaquetas gigan -\ntes. Se hereda de forma autosómica dominante y se carac-\nteriza por la observación en el citoplasma de neutrófilos\n\nGLOSARIO\n\nde inclusión grande y basófila que también puede estar\npresente en los granulocitos y monocitos restantes. El es-\ntudio funcional demuestra alteración del quimiotactismo\ny de la movilidad de los neutrófilos afectados.\n\nanticuerpos monoclonales.\n \nAquellos obtenidos de\nla respuesta inmunitaria de ratones o humanos a los que\nse les inmuniza con antígenos tumorales humanos. Tal\nrespuesta produce anticuerpos específicos, y mediante\nbiotecnología, los murinos se pueden “humanizar” y pro-\nducir a gran escala.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":396,"lines":{"from":85,"to":117}}}}],["2011",{"pageContent":"antígenos Rh.\n \nProteínas ligadas a los lípidos de la mem-\nbrana eritrocitaria. Considerados como parte del sistema\ntransfusional más importante después del sistema ABO.\n\nantimetabolitos.\n \nSustancias similares a los metabolitos\nnaturales, pero en las que se han introducido cambios en\nsu estructura química. La célula los utiliza indistinta-\nmente, pero el antimetabolito induce la síntesis letal de\nbases purínicas o pirimidínicas.\n\nantirresortivos.\n \nFármacos que actúan inhibiendo los\nosteoclastos: estrógenos, difosfonatos y la calcitonina;\nconstituyen la base del tratamiento de la osteoporosis.\n\nantraciclinas.\n \nSe intercalan entre las cadenas de DNA,\nbloqueándolo; inhiben la síntesis de RNA y proteínas;\ninteracción con la topoisomerasa I; mecanismo de cito-\ntoxicidad más importante.\n\napoferritina.\n \nProteína formada en la mucosa intestinal\nque capta el hierro contenido en los alimentos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":396,"lines":{"from":119,"to":149}}}}],["2012",{"pageContent":"apoferritina.\n \nProteína formada en la mucosa intestinal\nque capta el hierro contenido en los alimentos.\n\napolipoproteína\n \nβ\n.\n \nPrincipal\n \nconstituyente\n \nproteico\n(95%) de la lipoproteína de baja densidad (LDL); además\nconstituye alrededor del 40% de la parte proteica de la\nlipoproteína de muy baja densidad (VLDL) y de los qui-\nlomicrones.\n\narabinósido de citosina.\n \nAntimetabolito específico de\nfase S, empleado como antineoplásico y antivírico.\n\nataxia.\n \nTrastorno del movimiento voluntario, caracte-\nrizado por incoordinación motora y conservación de la\nfuerza muscular.\n\nautólogo.\n \nProducto o componente de un mismo orga-\nnismo individual.\n\nautosómico recesivo.\n \nGen o alelo que necesita ser he\n-\nredado de ambos padres para poder expresarse.\n\nazatioprina.\n \nDerivado del imidazol citotóxico de la\nmercaptopurina.\n\nazoemia.\n \nPresencia de urea o de otros cuerpos nitroge -\nnados en la sangre.\n\nA","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":396,"lines":{"from":149,"to":201}}}}],["2013",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n370\n\nB2-microglobulina.\n \nCadena ligera de la molécula\nMHC clase I. Proteína extracelular codificada por un\ngen no polimorfo ubicado fuera del MHC; es estructu-\nralmente homólogo al dominio Ig, y es invariante en\ntodas las moléculas clase I.\n\nBillroth II.\n \nGastrectomía amplia seguida de anasto-\nmosis lateral entre el muñón gástrico y un asa yeyunal,\ncon cierre del cabo de duodeno.\n\nbradicinina.\n \nPolipéptido endógeno formado por nue-\nve aminoácidos, contenido en las plaquetas y liberado\npor la acción de la tripsina o algunos venenos de víbora.\n\nbypass\n.\n \nAnastomosis quirúrgica para eludir un seg-\nmento vascular obturado o estenosado mediante un in-\njerto de arteria, vena o tubo de sustancia plástica.\nunión entre ambas hebras del DNA. El clorambucilo es\nactivo en la leucemia linfática crónica.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":397,"lines":{"from":1,"to":32}}}}],["2014",{"pageContent":"coagulopatía por consumo.\n \nTrastorno adquirido\nen el que se produce una coagulación intravascular di-\nseminada, depósito de fibrina en los vasos, descenso del\nfibrinógeno y otros factores de la coagulación, plaque-\ntopenia y tendencia a las hemorragias.\n\nconstante de Michaelis (K\n \nM\n \n).\n \nVelocidad de elimi-\nnación de una sustancia en plasma igual a la mitad de la\nvelocidad de eliminación máxima posible.\n\ncrioprecipitados.\n \nPrecipitado formado al congelar y\nposteriormente descongelar el plasma humano. Prepa-\nrado rico en factor VIII y fibrinógeno.\n\ncrisis aplásica.\n \nTrastorno transitorio caracterizado\npor una hipoplasia medular.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":397,"lines":{"from":34,"to":61}}}}],["2015",{"pageContent":"crisis aplásica.\n \nTrastorno transitorio caracterizado\npor una hipoplasia medular.\n\ncrisis blástica.\nPaso de la fase crónica a un cuadro simi-\nlar al de la leucemia aguda, con invasión rápida de la mé-\ndula ósea, la sangre periférica y a veces otros órganos por\nblastos. Se observa un rápido deterioro de los enfermos,\nsíndrome anémico, infecciones, hemorragias o síntomas\nde leucostasis. Los blastos en su mayoría son de estirpe\nmieloide. La supervivencia media es de solo 5 meses\ndesde el diagnóstico de la crisis blástica mieloide. La\nsupervivencia es mayor en los pacientes con crisis blás-\ntica linfoide.\n\ncromosomas dicéntricos.\n \nCromosomas que tienen\ndos centrómeros localizados.\n\ncromosomas en anillo.\n \nDeleción de la porción final\nde los cromosomas, con reunión de las porciones dista-\nles nuevas para formar un anillo.\n\ncuerpos de Heinz.\n \nCuerpos de inclusión, resultado\nde la precipitación de la hemoglobina. Se encuentran en\nlas talasemias\n\u0003α\n \ny en otras hemoglobinopatías.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":397,"lines":{"from":61,"to":96}}}}],["2016",{"pageContent":"cuerpos de Heinz.\n \nCuerpos de inclusión, resultado\nde la precipitación de la hemoglobina. Se encuentran en\nlas talasemias\n\u0003α\n \ny en otras hemoglobinopatías.\n\ncuerpos de Howell-Jolly.\n \nInclusiones redondea-\ndas, densas y en general únicas, debidas a fragmentos\nde cromosomas procedentes de mitosis eritroblásticas\nanómalas.\n\ncuerpos de Weibel-Palade.\n \nCorpúsculos conteni-\ndos en las células endoteliales de los vasos sanguíneos\nque almacenan al factor von Willebrand, así como a la\nselectina P\n.\n\ncuerpos o bastones de Aüer.\n \nEstructuras alar-\ngadas en el citoplasma que corresponden a agregados\nde granulación primaria; son específicos de blastos de\nestirpe mieloide.\n\ncalicreína.\n \nEnzima o sistema enzimático que, al\nactuar sobre un sustrato perteneciente al grupo de\nlas globulinas\n \nα\n2, da lugar a la liberación de pépti -\ndos vasodilatadores del tipo de la bradicinina y de la\nlisilbradicinina.\n\ncarcinomatosis.\n \nCarcinoma\n \ndiseminado\n \npor\n \nel\ncuerpo (metastásico).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":397,"lines":{"from":96,"to":147}}}}],["2017",{"pageContent":"carcinomatosis.\n \nCarcinoma\n \ndiseminado\n \npor\n \nel\ncuerpo (metastásico).\n\ncélulas de Kupffer.\n \nCélulas especializadas del sis-\ntema reticuloendotelial que tapizan los sinusoides he-\npáticos. Su misión es filtrar bacterias y otras pequeñas\nproteínas extrañas contenidas en la sangre.\n\ncepa murina.\n \nRoedores seleccionados y empleados\npara fines de experimentación.\n\nciclosporina A.\n \nAntiinflamatorio e inmunomodula-\ndor que inhibe los estadios iniciales de la activación de\nlas células T mediante la supresión de la producción\nde citocinas.\n\ncinética celular.\n \nSecuencia ordenada de eventos que\nvan desde el momento en que la célula se divide para\nformar dos células hijas hasta el momento en que dichas\ncélulas hijas se dividen otra vez.\n\ncitotóxicos.\n \nSustancias que tienen un efecto tóxico\nsobre determinadas células.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":397,"lines":{"from":147,"to":187}}}}],["2018",{"pageContent":"citotóxicos.\n \nSustancias que tienen un efecto tóxico\nsobre determinadas células.\n\n2-clorodeoxiadenosina (CdA; cladribina).\n \nFár-\nmaco análogo de la purina; se acumula en los linfocitos\nen su forma fosforilada. Estos derivados pueden inducir\napoptosis por medio de diversos mecanismos: inhibi-\nción de DNA-ligasa, DNA-primasa, reductasa de ribo-\nnucleótido, y DNA o RNA-polimerasas. Incorporación\nde un análogo nucleósido en el DNA o RNA y la inhi-\nbición de la reparación de daños estructurales al DNA.\n\nclorambucilo.\n \nAgente alquilante. Compuesto quí-\nmico que interfiere en la división celular al inhibir la\nreplicación del DNA estableciendo sólidos puentes de\n\nB\nC\nD\n\ndanazol.\n \nAndrógeno sintético. Inhibe la liberación de\ngonadotropinas por la hipófisis.\n\ndedos hipocráticos.\n \nEngrosamiento anormal de las\nfalanges terminales de los dedos. Se observa en neu-\nmopatías y cardiopatías crónicas, cirrosis, colitis y ti-\nrotoxicosis.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":397,"lines":{"from":187,"to":223}}}}],["2019",{"pageContent":"GLOSARIO\n\n371\n\nendotelio.\n \nCapa muy vascularizada de células epi -\nteliales escamosas, derivada del mesodermo; recubre\nel corazón, los vasos sanguíneos y linfáticos y las ca-\nvidades serosas.\n\nenfermedad de Gaucher.\n \nEsfingolipidosis de ca-\nrácter autosómico recesivo causada por deficiencia de la\nenzima glucocerebrosidasa. Este déficit determina una\nacumulación de glucocerebrósido en el sistema fagocí-\ntico mononuclear.\n\nenfermedad de Gilbert.\n \nDéficit de glucuronocon-\njugación, transmitida hereditariamente como carácter\nrecesivo ligado al sexo. Se caracteriza por una ligera hi-\nperbilirrubinemia no conjugada crónica e intermitente\nque aumenta con el ayuno, el estrés, el ejercicio físico,\nla menstruación y con enfermedades intercurrentes. La\nmayoría de los casos son asintomáticos.\n\nendoteliosis.\n \nTumefacción de las células endoteliales\nde los capilares glomerulares.\n\nepistaxis.\n \nHemorragia de las fosas nasales.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":398,"lines":{"from":1,"to":37}}}}],["2020",{"pageContent":"endoteliosis.\n \nTumefacción de las células endoteliales\nde los capilares glomerulares.\n\nepistaxis.\n \nHemorragia de las fosas nasales.\n\nequimosis.\n \nCambio de color de un área cutánea o mu-\ncosa, por extravasación de sangre hacia el tejido celu-\nlar subcutáneo, causada por traumatismo o fragilidad\nvascular.\n\nesclerodermia.\n \nEnfermedad\n \nautoinmunitaria\n \nque\nafecta a los vasos sanguíneos y al tejido conjuntivo. Se\ncaracteriza por degeneración fibrosa del tejido conjun-\ntivo de la piel, los pulmones y los órganos internos, es-\npecialmente el esófago y los riñones.\n\nesclerosis.\n \nEndurecimiento de los tejidos debido a\ndistintas causas: inflamación, depósito de sales mine-\nrales e infiltración en las fibras conjuntivas.\n\nespecificidad.\n \nMide la proporción de individuos no en-\nfermos que la prueba diagnóstica calificará como sanos.\n\nesquistocitos.\n \nEritrocitos fragmentados.\n\nésteres de forbol.\n \nAlcohol relacionado con com-\npuestos cancerígenos del aceite de notón.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":398,"lines":{"from":37,"to":83}}}}],["2021",{"pageContent":"esquistocitos.\n \nEritrocitos fragmentados.\n\nésteres de forbol.\n \nAlcohol relacionado con com-\npuestos cancerígenos del aceite de notón.\n\nestreptocinasa.\nEnzima producida por estreptococos.\nCataliza la conversión del plasminógeno en plasmina.\n\nestroma.\n \nTejido de sostén o matriz de un órgano, in-\ndependiente del parénquima.\n\nestudio citológico.\n \nEstudio microscópico, morfoló-\ngico y funcional de células obtenidas de lesiones super-\nficiales externas e internas.\n\nestudios baritados.\n \nEstudios radiológicos que uti-\nlizan el bario en ingestión o enemas como medio de\ncontraste.\n\netanolamina.\n \nAlcohol amino; líquido viscoso, inco-\nloro, que se utiliza como disolvente de aceites, grasas,\netcétera, y como agente esclerosante de venas varicosas.\n\neuploide.\n \nNúmero equilibrado de cromosomas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":398,"lines":{"from":83,"to":121}}}}],["2022",{"pageContent":"euploide.\n \nNúmero equilibrado de cromosomas.\n\nevolución clonal.\n \nTeoría selectiva de la formación de\nlos anticuerpos. En el individuo normal está presente\nuna dotación de clonas de células linfoides que son ca-\npaces de reaccionar con todos los factores antigénicos\nposibles.\n\nexón.\n \nPorción de DNA que produce el codón para la\nterminación del RNA.\n\ndeferroxiamina.\n \nAgente quelante (fijador) de hierro\naislado de\n \nStreptomyces pilosus\n; se usa en la sobrecarga de\nhierro o aluminio.\n\nderivados de la vinca.\n \nAlcaloides que provocan la\ndisrupción de los microtúbulos como resultado de su\nunión a la tubulina, subunidad proteica del microtúbu-\nlo, provocando que la célula se detenga en la metafase.\n\ndescendientes homocigotos.\n \nPortadores de dos\ncopias del mismo alelo de un gen dado.\n\ndeshidrogenasa láctica.\n \nCataliza la oxidación del\nácido láctico a ácido pirúvico por deshidrogenación\nen presencia de difosfopiridina-nucleótido.\n\ndesoxicoformicina.\n \nAnálogo de las purinas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":398,"lines":{"from":121,"to":167}}}}],["2023",{"pageContent":"deshidrogenasa láctica.\n \nCataliza la oxidación del\nácido láctico a ácido pirúvico por deshidrogenación\nen presencia de difosfopiridina-nucleótido.\n\ndesoxicoformicina.\n \nAnálogo de las purinas.\n\ndiátesis hemorrágica.\n \nPredisposición a las enferme-\ndades hemorragíparas.\n\ndiscinesia.\n \nTrastorno de la capacidad para realizar\nmovimientos voluntarios.\n\ndiscrasias sanguíneas.\n \nAnomalía en cuanto a la\ncualidad o la cantidad de cualquiera de los constituyen-\ntes de la sangre, por ejemplo, la leucemia y la hemofilia.\n\ndisplasia.\n \nAnomalía de desarrollo.\n\ndistribución gaussiana.\n \nDistribución normal; es el\nlímite de la distribución binomial cuando el número de\npruebas tiende a infinito.\n\nefecto de injerto contra huésped u hospedero.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":398,"lines":{"from":167,"to":203}}}}],["2024",{"pageContent":"distribución gaussiana.\n \nDistribución normal; es el\nlímite de la distribución binomial cuando el número de\npruebas tiende a infinito.\n\nefecto de injerto contra huésped u hospedero.\n\nRespuesta inmunitaria observada en los trasplantes alo-\ngénicos de células hematopoyéticas, donde el injerto\nreacciona en contra del huésped causando en él diversas\nafecciones en piel, mucosas, sistema gastrointestinal,\netcétera. Según el momento en el que se presente, se\nclasifica en\n \naguda\n \ncuando ocurre en los primeros 100\ndías y\n \ncrónica\n \ndespués de los 100 días postrasplante.\n\nelectroforesis.\n \nMétodo basado en el movimiento de\nlas partículas cargadas eléctricamente suspendidas en un\nmedio líquido, en repuesta a los cambios de un campo\neléctrico. Las partículas emigran en dirección predecible\ny con rapidez característica. Técnica utilizada para sepa-\nrar e identificar las proteínas séricas y otras sustancias.\n\neliptocitosis.\n \nEritrocitos de forma ovalada.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":398,"lines":{"from":203,"to":238}}}}],["2025",{"pageContent":"eliptocitosis.\n \nEritrocitos de forma ovalada.\n\nembolia grasa.\n \nOcurre como consecuencia de la em-\nbolización de la grasa existente en la médula ósea libe -\nrada a partir de los huesos fracturados.\n\nempiema.\n \nAcúmulo de pus en una cavidad corporal,\nespecialmente el espacio pleural, como resultado de una\ninfección bacteriana.\n\nencefalopatía hepática.\n \nSe manifiesta con trastor-\nnos de conciencia que pueden llegar a coma profundo,\ncambios psiquiátricos de distinto grado, asterixis y he -\ndor hepático.\n\nendorreduplicaciones.\n \nReduplicaciones\n \ncromosó-\nmicas sin división celular posterior.\n\nE","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":398,"lines":{"from":238,"to":268}}}}],["2026",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n372\n\nfalciformes.\n \nEritrocitos de forma alargada, ligera-\nmente curvada y con extremos puntiagudos, que reme -\nda la forma de una hoz.\n\nfenacetina.\n \nDerivado del p-aminofenol con propieda-\ndes antitérmicas y analgésicas.\n\nfenómeno de Raynaud.\n \nTrastornos en los que exis-\nten cambios intermitentes de coloración cutánea distal,\ncomo palidez o cianosis, seguidas de coloración roja.\n\nferritina.\n \nProteína férrica que se encuentra en la mu-\ncosa intestinal, bazo e hígado. Contiene más de 20% de\nhierro y es esencial para la hematopoyesis.\n\nfibrina.\n \nProteína insoluble que proporciona su ca -\nrácter semisólido al coágulo sanguíneo. Producida\npor el efecto de la trombina sobre el fibrinógeno en\nla coagulación.\n\nfibronectina.\n \nGlicoproteína\n \nadhesiva\n \nque\n \nforma\nparte del tejido conectivo, en donde se une por cruza-\nmiento al colágeno. Está implicada en la agregación\nplaquetaria.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":399,"lines":{"from":1,"to":46}}}}],["2027",{"pageContent":"fibronectina.\n \nGlicoproteína\n \nadhesiva\n \nque\n \nforma\nparte del tejido conectivo, en donde se une por cruza-\nmiento al colágeno. Está implicada en la agregación\nplaquetaria.\n\nfiebre de Pel-Ebstein.\n \nFiebre remitente que se ob-\nserva en la enfermedad de Hodgkin, caracterizada por\nperíodos de fiebre elevada de 7 a 10 días, seguidos de\ntemperatura normal durante 2 o 3 semanas.\n\nfludarabina.\n \nAnálogo de las purinas.\n\nflujo laminar.\n \nMovimiento de fluidos y gases organi-\nzados en un conjunto de láminas o capas que se des -\nlizan unas sobre otras sin intercambio de partículas\nentre ellas.\n\nfolicular.\n \nDepresión en forma de bolsa, como los fo -\nlículos pilosos de la epidermis.\n\nfosfatasa ácida resistente al tartrato.\n \nEl ácido\ntartárico inhibe a las isoenzimas de la fosfatasa ácida\nque se encuentran en muchas células, pero no las de la\ntricoleucemia.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":399,"lines":{"from":46,"to":87}}}}],["2028",{"pageContent":"fosfatasa ácida resistente al tartrato.\n \nEl ácido\ntartárico inhibe a las isoenzimas de la fosfatasa ácida\nque se encuentran en muchas células, pero no las de la\ntricoleucemia.\n\nfosfatasa alcalina leucocitaria.\n \nLa enzima se loca-\nliza en los neutrófilos, desde el matamielocito hasta el\nestadio segmentado. Experimenta una fuerte reducción\no no existe en más del 90% de pacientes con leucemia\nmieloide crónica, y es normal o elevada en las reaccio-\nnes leucemoides.\n\nfrotis.\n \nPreparación microscópica delgada y transpa-\nrente extendida entre dos cristales, obtenida de un lí-\nquido espeso o tejido semilíquido o pastoso.\n\ngammagrama.\n \nRepresentación gráfica bidimensio-\nnal de la intensidad, localización y distribución de los\nrayos gamma emitidos por un tejido.\n\ngammapatías monoclonales.\n \nRefleja la presencia\nde cantidades excesivas de un tipo de inmunoglobulina\nsegregado por una sola clona de células B.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":399,"lines":{"from":87,"to":119}}}}],["2029",{"pageContent":"gammapatías monoclonales.\n \nRefleja la presencia\nde cantidades excesivas de un tipo de inmunoglobulina\nsegregado por una sola clona de células B.\n\ngammapatías policlonales.\n \nRefleja la presencia\nde hipergammaglobulinemia difusa, en la que existe\naumento proporcional de todas las clases de inmuno-\nglobulina.\n\ngelfoam.\n \nAgente hemostático local absorbible.\n\ngenes quiméricos.\n \nCombinación de dos o más\ngenes.\n\nglobinas.\n \nProteínas constitutivas de la hemoglobina,\nsolubles en agua, en soluciones ácidas y alcalinas y coa-\ngulables por el calor.\n\nglobulina antitimocito.\n \nInmunoglobulina con in-\ntenso efecto inmunodepresor que reduce el número y\naltera la función de los linfocitos T circulantes. Se em-\nplea en hipoplasia medular autoinmunitaria.\n\nglucoforina.\n \nSialoglucoproteína que se proyecta des-\nde el grosor de la membrana celular de los eritrocitos.\nMarcador eritroide específico de aparición tardía en la\neritropoyesis.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":399,"lines":{"from":119,"to":159}}}}],["2030",{"pageContent":"glucoforina.\n \nSialoglucoproteína que se proyecta des-\nde el grosor de la membrana celular de los eritrocitos.\nMarcador eritroide específico de aparición tardía en la\neritropoyesis.\n\ngradientes de Percoll.\n \nMétodo de separación y de-\nterminación de la viabilidad celular.\n\nF\n\nγ\n-glutamil-transpeptidasa (GGTP).\n \nEnzima que\ncataliza la transferencia de grupos gammaglutamil de un\npéptido a otro, o de un péptido a un aminoácido. El tejido\nmás rico en esta enzima es el riñón, seguido del páncreas,\nel hígado, el bazo y el pulmón.\n\nG\nH\n\nhaptoglobina.\n \nProteína que se combina con la he-\nmoglobina libre; es captada por el sistema reticuloen-\ndotelial, donde la hemoglobina se degrada en globina y\nel hemo, y posteriormente se transforma en hierro y bi-\nlirrubina. Las cifras de haptoglobina libre se reducen en\nsituaciones que cursan con hemólisis y alta liberación y\ncaptación de hierro.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":399,"lines":{"from":159,"to":193}}}}],["2031",{"pageContent":"hemocromatosis.\n \nEnfermedad autosómica recesiva\ncaracterizada por un incremento en la absorción de hie\n-\nrro, con el depósito progresivo de este metal, que puede\nproducir daño tisular y que puede llegar a ser fatal si no\nse detecta oportunamente.\n\nhemosiderina.\n \nPrincipal forma de almacenamiento.\n\nHenoch-Schönlein, púrpura de.\n \nVasculitis por\nhipersensibilidad autolimitada que afecta principal-\nmente a niños. Se caracteriza por lesiones cutáneas\npurpúricas ubicadas en la región inferior del abdomen,\nglúteos y piernas. Con frecuencia existen síntomas ar-\nticulares, hemorragias gastrointestinales y hematuria.\n\nheparina.\n \nMucopolisacárido natural que actúa como\nfactor antitrombina que evita la coagulación; es produ -\ncida por los basófilos y mastocitos.\n\nheteroanticuerpos.\n \nAnticuerpos\n \nespecíficos\n \npara\nantígenos que se originan en una especie, distintos a los\ndel productor de anticuerpos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":399,"lines":{"from":195,"to":231}}}}],["2032",{"pageContent":"GLOSARIO\n\n373\n\nheterocigoto.\n \nIndividuo con alelos distintos en un\nlocus determinado del mismo par cromosómico.\n\nheterodímero.\n \nCompuesto formado por la unión de\ndos radicales o dos moléculas de un compuesto más\nsencillo, cuyo origen y estructura es diferente entre uno\ny otro.\n\nheterogéneo.\n \nQue no es de la misma naturaleza u\norigen.\n\nheterólogo.\n \nPosee dos genes distintos en loci corres-\npondientes de cromosomas homólogos. Un individuo\nheterocigoto, para una característica en particular,\nha heredado un gen para ese carácter de un progenitor\ny el gen alternativo del otro.\n\nhidroxiurea.\n \nAgente antineoplásico, inhibidor de la\nribonucleótido reductasa.\n\nhiperdiploide.\n \nCélula con más de dos juegos comple-\ntos de cromosomas homólogos.\n\nhiperesplenismo.\n \nAumento del tamaño del bazo, por\nlo que atrapa y destruye a los eritrocitos normales, pla-\nquetas y otro componentes de la sangre. Ello ocurre en\nhepatopatías crónicas, síndromes mieloproliferativos,\nlinfomas, etcétera.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":400,"lines":{"from":1,"to":46}}}}],["2033",{"pageContent":"hiporreflexia miotática.\n \nDisminución o debilita-\nción de los reflejos musculares.\n\nhipoesplenismo.\n \nAusencia anatómica o funcional\ndel bazo; provoca varias alteraciones hemáticas: dia-\nnocitos y acantocitos, eritroblastosis, leucocitosis y\ntrombocitosis.\n\nhirudina.\n \nObtenida de la sanguijuela\n \nHirudo medicina-\nlis\n, es un inhibidor directo y específico de la trombina.\nResulta más eficaz que las heparinas en la neutraliza-\nción de la trombina unida a la fibrina. La hemorragia\nes su principal efecto secundario y carece de antídoto.\n\nhistiocitos.\n \nMonocitos tisulares, localizados en los di-\nferentes órganos y tejidos del organismo.\n\nhomeostático.\n \nTendencia al equilibrio para conser-\nvar las constantes fisiológicas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":400,"lines":{"from":48,"to":79}}}}],["2034",{"pageContent":"histiocitos.\n \nMonocitos tisulares, localizados en los di-\nferentes órganos y tejidos del organismo.\n\nhomeostático.\n \nTendencia al equilibrio para conser-\nvar las constantes fisiológicas.\n\nhomocistinuria.\n \nEnfermedades hereditarias del ca-\ntabolismo de los aminoácidos que se caracterizan por\nun aumento de la concentración del aminoácido homo-\ncistina en sangre (homocistinemia) y en orina. Produce\nmanifestaciones clínicas neuropsiquiátricas, luxación\ninferointerna del cristalino, anormalidades esqueléticas\ny tromboembolismos.\n\ninmunodeficiencia\n \ncombinada\n \ngrave.\n \nAgam-\nmaglobulinemia\n \nautosómica\n \nrecesiva\n \ncon\n \nmarcada\ndisminución de linfocitos circulantes. Se divide mayori-\ntariamente en dos grupos: los que presentan una ausen-\ncia total de linfocitos T y B (T–B–) y los que tienen un\nnúmero normal o elevado de linfocitos B y ausencia total\nde linfocitos T (T–B+).\n\ninmunofenotipo.\n \nMarcadores moleculares (CD) que\ncaracterizan a una estirpe celular.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":400,"lines":{"from":79,"to":124}}}}],["2035",{"pageContent":"inmunofenotipo.\n \nMarcadores moleculares (CD) que\ncaracterizan a una estirpe celular.\n\ninmunorreactivos.\n \nMoléculas empleadas para reco-\nnocer y acoplarse a marcadores específicos de la superficie\ncelular. Empleados con fines diagnósticos.\n\nintratecal.\n \nSe refiere a la administración de algún fár-\nmaco en el canal raquídeo.\n\nisocromosomas.\n \nCromosomas simétricos por dupli-\ncación de los brazos largos con ausencia de los cortos, o\nde los cortos con ausencia de los largos.\n\nisoenzima A y B.\n \nVariantes de la glucosa-6-fosfa-\nto-deshidrogenasa (G-6-PD).\n\nkernícterus.\n \nFijación de la bilirrubina a los núcleos\nbasales cerebrales. Causa procesos neurológicos graves.\n\nI\nK\nL\n\nidiopático.\n \nRelativo a enfermedad de origen des -\nconocido.\n\nincidencia.\n \nCasos nuevos de una enfermedad por mil\nhabitantes en un año.\n\ninfiltración.\n \nAcumulación o depósito en un tejido de\nuna sustancia extraña a él, y estado morboso consecuti-\nvo a esta acumulación.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":400,"lines":{"from":124,"to":174}}}}],["2036",{"pageContent":"infiltración.\n \nAcumulación o depósito en un tejido de\nuna sustancia extraña a él, y estado morboso consecuti-\nvo a esta acumulación.\n\nlactato.\n \nProducto final del metabolismo de la glu-\ncosa. La única vía de degradación es su oxidación a\nácido pirúvico. En condiciones anaerobias se acumula\npiruvato en el citoplasma por producción aumentada\ny utilización disminuida, ya que al estar las funcio-\nnes mitocondriales alteradas, se estimula por un lado\nla glucólisis como principal fuente de energía y, por el\notro, se inhibe la piruvato-deshidrogenasa dificultando\nel metabolismo del piruvato. Normalmente se produce\nen eritrocitos, piel, cerebro, músculo esquelético, entre\notros sitios. Es metabolizado en el riñón y el hígado. Su\ncoexistencia con la anemia favorece la lactoacidosis por\nhipoperfusión. Se ha descrito acidosis láctica asociada\na tumores sólidos, leucemias, etcétera.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":400,"lines":{"from":174,"to":195}}}}],["2037",{"pageContent":"lactoferrina.\n \nProteína secretada por el páncreas; con-\ntribuye a reducir la población bacteriana del colon. En el\nlactante un mecanismo de protección es la lactoferrina\nno saturada en la leche materna, que, al unirse al hierro,\nproduce un efecto bacteriostático.\n\nlaminina.\n \nComponente de las fibras de anclaje; fun-\nciona como ligando para moléculas de colágeno. In-\nteractúa con CD44, receptor de adherencia que se\nexpresa en la mayoría de los leucocitos y está involucra-\ndo en la extravasación de focos de inflamación, así como","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":400,"lines":{"from":197,"to":211}}}}],["2038",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n374\n\nen la migración de linfocitos a órganos linfoides secun-\ndarios. Algunas isoformas de CD44 parecen desempe-\nñar un papel importante en el desarrollo de metástasis\nde carcinomas.\n\nL-asparaginasa.\n \nAlgunas células leucémicas se ca-\nracterizan por su déficit intracelular de L-asparagina,\npor lo que dependen, a diferencia de las células norma-\nles, de la L-asparagina extracelular. Esta es inactivada\npor la L-asparaginasa, que produce su desaminación.\nEste citostático se incluye en las pautas de inducción de\nla leucemia linfoblástica aguda. Su mayor importancia\nterapéutica es la quimioprevención.\n\nlocus.\n \nPosición definida de una secuencia de DNA de-\nterminada en un cromosoma. Si la mencionada secuen-\ncia corresponde a un gen, hablaremos de\n \nlocus genético\n.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":401,"lines":{"from":1,"to":28}}}}],["2039",{"pageContent":"locus.\n \nPosición definida de una secuencia de DNA de-\nterminada en un cromosoma. Si la mencionada secuen-\ncia corresponde a un gen, hablaremos de\n \nlocus genético\n.\n\nlionización extrema al azar.\n \nDurante el período\nembrionario, ocurre la inactivación al azar de uno de\nlos cromosomas X de los individuos del sexo femenino,\ngenerando así un sujeto con un determinado número\nde células normales y otro con células anormales que\nperdurará durante el resto de su vida. En el caso de las\nenfermedades hereditarias relacionadas con el sexo, si\nel cromosoma inactivado es el que tiene la mutación,\nno se expresará la enfermedad clínicamente; pero al\ncontrario, si el cromosoma que permanece activo es\nel que contiene la alteración, la patología se expresará\nclínicamente.\n\nmortalidad.\n \nNúmero de muertes por unidad de pobla-\nción en cualquier región, grupo de edad o enfermedad\nespecífica; generalmente se expresa por 1 000, 10 000\no 100 000.\n\nmutación de novo.\n \nCasos donde ocurren mutacio-\nnes espontáneas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":401,"lines":{"from":28,"to":62}}}}],["2040",{"pageContent":"mutación de novo.\n \nCasos donde ocurren mutacio-\nnes espontáneas.\n\nmelfalán.\n \nAgente alquilante derivado de la mostaza\nnitrogenada.\n\nmesterolona.\n \nAndrógeno sintético antes utilizado\ncomo terapia en la hipoplasia medular, pero sin demos-\ntrar resultados convincentes.\n\nmeteorismo.\n \nDistensión del abdomen por gases con-\ntenidos en el tubo digestivo.\n\nmetotrexato.\n \nAntagonista del ácido fólico empleado\nen el tratamiento de las leucemias.\n\nmielograma.\n \nRecuento diferencial de la celularidad\nde la médula ósea.\n\nmielotóxicos.\n \nAgentes físicos o químicos que depri-\nmen la celularidad medular.\n\nmitomicina-C.\n \nAntibiótico antitumoral. Se aisló de\nun cultivo de\n \nStreptomyces caespitosus\n. Actúa como los\nalquilantes, a través de su anillo de aziridina y su grupo\nuretano, aunque por otra parte es similar a los derivados\nantraciclínicos por su grupo quinona.\n\nmonosomías.\n \nCélulas o individuos con ausencia de\nun cromosoma (45 cromosomas).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":401,"lines":{"from":62,"to":112}}}}],["2041",{"pageContent":"monosomías.\n \nCélulas o individuos con ausencia de\nun cromosoma (45 cromosomas).\n\nmorbilidad.\n \nFrecuencia con la que se produce una enfer\n-\nmedad o anomalía en una determinada población o área; se\ncalcula dividiendo el número total de personas de un grupo\npor el número de las afectadas por la enfermedad o anomalía.\n\nM\nN\nO\nP\n\nnadir.\n \nEl punto más bajo.\n\noro coloidal.\n \nInmunomarcador ultraestructural que\npermite la detección de antígenos intracelulares y de\nmembrana.\n\nortocromáticos.\n \nDe color normal, o que se tiñe nor-\nmalmente. Emulsiones fotográficas sensibles a todos los\ncolores excepto al rojo.\n\noximetolona.\n \nAndrógeno sintético.\n\np47.\n \nProteína citosólica responsable de la actividad\nbactericida de los fagocitos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":401,"lines":{"from":112,"to":153}}}}],["2042",{"pageContent":"oximetolona.\n \nAndrógeno sintético.\n\np47.\n \nProteína citosólica responsable de la actividad\nbactericida de los fagocitos.\n\nP50 de oxígeno.\n \nValor de la presión parcial de oxí-\ngeno en la que la hemoglobina presenta una saturación\nde oxígeno igual a 0,5. Los valores obtenidos depen-\nden de los factores que afectan a la capacidad de unión\nentre la hemoglobina y el oxígeno (pH, presión parcial\nde dióxido de carbono, temperatura y concentración\nde 2,3-difosfoglicerato). Cuando P50 es menor que el\nlímite inferior de referencia, puede indicar la existen-\ncia de otras variantes de la hemoglobina con menor\nafinidad por el oxígeno. Su determinación está indi-\ncada en casos en los que se sospeche una alteración\nde la afinidad de la hemoglobina por el oxígeno, tanto\npor un aumento de esta y la consiguiente pérdida de\nla capacidad de ceder el gas a los tejidos, como por\nuna disminución que suponga una menor capacidad\nde transporte de oxígeno.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":401,"lines":{"from":153,"to":179}}}}],["2043",{"pageContent":"padecimiento clonal.\n \nEnfermedad causada por la\nproliferación de un solo tipo de clona celular.\n\npaliativo.\n \nTerapéutica dirigida a reducir la intensidad\nde síntomas desagradables, pero no a producir curación.\n\npanóptica.\n \nMétodo micrográfico de tinción, median-\nte el cual es posible diferenciar las distintas partes de\nun tejido.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":401,"lines":{"from":181,"to":195}}}}],["2044",{"pageContent":"GLOSARIO\n\n375\n\nparestesias.\n \nTrastorno subjetivo de la sensibilidad,\ncon sensaciones espontáneas que alcanzan diversos ma-\ntices de hormigueo, pinchazo, calor, frío, etcétera.\n\nproteína C.\n \nGlucoproteína dependiente de la vitamina\nK. Para ejercer su acción anticoagulante debe ser activa-\nda por la trombina, actuando como cofactor la proteína\nendotelial denominada\n \ntrombomodulina\n. La acción de la\nproteína C en el control de la coagulación se ejerce me-\ndiante la actividad proteolítica de los factores Va y VIIIa.\n\nproteína S.\n \nGlucoproteína dependiente del calcio\nque funciona como un cofactor de la proteína C en\nla inactivación de los factores Va y VIIIa. Requiere la\nvitamina K para su síntesis; no es una serinproteasa.\nLa proteína S se encuentra en el plasma en dos frac-\nciones libre y unida al componente del complemento\nC4b-\nbinding protein\n.\n\npetequias.\n \nPequeñas manchas hemorrágicas, pareci-\ndas en la forma a la semilla de la lenteja, del tamaño de\nuna cabeza de alfiler.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":402,"lines":{"from":1,"to":39}}}}],["2045",{"pageContent":"petequias.\n \nPequeñas manchas hemorrágicas, pareci-\ndas en la forma a la semilla de la lenteja, del tamaño de\nuna cabeza de alfiler.\n\npiropoiquilocitosis.\n \nForma\n \ngrave\n \nde\n \neliptocitosis\ncongénita que cursa con hemólisis neonatal intensa,\nacompañada de una marcada alteración de la morfolo-\ngía eritrocitaria, más evidente cuando los eritrocitos se\ncalientan.\n\nplasmocitoma.\n \nNeoplasia focal constituida por cé-\nlulas plasmáticas. Puede desarrollarse en la médula\nósea, como sucede en el mieloma múltiple, o fuera de\nesta, en determinadas vísceras y en la mucosa de las\nregiones nasal, oral y faríngea.\n\nplasmocitos.\n \nCélulas plasmáticas.\n\npleio-, pleo-.\n \nPrefijo que significa “más”: pleocromá-\ntico, pleiomorfismo.\n\npleotrópico.\n \nGen que influye en más de un carácter.\n\npoiquilo-.\n \nPrefijo que significa “variado” o “irregular”:\npoiquilocitosis.\n\npolietilenglicol.\n \nMolécula que al asociarse con el in-\nterferón, consigue prolongar su vida media al reducir su\naclaramiento renal.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":402,"lines":{"from":39,"to":89}}}}],["2046",{"pageContent":"polietilenglicol.\n \nMolécula que al asociarse con el in-\nterferón, consigue prolongar su vida media al reducir su\naclaramiento renal.\n\nponderal.\n \nRelativo al peso.\n\nportadora.\n \nPersona enferma, convaleciente o sana,\nque lleva en su cuerpo el germen de una enfermedad y\nactúa como propagador de esta.\n\nproteína C reactiva.\n \nProteína cuya función resi-\nde en recoger y transportar los restos celulares y los\nproductos de desdoblamiento de las células fagocitarias\npara procesarlos y conservar las sustancias necesarias.\nSe eleva en respuesta a estados de estrés o inflamatorios\nproducidos por infecciones, heridas, cirugía, trauma-\ntismos, etcétera.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":402,"lines":{"from":89,"to":113}}}}],["2047",{"pageContent":"protoporfirina/cinc (PPZ).\n \nMetabolito\n \nnormal-\nmente formado durante la biosíntesis del grupo hemo.\nDurante este proceso, la última reacción tiene como\nobjetivo la quelación del hierro con la protoporfirina,\npero cuando existe deficiencia de hierro, el cinc es usa -\ndo por la ferroquelatasa como sustrato metálico alter-\nnativo, formando así el complejo PPZ. Esta sustitución\nes una de las primeras respuestas bioquímicas a la de-\nficiencia de hierro, conduciendo a una elevación de la\nPPZ en los eritrocitos circulantes.\n\nprueba de inducción de los drepanocitos.\n \nRe-\nducción en la tensión de oxígeno que provoca la clásica\ndeformación de los eritrocitos en forma de hoz.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":402,"lines":{"from":115,"to":134}}}}],["2048",{"pageContent":"prueba de inducción de los drepanocitos.\n \nRe-\nducción en la tensión de oxígeno que provoca la clásica\ndeformación de los eritrocitos en forma de hoz.\n\nprueba de fragilidad osmótica.\n \nIndica la propie-\ndad de los eritrocitos de captar agua sin experimentar\nlisis; esto depende de la relación de superficie/volumen\no de su forma. Las células gruesas, como los esferocitos,\ntienen una fragilidad osmótica aumentada, y las más fi-\nnas, como las células hipocrómicas, muestran reducción\nde la fragilidad osmótica.\n\nprueba de hemólisis ácida o de Ham.\n \nGeneral-\nmente en una prueba positiva se produce lisis en el 10 a\n50% de los casos, lo cual indica que una proporción de\nlos eritrocitos del paciente es especialmente sensible a\nla lisis mediada por componentes del complemento del\nsuero normal. Un resultado positivo indica la presencia\nde hemoglobinuria paroxística nocturna.\n\npsitacosis.\n \n“Fiebre de los loros”. Infección causada por","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":402,"lines":{"from":134,"to":162}}}}],["2049",{"pageContent":"psitacosis.\n \n“Fiebre de los loros”. Infección causada por\n\nChlamydia psittaci\n, caracterizada por un estado tifoídico\ncon hipertermia y complicaciones pulmonares.\n\npuerperio.\n \nPeríodo que transcurre desde el parto has-\nta que los órganos genitales y el estado general de la\nmujer vuelven al estado previo a la gestación.\n\npúrpura.\n \nExtravasación hemática en la dermis, que\nse puede deber a alteraciones de los componentes de la\nsangre (púrpuras intravasculares), del propio vaso (púr-\npuras vasculares) o extravasculares, como trastornos de\nlos tejidos de sostén del vaso.\n\npúrpura senil.\n \nManchas equimóticas de color violá-\nceo y bordes irregulares que aparecen en el dorso de\nlas manos, brazos y piernas de individuos ancianos y\nde pacientes afectos de procesos consuntivos (alto con-\nsumo). Se atribuyen a la fragilidad de la pared vascular\npor atrofia del tejido conjuntivo perivascular.\n\nQ\nR\n\nquinidina.\n \nFármaco usado para el tratamiento de la\nmalaria.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":402,"lines":{"from":162,"to":199}}}}],["2050",{"pageContent":"Q\nR\n\nquinidina.\n \nFármaco usado para el tratamiento de la\nmalaria.\n\nreacción de Coombs.\n \nPrueba antiglobulínica para\ndeterminar la presencia de anticuerpos que cubren y\nlesionan los eritrocitos como consecuencia de diversas\nenfermedades o afecciones. La prueba puede descubrir\nanticuerpos Rh de la sangre materna, y se utiliza para\ndiagnosticar la enfermedad hemolítica del recién nacido.\nSe usa también para diagnosticar y seleccionar personas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":402,"lines":{"from":199,"to":215}}}}],["2051",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n376\n\ncon anemias hemolíticas autoinmunitarias y para deter-\nminar la compatibilidad de los tipos sanguíneos. Cuando\nse pone en contacto con el suero del enfermo, el suero\nantiglobulínico provoca la aglutinación si hay un anti-\ncuerpo globulínico humano o su complemento.\n\nreactivos.\n \nSustancias químicas que reaccionan de for-\nma específica. Se usan para detectar o sintetizar otras\nsustancias en una reacción química.\n\nreactivos de fase aguda.\n \nComponentes que se ele-\nvan ante la presencia de estrés, infecciones, cirugía, neo-\nplasia, etcétera. Ejemplo de ello es la proteína C reactiva.\n\nrefractariedad.\n \nRebelde, que no cede fácilmente al\ntratamiento.\n\nremisión.\n \nDesaparición parcial o total de los signos y\nsíntomas clínicos de una enfermedad crónica o malig-\nna. La remisión puede ser espontánea o secundaria al\ntratamiento. En algunos casos es completa y la enfer-\nmedad se considera curada.\n\nreticulina.\n \nEscleroproteína de la trama conjuntiva de\nlos tejidos linfáticos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":403,"lines":{"from":1,"to":39}}}}],["2052",{"pageContent":"reticulina.\n \nEscleroproteína de la trama conjuntiva de\nlos tejidos linfáticos.\n\nriesgo relativo.\n \nIndica cuántas veces es más frecuen-\nte la enfermedad en los individuos expuestos en com-\nparación con los no expuestos. En la probabilidad de\nque una persona presente la enfermedad en un período\ndeterminado, el RR indica el número de veces que es\nmayor (o menor) el riesgo de presentar la enfermedad\nen los expuestos respecto a los no expuestos.\n\nristocetina.\n \nAntibiótico usado para la estimulación de\nla aglutinación del plasma rico en plaquetas de un en-\nfermo para la determinación funcional del factor de von\nWillebrand circulante.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":403,"lines":{"from":39,"to":59}}}}],["2053",{"pageContent":"ristocetina.\n \nAntibiótico usado para la estimulación de\nla aglutinación del plasma rico en plaquetas de un en-\nfermo para la determinación funcional del factor de von\nWillebrand circulante.\n\nrituximab.\n \nAnticuerpo monoclonal humanizado que se\nune específicamente al antígeno CD20 y que ejerce efec-\ntos citolíticos sobre las células B que los expresan debido\na la inducción de citotoxicidad celular dependiente de\nanticuerpos, complemento y por la inducción de apopto-\nsis. Tiene actividad antitumoral en pacientes con linfo-\nmas no Hodgkin foliculares o de bajo grado de células B\nCD20-positivos recidivantes o resistentes a quimioterapia.\nrespiraciones/ min o PaCO\n2\n \ninferior a 32 mm Hg, y d)\nrecuento leucocitario con más de 12 × 10\n9\n/L o menos de\n4 × 10\n9\n/L, o fórmula con más de 10% de formas jóvenes.\n\nseudo-.\n \nFalso, irreal.\n\nsideroblastos.\n \nEritrocitos con el hierro dispuesto alre-\ndedor del núcleo debido a su situación intramitocondrial.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":403,"lines":{"from":59,"to":94}}}}],["2054",{"pageContent":"seudo-.\n \nFalso, irreal.\n\nsideroblastos.\n \nEritrocitos con el hierro dispuesto alre-\ndedor del núcleo debido a su situación intramitocondrial.\n\nsíndrome de Alport.\n \nSíndrome caracterizado por\nuna nefropatía hereditaria acompañada de sordera neu-\nrosensorial. En la forma ligada al cromosoma X, la en-\nfermedad progresa a la insuficiencia renal terminal en\nlos varones, mientras que en las mujeres portadoras la\nafección renal es más discreta, resultando poco frecuente\nla presencia de insuficiencia renal crónica terminal.\n\nsíndrome de anticuerpos antifosfolípido.\n \nA la pre-\nsencia de anticoagulante lúpico o anticuerpo anticardio-\nlipina junto con manifestaciones clínicas de trombosis,\ntrombocitopenia o pérdidas fetales recurrentes se le deno\n-\nmina\n \nsíndrome antifosfolípido\n, que se considera\n \nprimario\n \nsi\nno se comprueba una enfermedad subyacente y\n \nsecundario\n\ncuando existe alguna otra enfermedad concurrente.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":403,"lines":{"from":94,"to":132}}}}],["2055",{"pageContent":"cuando existe alguna otra enfermedad concurrente.\n\nsíndrome de Bernard-Soulier.\n \nTrastorno\n \ninfre-\ncuente, heredado de forma autosómica recesiva. La al-\nteración consiste en el déficit de la glucoproteína Ib de la\nmembrana, que se considera el principal receptor plaque-\ntario del factor de von Willebrand (FvW). La deficiencia\nde esta proteína implica el defecto de adherencia de las\nplaquetas al subendotelio y las restantes manifestaciones\nde este proceso.\n\nsíndrome de coagulación intravascular dise-\nminada (CID).\n \nGeneración extensa de trombina en\nla sangre circulante, con el consiguiente consumo de\nfactores de coagulación y plaquetas, posible obstruc -\nción de la microcirculación y activación secundaria de\nla fibrinólisis. El consumo de plaquetas y factores\nde coagulación (coagulopatía) conduce a la aparición de\nhemorragias y las trombosis obstructivas de la micro-\ncirculación a necrosis y disfunciones orgánicas.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":403,"lines":{"from":132,"to":157}}}}],["2056",{"pageContent":"síndrome de Evans o Fisher-Evans.\n \nAsociación\nde anemia hemolítica y púrpura trombocitopénica au-\ntoinmunitarias simultáneas.\n\nsíndrome de Fanconi.\n \nPancitopenia\n \nhereditaria:\nanemia aplásica familiar, hemorragias, malformaciones\ndel esqueleto y muerte antes de alcanzar la edad adulta.\n\nsíndrome de Felty.\n \nCombinación de artritis crónica\ndeformante, esplenomegalia, linfadenopatía, leucope-\nnia y pigmentación cutánea.\n\nsíndrome de Sézary.\n \nForma más agresiva de lin-\nfoma cutáneo de células T que se manifiesta por eri-\ntrodermia\n \npruriginosa,\n \nadenopatías\n \ngeneralizadas\ny presencia de células de Sézary en la piel, ganglios\nlinfáticos y sangre periférica, en esta última con cifras\nsuperiores a 1 × 10\n \n9\n \n/L. La supervivencia a los 5 años es\ndel 10%. Responden mal al tratamiento: clorambucilo y\nprednisona, PUVA y fotoquimioterapia extracorpórea.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":403,"lines":{"from":159,"to":198}}}}],["2057",{"pageContent":"síndrome de Trousseau.\n \nTromboflebitis migratoria,\npuede hallarse junto con carcinomas de origen oculto,\ncon frecuencia carcinomas de páncreas o pulmón.\n\nsarcoidosis.\n \nEnfermedad sistémica crónica caracte-\nrizada histológicamente por una reacción inflamatoria\ngranulomatosa no necrotizante.\n\nsensibilidad.\n \nMide la proporción de individuos enfer-\nmos en los que la prueba diagnóstica ha detectado la\nenfermedad.\n\nsepsis.\n \nSíndrome de respuesta inflamatoria sistémica de-\nbido a una infección. Para su diagnóstico debe ser causada\npor una infección y requiere la presencia de dos o más de\nlos siguientes criterios: a) temperatura central superior a\n38 ºC o inferior a 36 ºC; b) frecuencia cardíaca mayor de\n90 latidos/min; c) frecuencia respiratoria superior a 20\n\nS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":403,"lines":{"from":200,"to":227}}}}],["2058",{"pageContent":"GLOSARIO\n\n377\n\nsíndrome de Turner.\n \nAnomalía genética que afecta\na individuos con fenotipo femenino y que se caracteriza\npor gónadas rudimentarias, enanismo, infantilismo se-\nxual,\n \npterigium colli\n \ny cúbito valgo.\n\nsíndrome de Wiskott-Aldrich.\n \nDermatitis ecce-\nmatoide crónica en la que los pacientes muestran mayor\nsensibilidad a las infecciones recurrentes y trombocito-\npenia con hepatoesplenomegalia.\n\nsíndrome del túnel del carpo.\n \nCompresión del\nnervio mediano a nivel del ligamento anular del carpo,\nmanifestado por disestesias, dolores, parestesias y tras -\ntornos motores y vasomotores, frecuentemente de los\ndedos segundo y tercero.\n\ntalidomida.\n \nFármaco con efecto inmunomodulador y\nantiinflamatorio, útil en el tratamiento de diversos tras-\ntornos autoinmunitarios, control de la enfermedad de\ninjerto contra huésped, mantenimiento de la remisión\nen mieloma múltiple, entre otros usos.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":404,"lines":{"from":1,"to":37}}}}],["2059",{"pageContent":"trombina.\n \nFermento o enzima que existe en la sangre\nderramada, pero no en la circulante, y que convierte el\nfibrinógeno en fibrina.\n\ntrombosis.\n \nFormación o desarrollo de un trombo y\noclusión vascular por este.\n\ntrombospondina.\n \nInhibidor endógeno de prolifera-\nción y migración de células endoteliales.\n\ntularemia.\n \nInfección producida por\n \nFrancisella tularen-\nsis\n, transmitida por insectos que actúan como vectores.\nAfecta fundamentalmente a los animales. En los huma-\nnos se caracteriza por fiebre, cefalea, lesiones ulcerativas\nen la piel, adenomegalias, infección ocular, ulceraciones\ngastrointestinales o neumonía, dependiendo del lugar de\nentrada del bacilo y de la respuesta del huésped.\n\ntaquifilaxia.\n \nInmunización rápida contra los efectos\nde dosis tóxicas de un veneno orgánico, por la inyección\nprevia de pequeñas dosis de este.\n\ntelangiectasia.\n \nDilatación de los vasos capilares de\npequeño calibre, generalizada o localizada.\n\ntomografía por emisión de positrones (PET).","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":404,"lines":{"from":39,"to":79}}}}],["2060",{"pageContent":"telangiectasia.\n \nDilatación de los vasos capilares de\npequeño calibre, generalizada o localizada.\n\ntomografía por emisión de positrones (PET).\n\nTécnica morfofuncional que utiliza fluorodesoxigluco-\nsa marcada, auxiliar en la localización de tejido tumoral\nno detectado en otras exploraciones, por el hipermeta-\nbolismo celular que capta la glucosa marcada.\n\ntopoisomerasa II.\n \nEnzima esencial para la replica-\nción y transcripción del DNA, así como para la recom-\nbinación y segregación cromosómica. Esta enzima hace\nposible el acceso al DNA mediante rotura y reparación\nde la doble cadena al modificar el superenrrollamiento\ny relajación de la hebra de DNA. Proteína homóloga de\nla DNA-girasa bacteriana.\n\ntoxemia gravídica.\n \nConvulsiones tonicoclónicas de\ncarácter paroxístico que se observan en embarazadas\nque presentan un cuadro caracterizado por hipertensión\narterial, albuminuria, edema y coma.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":404,"lines":{"from":79,"to":106}}}}],["2061",{"pageContent":"toxemia gravídica.\n \nConvulsiones tonicoclónicas de\ncarácter paroxístico que se observan en embarazadas\nque presentan un cuadro caracterizado por hipertensión\narterial, albuminuria, edema y coma.\n\ntransferrina.\n \nGlobulina B1 presente en el plasma,\nque se combina con el hierro y sirve como vehículo\nde este.\n\ntranslocación.\n \nAlteración cromosómica debida al in-\ntercambio de un fragmento cromosómico de un cromo-\nsoma a otro.\n\ntrombastenia de Glanzmann.\n \nForma de diáte-\nsis hemorrágica congénita caracterizada por tiempo\nde\n \nsangría\n \nprolongado,\n \nretracción\n \ndefectuosa\n \ndel\ncoágulo, agregación plaquetaria anormal en presen -\ncia de difosfato de adenosina y número de plaquetas\nnormal.\n\nT\nU\nV\nZ\n\nuremia.\n \nSíndrome causado por un exceso de sustancias\nnitrogenadas en la sangre, secundario a insuficiencia\nrenal, con náuseas, vómitos, cefalalgia, vértigos, som-\nnolencia, coma, convulsiones y olor urinoso del aliento\ny del sudor.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":404,"lines":{"from":106,"to":155}}}}],["2062",{"pageContent":"urobilinógeno.\n \nProducto de transformación de los\npigmentos biliares por las bacterias intestinales, pre-\ncursor de la urobilina.\n\nurocinasa.\n \nSustancia secretada por las células en-\ndoteliales y epiteliales que revisten los conductos\nexcretores del organismo (principalmente los túbulos\nrenales), considerada como el activador fisiológico\nque comienza la lisis de la fibrina depositada en estos\nconductos.\n\nvalor predictivo positivo o negativo.\n \nEs la proba-\nbilidad de que una persona con una prueba diagnóstica\npositiva o negativa esté realmente enferma o no.\n\nvelocidad\n \nde\n \neritrosedimentación.\n \nÍndice\n \nde\nsedimentación de los eritrocitos en un tubo en el cual\nse ha introducido sangre no coagulada, expresada en\nmilímetros por hora. La sangre obtenida se mezcla con\nun anticoagulante y se deja sedimentar en una columna\nde vidrio calibrada.\n\nzidovudina.\n \nAntirretroviral que actúa inhibiendo la\ntranscriptasa inversa.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":404,"lines":{"from":157,"to":196}}}}],["2063",{"pageContent":"379\n\nÍNDICE ANALÍTICO\n\nAbetalipoproteinemia,\n \n86-87\n\ncongénita, 80c, 86\nmanifestaciones clínicas, 87\npatogénesis, 86\ntratamiento, 87\n\nAbscesos,\n \n22\n\nAcantocitosis,\n \n80c\n\nasociada con hepatopatía, 80c\n\nAciclovir,\n \n55c\n\nÁcido, fólico,\n \n82, 94\n\ndesoxirribonucleico (DNA) nuclear, 3\ngrasos, 78\nmetilmalónico, medición del, 59\nribonucleico mensajero (mRNA), 3\nsiálico terminal de la eritropoyetina (EPO), 10\n\nAcidosis,\n \n22\n\nAdenosina desaminasa,\n \n124.\n \nVéase\n \nADA\nAdipocito,\n \n5, 5c\n\nAlcoholismo,\n \n59\n\ncrónico, 152, 160\n\nAlteración, del estado mental,\n \n53c\n\nen la mejoría, 53c\n\nAmigdalectomía,\n \n223\n\nAmigdalitis,\n \n22\n\nAmiloidosis,\n \n54c, 251\n\nprimaria, 246\n\nAnemias,\n \n151-159","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":406,"lines":{"from":1,"to":81}}}}],["2064",{"pageContent":"en cáncer no hemático, causas, 161c\ninsuficiencia renal crónica, 156\ndatos clínicos y de laboratorio, 157\ndepresión de la eritropoyesis, 156\nmecanismos, 157c\nsecreción disminuida de eritropoyetina, 156\nsupervivencia acortada de los eritrocitos, 156\ntratamiento, 157\npacientes con trastornos endocrinos y metabólicos,\n158-159\ndiabetes mellitus, 158-159\nhipogonadismo, 159\nhipotiroidismo, 158\npor desnutrición, 162\nprincipales, secundarias a padecimientos no hemáticos\nanemia de la insuficiencia renal crónica, 151\nanemia de los trastornos crónicos, 151\nanemias secundarias a infecciones, 151\nsecundarias a alcoholismo crónico y cirrosis, 160-161\nsecundarias a infecciones, 151, 153\nasociada al sida, 156\nBartonelosis, 155\ncrónicas, 153\notras infecciones por protozoarios, 155\npaludismo, 154\npatogenia, 154\npor hemólisis exagerada, 154\nsecundarias a inflamaciones crónicas, 161\nsecundarias a neoplasias malignas no hemáticas, 159\nanemia, de los trastornos crónicos, 159\nhemolítica microangiopática, 160","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":406,"lines":{"from":83,"to":113}}}}],["2065",{"pageContent":"por hemólisis exagerada, 154\nsecundarias a inflamaciones crónicas, 161\nsecundarias a neoplasias malignas no hemáticas, 159\nanemia, de los trastornos crónicos, 159\nhemolítica microangiopática, 160\nefectos secundarios al tratamiento, 159\nfactores nutricionales, 160\nhemorragias, 159\nmetástasis a médula ósea, 160\ntratamiento, 160\ntrastornos crónicos, 151, 152\ndiagnóstico, 152-153\nmecanismos que condicionan su producción\nalteración en el metabolismo del hierro, 152\ndestrucción eritrocítica exagerada, 152\neritropoyetina e insuficiencia de la médula ósea,\n152\nmacrófagos y citosinas, 152\ntratamiento, 153","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":406,"lines":{"from":113,"to":131}}}}],["2066",{"pageContent":"Anemia, aplásica,\n \n25-26, 280\n\nadquirida, 282, 288\ngrave refractarios a tratamiento inmunosupresor, 282\ndefinición de, 16\nmacrocítica por deficiencia de vitamina B12, 21\nmegaloblástica o de granulocitosis, 23\nmegaloblástica, 26, 281\nperniciosa, 25, 46-47, 51f, 54.\n \nVéase también\n \nAnemias\nmegaloblásticas\nlengua lisa y sensible, 51f\npor deficiencia de, hierro, 281\nvitamina B12, 281\n\nAnemias hemolíticas,\n \n67-74\n\nabordaje diagnóstico de las, 72\nadquididas, 68c\naloinmunitarias, enfermedad hemolítica del recién\nnacido, 68c\nincompatibilidad ABO en transfusión, 68c\nautoinmunitarias, 68c\nhemólisis en otras condiciones patológicas, 69c\ninducidas por medicamentos, 67c\n\nA\n\nNota: los números de página seguidos de “ f ” corresponden a\nfiguras; los que van seguidos por “c” indican cuadros.","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":406,"lines":{"from":133,"to":169}}}}],["2067",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n380","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":407,"lines":{"from":1,"to":3}}}}],["2068",{"pageContent":"no inmunitarias, 68c\naloinmunitaria, 132\nasociada a cáncer, 293\nasociadas con defectos de membrana eritrocítica,80-94\nabetalipoproteinemia, 86\nacantocitosis asociada con hepatopatía, 86\nadquirida, acantocitosis asociada con hepatopatía, 80c\nestomatocitosis adquirida, 80c\nhemoglobinuria paroxística nocturna, 80c\ndeficiencia hereditaria de CD59, 94\neliptocitosis hereditaria y padecimientos\nrelacionados, 83-86\ndefectos del citoesqueleto, 83-84\ndefinición, 83\ndiagnóstico, 84\nmanifestaciones clínicas, 84\nEL-H común, 84\neliptocitosis esferocítica (ovalocitosis he-\nreditaria), 84\neliptocitosis estomatocítica (ovalocitosis\ndel sureste de Asia), 84, 85f\npiropoiquilocitosis hereditaria, 84\npatogénesis, 83\ntratamiento, 86\nesferocitosis hereditaria, 80-81\nactividad esplénica y destrucción de esfero-\ncitos, 81\ndefectos de la membrana eritrocitaria, 81\ndefinición, 80\nepidemiología, 80\nmanifestaciones clínicas, 81-82\ncomplicaciones, 82\ndiagnóstico, 82\nestado de portador asintomático, 82\nforma moderada, 82\nforma típica, 81","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":407,"lines":{"from":5,"to":40}}}}],["2069",{"pageContent":"definición, 80\nepidemiología, 80\nmanifestaciones clínicas, 81-82\ncomplicaciones, 82\ndiagnóstico, 82\nestado de portador asintomático, 82\nforma moderada, 82\nforma típica, 81\ntratamiento, 82\npatogénesis, 81\nestomatocitosis, adquirida, 88\nhereditaria, 88\ny padecimientos afines, 88\nhemoglobinuria paroxística nocturna, 89\nhereditarias, acantocitosis, 80c\neliptocitosis común, 80c\neliptocitosis esferocítica u ovalocitosis here-\nditaria, 80c\nestomatocitosis hereditaria, 80c\nxerocitosis hereditaria, 80c\nneuroacantocitosis, 86\nsíndrome, corea-acantocitosis (síndrome de Le-\nvine-Critchley), 87\ndeficiencia de Rh, 89\nHARP, 87\nMcLeod, 88\nxerocitosis hereditaria, 88\nautoinmunitaria, 127-132, 293\nfisiopatología, 128\ninhibidores del complemento, CD55 y CD59,\nen proceso hemolítico, 130-131\nmanifestaciones clínicas, 128","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":407,"lines":{"from":40,"to":71}}}}],["2070",{"pageContent":"α\n-metildopa, 128\nenfermedad por crioaglutininas, 128\nhemoglobinuria paroxística del frío, 128\nibuprofeno, 128\nL-dopa, 128\nprocainamida, 128\nprueba directa de Coombs en, 129\ntratamiento y pronóstico, 131\nazatioprina, 131\nciclofosfamida, 131\ncorticoides, 131\nesplenectomía, 131\ntioguanina, 131\ncausadas por trastornos de la membrana eritrocí-\ntica, 77-80\ncomponentes de la membrana, 78\nactina, 78\naducina, 78\nanclaje glucolípido, 78-79\nankirina, 78\nbanda 4.2, 78, 79\ndematina (banda 4.9), 78-79\nespectrina, 78\nproteína 4.1, 78\ntransportador de aniones (banda 3), 78\ntropomiosina, 78-79\ntropomodulina, 78-79\nestructura del citoesqueleto, 78f, 79\ncon esquistocitos, 294c\ncrónica, 23\ndel recién nacido, 133\ndiagnóstico, 71\nhereditarias, 70c\nalteraciones de la membrana eritrocitaria, 70c\neliptocitosis, 70c\nestomatocitosis hereditaria, 70c\nmicroesferocitosis hereditaria, 70c\nenzimopatías, 70c\nhemoglobinopatías, 70\nD, 70\nE, 70c\ninestables, 70c\ntalasemias (\nα\n,\n \nβ\n, d\nβ\n, g\nβ\n,\n \nαβ\n), 70c\ninducida por fármacos, 133-134","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":407,"lines":{"from":73,"to":129}}}}],["2071",{"pageContent":"α\n-metildopa 134f, 134\ncloropropamida, 134\nfenacetina, 134f\npenicilina, 134f\nquinidina, 134\nmicroangiopática, 292, 293\npruebas para el diagnóstico, 72f\ntratamiento, 72, 73c\n\nAnemias megaloblásticas,\n \n45-65, 58f\n\naguda, 57\nóxido nitroso (N2O), 57\ncuadro hematológico, 56\nanemias macrocíticas, 56\nserie blanca, 56\ndéficit de ácido fólico, 54\ndermatitis exfoliativas, 54","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":407,"lines":{"from":131,"to":151}}}}],["2072",{"pageContent":"CAPÍTULO 11\n\n381\n\ndieta inadecuada, 54\nembarazo, 54\nesprúe, 54\nradioterapia por cáncer cervicouterino (afecta el\níleon), 54\ntratamiento de, con ácido fólico, 62\ndéficit de cobalamina (B12), 46-47, 54c, 59-62\naclorhidria, 46\namiloidosis, 54c\nanemia perniciosa, 46-47, 51f, 54c\ncriterios diagnósticos, 59c\ndieta vegetariana estricta, 54c","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":408,"lines":{"from":1,"to":16}}}}],["2073",{"pageContent":"Diphyllobothrium latum\n, 53, 54c\nelevación de ácido metilmalónico, 46\nenfermedad del íleon terminal, 54c\nexámenes para determinar la causa, 60-61\nhiperhomocisteinemia, 46, 48\ntratamiento, 62\npor vía parenteral vitamina B12, 62\ndiagnóstico, 57-59\nalcoholismo, 59\naspirado de médula ósea, 57-58\nbiopsia de hueso, 57f\nblastos en médula ósea positivos para CD34, 58\ncitometría hemática, 57\ndeterminación sérica de la enzima deshidroge-\nnasa láctica, 57\nembarazo, 59\nhipotiroidismo, 59\nhomocisteína total, 59\nmedición del ácido metilmalónico, 59\nperíodo neonata, 59\nfármacos que causan, aciclovir, 55c\nazatioprina, 55c\n5-fluoruracilo, 55c\n6-mercaptopurina, 55c\nmetotrexato, 55c\npirimetamina, 55c\ntrimetoprim, 55c\nzidovudina (AZT), 55c\notras causas de, 56\ndeficiencia en la dieta, 56\ndeficiencias congénitas, 56\nenfermedad pancreática, 56\n\nAnemia por deficiencia de hierro,\n \n16, 18f, 19f, 20,\n25, 31-43","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":408,"lines":{"from":18,"to":55}}}}],["2074",{"pageContent":"causas, 35c\nabsorción de hierro alterada, 35c, 35\ndisrupción de la mucosa gastrointestinal, 35c, 36\npérdida funcional de intestino, 35c, 36\npérdidas sanguíneas, 35c, 36\ndefectos estructurales, 36\nfisiológicas, 36\nparásitos, 36\nsangrado uterino disfuncional, 36\npobre disponibilidad de hierro, 35c, 35\nsistema reproductor, 35c\ndeficiencia genética de hierro, 41\nembarazo, recién nacido y lactancia, 37\nepidemiología, 34\nestadios tardíos en el desarrollo, 33, 34c\netiología, 35\nhistograma de los eritrocitos en, 19f, 20f\nmanifestaciones clínicas, 37-38\ndurante la niñez, 37\nbajo rendimiento escolar, 37\nfatiga con pequeños esfuerzos, 37\nen adultos, 38\ncoiloniquia, 38\nenfermedad de Crohn, 38\nrectorragia, 38\nsíndrome de Plummer-Vinson, 38\nfrotis de sangre periférica, 38\nmetabolismo y regulación de la homeostasis del\nhierro, 31\npruebas de laboratorio, 38-39\ncitometría hemática, 38\nmedición de hierro medular, 38\notros marcadores de deficiencia de hierro, 39\nperfil de hierro, 39\nsituación de México frente, 37\ntratamiento, 39-41","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":408,"lines":{"from":57,"to":92}}}}],["2075",{"pageContent":"pruebas de laboratorio, 38-39\ncitometría hemática, 38\nmedición de hierro medular, 38\notros marcadores de deficiencia de hierro, 39\nperfil de hierro, 39\nsituación de México frente, 37\ntratamiento, 39-41\nevaluación de la respuesta, 41\nsuplementación con hierro oral, 39\ncomplejo de hierro-polisacárido, 40\nfumarato ferroso, 40\ngluconato ferroso, 40\nhierro carbonil, 40\nhierro iónico Fe (III), 40\nsuplementación parenteral de hierro, 40\nhierro dextrán, 40\nvalores normales de la ferritina en suero, 39c","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":408,"lines":{"from":92,"to":108}}}}],["2076",{"pageContent":"Anillo de Waldeyer,\n \n227\n\nAnisocromía,\n \n21\n\nAnn Arbor, clasificación de,\n \n228\n\nAnticuerpos monoclonales,\n \n223, 233\n\nanti-CD20 o rituximab, 233, 251\nanti-CD41 y anti-CD42a, 8\n\nAntígeno(s), CD14 (monocítico),\n \n7\n\ndiferenciación, asociados a linaje granulocítico, 4\nT, 7\nCD117, 4\nCD34, 6\ngp IIb/IIIa, 8\nHLA-DR, 6-8\n\nApendicitis,\n \n22\n\nArtritis reumatoide,\n \n22, 206c\n\nArtropatía hemofílica,\n \n322\n\nAsma,\n \n12\n\nAspirado de médula ósea,\n \n57-58\n\nAtaxia-telangiectasia, síndrome de,\n \n206c\n\nAutorrenovación,\n \n4, 12\n\nAzatioprina,\n \n55c\n\nBicitopenia,\n \n52\n\nBilirrubinas,\n \n227\n\nindirecta, 71, 72c.\n \nVéase\n \nBI\n\nB","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":408,"lines":{"from":110,"to":186}}}}],["2077",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n382\n\nBiopsia, hueso,\n \n57f\n\nmédula ósea, 227\n\nBlastos en médula ósea positivos para CD34,\n \n58\n\nBusulfán,\n \n185, 364\n\nCambios en la personalidad,\n \n53c\n\nCáncer,\n \n328c\n\nCaquexia,\n \n22\n\nCarcinomas metastásicos a médula ósea,\n \n23\n\nCefalotina en anemia hemolítica adquirida,\n \n133\n\nCélula, diana,\n \n9c\n\nprecursoras, 8\nplasmática, 9, 11\npluripotencial mieloide, 6\nprogenitora totipotencial hematopoyética (CTH), 137\nrojas nucleadas, 118\n\nCélula troncal hematopoyética (CTH),\n \n4-5","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":409,"lines":{"from":1,"to":51}}}}],["2078",{"pageContent":"Célula, diana,\n \n9c\n\nprecursoras, 8\nplasmática, 9, 11\npluripotencial mieloide, 6\nprogenitora totipotencial hematopoyética (CTH), 137\nrojas nucleadas, 118\n\nCélula troncal hematopoyética (CTH),\n \n4-5\n\nautorrenovación y diferenciación de las, 4, 12\ngenes PcG en, 12\nproteínas del grupo polycomb (PcG), 12\ncompartimentos hematopoyéticos, 7c\nbipotencial, 7, 7c\npluripotencial, 6, 7c\nterminal, 7c, 8\nunipotencial, 7c, 7\ncélulas precursoras, 7c, 8\ncélulas progenitoras, 7c, 8\ncorolario, 12\nembrión, sitios generadores de, 4f\nen la MO, 4\ninmunofenotipo (CD34+, CD38+/–, Lin–, CD117+), 4\nmicroambiente hematopoyético, 5\nadipocitos, 5\ncélulas endoteliales (vasos sanguíneos), 5\ncélulas estromales, 5\ncitoplasma de las células reticulares adventicias,5\nfibroblastos (tejido conectivo), 5\nmonocitos/macrófagos, 5\nosteoblastos (hueso), 5\nosteoblastos, 5c\nnicho hematopoyético en el adulto, 6f\nprimitiva, 4, 5\n\nCiclofosfamida,\n \n364\n\nCitometría hemática,\n \n15","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":409,"lines":{"from":51,"to":97}}}}],["2079",{"pageContent":"Ciclofosfamida,\n \n364\n\nCitometría hemática,\n \n15\n\notras células en sangre periférica, 24-25\nblastos, 25\nplasmocitos, 24\nserie blanca, 21-24\nbasófilos, 23\ncuenta diferencial de glóbulos blancos, 23\neosinófilos, 23\nlinfocitos, 24\nmonocitos, 24\nneutrófilos, 23\nnúmero de leucocitos, 21\nserie roja, 15-21\ncoeficiente de variación del VGM (CV-VGM), 17\nconcentración media de hemoglobina globular, 17\ncuenta corregida de reticulocitos (CCR), 18\ncurvas de distribución de frecuencias del VGM,17\nhematocrito (Htc), 16\nhemoglobina, corpuscular media, 17\ny definición de anemia, 16\nhistograma de los eritrocitos de un individuo\nsano, 19f\nnúmero de eritrocitos o glóbulos rojos, 16\nvolumen globular medio, 16\nserie trombocítica, 25-26\nmorfología de las plaquetas, 26\nnúmero de plaquetas, 25\nvolumen plaquetario medio, 25\n\nCimógeno,\n \n258\n\nCirrosis,\n \n152, 160\n\nhepática, 25\n\nCitoféresis,\n \n347\n\nCitomegalovirus,\n \n280\n\nCitometría hemática,\n \n57\n\ncompleta, 245\n\nCitoplasma, de las células reticulares\nadventicias,\n \n5","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":409,"lines":{"from":97,"to":160}}}}],["2080",{"pageContent":"Cimógeno,\n \n258\n\nCirrosis,\n \n152, 160\n\nhepática, 25\n\nCitoféresis,\n \n347\n\nCitomegalovirus,\n \n280\n\nCitometría hemática,\n \n57\n\ncompleta, 245\n\nCitoplasma, de las células reticulares\nadventicias,\n \n5\n\nplaquetario, 261\n\nClasificación de las anormalidades\nhemostáticas,\n \n273c\n\nCoagulación intravascular diseminada,\n \n68-69,\n72f.\n \nVéase\n \nDIC\nCoágulo,\n \n258\n\nCoagulopatías hereditarias,\n \n303-325","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":409,"lines":{"from":160,"to":210}}}}],["2081",{"pageContent":"plaquetario, 261\n\nClasificación de las anormalidades\nhemostáticas,\n \n273c\n\nCoagulación intravascular diseminada,\n \n68-69,\n72f.\n \nVéase\n \nDIC\nCoágulo,\n \n258\n\nCoagulopatías hereditarias,\n \n303-325\n\nárbol genealógico de una familia con hemofilia, 308f\nclasificación, 303\ncoagulopatías o defectos de la hemostasia se-\ncundaria, 304\nadquiridas. 304\ncombinadas, 304\nhereditarias, 304\nenfermedades hemorrágicas, 305c\ncirrosis hepática, 305\nfibrinogenólisis anormal primaria, 305c\nhemofilias A y B, 305c\npúrpura de Henoch-Schönlein, 30c\npúrpura senil, 305c\npúrpura simple, 305c\ntelangiectasia hemorrágica hereditaria, 305\ncomplicaciones, 320-322\nartropatía hemofílica, 322\ncontaminación viral, 322\ninhibidores, 320-321\nseudotumor hemofílico, 322\ndiagnóstico, 311-315\ncuantificación de factores, 313\nmétodos, 313\ndiferencial, 315\nestudio de portadoras, 314\nestudios de laboratorio, 311\nhistoria familiar, 311\ninhibidores en hemofilia, 314\nprueba modificada, clásica de Bethesda,314, 315f\nde Nijmegen, 314, 316\n\nC","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":409,"lines":{"from":210,"to":264}}}}],["2082",{"pageContent":"CAPÍTULO 11\n\n383","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":410,"lines":{"from":1,"to":3}}}}],["2083",{"pageContent":"pruebas de escrutinio, 312-313\nequipo multidisciplinario en las clínicas de hemo-\nfilia, 317f\nhemofilia A y B, 304-311\nfisiopatología de la enfermedad, 308\ngravedad de la enfermedad, 307\nherencia, 307\nhistoria, 304\nincidencia, 305\nnaturaleza de la alteración genética, 306\npresentación clínica, 308-311\nhemartrosis, 310\nhematomas musculares, 310\nhematuria, 310\nhemorragia del sistema nervioso central, 310\nhemorragia posoperatoria, 311\nhemorragias bucales, 311\nhemorragias gastrointestinales, 310\ny enfermedad de von Willebrand, pruebas de\nhemostasia, 314f\notros defectos hereditarios raros de la coagulación,\n322-323\ndefectos del fibrinógeno, 322, 323\ndeficiencia del factor XI, 323\ndeficiencia congénita de factor X, 323\ntratamiento, 315-320\nfarmacológico, 318-320\ndesmopresina (1 desamino-8-d-arginina va-\nsopresina/DDAVP), 318-320\nantifibrinolíticos, 320\nhemostáticos locales, 320\nhemofilia A, 316-317\nhemofilia B, 317\nconcentrados de factor IX, 317\nterapia transfusional o no farmacológica, 318","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":410,"lines":{"from":5,"to":39}}}}],["2084",{"pageContent":"Cobalamina.\n \nVéase también\n \nVitamina B12\nCoeficiente de variación del VGM (CV-VGM),\n \n17\n\nCoiloniquia,\n \n38\n\nColitis ulcerosa crónica inespecífica,\n \n24\n\nColoides radioactivos,\n \n3\n\nCompartimento unipotencial,\n \n7, 7c\n\nComplejo, de hierro-polisacárido,\n \n40\n\nhaptoglobina-hemoglobina, 90\n\nComplicaciones hemorrágicas,\n \n352\n\nCrioglobulinemia,\n \n251\n\nCromosoma,\n \n1, 11\n\n2, 10\n5, 10, 11\n7, 10, 11\n9, 87\n11q13, 205\n17, 10\nX, 88, 89\n\nCuantificación, de inmunoglobulinas en el suero,\n \n245\n\nde las proteínas urinarias, 245\n\nCuenta plaquetaria,\n \n271\n\nCuerpos de Heinz,\n \n120\n\nCH.\n \n15.\n \nVéase también\n \nCitometría hemática\nChédiak-Higashi, síndrome de,\n \n206c\n\nChoque anafiláctico,\n \n22\n\nDebilidad simétrica,\n \n53c\n\nDefectos, cognitivos,\n \n53c\n\ndel fibrinógeno, 322.323\n\nDeficiencia, ácido fólico,\n \n160, 161","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":410,"lines":{"from":41,"to":133}}}}],["2085",{"pageContent":"Choque anafiláctico,\n \n22\n\nDebilidad simétrica,\n \n53c\n\nDefectos, cognitivos,\n \n53c\n\ndel fibrinógeno, 322.323\n\nDeficiencia, ácido fólico,\n \n160, 161\n\naldolasa, 119\nconcomitante de espectrina (\nα\n \no\n \nβ\n) y ankirina, 81\ncongénita de factor X, 323\nenzimas, glucolíticas, hemólisis asociada a, 116\nglucosa-6-fosfato-deshidrogenasa (vía de las\npentosas), 115\nfactor(es), hematopoyéticos, 158\nVIII, 304\nXI, 323\nfolatos, 156, 161\nfosfofructocinasa, 118\nhereditaria, de CD59, 94\nde HRF20/CD59, 80c\nhexocinasa, 118\nhierro, 153, 157, 161, 162\nisomerasa del fosfato de glucosa (GPI), 118\nPC o PS, 328c\npiruvatocinasa, 117\nprotrombina, 323\ntriosa fosfato isomerasa, 119\nvitamina B12, 161\n\nG6PD, anemia por deficiencia de,\n \n122\n\nanemia hemolítica crónica no esferocítica, 122\nhemólisis inducida por, fármacos, 122, 123\ninfecciones, 122\ningestión de habas, 122\nictericia neonatal, 122\ndiagnóstico de laboratorio de la deficiencia de, 123\nen estrés oxidativo, 121\nvariantes, 120-121\nA–, 120\nA+, 120\nB+, 120\nmediterránea, 120","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":410,"lines":{"from":133,"to":194}}}}],["2086",{"pageContent":"Degeneración, combinada subaguda,\n \n53c\n\ndel núcleo pálido, 87.\n \nVéase\n \nSíndrome de HARP\n\nDengue,\n \n280\n\nDeshidrogenasa láctica,\n \n72c, 73, 227.\n \nVéase\n\nDHL\nDeterminación, de microglobulina b2 en el\nsuero,\n \n245\n\nsérica de la enzima deshidrogenasa láctica, 57\n\nDiabetes mellitus,\n \n158-159\n\nDiálisis,\n \n247\n\nDiarrea,\n \n52\n\nDieta vegetariana estricta,\n \n54c\n\nDifenilhidantoína,\n \n206\n\nen hiperplasia linfoide, 206\n\nDiferenciación,\n \n4, 12\n\nDiphyllobothrium latum,\n \n53, 54c\n\nDisfibrinogenemias,\n \n328c\n\nDisplasminogenemia,\n \n328c\n\nDNA, síntesis de,\n \n141\n\nDolor epigástrico,\n \n52\nD","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":410,"lines":{"from":196,"to":269}}}}],["2087",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n384\n\nElectroforesis de las proteínas de la orina,\n \n245\n\nEliptocitosis, esferocítica,\n \n80c\n\nhereditaria común, 80c\n\nEmbarazo,\n \n59\n\nanemia megaloblástica, 47, 55\ndeficiencia de ácido fólico, 46-47, 54\n\nEmbolismo pulmonar,\n \n53c\n\nEndocarditis infecciosa,\n \n25\n\nEnfermedad(es), cadenas pesadas,\n \nα\n,\n \n240c\n\nγ\n, 240c\n\nδ\n, 240c\n\nμ\n, 240c\nCrohn, 38\nGaucher, 22\nhemolítica del recién nacido, 68\níleon terminal, 54\nlinfoproliferativas malignas, 240c\n\nEnteritis regional,\n \n24\n\nEnzima UDP-glucuroniltransferasa,\n \n123\n\nEritrocitoféresis o recambio eritrocitario,\n \n347\n\nsecundaria a hipoxemia crónica, 16\n\nEritropoyesis deficiente de hierro,\n \n33\n\nEritropoyetina,\n \n10\n\nEsplenectomía,\n \n26, 201\n\nEsplenomegalia e hiperesplenismo, causas de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":411,"lines":{"from":1,"to":77}}}}],["2088",{"pageContent":"secundaria a hipoxemia crónica, 16\n\nEritropoyesis deficiente de hierro,\n \n33\n\nEritropoyetina,\n \n10\n\nEsplenectomía,\n \n26, 201\n\nEsplenomegalia e hiperesplenismo, causas de\n\nanemias, 298c\nbacterianas (salmonelosis, brucelosis), 298c\ncirrosis, 298c\ncongestivas, 298c\ndrepanocitosis, 298c\nfiebre reumática, 298c\nhemolítica autoinmunitaria, 298c\ninflamación, 298c\nleucemias agudas o crónicas, 298c\nlinfomas, 298c\nlupus eritematoso, 298c\nneoplasias, 298c\nobstrucción venosa portal o esplénica, 298c\npaludismo, 298c\nsíndrome de Felty, 298c\nsíndromes mieloproliferativos crónicos, 298c\ntalasemia, 298c\ntrombosis de venas suprahepáticas. 298c\ntuberculosis, 298c\nvirales (hepatitis, mononucleosis), 298c\n\nEstomatocitosis,\n \n88\n\nadquirida, 80c, 88\nhereditaria, 80c, 88\n\nEstudio electroforético de las proteínas del\nsuero,\n \n245\n\nFactor(es), antihemostáticos como la antitrom-\nbina (AT),\n \n258","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":411,"lines":{"from":77,"to":129}}}}],["2089",{"pageContent":"Estomatocitosis,\n \n88\n\nadquirida, 80c, 88\nhereditaria, 80c, 88\n\nEstudio electroforético de las proteínas del\nsuero,\n \n245\n\nFactor(es), antihemostáticos como la antitrom-\nbina (AT),\n \n258\n\ncrecimiento, 9c\nderivado de plaquetas (FCDP), 261\nhemolinfopoyéticos, 9\nestimulante de células asesinas naturales (NK), 11\nhemostático, 258\nactivado (Fa), 258\nIX de la coagulación, deficiencia del, 306\nIX, 307\nplaquetario 4 (FP4), 261\nrelajación endotelial (óxido nítrico, NO), 258\nVIII, 306, 307c\nconcentrados de, 309c\nvon Willebrand, 5\nX, deficiencia congénita, 323\nXI, deficiencia, 323\n\nFase fluida de la hemostasia (antes cascadas de\ncoagulación,\n \n257\n\nFEC de monocitos,\n \n10\n\nFenómeno de Raynaud,\n \n251\n\nFibrinólisis,\n \n257\n\nFibroblastos,\n \n7f\n\nFisiología de la hemostasia,\n \n257-275","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":411,"lines":{"from":129,"to":185}}}}],["2090",{"pageContent":"definiciones, cimógeno, 258\ncoágulo, 258\nfactor hemostático, 258\nactivado (Fa), 258\nfase fluida de la hemostasia (antes cascadas de\ncoagulación, 257\nfibrinólisis, 257\nhemorragia, 258\nhemostasia, 257\nproteasa de serina, 258\nsistema de coagulación, 257\ntrombo, 258\ntrombosis, 258\nfibrinólisis, 267\nesquema simplificado, 270\nhemostasia, 258-268, 259f\ncélulas hemáticas circulantes y, 260\neritrocitos, 260\nleucocitos, 260\nendotelio y, 258\nactivación plaquetaria, 259\nefectos anticoagulantes del, 259f\nfactor de von Willebrand, IaTP-1 y FV, 259\nfactores IX, IXa y X, 259\nformación de coagulo, 259f\nfase fluida de la, 262-263, 266f\nanticoagulantes coumadínicos, 263\nconsideraciones básicas, 262\nfibrinógeno, 267c\nformación de malla de fibrina, 263f\nleucocitos, 263f\ntrombina y la formación de fibrina, 266\nvía extrínseca, 266\nvía intrínseca, 266\nflujo sanguíneo y, 260\ncaracterísticas, 260f\nfactores hemostáticos, 260\ntransporte de plaquetas, 260\nplaquetas, 260-262\ncitoplasma plaquetario, 261\n\nF\nE","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":411,"lines":{"from":187,"to":229}}}}],["2091",{"pageContent":"CAPÍTULO 11\n\n385\n\ncoágulo plaquetario, 261-262\nadhesión plaquetaria, 261, 261f\nagregación plaquetaria, 261, 261f, 262\nprostaglandinas, 262\neficiencia de gránulos a, 261\nen la formación de fibrina, 262\nfactor de crecimiento derivado de pla\nquetas, 261\nfactor plaquetario 4 (FP4), 261\ntrombospondina, 261\npared vascular en la, 258\ntromboxano A2 (TxA2), 258\nvasoconstricción, 258, 259f\nprimaria, 258\nsecundaria, 258\nmecanismos de regulación del sistema de coagulación,\n268-270\nflujo sanguíneo, 268\ninhibidores fibrinolíticos, 270\nregulación de la fase fluida de la hemostasia,\n269-270\npruebas de escrutinio hemostático, 270-273\nclasificación de las anormalidades, 273c\ncuenta plaquetaria, 271\ndiagnóstico diferencial, 272\ntiempo de, hemorragia, 271\nprotrombina, 272\ntrombina, 272\ntromboplastina parcial activada, 271-272\nsistema de coagulación en condiciones normales,258\nfunciones del endotelio, 258\ntiempo de, hemorragia, 271\nprotrombina, 272\ntrombina, 272\ntromboplastina parcial activada, 271-272","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":412,"lines":{"from":1,"to":39}}}}],["2092",{"pageContent":"Fludarabina,\n \n364\n\n5-Fluoruracilo,\n \n55c\n\nFolatos,\n \n48, 52, 87\n\ndeficiencia de, 49, 54\nalcoholismo, 49\nanemias hemolíticas, 49\nanticonceptivos orales, 49\ndermatitis exfoliativas, 54, 62\ndieta inadecuada, 54\nembarazo, 49, 62\nhipertiroidismo, 49\nmetotrexato, 54\nneoplasias mieloproliferativas, 49\npirimetamina, 54c\nresecciones intestinales, 54c\ntratamiento, 52\nproteínas fijadora de, 79c\n\nFosfoglicerato cinasa,\n \n116, 119\n\nFrotis de sangre periférica,\n \n38\n\nFructosa,\n \n119\n\nFumarato ferroso,\n \n40\n\nGangrena,\n \n22\n\nde los dedos, 244\n\nGastroenteritis eosinofílica,\n \n24\n\nGen quimérico\nBCR-ABL,\n \n184\n\nGilbert, síndrome de,\n \n123\n\nGluconato ferroso,\n \n40\n\nGlucosa,\n \n115, 116, 117f\n\nGlucosa-6-fosfato deshidrogenasa,\n \n110\n\ng-glutamil transpeptidasa,\n \n227\n\nGota aguda,\n \n22\n\nGranulomatosis linfomatoide,\n \n206\n\nG6PD,\n \n122, 122c.\n \nVéase también\n \nGlucosa-6-fosfato\ndeshidrogenasa","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":412,"lines":{"from":41,"to":134}}}}],["2093",{"pageContent":"Glucosa-6-fosfato deshidrogenasa,\n \n110\n\ng-glutamil transpeptidasa,\n \n227\n\nGota aguda,\n \n22\n\nGranulomatosis linfomatoide,\n \n206\n\nG6PD,\n \n122, 122c.\n \nVéase también\n \nGlucosa-6-fosfato\ndeshidrogenasa\n\nA, 121\nclasificación de variantes de, de acuerdo a su\nactividad enzimática, 121c\nen México, 121\neritrocítica, 122c\nhemólisis, 122\nictericia neonatal, 122\nmediterránea , 121\n\nHARP, síndrome de,\n \n87\n\nHelicobacter pylori,\n \n206\n\nHemartrosis,\n \n310\n\nen rodilla izquierda, 311f\n\nHematocrito (Htc),\n \n16\n\nHematoma muscular,\n \n310, 312f\n\nHematuria,\n \n310\n\nHemoglobina(s),\n \n16, 99","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":412,"lines":{"from":134,"to":196}}}}],["2094",{"pageContent":"HARP, síndrome de,\n \n87\n\nHelicobacter pylori,\n \n206\n\nHemartrosis,\n \n310\n\nen rodilla izquierda, 311f\n\nHematocrito (Htc),\n \n16\n\nHematoma muscular,\n \n310, 312f\n\nHematuria,\n \n310\n\nHemoglobina(s),\n \n16, 99\n\nanormales, nomenclatura de, 103\nclasificación de las anormalidades de, 104\nagregantes, 104\ncon alteraciones de afinidad al oxígeno, 104\ninestables, 104\nmetahemoglobinas, 104\ncorpuscular media, 17\ndesignación científica de las variantes de la, 103\ncadena de polipéptidos afectada, 103\nsitios de sustituciones de los aminoácidos, 103\ntipo de mutación observada, 103\ngenética de las anormalidades, 103\nglobular, concentración media de, 17\nlaboratorio en identificación de las anormalidades,104\ncitometría hemática completa, 104\ncuantificación de hemoglobina fetal, 104\nestudio electroforético en acetato de celulosa. 104\nestudio electroforético en agar citrato, 104\nprueba de inducción de los drepanocitos, 104\n\nHemoglobinopatías,\n \n99-108, 363","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":412,"lines":{"from":196,"to":248}}}}],["2095",{"pageContent":"Hemoglobinopatías,\n \n99-108, 363\n\ndrepanocitosis, 104, 104f\nejemplos de patrones de herencia mendeliana, 103f\nestructura de la hemoglobina adulta, 100f\nhemoglobina S, homocigota (SS), 106\no forma heterocigota, 105\nlaboratorio en la identificación de las anormalidades\nde la hemoglobina, 104\nmenos frecuentes, otras, 108\npresentes en la vida adulta, fetal y embrionaria, 100c\n\nG\nH","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":412,"lines":{"from":248,"to":263}}}}],["2096",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n386\n\nS-talasemia\n \nβ\n \n0, 108\nS-talasemia\n \nβ\n \n+, 108\nS-talasemia\n \nβ\n \n++, 108\ntalasemias y, 108-113\n\nα\n, 109\nhidropesía fetal, 110\nmenor o rasgo talasémico, 110\n\nβ\n, 110\ndistinción entre anemia por deficiencia de\nhierro y, 111\nhomocigota, o anemia de Cooley, 111\n\nγ\n/\nδ\n/\nβ\n, 109\nclasificación, 109\nintermedia, 109\nmínima, 109\npersistencia hereditaria de hemoglobina fe-\ntal, 109\nfrecuencia, 109\ntipos de, hemoglobinas, agregantes, 104\ncon alteraciones de afinidad al oxígeno, 104\ninestables, 104\nmetahemoglobinas, 104\n\nHemoglobinuria paroxística nocturna,\n \n69, 71,\n73c, 73, 89, 328c\n\nHemólisis,\n \n67, 69, 72","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":413,"lines":{"from":1,"to":57}}}}],["2097",{"pageContent":"Hemoglobinuria paroxística nocturna,\n \n69, 71,\n73c, 73, 89, 328c\n\nHemólisis,\n \n67, 69, 72\n\nasociada a anormalidades eritrocíticas del metabo-\nlismo de nucleótidos, 123\nexceso de adenosina desaminasa, 124\npirimidina 5’-nucleotidasa (Pir 5’-N), 124\nasociada a deficiencia de enzimas de la vía de las\npentosas, 119\nG6PD eritrocítica, 120\nglutamil-cisteín-sintetasa y de glutatión sinte-\ntasa, 123\nglutatión reductasa, 123\nasociada a deficiencia de enzimas glucolíticas,116-119\naldolasa, 119\nfosfofructocinasa, 116, 118\nfosfoglicerato cinasa, 116, 119\nglucosa-6-fosfato-deshidrogenasa, 118\nglucosa-6-fosfato isomerasa, 116\nhexocinasa, 116, 118\npiruvatocinasa, 116, 117\ntriosa fosfato isomerasa, 116, 119\ncaracterísticas generales, 116\ndiagnóstico, 116\nfrecuencia, 116\nherencia, 116\nmanifestaciones clínicas. 116\ntratamiento, 116\nfisiopatología, 116\nintravascular, coluria en, 70\npor ictericia, 70\n\nHemorragia(s),\n \n244, 258","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":413,"lines":{"from":57,"to":97}}}}],["2098",{"pageContent":"Hemorragia(s),\n \n244, 258\n\nbucal, 311, 313f\ncerebral en hemofilia, 312f\ngastrointestinales, 310\nposoperatoria, 311\nsistema nervioso central, 310\n\nHemostasia,\n \n258-268, 259f","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":413,"lines":{"from":97,"to":109}}}}],["2099",{"pageContent":"células hemáticas circulantes y, 260\neritrocitos, 260\nleucocitos, 260\nendotelio y, 258\nactivación plaquetaria, 259\nefectos anticoagulantes del, 259f\nfactor de von Willebrand, IaTP-1 y FV, 259\nfactores IX, IXa y X, 259\nformación de coagulo, 259f\nfase fluida de la, 262-263, 266f\nanticoagulantes coumadínicos, 263\nconsideraciones básicas, 262\nfibrinógeno, 267c\nformación de malla de fibrina, 263f\nleucocitos, 263f\ntrombina y la formación de fibrina, 266\nvía extrínseca, 266\nvía intrínseca, 266\nflujo sanguíneo y, 260\ncaracterísticas, 260f\nfactores hemostáticos, 260\ntransporte de plaquetas, 260\nplaquetas, 260-262\ncitoplasma plaquetario, 261\ncoágulo plaquetario, 261-262\nadhesión plaquetaria, 261, 261f\nagregación plaquetaria, 261, 261f, 262\nprostaglandinas, 262\neficiencia de gránulos a, 261\nen la formación de fibrina, 262\nfactor de crecimiento derivado de pla\nquetas, 261\nfactor plaquetario 4 (FP4), 261\ntrombospondina, 261\npared vascular en la, 258\ntromboxano A2 (TxA2), 258\nvasoconstricción, 258, 259f\nprimaria, 258\nsecundaria, 258","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":413,"lines":{"from":111,"to":149}}}}],["2100",{"pageContent":"Hemovigilancia,\n \n356-357\n\nHibridomas,\n \n11\n\nHidroxiurea,\n \n201\n\nHierro,\n \n87\n\ncarbonil, 40\ndeficiencia de, 85, 94\nanemia por, 16, 18f, 19f, 20, 25\ningestión de, 116\niónico Fe (III), 40\n\nHipercalemia,\n \n352\n\nHiperesplenismo,\n \n25-26\n\nHiperproteinemia, síndrome de hiperviscosi-\ndad por,\n \n246\n\nHipocromía,\n \n17, 21, 26\n\nHipoferremia,\n \n17\n\nHipoferritinemia,\n \n17\n\nHipogonadismo,\n \n159\n\nHipoplasias,\n \n137-143\n\nalgunos conceptos de la hematopoyesis, 137-143\ndisplasias medulares o síndromes mielodisplásicos,\n143-149, 145f\nadquiridas, clasificación, 144, 144c","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":413,"lines":{"from":151,"to":209}}}}],["2101",{"pageContent":"CAPÍTULO 11\n\n387\n\nalteraciones cromosómicas, 146\nclasificación, de la OMS, 146c\ntipo I (anemia refractaria indiferenciada), 144\ntipo II (anemia sideroblástica idiopática ad-\nquirida), 144\ntipo III (anemia refractaria con exceso de\nblastos), 144\ntipo IV (leucemia mielomonocítica cróni-\nca), 145\ntipo V (anemia refractaria con exceso de\nblastos, en transformación), 145-146\nglosario de términos para, diseritropoyesis, 143\ndisgranulopoyesis, 143\ndishemopoyesis, 143\ndismegacariocitopoyesis, 143\npronóstico, 146\nsecundarias, 146\ntratamiento, 147\nmedulares, 138\nasociada a infección, 140\nautoinmunitaria, 140\ncausas, anticonvulsivos, 139\nbutazona, 139\ncloranfenicol, 139\nindometacina, 139\ninsecticidas, 139\nparvovirus B19, 140\ncuadro clínico, 141\ndiagnóstico, 142\netiología, 139, 240c\nfisiopatología, 138\ngrave, 363\nhereditarias o constitucionales, 141\nincidencia y pronóstico, 138-139\níndices pronósticos, 142, 142c\ntinción Masson, 139f\ntratamiento, 142\n\nHiporreflexia,\n \n53c\n\nHipotermia,\n \n352","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":414,"lines":{"from":1,"to":49}}}}],["2102",{"pageContent":"Hiporreflexia,\n \n53c\n\nHipotermia,\n \n352\n\nHipotiroidismo,\n \n59, 158\n\nHIV,\n \n205\n\nHomocisteína total,\n \n59\n\nHomocistinuria, mutación MTHFR,\n \n328c\n\nIctericia,\n \n52, 70\n\nImatinib,\n \n185\n\nIncompatibilidad ABO en transfusión,\n \n68\n\nInfarto del miocardio,\n \n22, 53c\n\nInfecciones agudas,\n \n25\n\nInhibidor(es),\n \n320-321\n\nde la tirosina-cinasa, 185\nfibrinolíticos, 270\nselectivo de JAK1/JAK2, 201\n\nInmunodeficiencias graves,\n \n363\n\nInmunofijación, en el suero,\n \n245\n\nen orina de 24 horas concentrada, 245\n\nInmunoglobulina(s), IgA,\n \n241\n\nIgD, 241\nIgG, 241\nIgM, 241\nMolécula, 240f\nmonoclonal, clasificación, 246\nséricas, inmunofijación, 241f\n\nInsuficiencia renal,\n \n22\n\nInterferón,\n \n10, 185\n\na, 186, 214\n\nγ\n, 140\n\nInterleucinas (IL),\n \n5\n\n2, 11\n3, 10\n4, 9-11\nlinfocitos T en, 10\n5, 9, 11\n6, producción de hibridomas, 11\n8, 11\n\nIntoxicación por citrato,\n \n351\n\nLenalidomida,\n \n201\n\nLeucemias agudas,\n \n167-181","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":414,"lines":{"from":49,"to":157}}}}],["2103",{"pageContent":"γ\n, 140\n\nInterleucinas (IL),\n \n5\n\n2, 11\n3, 10\n4, 9-11\nlinfocitos T en, 10\n5, 9, 11\n6, producción de hibridomas, 11\n8, 11\n\nIntoxicación por citrato,\n \n351\n\nLenalidomida,\n \n201\n\nLeucemias agudas,\n \n167-181\n\nbifenotípicas y de linaje mixto, 179\nclasificación, citogenética, 169\ninmunológica, 168, 170f\nmorfológica, 168, 169\ncuadro clínico, 170\ndiagnóstico, 171\netiología, 167\nlinfoblástica(s), 173\nL1, 169f\ntratamiento, 173\nde continuación, 174\nposremisión, 174\npreventivo de la leucemia meníngea, 174\ninducción a la remisión, 173\notras alternativas terapéuticas en, 179\nmieloblástica(s), 174-179\ninducción a la remisión, 176\nM1, 172f\nM4, 174f\nM5 y M5b, 175f\nM6, 175f\nM7, 176f\ntratamiento, de algunas formas específicas, 176\nde continuación, 176\nposremisión, 176\ntratamiento, 172\n\nLeucemias crónicas,\n \n183-193","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":414,"lines":{"from":157,"to":213}}}}],["2104",{"pageContent":"Leucemias crónicas,\n \n183-193\n\nde importancia en México, células peludas o trico-\nleucemia, 183, 190, 190f\nanatomía patológica, 190\ndiagnóstico, 191\netiopatogenia, fisiopatología y cuadro clíni-\nco, 190-191\nevolución, tratamiento y pronóstico, 191\nalemtuzumab (anti-CD52), 191\n\nI\nL","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":414,"lines":{"from":213,"to":227}}}}],["2105",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n388\n\nclorodeoxiadenosina, 191\npentostatina, 191\ngranulocítica, 183-187, 185f\nanatomía patológica, 183\ndiagnóstico, 184\ndeterminación del CrPh1, 184\nhibridación fluorescente\n \nin situ\n, 184\nniveles de fosfatasa alcalina leucocitaria,\n184\netiopatogenia, 184\nevolución, tratamiento y pronóstico, 184-187\nbusulfán, 185\nimatinib, 185\ninterferón a, 186\ninterferón, 185\nmesilato de imatinib, 186\nsupervivencias mayores de 10 años, 187\nfisiopatología y cuadro clínico, 184\nlinfocítica, 187, 187f\nanatomía patológica, 187\ndiagnóstico, 188-189\nestadios de Binet, 188c\netiopatogenia, 188\nevolución, tratamiento y pronóstico, 189-190\nfisiopatología y cuadro clínico, 188\n\nLeucemia(s), de células plasmáticas,\n \n240c\n\neosinofílica crónica, 196c\ngranulocítica crónica, 196c\nlinfocítica crónica, 11\nmieloide crónica, 24c\nneutrofílica crónica, 196c.\n \nVéase\n \nNeoplasias mielo-\nproliferativas crónicas\npromielocítica, 328c\n\nLeucoblastosis o leucoeritroblastosis, causas de","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":415,"lines":{"from":1,"to":50}}}}],["2106",{"pageContent":"Leucoblastosis o leucoeritroblastosis, causas de\n\ncarcinomas metastásicos a médula ósea, 23\neclampsia, 23\nendocarditis infecciosa, 23\nenvenenamientos, 23\nhemólisis aguda, 23\nhemorragia aguda, 23\nleptospirosis, 23\nneumonía, 23\nquemaduras, 23\nrecuperación de anemia megaloblástica, 23\nsepticemia, 23\n\nLeucocitosis, causas de\n\ninfecciones, bacterianas, brucelosis, 22\nsepticemia, 22\ntifoidea, 22\ntuberculosis miliar, 22\ntularemia, 22\npor rickettsias (tifo), 22\nvirales, hepatitis, 22\ninfluenza, 22\nmononucleosis infecciosa, 22\nparotiditis, 22\npsitacosis, 22\notras infecciones, kala-azar, 22\npaludismo, 22\n\nLeucoféresis,\n \n347\n\nLeucorreducción,\n \n355-356\n\nLigando de c-kit (LK),\n \n12\n\nLinfocitos T,\n \n10\n\nIL-2 y crecimiento de, 10\n\nLinfoma(s),\n \n205-221, 363","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":415,"lines":{"from":50,"to":100}}}}],["2107",{"pageContent":"Leucoféresis,\n \n347\n\nLeucorreducción,\n \n355-356\n\nLigando de c-kit (LK),\n \n12\n\nLinfocitos T,\n \n10\n\nIL-2 y crecimiento de, 10\n\nLinfoma(s),\n \n205-221, 363\n\ncutáneos, 216-218\nde células B, 218\nprimarios (EORTC), clasificación de, 217c\nde células T (LCPCT), 217\ntratamiento, 218\nmaligno, 240c\nno Hodgkin\nalteración cromosómica t(14;18) (q32;21) aso-\nciada, 205\nasociada a la infección del VIH, 206\nclasificación, 207, 208c\ndenominada\n \nWorking Formulation\n, 207\nlinfomas folicular(es) (FLIPI), de células\ngrandes (LFCG), 209\níndice pronóstico internacional para, 213c\nnuevas terapias para, ibritumomab tiu-\nxetán Y-90, 214\ninterferón-a (IFN-a), 214\nradioinmunoconjugados\n \ncon\n \nanti-\ncuerpos anti-CD20, 214\nrituximab en combinación con qui-\nmioterapia tipo CHOP, 214\ntositumomab I-131, 214\nREAL/WHO de neoplasias linfoides, 210c\ndeterminación de la extensión, 211","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":415,"lines":{"from":100,"to":153}}}}],["2108",{"pageContent":"sistema de Ann Arbor\n, 211\ndiagnóstico y evaluación inicial, 208c\nácido úrico, 208c\nbiopsia de ganglio linfático, 207\ncitometría hemática con sedimentación glo-\nbular, 208c\ndeshidrogenasa láctica, 208c\npruebas de función hepática y renal, 208c\nradiografía de tórax PA y lateral, 208c\nTC abdominopélvica, 208c\nTC de tórax, 208c\nTC o RM de cráneo, 208c\ndifenilhidantoína, 206\nen sobrevivientes de explosiones nucleares, 206\nepidemiología, 205\netiología, 205-207\nfactores industriales asociados al, arsénico, 206\nasbesto, 206\nclorofenoles, 206\ncloruro de vinilo, 206\nplomo, 206\nsolventes orgánicos, 206\npacientes con enfermedad de Hodgkin, 206\nquimioterapia, 206\nradiación, 206\nradioterapia, 206\nsíndrome de, Chédiak-Higashi, 206\nKlinefelter, 206c\ntrasplante autólogo de células progenitoras he-\nmatopoyéticas, 218","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":415,"lines":{"from":155,"to":185}}}}],["2109",{"pageContent":"CAPÍTULO 11\n\n389\n\ntratamiento, 212-216\n\nLinfoma de Hodgkin,\n \n223-237\n\nanatomía patológica, 224\ncélula de Reed-Sternberg, 224f\nclasificación histológica\ncelularidad mixta (CM), 225c\ndisminución linfocítica (DL), 225c\nesclerosis nodular (EN), 225c\npredominio linfocítico (PL), 225c\nrico en linfocitos (RL), 225c\nclasificación por estadios, 229f\ncuadro clínico, 224\ncrecimientos ganglionares exuberantes, 224, 226f","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":416,"lines":{"from":1,"to":21}}}}],["2110",{"pageContent":"fiebre de Pel-Ebstein\n, 224\nvariedad de esclerosis nodular, 224, 226f\ndiagnóstico diferencial, 227\nlinfoma(s), de zona gris, 227\nmediastínico de células grandes, 227\nunicelulares (no Hodgkin), 227\ntumores germinales, 227\nvariedad, anaplásica, 227\ninmunoblástica, 227\npleomórfica, 227\nestadios de extensión, 228\nclasificación de\n \nAnn Arbor\n \npor, 228\nI, 228c\nII, 228c\nIII, 228c\nIV, 228c\nestudios de gabinete, 227-228\nradiografía simple de tórax, 227\ntomografía, computarizada torácica de alta re-\nsolución, 227\npor emisión de positrones (PET, por sus si-\nglas en inglés), 227\nestudios de laboratorio, 227\nbiopsia de médula ósea, 227\nnivel de fibrinógeno, 227\nproteína C reactiva de alta sensibilidad, 227\nprueba de Coombs, 227\nvelocidad de eritrosedimentación, 227\nevaluación clínica, 228\nganglio linfático de un, 224f, 229f\nterapia para recaída o enfermedad refractaria, 233\ncomplicaciones del tratamiento, 234\ninmunoterapia, 230, 233\ntrasplante de médula ósea, 233\ntratamiento, 230\nfactores de crecimiento hematopoyético, 230","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":416,"lines":{"from":23,"to":63}}}}],["2111",{"pageContent":"terapia para recaída o enfermedad refractaria, 233\ncomplicaciones del tratamiento, 234\ninmunoterapia, 230, 233\ntrasplante de médula ósea, 233\ntratamiento, 230\nfactores de crecimiento hematopoyético, 230\nmodificadores de la respuesta inmunitaria, 230\nquimioterapia (QT), 230, 232\nconcepto de intensidad de dosis, 232\nmodalidad de la terapia combinada, 232\nradioterapia (RT), 230, 231\ncombinada con quimioterapia, 230, 231\nrecomendaciones según estadio evolutivo, 231c\ntécnicas de radioterapia más usadas, 231c\nvirus de Epstein-Barr (EBV), 223","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":416,"lines":{"from":63,"to":77}}}}],["2112",{"pageContent":"LNH, 205-221.\n \nVéase también\n \nLinfomas\nLupus eritematoso generalizado,\n \n22, 25, 206c, 332\n\nMacrocitosis,\n \n18, 21f, 160\n\nMacrófagos,\n \n3-5, 10\n\nMacroglobulinemia de Waldenström,\n \n240c\n\nMastocitosis,\n \n196c\n\nMédula ósea (MO),\n \n3, 6f, 53c, 55-56\n\naspirado de, 58\nbiopsia por aspiración de, 61\ncélulas maduras, 8\nestudio de, para diagnóstico de anemia megaloblás\n-\ntica, 63\nhipercelular con predominio de la serie roja, 57f\nMéxico y diagnóstico de, 58\n\nMegacarioblasto,\n \n7-8\n\nMembrana eritrocítica, actina eritrocitaria,\n\n78, 78f\n\naducina, 78f\nankirina, 78\nespectrina\n \nα\n \ny\n \nβ\n, 78\nesqueleto de la, 78\nestructuras de la, 78f\n\nMeningitis,\n \n22\n\nMenstruación,\n \n22\n\n6-mercaptopurina,\n \n55c\n\nMesilato de imatinib,\n \n186\n\nMetotrexato,\n \n55c\n\nMicroambiente\n \ninductivo\n \nhematopoyético\n(MIH),\n \n5, 5c\n\nMicrocitosis,\n \n18f, 19f, 21, 152\n\nMielofibrosis,\n \n26\n\nprimaria, 196c.\n \nVéase\n \nNeoplasias mieloproliferati-\nvas crónicas\n\nMielograma y biopsia de médula ósea,\n \n245\n\nMieloma múltiple,\n \n242-247, 249c, 250f","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":416,"lines":{"from":79,"to":188}}}}],["2113",{"pageContent":"Microcitosis,\n \n18f, 19f, 21, 152\n\nMielofibrosis,\n \n26\n\nprimaria, 196c.\n \nVéase\n \nNeoplasias mieloproliferati-\nvas crónicas\n\nMielograma y biopsia de médula ósea,\n \n245\n\nMieloma múltiple,\n \n242-247, 249c, 250f\n\nclasificación de la inmunoglobulina monoclonal,\n246\ncriterios de diagnóstico, 247c\ncuadro clínico, 243\ndiagnóstico, 245-246\nbiopsia de médula ósea, 245\ncitometría hemática completa, 245\ncuantificación de inmunoglobulinas en el sue-\nro, 245\ncuantificación de las proteínas urinarias, 245\ndeterminación de microglobulina b2 en el sue-\nro, 245\nelectroforesis de las proteínas de la orina, 245\nestudio electroforético de las proteínas del sue-\nro, 245\ninmunofijación en el suero, 245\ninmunofijación en orina de 24 horas concentra-\nda, 245\nmielograma, 245\nradiografía(s), cráneo, 243f\nesqueleto, 245\nde pelvis, 244f\nhallazgos de laboratorio, 244-245\ninsuficiencia renal, 243\nmanifestaciones hemorrágicas, 244\n\nM","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":416,"lines":{"from":188,"to":237}}}}],["2114",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n390\n\npatogenia, 243\npronóstico, 247\nsíndrome de hiperviscosidad, 244\ntratamiento, 247\nbortezomib, 247\ncombinación de talidomida-dexametasona, 247\ntalidomida, dexametasona y melfalán, 247\ntrasplante de células hematopoyéticas autólo-\ngas, 247\n\nMielopatía,\n \n53c\n\nMieloptisis,\n \n25\n\nMonocitos,\n \n3, 5, 7\n\nMutación, del gen MYH9,\n \n278c, 279\n\nJAK2\nV617F\n, 196\nprotrombina, 328cK\n\nNecrosis, bacteriana,\n \n22\n\nde tumores, 22\n\nNeoplasia(s), malignas,\n \n332\n\nmieloproliferativa no clasificable, 196c\n\nNeoplasias mieloproliferativas crónicas,\n \n195-\n203, 196c","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":417,"lines":{"from":1,"to":51}}}}],["2115",{"pageContent":"leucemia, eosinofílica crónica, 196c\ngranulocítica crónica, 196c\nneutrofílica crónica, 196c\nmastocitosis, 196c\nmielofibrosis primaria, 196c, 200-201\ncriterios de la OMS, 201c\ndiagnóstico, 199\nepidemiología, 200\nfisiopatología, 200\npresentación clínica, 200\ntratamiento, 201\nesplenectomía, 201\ninhibidor selectivo de JAK1/JAK2, 201\nlenalidomida, 201\nquimioterapia con hidroxiurea, 201\nradiación al bazo, 201\nruxolitinib, 201\ntalidomida, 201\ntrasplante de médula ósea, 201\nmutación JAK2\nV617F\n, 196\nno clasificable, 196c\npolicitemia vera, 196c, 197\ncriterios de la OMS para el diagnóstico, 198c\ndiagnóstico, 198\nepidemiología, 197\nfisiopatología, 197\npresentación clínica, 197\ntratamiento, 198\ntrombocitosis esencial, 196c, 198.200\ncriterios diagnósticos, 199c\ndiagnóstico, 199\nbiopsia de médula ósea, 199c\ncuenta plaquetaria, 199, 199c\nmarcador de clonalidad, 199c\nepidemiología, 198\nfisiopatología, 198\npresentación clínica, 199\ntratamiento, 200\n\nNeumonías,\n \n22\n\nNeuroacantocitosis,\n \n86","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":417,"lines":{"from":53,"to":100}}}}],["2116",{"pageContent":"Neumonías,\n \n22\n\nNeuroacantocitosis,\n \n86\n\nNeutrófilos,\n \n23\n\nNicho hematopoyético en el adulto,\n \n6f\n\n5’-nucleotidasa,\n \n227\n\nOsteomielitis por salmonella,\n \n108\n\nPancitopenia,\n \n52\n\nPancreatitis crónica,\n \n25\n\nParestesias,\n \n53c\n\nParvovirus,\n \n280\n\nB19, 82, 141\n\nPenicilina en anemia hemolítica adquirida,\n \n133\n\nPérdida, de la sensibilidad cutánea,\n \n53c\n\nde peso, 52\n\nPeríodo, neonatal,\n \n59\n\nposparto, 331\n\nPir 5’-N, deficiencia adquirida,\n \n124\n\nPirimetamina,\n \n55c\n\nPirimidina 5’-nucleotidasa,\n \n124.\n \nVéase\n \nPir 5’-N\nPiruvatocinasa,\n \n116, 117, 117f\n\nPlaquetas,\n \n260-262\n\ncitoplasma plaquetario, 261\ncoágulo plaquetario, 261-262\nadhesión plaquetaria, 261, 261f\nagregación plaquetaria, 261, 261f, 262\nprostaglandinas, 262\neficiencia de gránulos a (síndrome de la plaqueta\ngris), 261\nen la formación de fibrina, 262\nfactor,\n \nde\n \ncrecimiento\n \nderivado\n \nde\n \npla quetas\n(FCDP), 261\nplaquetario 4 (FP4), 261\ntrombospondina, 261\n\nPlasmodium,\n \n21","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":417,"lines":{"from":100,"to":206}}}}],["2117",{"pageContent":"Plasmodium,\n \n21\n\nPolicitemia vera,\n \n22, 196c, 328c.\n \nVéase\n \nNeopla-\nsias mieloproliferativas crónicas\n\ncriterios de la OMS para el diagnóstico, 198c\ndiagnóstico, 198\nepidemiología, 197\nfisiopatología, 197\npresentación clínica, 197\ntratamiento, 198\n\nProstaciclina,\n \n258\n\nProteasa de serina,\n \n258\n\nProteína(s), C reactiva de alta sensibilidad,\n \n227\n\nde Bence-Jones, 250\nfijadora de folatos, 79\nfijadoras de C8 (HRF65/HRFC8bp), 79\nreguladora de la hemostasia, 258\n\nN\nO\nP","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":417,"lines":{"from":206,"to":245}}}}],["2118",{"pageContent":"CAPÍTULO 11\n\n391\n\nPrueba, fragilidad osmótica en la esferocitosis,\n\n71, 72f\n\nradioinmunoprecipitación (RIPA), 355\nrastreo (ELISA o EIA), 355\n\nPúrpura, autoinmunitaria,\n \n25\n\ntrombocitopénica trombótica, 25, 68-69, 72f\n\nQuemaduras,\n \n22\n\nQuimioterapia,\n \n206\n\nRadiación(s),\n \n206\n\nal bazo, 201\nionizantes, 25\n\nRadiografías del esqueleto,\n \n245\n\nRadioinmunoconjugados con anticuerpos an-\nti-CD20,\n \n214\n\nRadioterapia,\n \n206\n\nRectorragia,\n \n38\n\nReticulocitosis,\n \n161\n\nRetinitis pigmentosa,\n \n87\n\nRetraso en el crecimiento,\n \n53c\n\nRituximab,\n \n214\n\nRNA ribosómico,\n \n124\n\nRubéola,\n \n280\n\nRuxolitinib,\n \n201\n\nSangre homóloga, alternativas de la transfu-\nsión de\n\nautodonación preoperatoria, 356\nhemodilución normovolémica preoperatoria, 356\nrecuperación intraoperatoria o posoperatoria de\neritrocitos, 356\n\nSarampión,\n \n280\n\nSepticemia,\n \n25\n\nSeudotumor hemofílico,\n \n322\n\nSida,\n \n206c\n\nSignos de Romberg,\n \n53c\n\nSíndrome(s), anticuerpos antifosfolípido,\n \n332","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":418,"lines":{"from":1,"to":108}}}}],["2119",{"pageContent":"Sarampión,\n \n280\n\nSepticemia,\n \n25\n\nSeudotumor hemofílico,\n \n322\n\nSida,\n \n206c\n\nSignos de Romberg,\n \n53c\n\nSíndrome(s), anticuerpos antifosfolípido,\n \n332\n\nBernard-Soulier, 278c, 279\ncorea-acantocitosis\n \n(síndrome\n \nde\n \nLevine-Crit-\nchley), 87\nCushing, 23\nChédiak-Higashi, 206\ndeficiencia de Rh, 89\nFelty, 22\nHARP, 87\nhipereosinofílico, 24c\nKlinefelter, 206c\nMcLeod, 88\nmielodisplásicos, 278c, 281, 363\nplaquetas “pegajosas”, 328c\nPlummer-Vinson, 38\nSjögren, 206c\nurémico hemolítico, 68-69, 72f\nWiskott-Aldrich, 26\n\nSistema de coagulación,\n \n257\n\nfibrinólisis, 257\nregulación natural, 257, 268\n\nSjögren, síndrome de,\n \n206c\n\nSobrecarga circulatoria,\n \n352\n\nSulfato de protoheparán,\n \n79\n\nTalasemia(s),\n \n363\n\nβ\n, histograma de los eritrocitos, 19f\n\nTalidomida,\n \n201, 247\n\nTensión emocional,\n \n22\n\nTerapéutica transfusional,\n \n341-359","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":418,"lines":{"from":108,"to":192}}}}],["2120",{"pageContent":"Sobrecarga circulatoria,\n \n352\n\nSulfato de protoheparán,\n \n79\n\nTalasemia(s),\n \n363\n\nβ\n, histograma de los eritrocitos, 19f\n\nTalidomida,\n \n201, 247\n\nTensión emocional,\n \n22\n\nTerapéutica transfusional,\n \n341-359\n\nalternativas de la transfusión de sangre homóloga,356\nautodonación preoperatoria, 356\nhemodilución normovolémica preoperatoria, 356\nrecuperación intraoperatoria o posoperatoria de\neritrocitos, 356\ncomplicaciones de las transfusiones, 349c\nconcentrado, de factor IX, 343\neritrocitario, 342\ncrioprecipitado y concentrado de factor VIII, 343-344\nefectos adversos de las transfusiones, 347-355\ncomplicaciones infecciosas, 352-355\nenfermedad de Chagas, 355","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":418,"lines":{"from":192,"to":230}}}}],["2121",{"pageContent":"Yersinia enterocolitica\n, 355\nhepatitis, 353\nA, 353\nB, 353\nC, 353\npor virus Delta, 353\notras enfermedades virales, 354-355\ncitomegalovirus (CMV), 354\nvirus de Epstein-Barr (EBV), 354\nvirus del dengue, 354\nvirus linfotrópico T humano I (HTLV-I),\n354\npaludismo, 355\nsífilis, 354\nvirus de la inmunodeficiencia humana,353-354\ncomplicaciones inmunitarias, 348-351\nenfermedad de injerto contra huésped aso-\nciada a transfusión, 351\nhemolíticas, 349-350\ninmunomodulación. 350\nno hemolíticas, 348\nalérgicas, 348\nfebriles, 348\ncomplicaciones metabólicas, 351-352\nhemorrágicas, 352\nhipercalemia, 352\nhipotermia, 352\nintoxicación por citrato, 351\nsobrecarga circulatoria, 352\n\nQ\nT\nR\nS","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":418,"lines":{"from":232,"to":266}}}}],["2122",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n392\n\ngeneralidades de la aféresis, 346\nplaquetoféresis para obtención de concentrado\nplaquetario de donador único, 346\nterapéutica, 347\ncitoféresis, 347\neritrocitoféresis o recambio eritrocitario, 347\nleucoféresis, 347\nhemovigilancia, 356-357\nindicaciones de recambio plasmático, 348c\nleucorreducción, 355-356\nindicaciones, 356c\nplasma, 342-343\nfresco congelado, 343\nsangre total, 341-342\nposibilidades de fraccionamiento de la, 342\ntransfusión, albúmina, 346\nrecambio plasmático, 347\ngranulocitos, 345-346\nprocedimientos de obtención, 346\nplaquetas, 344-345\nindicaciones, 344\ndefectos funcionales plaquetarios, 345\ntrombocitopenia, 344\ninmunitaria, 345\notros aspectos importantes en, 345\n\nTifo,\n \n25\n\nTirosina-cinasa citoplasmática,\n \n196\n\nTositumomab I-131,\n \n214\n\nToxemia gravídica,\n \n22\n\nTrabajo de parto,\n \n22\n\nTransfusión(es), de albúmina,\n \n346","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":419,"lines":{"from":1,"to":53}}}}],["2123",{"pageContent":"Tifo,\n \n25\n\nTirosina-cinasa citoplasmática,\n \n196\n\nTositumomab I-131,\n \n214\n\nToxemia gravídica,\n \n22\n\nTrabajo de parto,\n \n22\n\nTransfusión(es), de albúmina,\n \n346\n\nrecambio plasmático, 347\ngranulocitos, 345-346\nprocedimientos de obtención, 346\nplaquetas, 344-345\nindicaciones, 344\ndefectos funcionales plaquetarios, 345\ntrombocitopenia, 344\ninmunitaria, 345\nsanguíneas, 25\n\nTrasplante de células hematopoyéticas,\n \n361-367","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":419,"lines":{"from":53,"to":89}}}}],["2124",{"pageContent":"autólogas (auto-TCH), 361, 362f\nalogénicas (alo-TCH), 361, 362f\nalo-TCH, 363\nhemoglobinopatías, 363\nhipoplasia medular grave, 363\ninmunodeficiencias graves, 363\nleucemias agudas o crónicas, 363\nlinfomas, 363\nmielomas, 363\nresultados en México de los, 365, 365f\nsíndromes mielodisplásicos, 363\ntalasemias, 363\ntumores malignos, 363\nauto-TCH, 362-363\ncáncer de mama, 362\nesclerosis múltiple, 362\nlinfomas de Hodgkin, 362\nlinfomas no Hodgkin, 362\nlupus eritematoso generalizado, 362\nmieloma múltiple, 362\ncélulas hematopoyéticas (CH) totipotenciales, 361\nautoperpetuables, 361\nantígeno CD34, 361\n“movilización” de las CH de la MO a la SP, 362\ncomplicaciones, 365\nauto-TCH e infecciones en período de mielo-\nsupresión, 365\nenfermedad de injerto contra huésped (EICH),365\ntrombocitopenia en período de máxima mielo-\nsupresión causante de sangrados graves, 365\nesquemas de acondicionamiento, ablativo, 364\nintensidad reducida, 364\nbusulfán, 364\nciclofosfamida, 364\nfludarabina, 364\netapas del trasplante, 364\npostrasplante, 364","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":419,"lines":{"from":91,"to":127}}}}],["2125",{"pageContent":"esquemas de acondicionamiento, ablativo, 364\nintensidad reducida, 364\nbusulfán, 364\nciclofosfamida, 364\nfludarabina, 364\netapas del trasplante, 364\npostrasplante, 364\nevaluación del paciente y donador, 364\nindicaciones, 363\nsupervivencia global de los pacientes, 365f\nresultados, 364-365","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":419,"lines":{"from":127,"to":137}}}}],["2126",{"pageContent":"Trasplante de médula ósea,\n \n201\n\nTrastornos\n \ninmunoproliferativos\n \nmalignos,\n\n239-253\n\namiloidosis, 251\nclasificación de las gammapatías monoclonales, 240c\nde significado indeterminado, 240\ngammapatías biclonales, 240\nmalignas\namiloidosis, 250f\ncon mieloma, 240c\nprimaria, 240c, 249c\nenfermedades de cadenas pesadas,\n \nα\n, 240c,\n249c\n\nγ\n, 240c\n\nδ\n, 240c\n\nμ\n, 240c\nenfermedades linfoproliferativas malignas,\n240c\nleucemias de células plasmáticas, 240c\nlinfoma maligno, 240c\nmacroglobulinemia de Waldenström, 240c\nmieloma no secretor, 240c\nplasmocitoma,\n \nextramedular,\n \nsolitario\n \ny\nmúltiple, 240c\nóseo solitario, 240c\nconceptos de policlonalidad y monoclonalidad,\n241-242\ninmunofijación de las inmunoglobulinas séri-\ncas, 241\ncrioglobulinemia, 252\ntipos, I (monoclonal), 251\nII (mixto), 251\nIII (policlonal), 251\nenfermedades de cadenas pesadas, 248-251, 249c\na, 250\nd, 251\ng, 250\nm, 250","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":419,"lines":{"from":139,"to":200}}}}],["2127",{"pageContent":"CAPÍTULO 11\n\n393\n\ninmunoglobulinas, IgA, 241\nIgD, 241\nIgG, 241\nIgM, 241\nmacroglobulinemia de Waldenström, 248, 249c, 250f\nmieloma múltiple, 242-247, 249c, 250f\nclasificación de la inmunoglobulina monoclo-\nnal, 246\ncriterios de diagnóstico, 247c\ncuadro clínico, 243\ndiagnóstico, 245-246\nbiopsia de médula ósea, 245\ncitometría hemática completa, 245\ncuantificación de inmunoglobulinas en el\nsuero, 245\ncuantificación de las proteínas urinarias, 245\ndeterminación de microglobulina b2 en el\nsuero, 245\nelectroforesis de las proteínas de la orina, 245\nestudio electroforético de las proteínas del\nsuero, 245\ninmunofijación en el suero, 245\ninmunofijación en orina de 24 horas concen\n-\ntrada, 245\nmielograma, 245\nradiografías del esqueleto, 245\nhallazgos de laboratorio, 244-245\npatogenia, 243\npronóstico, 247\ntratamiento, 247\nbortezomib, 247\ncombinación de talidomida-dexametasona,\n247\ntalidomida, dexametasona y melfalán, 247\ntrasplante de células hematopoyéticas autó-\nlogas, 247\n\nTrimetoprim,\n \n55c","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":420,"lines":{"from":1,"to":45}}}}],["2128",{"pageContent":"Trimetoprim,\n \n55c\n\nTrypanosoma cruzi,\n \n355\n\nprueba de rastreo para, para donadores de sangre, 355\n\nTrombo,\n \n258\n\nTrombocitopenias,\n \n52, 250, 277-301","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":420,"lines":{"from":45,"to":61}}}}],["2129",{"pageContent":"por aumento en la destrucción de plaquetas,282-297\norigen inmunitario, 282, 283c\nasociada a, infección por\n \nHelicobacter pylori\n,\n283c, 288\ninmunodeficiencia\n \ncomún\n \nvariable,\n283c, 290\nlupus eritematoso generalizado, 283c,\n287\nmalignidad, 283c, 288\nsíndrome antifosfolípido, 283c, 288\ntrombocitopenia, aloinmunitaria neonatal,\n283c, 292\ninducida por heparina, 283c, 290\ninmunitaria por medicamentos, 283c, 288\ninmunitaria primaria, 282-286, 283c\ndurante el embarazo, 283c, 286-287\npostransfusional, 283c, 291-292\norigen no inmunitario, 283c, 292\nasociada a, cirugía cardíaca, 283c, 296\nenfermedad de von Willebrand, 283c, 297\npreeclampsia y síndrome de HELLP,\n283c, 293-295\nsíndrome de Kasabach-Merritt, 283c, 296\ntrasplante de células progenitoras hema-\ntopoyéticas, 283c, 295\npúrpura trombocitopénica trombótica y sín-\ndrome urémico hemolítico, 283c, 292\ntrombocitopenia\n \nasociada\n \na\n \ninfecciones,\n283c, 295\ntrombocitopenia gestacional, 283c, 296\npor distribución y almacenamiento inadecuados de\nplaquetas","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":420,"lines":{"from":63,"to":107}}}}],["2130",{"pageContent":"drome urémico hemolítico, 283c, 292\ntrombocitopenia\n \nasociada\n \na\n \ninfecciones,\n283c, 295\ntrombocitopenia gestacional, 283c, 296\npor distribución y almacenamiento inadecuados de\nplaquetas\nesplenomegalia e hiperesplenismo, 297\npor producción insuficiente de plaquetas, 277-282\norigen adquirido, 277c, 280-282\naplasia pura de serie megacariocítica,278c, 280\nasociada a, consumo de alcohol, 278c, 281\ndeficiencia de ácido fólico y vitamina\nB12, 278c, 281\ndeficiencia de hierro, 278c, 281\ninfecciones virales, 278c, 280\ninfiltración de la médula ósea, 278c, 281\nquimioterapia, radioterapia y otros fár-\nmacos, 278c, 280\nsida, 278c, 281-282\nsíndromes mielodisplásicos, 278c, 281\norigen congénito, 277c, 278-280\nasociada, a la mutación del gen MYH9,\n278c, 279\nal síndrome de, Bernard-Soulier,278c, 279\nWiskott-Aldrich, 278c, 279-280\ncon ausencia de radio, 278c, 278-279\ncongénita amegacariocítica, 278c, 278","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":420,"lines":{"from":107,"to":139}}}}],["2131",{"pageContent":"Trombocitosis esencial,\n \n196c, 198.200\n\ncriterios diagnósticos, 199c\ndiagnóstico, 199\nbiopsia de médula ósea, 199c\ncuenta plaquetaria, 199, 199c\nmarcador de clonalidad, 199c\n\nTrombofilia,\n \n327-336\n\ncaracterísticas generales, 328\ndiagnóstico de la trombosis, 328-329\nestados de, 329.332\nprimaria o hereditaria, 329-331\ndeficiencia de, antitrombina III, 331\nproteína C, 330-331\nproteína S, 331\nmutación C677T del gen MTHFR, 330\nresistencia a la proteína C activada, 330\nmutación tipo Leiden del factor V de la\ncoagulación, 330\nsíndrome de las plaquetas “pegajosas”, 329\nsecundaria, 331-332\nlupus eritematoso generalizado, 332\nneoplasias malignas, 332\nperíodo posparto, 331\nsíndrome de anticuerpos antifosfolípido, 332\nevaluación de pacientes con riesgo trombótico alto,\n332","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":420,"lines":{"from":141,"to":173}}}}],["2132",{"pageContent":"FUNDAMENTOS DE HEMATOLOGÍA\n\n394\n\nprofilaxis y tratamiento de los trastornos trombó-\nticos, 332-333\nantiplaquetarios, aspirina, 334\nanticoagulantes orales, 333\nfibrinolíticos, 333\nheparinas, 333\notros antiplaquetarios, anticuerpos monoclona-\nles, 334\nclopidogrel, 334\ndiltiazem, 334\nnifedipino, 334\npropranolol, 334\nticagrelor, 334\ntrombosis arterial, 327\ntrombosis venosa, 327-328\n\nTrombomodulina (Tm),\n \n258\n\nTrombopoyetina,\n \n8\n\nTrombosis,\n \n244, 258\n\nTrombospondina,\n \n261\n\nTromboxano A2 (TxA2),\n \n258\n\nTumores malignos,\n \n363\n\nUnidades formadoras de colonias (UFC),\n \n3, 4\n\nUremia,\n \n22\n\nVaricela,\n \n280\n\nVasoconstricción,\n \n258, 259f\n\nVelocidad de eritrosedimentación,\n \n227\n\nVirus, de Epstein-Barr (EBV),\n \n206, 280\n\nlinfotrópico T humano 1 (HTLV-1), 206\n\nVitamina B12,\n \n16, 70-71, 160\n\ndeficiencia de, 21f\n\nVitamina K,\n \n317, 318\n\nanticoagulantes antagonistas, 272\nproteína S dependiente de, 331\nsangrados por deficiencia de, 343\n\nVómito,\n \n52\n\nvon Willebrand adquirida, enfermedad de,\n\n199\n\nWaldeyer, anillo de,\n \n227-228","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":421,"lines":{"from":1,"to":95}}}}],["2133",{"pageContent":"anticoagulantes antagonistas, 272\nproteína S dependiente de, 331\nsangrados por deficiencia de, 343\n\nVómito,\n \n52\n\nvon Willebrand adquirida, enfermedad de,\n\n199\n\nWaldeyer, anillo de,\n \n227-228\n\nWiskott-Aldrich, síndrome de,\n \n206c\n\nvon Willebrand, enfermedad de,\n \n310, 315, 320\n\nhemofilias y, adquiridas, 305c\n\nXerocitosis hereditaria,\n \n80c, 88\n\nYersinia enterocolitica,\n \n355\n\nZidovudina (AZT),\n \n55c\nU\nV\nW\nX\nY\nZ","metadata":{"source":"blob","blobType":"application/pdf","pdf":{"version":"3.4.120","info":{"PDFFormatVersion":"1.6","Language":null,"EncryptFilterName":null,"IsLinearized":false,"IsAcroFormPresent":false,"IsXFAPresent":false,"IsCollectionPresent":false,"IsSignaturesPresent":false,"CreationDate":"D:20140326203540-06'00'","Creator":"Adobe InDesign CS6 (Macintosh)","ModDate":"D:20221111143141+01'00'","Producer":"Adobe PDF Library 10.0.1","Trapped":{"name":"False"}},"metadata":{},"totalPages":422},"loc":{"pageNumber":421,"lines":{"from":95,"to":137}}}}]]